(function(){const P=document.createElement("link").relList;if(P&&P.supports&&P.supports("modulepreload"))return;for(const S of document.querySelectorAll('link[rel="modulepreload"]'))f(S);new MutationObserver(S=>{for(const w of S)if(w.type==="childList")for(const W of w.addedNodes)W.tagName==="LINK"&&W.rel==="modulepreload"&&f(W)}).observe(document,{childList:!0,subtree:!0});function x(S){const w={};return S.integrity&&(w.integrity=S.integrity),S.referrerPolicy&&(w.referrerPolicy=S.referrerPolicy),S.crossOrigin==="use-credentials"?w.credentials="include":S.crossOrigin==="anonymous"?w.credentials="omit":w.credentials="same-origin",w}function f(S){if(S.ep)return;S.ep=!0;const w=x(S);fetch(S.href,w)}})();function qu(h){return h&&h.__esModule&&Object.prototype.hasOwnProperty.call(h,"default")?h.default:h}var Dc={exports:{}},Mt={};/**
 * @license React
 * react-jsx-runtime.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var _u;function Ph(){if(_u)return Mt;_u=1;var h=Symbol.for("react.transitional.element"),P=Symbol.for("react.fragment");function x(f,S,w){var W=null;if(w!==void 0&&(W=""+w),S.key!==void 0&&(W=""+S.key),"key"in S){w={};for(var X in S)X!=="key"&&(w[X]=S[X])}else w=S;return S=w.ref,{$$typeof:h,type:f,key:W,ref:S!==void 0?S:null,props:w}}return Mt.Fragment=P,Mt.jsx=x,Mt.jsxs=x,Mt}var Nu;function Th(){return Nu||(Nu=1,Dc.exports=Ph()),Dc.exports}var m=Th(),Rc={exports:{}},Z={};/**
 * @license React
 * react.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Yu;function xh(){if(Yu)return Z;Yu=1;var h=Symbol.for("react.transitional.element"),P=Symbol.for("react.portal"),x=Symbol.for("react.fragment"),f=Symbol.for("react.strict_mode"),S=Symbol.for("react.profiler"),w=Symbol.for("react.consumer"),W=Symbol.for("react.context"),X=Symbol.for("react.forward_ref"),O=Symbol.for("react.suspense"),E=Symbol.for("react.memo"),L=Symbol.for("react.lazy"),_=Symbol.for("react.activity"),K=Symbol.iterator;function Ae(y){return y===null||typeof y!="object"?null:(y=K&&y[K]||y["@@iterator"],typeof y=="function"?y:null)}var z={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},Ie=Object.assign,ke={};function Pe(y,g,U){this.props=y,this.context=g,this.refs=ke,this.updater=U||z}Pe.prototype.isReactComponent={},Pe.prototype.setState=function(y,g){if(typeof y!="object"&&typeof y!="function"&&y!=null)throw Error("takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,y,g,"setState")},Pe.prototype.forceUpdate=function(y){this.updater.enqueueForceUpdate(this,y,"forceUpdate")};function qe(){}qe.prototype=Pe.prototype;function Q(y,g,U){this.props=y,this.context=g,this.refs=ke,this.updater=U||z}var se=Q.prototype=new qe;se.constructor=Q,Ie(se,Pe.prototype),se.isPureReactComponent=!0;var ti=Array.isArray;function de(){}var F={H:null,A:null,T:null,S:null},Ve=Object.prototype.hasOwnProperty;function bi(y,g,U){var T=U.ref;return{$$typeof:h,type:y,key:g,ref:T!==void 0?T:null,props:U}}function ki(y,g){return bi(y.type,g,y.props)}function gi(y){return typeof y=="object"&&y!==null&&y.$$typeof===h}function Qe(y){var g={"=":"=0",":":"=2"};return"$"+y.replace(/[=:]/g,function(U){return g[U]})}var _i=/\/+/g;function Pi(y,g){return typeof y=="object"&&y!==null&&y.key!=null?Qe(""+y.key):g.toString(36)}function oi(y){switch(y.status){case"fulfilled":return y.value;case"rejected":throw y.reason;default:switch(typeof y.status=="string"?y.then(de,de):(y.status="pending",y.then(function(g){y.status==="pending"&&(y.status="fulfilled",y.value=g)},function(g){y.status==="pending"&&(y.status="rejected",y.reason=g)})),y.status){case"fulfilled":return y.value;case"rejected":throw y.reason}}throw y}function C(y,g,U,T,B){var q=typeof y;(q==="undefined"||q==="boolean")&&(y=null);var J=!1;if(y===null)J=!0;else switch(q){case"bigint":case"string":case"number":J=!0;break;case"object":switch(y.$$typeof){case h:case P:J=!0;break;case L:return J=y._init,C(J(y._payload),g,U,T,B)}}if(J)return B=B(y),J=T===""?"."+Pi(y,0):T,ti(B)?(U="",J!=null&&(U=J.replace(_i,"$&/")+"/"),C(B,g,U,"",function(Ze){return Ze})):B!=null&&(gi(B)&&(B=ki(B,U+(B.key==null||y&&y.key===B.key?"":(""+B.key).replace(_i,"$&/")+"/")+J)),g.push(B)),1;J=0;var he=T===""?".":T+":";if(ti(y))for(var le=0;le<y.length;le++)T=y[le],q=he+Pi(T,le),J+=C(T,g,U,q,B);else if(le=Ae(y),typeof le=="function")for(y=le.call(y),le=0;!(T=y.next()).done;)T=T.value,q=he+Pi(T,le++),J+=C(T,g,U,q,B);else if(q==="object"){if(typeof y.then=="function")return C(oi(y),g,U,T,B);throw g=String(y),Error("Objects are not valid as a React child (found: "+(g==="[object Object]"?"object with keys {"+Object.keys(y).join(", ")+"}":g)+"). If you meant to render a collection of children, use an array instead.")}return J}function H(y,g,U){if(y==null)return y;var T=[],B=0;return C(y,T,"","",function(q){return g.call(U,q,B++)}),T}function V(y){if(y._status===-1){var g=y._result;g=g(),g.then(function(U){(y._status===0||y._status===-1)&&(y._status=1,y._result=U)},function(U){(y._status===0||y._status===-1)&&(y._status=2,y._result=U)}),y._status===-1&&(y._status=0,y._result=g)}if(y._status===1)return y._result.default;throw y._result}var pe=typeof reportError=="function"?reportError:function(y){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var g=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof y=="object"&&y!==null&&typeof y.message=="string"?String(y.message):String(y),error:y});if(!window.dispatchEvent(g))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",y);return}console.error(y)},ce={map:H,forEach:function(y,g,U){H(y,function(){g.apply(this,arguments)},U)},count:function(y){var g=0;return H(y,function(){g++}),g},toArray:function(y){return H(y,function(g){return g})||[]},only:function(y){if(!gi(y))throw Error("React.Children.only expected to receive a single React element child.");return y}};return Z.Activity=_,Z.Children=ce,Z.Component=Pe,Z.Fragment=x,Z.Profiler=S,Z.PureComponent=Q,Z.StrictMode=f,Z.Suspense=O,Z.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=F,Z.__COMPILER_RUNTIME={__proto__:null,c:function(y){return F.H.useMemoCache(y)}},Z.cache=function(y){return function(){return y.apply(null,arguments)}},Z.cacheSignal=function(){return null},Z.cloneElement=function(y,g,U){if(y==null)throw Error("The argument must be a React element, but you passed "+y+".");var T=Ie({},y.props),B=y.key;if(g!=null)for(q in g.key!==void 0&&(B=""+g.key),g)!Ve.call(g,q)||q==="key"||q==="__self"||q==="__source"||q==="ref"&&g.ref===void 0||(T[q]=g[q]);var q=arguments.length-2;if(q===1)T.children=U;else if(1<q){for(var J=Array(q),he=0;he<q;he++)J[he]=arguments[he+2];T.children=J}return bi(y.type,B,T)},Z.createContext=function(y){return y={$$typeof:W,_currentValue:y,_currentValue2:y,_threadCount:0,Provider:null,Consumer:null},y.Provider=y,y.Consumer={$$typeof:w,_context:y},y},Z.createElement=function(y,g,U){var T,B={},q=null;if(g!=null)for(T in g.key!==void 0&&(q=""+g.key),g)Ve.call(g,T)&&T!=="key"&&T!=="__self"&&T!=="__source"&&(B[T]=g[T]);var J=arguments.length-2;if(J===1)B.children=U;else if(1<J){for(var he=Array(J),le=0;le<J;le++)he[le]=arguments[le+2];B.children=he}if(y&&y.defaultProps)for(T in J=y.defaultProps,J)B[T]===void 0&&(B[T]=J[T]);return bi(y,q,B)},Z.createRef=function(){return{current:null}},Z.forwardRef=function(y){return{$$typeof:X,render:y}},Z.isValidElement=gi,Z.lazy=function(y){return{$$typeof:L,_payload:{_status:-1,_result:y},_init:V}},Z.memo=function(y,g){return{$$typeof:E,type:y,compare:g===void 0?null:g}},Z.startTransition=function(y){var g=F.T,U={};F.T=U;try{var T=y(),B=F.S;B!==null&&B(U,T),typeof T=="object"&&T!==null&&typeof T.then=="function"&&T.then(de,pe)}catch(q){pe(q)}finally{g!==null&&U.types!==null&&(g.types=U.types),F.T=g}},Z.unstable_useCacheRefresh=function(){return F.H.useCacheRefresh()},Z.use=function(y){return F.H.use(y)},Z.useActionState=function(y,g,U){return F.H.useActionState(y,g,U)},Z.useCallback=function(y,g){return F.H.useCallback(y,g)},Z.useContext=function(y){return F.H.useContext(y)},Z.useDebugValue=function(){},Z.useDeferredValue=function(y,g){return F.H.useDeferredValue(y,g)},Z.useEffect=function(y,g){return F.H.useEffect(y,g)},Z.useEffectEvent=function(y){return F.H.useEffectEvent(y)},Z.useId=function(){return F.H.useId()},Z.useImperativeHandle=function(y,g,U){return F.H.useImperativeHandle(y,g,U)},Z.useInsertionEffect=function(y,g){return F.H.useInsertionEffect(y,g)},Z.useLayoutEffect=function(y,g){return F.H.useLayoutEffect(y,g)},Z.useMemo=function(y,g){return F.H.useMemo(y,g)},Z.useOptimistic=function(y,g){return F.H.useOptimistic(y,g)},Z.useReducer=function(y,g,U){return F.H.useReducer(y,g,U)},Z.useRef=function(y){return F.H.useRef(y)},Z.useState=function(y){return F.H.useState(y)},Z.useSyncExternalStore=function(y,g,U){return F.H.useSyncExternalStore(y,g,U)},Z.useTransition=function(){return F.H.useTransition()},Z.version="19.2.0",Z}var Lu;function Mc(){return Lu||(Lu=1,Rc.exports=xh()),Rc.exports}var re=Mc();const Oh=qu(re);var vc={exports:{}},Pt={},Ac={exports:{}},Cc={};/**
 * @license React
 * scheduler.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Bu;function Sh(){return Bu||(Bu=1,(function(h){function P(C,H){var V=C.length;C.push(H);e:for(;0<V;){var pe=V-1>>>1,ce=C[pe];if(0<S(ce,H))C[pe]=H,C[V]=ce,V=pe;else break e}}function x(C){return C.length===0?null:C[0]}function f(C){if(C.length===0)return null;var H=C[0],V=C.pop();if(V!==H){C[0]=V;e:for(var pe=0,ce=C.length,y=ce>>>1;pe<y;){var g=2*(pe+1)-1,U=C[g],T=g+1,B=C[T];if(0>S(U,V))T<ce&&0>S(B,U)?(C[pe]=B,C[T]=V,pe=T):(C[pe]=U,C[g]=V,pe=g);else if(T<ce&&0>S(B,V))C[pe]=B,C[T]=V,pe=T;else break e}}return H}function S(C,H){var V=C.sortIndex-H.sortIndex;return V!==0?V:C.id-H.id}if(h.unstable_now=void 0,typeof performance=="object"&&typeof performance.now=="function"){var w=performance;h.unstable_now=function(){return w.now()}}else{var W=Date,X=W.now();h.unstable_now=function(){return W.now()-X}}var O=[],E=[],L=1,_=null,K=3,Ae=!1,z=!1,Ie=!1,ke=!1,Pe=typeof setTimeout=="function"?setTimeout:null,qe=typeof clearTimeout=="function"?clearTimeout:null,Q=typeof setImmediate<"u"?setImmediate:null;function se(C){for(var H=x(E);H!==null;){if(H.callback===null)f(E);else if(H.startTime<=C)f(E),H.sortIndex=H.expirationTime,P(O,H);else break;H=x(E)}}function ti(C){if(Ie=!1,se(C),!z)if(x(O)!==null)z=!0,de||(de=!0,Qe());else{var H=x(E);H!==null&&oi(ti,H.startTime-C)}}var de=!1,F=-1,Ve=5,bi=-1;function ki(){return ke?!0:!(h.unstable_now()-bi<Ve)}function gi(){if(ke=!1,de){var C=h.unstable_now();bi=C;var H=!0;try{e:{z=!1,Ie&&(Ie=!1,qe(F),F=-1),Ae=!0;var V=K;try{i:{for(se(C),_=x(O);_!==null&&!(_.expirationTime>C&&ki());){var pe=_.callback;if(typeof pe=="function"){_.callback=null,K=_.priorityLevel;var ce=pe(_.expirationTime<=C);if(C=h.unstable_now(),typeof ce=="function"){_.callback=ce,se(C),H=!0;break i}_===x(O)&&f(O),se(C)}else f(O);_=x(O)}if(_!==null)H=!0;else{var y=x(E);y!==null&&oi(ti,y.startTime-C),H=!1}}break e}finally{_=null,K=V,Ae=!1}H=void 0}}finally{H?Qe():de=!1}}}var Qe;if(typeof Q=="function")Qe=function(){Q(gi)};else if(typeof MessageChannel<"u"){var _i=new MessageChannel,Pi=_i.port2;_i.port1.onmessage=gi,Qe=function(){Pi.postMessage(null)}}else Qe=function(){Pe(gi,0)};function oi(C,H){F=Pe(function(){C(h.unstable_now())},H)}h.unstable_IdlePriority=5,h.unstable_ImmediatePriority=1,h.unstable_LowPriority=4,h.unstable_NormalPriority=3,h.unstable_Profiling=null,h.unstable_UserBlockingPriority=2,h.unstable_cancelCallback=function(C){C.callback=null},h.unstable_forceFrameRate=function(C){0>C||125<C?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):Ve=0<C?Math.floor(1e3/C):5},h.unstable_getCurrentPriorityLevel=function(){return K},h.unstable_next=function(C){switch(K){case 1:case 2:case 3:var H=3;break;default:H=K}var V=K;K=H;try{return C()}finally{K=V}},h.unstable_requestPaint=function(){ke=!0},h.unstable_runWithPriority=function(C,H){switch(C){case 1:case 2:case 3:case 4:case 5:break;default:C=3}var V=K;K=C;try{return H()}finally{K=V}},h.unstable_scheduleCallback=function(C,H,V){var pe=h.unstable_now();switch(typeof V=="object"&&V!==null?(V=V.delay,V=typeof V=="number"&&0<V?pe+V:pe):V=pe,C){case 1:var ce=-1;break;case 2:ce=250;break;case 5:ce=1073741823;break;case 4:ce=1e4;break;default:ce=5e3}return ce=V+ce,C={id:L++,callback:H,priorityLevel:C,startTime:V,expirationTime:ce,sortIndex:-1},V>pe?(C.sortIndex=V,P(E,C),x(O)===null&&C===x(E)&&(Ie?(qe(F),F=-1):Ie=!0,oi(ti,V-pe))):(C.sortIndex=ce,P(O,C),z||Ae||(z=!0,de||(de=!0,Qe()))),C},h.unstable_shouldYield=ki,h.unstable_wrapCallback=function(C){var H=K;return function(){var V=K;K=H;try{return C.apply(this,arguments)}finally{K=V}}}})(Cc)),Cc}var Fu;function Hh(){return Fu||(Fu=1,Ac.exports=Sh()),Ac.exports}var Gc={exports:{}},We={};/**
 * @license React
 * react-dom.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var ju;function zh(){if(ju)return We;ju=1;var h=Mc();function P(O){var E="https://react.dev/errors/"+O;if(1<arguments.length){E+="?args[]="+encodeURIComponent(arguments[1]);for(var L=2;L<arguments.length;L++)E+="&args[]="+encodeURIComponent(arguments[L])}return"Minified React error #"+O+"; visit "+E+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function x(){}var f={d:{f:x,r:function(){throw Error(P(522))},D:x,C:x,L:x,m:x,X:x,S:x,M:x},p:0,findDOMNode:null},S=Symbol.for("react.portal");function w(O,E,L){var _=3<arguments.length&&arguments[3]!==void 0?arguments[3]:null;return{$$typeof:S,key:_==null?null:""+_,children:O,containerInfo:E,implementation:L}}var W=h.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE;function X(O,E){if(O==="font")return"";if(typeof E=="string")return E==="use-credentials"?E:""}return We.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=f,We.createPortal=function(O,E){var L=2<arguments.length&&arguments[2]!==void 0?arguments[2]:null;if(!E||E.nodeType!==1&&E.nodeType!==9&&E.nodeType!==11)throw Error(P(299));return w(O,E,null,L)},We.flushSync=function(O){var E=W.T,L=f.p;try{if(W.T=null,f.p=2,O)return O()}finally{W.T=E,f.p=L,f.d.f()}},We.preconnect=function(O,E){typeof O=="string"&&(E?(E=E.crossOrigin,E=typeof E=="string"?E==="use-credentials"?E:"":void 0):E=null,f.d.C(O,E))},We.prefetchDNS=function(O){typeof O=="string"&&f.d.D(O)},We.preinit=function(O,E){if(typeof O=="string"&&E&&typeof E.as=="string"){var L=E.as,_=X(L,E.crossOrigin),K=typeof E.integrity=="string"?E.integrity:void 0,Ae=typeof E.fetchPriority=="string"?E.fetchPriority:void 0;L==="style"?f.d.S(O,typeof E.precedence=="string"?E.precedence:void 0,{crossOrigin:_,integrity:K,fetchPriority:Ae}):L==="script"&&f.d.X(O,{crossOrigin:_,integrity:K,fetchPriority:Ae,nonce:typeof E.nonce=="string"?E.nonce:void 0})}},We.preinitModule=function(O,E){if(typeof O=="string")if(typeof E=="object"&&E!==null){if(E.as==null||E.as==="script"){var L=X(E.as,E.crossOrigin);f.d.M(O,{crossOrigin:L,integrity:typeof E.integrity=="string"?E.integrity:void 0,nonce:typeof E.nonce=="string"?E.nonce:void 0})}}else E==null&&f.d.M(O)},We.preload=function(O,E){if(typeof O=="string"&&typeof E=="object"&&E!==null&&typeof E.as=="string"){var L=E.as,_=X(L,E.crossOrigin);f.d.L(O,L,{crossOrigin:_,integrity:typeof E.integrity=="string"?E.integrity:void 0,nonce:typeof E.nonce=="string"?E.nonce:void 0,type:typeof E.type=="string"?E.type:void 0,fetchPriority:typeof E.fetchPriority=="string"?E.fetchPriority:void 0,referrerPolicy:typeof E.referrerPolicy=="string"?E.referrerPolicy:void 0,imageSrcSet:typeof E.imageSrcSet=="string"?E.imageSrcSet:void 0,imageSizes:typeof E.imageSizes=="string"?E.imageSizes:void 0,media:typeof E.media=="string"?E.media:void 0})}},We.preloadModule=function(O,E){if(typeof O=="string")if(E){var L=X(E.as,E.crossOrigin);f.d.m(O,{as:typeof E.as=="string"&&E.as!=="script"?E.as:void 0,crossOrigin:L,integrity:typeof E.integrity=="string"?E.integrity:void 0})}else f.d.m(O)},We.requestFormReset=function(O){f.d.r(O)},We.unstable_batchedUpdates=function(O,E){return O(E)},We.useFormState=function(O,E,L){return W.H.useFormState(O,E,L)},We.useFormStatus=function(){return W.H.useHostTransitionStatus()},We.version="19.2.0",We}var Vu;function wh(){if(Vu)return Gc.exports;Vu=1;function h(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(h)}catch(P){console.error(P)}}return h(),Gc.exports=zh(),Gc.exports}/**
 * @license React
 * react-dom-client.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Qu;function kh(){if(Qu)return Pt;Qu=1;var h=Hh(),P=Mc(),x=wh();function f(a){var t="https://react.dev/errors/"+a;if(1<arguments.length){t+="?args[]="+encodeURIComponent(arguments[1]);for(var o=2;o<arguments.length;o++)t+="&args[]="+encodeURIComponent(arguments[o])}return"Minified React error #"+a+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function S(a){return!(!a||a.nodeType!==1&&a.nodeType!==9&&a.nodeType!==11)}function w(a){var t=a,o=a;if(a.alternate)for(;t.return;)t=t.return;else{a=t;do t=a,(t.flags&4098)!==0&&(o=t.return),a=t.return;while(a)}return t.tag===3?o:null}function W(a){if(a.tag===13){var t=a.memoizedState;if(t===null&&(a=a.alternate,a!==null&&(t=a.memoizedState)),t!==null)return t.dehydrated}return null}function X(a){if(a.tag===31){var t=a.memoizedState;if(t===null&&(a=a.alternate,a!==null&&(t=a.memoizedState)),t!==null)return t.dehydrated}return null}function O(a){if(w(a)!==a)throw Error(f(188))}function E(a){var t=a.alternate;if(!t){if(t=w(a),t===null)throw Error(f(188));return t!==a?null:a}for(var o=a,r=t;;){var s=o.return;if(s===null)break;var c=s.alternate;if(c===null){if(r=s.return,r!==null){o=r;continue}break}if(s.child===c.child){for(c=s.child;c;){if(c===o)return O(s),a;if(c===r)return O(s),t;c=c.sibling}throw Error(f(188))}if(o.return!==r.return)o=s,r=c;else{for(var l=!1,d=s.child;d;){if(d===o){l=!0,o=s,r=c;break}if(d===r){l=!0,r=s,o=c;break}d=d.sibling}if(!l){for(d=c.child;d;){if(d===o){l=!0,o=c,r=s;break}if(d===r){l=!0,r=c,o=s;break}d=d.sibling}if(!l)throw Error(f(189))}}if(o.alternate!==r)throw Error(f(190))}if(o.tag!==3)throw Error(f(188));return o.stateNode.current===o?a:t}function L(a){var t=a.tag;if(t===5||t===26||t===27||t===6)return a;for(a=a.child;a!==null;){if(t=L(a),t!==null)return t;a=a.sibling}return null}var _=Object.assign,K=Symbol.for("react.element"),Ae=Symbol.for("react.transitional.element"),z=Symbol.for("react.portal"),Ie=Symbol.for("react.fragment"),ke=Symbol.for("react.strict_mode"),Pe=Symbol.for("react.profiler"),qe=Symbol.for("react.consumer"),Q=Symbol.for("react.context"),se=Symbol.for("react.forward_ref"),ti=Symbol.for("react.suspense"),de=Symbol.for("react.suspense_list"),F=Symbol.for("react.memo"),Ve=Symbol.for("react.lazy"),bi=Symbol.for("react.activity"),ki=Symbol.for("react.memo_cache_sentinel"),gi=Symbol.iterator;function Qe(a){return a===null||typeof a!="object"?null:(a=gi&&a[gi]||a["@@iterator"],typeof a=="function"?a:null)}var _i=Symbol.for("react.client.reference");function Pi(a){if(a==null)return null;if(typeof a=="function")return a.$$typeof===_i?null:a.displayName||a.name||null;if(typeof a=="string")return a;switch(a){case Ie:return"Fragment";case Pe:return"Profiler";case ke:return"StrictMode";case ti:return"Suspense";case de:return"SuspenseList";case bi:return"Activity"}if(typeof a=="object")switch(a.$$typeof){case z:return"Portal";case Q:return a.displayName||"Context";case qe:return(a._context.displayName||"Context")+".Consumer";case se:var t=a.render;return a=a.displayName,a||(a=t.displayName||t.name||"",a=a!==""?"ForwardRef("+a+")":"ForwardRef"),a;case F:return t=a.displayName||null,t!==null?t:Pi(a.type)||"Memo";case Ve:t=a._payload,a=a._init;try{return Pi(a(t))}catch{}}return null}var oi=Array.isArray,C=P.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,H=x.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,V={pending:!1,data:null,method:null,action:null},pe=[],ce=-1;function y(a){return{current:a}}function g(a){0>ce||(a.current=pe[ce],pe[ce]=null,ce--)}function U(a,t){ce++,pe[ce]=a.current,a.current=t}var T=y(null),B=y(null),q=y(null),J=y(null);function he(a,t){switch(U(q,t),U(B,a),U(T,null),t.nodeType){case 9:case 11:a=(a=t.documentElement)&&(a=a.namespaceURI)?su(a):0;break;default:if(a=t.tagName,t=t.namespaceURI)t=su(t),a=cu(t,a);else switch(a){case"svg":a=1;break;case"math":a=2;break;default:a=0}}g(T),U(T,a)}function le(){g(T),g(B),g(q)}function Ze(a){a.memoizedState!==null&&U(J,a);var t=T.current,o=cu(t,a.type);t!==o&&(U(B,a),U(T,o))}function on(a){B.current===a&&(g(T),g(B)),J.current===a&&(g(J),Gt._currentValue=V)}var ri,kc;function On(a){if(ri===void 0)try{throw Error()}catch(o){var t=o.stack.trim().match(/\n( *(at )?)/);ri=t&&t[1]||"",kc=-1<o.stack.indexOf(`
    at`)?" (<anonymous>)":-1<o.stack.indexOf("@")?"@unknown:0:0":""}return`
`+ri+a+kc}var nr=!1;function ar(a,t){if(!a||nr)return"";nr=!0;var o=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{var r={DetermineComponentFrameRoot:function(){try{if(t){var M=function(){throw Error()};if(Object.defineProperty(M.prototype,"props",{set:function(){throw Error()}}),typeof Reflect=="object"&&Reflect.construct){try{Reflect.construct(M,[])}catch(A){var v=A}Reflect.construct(a,[],M)}else{try{M.call()}catch(A){v=A}a.call(M.prototype)}}else{try{throw Error()}catch(A){v=A}(M=a())&&typeof M.catch=="function"&&M.catch(function(){})}}catch(A){if(A&&v&&typeof A.stack=="string")return[A.stack,v.stack]}return[null,null]}};r.DetermineComponentFrameRoot.displayName="DetermineComponentFrameRoot";var s=Object.getOwnPropertyDescriptor(r.DetermineComponentFrameRoot,"name");s&&s.configurable&&Object.defineProperty(r.DetermineComponentFrameRoot,"name",{value:"DetermineComponentFrameRoot"});var c=r.DetermineComponentFrameRoot(),l=c[0],d=c[1];if(l&&d){var u=l.split(`
`),R=d.split(`
`);for(s=r=0;r<u.length&&!u[r].includes("DetermineComponentFrameRoot");)r++;for(;s<R.length&&!R[s].includes("DetermineComponentFrameRoot");)s++;if(r===u.length||s===R.length)for(r=u.length-1,s=R.length-1;1<=r&&0<=s&&u[r]!==R[s];)s--;for(;1<=r&&0<=s;r--,s--)if(u[r]!==R[s]){if(r!==1||s!==1)do if(r--,s--,0>s||u[r]!==R[s]){var G=`
`+u[r].replace(" at new "," at ");return a.displayName&&G.includes("<anonymous>")&&(G=G.replace("<anonymous>",a.displayName)),G}while(1<=r&&0<=s);break}}}finally{nr=!1,Error.prepareStackTrace=o}return(o=a?a.displayName||a.name:"")?On(o):""}function rf(a,t){switch(a.tag){case 26:case 27:case 5:return On(a.type);case 16:return On("Lazy");case 13:return a.child!==t&&t!==null?On("Suspense Fallback"):On("Suspense");case 19:return On("SuspenseList");case 0:case 15:return ar(a.type,!1);case 11:return ar(a.type.render,!1);case 1:return ar(a.type,!0);case 31:return On("Activity");default:return""}}function _c(a){try{var t="",o=null;do t+=rf(a,o),o=a,a=a.return;while(a);return t}catch(r){return`
Error generating stack: `+r.message+`
`+r.stack}}var tr=Object.prototype.hasOwnProperty,or=h.unstable_scheduleCallback,rr=h.unstable_cancelCallback,sf=h.unstable_shouldYield,cf=h.unstable_requestPaint,si=h.unstable_now,lf=h.unstable_getCurrentPriorityLevel,Nc=h.unstable_ImmediatePriority,Yc=h.unstable_UserBlockingPriority,Ht=h.unstable_NormalPriority,df=h.unstable_LowPriority,Lc=h.unstable_IdlePriority,mf=h.log,uf=h.unstable_setDisableYieldValue,wa=null,ci=null;function rn(a){if(typeof mf=="function"&&uf(a),ci&&typeof ci.setStrictMode=="function")try{ci.setStrictMode(wa,a)}catch{}}var li=Math.clz32?Math.clz32:hf,ff=Math.log,pf=Math.LN2;function hf(a){return a>>>=0,a===0?32:31-(ff(a)/pf|0)|0}var zt=256,wt=262144,kt=4194304;function Sn(a){var t=a&42;if(t!==0)return t;switch(a&-a){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:return 64;case 128:return 128;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:return a&261888;case 262144:case 524288:case 1048576:case 2097152:return a&3932160;case 4194304:case 8388608:case 16777216:case 33554432:return a&62914560;case 67108864:return 67108864;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 0;default:return a}}function _t(a,t,o){var r=a.pendingLanes;if(r===0)return 0;var s=0,c=a.suspendedLanes,l=a.pingedLanes;a=a.warmLanes;var d=r&134217727;return d!==0?(r=d&~c,r!==0?s=Sn(r):(l&=d,l!==0?s=Sn(l):o||(o=d&~a,o!==0&&(s=Sn(o))))):(d=r&~c,d!==0?s=Sn(d):l!==0?s=Sn(l):o||(o=r&~a,o!==0&&(s=Sn(o)))),s===0?0:t!==0&&t!==s&&(t&c)===0&&(c=s&-s,o=t&-t,c>=o||c===32&&(o&4194048)!==0)?t:s}function ka(a,t){return(a.pendingLanes&~(a.suspendedLanes&~a.pingedLanes)&t)===0}function yf(a,t){switch(a){case 1:case 2:case 4:case 8:case 64:return t+250;case 16:case 32:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;case 4194304:case 8388608:case 16777216:case 33554432:return-1;case 67108864:case 134217728:case 268435456:case 536870912:case 1073741824:return-1;default:return-1}}function Bc(){var a=kt;return kt<<=1,(kt&62914560)===0&&(kt=4194304),a}function sr(a){for(var t=[],o=0;31>o;o++)t.push(a);return t}function _a(a,t){a.pendingLanes|=t,t!==268435456&&(a.suspendedLanes=0,a.pingedLanes=0,a.warmLanes=0)}function bf(a,t,o,r,s,c){var l=a.pendingLanes;a.pendingLanes=o,a.suspendedLanes=0,a.pingedLanes=0,a.warmLanes=0,a.expiredLanes&=o,a.entangledLanes&=o,a.errorRecoveryDisabledLanes&=o,a.shellSuspendCounter=0;var d=a.entanglements,u=a.expirationTimes,R=a.hiddenUpdates;for(o=l&~o;0<o;){var G=31-li(o),M=1<<G;d[G]=0,u[G]=-1;var v=R[G];if(v!==null)for(R[G]=null,G=0;G<v.length;G++){var A=v[G];A!==null&&(A.lane&=-536870913)}o&=~M}r!==0&&Fc(a,r,0),c!==0&&s===0&&a.tag!==0&&(a.suspendedLanes|=c&~(l&~t))}function Fc(a,t,o){a.pendingLanes|=t,a.suspendedLanes&=~t;var r=31-li(t);a.entangledLanes|=t,a.entanglements[r]=a.entanglements[r]|1073741824|o&261930}function jc(a,t){var o=a.entangledLanes|=t;for(a=a.entanglements;o;){var r=31-li(o),s=1<<r;s&t|a[r]&t&&(a[r]|=t),o&=~s}}function Vc(a,t){var o=t&-t;return o=(o&42)!==0?1:cr(o),(o&(a.suspendedLanes|t))!==0?0:o}function cr(a){switch(a){case 2:a=1;break;case 8:a=4;break;case 32:a=16;break;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:a=128;break;case 268435456:a=134217728;break;default:a=0}return a}function lr(a){return a&=-a,2<a?8<a?(a&134217727)!==0?32:268435456:8:2}function Qc(){var a=H.p;return a!==0?a:(a=window.event,a===void 0?32:xu(a.type))}function Wc(a,t){var o=H.p;try{return H.p=a,t()}finally{H.p=o}}var sn=Math.random().toString(36).slice(2),Ye="__reactFiber$"+sn,Xe="__reactProps$"+sn,Xn="__reactContainer$"+sn,dr="__reactEvents$"+sn,gf="__reactListeners$"+sn,Df="__reactHandles$"+sn,qc="__reactResources$"+sn,Na="__reactMarker$"+sn;function mr(a){delete a[Ye],delete a[Xe],delete a[dr],delete a[gf],delete a[Df]}function Jn(a){var t=a[Ye];if(t)return t;for(var o=a.parentNode;o;){if(t=o[Xn]||o[Ye]){if(o=t.alternate,t.child!==null||o!==null&&o.child!==null)for(a=hu(a);a!==null;){if(o=a[Ye])return o;a=hu(a)}return t}a=o,o=a.parentNode}return null}function $n(a){if(a=a[Ye]||a[Xn]){var t=a.tag;if(t===5||t===6||t===13||t===31||t===26||t===27||t===3)return a}return null}function Ya(a){var t=a.tag;if(t===5||t===26||t===27||t===6)return a.stateNode;throw Error(f(33))}function ea(a){var t=a[qc];return t||(t=a[qc]={hoistableStyles:new Map,hoistableScripts:new Map}),t}function _e(a){a[Na]=!0}var Kc=new Set,Zc={};function Hn(a,t){ia(a,t),ia(a+"Capture",t)}function ia(a,t){for(Zc[a]=t,a=0;a<t.length;a++)Kc.add(t[a])}var Rf=RegExp("^[:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD][:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD\\-.0-9\\u00B7\\u0300-\\u036F\\u203F-\\u2040]*$"),Xc={},Jc={};function vf(a){return tr.call(Jc,a)?!0:tr.call(Xc,a)?!1:Rf.test(a)?Jc[a]=!0:(Xc[a]=!0,!1)}function Nt(a,t,o){if(vf(t))if(o===null)a.removeAttribute(t);else{switch(typeof o){case"undefined":case"function":case"symbol":a.removeAttribute(t);return;case"boolean":var r=t.toLowerCase().slice(0,5);if(r!=="data-"&&r!=="aria-"){a.removeAttribute(t);return}}a.setAttribute(t,""+o)}}function Yt(a,t,o){if(o===null)a.removeAttribute(t);else{switch(typeof o){case"undefined":case"function":case"symbol":case"boolean":a.removeAttribute(t);return}a.setAttribute(t,""+o)}}function Ni(a,t,o,r){if(r===null)a.removeAttribute(o);else{switch(typeof r){case"undefined":case"function":case"symbol":case"boolean":a.removeAttribute(o);return}a.setAttributeNS(t,o,""+r)}}function Di(a){switch(typeof a){case"bigint":case"boolean":case"number":case"string":case"undefined":return a;case"object":return a;default:return""}}function $c(a){var t=a.type;return(a=a.nodeName)&&a.toLowerCase()==="input"&&(t==="checkbox"||t==="radio")}function Af(a,t,o){var r=Object.getOwnPropertyDescriptor(a.constructor.prototype,t);if(!a.hasOwnProperty(t)&&typeof r<"u"&&typeof r.get=="function"&&typeof r.set=="function"){var s=r.get,c=r.set;return Object.defineProperty(a,t,{configurable:!0,get:function(){return s.call(this)},set:function(l){o=""+l,c.call(this,l)}}),Object.defineProperty(a,t,{enumerable:r.enumerable}),{getValue:function(){return o},setValue:function(l){o=""+l},stopTracking:function(){a._valueTracker=null,delete a[t]}}}}function ur(a){if(!a._valueTracker){var t=$c(a)?"checked":"value";a._valueTracker=Af(a,t,""+a[t])}}function el(a){if(!a)return!1;var t=a._valueTracker;if(!t)return!0;var o=t.getValue(),r="";return a&&(r=$c(a)?a.checked?"true":"false":a.value),a=r,a!==o?(t.setValue(a),!0):!1}function Lt(a){if(a=a||(typeof document<"u"?document:void 0),typeof a>"u")return null;try{return a.activeElement||a.body}catch{return a.body}}var Cf=/[\n"\\]/g;function Ri(a){return a.replace(Cf,function(t){return"\\"+t.charCodeAt(0).toString(16)+" "})}function fr(a,t,o,r,s,c,l,d){a.name="",l!=null&&typeof l!="function"&&typeof l!="symbol"&&typeof l!="boolean"?a.type=l:a.removeAttribute("type"),t!=null?l==="number"?(t===0&&a.value===""||a.value!=t)&&(a.value=""+Di(t)):a.value!==""+Di(t)&&(a.value=""+Di(t)):l!=="submit"&&l!=="reset"||a.removeAttribute("value"),t!=null?pr(a,l,Di(t)):o!=null?pr(a,l,Di(o)):r!=null&&a.removeAttribute("value"),s==null&&c!=null&&(a.defaultChecked=!!c),s!=null&&(a.checked=s&&typeof s!="function"&&typeof s!="symbol"),d!=null&&typeof d!="function"&&typeof d!="symbol"&&typeof d!="boolean"?a.name=""+Di(d):a.removeAttribute("name")}function il(a,t,o,r,s,c,l,d){if(c!=null&&typeof c!="function"&&typeof c!="symbol"&&typeof c!="boolean"&&(a.type=c),t!=null||o!=null){if(!(c!=="submit"&&c!=="reset"||t!=null)){ur(a);return}o=o!=null?""+Di(o):"",t=t!=null?""+Di(t):o,d||t===a.value||(a.value=t),a.defaultValue=t}r=r??s,r=typeof r!="function"&&typeof r!="symbol"&&!!r,a.checked=d?a.checked:!!r,a.defaultChecked=!!r,l!=null&&typeof l!="function"&&typeof l!="symbol"&&typeof l!="boolean"&&(a.name=l),ur(a)}function pr(a,t,o){t==="number"&&Lt(a.ownerDocument)===a||a.defaultValue===""+o||(a.defaultValue=""+o)}function na(a,t,o,r){if(a=a.options,t){t={};for(var s=0;s<o.length;s++)t["$"+o[s]]=!0;for(o=0;o<a.length;o++)s=t.hasOwnProperty("$"+a[o].value),a[o].selected!==s&&(a[o].selected=s),s&&r&&(a[o].defaultSelected=!0)}else{for(o=""+Di(o),t=null,s=0;s<a.length;s++){if(a[s].value===o){a[s].selected=!0,r&&(a[s].defaultSelected=!0);return}t!==null||a[s].disabled||(t=a[s])}t!==null&&(t.selected=!0)}}function nl(a,t,o){if(t!=null&&(t=""+Di(t),t!==a.value&&(a.value=t),o==null)){a.defaultValue!==t&&(a.defaultValue=t);return}a.defaultValue=o!=null?""+Di(o):""}function al(a,t,o,r){if(t==null){if(r!=null){if(o!=null)throw Error(f(92));if(oi(r)){if(1<r.length)throw Error(f(93));r=r[0]}o=r}o==null&&(o=""),t=o}o=Di(t),a.defaultValue=o,r=a.textContent,r===o&&r!==""&&r!==null&&(a.value=r),ur(a)}function aa(a,t){if(t){var o=a.firstChild;if(o&&o===a.lastChild&&o.nodeType===3){o.nodeValue=t;return}}a.textContent=t}var Gf=new Set("animationIterationCount aspectRatio borderImageOutset borderImageSlice borderImageWidth boxFlex boxFlexGroup boxOrdinalGroup columnCount columns flex flexGrow flexPositive flexShrink flexNegative flexOrder gridArea gridRow gridRowEnd gridRowSpan gridRowStart gridColumn gridColumnEnd gridColumnSpan gridColumnStart fontWeight lineClamp lineHeight opacity order orphans scale tabSize widows zIndex zoom fillOpacity floodOpacity stopOpacity strokeDasharray strokeDashoffset strokeMiterlimit strokeOpacity strokeWidth MozAnimationIterationCount MozBoxFlex MozBoxFlexGroup MozLineClamp msAnimationIterationCount msFlex msZoom msFlexGrow msFlexNegative msFlexOrder msFlexPositive msFlexShrink msGridColumn msGridColumnSpan msGridRow msGridRowSpan WebkitAnimationIterationCount WebkitBoxFlex WebKitBoxFlexGroup WebkitBoxOrdinalGroup WebkitColumnCount WebkitColumns WebkitFlex WebkitFlexGrow WebkitFlexPositive WebkitFlexShrink WebkitLineClamp".split(" "));function tl(a,t,o){var r=t.indexOf("--")===0;o==null||typeof o=="boolean"||o===""?r?a.setProperty(t,""):t==="float"?a.cssFloat="":a[t]="":r?a.setProperty(t,o):typeof o!="number"||o===0||Gf.has(t)?t==="float"?a.cssFloat=o:a[t]=(""+o).trim():a[t]=o+"px"}function ol(a,t,o){if(t!=null&&typeof t!="object")throw Error(f(62));if(a=a.style,o!=null){for(var r in o)!o.hasOwnProperty(r)||t!=null&&t.hasOwnProperty(r)||(r.indexOf("--")===0?a.setProperty(r,""):r==="float"?a.cssFloat="":a[r]="");for(var s in t)r=t[s],t.hasOwnProperty(s)&&o[s]!==r&&tl(a,s,r)}else for(var c in t)t.hasOwnProperty(c)&&tl(a,c,t[c])}function hr(a){if(a.indexOf("-")===-1)return!1;switch(a){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var Uf=new Map([["acceptCharset","accept-charset"],["htmlFor","for"],["httpEquiv","http-equiv"],["crossOrigin","crossorigin"],["accentHeight","accent-height"],["alignmentBaseline","alignment-baseline"],["arabicForm","arabic-form"],["baselineShift","baseline-shift"],["capHeight","cap-height"],["clipPath","clip-path"],["clipRule","clip-rule"],["colorInterpolation","color-interpolation"],["colorInterpolationFilters","color-interpolation-filters"],["colorProfile","color-profile"],["colorRendering","color-rendering"],["dominantBaseline","dominant-baseline"],["enableBackground","enable-background"],["fillOpacity","fill-opacity"],["fillRule","fill-rule"],["floodColor","flood-color"],["floodOpacity","flood-opacity"],["fontFamily","font-family"],["fontSize","font-size"],["fontSizeAdjust","font-size-adjust"],["fontStretch","font-stretch"],["fontStyle","font-style"],["fontVariant","font-variant"],["fontWeight","font-weight"],["glyphName","glyph-name"],["glyphOrientationHorizontal","glyph-orientation-horizontal"],["glyphOrientationVertical","glyph-orientation-vertical"],["horizAdvX","horiz-adv-x"],["horizOriginX","horiz-origin-x"],["imageRendering","image-rendering"],["letterSpacing","letter-spacing"],["lightingColor","lighting-color"],["markerEnd","marker-end"],["markerMid","marker-mid"],["markerStart","marker-start"],["overlinePosition","overline-position"],["overlineThickness","overline-thickness"],["paintOrder","paint-order"],["panose-1","panose-1"],["pointerEvents","pointer-events"],["renderingIntent","rendering-intent"],["shapeRendering","shape-rendering"],["stopColor","stop-color"],["stopOpacity","stop-opacity"],["strikethroughPosition","strikethrough-position"],["strikethroughThickness","strikethrough-thickness"],["strokeDasharray","stroke-dasharray"],["strokeDashoffset","stroke-dashoffset"],["strokeLinecap","stroke-linecap"],["strokeLinejoin","stroke-linejoin"],["strokeMiterlimit","stroke-miterlimit"],["strokeOpacity","stroke-opacity"],["strokeWidth","stroke-width"],["textAnchor","text-anchor"],["textDecoration","text-decoration"],["textRendering","text-rendering"],["transformOrigin","transform-origin"],["underlinePosition","underline-position"],["underlineThickness","underline-thickness"],["unicodeBidi","unicode-bidi"],["unicodeRange","unicode-range"],["unitsPerEm","units-per-em"],["vAlphabetic","v-alphabetic"],["vHanging","v-hanging"],["vIdeographic","v-ideographic"],["vMathematical","v-mathematical"],["vectorEffect","vector-effect"],["vertAdvY","vert-adv-y"],["vertOriginX","vert-origin-x"],["vertOriginY","vert-origin-y"],["wordSpacing","word-spacing"],["writingMode","writing-mode"],["xmlnsXlink","xmlns:xlink"],["xHeight","x-height"]]),If=/^[\u0000-\u001F ]*j[\r\n\t]*a[\r\n\t]*v[\r\n\t]*a[\r\n\t]*s[\r\n\t]*c[\r\n\t]*r[\r\n\t]*i[\r\n\t]*p[\r\n\t]*t[\r\n\t]*:/i;function Bt(a){return If.test(""+a)?"javascript:throw new Error('React has blocked a javascript: URL as a security precaution.')":a}function Yi(){}var yr=null;function br(a){return a=a.target||a.srcElement||window,a.correspondingUseElement&&(a=a.correspondingUseElement),a.nodeType===3?a.parentNode:a}var ta=null,oa=null;function rl(a){var t=$n(a);if(t&&(a=t.stateNode)){var o=a[Xe]||null;e:switch(a=t.stateNode,t.type){case"input":if(fr(a,o.value,o.defaultValue,o.defaultValue,o.checked,o.defaultChecked,o.type,o.name),t=o.name,o.type==="radio"&&t!=null){for(o=a;o.parentNode;)o=o.parentNode;for(o=o.querySelectorAll('input[name="'+Ri(""+t)+'"][type="radio"]'),t=0;t<o.length;t++){var r=o[t];if(r!==a&&r.form===a.form){var s=r[Xe]||null;if(!s)throw Error(f(90));fr(r,s.value,s.defaultValue,s.defaultValue,s.checked,s.defaultChecked,s.type,s.name)}}for(t=0;t<o.length;t++)r=o[t],r.form===a.form&&el(r)}break e;case"textarea":nl(a,o.value,o.defaultValue);break e;case"select":t=o.value,t!=null&&na(a,!!o.multiple,t,!1)}}}var gr=!1;function sl(a,t,o){if(gr)return a(t,o);gr=!0;try{var r=a(t);return r}finally{if(gr=!1,(ta!==null||oa!==null)&&(To(),ta&&(t=ta,a=oa,oa=ta=null,rl(t),a)))for(t=0;t<a.length;t++)rl(a[t])}}function La(a,t){var o=a.stateNode;if(o===null)return null;var r=o[Xe]||null;if(r===null)return null;o=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(a=a.type,r=!(a==="button"||a==="input"||a==="select"||a==="textarea")),a=!r;break e;default:a=!1}if(a)return null;if(o&&typeof o!="function")throw Error(f(231,t,typeof o));return o}var Li=!(typeof window>"u"||typeof window.document>"u"||typeof window.document.createElement>"u"),Dr=!1;if(Li)try{var Ba={};Object.defineProperty(Ba,"passive",{get:function(){Dr=!0}}),window.addEventListener("test",Ba,Ba),window.removeEventListener("test",Ba,Ba)}catch{Dr=!1}var cn=null,Rr=null,Ft=null;function cl(){if(Ft)return Ft;var a,t=Rr,o=t.length,r,s="value"in cn?cn.value:cn.textContent,c=s.length;for(a=0;a<o&&t[a]===s[a];a++);var l=o-a;for(r=1;r<=l&&t[o-r]===s[c-r];r++);return Ft=s.slice(a,1<r?1-r:void 0)}function jt(a){var t=a.keyCode;return"charCode"in a?(a=a.charCode,a===0&&t===13&&(a=13)):a=t,a===10&&(a=13),32<=a||a===13?a:0}function Vt(){return!0}function ll(){return!1}function Je(a){function t(o,r,s,c,l){this._reactName=o,this._targetInst=s,this.type=r,this.nativeEvent=c,this.target=l,this.currentTarget=null;for(var d in a)a.hasOwnProperty(d)&&(o=a[d],this[d]=o?o(c):c[d]);return this.isDefaultPrevented=(c.defaultPrevented!=null?c.defaultPrevented:c.returnValue===!1)?Vt:ll,this.isPropagationStopped=ll,this}return _(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var o=this.nativeEvent;o&&(o.preventDefault?o.preventDefault():typeof o.returnValue!="unknown"&&(o.returnValue=!1),this.isDefaultPrevented=Vt)},stopPropagation:function(){var o=this.nativeEvent;o&&(o.stopPropagation?o.stopPropagation():typeof o.cancelBubble!="unknown"&&(o.cancelBubble=!0),this.isPropagationStopped=Vt)},persist:function(){},isPersistent:Vt}),t}var zn={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(a){return a.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},Qt=Je(zn),Fa=_({},zn,{view:0,detail:0}),Ef=Je(Fa),vr,Ar,ja,Wt=_({},Fa,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Gr,button:0,buttons:0,relatedTarget:function(a){return a.relatedTarget===void 0?a.fromElement===a.srcElement?a.toElement:a.fromElement:a.relatedTarget},movementX:function(a){return"movementX"in a?a.movementX:(a!==ja&&(ja&&a.type==="mousemove"?(vr=a.screenX-ja.screenX,Ar=a.screenY-ja.screenY):Ar=vr=0,ja=a),vr)},movementY:function(a){return"movementY"in a?a.movementY:Ar}}),dl=Je(Wt),Mf=_({},Wt,{dataTransfer:0}),Pf=Je(Mf),Tf=_({},Fa,{relatedTarget:0}),Cr=Je(Tf),xf=_({},zn,{animationName:0,elapsedTime:0,pseudoElement:0}),Of=Je(xf),Sf=_({},zn,{clipboardData:function(a){return"clipboardData"in a?a.clipboardData:window.clipboardData}}),Hf=Je(Sf),zf=_({},zn,{data:0}),ml=Je(zf),wf={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},kf={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},_f={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Nf(a){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(a):(a=_f[a])?!!t[a]:!1}function Gr(){return Nf}var Yf=_({},Fa,{key:function(a){if(a.key){var t=wf[a.key]||a.key;if(t!=="Unidentified")return t}return a.type==="keypress"?(a=jt(a),a===13?"Enter":String.fromCharCode(a)):a.type==="keydown"||a.type==="keyup"?kf[a.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Gr,charCode:function(a){return a.type==="keypress"?jt(a):0},keyCode:function(a){return a.type==="keydown"||a.type==="keyup"?a.keyCode:0},which:function(a){return a.type==="keypress"?jt(a):a.type==="keydown"||a.type==="keyup"?a.keyCode:0}}),Lf=Je(Yf),Bf=_({},Wt,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),ul=Je(Bf),Ff=_({},Fa,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Gr}),jf=Je(Ff),Vf=_({},zn,{propertyName:0,elapsedTime:0,pseudoElement:0}),Qf=Je(Vf),Wf=_({},Wt,{deltaX:function(a){return"deltaX"in a?a.deltaX:"wheelDeltaX"in a?-a.wheelDeltaX:0},deltaY:function(a){return"deltaY"in a?a.deltaY:"wheelDeltaY"in a?-a.wheelDeltaY:"wheelDelta"in a?-a.wheelDelta:0},deltaZ:0,deltaMode:0}),qf=Je(Wf),Kf=_({},zn,{newState:0,oldState:0}),Zf=Je(Kf),Xf=[9,13,27,32],Ur=Li&&"CompositionEvent"in window,Va=null;Li&&"documentMode"in document&&(Va=document.documentMode);var Jf=Li&&"TextEvent"in window&&!Va,fl=Li&&(!Ur||Va&&8<Va&&11>=Va),pl=" ",hl=!1;function yl(a,t){switch(a){case"keyup":return Xf.indexOf(t.keyCode)!==-1;case"keydown":return t.keyCode!==229;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function bl(a){return a=a.detail,typeof a=="object"&&"data"in a?a.data:null}var ra=!1;function $f(a,t){switch(a){case"compositionend":return bl(t);case"keypress":return t.which!==32?null:(hl=!0,pl);case"textInput":return a=t.data,a===pl&&hl?null:a;default:return null}}function ep(a,t){if(ra)return a==="compositionend"||!Ur&&yl(a,t)?(a=cl(),Ft=Rr=cn=null,ra=!1,a):null;switch(a){case"paste":return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return fl&&t.locale!=="ko"?null:t.data;default:return null}}var ip={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function gl(a){var t=a&&a.nodeName&&a.nodeName.toLowerCase();return t==="input"?!!ip[a.type]:t==="textarea"}function Dl(a,t,o,r){ta?oa?oa.push(r):oa=[r]:ta=r,t=ko(t,"onChange"),0<t.length&&(o=new Qt("onChange","change",null,o,r),a.push({event:o,listeners:t}))}var Qa=null,Wa=null;function np(a){iu(a,0)}function qt(a){var t=Ya(a);if(el(t))return a}function Rl(a,t){if(a==="change")return t}var vl=!1;if(Li){var Ir;if(Li){var Er="oninput"in document;if(!Er){var Al=document.createElement("div");Al.setAttribute("oninput","return;"),Er=typeof Al.oninput=="function"}Ir=Er}else Ir=!1;vl=Ir&&(!document.documentMode||9<document.documentMode)}function Cl(){Qa&&(Qa.detachEvent("onpropertychange",Gl),Wa=Qa=null)}function Gl(a){if(a.propertyName==="value"&&qt(Wa)){var t=[];Dl(t,Wa,a,br(a)),sl(np,t)}}function ap(a,t,o){a==="focusin"?(Cl(),Qa=t,Wa=o,Qa.attachEvent("onpropertychange",Gl)):a==="focusout"&&Cl()}function tp(a){if(a==="selectionchange"||a==="keyup"||a==="keydown")return qt(Wa)}function op(a,t){if(a==="click")return qt(t)}function rp(a,t){if(a==="input"||a==="change")return qt(t)}function sp(a,t){return a===t&&(a!==0||1/a===1/t)||a!==a&&t!==t}var di=typeof Object.is=="function"?Object.is:sp;function qa(a,t){if(di(a,t))return!0;if(typeof a!="object"||a===null||typeof t!="object"||t===null)return!1;var o=Object.keys(a),r=Object.keys(t);if(o.length!==r.length)return!1;for(r=0;r<o.length;r++){var s=o[r];if(!tr.call(t,s)||!di(a[s],t[s]))return!1}return!0}function Ul(a){for(;a&&a.firstChild;)a=a.firstChild;return a}function Il(a,t){var o=Ul(a);a=0;for(var r;o;){if(o.nodeType===3){if(r=a+o.textContent.length,a<=t&&r>=t)return{node:o,offset:t-a};a=r}e:{for(;o;){if(o.nextSibling){o=o.nextSibling;break e}o=o.parentNode}o=void 0}o=Ul(o)}}function El(a,t){return a&&t?a===t?!0:a&&a.nodeType===3?!1:t&&t.nodeType===3?El(a,t.parentNode):"contains"in a?a.contains(t):a.compareDocumentPosition?!!(a.compareDocumentPosition(t)&16):!1:!1}function Ml(a){a=a!=null&&a.ownerDocument!=null&&a.ownerDocument.defaultView!=null?a.ownerDocument.defaultView:window;for(var t=Lt(a.document);t instanceof a.HTMLIFrameElement;){try{var o=typeof t.contentWindow.location.href=="string"}catch{o=!1}if(o)a=t.contentWindow;else break;t=Lt(a.document)}return t}function Mr(a){var t=a&&a.nodeName&&a.nodeName.toLowerCase();return t&&(t==="input"&&(a.type==="text"||a.type==="search"||a.type==="tel"||a.type==="url"||a.type==="password")||t==="textarea"||a.contentEditable==="true")}var cp=Li&&"documentMode"in document&&11>=document.documentMode,sa=null,Pr=null,Ka=null,Tr=!1;function Pl(a,t,o){var r=o.window===o?o.document:o.nodeType===9?o:o.ownerDocument;Tr||sa==null||sa!==Lt(r)||(r=sa,"selectionStart"in r&&Mr(r)?r={start:r.selectionStart,end:r.selectionEnd}:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection(),r={anchorNode:r.anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset}),Ka&&qa(Ka,r)||(Ka=r,r=ko(Pr,"onSelect"),0<r.length&&(t=new Qt("onSelect","select",null,t,o),a.push({event:t,listeners:r}),t.target=sa)))}function wn(a,t){var o={};return o[a.toLowerCase()]=t.toLowerCase(),o["Webkit"+a]="webkit"+t,o["Moz"+a]="moz"+t,o}var ca={animationend:wn("Animation","AnimationEnd"),animationiteration:wn("Animation","AnimationIteration"),animationstart:wn("Animation","AnimationStart"),transitionrun:wn("Transition","TransitionRun"),transitionstart:wn("Transition","TransitionStart"),transitioncancel:wn("Transition","TransitionCancel"),transitionend:wn("Transition","TransitionEnd")},xr={},Tl={};Li&&(Tl=document.createElement("div").style,"AnimationEvent"in window||(delete ca.animationend.animation,delete ca.animationiteration.animation,delete ca.animationstart.animation),"TransitionEvent"in window||delete ca.transitionend.transition);function kn(a){if(xr[a])return xr[a];if(!ca[a])return a;var t=ca[a],o;for(o in t)if(t.hasOwnProperty(o)&&o in Tl)return xr[a]=t[o];return a}var xl=kn("animationend"),Ol=kn("animationiteration"),Sl=kn("animationstart"),lp=kn("transitionrun"),dp=kn("transitionstart"),mp=kn("transitioncancel"),Hl=kn("transitionend"),zl=new Map,Or="abort auxClick beforeToggle cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");Or.push("scrollEnd");function Ti(a,t){zl.set(a,t),Hn(t,[a])}var Kt=typeof reportError=="function"?reportError:function(a){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var t=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof a=="object"&&a!==null&&typeof a.message=="string"?String(a.message):String(a),error:a});if(!window.dispatchEvent(t))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",a);return}console.error(a)},vi=[],la=0,Sr=0;function Zt(){for(var a=la,t=Sr=la=0;t<a;){var o=vi[t];vi[t++]=null;var r=vi[t];vi[t++]=null;var s=vi[t];vi[t++]=null;var c=vi[t];if(vi[t++]=null,r!==null&&s!==null){var l=r.pending;l===null?s.next=s:(s.next=l.next,l.next=s),r.pending=s}c!==0&&wl(o,s,c)}}function Xt(a,t,o,r){vi[la++]=a,vi[la++]=t,vi[la++]=o,vi[la++]=r,Sr|=r,a.lanes|=r,a=a.alternate,a!==null&&(a.lanes|=r)}function Hr(a,t,o,r){return Xt(a,t,o,r),Jt(a)}function _n(a,t){return Xt(a,null,null,t),Jt(a)}function wl(a,t,o){a.lanes|=o;var r=a.alternate;r!==null&&(r.lanes|=o);for(var s=!1,c=a.return;c!==null;)c.childLanes|=o,r=c.alternate,r!==null&&(r.childLanes|=o),c.tag===22&&(a=c.stateNode,a===null||a._visibility&1||(s=!0)),a=c,c=c.return;return a.tag===3?(c=a.stateNode,s&&t!==null&&(s=31-li(o),a=c.hiddenUpdates,r=a[s],r===null?a[s]=[t]:r.push(t),t.lane=o|536870912),c):null}function Jt(a){if(50<bt)throw bt=0,Fs=null,Error(f(185));for(var t=a.return;t!==null;)a=t,t=a.return;return a.tag===3?a.stateNode:null}var da={};function up(a,t,o,r){this.tag=a,this.key=o,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.refCleanup=this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function mi(a,t,o,r){return new up(a,t,o,r)}function zr(a){return a=a.prototype,!(!a||!a.isReactComponent)}function Bi(a,t){var o=a.alternate;return o===null?(o=mi(a.tag,t,a.key,a.mode),o.elementType=a.elementType,o.type=a.type,o.stateNode=a.stateNode,o.alternate=a,a.alternate=o):(o.pendingProps=t,o.type=a.type,o.flags=0,o.subtreeFlags=0,o.deletions=null),o.flags=a.flags&65011712,o.childLanes=a.childLanes,o.lanes=a.lanes,o.child=a.child,o.memoizedProps=a.memoizedProps,o.memoizedState=a.memoizedState,o.updateQueue=a.updateQueue,t=a.dependencies,o.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext},o.sibling=a.sibling,o.index=a.index,o.ref=a.ref,o.refCleanup=a.refCleanup,o}function kl(a,t){a.flags&=65011714;var o=a.alternate;return o===null?(a.childLanes=0,a.lanes=t,a.child=null,a.subtreeFlags=0,a.memoizedProps=null,a.memoizedState=null,a.updateQueue=null,a.dependencies=null,a.stateNode=null):(a.childLanes=o.childLanes,a.lanes=o.lanes,a.child=o.child,a.subtreeFlags=0,a.deletions=null,a.memoizedProps=o.memoizedProps,a.memoizedState=o.memoizedState,a.updateQueue=o.updateQueue,a.type=o.type,t=o.dependencies,a.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext}),a}function $t(a,t,o,r,s,c){var l=0;if(r=a,typeof a=="function")zr(a)&&(l=1);else if(typeof a=="string")l=bh(a,o,T.current)?26:a==="html"||a==="head"||a==="body"?27:5;else e:switch(a){case bi:return a=mi(31,o,t,s),a.elementType=bi,a.lanes=c,a;case Ie:return Nn(o.children,s,c,t);case ke:l=8,s|=24;break;case Pe:return a=mi(12,o,t,s|2),a.elementType=Pe,a.lanes=c,a;case ti:return a=mi(13,o,t,s),a.elementType=ti,a.lanes=c,a;case de:return a=mi(19,o,t,s),a.elementType=de,a.lanes=c,a;default:if(typeof a=="object"&&a!==null)switch(a.$$typeof){case Q:l=10;break e;case qe:l=9;break e;case se:l=11;break e;case F:l=14;break e;case Ve:l=16,r=null;break e}l=29,o=Error(f(130,a===null?"null":typeof a,"")),r=null}return t=mi(l,o,t,s),t.elementType=a,t.type=r,t.lanes=c,t}function Nn(a,t,o,r){return a=mi(7,a,r,t),a.lanes=o,a}function wr(a,t,o){return a=mi(6,a,null,t),a.lanes=o,a}function _l(a){var t=mi(18,null,null,0);return t.stateNode=a,t}function kr(a,t,o){return t=mi(4,a.children!==null?a.children:[],a.key,t),t.lanes=o,t.stateNode={containerInfo:a.containerInfo,pendingChildren:null,implementation:a.implementation},t}var Nl=new WeakMap;function Ai(a,t){if(typeof a=="object"&&a!==null){var o=Nl.get(a);return o!==void 0?o:(t={value:a,source:t,stack:_c(t)},Nl.set(a,t),t)}return{value:a,source:t,stack:_c(t)}}var ma=[],ua=0,eo=null,Za=0,Ci=[],Gi=0,ln=null,Si=1,Hi="";function Fi(a,t){ma[ua++]=Za,ma[ua++]=eo,eo=a,Za=t}function Yl(a,t,o){Ci[Gi++]=Si,Ci[Gi++]=Hi,Ci[Gi++]=ln,ln=a;var r=Si;a=Hi;var s=32-li(r)-1;r&=~(1<<s),o+=1;var c=32-li(t)+s;if(30<c){var l=s-s%5;c=(r&(1<<l)-1).toString(32),r>>=l,s-=l,Si=1<<32-li(t)+s|o<<s|r,Hi=c+a}else Si=1<<c|o<<s|r,Hi=a}function _r(a){a.return!==null&&(Fi(a,1),Yl(a,1,0))}function Nr(a){for(;a===eo;)eo=ma[--ua],ma[ua]=null,Za=ma[--ua],ma[ua]=null;for(;a===ln;)ln=Ci[--Gi],Ci[Gi]=null,Hi=Ci[--Gi],Ci[Gi]=null,Si=Ci[--Gi],Ci[Gi]=null}function Ll(a,t){Ci[Gi++]=Si,Ci[Gi++]=Hi,Ci[Gi++]=ln,Si=t.id,Hi=t.overflow,ln=a}var Le=null,Ce=null,oe=!1,dn=null,Ui=!1,Yr=Error(f(519));function mn(a){var t=Error(f(418,1<arguments.length&&arguments[1]!==void 0&&arguments[1]?"text":"HTML",""));throw Xa(Ai(t,a)),Yr}function Bl(a){var t=a.stateNode,o=a.type,r=a.memoizedProps;switch(t[Ye]=a,t[Xe]=r,o){case"dialog":ne("cancel",t),ne("close",t);break;case"iframe":case"object":case"embed":ne("load",t);break;case"video":case"audio":for(o=0;o<Dt.length;o++)ne(Dt[o],t);break;case"source":ne("error",t);break;case"img":case"image":case"link":ne("error",t),ne("load",t);break;case"details":ne("toggle",t);break;case"input":ne("invalid",t),il(t,r.value,r.defaultValue,r.checked,r.defaultChecked,r.type,r.name,!0);break;case"select":ne("invalid",t);break;case"textarea":ne("invalid",t),al(t,r.value,r.defaultValue,r.children)}o=r.children,typeof o!="string"&&typeof o!="number"&&typeof o!="bigint"||t.textContent===""+o||r.suppressHydrationWarning===!0||ou(t.textContent,o)?(r.popover!=null&&(ne("beforetoggle",t),ne("toggle",t)),r.onScroll!=null&&ne("scroll",t),r.onScrollEnd!=null&&ne("scrollend",t),r.onClick!=null&&(t.onclick=Yi),t=!0):t=!1,t||mn(a,!0)}function Fl(a){for(Le=a.return;Le;)switch(Le.tag){case 5:case 31:case 13:Ui=!1;return;case 27:case 3:Ui=!0;return;default:Le=Le.return}}function fa(a){if(a!==Le)return!1;if(!oe)return Fl(a),oe=!0,!1;var t=a.tag,o;if((o=t!==3&&t!==27)&&((o=t===5)&&(o=a.type,o=!(o!=="form"&&o!=="button")||tc(a.type,a.memoizedProps)),o=!o),o&&Ce&&mn(a),Fl(a),t===13){if(a=a.memoizedState,a=a!==null?a.dehydrated:null,!a)throw Error(f(317));Ce=pu(a)}else if(t===31){if(a=a.memoizedState,a=a!==null?a.dehydrated:null,!a)throw Error(f(317));Ce=pu(a)}else t===27?(t=Ce,Un(a.type)?(a=lc,lc=null,Ce=a):Ce=t):Ce=Le?Ei(a.stateNode.nextSibling):null;return!0}function Yn(){Ce=Le=null,oe=!1}function Lr(){var a=dn;return a!==null&&(ni===null?ni=a:ni.push.apply(ni,a),dn=null),a}function Xa(a){dn===null?dn=[a]:dn.push(a)}var Br=y(null),Ln=null,ji=null;function un(a,t,o){U(Br,t._currentValue),t._currentValue=o}function Vi(a){a._currentValue=Br.current,g(Br)}function Fr(a,t,o){for(;a!==null;){var r=a.alternate;if((a.childLanes&t)!==t?(a.childLanes|=t,r!==null&&(r.childLanes|=t)):r!==null&&(r.childLanes&t)!==t&&(r.childLanes|=t),a===o)break;a=a.return}}function jr(a,t,o,r){var s=a.child;for(s!==null&&(s.return=a);s!==null;){var c=s.dependencies;if(c!==null){var l=s.child;c=c.firstContext;e:for(;c!==null;){var d=c;c=s;for(var u=0;u<t.length;u++)if(d.context===t[u]){c.lanes|=o,d=c.alternate,d!==null&&(d.lanes|=o),Fr(c.return,o,a),r||(l=null);break e}c=d.next}}else if(s.tag===18){if(l=s.return,l===null)throw Error(f(341));l.lanes|=o,c=l.alternate,c!==null&&(c.lanes|=o),Fr(l,o,a),l=null}else l=s.child;if(l!==null)l.return=s;else for(l=s;l!==null;){if(l===a){l=null;break}if(s=l.sibling,s!==null){s.return=l.return,l=s;break}l=l.return}s=l}}function pa(a,t,o,r){a=null;for(var s=t,c=!1;s!==null;){if(!c){if((s.flags&524288)!==0)c=!0;else if((s.flags&262144)!==0)break}if(s.tag===10){var l=s.alternate;if(l===null)throw Error(f(387));if(l=l.memoizedProps,l!==null){var d=s.type;di(s.pendingProps.value,l.value)||(a!==null?a.push(d):a=[d])}}else if(s===J.current){if(l=s.alternate,l===null)throw Error(f(387));l.memoizedState.memoizedState!==s.memoizedState.memoizedState&&(a!==null?a.push(Gt):a=[Gt])}s=s.return}a!==null&&jr(t,a,o,r),t.flags|=262144}function io(a){for(a=a.firstContext;a!==null;){if(!di(a.context._currentValue,a.memoizedValue))return!0;a=a.next}return!1}function Bn(a){Ln=a,ji=null,a=a.dependencies,a!==null&&(a.firstContext=null)}function Be(a){return jl(Ln,a)}function no(a,t){return Ln===null&&Bn(a),jl(a,t)}function jl(a,t){var o=t._currentValue;if(t={context:t,memoizedValue:o,next:null},ji===null){if(a===null)throw Error(f(308));ji=t,a.dependencies={lanes:0,firstContext:t},a.flags|=524288}else ji=ji.next=t;return o}var fp=typeof AbortController<"u"?AbortController:function(){var a=[],t=this.signal={aborted:!1,addEventListener:function(o,r){a.push(r)}};this.abort=function(){t.aborted=!0,a.forEach(function(o){return o()})}},pp=h.unstable_scheduleCallback,hp=h.unstable_NormalPriority,Oe={$$typeof:Q,Consumer:null,Provider:null,_currentValue:null,_currentValue2:null,_threadCount:0};function Vr(){return{controller:new fp,data:new Map,refCount:0}}function Ja(a){a.refCount--,a.refCount===0&&pp(hp,function(){a.controller.abort()})}var $a=null,Qr=0,ha=0,ya=null;function yp(a,t){if($a===null){var o=$a=[];Qr=0,ha=Ks(),ya={status:"pending",value:void 0,then:function(r){o.push(r)}}}return Qr++,t.then(Vl,Vl),t}function Vl(){if(--Qr===0&&$a!==null){ya!==null&&(ya.status="fulfilled");var a=$a;$a=null,ha=0,ya=null;for(var t=0;t<a.length;t++)(0,a[t])()}}function bp(a,t){var o=[],r={status:"pending",value:null,reason:null,then:function(s){o.push(s)}};return a.then(function(){r.status="fulfilled",r.value=t;for(var s=0;s<o.length;s++)(0,o[s])(t)},function(s){for(r.status="rejected",r.reason=s,s=0;s<o.length;s++)(0,o[s])(void 0)}),r}var Ql=C.S;C.S=function(a,t){Pm=si(),typeof t=="object"&&t!==null&&typeof t.then=="function"&&yp(a,t),Ql!==null&&Ql(a,t)};var Fn=y(null);function Wr(){var a=Fn.current;return a!==null?a:ve.pooledCache}function ao(a,t){t===null?U(Fn,Fn.current):U(Fn,t.pool)}function Wl(){var a=Wr();return a===null?null:{parent:Oe._currentValue,pool:a}}var ba=Error(f(460)),qr=Error(f(474)),to=Error(f(542)),oo={then:function(){}};function ql(a){return a=a.status,a==="fulfilled"||a==="rejected"}function Kl(a,t,o){switch(o=a[o],o===void 0?a.push(t):o!==t&&(t.then(Yi,Yi),t=o),t.status){case"fulfilled":return t.value;case"rejected":throw a=t.reason,Xl(a),a;default:if(typeof t.status=="string")t.then(Yi,Yi);else{if(a=ve,a!==null&&100<a.shellSuspendCounter)throw Error(f(482));a=t,a.status="pending",a.then(function(r){if(t.status==="pending"){var s=t;s.status="fulfilled",s.value=r}},function(r){if(t.status==="pending"){var s=t;s.status="rejected",s.reason=r}})}switch(t.status){case"fulfilled":return t.value;case"rejected":throw a=t.reason,Xl(a),a}throw Vn=t,ba}}function jn(a){try{var t=a._init;return t(a._payload)}catch(o){throw o!==null&&typeof o=="object"&&typeof o.then=="function"?(Vn=o,ba):o}}var Vn=null;function Zl(){if(Vn===null)throw Error(f(459));var a=Vn;return Vn=null,a}function Xl(a){if(a===ba||a===to)throw Error(f(483))}var ga=null,et=0;function ro(a){var t=et;return et+=1,ga===null&&(ga=[]),Kl(ga,a,t)}function it(a,t){t=t.props.ref,a.ref=t!==void 0?t:null}function so(a,t){throw t.$$typeof===K?Error(f(525)):(a=Object.prototype.toString.call(t),Error(f(31,a==="[object Object]"?"object with keys {"+Object.keys(t).join(", ")+"}":a)))}function Jl(a){function t(b,p){if(a){var D=b.deletions;D===null?(b.deletions=[p],b.flags|=16):D.push(p)}}function o(b,p){if(!a)return null;for(;p!==null;)t(b,p),p=p.sibling;return null}function r(b){for(var p=new Map;b!==null;)b.key!==null?p.set(b.key,b):p.set(b.index,b),b=b.sibling;return p}function s(b,p){return b=Bi(b,p),b.index=0,b.sibling=null,b}function c(b,p,D){return b.index=D,a?(D=b.alternate,D!==null?(D=D.index,D<p?(b.flags|=67108866,p):D):(b.flags|=67108866,p)):(b.flags|=1048576,p)}function l(b){return a&&b.alternate===null&&(b.flags|=67108866),b}function d(b,p,D,I){return p===null||p.tag!==6?(p=wr(D,b.mode,I),p.return=b,p):(p=s(p,D),p.return=b,p)}function u(b,p,D,I){var Y=D.type;return Y===Ie?G(b,p,D.props.children,I,D.key):p!==null&&(p.elementType===Y||typeof Y=="object"&&Y!==null&&Y.$$typeof===Ve&&jn(Y)===p.type)?(p=s(p,D.props),it(p,D),p.return=b,p):(p=$t(D.type,D.key,D.props,null,b.mode,I),it(p,D),p.return=b,p)}function R(b,p,D,I){return p===null||p.tag!==4||p.stateNode.containerInfo!==D.containerInfo||p.stateNode.implementation!==D.implementation?(p=kr(D,b.mode,I),p.return=b,p):(p=s(p,D.children||[]),p.return=b,p)}function G(b,p,D,I,Y){return p===null||p.tag!==7?(p=Nn(D,b.mode,I,Y),p.return=b,p):(p=s(p,D),p.return=b,p)}function M(b,p,D){if(typeof p=="string"&&p!==""||typeof p=="number"||typeof p=="bigint")return p=wr(""+p,b.mode,D),p.return=b,p;if(typeof p=="object"&&p!==null){switch(p.$$typeof){case Ae:return D=$t(p.type,p.key,p.props,null,b.mode,D),it(D,p),D.return=b,D;case z:return p=kr(p,b.mode,D),p.return=b,p;case Ve:return p=jn(p),M(b,p,D)}if(oi(p)||Qe(p))return p=Nn(p,b.mode,D,null),p.return=b,p;if(typeof p.then=="function")return M(b,ro(p),D);if(p.$$typeof===Q)return M(b,no(b,p),D);so(b,p)}return null}function v(b,p,D,I){var Y=p!==null?p.key:null;if(typeof D=="string"&&D!==""||typeof D=="number"||typeof D=="bigint")return Y!==null?null:d(b,p,""+D,I);if(typeof D=="object"&&D!==null){switch(D.$$typeof){case Ae:return D.key===Y?u(b,p,D,I):null;case z:return D.key===Y?R(b,p,D,I):null;case Ve:return D=jn(D),v(b,p,D,I)}if(oi(D)||Qe(D))return Y!==null?null:G(b,p,D,I,null);if(typeof D.then=="function")return v(b,p,ro(D),I);if(D.$$typeof===Q)return v(b,p,no(b,D),I);so(b,D)}return null}function A(b,p,D,I,Y){if(typeof I=="string"&&I!==""||typeof I=="number"||typeof I=="bigint")return b=b.get(D)||null,d(p,b,""+I,Y);if(typeof I=="object"&&I!==null){switch(I.$$typeof){case Ae:return b=b.get(I.key===null?D:I.key)||null,u(p,b,I,Y);case z:return b=b.get(I.key===null?D:I.key)||null,R(p,b,I,Y);case Ve:return I=jn(I),A(b,p,D,I,Y)}if(oi(I)||Qe(I))return b=b.get(D)||null,G(p,b,I,Y,null);if(typeof I.then=="function")return A(b,p,D,ro(I),Y);if(I.$$typeof===Q)return A(b,p,D,no(p,I),Y);so(p,I)}return null}function k(b,p,D,I){for(var Y=null,me=null,N=p,ee=p=0,te=null;N!==null&&ee<D.length;ee++){N.index>ee?(te=N,N=null):te=N.sibling;var ue=v(b,N,D[ee],I);if(ue===null){N===null&&(N=te);break}a&&N&&ue.alternate===null&&t(b,N),p=c(ue,p,ee),me===null?Y=ue:me.sibling=ue,me=ue,N=te}if(ee===D.length)return o(b,N),oe&&Fi(b,ee),Y;if(N===null){for(;ee<D.length;ee++)N=M(b,D[ee],I),N!==null&&(p=c(N,p,ee),me===null?Y=N:me.sibling=N,me=N);return oe&&Fi(b,ee),Y}for(N=r(N);ee<D.length;ee++)te=A(N,b,ee,D[ee],I),te!==null&&(a&&te.alternate!==null&&N.delete(te.key===null?ee:te.key),p=c(te,p,ee),me===null?Y=te:me.sibling=te,me=te);return a&&N.forEach(function(Tn){return t(b,Tn)}),oe&&Fi(b,ee),Y}function j(b,p,D,I){if(D==null)throw Error(f(151));for(var Y=null,me=null,N=p,ee=p=0,te=null,ue=D.next();N!==null&&!ue.done;ee++,ue=D.next()){N.index>ee?(te=N,N=null):te=N.sibling;var Tn=v(b,N,ue.value,I);if(Tn===null){N===null&&(N=te);break}a&&N&&Tn.alternate===null&&t(b,N),p=c(Tn,p,ee),me===null?Y=Tn:me.sibling=Tn,me=Tn,N=te}if(ue.done)return o(b,N),oe&&Fi(b,ee),Y;if(N===null){for(;!ue.done;ee++,ue=D.next())ue=M(b,ue.value,I),ue!==null&&(p=c(ue,p,ee),me===null?Y=ue:me.sibling=ue,me=ue);return oe&&Fi(b,ee),Y}for(N=r(N);!ue.done;ee++,ue=D.next())ue=A(N,b,ee,ue.value,I),ue!==null&&(a&&ue.alternate!==null&&N.delete(ue.key===null?ee:ue.key),p=c(ue,p,ee),me===null?Y=ue:me.sibling=ue,me=ue);return a&&N.forEach(function(Mh){return t(b,Mh)}),oe&&Fi(b,ee),Y}function Re(b,p,D,I){if(typeof D=="object"&&D!==null&&D.type===Ie&&D.key===null&&(D=D.props.children),typeof D=="object"&&D!==null){switch(D.$$typeof){case Ae:e:{for(var Y=D.key;p!==null;){if(p.key===Y){if(Y=D.type,Y===Ie){if(p.tag===7){o(b,p.sibling),I=s(p,D.props.children),I.return=b,b=I;break e}}else if(p.elementType===Y||typeof Y=="object"&&Y!==null&&Y.$$typeof===Ve&&jn(Y)===p.type){o(b,p.sibling),I=s(p,D.props),it(I,D),I.return=b,b=I;break e}o(b,p);break}else t(b,p);p=p.sibling}D.type===Ie?(I=Nn(D.props.children,b.mode,I,D.key),I.return=b,b=I):(I=$t(D.type,D.key,D.props,null,b.mode,I),it(I,D),I.return=b,b=I)}return l(b);case z:e:{for(Y=D.key;p!==null;){if(p.key===Y)if(p.tag===4&&p.stateNode.containerInfo===D.containerInfo&&p.stateNode.implementation===D.implementation){o(b,p.sibling),I=s(p,D.children||[]),I.return=b,b=I;break e}else{o(b,p);break}else t(b,p);p=p.sibling}I=kr(D,b.mode,I),I.return=b,b=I}return l(b);case Ve:return D=jn(D),Re(b,p,D,I)}if(oi(D))return k(b,p,D,I);if(Qe(D)){if(Y=Qe(D),typeof Y!="function")throw Error(f(150));return D=Y.call(D),j(b,p,D,I)}if(typeof D.then=="function")return Re(b,p,ro(D),I);if(D.$$typeof===Q)return Re(b,p,no(b,D),I);so(b,D)}return typeof D=="string"&&D!==""||typeof D=="number"||typeof D=="bigint"?(D=""+D,p!==null&&p.tag===6?(o(b,p.sibling),I=s(p,D),I.return=b,b=I):(o(b,p),I=wr(D,b.mode,I),I.return=b,b=I),l(b)):o(b,p)}return function(b,p,D,I){try{et=0;var Y=Re(b,p,D,I);return ga=null,Y}catch(N){if(N===ba||N===to)throw N;var me=mi(29,N,null,b.mode);return me.lanes=I,me.return=b,me}finally{}}}var Qn=Jl(!0),$l=Jl(!1),fn=!1;function Kr(a){a.updateQueue={baseState:a.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,lanes:0,hiddenCallbacks:null},callbacks:null}}function Zr(a,t){a=a.updateQueue,t.updateQueue===a&&(t.updateQueue={baseState:a.baseState,firstBaseUpdate:a.firstBaseUpdate,lastBaseUpdate:a.lastBaseUpdate,shared:a.shared,callbacks:null})}function pn(a){return{lane:a,tag:0,payload:null,callback:null,next:null}}function hn(a,t,o){var r=a.updateQueue;if(r===null)return null;if(r=r.shared,(fe&2)!==0){var s=r.pending;return s===null?t.next=t:(t.next=s.next,s.next=t),r.pending=t,t=Jt(a),wl(a,null,o),t}return Xt(a,r,t,o),Jt(a)}function nt(a,t,o){if(t=t.updateQueue,t!==null&&(t=t.shared,(o&4194048)!==0)){var r=t.lanes;r&=a.pendingLanes,o|=r,t.lanes=o,jc(a,o)}}function Xr(a,t){var o=a.updateQueue,r=a.alternate;if(r!==null&&(r=r.updateQueue,o===r)){var s=null,c=null;if(o=o.firstBaseUpdate,o!==null){do{var l={lane:o.lane,tag:o.tag,payload:o.payload,callback:null,next:null};c===null?s=c=l:c=c.next=l,o=o.next}while(o!==null);c===null?s=c=t:c=c.next=t}else s=c=t;o={baseState:r.baseState,firstBaseUpdate:s,lastBaseUpdate:c,shared:r.shared,callbacks:r.callbacks},a.updateQueue=o;return}a=o.lastBaseUpdate,a===null?o.firstBaseUpdate=t:a.next=t,o.lastBaseUpdate=t}var Jr=!1;function at(){if(Jr){var a=ya;if(a!==null)throw a}}function tt(a,t,o,r){Jr=!1;var s=a.updateQueue;fn=!1;var c=s.firstBaseUpdate,l=s.lastBaseUpdate,d=s.shared.pending;if(d!==null){s.shared.pending=null;var u=d,R=u.next;u.next=null,l===null?c=R:l.next=R,l=u;var G=a.alternate;G!==null&&(G=G.updateQueue,d=G.lastBaseUpdate,d!==l&&(d===null?G.firstBaseUpdate=R:d.next=R,G.lastBaseUpdate=u))}if(c!==null){var M=s.baseState;l=0,G=R=u=null,d=c;do{var v=d.lane&-536870913,A=v!==d.lane;if(A?(ae&v)===v:(r&v)===v){v!==0&&v===ha&&(Jr=!0),G!==null&&(G=G.next={lane:0,tag:d.tag,payload:d.payload,callback:null,next:null});e:{var k=a,j=d;v=t;var Re=o;switch(j.tag){case 1:if(k=j.payload,typeof k=="function"){M=k.call(Re,M,v);break e}M=k;break e;case 3:k.flags=k.flags&-65537|128;case 0:if(k=j.payload,v=typeof k=="function"?k.call(Re,M,v):k,v==null)break e;M=_({},M,v);break e;case 2:fn=!0}}v=d.callback,v!==null&&(a.flags|=64,A&&(a.flags|=8192),A=s.callbacks,A===null?s.callbacks=[v]:A.push(v))}else A={lane:v,tag:d.tag,payload:d.payload,callback:d.callback,next:null},G===null?(R=G=A,u=M):G=G.next=A,l|=v;if(d=d.next,d===null){if(d=s.shared.pending,d===null)break;A=d,d=A.next,A.next=null,s.lastBaseUpdate=A,s.shared.pending=null}}while(!0);G===null&&(u=M),s.baseState=u,s.firstBaseUpdate=R,s.lastBaseUpdate=G,c===null&&(s.shared.lanes=0),Rn|=l,a.lanes=l,a.memoizedState=M}}function ed(a,t){if(typeof a!="function")throw Error(f(191,a));a.call(t)}function id(a,t){var o=a.callbacks;if(o!==null)for(a.callbacks=null,a=0;a<o.length;a++)ed(o[a],t)}var Da=y(null),co=y(0);function nd(a,t){a=en,U(co,a),U(Da,t),en=a|t.baseLanes}function $r(){U(co,en),U(Da,Da.current)}function es(){en=co.current,g(Da),g(co)}var ui=y(null),Ii=null;function yn(a){var t=a.alternate;U(Te,Te.current&1),U(ui,a),Ii===null&&(t===null||Da.current!==null||t.memoizedState!==null)&&(Ii=a)}function is(a){U(Te,Te.current),U(ui,a),Ii===null&&(Ii=a)}function ad(a){a.tag===22?(U(Te,Te.current),U(ui,a),Ii===null&&(Ii=a)):bn()}function bn(){U(Te,Te.current),U(ui,ui.current)}function fi(a){g(ui),Ii===a&&(Ii=null),g(Te)}var Te=y(0);function lo(a){for(var t=a;t!==null;){if(t.tag===13){var o=t.memoizedState;if(o!==null&&(o=o.dehydrated,o===null||sc(o)||cc(o)))return t}else if(t.tag===19&&(t.memoizedProps.revealOrder==="forwards"||t.memoizedProps.revealOrder==="backwards"||t.memoizedProps.revealOrder==="unstable_legacy-backwards"||t.memoizedProps.revealOrder==="together")){if((t.flags&128)!==0)return t}else if(t.child!==null){t.child.return=t,t=t.child;continue}if(t===a)break;for(;t.sibling===null;){if(t.return===null||t.return===a)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var Qi=0,$=null,ge=null,Se=null,mo=!1,Ra=!1,Wn=!1,uo=0,ot=0,va=null,gp=0;function Ee(){throw Error(f(321))}function ns(a,t){if(t===null)return!1;for(var o=0;o<t.length&&o<a.length;o++)if(!di(a[o],t[o]))return!1;return!0}function as(a,t,o,r,s,c){return Qi=c,$=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,C.H=a===null||a.memoizedState===null?Yd:gs,Wn=!1,c=o(r,s),Wn=!1,Ra&&(c=od(t,o,r,s)),td(a),c}function td(a){C.H=ct;var t=ge!==null&&ge.next!==null;if(Qi=0,Se=ge=$=null,mo=!1,ot=0,va=null,t)throw Error(f(300));a===null||He||(a=a.dependencies,a!==null&&io(a)&&(He=!0))}function od(a,t,o,r){$=a;var s=0;do{if(Ra&&(va=null),ot=0,Ra=!1,25<=s)throw Error(f(301));if(s+=1,Se=ge=null,a.updateQueue!=null){var c=a.updateQueue;c.lastEffect=null,c.events=null,c.stores=null,c.memoCache!=null&&(c.memoCache.index=0)}C.H=Ld,c=t(o,r)}while(Ra);return c}function Dp(){var a=C.H,t=a.useState()[0];return t=typeof t.then=="function"?rt(t):t,a=a.useState()[0],(ge!==null?ge.memoizedState:null)!==a&&($.flags|=1024),t}function ts(){var a=uo!==0;return uo=0,a}function os(a,t,o){t.updateQueue=a.updateQueue,t.flags&=-2053,a.lanes&=~o}function rs(a){if(mo){for(a=a.memoizedState;a!==null;){var t=a.queue;t!==null&&(t.pending=null),a=a.next}mo=!1}Qi=0,Se=ge=$=null,Ra=!1,ot=uo=0,va=null}function Ke(){var a={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return Se===null?$.memoizedState=Se=a:Se=Se.next=a,Se}function xe(){if(ge===null){var a=$.alternate;a=a!==null?a.memoizedState:null}else a=ge.next;var t=Se===null?$.memoizedState:Se.next;if(t!==null)Se=t,ge=a;else{if(a===null)throw $.alternate===null?Error(f(467)):Error(f(310));ge=a,a={memoizedState:ge.memoizedState,baseState:ge.baseState,baseQueue:ge.baseQueue,queue:ge.queue,next:null},Se===null?$.memoizedState=Se=a:Se=Se.next=a}return Se}function fo(){return{lastEffect:null,events:null,stores:null,memoCache:null}}function rt(a){var t=ot;return ot+=1,va===null&&(va=[]),a=Kl(va,a,t),t=$,(Se===null?t.memoizedState:Se.next)===null&&(t=t.alternate,C.H=t===null||t.memoizedState===null?Yd:gs),a}function po(a){if(a!==null&&typeof a=="object"){if(typeof a.then=="function")return rt(a);if(a.$$typeof===Q)return Be(a)}throw Error(f(438,String(a)))}function ss(a){var t=null,o=$.updateQueue;if(o!==null&&(t=o.memoCache),t==null){var r=$.alternate;r!==null&&(r=r.updateQueue,r!==null&&(r=r.memoCache,r!=null&&(t={data:r.data.map(function(s){return s.slice()}),index:0})))}if(t==null&&(t={data:[],index:0}),o===null&&(o=fo(),$.updateQueue=o),o.memoCache=t,o=t.data[t.index],o===void 0)for(o=t.data[t.index]=Array(a),r=0;r<a;r++)o[r]=ki;return t.index++,o}function Wi(a,t){return typeof t=="function"?t(a):t}function ho(a){var t=xe();return cs(t,ge,a)}function cs(a,t,o){var r=a.queue;if(r===null)throw Error(f(311));r.lastRenderedReducer=o;var s=a.baseQueue,c=r.pending;if(c!==null){if(s!==null){var l=s.next;s.next=c.next,c.next=l}t.baseQueue=s=c,r.pending=null}if(c=a.baseState,s===null)a.memoizedState=c;else{t=s.next;var d=l=null,u=null,R=t,G=!1;do{var M=R.lane&-536870913;if(M!==R.lane?(ae&M)===M:(Qi&M)===M){var v=R.revertLane;if(v===0)u!==null&&(u=u.next={lane:0,revertLane:0,gesture:null,action:R.action,hasEagerState:R.hasEagerState,eagerState:R.eagerState,next:null}),M===ha&&(G=!0);else if((Qi&v)===v){R=R.next,v===ha&&(G=!0);continue}else M={lane:0,revertLane:R.revertLane,gesture:null,action:R.action,hasEagerState:R.hasEagerState,eagerState:R.eagerState,next:null},u===null?(d=u=M,l=c):u=u.next=M,$.lanes|=v,Rn|=v;M=R.action,Wn&&o(c,M),c=R.hasEagerState?R.eagerState:o(c,M)}else v={lane:M,revertLane:R.revertLane,gesture:R.gesture,action:R.action,hasEagerState:R.hasEagerState,eagerState:R.eagerState,next:null},u===null?(d=u=v,l=c):u=u.next=v,$.lanes|=M,Rn|=M;R=R.next}while(R!==null&&R!==t);if(u===null?l=c:u.next=d,!di(c,a.memoizedState)&&(He=!0,G&&(o=ya,o!==null)))throw o;a.memoizedState=c,a.baseState=l,a.baseQueue=u,r.lastRenderedState=c}return s===null&&(r.lanes=0),[a.memoizedState,r.dispatch]}function ls(a){var t=xe(),o=t.queue;if(o===null)throw Error(f(311));o.lastRenderedReducer=a;var r=o.dispatch,s=o.pending,c=t.memoizedState;if(s!==null){o.pending=null;var l=s=s.next;do c=a(c,l.action),l=l.next;while(l!==s);di(c,t.memoizedState)||(He=!0),t.memoizedState=c,t.baseQueue===null&&(t.baseState=c),o.lastRenderedState=c}return[c,r]}function rd(a,t,o){var r=$,s=xe(),c=oe;if(c){if(o===void 0)throw Error(f(407));o=o()}else o=t();var l=!di((ge||s).memoizedState,o);if(l&&(s.memoizedState=o,He=!0),s=s.queue,us(ld.bind(null,r,s,a),[a]),s.getSnapshot!==t||l||Se!==null&&Se.memoizedState.tag&1){if(r.flags|=2048,Aa(9,{destroy:void 0},cd.bind(null,r,s,o,t),null),ve===null)throw Error(f(349));c||(Qi&127)!==0||sd(r,t,o)}return o}function sd(a,t,o){a.flags|=16384,a={getSnapshot:t,value:o},t=$.updateQueue,t===null?(t=fo(),$.updateQueue=t,t.stores=[a]):(o=t.stores,o===null?t.stores=[a]:o.push(a))}function cd(a,t,o,r){t.value=o,t.getSnapshot=r,dd(t)&&md(a)}function ld(a,t,o){return o(function(){dd(t)&&md(a)})}function dd(a){var t=a.getSnapshot;a=a.value;try{var o=t();return!di(a,o)}catch{return!0}}function md(a){var t=_n(a,2);t!==null&&ai(t,a,2)}function ds(a){var t=Ke();if(typeof a=="function"){var o=a;if(a=o(),Wn){rn(!0);try{o()}finally{rn(!1)}}}return t.memoizedState=t.baseState=a,t.queue={pending:null,lanes:0,dispatch:null,lastRenderedReducer:Wi,lastRenderedState:a},t}function ud(a,t,o,r){return a.baseState=o,cs(a,ge,typeof r=="function"?r:Wi)}function Rp(a,t,o,r,s){if(go(a))throw Error(f(485));if(a=t.action,a!==null){var c={payload:s,action:a,next:null,isTransition:!0,status:"pending",value:null,reason:null,listeners:[],then:function(l){c.listeners.push(l)}};C.T!==null?o(!0):c.isTransition=!1,r(c),o=t.pending,o===null?(c.next=t.pending=c,fd(t,c)):(c.next=o.next,t.pending=o.next=c)}}function fd(a,t){var o=t.action,r=t.payload,s=a.state;if(t.isTransition){var c=C.T,l={};C.T=l;try{var d=o(s,r),u=C.S;u!==null&&u(l,d),pd(a,t,d)}catch(R){ms(a,t,R)}finally{c!==null&&l.types!==null&&(c.types=l.types),C.T=c}}else try{c=o(s,r),pd(a,t,c)}catch(R){ms(a,t,R)}}function pd(a,t,o){o!==null&&typeof o=="object"&&typeof o.then=="function"?o.then(function(r){hd(a,t,r)},function(r){return ms(a,t,r)}):hd(a,t,o)}function hd(a,t,o){t.status="fulfilled",t.value=o,yd(t),a.state=o,t=a.pending,t!==null&&(o=t.next,o===t?a.pending=null:(o=o.next,t.next=o,fd(a,o)))}function ms(a,t,o){var r=a.pending;if(a.pending=null,r!==null){r=r.next;do t.status="rejected",t.reason=o,yd(t),t=t.next;while(t!==r)}a.action=null}function yd(a){a=a.listeners;for(var t=0;t<a.length;t++)(0,a[t])()}function bd(a,t){return t}function gd(a,t){if(oe){var o=ve.formState;if(o!==null){e:{var r=$;if(oe){if(Ce){i:{for(var s=Ce,c=Ui;s.nodeType!==8;){if(!c){s=null;break i}if(s=Ei(s.nextSibling),s===null){s=null;break i}}c=s.data,s=c==="F!"||c==="F"?s:null}if(s){Ce=Ei(s.nextSibling),r=s.data==="F!";break e}}mn(r)}r=!1}r&&(t=o[0])}}return o=Ke(),o.memoizedState=o.baseState=t,r={pending:null,lanes:0,dispatch:null,lastRenderedReducer:bd,lastRenderedState:t},o.queue=r,o=kd.bind(null,$,r),r.dispatch=o,r=ds(!1),c=bs.bind(null,$,!1,r.queue),r=Ke(),s={state:t,dispatch:null,action:a,pending:null},r.queue=s,o=Rp.bind(null,$,s,c,o),s.dispatch=o,r.memoizedState=a,[t,o,!1]}function Dd(a){var t=xe();return Rd(t,ge,a)}function Rd(a,t,o){if(t=cs(a,t,bd)[0],a=ho(Wi)[0],typeof t=="object"&&t!==null&&typeof t.then=="function")try{var r=rt(t)}catch(l){throw l===ba?to:l}else r=t;t=xe();var s=t.queue,c=s.dispatch;return o!==t.memoizedState&&($.flags|=2048,Aa(9,{destroy:void 0},vp.bind(null,s,o),null)),[r,c,a]}function vp(a,t){a.action=t}function vd(a){var t=xe(),o=ge;if(o!==null)return Rd(t,o,a);xe(),t=t.memoizedState,o=xe();var r=o.queue.dispatch;return o.memoizedState=a,[t,r,!1]}function Aa(a,t,o,r){return a={tag:a,create:o,deps:r,inst:t,next:null},t=$.updateQueue,t===null&&(t=fo(),$.updateQueue=t),o=t.lastEffect,o===null?t.lastEffect=a.next=a:(r=o.next,o.next=a,a.next=r,t.lastEffect=a),a}function Ad(){return xe().memoizedState}function yo(a,t,o,r){var s=Ke();$.flags|=a,s.memoizedState=Aa(1|t,{destroy:void 0},o,r===void 0?null:r)}function bo(a,t,o,r){var s=xe();r=r===void 0?null:r;var c=s.memoizedState.inst;ge!==null&&r!==null&&ns(r,ge.memoizedState.deps)?s.memoizedState=Aa(t,c,o,r):($.flags|=a,s.memoizedState=Aa(1|t,c,o,r))}function Cd(a,t){yo(8390656,8,a,t)}function us(a,t){bo(2048,8,a,t)}function Ap(a){$.flags|=4;var t=$.updateQueue;if(t===null)t=fo(),$.updateQueue=t,t.events=[a];else{var o=t.events;o===null?t.events=[a]:o.push(a)}}function Gd(a){var t=xe().memoizedState;return Ap({ref:t,nextImpl:a}),function(){if((fe&2)!==0)throw Error(f(440));return t.impl.apply(void 0,arguments)}}function Ud(a,t){return bo(4,2,a,t)}function Id(a,t){return bo(4,4,a,t)}function Ed(a,t){if(typeof t=="function"){a=a();var o=t(a);return function(){typeof o=="function"?o():t(null)}}if(t!=null)return a=a(),t.current=a,function(){t.current=null}}function Md(a,t,o){o=o!=null?o.concat([a]):null,bo(4,4,Ed.bind(null,t,a),o)}function fs(){}function Pd(a,t){var o=xe();t=t===void 0?null:t;var r=o.memoizedState;return t!==null&&ns(t,r[1])?r[0]:(o.memoizedState=[a,t],a)}function Td(a,t){var o=xe();t=t===void 0?null:t;var r=o.memoizedState;if(t!==null&&ns(t,r[1]))return r[0];if(r=a(),Wn){rn(!0);try{a()}finally{rn(!1)}}return o.memoizedState=[r,t],r}function ps(a,t,o){return o===void 0||(Qi&1073741824)!==0&&(ae&261930)===0?a.memoizedState=t:(a.memoizedState=o,a=xm(),$.lanes|=a,Rn|=a,o)}function xd(a,t,o,r){return di(o,t)?o:Da.current!==null?(a=ps(a,o,r),di(a,t)||(He=!0),a):(Qi&42)===0||(Qi&1073741824)!==0&&(ae&261930)===0?(He=!0,a.memoizedState=o):(a=xm(),$.lanes|=a,Rn|=a,t)}function Od(a,t,o,r,s){var c=H.p;H.p=c!==0&&8>c?c:8;var l=C.T,d={};C.T=d,bs(a,!1,t,o);try{var u=s(),R=C.S;if(R!==null&&R(d,u),u!==null&&typeof u=="object"&&typeof u.then=="function"){var G=bp(u,r);st(a,t,G,yi(a))}else st(a,t,r,yi(a))}catch(M){st(a,t,{then:function(){},status:"rejected",reason:M},yi())}finally{H.p=c,l!==null&&d.types!==null&&(l.types=d.types),C.T=l}}function Cp(){}function hs(a,t,o,r){if(a.tag!==5)throw Error(f(476));var s=Sd(a).queue;Od(a,s,t,V,o===null?Cp:function(){return Hd(a),o(r)})}function Sd(a){var t=a.memoizedState;if(t!==null)return t;t={memoizedState:V,baseState:V,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:Wi,lastRenderedState:V},next:null};var o={};return t.next={memoizedState:o,baseState:o,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:Wi,lastRenderedState:o},next:null},a.memoizedState=t,a=a.alternate,a!==null&&(a.memoizedState=t),t}function Hd(a){var t=Sd(a);t.next===null&&(t=a.alternate.memoizedState),st(a,t.next.queue,{},yi())}function ys(){return Be(Gt)}function zd(){return xe().memoizedState}function wd(){return xe().memoizedState}function Gp(a){for(var t=a.return;t!==null;){switch(t.tag){case 24:case 3:var o=yi();a=pn(o);var r=hn(t,a,o);r!==null&&(ai(r,t,o),nt(r,t,o)),t={cache:Vr()},a.payload=t;return}t=t.return}}function Up(a,t,o){var r=yi();o={lane:r,revertLane:0,gesture:null,action:o,hasEagerState:!1,eagerState:null,next:null},go(a)?_d(t,o):(o=Hr(a,t,o,r),o!==null&&(ai(o,a,r),Nd(o,t,r)))}function kd(a,t,o){var r=yi();st(a,t,o,r)}function st(a,t,o,r){var s={lane:r,revertLane:0,gesture:null,action:o,hasEagerState:!1,eagerState:null,next:null};if(go(a))_d(t,s);else{var c=a.alternate;if(a.lanes===0&&(c===null||c.lanes===0)&&(c=t.lastRenderedReducer,c!==null))try{var l=t.lastRenderedState,d=c(l,o);if(s.hasEagerState=!0,s.eagerState=d,di(d,l))return Xt(a,t,s,0),ve===null&&Zt(),!1}catch{}finally{}if(o=Hr(a,t,s,r),o!==null)return ai(o,a,r),Nd(o,t,r),!0}return!1}function bs(a,t,o,r){if(r={lane:2,revertLane:Ks(),gesture:null,action:r,hasEagerState:!1,eagerState:null,next:null},go(a)){if(t)throw Error(f(479))}else t=Hr(a,o,r,2),t!==null&&ai(t,a,2)}function go(a){var t=a.alternate;return a===$||t!==null&&t===$}function _d(a,t){Ra=mo=!0;var o=a.pending;o===null?t.next=t:(t.next=o.next,o.next=t),a.pending=t}function Nd(a,t,o){if((o&4194048)!==0){var r=t.lanes;r&=a.pendingLanes,o|=r,t.lanes=o,jc(a,o)}}var ct={readContext:Be,use:po,useCallback:Ee,useContext:Ee,useEffect:Ee,useImperativeHandle:Ee,useLayoutEffect:Ee,useInsertionEffect:Ee,useMemo:Ee,useReducer:Ee,useRef:Ee,useState:Ee,useDebugValue:Ee,useDeferredValue:Ee,useTransition:Ee,useSyncExternalStore:Ee,useId:Ee,useHostTransitionStatus:Ee,useFormState:Ee,useActionState:Ee,useOptimistic:Ee,useMemoCache:Ee,useCacheRefresh:Ee};ct.useEffectEvent=Ee;var Yd={readContext:Be,use:po,useCallback:function(a,t){return Ke().memoizedState=[a,t===void 0?null:t],a},useContext:Be,useEffect:Cd,useImperativeHandle:function(a,t,o){o=o!=null?o.concat([a]):null,yo(4194308,4,Ed.bind(null,t,a),o)},useLayoutEffect:function(a,t){return yo(4194308,4,a,t)},useInsertionEffect:function(a,t){yo(4,2,a,t)},useMemo:function(a,t){var o=Ke();t=t===void 0?null:t;var r=a();if(Wn){rn(!0);try{a()}finally{rn(!1)}}return o.memoizedState=[r,t],r},useReducer:function(a,t,o){var r=Ke();if(o!==void 0){var s=o(t);if(Wn){rn(!0);try{o(t)}finally{rn(!1)}}}else s=t;return r.memoizedState=r.baseState=s,a={pending:null,lanes:0,dispatch:null,lastRenderedReducer:a,lastRenderedState:s},r.queue=a,a=a.dispatch=Up.bind(null,$,a),[r.memoizedState,a]},useRef:function(a){var t=Ke();return a={current:a},t.memoizedState=a},useState:function(a){a=ds(a);var t=a.queue,o=kd.bind(null,$,t);return t.dispatch=o,[a.memoizedState,o]},useDebugValue:fs,useDeferredValue:function(a,t){var o=Ke();return ps(o,a,t)},useTransition:function(){var a=ds(!1);return a=Od.bind(null,$,a.queue,!0,!1),Ke().memoizedState=a,[!1,a]},useSyncExternalStore:function(a,t,o){var r=$,s=Ke();if(oe){if(o===void 0)throw Error(f(407));o=o()}else{if(o=t(),ve===null)throw Error(f(349));(ae&127)!==0||sd(r,t,o)}s.memoizedState=o;var c={value:o,getSnapshot:t};return s.queue=c,Cd(ld.bind(null,r,c,a),[a]),r.flags|=2048,Aa(9,{destroy:void 0},cd.bind(null,r,c,o,t),null),o},useId:function(){var a=Ke(),t=ve.identifierPrefix;if(oe){var o=Hi,r=Si;o=(r&~(1<<32-li(r)-1)).toString(32)+o,t="_"+t+"R_"+o,o=uo++,0<o&&(t+="H"+o.toString(32)),t+="_"}else o=gp++,t="_"+t+"r_"+o.toString(32)+"_";return a.memoizedState=t},useHostTransitionStatus:ys,useFormState:gd,useActionState:gd,useOptimistic:function(a){var t=Ke();t.memoizedState=t.baseState=a;var o={pending:null,lanes:0,dispatch:null,lastRenderedReducer:null,lastRenderedState:null};return t.queue=o,t=bs.bind(null,$,!0,o),o.dispatch=t,[a,t]},useMemoCache:ss,useCacheRefresh:function(){return Ke().memoizedState=Gp.bind(null,$)},useEffectEvent:function(a){var t=Ke(),o={impl:a};return t.memoizedState=o,function(){if((fe&2)!==0)throw Error(f(440));return o.impl.apply(void 0,arguments)}}},gs={readContext:Be,use:po,useCallback:Pd,useContext:Be,useEffect:us,useImperativeHandle:Md,useInsertionEffect:Ud,useLayoutEffect:Id,useMemo:Td,useReducer:ho,useRef:Ad,useState:function(){return ho(Wi)},useDebugValue:fs,useDeferredValue:function(a,t){var o=xe();return xd(o,ge.memoizedState,a,t)},useTransition:function(){var a=ho(Wi)[0],t=xe().memoizedState;return[typeof a=="boolean"?a:rt(a),t]},useSyncExternalStore:rd,useId:zd,useHostTransitionStatus:ys,useFormState:Dd,useActionState:Dd,useOptimistic:function(a,t){var o=xe();return ud(o,ge,a,t)},useMemoCache:ss,useCacheRefresh:wd};gs.useEffectEvent=Gd;var Ld={readContext:Be,use:po,useCallback:Pd,useContext:Be,useEffect:us,useImperativeHandle:Md,useInsertionEffect:Ud,useLayoutEffect:Id,useMemo:Td,useReducer:ls,useRef:Ad,useState:function(){return ls(Wi)},useDebugValue:fs,useDeferredValue:function(a,t){var o=xe();return ge===null?ps(o,a,t):xd(o,ge.memoizedState,a,t)},useTransition:function(){var a=ls(Wi)[0],t=xe().memoizedState;return[typeof a=="boolean"?a:rt(a),t]},useSyncExternalStore:rd,useId:zd,useHostTransitionStatus:ys,useFormState:vd,useActionState:vd,useOptimistic:function(a,t){var o=xe();return ge!==null?ud(o,ge,a,t):(o.baseState=a,[a,o.queue.dispatch])},useMemoCache:ss,useCacheRefresh:wd};Ld.useEffectEvent=Gd;function Ds(a,t,o,r){t=a.memoizedState,o=o(r,t),o=o==null?t:_({},t,o),a.memoizedState=o,a.lanes===0&&(a.updateQueue.baseState=o)}var Rs={enqueueSetState:function(a,t,o){a=a._reactInternals;var r=yi(),s=pn(r);s.payload=t,o!=null&&(s.callback=o),t=hn(a,s,r),t!==null&&(ai(t,a,r),nt(t,a,r))},enqueueReplaceState:function(a,t,o){a=a._reactInternals;var r=yi(),s=pn(r);s.tag=1,s.payload=t,o!=null&&(s.callback=o),t=hn(a,s,r),t!==null&&(ai(t,a,r),nt(t,a,r))},enqueueForceUpdate:function(a,t){a=a._reactInternals;var o=yi(),r=pn(o);r.tag=2,t!=null&&(r.callback=t),t=hn(a,r,o),t!==null&&(ai(t,a,o),nt(t,a,o))}};function Bd(a,t,o,r,s,c,l){return a=a.stateNode,typeof a.shouldComponentUpdate=="function"?a.shouldComponentUpdate(r,c,l):t.prototype&&t.prototype.isPureReactComponent?!qa(o,r)||!qa(s,c):!0}function Fd(a,t,o,r){a=t.state,typeof t.componentWillReceiveProps=="function"&&t.componentWillReceiveProps(o,r),typeof t.UNSAFE_componentWillReceiveProps=="function"&&t.UNSAFE_componentWillReceiveProps(o,r),t.state!==a&&Rs.enqueueReplaceState(t,t.state,null)}function qn(a,t){var o=t;if("ref"in t){o={};for(var r in t)r!=="ref"&&(o[r]=t[r])}if(a=a.defaultProps){o===t&&(o=_({},o));for(var s in a)o[s]===void 0&&(o[s]=a[s])}return o}function jd(a){Kt(a)}function Vd(a){console.error(a)}function Qd(a){Kt(a)}function Do(a,t){try{var o=a.onUncaughtError;o(t.value,{componentStack:t.stack})}catch(r){setTimeout(function(){throw r})}}function Wd(a,t,o){try{var r=a.onCaughtError;r(o.value,{componentStack:o.stack,errorBoundary:t.tag===1?t.stateNode:null})}catch(s){setTimeout(function(){throw s})}}function vs(a,t,o){return o=pn(o),o.tag=3,o.payload={element:null},o.callback=function(){Do(a,t)},o}function qd(a){return a=pn(a),a.tag=3,a}function Kd(a,t,o,r){var s=o.type.getDerivedStateFromError;if(typeof s=="function"){var c=r.value;a.payload=function(){return s(c)},a.callback=function(){Wd(t,o,r)}}var l=o.stateNode;l!==null&&typeof l.componentDidCatch=="function"&&(a.callback=function(){Wd(t,o,r),typeof s!="function"&&(vn===null?vn=new Set([this]):vn.add(this));var d=r.stack;this.componentDidCatch(r.value,{componentStack:d!==null?d:""})})}function Ip(a,t,o,r,s){if(o.flags|=32768,r!==null&&typeof r=="object"&&typeof r.then=="function"){if(t=o.alternate,t!==null&&pa(t,o,s,!0),o=ui.current,o!==null){switch(o.tag){case 31:case 13:return Ii===null?xo():o.alternate===null&&Me===0&&(Me=3),o.flags&=-257,o.flags|=65536,o.lanes=s,r===oo?o.flags|=16384:(t=o.updateQueue,t===null?o.updateQueue=new Set([r]):t.add(r),Qs(a,r,s)),!1;case 22:return o.flags|=65536,r===oo?o.flags|=16384:(t=o.updateQueue,t===null?(t={transitions:null,markerInstances:null,retryQueue:new Set([r])},o.updateQueue=t):(o=t.retryQueue,o===null?t.retryQueue=new Set([r]):o.add(r)),Qs(a,r,s)),!1}throw Error(f(435,o.tag))}return Qs(a,r,s),xo(),!1}if(oe)return t=ui.current,t!==null?((t.flags&65536)===0&&(t.flags|=256),t.flags|=65536,t.lanes=s,r!==Yr&&(a=Error(f(422),{cause:r}),Xa(Ai(a,o)))):(r!==Yr&&(t=Error(f(423),{cause:r}),Xa(Ai(t,o))),a=a.current.alternate,a.flags|=65536,s&=-s,a.lanes|=s,r=Ai(r,o),s=vs(a.stateNode,r,s),Xr(a,s),Me!==4&&(Me=2)),!1;var c=Error(f(520),{cause:r});if(c=Ai(c,o),yt===null?yt=[c]:yt.push(c),Me!==4&&(Me=2),t===null)return!0;r=Ai(r,o),o=t;do{switch(o.tag){case 3:return o.flags|=65536,a=s&-s,o.lanes|=a,a=vs(o.stateNode,r,a),Xr(o,a),!1;case 1:if(t=o.type,c=o.stateNode,(o.flags&128)===0&&(typeof t.getDerivedStateFromError=="function"||c!==null&&typeof c.componentDidCatch=="function"&&(vn===null||!vn.has(c))))return o.flags|=65536,s&=-s,o.lanes|=s,s=qd(s),Kd(s,a,o,r),Xr(o,s),!1}o=o.return}while(o!==null);return!1}var As=Error(f(461)),He=!1;function Fe(a,t,o,r){t.child=a===null?$l(t,null,o,r):Qn(t,a.child,o,r)}function Zd(a,t,o,r,s){o=o.render;var c=t.ref;if("ref"in r){var l={};for(var d in r)d!=="ref"&&(l[d]=r[d])}else l=r;return Bn(t),r=as(a,t,o,l,c,s),d=ts(),a!==null&&!He?(os(a,t,s),qi(a,t,s)):(oe&&d&&_r(t),t.flags|=1,Fe(a,t,r,s),t.child)}function Xd(a,t,o,r,s){if(a===null){var c=o.type;return typeof c=="function"&&!zr(c)&&c.defaultProps===void 0&&o.compare===null?(t.tag=15,t.type=c,Jd(a,t,c,r,s)):(a=$t(o.type,null,r,t,t.mode,s),a.ref=t.ref,a.return=t,t.child=a)}if(c=a.child,!Ts(a,s)){var l=c.memoizedProps;if(o=o.compare,o=o!==null?o:qa,o(l,r)&&a.ref===t.ref)return qi(a,t,s)}return t.flags|=1,a=Bi(c,r),a.ref=t.ref,a.return=t,t.child=a}function Jd(a,t,o,r,s){if(a!==null){var c=a.memoizedProps;if(qa(c,r)&&a.ref===t.ref)if(He=!1,t.pendingProps=r=c,Ts(a,s))(a.flags&131072)!==0&&(He=!0);else return t.lanes=a.lanes,qi(a,t,s)}return Cs(a,t,o,r,s)}function $d(a,t,o,r){var s=r.children,c=a!==null?a.memoizedState:null;if(a===null&&t.stateNode===null&&(t.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),r.mode==="hidden"){if((t.flags&128)!==0){if(c=c!==null?c.baseLanes|o:o,a!==null){for(r=t.child=a.child,s=0;r!==null;)s=s|r.lanes|r.childLanes,r=r.sibling;r=s&~c}else r=0,t.child=null;return em(a,t,c,o,r)}if((o&536870912)!==0)t.memoizedState={baseLanes:0,cachePool:null},a!==null&&ao(t,c!==null?c.cachePool:null),c!==null?nd(t,c):$r(),ad(t);else return r=t.lanes=536870912,em(a,t,c!==null?c.baseLanes|o:o,o,r)}else c!==null?(ao(t,c.cachePool),nd(t,c),bn(),t.memoizedState=null):(a!==null&&ao(t,null),$r(),bn());return Fe(a,t,s,o),t.child}function lt(a,t){return a!==null&&a.tag===22||t.stateNode!==null||(t.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),t.sibling}function em(a,t,o,r,s){var c=Wr();return c=c===null?null:{parent:Oe._currentValue,pool:c},t.memoizedState={baseLanes:o,cachePool:c},a!==null&&ao(t,null),$r(),ad(t),a!==null&&pa(a,t,r,!0),t.childLanes=s,null}function Ro(a,t){return t=Ao({mode:t.mode,children:t.children},a.mode),t.ref=a.ref,a.child=t,t.return=a,t}function im(a,t,o){return Qn(t,a.child,null,o),a=Ro(t,t.pendingProps),a.flags|=2,fi(t),t.memoizedState=null,a}function Ep(a,t,o){var r=t.pendingProps,s=(t.flags&128)!==0;if(t.flags&=-129,a===null){if(oe){if(r.mode==="hidden")return a=Ro(t,r),t.lanes=536870912,lt(null,a);if(is(t),(a=Ce)?(a=fu(a,Ui),a=a!==null&&a.data==="&"?a:null,a!==null&&(t.memoizedState={dehydrated:a,treeContext:ln!==null?{id:Si,overflow:Hi}:null,retryLane:536870912,hydrationErrors:null},o=_l(a),o.return=t,t.child=o,Le=t,Ce=null)):a=null,a===null)throw mn(t);return t.lanes=536870912,null}return Ro(t,r)}var c=a.memoizedState;if(c!==null){var l=c.dehydrated;if(is(t),s)if(t.flags&256)t.flags&=-257,t=im(a,t,o);else if(t.memoizedState!==null)t.child=a.child,t.flags|=128,t=null;else throw Error(f(558));else if(He||pa(a,t,o,!1),s=(o&a.childLanes)!==0,He||s){if(r=ve,r!==null&&(l=Vc(r,o),l!==0&&l!==c.retryLane))throw c.retryLane=l,_n(a,l),ai(r,a,l),As;xo(),t=im(a,t,o)}else a=c.treeContext,Ce=Ei(l.nextSibling),Le=t,oe=!0,dn=null,Ui=!1,a!==null&&Ll(t,a),t=Ro(t,r),t.flags|=4096;return t}return a=Bi(a.child,{mode:r.mode,children:r.children}),a.ref=t.ref,t.child=a,a.return=t,a}function vo(a,t){var o=t.ref;if(o===null)a!==null&&a.ref!==null&&(t.flags|=4194816);else{if(typeof o!="function"&&typeof o!="object")throw Error(f(284));(a===null||a.ref!==o)&&(t.flags|=4194816)}}function Cs(a,t,o,r,s){return Bn(t),o=as(a,t,o,r,void 0,s),r=ts(),a!==null&&!He?(os(a,t,s),qi(a,t,s)):(oe&&r&&_r(t),t.flags|=1,Fe(a,t,o,s),t.child)}function nm(a,t,o,r,s,c){return Bn(t),t.updateQueue=null,o=od(t,r,o,s),td(a),r=ts(),a!==null&&!He?(os(a,t,c),qi(a,t,c)):(oe&&r&&_r(t),t.flags|=1,Fe(a,t,o,c),t.child)}function am(a,t,o,r,s){if(Bn(t),t.stateNode===null){var c=da,l=o.contextType;typeof l=="object"&&l!==null&&(c=Be(l)),c=new o(r,c),t.memoizedState=c.state!==null&&c.state!==void 0?c.state:null,c.updater=Rs,t.stateNode=c,c._reactInternals=t,c=t.stateNode,c.props=r,c.state=t.memoizedState,c.refs={},Kr(t),l=o.contextType,c.context=typeof l=="object"&&l!==null?Be(l):da,c.state=t.memoizedState,l=o.getDerivedStateFromProps,typeof l=="function"&&(Ds(t,o,l,r),c.state=t.memoizedState),typeof o.getDerivedStateFromProps=="function"||typeof c.getSnapshotBeforeUpdate=="function"||typeof c.UNSAFE_componentWillMount!="function"&&typeof c.componentWillMount!="function"||(l=c.state,typeof c.componentWillMount=="function"&&c.componentWillMount(),typeof c.UNSAFE_componentWillMount=="function"&&c.UNSAFE_componentWillMount(),l!==c.state&&Rs.enqueueReplaceState(c,c.state,null),tt(t,r,c,s),at(),c.state=t.memoizedState),typeof c.componentDidMount=="function"&&(t.flags|=4194308),r=!0}else if(a===null){c=t.stateNode;var d=t.memoizedProps,u=qn(o,d);c.props=u;var R=c.context,G=o.contextType;l=da,typeof G=="object"&&G!==null&&(l=Be(G));var M=o.getDerivedStateFromProps;G=typeof M=="function"||typeof c.getSnapshotBeforeUpdate=="function",d=t.pendingProps!==d,G||typeof c.UNSAFE_componentWillReceiveProps!="function"&&typeof c.componentWillReceiveProps!="function"||(d||R!==l)&&Fd(t,c,r,l),fn=!1;var v=t.memoizedState;c.state=v,tt(t,r,c,s),at(),R=t.memoizedState,d||v!==R||fn?(typeof M=="function"&&(Ds(t,o,M,r),R=t.memoizedState),(u=fn||Bd(t,o,u,r,v,R,l))?(G||typeof c.UNSAFE_componentWillMount!="function"&&typeof c.componentWillMount!="function"||(typeof c.componentWillMount=="function"&&c.componentWillMount(),typeof c.UNSAFE_componentWillMount=="function"&&c.UNSAFE_componentWillMount()),typeof c.componentDidMount=="function"&&(t.flags|=4194308)):(typeof c.componentDidMount=="function"&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=R),c.props=r,c.state=R,c.context=l,r=u):(typeof c.componentDidMount=="function"&&(t.flags|=4194308),r=!1)}else{c=t.stateNode,Zr(a,t),l=t.memoizedProps,G=qn(o,l),c.props=G,M=t.pendingProps,v=c.context,R=o.contextType,u=da,typeof R=="object"&&R!==null&&(u=Be(R)),d=o.getDerivedStateFromProps,(R=typeof d=="function"||typeof c.getSnapshotBeforeUpdate=="function")||typeof c.UNSAFE_componentWillReceiveProps!="function"&&typeof c.componentWillReceiveProps!="function"||(l!==M||v!==u)&&Fd(t,c,r,u),fn=!1,v=t.memoizedState,c.state=v,tt(t,r,c,s),at();var A=t.memoizedState;l!==M||v!==A||fn||a!==null&&a.dependencies!==null&&io(a.dependencies)?(typeof d=="function"&&(Ds(t,o,d,r),A=t.memoizedState),(G=fn||Bd(t,o,G,r,v,A,u)||a!==null&&a.dependencies!==null&&io(a.dependencies))?(R||typeof c.UNSAFE_componentWillUpdate!="function"&&typeof c.componentWillUpdate!="function"||(typeof c.componentWillUpdate=="function"&&c.componentWillUpdate(r,A,u),typeof c.UNSAFE_componentWillUpdate=="function"&&c.UNSAFE_componentWillUpdate(r,A,u)),typeof c.componentDidUpdate=="function"&&(t.flags|=4),typeof c.getSnapshotBeforeUpdate=="function"&&(t.flags|=1024)):(typeof c.componentDidUpdate!="function"||l===a.memoizedProps&&v===a.memoizedState||(t.flags|=4),typeof c.getSnapshotBeforeUpdate!="function"||l===a.memoizedProps&&v===a.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=A),c.props=r,c.state=A,c.context=u,r=G):(typeof c.componentDidUpdate!="function"||l===a.memoizedProps&&v===a.memoizedState||(t.flags|=4),typeof c.getSnapshotBeforeUpdate!="function"||l===a.memoizedProps&&v===a.memoizedState||(t.flags|=1024),r=!1)}return c=r,vo(a,t),r=(t.flags&128)!==0,c||r?(c=t.stateNode,o=r&&typeof o.getDerivedStateFromError!="function"?null:c.render(),t.flags|=1,a!==null&&r?(t.child=Qn(t,a.child,null,s),t.child=Qn(t,null,o,s)):Fe(a,t,o,s),t.memoizedState=c.state,a=t.child):a=qi(a,t,s),a}function tm(a,t,o,r){return Yn(),t.flags|=256,Fe(a,t,o,r),t.child}var Gs={dehydrated:null,treeContext:null,retryLane:0,hydrationErrors:null};function Us(a){return{baseLanes:a,cachePool:Wl()}}function Is(a,t,o){return a=a!==null?a.childLanes&~o:0,t&&(a|=hi),a}function om(a,t,o){var r=t.pendingProps,s=!1,c=(t.flags&128)!==0,l;if((l=c)||(l=a!==null&&a.memoizedState===null?!1:(Te.current&2)!==0),l&&(s=!0,t.flags&=-129),l=(t.flags&32)!==0,t.flags&=-33,a===null){if(oe){if(s?yn(t):bn(),(a=Ce)?(a=fu(a,Ui),a=a!==null&&a.data!=="&"?a:null,a!==null&&(t.memoizedState={dehydrated:a,treeContext:ln!==null?{id:Si,overflow:Hi}:null,retryLane:536870912,hydrationErrors:null},o=_l(a),o.return=t,t.child=o,Le=t,Ce=null)):a=null,a===null)throw mn(t);return cc(a)?t.lanes=32:t.lanes=536870912,null}var d=r.children;return r=r.fallback,s?(bn(),s=t.mode,d=Ao({mode:"hidden",children:d},s),r=Nn(r,s,o,null),d.return=t,r.return=t,d.sibling=r,t.child=d,r=t.child,r.memoizedState=Us(o),r.childLanes=Is(a,l,o),t.memoizedState=Gs,lt(null,r)):(yn(t),Es(t,d))}var u=a.memoizedState;if(u!==null&&(d=u.dehydrated,d!==null)){if(c)t.flags&256?(yn(t),t.flags&=-257,t=Ms(a,t,o)):t.memoizedState!==null?(bn(),t.child=a.child,t.flags|=128,t=null):(bn(),d=r.fallback,s=t.mode,r=Ao({mode:"visible",children:r.children},s),d=Nn(d,s,o,null),d.flags|=2,r.return=t,d.return=t,r.sibling=d,t.child=r,Qn(t,a.child,null,o),r=t.child,r.memoizedState=Us(o),r.childLanes=Is(a,l,o),t.memoizedState=Gs,t=lt(null,r));else if(yn(t),cc(d)){if(l=d.nextSibling&&d.nextSibling.dataset,l)var R=l.dgst;l=R,r=Error(f(419)),r.stack="",r.digest=l,Xa({value:r,source:null,stack:null}),t=Ms(a,t,o)}else if(He||pa(a,t,o,!1),l=(o&a.childLanes)!==0,He||l){if(l=ve,l!==null&&(r=Vc(l,o),r!==0&&r!==u.retryLane))throw u.retryLane=r,_n(a,r),ai(l,a,r),As;sc(d)||xo(),t=Ms(a,t,o)}else sc(d)?(t.flags|=192,t.child=a.child,t=null):(a=u.treeContext,Ce=Ei(d.nextSibling),Le=t,oe=!0,dn=null,Ui=!1,a!==null&&Ll(t,a),t=Es(t,r.children),t.flags|=4096);return t}return s?(bn(),d=r.fallback,s=t.mode,u=a.child,R=u.sibling,r=Bi(u,{mode:"hidden",children:r.children}),r.subtreeFlags=u.subtreeFlags&65011712,R!==null?d=Bi(R,d):(d=Nn(d,s,o,null),d.flags|=2),d.return=t,r.return=t,r.sibling=d,t.child=r,lt(null,r),r=t.child,d=a.child.memoizedState,d===null?d=Us(o):(s=d.cachePool,s!==null?(u=Oe._currentValue,s=s.parent!==u?{parent:u,pool:u}:s):s=Wl(),d={baseLanes:d.baseLanes|o,cachePool:s}),r.memoizedState=d,r.childLanes=Is(a,l,o),t.memoizedState=Gs,lt(a.child,r)):(yn(t),o=a.child,a=o.sibling,o=Bi(o,{mode:"visible",children:r.children}),o.return=t,o.sibling=null,a!==null&&(l=t.deletions,l===null?(t.deletions=[a],t.flags|=16):l.push(a)),t.child=o,t.memoizedState=null,o)}function Es(a,t){return t=Ao({mode:"visible",children:t},a.mode),t.return=a,a.child=t}function Ao(a,t){return a=mi(22,a,null,t),a.lanes=0,a}function Ms(a,t,o){return Qn(t,a.child,null,o),a=Es(t,t.pendingProps.children),a.flags|=2,t.memoizedState=null,a}function rm(a,t,o){a.lanes|=t;var r=a.alternate;r!==null&&(r.lanes|=t),Fr(a.return,t,o)}function Ps(a,t,o,r,s,c){var l=a.memoizedState;l===null?a.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:o,tailMode:s,treeForkCount:c}:(l.isBackwards=t,l.rendering=null,l.renderingStartTime=0,l.last=r,l.tail=o,l.tailMode=s,l.treeForkCount=c)}function sm(a,t,o){var r=t.pendingProps,s=r.revealOrder,c=r.tail;r=r.children;var l=Te.current,d=(l&2)!==0;if(d?(l=l&1|2,t.flags|=128):l&=1,U(Te,l),Fe(a,t,r,o),r=oe?Za:0,!d&&a!==null&&(a.flags&128)!==0)e:for(a=t.child;a!==null;){if(a.tag===13)a.memoizedState!==null&&rm(a,o,t);else if(a.tag===19)rm(a,o,t);else if(a.child!==null){a.child.return=a,a=a.child;continue}if(a===t)break e;for(;a.sibling===null;){if(a.return===null||a.return===t)break e;a=a.return}a.sibling.return=a.return,a=a.sibling}switch(s){case"forwards":for(o=t.child,s=null;o!==null;)a=o.alternate,a!==null&&lo(a)===null&&(s=o),o=o.sibling;o=s,o===null?(s=t.child,t.child=null):(s=o.sibling,o.sibling=null),Ps(t,!1,s,o,c,r);break;case"backwards":case"unstable_legacy-backwards":for(o=null,s=t.child,t.child=null;s!==null;){if(a=s.alternate,a!==null&&lo(a)===null){t.child=s;break}a=s.sibling,s.sibling=o,o=s,s=a}Ps(t,!0,o,null,c,r);break;case"together":Ps(t,!1,null,null,void 0,r);break;default:t.memoizedState=null}return t.child}function qi(a,t,o){if(a!==null&&(t.dependencies=a.dependencies),Rn|=t.lanes,(o&t.childLanes)===0)if(a!==null){if(pa(a,t,o,!1),(o&t.childLanes)===0)return null}else return null;if(a!==null&&t.child!==a.child)throw Error(f(153));if(t.child!==null){for(a=t.child,o=Bi(a,a.pendingProps),t.child=o,o.return=t;a.sibling!==null;)a=a.sibling,o=o.sibling=Bi(a,a.pendingProps),o.return=t;o.sibling=null}return t.child}function Ts(a,t){return(a.lanes&t)!==0?!0:(a=a.dependencies,!!(a!==null&&io(a)))}function Mp(a,t,o){switch(t.tag){case 3:he(t,t.stateNode.containerInfo),un(t,Oe,a.memoizedState.cache),Yn();break;case 27:case 5:Ze(t);break;case 4:he(t,t.stateNode.containerInfo);break;case 10:un(t,t.type,t.memoizedProps.value);break;case 31:if(t.memoizedState!==null)return t.flags|=128,is(t),null;break;case 13:var r=t.memoizedState;if(r!==null)return r.dehydrated!==null?(yn(t),t.flags|=128,null):(o&t.child.childLanes)!==0?om(a,t,o):(yn(t),a=qi(a,t,o),a!==null?a.sibling:null);yn(t);break;case 19:var s=(a.flags&128)!==0;if(r=(o&t.childLanes)!==0,r||(pa(a,t,o,!1),r=(o&t.childLanes)!==0),s){if(r)return sm(a,t,o);t.flags|=128}if(s=t.memoizedState,s!==null&&(s.rendering=null,s.tail=null,s.lastEffect=null),U(Te,Te.current),r)break;return null;case 22:return t.lanes=0,$d(a,t,o,t.pendingProps);case 24:un(t,Oe,a.memoizedState.cache)}return qi(a,t,o)}function cm(a,t,o){if(a!==null)if(a.memoizedProps!==t.pendingProps)He=!0;else{if(!Ts(a,o)&&(t.flags&128)===0)return He=!1,Mp(a,t,o);He=(a.flags&131072)!==0}else He=!1,oe&&(t.flags&1048576)!==0&&Yl(t,Za,t.index);switch(t.lanes=0,t.tag){case 16:e:{var r=t.pendingProps;if(a=jn(t.elementType),t.type=a,typeof a=="function")zr(a)?(r=qn(a,r),t.tag=1,t=am(null,t,a,r,o)):(t.tag=0,t=Cs(null,t,a,r,o));else{if(a!=null){var s=a.$$typeof;if(s===se){t.tag=11,t=Zd(null,t,a,r,o);break e}else if(s===F){t.tag=14,t=Xd(null,t,a,r,o);break e}}throw t=Pi(a)||a,Error(f(306,t,""))}}return t;case 0:return Cs(a,t,t.type,t.pendingProps,o);case 1:return r=t.type,s=qn(r,t.pendingProps),am(a,t,r,s,o);case 3:e:{if(he(t,t.stateNode.containerInfo),a===null)throw Error(f(387));r=t.pendingProps;var c=t.memoizedState;s=c.element,Zr(a,t),tt(t,r,null,o);var l=t.memoizedState;if(r=l.cache,un(t,Oe,r),r!==c.cache&&jr(t,[Oe],o,!0),at(),r=l.element,c.isDehydrated)if(c={element:r,isDehydrated:!1,cache:l.cache},t.updateQueue.baseState=c,t.memoizedState=c,t.flags&256){t=tm(a,t,r,o);break e}else if(r!==s){s=Ai(Error(f(424)),t),Xa(s),t=tm(a,t,r,o);break e}else{switch(a=t.stateNode.containerInfo,a.nodeType){case 9:a=a.body;break;default:a=a.nodeName==="HTML"?a.ownerDocument.body:a}for(Ce=Ei(a.firstChild),Le=t,oe=!0,dn=null,Ui=!0,o=$l(t,null,r,o),t.child=o;o;)o.flags=o.flags&-3|4096,o=o.sibling}else{if(Yn(),r===s){t=qi(a,t,o);break e}Fe(a,t,r,o)}t=t.child}return t;case 26:return vo(a,t),a===null?(o=Du(t.type,null,t.pendingProps,null))?t.memoizedState=o:oe||(o=t.type,a=t.pendingProps,r=_o(q.current).createElement(o),r[Ye]=t,r[Xe]=a,je(r,o,a),_e(r),t.stateNode=r):t.memoizedState=Du(t.type,a.memoizedProps,t.pendingProps,a.memoizedState),null;case 27:return Ze(t),a===null&&oe&&(r=t.stateNode=yu(t.type,t.pendingProps,q.current),Le=t,Ui=!0,s=Ce,Un(t.type)?(lc=s,Ce=Ei(r.firstChild)):Ce=s),Fe(a,t,t.pendingProps.children,o),vo(a,t),a===null&&(t.flags|=4194304),t.child;case 5:return a===null&&oe&&((s=r=Ce)&&(r=th(r,t.type,t.pendingProps,Ui),r!==null?(t.stateNode=r,Le=t,Ce=Ei(r.firstChild),Ui=!1,s=!0):s=!1),s||mn(t)),Ze(t),s=t.type,c=t.pendingProps,l=a!==null?a.memoizedProps:null,r=c.children,tc(s,c)?r=null:l!==null&&tc(s,l)&&(t.flags|=32),t.memoizedState!==null&&(s=as(a,t,Dp,null,null,o),Gt._currentValue=s),vo(a,t),Fe(a,t,r,o),t.child;case 6:return a===null&&oe&&((a=o=Ce)&&(o=oh(o,t.pendingProps,Ui),o!==null?(t.stateNode=o,Le=t,Ce=null,a=!0):a=!1),a||mn(t)),null;case 13:return om(a,t,o);case 4:return he(t,t.stateNode.containerInfo),r=t.pendingProps,a===null?t.child=Qn(t,null,r,o):Fe(a,t,r,o),t.child;case 11:return Zd(a,t,t.type,t.pendingProps,o);case 7:return Fe(a,t,t.pendingProps,o),t.child;case 8:return Fe(a,t,t.pendingProps.children,o),t.child;case 12:return Fe(a,t,t.pendingProps.children,o),t.child;case 10:return r=t.pendingProps,un(t,t.type,r.value),Fe(a,t,r.children,o),t.child;case 9:return s=t.type._context,r=t.pendingProps.children,Bn(t),s=Be(s),r=r(s),t.flags|=1,Fe(a,t,r,o),t.child;case 14:return Xd(a,t,t.type,t.pendingProps,o);case 15:return Jd(a,t,t.type,t.pendingProps,o);case 19:return sm(a,t,o);case 31:return Ep(a,t,o);case 22:return $d(a,t,o,t.pendingProps);case 24:return Bn(t),r=Be(Oe),a===null?(s=Wr(),s===null&&(s=ve,c=Vr(),s.pooledCache=c,c.refCount++,c!==null&&(s.pooledCacheLanes|=o),s=c),t.memoizedState={parent:r,cache:s},Kr(t),un(t,Oe,s)):((a.lanes&o)!==0&&(Zr(a,t),tt(t,null,null,o),at()),s=a.memoizedState,c=t.memoizedState,s.parent!==r?(s={parent:r,cache:r},t.memoizedState=s,t.lanes===0&&(t.memoizedState=t.updateQueue.baseState=s),un(t,Oe,r)):(r=c.cache,un(t,Oe,r),r!==s.cache&&jr(t,[Oe],o,!0))),Fe(a,t,t.pendingProps.children,o),t.child;case 29:throw t.pendingProps}throw Error(f(156,t.tag))}function Ki(a){a.flags|=4}function xs(a,t,o,r,s){if((t=(a.mode&32)!==0)&&(t=!1),t){if(a.flags|=16777216,(s&335544128)===s)if(a.stateNode.complete)a.flags|=8192;else if(zm())a.flags|=8192;else throw Vn=oo,qr}else a.flags&=-16777217}function lm(a,t){if(t.type!=="stylesheet"||(t.state.loading&4)!==0)a.flags&=-16777217;else if(a.flags|=16777216,!Gu(t))if(zm())a.flags|=8192;else throw Vn=oo,qr}function Co(a,t){t!==null&&(a.flags|=4),a.flags&16384&&(t=a.tag!==22?Bc():536870912,a.lanes|=t,Ia|=t)}function dt(a,t){if(!oe)switch(a.tailMode){case"hidden":t=a.tail;for(var o=null;t!==null;)t.alternate!==null&&(o=t),t=t.sibling;o===null?a.tail=null:o.sibling=null;break;case"collapsed":o=a.tail;for(var r=null;o!==null;)o.alternate!==null&&(r=o),o=o.sibling;r===null?t||a.tail===null?a.tail=null:a.tail.sibling=null:r.sibling=null}}function Ge(a){var t=a.alternate!==null&&a.alternate.child===a.child,o=0,r=0;if(t)for(var s=a.child;s!==null;)o|=s.lanes|s.childLanes,r|=s.subtreeFlags&65011712,r|=s.flags&65011712,s.return=a,s=s.sibling;else for(s=a.child;s!==null;)o|=s.lanes|s.childLanes,r|=s.subtreeFlags,r|=s.flags,s.return=a,s=s.sibling;return a.subtreeFlags|=r,a.childLanes=o,t}function Pp(a,t,o){var r=t.pendingProps;switch(Nr(t),t.tag){case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Ge(t),null;case 1:return Ge(t),null;case 3:return o=t.stateNode,r=null,a!==null&&(r=a.memoizedState.cache),t.memoizedState.cache!==r&&(t.flags|=2048),Vi(Oe),le(),o.pendingContext&&(o.context=o.pendingContext,o.pendingContext=null),(a===null||a.child===null)&&(fa(t)?Ki(t):a===null||a.memoizedState.isDehydrated&&(t.flags&256)===0||(t.flags|=1024,Lr())),Ge(t),null;case 26:var s=t.type,c=t.memoizedState;return a===null?(Ki(t),c!==null?(Ge(t),lm(t,c)):(Ge(t),xs(t,s,null,r,o))):c?c!==a.memoizedState?(Ki(t),Ge(t),lm(t,c)):(Ge(t),t.flags&=-16777217):(a=a.memoizedProps,a!==r&&Ki(t),Ge(t),xs(t,s,a,r,o)),null;case 27:if(on(t),o=q.current,s=t.type,a!==null&&t.stateNode!=null)a.memoizedProps!==r&&Ki(t);else{if(!r){if(t.stateNode===null)throw Error(f(166));return Ge(t),null}a=T.current,fa(t)?Bl(t):(a=yu(s,r,o),t.stateNode=a,Ki(t))}return Ge(t),null;case 5:if(on(t),s=t.type,a!==null&&t.stateNode!=null)a.memoizedProps!==r&&Ki(t);else{if(!r){if(t.stateNode===null)throw Error(f(166));return Ge(t),null}if(c=T.current,fa(t))Bl(t);else{var l=_o(q.current);switch(c){case 1:c=l.createElementNS("http://www.w3.org/2000/svg",s);break;case 2:c=l.createElementNS("http://www.w3.org/1998/Math/MathML",s);break;default:switch(s){case"svg":c=l.createElementNS("http://www.w3.org/2000/svg",s);break;case"math":c=l.createElementNS("http://www.w3.org/1998/Math/MathML",s);break;case"script":c=l.createElement("div"),c.innerHTML="<script><\/script>",c=c.removeChild(c.firstChild);break;case"select":c=typeof r.is=="string"?l.createElement("select",{is:r.is}):l.createElement("select"),r.multiple?c.multiple=!0:r.size&&(c.size=r.size);break;default:c=typeof r.is=="string"?l.createElement(s,{is:r.is}):l.createElement(s)}}c[Ye]=t,c[Xe]=r;e:for(l=t.child;l!==null;){if(l.tag===5||l.tag===6)c.appendChild(l.stateNode);else if(l.tag!==4&&l.tag!==27&&l.child!==null){l.child.return=l,l=l.child;continue}if(l===t)break e;for(;l.sibling===null;){if(l.return===null||l.return===t)break e;l=l.return}l.sibling.return=l.return,l=l.sibling}t.stateNode=c;e:switch(je(c,s,r),s){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}r&&Ki(t)}}return Ge(t),xs(t,t.type,a===null?null:a.memoizedProps,t.pendingProps,o),null;case 6:if(a&&t.stateNode!=null)a.memoizedProps!==r&&Ki(t);else{if(typeof r!="string"&&t.stateNode===null)throw Error(f(166));if(a=q.current,fa(t)){if(a=t.stateNode,o=t.memoizedProps,r=null,s=Le,s!==null)switch(s.tag){case 27:case 5:r=s.memoizedProps}a[Ye]=t,a=!!(a.nodeValue===o||r!==null&&r.suppressHydrationWarning===!0||ou(a.nodeValue,o)),a||mn(t,!0)}else a=_o(a).createTextNode(r),a[Ye]=t,t.stateNode=a}return Ge(t),null;case 31:if(o=t.memoizedState,a===null||a.memoizedState!==null){if(r=fa(t),o!==null){if(a===null){if(!r)throw Error(f(318));if(a=t.memoizedState,a=a!==null?a.dehydrated:null,!a)throw Error(f(557));a[Ye]=t}else Yn(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;Ge(t),a=!1}else o=Lr(),a!==null&&a.memoizedState!==null&&(a.memoizedState.hydrationErrors=o),a=!0;if(!a)return t.flags&256?(fi(t),t):(fi(t),null);if((t.flags&128)!==0)throw Error(f(558))}return Ge(t),null;case 13:if(r=t.memoizedState,a===null||a.memoizedState!==null&&a.memoizedState.dehydrated!==null){if(s=fa(t),r!==null&&r.dehydrated!==null){if(a===null){if(!s)throw Error(f(318));if(s=t.memoizedState,s=s!==null?s.dehydrated:null,!s)throw Error(f(317));s[Ye]=t}else Yn(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;Ge(t),s=!1}else s=Lr(),a!==null&&a.memoizedState!==null&&(a.memoizedState.hydrationErrors=s),s=!0;if(!s)return t.flags&256?(fi(t),t):(fi(t),null)}return fi(t),(t.flags&128)!==0?(t.lanes=o,t):(o=r!==null,a=a!==null&&a.memoizedState!==null,o&&(r=t.child,s=null,r.alternate!==null&&r.alternate.memoizedState!==null&&r.alternate.memoizedState.cachePool!==null&&(s=r.alternate.memoizedState.cachePool.pool),c=null,r.memoizedState!==null&&r.memoizedState.cachePool!==null&&(c=r.memoizedState.cachePool.pool),c!==s&&(r.flags|=2048)),o!==a&&o&&(t.child.flags|=8192),Co(t,t.updateQueue),Ge(t),null);case 4:return le(),a===null&&$s(t.stateNode.containerInfo),Ge(t),null;case 10:return Vi(t.type),Ge(t),null;case 19:if(g(Te),r=t.memoizedState,r===null)return Ge(t),null;if(s=(t.flags&128)!==0,c=r.rendering,c===null)if(s)dt(r,!1);else{if(Me!==0||a!==null&&(a.flags&128)!==0)for(a=t.child;a!==null;){if(c=lo(a),c!==null){for(t.flags|=128,dt(r,!1),a=c.updateQueue,t.updateQueue=a,Co(t,a),t.subtreeFlags=0,a=o,o=t.child;o!==null;)kl(o,a),o=o.sibling;return U(Te,Te.current&1|2),oe&&Fi(t,r.treeForkCount),t.child}a=a.sibling}r.tail!==null&&si()>Mo&&(t.flags|=128,s=!0,dt(r,!1),t.lanes=4194304)}else{if(!s)if(a=lo(c),a!==null){if(t.flags|=128,s=!0,a=a.updateQueue,t.updateQueue=a,Co(t,a),dt(r,!0),r.tail===null&&r.tailMode==="hidden"&&!c.alternate&&!oe)return Ge(t),null}else 2*si()-r.renderingStartTime>Mo&&o!==536870912&&(t.flags|=128,s=!0,dt(r,!1),t.lanes=4194304);r.isBackwards?(c.sibling=t.child,t.child=c):(a=r.last,a!==null?a.sibling=c:t.child=c,r.last=c)}return r.tail!==null?(a=r.tail,r.rendering=a,r.tail=a.sibling,r.renderingStartTime=si(),a.sibling=null,o=Te.current,U(Te,s?o&1|2:o&1),oe&&Fi(t,r.treeForkCount),a):(Ge(t),null);case 22:case 23:return fi(t),es(),r=t.memoizedState!==null,a!==null?a.memoizedState!==null!==r&&(t.flags|=8192):r&&(t.flags|=8192),r?(o&536870912)!==0&&(t.flags&128)===0&&(Ge(t),t.subtreeFlags&6&&(t.flags|=8192)):Ge(t),o=t.updateQueue,o!==null&&Co(t,o.retryQueue),o=null,a!==null&&a.memoizedState!==null&&a.memoizedState.cachePool!==null&&(o=a.memoizedState.cachePool.pool),r=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(r=t.memoizedState.cachePool.pool),r!==o&&(t.flags|=2048),a!==null&&g(Fn),null;case 24:return o=null,a!==null&&(o=a.memoizedState.cache),t.memoizedState.cache!==o&&(t.flags|=2048),Vi(Oe),Ge(t),null;case 25:return null;case 30:return null}throw Error(f(156,t.tag))}function Tp(a,t){switch(Nr(t),t.tag){case 1:return a=t.flags,a&65536?(t.flags=a&-65537|128,t):null;case 3:return Vi(Oe),le(),a=t.flags,(a&65536)!==0&&(a&128)===0?(t.flags=a&-65537|128,t):null;case 26:case 27:case 5:return on(t),null;case 31:if(t.memoizedState!==null){if(fi(t),t.alternate===null)throw Error(f(340));Yn()}return a=t.flags,a&65536?(t.flags=a&-65537|128,t):null;case 13:if(fi(t),a=t.memoizedState,a!==null&&a.dehydrated!==null){if(t.alternate===null)throw Error(f(340));Yn()}return a=t.flags,a&65536?(t.flags=a&-65537|128,t):null;case 19:return g(Te),null;case 4:return le(),null;case 10:return Vi(t.type),null;case 22:case 23:return fi(t),es(),a!==null&&g(Fn),a=t.flags,a&65536?(t.flags=a&-65537|128,t):null;case 24:return Vi(Oe),null;case 25:return null;default:return null}}function dm(a,t){switch(Nr(t),t.tag){case 3:Vi(Oe),le();break;case 26:case 27:case 5:on(t);break;case 4:le();break;case 31:t.memoizedState!==null&&fi(t);break;case 13:fi(t);break;case 19:g(Te);break;case 10:Vi(t.type);break;case 22:case 23:fi(t),es(),a!==null&&g(Fn);break;case 24:Vi(Oe)}}function mt(a,t){try{var o=t.updateQueue,r=o!==null?o.lastEffect:null;if(r!==null){var s=r.next;o=s;do{if((o.tag&a)===a){r=void 0;var c=o.create,l=o.inst;r=c(),l.destroy=r}o=o.next}while(o!==s)}}catch(d){be(t,t.return,d)}}function gn(a,t,o){try{var r=t.updateQueue,s=r!==null?r.lastEffect:null;if(s!==null){var c=s.next;r=c;do{if((r.tag&a)===a){var l=r.inst,d=l.destroy;if(d!==void 0){l.destroy=void 0,s=t;var u=o,R=d;try{R()}catch(G){be(s,u,G)}}}r=r.next}while(r!==c)}}catch(G){be(t,t.return,G)}}function mm(a){var t=a.updateQueue;if(t!==null){var o=a.stateNode;try{id(t,o)}catch(r){be(a,a.return,r)}}}function um(a,t,o){o.props=qn(a.type,a.memoizedProps),o.state=a.memoizedState;try{o.componentWillUnmount()}catch(r){be(a,t,r)}}function ut(a,t){try{var o=a.ref;if(o!==null){switch(a.tag){case 26:case 27:case 5:var r=a.stateNode;break;case 30:r=a.stateNode;break;default:r=a.stateNode}typeof o=="function"?a.refCleanup=o(r):o.current=r}}catch(s){be(a,t,s)}}function zi(a,t){var o=a.ref,r=a.refCleanup;if(o!==null)if(typeof r=="function")try{r()}catch(s){be(a,t,s)}finally{a.refCleanup=null,a=a.alternate,a!=null&&(a.refCleanup=null)}else if(typeof o=="function")try{o(null)}catch(s){be(a,t,s)}else o.current=null}function fm(a){var t=a.type,o=a.memoizedProps,r=a.stateNode;try{e:switch(t){case"button":case"input":case"select":case"textarea":o.autoFocus&&r.focus();break e;case"img":o.src?r.src=o.src:o.srcSet&&(r.srcset=o.srcSet)}}catch(s){be(a,a.return,s)}}function Os(a,t,o){try{var r=a.stateNode;Jp(r,a.type,o,t),r[Xe]=t}catch(s){be(a,a.return,s)}}function pm(a){return a.tag===5||a.tag===3||a.tag===26||a.tag===27&&Un(a.type)||a.tag===4}function Ss(a){e:for(;;){for(;a.sibling===null;){if(a.return===null||pm(a.return))return null;a=a.return}for(a.sibling.return=a.return,a=a.sibling;a.tag!==5&&a.tag!==6&&a.tag!==18;){if(a.tag===27&&Un(a.type)||a.flags&2||a.child===null||a.tag===4)continue e;a.child.return=a,a=a.child}if(!(a.flags&2))return a.stateNode}}function Hs(a,t,o){var r=a.tag;if(r===5||r===6)a=a.stateNode,t?(o.nodeType===9?o.body:o.nodeName==="HTML"?o.ownerDocument.body:o).insertBefore(a,t):(t=o.nodeType===9?o.body:o.nodeName==="HTML"?o.ownerDocument.body:o,t.appendChild(a),o=o._reactRootContainer,o!=null||t.onclick!==null||(t.onclick=Yi));else if(r!==4&&(r===27&&Un(a.type)&&(o=a.stateNode,t=null),a=a.child,a!==null))for(Hs(a,t,o),a=a.sibling;a!==null;)Hs(a,t,o),a=a.sibling}function Go(a,t,o){var r=a.tag;if(r===5||r===6)a=a.stateNode,t?o.insertBefore(a,t):o.appendChild(a);else if(r!==4&&(r===27&&Un(a.type)&&(o=a.stateNode),a=a.child,a!==null))for(Go(a,t,o),a=a.sibling;a!==null;)Go(a,t,o),a=a.sibling}function hm(a){var t=a.stateNode,o=a.memoizedProps;try{for(var r=a.type,s=t.attributes;s.length;)t.removeAttributeNode(s[0]);je(t,r,o),t[Ye]=a,t[Xe]=o}catch(c){be(a,a.return,c)}}var Zi=!1,ze=!1,zs=!1,ym=typeof WeakSet=="function"?WeakSet:Set,Ne=null;function xp(a,t){if(a=a.containerInfo,nc=Vo,a=Ml(a),Mr(a)){if("selectionStart"in a)var o={start:a.selectionStart,end:a.selectionEnd};else e:{o=(o=a.ownerDocument)&&o.defaultView||window;var r=o.getSelection&&o.getSelection();if(r&&r.rangeCount!==0){o=r.anchorNode;var s=r.anchorOffset,c=r.focusNode;r=r.focusOffset;try{o.nodeType,c.nodeType}catch{o=null;break e}var l=0,d=-1,u=-1,R=0,G=0,M=a,v=null;i:for(;;){for(var A;M!==o||s!==0&&M.nodeType!==3||(d=l+s),M!==c||r!==0&&M.nodeType!==3||(u=l+r),M.nodeType===3&&(l+=M.nodeValue.length),(A=M.firstChild)!==null;)v=M,M=A;for(;;){if(M===a)break i;if(v===o&&++R===s&&(d=l),v===c&&++G===r&&(u=l),(A=M.nextSibling)!==null)break;M=v,v=M.parentNode}M=A}o=d===-1||u===-1?null:{start:d,end:u}}else o=null}o=o||{start:0,end:0}}else o=null;for(ac={focusedElem:a,selectionRange:o},Vo=!1,Ne=t;Ne!==null;)if(t=Ne,a=t.child,(t.subtreeFlags&1028)!==0&&a!==null)a.return=t,Ne=a;else for(;Ne!==null;){switch(t=Ne,c=t.alternate,a=t.flags,t.tag){case 0:if((a&4)!==0&&(a=t.updateQueue,a=a!==null?a.events:null,a!==null))for(o=0;o<a.length;o++)s=a[o],s.ref.impl=s.nextImpl;break;case 11:case 15:break;case 1:if((a&1024)!==0&&c!==null){a=void 0,o=t,s=c.memoizedProps,c=c.memoizedState,r=o.stateNode;try{var k=qn(o.type,s);a=r.getSnapshotBeforeUpdate(k,c),r.__reactInternalSnapshotBeforeUpdate=a}catch(j){be(o,o.return,j)}}break;case 3:if((a&1024)!==0){if(a=t.stateNode.containerInfo,o=a.nodeType,o===9)rc(a);else if(o===1)switch(a.nodeName){case"HEAD":case"HTML":case"BODY":rc(a);break;default:a.textContent=""}}break;case 5:case 26:case 27:case 6:case 4:case 17:break;default:if((a&1024)!==0)throw Error(f(163))}if(a=t.sibling,a!==null){a.return=t.return,Ne=a;break}Ne=t.return}}function bm(a,t,o){var r=o.flags;switch(o.tag){case 0:case 11:case 15:Ji(a,o),r&4&&mt(5,o);break;case 1:if(Ji(a,o),r&4)if(a=o.stateNode,t===null)try{a.componentDidMount()}catch(l){be(o,o.return,l)}else{var s=qn(o.type,t.memoizedProps);t=t.memoizedState;try{a.componentDidUpdate(s,t,a.__reactInternalSnapshotBeforeUpdate)}catch(l){be(o,o.return,l)}}r&64&&mm(o),r&512&&ut(o,o.return);break;case 3:if(Ji(a,o),r&64&&(a=o.updateQueue,a!==null)){if(t=null,o.child!==null)switch(o.child.tag){case 27:case 5:t=o.child.stateNode;break;case 1:t=o.child.stateNode}try{id(a,t)}catch(l){be(o,o.return,l)}}break;case 27:t===null&&r&4&&hm(o);case 26:case 5:Ji(a,o),t===null&&r&4&&fm(o),r&512&&ut(o,o.return);break;case 12:Ji(a,o);break;case 31:Ji(a,o),r&4&&Rm(a,o);break;case 13:Ji(a,o),r&4&&vm(a,o),r&64&&(a=o.memoizedState,a!==null&&(a=a.dehydrated,a!==null&&(o=Yp.bind(null,o),rh(a,o))));break;case 22:if(r=o.memoizedState!==null||Zi,!r){t=t!==null&&t.memoizedState!==null||ze,s=Zi;var c=ze;Zi=r,(ze=t)&&!c?$i(a,o,(o.subtreeFlags&8772)!==0):Ji(a,o),Zi=s,ze=c}break;case 30:break;default:Ji(a,o)}}function gm(a){var t=a.alternate;t!==null&&(a.alternate=null,gm(t)),a.child=null,a.deletions=null,a.sibling=null,a.tag===5&&(t=a.stateNode,t!==null&&mr(t)),a.stateNode=null,a.return=null,a.dependencies=null,a.memoizedProps=null,a.memoizedState=null,a.pendingProps=null,a.stateNode=null,a.updateQueue=null}var Ue=null,$e=!1;function Xi(a,t,o){for(o=o.child;o!==null;)Dm(a,t,o),o=o.sibling}function Dm(a,t,o){if(ci&&typeof ci.onCommitFiberUnmount=="function")try{ci.onCommitFiberUnmount(wa,o)}catch{}switch(o.tag){case 26:ze||zi(o,t),Xi(a,t,o),o.memoizedState?o.memoizedState.count--:o.stateNode&&(o=o.stateNode,o.parentNode.removeChild(o));break;case 27:ze||zi(o,t);var r=Ue,s=$e;Un(o.type)&&(Ue=o.stateNode,$e=!1),Xi(a,t,o),vt(o.stateNode),Ue=r,$e=s;break;case 5:ze||zi(o,t);case 6:if(r=Ue,s=$e,Ue=null,Xi(a,t,o),Ue=r,$e=s,Ue!==null)if($e)try{(Ue.nodeType===9?Ue.body:Ue.nodeName==="HTML"?Ue.ownerDocument.body:Ue).removeChild(o.stateNode)}catch(c){be(o,t,c)}else try{Ue.removeChild(o.stateNode)}catch(c){be(o,t,c)}break;case 18:Ue!==null&&($e?(a=Ue,mu(a.nodeType===9?a.body:a.nodeName==="HTML"?a.ownerDocument.body:a,o.stateNode),Ha(a)):mu(Ue,o.stateNode));break;case 4:r=Ue,s=$e,Ue=o.stateNode.containerInfo,$e=!0,Xi(a,t,o),Ue=r,$e=s;break;case 0:case 11:case 14:case 15:gn(2,o,t),ze||gn(4,o,t),Xi(a,t,o);break;case 1:ze||(zi(o,t),r=o.stateNode,typeof r.componentWillUnmount=="function"&&um(o,t,r)),Xi(a,t,o);break;case 21:Xi(a,t,o);break;case 22:ze=(r=ze)||o.memoizedState!==null,Xi(a,t,o),ze=r;break;default:Xi(a,t,o)}}function Rm(a,t){if(t.memoizedState===null&&(a=t.alternate,a!==null&&(a=a.memoizedState,a!==null))){a=a.dehydrated;try{Ha(a)}catch(o){be(t,t.return,o)}}}function vm(a,t){if(t.memoizedState===null&&(a=t.alternate,a!==null&&(a=a.memoizedState,a!==null&&(a=a.dehydrated,a!==null))))try{Ha(a)}catch(o){be(t,t.return,o)}}function Op(a){switch(a.tag){case 31:case 13:case 19:var t=a.stateNode;return t===null&&(t=a.stateNode=new ym),t;case 22:return a=a.stateNode,t=a._retryCache,t===null&&(t=a._retryCache=new ym),t;default:throw Error(f(435,a.tag))}}function Uo(a,t){var o=Op(a);t.forEach(function(r){if(!o.has(r)){o.add(r);var s=Lp.bind(null,a,r);r.then(s,s)}})}function ei(a,t){var o=t.deletions;if(o!==null)for(var r=0;r<o.length;r++){var s=o[r],c=a,l=t,d=l;e:for(;d!==null;){switch(d.tag){case 27:if(Un(d.type)){Ue=d.stateNode,$e=!1;break e}break;case 5:Ue=d.stateNode,$e=!1;break e;case 3:case 4:Ue=d.stateNode.containerInfo,$e=!0;break e}d=d.return}if(Ue===null)throw Error(f(160));Dm(c,l,s),Ue=null,$e=!1,c=s.alternate,c!==null&&(c.return=null),s.return=null}if(t.subtreeFlags&13886)for(t=t.child;t!==null;)Am(t,a),t=t.sibling}var xi=null;function Am(a,t){var o=a.alternate,r=a.flags;switch(a.tag){case 0:case 11:case 14:case 15:ei(t,a),ii(a),r&4&&(gn(3,a,a.return),mt(3,a),gn(5,a,a.return));break;case 1:ei(t,a),ii(a),r&512&&(ze||o===null||zi(o,o.return)),r&64&&Zi&&(a=a.updateQueue,a!==null&&(r=a.callbacks,r!==null&&(o=a.shared.hiddenCallbacks,a.shared.hiddenCallbacks=o===null?r:o.concat(r))));break;case 26:var s=xi;if(ei(t,a),ii(a),r&512&&(ze||o===null||zi(o,o.return)),r&4){var c=o!==null?o.memoizedState:null;if(r=a.memoizedState,o===null)if(r===null)if(a.stateNode===null){e:{r=a.type,o=a.memoizedProps,s=s.ownerDocument||s;i:switch(r){case"title":c=s.getElementsByTagName("title")[0],(!c||c[Na]||c[Ye]||c.namespaceURI==="http://www.w3.org/2000/svg"||c.hasAttribute("itemprop"))&&(c=s.createElement(r),s.head.insertBefore(c,s.querySelector("head > title"))),je(c,r,o),c[Ye]=a,_e(c),r=c;break e;case"link":var l=Au("link","href",s).get(r+(o.href||""));if(l){for(var d=0;d<l.length;d++)if(c=l[d],c.getAttribute("href")===(o.href==null||o.href===""?null:o.href)&&c.getAttribute("rel")===(o.rel==null?null:o.rel)&&c.getAttribute("title")===(o.title==null?null:o.title)&&c.getAttribute("crossorigin")===(o.crossOrigin==null?null:o.crossOrigin)){l.splice(d,1);break i}}c=s.createElement(r),je(c,r,o),s.head.appendChild(c);break;case"meta":if(l=Au("meta","content",s).get(r+(o.content||""))){for(d=0;d<l.length;d++)if(c=l[d],c.getAttribute("content")===(o.content==null?null:""+o.content)&&c.getAttribute("name")===(o.name==null?null:o.name)&&c.getAttribute("property")===(o.property==null?null:o.property)&&c.getAttribute("http-equiv")===(o.httpEquiv==null?null:o.httpEquiv)&&c.getAttribute("charset")===(o.charSet==null?null:o.charSet)){l.splice(d,1);break i}}c=s.createElement(r),je(c,r,o),s.head.appendChild(c);break;default:throw Error(f(468,r))}c[Ye]=a,_e(c),r=c}a.stateNode=r}else Cu(s,a.type,a.stateNode);else a.stateNode=vu(s,r,a.memoizedProps);else c!==r?(c===null?o.stateNode!==null&&(o=o.stateNode,o.parentNode.removeChild(o)):c.count--,r===null?Cu(s,a.type,a.stateNode):vu(s,r,a.memoizedProps)):r===null&&a.stateNode!==null&&Os(a,a.memoizedProps,o.memoizedProps)}break;case 27:ei(t,a),ii(a),r&512&&(ze||o===null||zi(o,o.return)),o!==null&&r&4&&Os(a,a.memoizedProps,o.memoizedProps);break;case 5:if(ei(t,a),ii(a),r&512&&(ze||o===null||zi(o,o.return)),a.flags&32){s=a.stateNode;try{aa(s,"")}catch(k){be(a,a.return,k)}}r&4&&a.stateNode!=null&&(s=a.memoizedProps,Os(a,s,o!==null?o.memoizedProps:s)),r&1024&&(zs=!0);break;case 6:if(ei(t,a),ii(a),r&4){if(a.stateNode===null)throw Error(f(162));r=a.memoizedProps,o=a.stateNode;try{o.nodeValue=r}catch(k){be(a,a.return,k)}}break;case 3:if(Lo=null,s=xi,xi=No(t.containerInfo),ei(t,a),xi=s,ii(a),r&4&&o!==null&&o.memoizedState.isDehydrated)try{Ha(t.containerInfo)}catch(k){be(a,a.return,k)}zs&&(zs=!1,Cm(a));break;case 4:r=xi,xi=No(a.stateNode.containerInfo),ei(t,a),ii(a),xi=r;break;case 12:ei(t,a),ii(a);break;case 31:ei(t,a),ii(a),r&4&&(r=a.updateQueue,r!==null&&(a.updateQueue=null,Uo(a,r)));break;case 13:ei(t,a),ii(a),a.child.flags&8192&&a.memoizedState!==null!=(o!==null&&o.memoizedState!==null)&&(Eo=si()),r&4&&(r=a.updateQueue,r!==null&&(a.updateQueue=null,Uo(a,r)));break;case 22:s=a.memoizedState!==null;var u=o!==null&&o.memoizedState!==null,R=Zi,G=ze;if(Zi=R||s,ze=G||u,ei(t,a),ze=G,Zi=R,ii(a),r&8192)e:for(t=a.stateNode,t._visibility=s?t._visibility&-2:t._visibility|1,s&&(o===null||u||Zi||ze||Kn(a)),o=null,t=a;;){if(t.tag===5||t.tag===26){if(o===null){u=o=t;try{if(c=u.stateNode,s)l=c.style,typeof l.setProperty=="function"?l.setProperty("display","none","important"):l.display="none";else{d=u.stateNode;var M=u.memoizedProps.style,v=M!=null&&M.hasOwnProperty("display")?M.display:null;d.style.display=v==null||typeof v=="boolean"?"":(""+v).trim()}}catch(k){be(u,u.return,k)}}}else if(t.tag===6){if(o===null){u=t;try{u.stateNode.nodeValue=s?"":u.memoizedProps}catch(k){be(u,u.return,k)}}}else if(t.tag===18){if(o===null){u=t;try{var A=u.stateNode;s?uu(A,!0):uu(u.stateNode,!1)}catch(k){be(u,u.return,k)}}}else if((t.tag!==22&&t.tag!==23||t.memoizedState===null||t===a)&&t.child!==null){t.child.return=t,t=t.child;continue}if(t===a)break e;for(;t.sibling===null;){if(t.return===null||t.return===a)break e;o===t&&(o=null),t=t.return}o===t&&(o=null),t.sibling.return=t.return,t=t.sibling}r&4&&(r=a.updateQueue,r!==null&&(o=r.retryQueue,o!==null&&(r.retryQueue=null,Uo(a,o))));break;case 19:ei(t,a),ii(a),r&4&&(r=a.updateQueue,r!==null&&(a.updateQueue=null,Uo(a,r)));break;case 30:break;case 21:break;default:ei(t,a),ii(a)}}function ii(a){var t=a.flags;if(t&2){try{for(var o,r=a.return;r!==null;){if(pm(r)){o=r;break}r=r.return}if(o==null)throw Error(f(160));switch(o.tag){case 27:var s=o.stateNode,c=Ss(a);Go(a,c,s);break;case 5:var l=o.stateNode;o.flags&32&&(aa(l,""),o.flags&=-33);var d=Ss(a);Go(a,d,l);break;case 3:case 4:var u=o.stateNode.containerInfo,R=Ss(a);Hs(a,R,u);break;default:throw Error(f(161))}}catch(G){be(a,a.return,G)}a.flags&=-3}t&4096&&(a.flags&=-4097)}function Cm(a){if(a.subtreeFlags&1024)for(a=a.child;a!==null;){var t=a;Cm(t),t.tag===5&&t.flags&1024&&t.stateNode.reset(),a=a.sibling}}function Ji(a,t){if(t.subtreeFlags&8772)for(t=t.child;t!==null;)bm(a,t.alternate,t),t=t.sibling}function Kn(a){for(a=a.child;a!==null;){var t=a;switch(t.tag){case 0:case 11:case 14:case 15:gn(4,t,t.return),Kn(t);break;case 1:zi(t,t.return);var o=t.stateNode;typeof o.componentWillUnmount=="function"&&um(t,t.return,o),Kn(t);break;case 27:vt(t.stateNode);case 26:case 5:zi(t,t.return),Kn(t);break;case 22:t.memoizedState===null&&Kn(t);break;case 30:Kn(t);break;default:Kn(t)}a=a.sibling}}function $i(a,t,o){for(o=o&&(t.subtreeFlags&8772)!==0,t=t.child;t!==null;){var r=t.alternate,s=a,c=t,l=c.flags;switch(c.tag){case 0:case 11:case 15:$i(s,c,o),mt(4,c);break;case 1:if($i(s,c,o),r=c,s=r.stateNode,typeof s.componentDidMount=="function")try{s.componentDidMount()}catch(R){be(r,r.return,R)}if(r=c,s=r.updateQueue,s!==null){var d=r.stateNode;try{var u=s.shared.hiddenCallbacks;if(u!==null)for(s.shared.hiddenCallbacks=null,s=0;s<u.length;s++)ed(u[s],d)}catch(R){be(r,r.return,R)}}o&&l&64&&mm(c),ut(c,c.return);break;case 27:hm(c);case 26:case 5:$i(s,c,o),o&&r===null&&l&4&&fm(c),ut(c,c.return);break;case 12:$i(s,c,o);break;case 31:$i(s,c,o),o&&l&4&&Rm(s,c);break;case 13:$i(s,c,o),o&&l&4&&vm(s,c);break;case 22:c.memoizedState===null&&$i(s,c,o),ut(c,c.return);break;case 30:break;default:$i(s,c,o)}t=t.sibling}}function ws(a,t){var o=null;a!==null&&a.memoizedState!==null&&a.memoizedState.cachePool!==null&&(o=a.memoizedState.cachePool.pool),a=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(a=t.memoizedState.cachePool.pool),a!==o&&(a!=null&&a.refCount++,o!=null&&Ja(o))}function ks(a,t){a=null,t.alternate!==null&&(a=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==a&&(t.refCount++,a!=null&&Ja(a))}function Oi(a,t,o,r){if(t.subtreeFlags&10256)for(t=t.child;t!==null;)Gm(a,t,o,r),t=t.sibling}function Gm(a,t,o,r){var s=t.flags;switch(t.tag){case 0:case 11:case 15:Oi(a,t,o,r),s&2048&&mt(9,t);break;case 1:Oi(a,t,o,r);break;case 3:Oi(a,t,o,r),s&2048&&(a=null,t.alternate!==null&&(a=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==a&&(t.refCount++,a!=null&&Ja(a)));break;case 12:if(s&2048){Oi(a,t,o,r),a=t.stateNode;try{var c=t.memoizedProps,l=c.id,d=c.onPostCommit;typeof d=="function"&&d(l,t.alternate===null?"mount":"update",a.passiveEffectDuration,-0)}catch(u){be(t,t.return,u)}}else Oi(a,t,o,r);break;case 31:Oi(a,t,o,r);break;case 13:Oi(a,t,o,r);break;case 23:break;case 22:c=t.stateNode,l=t.alternate,t.memoizedState!==null?c._visibility&2?Oi(a,t,o,r):ft(a,t):c._visibility&2?Oi(a,t,o,r):(c._visibility|=2,Ca(a,t,o,r,(t.subtreeFlags&10256)!==0||!1)),s&2048&&ws(l,t);break;case 24:Oi(a,t,o,r),s&2048&&ks(t.alternate,t);break;default:Oi(a,t,o,r)}}function Ca(a,t,o,r,s){for(s=s&&((t.subtreeFlags&10256)!==0||!1),t=t.child;t!==null;){var c=a,l=t,d=o,u=r,R=l.flags;switch(l.tag){case 0:case 11:case 15:Ca(c,l,d,u,s),mt(8,l);break;case 23:break;case 22:var G=l.stateNode;l.memoizedState!==null?G._visibility&2?Ca(c,l,d,u,s):ft(c,l):(G._visibility|=2,Ca(c,l,d,u,s)),s&&R&2048&&ws(l.alternate,l);break;case 24:Ca(c,l,d,u,s),s&&R&2048&&ks(l.alternate,l);break;default:Ca(c,l,d,u,s)}t=t.sibling}}function ft(a,t){if(t.subtreeFlags&10256)for(t=t.child;t!==null;){var o=a,r=t,s=r.flags;switch(r.tag){case 22:ft(o,r),s&2048&&ws(r.alternate,r);break;case 24:ft(o,r),s&2048&&ks(r.alternate,r);break;default:ft(o,r)}t=t.sibling}}var pt=8192;function Ga(a,t,o){if(a.subtreeFlags&pt)for(a=a.child;a!==null;)Um(a,t,o),a=a.sibling}function Um(a,t,o){switch(a.tag){case 26:Ga(a,t,o),a.flags&pt&&a.memoizedState!==null&&gh(o,xi,a.memoizedState,a.memoizedProps);break;case 5:Ga(a,t,o);break;case 3:case 4:var r=xi;xi=No(a.stateNode.containerInfo),Ga(a,t,o),xi=r;break;case 22:a.memoizedState===null&&(r=a.alternate,r!==null&&r.memoizedState!==null?(r=pt,pt=16777216,Ga(a,t,o),pt=r):Ga(a,t,o));break;default:Ga(a,t,o)}}function Im(a){var t=a.alternate;if(t!==null&&(a=t.child,a!==null)){t.child=null;do t=a.sibling,a.sibling=null,a=t;while(a!==null)}}function ht(a){var t=a.deletions;if((a.flags&16)!==0){if(t!==null)for(var o=0;o<t.length;o++){var r=t[o];Ne=r,Mm(r,a)}Im(a)}if(a.subtreeFlags&10256)for(a=a.child;a!==null;)Em(a),a=a.sibling}function Em(a){switch(a.tag){case 0:case 11:case 15:ht(a),a.flags&2048&&gn(9,a,a.return);break;case 3:ht(a);break;case 12:ht(a);break;case 22:var t=a.stateNode;a.memoizedState!==null&&t._visibility&2&&(a.return===null||a.return.tag!==13)?(t._visibility&=-3,Io(a)):ht(a);break;default:ht(a)}}function Io(a){var t=a.deletions;if((a.flags&16)!==0){if(t!==null)for(var o=0;o<t.length;o++){var r=t[o];Ne=r,Mm(r,a)}Im(a)}for(a=a.child;a!==null;){switch(t=a,t.tag){case 0:case 11:case 15:gn(8,t,t.return),Io(t);break;case 22:o=t.stateNode,o._visibility&2&&(o._visibility&=-3,Io(t));break;default:Io(t)}a=a.sibling}}function Mm(a,t){for(;Ne!==null;){var o=Ne;switch(o.tag){case 0:case 11:case 15:gn(8,o,t);break;case 23:case 22:if(o.memoizedState!==null&&o.memoizedState.cachePool!==null){var r=o.memoizedState.cachePool.pool;r!=null&&r.refCount++}break;case 24:Ja(o.memoizedState.cache)}if(r=o.child,r!==null)r.return=o,Ne=r;else e:for(o=a;Ne!==null;){r=Ne;var s=r.sibling,c=r.return;if(gm(r),r===o){Ne=null;break e}if(s!==null){s.return=c,Ne=s;break e}Ne=c}}}var Sp={getCacheForType:function(a){var t=Be(Oe),o=t.data.get(a);return o===void 0&&(o=a(),t.data.set(a,o)),o},cacheSignal:function(){return Be(Oe).controller.signal}},Hp=typeof WeakMap=="function"?WeakMap:Map,fe=0,ve=null,ie=null,ae=0,ye=0,pi=null,Dn=!1,Ua=!1,_s=!1,en=0,Me=0,Rn=0,Zn=0,Ns=0,hi=0,Ia=0,yt=null,ni=null,Ys=!1,Eo=0,Pm=0,Mo=1/0,Po=null,vn=null,we=0,An=null,Ea=null,nn=0,Ls=0,Bs=null,Tm=null,bt=0,Fs=null;function yi(){return(fe&2)!==0&&ae!==0?ae&-ae:C.T!==null?Ks():Qc()}function xm(){if(hi===0)if((ae&536870912)===0||oe){var a=wt;wt<<=1,(wt&3932160)===0&&(wt=262144),hi=a}else hi=536870912;return a=ui.current,a!==null&&(a.flags|=32),hi}function ai(a,t,o){(a===ve&&(ye===2||ye===9)||a.cancelPendingCommit!==null)&&(Ma(a,0),Cn(a,ae,hi,!1)),_a(a,o),((fe&2)===0||a!==ve)&&(a===ve&&((fe&2)===0&&(Zn|=o),Me===4&&Cn(a,ae,hi,!1)),wi(a))}function Om(a,t,o){if((fe&6)!==0)throw Error(f(327));var r=!o&&(t&127)===0&&(t&a.expiredLanes)===0||ka(a,t),s=r?kp(a,t):Vs(a,t,!0),c=r;do{if(s===0){Ua&&!r&&Cn(a,t,0,!1);break}else{if(o=a.current.alternate,c&&!zp(o)){s=Vs(a,t,!1),c=!1;continue}if(s===2){if(c=t,a.errorRecoveryDisabledLanes&c)var l=0;else l=a.pendingLanes&-536870913,l=l!==0?l:l&536870912?536870912:0;if(l!==0){t=l;e:{var d=a;s=yt;var u=d.current.memoizedState.isDehydrated;if(u&&(Ma(d,l).flags|=256),l=Vs(d,l,!1),l!==2){if(_s&&!u){d.errorRecoveryDisabledLanes|=c,Zn|=c,s=4;break e}c=ni,ni=s,c!==null&&(ni===null?ni=c:ni.push.apply(ni,c))}s=l}if(c=!1,s!==2)continue}}if(s===1){Ma(a,0),Cn(a,t,0,!0);break}e:{switch(r=a,c=s,c){case 0:case 1:throw Error(f(345));case 4:if((t&4194048)!==t)break;case 6:Cn(r,t,hi,!Dn);break e;case 2:ni=null;break;case 3:case 5:break;default:throw Error(f(329))}if((t&62914560)===t&&(s=Eo+300-si(),10<s)){if(Cn(r,t,hi,!Dn),_t(r,0,!0)!==0)break e;nn=t,r.timeoutHandle=lu(Sm.bind(null,r,o,ni,Po,Ys,t,hi,Zn,Ia,Dn,c,"Throttled",-0,0),s);break e}Sm(r,o,ni,Po,Ys,t,hi,Zn,Ia,Dn,c,null,-0,0)}}break}while(!0);wi(a)}function Sm(a,t,o,r,s,c,l,d,u,R,G,M,v,A){if(a.timeoutHandle=-1,M=t.subtreeFlags,M&8192||(M&16785408)===16785408){M={stylesheets:null,count:0,imgCount:0,imgBytes:0,suspenseyImages:[],waitingForImages:!0,waitingForViewTransition:!1,unsuspend:Yi},Um(t,c,M);var k=(c&62914560)===c?Eo-si():(c&4194048)===c?Pm-si():0;if(k=Dh(M,k),k!==null){nn=c,a.cancelPendingCommit=k(Lm.bind(null,a,t,c,o,r,s,l,d,u,G,M,null,v,A)),Cn(a,c,l,!R);return}}Lm(a,t,c,o,r,s,l,d,u)}function zp(a){for(var t=a;;){var o=t.tag;if((o===0||o===11||o===15)&&t.flags&16384&&(o=t.updateQueue,o!==null&&(o=o.stores,o!==null)))for(var r=0;r<o.length;r++){var s=o[r],c=s.getSnapshot;s=s.value;try{if(!di(c(),s))return!1}catch{return!1}}if(o=t.child,t.subtreeFlags&16384&&o!==null)o.return=t,t=o;else{if(t===a)break;for(;t.sibling===null;){if(t.return===null||t.return===a)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}function Cn(a,t,o,r){t&=~Ns,t&=~Zn,a.suspendedLanes|=t,a.pingedLanes&=~t,r&&(a.warmLanes|=t),r=a.expirationTimes;for(var s=t;0<s;){var c=31-li(s),l=1<<c;r[c]=-1,s&=~l}o!==0&&Fc(a,o,t)}function To(){return(fe&6)===0?(gt(0),!1):!0}function js(){if(ie!==null){if(ye===0)var a=ie.return;else a=ie,ji=Ln=null,rs(a),ga=null,et=0,a=ie;for(;a!==null;)dm(a.alternate,a),a=a.return;ie=null}}function Ma(a,t){var o=a.timeoutHandle;o!==-1&&(a.timeoutHandle=-1,ih(o)),o=a.cancelPendingCommit,o!==null&&(a.cancelPendingCommit=null,o()),nn=0,js(),ve=a,ie=o=Bi(a.current,null),ae=t,ye=0,pi=null,Dn=!1,Ua=ka(a,t),_s=!1,Ia=hi=Ns=Zn=Rn=Me=0,ni=yt=null,Ys=!1,(t&8)!==0&&(t|=t&32);var r=a.entangledLanes;if(r!==0)for(a=a.entanglements,r&=t;0<r;){var s=31-li(r),c=1<<s;t|=a[s],r&=~c}return en=t,Zt(),o}function Hm(a,t){$=null,C.H=ct,t===ba||t===to?(t=Zl(),ye=3):t===qr?(t=Zl(),ye=4):ye=t===As?8:t!==null&&typeof t=="object"&&typeof t.then=="function"?6:1,pi=t,ie===null&&(Me=1,Do(a,Ai(t,a.current)))}function zm(){var a=ui.current;return a===null?!0:(ae&4194048)===ae?Ii===null:(ae&62914560)===ae||(ae&536870912)!==0?a===Ii:!1}function wm(){var a=C.H;return C.H=ct,a===null?ct:a}function km(){var a=C.A;return C.A=Sp,a}function xo(){Me=4,Dn||(ae&4194048)!==ae&&ui.current!==null||(Ua=!0),(Rn&134217727)===0&&(Zn&134217727)===0||ve===null||Cn(ve,ae,hi,!1)}function Vs(a,t,o){var r=fe;fe|=2;var s=wm(),c=km();(ve!==a||ae!==t)&&(Po=null,Ma(a,t)),t=!1;var l=Me;e:do try{if(ye!==0&&ie!==null){var d=ie,u=pi;switch(ye){case 8:js(),l=6;break e;case 3:case 2:case 9:case 6:ui.current===null&&(t=!0);var R=ye;if(ye=0,pi=null,Pa(a,d,u,R),o&&Ua){l=0;break e}break;default:R=ye,ye=0,pi=null,Pa(a,d,u,R)}}wp(),l=Me;break}catch(G){Hm(a,G)}while(!0);return t&&a.shellSuspendCounter++,ji=Ln=null,fe=r,C.H=s,C.A=c,ie===null&&(ve=null,ae=0,Zt()),l}function wp(){for(;ie!==null;)_m(ie)}function kp(a,t){var o=fe;fe|=2;var r=wm(),s=km();ve!==a||ae!==t?(Po=null,Mo=si()+500,Ma(a,t)):Ua=ka(a,t);e:do try{if(ye!==0&&ie!==null){t=ie;var c=pi;i:switch(ye){case 1:ye=0,pi=null,Pa(a,t,c,1);break;case 2:case 9:if(ql(c)){ye=0,pi=null,Nm(t);break}t=function(){ye!==2&&ye!==9||ve!==a||(ye=7),wi(a)},c.then(t,t);break e;case 3:ye=7;break e;case 4:ye=5;break e;case 7:ql(c)?(ye=0,pi=null,Nm(t)):(ye=0,pi=null,Pa(a,t,c,7));break;case 5:var l=null;switch(ie.tag){case 26:l=ie.memoizedState;case 5:case 27:var d=ie;if(l?Gu(l):d.stateNode.complete){ye=0,pi=null;var u=d.sibling;if(u!==null)ie=u;else{var R=d.return;R!==null?(ie=R,Oo(R)):ie=null}break i}}ye=0,pi=null,Pa(a,t,c,5);break;case 6:ye=0,pi=null,Pa(a,t,c,6);break;case 8:js(),Me=6;break e;default:throw Error(f(462))}}_p();break}catch(G){Hm(a,G)}while(!0);return ji=Ln=null,C.H=r,C.A=s,fe=o,ie!==null?0:(ve=null,ae=0,Zt(),Me)}function _p(){for(;ie!==null&&!sf();)_m(ie)}function _m(a){var t=cm(a.alternate,a,en);a.memoizedProps=a.pendingProps,t===null?Oo(a):ie=t}function Nm(a){var t=a,o=t.alternate;switch(t.tag){case 15:case 0:t=nm(o,t,t.pendingProps,t.type,void 0,ae);break;case 11:t=nm(o,t,t.pendingProps,t.type.render,t.ref,ae);break;case 5:rs(t);default:dm(o,t),t=ie=kl(t,en),t=cm(o,t,en)}a.memoizedProps=a.pendingProps,t===null?Oo(a):ie=t}function Pa(a,t,o,r){ji=Ln=null,rs(t),ga=null,et=0;var s=t.return;try{if(Ip(a,s,t,o,ae)){Me=1,Do(a,Ai(o,a.current)),ie=null;return}}catch(c){if(s!==null)throw ie=s,c;Me=1,Do(a,Ai(o,a.current)),ie=null;return}t.flags&32768?(oe||r===1?a=!0:Ua||(ae&536870912)!==0?a=!1:(Dn=a=!0,(r===2||r===9||r===3||r===6)&&(r=ui.current,r!==null&&r.tag===13&&(r.flags|=16384))),Ym(t,a)):Oo(t)}function Oo(a){var t=a;do{if((t.flags&32768)!==0){Ym(t,Dn);return}a=t.return;var o=Pp(t.alternate,t,en);if(o!==null){ie=o;return}if(t=t.sibling,t!==null){ie=t;return}ie=t=a}while(t!==null);Me===0&&(Me=5)}function Ym(a,t){do{var o=Tp(a.alternate,a);if(o!==null){o.flags&=32767,ie=o;return}if(o=a.return,o!==null&&(o.flags|=32768,o.subtreeFlags=0,o.deletions=null),!t&&(a=a.sibling,a!==null)){ie=a;return}ie=a=o}while(a!==null);Me=6,ie=null}function Lm(a,t,o,r,s,c,l,d,u){a.cancelPendingCommit=null;do So();while(we!==0);if((fe&6)!==0)throw Error(f(327));if(t!==null){if(t===a.current)throw Error(f(177));if(c=t.lanes|t.childLanes,c|=Sr,bf(a,o,c,l,d,u),a===ve&&(ie=ve=null,ae=0),Ea=t,An=a,nn=o,Ls=c,Bs=s,Tm=r,(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?(a.callbackNode=null,a.callbackPriority=0,Bp(Ht,function(){return Qm(),null})):(a.callbackNode=null,a.callbackPriority=0),r=(t.flags&13878)!==0,(t.subtreeFlags&13878)!==0||r){r=C.T,C.T=null,s=H.p,H.p=2,l=fe,fe|=4;try{xp(a,t,o)}finally{fe=l,H.p=s,C.T=r}}we=1,Bm(),Fm(),jm()}}function Bm(){if(we===1){we=0;var a=An,t=Ea,o=(t.flags&13878)!==0;if((t.subtreeFlags&13878)!==0||o){o=C.T,C.T=null;var r=H.p;H.p=2;var s=fe;fe|=4;try{Am(t,a);var c=ac,l=Ml(a.containerInfo),d=c.focusedElem,u=c.selectionRange;if(l!==d&&d&&d.ownerDocument&&El(d.ownerDocument.documentElement,d)){if(u!==null&&Mr(d)){var R=u.start,G=u.end;if(G===void 0&&(G=R),"selectionStart"in d)d.selectionStart=R,d.selectionEnd=Math.min(G,d.value.length);else{var M=d.ownerDocument||document,v=M&&M.defaultView||window;if(v.getSelection){var A=v.getSelection(),k=d.textContent.length,j=Math.min(u.start,k),Re=u.end===void 0?j:Math.min(u.end,k);!A.extend&&j>Re&&(l=Re,Re=j,j=l);var b=Il(d,j),p=Il(d,Re);if(b&&p&&(A.rangeCount!==1||A.anchorNode!==b.node||A.anchorOffset!==b.offset||A.focusNode!==p.node||A.focusOffset!==p.offset)){var D=M.createRange();D.setStart(b.node,b.offset),A.removeAllRanges(),j>Re?(A.addRange(D),A.extend(p.node,p.offset)):(D.setEnd(p.node,p.offset),A.addRange(D))}}}}for(M=[],A=d;A=A.parentNode;)A.nodeType===1&&M.push({element:A,left:A.scrollLeft,top:A.scrollTop});for(typeof d.focus=="function"&&d.focus(),d=0;d<M.length;d++){var I=M[d];I.element.scrollLeft=I.left,I.element.scrollTop=I.top}}Vo=!!nc,ac=nc=null}finally{fe=s,H.p=r,C.T=o}}a.current=t,we=2}}function Fm(){if(we===2){we=0;var a=An,t=Ea,o=(t.flags&8772)!==0;if((t.subtreeFlags&8772)!==0||o){o=C.T,C.T=null;var r=H.p;H.p=2;var s=fe;fe|=4;try{bm(a,t.alternate,t)}finally{fe=s,H.p=r,C.T=o}}we=3}}function jm(){if(we===4||we===3){we=0,cf();var a=An,t=Ea,o=nn,r=Tm;(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?we=5:(we=0,Ea=An=null,Vm(a,a.pendingLanes));var s=a.pendingLanes;if(s===0&&(vn=null),lr(o),t=t.stateNode,ci&&typeof ci.onCommitFiberRoot=="function")try{ci.onCommitFiberRoot(wa,t,void 0,(t.current.flags&128)===128)}catch{}if(r!==null){t=C.T,s=H.p,H.p=2,C.T=null;try{for(var c=a.onRecoverableError,l=0;l<r.length;l++){var d=r[l];c(d.value,{componentStack:d.stack})}}finally{C.T=t,H.p=s}}(nn&3)!==0&&So(),wi(a),s=a.pendingLanes,(o&261930)!==0&&(s&42)!==0?a===Fs?bt++:(bt=0,Fs=a):bt=0,gt(0)}}function Vm(a,t){(a.pooledCacheLanes&=t)===0&&(t=a.pooledCache,t!=null&&(a.pooledCache=null,Ja(t)))}function So(){return Bm(),Fm(),jm(),Qm()}function Qm(){if(we!==5)return!1;var a=An,t=Ls;Ls=0;var o=lr(nn),r=C.T,s=H.p;try{H.p=32>o?32:o,C.T=null,o=Bs,Bs=null;var c=An,l=nn;if(we=0,Ea=An=null,nn=0,(fe&6)!==0)throw Error(f(331));var d=fe;if(fe|=4,Em(c.current),Gm(c,c.current,l,o),fe=d,gt(0,!1),ci&&typeof ci.onPostCommitFiberRoot=="function")try{ci.onPostCommitFiberRoot(wa,c)}catch{}return!0}finally{H.p=s,C.T=r,Vm(a,t)}}function Wm(a,t,o){t=Ai(o,t),t=vs(a.stateNode,t,2),a=hn(a,t,2),a!==null&&(_a(a,2),wi(a))}function be(a,t,o){if(a.tag===3)Wm(a,a,o);else for(;t!==null;){if(t.tag===3){Wm(t,a,o);break}else if(t.tag===1){var r=t.stateNode;if(typeof t.type.getDerivedStateFromError=="function"||typeof r.componentDidCatch=="function"&&(vn===null||!vn.has(r))){a=Ai(o,a),o=qd(2),r=hn(t,o,2),r!==null&&(Kd(o,r,t,a),_a(r,2),wi(r));break}}t=t.return}}function Qs(a,t,o){var r=a.pingCache;if(r===null){r=a.pingCache=new Hp;var s=new Set;r.set(t,s)}else s=r.get(t),s===void 0&&(s=new Set,r.set(t,s));s.has(o)||(_s=!0,s.add(o),a=Np.bind(null,a,t,o),t.then(a,a))}function Np(a,t,o){var r=a.pingCache;r!==null&&r.delete(t),a.pingedLanes|=a.suspendedLanes&o,a.warmLanes&=~o,ve===a&&(ae&o)===o&&(Me===4||Me===3&&(ae&62914560)===ae&&300>si()-Eo?(fe&2)===0&&Ma(a,0):Ns|=o,Ia===ae&&(Ia=0)),wi(a)}function qm(a,t){t===0&&(t=Bc()),a=_n(a,t),a!==null&&(_a(a,t),wi(a))}function Yp(a){var t=a.memoizedState,o=0;t!==null&&(o=t.retryLane),qm(a,o)}function Lp(a,t){var o=0;switch(a.tag){case 31:case 13:var r=a.stateNode,s=a.memoizedState;s!==null&&(o=s.retryLane);break;case 19:r=a.stateNode;break;case 22:r=a.stateNode._retryCache;break;default:throw Error(f(314))}r!==null&&r.delete(t),qm(a,o)}function Bp(a,t){return or(a,t)}var Ho=null,Ta=null,Ws=!1,zo=!1,qs=!1,Gn=0;function wi(a){a!==Ta&&a.next===null&&(Ta===null?Ho=Ta=a:Ta=Ta.next=a),zo=!0,Ws||(Ws=!0,jp())}function gt(a,t){if(!qs&&zo){qs=!0;do for(var o=!1,r=Ho;r!==null;){if(a!==0){var s=r.pendingLanes;if(s===0)var c=0;else{var l=r.suspendedLanes,d=r.pingedLanes;c=(1<<31-li(42|a)+1)-1,c&=s&~(l&~d),c=c&201326741?c&201326741|1:c?c|2:0}c!==0&&(o=!0,Jm(r,c))}else c=ae,c=_t(r,r===ve?c:0,r.cancelPendingCommit!==null||r.timeoutHandle!==-1),(c&3)===0||ka(r,c)||(o=!0,Jm(r,c));r=r.next}while(o);qs=!1}}function Fp(){Km()}function Km(){zo=Ws=!1;var a=0;Gn!==0&&eh()&&(a=Gn);for(var t=si(),o=null,r=Ho;r!==null;){var s=r.next,c=Zm(r,t);c===0?(r.next=null,o===null?Ho=s:o.next=s,s===null&&(Ta=o)):(o=r,(a!==0||(c&3)!==0)&&(zo=!0)),r=s}we!==0&&we!==5||gt(a),Gn!==0&&(Gn=0)}function Zm(a,t){for(var o=a.suspendedLanes,r=a.pingedLanes,s=a.expirationTimes,c=a.pendingLanes&-62914561;0<c;){var l=31-li(c),d=1<<l,u=s[l];u===-1?((d&o)===0||(d&r)!==0)&&(s[l]=yf(d,t)):u<=t&&(a.expiredLanes|=d),c&=~d}if(t=ve,o=ae,o=_t(a,a===t?o:0,a.cancelPendingCommit!==null||a.timeoutHandle!==-1),r=a.callbackNode,o===0||a===t&&(ye===2||ye===9)||a.cancelPendingCommit!==null)return r!==null&&r!==null&&rr(r),a.callbackNode=null,a.callbackPriority=0;if((o&3)===0||ka(a,o)){if(t=o&-o,t===a.callbackPriority)return t;switch(r!==null&&rr(r),lr(o)){case 2:case 8:o=Yc;break;case 32:o=Ht;break;case 268435456:o=Lc;break;default:o=Ht}return r=Xm.bind(null,a),o=or(o,r),a.callbackPriority=t,a.callbackNode=o,t}return r!==null&&r!==null&&rr(r),a.callbackPriority=2,a.callbackNode=null,2}function Xm(a,t){if(we!==0&&we!==5)return a.callbackNode=null,a.callbackPriority=0,null;var o=a.callbackNode;if(So()&&a.callbackNode!==o)return null;var r=ae;return r=_t(a,a===ve?r:0,a.cancelPendingCommit!==null||a.timeoutHandle!==-1),r===0?null:(Om(a,r,t),Zm(a,si()),a.callbackNode!=null&&a.callbackNode===o?Xm.bind(null,a):null)}function Jm(a,t){if(So())return null;Om(a,t,!0)}function jp(){nh(function(){(fe&6)!==0?or(Nc,Fp):Km()})}function Ks(){if(Gn===0){var a=ha;a===0&&(a=zt,zt<<=1,(zt&261888)===0&&(zt=256)),Gn=a}return Gn}function $m(a){return a==null||typeof a=="symbol"||typeof a=="boolean"?null:typeof a=="function"?a:Bt(""+a)}function eu(a,t){var o=t.ownerDocument.createElement("input");return o.name=t.name,o.value=t.value,a.id&&o.setAttribute("form",a.id),t.parentNode.insertBefore(o,t),a=new FormData(a),o.parentNode.removeChild(o),a}function Vp(a,t,o,r,s){if(t==="submit"&&o&&o.stateNode===s){var c=$m((s[Xe]||null).action),l=r.submitter;l&&(t=(t=l[Xe]||null)?$m(t.formAction):l.getAttribute("formAction"),t!==null&&(c=t,l=null));var d=new Qt("action","action",null,r,s);a.push({event:d,listeners:[{instance:null,listener:function(){if(r.defaultPrevented){if(Gn!==0){var u=l?eu(s,l):new FormData(s);hs(o,{pending:!0,data:u,method:s.method,action:c},null,u)}}else typeof c=="function"&&(d.preventDefault(),u=l?eu(s,l):new FormData(s),hs(o,{pending:!0,data:u,method:s.method,action:c},c,u))},currentTarget:s}]})}}for(var Zs=0;Zs<Or.length;Zs++){var Xs=Or[Zs],Qp=Xs.toLowerCase(),Wp=Xs[0].toUpperCase()+Xs.slice(1);Ti(Qp,"on"+Wp)}Ti(xl,"onAnimationEnd"),Ti(Ol,"onAnimationIteration"),Ti(Sl,"onAnimationStart"),Ti("dblclick","onDoubleClick"),Ti("focusin","onFocus"),Ti("focusout","onBlur"),Ti(lp,"onTransitionRun"),Ti(dp,"onTransitionStart"),Ti(mp,"onTransitionCancel"),Ti(Hl,"onTransitionEnd"),ia("onMouseEnter",["mouseout","mouseover"]),ia("onMouseLeave",["mouseout","mouseover"]),ia("onPointerEnter",["pointerout","pointerover"]),ia("onPointerLeave",["pointerout","pointerover"]),Hn("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),Hn("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),Hn("onBeforeInput",["compositionend","keypress","textInput","paste"]),Hn("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),Hn("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),Hn("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Dt="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),qp=new Set("beforetoggle cancel close invalid load scroll scrollend toggle".split(" ").concat(Dt));function iu(a,t){t=(t&4)!==0;for(var o=0;o<a.length;o++){var r=a[o],s=r.event;r=r.listeners;e:{var c=void 0;if(t)for(var l=r.length-1;0<=l;l--){var d=r[l],u=d.instance,R=d.currentTarget;if(d=d.listener,u!==c&&s.isPropagationStopped())break e;c=d,s.currentTarget=R;try{c(s)}catch(G){Kt(G)}s.currentTarget=null,c=u}else for(l=0;l<r.length;l++){if(d=r[l],u=d.instance,R=d.currentTarget,d=d.listener,u!==c&&s.isPropagationStopped())break e;c=d,s.currentTarget=R;try{c(s)}catch(G){Kt(G)}s.currentTarget=null,c=u}}}}function ne(a,t){var o=t[dr];o===void 0&&(o=t[dr]=new Set);var r=a+"__bubble";o.has(r)||(nu(t,a,2,!1),o.add(r))}function Js(a,t,o){var r=0;t&&(r|=4),nu(o,a,r,t)}var wo="_reactListening"+Math.random().toString(36).slice(2);function $s(a){if(!a[wo]){a[wo]=!0,Kc.forEach(function(o){o!=="selectionchange"&&(qp.has(o)||Js(o,!1,a),Js(o,!0,a))});var t=a.nodeType===9?a:a.ownerDocument;t===null||t[wo]||(t[wo]=!0,Js("selectionchange",!1,t))}}function nu(a,t,o,r){switch(xu(t)){case 2:var s=Ah;break;case 8:s=Ch;break;default:s=pc}o=s.bind(null,t,o,a),s=void 0,!Dr||t!=="touchstart"&&t!=="touchmove"&&t!=="wheel"||(s=!0),r?s!==void 0?a.addEventListener(t,o,{capture:!0,passive:s}):a.addEventListener(t,o,!0):s!==void 0?a.addEventListener(t,o,{passive:s}):a.addEventListener(t,o,!1)}function ec(a,t,o,r,s){var c=r;if((t&1)===0&&(t&2)===0&&r!==null)e:for(;;){if(r===null)return;var l=r.tag;if(l===3||l===4){var d=r.stateNode.containerInfo;if(d===s)break;if(l===4)for(l=r.return;l!==null;){var u=l.tag;if((u===3||u===4)&&l.stateNode.containerInfo===s)return;l=l.return}for(;d!==null;){if(l=Jn(d),l===null)return;if(u=l.tag,u===5||u===6||u===26||u===27){r=c=l;continue e}d=d.parentNode}}r=r.return}sl(function(){var R=c,G=br(o),M=[];e:{var v=zl.get(a);if(v!==void 0){var A=Qt,k=a;switch(a){case"keypress":if(jt(o)===0)break e;case"keydown":case"keyup":A=Lf;break;case"focusin":k="focus",A=Cr;break;case"focusout":k="blur",A=Cr;break;case"beforeblur":case"afterblur":A=Cr;break;case"click":if(o.button===2)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":A=dl;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":A=Pf;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":A=jf;break;case xl:case Ol:case Sl:A=Of;break;case Hl:A=Qf;break;case"scroll":case"scrollend":A=Ef;break;case"wheel":A=qf;break;case"copy":case"cut":case"paste":A=Hf;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":A=ul;break;case"toggle":case"beforetoggle":A=Zf}var j=(t&4)!==0,Re=!j&&(a==="scroll"||a==="scrollend"),b=j?v!==null?v+"Capture":null:v;j=[];for(var p=R,D;p!==null;){var I=p;if(D=I.stateNode,I=I.tag,I!==5&&I!==26&&I!==27||D===null||b===null||(I=La(p,b),I!=null&&j.push(Rt(p,I,D))),Re)break;p=p.return}0<j.length&&(v=new A(v,k,null,o,G),M.push({event:v,listeners:j}))}}if((t&7)===0){e:{if(v=a==="mouseover"||a==="pointerover",A=a==="mouseout"||a==="pointerout",v&&o!==yr&&(k=o.relatedTarget||o.fromElement)&&(Jn(k)||k[Xn]))break e;if((A||v)&&(v=G.window===G?G:(v=G.ownerDocument)?v.defaultView||v.parentWindow:window,A?(k=o.relatedTarget||o.toElement,A=R,k=k?Jn(k):null,k!==null&&(Re=w(k),j=k.tag,k!==Re||j!==5&&j!==27&&j!==6)&&(k=null)):(A=null,k=R),A!==k)){if(j=dl,I="onMouseLeave",b="onMouseEnter",p="mouse",(a==="pointerout"||a==="pointerover")&&(j=ul,I="onPointerLeave",b="onPointerEnter",p="pointer"),Re=A==null?v:Ya(A),D=k==null?v:Ya(k),v=new j(I,p+"leave",A,o,G),v.target=Re,v.relatedTarget=D,I=null,Jn(G)===R&&(j=new j(b,p+"enter",k,o,G),j.target=D,j.relatedTarget=Re,I=j),Re=I,A&&k)i:{for(j=Kp,b=A,p=k,D=0,I=b;I;I=j(I))D++;I=0;for(var Y=p;Y;Y=j(Y))I++;for(;0<D-I;)b=j(b),D--;for(;0<I-D;)p=j(p),I--;for(;D--;){if(b===p||p!==null&&b===p.alternate){j=b;break i}b=j(b),p=j(p)}j=null}else j=null;A!==null&&au(M,v,A,j,!1),k!==null&&Re!==null&&au(M,Re,k,j,!0)}}e:{if(v=R?Ya(R):window,A=v.nodeName&&v.nodeName.toLowerCase(),A==="select"||A==="input"&&v.type==="file")var me=Rl;else if(gl(v))if(vl)me=rp;else{me=tp;var N=ap}else A=v.nodeName,!A||A.toLowerCase()!=="input"||v.type!=="checkbox"&&v.type!=="radio"?R&&hr(R.elementType)&&(me=Rl):me=op;if(me&&(me=me(a,R))){Dl(M,me,o,G);break e}N&&N(a,v,R),a==="focusout"&&R&&v.type==="number"&&R.memoizedProps.value!=null&&pr(v,"number",v.value)}switch(N=R?Ya(R):window,a){case"focusin":(gl(N)||N.contentEditable==="true")&&(sa=N,Pr=R,Ka=null);break;case"focusout":Ka=Pr=sa=null;break;case"mousedown":Tr=!0;break;case"contextmenu":case"mouseup":case"dragend":Tr=!1,Pl(M,o,G);break;case"selectionchange":if(cp)break;case"keydown":case"keyup":Pl(M,o,G)}var ee;if(Ur)e:{switch(a){case"compositionstart":var te="onCompositionStart";break e;case"compositionend":te="onCompositionEnd";break e;case"compositionupdate":te="onCompositionUpdate";break e}te=void 0}else ra?yl(a,o)&&(te="onCompositionEnd"):a==="keydown"&&o.keyCode===229&&(te="onCompositionStart");te&&(fl&&o.locale!=="ko"&&(ra||te!=="onCompositionStart"?te==="onCompositionEnd"&&ra&&(ee=cl()):(cn=G,Rr="value"in cn?cn.value:cn.textContent,ra=!0)),N=ko(R,te),0<N.length&&(te=new ml(te,a,null,o,G),M.push({event:te,listeners:N}),ee?te.data=ee:(ee=bl(o),ee!==null&&(te.data=ee)))),(ee=Jf?$f(a,o):ep(a,o))&&(te=ko(R,"onBeforeInput"),0<te.length&&(N=new ml("onBeforeInput","beforeinput",null,o,G),M.push({event:N,listeners:te}),N.data=ee)),Vp(M,a,R,o,G)}iu(M,t)})}function Rt(a,t,o){return{instance:a,listener:t,currentTarget:o}}function ko(a,t){for(var o=t+"Capture",r=[];a!==null;){var s=a,c=s.stateNode;if(s=s.tag,s!==5&&s!==26&&s!==27||c===null||(s=La(a,o),s!=null&&r.unshift(Rt(a,s,c)),s=La(a,t),s!=null&&r.push(Rt(a,s,c))),a.tag===3)return r;a=a.return}return[]}function Kp(a){if(a===null)return null;do a=a.return;while(a&&a.tag!==5&&a.tag!==27);return a||null}function au(a,t,o,r,s){for(var c=t._reactName,l=[];o!==null&&o!==r;){var d=o,u=d.alternate,R=d.stateNode;if(d=d.tag,u!==null&&u===r)break;d!==5&&d!==26&&d!==27||R===null||(u=R,s?(R=La(o,c),R!=null&&l.unshift(Rt(o,R,u))):s||(R=La(o,c),R!=null&&l.push(Rt(o,R,u)))),o=o.return}l.length!==0&&a.push({event:t,listeners:l})}var Zp=/\r\n?/g,Xp=/\u0000|\uFFFD/g;function tu(a){return(typeof a=="string"?a:""+a).replace(Zp,`
`).replace(Xp,"")}function ou(a,t){return t=tu(t),tu(a)===t}function De(a,t,o,r,s,c){switch(o){case"children":typeof r=="string"?t==="body"||t==="textarea"&&r===""||aa(a,r):(typeof r=="number"||typeof r=="bigint")&&t!=="body"&&aa(a,""+r);break;case"className":Yt(a,"class",r);break;case"tabIndex":Yt(a,"tabindex",r);break;case"dir":case"role":case"viewBox":case"width":case"height":Yt(a,o,r);break;case"style":ol(a,r,c);break;case"data":if(t!=="object"){Yt(a,"data",r);break}case"src":case"href":if(r===""&&(t!=="a"||o!=="href")){a.removeAttribute(o);break}if(r==null||typeof r=="function"||typeof r=="symbol"||typeof r=="boolean"){a.removeAttribute(o);break}r=Bt(""+r),a.setAttribute(o,r);break;case"action":case"formAction":if(typeof r=="function"){a.setAttribute(o,"javascript:throw new Error('A React form was unexpectedly submitted. If you called form.submit() manually, consider using form.requestSubmit() instead. If you\\'re trying to use event.stopPropagation() in a submit event handler, consider also calling event.preventDefault().')");break}else typeof c=="function"&&(o==="formAction"?(t!=="input"&&De(a,t,"name",s.name,s,null),De(a,t,"formEncType",s.formEncType,s,null),De(a,t,"formMethod",s.formMethod,s,null),De(a,t,"formTarget",s.formTarget,s,null)):(De(a,t,"encType",s.encType,s,null),De(a,t,"method",s.method,s,null),De(a,t,"target",s.target,s,null)));if(r==null||typeof r=="symbol"||typeof r=="boolean"){a.removeAttribute(o);break}r=Bt(""+r),a.setAttribute(o,r);break;case"onClick":r!=null&&(a.onclick=Yi);break;case"onScroll":r!=null&&ne("scroll",a);break;case"onScrollEnd":r!=null&&ne("scrollend",a);break;case"dangerouslySetInnerHTML":if(r!=null){if(typeof r!="object"||!("__html"in r))throw Error(f(61));if(o=r.__html,o!=null){if(s.children!=null)throw Error(f(60));a.innerHTML=o}}break;case"multiple":a.multiple=r&&typeof r!="function"&&typeof r!="symbol";break;case"muted":a.muted=r&&typeof r!="function"&&typeof r!="symbol";break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"defaultValue":case"defaultChecked":case"innerHTML":case"ref":break;case"autoFocus":break;case"xlinkHref":if(r==null||typeof r=="function"||typeof r=="boolean"||typeof r=="symbol"){a.removeAttribute("xlink:href");break}o=Bt(""+r),a.setAttributeNS("http://www.w3.org/1999/xlink","xlink:href",o);break;case"contentEditable":case"spellCheck":case"draggable":case"value":case"autoReverse":case"externalResourcesRequired":case"focusable":case"preserveAlpha":r!=null&&typeof r!="function"&&typeof r!="symbol"?a.setAttribute(o,""+r):a.removeAttribute(o);break;case"inert":case"allowFullScreen":case"async":case"autoPlay":case"controls":case"default":case"defer":case"disabled":case"disablePictureInPicture":case"disableRemotePlayback":case"formNoValidate":case"hidden":case"loop":case"noModule":case"noValidate":case"open":case"playsInline":case"readOnly":case"required":case"reversed":case"scoped":case"seamless":case"itemScope":r&&typeof r!="function"&&typeof r!="symbol"?a.setAttribute(o,""):a.removeAttribute(o);break;case"capture":case"download":r===!0?a.setAttribute(o,""):r!==!1&&r!=null&&typeof r!="function"&&typeof r!="symbol"?a.setAttribute(o,r):a.removeAttribute(o);break;case"cols":case"rows":case"size":case"span":r!=null&&typeof r!="function"&&typeof r!="symbol"&&!isNaN(r)&&1<=r?a.setAttribute(o,r):a.removeAttribute(o);break;case"rowSpan":case"start":r==null||typeof r=="function"||typeof r=="symbol"||isNaN(r)?a.removeAttribute(o):a.setAttribute(o,r);break;case"popover":ne("beforetoggle",a),ne("toggle",a),Nt(a,"popover",r);break;case"xlinkActuate":Ni(a,"http://www.w3.org/1999/xlink","xlink:actuate",r);break;case"xlinkArcrole":Ni(a,"http://www.w3.org/1999/xlink","xlink:arcrole",r);break;case"xlinkRole":Ni(a,"http://www.w3.org/1999/xlink","xlink:role",r);break;case"xlinkShow":Ni(a,"http://www.w3.org/1999/xlink","xlink:show",r);break;case"xlinkTitle":Ni(a,"http://www.w3.org/1999/xlink","xlink:title",r);break;case"xlinkType":Ni(a,"http://www.w3.org/1999/xlink","xlink:type",r);break;case"xmlBase":Ni(a,"http://www.w3.org/XML/1998/namespace","xml:base",r);break;case"xmlLang":Ni(a,"http://www.w3.org/XML/1998/namespace","xml:lang",r);break;case"xmlSpace":Ni(a,"http://www.w3.org/XML/1998/namespace","xml:space",r);break;case"is":Nt(a,"is",r);break;case"innerText":case"textContent":break;default:(!(2<o.length)||o[0]!=="o"&&o[0]!=="O"||o[1]!=="n"&&o[1]!=="N")&&(o=Uf.get(o)||o,Nt(a,o,r))}}function ic(a,t,o,r,s,c){switch(o){case"style":ol(a,r,c);break;case"dangerouslySetInnerHTML":if(r!=null){if(typeof r!="object"||!("__html"in r))throw Error(f(61));if(o=r.__html,o!=null){if(s.children!=null)throw Error(f(60));a.innerHTML=o}}break;case"children":typeof r=="string"?aa(a,r):(typeof r=="number"||typeof r=="bigint")&&aa(a,""+r);break;case"onScroll":r!=null&&ne("scroll",a);break;case"onScrollEnd":r!=null&&ne("scrollend",a);break;case"onClick":r!=null&&(a.onclick=Yi);break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"innerHTML":case"ref":break;case"innerText":case"textContent":break;default:if(!Zc.hasOwnProperty(o))e:{if(o[0]==="o"&&o[1]==="n"&&(s=o.endsWith("Capture"),t=o.slice(2,s?o.length-7:void 0),c=a[Xe]||null,c=c!=null?c[o]:null,typeof c=="function"&&a.removeEventListener(t,c,s),typeof r=="function")){typeof c!="function"&&c!==null&&(o in a?a[o]=null:a.hasAttribute(o)&&a.removeAttribute(o)),a.addEventListener(t,r,s);break e}o in a?a[o]=r:r===!0?a.setAttribute(o,""):Nt(a,o,r)}}}function je(a,t,o){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"img":ne("error",a),ne("load",a);var r=!1,s=!1,c;for(c in o)if(o.hasOwnProperty(c)){var l=o[c];if(l!=null)switch(c){case"src":r=!0;break;case"srcSet":s=!0;break;case"children":case"dangerouslySetInnerHTML":throw Error(f(137,t));default:De(a,t,c,l,o,null)}}s&&De(a,t,"srcSet",o.srcSet,o,null),r&&De(a,t,"src",o.src,o,null);return;case"input":ne("invalid",a);var d=c=l=s=null,u=null,R=null;for(r in o)if(o.hasOwnProperty(r)){var G=o[r];if(G!=null)switch(r){case"name":s=G;break;case"type":l=G;break;case"checked":u=G;break;case"defaultChecked":R=G;break;case"value":c=G;break;case"defaultValue":d=G;break;case"children":case"dangerouslySetInnerHTML":if(G!=null)throw Error(f(137,t));break;default:De(a,t,r,G,o,null)}}il(a,c,d,u,R,l,s,!1);return;case"select":ne("invalid",a),r=l=c=null;for(s in o)if(o.hasOwnProperty(s)&&(d=o[s],d!=null))switch(s){case"value":c=d;break;case"defaultValue":l=d;break;case"multiple":r=d;default:De(a,t,s,d,o,null)}t=c,o=l,a.multiple=!!r,t!=null?na(a,!!r,t,!1):o!=null&&na(a,!!r,o,!0);return;case"textarea":ne("invalid",a),c=s=r=null;for(l in o)if(o.hasOwnProperty(l)&&(d=o[l],d!=null))switch(l){case"value":r=d;break;case"defaultValue":s=d;break;case"children":c=d;break;case"dangerouslySetInnerHTML":if(d!=null)throw Error(f(91));break;default:De(a,t,l,d,o,null)}al(a,r,s,c);return;case"option":for(u in o)if(o.hasOwnProperty(u)&&(r=o[u],r!=null))switch(u){case"selected":a.selected=r&&typeof r!="function"&&typeof r!="symbol";break;default:De(a,t,u,r,o,null)}return;case"dialog":ne("beforetoggle",a),ne("toggle",a),ne("cancel",a),ne("close",a);break;case"iframe":case"object":ne("load",a);break;case"video":case"audio":for(r=0;r<Dt.length;r++)ne(Dt[r],a);break;case"image":ne("error",a),ne("load",a);break;case"details":ne("toggle",a);break;case"embed":case"source":case"link":ne("error",a),ne("load",a);case"area":case"base":case"br":case"col":case"hr":case"keygen":case"meta":case"param":case"track":case"wbr":case"menuitem":for(R in o)if(o.hasOwnProperty(R)&&(r=o[R],r!=null))switch(R){case"children":case"dangerouslySetInnerHTML":throw Error(f(137,t));default:De(a,t,R,r,o,null)}return;default:if(hr(t)){for(G in o)o.hasOwnProperty(G)&&(r=o[G],r!==void 0&&ic(a,t,G,r,o,void 0));return}}for(d in o)o.hasOwnProperty(d)&&(r=o[d],r!=null&&De(a,t,d,r,o,null))}function Jp(a,t,o,r){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"input":var s=null,c=null,l=null,d=null,u=null,R=null,G=null;for(A in o){var M=o[A];if(o.hasOwnProperty(A)&&M!=null)switch(A){case"checked":break;case"value":break;case"defaultValue":u=M;default:r.hasOwnProperty(A)||De(a,t,A,null,r,M)}}for(var v in r){var A=r[v];if(M=o[v],r.hasOwnProperty(v)&&(A!=null||M!=null))switch(v){case"type":c=A;break;case"name":s=A;break;case"checked":R=A;break;case"defaultChecked":G=A;break;case"value":l=A;break;case"defaultValue":d=A;break;case"children":case"dangerouslySetInnerHTML":if(A!=null)throw Error(f(137,t));break;default:A!==M&&De(a,t,v,A,r,M)}}fr(a,l,d,u,R,G,c,s);return;case"select":A=l=d=v=null;for(c in o)if(u=o[c],o.hasOwnProperty(c)&&u!=null)switch(c){case"value":break;case"multiple":A=u;default:r.hasOwnProperty(c)||De(a,t,c,null,r,u)}for(s in r)if(c=r[s],u=o[s],r.hasOwnProperty(s)&&(c!=null||u!=null))switch(s){case"value":v=c;break;case"defaultValue":d=c;break;case"multiple":l=c;default:c!==u&&De(a,t,s,c,r,u)}t=d,o=l,r=A,v!=null?na(a,!!o,v,!1):!!r!=!!o&&(t!=null?na(a,!!o,t,!0):na(a,!!o,o?[]:"",!1));return;case"textarea":A=v=null;for(d in o)if(s=o[d],o.hasOwnProperty(d)&&s!=null&&!r.hasOwnProperty(d))switch(d){case"value":break;case"children":break;default:De(a,t,d,null,r,s)}for(l in r)if(s=r[l],c=o[l],r.hasOwnProperty(l)&&(s!=null||c!=null))switch(l){case"value":v=s;break;case"defaultValue":A=s;break;case"children":break;case"dangerouslySetInnerHTML":if(s!=null)throw Error(f(91));break;default:s!==c&&De(a,t,l,s,r,c)}nl(a,v,A);return;case"option":for(var k in o)if(v=o[k],o.hasOwnProperty(k)&&v!=null&&!r.hasOwnProperty(k))switch(k){case"selected":a.selected=!1;break;default:De(a,t,k,null,r,v)}for(u in r)if(v=r[u],A=o[u],r.hasOwnProperty(u)&&v!==A&&(v!=null||A!=null))switch(u){case"selected":a.selected=v&&typeof v!="function"&&typeof v!="symbol";break;default:De(a,t,u,v,r,A)}return;case"img":case"link":case"area":case"base":case"br":case"col":case"embed":case"hr":case"keygen":case"meta":case"param":case"source":case"track":case"wbr":case"menuitem":for(var j in o)v=o[j],o.hasOwnProperty(j)&&v!=null&&!r.hasOwnProperty(j)&&De(a,t,j,null,r,v);for(R in r)if(v=r[R],A=o[R],r.hasOwnProperty(R)&&v!==A&&(v!=null||A!=null))switch(R){case"children":case"dangerouslySetInnerHTML":if(v!=null)throw Error(f(137,t));break;default:De(a,t,R,v,r,A)}return;default:if(hr(t)){for(var Re in o)v=o[Re],o.hasOwnProperty(Re)&&v!==void 0&&!r.hasOwnProperty(Re)&&ic(a,t,Re,void 0,r,v);for(G in r)v=r[G],A=o[G],!r.hasOwnProperty(G)||v===A||v===void 0&&A===void 0||ic(a,t,G,v,r,A);return}}for(var b in o)v=o[b],o.hasOwnProperty(b)&&v!=null&&!r.hasOwnProperty(b)&&De(a,t,b,null,r,v);for(M in r)v=r[M],A=o[M],!r.hasOwnProperty(M)||v===A||v==null&&A==null||De(a,t,M,v,r,A)}function ru(a){switch(a){case"css":case"script":case"font":case"img":case"image":case"input":case"link":return!0;default:return!1}}function $p(){if(typeof performance.getEntriesByType=="function"){for(var a=0,t=0,o=performance.getEntriesByType("resource"),r=0;r<o.length;r++){var s=o[r],c=s.transferSize,l=s.initiatorType,d=s.duration;if(c&&d&&ru(l)){for(l=0,d=s.responseEnd,r+=1;r<o.length;r++){var u=o[r],R=u.startTime;if(R>d)break;var G=u.transferSize,M=u.initiatorType;G&&ru(M)&&(u=u.responseEnd,l+=G*(u<d?1:(d-R)/(u-R)))}if(--r,t+=8*(c+l)/(s.duration/1e3),a++,10<a)break}}if(0<a)return t/a/1e6}return navigator.connection&&(a=navigator.connection.downlink,typeof a=="number")?a:5}var nc=null,ac=null;function _o(a){return a.nodeType===9?a:a.ownerDocument}function su(a){switch(a){case"http://www.w3.org/2000/svg":return 1;case"http://www.w3.org/1998/Math/MathML":return 2;default:return 0}}function cu(a,t){if(a===0)switch(t){case"svg":return 1;case"math":return 2;default:return 0}return a===1&&t==="foreignObject"?0:a}function tc(a,t){return a==="textarea"||a==="noscript"||typeof t.children=="string"||typeof t.children=="number"||typeof t.children=="bigint"||typeof t.dangerouslySetInnerHTML=="object"&&t.dangerouslySetInnerHTML!==null&&t.dangerouslySetInnerHTML.__html!=null}var oc=null;function eh(){var a=window.event;return a&&a.type==="popstate"?a===oc?!1:(oc=a,!0):(oc=null,!1)}var lu=typeof setTimeout=="function"?setTimeout:void 0,ih=typeof clearTimeout=="function"?clearTimeout:void 0,du=typeof Promise=="function"?Promise:void 0,nh=typeof queueMicrotask=="function"?queueMicrotask:typeof du<"u"?function(a){return du.resolve(null).then(a).catch(ah)}:lu;function ah(a){setTimeout(function(){throw a})}function Un(a){return a==="head"}function mu(a,t){var o=t,r=0;do{var s=o.nextSibling;if(a.removeChild(o),s&&s.nodeType===8)if(o=s.data,o==="/$"||o==="/&"){if(r===0){a.removeChild(s),Ha(t);return}r--}else if(o==="$"||o==="$?"||o==="$~"||o==="$!"||o==="&")r++;else if(o==="html")vt(a.ownerDocument.documentElement);else if(o==="head"){o=a.ownerDocument.head,vt(o);for(var c=o.firstChild;c;){var l=c.nextSibling,d=c.nodeName;c[Na]||d==="SCRIPT"||d==="STYLE"||d==="LINK"&&c.rel.toLowerCase()==="stylesheet"||o.removeChild(c),c=l}}else o==="body"&&vt(a.ownerDocument.body);o=s}while(o);Ha(t)}function uu(a,t){var o=a;a=0;do{var r=o.nextSibling;if(o.nodeType===1?t?(o._stashedDisplay=o.style.display,o.style.display="none"):(o.style.display=o._stashedDisplay||"",o.getAttribute("style")===""&&o.removeAttribute("style")):o.nodeType===3&&(t?(o._stashedText=o.nodeValue,o.nodeValue=""):o.nodeValue=o._stashedText||""),r&&r.nodeType===8)if(o=r.data,o==="/$"){if(a===0)break;a--}else o!=="$"&&o!=="$?"&&o!=="$~"&&o!=="$!"||a++;o=r}while(o)}function rc(a){var t=a.firstChild;for(t&&t.nodeType===10&&(t=t.nextSibling);t;){var o=t;switch(t=t.nextSibling,o.nodeName){case"HTML":case"HEAD":case"BODY":rc(o),mr(o);continue;case"SCRIPT":case"STYLE":continue;case"LINK":if(o.rel.toLowerCase()==="stylesheet")continue}a.removeChild(o)}}function th(a,t,o,r){for(;a.nodeType===1;){var s=o;if(a.nodeName.toLowerCase()!==t.toLowerCase()){if(!r&&(a.nodeName!=="INPUT"||a.type!=="hidden"))break}else if(r){if(!a[Na])switch(t){case"meta":if(!a.hasAttribute("itemprop"))break;return a;case"link":if(c=a.getAttribute("rel"),c==="stylesheet"&&a.hasAttribute("data-precedence"))break;if(c!==s.rel||a.getAttribute("href")!==(s.href==null||s.href===""?null:s.href)||a.getAttribute("crossorigin")!==(s.crossOrigin==null?null:s.crossOrigin)||a.getAttribute("title")!==(s.title==null?null:s.title))break;return a;case"style":if(a.hasAttribute("data-precedence"))break;return a;case"script":if(c=a.getAttribute("src"),(c!==(s.src==null?null:s.src)||a.getAttribute("type")!==(s.type==null?null:s.type)||a.getAttribute("crossorigin")!==(s.crossOrigin==null?null:s.crossOrigin))&&c&&a.hasAttribute("async")&&!a.hasAttribute("itemprop"))break;return a;default:return a}}else if(t==="input"&&a.type==="hidden"){var c=s.name==null?null:""+s.name;if(s.type==="hidden"&&a.getAttribute("name")===c)return a}else return a;if(a=Ei(a.nextSibling),a===null)break}return null}function oh(a,t,o){if(t==="")return null;for(;a.nodeType!==3;)if((a.nodeType!==1||a.nodeName!=="INPUT"||a.type!=="hidden")&&!o||(a=Ei(a.nextSibling),a===null))return null;return a}function fu(a,t){for(;a.nodeType!==8;)if((a.nodeType!==1||a.nodeName!=="INPUT"||a.type!=="hidden")&&!t||(a=Ei(a.nextSibling),a===null))return null;return a}function sc(a){return a.data==="$?"||a.data==="$~"}function cc(a){return a.data==="$!"||a.data==="$?"&&a.ownerDocument.readyState!=="loading"}function rh(a,t){var o=a.ownerDocument;if(a.data==="$~")a._reactRetry=t;else if(a.data!=="$?"||o.readyState!=="loading")t();else{var r=function(){t(),o.removeEventListener("DOMContentLoaded",r)};o.addEventListener("DOMContentLoaded",r),a._reactRetry=r}}function Ei(a){for(;a!=null;a=a.nextSibling){var t=a.nodeType;if(t===1||t===3)break;if(t===8){if(t=a.data,t==="$"||t==="$!"||t==="$?"||t==="$~"||t==="&"||t==="F!"||t==="F")break;if(t==="/$"||t==="/&")return null}}return a}var lc=null;function pu(a){a=a.nextSibling;for(var t=0;a;){if(a.nodeType===8){var o=a.data;if(o==="/$"||o==="/&"){if(t===0)return Ei(a.nextSibling);t--}else o!=="$"&&o!=="$!"&&o!=="$?"&&o!=="$~"&&o!=="&"||t++}a=a.nextSibling}return null}function hu(a){a=a.previousSibling;for(var t=0;a;){if(a.nodeType===8){var o=a.data;if(o==="$"||o==="$!"||o==="$?"||o==="$~"||o==="&"){if(t===0)return a;t--}else o!=="/$"&&o!=="/&"||t++}a=a.previousSibling}return null}function yu(a,t,o){switch(t=_o(o),a){case"html":if(a=t.documentElement,!a)throw Error(f(452));return a;case"head":if(a=t.head,!a)throw Error(f(453));return a;case"body":if(a=t.body,!a)throw Error(f(454));return a;default:throw Error(f(451))}}function vt(a){for(var t=a.attributes;t.length;)a.removeAttributeNode(t[0]);mr(a)}var Mi=new Map,bu=new Set;function No(a){return typeof a.getRootNode=="function"?a.getRootNode():a.nodeType===9?a:a.ownerDocument}var an=H.d;H.d={f:sh,r:ch,D:lh,C:dh,L:mh,m:uh,X:ph,S:fh,M:hh};function sh(){var a=an.f(),t=To();return a||t}function ch(a){var t=$n(a);t!==null&&t.tag===5&&t.type==="form"?Hd(t):an.r(a)}var xa=typeof document>"u"?null:document;function gu(a,t,o){var r=xa;if(r&&typeof t=="string"&&t){var s=Ri(t);s='link[rel="'+a+'"][href="'+s+'"]',typeof o=="string"&&(s+='[crossorigin="'+o+'"]'),bu.has(s)||(bu.add(s),a={rel:a,crossOrigin:o,href:t},r.querySelector(s)===null&&(t=r.createElement("link"),je(t,"link",a),_e(t),r.head.appendChild(t)))}}function lh(a){an.D(a),gu("dns-prefetch",a,null)}function dh(a,t){an.C(a,t),gu("preconnect",a,t)}function mh(a,t,o){an.L(a,t,o);var r=xa;if(r&&a&&t){var s='link[rel="preload"][as="'+Ri(t)+'"]';t==="image"&&o&&o.imageSrcSet?(s+='[imagesrcset="'+Ri(o.imageSrcSet)+'"]',typeof o.imageSizes=="string"&&(s+='[imagesizes="'+Ri(o.imageSizes)+'"]')):s+='[href="'+Ri(a)+'"]';var c=s;switch(t){case"style":c=Oa(a);break;case"script":c=Sa(a)}Mi.has(c)||(a=_({rel:"preload",href:t==="image"&&o&&o.imageSrcSet?void 0:a,as:t},o),Mi.set(c,a),r.querySelector(s)!==null||t==="style"&&r.querySelector(At(c))||t==="script"&&r.querySelector(Ct(c))||(t=r.createElement("link"),je(t,"link",a),_e(t),r.head.appendChild(t)))}}function uh(a,t){an.m(a,t);var o=xa;if(o&&a){var r=t&&typeof t.as=="string"?t.as:"script",s='link[rel="modulepreload"][as="'+Ri(r)+'"][href="'+Ri(a)+'"]',c=s;switch(r){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":c=Sa(a)}if(!Mi.has(c)&&(a=_({rel:"modulepreload",href:a},t),Mi.set(c,a),o.querySelector(s)===null)){switch(r){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":if(o.querySelector(Ct(c)))return}r=o.createElement("link"),je(r,"link",a),_e(r),o.head.appendChild(r)}}}function fh(a,t,o){an.S(a,t,o);var r=xa;if(r&&a){var s=ea(r).hoistableStyles,c=Oa(a);t=t||"default";var l=s.get(c);if(!l){var d={loading:0,preload:null};if(l=r.querySelector(At(c)))d.loading=5;else{a=_({rel:"stylesheet",href:a,"data-precedence":t},o),(o=Mi.get(c))&&dc(a,o);var u=l=r.createElement("link");_e(u),je(u,"link",a),u._p=new Promise(function(R,G){u.onload=R,u.onerror=G}),u.addEventListener("load",function(){d.loading|=1}),u.addEventListener("error",function(){d.loading|=2}),d.loading|=4,Yo(l,t,r)}l={type:"stylesheet",instance:l,count:1,state:d},s.set(c,l)}}}function ph(a,t){an.X(a,t);var o=xa;if(o&&a){var r=ea(o).hoistableScripts,s=Sa(a),c=r.get(s);c||(c=o.querySelector(Ct(s)),c||(a=_({src:a,async:!0},t),(t=Mi.get(s))&&mc(a,t),c=o.createElement("script"),_e(c),je(c,"link",a),o.head.appendChild(c)),c={type:"script",instance:c,count:1,state:null},r.set(s,c))}}function hh(a,t){an.M(a,t);var o=xa;if(o&&a){var r=ea(o).hoistableScripts,s=Sa(a),c=r.get(s);c||(c=o.querySelector(Ct(s)),c||(a=_({src:a,async:!0,type:"module"},t),(t=Mi.get(s))&&mc(a,t),c=o.createElement("script"),_e(c),je(c,"link",a),o.head.appendChild(c)),c={type:"script",instance:c,count:1,state:null},r.set(s,c))}}function Du(a,t,o,r){var s=(s=q.current)?No(s):null;if(!s)throw Error(f(446));switch(a){case"meta":case"title":return null;case"style":return typeof o.precedence=="string"&&typeof o.href=="string"?(t=Oa(o.href),o=ea(s).hoistableStyles,r=o.get(t),r||(r={type:"style",instance:null,count:0,state:null},o.set(t,r)),r):{type:"void",instance:null,count:0,state:null};case"link":if(o.rel==="stylesheet"&&typeof o.href=="string"&&typeof o.precedence=="string"){a=Oa(o.href);var c=ea(s).hoistableStyles,l=c.get(a);if(l||(s=s.ownerDocument||s,l={type:"stylesheet",instance:null,count:0,state:{loading:0,preload:null}},c.set(a,l),(c=s.querySelector(At(a)))&&!c._p&&(l.instance=c,l.state.loading=5),Mi.has(a)||(o={rel:"preload",as:"style",href:o.href,crossOrigin:o.crossOrigin,integrity:o.integrity,media:o.media,hrefLang:o.hrefLang,referrerPolicy:o.referrerPolicy},Mi.set(a,o),c||yh(s,a,o,l.state))),t&&r===null)throw Error(f(528,""));return l}if(t&&r!==null)throw Error(f(529,""));return null;case"script":return t=o.async,o=o.src,typeof o=="string"&&t&&typeof t!="function"&&typeof t!="symbol"?(t=Sa(o),o=ea(s).hoistableScripts,r=o.get(t),r||(r={type:"script",instance:null,count:0,state:null},o.set(t,r)),r):{type:"void",instance:null,count:0,state:null};default:throw Error(f(444,a))}}function Oa(a){return'href="'+Ri(a)+'"'}function At(a){return'link[rel="stylesheet"]['+a+"]"}function Ru(a){return _({},a,{"data-precedence":a.precedence,precedence:null})}function yh(a,t,o,r){a.querySelector('link[rel="preload"][as="style"]['+t+"]")?r.loading=1:(t=a.createElement("link"),r.preload=t,t.addEventListener("load",function(){return r.loading|=1}),t.addEventListener("error",function(){return r.loading|=2}),je(t,"link",o),_e(t),a.head.appendChild(t))}function Sa(a){return'[src="'+Ri(a)+'"]'}function Ct(a){return"script[async]"+a}function vu(a,t,o){if(t.count++,t.instance===null)switch(t.type){case"style":var r=a.querySelector('style[data-href~="'+Ri(o.href)+'"]');if(r)return t.instance=r,_e(r),r;var s=_({},o,{"data-href":o.href,"data-precedence":o.precedence,href:null,precedence:null});return r=(a.ownerDocument||a).createElement("style"),_e(r),je(r,"style",s),Yo(r,o.precedence,a),t.instance=r;case"stylesheet":s=Oa(o.href);var c=a.querySelector(At(s));if(c)return t.state.loading|=4,t.instance=c,_e(c),c;r=Ru(o),(s=Mi.get(s))&&dc(r,s),c=(a.ownerDocument||a).createElement("link"),_e(c);var l=c;return l._p=new Promise(function(d,u){l.onload=d,l.onerror=u}),je(c,"link",r),t.state.loading|=4,Yo(c,o.precedence,a),t.instance=c;case"script":return c=Sa(o.src),(s=a.querySelector(Ct(c)))?(t.instance=s,_e(s),s):(r=o,(s=Mi.get(c))&&(r=_({},o),mc(r,s)),a=a.ownerDocument||a,s=a.createElement("script"),_e(s),je(s,"link",r),a.head.appendChild(s),t.instance=s);case"void":return null;default:throw Error(f(443,t.type))}else t.type==="stylesheet"&&(t.state.loading&4)===0&&(r=t.instance,t.state.loading|=4,Yo(r,o.precedence,a));return t.instance}function Yo(a,t,o){for(var r=o.querySelectorAll('link[rel="stylesheet"][data-precedence],style[data-precedence]'),s=r.length?r[r.length-1]:null,c=s,l=0;l<r.length;l++){var d=r[l];if(d.dataset.precedence===t)c=d;else if(c!==s)break}c?c.parentNode.insertBefore(a,c.nextSibling):(t=o.nodeType===9?o.head:o,t.insertBefore(a,t.firstChild))}function dc(a,t){a.crossOrigin==null&&(a.crossOrigin=t.crossOrigin),a.referrerPolicy==null&&(a.referrerPolicy=t.referrerPolicy),a.title==null&&(a.title=t.title)}function mc(a,t){a.crossOrigin==null&&(a.crossOrigin=t.crossOrigin),a.referrerPolicy==null&&(a.referrerPolicy=t.referrerPolicy),a.integrity==null&&(a.integrity=t.integrity)}var Lo=null;function Au(a,t,o){if(Lo===null){var r=new Map,s=Lo=new Map;s.set(o,r)}else s=Lo,r=s.get(o),r||(r=new Map,s.set(o,r));if(r.has(a))return r;for(r.set(a,null),o=o.getElementsByTagName(a),s=0;s<o.length;s++){var c=o[s];if(!(c[Na]||c[Ye]||a==="link"&&c.getAttribute("rel")==="stylesheet")&&c.namespaceURI!=="http://www.w3.org/2000/svg"){var l=c.getAttribute(t)||"";l=a+l;var d=r.get(l);d?d.push(c):r.set(l,[c])}}return r}function Cu(a,t,o){a=a.ownerDocument||a,a.head.insertBefore(o,t==="title"?a.querySelector("head > title"):null)}function bh(a,t,o){if(o===1||t.itemProp!=null)return!1;switch(a){case"meta":case"title":return!0;case"style":if(typeof t.precedence!="string"||typeof t.href!="string"||t.href==="")break;return!0;case"link":if(typeof t.rel!="string"||typeof t.href!="string"||t.href===""||t.onLoad||t.onError)break;switch(t.rel){case"stylesheet":return a=t.disabled,typeof t.precedence=="string"&&a==null;default:return!0}case"script":if(t.async&&typeof t.async!="function"&&typeof t.async!="symbol"&&!t.onLoad&&!t.onError&&t.src&&typeof t.src=="string")return!0}return!1}function Gu(a){return!(a.type==="stylesheet"&&(a.state.loading&3)===0)}function gh(a,t,o,r){if(o.type==="stylesheet"&&(typeof r.media!="string"||matchMedia(r.media).matches!==!1)&&(o.state.loading&4)===0){if(o.instance===null){var s=Oa(r.href),c=t.querySelector(At(s));if(c){t=c._p,t!==null&&typeof t=="object"&&typeof t.then=="function"&&(a.count++,a=Bo.bind(a),t.then(a,a)),o.state.loading|=4,o.instance=c,_e(c);return}c=t.ownerDocument||t,r=Ru(r),(s=Mi.get(s))&&dc(r,s),c=c.createElement("link"),_e(c);var l=c;l._p=new Promise(function(d,u){l.onload=d,l.onerror=u}),je(c,"link",r),o.instance=c}a.stylesheets===null&&(a.stylesheets=new Map),a.stylesheets.set(o,t),(t=o.state.preload)&&(o.state.loading&3)===0&&(a.count++,o=Bo.bind(a),t.addEventListener("load",o),t.addEventListener("error",o))}}var uc=0;function Dh(a,t){return a.stylesheets&&a.count===0&&jo(a,a.stylesheets),0<a.count||0<a.imgCount?function(o){var r=setTimeout(function(){if(a.stylesheets&&jo(a,a.stylesheets),a.unsuspend){var c=a.unsuspend;a.unsuspend=null,c()}},6e4+t);0<a.imgBytes&&uc===0&&(uc=62500*$p());var s=setTimeout(function(){if(a.waitingForImages=!1,a.count===0&&(a.stylesheets&&jo(a,a.stylesheets),a.unsuspend)){var c=a.unsuspend;a.unsuspend=null,c()}},(a.imgBytes>uc?50:800)+t);return a.unsuspend=o,function(){a.unsuspend=null,clearTimeout(r),clearTimeout(s)}}:null}function Bo(){if(this.count--,this.count===0&&(this.imgCount===0||!this.waitingForImages)){if(this.stylesheets)jo(this,this.stylesheets);else if(this.unsuspend){var a=this.unsuspend;this.unsuspend=null,a()}}}var Fo=null;function jo(a,t){a.stylesheets=null,a.unsuspend!==null&&(a.count++,Fo=new Map,t.forEach(Rh,a),Fo=null,Bo.call(a))}function Rh(a,t){if(!(t.state.loading&4)){var o=Fo.get(a);if(o)var r=o.get(null);else{o=new Map,Fo.set(a,o);for(var s=a.querySelectorAll("link[data-precedence],style[data-precedence]"),c=0;c<s.length;c++){var l=s[c];(l.nodeName==="LINK"||l.getAttribute("media")!=="not all")&&(o.set(l.dataset.precedence,l),r=l)}r&&o.set(null,r)}s=t.instance,l=s.getAttribute("data-precedence"),c=o.get(l)||r,c===r&&o.set(null,s),o.set(l,s),this.count++,r=Bo.bind(this),s.addEventListener("load",r),s.addEventListener("error",r),c?c.parentNode.insertBefore(s,c.nextSibling):(a=a.nodeType===9?a.head:a,a.insertBefore(s,a.firstChild)),t.state.loading|=4}}var Gt={$$typeof:Q,Provider:null,Consumer:null,_currentValue:V,_currentValue2:V,_threadCount:0};function vh(a,t,o,r,s,c,l,d,u){this.tag=1,this.containerInfo=a,this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.next=this.pendingContext=this.context=this.cancelPendingCommit=null,this.callbackPriority=0,this.expirationTimes=sr(-1),this.entangledLanes=this.shellSuspendCounter=this.errorRecoveryDisabledLanes=this.expiredLanes=this.warmLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=sr(0),this.hiddenUpdates=sr(null),this.identifierPrefix=r,this.onUncaughtError=s,this.onCaughtError=c,this.onRecoverableError=l,this.pooledCache=null,this.pooledCacheLanes=0,this.formState=u,this.incompleteTransitions=new Map}function Uu(a,t,o,r,s,c,l,d,u,R,G,M){return a=new vh(a,t,o,l,u,R,G,M,d),t=1,c===!0&&(t|=24),c=mi(3,null,null,t),a.current=c,c.stateNode=a,t=Vr(),t.refCount++,a.pooledCache=t,t.refCount++,c.memoizedState={element:r,isDehydrated:o,cache:t},Kr(c),a}function Iu(a){return a?(a=da,a):da}function Eu(a,t,o,r,s,c){s=Iu(s),r.context===null?r.context=s:r.pendingContext=s,r=pn(t),r.payload={element:o},c=c===void 0?null:c,c!==null&&(r.callback=c),o=hn(a,r,t),o!==null&&(ai(o,a,t),nt(o,a,t))}function Mu(a,t){if(a=a.memoizedState,a!==null&&a.dehydrated!==null){var o=a.retryLane;a.retryLane=o!==0&&o<t?o:t}}function fc(a,t){Mu(a,t),(a=a.alternate)&&Mu(a,t)}function Pu(a){if(a.tag===13||a.tag===31){var t=_n(a,67108864);t!==null&&ai(t,a,67108864),fc(a,67108864)}}function Tu(a){if(a.tag===13||a.tag===31){var t=yi();t=cr(t);var o=_n(a,t);o!==null&&ai(o,a,t),fc(a,t)}}var Vo=!0;function Ah(a,t,o,r){var s=C.T;C.T=null;var c=H.p;try{H.p=2,pc(a,t,o,r)}finally{H.p=c,C.T=s}}function Ch(a,t,o,r){var s=C.T;C.T=null;var c=H.p;try{H.p=8,pc(a,t,o,r)}finally{H.p=c,C.T=s}}function pc(a,t,o,r){if(Vo){var s=hc(r);if(s===null)ec(a,t,r,Qo,o),Ou(a,r);else if(Uh(s,a,t,o,r))r.stopPropagation();else if(Ou(a,r),t&4&&-1<Gh.indexOf(a)){for(;s!==null;){var c=$n(s);if(c!==null)switch(c.tag){case 3:if(c=c.stateNode,c.current.memoizedState.isDehydrated){var l=Sn(c.pendingLanes);if(l!==0){var d=c;for(d.pendingLanes|=2,d.entangledLanes|=2;l;){var u=1<<31-li(l);d.entanglements[1]|=u,l&=~u}wi(c),(fe&6)===0&&(Mo=si()+500,gt(0))}}break;case 31:case 13:d=_n(c,2),d!==null&&ai(d,c,2),To(),fc(c,2)}if(c=hc(r),c===null&&ec(a,t,r,Qo,o),c===s)break;s=c}s!==null&&r.stopPropagation()}else ec(a,t,r,null,o)}}function hc(a){return a=br(a),yc(a)}var Qo=null;function yc(a){if(Qo=null,a=Jn(a),a!==null){var t=w(a);if(t===null)a=null;else{var o=t.tag;if(o===13){if(a=W(t),a!==null)return a;a=null}else if(o===31){if(a=X(t),a!==null)return a;a=null}else if(o===3){if(t.stateNode.current.memoizedState.isDehydrated)return t.tag===3?t.stateNode.containerInfo:null;a=null}else t!==a&&(a=null)}}return Qo=a,null}function xu(a){switch(a){case"beforetoggle":case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"toggle":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 2;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 8;case"message":switch(lf()){case Nc:return 2;case Yc:return 8;case Ht:case df:return 32;case Lc:return 268435456;default:return 32}default:return 32}}var bc=!1,In=null,En=null,Mn=null,Ut=new Map,It=new Map,Pn=[],Gh="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset".split(" ");function Ou(a,t){switch(a){case"focusin":case"focusout":In=null;break;case"dragenter":case"dragleave":En=null;break;case"mouseover":case"mouseout":Mn=null;break;case"pointerover":case"pointerout":Ut.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":It.delete(t.pointerId)}}function Et(a,t,o,r,s,c){return a===null||a.nativeEvent!==c?(a={blockedOn:t,domEventName:o,eventSystemFlags:r,nativeEvent:c,targetContainers:[s]},t!==null&&(t=$n(t),t!==null&&Pu(t)),a):(a.eventSystemFlags|=r,t=a.targetContainers,s!==null&&t.indexOf(s)===-1&&t.push(s),a)}function Uh(a,t,o,r,s){switch(t){case"focusin":return In=Et(In,a,t,o,r,s),!0;case"dragenter":return En=Et(En,a,t,o,r,s),!0;case"mouseover":return Mn=Et(Mn,a,t,o,r,s),!0;case"pointerover":var c=s.pointerId;return Ut.set(c,Et(Ut.get(c)||null,a,t,o,r,s)),!0;case"gotpointercapture":return c=s.pointerId,It.set(c,Et(It.get(c)||null,a,t,o,r,s)),!0}return!1}function Su(a){var t=Jn(a.target);if(t!==null){var o=w(t);if(o!==null){if(t=o.tag,t===13){if(t=W(o),t!==null){a.blockedOn=t,Wc(a.priority,function(){Tu(o)});return}}else if(t===31){if(t=X(o),t!==null){a.blockedOn=t,Wc(a.priority,function(){Tu(o)});return}}else if(t===3&&o.stateNode.current.memoizedState.isDehydrated){a.blockedOn=o.tag===3?o.stateNode.containerInfo:null;return}}}a.blockedOn=null}function Wo(a){if(a.blockedOn!==null)return!1;for(var t=a.targetContainers;0<t.length;){var o=hc(a.nativeEvent);if(o===null){o=a.nativeEvent;var r=new o.constructor(o.type,o);yr=r,o.target.dispatchEvent(r),yr=null}else return t=$n(o),t!==null&&Pu(t),a.blockedOn=o,!1;t.shift()}return!0}function Hu(a,t,o){Wo(a)&&o.delete(t)}function Ih(){bc=!1,In!==null&&Wo(In)&&(In=null),En!==null&&Wo(En)&&(En=null),Mn!==null&&Wo(Mn)&&(Mn=null),Ut.forEach(Hu),It.forEach(Hu)}function qo(a,t){a.blockedOn===t&&(a.blockedOn=null,bc||(bc=!0,h.unstable_scheduleCallback(h.unstable_NormalPriority,Ih)))}var Ko=null;function zu(a){Ko!==a&&(Ko=a,h.unstable_scheduleCallback(h.unstable_NormalPriority,function(){Ko===a&&(Ko=null);for(var t=0;t<a.length;t+=3){var o=a[t],r=a[t+1],s=a[t+2];if(typeof r!="function"){if(yc(r||o)===null)continue;break}var c=$n(o);c!==null&&(a.splice(t,3),t-=3,hs(c,{pending:!0,data:s,method:o.method,action:r},r,s))}}))}function Ha(a){function t(u){return qo(u,a)}In!==null&&qo(In,a),En!==null&&qo(En,a),Mn!==null&&qo(Mn,a),Ut.forEach(t),It.forEach(t);for(var o=0;o<Pn.length;o++){var r=Pn[o];r.blockedOn===a&&(r.blockedOn=null)}for(;0<Pn.length&&(o=Pn[0],o.blockedOn===null);)Su(o),o.blockedOn===null&&Pn.shift();if(o=(a.ownerDocument||a).$$reactFormReplay,o!=null)for(r=0;r<o.length;r+=3){var s=o[r],c=o[r+1],l=s[Xe]||null;if(typeof c=="function")l||zu(o);else if(l){var d=null;if(c&&c.hasAttribute("formAction")){if(s=c,l=c[Xe]||null)d=l.formAction;else if(yc(s)!==null)continue}else d=l.action;typeof d=="function"?o[r+1]=d:(o.splice(r,3),r-=3),zu(o)}}}function wu(){function a(c){c.canIntercept&&c.info==="react-transition"&&c.intercept({handler:function(){return new Promise(function(l){return s=l})},focusReset:"manual",scroll:"manual"})}function t(){s!==null&&(s(),s=null),r||setTimeout(o,20)}function o(){if(!r&&!navigation.transition){var c=navigation.currentEntry;c&&c.url!=null&&navigation.navigate(c.url,{state:c.getState(),info:"react-transition",history:"replace"})}}if(typeof navigation=="object"){var r=!1,s=null;return navigation.addEventListener("navigate",a),navigation.addEventListener("navigatesuccess",t),navigation.addEventListener("navigateerror",t),setTimeout(o,100),function(){r=!0,navigation.removeEventListener("navigate",a),navigation.removeEventListener("navigatesuccess",t),navigation.removeEventListener("navigateerror",t),s!==null&&(s(),s=null)}}}function gc(a){this._internalRoot=a}Zo.prototype.render=gc.prototype.render=function(a){var t=this._internalRoot;if(t===null)throw Error(f(409));var o=t.current,r=yi();Eu(o,r,a,t,null,null)},Zo.prototype.unmount=gc.prototype.unmount=function(){var a=this._internalRoot;if(a!==null){this._internalRoot=null;var t=a.containerInfo;Eu(a.current,2,null,a,null,null),To(),t[Xn]=null}};function Zo(a){this._internalRoot=a}Zo.prototype.unstable_scheduleHydration=function(a){if(a){var t=Qc();a={blockedOn:null,target:a,priority:t};for(var o=0;o<Pn.length&&t!==0&&t<Pn[o].priority;o++);Pn.splice(o,0,a),o===0&&Su(a)}};var ku=P.version;if(ku!=="19.2.0")throw Error(f(527,ku,"19.2.0"));H.findDOMNode=function(a){var t=a._reactInternals;if(t===void 0)throw typeof a.render=="function"?Error(f(188)):(a=Object.keys(a).join(","),Error(f(268,a)));return a=E(t),a=a!==null?L(a):null,a=a===null?null:a.stateNode,a};var Eh={bundleType:0,version:"19.2.0",rendererPackageName:"react-dom",currentDispatcherRef:C,reconcilerVersion:"19.2.0"};if(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__<"u"){var Xo=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!Xo.isDisabled&&Xo.supportsFiber)try{wa=Xo.inject(Eh),ci=Xo}catch{}}return Pt.createRoot=function(a,t){if(!S(a))throw Error(f(299));var o=!1,r="",s=jd,c=Vd,l=Qd;return t!=null&&(t.unstable_strictMode===!0&&(o=!0),t.identifierPrefix!==void 0&&(r=t.identifierPrefix),t.onUncaughtError!==void 0&&(s=t.onUncaughtError),t.onCaughtError!==void 0&&(c=t.onCaughtError),t.onRecoverableError!==void 0&&(l=t.onRecoverableError)),t=Uu(a,1,!1,null,null,o,r,null,s,c,l,wu),a[Xn]=t.current,$s(a),new gc(t)},Pt.hydrateRoot=function(a,t,o){if(!S(a))throw Error(f(299));var r=!1,s="",c=jd,l=Vd,d=Qd,u=null;return o!=null&&(o.unstable_strictMode===!0&&(r=!0),o.identifierPrefix!==void 0&&(s=o.identifierPrefix),o.onUncaughtError!==void 0&&(c=o.onUncaughtError),o.onCaughtError!==void 0&&(l=o.onCaughtError),o.onRecoverableError!==void 0&&(d=o.onRecoverableError),o.formState!==void 0&&(u=o.formState)),t=Uu(a,1,!0,t,o??null,r,s,u,c,l,d,wu),t.context=Iu(null),o=t.current,r=yi(),r=cr(r),s=pn(r),s.callback=null,hn(o,s,r),o=r,t.current.lanes=o,_a(t,o),wi(t),a[Xn]=t.current,$s(a),new Zo(t)},Pt.version="19.2.0",Pt}var Wu;function _h(){if(Wu)return vc.exports;Wu=1;function h(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(h)}catch(P){console.error(P)}}return h(),vc.exports=kh(),vc.exports}var Nh=_h();const Yh=qu(Nh);var i=(h=>(h.HIGH="HIGH",h.MODERATE="MODERATE",h.LOW="LOW",h.CONTRAINDICATED="CONTRAINDICATED",h.UNKNOWN="UNKNOWN",h))(i||{}),e=(h=>(h.DRUG_DRUG="DRUG_DRUG",h.DRUG_FOOD="DRUG_FOOD",h.DRUG_DISEASE="DRUG_DISEASE",h.DRUG_LAB="DRUG_LAB",h.DRUG_VACCINE="DRUG_VACCINE",h.DRUG_PREGNANCY_LACTATION="DRUG_PREGNANCY_LACTATION",h))(e||{});const Lh=h=>h?h.split(" ").map(P=>/^[a-zA-Z]/.test(P)?P.charAt(0).toUpperCase()+P.slice(1).toLowerCase():P).join(" ").trim():"",Uc=h=>{if(!h)return"";let P=h;return P=P.replace(/[\u0600-\u06FF]+/g,""),P=P.replace(/\([^)]*\)/g,""),P=P.split(/ [-] /)[0],P=P.split(" - ")[0],P=P.replace(/\s*\/\s*/g," / "),P=P.replace(/[\[\]]/g,""),P=P.replace(/^[\s\-\/]+|[\s\-\/]+$/g,""),P=P.replace(/\s+/g," ").trim(),Lh(P)},Bh=h=>{const P=new Map;return h.forEach(f=>{var K,Ae,z,Ie,ke,Pe,qe;if(!f.drugA)return;const S=Uc(f.drugA),w=f.drugB?Uc(f.drugB):void 0,W=f.foodOrCondition?Uc(f.foodOrCondition):void 0;if(!S||f.type===e.DRUG_DRUG&&!w||(f.type===e.DRUG_FOOD||f.type===e.DRUG_DISEASE)&&!W)return;let X="";if(f.type===e.DRUG_DRUG&&w){const Q=[S,w].sort();X=`${e.DRUG_DRUG}:${Q[0]}:${Q[1]}`}else{const Q=W||"GENERAL";X=`${f.type}:${S}:${Q}`}const O={[i.CONTRAINDICATED]:4,[i.HIGH]:3,[i.MODERATE]:2,[i.LOW]:1,[i.UNKNOWN]:0},E=P.get(X),L=O[f.severity]||0,_=E?O[E.severity]||0:-1;if(!E||L>_)P.set(X,{...f,drugA:S,drugB:w,foodOrCondition:W,mechanism:((K=f.mechanism)==null?void 0:K.trim())||" ",effect:((Ae=f.effect)==null?void 0:Ae.trim())||" ",management:((z=f.management)==null?void 0:z.trim())||" "});else if(L===_){const Q=(((Ie=f.mechanism)==null?void 0:Ie.length)||0)+(((ke=f.effect)==null?void 0:ke.length)||0),se=(((Pe=E.mechanism)==null?void 0:Pe.length)||0)+(((qe=E.effect)==null?void 0:qe.length)||0);Q>se&&P.set(X,{...f,drugA:S,drugB:w,foodOrCondition:W})}}),Array.from(P.values()).sort((f,S)=>f.drugA.localeCompare(S.drugA,"en")).map((f,S)=>({...f,id:(S+1).toString()}))},Fh=h=>{const P=new Set;return h.forEach(x=>{x.drugA&&P.add(x.drugA),x.drugB&&P.add(x.drugB)}),Array.from(P).filter(x=>x&&x.length>1).sort((x,f)=>x.localeCompare(f,"en")).map((x,f)=>({id:`drug-${f}`,name:x}))},Ku=["Androstanolone","Nandrolone decanoate","Nandrolone","Testosterone","Danazol","Fluxymesterone","Methyltestosterone","Oxandrolone","Oxymetholone","Stanozolol"],tn=["Ferrous fumarate","Ferrous gluconate","Ferrous sulfate","Iron polysaccharide"],Pc=["Aluminum hydroxide","Aluminum-magnesium hydroxide","Calcium acetate","Calcium carbonate","Magnesium hydroxide","Magnesium oxide","Magnesium sulfate","Magnesium trisilicate","Aluminum carbonate","Aluminum phosphate","Attapulgite","Kaolin","Magaldrate","Sodium bicarbonate"],$o=["Acebutolol","Atenolol","Betaxolol","Bisoprolol","Esmolol","Metoprolol","Nadolol"],za=["Carteolol","Carvedilol","Labetalol","Penbutolol","Pindolol","Propranolol","Sotalol","Timolol"],xn=[...$o,...za],Zu=["Amitriptyline","Amoxapine","Clomipramine","Desipramine","Doxepin","Imipramine","Nortriptyline","Protriptyline","Trimipramine"],jh=["Dobutamine","Dopamine","Ephedrine","Epinephrine","Mephentermine","Metaraminol","Methoxamine","Norepinephrine","Phenylephrine","Pseudoephedrine"],Tc=["Benazepril","Captopril","Enalapril","Fosinopril","Lisinopril","Moexipril","Perindopril","Quinapril","Trandolapril"],Vh=["Amiloride","Spironolactone","Triamterene"],Qh=["Candesartan","Eprosartan","Irbesartan","Losartan","Olmesartan","Telmisartan","Valsartan"],Tt=["Amobarbital","Aprobarbital","Butabarbital","Butalbital","Mephobarbital","Pentobarbital","Phenobarbital","Primidone","Secobarbital"],xc=["Ibuprofen","Indomethacin","Naproxen","Piroxicam","Diclofenac","Etodolac","Fenoprofen","Flubiprofen","Ketoprofen","Ketorolac","Meclofenamic acid","Nabumetone","Oxaprozin","Sulindac","Tolmetin","Celecoxib","Meloxicam","Mefenamic Acid"],Oc=["Rifabutin","Rifampin","Rifapentine"],Wh=["Methimazole","Propylthiouracil"],Xu=["Prednisone","Prednisolone","Hydrocortisone","Dexamethasone","Betamethasone","Methylprednisolone"],qh=["Pseudoephedrine","Phenylephrine","Ephedrine"],Kh=["Desflurane","Enflurane","Halothane","Isoflurane","Sevoflurane"],xt=["Gatifloxacin","Moxifloxacin","Sparfloxacin","Ciprofloxacin","Gemifloxacin","Levofloxacin","Lomefloxacin","Nalidixic Acid","Norfloxacin","Ofloxacin","Trovafloxacin"],Ju=["Alprazolam","Clonazepam","Diazepam","Lorazepam","Midazolam","Triazolam"],Sc=["Fluvastatin","Lovastatin","Simvastatin","Atorvastatin","Pravastatin","Rosuvastatin"],er=["Ethotoin","Fosphenytoin","Mephenytoin","Phenytoin"],Zh=["Calcium acetate","Calcium carbonate","Calcium chloride","Calcium citrate","Calcium glubionate","Calcium gluconate","Calcium glycerophosphate","Calcium lactate","Calcium levulinate","Tricalcium phosphate"],Xh=["Atracurium","Doxacurium","Mivacurium","Pancuronium","Pipecuronium","Rocuronium","Tubocurarine","Vecuronium","Gallamine triethiodide"],Jh=["Indinavir","Ritonavir","Nelfinavir","Saquinavir","Amprenavir","Fosamprenavir","Lopinavir","Atazanavir","Tipranavir","Darunavir"],$h=["Sildenafil","Tadalafil","Vardenafil"],Ot=["Amikacin","Gentamicin","Kanamycin","Neomycin","Streptomycin","Tobramycin","Paromomycin"],Hc=["Cefamandole","Cefazolin","Cefonicid","Cefoperazone","Cefotaxime","Cefotetan","Cefoxitin","Ceftazidime","Ceftizoxime","Ceftriaxone","Cefuroxime","Cephalothin","Cephapirin","Cephradine","Ceforanide","Moxalactam"],zc=["Amoxicillin","Ampicillin","Bacampicillin","Carbenicillin","Cloxacillin","Dicloxacillin","Methicillin","Mezlocillin","Nafcillin","Oxacillin","Penicillin G","Penicillin V","Piperacillin","Ticarcillin"],ir=["Azithromycin","Clarithromycin","Erythromycin","Troleandomycin"],St=["Demeclocycline","Doxycycline","Methacycline","Minocycline","Oxytetracycline","Tetracycline"],wc=["Fluconazole","Itraconazole","Ketoconazole","Miconazole","Voriconazole"],ey=["Bleomycin","Carboplatin","Carmustine","Cisplatin","Cyclophosphamide","Cytarabine","Doxorubicin","Methotrexate","Vinblastine","Vincristine"],iy=["Clofibrate","Fenofibrate","Gemfibrozil"],$u=["Bumetanide","Ethacrynic acid","Furosemide","Torsemide"],ny=["Bendroflumethiazide","Chlorothiazide","Chlorthalidone","Hydrochlorothiazide","Hydroflumethiazide","Indapamide","Metolazone","Polythiazide","Trichlormethiazide"],ay=["Chlorpromazine","Thioridazine","Mesoridazine","Fluphenazine","Perphenazine","Prochlorperazine","Trifluoperazine"],ef=["Glibenclamide","Gliclazide","Glimepiride"],nf=[],n=(h,P,x,f,S,w,W,X,O,E)=>{const L=Array.isArray(h)?h:[h],_=Array.isArray(P)?P:[P];L.forEach(K=>{_.forEach(Ae=>{K!==Ae&&nf.push({id:`${K}-${Ae}-${Math.random().toString(36).substr(2,9)}`,drugA:K,drugB:x===e.DRUG_DRUG?Ae:void 0,foodOrCondition:x!==e.DRUG_DRUG?Ae:void 0,type:x,severity:f,mechanism:`${S}||${w}`,effect:`${W}||${X}`,management:`${O}||${E}`})})})};n("5-Fluorouracil - -","Leucovorin - ",e.DRUG_DRUG,i.MODERATE," ( )       5-    (TS)           (DNA)    .","Leucovorin (folinic acid) stabilizes and strengthens the binding of 5-Fluorouracil to the thymidylate synthase (TS) enzyme, leading to more effective and efficient inhibition of DNA synthesis in both cancerous and normal cells.","        (    )   (     ).         .","Increased severity and incidence of toxicities, particularly gastrointestinal toxicity (stomatitis, diarrhea, nausea, vomiting) and myelosuppression (neutropenia, thrombocytopenia, anemia). Diarrhea and stomatitis can become severe and life-threatening.","        .     (   )    .         .","This interaction is intentional and planned to enhance the drug's therapeutic efficacy. Close monitoring for toxicity (especially diarrhea and stomatitis) and proactive symptom management is crucial. Dose adjustment based on toxicity severity per established protocols is required.");n("Abaloparatide","Digoxin",e.DRUG_DRUG,i.MODERATE,"    .          .","Indirect pharmacokinetic interaction. No enzymatic mechanism, but both affect cardiac calcium.","     (Hypercalcemia)      Digoxin  .","Increased risk of Hypercalcemia, which can potentiate Digoxin cardiac toxicity."," .        .","Calcium monitoring. Serum calcium and creatinine levels must be monitored regularly.");n("Abatacept","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Abatacept   (T-cell co-stimulation inhibitor).","Increased risk of infection. Abatacept is an immunosuppressant (T-cell co-stimulation inhibitor).","     .","Risk of developing infection from live vaccines."," .      .","Contraindicated. Live vaccines must be avoided during treatment.");n("Abemaciclib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. Clarithromycin    CYP3A4      Abemaciclib.","Increased Abemaciclib concentration. Clarithromycin is a strong CYP3A4 inhibitor, the primary metabolic pathway for Abemaciclib.","         .","Increased risk of severe side effects, especially myelosuppression and diarrhea."," .    Abemaciclib     CYP3A4 .","Dose adjustment. Abemaciclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Abemaciclib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. Rifampin    CYP3A4    Abemaciclib.","Decreased Abemaciclib efficacy. Rifampin is a strong inducer of CYP3A4, an Abemaciclib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Abemaciclib","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. Diltiazem    CYP3A4    Abemaciclib.","Increased Abemaciclib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a metabolic pathway for Abemaciclib.","    (  ) .","Increased risk of hematological toxicity (myelosuppression) and diarrhea."," .    Abemaciclib     CYP3A4 .","Dose adjustment. Abemaciclib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Abemaciclib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. Efavirenz    CYP3A4    Abemaciclib.","Decreased Abemaciclib efficacy. Efavirenz is a moderate inducer of CYP3A4, an Abemaciclib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Abemaciclib","St. John's Wort",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. St. John's Wort    CYP3A4    Abemaciclib.","Decreased Abemaciclib efficacy. St. John's Wort is a strong inducer of CYP3A4, an Abemaciclib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .       (St. John's Wort).","Avoid Combination. St. John's Wort must be avoided.");n("Abemaciclib","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. Fluconazole    CYP3A4    Abemaciclib.","Increased Abemaciclib concentration. Fluconazole is a strong CYP3A4 inhibitor, an Abemaciclib metabolic pathway.","     .","Increased risk of diarrhea and myelosuppression."," .    Abemaciclib     CYP3A4 .","Dose adjustment. Abemaciclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Abemaciclib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Abemaciclib. Clarithromycin    CYP3A4.","Increased Abemaciclib concentration. Clarithromycin is a strong inhibitor of CYP3A4.","    .","Increased risk of diarrhea and hematological toxicity."," .    Abemaciclib  .","Dose adjustment. Abemaciclib dose must be significantly reduced.");n("Abiraterone","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Abiraterone. Carbamazepine    CYP3A4    Abiraterone.","Decreased Abiraterone efficacy. Carbamazepine is a strong inducer of CYP3A4, an Abiraterone metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Abiraterone","Dextromethorphan",e.DRUG_DRUG,i.HIGH,"  Dextromethorphan. Abiraterone   CYP2D6    Dextromethorphan.","Increased Dextromethorphan concentration. Abiraterone inhibits CYP2D6, a Dextromethorphan metabolic pathway.","       .","Increased risk of side effects, especially neurotoxicity and hallucinations.","    .     CYP2D6   .","Avoid Combination or Dose Adjustment. Avoid sensitive CYP2D6 substrates or reduce their dose.");n("Abiraterone","Dextromethorphan",e.DRUG_DRUG,i.MODERATE,"     CYP2D6           .                 200-300%      .","Abiraterone is a potent inhibitor of hepatic CYP2D6 enzyme, which is responsible for metabolizing dextromethorphan to its active metabolite dextrorphan. Inhibition of this enzyme leads to dextromethorphan accumulation in blood and increased plasma concentration by up to 200-300%, enhancing its pharmacological and adverse effects.","        :              (      ).         .","Significant increase in central effects of dextromethorphan, including: severe drowsiness, dizziness, confusion, visual disturbances, and in severe cases serotonin syndrome may occur (especially when combined with other serotonergic drugs). Toxicity-like symptoms such as hallucinations and agitation may also appear.","        .      50%    .       .             .","Use with extreme caution with close monitoring of central nervous system symptoms. Preferably reduce dextromethorphan dose by at least 50% when combined. Avoid concurrent use with other serotonergic drugs. Educate patient about warning signs and necessity of immediate reporting of any abnormal symptoms.");n("Acalabrutinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Acalabrutinib. PPIs        Acalabrutinib.","Decreased Acalabrutinib concentration. PPIs reduce gastric acidity, which is necessary for Acalabrutinib absorption.","           .","Severe decrease in drug plasma concentration, leading to treatment failure."," .       (PPIs).","Avoid Combination. Proton pump inhibitors (PPIs) must be avoided.");n("Acalabrutinib","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,"  Acalabrutinib.          Acalabrutinib.","Decreased Acalabrutinib concentration. Antacids reduce gastric acidity, which is necessary for Acalabrutinib absorption.","  .","Reduced efficacy of treatment."," .   Acalabrutinib       .","Separate timing. Acalabrutinib must be taken 2 hours before or 2 hours after antacids.");n("Acalabrutinib","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Acalabrutinib. Fluconazole   CYP3A4    Acalabrutinib.","Increased Acalabrutinib concentration. Fluconazole is a CYP3A4 inhibitor, an Acalabrutinib metabolic pathway.","      .","Increased risk of myelosuppression, infection, and hemorrhage."," .    Acalabrutinib     CYP3A4   .","Dose adjustment. Acalabrutinib dose must be reduced when co-administered with moderate or strong CYP3A4 inhibitors.");n("Acalabrutinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Acalabrutinib.    (PPIs)       Acalabrutinib.","Decreased Acalabrutinib absorption. PPIs reduce gastric acidity, which is essential for Acalabrutinib absorption.","   .","Reduced anticancer efficacy."," .   .          H2 Blockers ( ).","Contraindicated. Avoid the combination. Antacids that do not affect acidity like H2 Blockers (at a suitable time) must be used.");n("Acalabrutinib (Calquence)","Proton Pump Inhibitors (Omeprazole)",e.DRUG_DRUG,i.MODERATE,": **   **.  Acalabrutinib   .","Mechanism: **Reduced GI absorption**. Acalabrutinib requires acidic environment."," : **    **.","Clinical Significance: **Reduced leukemia treatment efficacy**."," Acalabrutinib    PPI.    H2  10 .","Take Acalabrutinib 2 hours before PPI. Or use H2 antagonist 10 hours apart.");n("Acalabrutinib (Calquence)","Atrial Fibrillation History",e.DRUG_DISEASE,i.HIGH,": **   **.  BTK    .","Mechanism: **Increased atrial fibrillation risk**. BTK inhibitors may trigger atrial fibrillation."," : ** **   .","Clinical Significance: **Atrial fibrillation** and stroke risk.","   .   .","Close cardiac rhythm monitoring. Regular ECG.");n("Acarbose","Digestive Enzymes",e.DRUG_DRUG,i.MODERATE,"     - (   )         .   (  )                         .","Acarbose acts as a competitive inhibitor of alpha-glucosidase enzymes (such as sucrase, maltase, and isomaltase) in the small intestine, delaying digestion and absorption of complex carbohydrates. Digestive enzymes (such as amylase and lipase) given as supplements enhance carbohydrate and fat digestion, counteracting acarbose inhibitory effect and reducing its efficacy in controlling postprandial hyperglycemia.","                     .                    .        (  )    .","Significant reduction in acarbose efficacy in lowering postprandial glucose levels, leading to poor control of type 2 diabetes. Patient may need increased doses of other diabetes medications or insulin for compensation, increasing risk of hypoglycemia and treatment complexity. Gastrointestinal side effects of acarbose (bloating, gas, diarrhea) may also increase without adequate therapeutic benefit.","      .                      (    DPP-4).                          .","Avoiding combination of acarbose and digestive enzymes is recommended. If enzymes are necessary for treating exocrine pancreatic insufficiency, consider using alternative diabetes medication that does not depend on digestive enzyme inhibition (such as metformin or DPP-4 inhibitors). If combination is unavoidable, closely monitor postprandial glucose levels and adjust treatment accordingly, with patient education about importance of dietary compliance.");n(Tc,"Indomethacin",e.DRUG_DRUG,i.MODERATE,": **   **.    (PGE2 & PGI2)         ACE  .","Mechanism: **Renal mechanism antagonism**. Indomethacin inhibits vasodilatory prostaglandins (PGE2 & PGI2), counteracting the antihypertensive effect of ACE inhibitors."," : **    **       .","Clinical Significance: **Reduced antihypertensive efficacy**, and increased risk of acute renal impairment and potassium retention.","    .      ( )  NSAID   ( ).","Monitor BP and renal function. Consider using another analgesic (e.g., Paracetamol) or a less interacting NSAID (e.g., Sulindac).");n(Tc,"Lithium",e.DRUG_DRUG,i.HIGH,": **   **.  ACE             .","Mechanism: **Reduced renal lithium excretion**. ACE inhibitors decrease glomerular filtration rate and increase proximal tubular reabsorption of lithium."," : **      400%**      (     ).","Clinical Significance: **Increased lithium levels by up to 400%**, leading to lithium toxicity (tremors, confusion, nausea, renal failure).","     .        50%  .","Monitor lithium levels weekly upon initiation. Lithium dose reduction by 50% or more may be required.");n(Tc,Vh,e.DRUG_DRUG,i.HIGH,": **    **.        ( ACE      ).","Mechanism: **Synergistic potassium retention**. Both reduce renal potassium excretion (ACE inhibitors via aldosterone reduction, diuretics directly)."," : **    (Severe Hyperkalemia)**         ( ).","Clinical Significance: **Severe Hyperkalemia**, which can lead to fatal cardiac arrhythmias (cardiac arrest).","     (   ).      .","Avoid combination unless strictly necessary (e.g., severe heart failure). Monitor potassium regularly and avoid potassium supplements.");n("Acebutolol","Amlodipine",e.DRUG_DRUG,i.MODERATE,"   .         (Inotropic)   (Chronotropic)  .","Synergistic Cardiodepressant Effect. Both drugs may compound negative inotropic and/or chronotropic effects, increasing the risk of cardiac dysfunction.","    .       .","Hypotension & Bradycardia. Risk of severe bradycardia, excessive hypotension, and potential hemodynamic collapse.","  .           .","Monitor Vital Signs. Check BP and Heart Rate regularly. Use caution, especially when initiating therapy or increasing doses.");n("Acebutolol","Diltiazem",e.DRUG_DRUG,i.MODERATE,"   .                 .","Synergistic Cardiodepressant Effect. The combination significantly increases the risk of impaired cardiac conduction (AV block) and reduced contractility.","    .       .","Hypotension & Bradycardia. Risk of severe bradycardia, AV block, and potential hemodynamic collapse.","  .           .","Monitor Vital Signs. Check BP and Heart Rate regularly. Avoid combination in patients with pre-existing conduction abnormalities.");n("Acebutolol","Verapamil",e.DRUG_DRUG,i.MODERATE,"   .          (AV block)       .","Synergistic Cardiodepressant Effect. The combination significantly increases the risk of AV block, severe bradycardia, and left ventricular failure due to additive cardiac depression.","    .       .","Hypotension & Bradycardia. Risk of severe bradycardia and potential hemodynamic collapse.","  .           .","Monitor Vital Signs. Check BP and Heart Rate regularly. This combination is generally avoided in high-risk cardiac patients.");n("Acebutolol","Nifedipine",e.DRUG_DRUG,i.MODERATE,"   .                   .","Synergistic Cardiodepressant Effect. While Nifedipine has less effect on conduction than Verapamil/Diltiazem, the combination still poses a risk of additive hypotension and possible negative inotropy.","    .       .","Hypotension & Bradycardia. Risk of symptomatic low blood pressure.","  .           .","Monitor Vital Signs. Check BP and Heart Rate regularly. Adjust doses based on therapeutic response.");n("Acetaminophen","Alcohol",e.DRUG_FOOD,i.HIGH," ()         .  :   (85-90%)     (glucuronidation  sulfation)  5-10%    CYP2E1      NAPQI (N-acetyl-p-benzoquinone imine).        .   : (1)      CYP2E1      NAPQI   2-3  (2)      (   )      NAPQI (3) :  NAPQI          (  ).       (3-4  )        .","Paracetamol (acetaminophen) and alcohol both metabolize in liver, their interaction complex and very dangerous. Normal pathway: most paracetamol (85-90%) metabolizes via safe routes (glucuronidation and sulfation), but 5-10% metabolizes via CYP2E1 enzymes producing highly toxic metabolite called NAPQI (N-acetyl-p-benzoquinone imine). Normally, hepatic glutathione rapidly neutralizes this toxic metabolite. With alcohol consumption: (1) chronic alcohol use significantly induces CYP2E1 enzyme, increasing toxic NAPQI production 2-3 fold, (2) alcohol depletes hepatic glutathione stores (consumes them in its own metabolism), reducing capacity to neutralize NAPQI, (3) result: toxic NAPQI accumulation that directly attacks liver cells causing hepatic necrosis (liver cell death). Even normal therapeutic paracetamol doses (3-4g daily) may be hepatotoxic in regular alcohol drinkers.","                 .     :   (0-24 ):         -     .   (24-72 ):        (ALT, AST)    (   ).   (72-96 ):  (  )             (  )    .   (4-14 ):             (20-40%   ).      .    :      (  3  )          .","Dangerous, potentially life-threatening liver damage, ranging from mild liver enzyme elevation to acute fatal liver failure. Symptoms usually appear in stages: Stage 1 (0-24 hours): nausea, vomiting, anorexia, pallor, sweating, general malaise - may be mistaken for flu symptoms. Stage 2 (24-72 hours): false symptom improvement but liver enzymes (ALT, AST) rise dramatically (may reach thousands of units). Stage 3 (72-96 hours): jaundice (yellowing of skin and eyes), severe right upper quadrant abdominal pain, bleeding tendency and easy bruising, confusion (hepatic encephalopathy), dark urine, pale stool. Stage 4 (4-14 days): either gradual recovery or progression to acute liver failure with coma and death (20-40% of severe cases). Patient may need emergency liver transplant. Risk is much higher in: regular alcohol drinkers (>3 drinks daily), chronic liver disease patients, malnourished individuals, paracetamol use for consecutive days.","  : (1)      (3    ):           (    ) (2)      ( ):        48     (3)       (4    2-3          ) (4)   :      (       ) -         (5)              :        (6)    (  ):           (7)        (N-acetylcysteine)     -    .     .","Strict safety warnings: (1) if regularly drinking alcohol (3 drinks daily): completely avoid paracetamol or use safer alternative like ibuprofen (if no contraindications), (2) if taking paracetamol for treatment (fever, pain): completely avoid alcohol during treatment period and until 48 hours after last dose, (3) never exceed maximum daily dose (4g for healthy adults, 2-3g for alcohol drinkers or liver patients if absolutely necessary), (4) beware hidden paracetamol: present in hundreds of combination medications (cold and flu medicines, analgesics with caffeine, cough medicines) - always read ingredients to avoid unintentional overdose, (5) if treating alcohol addiction or have cirrhosis or any liver disease: consult physician before any paracetamol dose, (6) immediate emergency signs (go to ER immediately): persistent vomiting, severe abdominal pain, jaundice, confusion, unusual bleeding, (7) paracetamol poisoning is emergency requiring antidote treatment (N-acetylcysteine) as soon as possible - don't wait for symptoms.Awareness of this risk is lifesaving.");n("Acetaminophen","Liver Disease / Hepatic Impairment",e.DRUG_DISEASE,i.HIGH,"       NAPQI -   ","Reduced liver capacity to detoxify NAPQI metabolite - accumulation of toxic metabolite.","   -  ","Acute liver damage - hepatic failure.","   -     ","Reduce max dose - avoid in acute hepatic failure.");n("Acetaminophen","Warfarin",e.DRUG_DRUG,i.MODERATE,"            K","High doses of Acetaminophen may inhibit synthesis of Vitamin K-dependent clotting factors.","       ","Increased anticoagulant effect of Warfarin and bleeding risk.","   .  INR ","Avoid chronic high doses. Monitor INR regularly.");n("Acetazolamide - ","Carbonic Beverages -  ",e.DRUG_FOOD,i.LOW,'              CA-IV CA-VI.                    ""   .        locally                 .         .','Acetazolamide inhibits carbonic anhydrase enzyme present in taste buds on the tongue, particularly isozymes CA-IV and CA-VI. This enzyme is responsible for converting carbon dioxide to bicarbonate ions and protons, a process essential for sensing the fizz or "bubbles" in carbonated beverages. Inhibition leads to local accumulation of carbon dioxide in taste buds, causing an abnormal taste signal interpreted by the brain as metallic or bitter. This effect may persist for several hours after each dose.',"             : 1.      . 2.           . 3.                 . 4.       .","Metallic or bitter unpleasant taste when consuming carbonated beverages, which may lead to: 1. Avoidance of these beverages and search for alternatives. 2. General decrease in fluid intake due to dissatisfaction with drink options. 3. Risk of mild dehydration, especially in elderly patients or those with conditions that increase fluid requirements. 4. Negative impact on quality of life and meal enjoyment.","1.  :           . 2.  :                    . 3.   :              . 4. :                 . 5. :           .","1. Advance warning: Inform the patient about this side effect before starting treatment to prevent surprise and anxiety. 2. Suggest alternatives: Recommend non-carbonated beverages such as plain water, flavored water, iced tea, diluted juices, or calorie-free flavored waters. 3. Focus on hydration: Emphasize the importance of maintaining adequate fluid intake regardless of taste changes. 4. Timing: If a carbonated beverage must be consumed, consider having it at a time furthest from the drug dose. 5. Reassurance: Reassure the patient that this effect is temporary and reversible and will resolve after discontinuing the medication.");n("Acetohexamide","Ethanol",e.DRUG_DRUG,i.HIGH,"       +   ","Ethanol inhibits gluconeogenesis and enhances drug effect + Disulfiram-like reaction.","        ","Severe hypoglycemia, nausea, vomiting, flushing.","   .   ","Avoid alcohol during therapy. Monitor blood glucose.");n("Acetohexamide - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Acetohexamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Acetohexamide dose if necessary");n("Acetohexamide - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Acetohexamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Acetohexamide dose if necessary");n("Acetohexamide - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Acetohexamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Acetohexamide dose if necessary");n("Acetohexamide - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Acetohexamide","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Acetohexamide dose if necessary - Use alternative NSAID");n("Acetohexamide - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Acetohexamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Acetohexamide dose if necessary");n("Acetohexamide - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Acetohexamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Acetohexamide dose if necessary");n("Acetohexamide - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"    ","Increased concentrations of Acetohexamide","    ","Increased risk of hypoglycemia","     -       -      ( )","Monitor blood glucose concentration - Decrease Acetohexamide dose if necessary - Use noninteracting sulfonylurea (eg, glyburide)");n("Acetohexamide - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Acetohexamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Acetohexamide dose if necessary");n("Acitretin - ","Methotrexate - ",e.DRUG_DRUG,i.HIGH,"         .                          .","Both drugs are metabolized in the liver and have independent hepatotoxicity. When combined, they exert a synergistic effect on liver toxicity, working together to increase oxidative stress, hepatocyte cell death, and the risk of hepatitis and fibrosis.","      (ALT, AST)            .                .","Sharp and rapid elevation of liver enzymes (ALT, AST), drug-induced hepatitis, hepatic fibrosis, and acute liver failure which can be life-threatening. The risk is significantly higher in patients with pre-existing liver disease or alcohol consumption.","             .               .          .","The combination of these two drugs is absolutely contraindicated due to the high risk of life-threatening hepatotoxicity. Completion of one therapy and confirmation of normalized liver function tests are required before starting the other drug. Periodic monitoring of liver function is mandatory with each drug individually.");n("Activated Charcoal -  ","Oral Medications -  ",e.DRUG_DRUG,i.HIGH,"            ()               .","Activated charcoal has a very large surface area and porous structure that enables it to bind (adsorb) a wide range of drugs and chemical compounds in the gastrointestinal tract, preventing their absorption into the bloodstream.","             .        90      .","Significant reduction in the bioavailability and efficacy of the oral medication, leading to potential therapeutic failure. Can reduce absorption by up to 90% for some medications if taken together.","       .          ( 4-6      ).                   .","Avoid taking activated charcoal with other oral medications. Separate administration by at least 2 hours (preferably 4-6 hours for drugs with narrow therapeutic indices). In acute poisoning cases, activated charcoal is deliberately administered to adsorb toxins, and other medications are delayed until the charcoal is excreted.");n("Acyclovir","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"   .    .","Increased risk of nephrotoxicity. Additive nephrotoxic effect.","  .","Deterioration of renal function."," .     .","Close monitoring. Renal function must be monitored regularly.");n("Acyclovir","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Acyclovir. Probenecid       Acyclovir.","Increased Acyclovir concentration. Probenecid reduces renal tubular clearance of Acyclovir.","     (  ).","Increased risk of neurological side effects (e.g., tremor, confusion).","  .       .","Side effect monitoring. The patient must be monitored for neurotoxicity.");n("Acyclovir","Theophylline",e.DRUG_DRUG,i.MODERATE,"      ","Acyclovir may reduce renal clearance of Theophylline.","       ","Increased plasma Theophylline levels and toxicity risk.","  .    ","Monitor Theophylline levels. Dose reduction may be needed.");n("Acyclovir","Mycophenolate",e.DRUG_DRUG,i.MODERATE,"    ","Competition for renal tubular secretion.","   ","Increased levels of both drugs.","  ","Monitor renal function.");n("Adagrasib","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Adagrasib    P-gp    Digoxin.","Increased Digoxin levels. Adagrasib is an inhibitor of P-gp, responsible for Digoxin efflux.","   Digoxin (      )   .","Increased risk of Digoxin toxicity (e.g., bradycardia and arrhythmias) due to elevated concentration."," .    Digoxin  50%    .","Dose monitoring. Digoxin dose should be reduced by 50% and its serum levels monitored.");n("Adagrasib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Adagrasib. Rifampin    CYP3A4    Adagrasib.","Decreased Adagrasib efficacy. Rifampin is a strong inducer of CYP3A4, a metabolic pathway for Adagrasib.","            .","Severe decrease in drug plasma concentration, leading to cancer treatment failure."," .     CYP3A4  .","Avoid Combination. Strong CYP3A4 inducers must be avoided concomitantly.");n("Adagrasib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Adagrasib. PPIs        Adagrasib.","Decreased Adagrasib concentration. PPIs reduce gastric acidity, which is necessary for Adagrasib absorption.","           .","Severe decrease in drug plasma concentration, leading to treatment failure."," .       (PPIs).","Avoid Combination. Proton pump inhibitors (PPIs) must be avoided.");n("Adagrasib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Adagrasib. Itraconazole    CYP3A4    Adagrasib.","Increased Adagrasib concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Adagrasib.","    QT  .","Increased risk of QT prolongation and hepatotoxicity."," .    Adagrasib     CYP3A4 .","Dose adjustment. Adagrasib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Adagrasib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Adagrasib. Phenytoin    CYP3A4    Adagrasib.","Decreased Adagrasib efficacy. Phenytoin is a strong inducer of CYP3A4, an Adagrasib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Adagrasib","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Adagrasib. Diltiazem    CYP3A4    Adagrasib.","Increased Adagrasib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a metabolic pathway for Adagrasib.","    QT  .","Increased risk of QT prolongation and hepatotoxicity."," .    Adagrasib     CYP3A4 .","Dose adjustment. Adagrasib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Adagrasib","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Adagrasib   CYP3A4    Simvastatin.","Increased Simvastatin concentration. Adagrasib is a CYP3A4 inhibitor, a Simvastatin metabolic pathway.","    (Rhabdomyolysis)  .","Increased risk of Rhabdomyolysis and myotoxicity."," .   .","Contraindicated. Avoid the combination.");n("Adagrasib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Adagrasib. Carbamazepine    CYP3A4    Adagrasib.","Decreased Adagrasib efficacy. Carbamazepine is a strong inducer of CYP3A4, an Adagrasib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Adagrasib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Adagrasib. Itraconazole    CYP3A4.","Increased Adagrasib concentration. Itraconazole is a strong inhibitor of CYP3A4.","    QT  .","Increased risk of QT prolongation and liver toxicity."," .    Adagrasib.","Dose adjustment. Adagrasib dose must be reduced.");n("Adagrasib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Adagrasib. Rifampin    CYP3A4.","Decreased Adagrasib concentration. Rifampin is a strong inducer of CYP3A4.","     .","Reduced drug efficacy and failure of cancer treatment."," .   .","Contraindicated. Avoid the combination.");n("Adagrasib (Krazati)","Strong CYP3A4 Substrates (Simvastatin)",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.   Simvastatin  .","Mechanism: **Potent CYP3A4 inhibition**. Significantly increased Simvastatin concentration."," : ** **  .","Clinical Significance: **Life-threatening rhabdomyolysis**."," .      CYP3A4  Rosuvastatin.","Contraindicated. Use non-CYP3A4 statin such as Rosuvastatin.");n("Adagrasib (Krazati)","Sensitive CYP2C9 Substrates (Warfarin)",e.DRUG_DRUG,i.HIGH,": **  CYP2C9**.   Warfarin.","Mechanism: **CYP2C9 inhibition**. Increased Warfarin concentration."," : ** **.","Clinical Significance: **Severe bleeding**."," INR  .   Warfarin  50%.","Monitor INR frequently. Reduce Warfarin dose by 50%.");n("Adagrasib (Krazati)","QT-Prolonging Drugs",e.DRUG_DRUG,i.HIGH,": **  QT**. Adagrasib   QT    .","Mechanism: **QT prolongation**. Adagrasib prolongs QT interval in dose-dependent manner."," : **   **.","Clinical Significance: **Ventricular arrhythmia**."," .   .  .","Avoid combination. Monitor ECG. Correct electrolytes.");n("Adalimumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Adalimumab   (TNF inhibitor).","Increased risk of infection. Adalimumab is an immunosuppressant (TNF inhibitor).","     .","Risk of developing infection from live vaccines."," .      .","Contraindicated. Live vaccines must be avoided during treatment.");n("Adalimumab","Methotrexate",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic immunosuppression.","  ","Increased infection risk.","  -   ","Monitor for infection - may be beneficial.");n("Adalimumab (TNF-alpha Inhibitor)","Live Vaccines",e.DRUG_DRUG,i.HIGH,"  . Adalimumab    .","Increased risk of infection. Adalimumab is a strong immunosuppressant.","     .","Increased risk of developing the disease from the vaccine."," .        Adalimumab.","Contraindicated. Avoid live vaccines during Adalimumab therapy.");n("Adalimumab (TNF-alpha Inhibitor)","Anakinra (IL-1R Antagonist)",e.DRUG_DRUG,i.HIGH,"     .    .","Increased risk of serious infection and neutropenia. Synergy in immunosuppression.","     .","Serious infection and immune system failure."," .       .","Contraindicated. Avoid the combination due to additive adverse effects.");n("Adapalene - ","Salicylic Acid -  ",e.DRUG_DRUG,i.MODERATE,"      .  ( )            (  )           .          .","Both substances have exfoliating and irritant effects on the skin. Adapalene (a retinoid derivative) accelerates keratinocyte turnover and reduces cohesion between them, while salicylic acid (a beta-hydroxy acid) exfoliates the stratum corneum and dissolves materials binding dead cells. Their combination synergistically increases the compromise of the protective skin barrier.","            .                      .","Severe skin irritation, dryness, erythema, burning, pruritus, excessive peeling, and pain at the application site. In severe cases, it may lead to allergic contact dermatitis or skin erosion, increasing the risk of secondary infection and prolonging recovery time.","      .            (:    )    .     (  )   .         .       .","Avoid simultaneous application to the same skin area. If use of both is necessary, apply them at different times of the day (e.g., one in the morning and the other in the evening) or on alternate days. Start with a low application frequency (e.g., every other day) and monitor skin reaction. Use a gentle, fragrance-free moisturizer to repair the skin barrier. Discontinue use immediately if severe irritation occurs.");n("Adenosine","Dipyridamole",e.DRUG_DRUG,i.HIGH,"       ","Dipyridamole inhibits Adenosine uptake, increasing its levels.","   (    )","Potentiated cardiac effects (bradycardia, hypotension).","     (25%).  ","Reduce Adenosine dose to 25%. Close monitoring.");n("Ado-trastuzumab emtansine","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"   DM1 . Ketoconazole   CYP3A4/5    DM1.","Increased concentration of active DM1 metabolite. Ketoconazole inhibits CYP3A4/5, a DM1 metabolic pathway.","      .","Increased risk of liver toxicity and myelosuppression.","    .    CYP3A4 .","Avoid combination or close monitoring. Strong CYP3A4 inhibitors must be avoided.");n("Aducanumab (Aduhelm)","Anticoagulants (Warfarin)",e.DRUG_DRUG,i.HIGH,": **  **. Aducanumab  ARIA (/ ).","Mechanism: **Cerebral bleeding risk**. Aducanumab causes ARIA (cerebral hemorrhage/edema)."," : ** **  .","Clinical Significance: **Life-threatening cerebral hemorrhage**.","  .  MRI .","Use with extreme caution. Regular MRI monitoring.");n("Albuterol - ","Beta-blockers -  ",e.DRUG_DRUG,i.HIGH,":      (Direct Receptor Antagonism).   (  )   -2 ($\beta_2$)               .","Mechanism: Direct pharmacodynamic receptor antagonism. Beta-blockers (especially non-selective ones) block beta-2 ($\beta_2$) receptors in bronchial smooth muscle, directly opposing the bronchodilator effect of Albuterol."," :      (Severe Life-Threatening Bronchospasm)              .          COPD.","Clinical Significance: Severe life-threatening bronchospasm, complete asthma treatment failure, and increased risk of acute exacerbations requiring hospitalization. This interaction is particularly dangerous in asthma and COPD patients.","     ( )     .         -1    (   )        .","Avoid non-selective beta-blockers (e.g., propranolol) absolutely in asthma patients. If beta-blockers are essential for cardiac conditions, use highly selective beta-1 blockers with extreme caution (e.g., metoprolol or atenolol) at the lowest effective dose, with close pulmonary function monitoring.");n("Albuterol","Alcohol",e.DRUG_FOOD,i.MODERATE,": **  **.          (     )   Albuterol.","Mechanism: **Additive Side Effects**. Alcohol can increase stimulant-related side effects (e.g., dizziness, heart palpitations) associated with Albuterol.",":       (Tachycardia)   .","Result: Increased risk of tachycardia, dizziness, or nervousness.",":     .","Management: Advise moderate consumption of alcohol.");n("Albuterol","Caffeine",e.DRUG_FOOD,i.LOW,": **  **.       Albuterol  .","Mechanism: **Additive Side Effects**. Caffeine is a stimulant that increases the bronchodilatory and cardiac effects of Albuterol.",":       .","Result: Increase in heart palpitations, tremor, or nervousness.",":       .","Management: Advise limitation of caffeine consumption during therapy.");n("Albuterol","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,":      . ( ).","Mechanism: No known clinically significant interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Green Tea",e.DRUG_FOOD,i.MODERATE,": **  **.          Albuterol .","Mechanism: **Additive Side Effects**. Green tea contains caffeine, which increases the stimulant effects of Albuterol.",":     .","Result: Increase in tremor or nervousness.",":      .","Management: Advise limitation of green tea consumption.");n("Albuterol","Milk",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","High-fat meals",e.DRUG_FOOD,i.HIGH,": **  ( )**.       Albuterol .","Mechanism: **Delayed Absorption (Oral Formulations)**. Food delays the time to reach peak concentration of oral Albuterol.",":     ( )       .","Result: Delay in onset of efficacy (for oral formulations), but no effect on overall efficacy.",":    .        .","Management: No routine adjustment required. Prefer taking oral doses consistently relative to meals.");n("Albuterol","High-fiber foods",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Vitamin C",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Vitamin D",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Vitamin E",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Vitamin K",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Vitamin B12",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Folic Acid",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Iron",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Calcium",e.DRUG_FOOD,i.HIGH,":     . ( ).","Mechanism: No direct interaction is known. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Magnesium",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Zinc",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Albuterol","Potassium",e.DRUG_FOOD,i.HIGH,": **   (Hypokalemia)**.        .","Mechanism: **Hypokalemia**. Albuterol causes a transcellular shift of potassium from the blood into the cells.",":               .","Result: Acute and temporary decrease in blood potassium levels, increasing the risk of cardiac arrhythmia.",":   .      .","Management: Monitor potassium levels. Avoid potassium-depleting diuretics.");n("Albuterol","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,":      Albuterol       .","Mechanism: Bicarbonate may increase the renal clearance of Albuterol, potentially lowering its blood concentration.",":            .","Result: No confirmed clinical effect, but caution may be warranted in specific cases.",":  .     .","Management: Routine monitoring. Prefer separation of doses by two hours.");n("Albuterol","Antacids",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Alectinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Alectinib. Rifampin    CYP3A4    Alectinib.","Decreased Alectinib efficacy. Rifampin is a strong inducer of CYP3A4, an Alectinib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Alectinib","High Fat Meal",e.DRUG_FOOD,i.MODERATE,"  Alectinib.          .","Increased Alectinib absorption. Taking the drug with a high-fat meal increases bioavailability.","          .","Increased drug plasma concentration, increasing the risk of side effects."," .   Alectinib   .","Dose consistency. Alectinib must be taken consistently with food.");n("Alectinib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Alectinib. Ketoconazole    CYP3A4    Alectinib.","Increased Alectinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, an Alectinib metabolic pathway.","      .","Increased risk of side effects, especially hepatotoxicity.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Alendronate - ","Calcium Supplements -  ",e.DRUG_DRUG,i.MODERATE," ( )               .                .","Alendronate (a bisphosphonate) has a high affinity for forming non-absorbable complexes with divalent cations like calcium. When taken together, alendronate binds with calcium in the stomach and intestines, forming an insoluble, non-absorbable complex.","           90               .","Significant reduction in systemic absorption of alendronate by up to 90% or more, leading to therapeutic failure and loss of intended benefit in treating osteoporosis and preventing fractures.","          ( )  30    ( 60 )              .            .","Alendronate should be taken on an empty stomach with plain water only (not mineral water), and wait at least 30 minutes (preferably 60 minutes) before consuming any food, beverages, or other medications including calcium and vitamin supplements. Calcium supplements can be taken with meals or at a different time of day.");n("Aliskiren (DRI)","Diclofenac (NSAID)",e.DRUG_DRUG,i.HIGH,"     (AKI).       (  ).","Increased risk of Acute Kidney Injury (AKI). Synergistic effects on renal dynamics (especially in dehydration).","  .","Acute renal failure."," .      .      .","Close monitoring. Avoid combination in high-risk patients. Monitor renal function upon initiation.");n("Allopurinol","Azathioprine / 6-MP",e.DRUG_DRUG,i.HIGH,"    (XO).       6-MP     .","Xanthine Oxidase Inhibition. Allopurinol potently inhibits XO, the enzyme responsible for the metabolic inactivation of Azathioprine and 6-Mercaptopurine (6-MP), leading to accumulation of toxic metabolites.","  .        .","Bone Marrow Suppression. Accumulation of the active metabolites leads to severe leukopenia, thrombocytopenia, and potentially fatal myelosuppression (anemia/agranulocytosis).","   75%.      .","Reduce Azathioprine/6-MP Dose by 75%. This reduction is essential and non-negotiable to prevent life-threatening marrow toxicity.");n("Allopurinol","Amoxicillin / Ampicillin",e.DRUG_DRUG,i.MODERATE,"   .        .","Unknown Mechanism. The exact pathophysiological basis is not fully elucidated, but studies show a significantly increased risk of rash when these agents are co-administered.","     (Skin Rash).    .","Increased Risk of Skin Rash. Significantly higher incidence of maculopapular rash, indicative of a systemic hypersensitivity reaction.","        .      .","Avoid or Monitor for Rash. Monitor the patient closely, especially during the initial weeks. Consider alternative antibiotics if the patient has a history of rash with this combination.");n("Allopurinol","Azathioprine/Mercaptopurine",e.DRUG_DRUG,i.HIGH,"  Azathioprine/Mercaptopurine. Allopurinol   Xanthine oxidase     .","Increased Azathioprine/Mercaptopurine concentration. Allopurinol inhibits Xanthine oxidase enzyme, the metabolic pathway for these two drugs.","      (Severe myelosuppression).","Increased risk of severe myelosuppression."," .    Azathioprine/Mercaptopurine   ( 25-33%   ).","Dose adjustment. Azathioprine/Mercaptopurine dose must be significantly reduced (to 25-33% of the usual dose).");n("Allopurinol - ","Vitamin C (High Dose) -   ( )",e.DRUG_FOOD,i.MODERATE,"    (  500 /)        (pH).                  .            .","High doses of Vitamin C (more than 500 mg/day) acidify urine and lower its pH. In acidic urine, uric acid solubility decreases, increasing the likelihood of precipitation and formation of uric acid kidney stones. Allopurinol lowers uric acid levels, but the acidic environment counteracts this protective effect.","                     .           .","Significant increased risk of uric acid kidney stone formation, particularly in predisposed patients or those with previous stone history. May lead to renal colic, hematuria, or urinary tract obstruction.","      (  500 /)     .     ( 2-3   ).       .       .","Avoid high-dose Vitamin C (more than 500 mg/day) in patients taking allopurinol. Maintain good hydration (drink 2-3 liters of water daily). Monitor urine pH and adjust if necessary. Consult doctor before taking vitamin C supplements.");n("Allopurinol - ","Warfarin - ",e.DRUG_DRUG,i.MODERATE,"      CYP450 ( CYP2C9)         .                .","Allopurinol inhibits hepatic CYP450 enzymes (particularly CYP2C9) responsible for warfarin metabolism and its conversion to inactive metabolites. Allopurinol may also increase warfarin plasma concentration through other not fully specified mechanisms.","           (INR)   .               .","Enhanced anticoagulant effect of warfarin, leading to increased prothrombin time (INR) and elevated bleeding risk. May cause gastrointestinal bleeding, bruising, gum bleeding, or intracranial hemorrhage in severe cases."," INR   (  )          .       INR   .        .","Monitor INR frequently (weekly initially) when starting or stopping allopurinol in patients taking warfarin. Adjust warfarin dose as needed to maintain INR within therapeutic range. Educate patient about bleeding signs and prompt reporting.");n("Aloe Vera - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE," (  )        ( )                 .                .","Aloe vera (when taken internally) has a strong laxative effect due to its anthraquinone compounds (anthraquinone glycosides) that increase water and electrolyte secretion in the colon, leading to potassium loss and hypokalemia. Hypokalemia increases cardiac cell sensitivity to digoxin and enhances its binding to receptors in heart muscle cells.","            .  :     (   )       .          .","Increased risk of digoxin toxicity, even at normal therapeutic blood levels of the drug. Symptoms include: cardiac arrhythmias (particularly atrial and ventricular disturbances), nausea, vomiting, headache, dizziness, and vision changes. May progress to serious, life-threatening cardiac rhythm disturbances.","     ( )      .      .          .            .","Avoid internal use of aloe vera (oral preparations) completely in patients taking digoxin. Topical aloe vera preparations can be used safely. Monitor serum potassium levels regularly and watch for signs of digoxin toxicity. If a laxative is necessary, choose types that do not cause hypokalemia.");n("Alpelisib (Piqray)","Diabetes Medications",e.DRUG_DRUG,i.HIGH,": **   **. Alpelisib   .","Mechanism: **Severe hyperglycemia**. Alpelisib causes insulin resistance."," : **  **    .","Clinical Significance: **Hyperglycemia** and potential diabetic ketoacidosis.","  .         .","Monitor glucose daily. May need to start or significantly increase diabetes medications.");n("Alpelisib (Piqray)","QT-Prolonging Drugs (Ondansetron)",e.DRUG_DRUG,i.MODERATE,": **    QT**.     QT.","Mechanism: **Synergistic QT prolongation**. Both drugs prolong QT interval."," : **  **  Torsades de Pointes.","Clinical Significance: **Cardiac arrhythmia** such as Torsades de Pointes.","  .  .      .","Monitor ECG. Correct electrolytes. Use alternative antiemetic if possible.");n("Alpha-Galactosidase - -","Acarbose - ",e.DRUG_DRUG,i.MODERATE,"    -           .    -                .","Acarbose acts as an inhibitor of alpha-glucosidase enzymes in the small intestine, slowing the breakdown of complex carbohydrates and reducing glucose absorption. Whereas alpha-galactosidase enzyme acts as a catalyst for this same breakdown, particularly for complex carbohydrates in legumes and vegetables, directly opposing acarbose's mechanism of action.","                              .","Reduction or negation of acarbose's blood glucose-lowering effect, leading to uncontrolled postprandial glucose spikes and failure to achieve glycemic control in diabetic patients.","    .      -                 .","Avoid concurrent use of these two preparations. If the patient requires alpha-galactosidase for gastrointestinal symptom management, alternative therapeutic options for blood glucose control should be discussed with the treating physician.");n("Alprazolam","Fluconazole",e.DRUG_DRUG,i.HIGH,"   CYP3A4           .","CYP3A4 Inhibition. Fluconazole inhibits the metabolism of Alprazolam, leading to increased and prolonged plasma levels and enhanced effect.","    .     .","Enhanced Sedation & Respiratory Depression. Due to elevated benzodiazepine levels, there is a risk of profound drowsiness, dizziness, and respiratory depression.","    .     .","Avoid combination if possible (Alprazolam is highly sensitive to CYP3A4 inhibition). Otherwise, reduce the benzodiazepine dose significantly and monitor for excessive CNS effects.");n("Alprazolam","Itraconazole",e.DRUG_DRUG,i.HIGH,"    CYP3A4      .","CYP3A4 Inhibition. Itraconazole is a potent inhibitor, causing significantly increased serum concentrations of Alprazolam and heightening the risk of toxicity.","    .     .","Enhanced Sedation & Respiratory Depression. Excessive CNS depression, profound drowsiness, and potential for respiratory depression are possible.","    .     .","Avoid combination if possible. Otherwise, reduce the benzodiazepine dose by 50% or more and monitor closely.");n("Alprazolam","Ketoconazole",e.DRUG_DRUG,i.HIGH,"     CYP3A4        .","CYP3A4 Inhibition. Ketoconazole is one of the most potent inhibitors of Alprazolam metabolism, resulting in significant and potentially dangerous toxicity risk.","    .     .","Enhanced Sedation & Respiratory Depression. Excessive CNS depression, potentially leading to respiratory arrest. This combination is often considered contraindicated.","    .     .","Avoid combination if possible (Alprazolam/Triazolam are often **contraindicated** with Ketoconazole). Consider switching to a non-interacting benzodiazepine.");n("Alprazolam","Voriconazole",e.DRUG_DRUG,i.HIGH,"    CYP3A4      .","CYP3A4 Inhibition. Voriconazole significantly impairs the metabolism of Alprazolam, causing elevated plasma levels and increased risk of CNS toxicity.","    .     .","Enhanced Sedation & Respiratory Depression. Excessive CNS depression and psychomotor impairment.","    .     .","Avoid combination if possible. Otherwise, reduce the benzodiazepine dose significantly and monitor for excessive CNS effects.");n("Alprazolam","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  .      CYP3A4    .","Increased Benzodiazepine Effect. Diltiazem moderately inhibits CYP3A4, leading to elevated levels of Alprazolam and increased risk of sedation and psychomotor impairment.","    .     .","Enhanced Sedation. Increased drowsiness and dizziness.","   .","Reduce benzodiazepine dose. Monitor for increased CNS side effects upon co-administration.");n("Alprazolam","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  .      CYP3A4   .","Enhanced Benzodiazepine Effect. Components of grapefruit juice inhibit intestinal CYP3A4, increasing oral bioavailability and the risk of profound sedation.","    .     .","Enhanced Sedation. Risk of excessive CNS depression.","    .","Avoid this combination if possible. Minimize or eliminate grapefruit juice consumption while on Alprazolam.");n("Alprazolam","Macrolide Antibiotics",e.DRUG_DRUG,i.HIGH,"  .   ( )  CYP3A4 .","Increased Benzodiazepine Effect. Macrolides (e.g., erythromycin, clarithromycin) strongly inhibit CYP3A4, causing a marked increase in Alprazolam levels.","    .     .","Enhanced Sedation. Excessive CNS depression, potentially leading to respiratory arrest.","    .      CYP3A4.","Avoid combination if possible. Use benzodiazepines not metabolized by CYP3A4 (e.g., Lorazepam, Oxazepam, Temazepam).");n("Alprazolam",["Alcohol","Opioids"],e.DRUG_DRUG,i.HIGH,": **   **. (   - Black Box Warning).","Mechanism: **Combined Respiratory and CNS Depression**. (Black Box Warning)."," : ** **      .","Clinical Significance: **Risk of death** due to respiratory arrest, coma, and profound sedation.","          .","Strictly avoid combination unless absolutely necessary with close monitoring.");n("Alprazolam",["Ketoconazole","Itraconazole","Nefazodone"],e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   .","Mechanism: **Potent CYP3A4 Inhibition**. Blocks Alprazolam clearance."," : **    **     .","Clinical Significance: **Severely increased Alprazolam levels**, prolonged sedation, and dependency risks.","  (Contraindicated)   .      CYP3A4 ( ).","Contraindicated with Ketoconazole/Itraconazole. Use a non-CYP3A4 benzodiazepine (e.g., Lorazepam).");n("Alprazolam","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4**.    .","Mechanism: **CYP3A4 Inhibition**. Increases Alprazolam bioavailability."," : **  **  .","Clinical Significance: **Increased sedative effect** and side effects.","   .","Avoid grapefruit juice.");n("Alprazolam - ","Fluoxetine - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4           ","Fluoxetine inhibits hepatic CYP3A4 enzymes responsible for Alprazolam metabolism, reducing its clearance and prolonging its half-life","           ","Increased sedative and hypnotic effects of Alprazolam, excessive drowsiness, dizziness, and impaired cognitive and motor functions","    25-50% -     -       ","Reduce Alprazolam dose by 25-50% - monitor for signs of excessive sedation - avoid activities requiring alertness such as driving");n("Alprazolam - ","Fluvoxamine - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4           ","Fluvoxamine inhibits hepatic CYP3A4 enzymes responsible for Alprazolam metabolism, increasing its plasma concentration","              ","Enhanced sedative and hypnotic effects, increased risk of physical dependence, memory impairment, and respiratory depression at high doses","    30-60% -     -    ","Reduce Alprazolam dose by 30-60% - close monitoring of respiratory function - avoid alcohol and other sedatives");n("Alprazolam - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4           ","Cimetidine inhibits hepatic CYP3A4 enzymes and reduces metabolic clearance of Alprazolam, increasing its bioavailability","              ","Prolonged sedative effect, increased side effect severity, and higher risk of toxicity especially in elderly patients","    40-50% -      -     ","Reduce Alprazolam dose by 40-50% - adjust dose based on clinical response - special monitoring for elderly patients");n("Alteplase - ","Aspirin - ",e.DRUG_DRUG,i.HIGH,"              ( ).         -1         A2    .             .","Alteplase converts plasminogen to plasmin, leading to fibrin degradation within the thrombus (fibrinolysis). Meanwhile, aspirin irreversibly inhibits cyclooxygenase-1 in platelets, reducing thromboxane A2 production and inhibiting platelet aggregation. Their combination produces an additive effect on the coagulation system through two distinct mechanisms.","             .           .                .","Significantly increased risk of bleeding, particularly intracranial hemorrhage which can be life-threatening. Also increases risk of gastrointestinal bleeding, bleeding at puncture sites, and extensive bruising. This interaction is intentional in acute myocardial infarction treatment, but requires careful risk-benefit assessment.","         (   )   . : 1)       2)     3)       4)    5)        .","This combination is essential in many acute cardiac conditions (e.g., myocardial infarction) and cannot be avoided. Must: 1) Carefully assess bleeding risk before initiation, 2) Use the lowest effective dose, 3) Monitor vital signs and neurological signs closely, 4) Avoid intramuscular injections, 5) Ensure no absolute contraindications for bleeding exist.");n("Aluminium Hydroxide -  ","Food (General) -  ()",e.DRUG_FOOD,i.LOW,"          .              .          .                             .","Aluminum hydroxide, as an antacid, works by directly neutralizing stomach acid. The formulation itself has astringent properties and can leave fine deposits on the tongue and palate. This creates a physical barrier that reversibly disrupts taste receptor function. Additionally, the compound can temporarily reduce saliva secretion, increasing dry mouth and reducing saliva`s ability to wash away taste particles, prolonging the unpleasant sensation.","         : 1.      . 2.          . 3.                  . 4.       .","Persistent earthy or chalky taste in the mouth, leading to: 1. Reduced enjoyment of food and drink. 2. Potential aversion to taking the medication, compromising adherence. 3. Unintentional avoidance of meals or reduced food intake, potentially contributing to malnutrition with long-term use. 4. Negative impact on health-related quality of life.","1.   :     generous   (   )       . 2.  :               . 3.  :            . 4.  :                     . 5.  :                 .","1. Administration with liquids: Take the dose with a generous amount of juice (e.g., apple or grape) or cold water to mask the taste and facilitate swallowing. 2. Oral hygiene: Rinse the mouth thoroughly with water or use mouthwash immediately after taking the medication to remove any residues. 3. Alternative formulations: Inquire about the availability of flavored liquid or chewable preparations that may be more palatable. 4. Treatment alternatives: Discuss with a doctor the possibility of using alternative antacids like calcium carbonate or proton pump inhibitors if the taste is a significant issue. 5. Dose splitting: If appropriate, split the daily dose into multiple smaller doses to reduce the intensity of the taste at any one time.");n("Aluminum Carbonate","Clindamycin",e.DRUG_DRUG,i.MODERATE,"           .","Aluminum salts form non-absorbable complexes with clindamycin in the GI tract.","        .","Reduced clindamycin absorption, bioavailability, and antibiotic efficacy.","           2-4 .","Separate aluminum salts and clindamycin doses by at least 2-4 hours.");n("Aluminum Carbonate","Tetracyclines",e.DRUG_DRUG,i.HIGH,"         .","Aluminum salts form insoluble complexes with tetracyclines in the stomach.","        .","Severe reduction in tetracycline absorption and loss of antimicrobial efficacy.","  .        2-4   .","Avoid concurrent use. If necessary, separate doses by at least 2-4 hours.");n("Aluminum Hydroxide","Levofloxacin",e.DRUG_DRUG,i.MODERATE," .       (Chelation).","Reduced Absorption. Aluminum ions chelate (bind) with the fluoroquinolone (Levofloxacin) in the gastrointestinal tract, forming an insoluble complex.","    .  .","Reduced Antibiotic Efficacy. Significant decrease in Levofloxacin bioavailability, potentially leading to treatment failure.","     .         .","Separate doses by at least 2 hours. Take the Fluoroquinolone at least 2 hours before or 6 hours after the antacid.");n("Aluminum Hydroxide","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE," .        ().","Reduced Absorption. Aluminum ions chelate with Ciprofloxacin, impairing its absorption and decreasing drug bioavailability.","   .       .","Reduced Antibiotic Efficacy. Significant decrease in Ciprofloxacin plasma levels, risking treatment failure.","     .         .","Separate doses by at least 2 hours. Take the Fluoroquinolone at least 2 hours before or 6 hours after the antacid.");n("Aluminum Hydroxide","Moxifloxacin",e.DRUG_DRUG,i.MODERATE," .      ().","Reduced Absorption. Aluminum ions chelate with Moxifloxacin, reducing its oral bioavailability and systemic exposure.","   .       .","Reduced Antibiotic Efficacy. Subtherapeutic antibiotic concentrations, increasing risk of clinical failure.","     .         .","Separate doses by at least 2 hours. Take the Fluoroquinolone at least 2 hours before or 6 hours after the antacid.");n("Aluminum Hydroxide","Ofloxacin",e.DRUG_DRUG,i.MODERATE," .      ().","Reduced Absorption. Aluminum ions chelate with Ofloxacin, limiting its systemic absorption from the GI tract.","   .       .","Reduced Antibiotic Efficacy. Failure to achieve minimum inhibitory concentrations.","     .         .","Separate doses by at least 2 hours. Take the Fluoroquinolone at least 2 hours before or 6 hours after the antacid.");n("Aluminum Hydroxide","Norfloxacin",e.DRUG_DRUG,i.MODERATE," .      ().","Reduced Absorption. Aluminum ions chelate with Norfloxacin, significantly decreasing its absorption and bioavailability.","   .       .","Reduced Antibiotic Efficacy. Risk of treatment failure and resistance development.","     .         .","Separate doses by at least 2 hours. Take the Fluoroquinolone at least 2 hours before or 6 hours after the antacid.");n("Aluminum Hydroxide","Lidocaine",e.DRUG_DRUG,i.MODERATE," .        (    ).","Local Factors. Aluminum Hydroxide may affect the absorption or localized activity of Lidocaine, although the clinical significance is generally minor unless used systemically.","   .    .","Altered Lidocaine Efficacy. Potential for minor changes in systemic exposure or local effect.","  .      .","Monitor patient response. Assess for signs of increased systemic absorption or reduced local effect.");n("Aluminum Hydroxide","Tetracycline",e.DRUG_DRUG,i.MODERATE," (Chelation)  .         .","Reduced Absorption. Aluminum ions chelate with Tetracycline, forming a non-absorbable complex in the GI tract.","  .       .","Reduced Tetracycline Absorption. Significant reduction in serum levels, risking treatment failure.","     .         .","Separate doses by at least 2 hours. Take Tetracycline at least 2 hours before or 4 hours after the antacid.");n("Aluminum Hydroxide","Clindamycin",e.DRUG_DRUG,i.MODERATE,"        .","Formation of non-absorbable complexes between aluminum hydroxide and clindamycin.","       .","Reduced clindamycin absorption and therapeutic blood levels.","       2-4 .","Separate aluminum hydroxide and clindamycin doses by 2-4 hours.");n("Aluminum Hydroxide","Quinidine",e.DRUG_DRUG,i.MODERATE,"           .","Urine alkalinization by aluminum hydroxide reduces renal quinidine excretion.","        (  QT    ).","Increased plasma quinidine levels and toxicity risk (QT prolongation, arrhythmias).","      .    .","Monitor serum quinidine and ECG. Adjust dose as needed.");n("Aluminum Hydroxide","Quinolones",e.DRUG_DRUG,i.HIGH,"      .","Chelation complex formation between aluminum hydroxide and quinolones.","        .","Severe reduction in quinolone absorption and antibacterial efficacy.","    2-4           .","Separate doses by at least 2-4 hours or use aluminum-free antacids.");n("Aluminum Hydroxide","Tetracyclines",e.DRUG_DRUG,i.HIGH,"        .","Formation of non-absorbable complexes between aluminum hydroxide and tetracyclines.","      .","Significant reduction in tetracycline absorption and therapeutic efficacy.","  .        2-4 .","Avoid concurrent use. If necessary, separate doses by 2-4 hours.");n("Aluminum Hydroxide","Tetracycline",e.DRUG_DRUG,i.MODERATE,"  -","Aluminum-tetracycline complex formation.","  ","Reduced tetracycline absorption.","   2-4 ","Separate doses by 2-4 hours.");n("Aluminum Phosphate","Clindamycin",e.DRUG_DRUG,i.MODERATE,"        .","Formation of insoluble complexes between aluminum phosphate and clindamycin.","    .","Reduced clindamycin absorption and efficacy.","       2-4 .","Separate aluminum phosphate and clindamycin doses by 2-4 hours.");n("Aluminum Salts","Clindamycin",e.DRUG_DRUG,i.MODERATE,"        .","Aluminum salts form non-absorbable complexes with clindamycin.","      .","Reduced clindamycin bioavailability and antibacterial efficacy.","           2-4 .","Separate aluminum salts and clindamycin doses by at least 2-4 hours.");n("Aluminum-Magnesium Hydroxide","Quinolones",e.DRUG_DRUG,i.HIGH,"  -    .","Aluminum-magnesium hydroxide forms chelation complexes with quinolones.","       .","Severe reduction in quinolone absorption and antibacterial efficacy.","    2-4        .","Separate doses by at least 2-4 hours or use alternative antacids.");n("Ambenonium","Corticosteroids",e.DRUG_DRUG,i.MODERATE,"                 .","Corticosteroids suppress immune system and reduce neuromuscular efficacy, potentially antagonizing ambenonium's neuromuscular enhancing effect.","                .","Reduced therapeutic efficacy of ambenonium in myasthenia gravis, potentially worsening muscle weakness.","    .             .","Close monitoring of neuromuscular symptoms. Ambenonium dose increase may be needed during corticosteroid therapy, and readjustment after stopping.");n("Amifampridine","Citalopram",e.DRUG_DRUG,i.HIGH,"    QTc.        QT.","Increased risk of QTc prolongation. Both drugs have an additive effect on the QT interval.","         Torsades de Pointes.","Increased risk of serious ventricular arrhythmias, such as Torsades de Pointes."," /.   .         ECG.","Contraindicated/Avoid. Avoid the combination. If necessary, intensive ECG monitoring must be performed.");n("Amifampridine","Rifampin",e.DRUG_DRUG,i.HIGH,"  Amifampridine. Rifampin   CYP3A4    Amifampridine.","Decreased Amifampridine efficacy. Rifampin is a CYP3A4 inducer, an Amifampridine metabolic pathway.","            .","Reduced drug plasma concentration, leading to loss of muscle weakness control."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Amikacin - ","Vancomycin - ",e.DRUG_DRUG,i.HIGH,"          .                   .                  .","Both drugs cause nephrotoxicity by damaging proximal renal tubules. Amikacin accumulates in renal epithelial cells leading to cell death, while vancomycin causes oxidative stress and mitochondrial damage. Their combination produces synergistic kidney damage and enhances ototoxicity through cochlear hair cell destruction.","      (   20-30)      .            .          .","Increased risk of acute renal failure (up to 20-30%), with elevated creatinine and urea levels. Additionally, higher risk of permanent hearing loss, vertigo, and balance disorders. Toxicity may be irreversible even after drug discontinuation.","   .   : 1)     (    ) 2)       3)     4)     5)      .","Avoid combination if possible. If necessary: 1) Monitor renal function daily (creatinine, urea, GFR) 2) Measure amikacin and vancomycin serum levels 3) Perform weekly auditory tests 4) Maintain adequate hydration 5) Use lowest dose for shortest duration possible.");n("Amikacin - ","Cephalexin - ",e.DRUG_DRUG,i.MODERATE,"    .            .","Additive nephrotoxic effect. Both cause renal tubular damage and may lead to interstitial nephritis.","               .","Increased risk of acute renal failure, especially in elderly patients or those with pre-existing kidney disease.","    2-3          .","Monitor renal function every 2-3 days, measure amikacin levels, and avoid combination in high-risk patients.");n("Amikacin - ","Ceftriaxone - ",e.DRUG_DRUG,i.MODERATE,"    .                  .","Additive nephrotoxic effect. Ceftriaxone has lower nephrotoxicity than other cephalosporins but still increases toxicity risk when combined with amikacin.","      .","Moderate increase in acute renal failure risk.","       .","Monitor renal function regularly, and maintain adequate hydration.");n("Amikacin - ","Cefuroxime - ",e.DRUG_DRUG,i.MODERATE,"    .          .","Additive nephrotoxic effect. Both cause damage to renal units and may impair kidney function.","      .","Increased risk of nephritis and renal failure.","       .","Monitor kidney function indicators, and adjust doses as needed.");n("Amikacin - ","Cefixime - ",e.DRUG_DRUG,i.MODERATE,"    .                .","Additive nephrotoxic effect. Cefixime has low nephrotoxicity but still contributes to increased renal load when combined with amikacin.","       .","Mild to moderate increase in nephrotoxicity risk.","      .","Monitor renal function in high-risk patients.");n("Amikacin - ","Cefotaxime - ",e.DRUG_DRUG,i.MODERATE,"    .            .","Additive nephrotoxic effect. Both increase the load on renal function and may cause tubular damage.","          .","Increased risk of acute renal failure in patients with compromised renal function.","         .","Monitor creatinine and urea regularly, and avoid combination in renal failure cases.");n("Amikacin - ","Furosemide - ",e.DRUG_DRUG,i.HIGH,"     .            .","Synergistic ototoxic and nephrotoxic effect. Furosemide increases amikacin concentration in the inner ear and causes hypovolemia.","         .","Acute and permanent hearing loss, vertigo, and increased risk of acute renal failure.","          .","Avoid simultaneous IV administration, separate doses, and monitor auditory and renal function.");n("Amikacin - ","Torsemide - ",e.DRUG_DRUG,i.HIGH,"    .        .","Synergistic ototoxic effect. Torsemide increases inner ear sensitivity to amikacin toxicity.","        .","Sensorineural hearing loss, tinnitus, and balance disorders.","         .","Monitor auditory function weekly, and avoid combination in high-risk patients.");n("Amikacin - ","Bumetanide - ",e.DRUG_DRUG,i.HIGH,"    .         .","Synergistic ototoxic effect. Bumetanide increases amikacin concentration in perilymph.","     .","Permanent hearing loss, vertigo, and severe tinnitus.","          .","Avoid combination if possible, or separate doses with adequate time interval.");n("Amikacin - ","Aspirin - ",e.DRUG_DRUG,i.MODERATE,"          .","Aspirin reduces renal clearance of amikacin and increases its accumulation in kidneys.","     .","Increased risk of amikacin nephrotoxicity and ototoxicity.","          .","Monitor amikacin blood levels, and reduce amikacin dose if necessary.");n("Amikacin - ","Ibuprofen - ",e.DRUG_DRUG,i.MODERATE,"           .","Ibuprofen inhibits renal prostaglandins reducing renal perfusion and increasing amikacin toxicity.","      .","Increased risk of acute renal failure and nephrotoxicity.","          .","Avoid combination in high-risk patients, and monitor renal function closely.");n("Amikacin - ","Diclofenac - ",e.DRUG_DRUG,i.MODERATE,"             .","Diclofenac impairs renal function and reduces amikacin clearance, increasing its accumulation in kidneys.","       .","Increased risk of interstitial nephritis and renal failure.","    48      .","Monitor renal function every 48 hours, and adjust amikacin dose as needed.");n("Amikacin - ","Naproxen - ",e.DRUG_DRUG,i.MODERATE,"         .","Naproxen causes renal vasoconstriction and reduces renal clearance of amikacin.","        .","Increased amikacin accumulation in kidneys and higher nephrotoxicity risk.","       .","Monitor amikacin and creatinine levels, and avoid long-term use.");n("Amikacin - ","Ketoprofen - ",e.DRUG_DRUG,i.MODERATE,"            .","Ketoprofen inhibits renal prostaglandin synthesis impairing renal function and increasing amikacin toxicity.","      .","Increased risk of acute renal failure and fluid retention.","        .","Monitor renal function and urine output, and maintain adequate hydration.");n("Amikacin - ","Indomethacin - ",e.DRUG_DRUG,i.MODERATE,"           .","Indomethacin causes severe renal vasoconstriction and significantly reduces amikacin clearance.","        .","Significant increase in nephrotoxicity risk and acute renal failure.","         .","Avoid combination if possible, or use less nephrotoxic alternatives.");n("Amikacin - ","Celecoxib - ",e.DRUG_DRUG,i.MODERATE,"  COX-2 selectively               .","Celecoxib inhibits COX-2 selectively reducing renal effects but still increases toxicity risk when combined with amikacin.","            .","Moderate increase in nephrotoxicity risk, lower than traditional NSAIDs.","      .","Monitor renal function in high-risk patients.");n("Amikacin - ","Mefenamic Acid -  ",e.DRUG_DRUG,i.MODERATE,"              .","Mefenamic acid inhibits renal prostaglandins and causes vasoconstriction, increasing amikacin nephrotoxicity.","       .","Increased risk of interstitial nephritis and renal failure.","         .","Avoid combination in elderly patients or those with kidney disease.");n("Amikacin - ","Amphotericin B -  ",e.DRUG_DRUG,i.HIGH,"     .            .","Strong synergistic nephrotoxic effect. Both cause severe renal tubular damage leading to rapid renal failure.","             .","Severe acute renal failure potentially requiring hemodialysis, with permanent risk to kidney function.","    .   :  intensiva   .","Avoid combination completely if possible. If necessary: intensive monitoring of renal function and electrolytes.");n("Amiloride","Angiotensin Converting Enzyme Inhibitors",e.DRUG_DRUG,i.HIGH,"          ( )    (    )     .","Combination of potassium-sparing effect (Amiloride) and reduced aldosterone secretion (ACE inhibitors) leads to decreased potassium excretion.","                  .","Increased risk of life-threatening hyperkalemia, especially in patients with renal impairment or diabetes.","     .                .","Monitor serum potassium regularly. Avoid this combination in at-risk patients, consider non-potassium-sparing diuretics.");n("Amiloride","Quinidine",e.DRUG_DRUG,i.MODERATE,"                 .","Amiloride increases urine alkalinity, reducing renal quinidine excretion and increasing tubular reabsorption.","        (  QT      ).","Increased plasma quinidine levels and toxicity risk (QT prolongation, arrhythmias, dizziness, tinnitus).","         .     .","Monitor serum quinidine, ECG, and toxicity signs. Quinidine dose adjustment may be required.");n("Aminocaproic Acid -  ","Factor IX Complex -   ",e.DRUG_DRUG,i.HIGH,"              .           .               .","Aminocaproic acid acts as an antifibrinolytic agent by inhibiting plasminogen activators, preventing clot breakdown. Meanwhile, factor IX complex provides multiple clotting factors that promote thrombus formation. Their combination produces a powerful synergistic prothrombotic effect without a balanced counteracting mechanism.","                   (  ).           .","Massive increased risk of disseminated intravascular coagulation, deep vein thrombosis, pulmonary embolism, arterial thrombosis, and infarction of vital organs (heart, brain, lungs). This can be life-threatening, particularly in patients predisposed to thrombosis.","      .        (       )                 .","The combination of these two preparations is absolutely contraindicated. If use is mandatory in rare cases (e.g., uncontrolled bleeding in hemophilia patients), it must be in an ICU setting with continuous monitoring of coagulation parameters and hematology consultant supervision.");n("Aminoglutethimide","Dexamethasone",e.DRUG_DRUG,i.HIGH,"        CYP3A4      .","Aminoglutethimide induces CYP3A4 hepatic metabolism of dexamethasone, accelerating its clearance.","      .","Significant reduction in dexamethasone levels and therapeutic efficacy.","       ( 2-3 )    .    .","Dexamethasone dose may need substantial increase (up to 2-3 fold) to achieve desired effect. Monitor clinical response closely.");n(Ot,$u,e.DRUG_DRUG,i.HIGH,": **     **.   ( )      .","Mechanism: **Synergistic oto- and nephrotoxicity**. Loop diuretics (e.g., Furosemide) and Aminoglycosides are both ototoxic and nephrotoxic."," : **   **  .","Clinical Significance: **Risk of permanent hearing loss** and renal failure.","   .       .","Monitor hearing and renal function. Avoid high doses and rapid injection of loop diuretics.");n(Ot,Hc,e.DRUG_DRUG,i.HIGH,": **     (Synergistic Nephrotoxicity)**.          .","Mechanism: **Synergistic nephrotoxicity**. Both have nephrotoxic potential, and the combination exacerbates tubular damage."," : **    **         .","Clinical Significance: **Increased risk of acute renal failure**, especially in elderly or dehydrated patients.","   () .    .","Monitor renal function (creatinine) regularly. Ensure adequate hydration.");n(Ot,zc,e.DRUG_DRUG,i.MODERATE,": **   **.         .","Mechanism: **Chemical interaction in solution**. Penicillins chemically react with Aminoglycosides in the same IV solution."," : **  **  .","Clinical Significance: **Inactivation of Aminoglycoside** and treatment failure.","       .     .","Do not mix drugs in same solution or syringe. Administer each drug separately.");n(Ot,xc,e.DRUG_DRUG,i.MODERATE,": **  **.            .","Mechanism: **Reduced renal perfusion**. NSAIDs reduce renal blood flow, decreasing Aminoglycoside excretion."," : **  **       .","Clinical Significance: **Increased Aminoglycoside levels** and risk of nephro- and ototoxicity, especially in premature infants.","   .        .","Avoid combination if possible. If necessary, monitor Aminoglycoside levels and renal function.");n("Amiodarone","Hydantoins",e.DRUG_DRUG,i.HIGH,": **  **.     (CYP2C9)     (CYP3A4).","Mechanism: **Mutual metabolism inhibition/induction**. Amiodarone inhibits Phenytoin metabolism (CYP2C9), while Phenytoin induces Amiodarone metabolism (CYP3A4)."," : **   ( :  )**    ( ).","Clinical Significance: **Increased Phenytoin levels (toxicity risk: ataxia, nystagmus)**, and decreased Amiodarone levels (reduced efficacy).","   .     30-50%   .","Monitor Phenytoin and Amiodarone levels. Reduce Phenytoin dose by 30-50% when adding Amiodarone.");n("Amiodarone",Jh,e.DRUG_DRUG,i.HIGH,": **  (CYP3A4)**.   ( )   .","Mechanism: **Metabolism inhibition (CYP3A4)**. Protease inhibitors (e.g., Ritonavir) inhibit Amiodarone metabolism."," : **    **      ( QT  ) .","Clinical Significance: **Dangerously increased Amiodarone levels**, increasing risk of cardiotoxicity (QT prolongation, arrhythmias) and pulmonary toxicity.","   .          .","Avoid combination if possible. If necessary, reduce Amiodarone dose and monitor heart closely.");n("Amiodarone","Digoxin",e.DRUG_DRUG,i.HIGH,"   ","Increased Digoxin and Cyclosporine concentrations.","    (    )      ( /).","Increased risk of Digoxin toxicity (bradycardia, nausea, visual disturbances) or Cyclosporine side effects (nephrotoxicity/neurotoxicity).","        .    .","Review cardiovascular and antiarrhythmic drugs. Monitor levels of other drugs.");n("Amiodarone","Hydantoins",e.DRUG_DRUG,i.HIGH,"   (  )    .","Increased Hydantoin levels (due to metabolism inhibition) and decreased Amiodarone levels.","   (  ).   .","Increased Hydantoin toxicity (e.g., ataxia, nystagmus). Reduced Amiodarone efficacy.","        .         .","Monitor cardiovascular status and signs of Hydantoin toxicity. Adjust doses of one or both drugs as directed.");n("Amiodarone","Protease Inhibitors",e.DRUG_DRUG,i.HIGH,"   (   CYP).","Increased Amiodarone levels (due to CYP inhibition).","    (     ).","Increased risk of Amiodarone toxicity (pulmonary, hepatic, cardiac).","    . (:    /    ).","Avoid this combination if possible. (Note: Procainamide and Quinidine are listed as comparisons/references for cardiovascular drugs).");n("Amiodarone - ","Ciprofloxacin - ",e.DRUG_DRUG,i.HIGH,"    QT      hERG          .           .","Both drugs prolong QT interval by inhibiting hERG potassium channels in the heart, leading to prolonged ventricular repolarization. This additive effect significantly increases the risk of cardiac arrhythmias.","      QT   (Torsades de Pointes)                      .","Significant increased risk of QT prolongation, Torsades de Pointes, and other life-threatening ventricular arrhythmias, particularly in patients with underlying heart disease or electrolyte imbalances.","   .          (  )      . :  ()  .","Avoid combination if possible. If necessary, perform regular ECG, monitor electrolytes (especially potassium and magnesium), and use lowest possible dose for shortest duration. Alternatives: Azithromycin (with caution) or Doxycycline.");n("Amiodarone - ","Levofloxacin - ",e.DRUG_DRUG,i.HIGH,"      hERG        QT    .","Synergistic effect on hERG potassium channel inhibition, leading to significant QT prolongation and increased arrhythmia risk.","              .","High risk of Torsades de Pointes and serious cardiac arrhythmias, with potential for sudden cardiac arrest.","         .         .","Avoid combination completely in patients with additional risk factors. Continuous monitoring in cardiac care unit if combination is necessary.");n("Amiodarone - ","Moxifloxacin - ",e.DRUG_DRUG,i.HIGH,"       QT           .","Moxifloxacin is one of the most QT-prolonging fluoroquinolones, and when combined with amiodarone produces a dangerous synergistic effect on cardiac repolarization.","                   .","Severe risk of Torsades de Pointes and life-threatening cardiac arrhythmias, even in patients without obvious risk factors.","    .         QT  .","Absolute contraindication for combination. Use antimicrobial alternatives with less QT effect such as ceftriaxone.");n("Amiodarone - ","Ofloxacin - ",e.DRUG_DRUG,i.HIGH,"                 .","Additive effect on cardiac potassium channel inhibition, impairing ventricular repolarization and increasing cardiac electrical instability.","     QT    .","Increased incidence of QT prolongation and serious ventricular arrhythmias."," .       .      .","Avoid combination. Close ECG monitoring if forced to combine. Choose safer alternative antibiotics.");n("Amiodarone - ","Norfloxacin - ",e.DRUG_DRUG,i.HIGH,"         QT                   .","Although norfloxacin has less QT effect than others, when combined with amiodarone it still poses significant risk due to cumulative effect on cardiac repolarization.","             .","Increased risk of cardiac arrhythmias, especially in elderly patients or those with diminished renal function.","            .","Prefer non-fluoroquinolone alternatives for UTI treatment in patients taking amiodarone.");n("Amiodarone","Thyroid Disease (Hyper/Hypothyroidism)",e.DRUG_DISEASE,i.HIGH,"     (100    )       (Wolff-Chaikoff/Jod-Basedow).","Amiodarone has a high iodine content (100x daily need) and directly affects thyroid hormone synthesis and release.","       (Amiodarone-Induced Thyroid Dysfunction)   .","Amiodarone-Induced Hyper- or Hypothyroidism, which is often challenging to treat.","   (TSH, T4)  6    .       .","Monitor thyroid function (TSH, T4) every 6 months before and during therapy. Discontinue if severe thyroid dysfunction occurs.");n("Amiodarone - ","Simvastatin - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4     .        (55-60 )           .           (   3-4 ).","Amiodarone potently inhibits hepatic CYP3A4 enzyme responsible for simvastatin metabolism. It also has a very long half-life (55-60 days) meaning this inhibition persists for weeks even after drug discontinuation. This leads to significant increase in simvastatin blood levels (up to 3-4 fold).","       :        (CK)    (Rhabdomyolysis)        .              .","Substantial increased risk of myotoxicity including: myalgia, muscle weakness, elevated muscle enzymes (CK), and rhabdomyolysis which may lead to acute renal failure and death. Risk is higher in elderly, renal impaired patients, and those taking high simvastatin doses.","   .   : 1)     20 / 2)       CK  3)          CYP3A4 (  ) 4)      .","Avoid combination if possible. If necessary: 1) Do not exceed simvastatin 20mg/day 2) Monitor for myotoxicity symptoms and measure CK regularly 3) Consider alternative statins not dependent on CYP3A4 (e.g., pravastatin, rosuvastatin) 4) Educate patient about rhabdomyolysis signs.");n("Amiodarone - ","Warfarin - ",e.DRUG_DRUG,i.HIGH,"   CYP2C9 CYP1A2     (  S- ).           .           .","Amiodarone inhibits CYP2C9 and CYP1A2 enzymes responsible for warfarin metabolism (particularly the more potent S-isomer). It also inhibits warfarin metabolism through other enzymes and reduces its renal clearance. Amiodarone's long half-life means this interaction persists for extended periods.","            INR (   4-6  ).                      .","Significant and sustained enhancement of warfarin anticoagulant effect, with sharp INR elevation (may reach 4-6 or higher). This leads to increased risk of severe bleeding including gastrointestinal bleeding, intracranial hemorrhage, and other site bleeding that may be life-threatening.","  :     30-50%   .    INR (     2-3    ).   :    INR closely     .     .","When starting amiodarone: Reduce warfarin dose by 30-50% and avoid loading doses. Frequent INR monitoring (daily in first week, then 2-3 times weekly until stabilization). When discontinuing amiodarone: Continue close INR monitoring as effect persists for weeks. Educate patient about bleeding signs.");n("Amiodarone - ","Fentanyl - ",e.DRUG_DRUG,i.HIGH,"   CYP3A4          .               QT","Amiodarone inhibits CYP3A4 enzyme responsible for fentanyl metabolism, significantly increasing its concentration. Additionally, both drugs can cause sinus node depression and prolong QT interval","    2-3            QT     including Torsades de Pointes","2-3 fold increase in fentanyl concentration, severe respiratory depression, hypotension, bradycardia, QT prolongation, and risk of cardiac arrhythmias including Torsades de Pointes","    -   :     50-75%             24   ","Avoid combination if possible - if necessary: reduce fentanyl dose by 50-75%, continuous monitoring of vital signs and ECG, have resuscitation equipment available, monitor respiration for at least 24 hours");n("Amiodarone - ","Food (General) -  ()",e.DRUG_FOOD,i.LOW,"      ( )    .                .             .               .       (55-60 )           .","Amiodarone causes taste alterations (dysgeusia) through multiple mechanisms. First, it is actively secreted into saliva, directly exposing taste buds to high drug concentrations. Second, as an iodine-containing drug, it can accumulate in salivary gland tissue and the tongue. Third, its effect on ion channels in sensory neurons may contribute to altered taste signaling. Finally, amiodarone`s very long half-life (55-60 days) means these effects can persist and accumulate with chronic therapy.","  ()          : 1.      (  )      . 2.          . 3.     . 4.                  .","Persistent metallic or chemical annoying taste in the mouth, leading to: 1. Sharp decline in taste sensation (hypogeusia) or distortion of the taste of familiar foods. 2. Loss of appetite and unintentional weight loss, especially in the elderly. 3. Decreased quality of life and enjoyment of food. 4. Potential impact of malnutrition on overall health status, which can be particularly significant in cardiac patients.","1.  :                  . 2.   :                  . 3.  :                      . 4.   :       (   )      . 5. :      .             .","1. Reassurance and preparation: Inform the patient that this is a common side effect and usually improves or stabilizes after several months of continuous therapy. 2. Enhanced oral hygiene: Regular brushing, flossing, and using a non-alcoholic mouthwash can help reduce the taste. 3. Saliva stimulants: Chewing sugar-free gum or sucking sugar-free lozenges can stimulate saliva flow and help clear the taste. 4. Dietary modification: Avoiding foods that may exacerbate the taste (e.g., red meat, coffee) and using spices and herbs to enhance food flavor. 5. Monitoring: Monitor the patient`s weight and nutritional status regularly. If weight loss becomes significant, reevaluation of the necessity of therapy may be required.");n("Amitriptyline","Digoxin",e.DRUG_DRUG,i.MODERATE,"                .","Additive cardiac effects and anticholinergic effects, which may increase Digoxin toxicity or alter its absorption.","        .","Increased risk of cardiac arrhythmia or Digoxin toxicity.","       (ECG).","Monitor blood Digoxin levels and ECG.");n("Amitriptyline","Clonidine",e.DRUG_DRUG,i.MODERATE," .               .","Antagonism. Amitriptyline blocks the entry of Clonidine to its central active site, reducing its antihypertensive effect.","             .","Reduced Clonidine efficacy, leading to hypertension or loss of blood pressure control.","  .           .","Monitor BP. May require increasing the Clonidine dose or using an alternative antidepressant.");n("Amitriptyline","Smoking",e.DRUG_FOOD,i.MODERATE,"  CYP1A2    (   ).","CYP1A2 Induction. Polycyclic aromatic hydrocarbons (e.g., from smoking) induce CYP1A2 (which accelerates Amitriptyline metabolism).","         .","Reduced blood drug levels, decreasing therapeutic effect.","    .     .","Adjust dose and monitor clinical efficacy. Smokers may require higher doses.");n("Amitriptyline","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"    .       .","Severe Serotonin Toxicity Risk. Both significantly increase Serotonin and Norepinephrine levels.","         .","Increased risk of Serotonin Syndrome and neurotoxicity/cardiotoxicity, potentially life-threatening.","   (  ).         .","Avoid combination (absolute contraindication). Allow at least 2 weeks washout period.");n("Amitriptyline","Fluoxetine",e.DRUG_DRUG,i.HIGH,"   (CYP2D6)    .","Potent Metabolic Inhibition (CYP2D6) and additive serotonergic effects.","  TCA (   )   .","Increased TCA toxicity (seizures, arrhythmia) and Serotonin Syndrome risk.","    .          .","Avoid this combination if possible. If necessary, significantly reduce the Amitriptyline dose and monitor closely.");n("Amitriptyline","Sertraline",e.DRUG_DRUG,i.MODERATE,"   (CYP2D6  CYP2C19)    .","Moderate Metabolic Inhibition (CYP2D6 and CYP2C19) and additive serotonergic effects.","  TCA      .","Increased TCA concentration, raising the risk of side effects and Serotonin Syndrome.","  TCA  .    TCA  .","Monitor TCA levels and toxicity signs. Reduce TCA dose if needed.");n("Amitriptyline","Paroxetine",e.DRUG_DRUG,i.HIGH,"   (CYP2D6)    .","Potent Metabolic Inhibition (CYP2D6) and additive serotonergic effects.","  TCA (   )   .","Increased TCA toxicity (seizures, arrhythmia) and Serotonin Syndrome risk.","    .          .","Avoid this combination if possible. If necessary, significantly reduce the Amitriptyline dose and monitor closely.");n("Amitriptyline","Citalopram",e.DRUG_DRUG,i.MODERATE,"      .      QT.","Weak Metabolic Inhibition and additive serotonergic effects. Both drugs may prolong the QT interval.","    TCA        QT.","Slight increase in TCA concentration, raising the risk of side effects, Serotonin Syndrome, and QT prolongation.","  TCA  .    TCA  .","Monitor TCA levels and toxicity signs. Reduce TCA dose if needed.");n("Amitriptyline","Escitalopram",e.DRUG_DRUG,i.MODERATE,"      .      QT.","Weak Metabolic Inhibition and additive serotonergic effects. Both drugs may prolong the QT interval.","    TCA        QT.","Slight increase in TCA concentration, raising the risk of side effects, Serotonin Syndrome, and QT prolongation.","  TCA  .    TCA  .","Monitor TCA levels and toxicity signs. Reduce TCA dose if needed.");n("Amitriptyline","Cimetidine",e.DRUG_DRUG,i.MODERATE,"  TCA (     CYP2D6/2C19).","Increased TCA Levels (Non-specific enzyme inhibition of CYP2D6/2C19).","      (     ).","Increased TCA toxicity (e.g., sedation, anticholinergic effects, cardiotoxicity).","  TCA -   -     H2     (   ).","Monitor TCA levels. Adjust dose. Prefer using an alternative non-enzyme-inhibiting H2 blocker (e.g., Ranitidine or Famotidine).");n("Amitriptyline","Rifampin",e.DRUG_DRUG,i.MODERATE,"  TCA (    CYP).","Reduced TCA Levels (Potent enzyme induction of CYP enzymes).","         .","Reduced antidepressant efficacy, potentially leading to relapse.","  TCA  .       .","Monitor TCA levels and clinical symptoms. Increase antidepressant dose if needed.");n("Amitriptyline","Valproic Acid",e.DRUG_DRUG,i.MODERATE,"  TCA.     CYP2C9        .","Increased TCA Concentrations. Valproic acid inhibits CYP2C9 and some glucuronidation pathways, reducing Amitriptyline metabolism.","  TCA (     ).","Increased TCA toxicity (e.g., sedation, anticholinergic effects, cardiotoxicity).","  TCA  .   TCA  .","Monitor TCA levels and toxicity signs. Reduce TCA dose if needed.");n("Amitriptyline","Pseudoephedrine",e.DRUG_DRUG,i.HIGH,"    (NET).           .","Norepinephrine Reuptake Inhibition (NET). Amitriptyline blocks the reuptake of neurotransmitters, greatly potentiating the pressor effect.","      (   )    .","Severely increased risk of hypertension (hypertensive crisis) and cardiac arrhythmias.","   .          .","This combination must be avoided. Use an alternative decongestant that does not act as a pressor agent.");n("Amitriptyline","Phenylephrine",e.DRUG_DRUG,i.HIGH,"    (NET).           .","Norepinephrine Reuptake Inhibition (NET). Amitriptyline blocks the reuptake of neurotransmitters, greatly potentiating the pressor effect.","      (   )    .","Severely increased risk of hypertension (hypertensive crisis) and cardiac arrhythmias.","   .          .","This combination must be avoided. Use an alternative decongestant that does not act as a pressor agent.");n("Amitriptyline","Ephedrine",e.DRUG_DRUG,i.HIGH,"    (NET).           .","Norepinephrine Reuptake Inhibition (NET). Amitriptyline blocks the reuptake of neurotransmitters, greatly potentiating the pressor effect.","      (   )    .","Severely increased risk of hypertension (hypertensive crisis) and cardiac arrhythmias.","   .          .","This combination must be avoided. Use an alternative decongestant that does not act as a pressor agent.");n("Amitriptyline","Phenelzine",e.DRUG_DRUG,i.HIGH,"        .         .","Acute increase in Serotonin and Norepinephrine concentrations in the synaptic cleft. Phenelzine prevents the breakdown, and Amitriptyline blocks the reuptake.","                (Hypertensive Crisis)   .","Increased risk of severe Serotonin Syndrome, neurotoxicity, and cardiotoxicity, in addition to the risk of Hypertensive Crisis, potentially life-threatening.","     .     (Washout Period)          .","Co-administration is strictly prohibited (Absolute Contraindication). A washout period of at least two weeks must be observed between stopping one drug and starting the other.");n("Amitriptyline","Sparfloxacin",e.DRUG_DRUG,i.CONTRAINDICATED,"    QT.     QT           .","Additive QT Prolongation effects. Both drugs independently prolong the QT interval, significantly increasing the risk of life-threatening ventricular arrhythmia.","      QT       (Torsades de Pointes).","Severely increased risk of QT interval prolongation and life-threatening ventricular arrhythmia (Torsades de Pointes).","      ( ).         QT.","Co-administration is strictly prohibited (Contraindication). An alternative antibiotic that does not prolong the QT interval must be used.");n("Amitriptyline","Dobutamine",e.DRUG_DRUG,i.HIGH,"    (NET).             .","Inhibition of Catecholamine Reuptake (NET). Amitriptyline blocks the reuptake of Dobutamine and Norepinephrine, greatly potentiating the inotropic and pressor effects.","              (Tachycardia)         .","Seriously increased cardiovascular effect of Dobutamine, leading to tachycardia, hypertension, and increased risk of severe cardiac arrhythmias.","   .            ( 1/10   )         .","This combination should be avoided. If necessary, use much lower initial doses of Dobutamine (typically 1/10th the usual dose) and closely monitor the patient for hypertension and arrhythmias.");n("Amitriptyline","Dopamine, Epinephrine (), Mephentermine, Metaraminol, Methoxamine",e.DRUG_DRUG,i.HIGH,"    (NET).             .","Inhibition of Catecholamine Reuptake (NET). Amitriptyline blocks the clearance of these agents from the synaptic cleft, greatly potentiating their cardiovascular effects.","              (Hypertensive Crisis)     .","Acute and severe increase in pressor effect, leading to Hypertensive Crisis and severe ventricular arrhythmias.","     .                 (1/10  1/5   ).","Co-administration is strictly prohibited. If necessary, use pressor agents that do not rely on reuptake and use extremely reduced doses (1/10th to 1/5th the usual dose).");n("Amitriptyline","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"   (CYP2C19  CYP2D6).         .","Enzymatic Metabolic Induction (CYP2C19 and CYP2D6). Carbamazepine is a potent inducer of hepatic enzymes responsible for Amitriptyline metabolism.","                  .","Significant decrease in Amitriptyline plasma concentration, potentially leading to loss of therapeutic efficacy and recurrence of depressive symptoms or pain.","  .            .","Closely monitor symptoms. It is often necessary to increase the Amitriptyline dose to restore the desired therapeutic efficacy.");n("Amlodipine - ","Ketoconazole - ",e.DRUG_DRUG,i.MODERATE,"    CYP3A4                  50-60.       (60-80)       .","Ketoconazole potently inhibits hepatic CYP3A4 enzyme responsible for amlodipine metabolism, leading to reduced clearance and increased plasma concentrations by up to 50-60%. Amlodipine itself has high bioavailability (60-80%) and relies heavily on this metabolic pathway.","                  .             .","Marked enhancement of amlodipine pharmacological effects, leading to severe hypotension, dizziness, syncope, bradycardia, and fluid retention. Other side effects like headache, fatigue, and nausea may also be exaggerated.","        (   ).     25-50   .      .         CYP3A4.","Monitor blood pressure and heart rate frequently (daily in first week). Reduce amlodipine dose by 25-50% if necessary. Avoid high doses of both drugs. Consider alternative antifungal agents that do not inhibit CYP3A4.");n("Amlodipine - ","Simvastatin - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4        (      )       30-50.            .","Amlodipine moderately inhibits CYP3A4 enzyme, reducing simvastatin metabolism (which heavily depends on this enzyme) and increasing its plasma concentrations by 30-50%. This interaction is less severe than with amiodarone but remains clinically significant.","               (Rhabdomyolysis)             .","Increased risk of statin-associated myotoxicity, ranging from mild myalgia to rhabdomyolysis in severe cases, particularly with high simvastatin doses or in elderly patients.","    20 /    .       CK   .         .","Do not exceed simvastatin 20mg/day when combined with amlodipine. Monitor for myotoxicity symptoms and measure CK if symptoms appear. Consider alternative statins such as pravastatin or rosuvastatin.");n("Amlodipine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.HIGH,"     CYP3A4                     15-20.        24    .","Grapefruit juice inhibits intestinal CYP3A4 enzyme and prevents first-pass metabolism of amlodipine, increasing its bioavailability by up to 15-20%. This effect may persist for up to 24 hours after juice consumption.","                           .","Sudden enhancement of amlodipine hypotensive effect, leading to severe hypotension, dizziness, severe headache, and potential syncope, especially after the first dose or dose increase.","        .                  .       .","Completely avoid grapefruit juice during amlodipine therapy. If accidentally consumed, monitor blood pressure closely and temporarily reduce amlodipine dose if necessary. Use alternative juices like orange or apple.");n("Amobarbital","Doxycycline",e.DRUG_DRUG,i.MODERATE,"    CYP3A4              .","Amobarbital induces hepatic CYP3A4 enzymes responsible for doxycycline metabolism, increasing its clearance and reducing bioavailability.","         .","Decreased plasma doxycycline levels and reduced therapeutic antibiotic efficacy.","   .                    CYP3A4.","Monitor clinical response. May need to increase doxycycline dose, shorten dosing interval, or use alternative antibiotic not dependent on CYP3A4.");n("Amobarbital","Estrogens",e.DRUG_DRUG,i.HIGH,"    CYP3A4             .","Amobarbital induces hepatic CYP3A4 enzymes responsible for estrogen metabolism, increasing metabolic rate and reducing therapeutic levels.","                    .","Reduced estrogen efficacy, compromising hormonal contraception effectiveness and increasing risk of breakthrough bleeding and unintended pregnancy.","                    .","Use additional non-hormonal contraception or switch to higher estrogen dose method under medical supervision.");n("Amobarbital","Ethanol",e.DRUG_DRUG,i.HIGH,"                .","Additive CNS depressant effect from both substances with inhibition of alcohol-metabolizing enzymes.","                  .","Severe CNS depression leading to dizziness, drowsiness, respiratory depression, hypotension, potentially coma and death.","       .        .         .","Avoid alcohol completely during treatment. Warn patient against driving or operating heavy machinery. Urgent medical care required if severe depression occurs.");n("Amobarbital","Griseofulvin",e.DRUG_DRUG,i.MODERATE,"             .","Amobarbital induces hepatic enzymes responsible for griseofulvin metabolism, accelerating its clearance.","         .","Decreased blood griseofulvin levels and reduced antifungal therapeutic efficacy.","    .            .","Monitor clinical response to antifungal therapy. May need to increase griseofulvin dose or extend treatment duration under medical supervision.");n("Amobarbital","Methadone",e.DRUG_DRUG,i.HIGH,"    CYP3A4 CYP2B6         .","Amobarbital induces hepatic CYP3A4 and CYP2B6 enzymes responsible for methadone metabolism, reducing its therapeutic levels.","                   .","Decreased plasma methadone levels leading to opioid withdrawal symptoms and loss of efficacy in addiction or pain management.","   .             .","Close monitoring for withdrawal symptoms. Increase methadone dose with continuous monitoring, and adjust dose when stopping amobarbital to avoid toxicity.");n("Amobarbital","Metronidazole",e.DRUG_DRUG,i.MODERATE,"         CYP3A4.","Amobarbital induces hepatic enzymes responsible for metronidazole metabolism, especially CYP3A4.","        .","Reduced therapeutic concentration of metronidazole and decreased antibacterial/antiparasitic efficacy.","   .              .","Monitor clinical response. Metronidazole dose increase or alternative therapy unaffected by hepatic enzyme inducers may be needed.");n("Amobarbital","Nifedipine",e.DRUG_DRUG,i.MODERATE,"    CYP3A4     .","Amobarbital induces hepatic CYP3A4 enzymes responsible for nifedipine first-pass metabolism.","                .","Decreased plasma nifedipine levels reducing its efficacy in lowering blood pressure and controlling angina.","     .               .","Monitor BP and heart rate. Increase nifedipine dose or switch to calcium channel blockers less affected by enzyme inducers, like amlodipine.");n("Amobarbital","Quinidine",e.DRUG_DRUG,i.HIGH,"    CYP3A4    .","Amobarbital induces hepatic CYP3A4 enzymes responsible for quinidine metabolism.","                   .","Reduced therapeutic quinidine levels decreasing efficacy in treating arrhythmias and increasing risk of arrhythmia recurrence.","      .          .","Monitor ECG and serum quinidine levels. Increase quinidine dose with careful monitoring to achieve therapeutic levels.");n("Amobarbital","Theophylline",e.DRUG_DRUG,i.MODERATE,"    CYP1A2    .","Amobarbital induces hepatic CYP1A2 enzymes responsible for theophylline metabolism.","                 .","Decreased plasma theophylline levels and reduced efficacy in treating respiratory diseases like asthma and COPD.","      .         .","Monitor serum theophylline levels and clinical response. Increase theophylline dose, and readjust when stopping amobarbital.");n("Amobarbital","Warfarin",e.DRUG_DRUG,i.HIGH,"    CYP2C9 CYP3A4    .","Amobarbital induces hepatic CYP2C9 and CYP3A4 enzymes responsible for warfarin metabolism.","            .","Decreased warfarin levels and reduced anticoagulant effect, increasing risk of thrombosis and clots.","    (INR)  .              .","Monitor INR frequently. Increase warfarin dose with careful monitoring, and reduce dose when stopping amobarbital to avoid bleeding risk.");n("Amoxicillin","Khat",e.DRUG_FOOD,i.MODERATE,"      ","Tannins in Khat bind to the antibiotic.","   ","Reduced antibiotic absorption.","       ","Take medication immediately before Khat or 2 hours after.");n("Amoxicillin","Allopurinol",e.DRUG_DRUG,i.MODERATE,"   .            .","Unknown Mechanism. The exact pathophysiological basis is not fully elucidated, but studies show a significantly increased risk of rash when these agents are co-administered (a class effect with aminopenicillins).","    .     (maculopapular rash).","Increased incidence of skin rash (maculopapular rash). This is considered a non-IgE mediated hypersensitivity reaction.","           .      .","Avoid combination if possible. If concomitant use is necessary, monitor closely for the appearance of a skin rash, especially in the initial weeks. Consider alternative antibiotics.");n("Amoxicillin","Tetracycline",e.DRUG_DRUG,i.MODERATE,"   ().     (Bacteriostatic)          (Bactericidal).","Reduced Penicillin Efficacy. Tetracyclines, which are bacteriostatic agents, may antagonize the bactericidal action of Amoxicillin (a penicillin). Penicillins require actively growing bacteria to be effective.","    .       /  .","Bacterial infection treatment failure. Potential for sub-optimal clinical outcomes and increased risk of resistance development.","  .           .","Avoid this combination, particularly in severe infections where rapid bacterial killing is essential. Consider alternative antibiotic therapy.");n("Amoxicillin","Doxycycline",e.DRUG_DRUG,i.MODERATE,"   ().             .","Reduced Penicillin Efficacy. Doxycycline (bacteriostatic) may interfere with the bactericidal action of Amoxicillin, which depends on actively dividing cells.","    .       /  .","Bacterial infection treatment failure. Potential for sub-optimal clinical outcomes and increased risk of resistance development.","  .           .","Avoid this combination, particularly in severe infections where rapid bacterial killing is essential. Consider alternative antibiotic therapy.");n("Amoxicillin","Minocycline",e.DRUG_DRUG,i.MODERATE,"   ().             .","Reduced Penicillin Efficacy. Minocycline (bacteriostatic) may interfere with the bactericidal action of Amoxicillin, which depends on bacterial cell wall synthesis during growth.","    .       /  .","Bacterial infection treatment failure. Potential for sub-optimal clinical outcomes and increased risk of resistance development.","  .           .","Avoid this combination, particularly in severe infections where rapid bacterial killing is essential. Consider alternative antibiotic therapy.");n("Amoxicillin","Food",e.DRUG_FOOD,i.MODERATE,"        ( )               .","Reduced Penicillin Absorption. Although Amoxicillin absorption is generally minimally affected by food, other oral penicillins suffer a reduction in gastrointestinal bioavailability when taken with meals.","   .         .","Reduced antibiotic efficacy. Lower plasma concentrations may lead to inadequate therapeutic effect and potential treatment failure.","                    .","Administer Penicillins 2 hours before or after food, especially for other penicillins. For Amoxicillin, administration with or without food is acceptable, but separating doses ensures optimal absorption.");n("Amoxicillin - ","Methotrexate - ",e.DRUG_DRUG,i.HIGH,"                ( OAT1  OAT3).               30-40.          .","Amoxicillin inhibits renal tubular secretion of methotrexate by competing for organic anion transporters in renal tubules (particularly OAT1 and OAT3). This leads to decreased methotrexate clearance and increased plasma concentrations by up to 30-40%. Risk is higher with low-dose methotrexate used in rheumatic diseases.","     :     (  )             .                .","Significant increase in methotrexate toxicity, including: severe bone marrow suppression (pancytopenia), oral and gastrointestinal ulcerations, hepatotoxicity, and potentially life-threatening systemic toxicity. Risk is higher in elderly, renal impaired patients, or those taking high methotrexate doses.","   .   : 1)     (CBC)  1-2  2)      3)    (leucovorin)  4)      5)           ( ).","Avoid combination if possible. If necessary: 1) Monitor complete blood count (CBC) every 1-2 weeks 2) Measure renal and liver function weekly 3) Administer leucovorin prophylactically 4) Avoid high amoxicillin doses 5) Consider alternative antibiotics that do not interact with methotrexate secretion (e.g., quinolones).");n("Amoxicillin","Alcohol",e.DRUG_FOOD,i.HIGH,": **     ** (   ).           .","Mechanism: **No direct drug interaction is known** (unlike some antibiotics). The High severity rating is due to general health risks and potential additive GI irritation.",":        ( )   Amoxicillin    .","Result: Alcohol may increase GI side effects (nausea, diarrhea) associated with Amoxicillin, and may mask infection symptoms.",":            .","Management: Advise avoidance of alcohol during treatment to minimize GI side effects and ensure patient comfort.");n("Amoxicillin","Caffeine",e.DRUG_FOOD,i.MODERATE,": ** **. Amoxicillin        (CYP450).","Mechanism: **Low Interaction**. Amoxicillin does not significantly affect Caffeine metabolism (CYP450).",":      .        .","Result: No major clinical effect expected. Caffeine may slightly increase stomach irritation.",":    .    .","Management: No routine adjustment required. GI symptoms can be monitored.");n("Amoxicillin","Grapefruit Juice",e.DRUG_FOOD,i.LOW,":    . Amoxicillin      CYP3A4.","Mechanism: No known interaction. Amoxicillin is not significantly metabolized by CYP3A4.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Amoxicillin","Green Tea",e.DRUG_FOOD,i.HIGH,":     . (          ).","Mechanism: No direct interaction is known. (Hypothetical interaction possibly due to caffeine content or absorption interference).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Milk",e.DRUG_FOOD,i.MODERATE,": **   **.  Amoxicillin       (   ).","Mechanism: **No significant interaction**. Amoxicillin absorption is not significantly affected by dairy products (unlike tetracyclines or quinolones).",":      .","Result: No major clinical effect expected.",":    .       .","Management: No routine adjustment required. The drug can be taken with milk if necessary.");n("Amoxicillin","High-fat meals",e.DRUG_FOOD,i.LOW,":    .       Amoxicillin.","Mechanism: No significant interaction. Food generally does not affect Amoxicillin absorption.",":               .","Result: May only lead to a slight delay in reaching peak concentration, with no effect on overall efficacy.",":    .","Management: No routine adjustment required.");n("Amoxicillin","High-fiber foods",e.DRUG_FOOD,i.HIGH,":     .      .","Mechanism: No direct interaction is known. May delay absorption through physical interference.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Vitamin C",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Vitamin D",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Vitamin E",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Vitamin K",e.DRUG_FOOD,i.MODERATE,":             Vitamin K        (Warfarin).","Mechanism: Antibiotics can sometimes reduce gut bacteria production of Vitamin K, especially in patients taking blood thinners (Warfarin).",":      (     ).","Result: Theoretical increase in bleeding risk (if concurrent with anticoagulants).",":       .","Management: Closely monitor patients taking Warfarin.");n("Amoxicillin","Vitamin B12",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Folic Acid",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Iron",e.DRUG_FOOD,i.MODERATE,":      (  )  Amoxicillin .","Mechanism: No significant chemical interaction (like chelation) is known between Amoxicillin and Iron.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Amoxicillin","Calcium",e.DRUG_FOOD,i.LOW,":      ( ).","Mechanism: No significant chemical interaction (chelation).",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Amoxicillin","Magnesium",e.DRUG_FOOD,i.HIGH,":      ( ). ( ).","Mechanism: No significant chemical interaction (chelation). (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Zinc",e.DRUG_FOOD,i.MODERATE,":      ( ).","Mechanism: No significant chemical interaction (chelation).",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Amoxicillin","Potassium",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Amoxicillin","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,": **  /**.      (pH)           .","Mechanism: **Altered Gastric/Urine pH**. Sodium Bicarbonate increases gastric and urinary alkalinity (pH), which could theoretically affect Amoxicillin absorption or excretion.",":            .","Result: No confirmed clinical effect, but caution may be warranted in specific cases.",":  .     .","Management: Routine monitoring. Prefer separation of doses by two hours.");n("Amoxicillin","Antacids",e.DRUG_FOOD,i.MODERATE,": **  **.              Amoxicillin .","Mechanism: **Altered Gastric pH**. Antacids may slightly raise gastric pH, but the effect on Amoxicillin absorption is minimal.",":      .","Result: No major clinical effect expected.",":         .","Management: Prefer separation of doses and antacids by two hours as a precaution.");n("Amoxicillin - ","Allopurinol - ",e.DRUG_DRUG,i.MODERATE,"                  .                  .                       .","The combination of Amoxicillin and Allopurinol significantly increases the incidence of skin rash compared to taking either drug alone. The exact mechanism is not fully understood but is thought to involve an immune-mediated interaction or an effect of Allopurinol on the inflammatory response. It is important to note that this rash may be non-allergic in nature in many cases, but can be severe in some patients.","      ()     .                       -      .       .","The primary risk is the appearance of a rash (erythematous) that can vary in pattern and severity. It can range from a mild, widespread morbilliform rash to a papular rash, and rarely may progress to serious skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis. The rash may sometimes be accompanied by fever.","1.           (  )    . 2.                    . 3.              . 4.         .                     . 5.           .","1. Avoid the combination if possible, and choose an alternative antibiotic (e.g., non-penicillins) for patients taking Allopurinol. 2. If co-administration is necessary, the patient should be warned about the risk of rash and instructed to report it immediately to their doctor. 3. Monitor the patient closely for the appearance of any skin rash, especially during the first few weeks of therapy. 4. If a rash appears, Amoxicillin should be discontinued immediately. Allopurinol may not need to be stopped if the rash is mild and not associated with systemic symptoms, but the situation must be evaluated by a physician. 5. In cases of severe rash, both drugs should be discontinued and not restarted.");n("Amoxicillin - ","Atenolol - ",e.DRUG_DRUG,i.MODERATE,"        .                     (OCT1, OCT2, MATE1, MATE2-K)  .                                .","Amoxicillin reduces the bioavailability of Atenolol when taken concomitantly. The mechanism of this interaction relies on the fact that Atenolol is a drug with low membrane permeability and depends on intestinal solute carrier transporters (OCT1, OCT2, MATE1, MATE2-K) for its absorption and secretion. Amoxicillin, being a competitive substrate for these transporters, competes with Atenolol for binding sites, leading to decreased intestinal absorption and increased renal secretion of Atenolol, overall lowering its plasma concentration and efficacy.","      .    : 1.      (  ). 2.                   . 3.            . 4.         .","The primary risk is a reduction in the therapeutic efficacy of Atenolol. This may lead to: 1. Inadequate control of blood pressure (hypertension). 2. Inadequate control of heart rate, especially in patients taking the drug for tachycardia or angina pectoris. 3. Increased risk of angina pectoris or myocardial infarction in susceptible patients. 4. Failure to achieve the vascular and cardioprotective benefits of Atenolol.","1.   :          2-4  ( 4 )        . 2. :                   . 3.  :                . 4. :             . 5. :                      (  ).","1. Dosing Interval: It is recommended to administer Amoxicillin and Atenolol at least 2-4 hours apart (preferably 4 hours) to reduce the chance of competition for intestinal absorption transporters. 2. Monitoring: Monitor for signs of uncontrolled blood pressure and heart rate closely, especially when initiating or discontinuing Amoxicillin therapy. 3. Dose Adjustment: A temporary increase in the Atenolol dose may be necessary during Amoxicillin treatment to maintain therapeutic control. 4. Patient Education: Advise the patient to report any symptoms such as headache, dizziness, or palpitations. 5. Alternatives: In cases requiring long-term antibiotic therapy, consider using an antibiotic that does not interact with solute carrier transporters (e.g., suitable Cephalosporins).");n("Amoxicillin / Ampicillin","Methotrexate",e.DRUG_DRUG,i.HIGH,"      .","Reduced renal excretion and increased Methotrexate half-life.","       .","Increased blood Methotrexate levels and toxicity risk.","      .","Avoid combination, or closely monitor Methotrexate levels.");n("Amoxicillin / Ampicillin","Khat",e.DRUG_FOOD,i.MODERATE," Tannins       .","Tannins in Khat bind to the antibiotic and prevent absorption.","  (Non-absorbable complex).","Treatment failure (Non-absorbable complex).","        .","Separate Khat consumption and antibiotic by at least 2 hours.");n("Amoxicillin/Clavulanate","Warfarin",e.DRUG_DRUG,i.MODERATE,"     K","Inhibition of Vitamin K-producing bacterial flora.","     ","Increased Warfarin effect and bleeding risk."," INR    ","Monitor INR during and after treatment.");n("Ampicillin","Atenolol",e.DRUG_DRUG,i.MODERATE,"              .","Reduced Atenolol efficacy. Ampicillin impairs the gastrointestinal absorption of Atenolol, likely due to an adsorption mechanism, leading to lower plasma concentrations.","     /    .      .","Reduced antihypertensive and/or anti-anginal efficacy. May result in inadequate control of hypertension or angina.","       .                 .","Monitor BP and heart rate closely. If necessary, increase the Atenolol dose or separate the administration of the two drugs by at least 2 hours to minimize the interaction.");n("Ampicillin","Tetracycline",e.DRUG_DRUG,i.MODERATE,"   ().     (Bacteriostatic)          (Bactericidal).","Reduced Penicillin Efficacy. Tetracyclines, which are bacteriostatic agents, may antagonize the bactericidal action of Ampicillin (a penicillin). Penicillins require actively growing bacteria to be effective.","    .       /  .","Bacterial infection treatment failure. Potential for sub-optimal clinical outcomes and increased risk of resistance development.","  .           .","Avoid this combination, particularly in severe infections where rapid bacterial killing is essential. Consider alternative antibiotic therapy.");n("Ampicillin","Doxycycline",e.DRUG_DRUG,i.MODERATE,"   ().             .","Reduced Penicillin Efficacy. Doxycycline (bacteriostatic) may interfere with the bactericidal action of Ampicillin, which depends on actively dividing cells.","    .       /  .","Bacterial infection treatment failure. Potential for sub-optimal clinical outcomes and increased risk of resistance development.","  .           .","Avoid this combination, particularly in severe infections where rapid bacterial killing is essential. Consider alternative antibiotic therapy.");n("Ampicillin","Minocycline",e.DRUG_DRUG,i.MODERATE,"   ().             .","Reduced Penicillin Efficacy. Minocycline (bacteriostatic) may interfere with the bactericidal action of Ampicillin, which depends on bacterial cell wall synthesis during growth.","    .       /  .","Bacterial infection treatment failure. Potential for sub-optimal clinical outcomes and increased risk of resistance development.","  .           .","Avoid this combination, particularly in severe infections where rapid bacterial killing is essential. Consider alternative antibiotic therapy.");n("Ampicillin","Food",e.DRUG_FOOD,i.MODERATE,"             .","Reduced Penicillin Absorption. Food significantly interferes with the gastrointestinal absorption and bioavailability of Ampicillin, requiring dose separation.","   .         .","Reduced antibiotic efficacy. Lower plasma concentrations may lead to inadequate therapeutic effect and potential treatment failure.","          .","Administer Ampicillin 2 hours before or after food to ensure optimal absorption and systemic exposure.");n("Ampicillin","Aminoglycosides",e.DRUG_DRUG,i.HIGH,"                 .","Direct chemical interaction between ampicillin and aminoglycosides when mixed in IV solutions, forming inactive complexes.","         .","Inactivation of antibacterial activity of both drugs upon direct physical mixing.","      .            .","Avoid direct mixing in the same IV solution. Administer via separate lines or with sufficient time intervals.");n("Ampicillin","Atenolol",e.DRUG_DRUG,i.MODERATE,"               .","Reduced atenolol GI absorption due to altered bacterial flora or drug kinetics.","            .","Decreased plasma atenolol levels and reduced antihypertensive/heart rate lowering effect.","     .             .","Monitor BP and heart rate. May need to increase atenolol dose or use alternative beta-blocker not affected by ampicillin.");n("Ampicillin","Warfarin",e.DRUG_DRUG,i.MODERATE,"      K        .","Inhibition of vitamin K-producing intestinal flora, plus potential ampicillin effect on warfarin metabolism.","       .","Increased warfarin anticoagulant effect and bleeding risk.","    (INR)        .     .","Monitor INR frequently during and after ampicillin therapy. Adjust warfarin dose as needed.");n("Ampicillin","Oral Contraceptives",e.DRUG_DRUG,i.MODERATE,"   -     ","Gut flora alteration disrupts enterohepatic recirculation of estrogen.","    ","Potential contraceptive failure.","      ","Use backup contraception during treatment and 1 week after.");n("Amprenavir - ","Ergot Alkaloids -  ",e.DRUG_DRUG,i.HIGH,"       CYP3A4        ( ).","Amprenavir is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which is primarily responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine).","             (Ergotism)     (Vasospasm)      .","Dangerous increase in Ergot Alkaloids blood concentrations, leading to acute Ergotism, which includes vasoconstriction (Vasospasm) and ischemia that may threaten limb viability.","     ().     .","This drug combination is absolutely contraindicated (forbidden). This co-administration must be avoided entirely.");n("Amyl Nitrite","Ergot Alkaloids",e.DRUG_DRUG,i.HIGH,"                          .","Potent antagonistic vasoactive effects; amyl nitrite causes vasodilation while ergot alkaloids cause vasoconstriction, leading to vascular instability.","                   .","Unpredictable BP changes, risk of severe hypertension or hypotension, peripheral ischemia, MI, stroke.","    .               .","Avoid combination completely. Monitor vital signs and watch for peripheral ischemia or consciousness changes.");n("Anakinra","Adalimumab",e.DRUG_DRUG,i.HIGH,"   .        (IL-1 vs TNF).","Increased risk of serious infection. Both act as immunosuppressants, but via different mechanisms (IL-1 vs TNF).","      .","Increased risk of opportunistic infections and acute neutropenia."," .     Anakinra  TNF.","Contraindicated. Combination of Anakinra and TNF blockers should be avoided.");n("Anastrozole - ","Estrogen-containing drugs -    ",e.DRUG_DRUG,i.HIGH,"      aromatase             .      (         )               .","Anastrozole acts as a non-steroidal aromatase inhibitor, preventing the conversion of androgens to estrogen in peripheral tissues and reducing systemic estrogen levels. Administration of estrogen-containing drugs (such as hormone replacement therapy, oral contraceptives, or topical treatments) directly counteracts this mechanism and increases estrogen levels in the body, negating the therapeutic effect of anastrozole.","                 .              .","Complete therapeutic failure in controlling hormone receptor-positive breast cancer, with increased risk of tumor recurrence and disease progression. This interaction is life-threatening and undermines the primary goal of adjuvant or therapeutic hormonal treatment.","    .        :              .               .","Absolute contraindication for combination. Avoid all forms of exogenous estrogen including: hormone replacement therapy, oral contraceptives, topical vaginal treatments, and natural products containing estrogen. Educate patients about avoiding personal care products or dietary supplements that may contain estrogen.");n("Anastrozole - ","Tamoxifen - ",e.DRUG_DRUG,i.MODERATE,"      (SERM)               .                      .             .","Tamoxifen acts as a selective estrogen receptor modulator (SERM) with partial agonist activity in some tissues, while anastrozole acts as an aromatase inhibitor that systemically lowers estrogen levels. When combined, tamoxifen may stimulate estrogen-related signaling pathways in breast cancer cells, reducing the antitumor efficacy of anastrozole. Additionally, tamoxifen may increase estrogen levels by stimulating aromatase enzyme activity.","                    .                 .","Reduced therapeutic efficacy of anastrozole in preventing recurrence of hormone receptor-positive breast cancer, potentially leading to increased risk of disease relapse. May also diminish the survival benefits associated with aromatase inhibitors compared to tamoxifen in adjuvant therapy.","       .            .           completamente   .","Avoid combination in adjuvant breast cancer therapy. Choose only one based on menopausal status and patient risk factors. When switching from tamoxifen to anastrozole, discontinue tamoxifen completely before initiating anastrozole.");n(Ku,"Cyclosporine",e.DRUG_DRUG,i.HIGH,":               CYP3A4  .","Mechanism: Mechanism not fully elucidated, likely via inhibition of Cyclosporine metabolism dependent on the hepatic CYP3A4 enzyme."," :        (Nephrotoxicity)        .","Clinical Significance: Increased risk of Cyclosporine toxicity, particularly nephrotoxicity and hypertension, due to the drug's narrow therapeutic index.","     (Trough levels)         .","Monitor blood Cyclosporine trough levels and adjust dose immediately to maintain levels within the therapeutic range.");n(Ku,"Warfarin",e.DRUG_DRUG,i.HIGH,":        (CYP450)      K  .","Mechanism: Inhibition of Warfarin metabolism via hepatic enzyme (CYP450) suppression and increased sensitivity of Vitamin K receptors to anticoagulants."," :       INR    (INR > 4.0)    .","Clinical Significance: Significant increase in bleeding risk and INR elevation above therapeutic range (INR > 4.0), necessitating immediate intervention.","   .     INR            50%.","Avoid combination if possible. Otherwise, monitor INR regularly (daily/every other day) and reduce Warfarin dose by up to 50%.");n("Anifrolumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Anifrolumab   IFN   1.","Reduced vaccine response/Increased infection risk. Anifrolumab is a Type 1 IFN receptor blocker.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Anifrolumab","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  . Anifrolumab  .","Increased risk of infection. Anifrolumab is an immunosuppressant.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Anifrolumab","Adalimumab (Biologic)",e.DRUG_DRUG,i.MODERATE,"  .    .","Increased risk of infection. Additive immunosuppressive effects.","     .","Increased risk of opportunistic and serious infections.","  .        .","Relative contraindication. Combination with other immunosuppressive biologics is not recommended.");n("Antacids (Aluminum, Calcium, Magnesium Salts)","Iron Salts (Ferrous Sulfate, Ferrous Gluconate, etc.)",e.DRUG_DRUG,i.MODERATE,"   (  )","Reduced iron absorption (requires acidic environment)","   ","Reduced iron supplement efficacy","   (  )","Separate doses (at least 2 hours)");n("Antacids (Aluminum, Calcium, Magnesium Salts)","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"   (  )","Reduced ketoconazole absorption (requires acidic environment)","  ","Reduced ketoconazole efficacy","   (  ) -      ( )","Separate doses (at least 2 hours) - take ketoconazole with an acidic drink (e.g., cola)");n("Antacids (Aluminum, Calcium, Magnesium Salts)","Quinidine",e.DRUG_DRUG,i.HIGH,"    ","Urine alkalinization reduces quinidine excretion","    ","Increased quinidine concentrations and toxicity risk","   -         ","Monitor quinidine concentrations - avoid concurrent use of antibiotics that cause urine alkalinity");n("Antacids (Aluminum, Calcium, Magnesium Salts)","Quinolones (Ciprofloxacin, Levofloxacin, Ofloxacin, etc.)",e.DRUG_DRUG,i.HIGH,"     (Chelation)","Formation of non-absorbable complexes (Chelation)","     ","Severely reduced antibiotic efficacy","   (   6    )","Separate doses (2 hours before or 6 hours after antacid)");n("Antacids (Aluminum, Calcium, Magnesium Salts)","Polystyrene Sulfonate (Kayexalate)",e.DRUG_DRUG,i.HIGH,"    ","Chemical reaction causing metabolic alkalosis","   (Metabolic Alkalosis)    ","Risk of metabolic alkalosis and failure to reduce potassium","  ","Avoid concurrent use");n("Antacids (Aluminum, Calcium, Magnesium Salts)","Tetracyclines (Doxycycline, Minocycline, Tetracycline)",e.DRUG_DRUG,i.HIGH,"     (Chelation)","Formation of non-absorbable complexes (Chelation)","     ","Severely reduced antibiotic efficacy","   (  )","Separate doses (at least 2 hours)");n("Antibiotics","Ethinylestradiol/Levonorgestrel (Combined Oral Contraceptive)",e.DRUG_DRUG,i.MODERATE,"              .","Gut Flora Alteration. Some antibiotics (especially rifampicin, but also others like penicillins and tetracyclines) may disrupt the intestinal microbiome responsible for enterohepatic recirculation of Ethinylestradiol, leading to reduced estrogen levels.","    .           .","Reduced contraceptive efficacy. Decreased absorption and plasma levels of Ethinylestradiol may lead to contraceptive failure and risk of unintended pregnancy.","       (  )       7   .","Use additional non-hormonal contraceptive method (e.g., condoms) during the antibiotic course and for 7 days after discontinuation.");n("Antibiotics","Ethinylestradiol/Desogestrel (Combined Oral Contraceptive)",e.DRUG_DRUG,i.MODERATE,"              .","Gut Flora Alteration. Some antibiotics (especially rifampicin, but also others like penicillins and tetracyclines) may disrupt the intestinal microbiome responsible for enterohepatic recirculation of Ethinylestradiol, leading to reduced estrogen levels.","    .           .","Reduced contraceptive efficacy. Decreased absorption and plasma levels of Ethinylestradiol may lead to contraceptive failure and risk of unintended pregnancy.","       (  )       7   .","Use additional non-hormonal contraceptive method (e.g., condoms) during the antibiotic course and for 7 days after discontinuation.");n("Antibiotics","Ethinylestradiol/Drospirenone (Combined Oral Contraceptive)",e.DRUG_DRUG,i.MODERATE,"              .","Gut Flora Alteration. Some antibiotics (especially rifampicin, but also others like penicillins and tetracyclines) may disrupt the intestinal microbiome responsible for enterohepatic recirculation of Ethinylestradiol, leading to reduced estrogen levels.","    .           .","Reduced contraceptive efficacy. Decreased absorption and plasma levels of Ethinylestradiol may lead to contraceptive failure and risk of unintended pregnancy.","       (  )       7   .","Use additional non-hormonal contraceptive method (e.g., condoms) during the antibiotic course and for 7 days after discontinuation.");n("Antiplatelet Drugs (Aspirin, Clopidogrel)","Garlic ()",e.DRUG_FOOD,i.MODERATE,"           .","Synergistic antiplatelet effect between Garlic and antiplatelet medications.","     .","Significantly increased risk of bleeding and bruising.","        .   .","Avoid high therapeutic doses or concentrated Garlic supplements. Monitor for signs of bleeding.");n("Apalutamide","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Apalutamide    CYP3A4    Midazolam.","Decreased Midazolam concentration. Apalutamide is a potent CYP3A4 inducer, a Midazolam metabolic pathway.","  Midazolam (/)          .","Reduced efficacy of Midazolam (sedative/hypnotic), potentially leading to failure of sedation or seizure control."," .           CYP3A4.","Avoid Combination. Narrow therapeutic index drugs metabolized by CYP3A4 must be avoided.");n("Apalutamide - ","Midazolam - ",e.DRUG_DRUG,i.HIGH,"      CYP3A4 UGT     .                85-90.     4        .","Apalutamide is a strong inducer of hepatic enzymes, particularly CYP3A4 and UGT, which are the primary metabolic pathways for midazolam. This induction leads to a significant increase in midazolam clearance and reduction in systemic exposure by up to 85-90%. This effect begins within 4 days of starting apalutamide and persists throughout treatment.","                  .              .         .","Complete therapeutic failure in anesthesia and sedation, with failure to achieve required sedation levels or loss of consciousness during medical procedures. This may lead to patient awareness during surgery, discomfort, and increased anesthetic requirements. In critical situations, this may compromise patient safety.","   .            CYP3A4 (  ).                3-4     .       .","Completely avoid combination. If anesthesia is necessary, use alternative anesthetic agents not dependent on CYP3A4 (e.g., propofol, ketamine). If midazolam must be used, dose increases of more than 3-4 fold may be required with close clinical monitoring. Re-evaluate anesthetic requirements after apalutamide discontinuation.");n("Apalutamide - ","Phenytoin - ",e.DRUG_DRUG,i.HIGH,"      CYP2C9 CYP2C19     .                50-70.            .","Apalutamide is a strong inducer of hepatic enzymes, particularly CYP2C9 and CYP2C19, which are the primary metabolic pathways for phenytoin. This induction leads to increased phenytoin metabolism and reduction in therapeutic blood levels by up to 50-70%. Phenytoin itself is a moderate enzyme inducer, which may enhance this effect.","             (10-20 /).           .            .","Failure to control epileptic seizures due to phenytoin levels falling below therapeutic range (10-20 mcg/mL). Increased frequency and severity of seizures, with risk of life-threatening status epilepticus. Phenytoin withdrawal symptoms may appear despite continued administration of usual dose.","        4-6    .     50-100     .           (  ).       .","Monitor phenytoin blood levels weekly during the first 4-6 weeks of apalutamide initiation. Increase phenytoin dose by 50-100% with continued periodic monitoring. Consider alternative antiepileptics not affected by enzyme inducers (e.g., levetiracetam, gabapentin). Readjust phenytoin dose after apalutamide discontinuation.");n("Apalutamide - ","Dexamethasone - ",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    .           40-60.      UGT1A1    .","Apalutamide is a strong inducer of CYP3A4 enzyme responsible for dexamethasone metabolism. This leads to increased dexamethasone clearance and reduction in systemic exposure by 40-60%. Apalutamide also induces UGT1A1 enzyme involved in steroid metabolism.","     .        .                  .","Reduced anti-inflammatory and immunosuppressive efficacy of dexamethasone. Failure to control inflammatory or autoimmune diseases. In cancer patients, may lead to failure in controlling chemotherapy-induced nausea/vomiting or cerebral edema.","    50-100      .       .      .             NK1 .","Increase dexamethasone dose by 50-100% with close clinical monitoring of therapeutic response. Monitor for signs of uncontrolled underlying disease. Re-evaluate dose after apalutamide discontinuation. For chemotherapy-induced nausea/vomiting, consider alternative NK1 receptor antagonists.");n("Apixaban","Food",e.DRUG_FOOD,i.LOW," (    )   :          .      : (1)   (AUC)        -           (2)   (Cmax)     (3)    (Tmax)     ( 30-60 )         (4)      .              .","Apixaban (another direct oral anticoagulant) has unique property: its absorption is completely independent of food presence or absence in stomach. Comprehensive pharmacokinetic studies showed: (1) bioavailability (AUC) remains stable regardless of food status - no statistical or clinical difference between empty stomach and fatty meal, (2) maximum concentration (Cmax) not noticeably affected, (3) time to peak (Tmax) may delay very slightly (30-60 minutes) with food but this is clinically irrelevant, (4) final anticoagulant effect completely identical. This property gives apixaban major advantage in flexibility and ease of use compared to rivaroxaban.","        .   (         )   ( )          .  : (1)       (2)              (3)          .","No clinically significant interaction between apixaban and food. Therapeutic efficacy (preventing strokes in atrial fibrillation, treating and preventing venous clots) and safety profile (bleeding risk) remain identical whether patient takes drug with or without food. This means: (1) complete flexibility in timing relative to meals, (2) no need to worry if patient forgets to take with meal or is fasting, (3) same thrombosis protection and safety profile in all circumstances.","  : (1) **      ** -       (2) :       (      ) -        (3)  : 5    ( 2.5        ) (4)  :           -       8  8      (5)   :            6 .      6         (6) **     **: ()    ()    NSAIDs   ()         (   -      ) ()       (7) ** **:               (8)   :    (24-48     ) -     (9)       :    -   (10) **  **:         -         .","Simple, convenient instructions: (1) **Apixaban can be taken with or without food** - choice left to patient comfort and personal preference, (2) most important: take at same time each day (morning and evening if twice-daily dosing) - timing consistency more important than food relationship, (3) usual dose: 5mg twice daily (or 2.5mg twice daily for some patients per specific factors), (4) practical tip: many patients prefer linking drug to certain routine for easy remembering - e.g., with breakfast and dinner, or 8 AM and 8 PM regardless of food, (5) if missed dose: take immediately if remembered and next dose is more than 6 hours away. If next dose within 6 hours or less, skip missed dose and don't double, (6) **Same warnings as other anticoagulants apply**: (a) monitor bleeding signs, (b) avoid NSAIDs as much as possible, (c) beware dangerous drug interactions with other medications (like ketoconazole, rifampicin - inform any doctor you're taking apixaban), (d) don't stop suddenly without consulting physician, (7) **Additional advantage**: apixaban causes less gastrointestinal bleeding than some other anticoagulants in some studies, (8) before surgical procedures: must temporarily discontinue (usually 24-48 hours depending on surgery type) - discuss with physician in advance, (9) if you have mechanical prosthetic heart valves: apixaban unsuitable - warfarin used, (10) **Treatment adherence crucial**: even one missed dose reduces clot protection - use alarms or weekly pill organizer to help remember.");n("Dabigatran","Food",e.DRUG_FOOD,i.LOW,"       (Tmax)              (AUC)    (Cmax).","Food delays the time to reach maximum concentration (Tmax) for Dabigatran by approximately two hours, but there is no significant clinical effect on overall absorption (AUC) or maximum concentration (Cmax).","               .             .","A slight delay in the onset of anticoagulant action, but the overall long-term therapeutic effect remains unchanged. Taking it with food may help reduce gastrointestinal side effects like dyspepsia.","     .                 .","Can be taken with or without food. Recommended to be taken with food if the patient experiences dyspepsia or heartburn to improve gastric tolerance.");n("Apixaban - ","Ketoconazole - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4   P-glycoprotein       .                  100-150    (AUC)  60-100.","Ketoconazole potently inhibits both hepatic CYP3A4 enzyme and intestinal P-glycoprotein transporter, which are responsible for apixaban metabolism and excretion. This dual inhibition leads to a significant increase in apixaban systemic exposure, with plasma concentrations rising by 100-150% and area under curve (AUC) by 60-100%.","             2-3 .                .             .","Significant enhancement of anticoagulant effect, leading to 2-3 fold increased bleeding risk. This includes gastrointestinal bleeding, intracranial hemorrhage, and other site bleeding that may be life-threatening. Risk is higher in elderly, low body weight patients, or those with renal impairment.","    50     ( 5     2.5      2.5     2.5   ).    .       .         .","Reduce apixaban dose by 50% when combined with ketoconazole (from 5 mg twice daily to 2.5 mg twice daily, or from 2.5 mg twice daily to 2.5 mg once daily). Monitor for clinical bleeding signs. Avoid combination in patients at high bleeding risk. Consider alternative antifungal agents with less enzyme inhibition.");n("Apixaban - ","Carbamazepine - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4  P-glycoprotein      .                  50-70    (AUC)  30-50.","Carbamazepine is a strong inducer of both CYP3A4 enzyme and P-glycoprotein transporter, which are responsible for apixaban metabolism and excretion. This dual induction leads to a sharp decrease in apixaban systemic exposure, with plasma concentrations dropping by 50-70% and area under curve (AUC) by 30-50%.","            3-4 .                .       .","Complete therapeutic failure in thrombosis prevention, with 3-4 fold increased thrombosis risk. This includes risk of pulmonary embolism, deep vein thrombosis, and stroke in atrial fibrillation patients. Thrombotic events may occur despite treatment adherence.","    .                (    INR).                     .","Absolute contraindication for combination. Use alternative anticoagulants not affected by enzyme inducers such as low molecular weight heparin or warfarin (with close INR monitoring). If combination is unavoidable, apixaban dose may need to be more than doubled with frequent monitoring for thrombotic signs.");n("Apremilast","Rifampin",e.DRUG_DRUG,i.HIGH,"  Apremilast. Rifampin    CYP3A4      Apremilast.","Decreased Apremilast efficacy. Rifampin is a potent CYP3A4 inducer, the major metabolic pathway for Apremilast.","               .","Reduced drug plasma levels, leading to loss of control over psoriasis or psoriatic arthritis."," .   Rifampin     CYP3A4.","Avoid Combination. Rifampin must be replaced with an antibiotic that does not induce CYP3A4.");n("Apremilast","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Apremilast. Phenytoin    CYP3A4  CYP1A2    Apremilast.","Decreased Apremilast concentration. Phenytoin is a strong inducer of CYP3A4 and CYP1A2, Apremilast metabolic pathways.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP .","Avoid Combination. Strong CYP inducers must be avoided.");n("Aprepitant","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Aprepitant   CYP3A4    .","Decreased oral contraceptive concentration. Aprepitant is an inducer of CYP3A4, a hormone metabolic pathway.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .                 Aprepitant.","Relative contraindication. An additional non-hormonal or alternative contraceptive method must be used for one month after the last Aprepitant dose.");n("Aprepitant - ","Warfarin - ",e.DRUG_DRUG,i.MODERATE,"     CYP2C9       S-   ( ).        CYP3A4      .          .","Aprepitant moderately inhibits hepatic CYP2C9 enzyme, the primary metabolic pathway for the more potent S-isomer of warfarin. It also has a moderate effect on CYP3A4 enzyme which is also involved in warfarin metabolism. This leads to decreased warfarin clearance and increased plasma concentrations.","              INR  7-10    .   INR      4          .","Gradual decrease in warfarin anticoagulant effect during initial days, followed by significant INR elevation after 7-10 days of starting aprepitant. INR may reach dangerous levels above 4, increasing bleeding risk, particularly gastrointestinal bleeding and extensive bruising."," INR  :      3-5     7-10    14    .        15-30   .      2-4    .","Monitor INR frequently: before starting aprepitant, then after 3-5 days, again after 7-10 days, and finally after 14 days of therapy initiation. May need to reduce warfarin dose by 15-30% when starting aprepitant. Continue weekly monitoring for 2-4 weeks after aprepitant discontinuation.");n(Qh,"Lithium",e.DRUG_DRUG,i.HIGH,": **   **.    (ARBs)        .","Mechanism: **Reduced renal lithium excretion**. ARBs decrease glomerular filtration pressure and increase lithium reabsorption."," : **    ** (   ).    ACE     .","Clinical Significance: **Increased lithium levels and toxicity risk** (tremor, diarrhea, vomiting, ataxia). Interaction is similar to ACE inhibitors but may develop more slowly.","   .        ARB.","Monitor lithium levels regularly. Lithium dose reduction may be required when adding an ARB.");n("Aripiprazole - ","Ketoconazole - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4      .         CYP2D6  .                  60-70    (AUC)  40-50.","Ketoconazole potently inhibits hepatic CYP3A4 enzyme, the primary metabolic pathway for aripiprazole. Aripiprazole is also metabolized secondarily via CYP2D6 enzyme. This dual inhibition leads to significant reduction in aripiprazole clearance and increases plasma concentrations by up to 60-70%, with area under curve (AUC) increasing by 40-50%.","       :   ()          .            .                 .","Significant increase in aripiprazole pharmacological effects and side effects, including: akathisia, excessive somnolence, dizziness, orthostatic hypotension, and other extrapyramidal symptoms. In severe cases, may lead to neuroleptic malignant syndrome or neurotoxicity. Risk is higher in patients taking high aripiprazole doses or those with impaired liver function.","        .     10-15 /    5-7.5 /.       .      .           .","Reduce aripiprazole dose by half when initiating with ketoconazole. If patient is taking 10-15 mg/day, reduce dose to 5-7.5 mg/day. Closely monitor for neurological and psychiatric side effects. Readjust dose after ketoconazole discontinuation. Consider alternative antifungal agents with less enzyme inhibition if possible.");n("Aripiprazole - ","Encorafenib - ",e.DRUG_DRUG,i.MODERATE,"    CYP3A4      .             20-30.       CYP2C9       .","Encorafenib is a moderate inducer of hepatic CYP3A4 enzyme, the primary metabolic pathway for aripiprazole. This induction leads to increased aripiprazole metabolism and reduction in plasma concentrations by 20-30%. Encorafenib may also induce CYP2C9 enzyme which is secondarily involved in aripiprazole metabolism.","             .          .                .","Reduced therapeutic efficacy of aripiprazole, potentially leading to worsening psychiatric symptoms or disease relapse. May manifest as psychological instability or mild withdrawal symptoms. Risk is higher in patients relying on high aripiprazole doses for acute psychotic symptom control.","          .        25-50    .     2-3    .         .","Monitor aripiprazole therapeutic response closely when starting or stopping encorafenib. May need to increase aripiprazole dose by 25-50% to maintain therapeutic efficacy. Re-evaluate dose after 2-3 weeks of encorafenib initiation. Regular psychiatric monitoring to detect any clinical deterioration.");n("Alfentanil - ","Aripiprazole - ",e.DRUG_DRUG,i.MODERATE,"     CYP3A4      .             20-40.                      .","Aripiprazole moderately inhibits hepatic CYP3A4 enzyme, the primary metabolic pathway for alfentanil. This inhibition leads to reduced alfentanil metabolism and increased plasma concentrations by 20-40%. Additionally, both drugs have sedative and CNS depressant effects, which may lead to synergistic respiratory depression.","                    .          .                    .","Enhanced sedative and respiratory depressant effects of alfentanil, potentially leading to deeper and prolonged respiratory depression with risk of hypoxia. May also increase incidence of dizziness, excessive somnolence, and hypotension. Risk is higher in elderly, patients with pulmonary diseases, or when using high doses of either drug.","    25-30    .            .          .        ( )   .","Reduce alfentanil dose by 25-30% when used with aripiprazole. Close monitoring of vital signs, particularly respiratory rate and oxygen saturation, during and after administration. Avoid high aripiprazole doses prior to procedures requiring anesthesia. Ensure availability of resuscitation equipment and opioid antagonists (e.g., naloxone) for emergencies.");n("Asciminib - ","Itraconazole - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4      .               150-200 (  2.5-3      AUC).","Itraconazole potently inhibits hepatic CYP3A4 enzyme, the primary metabolic pathway for asciminib. This inhibition leads to decreased asciminib clearance and increased plasma concentrations by up to 150-200% (2.5-3 fold increase in AUC).","           (     )   QT    (     ).         .","Significant increase in asciminib-associated toxicity, particularly myelosuppression (neutropenia, thrombocytopenia, anemia), QT prolongation, and elevated pancreatic enzymes (which may progress to pancreatitis). These effects may occur even with usual asciminib doses.","    20          CYP3A4  .         .           3-5  .","Reduce asciminib dose to 20 mg once daily when combined with itraconazole or other strong CYP3A4 inhibitors. Monitor complete blood count, ECG, and pancreatic enzymes weekly. Resume normal dose after discontinuing itraconazole for a period equivalent to 3-5 half-lives.");n("Asciminib - ","Phenytoin - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4        .              70-80 (    AUC  20-30   ).","Phenytoin is a strong inducer of hepatic CYP3A4 enzyme, significantly increasing asciminib metabolism. This leads to a sharp decrease in asciminib plasma concentrations by up to 70-80% (AUC reduced to 20-30% of normal levels).","          (CML)       .          .","Complete therapeutic failure in controlling chronic myeloid leukemia (CML), with risk of treatment resistance development and disease relapse. Loss of molecular and cytogenetic response, and potential disease progression to more advanced stages.","    .        CYP3A4 (    ).                3      .","Absolute contraindication for combination. Use alternative antiepileptics that do not induce CYP3A4 enzyme (e.g., levetiracetam, gabapentin, or valproate). If combination is unavoidable, asciminib dose may need to be more than tripled with frequent therapeutic level monitoring.");n("Asciminib - ","Proton Pump Inhibitors (Omeprazole) -    ()",e.DRUG_DRUG,i.MODERATE,"            (      )  .         40-50.","Proton pump inhibitors increase gastric pH, reducing the solubility of asciminib (a poorly soluble drug in alkaline medium) and impairing its absorption. This leads to decreased systemic exposure to asciminib by 40-50%.","              .             .","Reduced therapeutic efficacy of asciminib, with risk of losing molecular response in CML treatment. Disease progression or development of resistance mutations may occur due to inadequate therapeutic levels.","         . :    H2 ( )            .     .","Take asciminib at least 2 hours before proton pump inhibitors. Alternative: use H2 receptor antagonists (e.g., famotidine) with 2-hour separation, or antacids with 1-hour separation. Monitor therapeutic response closely.");n("Asciminib - ","Strong CYP3A4 Inhibitors (Clarithromycin) -  CYP3A4  ()",e.DRUG_DRUG,i.MODERATE," CYP3A4              2.2  ( 120     AUC).    2-3    .","Strong CYP3A4 inhibitors like clarithromycin inhibit asciminib metabolism, increasing its plasma concentrations by 2.2-fold (120% increase in AUC). The effect begins within 2-3 days of inhibitor initiation.","         ( )      QT.         .","Increased risk of asciminib-associated toxicity, particularly elevated pancreatic enzymes (amylase and lipase), myelosuppression, and QT prolongation. These effects may appear even with standard asciminib doses.","    40        CYP3A4 .         .        .","Reduce asciminib dose to 40 mg once daily when combined with strong CYP3A4 inhibitors. Monitor pancreatic enzymes, complete blood count, and ECG weekly. Resume normal dose after discontinuing the inhibitor.");n("Asciminib - ","Strong CYP3A4 Inducers (St. John's Wort) -  CYP3A4  (  )",e.DRUG_DRUG,i.HIGH,"      CYP3A4   PXR            60-70.     3-5     .","St. John's Wort potently induces CYP3A4 enzyme and activates nuclear PXR receptors, increasing asciminib clearance and reducing systemic exposure by 60-70%. This effect begins within 3-5 days and persists throughout use.","                       .","Complete therapeutic failure in controlling CML, with risk of losing molecular and cytogenetic response, development of treatment resistance, and disease progression to blast phase.","       .       .               .","Completely avoid St. John's Wort during asciminib therapy. Educate patients about risks associated with herbal supplements. If exposure occurs, monitor asciminib therapeutic levels and increase dose as needed with close toxicity monitoring.");n("Asparaginase","Methotrexate",e.DRUG_DRUG,i.MODERATE,"  Methotrexate. Asparaginase      (Serum protein binding)  Methotrexate.","Increased Methotrexate toxicity. Asparaginase decreases the serum protein binding of Methotrexate.","  Methotrexate          .","Elevated free Methotrexate levels, increasing the risk of bone marrow suppression and mucositis."," .    Methotrexate       (Leucovorin Rescue).","Level monitoring. Plasma Methotrexate levels must be closely monitored to adjust the Leucovorin rescue dose.");n("Aspirin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"   COX-1.            Cyclooxygenase (COX-1).","Competition for COX-1 enzyme. Ibuprofen competitively and reversibly blocks the binding site on platelet COX-1, preventing Aspirin (Acetylsalicylic Acid) from irreversibly acetylating the enzyme.","      .          .","Reduced Aspirin antiplatelet effect. Decreases the cardiovascular protective benefit of low-dose Aspirin when Ibuprofen is taken shortly before or after.","  .                .","Avoid concomitant administration. If both are necessary, administer Aspirin at least 2 hours before or 8 hours after Ibuprofen to minimize the competition at the COX-1 binding site.");n("Aspirin","Prednisone",e.DRUG_DRUG,i.HIGH,"     ( ) .             .","Corticosteroids increase the renal clearance of salicylate (Aspirin metabolite). Upon discontinuation of the corticosteroid, the clearance falls rapidly, leading to a spike in Aspirin plasma levels (toxicity risk).","          .","Increased Aspirin toxicity (salicylism risk) due to elevated levels, combined with a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.","  .                .","Avoid concurrent use. If necessary, adjust the Aspirin dose (usually reduction) upon initiating the corticosteroid and monitor closely for signs of GI bleeding and salicylate toxicity.");n("Aspirin","Prednisolone",e.DRUG_DRUG,i.HIGH,"     ( ) .             .","Corticosteroids increase the renal clearance of salicylate (Aspirin metabolite). Upon discontinuation of the corticosteroid, the clearance falls rapidly, leading to a spike in Aspirin plasma levels (toxicity risk).","          .","Increased Aspirin toxicity (salicylism risk) due to elevated levels, combined with a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.","  .                .","Avoid concurrent use. If necessary, adjust the Aspirin dose (usually reduction) upon initiating the corticosteroid and monitor closely for signs of GI bleeding and salicylate toxicity.");n("Aspirin","Hydrocortisone",e.DRUG_DRUG,i.HIGH,"     ( ) .             .","Corticosteroids increase the renal clearance of salicylate (Aspirin metabolite). Upon discontinuation of the corticosteroid, the clearance falls rapidly, leading to a spike in Aspirin plasma levels (toxicity risk).","          .","Increased Aspirin toxicity (salicylism risk) due to elevated levels, combined with a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.","  .                .","Avoid concurrent use. If necessary, adjust the Aspirin dose (usually reduction) upon initiating the corticosteroid and monitor closely for signs of GI bleeding and salicylate toxicity.");n("Aspirin","Dexamethasone",e.DRUG_DRUG,i.HIGH,"     ( ) .             .","Corticosteroids increase the renal clearance of salicylate (Aspirin metabolite). Upon discontinuation of the corticosteroid, the clearance falls rapidly, leading to a spike in Aspirin plasma levels (toxicity risk).","          .","Increased Aspirin toxicity (salicylism risk) due to elevated levels, combined with a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.","  .                .","Avoid concurrent use. If necessary, adjust the Aspirin dose (usually reduction) upon initiating the corticosteroid and monitor closely for signs of GI bleeding and salicylate toxicity.");n("Aspirin","Betamethasone",e.DRUG_DRUG,i.HIGH,"     ( ) .             .","Corticosteroids increase the renal clearance of salicylate (Aspirin metabolite). Upon discontinuation of the corticosteroid, the clearance falls rapidly, leading to a spike in Aspirin plasma levels (toxicity risk).","          .","Increased Aspirin toxicity (salicylism risk) due to elevated levels, combined with a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.","  .                .","Avoid concurrent use. If necessary, adjust the Aspirin dose (usually reduction) upon initiating the corticosteroid and monitor closely for signs of GI bleeding and salicylate toxicity.");n("Aspirin","Methylprednisolone",e.DRUG_DRUG,i.HIGH,"     ( ) .             .","Corticosteroids increase the renal clearance of salicylate (Aspirin metabolite). Upon discontinuation of the corticosteroid, the clearance falls rapidly, leading to a spike in Aspirin plasma levels (toxicity risk).","          .","Increased Aspirin toxicity (salicylism risk) due to elevated levels, combined with a synergistic increase in the risk of serious gastrointestinal ulceration and bleeding.","  .                .","Avoid concurrent use. If necessary, adjust the Aspirin dose (usually reduction) upon initiating the corticosteroid and monitor closely for signs of GI bleeding and salicylate toxicity.");n("Aspirin","Peptic Ulcer (Active)",e.DRUG_DISEASE,i.HIGH,"                 .","Irritation and Inhibition. Aspirin causes direct mucosal injury, inhibits protective prostaglandin synthesis (due to COX inhibition), and impairs platelet function, severely compromising the integrity of the ulcer site.","     .   (Hemorrhage)   .","Severe Gastrointestinal Hemorrhage and Perforation. High risk of life-threatening bleeding and ulcer complications.","             .","Avoid Aspirin completely in patients with active peptic ulcer disease or recent GI bleeding unless the cardiovascular indication is critical and managed with maximal protective therapy (e.g., PPIs).");n("Aspirin","Heart Failure (Congestive)",e.DRUG_DISEASE,i.MODERATE,"  .    ( )           .","Fluid Retention. Aspirin (particularly at anti-inflammatory doses) inhibits renal prostaglandin synthesis, which can lead to sodium and water retention, exacerbating volume overload.","   .           .","Worsening Heart Failure. Exacerbation of volume overload, pulmonary congestion, and symptoms of heart failure.","           .    ( )     .","Avoid high-dose Aspirin in patients with unstable or severe heart failure. Low-dose cardioprotective Aspirin is generally acceptable but requires close monitoring for signs of fluid retention and worsening failure.");n("Aspirin - ","Peptic Ulcer -  ",e.DRUG_DISEASE,i.HIGH,"   COX-1 COX-2        ( PGE2 PGI2).                      .","Aspirin inhibits COX-1 and COX-2 enzymes, reducing synthesis of protective gastric prostaglandins (particularly PGE2 and PGI2). This leads to decreased mucus and bicarbonate secretion, increased gastric acid secretion, and impaired mucosal blood flow, compromising the protective barrier of stomach and duodenum.","      (    )              .        .","Exacerbation of existing peptic ulcers, gastrointestinal bleeding (which may be massive and life-threatening), perforation of gastric or duodenal wall, severe abdominal pain, and failure of ulcer healing. Risk is higher in elderly, smokers, and alcohol users.","       .    :               .     .","Avoid aspirin in patients with active peptic ulcers. If absolutely necessary: use lowest effective dose, combine with high-dose proton pump inhibitors, and employ gastric protective coverage. Close monitoring for GI bleeding symptoms.");n("Aspirin - ","Carbonic Anhydrase Inhibitors -   ",e.DRUG_DRUG,i.HIGH,"       ( )              .               -.","Aspirin increases concentrations of carbonic anhydrase inhibitors (e.g., acetazolamide) by displacing them from protein binding sites, increasing the free active form. Both drugs also cause metabolic acidosis, creating a synergistic effect on acid-base balance disruption.","      :          .      (   )    .","Increased systemic toxicity of carbonic anhydrase inhibitors, including: severe metabolic acidosis, encephalopathy, coma, renal toxicity, and electrolyte disturbances. Salicylate toxicity symptoms (tinnitus, dizziness, hyperpnea) may appear at lower than usual levels.","   .   :         .     .        .","Completely avoid combination. If exposure occurs: closely monitor arterial blood gases, electrolytes, and neurological function. Immediate treatment of metabolic acidosis. Use aspirin alternatives like paracetamol for pain control.");n("Aspirin - ","Corticosteroids - ",e.DRUG_DRUG,i.MODERATE,"          ( UGTs)   .                 .","Corticosteroids increase salicylate clearance by inducing hepatic enzymes (particularly UGTs) and enhancing renal excretion. Upon corticosteroid discontinuation, sudden reversal of this effect occurs, leading to salicylate accumulation and increased toxicity risk.","   :            .           .","Fluctuations in salicylate levels: reduced therapeutic efficacy during corticosteroid use, followed by salicylate toxicity risk after discontinuation. Toxicity symptoms include tinnitus, hyperventilation, metabolic acidosis, and encephalopathy.","        .     25-50        .      .","Monitor salicylate blood levels during and after corticosteroid therapy. Increase aspirin dose by 25-50% during combination, then gradually reduce after corticosteroid discontinuation. Educate patient about salicylate toxicity symptoms.");n("Aspirin - ","Anticoagulants -  ",e.DRUG_DRUG,i.HIGH,"            COX-1     .      (  DOACs)       :      .","Aspirin irreversibly inhibits platelet function via COX-1 inhibition, impairing primary platelet aggregation. When combined with anticoagulants (warfarin, heparin, DOACs), this attacks the hemostatic system from two independent pathways: platelet pathway and coagulation cascade.","      2-4 .        .            .","Significant 2-4 fold increase in bleeding risk. Includes gastrointestinal, intracranial, muscular, and articular bleeding. Bleeding may be massive and life-threatening even with low aspirin doses.","         (       ).   :     (81 /)        .","Avoid combination unless proven benefit outweighs risk (e.g., mechanical valves or acute coronary syndrome). If necessary: use lowest aspirin dose (81 mg/day), close bleeding monitoring, and gastric protection with PPIs.");n("Aspirin - ","Apixaban - ",e.DRUG_DRUG,i.HIGH,"       -1 (COX-1)         A2    .       Xa        .           (   )        .","Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, reducing thromboxane A2 production and impairing platelet aggregation. Apixaban directly and competitively inhibits factor Xa in the coagulation cascade, decreasing thrombin formation. This combination attacks hemostasis from two independent but complementary pathways (platelets and coagulation cascade), creating a powerful synergistic anticoagulant effect.","           2-3       .         (   )    .                   .","Significant increase in bleeding risk, with major bleeding rates 2-3 times higher compared to either drug alone. This includes gastrointestinal bleeding, intracranial hemorrhage (which may be fatal), and bleeding at other sites. Risk is higher in elderly patients, those with renal impairment, or those taking high aspirin doses.","          (           ).    : 1)       ( 81 /) 2)       3)        4)    .","Avoid combination unless there is a clear established benefit outweighing the risk (e.g., thrombosis prevention in mechanical valves or acute coronary syndrome). If combination is necessary: 1) Use the lowest effective aspirin dose (typically 81 mg/day) 2) Monitor patient closely for bleeding signs 3) Consider gastric protection with proton pump inhibitors 4) Regularly reassess risk-benefit ratio.");n("Aspirin","Insulin/Antidiabetics",e.DRUG_DRUG,i.MODERATE," ( )         :             .","Aspirin (especially at higher doses) potentiates the hypoglycemic effect of insulin and oral antidiabetic agents (Sulfonylureas) through multiple mechanisms: enhancing insulin secretion, improving insulin sensitivity, and displacing Sulfonylureas from plasma protein binding sites.","     (Hypoglycemia).","Increased risk of hypoglycemia (dangerously low blood sugar) due to the additive effects on glucose lowering.","     .                 .","Monitor blood glucose levels closely. Adjust the doses of insulin or antidiabetic agents as necessary, especially when initiating or discontinuing high-dose Aspirin therapy.");n("Aspirin - ","Aspirin - ",e.DRUG_DRUG,i.HIGH,"              COX-1 COX-2.   COX-1                     .","Taking multiple doses or different preparations of aspirin leads to cumulative and synergistic inhibition of COX-1 and COX-2 enzymes. Aspirin irreversibly inhibits platelet COX-1, and additional doses enhance this inhibition in other tissues, particularly gastric mucosa and kidneys.","            .                .","Exponential increase in gastrointestinal bleeding risk, gastric ulcers, intestinal perforation, and acute renal toxicity. Life-threatening GI bleeding may occur even with moderate doses when combining multiple preparations.","      .       .     .        .","Completely avoid combining different aspirin preparations. Use lowest effective dose for single purpose only. Monitor for bleeding signs and renal function. Educate patients about unintentional overdose risks.");n("Aspirin - ","Ibuprofen - ",e.DRUG_DRUG,i.HIGH,"         COX-1          .            .","Ibuprofen competes with aspirin for the COX-1 binding site, potentially preventing aspirin from achieving its irreversible platelet inhibition. Their combination also causes synergistic inhibition of protective prostaglandins in stomach and kidneys.","             (4-6 )      .","Failure of cardiovascular protection from aspirin, significant increase in GI bleeding risk (4-6 fold), acute renal failure, and hypertension."," .           .     .    .","Avoid combination. If necessary, take aspirin at least 2 hours before ibuprofen. Monitor GI symptoms and renal function. Use paracetamol as analgesic alternative.");n("Aspirin - ","Diclofenac - ",e.DRUG_DRUG,i.HIGH,"     COX-2   COX-1 .                   .","Diclofenac has high affinity for COX-2 but also inhibits COX-1. When combined with aspirin, synergistic inhibition of both enzymes occurs, with particularly devastating effects on gastric mucosa and renal function.","     (       )        .","Severe risk of GI bleeding and ulcers (higher than most other NSAIDs), increased hepatorenal toxicity, and failure of cardiac protection.","  .        .       .","Completely avoid combination. Monitor liver enzymes and renal function if forced combination. Use safer alternatives for pain control.");n("Aspirin - ","Naproxen - ",e.DRUG_DRUG,i.HIGH,"     (12-17 )      COX-1.              .","Naproxen has long half-life (12-17 hours) and causes strong, sustained COX-1 inhibition. When combined with aspirin, this creates continuous and intensive prostaglandin inhibition exposure in all tissues.","            .       .","Prolonged and continuous GI bleeding, intestinal ulcers, progressive renal toxicity, and severe fluid retention. Risk persists for several days after last dose.","     .       .        .","Avoid combination, especially in elderly. If used, intensive GI and renal monitoring required. Long washout period needed before returning to aspirin alone.");n("Aspirin - ","Ketoprofen - ",e.DRUG_DRUG,i.HIGH,"      COX-1        .          .","Ketoprofen has potent COX-1 inhibitory effects and particularly interferes with aspirin's antiplatelet activity. Combination causes dual and dangerous inhibition of protective pathways in stomach and kidneys.","            .        .","Acute GI bleeding, rapid renal failure, and ineffectiveness of aspirin in thrombosis prevention. Spontaneous bleeding may occur even with low doses.","  .       .       .","Relative contraindication. Completely avoid in high-risk patients. Monitor platelet function if forced combination.");n("Aspirin - ","Indomethacin - ",e.DRUG_DRUG,i.HIGH,"    COX    .               .","Indomethacin is one of the most potent COX inhibitors and causes comprehensive prostaglandin inhibition. When combined with aspirin, produces devastating synergistic effects on gastric mucosa and renal vasculature.","                   .","Highest rate of GI ulcers and bleeding among NSAIDs, acute and rapid renal failure, and encephalopathy in elderly patients.","  .          .     .","Complete and absolute avoidance. Use only in exceptional cases under intensive medical supervision. Neurological monitoring in elderly.");n("Aspirin - ","Celecoxib - ",e.DRUG_DRUG,i.MODERATE,"   COX-2     COX-1             COX       .","Celecoxib selectively inhibits COX-2 with minimal COX-1 effect, but combination with aspirin abolishes this selectivity and leads to dual COX pathway inhibition, while maintaining some GI and renal risks.","      (      )       .    .","Moderate increase in GI bleeding risk (less than traditional NSAIDs), but with persistent renal and cardiovascular risks. Additional cardiovascular risks.","    .       .     .      .","Can combine cautiously with monitoring. Use lowest possible doses of both drugs. Monitor blood pressure and renal function. Avoid in patients with cardiovascular diseases.");n("Aspirin - ","Mefenamic Acid -  ",e.DRUG_DRUG,i.HIGH,"         COX   .               .","Mefenamic acid has unique properties inhibiting both COX forms and causes intestinal spasms. Combination with aspirin significantly increases intestinal and renal toxicity, with special risk to colon.","         .     .","Lower GI bleeding, colitis, severe intestinal cramps, and renal failure. May mimic ulcerative colitis.","  .      .      .","Completely avoid combination. Special risk for patients with colon diseases. Careful intestinal monitoring if forced combination.");n("Aspirin","Methotrexate",e.DRUG_DRUG,i.HIGH,"                 .","Aspirin significantly reduces the renal clearance of Methotrexate (MTX) by inhibiting its tubular secretion, and also displaces it from plasma protein binding sites, leading to drastically increased free MTX levels.","  .","Increased Methotrexate toxicity, potentially leading to severe, life-threatening myelosuppression (bone marrow suppression) and hepatotoxicity.","     (  ).    .        .","Avoid co-administration, especially with high-dose MTX. Monitor MTX plasma concentrations, renal function, and complete blood count (for bone marrow suppression) very closely. A reduction in the MTX dose is often mandatory.");n("Aspirin","Probenecid",e.DRUG_DRUG,i.MODERATE,"  (     2 /)             .","Aspirin (especially at low doses, <2 g/day) competitively inhibits the uricosuric effect of Probenecid by interfering with its transport mechanism in the renal tubules.","      .","Reduced effectiveness of Probenecid. This leads to inadequate control of hyperuricemia and potential exacerbation of gout.","  .         ( )      .","Avoid this combination if the patient relies on Probenecid for uricosuric therapy. If low-dose Aspirin is essential, consider alternative anti-gout medication (e.g., allopurinol).");n("Aspirin","Sulfonylurea (e.g., Glimepiride, Glyburide)",e.DRUG_DRUG,i.MODERATE," (  )             (    ).","Aspirin (especially at high doses) potentiates the hypoglycemic effect of Sulfonylureas by displacing them from plasma protein binding sites, increasing the free drug concentration.","    .","Increased risk of hypoglycemia (dangerously low blood sugar) due to the synergistic effects.","    .           (  )       .","Monitor blood glucose levels closely. Adjust the Sulfonylurea dose (typically reduce it) when initiating or discontinuing high-dose Aspirin therapy.");n("Aspirin","Valproic Acid",e.DRUG_DRUG,i.MODERATE,"           ()          .","Aspirin displaces Valproic Acid from its plasma protein binding sites and inhibits its metabolism. This leads to increased levels of unbound (free) Valproic Acid.","   .","Increased Valproic Acid toxicity and risk of adverse effects.","       (   ).          .","Monitor free and total Valproic Acid concentrations closely. Clinical toxicity (nausea, vomiting, sedation, tremor) is likely. A reduction in the Valproic Acid dose may be necessary.");n("Aspirin","Alcohol",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Caffeine",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Green Tea",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Milk",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","High-fat meals",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","High-fiber foods",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Vitamin C",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Vitamin D",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Vitamin E",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Vitamin K",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Vitamin B12",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Folic Acid",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Iron",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Calcium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Magnesium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Zinc",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Potassium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin","Antacids",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Aspirin (High Dose)","Methotrexate",e.DRUG_DRUG,i.HIGH,"  Methotrexate.        Methotrexate.","Increased Methotrexate concentration. Aspirin reduces renal tubular clearance of Methotrexate.","   Methotrexate (    ).","Increased risk of Methotrexate toxicity (myelosuppression, renal toxicity).","      .     .","Avoid combination at high Aspirin doses. Close monitoring at low doses.");n("Aspirin (High Dose)","Vitamin C (High Dose)",e.DRUG_FOOD,i.MODERATE," C ( )   (  1000  )         : (1)  pH  ( )                (2)     (  )            (3)       . :            30-50%.","Vitamin C (ascorbic acid) at high doses (>1000mg daily) affects aspirin absorption and levels through several mechanisms: (1) lowers gastric pH (increases acidity), increasing non-ionized aspirin form that absorbs more easily across gastric mucosa, (2) reduces urinary salicylate (active aspirin metabolite) excretion via urine acidification, prolonging drug retention in body, (3) may increase aspirin plasma protein binding. Result: aspirin and metabolite accumulation with blood concentration rise up to 30-50%.","           (salicylism)        (  3-4    ).   :     (tinnitus) -                        :   -  .             C        .","Increased blood aspirin levels with salicylism toxicity symptoms risk, especially with high aspirin doses (>3-4g daily for rheumatic conditions). Toxicity symptoms include: persistent tinnitus (ringing in ears) - first and most important sign, temporary or permanent hearing loss, nausea and vomiting, dizziness and vertigo, profuse sweating, hyperventilation, confusion and mental disorientation, and in very severe cases: acid-base balance disturbance, seizures, coma. Also increased gastrointestinal bleeding risk as both aspirin and high-dose vitamin C can irritate gastric mucosa.","       (  3  )        : (1)     C   (  500  ) (2)       C (      )    (3)   C        (50-200  ).      (75-100     ):           C.   :     -     .    C    .     C           .","If taking high aspirin doses (>3g daily) for conditions like rheumatoid arthritis or rheumatic fever: (1) completely avoid high-dose vitamin C supplements (>500mg daily), (2) limit foods extremely rich in vitamin C (very large citrus amounts, bell peppers, kiwi) to moderate quantities, (3) natural vitamin C amounts from balanced diet usually safe (50-200mg daily). For patients on low-dose aspirin (75-100mg daily for clot prevention): interaction less significant but avoid excessive vitamin C supplements. Monitor toxicity signs: tinnitus is early warning sign - inform physician immediately if appears. Avoid unnecessary vitamin C supplements. If needing vitamin C for documented deficiency treatment, inform physician for aspirin dose adjustment if needed.");n("Aspirin / NSAIDs","Aspirin-Exacerbated Respiratory Disease (AERD)",e.DRUG_DISEASE,i.HIGH," COX-1            .","COX-1 inhibition shunts arachidonic acid metabolism towards the leukotriene pathway, causing acute bronchoconstriction.","       (Asthma Attack)     .","Life-threatening acute asthma attack within minutes, often accompanied by rhinitis and nasal polyps.","   NSAIDs  .    (   COX-2 ).","Absolute avoidance of Aspirin and all NSAIDs. Use alternative analgesics (Paracetamol cautiously, or selective COX-2 inhibitors).");n("Atazanavir","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Atazanavir.    (PPIs)       Atazanavir.","Decreased Atazanavir absorption. PPIs reduce gastric acidity, which is essential for Atazanavir absorption.","          .","Reduced drug plasma concentration, leading to viral treatment failure.","    .  PPIs         (  ).","Avoid combination or modification. PPIs must be strictly avoided or used at a suitable time and very low dose (not always effective).");n(["Atenolol","Propranolol","Metoprolol","Timolol"],"Quinidine",e.DRUG_DRUG,i.MODERATE,": **    CYP2D6**.     CYP2D6      .","Mechanism: **Metabolism inhibition via CYP2D6**. Quinidine is a strong inhibitor of CYP2D6 enzyme, which metabolizes Metoprolol, Propranolol, and Timolol."," :           **   (Severe Bradycardia)**     .","Clinical Significance: Excessively increased levels and effects of beta-blockers, leading to **severe bradycardia** and potential hypotension.","  (    ) .          .","Monitor cardiovascular status (HR, BP) regularly. Decrease beta-blocker dose by half upon co-initiation.");n(["Atenolol","Bisoprolol","Metoprolol","Propranolol"],Oc,e.DRUG_DRUG,i.MODERATE,": **    (CYP3A4  CYP2D6)**.  ( )            .","Mechanism: **Potent hepatic enzyme induction (CYP3A4 and CYP2D6)**. Rifamycins (e.g., Rifampin) significantly increase the clearance of hepatically metabolized beta-blockers."," : **    **            .","Clinical Significance: **Decreased plasma levels and effects of beta-blocker**, leading to loss of control over hypertension or angina.","    .     (   )       .","Monitor cardiovascular status closely. Increase beta-blocker dose (up to double) if necessary to maintain therapeutic efficacy.");n("Atenolol","Ampicillin",e.DRUG_DRUG,i.MODERATE,": **   **.               .","Mechanism: **Reduced gastrointestinal absorption**. Mechanism not fully clear, possibly due to formation of insoluble complexes or altered gut motility."," : **   **              .","Clinical Significance: **Decreased plasma levels and effects of atenolol**, potentially leading to loss of BP control or arrhythmias.","     .            .","Separate doses by at least 2 hours. Increase atenolol dose if necessary to maintain target blood pressure.");n("Atenolol","Ampicillin",e.DRUG_DRUG,i.MODERATE,"            .","Ampicillin reduces the gastrointestinal absorption and bioavailability of Atenolol, likely due to an adsorption mechanism, leading to lower plasma concentrations.","     /    .","Reduced antihypertensive and/or anti-anginal efficacy, potentially resulting in inadequate blood pressure control or increased angina episodes.","   (    )       .","Separate the administration of the two drugs by at least 2 hours. Monitor blood pressure and heart rate closely to ensure the therapeutic efficacy of Atenolol.");n("Atenolol","Digoxin",e.DRUG_DRUG,i.MODERATE,"    .             (AV node).","Synergistic effect on cardiac conduction. Both Atenolol (a beta-blocker) and Digoxin slow the heart rate and suppress conduction through the atrioventricular (AV) node.","     (Bradycardia)   (Heart Block).","Increased risk of severe bradycardia and AV block, which can be clinically significant.","    .                  .","Monitor heart rate and ECG regularly. Adjust the dose of one or both drugs if the heart rate drops excessively or signs of bradycardia or heart block appear.");n("Atenolol","Verapamil",e.DRUG_DRUG,i.HIGH,"  (Cardiac Depression).        (Inotropic)  (Chronotropic)       .","Cardiac Depression. The combination of a beta-blocker (Atenolol) and a non-dihydropyridine calcium channel blocker (Verapamil) exerts profound negative effects on inotropy, chronotropy, and dromotropy.","   (Cardiac Arrest).               .","Cardiac Arrest. High risk of severe bradycardia, complete Atrioventricular (AV) block, asystole, or fatal arrhythmia, especially in patients with underlying cardiac dysfunction.",".             .","Contraindicated. This combination is generally contraindicated due to the high risk of cardiotoxicity and is reserved only for specialized clinical settings with intense monitoring.");n("Atenolol","Diabetes Mellitus",e.DRUG_DISEASE,i.HIGH,"   .        (  )      .","Masking Hypoglycemia. Beta-blockers, particularly non-selective ones, blunt the adrenergic warning signs of hypoglycemia (e.g., tremor, palpitations, anxiety) mediated by catecholamine release.","       (Hypoglycemia Unawareness).       .","Risk of Hypoglycemia Unawareness. May delay necessary treatment, leading to severe, prolonged hypoglycemia, coma, and potential fatality.","       .           .","Avoid non-selective beta-blockers in patients with poorly controlled diabetes or recurrent hypoglycemia. Educate the patient that sweating may be the only remaining warning sign.");n("Atenolol","Asthma / COPD",e.DRUG_DISEASE,i.HIGH,"  -2  .  (     )           -2.","Beta-2 Blockade. Even cardio-selective beta-blockers like Atenolol can block pulmonary Beta-2 receptors at high doses, leading to bronchoconstriction in susceptible patients.","    .      .","Acute Asthma Exacerbation. High risk of severe bronchospasm, wheezing, and life-threatening respiratory distress.","    .    ( Bisoprolol  Metoprolol)          .","Avoid non-selective beta-blockers. Use cardioselective alternatives (e.g., Bisoprolol) with extreme caution and only when there is a critical indication, monitoring pulmonary function closely.");n("Atenolol","Diltiazem",e.DRUG_DRUG,i.HIGH,"  (Synergistic Effect)            (SA node)    (AV node).          .","Pharmacodynamic synergy resulting in additive negative chronotropic and dromotropic effects on the heart. Both agents suppress electrical conduction across the Sinoatrial (SA) node and Atrioventricular (AV) node, reducing heart rate and contractility.","   (Severe Bradycardia)    (Hypotension)     (Heart Block)    .","Severe bradycardia, profound hypotension, potential for high-degree Atrioventricular (AV) block, or acute heart failure.","     .            (ECG)          .","This combination should be avoided. If essential, continuous monitoring of pulse, blood pressure, and ECG is mandatory. Use the lowest effective dose for each agent.");n("Atezolizumab","Rifampin",e.DRUG_DRUG,i.LOW,"     . Atezolizumab          CYP.","No clinically significant interaction expected. Atezolizumab is a monoclonal antibody and is not metabolized by CYP.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Atezolizumab","Live Vaccines",e.DRUG_DRUG,i.HIGH,"  ","Altered immune response.","   ","Risk of vaccine infection.","  ","Avoid live vaccines.");n("Atogepant","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Atogepant. Ketoconazole     CYP3A4      Atogepant.","Increased Atogepant concentration. Ketoconazole is a potent CYP3A4 inhibitor, the major metabolic pathway for Atogepant.","      Atogepant   .","Increased risk of Atogepant-related side effects, such as nausea and fatigue."," .    Atogepant     CYP3A4 .","Dose adjustment. Atogepant dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Atogepant","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Atogepant. Probenecid   OAT1 (Organic Anion Transporter 1)    Atogepant.","Increased Atogepant concentration. Probenecid inhibits OAT1 (Organic Anion Transporter 1), an Atogepant efflux transporter.","      .","Increased risk of side effects, especially nausea and constipation."," .    Atogepant     OAT1 .","Dose adjustment. Atogepant dose must be reduced when co-administered with strong OAT1 inhibitors.");n("Atomoxetine - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"    CYP2D6               ","Paroxetine is a potent inhibitor of hepatic CYP2D6 enzyme responsible for Atomoxetine primary metabolism, increasing drug exposure and prolonging its half-life","       5-6          ","Significant increase in Atomoxetine concentration up to 5-6 fold, with elevated risk of cardiovascular and nervous system adverse effects","    25-50%        -        ","Reduce Atomoxetine dose to 25-50% of usual dose in polypharmacy patients - initiate with low dose and titrate gradually with close monitoring");n("Atorvastatin","Gemfibrozil",e.DRUG_DRUG,i.HIGH,"  / .     ( CYP2C8)        ( OATP1B1  OATP1B3).","Metabolism and Transport Inhibition. Gemfibrozil inhibits the metabolism of Atorvastatin (via CYP2C8) and significantly reduces its hepatic uptake and clearance by blocking OATP transporters.","  (Rhabdomyolysis).              .","Rhabdomyolysis. Markedly increased plasma concentrations of Atorvastatin, resulting in a substantially elevated risk of severe myopathy, myalgia, and potentially fatal rhabdomyolysis.",".           .       (Fenofibrate).","Avoid. This combination is generally contraindicated due to the high risk of muscle toxicity. Use alternative fibrates (e.g., Fenofibrate) which have less inhibitory effect on statin metabolism and transport.");n("Atorvastatin","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE," CYP3A4 ","Intestinal CYP3A4 inhibition.","  ","Increased statin levels.","   -   ","Avoid large amounts - small glass acceptable.");n("Atorvastatin","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Caffeine",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Grapefruit Juice",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Atorvastatin / Simvastatin","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"     CYP3A4  .       .","Grapefruit juice is a potent inhibitor of intestinal CYP3A4 enzymes. Since Atorvastatin and Simvastatin are metabolized by this enzyme, its inhibition leads to reduced first-pass metabolism.","                (   ).","Markedly increased systemic exposure and plasma concentration of the statin, leading to a dose-dependent increase in adverse effects, especially muscle toxicity (myalgia, myopathy, and potential rhabdomyolysis).","           .          .","Avoid consuming grapefruit juice or grapefruit products entirely while on these medications, as the interaction is concentration-dependent and can be clinically significant.");n("Atovaquone","High-Fat Meal",e.DRUG_FOOD,i.HIGH,"      300% -     ","High-fat meal increases bioavailability by 300% - highly lipophilic drug.","    -  ","Massive increase in absorption - essential for efficacy.","        ","Must be taken with a high-fat meal or whole milk.");n("Atropine","Glaucoma (Narrow-Angle)",e.DRUG_DISEASE,i.HIGH,"   (Mydriasis)                 .","Mydriasis. Atropine causes pupillary dilation, physically blocking the trabecular meshwork and precipitating an acute angle-closure glaucoma attack.","       .","Acute rise in Intraocular Pressure (IOP) and irreversible vision loss.",".            .","Contraindicated. Avoid use in patients with known or suspected narrow-angle glaucoma.");n("Atropine","Disopyramide, Estramustine, Cefpodoxime",e.DRUG_DRUG,i.MODERATE,"   .            .","Delayed Gastric Emptying/Slowed GI Motility. Atropine delays gastric emptying, which can significantly alter the rate and extent of absorption for co-administered drugs.","   .             .","Altered Absorption Rate. May lead to delayed onset of action or reduced overall bioavailability of the co-administered drugs.","  .            .","Monitor drug efficacy. Assess the patient's response to the co-administered drugs and consider separating doses if the interaction is clinically relevant.");n("Atropine","Lidocaine",e.DRUG_DRUG,i.MODERATE,"  .         .","Delayed Gastric Emptying. Atropine slows GI motility, potentially delaying the absorption and peak concentration of orally administered Lidocaine.","   .       .","Altered Lidocaine Efficacy. Delay in achieving therapeutic concentrations for oral Lidocaine.","  .      /  .","Monitor patient response. Check for clinical efficacy and adjust the dose or timing of oral Lidocaine if necessary.");n("Atropine (eye drops)","Antihistamines",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic anticholinergic effect.","    ","Severe dryness and blurred vision."," ","Use cautiously.");n("Avacincaptad Pegol","Drugs affecting bleeding",e.DRUG_DRUG,i.MODERATE,"       ","Increased bleeding risk due to effect on complement system.","   ","Intraocular hemorrhage, bruising.","     ","Caution when using with anticoagulants.");n("Avacopan","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Avacopan. Ketoconazole     CYP3A4      Avacopan.","Increased Avacopan concentration. Ketoconazole is a potent inhibitor of CYP3A4, the primary metabolic pathway for Avacopan.","        .","Increased risk of side effects, including hepatotoxicity."," .    Avacopan  50%   .","Dose adjustment. Avacopan dose must be reduced by 50% upon co-administration.");n("Avacopan","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Avacopan. Efavirenz    CYP3A4    Avacopan.","Decreased Avacopan efficacy. Efavirenz is a moderate inducer of CYP3A4, an Avacopan metabolic pathway.","              (Vasculitis).","Reduced drug plasma concentration, leading to loss of control over vasculitis."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Avacopan","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Avacopan. Phenytoin    CYP3A4    Avacopan.","Decreased Avacopan efficacy. Phenytoin is a strong inducer of CYP3A4, an Avacopan metabolic pathway.","             .","Reduced drug plasma concentration, leading to loss of vasculitis control."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Avacopan","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Avacopan. Itraconazole    CYP3A4    Avacopan.","Increased Avacopan concentration. Itraconazole is a strong CYP3A4 inhibitor, an Avacopan metabolic pathway.","   .","Increased risk of hepatotoxicity."," .    Avacopan     CYP3A4 .","Dose adjustment. Avacopan dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Avacopan","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Avacopan. Carbamazepine    CYP3A4    Avacopan.","Decreased Avacopan concentration. Carbamazepine is a strong inducer of CYP3A4, an Avacopan metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Avacopan (C5a)","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Avacopan. Phenytoin    CYP3A4.","Decreased Avacopan concentration. Phenytoin is a strong inducer of CYP3A4.","          .","Reduced drug efficacy, leading to failure of vasculitis treatment."," .   .","Contraindicated. Avoid the combination.");n("Avacopan (C5a)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Avacopan. Ketoconazole    CYP3A4.","Increased Avacopan concentration. Ketoconazole is a strong inhibitor of CYP3A4.","   .","Increased risk of liver toxicity."," .    Avacopan  .","Dose adjustment. Avacopan dose must be significantly reduced.");n("Avapritinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Itraconazole    CYP3A4    Avapritinib.","Increased Avapritinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Avapritinib.","       QT.","Increased risk of cognitive toxicity, hemorrhage, and QT prolongation."," .    Avapritinib     CYP3A4 .","Dose adjustment. Avapritinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Avapritinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Rifampin    CYP3A4    Avapritinib.","Decreased Avapritinib efficacy. Rifampin is a strong inducer of CYP3A4, an Avapritinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Avapritinib","Posaconazole",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Posaconazole    CYP3A4    Avapritinib.","Increased Avapritinib concentration. Posaconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Avapritinib.","       QT.","Increased risk of cognitive toxicity, hemorrhage, and QT prolongation."," .    Avapritinib     CYP3A4 .","Dose adjustment. Avapritinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Avapritinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Carbamazepine    CYP3A4    Avapritinib.","Decreased Avapritinib efficacy. Carbamazepine is a strong inducer of CYP3A4, an Avapritinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Avapritinib","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Fluconazole    CYP3A4    Avapritinib.","Increased Avapritinib concentration. Fluconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Avapritinib.","       QT.","Increased risk of cognitive toxicity, hemorrhage, and QT prolongation."," .    Avapritinib     CYP3A4 .","Dose adjustment. Avapritinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Avapritinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Rifampin    CYP3A4    Avapritinib.","Decreased Avapritinib efficacy. Rifampin is a strong inducer of CYP3A4, an Avapritinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Avapritinib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Efavirenz    CYP3A4    Avapritinib.","Decreased Avapritinib efficacy. Efavirenz is a moderate inducer of CYP3A4, an Avapritinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Avapritinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Avapritinib.       CYP3A4  .","Increased Avapritinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","       .","Increased risk of side effects, especially hemorrhage and peripheral edema."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Avapritinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Rifampin    CYP3A4.","Decreased Avapritinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Avapritinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Avapritinib. Ketoconazole    CYP3A4.","Increased Avapritinib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    (Intracranial Hemorrhage)   .","Increased risk of Intracranial Hemorrhage and other side effects."," .    Avapritinib  .","Dose adjustment. Avapritinib dose must be significantly reduced.");n("Avapritinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Avapritinib.      CYP3A4.","Increased Avapritinib concentration. Grapefruit juice is a CYP3A4 inhibitor.","   .","Increased risk of Intracranial Hemorrhage."," .     .","Avoid combination. Avoid consuming grapefruit and its juice.");n("Avatrombopag","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Avatrombopag. Fluconazole    CYP2C9/3A4    Avatrombopag.","Increased Avatrombopag concentration. Fluconazole is a strong inhibitor of CYP2C9/3A4, which are Avatrombopag metabolic pathways.","   (Thromboembolism)    Avatrombopag (  ).","Increased risk of thromboembolism due to elevated concentration of Avatrombopag (platelet stimulator)."," .    Avatrombopag      CYP .","Dose adjustment. Avatrombopag dose must be reduced when co-administered with strong CYP inhibitors.");n("Avatrombopag (TPO)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Avatrombopag. Rifampin    CYP2C9  CYP3A4.","Decreased Avatrombopag concentration. Rifampin is a strong inducer of CYP2C9 and CYP3A4.","         .","Reduced drug efficacy, leading to failure of thrombocytopenia treatment.","  .    .","Relative contraindication. Avoid the combination.");n("Avelumab","Corticosteroids",e.DRUG_DRUG,i.MODERATE,"  ","Additive immunosuppression.","  ","Increased risk of infection.","     ","Monitor for infection signs, avoid high doses.");n("Avelumab (PD-L1)","High-dose Corticosteroids",e.DRUG_DRUG,i.MODERATE,"  Avelumab.       .","Decreased Avelumab efficacy. High-dose corticosteroids may inhibit the anti-tumor immune response.","   .","Failure of the anti-tumor immune response."," .       (  irAEs).","Avoid combination. Avoid high-dose systemic corticosteroids (except for management of irAEs).");n("Axitinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Axitinib. Itraconazole    CYP3A4    Axitinib.","Increased Axitinib concentration. Itraconazole is a strong CYP3A4 inhibitor, an Axitinib metabolic pathway.","       .","Increased risk of side effects, especially hypertension."," .    Axitinib     CYP3A4 .","Dose adjustment. Axitinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Axitinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Axitinib. Rifampin    CYP3A4.","Decreased Axitinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Axitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Axitinib. Ketoconazole    CYP3A4.","Increased Axitinib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    (    ).","Increased risk of side effects (e.g., hypertension and bleeding)."," .    Axitinib.","Dose adjustment. Axitinib dose must be reduced.");n("Azathioprine","Mesalamine",e.DRUG_DRUG,i.HIGH,"    (6-TGN)  Azathioprine.    TPMT (/).","Increased concentration of the active metabolite (6-TGN) of Azathioprine. Aminosalicylates inhibit the TPMT enzyme (theoretically/clinically).","     .","Increased risk of severe myelosuppression."," .     .","Close monitoring. Monitor blood counts intensively.");n("Azathioprine","Allopurinol",e.DRUG_DRUG,i.HIGH,"  xanthine oxidase    ","Xanthine oxidase inhibition reduces Azathioprine metabolism.","     ","Increased Azathioprine toxicity, severe cytopenia.","    25-33%   ","Reduce Azathioprine dose to 25-33% of normal.");n("Azathioprine","ACE Inhibitors",e.DRUG_DRUG,i.MODERATE,"  ","Bone marrow suppression."," ","Anemia.","  ","Monitor CBC.");n("Azelastine","CNS Depressants",e.DRUG_DRUG,i.MODERATE,"      ","Additive CNS Depression. Synergistic sedation.","    ","Increased drowsiness, dizziness, poor concentration.","     ","Avoid driving/machinery, adjust doses.");n("Azithromycin","Sotalol",e.DRUG_DRUG,i.HIGH,"    QTc.     QTc.","Increased risk of QTc prolongation. Additive QTc prolonging effect.","      .","Risk of serious ventricular arrhythmia."," .   .","Contraindicated. Avoid the combination.");n("Azithromycin","Drugs that prolong QT",e.DRUG_DRUG,i.HIGH,"  QT ","Additive QT prolongation.","      (Torsades de pointes)","Increased risk of arrhythmia (Torsades de pointes).","     QT   ","Avoid combination with QT-prolonging drugs, monitor ECG.");n("Azithromycin","Colchicine",e.DRUG_DRUG,i.HIGH," P-glycoprotein -  ","P-gp inhibition causes colchicine accumulation.","  -     ","Colchicine toxicity - diarrhea, vomiting, multi-organ failure.","    / -   ","Avoid in renal/hepatic impairment - reduce colchicine dose.");n("Azithromycin","Alcohol",e.DRUG_FOOD,i.LOW,":     .        (  )   Azithromycin.","Mechanism: No direct drug interaction. Alcohol may increase the gastrointestinal side effects (like nausea and diarrhea) common with Azithromycin.",":      .","Result: Slight increase in gastrointestinal upset.",":     .","Management: Advise moderate consumption of alcohol.");n("Azithromycin","Caffeine",e.DRUG_FOOD,i.HIGH,": Azithromycin  **   CYP1A2**    . (      ).","Mechanism: Azithromycin is a **weak inhibitor of the CYP1A2 enzyme** responsible for Caffeine metabolism. (Clinical interaction is low, but risk severity is high).",":       .           QT   .","Result: May slightly increase caffeine levels. Caution is recommended due to the potential of both substances to affect QT prolongation in sensitive patients.",":  .         .","Management: Monitor symptoms. Limit caffeine intake if neurological side effects are noted.");n("Azithromycin","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,":    CYP3A4.  Azithromycin     .","Mechanism: Weak inhibition of the CYP3A4 enzyme. Azithromycin metabolism is limited, so the interaction is weak.",":      .","Result: No major clinical effect expected.",":  .    .","Management: Routine monitoring. No routine adjustment required.");n("Azithromycin","Green Tea",e.DRUG_FOOD,i.LOW,":    .       .","Mechanism: No known interaction. Contains Caffeine but the combined effect is weak.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Azithromycin","Milk",e.DRUG_FOOD,i.HIGH,": ** **.             Azithromycin (  ).","Mechanism: **Decreased Absorption**. Food, including milk, significantly reduces the bioavailability of Azithromycin tablets (immediate-release formulation).",": **    **      .","Result: **Reduced drug concentration in the blood**, which may decrease therapeutic efficacy.",": **   Azithromycin   ** (     ).","Management: **Azithromycin tablets should be taken on an empty stomach** (1 hour before or 2 hours after food/milk).");n("Azithromycin","High-fat meals",e.DRUG_FOOD,i.MODERATE,": ** **.          Azithromycin.","Mechanism: **Decreased Absorption**. High-fat meals significantly reduce the absorption of Azithromycin tablets.",":    .","Result: Decreased drug bioavailability.",": **     .** (     ).","Management: **Advise taking tablets on an empty stomach.** (1 hour before or 2 hours after food).");n("Azithromycin","High-fiber foods",e.DRUG_FOOD,i.LOW,":    .      .","Mechanism: No known interaction. Fiber may slightly delay absorption.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Azithromycin","Vitamin C",e.DRUG_FOOD,i.HIGH,":     . (          ).","Mechanism: No direct interaction is known. (Hypothetical interaction due to increased acidity which may affect absorption).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Vitamin D",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Vitamin E",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Vitamin K",e.DRUG_FOOD,i.HIGH,":     . ( Azithromycin       Vitamin K).","Mechanism: No direct interaction is known. (Azithromycin is linked to increased Warfarin effects, which is affected by Vitamin K).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Vitamin B12",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Folic Acid",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Iron",e.DRUG_FOOD,i.HIGH,": **  (Chelation)**.   (Fe/Fe)   Azithromycin.","Mechanism: **Chelation**. Iron ions (Fe/Fe) bind to Azithromycin.",":     Azithromycin     .","Result: Significant reduction in Azithromycin absorption, reducing therapeutic efficacy.",": **   **    2  4 .","Management: **Doses must be separated** from Iron supplements by 2 to 4 hours.");n("Azithromycin","Calcium",e.DRUG_FOOD,i.MODERATE,": **  (Chelation)**.   (Ca)    Azithromycin.","Mechanism: **Chelation**. Calcium ions (Ca) may bind to Azithromycin.",":       Azithromycin.","Result: Slight to moderate reduction in Azithromycin absorption.",":       .","Management: Prefer separation of doses and Calcium supplements by two hours.");n("Azithromycin","Magnesium",e.DRUG_FOOD,i.LOW,": **  (Chelation)**.   (Mg)   Azithromycin.","Mechanism: **Chelation**. Magnesium ions (Mg) bind to Azithromycin.",":       Azithromycin.","Result: Slight to moderate reduction in Azithromycin absorption.",":       .","Management: Prefer separation of doses and Magnesium supplements by two hours.");n("Azithromycin","Zinc",e.DRUG_FOOD,i.HIGH,": **  (Chelation)**.   (Zn)   Azithromycin.","Mechanism: **Chelation**. Zinc ions (Zn) bind to Azithromycin.",":     Azithromycin     .","Result: Significant reduction in Azithromycin absorption, reducing therapeutic efficacy.",": **   **    2  4 .","Management: **Doses must be separated** from Zinc supplements by 2 to 4 hours.");n("Azithromycin","Potassium",e.DRUG_FOOD,i.MODERATE,":     . (      QT).","Mechanism: No direct interaction is known. (Hypothetical interaction due to QT prolongation risk).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Azithromycin","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,":         .","Mechanism: Sodium Bicarbonate may temporarily alter gastric pH.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Azithromycin","Antacids",e.DRUG_FOOD,i.HIGH,": **  (Chelation)**.          Azithromycin.","Mechanism: **Chelation**. Antacids containing Aluminum and Magnesium bind to Azithromycin.",": **    Azithromycin**   .","Result: **Significant reduction in Azithromycin absorption** and potential treatment failure.",": **   **   (  Al/Mg)  2  4 .","Management: **Doses must be separated** from Antacids (Al/Mg containing) by 2 to 4 hours.");n("Azithromycin","Magnesium/Aluminum Antacids (Specific)",e.DRUG_FOOD,i.HIGH,": **   (Chelation)**.        Azithromycin   .","Mechanism: **Strong Chelation**. Aluminum and Magnesium ions directly impede Azithromycin absorption in the GI tract.",": **    **       .","Result: **Potential antibiotic treatment failure** due to insufficient drug blood levels.",": **   **     2  4   .","Management: **Strict avoidance or separation** by at least 2 to 4 hours between doses.");n("Azithromycin","Licorice (Glycyrrhiza glabra)",e.DRUG_FOOD,i.MODERATE,": **  QT**.      (  )    (Hypokalemia)       QT      Azithromycin.","Mechanism: **QT Prolongation Risk**. Licorice (in high doses) can cause hypokalemia (low potassium), which increases the risk of QT prolongation, an effect also associated with Azithromycin.",":        ( Torsades de Pointes)   .","Result: Increased theoretical risk of cardiac arrhythmias (e.g., Torsades de Pointes) in susceptible patients.",":             .","Management: Advise moderate consumption, especially for patients with pre-existing cardiac conditions.");n(wc,"Warfarin",e.DRUG_DRUG,i.HIGH,": **  (CYP2C9)**.   (  )    .","Mechanism: **Metabolism inhibition (CYP2C9)**. Azoles (esp. Fluconazole, Miconazole) potently inhibit Warfarin metabolism."," : **   INR**  .","Clinical Significance: **Significant INR elevation** and bleeding risk.","    INR . (   INR   ).","Reduce Warfarin dose and monitor INR closely. (Oral Gel Miconazole raises INR very dangerously).");n(wc,Ju,e.DRUG_DRUG,i.HIGH,": **  (CYP3A4)**.      (  ).","Mechanism: **Metabolism inhibition (CYP3A4)**. Azoles inhibit metabolism of benzodiazepines (e.g., Midazolam, Triazolam)."," : **  **    .","Clinical Significance: **Increased benzodiazepine effects**, excessive sedation, and respiratory depression.","    .      .","Avoid combination with Midazolam and Triazolam. Use Lorazepam or Oxazepam as safe alternatives.");n("Bacitracin","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"      ","Synergistic nephrotoxicity and neurotoxicity with systemic use.","    ","Increased risk of renal/neuro toxicity.","       ","Avoid combination with systemic use, monitor renal function.");n("Baclofen","CNS Depressants",e.DRUG_DRUG,i.HIGH,"      ","Additive CNS Depression. Synergistic sedation.","     ","Severe respiratory depression, excessive sedation, coma.","     ","Avoid alcohol, adjust other sedative doses.");n("Baloxavir (Xofluza)","Dairy Products ( )",e.DRUG_FOOD,i.MODERATE,": ** **.    Baloxavir.","Mechanism: **Calcium binding**. Calcium reduces Baloxavir absorption."," : **  **.","Clinical Significance: **Reduced drug efficacy**.","           Baloxavir.","Avoid dairy, calcium, magnesium, iron, and zinc within 2 hours of Baloxavir.");n("Baloxavir (Xofluza)","Laxatives (Magnesium/Aluminum)",e.DRUG_DRUG,i.MODERATE,": ****.     .","Mechanism: **Chelation**. Formation of non-absorbable complexes."," : **  **.","Clinical Significance: **Influenza treatment failure**.","     .","Separate doses by at least 2 hours.");n("Baloxavir Marboxil","Aluminum Hydroxide",e.DRUG_DRUG,i.HIGH,"  Baloxavir.    ( )   Baloxavir  .","Reduced Baloxavir absorption. Multivalent cation-containing agents (like antacids) bind to Baloxavir in the gut.","            .","Significant decrease in drug plasma concentration, leading to influenza treatment failure."," .          .","Avoid simultaneous use. Antacids, dairy products, and multivalent cation salts should be avoided.");n("Baloxavir Marboxil","Antacids/Dairy",e.DRUG_FOOD,i.HIGH,"  Baloxavir.    (   )     .","Decreased Baloxavir absorption. Polyvalent cations (like calcium or magnesium) chelate the drug in the GI tract.","   .","Reduced efficacy of influenza treatment."," .             Baloxavir .","Separate timing. Dairy products, antacids, and mineral supplements must be avoided 2 hours before or after Baloxavir.");n("Baloxavir Marboxil","Antacids",e.DRUG_DRUG,i.MODERATE,"  Baloxavir.      .","Decreased Baloxavir absorption. Formation of insoluble chelation compounds.","        .","Reduced antiviral efficacy, leading to treatment failure."," .         //.","Dose separation. Avoid concurrent administration with antacids or calcium/magnesium/iron supplements.");n("Balsalazide","Warfarin",e.DRUG_DRUG,i.MODERATE,"      K","Effect on gut flora and Vitamin K metabolism.","   ","Altered Warfarin effect."," INR   ","Monitor INR, adjust Warfarin dose.");n("Barbiturates","Warfarin",e.DRUG_DRUG,i.HIGH,"   CYP2C9    ","Barbiturates induce CYP2C9 enzymes responsible for Warfarin metabolism.","      ( )","Decreased Warfarin levels and anticoagulant efficacy (clotting risk)."," INR         ","Monitor INR frequently, increase dose during therapy and reduce upon stopping.");n("Baricitinib","Probenecid",e.DRUG_DRUG,i.HIGH,"  Baricitinib. Probenecid      (OAT3)     Baricitinib.","Increased Baricitinib concentration. Probenecid inhibits Organic Anion Transporter 3 (OAT3), responsible for Baricitinib efflux.","           Baricitinib.","Increased risk of myelosuppression and infection, which are Baricitinib-related side effects."," .    Baricitinib       OAT3 .","Dose adjustment. Baricitinib dose must be halved when co-administered with potent OAT3 inhibitors.");n("Baricitinib","Rifampin",e.DRUG_DRUG,i.MODERATE,"  Baricitinib. Rifampin   CYP3A4    Baricitinib.","Decreased Baricitinib concentration. Rifampin is a CYP3A4 inducer, a Baricitinib metabolic pathway.","  Baricitinib         .","Reduced Baricitinib efficacy, leading to loss of rheumatoid arthritis control."," .        .","Efficacy monitoring. Clinical response must be monitored and drug levels checked.");n("Baricitinib","Measles, Mumps, Rubella",e.DRUG_VACCINE,i.HIGH,"  . Baricitinib   (JAK inhibitor).","Increased risk of infection. Baricitinib is an immunosuppressant (JAK inhibitor).","     .","Risk of developing infection from live vaccines."," .        Baricitinib.","Contraindicated. Live vaccines must be avoided during Baricitinib treatment.");n("Baricitinib","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Baricitinib. Probenecid   OAT3    Baricitinib.","Increased Baricitinib concentration. Probenecid inhibits OAT3, a Baricitinib efflux transporter.","     .","Increased risk of side effects, especially infections.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Baricitinib","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Baricitinib. Probenecid   OAT3    Baricitinib.","Increased Baricitinib concentration. Probenecid inhibits OAT3, a Baricitinib efflux transporter.","     .","Increased risk of side effects, especially infections.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Baricitinib (JAK Inhibitor)","Probenecid",e.DRUG_DRUG,i.HIGH,"  Baricitinib. Probenecid   OAT3    Baricitinib .","Increased Baricitinib concentration. Probenecid inhibits the OAT3 transporter, a Baricitinib renal clearance pathway.","     .","Increased risk of infection and myelosuppression."," .    Baricitinib ( ).","Dose adjustment. Baricitinib dose must be reduced (by half).");n("Baricitinib (JAK)","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Baricitinib. Probenecid   OAT3 (  2X).","Increased Baricitinib concentration. Probenecid inhibits OAT3 (increases exposure 2X).","  .","Increased risk of infection."," .    Baricitinib.","Dose adjustment. Baricitinib dose must be reduced.");n("Baricitinib (Olumiant)","Probenecid",e.DRUG_DRUG,i.MODERATE,": **  **. Probenecid   Baricitinib .","Mechanism: **Renal transport inhibition**. Probenecid inhibits Baricitinib renal excretion."," : **  Baricitinib**  .","Clinical Significance: **Increased Baricitinib concentration** and toxicity risk.","     Baricitinib.","Avoid combination or reduce Baricitinib dose.");n("Baricitinib (Olumiant)","Renal Impairment ( )",e.DRUG_DISEASE,i.HIGH,": ** **. Baricitinib     .","Mechanism: **Renal excretion**. Baricitinib is primarily renally excreted."," : ** **  .","Clinical Significance: **Drug accumulation** and increased toxicity.","    .     .","Dose adjustment based on renal function. Avoid in severe renal impairment.");n("Baricitinib (Olumiant)","Live Vaccines",e.DRUG_VACCINE,i.HIGH,": ** **.","Mechanism: **Immunosuppression**."," : ** **   .","Clinical Significance: **Immunological failure** and vaccine disease risk.","  .    .","Avoid live vaccines. Vaccinate before starting therapy.");n("Bedaquiline","Rifampin",e.DRUG_DRUG,i.HIGH,"  Bedaquiline. Rifampin    CYP3A4    Bedaquiline.","Decreased Bedaquiline concentration. Rifampin is a strong inducer of CYP3A4, a Bedaquiline metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Belantamab Mafodotin (BCMA ADC)","Itraconazole",e.DRUG_DRUG,i.MODERATE,"    (MMAF). Itraconazole   CYP3A4.","Increased concentration of toxic metabolite (MMAF). Itraconazole inhibits CYP3A4.","      .","Increased risk of renal toxicity and ocular side effects."," .        .","Close monitoring. Monitor side effects and adjust dose if necessary.");n("Belantamab Mafodotin (Blenrep)","Corneal Toxins (Amiodarone)",e.DRUG_DRUG,i.MODERATE,": **  **.      .","Mechanism: **Synergistic corneal toxicity**. Both drugs cause corneal deposits."," : **   **  .","Clinical Significance: **Severe vision impairment** and corneal damage.","   .    .","Avoid combination if possible. Frequent eye examinations necessary.");n("Belimumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Belimumab   B.","Reduced vaccine response/Increased infection risk. Belimumab modulates B-cells.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Belimumab","Live Vaccines",e.DRUG_DRUG,i.HIGH," ","Immunosuppression.","   ","Infection from live vaccines.","  ","Avoid live vaccines.");n("Belladonna","Haloperidol",e.DRUG_DRUG,i.MODERATE,"      ","Additive anticholinergic effect from both drugs.","       ","Dry mouth, constipation, urinary retention, worsening psychiatric symptoms.","     ","Monitor anticholinergic symptoms, adjust doses.");n("Belladonna","Phenothiazines",e.DRUG_DRUG,i.MODERATE,"           .","Additive anticholinergic effect due to both drug classes blocking muscarinic receptors.","     (   )    .","Increased risk of Anticholinergic Syndrome (severe dry mouth, acute delirium, and impaired thermoregulation).","     (   ).      .","Close monitoring for anticholinergic signs. Avoid high doses or consider an alternative agent.");n("Belumosudil","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Belumosudil. Fluconazole     CYP3A4  CYP2C9     Belumosudil.","Increased Belumosudil concentration. Fluconazole is a strong inhibitor of CYP3A4 and CYP2C9, both involved in Belumosudil metabolism.","         .","Increased risk of toxic side effects, including hepatotoxicity."," .    Belumosudil  50%   .","Dose adjustment. Belumosudil dose must be reduced by 50% upon co-administration.");n("Belumosudil","Rifampin",e.DRUG_DRUG,i.HIGH,"  Belumosudil. Rifampin    CYP3A4    Belumosudil.","Decreased Belumosudil efficacy. Rifampin is a strong inducer of CYP3A4, a Belumosudil metabolic pathway.","               .","Reduced drug plasma concentration, leading to loss of control over chronic graft-versus-host disease."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Belumosudil","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  Belumosudil. Fluconazole   CYP3A4    Belumosudil.","Increased Belumosudil concentration. Fluconazole is a CYP3A4 inhibitor, a Belumosudil metabolic pathway.","        .","Increased risk of side effects, especially infection and myelosuppression."," .    Belumosudil     CYP3A4 .","Dose adjustment. Belumosudil dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Belumosudil","High Fat Meal",e.DRUG_FOOD,i.MODERATE,"  Belumosudil.          .","Increased Belumosudil absorption. Taking the drug with a high-fat meal increases bioavailability.","          .","Increased drug plasma concentration, increasing the risk of side effects."," .   Belumosudil    .","Dose consistency. Belumosudil must be taken consistently with a meal.");n("Belumosudil","Rifampin",e.DRUG_DRUG,i.HIGH,"  Belumosudil. Rifampin    CYP3A4.","Decreased Belumosudil concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Belumosudil","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Belumosudil. Itraconazole    CYP3A4.","Increased Belumosudil concentration. Itraconazole is a strong inhibitor of CYP3A4.","    .","Increased risk of adrenal insufficiency."," .    Belumosudil.","Dose adjustment. Belumosudil dose must be reduced.");n("Belzutifan","Rifampin",e.DRUG_DRUG,i.HIGH,"  Belzutifan. Rifampin    CYP2C19  CYP3A4.","Decreased Belzutifan concentration. Rifampin is a strong inducer of CYP2C19 and CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Bempedoic Acid","Simvastatin (High Dose)",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Bempedoic Acid  OATP1B1.","Increased Simvastatin concentration. Bempedoic Acid inhibits OATP1B1.","    (Rhabdomyolysis).","Increased risk of Rhabdomyolysis.","  .    Simvastatin    20  .","Relative contraindication. Simvastatin doses greater than 20 mg daily must be avoided.");n("Bempedoic Acid (Nexletol)","Simvastatin",e.DRUG_DRUG,i.MODERATE,": ** OATP1B1**.   Simvastatin.","Mechanism: **OATP1B1 Inhibition**. Increased Simvastatin concentration."," : **  **  .","Clinical Significance: **Myalgia risk** and rhabdomyolysis.","   Simvastatin 20 mg/day    Bempedoic Acid.","Do not exceed Simvastatin 20 mg/day when combined with Bempedoic Acid.");n("Bempedoic Acid (Nexletol)","Pravastatin",e.DRUG_DRUG,i.MODERATE,": ** OATP1B1**.   Pravastatin  2 .","Mechanism: **OATP1B1 Inhibition**. Pravastatin concentration doubles."," : **  **.","Clinical Significance: **Myalgia risk**.","   Pravastatin 40 mg/day.","Do not exceed Pravastatin 40 mg/day.");n("Bempedoic Acid (Nexletol)","Gout ()",e.DRUG_DISEASE,i.MODERATE,": **  **. Bempedoic Acid     .","Mechanism: **Uric acid elevation**. Bempedoic Acid may increase uric acid levels."," : ** **.","Clinical Significance: **Gout exacerbation**.","   .     .","Monitor uric acid levels. Use cautiously in gout patients.");n("Benazepril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Benazepril - ","Potassium Supplements -  ",e.DRUG_DRUG,i.HIGH," ( ACE)     II      .         .            .","Benazepril (an ACE inhibitor) reduces Angiotensin II formation, which consequently decreases Aldosterone secretion. Reduced Aldosterone leads to decreased potassium excretion in the kidneys. Potassium supplements increase the potassium load, creating an additive effect for hyperkalemia.","       (Severe Hyperkalemia)        (Cardiac Arrhythmias)            .","Extremely high risk of severe hyperkalemia, which can cause life-threatening and fatal cardiac arrhythmias, especially in patients with impaired renal function or diabetes.","        .                .","Near-absolute contraindication, co-administration must be strictly avoided. Regularly monitor serum potassium levels and renal function, and discontinue supplements immediately if elevation occurs.");n("Benazepril","Lithium",e.DRUG_DRUG,i.HIGH,"    (ACE-I)           .","ACE inhibitors reduce renal lithium clearance due to their effect on renal blood flow and glomerular filtration.","            .","Rapid and significant increase in serum lithium levels and heightened risk of neurotoxicity and cardiotoxicity.","     ()     30-50%   .","Frequent monitoring of lithium levels. Reduce lithium dose by 30-50% if combination is mandatory.");n("Bendroflumethiazide","Digoxin",e.DRUG_DRUG,i.MODERATE,"             .","Thiazide diuretics cause hypokalemia, which significantly increases myocardial sensitivity to Digoxins effects.","    (      )     .","Increased risk of Digoxin toxicity (potentially fatal arrhythmias, nausea, vomiting) even at therapeutic Digoxin levels.","    .   (Potassium Supplementation)    .","Monitor Potassium and Digoxin levels closely. Potassium supplementation is required if necessary.");n("Bendroflumethiazide","Lithium",e.DRUG_DRUG,i.HIGH,"               .","Thiazide diuretics enhance sodium reabsorption in the renal tubules, which consequently decreases lithium excretion.","        .","Elevated lithium levels and increased risk of neurotoxicity, ataxia, and confusion.","    .      50%    .","Monitor lithium levels frequently. Lithium dose typically requires a reduction of approximately 50% when starting the thiazide.");n("Bendroflumethiazide","Loop Diuretics",e.DRUG_DRUG,i.MODERATE,"             .","Additive and synergistic diuretic effect as each drug acts on a different part of the nephron.","  (Dehydration)      (electrolytes)    .","Severe dehydration, acute electrolyte imbalance, and orthostatic hypotension.","  ( )  .         .","Monitor electrolytes (Sodium, Potassium) and blood pressure. Doses must be carefully adjusted to avoid volume depletion.");n("Bendroflumethiazide","Sulfonylureas",e.DRUG_DRUG,i.MODERATE,"             .","Thiazide diuretics have antagonistic effects on insulin secretion from Beta cells and increase peripheral insulin resistance.","   (Hyperglycemia)        .","Hyperglycemia and reduced efficacy of Sulfonylureas in controlling blood glucose.","    .           .","Monitor blood glucose closely. Sulfonylurea dose may need adjustment or an additional antidiabetic agent may be necessary.");n("Benzodiazepines","Liver Disease / Hepatic Impairment",e.DRUG_DISEASE,i.HIGH,"   -  -   -    ","Reduced hepatic metabolism - accumulation - increased sedation - risk of hepatic encephalopathy.","     ","Worsening hepatic failure or encephalopathy.","   -    ","Use low doses - prefer Oxazepam or Lorazepam.");n("Benzodiazepines","Ethanol",e.DRUG_DRUG,i.HIGH,"    (CNS)       GABA-A   .","Synergistic Central Nervous System (CNS) depression by enhancing GABA-A receptor activity from both substances.","           .","Life-threatening respiratory depression, profound sedation, severe motor incoordination, and coma.","     .        .","Total avoidance of alcohol during Benzodiazepine therapy. Warn the patient about driving and operating machinery risks.");n("Benzonatate","CNS Depressants",e.DRUG_DRUG,i.MODERATE,"     ","Additive CNS effect."," ","Drowsiness, dizziness.","   ","Avoid driving, adjust doses.");n("Benzonatate","Topical Anesthetics",e.DRUG_DRUG,i.MODERATE,": **     (Additive Local Anesthetic Effect)**.                  (      )      .","Mechanism: **Additive direct local anesthetic effect**. Benzonatate is a local anesthetic acting on stretch receptors in lungs and pharynx, and when combined with other topical anesthetics (e.g., lidocaine or benzocaine in throat lozenges), anesthetic effects accumulate on mucous membranes."," : **     **       **** ** ** (Aspiration)             .    **  **     .      .","Clinical Significance: **Severe numbness of throat, mouth, and tongue**, significantly increasing the risk of **choking** and **pulmonary aspiration** during eating or drinking, as patient loses ability to feel food or liquids. **Tracheal anesthesia** may also occur, impairing protective cough reflex. Special risk in children and elderly.","   .       **   4-6   **.       **    **     .     .         .","Avoid combination strictly. If patient needs both treatments, **separate doses by at least 4-6 hours**. Educate patient not to eat or drink **for at least 1 hour** after taking either medication. Special warning about choking risk. If severe numbness occurs, seek immediate medical attention.");n("Benzphetamine","Serotonergic Drugs",e.DRUG_DRUG,i.HIGH,"             .","Benzphetamine increases serotonin release and inhibits its reuptake, magnifying the effect of other serotonergic drugs.","  (Serotonin Syndrome)          (Autonomic Instability).","Serotonin syndrome, characterized by fever, tremors, confusion, and autonomic instability.","  .     .","Avoid combination entirely. Close monitoring for signs and symptoms of Serotonin Syndrome.");n("Benzthiazide","Sulfonylureas",e.DRUG_DRUG,i.MODERATE,"      .","Thiazide diuretics exert an antagonistic effect on insulin secretion.","   (Hyperglycemia)    .","Hyperglycemia and reduced efficacy of Sulfonylureas.","    .       .","Monitor blood glucose periodically. Sulfonylurea dose may require adjustment.");n("Benztropine","Glaucoma (Narrow-Angle)",e.DRUG_DISEASE,i.HIGH,"   (Mydriasis)                 .","Mydriasis. Benztropine causes pupillary dilation, physically blocking the trabecular meshwork and precipitating an acute angle-closure glaucoma attack.","       .","Acute rise in Intraocular Pressure (IOP) and irreversible vision loss.",".            .","Contraindicated. Avoid use in patients with known or suspected narrow-angle glaucoma.");n("Benztropine","Disopyramide, Estramustine, Cefpodoxime",e.DRUG_DRUG,i.MODERATE,"   .            .","Delayed Gastric Emptying/Slowed GI Motility. Benztropine delays gastric emptying, which can significantly alter the rate and extent of absorption for co-administered drugs.","   .             .","Altered Absorption Rate. May lead to delayed onset of action or reduced overall bioavailability of the co-administered drugs.","  .            .","Monitor drug efficacy. Assess the patient's response to the co-administered drugs and consider separating doses if the interaction is clinically relevant.");n("Benztropine","Lidocaine",e.DRUG_DRUG,i.MODERATE,"  .         .","Delayed Gastric Emptying. Benztropine slows GI motility, potentially delaying the absorption and peak concentration of orally administered Lidocaine.","   .       .","Altered Lidocaine Efficacy. Delay in achieving therapeutic concentrations for oral Lidocaine.","  .      /  .","Monitor patient response. Check for clinical efficacy and adjust the dose or timing of oral Lidocaine if necessary.");n("Benztropine","Antipsychotics",e.DRUG_DRUG,i.MODERATE,"   ","Additive Anticholinergic Burden.","    ","Dry mouth, blurred vision, constipation.","   ","Monitor anticholinergic symptoms.");n("Benztropine","Haloperidol",e.DRUG_DRUG,i.MODERATE,"       .","Additive anticholinergic burden resulting from both Benztropine and Haloperidol.","           .","Severe dry mouth, constipation, urinary retention, blurred vision, and increased risk of delirium/confusion.","     (  ).    .","Monitor anticholinergic symptoms closely (especially in the elderly). Adjust the dose of one of the agents.");n("Benztropine","Phenothiazines",e.DRUG_DRUG,i.MODERATE,"   .","Additive anticholinergic effect from both agents.","             (  ).","Increased anticholinergic side effects, including delirium and impaired thermoregulation (heatstroke risk).","   .     .","Monitor neuro-psychiatric symptoms. Avoid high doses of Benztropine.");n("Bepridil",xt,e.DRUG_DRUG,i.HIGH,": **  QT **.       QT           .","Mechanism: **Synergistic QT prolongation**. Bepridil itself prolongs the QT interval, and co-administration with quinolones enhances this effect via potassium channel blockade."," : **      (Torsades de pointes)**.","Clinical Significance: **High risk of life-threatening cardiac arrhythmias (Torsades de pointes)**.","  .         QT.","Avoid combination. Use alternative antibiotics that do not affect the QT interval.");n("Bepridil","Ritonavir",e.DRUG_DRUG,i.HIGH,": **    CYP3A4**.     CYP3A4    .","Mechanism: **Metabolism inhibition via CYP3A4**. Ritonavir is a potent inhibitor of CYP3A4, which metabolizes Bepridil."," : **  **            QT .","Clinical Significance: **Increased Bepridil concentrations** and blood levels, increasing the risk of cardiac toxicity and severe QT prolongation.","      QT .","Avoid combination due to the risk of fatal QT prolongation.");n("Bepridil","Digoxin",e.DRUG_DRUG,i.MODERATE,"          .","Bepridil may inhibit the renal excretion of Digoxin, decreasing Digoxin clearance.","        (  ).","Increased serum Digoxin levels and risk of cardiac toxicity (arrhythmias).","       (ECG).     .","Monitor serum Digoxin levels and ECG. Digoxin dose may require reduction.");n("Bepridil","Sparfloxacin",e.DRUG_DRUG,i.HIGH,"    QT     .","Both agents significantly prolong the QT interval on the electrocardiogram.","         Torsades de Pointes .","Increased risk of fatal ventricular arrhythmias, specifically Torsades de Pointes.","  .           .","Absolute contraindication. Avoid combination and monitor ECG if inadvertently co-administered.");n("Bepridil","Gatifloxacin",e.DRUG_DRUG,i.HIGH,"    QT            ","Additive QT Prolongation. Concurrent use significantly increases the risk of Torsades de Pointes.","         torsades de pointes","         torsades de pointes","    -     (  )","    -     (  )");n("Bepridil","Moxifloxacin",e.DRUG_DRUG,i.HIGH,"    QT            ","Additive QT Prolongation. Concurrent use significantly increases the risk of Torsades de Pointes.","         torsades de pointes","         torsades de pointes","    -     (  )","    -     (  )");n("Bepridil","Sparfloxacin",e.DRUG_DRUG,i.HIGH,"    QT            ","Additive QT Prolongation. Concurrent use significantly increases the risk of Torsades de Pointes.","         torsades de pointes","         torsades de pointes","    -     (  )","    -     (  )");n("Bepridil","Ritonavir",e.DRUG_DRUG,i.HIGH,"Ritonavir increases Bepridil plasma concentrations by inhibiting hepatic enzymes (CYP3A4) responsible for its metabolism.","           ","Increased Bepridil concentrations - heightened therapeutic effect and risk of toxicity, specifically QTc prolongation.","   -    ","Avoid the concomitant use of both drugs due to the high risk of serious cardiac side effects.","   ");n("Berotralstat","P-glycoprotein Inhibitors",e.DRUG_DRUG,i.MODERATE,"  ","Increased Berotralstat concentration.","  ","Increased side effects.","  ","Adjust dose, monitor.");n(xn,"Cimetidine",e.DRUG_DRUG,i.MODERATE,": **     **.    CYP2D6  CYP3A4         .","Mechanism: **Enzyme inhibition and reduced hepatic blood flow**. Cimetidine inhibits CYP2D6 and CYP3A4 enzymes and reduces hepatic blood flow, decreasing beta-blocker clearance."," : **   ** (  )       .","Clinical Significance: **Increased beta-blocker levels** (especially Propranolol and Metoprolol), increasing the risk of bradycardia and hypotension.","  .            .","Monitor vital signs. Use Ranitidine or Famotidine as safe alternatives to Cimetidine, or reduce the beta-blocker dose.");n(xn,"Verapamil",e.DRUG_DRUG,i.HIGH,": **   (Synergistic Cardiac Depression)**.       (AV Node)   .","Mechanism: **Synergistic cardiac depression** (negative inotropic and chronotropic effects) on the AV node function and myocardial contractility."," : **   (Severe Bradycardia)**   (Heart Block)       .","Clinical Significance: Severe bradycardia, heart block, acute heart failure, and life-threatening hypotension.","     . ** **          .","Monitor cardiovascular status closely. **Avoid combination** in patients with left ventricular dysfunction or Congestive Heart Failure.");n(xn,xc,e.DRUG_DRUG,i.MODERATE,": **   (Prostaglandin Synthesis)** ( PGE2  PGI2)   NSAIDs   **  **            .","Mechanism: **Inhibition of Prostaglandin Synthesis** (especially PGE2 and PGI2) by NSAIDs leads to **sodium and water retention** in the kidneys, increasing blood volume and reducing the antihypertensive effect."," : **     **            (CHF)    .","Clinical Significance: **Decreased antihypertensive effects of beta-blocker** and increased risk of hypertension, potentially exacerbating Congestive Heart Failure (CHF) in susceptible patients.","   .  **NSAID  **  (  Solindac)    .       .","Monitor BP closely. Use a **noninteracting NSAID** (e.g., sulindac), or use paracetamol for analgesia. Adjust the beta-blocker dose if necessary.");n(xn,Tt,e.DRUG_DRUG,i.MODERATE,": **   (Enzyme Induction)**.           (    ).","Mechanism: **Hepatic enzyme induction**. Barbiturates increase the activity of liver enzymes responsible for metabolizing beta-blockers (especially lipid-soluble ones)."," : **    **           .","Clinical Significance: **Decreased beta-blocker levels and effects**, potentially leading to exacerbation of angina or hypertension.","  .          .","Monitor clinical response. Beta-blocker dose may need to be increased during concurrent use.");n(za,"Epinephrine",e.DRUG_DRUG,i.HIGH,": **     (Unopposed alpha stimulation)**.         $\beta_2$      (Vasoconstriction)  $alpha_1$   .","Mechanism: **Unopposed alpha stimulation**. Non-selective beta-blockers block $\beta_2$ vasodilation, leaving the vasoconstrictive effect of Epinephrine (via $alpha_1$ receptors) unopposed."," : **     (Acute Hypertensive Crisis)**     (Reflex Bradycardia).          .","Clinical Significance: **Acute hypertensive episode**, followed by reflex bradycardia. This is critical when Epinephrine is used in local anesthesia.","  .      3         .","Avoid combination. Discontinue beta-blocker 3 days prior to planned epinephrine administration.");n(za,"Ergot Alkaloids",e.DRUG_DRUG,i.HIGH,": **    **.                 (Vasodilation).","Mechanism: **Synergistic peripheral vasoconstrictive effect**. Non-selective beta-blockers enhance the vasoconstriction caused by Ergot Alkaloids by blocking $\beta_2$ vasodilation."," : **    (Severe Peripheral Ischemia)**         .","Clinical Significance: Severe peripheral ischemia, leading to cold extremities, pain, and potential gangrene.","  .         (Cardioselective).","Avoid combination. Use cardioselective beta-blockers if co-therapy is essential.");n(za,"Insulin",e.DRUG_DRUG,i.HIGH,": **    **.       (  )          .","Mechanism: **Blocking catecholamine response to hypoglycemia**. Beta-blockers prevent $\beta$-receptor mediated symptoms of hypoglycemia (tremor, palpitations) and delay hepatic glucose recovery."," : **   **           .","Clinical Significance: **Masking hypoglycemia symptoms**, increasing the risk of severe and prolonged unrecognized hypoglycemia.","          ( )    .      .","Monitor glucose regularly and educate patient on other unmasked symptoms (sweating, hunger). Use cardioselective beta-blockers if possible.");n(za,"Theophylline",e.DRUG_DRUG,i.MODERATE,": **  (Pharmacodynamic Antagonism)**.       (Bronchoconstriction)      (Beta-blockade vs Beta-stimulation).","Mechanism: **Pharmacodynamic antagonism**. Beta-blockers cause bronchoconstriction, opposing the bronchodilation effect of Theophylline (Beta-blockade vs Beta-stimulation)."," : **    **            (COPD).","Clinical Significance: **Reduced bronchodilation effect of Theophylline**, leading to exacerbation of asthma or COPD symptoms.","         COPD.      (Cardioselective) .","Avoid non-selective beta-blockers in asthma/COPD patients. Use cardioselective beta-blockers with caution.");n("Betamethasone","Diabetes Mellitus",e.DRUG_DISEASE,i.MODERATE," .             .","Insulin Resistance and Gluconeogenesis. Corticosteroids like Betamethasone induce glucose production and impair peripheral insulin sensitivity, severely impacting glucose control.","  (Hyperglycemia).         .","Hyperglycemia. Loss of glycemic control, requiring adjustment and potentially increased doses of antidiabetic medications.","  .       (  )       .","Monitor blood glucose closely and frequently. Antidiabetic medication doses must be adjusted during Betamethasone therapy and monitored after discontinuation.");n("Betamethasone","Diabetes / Hypertension",e.DRUG_DISEASE,i.MODERATE,"   (   )   (  )   .","Hyperglycemia & Fluid Retention. Corticosteroids induce gluconeogenesis (raising sugar) and possess some mineralocorticoid activity (retaining sodium and water), which raises blood pressure.","     .    .","Loss of Glycemic and Blood Pressure Control. Exacerbation of both chronic conditions.","   .            .","Monitor blood glucose and blood pressure meticulously. Antidiabetic and antihypertensive medication doses must be adjusted frequently during Corticosteroid therapy.");n("Betamethasone","NSAIDs",e.DRUG_DRUG,i.MODERATE,"   ","Additive effect on the stomach.","   ","Increased risk of gastric ulcer.","  ","Use gastric protectants.");n("Betaxolol","Clonidine",e.DRUG_DRUG,i.HIGH,"    .    (Betaxolol)         .","Antagonism in Blood Pressure Regulation. Co-administration of a beta-blocker (Betaxolol) and Clonidine alters the sympathetic nervous system feedback mechanisms.","    (Rebound Hypertension)            .","Severe Rebound Hypertension if Clonidine is withdrawn suddenly while the patient is on Betaxolol, or vice-versa, due to unopposed alpha-stimulation.","     .                .","Avoid abrupt discontinuation of either drug. If withdrawal is necessary, Betaxolol should be stopped several days *before* the gradual withdrawal of Clonidine is started, to prevent a hypertensive crisis.");n("Betaxolol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP3A4/2D6).        .","Enzymatic Metabolic Induction (CYP3A4/2D6). Barbiturates induce hepatic enzymes responsible for Betaxolol metabolism.","           (    ).","Decreased Betaxolol plasma concentration, leading to reduced drug efficacy (less beta-blockade).","     .          .","Monitor blood pressure and heart rate. Increase the Betaxolol dose if necessary to restore the desired therapeutic efficacy.");n("Betaxolol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Betaxolol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"         .                            .","Pharmacodynamic synergy combined with mutual pharmacokinetic effects. Betaxolol is partially hepatically metabolized; Hydralazine may increase Betaxolol concentration by reducing hepatic blood flow, while the primary blood pressure drop is due to the additive effects of both drugs.","            (Hypotension)   (Bradycardia)   .           .","Additive hypotensive effect, increasing the risk of severe hypotension and bradycardia (from Betaxolol). Possible increase in Hydralazine concentration exacerbates its side effects.","      .                   .","Closely monitor blood pressure and heart rate. Start with low doses and titrate gradually to avoid acute hypotension, and adjust the dose of one or both drugs if necessary.");n("Betaxolol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Betaxolol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic Hypotension. Combined effects lead to significant blood pressure drop.","     ","     ","     ","     ");n("Betrixaban","Rifampin",e.DRUG_DRUG,i.HIGH,"  Betrixaban. Rifampin   P-gp    Betrixaban.","Decreased Betrixaban efficacy. Rifampin is a P-gp inducer, a Betrixaban efflux transporter.","             .","Reduced drug plasma concentration, leading to failure of anti-coagulation and increased risk of thrombosis."," .   .","Contraindicated. Avoid the combination.");n("Bexagliflozin","Furosemide",e.DRUG_DRUG,i.HIGH,"    . Bexagliflozin (SGLT2i)      Furosemide    .","Increased risk of volume depletion. Bexagliflozin (SGLT2i) causes osmotic diuresis, and Furosemide is a potent loop diuretic.","              .","Acute increase in risk of dehydration, orthostatic hypotension, and potential acute kidney injury (AKI)."," .      .         .","Intensive monitoring. Signs of dehydration and blood pressure must be monitored. May require diuretic dose reduction or temporary discontinuation.");n("Bicalutamide","Ketoconazole",e.DRUG_DRUG,i.LOW,"    Bicalutamide. Ketoconazole   CYP3A4    Bicalutamide.","Slight increase in Bicalutamide concentration. Ketoconazole inhibits CYP3A4, a Bicalutamide metabolic pathway.","     .","No clinically significant effect expected.","    .   .","No special action required. They are used safely together.");n("Bicalutamide","Warfarin",e.DRUG_DRUG,i.MODERATE,"   ","Effect on Warfarin metabolism.","  ","Increased Warfarin effect."," INR","Monitor INR.");n("Bicalutamide","Warfarin",e.DRUG_DRUG,i.MODERATE,"  ","Protein displacement."," INR","Increased INR."," INR","Monitor INR.");n("Bictegravir","Antacids",e.DRUG_DRUG,i.HIGH,"  Bictegravir.          .","Decreased Bictegravir absorption. Formation of insoluble chelation compounds with polyvalent cations.","          .","Reduced drug plasma concentration, leading to viral treatment failure."," .   .    2   .","Dose separation. Avoid concurrent administration. Must be separated by at least 2 hours.");n("Bictegravir/Emtricitabine/Tenofovir","Antacids",e.DRUG_DRUG,i.MODERATE,"   ( )","Reduced Bictegravir absorption (chelation)."," ","Treatment failure."," 2    6    ","Separate 2 hours before or 6 hours after antacids.");n("Bictegravir/TAF/FTC (HIV Combination)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Bictegravir. Rifampin   UGT1A1  CYP3A4.","Decreased Bictegravir concentration. Rifampin is an inducer of UGT1A1 and CYP3A4.","      .","Reduced antiretroviral efficacy and treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Bictegravir/Tenofovir/Emtricitabine","Rifampin",e.DRUG_DRUG,i.HIGH,"  Bictegravir. Rifampin   UGT1A1  CYP3A4    Bictegravir.","Decreased Bictegravir concentration. Rifampin is an inducer of UGT1A1 and CYP3A4, Bictegravir metabolic pathways.","              .","Reduced drug plasma concentration, leading to failure of antiretroviral therapy and resistance development."," .   .","Contraindicated. Avoid the combination.");n("Bile Acid Sequestrants","HMG-CoA Reductase Inhibitors",e.DRUG_DRUG,i.MODERATE,"       (Statins)       .","Bile Acid Sequestrants form non-absorbable complexes with Statins in the intestine, reducing Statin absorption.","           .","Decreased Statin bioavailability and reduced efficacy in cholesterol lowering.","        4       ( ).","Administer Statins at least 1 hour before or 4 hours after the Bile Acid Sequestrant (Stagger Dosing).");n("Bile Acid Sequestrants","Hydrocortisone",e.DRUG_DRUG,i.MODERATE,"         .","Bile Acid Sequestrants bind to Hydrocortisone in the gastrointestinal tract, hindering its absorption.","            .","Decreased Hydrocortisone absorption and reduced therapeutic efficacy, potentially leading to adrenal insufficiency exacerbation.","         2-4    .","Separate the dosing times by at least 2-4 hours to ensure proper absorption.");n("Bimekizumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Bimekizumab    (IL-17A and IL-17F).","Increased risk of viral infection. Bimekizumab is an immunosuppressant (IL-17A and IL-17F inhibitor).","      (    ).","Risk of developing infection from live vaccines (same mechanism as other biological drugs)."," .       Bimekizumab.","Contraindicated. Live vaccines must be avoided during Bimekizumab treatment.");n("Bimekizumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Bimekizumab   IL-17A/F.","Reduced vaccine response/Increased infection risk. Bimekizumab is an IL-17A/F inhibitor.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Bimekizumab (IL-17A/F Inhibitor)","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  . Bimekizumab  .","Increased risk of infection. Bimekizumab is an immunosuppressant.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Binimetinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Binimetinib. Rifampin    CYP3A4    Binimetinib.","Decreased Binimetinib efficacy. Rifampin is a strong inducer of CYP3A4, a Binimetinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Binimetinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Binimetinib. Phenytoin    CYP3A4    Binimetinib.","Decreased Binimetinib concentration. Phenytoin is a strong inducer of CYP3A4, a Binimetinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Biperiden","Haloperidol",e.DRUG_DRUG,i.MODERATE,"            .","Additive anticholinergic effect from both agents, contributing to peripheral and psychiatric effects.","              .","Dry mouth, constipation, urinary retention, blurred vision, and potential for exacerbation of psychotic symptoms or delirium.","   .        .","Monitor for anticholinergic symptoms. Adjust doses as needed, especially in the elderly.");n("Biperiden","Phenothiazines",e.DRUG_DRUG,i.MODERATE,"         .","Additive anticholinergic effect and synergistic CNS depression.","         .","Increased anticholinergic side effects, delirium, and impaired thermoregulation.","       .   .","Close patient monitoring for anticholinergic toxicity signs. Avoid high doses.");n("Bisacodyl","PPIs/H2 Blockers",e.DRUG_DRUG,i.MODERATE,"  Bisacodyl.         Bisacodyl.","Decreased Bisacodyl efficacy. Reduced gastric acidity prematurely dissolves the Bisacodyl enteric coating.","  (Gastric irritation) .","Gastric irritation and cramps."," .   Bisacodyl         PPIs.","Dose separation. Bisacodyl must be taken at least one hour before antacids or PPIs.");n("Bisacodyl","Antacids",e.DRUG_DRUG,i.MODERATE,"   ","Dissolution of enteric coating."," ","Gastric irritation.","  ","Separate by 1 hour.");n("Bismuth Salts","Tetracyclines",e.DRUG_DRUG,i.HIGH,"       (Chelation)       /.","Bismuth salts are metallic ions that form non-absorbable complexes (Chelation) with Tetracyclines in the GI tract.","             .","Severe reduction in Tetracycline absorption and loss of their antimicrobial efficacy, leading to treatment failure.","  .      2-4   .","Avoid concurrent use. Separate the doses by at least 2-4 hours.");n("Bismuth Subgallate","Tetracyclines",e.DRUG_DRUG,i.HIGH,"         .","Bismuth Subgallate forms chelation complexes with Tetracyclines in the GI tract.","             .","Significant reduction in Tetracycline absorption and therapeutic efficacy, leading to sub-therapeutic levels.","  .     2-4   .","Avoid simultaneous combination. Separation of doses by 2-4 hours is mandatory.");n("Bismuth Subsalicylate","Tetracyclines",e.DRUG_DRUG,i.HIGH,"  ( )       .","Bismuth Subsalicylate (as a metallic element) forms insoluble complexes with Tetracyclines.","             .","Acute reduction in Tetracycline absorption and loss of its antibacterial effect, risking treatment failure.","  .     3-4   .","Avoid concurrent use. Separate the doses by at least 3-4 hours.");n("Bismuth Subsalicylate","Aspirin",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic salicylate effect."," ","Salicylate toxicity."," ","Avoid combination.");n("Bisoprolol","Verapamil (IV)",e.DRUG_DRUG,i.HIGH," .         (Inotropic)  (Chronotropic)       .","Cardiac Depression. The combination of a beta-blocker (Bisoprolol) and intravenous (IV) Verapamil (a non-dihydropyridine calcium channel blocker) exerts profound negative effects on inotropy, chronotropy, and dromotropy.","   (Cardiac Arrest).               .","Cardiac Arrest. High risk of severe bradycardia, complete Atrioventricular (AV) block, asystole, or fatal arrhythmia, especially when the IV route is used for Verapamil.",".             .","Contraindicated. This combination is generally contraindicated, particularly the use of IV Verapamil, due to the extreme risk of acute cardiotoxicity.");n("Bisoprolol","Diabetes Mellitus",e.DRUG_DISEASE,i.HIGH,"   .        (  )      .","Masking Hypoglycemia. Beta-blockers blunt the adrenergic warning signs of hypoglycemia (e.g., tremor, palpitations, anxiety) mediated by catecholamine release.","       (Hypoglycemia Unawareness).       .","Risk of Hypoglycemia Unawareness. May delay necessary treatment, leading to severe, prolonged hypoglycemia, coma, and potential fatality.","       ()   .           .","If beta-blocker therapy is necessary, use the lowest effective dose of a cardioselective agent like Bisoprolol. Educate the patient that sweating may be the only remaining warning sign.");n("Bisoprolol","Asthma / COPD ()",e.DRUG_DISEASE,i.HIGH," .      -1                  -2.","Bronchoconstriction. Bisoprolol is cardioselective (Beta-1), but at higher doses or in highly susceptible patients, it can cause bronchospasm by blocking pulmonary Beta-2 receptors.","    .","Acute Asthma Exacerbation. High risk of severe bronchospasm, wheezing, and life-threatening respiratory distress.","        .               .","Avoid beta-blockers in acute asthma. If mandatory, use Bisoprolol with extreme caution and closely monitor respiratory function, ensuring aggressive treatment for asthma is maintained.");n("Bisoprolol","Calcium Channel Blockers",e.DRUG_DRUG,i.MODERATE,"    (  )","Additive cardiac effect (conduction and contractility inhibition).","   ","Bradycardia, hypotension.","   ","Monitor vital signs regularly.");n("Bisoprolol - ","Verapamil - ",e.DRUG_DRUG,i.HIGH,"  (Pharmacodynamic Synergy).       (Inotropic)   (Chronotropic)   (Dromotropic)       (SA)   (AV).","Pharmacodynamic Synergy. Both have negative inotropic, chronotropic, and dromotropic effects, severely depressing SA and AV nodal function.","      (Severe Bradycardia)   (Heart Block)         (Heart Failure)        .","Critically increased risk of severe bradycardia, second- or third-degree heart block, and acute congestive heart failure, potentially leading to cardiogenic shock.","              .            ( ).","Absolute avoidance unless the patient is under close monitoring in an intensive care unit. Alternatives that do not heavily affect cardiac conduction (like Amlodipine) should be used.");n("Bisoprolol - ","Diltiazem - ",e.DRUG_DRUG,i.HIGH,"  (Pharmacodynamic Synergy).      AV    .","Pharmacodynamic Synergy. Both agents depress AV nodal conduction and myocardial contractility.","                         .","Critically increased risk of severe bradycardia, heart block, and heart failure risk. Although Diltiazem's risk is slightly lower than Verapamil, it is still very high.","                (ECG)      .","Absolute avoidance or use with extreme caution under continuous monitoring of heart rate and ECG, and titrate the dose to the lowest effective level.");n("Bisoprolol - ","Amlodipine - ",e.DRUG_DRUG,i.MODERATE,"      (Additive Hypotensive Synergy).      ( SVR)      (Cardiac Output).        AV.","Pharmacodynamic synergy in lowering blood pressure. Amlodipine causes vasodilation (lowers SVR), and Bisoprolol reduces cardiac output. They have minimal additive effect on AV conduction.","    (Excessive Hypotension)        .                .","Excessive hypotension and bradycardia, increasing the risk of dizziness and syncope. Rarely causes heart block but may worsen heart failure in susceptible patients.","         .               .","Monitor blood pressure and heart rate regularly upon initiation. This combination can be beneficial for hypertension, but dosages must be titrated cautiously.");n("Bisoprolol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP3A4).          .","Enzymatic Metabolic Induction (CYP3A4). Barbiturates induce hepatic enzymes responsible for part of Bisoprolol metabolism.","           (    ).","Decreased Bisoprolol plasma concentration, leading to reduced drug efficacy (less beta-blockade).","     .          .","Monitor blood pressure and heart rate. Increase the Bisoprolol dose if necessary to restore the desired therapeutic efficacy.");n("Bisoprolol - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       P450 (   CYP3A4  CYP2D6)      .         .","Cimetidine is a broad-spectrum inhibitor of Cytochrome P450 enzymes (including CYP3A4 and CYP2D6), which are responsible for Bisoprolol metabolism in the liver. This inhibition reduces the clearance rate of Bisoprolol from the body.","                    (Severe Bradycardia)    (Hypotension)    .","Significant increase in Bisoprolol plasma concentration, exacerbating the risk of beta-blocker related side effects such as severe bradycardia, hypotension, and increased potential for heart failure.","          .                 H2     CYP450 ( ).","Close monitoring of heart rate and blood pressure is required upon co-initiation. The dose of Bisoprolol may need to be reduced to mitigate the risk of cardiovascular toxicity, or Cimetidine may be substituted with another H2 blocker less likely to affect CYP450 (e.g., Famotidine).");n("Bisoprolol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"         .     50%                        .","Pharmacodynamic synergy combined with mutual pharmacokinetic effects. Bisoprolol is 50% hepatically metabolized; Hydralazine may increase Bisoprolol concentration by reducing hepatic blood flow, while the primary blood pressure drop is due to the additive effects of both drugs.","            (Hypotension)   (Bradycardia)   .           .","Additive hypotensive effect, increasing the risk of severe hypotension and bradycardia (from Bisoprolol). Possible increase in Hydralazine concentration exacerbates its side effects.","      .                   .","Closely monitor blood pressure and heart rate. Start with low doses and titrate gradually to avoid acute hypotension, and adjust the dose of one or both drugs if necessary.");n("Bisoprolol - ","Clonidine - ",e.DRUG_DRUG,i.HIGH,"         .        ( ).                  -1 ( ).","Unmasking of alpha-adrenergic effects upon abrupt Clonidine withdrawal. Clonidine withdrawal causes a Norepinephrine surge (rebound sympathetic activity). Bisoprolol blocks the Norepinephrine from acting on beta-receptors, forcing it to act unopposed on alpha-1 receptors (vasoconstriction).","       (Hypertensive Crisis)        .","Severe, life-threatening hypertensive crisis and severe bradycardia due to unopposed vasoconstriction.","     .         .             .","Near-absolute contraindication for abrupt withdrawal. Bisoprolol must be discontinued several days prior to Clonidine cessation. Clonidine must be tapered slowly over several weeks with close blood pressure monitoring.");n("Bisoprolol - ","Prazosin - ",e.DRUG_DRUG,i.MODERATE,"     (Synergistic Hypotension).       ( -1)          (SVR).","Synergistic Hypotension. Bisoprolol reduces cardiac output, while Prazosin (an alpha-1 blocker) causes vasodilation and reduces systemic vascular resistance (SVR).","            (Orthostatic Hypotension)         .","Significantly increased risk of hypotension, particularly orthostatic hypotension upon standing, which can lead to dizziness, syncope, and falls.","                   .    .","Close monitoring for symptoms of orthostatic hypotension, especially after the first dose of Prazosin or following a dose increase of either drug. Cautious dose titration is recommended.");n("Bisphosphonates","Calcium / Food",e.DRUG_FOOD,i.HIGH,"                  .","Reduced Absorption/Chelation. Bisphosphonates have extremely poor oral bioavailability, which is further diminished by the presence of calcium, food, or other minerals due to complex formation (chelation)."," .          .","Treatment Failure. Ineffective treatment of osteoporosis due to inadequate systemic absorption and resulting failure to reach therapeutic bone concentrations.","             30    (  )         .","Administer on an empty stomach with a full glass of plain water only. The patient must remain upright and wait at least 30 minutes (or as directed) before consuming food, beverages (other than water), or other medications.");n("Bleomycin","Digoxin",e.DRUG_DRUG,i.MODERATE,"               .","Bleomycin may cause renal damage and electrolyte changes that indirectly affect Digoxin clearance.","    ( )        .","Change in Digoxin levels (usually an increase) and heightened risk of cardiac toxicity and arrhythmias.","          .","Monitor Digoxin levels, electrolytes, and renal function regularly, with frequent ECG monitoring.");n("Bleomycin","Phenytoin",e.DRUG_DRUG,i.MODERATE,"             .","Unclear mechanism; Bleomycin may decrease Phenytoin absorption or increase its hepatic metabolism.","             .","Decreased Phenytoin levels and efficacy in seizure control, increasing the risk of breakthrough seizures.","      .          .","Monitor serum Phenytoin levels closely. The dose should be increased if necessary to maintain therapeutic concentration.");n("Bortezomib","Rifampin",e.DRUG_DRUG,i.MODERATE,"  Bortezomib. Rifampin   CYP3A4.","Decreased Bortezomib concentration. Rifampin is an inducer of CYP3A4.","    .","Reduced anti-tumor efficacy.","  .   CYP3A4 .","Relative contraindication. Avoid strong CYP3A4 inducers.");n("Bosutinib","Aluminum Hydroxide",e.DRUG_DRUG,i.HIGH,"  Bosutinib.          Bosutinib.","Decreased Bosutinib concentration. Antacids raise gastric pH, which is necessary for Bosutinib absorption.","            (CML).","Reduced drug plasma concentration, leading to failure of CML treatment."," .            Bosutinib.","Avoid simultaneous use. Antacids must be avoided for at least two hours before and after Bosutinib administration.");n("Bosutinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Bosutinib. Ketoconazole    CYP3A4    Bosutinib.","Increased Bosutinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Bosutinib metabolic pathway.","       .","Increased risk of side effects, especially diarrhea and hepatotoxicity."," .    Bosutinib     CYP3A4 .","Dose adjustment. Bosutinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Bosutinib","Famotidine (H2RA)",e.DRUG_DRUG,i.HIGH,"  Bosutinib. Bosutinib     .","Decreased Bosutinib concentration. Bosutinib requires an acidic environment for absorption.","     .","Reduced drug efficacy and failure of cancer treatment."," .   .","Contraindicated. Avoid the combination.");n("Brexanolone (Postpartum Depression)","Opioids",e.DRUG_DRUG,i.HIGH,"     .       .","Increased risk of sedation and respiratory depression. Additive CNS depressant effects.","   .","Life-threatening respiratory depression.","  .   .  .","Relative contraindication. Avoid the combination. Close monitoring.");n("Brexpiprazole","Itraconazole + Quinidine",e.DRUG_DRUG,i.HIGH,"  Brexpiprazole  . Itraconazole ( CYP3A4)  Quinidine ( CYP2D6)    .","Significantly increased Brexpiprazole concentration. Itraconazole (CYP3A4 inhibitor) and Quinidine (CYP2D6 inhibitor) block major metabolic pathways.","        (EPS)  .","Increased risk of side effects, especially Extrapyramidal Syndrome (EPS) and weight gain."," .    Brexpiprazole   (   ).","Dose adjustment. Brexpiprazole dose must be significantly reduced (to one quarter of the usual dose).");n("Brexpiprazole","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Brexpiprazole. Itraconazole    CYP3A4.","Increased Brexpiprazole concentration. Itraconazole is a strong inhibitor of CYP3A4.","   .","Increased risk of side effects."," .    Brexpiprazole ( ).","Dose adjustment. Brexpiprazole dose must be reduced (by half).");n("Brexpiprazole","CYP2D6 Inhibitors",e.DRUG_DRUG,i.MODERATE,"  xpiprazole","Increased Brexpiprazole concentration.","  ","Increased side effects.","  ()","Adjust dose (reduce).");n("Brexucabtagene Autoleucel","Methylprednisolone (High Dose)",e.DRUG_DRUG,i.HIGH,"   .     (T-cells)  .","Decreased cellular therapy efficacy. Corticosteroids kill genetically modified T-cells.","  CAR T-Cell        .","CAR T-Cell therapy failure and increased risk of cancer relapse due to destruction of therapeutic cells."," .        CRS    .","Avoid Combination. Systemic corticosteroids should be avoided except as treatment for severe CRS or neurotoxicity.");n("Brigatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Brigatinib. Ketoconazole    CYP3A4    Brigatinib.","Increased Brigatinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Brigatinib metabolic pathway.","         .","Increased risk of side effects, especially pulmonary toxicity and elevated liver enzymes."," .    Brigatinib     CYP3A4 .","Dose adjustment. Brigatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Brigatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Brigatinib. Rifampin    CYP3A4    Brigatinib.","Decreased Brigatinib concentration. Rifampin is a strong inducer of CYP3A4, a Brigatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Brigatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Brigatinib. Rifampin    CYP3A4.","Decreased Brigatinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Brimonidine","MAO Inhibitors",e.DRUG_DRUG,i.MODERATE,"    ","Potentiated effect on blood pressure.","   (  )","Blood pressure fluctuations.","  ","Caution with combination.");n("Brimonidine","MAO Inhibitors",e.DRUG_DRUG,i.MODERATE,"   ","Blood pressure effect.","  ","Hypertension."," ","Use cautiously.");n("Brivaracetam","CNS Depressants",e.DRUG_DRUG,i.MODERATE,"     ","Additive CNS effect."," ","Drowsiness, dizziness."," ","Avoid alcohol.");n("Brodalumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Brodalumab   IL-17.","Reduced vaccine response/Increased infection risk. Brodalumab is an IL-17 receptor antagonist.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Budesonide - ","Ritonavir -  (   CYP3A4)",e.DRUG_DRUG,i.HIGH,"      CYP3A4         (First-Pass Metabolism).","Ritonavir is a very potent inhibitor of CYP3A4, the primary enzyme responsible for the extensive metabolism (First-Pass Metabolism) of Budesonide.","     (Systemic Exposure) .                .","Profound increase in the systemic bioavailability of Budesonide. This rapidly leads to severe systemic corticosteroid toxicity symptoms, such as Cushings syndrome and adrenal suppression.","   ( ).         CYP3A4     .","Absolute Contraindication (Avoid). An alternative corticosteroid that does not rely on CYP3A4 metabolism must be used if the patient is taking Ritonavir.");n("Budesonide - ","Ketoconazole -  (   CYP3A4)",e.DRUG_DRUG,i.HIGH,"   CYP3A4            .","Ketoconazole inhibits CYP3A4, reducing Budesonide metabolism and increasing its systemic exposure.","         (Adrenal Suppression)  .","Increased risk of systemic side effects such as adrenal suppression and reduced bone density."," .           (Hypercorticism)         .","Avoid the combination. If co-administration is necessary, closely monitor for signs of hypercorticism, and a significant reduction in the Budesonide dose may be required.");n("Budesonide - ","Furosemide -  (  )",e.DRUG_DRUG,i.MODERATE,"     (Hypokalemia).        .","Additive hypokalemic effects. Corticosteroids increase renal potassium loss.","                .","Significantly increased risk of hypokalemia, potentially leading to serious cardiac arrhythmias and muscle weakness.",".                .","Monitor. Closely monitor serum potassium levels; potassium supplementation may be required.");n("Budesonide - ","Live Attenuated Vaccines (  )",e.DRUG_VACCINE,i.MODERATE,"          .","Budesonide, especially at high systemic doses, can suppress the immune response.","          .","Reduced vaccine efficacy, and increased risk of infection from the live vaccine.","                     .","Avoid administering live attenuated vaccines to patients receiving high systemic doses of Budesonide, or for at least one month after stopping therapy.");n("Bulevirtide","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Bulevirtide. Cyclosporine   OATP1B1/3    Bulevirtide.","Increased Bulevirtide concentration. Cyclosporine inhibits OATP1B1/3 transporters, which are essential for Bulevirtide transport.","      .","Increased risk of hepatotoxicity and other side effects."," .    OATP     Bulevirtide.","Dose adjustment. Strong OATP inhibitors should be avoided or Bulevirtide dose adjusted.");n("Bulevirtide","Rifampin",e.DRUG_DRUG,i.HIGH,"  Bulevirtide. Rifampin   OATP1B1/3     Bulevirtide.","Decreased Bulevirtide efficacy. Rifampin induces OATP1B1/3 transporters, reducing Bulevirtide exposure.","              (HDV).","Reduced drug plasma concentration, leading to HDV treatment failure."," .    OATP .","Avoid Combination. Strong OATP inducers must be avoided.");n("Bumetanide","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic ototoxicity.","   ","Increased risk of hearing loss."," ","Monitor hearing.");n("Bumetanide","Aminoglycosides",e.DRUG_DRUG,i.HIGH,"   (Ototoxicity)   (Nephrotoxicity)   .","Synergistic Ototoxicity and Nephrotoxicity from both agents.","              .","Increased risk of permanent hearing loss, tinnitus, and acute renal failure which may require dialysis.","   .         .","Avoid combination if possible. Monitor hearing and renal function regularly, with careful dose adjustment.");n("Bumetanide","Digoxin",e.DRUG_DRUG,i.MODERATE," ( )    /        .","Bumetanide (loop diuretic) causes hypokalemia and/or hypomagnesemia, increasing myocardial sensitivity to Digoxin.","    (   )    .","Increased risk of Digoxin toxicity (serious cardiac arrhythmias) even at therapeutic levels.","    .      .","Monitor Potassium and Digoxin levels closely. Potassium supplementation is essential for toxicity prevention.");n("Bumetanide","Aminoglycosides",e.DRUG_DRUG,i.HIGH,"   ","Synergistic ototoxicity and nephrotoxicity.","   ","Hearing loss and renal failure.","  -   ","Avoid - or close monitoring.");n("Buprenorphine","Benzodiazepines",e.DRUG_DRUG,i.HIGH,"     ","Additive CNS effect.","  ","Respiratory depression, coma.","       ","Avoid combination or use very low doses with monitoring.");n("Buprenorphine/Naloxone","Alprazolam",e.DRUG_DRUG,i.HIGH,"      .   .","Increased risk of CNS and respiratory depression. Additive depressant effects.","    .","Life-threatening respiratory depression and death."," .   .            .","Contraindicated. Avoid the combination. If usage is necessary, benzodiazepine doses must be reduced and strict warning given.");n("Bupropion","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"     (CYP450)  CYP2B6        .","Enzyme Induction. Carbamazepine is a potent inducer of hepatic enzymes (primarily CYP2B6), significantly increasing the metabolism and clearance of Bupropion.","  .              .","Reduced Bupropion Efficacy. Decreased plasma concentrations of Bupropion and its active metabolites, leading to reduced antidepressant or smoking cessation efficacy.","  .            .","Monitor clinical response closely. A significant increase in the Bupropion dosage may be required to maintain therapeutic effect, or an alternative combination should be considered.");n("Bupropion","MAO Inhibitors (MAOIs)",e.DRUG_DRUG,i.HIGH,"                 .","Metabolic Inhibition and Synergism. MAOIs inhibit the metabolism of catecholamines, while Bupropion increases their release, leading to synergistic central nervous system (CNS) stimulation.","             .","Increased risk of Neurotoxicity, Seizures, and Hypertensive Crisis. This combination can lead to severe CNS overstimulation and potentially fatal toxicity.",".     .       14      MAO   .","Contraindicated. Avoid concurrent use. A minimum washout period of 14 days is required after discontinuing an MAOI before initiating Bupropion therapy.");n("Bupropion","Ritonavir",e.DRUG_DRUG,i.HIGH,"   .      (  CYP2B6)     .","Inhibition of Metabolism. Ritonavir is a potent inhibitor of the enzyme CYP2B6, which is primarily responsible for the metabolism of Bupropion, leading to dramatically increased Bupropion plasma concentrations.","  .     (Seizures)     .","Increased Bupropion Toxicity. Significantly elevated risk of Bupropion-related adverse effects, particularly the dose-dependent risk of seizures.","    .              .","Avoid this combination if possible. If co-administration is necessary, drastically reduce the Bupropion dose and monitor closely for signs of toxicity, especially seizures.");n("Bupropion","Paroxetine",e.DRUG_DRUG,i.HIGH," .     CYP2D6          .","Metabolic Inhibition. Paroxetine is a strong inhibitor of CYP2D6, a minor metabolic pathway for Bupropion and responsible for clearing its active metabolites.","             (Seizures) .","Increased Bupropion and metabolite concentrations, substantially increasing the risk of seizures and toxicity."," .    Bupropion   (   50%)    .     .","Dose adjustment. The Bupropion dose must be significantly reduced (potentially by 50%) when initiating Paroxetine. Close monitoring for neurological symptoms is necessary.");n("Bupropion","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"     ","Increased risk of seizures and hypertensive reactions."," ","Seizures."," ","Avoid combination.");n("Bupropion","Caffeine",e.DRUG_FOOD,i.MODERATE,"       (Additive CNS Stimulation).      .","Additive CNS stimulant effects. Both Bupropion and Caffeine act as CNS stimulants.","              .","Increased risk of Nervousness, Anxiety, Insomnia, and potential Seizures at very high Caffeine doses.","     .          .","Monitor symptoms and limit Caffeine intake. Advise reduction of caffeinated beverages and monitor for anxiety and insomnia.");n("Bupropion","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"   .     CYP3A4      .","Partial Metabolic Inhibition. Grapefruit juice inhibits CYP3A4 enzymes, which are partially involved in Bupropion metabolism.","             .","May lead to a slight increase in Bupropion concentrations, with a potential increase in side effects.","    .             .","No routine dose adjustment required. Avoid consuming large amounts of juice at the same time as the medication and monitor for side effects.");n("Bupropion","Green Tea",e.DRUG_FOOD,i.MODERATE,"   ( )     CYP2D6.           .","Additive Stimulant Effect (due to Caffeine content) and Potential CYP2D6 Interference. Green tea contains Caffeine and compounds that may affect the metabolic pathway.","       .    .","Increased risk of Nervousness, Insomnia, and mild Blood Pressure elevation. Increased stimulant side effects.","      .        .","Monitor symptoms and limit Green Tea intake. Handle this interaction cautiously, especially for Caffeine-sensitive patients.");n("Bupropion","Milk",e.DRUG_FOOD,i.LOW,"      (XL).              .","May delay absorption of Extended-Release (XL) formulations. Taking the dose with a high-fat meal or milk may delay reaching the peak concentration.","           .       .","Slight delay in reaching peak concentration, no significant change in overall efficacy. May be relevant for initial doses.","  .           .","No adjustment required. If reduced efficacy is noted, advise taking the medication on an empty stomach.");n("Bupropion","Alcohol",e.DRUG_FOOD,i.HIGH,": **   (Seizure Threshold)**.                .","Mechanism: **Lowering of Seizure Threshold**. Both Bupropion and Alcohol can lower the seizure threshold, synergistically increasing the risk of seizures."," : **  **         .       .","Clinical Significance: **Risk of Seizures**, especially during abrupt alcohol withdrawal or excessive consumption. Alcohol may also reduce drug efficacy.","          .","Avoid alcohol completely or minimize consumption strictly during treatment.");n("Bupropion","Levodopa",e.DRUG_DRUG,i.HIGH,": **  **.           .","Mechanism: **Increased Dopaminergic Activity**. Bupropion inhibits dopamine reuptake, potentially potentiating Levodopa side effects."," : **     **     (Psychosis).","Clinical Significance: **Increased risk of neuropsychiatric side effects**, such as nausea, insomnia, and psychosis.","  .     .","Monitor patient closely. Levodopa dose reduction may be required.");n("Bupropion","MAOI_INHIBITORS",e.DRUG_DRUG,i.HIGH,": ** **.          .","Mechanism: **Catecholamine Accumulation**. Combination may lead to excessive dopamine and norepinephrine levels."," : **    **   .   (Contraindicated).","Clinical Significance: **Risk of acute hypertensive reactions** and severe toxicity. Contraindicated.","        14 .","Allow at least 14 days washout period between treatments.");n("Bupropion",["Ritonavir","Efavirenz","Lopinavir"],e.DRUG_DRUG,i.MODERATE,": **  CYP2B6**.           .","Mechanism: **CYP2B6 Induction**. These drugs induce the metabolism of Bupropion, reducing its plasma levels."," : **  **           .","Clinical Significance: **Reduced Bupropion efficacy**, potentially leading to failure of depression treatment or smoking cessation.","  .     .","Monitor therapeutic response. Bupropion dose increase may be necessary.");n("Burosumab","High-dose Phosphate or Vitamin D Analogs",e.DRUG_DRUG,i.MODERATE,"    .   .","Increased risk of hyperphosphatemia. Additive pharmacodynamic effect.","      .","Risk of high calcium and phosphate levels in the blood."," .         Burosumab.","Close monitoring. Oral supplements must be discontinued one week before initiating Burosumab.");n("Buspirone","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  ","Increased Buspirone Efficacy. Elevated levels enhance anxiolytic or sedative effects.","    ","    ","     ( /  /  )   ","     ( /  /  )   ");n("Buspirone","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  ","Increased Buspirone Efficacy. Elevated levels enhance anxiolytic or sedative effects.","    ","    ","     ( /  /  )   ","     ( /  /  )   ");n("Buspirone","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  ","Increased Buspirone Efficacy. Elevated levels enhance anxiolytic or sedative effects.","    ","    ","     ( /  /  )   ","     ( /  /  )   ");n("Buspirone","Voriconazole",e.DRUG_DRUG,i.MODERATE,"  ","Increased Buspirone Efficacy. Elevated levels enhance anxiolytic or sedative effects.","    ","    ","     ( /  /  )   ","     ( /  /  )   ");n("Buspirone","Macrolide Antibiotics",e.DRUG_DRUG,i.MODERATE,"  ","Increased Buspirone Efficacy. Elevated levels enhance anxiolytic or sedative effects.","    ","    ","        ( /  / )    -      ","        ( /  / )    -      ");n("Buspirone","Rifamycins",e.DRUG_DRUG,i.MODERATE,"  ","Increased Buspirone Efficacy. Elevated levels enhance anxiolytic or sedative effects.","    ","    ","    ( /  /  ) ","    ( /  /  ) ");n("Buspirone","Grapefruit Juice",e.DRUG_FOOD,i.HIGH," CYP3A4  -      900%","Intestinal CYP3A4 inhibition - bioavailability increase up to 900%.","     - ","Massive increase in drug levels - toxicity.","    ","Avoid grapefruit juice entirely.");n("Buspirone","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"  ","Hypertension.","   ","Hypertensive crisis."," ","Avoid combination.");n("Butalbital","Doxycycline",e.DRUG_DRUG,i.MODERATE," ( )    CYP3A4    .","Butalbital (as an enzyme inducer) induces hepatic CYP3A4 enzymes responsible for Doxycycline metabolism.","             .","Decreased Doxycycline plasma levels and reduced antimicrobial efficacy, potentially leading to treatment failure.","   .            .","Monitor clinical response. Doxycycline dose may need to be increased or an antibiotic not affected by induction should be used.");n("Butalbital","Estrogens",e.DRUG_DRUG,i.HIGH,"        (        ).","Butalbital induces hepatic enzymes responsible for Estrogen metabolism (including those in oral contraceptives).","                 .","Decreased Estrogen levels and efficacy, reducing contraceptive effectiveness and increasing unintended pregnancy risk.","        ( )    .","Advise use of an additional or alternative (non-hormonal) contraceptive method throughout Butalbital therapy.");n("Butalbital","Ethanol",e.DRUG_DRUG,i.HIGH,"           (Barbiturate + Alcohol).","Additive and synergistic CNS depressant effect from both substances (Barbiturate + Alcohol).","                .","Increased risk of severe CNS depression, leading to profound dizziness, somnolence, respiratory compromise, and loss of consciousness.","       .     .","Total avoidance of alcohol during Butalbital therapy. Warn the patient about safety hazards.");n("Butalbital","Felodipine",e.DRUG_DRUG,i.MODERATE,"   CYP3A4         .","Butalbital induces hepatic CYP3A4 enzymes responsible for the metabolism of calcium channel blockers like Felodipine.","            .","Decreased Felodipine plasma levels and reduced efficacy in lowering blood pressure and controlling angina.","    .             .","Monitor blood pressure and clinical response. Felodipine dose may need adjustment or an alternative drug should be used.");n("Butalbital","Griseofulvin",e.DRUG_DRUG,i.MODERATE,"       .","Butalbital induces hepatic enzymes responsible for Griseofulvin metabolism.","               .","Decreased Griseofulvin plasma levels and reduced antifungal efficacy, potentially leading to fungal treatment failure.","    .     .","Monitor clinical response to fungal treatment. Griseofulvin dose may need to be increased.");n("Butalbital","Methadone",e.DRUG_DRUG,i.HIGH,"    CYP3A4 CYP2B6     .","Butalbital induces hepatic CYP3A4 and CYP2B6 enzymes responsible for the metabolic clearance of Methadone.","            (Withdrawal)    .","Decreased Methadone plasma levels, which may lead to withdrawal symptoms and loss of analgesic efficacy.","   .         .","Monitor for withdrawal symptoms. Methadone dose may need careful upward adjustment to maintain therapeutic levels.");n("Butalbital","Metronidazole",e.DRUG_DRUG,i.MODERATE,"       .","Butalbital induces hepatic enzymes responsible for Metronidazole metabolism.","         .","Decreased Metronidazole plasma levels and reduced efficacy as an anti-parasitic and antibacterial agent.","   .         .","Monitor clinical response to infection. Metronidazole dose or treatment duration may need adjustment.");n("Butalbital","Nifedipine",e.DRUG_DRUG,i.MODERATE,"   CYP3A4     .","Butalbital induces hepatic CYP3A4 enzymes responsible for Nifedipine metabolism.","              .","Decreased Nifedipine plasma levels and reduced efficacy in lowering blood pressure and controlling angina.","    .          .","Monitor blood pressure and clinical response. Nifedipine dose may need to be increased or an alternative calcium blocker used.");n("Butalbital","Quinidine",e.DRUG_DRUG,i.HIGH,"       .","Butalbital induces hepatic enzymes responsible for Quinidine metabolism.","                   .","Decreased Quinidine plasma levels and loss of efficacy in treating cardiac arrhythmias, increasing the risk of relapse.","      .        .","Monitor ECG and serum Quinidine levels. Dose adjustment is necessary to achieve the required therapeutic level.");n("Butalbital","Theophylline",e.DRUG_DRUG,i.MODERATE,"     CYP1A2    .","Butalbital induces hepatic enzymes, particularly CYP1A2, responsible for Theophylline metabolism.","            (  ).","Decreased Theophylline plasma levels and reduced efficacy in treating respiratory diseases (asthma and COPD).","      .     .","Monitor serum Theophylline levels and clinical response. Theophylline dose may need to be increased.");n("C1 Esterase Inhibitor","Fibrinolytics",e.DRUG_DRUG,i.MODERATE,"   ","Effect on coagulation system.","  ","Increased risk of thrombosis.","     ","Caution with combination, monitor for thrombosis signs.");n("Cabotegravir/Rilpivirine (Cabenuva)","Rifampin",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.  Rifampin  Rilpivirine    80%.","Mechanism: **Potent CYP3A4 induction**. Rifampin reduces Rilpivirine concentration by >80%."," : **     **   .","Clinical Significance: **HIV treatment failure** and development of viral resistance.","  .     .","Absolute contraindication. Must completely avoid combination.");n("Cabotegravir/Rilpivirine (Cabenuva)","Carbamazepine",e.DRUG_DRUG,i.CONTRAINDICATED,": **   **.      .","Mechanism: **Hepatic metabolism induction**. Both drug concentrations significantly decrease."," : **     **  .","Clinical Significance: **HIV treatment failure** and drug resistance."," .      Levetiracetam.","Contraindicated. Use alternative anticonvulsant such as Levetiracetam.");n("Cabotegravir/Rilpivirine (Cabenuva)","St. John's Wort",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.       .","Mechanism: **Herbal CYP3A4 induction**. Reduces antiretroviral drug efficacy."," : **     **.","Clinical Significance: **HIV treatment failure**."," .      .","Contraindicated. Must completely avoid St. John's Wort.");n("Cabozantinib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Cabozantinib. Clarithromycin    CYP3A4    Cabozantinib.","Increased Cabozantinib concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Cabozantinib metabolic pathway.","       .","Increased risk of side effects, such as gastrointestinal perforation and hemorrhage."," .    Cabozantinib     CYP3A4 .","Dose adjustment. Cabozantinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Cabozantinib","Pantoprazole",e.DRUG_DRUG,i.MODERATE,"  Cabozantinib. PPIs        Cabozantinib.","Decreased Cabozantinib concentration. PPIs reduce gastric acidity, which is necessary for Cabozantinib absorption.","       .","Reduced drug concentration, leading to loss of efficacy."," .   PPIs         .","Avoid Combination. PPIs should preferably be avoided, and antacids used with a long time interval instead.");n("Cabozantinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Cabozantinib. Carbamazepine    CYP3A4    Cabozantinib.","Decreased Cabozantinib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Cabozantinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Cabozantinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Cabozantinib. Itraconazole    CYP3A4    Cabozantinib.","Increased Cabozantinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Cabozantinib metabolic pathway.","        QT.","Increased risk of hypertension, hemorrhage, and QT prolongation."," .    Cabozantinib     CYP3A4 .","Dose adjustment. Cabozantinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Cabozantinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Cabozantinib.       CYP3A4  .","Increased Cabozantinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","     QT.","Increased risk of hemorrhage and QT prolongation."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Cabozantinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Cabozantinib. Phenytoin    CYP3A4.","Decreased Cabozantinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure.","  .   CYP3A4 .","Relative contraindication. Strong CYP3A4 inducers must be avoided.");n("Cabozantinib","Omeprazole (PPI)",e.DRUG_DRUG,i.LOW,"    .        Cabozantinib.","No clinically significant interaction. Acid does not significantly affect Cabozantinib absorption.","   .","No known effect.","    .","No special action required.");n("Caffeine","Drugs affecting renal flow (e.g., Diuretics, NSAIDs)",e.DRUG_DRUG,i.MODERATE,"       (   )               .","Alteration of Renal Hemodynamics and Reabsorption. Caffeine itself can affect renal blood flow (mild vasoconstriction) and interfere with sodium and water reabsorption, potentially altering the efficacy or clearance of co-administered renal agents.","      .           .","Altered drug concentration and clearance. May result in increased urinary excretion for some drugs (e.g., Lithium) or enhanced effects/toxicity for others.","      .          .","Monitor renal function, fluid balance, and blood pressure closely. Dose adjustment of the affected drug (the one with altered clearance) may be necessary.");n("Calcipotriene","Salicylic Acid",e.DRUG_DRUG,i.MODERATE," ","Calcipotriene inactivation."," ","Reduced efficacy.","   ","Apply at different times.");n("Calcitonin-Salmon","Lithium",e.DRUG_DRUG,i.MODERATE,"  ","Reduced calcitonin efficacy.","   ","Reduced calcium effect."," ","Monitor calcium.");n("Calcitriol","Thiazide Diuretics",e.DRUG_DRUG,i.HIGH,"  ","Increased calcium absorption.","  ","Hypercalcemia."," ","Monitor calcium.");n("Calcium","Levothyroxine",e.DRUG_DRUG,i.MODERATE," ","Complex formation.","  ","Reduced hormone absorption.","  4 ","Separate by 4 hours.");n("Calcium Acetate","Tetracyclines",e.DRUG_DRUG,i.HIGH,"          ","Calcium forms non-absorbable complexes with Tetracyclines in the GI tract.","      ","Severe reduction in Tetracycline absorption and loss of efficacy.","  .     2-4 ","Avoid concurrent use. Separate doses by 2-4 hours.");n("Calcium Carbonate","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE," .              (Chelation).","Reduced Absorption/Chelation. Calcium and other divalent cations bind to Ciprofloxacin, forming non-absorbable complexes.","   .              .","Reduced Antibiotic Efficacy. Significantly lowered Ciprofloxacin plasma concentrations can result in treatment failure and potential bacterial resistance.","     .               .","Separate Doses by at least 2 hours (before) or 4-6 hours (after) the Ciprofloxacin dose.");n("Calcium Carbonate","Levofloxacin",e.DRUG_DRUG,i.MODERATE," .              (Chelation).","Reduced Absorption/Chelation. Calcium and other divalent cations bind to Levofloxacin, forming non-absorbable complexes.","   .              .","Reduced Antibiotic Efficacy. Significantly lowered Levofloxacin plasma concentrations can result in treatment failure and potential bacterial resistance.","     .               .","Separate Doses by at least 2 hours (before) or 4-6 hours (after) the Levofloxacin dose.");n("Calcium Carbonate","Moxifloxacin",e.DRUG_DRUG,i.MODERATE," .              (Chelation).","Reduced Absorption/Chelation. Calcium and other divalent cations bind to Moxifloxacin, forming non-absorbable complexes.","   .              .","Reduced Antibiotic Efficacy. Significantly lowered Moxifloxacin plasma concentrations can result in treatment failure and potential bacterial resistance.","     .               .","Separate Doses by at least 2 hours (before) or 4-6 hours (after) the Moxifloxacin dose.");n("Calcium Carbonate","Ofloxacin",e.DRUG_DRUG,i.MODERATE," .              (Chelation).","Reduced Absorption/Chelation. Calcium and other divalent cations bind to Ofloxacin, forming non-absorbable complexes.","   .              .","Reduced Antibiotic Efficacy. Significantly lowered Ofloxacin plasma concentrations can result in treatment failure and potential bacterial resistance.","     .               .","Separate Doses by at least 2 hours (before) or 4-6 hours (after) the Ofloxacin dose.");n("Calcium Carbonate","Norfloxacin",e.DRUG_DRUG,i.MODERATE," .              (Chelation).","Reduced Absorption/Chelation. Calcium and other divalent cations bind to Norfloxacin, forming non-absorbable complexes.","   .              .","Reduced Antibiotic Efficacy. Significantly lowered Norfloxacin plasma concentrations can result in treatment failure and potential bacterial resistance.","     .               .","Separate Doses by at least 2 hours (before) or 4-6 hours (after) the Norfloxacin dose.");n("Calcium Carbonate","Lidocaine",e.DRUG_DRUG,i.MODERATE,"   .    ( )           .","Altered pH/Local Factors. Calcium carbonate (as an antacid) increases gastric pH, which can affect the dissolution and absorption of orally administered Lidocaine.","   .         .","Altered Lidocaine Efficacy. Delay in achieving therapeutic concentrations for oral Lidocaine.","  .      /  .","Monitor patient response. Check for clinical efficacy and adjust the dose or timing of oral Lidocaine if necessary.");n("Calcium Carbonate","Tetracycline",e.DRUG_DRUG,i.MODERATE,"  .              (Chelation).","Reduced Absorption/Chelation. Calcium and other divalent cations bind to tetracycline antibiotics in the gastrointestinal tract, forming non-absorbable complexes (chelation).","   .           .","Reduced Antibiotic Efficacy. Significantly lowered antibiotic plasma concentrations can result in treatment failure.","     .                  .","Separate Doses by at least 2 hours (before) or 4 hours (after) the tetracycline dose. Advise the patient to avoid simultaneous consumption.");n("Calcium Carbonate","Levothyroxine",e.DRUG_DRUG,i.MODERATE,"  ","Intestinal binding.","    ","Uncontrolled hypothyroidism.","  4 ","Separate by 4 hours.");n("Calcium Channel Blockers (Verapamil, Diltiazem)","Advanced Heart Block / Sick Sinus Syndrome",e.DRUG_DISEASE,i.CONTRAINDICATED,"    (SA Node)  AV Node    .","Inhibition of the SA Node and AV Node, slowing electrical conduction.","   (Severe Bradycardia)   (Asystole)  (Syncope)   .","Severe bradycardia, asystole, syncope, and complete heart block.","    AV   /         .","Absolute contraindication in second/third-degree AV block or Sick Sinus Syndrome without a pacemaker.");n("Calcium Iodide","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Calcium Supplements","High-Fiber Foods",e.DRUG_FOOD,i.MODERATE,"       (       )    (   )        : (1)   :             (2)       (phytic acid)      (3)             (4)    pH  .     :   (  30-40   )   .","Dietary fiber, especially insoluble fiber (in whole grains, wheat bran, flaxseeds) and soluble fiber (pectin in apples, psyllium), affects calcium absorption through several mechanisms: (1) direct physical binding: fiber binds calcium ions and traps them in its network structure, forming non-absorbable complexes, (2) some fibers contain phytic acid and oxalates that chemically bind calcium, (3) fiber accelerates intestinal motility reducing contact time between calcium and intestinal mucosa, (4) may affect gastric and intestinal pH. Effect depends on fiber amount: high doses (>30-40g fiber daily) have greater impact.","      10-30%    -           - : (1)        (2)                       (3)         () (4)        .             -      .","Moderate calcium absorption decrease by 10-30%, which may lead - long-term with very high fiber intake - to: (1) decreased accumulated calcium levels in bones, (2) increased osteoporosis risk or reduced bone density especially in postmenopausal women, elderly, or those with other risk factors, (3) possible hypocalcemia in very severe cases (rare), (4) failure of osteoporosis treatment or prevention with calcium supplements. Note this effect requires very high fiber amounts for prolonged periods - moderate fiber is very healthy and necessary.","  : (1)    -    (     ) -        (2)            (3) :       ( )  7     10      5     (4)     (psyllium, Metamucil)    (5)       (  40  ):            D  (6)      D  (      ) (7)     :        (8)         .","Balanced, practical approach: (1) don't avoid fiber - it's essential for health (prevents constipation, lowers cholesterol, regulates glucose) - just space timing from calcium, (2) take calcium supplements two hours before high-fiber meal, or two hours after, (3) for example: if eating whole grain breakfast cereal (fiber-rich) at 7 AM, take calcium at 10 AM, or take calcium at 5 AM if waking early, (4) avoid taking fiber supplements (psyllium, Metamucil) directly with calcium, (5) for people on very high-fiber diet (>40g daily): discuss with physician possible calcium dose increase or vitamin D and calcium level testing, (6) ensure adequate vitamin D (improves calcium absorption even with fiber present), (7) for osteoporosis treatment patients: separate timing adherence very important for efficacy, (8) consume fiber from varied sources not just concentrated supplements.");n("Canagliflozin (SGLT2)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Canagliflozin. Rifampin    UGT    Canagliflozin.","Decreased Canagliflozin concentration. Rifampin is a strong inducer of UGT enzymes, a Canagliflozin metabolic pathway.","          .","Reduced glycemic efficacy, leading to hyperglycemia.","    .       Canagliflozin.","Avoid combination or dose increase. Canagliflozin dose may need to be increased.");n("Canagliflozin (SGLT2)","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  Canagliflozin. Phenytoin    UGT    Canagliflozin.","Decreased Canagliflozin concentration. Phenytoin is a strong inducer of UGT, a Canagliflozin metabolic pathway.","    .","Reduced glycemic efficacy."," .       Canagliflozin   .","Blood sugar monitoring. Closely monitor blood sugar and adjust Canagliflozin dose if necessary.");n("Cannabidiol","Clopidogrel",e.DRUG_DRUG,i.MODERATE,"  Cannabidiol. Clopidogrel   CYP2C19     Cannabidiol.","Increased Cannabidiol concentration. Clopidogrel inhibits CYP2C19, a metabolic pathway for Cannabidiol.","        .","Increased risk of side effects such as drowsiness and elevated liver enzymes.","  .         .","Liver enzyme monitoring. No contraindication, but liver functions must be checked.");n("Cannabidiol","Rifampin",e.DRUG_DRUG,i.HIGH,"  Cannabidiol. Rifampin    CYP3A4    Cannabidiol.","Decreased Cannabidiol efficacy. Rifampin is a strong inducer of CYP3A4, a Cannabidiol metabolic pathway.","           .","Reduced drug plasma concentration, leading to loss of seizure control."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Cannabidiol","Amiodarone",e.DRUG_DRUG,i.MODERATE,"  Cannabidiol. Amiodarone   CYP2C9    Cannabidiol.","Increased Cannabidiol concentration. Amiodarone inhibits CYP2C9, a Cannabidiol metabolic pathway.","        .","Increased risk of side effects such as drowsiness and elevated liver enzymes.","  .         .","Liver enzyme monitoring. No contraindication, but liver functions must be checked.");n("Cannabidiol","Clobazam",e.DRUG_DRUG,i.HIGH,"  Clobazam   (N-desmethylclobazam). Cannabidiol   CYP2C19  CYP3A4.","Increased concentration of Clobazam and its active metabolite (N-desmethylclobazam). Cannabidiol inhibits CYP2C19 and CYP3A4.","     .","Increased risk of sedation and neurological side effects."," .    Clobazam     .","Dose adjustment. Clobazam dose must be reduced and drug levels monitored.");n("Cannabidiol","Valproate",e.DRUG_DRUG,i.HIGH,"    .    .","Increased risk of elevated liver enzymes. Additive hepatotoxicity effect.","     .","Increased risk of liver damage and hepatitis."," .     (AST  ALT)  .","Close monitoring. Liver enzymes (AST and ALT) must be monitored frequently.");n("Cannabidiol (CBD)","Clobazam",e.DRUG_DRUG,i.HIGH,"  Clobazam    (N-desmethylclobazam). CBD   CYP2C19  CYP3A4.","Increased concentration of Clobazam and its active metabolite (N-desmethylclobazam). CBD inhibits CYP2C19 and CYP3A4.","    .","Increased risk of severe sedation and somnolence."," .    Clobazam   .","Dose adjustment. Clobazam dose must be reduced and side effects monitored.");n("Cannabidiol (CBD)","Valproate",e.DRUG_DRUG,i.MODERATE,"   .     .","Increased risk of liver toxicity. Both drugs are associated with liver toxicity.","    .","Elevated liver enzymes and hepatic insufficiency."," .     .","Close monitoring. Monitor liver enzymes frequently.");n("Capecitabine","Warfarin",e.DRUG_DRUG,i.HIGH,"  ","Warfarin metabolism inhibition.","   INR","Significant INR increase."," INR ","Monitor INR weekly.");n("Caplacizumab","Heparin",e.DRUG_DRUG,i.HIGH,"  . Caplacizumab      (vWF)    .","Increased bleeding risk. Caplacizumab is a vWF inhibitor and increases the risk of bleeding.","        .","Increased risk of excessive hemorrhage and bruising throughout the body."," .      .    .","Caution and Monitoring. Signs of bleeding must be closely monitored. Co-administration is generally not recommended.");n("Caplacizumab","Clopidogrel",e.DRUG_DRUG,i.HIGH,"  . Caplacizumab      Clopidogrel   .","Increased bleeding risk. Caplacizumab inhibits vWF, and Clopidogrel inhibits platelets.","    .","Increased risk of excessive hemorrhage and bruising."," .      .         .","Caution and Monitoring. Signs of bleeding must be closely monitored. Avoid co-administration unless benefits outweigh risks.");n("Capmatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Capmatinib. Rifampin    CYP3A4    Capmatinib.","Decreased Capmatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Capmatinib metabolic pathway.","             .","Severe decrease in drug plasma concentration, leading to failure of lung cancer treatment."," .   Rifampin     CYP3A4.","Avoid Combination. Rifampin must be replaced with an antibiotic that does not induce CYP3A4.");n("Capmatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Capmatinib. Ketoconazole    CYP3A4    Capmatinib.","Increased Capmatinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Capmatinib metabolic pathway.","        .","Increased risk of side effects, especially hepatotoxicity and skin effects."," .    Capmatinib     CYP3A4 .","Dose adjustment. Capmatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Capmatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Capmatinib. Phenytoin    CYP3A4    Capmatinib.","Decreased Capmatinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Capmatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Capmatinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Capmatinib. Carbamazepine    CYP3A4    Capmatinib.","Decreased Capmatinib concentration. Carbamazepine is a strong inducer of CYP3A4, a Capmatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Capmatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Capmatinib. Phenytoin    CYP3A4.","Decreased Capmatinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Capmatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Capmatinib. Ketoconazole    CYP3A4.","Increased Capmatinib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","      .","Increased risk of liver toxicity and other side effects."," .    Capmatinib  .","Dose adjustment. Capmatinib dose must be significantly reduced.");n("Captopril","Food",e.DRUG_FOOD,i.MODERATE,": **   (Bioavailability)**.          30-40%.","Mechanism: **Reduced bioavailability**. Food in the stomach decreases Captopril absorption by 30-40%."," : **  **             .","Clinical Significance: **Reduced therapeutic efficacy**, potentially leading to inadequate control of blood pressure or heart failure.","            .","Take Captopril on an empty stomach, at least 1 hour before or 2 hours after meals.");n("Captopril","Spironolactone",e.DRUG_DRUG,i.HIGH," .     (ACE-I)                .","Potassium Accumulation. ACE Inhibitors impair potassium excretion by reducing aldosterone, and Spironolactone provides additive anti-kaliuretic effects.","    (Hyperkalemia).    (Cardiac Arrest)    .","Severe Hyperkalemia. Extreme risk of life-threatening electrolyte imbalance, cardiac arrest, or fatal arrhythmia.","  .               .","Avoid or Monitor Closely. Avoid concurrent use unless absolutely necessary. If used, monitor serum potassium and renal function (creatinine) frequently and aggressively.");n("Captopril","Eplerenone",e.DRUG_DRUG,i.HIGH," .     (ACE-I)                .","Potassium Accumulation. ACE Inhibitors impair potassium excretion by reducing aldosterone, and Eplerenone provides additive anti-kaliuretic effects.","    (Hyperkalemia).    (Cardiac Arrest)    .","Severe Hyperkalemia. Extreme risk of life-threatening electrolyte imbalance, cardiac arrest, or fatal arrhythmia.","  .               .","Avoid or Monitor Closely. Avoid concurrent use unless absolutely necessary. If used, monitor serum potassium and renal function (creatinine) frequently and aggressively.");n("Captopril","Amiloride",e.DRUG_DRUG,i.HIGH," .     (ACE-I)                .","Potassium Accumulation. ACE Inhibitors impair potassium excretion by reducing aldosterone, and Amiloride provides additive anti-kaliuretic effects.","    (Hyperkalemia).    (Cardiac Arrest)    .","Severe Hyperkalemia. Extreme risk of life-threatening electrolyte imbalance, cardiac arrest, or fatal arrhythmia.","  .               .","Avoid or Monitor Closely. Avoid concurrent use unless absolutely necessary. If used, monitor serum potassium and renal function (creatinine) frequently and aggressively.");n("Captopril","Aspirin",e.DRUG_DRUG,i.HIGH,"  .  (   )                .","Pharmacodynamic Antagonism and Renal Insult. Aspirin (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     ( )  .        .","Avoid chronic or high-dose Aspirin use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Ibuprofen",e.DRUG_DRUG,i.HIGH,"  .  (   )                .","Pharmacodynamic Antagonism and Renal Insult. Ibuprofen (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     .        .","Avoid Ibuprofen use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Diclofenac",e.DRUG_DRUG,i.HIGH,"  .  (   )                .","Pharmacodynamic Antagonism and Renal Insult. Diclofenac (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     .        .","Avoid Diclofenac use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Naproxen",e.DRUG_DRUG,i.HIGH,"  .  (   )                .","Pharmacodynamic Antagonism and Renal Insult. Naproxen (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     .        .","Avoid Naproxen use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Ketoprofen",e.DRUG_DRUG,i.HIGH,"  .  (   )                .","Pharmacodynamic Antagonism and Renal Insult. Ketoprofen (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     .        .","Avoid Ketoprofen use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Indomethacin",e.DRUG_DRUG,i.HIGH,"  .  (   )                .","Pharmacodynamic Antagonism and Renal Insult. Indomethacin (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     .        .","Avoid Indomethacin use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Celecoxib",e.DRUG_DRUG,i.HIGH,"  .  (    )                .","Pharmacodynamic Antagonism and Renal Insult. Celecoxib (a selective NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .     .        .","Avoid Celecoxib use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"  .   (   )                .","Pharmacodynamic Antagonism and Renal Insult. Mefenamic Acid (an NSAID) inhibits renal prostaglandin synthesis, which antagonizes Captopril's antihypertensive effects and precipitates acute renal injury.","     .         .","Acute Renal Failure and Hyperkalemia. High risk of acute kidney injury (AKI) and life-threatening hyperkalemia.","    .      .        .","Avoid Mefenamic Acid use with Captopril. If necessary, monitor serum creatinine, potassium, and blood pressure closely.");n("Captopril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Carbamazepine","Isoniazid",e.DRUG_DRUG,i.HIGH," .      (CYP450)       .","Metabolic Inhibition. Isoniazid is a potent inhibitor of several hepatic CYP450 enzymes responsible for Carbamazepine metabolism.","  .           (  )  .","Increased Carbamazepine Toxicity. Elevated plasma concentrations lead to signs of CNS toxicity (ataxia, dizziness, nausea) and risk of hepatotoxicity.",".              .","Monitor. Routinely monitor Carbamazepine serum levels. A significant dose reduction of Carbamazepine is necessary upon initiation of Isoniazid.");n("Carbamazepine","Erythromycin",e.DRUG_DRUG,i.HIGH,"  Carbamazepine. Erythromycin    CYP3A4    Carbamazepine.","Increased Carbamazepine concentration. Erythromycin is a strong inhibitor of CYP3A4, a Carbamazepine metabolic pathway.","   Carbamazepine (   ).","Increased risk of Carbamazepine toxicity (ataxia, dizziness, diplopia)."," .   Carbamazepine      .","Close monitoring. Monitor Carbamazepine blood levels and neurotoxicity, and adjust the dose.");n("Carbamazepine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Carbamazepine.      CYP3A4.","Increased Carbamazepine concentration. Grapefruit juice is a CYP3A4 inhibitor.","    .","Increased risk of neurotoxicity and ataxia."," .       .","Close monitoring. Avoid consuming large quantities of grapefruit.");n("Carbamazepine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"       ( )    CYP3A4        .                    ( ).      24-72    .","Grapefruit juice contains furanocoumarins (such as bergamottin) that irreversibly inhibit the CYP3A4 enzyme in the small intestinal wall. This inhibition reduces first-pass metabolism of carbamazepine, increasing the amount of drug reaching systemic circulation (bioavailability). The effect can persist for 24-72 hours after juice consumption.","         40%       :  ( )  ( )             .","Carbamazepine blood levels may increase by up to 40%, raising the risk of toxicity symptoms including: ataxia (loss of balance), diplopia (double vision), dizziness, nausea, severe drowsiness, and in severe cases, central nervous system depression.","            .        (Therapeutic Drug Monitoring)             .","Grapefruit juice should be completely avoided during carbamazepine therapy, including the fruit itself. Therapeutic drug monitoring is recommended, especially for patients with a history of juice consumption, along with regular monitoring of clinical toxicity signs.");n("Carboplatin","Paclitaxel",e.DRUG_DRUG,i.MODERATE,"    (Synergistic Myelosuppression).       (     )          .","Synergistic bone marrow suppression (Myelosuppression). Both agents target rapidly dividing cells (including bone marrow precursors), leading to cumulative toxicity and increased severity of hematologic side effects.","   (Pancytopenia):       (    ).   (Infection)  (Bleeding)   (Anemia).","Pancytopenia: Reduction in all blood cell lines (WBC, RBC, and Platelets). Increased risk of infection, bleeding, and anemia.","    (CBC)     .       (Dose Reduction)          (CSFs)   .","Monitor Complete Blood Count (CBC) regularly before each cycle. Dose reduction, treatment delay, or use of Colony-Stimulating Factors (CSFs) may be necessary to support white blood cell counts.");n("Cariprazine","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Cariprazine. Ketoconazole    CYP3A4    Cariprazine.","Increased Cariprazine concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Cariprazine metabolic pathway.","        (EPS)   QT.","Increased risk of side effects, especially Extrapyramidal Syndrome (EPS) and QT prolongation."," .    Cariprazine     CYP3A4 .","Dose adjustment. Cariprazine dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Cariprazine","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Cariprazine. Carbamazepine    CYP3A4    Cariprazine.","Decreased Cariprazine efficacy. Carbamazepine is a strong inducer of CYP3A4, a Cariprazine metabolic pathway.","          .","Reduced drug plasma concentration, leading to psychotic treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Carteolol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP).        .","Enzymatic Metabolic Induction (CYP). Barbiturates induce hepatic enzymes responsible for Carteolol metabolism.","           (    ).","Decreased Carteolol plasma concentration, leading to reduced drug efficacy (less beta-blockade).","    .          .","Monitor intraocular pressure and blood pressure. Increase the Carteolol dose if necessary to restore the desired therapeutic efficacy.");n("Carteolol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Carteolol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"  (Pharmacodynamic Synergy).          (   ).                     .","Pharmacodynamic Synergy. Both drugs lower blood pressure through different mechanisms (beta-blockade and vasodilation). Carteolol is renally excreted and is not affected by changes in hepatic blood flow, making the previously mentioned mutual metabolic interactions clinically irrelevant.","           (Hypotension)    (Bradycardia)       .","Additive hypotensive effect, increasing the risk of severe hypotension and bradycardia (from Carteolol), especially upon initiation.","      .                .","Closely monitor blood pressure and heart rate. Start with low doses of both agents, or reduce the dose of one drug upon co-administration to avoid severe hypotension.");n("Carteolol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Carteolol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic Hypotension. Combined effects lead to significant blood pressure drop.","     ","     ","     ","     ");n("Carvedilol","Cyclosporine",e.DRUG_DRUG,i.MODERATE,": ** P-glycoprotein (P-gp)**.     P-gp      .","Mechanism: **P-glycoprotein (P-gp) inhibition**. Carvedilol inhibits the P-gp efflux pump responsible for transporting Cyclosporine out of cells."," : **    **      (   - Nephrotoxicity).","Clinical Significance: **Increased blood cyclosporine levels**, increasing the risk of toxicity (especially nephrotoxicity).","          .    .","Monitor cyclosporine levels closely when starting or stopping Carvedilol. Adjust cyclosporine dose immediately.");n("Carvedilol","Verapamil (IV)",e.DRUG_DRUG,i.HIGH," .         (Inotropic)  (Chronotropic)       .","Cardiac Depression. The combination of a beta-blocker (Carvedilol) and intravenous (IV) Verapamil (a non-dihydropyridine calcium channel blocker) exerts profound negative effects on inotropy, chronotropy, and dromotropy.","   (Cardiac Arrest).               .","Cardiac Arrest. High risk of severe bradycardia, complete Atrioventricular (AV) block, asystole, or fatal arrhythmia, especially when the IV route is used for Verapamil.",".             .","Contraindicated. This combination is generally contraindicated, particularly the use of IV Verapamil, due to the extreme risk of acute cardiotoxicity.");n("Carvedilol","Diabetes",e.DRUG_DISEASE,i.HIGH,"   .  (   )      (  )      .","Masking Hypoglycemia. Carvedilol (a non-selective beta-blocker) blunts the adrenergic warning signs of hypoglycemia (e.g., tremor, palpitations, anxiety) mediated by catecholamine release.","       (Hypoglycemia Unawareness).       .","Risk of Hypoglycemia Unawareness. May delay necessary treatment, leading to severe, prolonged hypoglycemia, coma, and potential fatality.","       .           .","Avoid non-selective beta-blockers in patients with poorly controlled diabetes. Educate the patient that sweating may be the only remaining warning sign.");n("Carvedilol","Diabetes ()",e.DRUG_DISEASE,i.MODERATE,"    (  ).         .","Masking Hypoglycemia Symptoms. Carvedilol reduces the physiological counter-regulatory response to hypoglycemia, blocking typical warning signs like tremors and palpitations.","      (Hypoglycemia Unawareness)    .","Hypoglycemia Unawareness. Patient fails to recognize a hypoglycemic episode, increasing the risk of severe events like coma.","          .        .","Educate the patient that sweating may be the only remaining warning sign of hypoglycemia. Frequent blood glucose monitoring is essential.");n("Carvedilol","Asthma ()",e.DRUG_DISEASE,i.HIGH,"  -2  .  (  )         -2.","Beta-2 Blockade. Carvedilol (a non-selective beta-blocker) blocks pulmonary Beta-2 receptors, leading to significant bronchoconstriction in susceptible patients.","    .      .","Acute Asthma Exacerbation. High risk of severe bronchospasm, wheezing, and life-threatening respiratory distress.",".      .     ( )     .","Contraindicated. Avoid Carvedilol in patients with asthma. If mandatory, use a cardioselective agent (e.g., Bisoprolol) with extreme caution.");n("Carvedilol","Asthma",e.DRUG_DISEASE,i.HIGH," .  (  )         -2.","Bronchoconstriction. Carvedilol (a non-selective beta-blocker) blocks pulmonary Beta-2 receptors, leading to narrowing of the airways."," .      .","Acute Asthma Exacerbation. High risk of severe bronchospasm and wheezing.",".      .","Contraindicated. Avoid Carvedilol in patients with asthma.");n("Carvedilol","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  .    CYP3A4             .","Inhibition of Cyclosporine Metabolism. Carvedilol inhibits CYP3A4, the primary enzyme responsible for Cyclosporine metabolism, thereby decreasing its systemic clearance.","  .                .","Increased Cyclosporine Levels. Elevated plasma concentrations of Cyclosporine increase the risk of its toxicity, particularly nephrotoxicity and neurotoxicity.","  .                .","Monitor Cyclosporine Levels. Cyclosporine trough concentrations must be monitored frequently, and dosage adjustments should be made upon initiation or discontinuation of Carvedilol.");n("Carvedilol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP2D6/2C9/3A4).        .","Enzymatic Metabolic Induction (CYP2D6/2C9/3A4). Barbiturates induce hepatic enzymes responsible for Carvedilol metabolism.","           (    /).","Decreased Carvedilol plasma concentration, leading to reduced drug efficacy (less beta/alpha-blockade).","     .          .","Monitor blood pressure and heart rate. Increase the Carvedilol dose if necessary to restore the desired therapeutic efficacy.");n("Carvedilol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Carvedilol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"                 .      .     ( )      .","Hydralazine reduces the hepatic clearance of Carvedilol by decreasing liver blood flow, increasing its bioavailability. Carvedilol also affects Hydralazine metabolism. This results in a mutual (bidirectional) increase in the plasma concentrations of both drugs.","           (Hypotension)   (Bradycardia)         .","Increased concentrations of both drugs lead to a risk of severe hypotension and bradycardia (from Carvedilol), in addition to exacerbating Hydralazine side effects.","       .                .","Closely monitor blood pressure and heart rate. The dose of one or both drugs should be reduced upon co-administration to avoid severe hypotension.");n("Carvedilol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Carvedilol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     (Synergistic Hypotension).     -1   -1  .          .","Synergistic hypotensive effect. Carvedilol blocks both Beta and Alpha-1 receptors, while Prazosin is a pure Alpha-1 blocker. This potent combination increases vasodilation and orthostatic risk.","    (Orthostatic Hypotension)  .","Increased risk of Orthostatic Hypotension and severe dizziness.","      .          .","Start with very low doses and titrate gradually. Monitor for symptoms of orthostatic hypotension upon sudden change in posture.");n("Carvedilol","Amlodipine",e.DRUG_DRUG,i.MODERATE,"     (Additive Hypotension).       (  )     .","Additive hypotensive effect. Carvedilol reduces cardiac output, while Amlodipine (CCB) causes potent peripheral vasodilation.","          (    ).","Orthostatic hypotension, dizziness, and potential bradycardia (especially with high Carvedilol dose).","     .       .","Start low doses and titrate gradually. Monitor BP and heart rate regularly.");n("Carvedilol","High-fat meals / Milk",e.DRUG_FOOD,i.MODERATE,"    (Bioavailability)           (First Pass Effect).       .","Fat increases Carvedilol bioavailability by slowing absorption and reducing first-pass hepatic metabolism. This leads to higher plasma concentrations (up to 30%).","      (    ).           .","Increased risk of dose-related side effects (hypotension, bradycardia). Dosing with food is recommended for consistent absorption.","         .     (   )  .","Carvedilol should be taken consistently with food to minimize orthostatic hypotension risk. Maintain the same routine (with or without food) daily.");n("Carvedilol","Alcohol ()",e.DRUG_FOOD,i.HIGH,"      .           .       (CNS).","Synergistic effect on vasculature and CNS. Alcohol causes additive vasodilation and impairs the body's response to hypotension, while also increasing CNS depression.","    (Severe Hypotension)        ().","Profound hypotension, dizziness, and increased CNS depression (syncope).","      .","Strictly avoid alcohol consumption during Carvedilol therapy.");n("Carvedilol","Grapefruit Juice (  )",e.DRUG_FOOD,i.LOW,"    CYP3A4.        (  CYP2D6  CYP2C9)        .","Contains CYP3A4 inhibitors. While Carvedilol is primarily metabolized by CYP2D6 and CYP2C9, slight CYP3A4 inhibition may cause a minimal increase in plasma concentration.","     (  ).","Minimal potential for increased side effects (e.g., mild hypotension).","             .","No restriction, but excessive consumption should be avoided.");n("Carvedilol","Antacids / Iron / Calcium",e.DRUG_FOOD,i.MODERATE,"  .    (      /)            .","Absorption interference. These agents (especially Aluminum/Magnesium antacids) may bind to Carvedilol or alter gastric pH, reducing its overall absorption and bioavailability.","            .","Reduced Carvedilol plasma levels, potentially leading to loss of BP control or heart failure management.","       (   )      .","Separate administration of Carvedilol from these agents (e.g., Iron, Antacids) by at least two hours.");n("Cascara","Diuretics",e.DRUG_DRUG,i.MODERATE,"   (Synergistic Hypokalemia).  ( )      .   ( )      .","Synergistic hypokalemia. Cascara (a stimulant laxative) increases potassium loss via the colon, while diuretics (e.g., Furosemide) increase potassium loss via the kidney.","   (Severe Hypokalemia)        (Cardiac arrhythmia) .","Severe hypokalemia, significantly increasing the risk of life-threatening cardiac arrhythmia.","     .          .","Monitor serum potassium levels regularly. Potassium supplementation or discontinuation of Cascara may be necessary.");n("Cefiderocol","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"   .     .","Increased risk of renal toxicity. Additive nephrotoxic effects."," .","Renal failure."," .     .","Close monitoring. Monitor renal function frequently.");n("Cefonicid","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"     .","Synergistic nephrotoxicity between Cephalosporins and Aminoglycosides.","      .","Increased risk of nephrotoxicity and acute renal failure.","        .","Monitor renal function regularly. Adjust doses based on renal clearance.");n("Cefoperazone","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"    .","Additive effect on nephrotoxicity.","    .","Increased risk of renal failure."," Creatinine   .","Monitor Creatinine and renal function regularly.");n("Cefoperazone","Ethanol",e.DRUG_DRUG,i.HIGH,"     .","Inhibition of aldehyde dehydrogenase enzyme by Cefoperazone.","  :       .","Disulfiram-like reaction: Nausea, vomiting, facial flushing, headache, tachycardia.","       3    .","Avoid alcoholic beverages and products during therapy and for 3 days after discontinuation.");n("Cefoperazone","Warfarin",e.DRUG_DRUG,i.HIGH,"   K   .","Inhibition of Vitamin K synthesis by gut flora.","       .","Potentiated anticoagulant effect of Warfarin and high risk of hemorrhage."," INR  .      .","Frequent INR monitoring. Reduce Warfarin dose if necessary.");n("Cefoperazone","Alcohol",e.DRUG_DRUG,i.HIGH,"   ","Aldehyde dehydrogenase inhibition causes acetaldehyde accumulation.","   -    ","Disulfiram-like reaction - flushing, nausea, vomiting, headache.","     3  ","Avoid alcohol completely during treatment and 3 days after.");n("Cefotaxime","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"  .","Synergistic nephrotoxicity.","    .","Increased risk of renal injury.","  .     .","Monitor renal function. Adjust doses based on renal status.");n("Cefotetan","Alcohol",e.DRUG_FOOD,i.MODERATE,"  . Cefotetan     (Aldehyde dehydrogenase).","Disulfiram-like reaction. Cefotetan inhibits aldehyde dehydrogenase.","   .","Flushing, nausea, vomiting, and headache."," .        72   .","Avoid Alcohol. Alcohol must be avoided during treatment and for 72 hours after discontinuation.");n("Cefotetan","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"   .","Additive effect on the kidneys.","   .","Increased risk of nephrotoxicity."," Creatinine  .","Monitor Creatinine and renal function.");n("Cefotetan","Ethanol",e.DRUG_DRUG,i.HIGH,"   .","Inhibition of aldehyde dehydrogenase enzyme.","  :      .","Disulfiram-like reaction: Nausea, vomiting, flushing, headache, tachycardia.","     3    .","Avoid alcohol during therapy and for 3 days after discontinuation.");n("Cefotetan","Warfarin",e.DRUG_DRUG,i.HIGH,"   K    .","Inhibition of Vitamin K synthesis and effect on platelet function.","     .","Potentiated Warfarin effect and high risk of hemorrhage."," INR  .   .","Frequent INR monitoring. Adjust Warfarin dose.");n("Cefotetan (Cephalosporin)","Ethanol (Alcohol)",e.DRUG_DRUG,i.MODERATE,"  .     .","Disulfiram-like reaction. Certain cephalosporins cause a disulfiram effect.","    .","Nausea, vomiting, abdominal cramps, and flushing."," .      3  .","Avoid combination. Avoid alcohol during therapy and for 3 days after.");n("Cefoxitin","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"  .","Synergistic Nephrotoxicity.","   .","Increased risk of renal failure.","  .   .","Monitor renal function. Avoid high doses.");n("Cefoxitin","Warfarin",e.DRUG_DRUG,i.MODERATE,"      K.","Effect on intestinal flora producing Vitamin K.","    .","Increased anticoagulant effect of Warfarin."," INR.   .","Monitor INR. Adjust Warfarin dose.");n("Ceftazidime","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"    .","Additive effect on nephrotoxicity.","    .","Increased risk of renal injury.","   .","Monitor renal function regularly.");n("Ceftizoxime","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"  .","Synergistic Nephrotoxicity.","    .","Increased risk of acute renal failure."," Creatinine  .","Monitor Creatinine and renal function.");n("Ceftriaxone","Calcium-containing solutions (IV)",e.DRUG_DRUG,i.HIGH,"    . Ceftriaxone    .","Risk of intravascular precipitation. Ceftriaxone binds to calcium to form a precipitate.","     .","Life-threatening precipitation in the lungs and kidneys."," .        .","Contraindicated. Absolutely avoid the combination, especially in neonates.");n("Ceftriaxone","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"   .","Additive effect on the kidneys.","   .","Increased risk of nephrotoxicity.","  .  .","Monitor renal function. Adjust doses.");n("Ceftriaxone","Warfarin",e.DRUG_DRUG,i.MODERATE,"     K.","Inhibition of intestinal flora producing Vitamin K.","     .","Increased Warfarin effect and high risk of hemorrhage."," INR.   .","Monitor INR. Adjust Warfarin dose.");n("Ceftriaxone","Calcium-containing IV Solutions",e.DRUG_DRUG,i.HIGH,"  -   ","Calcium-ceftriaxone precipitate formation in lungs and kidneys.","   -   ","Respiratory and renal failure - potentially fatal.","   -     ","Avoid combination completely - especially in neonates.");n("Cefuroxime","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"  .","Synergistic Nephrotoxicity.","    .","Increased risk of renal injury.","  .   .","Monitor renal function. Avoid high doses.");n("Celecoxib","Peptic Ulcer / GI Bleeding History",e.DRUG_DISEASE,i.HIGH,"     .       (NSAID)            .","Prostaglandin Inhibition. Although a COX-2 selective inhibitor, Celecoxib still depletes cytoprotective gastric prostaglandins, increasing the risk of mucosal injury.","      .        .","GI Bleeding & Perforation. High risk of severe gastrointestinal hemorrhage, ulceration, or perforation.",".           .                (PPIs).","Avoid use. Contraindicated in patients with active peptic ulcer or recent GI bleeding. If necessary, use the lowest effective dose for the shortest duration, along with a protective agent like a Proton Pump Inhibitor (PPI).");n("Celecoxib","Heart Failure",e.DRUG_DISEASE,i.MODERATE," .                  .","Fluid Retention. NSAIDs inhibit renal prostaglandin synthesis, leading to sodium and water retention, which exacerbates volume overload.","   .         .","Worsening Congestive Heart Failure. Exacerbation of heart failure symptoms (e.g., dyspnea, edema) and reduced efficacy of diuretic therapy.",".          .             .","Avoid use. Celecoxib should be avoided in patients with severe heart failure. If used, monitor weight, signs of fluid retention, and renal function closely.");n("Celecoxib (NSAID)","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin  . Celecoxib  CYP2C9    Warfarin.","Increased anticoagulant effect of Warfarin. Celecoxib inhibits CYP2C9, a Warfarin metabolic pathway.","   .","Increased risk of severe hemorrhage.","  .    Warfarin  INR  .","Dose adjustment and monitoring. Warfarin dose must be reduced and INR monitored frequently.");n("Cenobamate","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Cenobamate    CYP3A4    Midazolam.","Decreased Midazolam concentration. Cenobamate is a strong inducer of CYP3A4, a Midazolam metabolic pathway.","  Midazolam ()          .","Reduced efficacy of Midazolam (sedative), potentially leading to failure of sedation or seizure control.","    .    Midazolam   .","Avoid combination or dose adjustment. Midazolam dose must be adjusted or alternatives used.");n("Cenobamate","Omeprazole",e.DRUG_DRUG,i.MODERATE,"  Omeprazole. Cenobamate    CYP2C19.","Decreased Omeprazole concentration. Cenobamate is a strong inducer of CYP2C19.","  Omeprazole.","Reduced Omeprazole efficacy."," .     .","Close monitoring. Monitor clinical response and adjust the dose.");n("Cenobamate","Midazolam",e.DRUG_DRUG,i.MODERATE,"  Midazolam. Cenobamate   CYP3A4.","Decreased Midazolam concentration. Cenobamate is an inducer of CYP3A4.","   (Midazolam).","Reduced sedative efficacy (Midazolam)."," .     CYP3A4  .","Dose adjustment. Doses of CYP3A4 substrates may need to be increased.");n("Cephalosporins","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"          .","Additive effect on nephrotoxicity, especially with first-generation Cephalosporins.","          .","Increased risk of acute renal failure, particularly in patients with pre-existing kidney disease.","    (Creatinine  BUN).        .","Regular monitoring of renal function (Creatinine and BUN). Avoid high doses and adjust based on renal clearance.");n("Cephalosporins","Ethanol",e.DRUG_DRUG,i.HIGH,"  (  )        .","Some Cephalosporins (e.g., Cefoperazone, Cefotetan) inhibit aldehyde dehydrogenase, the enzyme responsible for alcohol metabolism.","  :     (Flushing)    .","Disulfiram-like reaction: Nausea, vomiting, facial flushing, headache, and hypotension.","         ( )   72   .","Strictly avoid alcohol with implicated Cephalosporins (Cefoperazone, Cefotetan) and for 72 hours after discontinuation.");n("Cephalosporins","Warfarin",e.DRUG_DRUG,i.HIGH,"   K    (    NMTT) +      .","Inhibition of Vitamin K synthesis by gut bacteria (especially NMTT-containing Cephalosporins) + potential effect on platelet function.","     ( INR)    .","Potentiated anticoagulant effect of Warfarin (increased INR) and high risk of acute hemorrhage."," INR      .     .","Frequent INR monitoring upon initiation or discontinuation. Warfarin dose requires careful adjustment.");n(Hc,"Ethanol",e.DRUG_FOOD,i.HIGH,": **  ALDH ( )**.   ( Cefoperazone)       .","Mechanism: **ALDH inhibition (Disulfiram-like reaction)**. Some cephalosporins (e.g., Cefoperazone) contain a side chain that inhibits alcohol metabolism."," : ** **        .","Clinical Significance: **Acetaldehyde accumulation** causing nausea, vomiting, flushing, palpitations, and hypotension.","      72   .","Strictly avoid alcohol during therapy and for 72 hours after completion.");n("Cephalothin","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"  .","Synergistic Nephrotoxicity.","    .","Increased risk of renal failure.","   (Creatinine) .   .","Monitor renal function (Creatinine) regularly. Avoid high doses.");n("Ceritinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Ceritinib. Phenytoin    CYP3A4    Ceritinib.","Decreased Ceritinib concentration. Phenytoin is a strong inducer of CYP3A4, a Ceritinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Certolizumab pegol","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Certolizumab pegol   (TNF inhibitor).","Increased risk of infection. Certolizumab pegol is an immunosuppressant (TNF inhibitor).","     .","Risk of developing infection from live vaccines."," .      .","Contraindicated. Live vaccines must be avoided during treatment.");n("Cetirizine","Ritonavir",e.DRUG_DRUG,i.MODERATE,": **  P-glycoprotein (P-gp Efflux Pump Inhibition)**.        P-gp.                   .","Mechanism: **P-glycoprotein (P-gp) efflux pump inhibition**. Cetirizine is eliminated from cells via P-gp pump. Ritonavir inhibits this pump, increasing cetirizine accumulation inside cells and in circulation, and reducing its renal excretion.",' : **  **  40-50%       ** ** (         " ")          QT.          .','Clinical Significance: **Increased cetirizine levels** by 40-50%, increasing adverse effects especially **excessive drowsiness** (even though cetirizine is a "non-sedating" second-generation antihistamine), dry mouth, headache, dizziness, and rarely QT prolongation. Effect is more pronounced in patients with renal impairment.',"    **** (5    10  ).    .  :  ****  ****     .     .      (CrCl < 30 mL/min)        .","Reduce cetirizine dose to **half** (5 mg instead of 10 mg daily). Monitor for drowsiness and adverse effects. Safe alternative: use **loratadine** or **fexofenadine** which are not affected similarly. Avoid driving if drowsiness occurs. In patients with renal impairment (CrCl < 30 mL/min), further dose reduction or avoiding combination may be necessary.");n("Cetirizine","Alcohol",e.DRUG_FOOD,i.LOW,": **  **.                  .","Mechanism: **Additive CNS Depression**. Although Cetirizine is less sedating, alcohol can increase its tranquilizing effects.",":              ( ).","Result: May lead to a slight increase in dizziness or drowsiness, especially in sensitive individuals (Low effect).",":     .","Management: Advise moderate consumption of alcohol.");n("Cetirizine","Caffeine",e.DRUG_FOOD,i.HIGH,":     . Cetirizine       CYP450.","Mechanism: No significant metabolic interaction. Cetirizine is not extensively metabolized by CYP450 enzymes.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,":      . Cetirizine      CYP3A4.","Mechanism: No known clinically significant interaction. Cetirizine is not significantly affected by CYP3A4 inhibition.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Green Tea",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Cetirizine","Milk",e.DRUG_FOOD,i.HIGH,":    .  Cetirizine     .","Mechanism: No known interaction. Cetirizine is well-absorbed and not affected by milk.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","High-fat meals",e.DRUG_FOOD,i.MODERATE,": ** **.              (Tmax)       (AUC).","Mechanism: **Delayed Absorption**. Meals may slightly delay the time to peak drug concentration (Tmax), without changing the total amount absorbed (AUC).",":     .","Result: Slight delay in onset of efficacy.",":       .","Management: Prefer taking it consistently relative to meals.");n("Cetirizine","High-fiber foods",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Vitamin C",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Vitamin D",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Vitamin E",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Vitamin K",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Vitamin B12",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Folic Acid",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Iron",e.DRUG_FOOD,i.HIGH,":    .   Cetirizine    .","Mechanism: No known interaction. Cetirizine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Calcium",e.DRUG_FOOD,i.MODERATE,":    .   Cetirizine    .","Mechanism: No known interaction. Cetirizine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Magnesium",e.DRUG_FOOD,i.LOW,":    .   Cetirizine    .","Mechanism: No known interaction. Cetirizine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Zinc",e.DRUG_FOOD,i.HIGH,":    .   Cetirizine    .","Mechanism: No known interaction. Cetirizine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Potassium",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Antacids",e.DRUG_FOOD,i.HIGH,":    .          Cetirizine.","Mechanism: No known interaction. Antacids have no clinically significant effect on Cetirizine absorption.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Cetirizine","Sedative Herbs (Valerian/Chamomile)",e.DRUG_FOOD,i.HIGH,": **   **.             Cetirizine.","Mechanism: **Severe Additive CNS Depression**. These herbs possess sedative properties, amplifying the drowsiness caused by Cetirizine.",":           .","Result: Significant increase in drowsiness, difficulty concentrating, and impaired motor coordination.",":          .","Management: Avoid using these or any other sedating herbs during treatment.");n("Cetirizine","St. John's Wort (Hypericum perforatum)",e.DRUG_FOOD,i.MODERATE,": ** P-glycoprotein (P-gp)**.   St. John's Wort   P-gp      Cetirizine  .","Mechanism: **P-glycoprotein (P-gp) Induction**. St. John's Wort may increase the activity of P-gp, a protein that contributes to the excretion of Cetirizine from the body.",":     Cetirizine        .","Result: Potential decrease in Cetirizine blood concentration, which may reduce its therapeutic efficacy.",":    .       .","Management: Prefer avoiding concurrent use. If necessary, monitor for allergy symptoms.");n("Chloramphenicol","Various drugs",e.DRUG_DRUG,i.MODERATE,"     .      P450   CYP2C19  CYP3A4.","Multiple Interactions due to Enzyme Inhibition. Chloramphenicol is a potent inhibitor of hepatic cytochrome P450 enzymes, particularly CYP2C19 and CYP3A4.","   .         (    )     .","Altered Drug Efficacy. Increased plasma levels of drugs metabolized by these enzymes (e.g., Phenytoin, Warfarin, Sulfonylureas), potentially leading to toxicity.","  .             .","Monitor Drug Levels. Dosage adjustments for affected co-administered drugs are necessary based on clinical monitoring and therapeutic drug monitoring (TDM).");n("Chlorpromazine","Atropine",e.DRUG_DRUG,i.MODERATE,"   -    ","   -    ","     ","Reduced Efficacy & Increased Toxicity. Poor therapeutic index.","      ","      ");n("Chlorpromazine","Hyoscine",e.DRUG_DRUG,i.MODERATE,"   -    ","   -    ","     ","Reduced Efficacy & Increased Toxicity. Poor therapeutic index.","      ","      ");n("Chlorpromazine","Benztropine",e.DRUG_DRUG,i.MODERATE,"   -    ","   -    ","     ","Reduced Efficacy & Increased Toxicity. Poor therapeutic index.","      ","      ");n("Chlorpromazine","Ethanol",e.DRUG_DRUG,i.HIGH,"     (CNS)","Additive CNS Depression. Combined sedative effects.","   ","Increased CNS Depression. Drowsiness and ataxia.","  () ","  () ");n("Chlorpromazine","Paroxetine",e.DRUG_DRUG,i.HIGH,"   (  )   .     CYP2D6    .","Increased Phenothiazine Efficacy/Toxicity. Paroxetine is a potent inhibitor of CYP2D6, the enzyme responsible for Chlorpromazine metabolism, leading to significantly elevated plasma levels.","    .         QT (QTc prolongation)     ( Torsades de Pointes).","Increased Cardiotoxicity and Arrhythmias. Elevated Chlorpromazine concentrations increase the risk of QTc prolongation and potentially fatal arrhythmias (e.g., Torsades de Pointes).","    .              (ECG)   QTc.","Avoid this combination if possible. If co-administration is necessary, significantly reduce the Chlorpromazine dosage and perform close monitoring of the patient's ECG for QTc prolongation.");n("Chlorpromazine","Propranolol",e.DRUG_DRUG,i.MODERATE,"      (  ) -        ","Mutual Metabolic Inhibition. Elevated levels of both drugs increase hypotensive and bradycardic risks.","     ","     ","   (    ) -        ","   (    ) -        ");n("Chlorpromazine","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"   (        )","Reduced Phenothiazine Efficacy. Potential metabolic induction.","   ","   ","   -    : (  )","   -    : (  )");n("Chlorpromazine","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"      (CNS).","Additive Central Nervous System (CNS) Depressant Effects.","           .","Substantially increased risk of severe drowsiness, dizziness, motor incoordination, and respiratory depression.","   .             .","Alcohol must be completely avoided. With other depressants, reduce dosages and closely monitor the patient for over-sedation.");n("Chlorpromazine","Paroxetine (or other strong CYP2D6 Inhibitors)",e.DRUG_DRUG,i.HIGH,"  (CYP2D6).       .","Metabolic Inhibition (CYP2D6). These drugs inhibit the enzyme responsible for Chlorpromazine metabolism.","             (Hypotension)   QT.","Increased Chlorpromazine plasma concentration, raising the risk of drowsiness, hypotension, and QT prolongation.","           .","Avoid co-administration or closely monitor the patient and significantly reduce the Chlorpromazine dosage.");n("Chlorpromazine","Amiodarone (or other QT Prolonging Drugs)",e.DRUG_DRUG,i.HIGH,"    QT.     QT.","Additive effects on the QT interval. Both drugs prolong the QT interval.","    QT        (Torsades de Pointes).","Increased risk of QT interval prolongation and life-threatening cardiac arrhythmias (Torsades de Pointes).","      ( )    .","Co-administration is strictly contraindicated due to the risk of cardiotoxicity.");n("Chlorpromazine","Benztropine (or other Anticholinergic Drugs)",e.DRUG_DRUG,i.HIGH,"   .","Additive Anticholinergic Effects.","                /.","Increased risk of severe anticholinergic side effects such as urinary retention, severe constipation, blurred vision, and risk of delirium/confusion.","        .        .","Avoid co-administration if possible, especially in the elderly. If necessary, anticholinergic symptoms must be monitored carefully.");n("Chlorpromazine","Meperidine",e.DRUG_DRUG,i.HIGH,"      (CNS)       (Hypotension).","Additive Central Nervous System (CNS) Depression and additive hypotensive effects.","                   (Hypotension).","Substantially increased risk of severe drowsiness, motor incoordination, life-threatening respiratory depression, and severe hypotension.","     .                    .","Avoid co-administration if possible. If necessary, significantly reduce the dosage of both drugs, start slowly, and closely monitor the patient for respiratory depression and hypotension.");n("Chlorpropamide","Dicumarol",e.DRUG_DRUG,i.HIGH,"  ","Inhibition of chlorpropamide metabolism","      (  )","Increased chlorpropamide hypoglycemic effect (hypoglycemia risk)","    -      .","Monitor blood glucose levels - reduce chlorpropamide dose if necessary.");n("Chlorpropamide","Urinary Alkalinizers (Sodium Acetate, Potassium Citrate, Sodium Bicarbonate)",e.DRUG_DRUG,i.MODERATE,"  ","Increased chlorpropamide excretion","  ","Reduced chlorpropamide efficacy","    -      ","Monitor blood glucose levels - increase chlorpropamide dose if necessary");n("Chlorpropamide - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Chlorpropamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Chlorpropamide dose if necessary");n("Chlorpropamide - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Chlorpropamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Chlorpropamide dose if necessary");n("Chlorpropamide - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Chlorpropamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Chlorpropamide dose if necessary");n("Chlorpropamide - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Chlorpropamide","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Chlorpropamide dose if necessary - Use alternative NSAID");n("Chlorpropamide - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Chlorpropamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Chlorpropamide dose if necessary");n("Chlorpropamide - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Chlorpropamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Chlorpropamide dose if necessary");n("Chlorpropamide - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"    ","Increased concentrations of Chlorpropamide","    ","Increased risk of hypoglycemia","     -       -      ( )","Monitor blood glucose concentration - Decrease Chlorpropamide dose if necessary - Use noninteracting sulfonylurea (eg, glyburide)");n("Chlorpropamide - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Chlorpropamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Chlorpropamide dose if necessary");n("Cholecalciferol","Orlistat",e.DRUG_DRUG,i.MODERATE,"   D","Reduced vitamin D absorption.","  D","Vitamin D deficiency.","  D    ","Give vitamin D 2 hours after orlistat.");n("Cholestyramine","Digoxin",e.DRUG_DRUG,i.MODERATE," .               .","Binding Agent. Cholestyramine, an anion-exchange resin, binds to Digoxin in the gastrointestinal tract, forming a non-absorbable complex.","  .              .","Reduced Digoxin Absorption. Binding results in significantly decreased Digoxin bioavailability, potentially leading to subtherapeutic levels and treatment failure.","     .              .","Separate Doses by at least 2 hours (before) or 4 hours (after) the Cholestyramine dose.");n("Cholestyramine","Warfarin",e.DRUG_DRUG,i.MODERATE,"   ","Warfarin binding in gut."," INR","Decreased INR.","      4 ","Take warfarin 1 hour before or 4 hours after.");n("Cholestyramine - ","Atorvastatin - ",e.DRUG_DRUG,i.MODERATE,"               ","Cholestyramine binds to Atorvastatin in the intestine and reduces its absorption, but this interaction can be managed with proper dosing timing","               ","Mild decrease in Atorvastatin levels, but overall cholesterol-lowering effect is synergistic when doses are separated","         4    -     ","Take Atorvastatin in evening and Cholestyramine in morning with at least 4-hour separation - monitor lipid levels and liver enzymes");n("Cholestyramine - ","Simvastatin - ",e.DRUG_DRUG,i.MODERATE,"             ","Cholestyramine reduces intestinal absorption of Simvastatin but synergistic cholesterol-lowering effect can be achieved","     20-30%         ","20-30% decrease in Simvastatin bioavailability, but better lipid profile improvement with combination","            -   ","Take Simvastatin at bedtime and Cholestyramine before meals with at least 2-hour separation - avoid concurrent administration");n("Cholestyramine - ","Lovastatin - ",e.DRUG_DRUG,i.MODERATE,"          ","Intestinal binding interaction reduces Lovastatin absorption but overall therapeutic effect is beneficial","           ","Decreased peak Lovastatin plasma levels while maintaining cholesterol-lowering efficacy","   4-6  -        ","Separate doses by 4-6 hours - take Lovastatin with evening meal and Cholestyramine in morning");n("Cholestyramine - ","Pravastatin - ",e.DRUG_DRUG,i.MODERATE,"          ","Cholestyramine reduces Pravastatin absorption but to a lesser extent than other statins","          ","Mild decrease in Pravastatin exposure while maintaining cholesterol-lowering efficacy","       -    ","Take Pravastatin at least 1 hour before Cholestyramine - routine lipid profile monitoring");n("Cholestyramine - ","Rosuvastatin - ",e.DRUG_DRUG,i.MODERATE,"        ","Limited effect on Rosuvastatin absorption due to its unique pharmacokinetic properties","           ","Very mild decrease in Rosuvastatin levels with minimal impact on clinical efficacy","    -    ","2-hour dose separation is sufficient - monitor therapeutic response as usual");n("Cholestyramine - ","Fluvastatin - ",e.DRUG_DRUG,i.MODERATE,"        ","Moderate intestinal binding interaction manageable with temporal dose separation","        ","Decrease in Fluvastatin bioavailability compensable with proper timing","       -    ","Take Fluvastatin at least 2 hours before Cholestyramine - adjust dose based on response");n("Cilostazol","Omeprazole",e.DRUG_DRUG,i.MODERATE," CYP2C19","CYP2C19 inhibition.","  ","Increased cilostazol levels.","  ","Reduce cilostazol dose.");n("Cimetidine","Glipizide",e.DRUG_DRUG,i.MODERATE,"     .              .","Increased Glipizide Levels. Cimetidine may mildly inhibit Glipizide metabolism (via CYP2C9) and potentially increase gastric emptying, leading to higher/faster absorption.","      .          (Hypoglycemia).","Increased Absorption and Hypoglycemic Effect. Elevated Glipizide concentrations enhance its glucose-lowering effect, increasing the risk of hypoglycemia.","  .                  .","Monitor Blood Glucose. Closely monitor blood glucose levels, and adjust the Glipizide dose as needed when initiating or discontinuing Cimetidine.");n("Cimetidine","Beta Blockers (Propranolol, Metoprolol, Labetalol)",e.DRUG_DRUG,i.MODERATE,"     ","Inhibition of hepatic beta-blocker metabolism","     (   )","Increased beta-blocker concentrations and effects (bradycardia, hypotension)","   -      ","Monitor vital signs - reduce beta-blocker dose if necessary");n("Cimetidine","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"  ","Inhibition of carbamazepine metabolism","    ","Increased carbamazepine concentrations and toxicity risk","   -    ","Monitor carbamazepine concentrations - reduce dose if necessary");n("Cimetidine","Lidocaine",e.DRUG_DRUG,i.HIGH,"  ","Inhibition of lidocaine metabolism","      ","Increased lidocaine concentrations and risk of cardiac and neurological toxicity","   -    ","Monitor lidocaine concentrations - reduce dose if necessary");n("Cimetidine","Phenytoin",e.DRUG_DRUG,i.HIGH,"  ","Inhibition of phenytoin metabolism","     ( )","Increased phenytoin concentrations and toxicity risk (ataxia, nystagmus)","   -    ","Monitor phenytoin concentrations - reduce dose if necessary");n("Cimetidine","Theophylline",e.DRUG_DRUG,i.HIGH,"  ","Inhibition of theophylline metabolism","     (  )","Increased theophylline concentrations and toxicity risk (seizures, tachycardia)","   -     -    ","Monitor theophylline concentrations - reduce dose if necessary - use ranitidine as a safe alternative");n("Cimetidine","Nifedipine",e.DRUG_DRUG,i.MODERATE,"  ","Inhibition of nifedipine metabolism","   (  )","Increased nifedipine concentrations (hypotension, edema)","   -  ","Monitor blood pressure - adjust dose");n("Cimetidine","Praziquantel",e.DRUG_DRUG,i.MODERATE,"  ","Inhibition of praziquantel metabolism","  ","Increased praziquantel concentrations","  ","Monitor for side effects");n("Cimetidine","Procainamide ()",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of renal procainamide excretion","  ","Increased procainamide concentrations","   -  ","Monitor drug concentrations - adjust dose");n("Cimetidine","Quinidine",e.DRUG_DRUG,i.HIGH,"  ","Inhibition of quinidine metabolism","    ","Increased quinidine concentrations and toxicity risk","   -  ","Monitor drug concentrations - adjust dose");n("Cimetidine","TCAs (Amitriptyline, Imipramine, Nortriptyline, etc.)",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of antidepressant metabolism","      (  )","Increased antidepressant concentrations and toxicity risk (anticholinergic, cardiac effects)"," -   -   ","Monitor - adjust dose - use ranitidine as alternative");n("Cimetidine","Warfarin",e.DRUG_DRUG,i.HIGH," CYP2C9","CYP2C9 inhibition."," INR  ","Increased INR and bleeding risk.","    ","Use ranitidine or famotidine instead.");n("Cinacalcet","CYP2D6 Substrates",e.DRUG_DRUG,i.MODERATE," CYP2D6","CYP2D6 inhibition.","   CYP2D6","Increased CYP2D6 substrate levels.","   ","Reduce affected drug dose.");n("Cinacalcet - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"    CYP2D6                 ","Paroxetine is a potent inhibitor of hepatic CYP2D6 enzyme, which is the primary metabolic pathway for Cinacalcet, leading to significantly increased plasma concentrations of Cinacalcet","             ","Increased risk of Cinacalcet adverse effects, particularly severe hypocalcemia, seizures, and cardiac arrhythmias","    50%      -         ","Reduce Cinacalcet dose by at least 50% when starting Paroxetine - monitor serum calcium levels weekly and perform regular ECG monitoring");n("Ciprofloxacin","Food",e.DRUG_FOOD,i.MODERATE,": **   **.          .","Mechanism: **Chelation with Calcium**. Calcium in milk and dairy products binds to Ciprofloxacin and prevents its absorption."," : **      40%**.","Clinical Significance: **Decreased Ciprofloxacin absorption by up to 40%**.","       .       .","Avoid taking Ciprofloxacin with milk or yogurt alone. Can be taken with a full meal containing calcium.");n("Ciprofloxacin","Theophylline",e.DRUG_DRUG,i.MODERATE,"   CYP1A2.        ()   .","Ciprofloxacin Inhibits CYP1A2. Ciprofloxacin is a potent inhibitor of the hepatic enzyme CYP1A2, which is responsible for the primary metabolism of Theophylline.","    .            (      ).","Increased Theophylline Levels and Toxicity Risk. Elevated Theophylline levels can lead to CNS and cardiac toxicity (e.g., nausea, seizures, palpitations, arrhythmias).","      .       (  25-50%)      .","Monitor Theophylline Levels or Reduce Dose. Theophylline dose should be significantly reduced (typically 25-50%) and plasma concentrations monitored closely upon initiation of Ciprofloxacin.");n("Ciprofloxacin","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","   ","  ","  ");n("Ciprofloxacin","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","   ","  ","  ");n("Ciprofloxacin","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","   ","  ","  ");n("Ciprofloxacin","Dairy Products",e.DRUG_FOOD,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability."," "," ","  ","  ");n("Ciprofloxacin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ciprofloxacin","Dairy Products ( )",e.DRUG_FOOD,i.MODERATE,"   ()         (Chelation)   .","Chelation. Calcium and other divalent cations found in dairy products (and fortified juices) bind to Ciprofloxacin in the gastrointestinal tract, forming a non-absorbable complex.","    .                .","Reduced Antibiotic Efficacy. Significantly decreased Ciprofloxacin plasma concentrations can result in therapeutic failure and the potential development of bacterial resistance.","       .            4-6   .","Separate Doses by at least 2 hours (before) or 4-6 hours (after) the dairy consumption to minimize chelation and ensure optimal drug absorption.");n("Ciprofloxacin","Theophylline",e.DRUG_DRUG,i.HIGH,"  Theophylline. Ciprofloxacin   CYP1A2    Theophylline.","Increased Theophylline concentration. Ciprofloxacin inhibits CYP1A2, a Theophylline metabolic pathway.","   Theophylline (     ).","Increased risk of Theophylline toxicity (seizures, arrhythmia, nausea).","   .   .         Theophylline  .","Avoid combination or monitoring. Avoid this combination. If usage is necessary, reduce Theophylline dose and monitor levels.");n("Ciprofloxacin","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,"     ","Chelation. Divalent cations bind to fluoroquinolone, preventing absorption.","      90%","Reduced ciprofloxacin absorption by up to 90%, risking treatment failure.","   2-6  (    )","Separate doses by 2-6 hours (calcium before or after antibiotic).");n("Ciprofloxacin","Zinc Sulfate",e.DRUG_DRUG,i.MODERATE," -   ","Chelation - zinc binds to quinolone structure.","  ","Reduced ciprofloxacin absorption.","   2   ","Separate by at least 2 hours.");n("Ciprofloxacin","Alcohol",e.DRUG_FOOD,i.MODERATE,": **     **.        Ciprofloxacin          (  ).","Mechanism: **Additive Central Nervous System (CNS) Effect**. Alcohol increases the CNS side effects of Ciprofloxacin like dizziness, and may theoretically increase seizure risk (lowered seizure threshold).",":     .    .","Result: Increased dizziness, drowsiness, and impaired judgment. Advised to use in moderation.",":  .      .","Management: Monitor symptoms. Advise avoiding excessive alcohol intake.");n("Ciprofloxacin","Caffeine",e.DRUG_FOOD,i.LOW,": **   (CYP1A2)**. Ciprofloxacin     CYP1A2    .","Mechanism: **Metabolic Enzyme Inhibition (CYP1A2)**. Ciprofloxacin is a potent inhibitor of the CYP1A2 enzyme, responsible for Caffeine metabolism.",":                      .","Result: Slight increase in blood Caffeine concentration, which may lead to increased anxiety or nervousness, despite the Low severity rating.",":  .        .","Management: Monitor symptoms. Limit caffeine intake if side effects are noted.");n("Ciprofloxacin","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,": ** CYP3A4** (). Ciprofloxacin     CYP3A4       .","Mechanism: **CYP3A4 Inhibition** (Hypothetical). Ciprofloxacin is not a major CYP3A4 substrate, so no major clinical interaction is known.",":          .","Result: No expected clinical effect on drug absorption or efficacy.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Green Tea",e.DRUG_FOOD,i.MODERATE,": ** **.    ( CYP1A2)         (Chelation) .","Mechanism: **Compound Interaction**. Contains Caffeine (CYP1A2 inhibition) and may contain minerals leading to mild chelation.",":             .","Result: May lead to slight increase in neurological symptoms or minor reduction in absorption.",":          .","Management: Prefer separation of doses and Green Tea by at least two hours.");n("Ciprofloxacin","Milk",e.DRUG_FOOD,i.LOW,": ** ** (Chelation).   (Ca)      Ciprofloxacin.","Mechanism: **Chelation**. Calcium ions (Ca) in milk bind to Ciprofloxacin.",":   Ciprofloxacin      . (     ).","Result: Reduced Ciprofloxacin absorption, potentially decreasing its therapeutic efficacy. (Clinical effect is usually more than low).",": **  **      2  6 .","Management: **Doses must be separated** from milk and dairy products by 2 to 6 hours.");n("Ciprofloxacin","High-fat meals",e.DRUG_FOOD,i.HIGH,": **  **.        .","Mechanism: **Delayed Gastric Emptying**. High-fat meals slow down gastrointestinal motility and gastric emptying.",":       Ciprofloxacin (Tmax)       .","Result: Delay in reaching Ciprofloxacin peak concentration (Tmax) in the blood, which may delay onset of efficacy.",":   Ciprofloxacin **     **    .","Management: Advise taking Ciprofloxacin **consistently with or without food** to ensure consistent absorption.");n("Ciprofloxacin","High-fiber foods",e.DRUG_FOOD,i.MODERATE,": **   **.          .","Mechanism: **Binding in the GI tract**. High-concentration fibers may hinder drug absorption through physical interference.",":       Ciprofloxacin.","Result: Slight delay or reduction in Ciprofloxacin absorption.",":           .","Management: Prefer separation of the drug and high-fiber foods by at least two hours.");n("Ciprofloxacin","Vitamin C",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Vitamin D",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with the absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Vitamin E",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Vitamin K",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Vitamin B12",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Folic Acid",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Iron",e.DRUG_FOOD,i.LOW,": ** ** (Chelation).   (Fe)   Ciprofloxacin.","Mechanism: **Chelation**. Iron ions (Fe) bind to Ciprofloxacin.",":     Ciprofloxacin. (    ).","Result: Significant reduction in Ciprofloxacin absorption. (Clinical effect is usually high).",":           2  6 .","Management: Doses and Iron-containing supplements must be separated by 2 to 6 hours.");n("Ciprofloxacin","Calcium",e.DRUG_FOOD,i.HIGH,": ** ** (Chelation).   (Ca)   Ciprofloxacin    .","Mechanism: **Chelation**. Calcium ions (Ca) strongly bind to Ciprofloxacin in the GI tract.",": **     Ciprofloxacin**   .","Result: **Very significant reduction in Ciprofloxacin absorption** and decreased therapeutic efficacy.",":        2  6 .","Management: Doses and Calcium supplements must be separated by 2 to 6 hours.");n("Ciprofloxacin","Magnesium",e.DRUG_FOOD,i.MODERATE,": ** ** (Chelation).   (Mg)   Ciprofloxacin.","Mechanism: **Chelation**. Magnesium ions (Mg) bind to Ciprofloxacin.",":     Ciprofloxacin. (    ).","Result: Significant reduction in Ciprofloxacin absorption. (Clinical effect is usually high).",":        2  6 .","Management: Doses and Magnesium supplements must be separated by 2 to 6 hours.");n("Ciprofloxacin","Zinc",e.DRUG_FOOD,i.LOW,": ** ** (Chelation).   (Zn)   Ciprofloxacin.","Mechanism: **Chelation**. Zinc ions (Zn) bind to Ciprofloxacin.",":     Ciprofloxacin. (    ).","Result: Significant reduction in Ciprofloxacin absorption. (Clinical effect is usually high).",":        2  6 .","Management: Doses and Zinc supplements must be separated by 2 to 6 hours.");n("Ciprofloxacin","Potassium",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with kidney function.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Ciprofloxacin","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,": **  **.      (pH)        Ciprofloxacin.","Mechanism: **Increased gastric pH**. Sodium Bicarbonate raises the pH in the stomach, which decreases Ciprofloxacin solubility and absorption.",":     Ciprofloxacin   .","Result: Significant reduction in Ciprofloxacin absorption and potential treatment failure.",":        2  6 .","Management: Separate doses and Sodium Bicarbonate by 2 to 6 hours.");n("Ciprofloxacin","Antacids",e.DRUG_FOOD,i.LOW,": ** ** (Chelation)  ** **.      Mg/Al      .","Mechanism: **Chelation** and **pH increase**. Antacids contain Mg/Al ions that bind the drug and raise pH.",":     Ciprofloxacin. (    ).","Result: Significant reduction in Ciprofloxacin absorption. (Clinical effect is usually high).",":        2  6 .","Management: Separate doses and Antacids by 2 to 6 hours.");n("Ciprofloxacin","Theophylline",e.DRUG_FOOD,i.HIGH,": ** **. Ciprofloxacin    CYP1A2    Theophylline (       ).","Mechanism: **Metabolism Inhibition**. Ciprofloxacin strongly inhibits the CYP1A2 enzyme responsible for Theophylline metabolism (a Xanthine compound similar to Caffeine in structure).",": **  **                  .","Result: **Toxic accumulation of Theophylline** in the blood, which can lead to nausea, vomiting, headache, and in severe cases, seizures or arrhythmias.",": /.             .","Management: Contraindicated/Avoid. If use is essential, Theophylline dose must be adjusted and blood levels monitored regularly.");n("Ciprofloxacin","Sucralfate ( /)",e.DRUG_FOOD,i.HIGH,": ** **.  Sucralfate       Ciprofloxacin   .","Mechanism: **Chelation**. Sucralfate contains Aluminum, which strongly binds to Ciprofloxacin in the GI tract.",": **     Ciprofloxacin**        .","Result: **Very significant reduction in Ciprofloxacin absorption**, potentially leading to antibiotic treatment failure.",":     Ciprofloxacin  Sucralfate  2  6   .","Management: Ciprofloxacin and Sucralfate doses must be separated by at least 2 to 6 hours.");n("Ciprofloxacin - ","Tizanidine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     CYP1A2        .                  10   (  AUC  1000   Cmax  700)    .","Ciprofloxacin potently inhibits the CYP1A2 enzyme, the primary hepatic enzyme responsible for Tizanidine metabolism. This inhibition significantly reduces Tizanidine metabolism, increasing systemic exposure by approximately 10-fold (increases AUC by 1000%, increases Cmax by 700%), and prolongs its half-life.","             .                       .               .","The primary risk is the occurrence of severe and profound hypotension, often accompanied by bradycardia. Additionally, the risk of sedative and depressant effects increases significantly, potentially leading to excessive drowsiness, dizziness, severe fatigue, and impaired cognitive and motor function. Other adverse effects associated with increased Tizanidine concentration, such as dry mouth and muscle weakness, may also occur.","      (Contraindicated).         .               CYP1A2 (  ).                (       )      .","This interaction is considered an absolute contraindication. Tizanidine must not be co-administered with Ciprofloxacin under any circumstances. If a patient is taking Tizanidine, an alternative antibiotic that does not affect CYP1A2 (e.g., non-fluoroquinolones) should be selected. If Ciprofloxacin use is absolutely necessary, Tizanidine must be discontinued well in advance (at least several days based on its half-life) before initiating Ciprofloxacin, with close monitoring of vital signs and consciousness.");n("Ciprofloxacin (eye drops)","Theophylline",e.DRUG_DRUG,i.LOW,"  ","Minor systemic absorption.","   ","Minor theophylline effect.","   ","Usually no adjustment needed.");n("Cisapride","Erythromycin",e.DRUG_DRUG,i.CONTRAINDICATED,"    QT.     CYP3A4          .","Metabolic Inhibition and QT Prolongation. Erythromycin is a potent CYP3A4 inhibitor, severely impairing Cisapride metabolism and drastically increasing its plasma levels.","  .        QT          (Torsades de Pointes)   .","Fatal Arrhythmia. High Cisapride levels cause life-threatening QTc prolongation, leading to Torsades de Pointes and sudden cardiac death.",".        CYP3A4    .","Contraindicated. The co-administration of Cisapride with any potent CYP3A4 inhibitor is absolutely contraindicated.");n("Cisapride","Clarithromycin",e.DRUG_DRUG,i.CONTRAINDICATED,"    QT.     CYP3A4          .","Metabolic Inhibition and QT Prolongation. Clarithromycin is a potent CYP3A4 inhibitor, severely impairing Cisapride metabolism and drastically increasing its plasma levels.","  .        QT          (Torsades de Pointes)   .","Fatal Arrhythmia. High Cisapride levels cause life-threatening QTc prolongation, leading to Torsades de Pointes and sudden cardiac death.",".        CYP3A4    .","Contraindicated. The co-administration of Cisapride with any potent CYP3A4 inhibitor is absolutely contraindicated.");n("Cisapride","Azithromycin",e.DRUG_DRUG,i.CONTRAINDICATED,"  QT (      ).       QT       .","QT Prolongation (despite weaker enzyme inhibition). Azithromycin is also associated with QTc prolongation, which can have an additive effect with Cisapride.","  .    QT           (Torsades de Pointes)   .","Fatal Arrhythmia. High risk of significant QTc prolongation, leading to Torsades de Pointes and sudden cardiac death.",".       QT      .","Contraindicated. Co-administration of Cisapride with other QT-prolonging drugs, including macrolides, should be avoided.");n("Cisapride","Drugs with rapid gastric emptying",e.DRUG_DRUG,i.MODERATE,"  .      (Prokinetic)         .","Accelerated Gastric Emptying. Cisapride is a prokinetic agent that increases gastrointestinal motility and speeds up the transfer of stomach contents to the small intestine.","   (Cmax)   .                .","Altered Absorption Rate. May cause a rapid increase in the peak concentration (Cmax) of some drugs, or decrease the overall absorption of sustained-release formulations.","  .                 .","Monitor Drug Efficacy. Monitor the therapeutic effect of the co-administered drug and adjust the dosage if absorption changes significantly. Avoid sustained-release medications if possible.");n("Cisplatin","Aminoglycosides",e.DRUG_DRUG,i.HIGH,"   ","Synergistic nephrotoxicity and ototoxicity.","    ","Renal failure and permanent hearing loss.","  -    ","Avoid - adequate hydration if necessary.");n("Citalopram","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"   ( )","Increased Cyclosporine (Enzyme Inhibition). CYP3A4 inhibition leads to toxic cyclosporine levels.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","   -     ","   -     ");n("Citalopram","Omeprazole",e.DRUG_DRUG,i.MODERATE,"  Citalopram. Omeprazole   CYP2C19.","Increased Citalopram concentration. Omeprazole inhibits CYP2C19.","    QT.","Increased risk of QT prolongation."," .      Citalopram   .","Dose adjustment. Maximum Citalopram dose must be reduced and ECG monitored.");n("Citalopram - ","Cyproheptadine - ",e.DRUG_DRUG,i.MODERATE,"     (5-HT)          ","Cyproheptadine is a serotonin receptor (5-HT) antagonist, counteracting the therapeutic effect of Citalopram through pharmacodynamic antagonism","           ","Reduced therapeutic efficacy of Citalopram, deterioration in depressive symptom improvement, and potential symptom relapse","    -                 ","Avoid combination if possible - if Cyproheptadine use is necessary, consider increasing Citalopram dose or switching to a different antidepressant class");n("Clarithromycin","Simvastatin",e.DRUG_DRUG,i.HIGH,"  CYP3A4 .     CYP3A4       () .","CYP3A4 Enzyme Inhibition. Clarithromycin is a potent inhibitor of CYP3A4, the primary hepatic enzyme responsible for the metabolism and clearance of Simvastatin.","        (Rhabdomyolysis)  .        .","Increased Statin Levels and Toxicity. Elevated Simvastatin plasma concentrations drastically increase the risk of severe myopathy, Rhabdomyolysis, and resulting acute renal failure.","/.                 ( )       CYP3A4.","Avoid/Substitution. Temporarily discontinue Simvastatin during Clarithromycin therapy, or substitute with an alternative antibiotic (like Azithromycin) or an alternative statin (like Pravastatin or Rosuvastatin) that is not primarily metabolized by CYP3A4.");n("Clarithromycin","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Clarithromycin    CYP3A4    Simvastatin.","Increased Simvastatin concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Simvastatin metabolic pathway.","    (Rhabdomyolysis).","Increased risk of Rhabdomyolysis."," .   Simvastatin        .","Contraindicated. Simvastatin must be temporarily discontinued during Clarithromycin therapy or an alternative statin used.");n("Clarithromycin","Grapefruit Juice",e.DRUG_FOOD,i.HIGH," CYP3A4","CYP3A4 inhibition","   -   ","Increased drug concentration - may cause toxicity","      ","Avoid grapefruit juice completely during treatment");n("Clarithromycin - ","Buspirone - ",e.DRUG_DRUG,i.HIGH,"   (Metabolic Inhibition).     CYP3A4       .         .","Metabolic Inhibition. Clarithromycin is a potent inhibitor of the CYP3A4 enzyme, which is primarily responsible for Buspirone metabolism. This inhibition prevents Buspirone clearance, leading to accumulation.","   (Buspirone Toxicity)      (Severe Sedation)     .","Increased risk of Buspirone toxicity, manifesting as severe sedation, dizziness, and impaired judgment and concentration.","     .          ( 50-75% )       .","Avoid this combination if possible. If co-administration is necessary, the Buspirone dose must be significantly reduced (typically by 50-75%) and the patient closely monitored for signs of CNS toxicity.");n("Clarithromycin","Atorvastatin",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition increases atorvastatin exposure.","   ","Increased myopathy risk.","     ","Reduce atorvastatin dose or use alternative.");n("Clindamycin","Aluminum Salts",e.DRUG_DRUG,i.MODERATE,"    ","    ","   .","Antibiotic Failure. Suboptimal killing.","       .","       .");n("Clindamycin","Vecuronium",e.DRUG_DRUG,i.MODERATE,"   .       .","Increased neuromuscular blockade. Clindamycin has an additive neuromuscular blocking effect.","   .","Prolonged period of respiratory paralysis."," .       .","Close monitoring. Respiratory function must be closely monitored.");n("Clindamycin","Fatty Foods",e.DRUG_FOOD,i.LOW," ","Gastric irritation"," ","Nausea only","    -    ","No serious interactions - only mild gastric irritation");n("Clindamycin (topical)","Erythromycin (topical)",e.DRUG_DRUG,i.MODERATE," ","Pharmacological antagonism.","   ","Reduced efficacy of both."," ","Avoid combination.");n("Clofibrate","Warfarin",e.DRUG_DRUG,i.HIGH,"     ","Displacement of warfarin from plasma protein binding","    ","Increased warfarin effect and bleeding risk","  /  ","Refer to Antiplatelets/Anticoagulants");n("Clomipramine","Clonidine",e.DRUG_DRUG,i.MODERATE," .  (   )          -2    .","Pharmacodynamic Antagonism. Clomipramine (a tricyclic antidepressant) blocks the antihypertensive effect of Clonidine by antagonizing postsynaptic alpha-2 adrenergic receptors.","  .          .","Hypertension. Failure to control blood pressure and potential rebound hypertension.",".      .               .","Avoid use. Avoid this combination if possible. Monitor blood pressure closely and consider alternative non-TCA antidepressants.");n("Clonazepam","Fluconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Clonazepam","Itraconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Clonazepam","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Clonazepam","Voriconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Clonazepam","Diltiazem",e.DRUG_DRUG,i.MODERATE,"   -      ","Increased Benzodiazepine Effect. Elevated levels lead to excessive sedation and psychomotor impairment.","    ","Enhanced Sedation. Excessive CNS depression.","   ","   ");n("Clonazepam","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"   -     ","Enhanced Benzodiazepine Effect. Risk of profound sedation.","    ","Enhanced Sedation. Excessive CNS depression.","    ","    ");n("Clonazepam","Macrolide Antibiotics",e.DRUG_DRUG,i.HIGH,"   -      ","Increased Benzodiazepine Effect. Elevated levels lead to excessive sedation and psychomotor impairment.","    ","Enhanced Sedation. Excessive CNS depression.","     -   :   ","     -   :   ");n("Clonazepam","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"      (CNS).","Additive Central Nervous System (CNS) Depressant Effects.","             .","Substantially increased risk of severe drowsiness, dizziness, impaired concentration, respiratory depression, and increased risk of falls.","   .    ( )            .","Alcohol must be completely avoided. With other depressants (especially Opioids), use the lowest possible effective doses and closely monitor for respiratory depression.");n("Clonazepam","Ketoconazole (or other strong CYP3A4 Inhibitors)",e.DRUG_DRUG,i.MODERATE,"  (CYP3A4).        .","Metabolic Inhibition (CYP3A4). These drugs inhibit the enzyme responsible for Clonazepam metabolism.","             .","Increased plasma concentration of Clonazepam, leading to increased and prolonged hypnotic effect and excessive drowsiness.","     .       .","Monitor the patient for excessive drowsiness. A reduction in the Clonazepam dose may be necessary.");n("Clonazepam","Rifampin (or other strong CYP3A4 Inducers)",e.DRUG_DRUG,i.MODERATE,"    (CYP3A4).      .","Potent Enzymatic Metabolic Induction (CYP3A4). These drugs increase the metabolism of Clonazepam.","             .","Decreased levels of Clonazepam, resulting in reduced drug efficacy and a return of seizures or panic symptoms.","     .       .","Monitor the patient for symptom recurrence. A Clonazepam dose increase may be needed.");n("Clonazepam","Valproic Acid",e.DRUG_DRUG,i.MODERATE,"            .","Unclear Pharmacokinetic interaction, potentially related to metabolic inhibition and additive effects.",'    " "  "" (Absence Status Epilepticus).',"Increased risk of developing Absence Status Epilepticus (a specific type of seizure exacerbation).","     .      .","Closely monitor for seizure symptoms and changes in seizure patterns. Use this combination with extreme caution.");n("Clonidine",xn,e.DRUG_DRUG,i.HIGH,": **  **     .  ( -2)               .","Mechanism: **Mechanism antagonism** and rebound effect upon sudden withdrawal. Clonidine (alpha-2 agonist) decreases sympathetic activity, while beta-blockers prevent sympathetic compensation upon Clonidine withdrawal."," :  **     (Rebound Hypertension)**            .","Clinical Significance: Risk of **severe Rebound Hypertension** and ventricular fibrillation, especially upon abrupt Clonidine cessation while the patient is still on beta-blockers.","     .  **   **        2-4 .","Monitor BP when starting or stopping. **Withdraw Beta-blocker first** (tapering) and then withdraw Clonidine gradually over 2-4 days.");n("Clonidine",Zu,e.DRUG_DRUG,i.HIGH,": **    **.     (TCAs)    (Norepinephrine)       -2 (Alpha-2 Receptors).","Mechanism: **Direct pharmacodynamic antagonism at receptors**. TCAs inhibit Norepinephrine reuptake and compete with Clonidine for the Alpha-2 receptor binding site."," : **     **   TCAs           .","Clinical Significance: **Complete loss of BP control**, as TCAs counteract the antihypertensive effect of Clonidine, increasing the risk of hypertensive crises.","  .         (     - SSRIs).","Avoid combination. If necessary, alternative antidepressants (e.g., SSRIs) should be chosen.");n("Clonidine","Atenolol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Atenolol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Atenolol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");n("Clonidine","Bisoprolol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Bisoprolol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Bisoprolol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");n("Clonidine","Carvedilol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Carvedilol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Carvedilol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");n("Clonidine","Metoprolol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Metoprolol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Metoprolol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");n("Clonidine","Propranolol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Propranolol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Propranolol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");n("Clonidine","Nebivolol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Nebivolol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Nebivolol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");n("Clonidine","Labetalol",e.DRUG_DRUG,i.MODERATE,"      .     -2.              ()  .","Withdrawal Rebound Exacerbation. Clonidine acts on alpha-2 receptors. Abrupt cessation leads to severe rebound sympathetic overactivity, which is dangerously aggravated by the presence of a beta-blocker (Labetalol).","   (Rebound Hypertension) .             .","Severe Rebound Hypertension. High risk of hypertensive crisis, tachycardia, and myocardial ischemia/infarction."," .      ()        .","Withdraw Slowly. Both Clonidine and the beta-blocker (Labetalol) must be tapered slowly and gradually. Abrupt discontinuation of either agent should be strictly avoided.");$o.forEach(h=>{n("Clonidine",h,e.DRUG_DRUG,i.HIGH,"     .       (     )            -1    (Unopposed Alpha Stimulation)    .","Antagonistic BP regulation. The main risk is abrupt clonidine withdrawal (causing a rebound norepinephrine surge). The beta-blocker prevents vasodilation via beta-receptors, leaving peripheral alpha-1 receptors unopposed, leading to severe vasoconstriction.","      (Hypertensive Crisis)      (Tachycardia).","Hypertensive Crisis (Severe BP elevation) potentially accompanied by reflex tachycardia.","      .      (   2-3 )       2-4      .","Taper both drugs gradually. Ideally, discontinue the beta-blocker first, followed by clonidine taper over 2-4 days, with strict BP monitoring throughout.")});Zu.forEach(h=>{n("Clonidine",h,e.DRUG_DRUG,i.CONTRAINDICATED,"    (TCAs)          (Norepinephrine Reuptake Inhibition)      -2         .","TCAs block the central antihypertensive action of clonidine by inhibiting norepinephrine reuptake and/or directly antagonizing central Alpha-2 adrenergic receptors. This results in the complete negation of clonidine's therapeutic effect.","              (Hypertensive Crisis).","Loss of blood pressure control, chronic hypertension, and increased risk of Hypertensive Crisis.","   .        SSRI/SNRI           .","Combination is contraindicated. Switch the antidepressant to an SSRI/SNRI or choose an alternative antihypertensive agent not affected by TCAs.")});n("Clonidine","Tricyclic Antidepressants",e.DRUG_DRUG,i.HIGH,"     ","Inhibition of clonidine's antihypertensive effect.","   ","Rebound hypertension.","  -    ","Avoid - or monitor BP closely.");n("Clonidine","Propranolol",e.DRUG_DRUG,i.HIGH,"   -    ","Upon abrupt withdrawal - severe rebound hypertension.","   ","Hypertensive crisis.","      ","Stop beta-blocker first, then taper clonidine.");n("Clopidogrel","Omeprazole",e.DRUG_DRUG,i.MODERATE,"   CYP2C19       ( ).","Omeprazole inhibits CYP2C19, the hepatic enzyme essential for the bioactivation of Clopidogrel (a prodrug) into its active metabolite.","     .                (     ).","Reduced Clopidogrel Efficacy and Increased Thrombotic Risk. Inhibition leads to subtherapeutic antiplatelet effect, raising the risk of cardiovascular events (e.g., stent thrombosis, MI, stroke).","             H2       ( ).","Substitute Omeprazole with an alternative PPI (e.g., Pantoprazole) or an H2 blocker. Alternatively, switch Clopidogrel to a different antiplatelet agent (e.g., Prasugrel).");n("Clopidogrel","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Clopidogrel   . Omeprazole    CYP2C19     .","Decreased conversion of Clopidogrel to active metabolite. Omeprazole is a strong inhibitor of CYP2C19, the activating enzyme.","  Clopidogrel       .","Reduced Clopidogrel efficacy, leading to risk of thrombosis and stent failure."," .   Omeprazole  Esomeprazole.    PPIs  ( Pantoprazole).","Contraindicated. Avoid Omeprazole or Esomeprazole. Other PPIs (e.g., Pantoprazole) are preferred.");n("Clopidogrel","Omeprazole",e.DRUG_DRUG,i.HIGH," CYP2C19 -     ","CYP2C19 inhibition prevents clopidogrel activation.","    -   ","Antiplatelet failure - increased clotting risk.","    ","Use pantoprazole or rabeprazole instead.");n("Clopidogrel","Aspirin",e.DRUG_DRUG,i.MODERATE,"    ","Synergistic platelet inhibition.","  ","Increased bleeding risk.","   -     ","Monitor for bleeding - beneficial in ACS.");n("Clopidogrel","Alcohol",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Caffeine",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Green Tea",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Milk",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","High-fat meals",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","High-fiber foods",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Vitamin C",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Vitamin D",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Vitamin E",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Vitamin K",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Vitamin B12",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Folic Acid",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Iron",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Calcium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Magnesium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Zinc",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Potassium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clopidogrel","Antacids",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Clorazepate","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"     .","Additive Central Nervous System (CNS) Depressant Effects.","              .","Substantially increased risk of severe drowsiness, dizziness, motor incoordination, respiratory depression, and increased risk of falls.","   .    ( )              .","Alcohol must be completely avoided. With other depressants (especially Opioids), use the lowest possible effective doses and closely monitor for over-sedation and breathing difficulties.");n("Clorazepate","Omeprazole (or other strong CYP2C19/3A4 Inhibitors)",e.DRUG_DRUG,i.MODERATE," .     CYP3A4 / CYP2C19      ().","Metabolic Inhibition. These drugs inhibit CYP3A4 and/or CYP2C19 enzymes responsible for metabolizing the active metabolite (Nordiazepam).","    ()         .","Increased concentration of the active metabolite (Nordiazepam), leading to increased and prolonged hypnotic effect and excessive drowsiness.","       .       .","Monitor the patient for excessive drowsiness and impaired consciousness. A reduction in the Clorazepate dose may be necessary.");n("Clorazepate","Rifampin (or other strong CYP3A4/2C19 Inducers)",e.DRUG_DRUG,i.MODERATE,"   .        ().","Potent Enzymatic Metabolic Induction. These drugs increase the metabolism of the active metabolite (Nordiazepam).","              .","Decreased levels of the active metabolite, resulting in reduced drug efficacy and a return of anxiety or seizure symptoms.","     .            .","Monitor the patient for symptom recurrence. A Clorazepate dose increase or switching to an alternative drug may be needed.");n("Clorazepate","Antacids",e.DRUG_DRUG,i.LOW,"    .","Reduction of gastric acidity.","      ()        .","Slowed conversion of Clorazepate to its active metabolite (Nordiazepam) in the stomach, leading to a delayed onset of action.","           .","Administer Clorazepate 2 hours before or after antacids to minimize the interaction.");n("Clozapine","Carbamazepine",e.DRUG_DRUG,i.HIGH,"    (Additive Bone Marrow Suppression).            .","Additive Bone Marrow Suppression. Both Clozapine and Carbamazepine have the potential to cause hematological toxicity, particularly severe neutropenia/agranulocytosis.","  (Agranulocytosis).                .","Agranulocytosis. Extremely high risk of life-threatening agranulocytosis (severe reduction in granulocytes/neutrophils).",".         .       (CBC)   .","Contraindicated. This combination must be avoided due to the fatal risk. If co-administration is absolutely necessary, perform extremely frequent hematological monitoring (CBC).");n("Clozapine","Ritonavir",e.DRUG_DRUG,i.HIGH,"  .     CYP1A2  CYP3A4    .","Increased Clozapine Concentrations. Ritonavir is a potent inhibitor of CYP1A2 and CYP3A4 enzymes, which are primarily responsible for Clozapine metabolism.","  .               .","Increased Clozapine Toxicity. Elevated plasma levels increase the risk of severe adverse effects, including seizures, hypotension, bradycardia, and respiratory depression.","  .                   .","Avoid this combination. If co-administration is mandatory, perform a drastic reduction in the Clozapine dose and monitor the patient clinically and via therapeutic drug monitoring (TDM).");n("Clozapine","Fluoxetine",e.DRUG_DRUG,i.HIGH," .     CYP2D6   CYP3A4     .","Metabolic Inhibition. Fluoxetine is a potent inhibitor of CYP2D6 and an inhibitor of CYP3A4, both involved in Clozapine metabolism.","            (Seizures)       .","Significant increase in Clozapine plasma concentration, increasing the risk of seizures, hypotension, severe sedation, and cardiotoxicity.","     (TDM).     (  )    .","Clozapine plasma levels (TDM) must be monitored. Reduce the Clozapine dose (often significantly) if necessary to avoid toxicity.");n("Clozapine","Sertraline",e.DRUG_DRUG,i.MODERATE," .     CYP    ( CYP2D6).","Metabolic Inhibition. Sertraline is a weak inhibitor of CYP enzymes that metabolize Clozapine (e.g., CYP2D6).","             .","Slight to moderate increase in Clozapine concentration, increasing the risk of sedation and side effects.","   (TDM).      .","Clozapine plasma levels (TDM) should be monitored. Reduce the Clozapine dose if necessary.");n("Clozapine","Paroxetine",e.DRUG_DRUG,i.HIGH," .     CYP2D6       .","Metabolic Inhibition. Paroxetine is a potent inhibitor of the CYP2D6 enzyme, a major pathway for Clozapine metabolism.","                  .","Significant increase in Clozapine plasma concentration, increasing the risk of seizures, hypotension, severe sedation, and cardiotoxicity.","     (TDM).     (  )    .","Clozapine plasma levels (TDM) must be monitored. Reduce the Clozapine dose (often significantly) if necessary to avoid toxicity.");n("Clozapine","Citalopram",e.DRUG_DRUG,i.MODERATE," .     CYP        .","Metabolic Inhibition. Citalopram is a weak inhibitor of CYP enzymes, with a potential for a slight increase in Clozapine concentration.","                    QT.","Slight increase in Clozapine concentration, increasing the risk of sedation and side effects, noting that both drugs can prolong the QT interval.","   (TDM)  .      .","Clozapine plasma levels (TDM) and side effects should be monitored. Reduce the Clozapine dose if necessary.");n("Clozapine","Escitalopram",e.DRUG_DRUG,i.MODERATE," .     CYP        .","Metabolic Inhibition. Escitalopram is a weak inhibitor of CYP enzymes, with a potential for a slight increase in Clozapine concentration.","                    QT.","Slight increase in Clozapine concentration, increasing the risk of sedation and side effects, noting that both drugs can prolong the QT interval.","   (TDM)  .      .","Clozapine plasma levels (TDM) and side effects should be monitored. Reduce the Clozapine dose if necessary.");n("Clozapine - ","Fluvoxamine - ",e.DRUG_DRUG,i.HIGH,"    CYP1A2          CYP2C19        3-5 ","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme responsible for Clozapine primary metabolism, with secondary inhibition of CYP2C19, increasing Clozapine concentration by 3-5 fold","              (    )  ","Significant increase in risk of seizures, orthostatic hypotension, confusion, bone marrow suppression (leukopenia, neutropenia), and serotonin syndrome","    30-40%       -          -      ","Reduce Clozapine dose to 30-40% of original dose when starting Fluvoxamine - monitor Clozapine blood levels weekly and blood neutrophils regularly - initiate with very low Clozapine dose");n("Cobicistat","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Cobicistat    CYP3A4    Simvastatin.","Increased Simvastatin concentration. Cobicistat is a strong CYP3A4 inhibitor, a Simvastatin metabolic pathway.","   .","Increased risk of Rhabdomyolysis."," .   Simvastatin  Cobicistat        CYP3A4.","Contraindicated. Simvastatin must be avoided with Cobicistat or an alternative statin not metabolized by CYP3A4 used.");n("Cobimetinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Cobimetinib. Voriconazole    CYP3A4    Cobimetinib.","Increased Cobimetinib concentration. Voriconazole is a strong CYP3A4 inhibitor, a Cobimetinib metabolic pathway.","      .","Increased risk of hemorrhage, hematological toxicity, and severe diarrhea."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Cobimetinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Cobimetinib. Carbamazepine    CYP3A4    Cobimetinib.","Decreased Cobimetinib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Cobimetinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Cobimetinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Cobimetinib. Rifampin    CYP3A4    Cobimetinib.","Decreased Cobimetinib concentration. Rifampin is a strong inducer of CYP3A4, a Cobimetinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Codeine","Quinidine",e.DRUG_DRUG,i.MODERATE,"   CYP2D6.     (Prodrug)   CYP2D6    .     .","Quinidine Inhibits CYP2D6. Codeine is a prodrug requiring CYP2D6 to be converted into its active metabolite, Morphine. Quinidine is a potent inhibitor of this enzyme.","  .                  .","Reduced Analgesic Efficacy. Enzyme inhibition leads to significantly lower active Morphine concentrations, diminishing the analgesic and antitussive effects of Codeine.","       CYP2D6      .          .","Use an alternative analgesic (not reliant on CYP2D6 for activation), or monitor response closely. If necessary, a careful dose increase of Codeine may be required, though generally discouraged.");n("Codeine - ","Fluoxetine - ",e.DRUG_DRUG,i.HIGH,"    CYP2D6     ( )        ","Fluoxetine is a potent inhibitor of hepatic CYP2D6 enzyme essential for converting Codeine (prodrug) to active Morphine, completely preventing metabolic conversion","              ","Complete failure of Codeine analgesic and antitussive effects, as it remains pharmacologically inactive in the body","      CYP2D6           -      ","Use alternative analgesics not dependent on CYP2D6 such as adjusted-dose tramadol, paracetamol, or NSAIDs - completely avoid Codeine use with Fluoxetine");n("Colchicine","Erythromycin",e.DRUG_DRUG,i.HIGH,"     (P-gp inhibitor).","P-gp Inhibition (Colchicine). Blockade of efflux leads to fatal colchicine toxicity.","      .","      .","         .","         .");n("Colchicine","Clarithromycin",e.DRUG_DRUG,i.HIGH,"     (P-gp inhibitor).","P-gp Inhibition (Colchicine). Blockade of efflux leads to fatal colchicine toxicity.","      .","      .","         .","         .");n("Colchicine","Azithromycin",e.DRUG_DRUG,i.HIGH,"     (P-gp inhibitor).","P-gp Inhibition (Colchicine). Blockade of efflux leads to fatal colchicine toxicity.","      .","      .","         .","         .");n("Colchicine","Simvastatin",e.DRUG_DRUG,i.HIGH,"  .     (    CYP3A4)            (Myopathy).","Increased Muscular Toxicity. Colchicine interacts with Simvastatin (which is metabolized by CYP3A4) to significantly increase the risk of myopathy, and Colchicine itself has inherent myotoxicity.","      (Rhabdomyolysis).               .","Increased Risk of Myopathy and Rhabdomyolysis. The combination drastically increases the risk of severe muscle damage and potential acute renal failure."," .        .                 CYP3A4.","Avoid Combination. The concurrent use of Colchicine and Simvastatin should be avoided. If Colchicine is necessary, use the lowest effective dose and consider switching the patient to an alternative statin (e.g., Pravastatin, Rosuvastatin) not metabolized by CYP3A4.");n("Colchicine","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Colchicine. Clarithromycin   CYP3A4  P-gp     Colchicine.","Increased Colchicine concentration. Clarithromycin inhibits CYP3A4 and P-gp, Colchicine metabolic and efflux pathways.","    (     ).","Increased risk of fatal toxicity (e.g., myelosuppression, myopathy)."," .             .","Contraindicated. Avoid the combination in patients with renal or hepatic impairment.");n("Colchicine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH," CYP3A4  P-glycoprotein -   ","Inhibition of CYP3A4 and P-glycoprotein - increased Colchicine levels."," (      )","Toxicity (severe diarrhea, renal failure, cytopenia).","    -     ","Avoid grapefruit juice - high risk especially with renal impairment.");n("Colchicine","Clarithromycin",e.DRUG_DRUG,i.HIGH," P-gp  CYP3A4","P-gp and CYP3A4 inhibition.","  ","Fatal colchicine toxicity.","    /","Contraindicated in renal/hepatic impairment.");n("Colchicine","Cyclosporine",e.DRUG_DRUG,i.HIGH," P-gp","P-glycoprotein inhibition.","   ","Myopathy and nephrotoxicity.","   50%","Reduce colchicine dose 50%.");n("Colesevelam","Levothyroxine",e.DRUG_DRUG,i.MODERATE,"  ","Intestinal binding."," ","Hypothyroidism.","  4 ","Separate by 4 hours.");n("Colestipol","Furosemide",e.DRUG_DRUG,i.MODERATE," .          .","Binding Agent. Colestipol, an anion-exchange resin, binds to Furosemide in the gastrointestinal tract.","  .               .","Reduced Furosemide Absorption. Binding results in significantly decreased Furosemide bioavailability, leading to reduced diuretic efficacy.","     .            .","Separate Doses by at least 2 hours (before) or 4 hours (after) the Colestipol dose.");n("Colestipol","Digoxin",e.DRUG_DRUG,i.MODERATE," ","Digoxin binding.","  ","Reduced digoxin efficacy.","   2 ","Separate doses by 2 hours.");n("Colestipol - ","Warfarin - ",e.DRUG_DRUG,i.MODERATE,"              ","Colestipol binds to Warfarin in the intestine and reduces its absorption, and may interfere with enterohepatic circulation","        ","Reduced Warfarin efficacy, decreased prothrombin time, increased thrombosis risk","   4-6  -  INR  -     ","Separate doses by 4-6 hours - monitor INR regularly - adjust Warfarin dose as needed");n("Colestipol - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE,"        ","Colestipol binds to Digoxin in the gastrointestinal tract and reduces its absorption","           ","Decreased Digoxin blood levels, reduced therapeutic efficacy, worsening heart failure symptoms","       -    -    ","Take Digoxin at least 1 hour before Colestipol - monitor Digoxin levels - adjust dose as needed");n("Colestipol - ","Thyroid Hormones -   ",e.DRUG_DRUG,i.MODERATE,"        ","Colestipol binds to thyroid hormones in the intestine and impairs their absorption","          TSH","Reduced thyroid hormone efficacy, hypothyroidism symptoms, elevated TSH","       4-6  -     ","Take thyroid hormones 4-6 hours before Colestipol - monitor thyroid function regularly");n("Colestipol - ","Fat-Soluble Vitamins -    ",e.DRUG_DRUG,i.MODERATE,"          ","Colestipol binds to bile acids and reduces absorption of fat-soluble vitamins","  A, D, E, K    (  K)  ","Deficiency of vitamins A, D, E, K, increased bleeding risk (vitamin K deficiency), osteoporosis","   -     -   ","Take vitamin supplements - separate doses from Colestipol - monitor for deficiency signs");n("Colestipol - ","Diuretics -  ",e.DRUG_DRUG,i.MODERATE,"        ","Colestipol may bind to some diuretics and reduce their absorption","        ","Reduced diuretic efficacy, hypertension, fluid retention","     -     ","Separate doses by at least 2 hours - monitor blood pressure and renal function");n("Colestipol - ","Propranolol - ",e.DRUG_DRUG,i.MODERATE,"         ","Colestipol reduces Propranolol absorption and lowers its blood levels","       ","Reduced Propranolol efficacy, tachycardia, hypertension","       -      ","Take Propranolol at least 2 hours before Colestipol - monitor blood pressure and heart rate");n("Colestipol - ","General Interaction Warning -   ",e.DRUG_DRUG,i.MODERATE,"              ","Colestipol may interfere with absorption of many drugs by binding to them in the gastrointestinal tract","        ","Reduced efficacy of concomitant medications, therapeutic failure, worsening of medical conditions","        -     ","Take other medications at least 1 hour before Colestipol - monitor therapeutic response for all medications");n("Hydrocortisone - ","Colestipol - ",e.DRUG_DRUG,i.MODERATE,"              ","Colestipol binds to Hydrocortisone in the intestine and reduces its absorption through direct binding and decreased bioavailability","              ","Decreased Hydrocortisone blood levels, reduced therapeutic efficacy, risk of exacerbating inflammatory condition or adrenal insufficiency","     2-4    -    -      ","Take Hydrocortisone at least 2-4 hours before Colestipol - monitor clinical response - adjust Hydrocortisone dose if necessary");n("Loop Diuretics -   ","Colestipol - ",e.DRUG_DRUG,i.MODERATE,"     (  )      ","Colestipol binds to loop diuretics (e.g., Furosemide, Bumetanide) in the gastrointestinal tract and reduces their absorption","           ","Reduced diuretic efficacy, fluid retention, worsening heart failure, hypertension","        -       -    ","Take diuretics at least 2 hours before Colestipol - monitor patient weight, renal function and electrolytes - adjust doses as needed");n("Colestipol - ","Maralixibat - ",e.DRUG_DRUG,i.MODERATE,"                      ","Both drugs reduce bile acid reabsorption in the intestine through different but complementary mechanisms, potentially leading to an additive effect","                ","Increased risk of bile acid-associated diarrhea, fat malabsorption, fat-soluble vitamin deficiencies, and adverse intestinal effects","    -        -     -      ","Monitor gastrointestinal symptoms - regularly check fat-soluble vitamin levels - adjust doses based on tolerance - may need to separate doses by 2 hours");n("Colestipol - ","Seladelpar - ",e.DRUG_DRUG,i.MODERATE,"               ","Colestipol may bind to Seladelpar in the intestine and reduce its absorption, while Seladelpar affects bile acid metabolism","                ","Decreased Seladelpar blood levels, reduced therapeutic efficacy in cholestatic liver diseases, disruption of bile acid metabolism","     4    -       -     ","Take Seladelpar at least 4 hours before Colestipol - monitor liver function and cholestasis markers - measure drug levels if possible");n("Colestipol - ","Mycophenolate Mofetil -  ",e.DRUG_DRUG,i.HIGH,"            ","Colestipol binds to Mycophenolate Mofetil in the intestine and significantly reduces its absorption and bioavailability","                ","Sharp decrease in Mycophenolate blood levels, risk of transplant rejection, reduced immunosuppressive efficacy, increased infection risk","    -   :    6    -      -      ","Avoid combination if possible - if necessary: separate doses by at least 6 hours - monitor Mycophenolate blood levels - increase Mycophenolate dose if needed");n("Colestipol - ","Ursodiol - ",e.DRUG_DRUG,i.MODERATE,"                 ","Colestipol binds to Ursodiol in the intestine and reduces its absorption, impairing its efficacy in dissolving gallstones and improving bile flow","               ","Reduced Ursodiol efficacy in treating gallstones and cholangitis, slowed stone dissolution, persistent biliary symptoms","     2-3    -      -    ","Take Ursodiol at least 2-3 hours before Colestipol - monitor gallstone size with imaging - regularly assess clinical response");n("Cholestyramine - ","Valproic Acid -  ",e.DRUG_DRUG,i.MODERATE,"                    ","Cholestyramine binds to Valproic Acid in the intestine and prevents its enterohepatic reabsorption, reducing its bioavailability and increasing its elimination","       15-40            ","15-40% decrease in Valproic Acid blood levels, reduced antiepileptic efficacy, increased seizure risk, especially with chronic concomitant use","   3-4    (   ) -       -        -    ","Separate doses by at least 3-4 hours (take Valproic Acid first) - monitor Valproic Acid blood levels - increase Valproic Acid dose if necessary - monitor seizure control");n("Colistin","Rocuronium",e.DRUG_DRUG,i.HIGH,"   .       .","Increased neuromuscular blockade. Colistin has an additive neuromuscular blocking effect.","    .","Respiratory paralysis or respiratory failure."," .       .","Close monitoring. Respiratory function must be closely monitored.");n("Colistin","Gentamicin",e.DRUG_DRUG,i.HIGH,"   .     .","Increased risk of nephrotoxicity. Additive toxic effect on the kidneys.","  .","Acute renal failure.","  .   .            .","Relative contraindication. Avoid combination. If usage is necessary, renal function must be monitored intensively.");n("Conjugated Estrogens","Lamotrigine",e.DRUG_DRUG,i.MODERATE,"  ","Glucuronidation induction.","   -  ","Decreased lamotrigine levels - breakthrough seizures.","  ","Increase lamotrigine dose.");n("Copanlisib (Aliqopa)","Insulin",e.DRUG_DRUG,i.HIGH,": **   **. Copanlisib    .","Mechanism: **Acute hyperglycemia**. Copanlisib causes transient insulin resistance."," : **   **    .","Clinical Significance: **Severe hyperglycemia** during and immediately after infusion.","      .     .","Monitor glucose before, during, and after each dose. Adjust insulin dose as needed.");n("Copanlisib (Aliqopa)","Antihypertensives",e.DRUG_DRUG,i.MODERATE,": **   **. Copanlisib      .","Mechanism: **Acute hypertension**. Copanlisib causes transient blood pressure elevation."," : **  **  .","Clinical Significance: **Hypertension** during infusion.","      .      .","Monitor blood pressure before, during, and after infusion. May need increased antihypertensive dose.");n("Corticosteroids (General)","Anticholinergics (Atropine, Ipratropium, Hyoscyamine, Benztropine, Scopolamine)",e.DRUG_DRUG,i.MODERATE,"  ","Increased intraocular pressure","    ( )","Increased risk of glaucoma","  -   ","Monitor eyes - refer to Anticholinergics");n("Corticosteroids (General)","Aspirin",e.DRUG_DRUG,i.HIGH,"     ","Corticosteroids increase aspirin clearance","     ","Reduced aspirin blood levels and efficacy","         ","Monitor corticosteroid and aspirin efficacy when starting or stopping either");n("Corticosteroids (Prednisone, Dexamethasone)","Peptic Ulcer Disease",e.DRUG_DISEASE,i.MODERATE,"             NSAIDs.","Reduction of gastric mucosal defenses, increased acid secretion, and synergistic negative effect with NSAIDs.","     .","Increased risk of peptic ulceration and gastrointestinal bleeding."," .     (PPI) .    NSAIDs.","Use with caution. Prescribe a prophylactic PPI. Avoid co-administration with NSAIDs.");n("Cranberry","Warfarin",e.DRUG_DRUG,i.MODERATE," CYP2C9 ","Potential CYP2C9 inhibition."," INR","Increased INR.","  ","Avoid large amounts.");n("Crizanlizumab","Voriconazole",e.DRUG_DRUG,i.MODERATE,"  . Voriconazole    CYP3A4       Crizanlizumab.","Increased metabolite concentration. Voriconazole is a potent CYP3A4 inhibitor, reducing the metabolism of a Crizanlizumab metabolite.","              .","Increased active metabolite concentration, which may raise the risk of cellular toxicity or other side effects.","   .            .","No adjustment required. Dose adjustment is typically not required, but general monitoring of clinical response is advised.");n("Crizanlizumab","Morphine",e.DRUG_DRUG,i.LOW,"     ( ).","No true interaction expected (biologic drug).","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Crizotinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Crizotinib. Ketoconazole    CYP3A4    Crizotinib.","Increased Crizotinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Crizotinib metabolic pathway.","    QT  .","Increased risk of QT prolongation and hepatotoxicity."," .    Crizotinib     CYP3A4 .","Dose adjustment. Crizotinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Crizotinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Crizotinib. Carbamazepine    CYP3A4    Crizotinib.","Decreased Crizotinib concentration. Carbamazepine is a strong inducer of CYP3A4, a Crizotinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Crizotinib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Crizotinib. Clarithromycin    CYP3A4.","Increased Crizotinib concentration. Clarithromycin is a strong inhibitor of CYP3A4.","    QT  .","Increased risk of QT prolongation and liver toxicity.","  .    CYP3A4 .","Relative contraindication. Strong CYP3A4 inhibitors must be avoided.");n("Crizotinib","Alfentanil",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition."," ","Respiratory depression.","  ","Reduce alfentanil dose.");n("Cyclophosphamide","Warfarin",e.DRUG_DRUG,i.MODERATE,"  ","Increased warfarin effect."," INR","Increased INR."," INR","Monitor INR.");n("Cycloserine","Alcohol",e.DRUG_FOOD,i.HIGH,"        (CNS).   .","Increased risk of Central Nervous System (CNS) side effects. Increased neurotoxicity.","    .","Increased risk of seizures, psychosis, and confusion."," .      .","Contraindicated. Alcohol must be avoided during treatment.");n("Cyclosporine","Ketoconazole",e.DRUG_DRUG,i.HIGH," CYP3A4.     CYP3A4    .","Potent CYP3A4 Inhibition. Ketoconazole is a strong inhibitor of CYP3A4, the major enzyme responsible for Cyclosporine metabolism.","     .             .","Vastly Increased Level and Nephrotoxicity. High Cyclosporine concentrations increase the risk of severe renal and neurotoxicity.","  70-80%.       (70-80%)       .","Reduce Dose by 70-80%. Cyclosporine dose must be significantly reduced and concentrations monitored closely.");n("Cyclosporine","Itraconazole",e.DRUG_DRUG,i.HIGH," CYP3A4.     CYP3A4    .","Potent CYP3A4 Inhibition. Itraconazole is a strong inhibitor of CYP3A4, the major enzyme responsible for Cyclosporine metabolism.","     .             .","Vastly Increased Level and Nephrotoxicity. High Cyclosporine concentrations increase the risk of severe renal and neurotoxicity.","  70-80%.       (70-80%)       .","Reduce Dose by 70-80%. Cyclosporine dose must be significantly reduced and concentrations monitored closely.");n("Cyclosporine","Erythromycin",e.DRUG_DRUG,i.HIGH," CYP3A4.    CYP3A4    .","CYP3A4 Inhibition. Erythromycin is an inhibitor of CYP3A4, the major enzyme responsible for Cyclosporine metabolism."," .            .","Increased Level. Elevated Cyclosporine concentrations increase the risk of renal and neurotoxicity."," .             .","Monitor Level. Cyclosporine levels must be monitored regularly, and the dose adjusted to maintain therapeutic range.");n("Cyclosporine","Clarithromycin",e.DRUG_DRUG,i.HIGH," CYP3A4.    CYP3A4    .","CYP3A4 Inhibition. Clarithromycin is an inhibitor of CYP3A4, the major enzyme responsible for Cyclosporine metabolism."," .            .","Increased Level. Elevated Cyclosporine concentrations increase the risk of renal and neurotoxicity."," .             .","Monitor Level. Cyclosporine levels must be monitored regularly, and the dose adjusted to maintain therapeutic range.");n("Cyclosporine","Diltiazem",e.DRUG_DRUG,i.HIGH," .    CYP3A4    .","Metabolic Inhibition. Diltiazem is an inhibitor of CYP3A4, the major enzyme responsible for Cyclosporine metabolism."," .            .","Increased Level. Elevated Cyclosporine concentrations increase the risk of renal and neurotoxicity."," .           .","Reduce Dose. Cyclosporine dose must be reduced upon co-administration of Diltiazem, and drug levels monitored closely.");n("Cyclosporine","Verapamil",e.DRUG_DRUG,i.HIGH," .    CYP3A4    .","Metabolic Inhibition. Verapamil is an inhibitor of CYP3A4, the major enzyme responsible for Cyclosporine metabolism."," .            .","Increased Level. Elevated Cyclosporine concentrations increase the risk of renal and neurotoxicity."," .           .","Reduce Dose. Cyclosporine dose must be reduced upon co-administration of Verapamil, and drug levels monitored closely.");n("Cyclosporine","Rifampin",e.DRUG_DRUG,i.HIGH," .     CYP3A4    .","Metabolic Induction. Rifampin is a potent inducer of CYP3A4, accelerating Cyclosporine metabolism.","       .           .","Significantly Decreased Level, Treatment Failure, and Organ Rejection. Severe reduction in Cyclosporine level leads to loss of immunosuppression."," .            .","Increase Dose. Cyclosporine dose must be significantly increased upon initiation of Rifampin, and drug levels monitored regularly.");n("Cyclosporine","Phenytoin",e.DRUG_DRUG,i.HIGH," .    CYP450    .","Metabolic Induction. Phenytoin is an inducer of CYP450 enzymes responsible for Cyclosporine metabolism."," .            .","Decreased Level. Reduced Cyclosporine concentration leads to treatment failure and risk of organ rejection."," .          .","Increase Dose. Cyclosporine dose must be increased upon initiation of Phenytoin, and drug levels monitored regularly.");n("Cyclosporine","Carbamazepine",e.DRUG_DRUG,i.HIGH," .    CYP450    .","Metabolic Induction. Carbamazepine is an inducer of CYP450 enzymes responsible for Cyclosporine metabolism."," .            .","Decreased Level. Reduced Cyclosporine concentration leads to treatment failure and risk of organ rejection."," .          .","Increase Dose. Cyclosporine dose must be increased upon initiation of Carbamazepine, and drug levels monitored regularly.");n("Cyclosporine","Gentamicin",e.DRUG_DRUG,i.HIGH,"  .             .","Additive Nephrotoxicity. Both drugs are nephrotoxic, and combining them increases the cumulative insult to renal tubular cells."," .      .","Renal Failure. High risk of acute and persistent kidney dysfunction."," .       (   )  .          .","Avoid Combination. Strictly avoid concurrent use. If mandatory, monitor renal function (creatinine, BUN) frequently and aggressively.");n("Cyclosporine","Amikacin",e.DRUG_DRUG,i.HIGH,"  .             .","Additive Nephrotoxicity. Both drugs are nephrotoxic, and combining them increases the cumulative insult to renal tubular cells."," .      .","Renal Failure. High risk of acute and persistent kidney dysfunction."," .       (   )  .          .","Avoid Combination. Strictly avoid concurrent use. If mandatory, monitor renal function (creatinine, BUN) frequently and aggressively.");n("Cyclosporine","Tobramycin",e.DRUG_DRUG,i.HIGH,"  .             .","Additive Nephrotoxicity. Both drugs are nephrotoxic, and combining them increases the cumulative insult to renal tubular cells."," .      .","Renal Failure. High risk of acute and persistent kidney dysfunction."," .       (   )  .          .","Avoid Combination. Strictly avoid concurrent use. If mandatory, monitor renal function (creatinine, BUN) frequently and aggressively.");n("Cyclosporine","Neomycin",e.DRUG_DRUG,i.HIGH,"  .             .","Additive Nephrotoxicity. Both drugs are nephrotoxic, and combining them increases the cumulative insult to renal tubular cells."," .      .","Renal Failure. High risk of acute and persistent kidney dysfunction."," .       (   )  .          .","Avoid Combination. Strictly avoid concurrent use. If mandatory, monitor renal function (creatinine, BUN) frequently and aggressively.");n("Cyclosporine","Aspirin",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Ibuprofen",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Diclofenac",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Naproxen",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Ketoprofen",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Indomethacin",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Celecoxib",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"   .             .","Renal Prostaglandin Inhibition. NSAIDs cause afferent arteriole constriction and reduced renal blood flow, exacerbating Cyclosporines intrinsic nephrotoxicity."," .        .","Renal Failure. High risk of acute kidney injury."," .             .","Avoid Combination. Avoid concurrent NSAID use. If mandatory, monitor renal function very closely and use the lowest possible dose.");n("Cyclosporine","St. Johns Wort (  )",e.DRUG_DRUG,i.HIGH," .        CYP3A4.","Metabolic Induction. St. Johns Wort is a potent inducer of CYP3A4, accelerating Cyclosporine metabolism.","      .           .","Severely Decreased Level and Organ Rejection. Severe reduction in Cyclosporine level leads to loss of immunosuppression."," .         .","Strictly Contraindicated. The concurrent use of St. Johns Wort with Cyclosporine is absolutely prohibited.");n("Cyclosporine","Grapefruit Juice (  )",e.DRUG_FOOD,i.HIGH," CYP3A4.      CYP3A4      .","CYP3A4 Inhibition. Grapefruit juice inhibits intestinal CYP3A4, impeding Cyclosporine metabolism.","   .         .","Increased Level and Toxicity. Elevated Cyclosporine concentrations increase the risk of severe renal and neurotoxicity."," .            .","Avoid Juice. Patients should strictly avoid consuming grapefruit or grapefruit juice during Cyclosporine therapy.");n("Cyclosporine","Atorvastatin",e.DRUG_DRUG,i.HIGH,"  .     OATP1B1      .","Statin Transport Inhibition. Cyclosporine inhibits the OATP1B1 transporter, which is essential for Atorvastatin clearance.","  (Rhabdomyolysis).            .","Rhabdomyolysis. Markedly elevated Atorvastatin levels significantly increase the risk of severe myopathy and rhabdomyolysis.","   .                    OATP1B1 ( ).","Avoid or Reduce Statin Dose. Avoid combination; if necessary, use the lowest Atorvastatin dose possible or choose an alternative statin not affected by OATP1B1 inhibition.");n("Cyclosporine","Simvastatin",e.DRUG_DRUG,i.HIGH,"  .     OATP1B1      .","Statin Transport Inhibition. Cyclosporine inhibits the OATP1B1 transporter, which is essential for Simvastatin clearance.","  (Rhabdomyolysis).            .","Rhabdomyolysis. Markedly elevated Simvastatin levels significantly increase the risk of severe myopathy and rhabdomyolysis.","   .                    OATP1B1 ( ).","Avoid or Reduce Statin Dose. Avoid combination; if necessary, use the lowest Simvastatin dose possible or choose an alternative statin not affected by OATP1B1 inhibition.");n("Cyclosporine","Rosuvastatin",e.DRUG_DRUG,i.HIGH,"  .     OATP1B1      .","Statin Transport Inhibition. Cyclosporine inhibits the OATP1B1 transporter, which is essential for Rosuvastatin clearance.","  (Rhabdomyolysis).            .","Rhabdomyolysis. Markedly elevated Rosuvastatin levels significantly increase the risk of severe myopathy and rhabdomyolysis.","   .                    OATP1B1 ( ).","Avoid or Reduce Statin Dose. Avoid combination; if necessary, use the lowest Rosuvastatin dose possible or choose an alternative statin not affected by OATP1B1 inhibition.");n("Cyclosporine","Pravastatin",e.DRUG_DRUG,i.HIGH,"  .     OATP1B1      .","Statin Transport Inhibition. Cyclosporine inhibits the OATP1B1 transporter, which is essential for Pravastatin clearance.","  (Rhabdomyolysis).            .","Rhabdomyolysis. Markedly elevated Pravastatin levels significantly increase the risk of severe myopathy and rhabdomyolysis.","   .                    OATP1B1 ( ).","Avoid or Reduce Statin Dose. Avoid combination; if necessary, use the lowest Pravastatin dose possible or choose an alternative statin not affected by OATP1B1 inhibition.");n("Cyclosporine","Amiodarone",e.DRUG_DRUG,i.HIGH,"  .    CYP3A4   P-glycoprotein    .","Increased Cyclosporine Levels. Amiodarone inhibits CYP3A4 and P-glycoprotein, both of which are involved in Cyclosporine elimination.","  .         (Renal Dysfunction)    (Hypertension).","Cyclosporine Toxicity. Elevated Cyclosporine levels increase the risk of renal dysfunction and hypertension.","     .       50%   .","Monitor Cyclosporine Concentrations and Signs of Toxicity. Cyclosporine dose should be decreased by 50% upon initiation of Amiodarone.");n("Cyclosporine","Testosterone",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -      ","      -      ");n("Cyclosporine","Nandrolone",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -      ","      -      ");n("Cyclosporine","Oxandrolone",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -      ","      -      ");n("Cyclosporine","Fluconazole",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -        ( / ) ","      -        ( / ) ");n("Cyclosporine","Itraconazole",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -        ( / ) ","      -        ( / ) ");n("Cyclosporine","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -        ( / ) ","      -        ( / ) ");n("Cyclosporine","Voriconazole",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -        ( / ) ","      -        ( / ) ");n("Cyclosporine","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Cyclosporine Levels. Enzyme induction lowers levels, risking transplant rejection.","  ","  ","       -      ","       -      ");n("Cyclosporine","Carbidopa",e.DRUG_DRUG,i.MODERATE,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -      ","      -      ");n("Cyclosporine","Caspofungin",e.DRUG_DRUG,i.HIGH,"  .         .","Increased Caspofungin Levels. Cyclosporine inhibits the hepatic clearance of Caspofungin, potentially increasing its systemic exposure.","    .             (  ).","Increased Caspofungin Toxicity and Liver Damage. Elevated levels may lead to deterioration in liver function test results (elevated liver enzymes).","    .         .     .","Avoid Combination if possible. Otherwise, monitor for signs of hepatotoxicity and liver function. Discontinue Caspofungin if liver abnormalities occur.");n("Cyclosporine","Colchicine",e.DRUG_DRUG,i.HIGH,"  ( /  /  /  / )  .             ( P-gp/CYP3A4).","Increased Multi-organ Toxicity for Both Drugs. Both Cyclosporine and Colchicine have inherent myotoxicity and nephrotoxicity, compounded by potential metabolic interference (P-gp/CYP3A4 inhibition).","   .           .","Increased Multi-organ Toxicity. High risk of severe myopathy, renal failure, neurotoxicity, and gastrointestinal disturbances.","     .           .","Monitor Cyclosporine Concentrations and Toxicity Signs. The doses of both Cyclosporine and Colchicine should be reduced if necessary, and co-administration should generally be avoided.");n("Cyclosporine","Etoposide",e.DRUG_DRUG,i.HIGH,"  .    P-glycoprotein          .","Increased Etoposide Concentrations. Cyclosporine inhibits P-glycoprotein, a transporter responsible for Etoposide efflux, thereby reducing its clearance.","  .          (Myelosuppression)   .","Increased Etoposide Toxicity. Elevated levels increase the risk of severe myelosuppression (e.g., neutropenia, thrombocytopenia) and gastrointestinal toxicity.","       .          (  50%)  .","Monitor Complete Blood Count (CBC) for Myelosuppression. Etoposide dose must be significantly reduced (up to 50%) and monitored closely.");n("Cyclosporine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","    ","    ");n("Cyclosporine","Hydantoins",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Cyclosporine Levels. Enzyme induction lowers levels, risking transplant rejection.","  ","  ","       -      ","       -      ");n("Cyclosporine","Imipenem/Cilastatin",e.DRUG_DRUG,i.MODERATE,"     .    /     (   )       .","Increased CNS Adverse Effects. Both Cyclosporine and Imipenem/Cilastatin have the potential to cause neurotoxicity (e.g., seizures, confusion, tremors), and the combination results in an additive risk.","   .      .","Increased Neurotoxicity. Higher risk of seizures, mental confusion, and tremors.","       .                 .","Substitute Antibiotic if Complications Occur. Monitor the patient closely for any signs of neurotoxicity; using an alternative non-carbapenem antibiotic may be necessary.");n("Cyclosporine","Macrolide Antibiotics",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -         (/  )","      -         (/  )");n("Cyclosporine","Metoclopramide",e.DRUG_DRUG,i.MODERATE,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -         (/    ) ","      -         (/    ) ");n("Cyclosporine","Nefazodone",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -      ","      -      ");n("Cyclosporine","Nicardipine",e.DRUG_DRUG,i.MODERATE,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","    -      ","    -      ");n("Cyclosporine","Orlistat",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","    ","    ");n("Cyclosporine","Probucol",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Cyclosporine Levels. Enzyme induction lowers levels, risking transplant rejection.","  ","  ","      -      ","      -      ");n("Cyclosporine","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"   ","Increased Neurotoxicity Risk. Additive toxic effects on the nervous system.","  ","  ","      -    : ()","      -    : ()");n("Cyclosporine","Levofloxacin",e.DRUG_DRUG,i.MODERATE,"   ","Increased Neurotoxicity Risk. Additive toxic effects on the nervous system.","  ","  ","      -    : ()","      -    : ()");n("Cyclosporine","Moxifloxacin",e.DRUG_DRUG,i.MODERATE,"   ","Increased Neurotoxicity Risk. Additive toxic effects on the nervous system.","  ","  ","      -    : ()","      -    : ()");n("Cyclosporine","Ofloxacin",e.DRUG_DRUG,i.MODERATE,"   ","Increased Neurotoxicity Risk. Additive toxic effects on the nervous system.","  ","  ","      -    : ()","      -    : ()");n("Cyclosporine","Norfloxacin",e.DRUG_DRUG,i.MODERATE,"   ","Increased Neurotoxicity Risk. Additive toxic effects on the nervous system.","  ","  ","      -    : ()","      -    : ()");n("Cyclosporine","Rifamycins",e.DRUG_DRUG,i.HIGH,"  ","Reduced Cyclosporine Levels. Enzyme induction lowers levels, risking transplant rejection.","  ","  ","     -        -         ( /  / )  ","     -        -         ( /  / )  ");n("Cyclosporine","Sulfonamides",e.DRUG_DRUG,i.HIGH," .           CYP3A4              .","Complex Interaction. Certain Sulfonamides may inhibit CYP3A4, increasing Cyclosporine levels, while others may synergistically increase the risk of Cyclosporine-induced neurotoxicity or nephrotoxicity.","  (  )     (  ).           .","Decreased Efficacy (with some) or Increased Neurotoxicity (with oral Sulfonamides). Risk of organ rejection or increased severity of CNS symptoms like seizures and tremors.","    .            .      ( /  /   ).","Avoid Combination if possible. Otherwise, monitor Cyclosporine concentrations and for signs of organ rejection or neurotoxicity. Adjust the Cyclosporine dose as guided when initiating, discontinuing, or changing the Sulfonamide dose.");n("Cyclosporine","Terbinafine",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Cyclosporine Levels. Enzyme induction lowers levels, risking transplant rejection.","  ","  ","       -      ( /  / )  ","       -      ( /  / )  ");n("Terbinafine - ","Flecainide / Propafenone (  )",e.DRUG_DRUG,i.HIGH,"    CYP2D6        .","Terbinafine strongly inhibits CYP2D6, the primary metabolic pathway for these antiarrhythmics.","    /              (Proarrhythmia)   .","Toxic accumulation of Flecainide/Propafenone in plasma, significantly increasing the risk of severe proarrhythmia or cardiotoxicity.","   ( ).            50%         (ECG).","Absolute Contraindication (Avoid). If the combination is essential, reduce the antiarrhythmic dose by 50% or more and closely monitor drug concentrations and ECG.");n("Terbinafine - ","TCAs (   )",e.DRUG_DRUG,i.HIGH,"   CYP2D6     ()      .","Terbinafine inhibits CYP2D6, significantly reducing the clearance (metabolism) of TCAs.","    TCAs       (Arrhythmias, QRS prolongation)    .","Profound increase in TCA concentrations, raising the risk of cardiotoxicity (arrhythmias, QRS prolongation), anticholinergic effects, and seizures.","      TCA  50-75%       (        2D6).","Avoid the combination, or reduce the TCA dose by 50-75% and closely monitor for toxicity symptoms (A non-2D6 metabolized antidepressant alternative is preferred).");n("Terbinafine - ","SSRIs/SNRIs (  )",e.DRUG_DRUG,i.MODERATE,"   CYP2D6            (  ).","Terbinafine inhibits CYP2D6, slowing the metabolism of many SSRIs (especially Paroxetine and Fluoxetine).","    (Serotonin Syndrome)           (CNS).","Increased risk of Serotonin Syndrome and CNS-related side effects due to high drug concentration.","    .               CYP2D6.","Closely monitor for Serotonin Syndrome symptoms. Consider reducing the antidepressant dose or selecting a non-CYP2D6 affected antidepressant.");n("Terbinafine - ","Beta-Blockers (    )",e.DRUG_DRUG,i.MODERATE,"   CYP2D6        (    ).","Terbinafine inhibits CYP2D6, the major metabolic route for most beta-blockers (those undergoing extensive metabolism).","             (Bradycardia)    (Hypotension)  .","Increased beta-blocker concentration, raising the risk of severe bradycardia, hypotension, and heart block.","       .      (   )   .","Closely monitor heart rate and blood pressure. Reduce the beta-blocker dose (especially Metoprolol or Propranolol) upon initiating Terbinafine.");n("Terbinafine - ","Rifampin -  ( )",e.DRUG_DRUG,i.MODERATE,"     CYP (   CYP3A4  2C19)      .","Rifampin is a potent inducer of CYP enzymes (including CYP3A4 and 2C19), accelerating Terbinafine metabolism.","               (    ).","Significant decrease in Terbinafine plasma concentration, which may lead to antifungal treatment failure (especially in onychomycosis).","   .                      .","Avoid the combination if possible. If Rifampin must be used, a substantial increase in the Terbinafine dose may be required, or switch to an alternative antifungal.");n("Cyclosporine","Verapamil",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Inhibition of CYP3A4 or P-glycoprotein reduces cyclosporine elimination.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","      -      ","      -      ");n("Cyclosporine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"       (   6,7-dihydroxybergamottin)        CYP3A4                 .    : (1)          60-70% (2)           (    50-200%) (3)           2-3   .       24-72        (    ).     (200 )         .","Grapefruit juice contains furanocoumarins (especially bergamottin and 6,7-dihydroxybergamottin) that potently and irreversibly inhibit CYP3A4 enzyme highly concentrated in small intestine wall, the main enzyme responsible for cyclosporine first-pass metabolism. This inhibition leads to: (1) sharp decrease in intestinal cyclosporine metabolism by up to 60-70%, (2) significant increase in drug amount reaching systemic circulation (bioavailability increases 50-200%), (3) dangerous elevation in blood cyclosporine levels reaching 2-3 times expected level. Effect begins within hours and persists 24-72+ hours because inhibition is irreversible (body needs to produce new enzymes). Even one small glass (200ml) grapefruit juice can cause dangerous interaction.","            : (1)  :    -                        (2)       (3)    (tremor)     (4)    (5)     (  ) (6)    (gingival hyperplasia) -    (7)    (hirsutism) (8)     (9)        (10)       .    :           .","Extremely dangerous elevation in cyclosporine levels with severe multi-system toxicity including: (1) nephrotoxicity: most serious effect - renal tubular damage, elevated creatinine and urea, decreased kidney function that may be permanent, may reach acute renal failure especially in kidney transplant patients, (2) severe treatment-resistant hypertension, (3) severe hand tremor disabling daily activities, (4) severe throbbing headache, (5) extremity numbness and tingling (peripheral neuropathy), (6) gingival hyperplasia - gum swelling and enlargement, (7) hirsutism, (8) nausea, vomiting and gastrointestinal disturbances, (9) increased infection risk due to excessive immunosuppression, (10) increased lymphoma risk long-term. In transplant patients: any major cyclosporine level fluctuation is extremely dangerous and threatens transplant success.","  : (1)        (   )    (2)        (  ) (3)      :  (pomelo)      (Seville oranges -    )    (4)        -        (5)             (6)  :         -       (7)  :      (trough levels)          (       ) (8)    ( BUN)    (9)       :       -           (10)                (11)       .","Total absolute prohibition: (1) completely avoid grapefruit juice in all forms (fresh, pasteurized, frozen, concentrate) during cyclosporine therapy, (2) also avoid eating whole grapefruit fruit (fresh or segments), (3) beware of similar-effect fruits: pomelo, bitter or Seville oranges (used in marmalade making), sweetie, tangelo, (4) carefully read mixed juice and flavored beverage ingredients - may contain small grapefruit percentages, (5) avoid dietary supplements or weight-loss products containing grapefruit extract, (6) safe alternatives: regular orange juice, apple, grape, pineapple, cranberry - all safe with no cyclosporine interaction, (7) strict monitoring: measure blood cyclosporine levels (trough levels) regularly every two weeks to monthly or as directed (target range varies by transplant type and time post-transplant), (8) regularly monitor kidney function (creatinine, BUN) and blood pressure, (9) if accidentally consumed grapefruit: contact physician or transplant center immediately - may need emergency drug level measurement and temporary dose adjustment, (10) educate family members about this dangerous interaction to avoid unintentionally offering grapefruit, (11) place warning label on refrigerator and in kitchen.");n("Cyclosporine","High-Fat Foods",e.DRUG_FOOD,i.MODERATE,"    (lipophilic)              .    (  20-30  )      : (1)                  (2)                (3)    (    )    . :       20-50%        .              .","Cyclosporine is highly lipophilic drug with poor water solubility, making its absorption significantly affected by dietary fat presence. High-fat food (>20-30g fat) affects cyclosporine absorption through: (1) stimulating greater bile salt secretion from gallbladder, improving dissolution and solubility of lipophilic cyclosporine in intestinal fluid, (2) slowing gastric emptying, prolonging drug residence time in GI tract allowing greater absorption opportunity, (3) stimulating lymphatic absorption (not just portal venous absorption), increasing bioavailability. Result: 20-50% increase in cyclosporine bioavailability when taken with fatty food versus empty stomach. Problem is not interaction itself but large fluctuations occurring with inconsistency.","             : (1)                  ( )   (  ) (2)   :                   (3)    :     -                 (4)        .","Wide, unpredictable fluctuations in blood cyclosporine levels with inconsistent pattern adherence: (1) if patient sometimes takes drug with fatty food and sometimes on empty stomach, levels will oscillate between too high (toxicity risk) and too low (organ rejection risk), (2) dose instability: physician adjusts dose based on certain levels, but if food pattern changes, this dose becomes inappropriate, (3) in transplant patients: this fluctuation is extremely dangerous - low levels increase acute or chronic rejection risk, high levels cause nephrotoxicity and severe side effects, (4) difficulty achieving optimal dose and stable levels.",'    : (1)         :          (        - Neoral, Sandimmune   ) (2)     :            - :           (   ) (3)   :        ( )     (4)         (: 8   8 )        (5)  :           (6)     (  " "  " "):     -               (7)  :              (      ) (8)          (   ).',`Golden strategy is absolute consistency: (1) choose one pattern and adhere daily without change: either always with food or always on empty stomach (per physician recommendation and your formulation type - Neoral, Sandimmune, or generics), (2) if deciding to take with food: must be approximately same food type at same time daily - e.g., always with breakfast containing moderate fat amount (eggs, buttered toast, milk), (3) avoid random switching: don't take today with rich fatty dinner (burger, pizza) and tomorrow on empty stomach, (4) most physicians recommend taking at same time daily (e.g., 8 AM and 8 PM) with or without food per chosen pattern, (5) log your pattern: keep simple diary for first two weeks to ensure timing and condition consistency, (6) if needing pattern change (e.g., from "with food" to "without food"): don't do it yourself - discuss with physician first as you'll likely need dose adjustment and closer level monitoring, (7) careful follow-up: measure cyclosporine levels regularly even if consistent, as other factors may affect (drug interactions, kidney or liver function changes), (8) inform physician of any dietary habit changes (starting diet, Ramadan, travel).`);n("Cyclosporine","St. John's Wort",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 induction."," ","Transplant rejection."," ","Avoid completely.");n("Cyclosporine (eye drops)","Systemic Immunosuppressants",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic immunosuppression.","  ","Increased infection risk."," ","Monitor for infection.");n("Dabigatran","Rifampin",e.DRUG_DRUG,i.HIGH," P-gp","P-gp induction.","   -   ","Reduced dabigatran efficacy - increased clotting risk."," ","Avoid combination.");n("Dabigatran (DOAC)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Dabigatran. Rifampin    P-gp    Dabigatran.","Decreased Dabigatran concentration. Rifampin is a strong inducer of P-gp, a Dabigatran efflux transporter.","  Dabigatran     .","Reduced Dabigatran efficacy, leading to risk of thrombosis."," .   .","Contraindicated. Avoid the combination.");n("Dabrafenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Dabrafenib. Rifampin    CYP3A4    Dabrafenib.","Decreased Dabrafenib efficacy. Rifampin is a strong inducer of CYP3A4, a Dabrafenib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Dabrafenib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Dabrafenib. Itraconazole   CYP3A4    Dabrafenib.","Increased Dabrafenib concentration. Itraconazole is a CYP3A4 inhibitor, a Dabrafenib metabolic pathway.","         QT.","Increased risk of side effects, especially skin reactions and QT prolongation."," .    Dabrafenib     CYP3A4 .","Dose adjustment. Dabrafenib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Dabrafenib","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Dabrafenib    CYP3A4    Midazolam.","Decreased Midazolam concentration. Dabrafenib is a strong inducer of CYP3A4, a Midazolam metabolic pathway.","  Midazolam ()          .","Reduced efficacy of Midazolam (sedative), potentially leading to failure of sedation or seizure control."," .           CYP3A4.      .","Avoid Combination. Narrow therapeutic index drugs metabolized by CYP3A4 must be avoided. Dose adjustment is required if necessary.");n("Dabrafenib","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Dabrafenib    CYP3A4    Midazolam.","Decreased Midazolam concentration. Dabrafenib is a strong inducer of CYP3A4, a Midazolam metabolic pathway.","  Midazolam ()          .","Reduced efficacy of Midazolam (sedative), potentially leading to failure of sedation or seizure control."," .    Midazolam   .","Dose adjustment. Midazolam dose must be increased or alternatives used.");n("Dabrafenib (Tafinlar)","Hormonal Contraceptives",e.DRUG_DRUG,i.MODERATE,": **  CYP**.    .","Mechanism: **CYP enzyme induction**. Decreased sex hormone concentration."," : **  **.","Clinical Significance: **Contraceptive failure**.","      .","Use additional non-hormonal contraception.");n("Dabrafenib (Tafinlar)","Warfarin",e.DRUG_DRUG,i.MODERATE,": **  CYP2C9**.   Warfarin.","Mechanism: **CYP2C9 induction**. Decreased Warfarin concentration."," : **   **  .","Clinical Significance: **Reduced anticoagulant efficacy** and clotting risk."," INR  .   Warfarin  .","Monitor INR frequently. Increase Warfarin dose as needed.");n("Dantrolene","Verapamil",e.DRUG_DRUG,i.HIGH,"      .         .","Increased risk of cardiotoxicity and hyperkalemia. Mechanism is not fully clear, but affects calcium movement.","       .","Increased risk of myocardial failure and cardiovascular collapse."," .   .","Contraindicated. Simultaneous use must be avoided.");n("Dapagliflozin (SGLT2)","Furosemide",e.DRUG_DRUG,i.MODERATE,"   .        .","Increased risk of volume depletion. Both drugs cause diuresis and increased fluid excretion.","        .","Risk of orthostatic hypotension, dehydration, and acute kidney injury."," .       .","Close monitoring. Monitor fluid status, blood pressure, and renal function.");n("Dapagliflozin (SGLT2)","Pioglitazone",e.DRUG_DRUG,i.LOW,"     .        .","Theoretical increase in bladder cancer risk. Both drugs have been theoretically associated with increased bladder cancer risk.","   .","Risk of bladder cancer."," .     .","Close monitoring. Monitor for hematuria.");n("Dapagliflozin - ","Insulin / Sulfonylureas (   )",e.DRUG_DRUG,i.HIGH,"    .                     .","Additive blood glucose lowering effects. Dapagliflozin reduces blood glucose by increasing urinary glucose excretion, while other drugs increase insulin secretion or are administered directly.","       (Hypoglycemia)         .","Significantly increased risk of hypoglycemia, especially at high doses or in the elderly.","              .     .","The dose of insulin or sulfonylurea must be reduced upon initiating Dapagliflozin to minimize the risk of hypoglycemia. Close blood glucose monitoring is essential.");n("Dapagliflozin - ","Loop Diuretics ( )",e.DRUG_DRUG,i.MODERATE,"      .       (Osmotic Diuresis)      .","Additive diuretic and volume depletion effects. Dapagliflozin increases osmotic diuresis, and diuretics increase fluid and salt excretion.","     (Volume Depletion)           (Orthostatic Hypotension)   .","Increased risk of volume depletion and dehydration, potentially leading to orthostatic hypotension and worsening renal function.",".      .           .","Monitor. Monitor signs of dehydration and blood pressure. A reduction in the diuretic dose may be required upon initiating Dapagliflozin.");n("Dapagliflozin - ","ACE Inhibitors / ARBs ( )",e.DRUG_DRUG,i.MODERATE,"       .               .","Additive effects on blood pressure lowering and renal function. Both agents lower blood pressure, and the drugs contribute to potential renal deterioration in dehydrated states.","     (Hypotension)        .","Increased risk of hypotension and exacerbation of acute renal failure in volume-depleted states.",".                 .","Monitor. Periodically and intensively monitor blood pressure and renal function, especially in patients with pre-existing renal impairment.");n("Dapagliflozin - ","Rifampin -  (   UGT)",e.DRUG_DRUG,i.LOW,"   UGT (Uridine 5-diphospho-glucuronosyltransferases)    .","Rifampin induces UGT enzymes (Uridine 5-diphospho-glucuronosyltransferases) responsible for Dapagliflozin metabolism.","   (Systemic Exposure)           .","Decreased systemic exposure of Dapagliflozin, which may lead to reduced efficacy in lowering blood glucose.",".              .","Monitor. Closely monitor blood glucose levels and adjust the Dapagliflozin dose if necessary.");n("Daprodustat","Clopidogrel",e.DRUG_DRUG,i.HIGH,"  Daprodustat. Clopidogrel   CYP2C8    Daprodustat.","Increased Daprodustat concentration. Clopidogrel is a CYP2C8 inhibitor, a Daprodustat metabolic pathway.","     .","Increased risk of hyperkalemia and thrombosis."," .    Daprodustat     CYP2C8 .","Dose adjustment. Daprodustat dose must be reduced when co-administered with strong CYP2C8 inhibitors.");n("Daprodustat","Rifampin",e.DRUG_DRUG,i.HIGH,"  Daprodustat. Rifampin   CYP2C8    Daprodustat.","Decreased Daprodustat efficacy. Rifampin is a CYP2C8 inducer, a Daprodustat metabolic pathway.","           .","Reduced drug plasma concentration, leading to failure of anemia treatment."," .    CYP2C8 .","Avoid Combination. Strong CYP2C8 inducers must be avoided.");n("Daprodustat","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Daprodustat. Phenytoin   CYP2C8    Daprodustat.","Decreased Daprodustat efficacy. Phenytoin is a CYP2C8 inducer, a Daprodustat metabolic pathway.","           .","Reduced drug plasma concentration, leading to failure of anemia treatment."," .    CYP2C8 .","Avoid Combination. Strong CYP2C8 inducers must be avoided.");n("Daprodustat","Warfarin",e.DRUG_DRUG,i.MODERATE,"   CYP2C9. Daprodustat  CYP2C9    Warfarin.","Competitive interaction on CYP2C9. Daprodustat inhibits CYP2C9, a Warfarin metabolic pathway.","  Warfarin     .","Increased Warfarin concentration, increasing the risk of hemorrhage."," INR.    INR    Warfarin.","INR monitoring. INR must be regularly monitored and Warfarin dose adjusted.");n("Daprodustat","Gemfibrozil",e.DRUG_DRUG,i.HIGH,"  Daprodustat. Gemfibrozil    CYP2C8    Daprodustat.","Increased Daprodustat concentration. Gemfibrozil is a potent inhibitor of CYP2C8, a Daprodustat metabolic pathway.","     .","Increased risk of hyperkalemia and thrombosis."," .    Daprodustat     CYP2C8 .","Dose adjustment. Daprodustat dose must be reduced when co-administered with potent CYP2C8 inhibitors.");n("Daprodustat - ","Gemfibrozil - ",e.DRUG_DRUG,i.HIGH,"    CYP2C8              ","Gemfibrozil is a potent inhibitor of hepatic CYP2C8 enzyme responsible for Daprodustat primary metabolism, significantly increasing drug exposure","      2-3       ( )       ","2-3 fold increase in Daprodustat plasma concentration, elevated risk of thromboembolism, hypertension, and erythrocytosis","    50-75%     -     2-4  -     ","Reduce Daprodustat dose by 50-75% when co-administered with Gemfibrozil - monitor hemoglobin and hematocrit every 2-4 weeks - monitor for thrombosis signs and blood pressure");n("Dapsone","Trimethoprim",e.DRUG_DRUG,i.MODERATE,"   .     (    CYP2C9)     .","Increased Concentrations of Both Drugs. Trimethoprim inhibits Dapsone metabolism (via CYP2C9 inhibition), and both drugs share common renal clearance pathways.","    .            (Methemoglobinemia).","Increased Toxicity Risk for Both Drugs. Elevated Dapsone levels increase the risk of hemolytic anemia and methemoglobinemia.","    .               .","Monitor Methemoglobin Levels. Closely monitor blood counts, differential, and methemoglobin levels. Dosage adjustment may be required.");n("Dapsone","Trimethoprim",e.DRUG_DRUG,i.HIGH,"  Dapsone. Trimethoprim   Dapsone.","Increased Dapsone concentration. Trimethoprim inhibits Dapsone metabolism.","    (    ).","Increased risk of hematological toxicity (hemolytic anemia and methemoglobinemia)."," .     .","Close monitoring. Monitor blood counts and side effects.");n("Daptomycin","Statins",e.DRUG_DRUG,i.MODERATE,"   /  (Rhabdomyolysis).     .","Increased risk of myopathy/rhabdomyolysis. Additive toxic effect on muscles.","    .","Muscle damage and acute renal failure."," .       (CK)   .","Close monitoring. Creatine Kinase (CK) levels must be monitored and statin temporarily discontinued.");n("Daratumumab (CD38)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"     . Daratumumab     .","No clinically significant interaction expected. Daratumumab is a monoclonal antibody.","   .   .","No known effect. They are used safely together.","    .","No special action required.");n("Daratumumab (CD38)","Digoxin",e.DRUG_DRUG,i.LOW,"     .    .","No clinically significant interaction expected. Monoclonal antibody.","   .","No known effect.","    .","No special action required.");n("Darbepoetin","Antihypertensives",e.DRUG_DRUG,i.MODERATE,"  ","Hypertension.","    ","Difficult BP control.","  ","Monitor BP.");n("Daridorexant","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Daridorexant. Itraconazole    CYP3A4    Daridorexant.","Increased Daridorexant concentration. Itraconazole is a strong CYP3A4 inhibitor, a Daridorexant metabolic pathway.","        (CNS).","Increased risk of excessive somnolence and Central Nervous System (CNS) depression."," .   .","Contraindicated. Avoid the combination.");n("Darolutamide","Rifampin",e.DRUG_DRUG,i.HIGH,"  Darolutamide. Rifampin    CYP3A4  P-gp     Darolutamide.","Decreased Darolutamide efficacy. Rifampin is a strong inducer of CYP3A4 and P-gp, which are Darolutamide metabolism and efflux pathways.","             .","Severe decrease in plasma drug concentration, leading to prostate cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Darolutamide","Erythromycin",e.DRUG_DRUG,i.MODERATE,"  Darolutamide. Erythromycin    CYP3A4    Darolutamide.","Increased Darolutamide concentration. Erythromycin is a moderate CYP3A4 inhibitor, a Darolutamide metabolic pathway.","        .","Increased risk of side effects, especially fatigue and elevated liver enzymes.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Darolutamide","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Darolutamide. Efavirenz    CYP3A4    Darolutamide.","Decreased Darolutamide efficacy. Efavirenz is a moderate inducer of CYP3A4, a Darolutamide metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Darolutamide","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Darolutamide. Ketoconazole    CYP3A4    Darolutamide.","Increased Darolutamide concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Darolutamide metabolic pathway.","        .","Increased risk of side effects, especially fatigue and elevated liver enzymes."," .        .","Dose adjustment. Patient must be monitored for increased side effects.");n("Darolutamide","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Darolutamide.      CYP3A4    Darolutamide.","Increased Darolutamide concentration. Grapefruit juice inhibits CYP3A4, a Darolutamide metabolic pathway.","        .","Increased risk of side effects, especially fatigue and elevated liver enzymes."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Darolutamide","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Darolutamide. Itraconazole    CYP3A4    Darolutamide.","Increased Darolutamide concentration. Itraconazole is a strong CYP3A4 inhibitor, a Darolutamide metabolic pathway.","   .","Increased risk of side effects."," .    Darolutamide     CYP3A4 .","Dose adjustment. Darolutamide dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Darolutamide","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Darolutamide. Itraconazole   CYP3A4.","Increased Darolutamide concentration. Itraconazole inhibits CYP3A4.","   .","Increased risk of side effects."," .     Darolutamide   .","Dose adjustment. Close monitoring and reduction of Darolutamide dose if necessary.");n("Dasatinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Dasatinib. PPIs        Dasatinib.","Decreased Dasatinib concentration. PPIs reduce gastric acidity, which is necessary for Dasatinib absorption.","              (CML).","Severe decrease in drug plasma concentration, leading to failure of CML treatment."," .      (PPIs).","Contraindicated. Proton pump inhibitors (PPIs) must be avoided.");n("Dasatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Dasatinib. Phenytoin    CYP3A4    Dasatinib.","Decreased Dasatinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Dasatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Dasatinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Dasatinib. Itraconazole    CYP3A4    Dasatinib.","Increased Dasatinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Dasatinib metabolic pathway.","    QT   .","Increased risk of QT prolongation and myelosuppression."," .    Dasatinib     CYP3A4 .","Dose adjustment. Dasatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Dasatinib","Antacids",e.DRUG_DRUG,i.MODERATE," pH ","Increased gastric pH.","  ","Reduced dasatinib absorption."," ","Separate by 2 hours.");n("DaxibotulinumtoxinA","Gentamicin",e.DRUG_DRUG,i.HIGH,"    .        .","Increased neuromuscular blocking effect of the toxin. Aminoglycosides potentiate the toxin effects on the neuromuscular blockade.","      .","Increased risk of severe muscle weakness and respiratory difficulty."," .          .","Avoid combination. Toxin must be used with extreme caution with other neuromuscular agents.");n("Decitabine/Cedazuridine","Quinidine",e.DRUG_DRUG,i.MODERATE,"  Decitabine. Cedazuridine    P-gp   Quinidine   P-gp.","Increased Decitabine concentration. Cedazuridine is a P-gp inhibitor, and Quinidine may interact with it and P-gp.","      Decitabine       .","Potential increase in Decitabine systemic exposure, raising the risk of myelosuppression."," .     (CBC)     .","Toxicity monitoring. Complete blood count (CBC) must be regularly monitored for myelosuppression.");n("Decitabine/Cedazuridine - /","Gemfibrozil - ",e.DRUG_DRUG,i.HIGH,"   CYP2C8              (CDA)          ","Gemfibrozil inhibits CYP2C8 enzyme responsible for Cedazuridine metabolism, increasing its concentration and enhancing its inhibition of cytidine deaminase (CDA), which in turn reduces Decitabine metabolism and increases its systemic exposure","         (     )   ","Increased concentrations of both components, elevated risk of severe hematological toxicity (neutropenia, thrombocytopenia, anemia), opportunistic infections, and bleeding","    -   :     2-3       -          -   ","Avoid combination if possible - if necessary: monitor complete blood count 2-3 times weekly during each treatment cycle - delay next dose or reduce it based on hematological toxicity severity - infection prophylaxis");n("Degarelix","Rifampin",e.DRUG_DRUG,i.LOW,"     . Degarelix       CYP.","No clinically significant interaction expected. Degarelix is a peptide drug and is not metabolized by CYP.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Delafloxacin","Antacids",e.DRUG_DRUG,i.HIGH,"  Delafloxacin.      .","Decreased Delafloxacin absorption. Formation of insoluble chelation compounds.","        .","Reduced antibiotic efficacy, leading to treatment failure."," .      2   .","Dose separation. The two drugs must be separated by at least 2 hours.");n("Delamanid","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Delamanid. Carbamazepine    CYP3A4    Delamanid.","Decreased Delamanid concentration. Carbamazepine is a strong inducer of CYP3A4, a Delamanid metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Denosumab","Immunosuppressants",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic immunosuppression.","  ","Increased infection risk."," ","Monitor for infection.");n("Desipramine","Phenylbutazone",e.DRUG_DRUG,i.MODERATE,"    .  (   )          .","Altered Gastrointestinal Motility. Desipramine (a TCA) has anticholinergic properties, reducing GI motility.","   .                     .","Altered Drug Efficacy. Slowed intestinal motility may increase the absorption or residence time of Phenylbutazone, potentially affecting its efficacy and toxicity.","  .              .","Monitor Drug Efficacy. Monitor the therapeutic response and signs of Phenylbutazone toxicity. Dosage adjustment may be necessary.");n("Deucravacitinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Deucravacitinib. Rifampin    CYP1A2  CYP2B6  CYP3A4    Deucravacitinib   P-gp.","Decreased Deucravacitinib efficacy. Rifampin is a strong inducer of CYP1A2, CYP2B6, and CYP3A4 (Deucravacitinib metabolic pathways) and a P-gp inducer.","           .","Reduced drug plasma levels, leading to loss of psoriasis control."," .      CYP .","Avoid Combination. Simultaneous use of strong CYP inducers must be avoided.");n("Deucravacitinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Deucravacitinib. Rifampin    CYP3A4    Deucravacitinib.","Decreased Deucravacitinib efficacy. Rifampin is a strong inducer of CYP3A4, a Deucravacitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Deucravacitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Deucravacitinib. Ketoconazole    CYP3A4    Deucravacitinib.","Increased Deucravacitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Deucravacitinib metabolic pathway.","       .","Increased risk of side effects, especially infection and hepatotoxicity."," .    Deucravacitinib     CYP3A4 .","Dose adjustment. Deucravacitinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Deucravacitinib","Smoking",e.DRUG_DRUG,i.MODERATE,"  Deucravacitinib.     CYP1A2    Deucravacitinib.","Decreased Deucravacitinib concentration. Smoking is a strong inducer of CYP1A2, a Deucravacitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    Deucravacitinib  .","Dose adjustment. Deucravacitinib dose must be increased for smoking patients.");n("Deucravacitinib - ","Fluvoxamine - ",e.DRUG_DRUG,i.HIGH,"    CYP1A2               2-3 ","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme, which is the primary metabolic pathway for Deucravacitinib, increasing drug exposure by 2-3 fold","               ","Increased risk of immunologic adverse effects and hepatotoxicity, particularly opportunistic infections, respiratory tract inflammation, and elevated liver enzymes","     (50%)     -       ","Reduce Deucravacitinib dose by half (50%) when co-administered with Fluvoxamine - monitor liver functions and signs of infection regularly");n("Deucravacitinib (Sotyktu)","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,": ** **.","Mechanism: **Immunosuppression**."," : ** **   .","Clinical Significance: **Immunological failure** and vaccine disease risk.","  .    .","Avoid live vaccines. Vaccinate before starting therapy.");n("Deucravacitinib (Sotyktu)","Tuberculosis ( )",e.DRUG_DISEASE,i.HIGH,": ** **.","Mechanism: **Immunosuppression**."," : **  **.","Clinical Significance: **Latent TB reactivation**.","    .","Screen for TB before starting therapy.");n("Deutetrabenazine","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"    ","Mutual inhibition of monoamine metabolism.","        ","Dangerous hypertension, hypertensive crisis.","     14 ","Avoid concurrent use, separate by 14 days.");n("Dexamethasone","Diabetes ()",e.DRUG_DISEASE,i.MODERATE,"    .  ()            ( ).","Insulin Resistance and Gluconeogenesis. Dexamethasone (a corticosteroid) increases insulin resistance and promotes hepatic glucose production (gluconeogenesis).","  (Hyperglycemia).                .","Hyperglycemia. Leads to elevated blood glucose levels, potentially requiring increased anti-diabetic medication doses or initiation of insulin therapy.",".                ( )      .","Monitor. Closely monitor blood glucose levels and adjust anti-diabetic therapy immediately and accurately (especially insulin) upon initiation or dose change of Dexamethasone.");n("Dexamethasone","Diabetes / Hypertension",e.DRUG_DISEASE,i.MODERATE,"     ( ).","Hyperglycemia & Fluid Retention. Corticosteroids induce gluconeogenesis and mineralocorticoid activity.","    .","    .","          .","          .");n("Dexamethasone","Aminoglutethimide",e.DRUG_DRUG,i.MODERATE,"   ","Aminoglutethimide accelerates dexamethasone metabolism","  ","Reduced dexamethasone efficacy","     ","Use another corticosteroid alternative like hydrocortisone");n("Dexamethasone","Phenytoin",e.DRUG_DRUG,i.MODERATE," CYP3A4 -   ","CYP3A4 induction accelerates dexamethasone metabolism.","  ","Reduced corticosteroid efficacy.","   ","May need to double the dose.");n("Dexamethasone","Aprepitant",e.DRUG_DRUG,i.MODERATE," CYP3A4 -   ","CYP3A4 inhibition increases dexamethasone levels.","  ","Increased corticosteroid effects.","   50%","Reduce dexamethasone dose 50%.");n("Dextromethorphan","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,": **    (MAO Inhibition)**.  MAO                    .","Mechanism: **MAO inhibition prevents serotonin and norepinephrine breakdown**. MAO inhibitors prevent the degradation of serotonin and norepinephrine, while dextromethorphan increases serotonin release, leading to dangerous serotonin accumulation in the CNS."," : **    (Life-Threatening Serotonin Syndrome)**   :   (>40C)          .            .","Clinical Significance: **Life-threatening serotonin syndrome** with serious symptoms: severe hyperthermia (>40C), muscle rigidity, tremor, diaphoresis, diarrhea, mental confusion, coma, and seizures. May progress to multi-organ failure and death if not treated immediately.","  . **  14   **    MAO  .      ( ).            .","Absolutely contraindicated. **Separate by at least 14 days** between stopping MAO inhibitors and starting dextromethorphan. Use safe alternative cough suppressants (e.g., guaifenesin). If serotonin syndrome occurs, immediately discontinue both drugs and provide intensive supportive care.");n("Dextromethorphan/Bupropion","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"       . Bupropion   /  Dextromethorphan .","Increased risk of Serotonin Syndrome and Hypertensive Crisis. Bupropion is a Dopamine/Norepinephrine Reuptake Inhibitor, and Dextromethorphan is serotonergic.","      .","Agitation, hyperreflexia, and dangerously high blood pressure."," .        14    .","Contraindicated. Avoid the combination with at least a 14-day washout period.");n("Dextromethorphan/Bupropion","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"    ","Serotonin syndrome due to metabolism inhibition.","     ","Dangerous serotonin levels, fever, tremors.","     14 ","Strictly avoid combination, separate by 14 days.");n("Diazepam","Fluconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Diazepam","Itraconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Diazepam","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Diazepam","Voriconazole",e.DRUG_DRUG,i.HIGH,"  ","Sedation & Respiratory Depression. Due to elevated benzodiazepine levels.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Diazepam","Diltiazem",e.DRUG_DRUG,i.MODERATE,"   -      ","Increased Benzodiazepine Effect. Elevated levels lead to excessive sedation and psychomotor impairment.","    ","Enhanced Sedation. Excessive CNS depression.","   ","   ");n("Diazepam","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"   -     ","Enhanced Benzodiazepine Effect. Risk of profound sedation.","    ","Enhanced Sedation. Excessive CNS depression.","    ","    ");n("Diazepam","Macrolide Antibiotics",e.DRUG_DRUG,i.HIGH,"   -      ","Increased Benzodiazepine Effect. Elevated levels lead to excessive sedation and psychomotor impairment.","    ","Enhanced Sedation. Excessive CNS depression.","     -   :   ","     -   :   ");n("Diclofenac","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Diclofenac","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,"  .           .","Irritation and Prostaglandin Inhibition. Diclofenac causes direct mucosal injury and inhibits the synthesis of cytoprotective prostaglandins.","  .          (Perforation)   .","Hemorrhage, Ulceration, and Perforation. High risk of severe, life-threatening gastrointestinal bleeding, ulceration, and perforation.",".          .                (   ).","Avoid use. Contraindicated in patients with active peptic ulcer or recent GI bleeding. If use is unavoidable, use the lowest effective dose for the shortest duration with a gastroprotective agent (e.g., PPI).");n("Diclofenac","Heart Failure",e.DRUG_DISEASE,i.MODERATE," .               .","Fluid Retention. Diclofenac inhibits renal prostaglandins, which impairs renal blood flow and leads to sodium and water retention, exacerbating volume overload.","  .      (Edema)        .","Worsening Failure. Exacerbation of congestive heart failure symptoms and reduced efficacy of diuretics and other heart failure treatments.",".       .                .","Avoid use. NSAIDs are generally discouraged in heart failure patients. If used, monitor weight, signs of fluid retention, and renal function closely.");n("Diclofenac","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,"     .","Prostaglandin Inhibition. COX inhibition depletes cytoprotective gastric prostaglandins, increasing ulcer risk.","      .","GI Bleeding & Perforation. Severe gastric injury.","         (PPIs) .","         (PPIs) .");n("Diclofenac (NSAID)","ACE Inhibitors/ARBs",e.DRUG_DRUG,i.HIGH,"     (Triple Whammy).          ACE/ARBs    .","Increased risk of Acute Kidney Injury (AKI) (Triple Whammy). NSAIDs cause afferent arteriole constriction, and ACE/ARBs cause efferent arteriole dilation.","  .","Acute renal failure."," .      .       .","Close monitoring. Avoid combination in high-risk patients. Renal function must be monitored upon initiation.");n("Dicyclomine","Anticholinergics",e.DRUG_DRUG,i.MODERATE,"   ","Additive Anticholinergic Burden.","    ","Dry mouth, constipation, urinary retention.","   ","Monitor symptoms, adjust doses.");n("Didanosine","Rifamycins",e.DRUG_DRUG,i.HIGH,"  .                  .","Decreased Didanosine Concentrations. Rifamycins significantly reduce the absorption of Didanosine, likely through direct binding or other unknown mechanisms.","     (HIV).                .","Failure in HIV Treatment. Subtherapeutic Didanosine levels lead to loss of antiviral efficacy and increase the risk of viral resistance development.","  .             .","Avoid this Combination. Seek an alternative Rifamycin or modify the antiretroviral regimen.");n("Didanosine","Food",e.DRUG_FOOD,i.MODERATE,"    .        .","Decreased Gastrointestinal Absorption of Didanosine. Food reduces the oral bioavailability of Didanosine significantly.","  .           .","Reduced Didanosine Efficacy. Decreased absorption results in inadequate drug levels in the plasma.","    .              .","Administer Didanosine on an Empty Stomach. Take Didanosine one hour before or at least two hours after a meal.");n("Digoxin",Ot,e.DRUG_DRUG,i.MODERATE,": **  **.        .","Mechanism: **Altered intestinal absorption**. Aminoglycosides may kill intestinal bacteria that metabolize Digoxin."," : **  **    ( 10%  ).","Clinical Significance: **Decreased Digoxin levels** in some patients (approximately 10% of patients).","  .       .","Monitor Digoxin levels. Dose increase may be required if necessary.");n("Digoxin",ey,e.DRUG_DRUG,i.MODERATE,": **   **.         .","Mechanism: **Intestinal mucosal damage**. Chemotherapy damages intestinal mucosa and reduces Digoxin absorption."," : **   **   .","Clinical Significance: **Decreased Digoxin absorption and levels** during chemotherapy.","  .        .","Monitor Digoxin levels. Dose increase or IV Digoxin may be required.");n("Digoxin","Amiodarone",e.DRUG_DRUG,i.HIGH,": ** P-gp  **.    P-gp     .","Mechanism: **P-gp inhibition and reduced clearance**. Amiodarone inhibits P-gp transporter and may reduce renal clearance of Digoxin."," : **   ( )**       (   ).","Clinical Significance: **Increased Digoxin levels (up to double)**, leading to severe Digoxin toxicity (heart block, arrhythmias).","    50%    .    .","Reduce Digoxin dose by 50% immediately upon starting Amiodarone. Monitor levels and ECG.");n("Digoxin","Cholestyramine",e.DRUG_DRUG,i.MODERATE,": **  **.       .","Mechanism: **Intestinal binding**. Cholestyramine binds to Digoxin in the intestines and prevents its absorption."," : **      25%**.","Clinical Significance: **Decreased Digoxin absorption by up to 25%**.","        6 .  .","Take Digoxin 2 hours before Cholestyramine or 6 hours after. Monitor levels.");n("Digoxin",$u,e.DRUG_DRUG,i.HIGH,": **  (Electrolyte Imbalance)**.           .","Mechanism: **Electrolyte imbalance**. Loop diuretics cause hypokalemia and hypomagnesemia, increasing cardiac sensitivity to Digoxin."," : **      **     .","Clinical Significance: **Increased risk of Digoxin toxicity and fatal arrhythmias** even with normal Digoxin levels.","     .    > 4.0 mEq/L.","Monitor potassium and magnesium regularly and supplement. Maintain Potassium > 4.0 mEq/L.");n("Digoxin",ir,e.DRUG_DRUG,i.MODERATE,": ** P-gp   **.  (  )  P-gp       .","Mechanism: **P-gp inhibition and intestinal flora depletion**. Macrolides (esp. Clarithromycin, Erythromycin) inhibit P-gp and kill intestinal bacteria that metabolize Digoxin."," : **   **    .","Clinical Significance: **Increased Digoxin absorption and levels**, increasing toxicity risk.","  .         .","Monitor Digoxin levels. Dose reduction may be required with Clarithromycin or Erythromycin.");n("Digoxin",St,e.DRUG_DRUG,i.MODERATE,": **  **.        .","Mechanism: **Killing intestinal flora**. Tetracyclines kill bacteria that metabolize Digoxin in the intestines."," : **  **   10%  .","Clinical Significance: **Increased Digoxin levels** in approximately 10% of patients.","       .","Monitor Digoxin levels when starting or stopping Tetracycline.");n("Digoxin",ny,e.DRUG_DRUG,i.HIGH,": **  **.           .","Mechanism: **Potassium and magnesium depletion**. Thiazide diuretics cause loss of potassium and magnesium, increasing cardiac sensitivity to Digoxin."," : **     **    .","Clinical Significance: **Increased risk of Digoxin toxicity and arrhythmias** even with normal levels.","   .      .","Monitor potassium and magnesium regularly. Supplement and maintain normal levels.");n("Digoxin","Verapamil",e.DRUG_DRUG,i.HIGH,": ** P-gp   **.    P-gp     .","Mechanism: **P-gp inhibition and reduced renal clearance**. Verapamil inhibits P-gp, increasing Digoxin absorption and reducing excretion."," : **    50-70%**       .","Clinical Significance: **Increased Digoxin levels by 50-70%**, with additive bradycardic effect.","    30-50%.    .","Reduce Digoxin dose by 30-50%. Monitor levels and ECG.");n("Digoxin","Amiodarone",e.DRUG_DRUG,i.HIGH,"   .          ( P-glycoprotein).","Reduced Clearance and Increased Absorption. Amiodarone inhibits renal Digoxin excretion and reduces its intestinal metabolism (P-glycoprotein inhibition).","  (Digoxin Toxicity).                 (Arrhythmias).","Digoxin Toxicity. Significantly elevated Digoxin levels increase the risk of potentially fatal cardiac arrhythmias.","  50%.      50%          .","Reduce Digoxin Dose by 50%. Digoxin dosage must be reduced by 50% upon initiating Amiodarone, and serum concentrations closely monitored.");n("Digoxin","Quinidine",e.DRUG_DRUG,i.HIGH,"    .           ( P-glycoprotein).","Tissue Displacement and Reduced Clearance. Quinidine displaces Digoxin from tissue binding sites and inhibits its renal excretion (P-glycoprotein inhibition).","  .              .","Doubled Digoxin Level. Plasma Digoxin concentration can double, dramatically increasing the risk of cardiac toxicity and adverse effects.","  50%.      50%         .","Reduce Digoxin Dose by 50%. Digoxin dosage must be reduced by 50% upon initiating Quinidine, and serum concentrations monitored regularly.");n("Digoxin","Furosemide",e.DRUG_DRUG,i.HIGH,"  .","Hypokalemia & Hypomagnesemia. Electrolyte depletion increases arrhythmia risk.","   .","   .","  .","  .");n("Digoxin","Hydrochlorothiazide",e.DRUG_DRUG,i.HIGH,"  .","Hypokalemia & Hypomagnesemia. Electrolyte depletion increases arrhythmia risk.","   .","   .","  .","  .");n("Digoxin","Spironolactone",e.DRUG_DRUG,i.HIGH,"  .","Hypokalemia & Hypomagnesemia. Electrolyte depletion increases arrhythmia risk.","   .","   .","  .","  .");n("Digoxin","Erythromycin",e.DRUG_DRUG,i.MODERATE,"     +  P-gp.","Digoxin Accumulation. Gut flora killing and P-gp inhibition increase bioavailability."," ."," .",".",".");n("Digoxin","Clarithromycin",e.DRUG_DRUG,i.MODERATE,"     +  P-gp.","Digoxin Accumulation. Gut flora killing and P-gp inhibition increase bioavailability."," ."," .",".",".");n("Digoxin","Azithromycin",e.DRUG_DRUG,i.MODERATE,"     +  P-gp.","Digoxin Accumulation. Gut flora killing and P-gp inhibition increase bioavailability."," ."," .",".",".");n("Digoxin","Metoclopramide",e.DRUG_DRUG,i.LOW,"  .","Increased intestinal motility.","   .","Slight decrease in absorption.",".","Monitor. Close clinical observation required.");n("Digoxin","Cholestyramine",e.DRUG_DRUG,i.MODERATE,"  .","Intestinal binding."," .","Decreased Absorption. Subtherapeutic drug levels."," .","Separate doses.");n("Digoxin","Licorice",e.DRUG_FOOD,i.HIGH," ()            (  ).","Licorice (Glycyrrhizin) acts as an aldosterone analogue, leading to increased renal potassium excretion and fluid retention (hypokalemia).","                        ( ).","Hypokalemia significantly increases myocardial sensitivity to Digoxin, leading to a dangerous rise in its effects and the potential for fatal cardiac arrhythmias (Digoxin toxicity).","  .        (     )   .","Combination is strictly contraindicated. The patient must completely avoid consuming licorice and its products (including candies and strong teas) during Digoxin therapy.");n("Digoxin","Furosemide",e.DRUG_DRUG,i.HIGH,"     (Hypokalemia).","Diuretics cause hypokalemia.","            .","Hypokalemia increases cardiac sensitivity to digoxin, leading to toxicity and arrhythmias.","            ( ).","Monitor potassium levels regularly and replace with supplements or potassium-rich foods (e.g., bananas).");n("Digoxin","Amiodarone / Quinidine / Verapamil",e.DRUG_DRUG,i.HIGH,"       .","These drugs reduce digoxin excretion and increase its concentration.","  (     ).","Digoxin toxicity (nausea, yellow halos vision, bradycardia).","          .","Reduce digoxin dose by half when adding these drugs and monitor levels.");n("Digoxin","Licorice",e.DRUG_FOOD,i.HIGH,"     .","Licorice causes sodium retention and potassium loss.","     .","Hypokalemia increases digoxin toxicity.","       .","Avoid licorice consumption in cardiac patients taking digoxin.");n("Digoxin","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"   ()    ","Increased digoxin metabolism (proposed), leading to reduced concentration","            .","Decreased digoxin efficacy, potentially worsening heart failure or arrhythmias.","   (Carbamazepine)    . (:          ).","Review anticonvulsants (Carbamazepine) as they may reduce digoxin concentrations. (Note: mechanism unclear but interaction is common).");n("Digoxin","Ciclosporin",e.DRUG_DRUG,i.HIGH,"   (  P-gp)","Increased digoxin concentrations (due to P-gp inhibition)","    (     ).","Increased risk of digoxin toxicity (e.g., bradycardia, nausea, visual disturbances).","    .   .      .","Monitor cardiovascular status. Monitor digoxin concentrations. Reduce digoxin dose if necessary.");n("Digoxin","High-Fiber Foods",e.DRUG_FOOD,i.MODERATE,"  ","Fiber-Induced Malabsorption. Dietary fiber binds drug.","  ","  ","      ","      ");n("Digoxin","Licorice",e.DRUG_FOOD,i.HIGH," ()            (  ).","Licorice (Glycyrrhizin) acts as an aldosterone analogue, leading to increased renal potassium excretion and fluid retention (hypokalemia).","                        ( ).","Hypokalemia significantly increases myocardial sensitivity to Digoxin, leading to a dangerous rise in its effects and the potential for fatal cardiac arrhythmias (Digoxin toxicity).","  .        (     )   .","Combination is strictly contraindicated. The patient must completely avoid consuming licorice and its products (including candies and strong teas) during Digoxin therapy.");n("Digoxin","Kanamycin",e.DRUG_DRUG,i.MODERATE,"      ","Aminoglycosides reduce intestinal absorption of digoxin.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","    -      ","Monitor digoxin concentrations - increase digoxin dose if necessary.");n("Digoxin","Neomycin",e.DRUG_DRUG,i.MODERATE,"      ","Neomycin reduces intestinal absorption of digoxin.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","    -      ","Monitor digoxin concentrations - increase digoxin dose if necessary.");n("Digoxin","Paromomycin",e.DRUG_DRUG,i.MODERATE,"      ","Paromomycin reduces intestinal absorption of digoxin.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","    -      ","Monitor digoxin concentrations and toxicity - adjust digoxin dose if necessary.");n("Digoxin","Amiodarone",e.DRUG_DRUG,i.HIGH,"        ","Amiodarone reduces renal clearance of digoxin and alters volume of distribution.","   -  ","Increased digoxin concentrations - risk of toxicity.","    -     50%","Monitor digoxin concentrations and toxicity - reduce digoxin dose by 50%.");n("Digoxin","Bleomycin",e.DRUG_DRUG,i.MODERATE,"      ","Antineoplastic agents reduce digoxin absorption.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","   -      ","Monitor digoxin concentrations - increase digoxin dose if necessary.");n("Digoxin","Cyclophosphamide",e.DRUG_DRUG,i.MODERATE,"    ","Cyclophosphamide reduces digoxin absorption.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","   -      ","Monitor digoxin concentrations - increase digoxin dose if necessary.");n("Digoxin","Doxorubicin",e.DRUG_DRUG,i.MODERATE,"    ","Doxorubicin reduces digoxin absorption.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","   -      ","Monitor digoxin concentrations - increase digoxin dose if necessary.");n("Digoxin","Bepridil",e.DRUG_DRUG,i.MODERATE,"    ","Bepridil increases digoxin concentration.","   -    ","Increased digoxin concentrations - increased negative chronotropic effects.","    -      ","Monitor cardiovascular status - reduce digoxin dose if necessary.");n("Digoxin","Cholestyramine",e.DRUG_DRUG,i.MODERATE,"      ","Cholestyramine binds digoxin in the intestine preventing absorption.","   -   ","Decreased digoxin concentrations - loss of therapeutic effect.","    -    ","Separate administration times - monitor for reduced digoxin efficacy.");n("Digoxin","Amiodarone",e.DRUG_DRUG,i.HIGH," P-glycoprotein +   ","P-gp inhibition + reduced renal clearance.","  -   ","Digoxin toxicity - nausea, arrhythmias.","   50% -  ","Reduce digoxin dose 50% - monitor levels.");n("Digoxin","Verapamil",e.DRUG_DRUG,i.HIGH," P-gp","P-glycoprotein inhibition.","  ","Increased digoxin levels.","  25-50%","Reduce dose 25-50%.");n("Digoxin","Clarithromycin",e.DRUG_DRUG,i.HIGH," P-gp +   ","P-gp inhibition + gut flora killing."," ","Digoxin toxicity.","  ","Monitor levels and symptoms.");n("Digoxin","Spironolactone",e.DRUG_DRUG,i.MODERATE,"    +  ","Interference with digoxin assay + reduced clearance.","  ","Misleading level readings.","   ","Use specific digoxin assay.");n("Digoxin","Atorvastatin",e.DRUG_DRUG,i.MODERATE," P-gp","P-gp inhibition.","    ","Slight increase in digoxin levels.","   ","Monitor when initiating therapy.");n("Diltiazem",Ju,e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.          (  ).","Mechanism: **CYP3A4 inhibition**. Diltiazem slows the metabolism of benzodiazepines that rely on this enzyme (e.g., midazolam and alprazolam)."," : **   **      (Excessive Sedation)    .","Clinical Significance: **Increased benzodiazepine levels and effects**, leading to excessive sedation, dizziness, and potential respiratory depression.","    .    (    CYP3A4)   .","Monitor sedation level and respiratory function. Benzodiazepine dose reduction (especially CYP3A4 substrates) may be necessary.");n("Diltiazem","Carbamazepine",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.    .","Mechanism: **CYP3A4 inhibition**. Diltiazem reduces the clearance of Carbamazepine."," : **  **  **  (Neurotoxicity)**    (Ataxia) .","Clinical Significance: **Increased carbamazepine levels** and risk of **neurotoxicity** manifesting as ataxia and dizziness.","   .     .","Monitor serum Carbamazepine levels. Decrease Carbamazepine dose to avoid toxicity.");n("Diltiazem","Cyclosporine",e.DRUG_DRUG,i.HIGH,": **  CYP3A4**.      .","Mechanism: **CYP3A4 inhibition**. Diltiazem prevents the breakdown of Cyclosporine in the liver."," : **  **    **  (Nephrotoxicity)**     .","Clinical Significance: **Increased cyclosporine levels** and risk of **nephrotoxicity** and severe hypertension.","        .       25-50%.","Monitor serum Cyclosporine levels closely when starting or stopping. Dose adjustment may require a 25-50% reduction.");n("Diltiazem",Sc,e.DRUG_DRUG,i.HIGH,": **  CYP3A4**.        CYP3A4 (  ).","Mechanism: **CYP3A4 inhibition**. Diltiazem inhibits the metabolism of CYP3A4-dependent statins (e.g., simvastatin and atorvastatin)."," : **    **       (Myopathy)   (Rhabdomyolysis)  .","Clinical Significance: **Greatly increased statin levels**, increasing the risk of myopathy and life-threatening rhabdomyolysis.","     CK.             CYP3A4 (   ).","Monitor for muscle pain and CK levels. Lower the statin dose significantly or switch to a non-CYP3A4 dependent statin (e.g., Pravastatin or Rosuvastatin).");n("Diltiazem","Moricizine",e.DRUG_DRUG,i.MODERATE,": **    (Pharmacokinetic Interaction)**.       .","Mechanism: **Complex Pharmacokinetic interaction**. Mutual inhibition of hepatic metabolism pathways occurs."," : **  ** (  )      .     .","Clinical Significance: **Increased moricizine levels** (antiarrhythmic) and decreased diltiazem levels. Moricizine cardiac toxicity may be increased.","    .      .","Monitor ECG and clinical symptoms. Adjust doses as needed to avoid toxicity.");n("Diltiazem","Theophylline",e.DRUG_DRUG,i.MODERATE,": **  CYP1A2**.     CYP1A2     .","Mechanism: **CYP1A2 inhibition**. Diltiazem is an inhibitor of CYP1A2, the major metabolic pathway for Theophylline."," : **  **            .","Clinical Significance: **Increased theophylline levels** and toxicity risk, which includes nausea, headaches, and in severe cases, seizures and arrhythmias.","    .      .","Monitor serum Theophylline levels closely. Decrease theophylline dose may be necessary.");n("Diltiazem","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Diltiazem   CYP3A4    Simvastatin.","Increased Simvastatin concentration. Diltiazem inhibits CYP3A4, a Simvastatin metabolic pathway.","    (Rhabdomyolysis)  .","Increased risk of Rhabdomyolysis and muscle toxicity."," .   Simvastatin  Diltiazem         .","Contraindicated. Simvastatin must be avoided with Diltiazem or a very low dose used, or an alternative statin used.");n("Diltiazem","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"Diltiazem inhibits the hepatic enzyme CYP3A4, which is responsible for the metabolism of Carbamazepine, leading to reduced clearance.","    CYP3A4    ","Increased Carbamazepine plasma concentrations - risk of toxicity (e.g., dizziness, ataxia, nausea, headache).","     -  ","Monitor Carbamazepine plasma concentrations closely. Adjust the Carbamazepine dose when initiating or discontinuing Diltiazem.","   -       ");n("Diltiazem","Moricizine ()",e.DRUG_DRUG,i.MODERATE,"Mutual effect on hepatic metabolism: Diltiazem increases Moricizine concentration, while Moricizine decreases Diltiazem concentration.","     -        ","Increased Moricizine concentrations - decreased Diltiazem concentrations, potentially leading to reduced efficacy of Diltiazem.","   -   ","Adjust the dose of one or both drugs as needed based on therapeutic response and monitoring.","       ");n("Diltiazem","Aminophylline",e.DRUG_DRUG,i.MODERATE,"Diltiazem inhibits hepatic enzymes CYP1A2 and CYP3A4, which are involved in Theophylline (active component of Aminophylline) metabolism.","    CYP1A2 CYP3A4    ","Increased Aminophylline plasma concentrations (leading to increased Theophylline levels) - risk of toxicity (e.g., nausea, vomiting, seizures, arrhythmias).","     -  ","Monitor Theophylline plasma concentrations. Adjust the Theophylline dose when initiating or discontinuing Diltiazem.","   -        ");n("Diltiazem","Oxtriphylline",e.DRUG_DRUG,i.MODERATE,"Diltiazem inhibits hepatic enzymes CYP1A2 and CYP3A4, which are involved in Theophylline (active component of Oxtriphylline) metabolism.","    CYP1A2 CYP3A4    ","Increased Oxtriphylline plasma concentrations (leading to increased Theophylline levels) - risk of toxicity (e.g., nausea, vomiting, seizures, arrhythmias).","     -  ","Monitor Theophylline plasma concentrations. Adjust the Theophylline dose when initiating or discontinuing Diltiazem.","   -        ");n("Diltiazem","Theophylline",e.DRUG_DRUG,i.MODERATE,"Diltiazem inhibits hepatic enzymes CYP1A2 and CYP3A4, which are responsible for Theophylline metabolism.","    CYP1A2 CYP3A4    ","Increased Theophylline plasma concentrations - risk of toxicity (e.g., nausea, vomiting, seizures, arrhythmias).","     -  ","Monitor Theophylline plasma concentrations. Adjust the Theophylline dose when initiating or discontinuing Diltiazem.","   -        ");n("Diltiazem","Benzodiazepines",e.DRUG_DRUG,i.MODERATE,"Diltiazem inhibits the hepatic enzyme CYP3A4, which is primarily responsible for the metabolism of many Benzodiazepines (e.g., Triazolam, Midazolam).","    CYP3A4    ","Increased sedative effect of Benzodiazepines - enhanced drowsiness, dizziness, and psychomotor impairment.","    -   ","Monitor for signs of excessive sedation and respiratory depression. Reduce the Benzodiazepine dose if necessary, especially for those metabolized by CYP3A4.","  excessive sedation -      ");n("Diltiazem","Cyclosporine",e.DRUG_DRUG,i.HIGH,"Diltiazem significantly inhibits the hepatic enzyme CYP3A4, which is responsible for the metabolism and elimination of Cyclosporine.","    CYP3A4    ","Increased Cyclosporine plasma concentrations - increased risk of nephrotoxicity (kidney damage) and neurotoxicity (nervous system damage).","   -     ","Monitor Cyclosporine trough plasma concentrations very closely. A dose reduction of Cyclosporine by 15-50% is typically required upon initiating Diltiazem.","   -     15-50%");n("Diltiazem","Carbamazepine",e.DRUG_DRUG,i.HIGH," CYP3A4 -   ","CYP3A4 inhibition increases carbamazepine levels.","  -  ","Carbamazepine toxicity - dizziness, ataxia.","  ","Monitor carbamazepine levels.");n("Diltiazem - ","Simvastatin - ",e.DRUG_DRUG,i.HIGH,"        P450 3A4 (CYP3A4)     .                 500 (  5      - AUC).       P-glycoprotein OATP1B1         .             ( 180 /)    ( 40 /).","Diltiazem is a moderate to potent inhibitor of cytochrome P450 3A4 (CYP3A4), the primary metabolic pathway for Simvastatin. Diltiazem significantly reduces Simvastatin metabolism, increasing its plasma concentration by up to 500% (a 5-fold increase in the area under the curve - AUC). Diltiazem also inhibits drug transporters like P-glycoprotein and OATP1B1, increasing Simvastatin absorption and reducing its hepatic clearance. This interaction is dose-dependent and more pronounced with high doses of Diltiazem ( 180 mg/day) and high doses of Simvastatin ( 40 mg/day).","                  : 1.     . 2.       (CPK) -   10,000 /. 3.         . 4.   .                  .","Significantly increased risk of myopathy that can progress to rhabdomyolysis, a life-threatening condition characterized by: 1. Severe muscle pain, weakness, and tenderness. 2. Sharp elevation of creatine kinase (CPK) - may exceed 10,000 U/L. 3. Myoglobinuria, which can lead to acute renal failure. 4. Serious electrolyte disturbances. The risk is higher in elderly patients, those with renal impairment, hepatic impairment, or hypothyroidism.","1.  :            20 /. 2.  :            CYP3A4. 3.    :    10 /       . 4.  :                 4-8   . 5.  :         2-4 . 6.  :     80-90    .","1. Avoid combination: This combination is relatively contraindicated, especially with Simvastatin doses  20 mg/day. 2. Use alternatives: Replace Simvastatin with pravastatin, rosuvastatin, or fluvastatin which are not CYP3A4-dependent. 3. If combination necessary: Do not exceed 10 mg/day of Simvastatin with weekly CK monitoring. 4. Close monitoring: Educate patient to immediately report any muscle pain, weakness, or unusual fatigue, especially during the first 4-8 weeks of combination. 5. Periodic testing: Measure CK, creatinine, and liver function tests every 2-4 weeks. 6. Dose adjustment: Reduce Simvastatin dose by 80-90% when initiating with Diltiazem.");n("Diltiazem - ","Lovastatin - ",e.DRUG_DRUG,i.HIGH,"     CYP3A4     .           400-600 (  4-6    ).       .             .","Diltiazem significantly inhibits CYP3A4, responsible for the primary metabolism of Lovastatin. Diltiazem increases Lovastatin plasma concentration by 400-600% (a 4-6 fold increase in systemic exposure). It also reduces the formation of active Lovastatin metabolites. The interaction is more pronounced with extended-release Lovastatin formulations and high Diltiazem doses.","       .                 CYP3A4.            :           .","Significantly increased risk of myopathy and rhabdomyolysis. Muscular toxicity is more common and severe with Lovastatin compared to some other statins due to its heavy dependence on CYP3A4. Symptoms may occur within days to weeks of starting the combination and include: severe muscle weakness, difficulty walking or climbing stairs, and dark urine.","1.   :         . 2.  :     (20-40 /)   (5-10 /). 3.    :     20 /      . 4.  :           . 5.  :        .","1. Absolute avoidance: Combination of Diltiazem and Lovastatin is not recommended under any circumstances. 2. Immediate alternatives: Replace Lovastatin with pravastatin (20-40 mg/day) or rosuvastatin (5-10 mg/day). 3. If combination unavoidable: Use Lovastatin dose not exceeding 20 mg/day with daily symptom monitoring. 4. Laboratory monitoring: Check CK twice weekly for one month then weekly thereafter. 5. Immediate discontinuation: Stop Lovastatin immediately if any muscular symptoms appear.");n("Diltiazem - ","Atorvastatin - ",e.DRUG_DRUG,i.MODERATE,"       CYP3A4        30-50.                   .           ( 40 /).","Diltiazem moderately inhibits Atorvastatin metabolism via CYP3A4, increasing its plasma concentration by 30-50%. This interaction is less severe compared to Simvastatin or Lovastatin because part of Atorvastatin metabolism occurs through other enzymatic pathways. The interaction remains clinically significant, especially with high Atorvastatin doses ( 40 mg/day).","                  .                        CYP3A4.","Moderate increase in the risk of myopathy, with symptoms such as muscle pain, fatigue, and mild to moderate elevation of creatine kinase. Rarely progresses to rhabdomyolysis unless additional risk factors are present such as renal impairment, advanced age, or use of other CYP3A4 inhibitors.","1.    :      (10-20 /)  . 2.  :         . 3.  :       4-8   . 4.   :    40 /    . 5.   :          .","1. Use lowest effective dose: Start with low Atorvastatin dose (10-20 mg/day) and increase gradually. 2. Clinical monitoring: Watch for any new muscular symptoms and educate patient to report them. 3. Laboratory monitoring: Check CK before initiation and after 4-8 weeks of combination. 4. Avoid high doses: Do not exceed 40 mg/day of Atorvastatin with Diltiazem. 5. Safer alternatives: Consider pravastatin or rosuvastatin as first-line options for patients taking Diltiazem.");n("Diltiazem - ","Quinidine - ",e.DRUG_DRUG,i.MODERATE,"      CYP3A4         40-60.         .                .","Diltiazem inhibits Quinidine metabolism via CYP3A4, increasing Quinidine plasma concentration by 40-60%. Additionally, Diltiazem reduces renal clearance of Quinidine. Both drugs work synergistically to inhibit calcium and sodium channels in the heart, enhancing electrophysiological effects.","        : 1.   QT   torsades de pointes. 2.    . 3.   . 4.     (      ).","Increased Quinidine effects on cardiac rhythm, including: 1. QT interval prolongation and increased risk of torsades de pointes. 2. Slowed atrioventricular conduction. 3. Hypotension. 4. Increased risk of Quinidine toxicity (tinnitus, hearing loss, dizziness, blurred vision).","1.   :        . 2.   :   QT    . 3.  :     25-35   . 4.  :        . 5.  :            .","1. Monitor Quinidine levels: Measure therapeutic Quinidine levels before and after starting Diltiazem. 2. ECG monitoring: Regularly assess QT interval and atrioventricular conduction. 3. Dose adjustment: Reduce Quinidine dose by 25-35% when adding Diltiazem. 4. Clinical monitoring: Watch for Quinidine toxicity symptoms and signs of hypotension. 5. Diltiazem alternatives: Consider other calcium channel blockers like amlodipine if interactions are problematic.");n("Diltiazem - ","Sirolimus - ",e.DRUG_DRUG,i.HIGH,"     CYP3A4  P-glycoprotein      .           200-300        (AUC).           .","Diltiazem significantly inhibits both CYP3A4 and P-glycoprotein, which are responsible for Sirolimus metabolism and excretion. Diltiazem increases Sirolimus plasma concentration by up to 200-300%, with a similar increase in area under the curve (AUC). The interaction is more pronounced with high Diltiazem doses and chronic therapy.","         : 1.    (      ). 2.   . 3.   . 4.  . 5. . 6.  .              .","Significantly increased risk of Sirolimus-associated toxicity, including: 1. Bone marrow toxicity (anemia, thrombocytopenia, leukopenia). 2. Hyperlipidemia. 3. Interstitial pneumonitis. 4. Arthralgia. 5. Edema. 6. Mouth ulcers. These effects may lead to graft rejection or other serious complications in transplant patients.","1.   :         . 2.  :     50-70   . 3.  :         . 4.  :          . 5.   :       2-4    .","1. Monitor Sirolimus levels: Measure therapeutic levels weekly after starting Diltiazem until stabilization. 2. Dose adjustment: Reduce Sirolimus dose by 50-70% when adding Diltiazem. 3. Comprehensive monitoring: Regularly monitor complete blood count, lipids, lung and kidney functions. 4. Diltiazem alternatives: Use other calcium channel blockers like amlodipine in transplant patients. 5. Long-term monitoring: Continue monitoring Sirolimus levels every 2-4 weeks even after stabilization.");n("Diltiazem - ","Tacrolimus - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4     .           400-600   .      .             .","Diltiazem potently inhibits CYP3A4, responsible for the primary metabolism of Tacrolimus. Diltiazem increases Tacrolimus plasma concentration by up to 400-600% in some patients. It also reduces renal clearance of Tacrolimus. The interaction is unpredictable and varies significantly between patients, requiring intensive monitoring.","       : 1.   (   ). 2.   (    ). 3.   (     ). 4.    ( ). 5.   ( QT    ).","Significantly increased risk of Tacrolimus-associated toxicity, particularly: 1. Renal toxicity (elevated creatinine, renal failure). 2. Neurotoxicity (tremors, headache, seizures, encephalopathy). 3. Metabolic disorders (hyperglycemia, hyperkalemia). 4. Gastrointestinal disorders (nausea, diarrhea). 5. Cardiac disorders (QT prolongation, arrhythmias).","1.   :          2-3    . 2.  :     60-80   . 3.  :        . 4.  :        . 5.  :          . 6.   :        .","1. Monitor Tacrolimus levels: Daily level measurement during the first week of combination, then 2-3 times weekly until stabilization. 2. Dose adjustment: Reduce Tacrolimus dose by 60-80% when initiating Diltiazem. 3. Clinical monitoring: Daily monitoring of renal function, neurological symptoms, and glucose levels. 4. Gradual adjustment: Gradually increase Tacrolimus dose based on target concentrations. 5. Diltiazem alternatives: Use other calcium channel blockers like amlodipine in transplant patients. 6. Long-term monitoring: Continue frequent monitoring even after dose adjustment.");n("Diphenhydramine","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"   ","Amplification of anticholinergic effects.","   ","Delirium, hallucinations, hyperthermia.","  ","Avoid combination completely.");n("Diphenhydramine","Alcohol",e.DRUG_DRUG,i.HIGH,": **     (Synergistic CNS Depression)**.       GABA          .  ( H1)         CNS.","Mechanism: **Synergistic central nervous system depression**. Both enhance the inhibitory neurotransmitter GABA and reduce CNS activity through different but complementary mechanisms. Diphenhydramine (H1 antagonist) has strong sedative properties, and alcohol is a direct CNS depressant."," : **  **                **** (   )     **  **.      **  **  .     (12-24 ).","Clinical Significance: **Severe and excessive drowsiness**, significantly impaired concentration and judgment, slowed reaction time, impaired motor coordination, increased risk of **falls** (especially in elderly), and greatly increased risk of **fatal motor vehicle accidents**. At high doses, **dangerous respiratory depression** or coma may occur. Effect persists for many hours (12-24 hours).","  ****   . **   **      24    .          (   ).        .        .","Avoid alcohol **completely** during diphenhydramine treatment. **Strict warning against driving** or operating heavy machinery for 24 hours after taking medication. Use non-sedating second-generation antihistamines as alternative (e.g., loratadine or cetirizine). Educate patient that effect may persist into next day. Special attention in elderly for fall and fracture risk.");n("Diphenoxylate-Atropine","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,"   ","Hypertensive crisis.","   ","Dangerous hypertension.","  -   14 ","Contraindicated - separate by 14 days.");n("Diphenoxylate/Atropine","Selegiline",e.DRUG_DRUG,i.MODERATE,"      ().     Diphenoxylate.","Increased risk of hypertensive crisis (theoretically). Weak opioid properties of Diphenoxylate.","   .","Severe hypertension."," .      .","Close monitoring. Blood pressure and side effects must be monitored.");n("Dipyridamole","Adenosine",e.DRUG_DRUG,i.MODERATE,"  ","Amplified adenosine effect.","  ","Severe bradycardia.","  ","Reduce adenosine dose.");n("Diroximel Fumarate","Alcohol",e.DRUG_FOOD,i.MODERATE,"     (GI).","Increased risk of gastrointestinal (GI) irritation.","    (Flushing)  .","Increased risk of flushing and stomach pain."," .       .","Avoid Consumption. Excessive alcohol intake must be avoided.");n("Disopyramide",er,e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4)**.     .","Mechanism: **Hepatic enzyme induction (CYP3A4)**. Phenytoin and hydantoins induce Disopyramide metabolism."," : **  **     (  ).","Clinical Significance: **Decreased Disopyramide levels** and increased toxic metabolite levels (anticholinergic effects).","    .     .","Monitor clinical response and ECG. Disopyramide dose increase may be required.");n("Disopyramide","Rifampin",e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4)**.      .","Mechanism: **Potent enzyme induction (CYP3A4)**. Rifampin significantly accelerates Disopyramide metabolism."," : **    **     .","Clinical Significance: **Significant decrease in Disopyramide levels** and loss of arrhythmia control."," .          .","Monitor heart. Significant Disopyramide dose increase or drug switch may be required.");n("Disopyramide","Ethotoin",e.DRUG_DRUG,i.MODERATE,"       ","Ethotoin induces hepatic enzymes responsible for disopyramide metabolism","   -     ","Decreased disopyramide concentrations - increased risk of anticholinergic effects","       -      ","Monitor cardiovascular status and anticholinergic effects - increase disopyramide dose if necessary");n("Disopyramide ","Levofloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Disopyramide ","Moxifloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Disopyramide ","Ofloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Disopyramide ","Norfloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Disopyramide - ","Fosphenytoin - ",e.DRUG_DRUG,i.MODERATE,"  (   )     P450   CYP3A4     .                          .             .","Fosphenytoin (which converts to phenytoin) acts as a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, the primary metabolic pathway for Disopyramide. This induction increases the rate of metabolism and clearance of Disopyramide from the body, leading to a significant decrease in its plasma concentration and thus reducing its therapeutic antiarrhythmic effect. Additionally, Disopyramide may increase phenytoin concentrations, complicating the pharmacokinetic profile.","                 ( ).                            (       )       .","The primary risk is reduced efficacy of Disopyramide, potentially leading to the recurrence or worsening of arrhythmia (therapeutic failure). Also, Disopyramide has strong anticholinergic properties, and a decrease in its level may not necessarily reduce these effects proportionally, potentially leading to anticholinergic side effects (dry mouth, constipation, blurred vision, urinary retention) in addition to failure in cardiac rhythm control.","1.   :     (ECG)        . 2.  :       . 3.    :            . 4.  :          .           . 5.   :                      .","1. Monitor Disopyramide Efficacy: Perform regular ECGs and assess arrhythmia control. 2. Therapeutic Drug Monitoring: Monitor Disopyramide plasma concentrations if possible. 3. Monitor Anticholinergic Effects: Watch for symptoms like severe dry mouth, constipation, or blurred vision. 4. Dose Adjustment: An increase in the Disopyramide dose may be necessary to maintain the therapeutic effect. Adjustments should be based on clinical response and plasma drug levels. 5. Post-Discontinuation Monitoring: When Fosphenytoin is discontinued, enzyme induction will gradually decrease, potentially leading to increased Disopyramide levels, necessitating a reduction in its dose again to avoid toxicity.");n("Disopyramide - ","Mephenytoin - ",e.DRUG_DRUG,i.MODERATE,"     P450     CYP3A4    .                 .         .","Mephenytoin acts as an inducer of hepatic cytochrome P450 enzymes, including CYP3A4, responsible for Disopyramide metabolism. This induction leads to increased metabolism and clearance of Disopyramide, reducing its plasma concentration and therapeutic efficacy. The interaction is similar to that of phenytoin but may differ in extent.","              (      ).              (    )     .","Reduced efficacy of Disopyramide leading to risk of recurrence or worsening of arrhythmia (atrial fibrillation, ventricular tachycardia). Also, fluctuations in Disopyramide levels may contribute to its anticholinergic effects (dry mouth, constipation, urinary retention) even with reduced cardiac efficacy.","1.  :         . 2.  :      . 3.  :     ( )    . 4.  :         . 5.  :              .","1. Cardiac Monitoring: Perform regular ECGs to assess cardiac rhythm control. 2. Drug Monitoring: Measure Disopyramide plasma levels periodically. 3. Symptom Monitoring: Watch for signs of treatment failure (palpitations, dizziness) and anticholinergic side effects. 4. Dose Adjustment: Gradually increase Disopyramide dose as needed with close monitoring. 5. Alternative Therapy: Consider using another antiarrhythmic less affected by hepatic enzyme inducers if possible.");n("Disopyramide - ","Phenytoin - ",e.DRUG_DRUG,i.MODERATE,"     P450  ( CYP3A4 CYP2C9)     .          25-50            (AUC).         .","Phenytoin is a potent inducer of hepatic cytochrome P450 enzymes (especially CYP3A4 and CYP2C9), responsible for Disopyramide metabolism. Phenytoin increases Disopyramide clearance by 25-50%, significantly reducing its half-life and area under the curve (AUC). This leads to a marked decrease in therapeutic Disopyramide levels.","                   .          (   )             .","Therapeutic failure in controlling cardiac arrhythmia with risk of recurrent atrial fibrillation or ventricular tachycardia. Additionally, symptoms of phenytoin toxicity (nystagmus, ataxia, confusion) may appear due to Disopyramide`s potential to inhibit phenytoin metabolism, creating a complex bidirectional drug interaction.","1.  :          . 2.   :       . 3.  :      (   )      . 4.  :      . 5. :        ecainide       .","1. Intensive Monitoring: Perform frequent ECGs and measure plasma levels of both drugs. 2. Dose Separation: Does not prevent but may reduce interaction severity. 3. Dose Adjustment: Significantly increase Disopyramide dose (possibly double) and decrease phenytoin dose if needed. 4. Clinical Monitoring: Watch for signs of toxicity for both drugs. 5. Alternatives: Consider alternatives like amiodarone or flecainide that don`t interact with phenytoin in the same way.");n("Disopyramide - ","Gatifloxacin - ",e.DRUG_DRUG,i.HIGH,"    QT          ( hERG).                .                    .","Both drugs prolong the QT interval by inhibiting cardiac potassium channels (hERG channel). Disopyramide inhibits voltage-gated potassium channels, while Gatifloxacin inhibits the rapid delayed rectifier potassium current. When combined, the cumulative effect on cardiac repolarization is substantial, significantly increasing the risk of arrhythmia.","    torsades de pointes                  .                       QT.","High risk of developing torsades de pointes, a dangerous form of polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and cardiac arrest. The risk is highest in patients with hypokalemia, bradycardia, heart failure, or those taking other QT-prolonging medications.","1.   :      . 2.  :        QT     (). 3.    :                     . 4.   :                   QT.","1. Absolute Avoidance: This combination is relatively contraindicated. 2. Gatifloxacin Alternatives: Use alternative antibiotics that don`t prolong QT like ceftriaxone or azithromycin (with caution). 3. If Combination is Unavoidable: Hospitalize for continuous cardiac monitoring, correct any electrolyte imbalances, and have a defibrillator readily available. 4. Disopyramide Alternative: In critical cases, consider using other sodium channel blockers with less effect on QT interval.");n("Disopyramide - ","Moxifloxacin - ",e.DRUG_DRUG,i.HIGH,"       QT        .     IKr     hERG .                 QT   50-80     .","Both drugs cause significant QT prolongation through synergistic inhibition mechanisms of cardiac potassium channels. Disopyramide inhibits IKr potassium channels while Moxifloxacin potently inhibits the hERG channel. Their combination leads to a dangerous cumulative effect on ventricular repolarization, with an additive increase in QT interval reaching 50-80 milliseconds in some cases.","    torsades de pointes    5-10%    .                  (    )        QT .","Severe risk of torsades de pointes reaching 5-10% in susceptible patients. Risk is particularly elevated in elderly, patients with heart failure, electrolyte disturbances (especially hypokalemia and hypomagnesemia), or those with genetic predisposition to long QT syndrome.","1.   :   . 2.  :            . 3.      :        48-72         . 4.  QT :         QT      QTc > 450     > 470   .","1. Absolute Contraindication: Avoid combination completely. 2. Immediate Alternatives: Replace Moxifloxacin with a cardio-safe antibiotic like third-generation cephalosporins or clindamycin. 3. If Accidental Combination Occurs: Discontinue both drugs immediately, continuous cardiac monitoring for 48-72 hours, correct electrolytes, and be prepared for CPR. 4. Baseline QT Check: Before prescribing either drug, measure baseline QT interval and avoid use if QTc > 450 ms for men or > 470 ms for women.");n("Disopyramide - ","Sparfloxacin - ",e.DRUG_DRUG,i.CONTRAINDICATED," (     1)  ()          (IKr)      QT   .","Disopyramide (a Class Ia antiarrhythmic) and Sparfloxacin (a quinolone) both have a known property of inhibiting cardiac potassium channels (IKr), leading to dose-dependent QT interval prolongation.",'       QT              "  " (Torsades de Pointes).','This additive effect on QT prolongation drastically increases the risk of severe, life-threatening ventricular arrhythmias, chiefly "Torsades de Pointes."',"  .              QT         ( ).","Absolute Contraindication. The combination of the two drugs must be strictly avoided. Use an alternative antibiotic that does not significantly prolong the QT interval, such as cephalosporins or lower-risk quinolones (e.g., Levofloxacin).");n("Disopyramide - ","Rifampin - ",e.DRUG_DRUG,i.MODERATE,"      P450   CYP3A4         (   ).","Rifampin is a potent inducer of Cytochrome P450 enzymes, particularly CYP3A4, which is the primary enzyme responsible for the rapid metabolism (clearance) of Disopyramide.","                        .","Enzyme induction accelerates Disopyramide metabolism, causing its therapeutic plasma concentrations to decrease significantly, leading to a loss of its antiarrhythmic efficacy.","         (  ).                     .","Monitor Disopyramide plasma concentrations and cardiovascular status (e.g., ECG). A significant increase in the Disopyramide dose may be required during co-therapy, and the patient must be monitored after Rifampin discontinuation to reduce the dose.");n("Disulfiram","Ethanol (Alcohol)",e.DRUG_DRUG,i.HIGH,"  . Disulfiram        .","Disulfiram-like reaction. Disulfiram prevents alcohol metabolism, leading to acetaldehyde accumulation.","        (  ).","Flushing, palpitations, hypotension, severe nausea, and vomiting (potentially fatal)."," .        (          ).","Contraindicated. Avoid consuming alcohol in any form (including alcohol-containing medications and personal care products).");n("Dobutamine","Atenolol",e.DRUG_DRUG,i.HIGH,"     ","Beta-Receptor Antagonism. Competitive binding at beta-adrenergic receptors.","   ","   ","  ","  ");n("Dobutamine - ","Bisoprolol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).       -1     ()  .         .","Competitive Antagonism. Bisoprolol is a highly selective beta-1 receptor blocker, while Dobutamine is an agonist for these receptors. Bisoprolol competitively blocks the binding site of Dobutamine on myocardial cells.","         ( ).                     .","Cancellation or significant reduction of the positive inotropic therapeutic effect of Dobutamine (therapeutic failure). This results in failure to improve cardiac output and treat conditions of cardiogenic shock or acute heart failure, which is life-threatening.","  .         (   )          .","Avoid simultaneous use. In critical cases, a non-beta agonist (e.g., phosphodiesterase inhibitor) should be considered, or attempt gradual discontinuation of the beta-blocker, with intensive patient monitoring.");za.forEach(h=>{n("Dobutamine",h,e.DRUG_DRUG,i.HIGH,"  (Pharmacodynamic Antagonism).     -1     (Inotropy).            .","Pharmacodynamic Antagonism. Dobutamine acts as an agonist on Beta-1 receptors to increase cardiac contractility (Inotropy). Beta-blockers bind competitively to these same receptors, preventing Dobutamine from exerting its therapeutic effect.","            (    )   .","Abolition of Dobutamine's therapeutic effect, resulting in failure to support cardiac function (failure to increase cardiac output) and worsening heart failure.","          .                 .","Avoid concurrent use in acute shock or severe failure. Significantly higher doses of Dobutamine may be needed to overcome competitive blockade, requiring continuous hemodynamic monitoring.")});n("Docetaxel","Ritonavir",e.DRUG_DRUG,i.HIGH,"   CYP3A4","Severe CYP3A4 inhibition.","  ","Severe docetaxel toxicity."," ","Contraindicated.");n("Dofetilide","Verapamil (CCB)",e.DRUG_DRUG,i.HIGH,"  Dofetilide. Verapamil     (Renal Tubular Secretion).","Increased Dofetilide concentration. Verapamil inhibits renal tubular secretion.","    QT      (TdP).","Increased risk of life-threatening QT prolongation and Torsade de Pointes (TdP)."," .   .","Contraindicated. Avoid the combination.");n("Dolutegravir","Dofetilide",e.DRUG_DRUG,i.HIGH,"  Dofetilide. Dolutegravir   OAT2  OAT3    Dofetilide.","Increased Dofetilide concentration. Dolutegravir inhibits OAT2 and OAT3, a Dofetilide efflux pathway.","    QT      (Torsades de Pointes).","Increased risk of QT prolongation and Torsades de Pointes."," .   .","Contraindicated. Avoid the combination.");n("Dolutegravir","Iron/Calcium Supplements",e.DRUG_DRUG,i.HIGH,"  Dolutegravir.          .","Decreased Dolutegravir absorption. Formation of insoluble chelation compounds with polyvalent cations.","          .","Reduced drug plasma concentration, leading to viral treatment failure."," .      2    6     .","Dose separation. The two drugs must be separated by 2 hours before or 6 hours after supplement intake.");n("Dolutegravir","Dofetilide",e.DRUG_DRUG,i.HIGH,"  Dofetilide. Dolutegravir   OCT2.","Increased Dofetilide concentration. Dolutegravir inhibits OCT2.","    QT  .","Increased risk of life-threatening QT prolongation."," .   .","Contraindicated. Avoid the combination.");n("Dolutegravir","Metformin",e.DRUG_DRUG,i.MODERATE,"  Metformin. Dolutegravir   OCT2.","Increased Metformin concentration. Dolutegravir inhibits OCT2.","    (Lactic Acidosis).","Increased risk of Lactic Acidosis."," .    Metformin   .","Dose adjustment. Metformin dose must be reduced and renal function monitored.");n("Domperidone","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Bioavailability. Lower systemic exposure.","  ","  ","  ","  ");n("Domperidone","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Bioavailability. Lower systemic exposure.","  ","  ","  ","  ");n("Domperidone","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,"  ","Reduced Bioavailability. Lower systemic exposure.","  ","  ","  ","  ");n("Domperidone - ","Ketoconazole - ",e.DRUG_DRUG,i.HIGH,"  ()       P450 3A4     .         .","The inhibiting drug (Ketoconazole) potently and effectively inhibits the Cytochrome P450 3A4 enzyme, which is the major metabolic pathway for Domperidone. This inhibition significantly raises Domperidone plasma concentrations.","           QT     (ECG)            (   ).","The elevated Domperidone blood concentration leads to a critical prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes).","  .          .       CYP3A4.","Absolute Contraindication. The combination of Domperidone and Ketoconazole must be avoided due to the high risk of cardiotoxicity. A non-CYP3A4 inhibiting alternative should be used.");n("Domperidone - ","Itraconazole - ",e.DRUG_DRUG,i.HIGH,"  ()       P450 3A4     .         .","The inhibiting drug (Itraconazole) potently and effectively inhibits the Cytochrome P450 3A4 enzyme, which is the major metabolic pathway for Domperidone. This inhibition significantly raises Domperidone plasma concentrations.","           QT     (ECG)            (   ).","The elevated Domperidone blood concentration leads to a critical prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes).","  .          .       CYP3A4.","Absolute Contraindication. The combination of Domperidone and Itraconazole must be avoided due to the high risk of cardiotoxicity. A non-CYP3A4 inhibiting alternative should be used.");n("Domperidone - ","Clarithromycin - ",e.DRUG_DRUG,i.HIGH,"  ()       P450 3A4     .         .","The inhibiting drug (Clarithromycin) potently and effectively inhibits the Cytochrome P450 3A4 enzyme, which is the major metabolic pathway for Domperidone. This inhibition significantly raises Domperidone plasma concentrations.","           QT     (ECG)            (   ).","The elevated Domperidone blood concentration leads to a critical prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes).","  .          .         CYP3A4 ( ).","Absolute Contraindication. The combination of Domperidone and Clarithromycin must be avoided due to the high risk of cardiotoxicity. A non-CYP3A4 inhibiting antibiotic (e.g., Azithromycin) should be used.");n("Domperidone - ","Erythromycin - ",e.DRUG_DRUG,i.HIGH,"  ()       P450 3A4     .         .","The inhibiting drug (Erythromycin) potently and effectively inhibits the Cytochrome P450 3A4 enzyme, which is the major metabolic pathway for Domperidone. This inhibition significantly raises Domperidone plasma concentrations.","           QT     (ECG)            (   ).","The elevated Domperidone blood concentration leads to a critical prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes).","  .          .         CYP3A4.","Absolute Contraindication. The combination of Domperidone and Erythromycin must be avoided due to the high risk of cardiotoxicity. A non-CYP3A4 inhibiting antibiotic should be used.");n("Domperidone - ","Voriconazole - ",e.DRUG_DRUG,i.HIGH,"  ()       P450 3A4     .         .","The inhibiting drug (Voriconazole) potently and effectively inhibits the Cytochrome P450 3A4 enzyme, which is the major metabolic pathway for Domperidone. This inhibition significantly raises Domperidone plasma concentrations.","           QT     (ECG)            (   ).","The elevated Domperidone blood concentration leads to a critical prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes).","  .          .       CYP3A4.","Absolute Contraindication. The combination of Domperidone and Voriconazole must be avoided due to the high risk of cardiotoxicity. A non-CYP3A4 inhibiting alternative should be used.");n("Domperidone - ","Ritonavir -  ( )",e.DRUG_DRUG,i.HIGH,"  ()       P450 3A4     .         .","The inhibiting drug (Ritonavir) potently and effectively inhibits the Cytochrome P450 3A4 enzyme, which is the major metabolic pathway for Domperidone. This inhibition significantly raises Domperidone plasma concentrations.","           QT     (ECG)            (   ).","The elevated Domperidone blood concentration leads to a critical prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes).","  .       (     )    .","Absolute Contraindication. The combination of Domperidone and Ritonavir (or any other potent protease inhibitor) must be avoided due to the high risk of cardiotoxicity.");n("Donepezil","NSAIDs",e.DRUG_DRUG,i.MODERATE,"   . Donepezil               .","Increased risk of peptic ulcer. Donepezil increases gastric acid secretion via its cholinergic effect, and NSAIDs damage the gastric lining.","    .","Ulcer and gastrointestinal bleeding."," .     .","Symptom monitoring. Monitor for signs of gastrointestinal bleeding.");n("Dopamine - ","Atenolol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine - ","Bisoprolol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine - ","Carvedilol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine - ","Metoprolol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine - ","Propranolol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine - ","Nebivolol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine - ","Labetalol - ",e.DRUG_DRUG,i.HIGH,"  (Competitive Antagonism).     -1   .               .","Competitive Antagonism. Dopamine acts as an agonist for beta-1 receptors to increase cardiac contractility. Beta-blockers act as antagonists, blocking these receptors and preventing Dopamine from binding and activating them.","          ( )                   .","Cancellation or significant reduction of the therapeutic cardiac effect of Dopamine (therapeutic failure), leading to persistent low cardiac output and failure to raise blood pressure, which is critical and potentially fatal in shock settings.","  .                 (         )      .","Avoid simultaneous use. If cardiovascular support is needed in the presence of beta-blockers, a non-beta agonist (e.g., phenylephrine or other agents not dependent on beta-receptors) should be used, or the beta-blocker should be discontinued if possible.");n("Dopamine Agonists (Pramipexole, Ropinirole)","Psychotic Disorders / Schizophrenia",e.DRUG_DISEASE,i.HIGH,"   (Dopamine Receptors)       .","Stimulation of Dopamine Receptors, counteracting the effects of antipsychotics and exacerbating the illness.","   .","Exacerbation of psychosis, hallucinations, and delusions.","    .         .","Avoid in patients with active psychosis. Use with extreme caution in Parkinson's patients with psychiatric symptoms.");n("Doravirine (Pifeltro)","Rifampin",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.   Doravirine  88%.","Mechanism: **Potent CYP3A4 induction**. Doravirine concentration decreases by 88%."," : **     **  .","Clinical Significance: **HIV treatment failure** and viral resistance."," .  Rifabutin  300 mg     Doravirine  100 mg  .","Contraindicated. Use Rifabutin 300 mg daily with increased Doravirine dose to 100 mg twice daily.");n("Dorzolamide","Oral Carbonic Anhydrase Inhibitors",e.DRUG_DRUG,i.MODERATE," ","Synergistic effect."," ","Metabolic acidosis."," ","Avoid combination.");n("Dostarlimab","Prednisone",e.DRUG_DRUG,i.MODERATE,"   . Dostarlimab   Prednisone () .","Conflict in immune effects. Dostarlimab activates immunity, while Prednisone (corticosteroid) suppresses it.","  Dostarlimab.        .","Reduced Dostarlimab efficacy. Immunosuppression by the corticosteroid may reduce the therapeutic response.",".             .","Caution. High doses of systemic corticosteroids should be avoided except for managing immune-related adverse reactions.");n("Doxazosin","Sildenafil",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic vasodilation.","   ","Orthostatic hypotension.","     (25 )","Start low sildenafil dose (25mg).");n("Doxorubicin","Trastuzumab",e.DRUG_DRUG,i.HIGH,"  ","Synergistic cardiotoxicity."," ","Heart failure.","   -    ","Monitor cardiac function - avoid if possible.");n("Doxycycline","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Doxycycline","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Doxycycline","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Doxycycline","Iron Supplements",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Doxycycline","Dairy Products",e.DRUG_FOOD,i.MODERATE," .","Calcium Binding. Formation of insoluble complexes."," ."," ."," ."," .");n("Doxycycline","Ferrous Sulfate",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      (3-4) .       .","      (3-4) .       .");n("Doxycycline","Ferrous Gluconate",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      (3-4) .       .","      (3-4) .       .");n("Doxycycline","Bismuth Salts",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      .","      .");n("Doxycycline","Phenobarbital",e.DRUG_DRUG,i.MODERATE,"   ","Reduced Doxycycline Levels. Enhanced metabolism shortens half-life.","    .","Treatment Failure. Persistent infection.","     .   .","     .   .");n("Doxycycline","Pentobarbital",e.DRUG_DRUG,i.MODERATE,"   ","Reduced Doxycycline Levels. Enhanced metabolism shortens half-life.","    .","Treatment Failure. Persistent infection.","     .   .","     .   .");n("Doxycycline","Secobarbital",e.DRUG_DRUG,i.MODERATE,"   ","Reduced Doxycycline Levels. Enhanced metabolism shortens half-life.","    .","Treatment Failure. Persistent infection.","     .   .","     .   .");n("Doxycycline","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"   ","Reduced Doxycycline Levels. Enhanced metabolism shortens half-life.","    .","Treatment Failure. Persistent infection.","   .   .","   .   .");n("Doxycycline","Hydantoins",e.DRUG_DRUG,i.MODERATE,"   ","   ","    .","Treatment Failure. Persistent infection.","      .   .","      .   .");n("Doxycycline","Rifamycins",e.DRUG_DRUG,i.MODERATE,"   ","Reduced Doxycycline Levels. Enhanced metabolism shortens half-life.","    .","Treatment Failure. Persistent infection.","      .   .","      .   .");n("Doxycycline","Dairy Products",e.DRUG_FOOD,i.MODERATE,"  Doxycycline.      .","Decreased Doxycycline absorption. Calcium chelates Doxycycline in the gastrointestinal tract.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   Doxycycline  1-2    4    .","Dose separation. Doxycycline must be taken 1-2 hours before or 4 hours after dairy products.");n("Doxycycline","Dairy Products",e.DRUG_FOOD,i.MODERATE,"      ","Calcium in dairy forms complexes with tetracycline.","    50-80%","Reduced doxycycline absorption by 50-80%.","      ","Avoid dairy within 2 hours of dose.");n("Doxycycline","Alcohol",e.DRUG_FOOD,i.HIGH,": **  **.           .","Mechanism: **Hepatic Metabolism Induction**. Alcohol accelerates Doxycycline metabolism by inducing liver enzymes.",": **    **         .","Result: **Rapid decrease in Doxycycline concentration** in the blood, leading to antibiotic treatment failure.",":     .         .","Management: Strictly avoid alcohol during therapy. Higher doses may be required for chronic alcohol users.");n("Doxycycline","Caffeine",e.DRUG_FOOD,i.MODERATE,":      .      .","Mechanism: No known direct metabolic interaction. Interaction is limited to potential side effects.",":               .","Result: May increase Doxycycline side effects like nausea or anxiety, but without affecting efficacy.",":  .       .","Management: Monitor symptoms. No need for separation or dose adjustment.");n("Doxycycline","Grapefruit Juice",e.DRUG_FOOD,i.LOW,":  CYP3A4.       CYP3A4    .","Mechanism: CYP3A4 Inhibition. Doxycycline does not rely heavily on CYP3A4 for metabolism, thus the interaction is low.",":          .","Result: No clinically significant effect on Doxycycline absorption or efficacy.",":    .","Management: No routine adjustment required.");n("Doxycycline","Green Tea",e.DRUG_FOOD,i.HIGH,": ** ** (Chelation)   (    )       .","Mechanism: **Chelation** with minerals (if tea contains them) or interference with polyphenols that hinder absorption.",": **    **   .","Result: **Significant reduction in Doxycycline absorption** and decreased therapeutic efficacy.",":        2-3   .","Management: Advise separation of doses and Green Tea by at least 2-3 hours.");n("Doxycycline","Milk",e.DRUG_FOOD,i.MODERATE,": ** ** (Chelation).  (Ca)        .","Mechanism: **Chelation**. Calcium (Ca) in milk binds to Doxycycline in the GI tract.",":       .","Result: Reduced Doxycycline absorption and decreased blood concentration.",":           .","Management: Advise separation of the drug dose and dairy products by at least two hours.");n("Doxycycline","High-fat meals",e.DRUG_FOOD,i.LOW,":           .       .","Mechanism: Mild to moderate meals do not significantly affect Doxycycline absorption. A heavy fatty meal may slightly delay absorption.",":       .","Result: No clinically significant effect on efficacy.",":         .","Management: Doxycycline can be taken with a meal to alleviate gastric irritation.");n("Doxycycline","High-fiber foods",e.DRUG_FOOD,i.HIGH,": **   **.            .","Mechanism: **Binding in the GI tract**. Fiber may hinder drug absorption through physical interference or reduced contact time.",":      .","Result: Reduced Doxycycline absorption and decreased efficacy.",":           .","Management: Advise separation of the drug and high-fiber foods by at least two hours.");n("Doxycycline","Vitamin C",e.DRUG_FOOD,i.MODERATE,":    .   C            .","Mechanism: No direct interaction. However, high doses of Vitamin C may alter urine pH, potentially affecting drug clearance.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Doxycycline","Vitamin D",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Doxycycline","Vitamin E",e.DRUG_FOOD,i.HIGH,":    .          E     .","Mechanism: No known interaction. Interaction is hypothetically due to Vitamin E's effect on bioavailability or clearance.",":             .","Result: No expected clinical effect, but monitor drug efficacy if changes are noted.",":  .","Management: Routine monitoring.");n("Doxycycline","Vitamin K",e.DRUG_FOOD,i.MODERATE,":    .         K      .","Mechanism: No direct interaction. Doxycycline may affect gut flora producing Vitamin K, but interaction with supplementary Vitamin is moderate.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Doxycycline","Vitamin B12",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Doxycycline","Folic Acid",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":          .","Result: No expected clinical effect, but monitor drug efficacy.",":  .","Management: Routine monitoring.");n("Doxycycline","Iron",e.DRUG_FOOD,i.MODERATE,": ** ** (Chelation).   (Fe)     .","Mechanism: **Chelation**. Iron ions (Fe) bind to Doxycycline in the GI tract.",":       .","Result: Reduced Doxycycline absorption and decreased blood concentration.",":           2-3   .","Management: Doses and Iron-containing supplements must be separated by at least 2-3 hours.");n("Doxycycline","Calcium",e.DRUG_FOOD,i.LOW,": ** ** (Chelation).   (Ca)         .","Mechanism: **Chelation**. Calcium ions (Ca) bind to Doxycycline, but the interaction is low compared to other Tetracyclines.",":     .","Result: Slight reduction in Doxycycline absorption.",":         .","Management: Separate doses and Calcium sources by at least two hours.");n("Doxycycline","Magnesium",e.DRUG_FOOD,i.HIGH,": ** ** (Chelation).   (Mg)      .","Mechanism: **Chelation**. Magnesium ions (Mg) strongly bind to Doxycycline in the GI tract.",": **     **   .","Result: **Very significant reduction in Doxycycline absorption** and decreased therapeutic efficacy.",":           2-3   .","Management: Doses and Magnesium-containing supplements must be separated by at least 2-3 hours.");n("Doxycycline","Zinc",e.DRUG_FOOD,i.MODERATE,": ** ** (Chelation).   (Zn)     .","Mechanism: **Chelation**. Zinc ions (Zn) bind to Doxycycline in the GI tract.",":       .","Result: Reduced Doxycycline absorption and decreased blood concentration.",":        2-3   .","Management: Doses and Zinc supplements must be separated by at least 2-3 hours.");n("Doxycycline","Potassium",e.DRUG_FOOD,i.LOW,":    .   (K)     .","Mechanism: No known interaction. Potassium ions (K) are monovalent and do not chelate Doxycycline.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Doxycycline","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,": **  **.      (pH)         .","Mechanism: **Increased gastric pH**. Sodium Bicarbonate raises the pH in the stomach, which decreases Doxycycline solubility and absorption.",": **    **   .","Result: **Significant reduction in Doxycycline absorption** and potential treatment failure.",":        2-3   .","Management: Separate doses and Sodium Bicarbonate by at least 2-3 hours.");n("Doxycycline","Antacids",e.DRUG_FOOD,i.MODERATE,": ** ** (Chelation)  ** **.      Mg/Al      .","Mechanism: **Chelation** and **pH increase**. Antacids contain Mg/Al ions that bind the drug and raise pH.",":       .","Result: Reduced Doxycycline absorption and decreased blood concentration.",":        2-3   .","Management: Separate doses and Antacids by at least 2-3 hours.");n("Doxycycline - ","Amoxicillin - ",e.DRUG_DRUG,i.MODERATE,"                  (chelation).                     .                          .","Amoxicillin reduces the bioavailability of Doxycycline by binding to it in the gastrointestinal tract and forming non-absorbable complexes (chelation). Although this mechanism is more common with divalent cations, penicillins can interfere with tetracycline absorption. Additionally, when Doxycycline is used as a bactericidal agent and Amoxicillin as a bacteriostatic agent, antimicrobial antagonism may occur, reducing overall efficacy against some organisms.","                   (  ).        antagonism             .            .","The primary risk is reduced therapeutic levels of Doxycycline, potentially leading to treatment failure in conditions like intracellular infections (e.g., Chlamydia, Rickettsia). Amoxicillin efficacy may also decrease due to potential antagonism between bactericidal and bacteriostatic agents, especially in infections requiring bactericidal action. There is also a risk of increased gastrointestinal side effects due to disruption of natural flora.","1.   :                . 2.  :          . 3.  :          . 4. :           (   ). 5.    :           .","1. Dosing Separation: Administer Doxycycline at least 2 hours before or 2 hours after Amoxicillin to reduce GI interaction. 2. Clinical Monitoring: Closely monitor patient response to therapy, especially in severe infections. 3. Dose Adjustment: May need to increase Doxycycline dose if combination is necessary. 4. Alternatives: Consider using an alternative antibiotic that doesn`t interact with Doxycycline (e.g., macrolides for some infections). 5. Avoid Unnecessary Combination: Do not combine unless there is proven benefit outweighing risks.");n("Doxycycline - ","Ampicillin - ",e.DRUG_DRUG,i.MODERATE,"       :          antagonism   .           30-50.         (  )      .","Ampicillin interferes with Doxycycline absorption through two mechanisms: formation of non-absorbable complexes in the GI tract, and potential antimicrobial antagonism. Ampicillin reduces Doxycycline plasma concentrations by up to 30-50%. This interaction occurs regardless of administration route (oral or IV) due to Ampicillin`s biliary excretion into the intestines.","                      .             .            .","Potential treatment failure in infections requiring high Doxycycline levels such as Lyme disease, Rocky Mountain spotted fever, or Ampicillin-resistant bacterial infections. May also reduce Ampicillin efficacy in infections requiring bactericidal action. Increased risk of antibiotic-associated diarrhea due to excessive elimination of natural flora.","1.  :    3       . 2.  :       . 3.     :           . 4.  :            . 5.  :          .","1. Timing Separation: Administer Doxycycline at least 3 hours before or after Ampicillin. 2. Drug Monitoring: Monitor Doxycycline plasma levels if possible. 3. Avoid Combination in Critical Infections: Do not use together in meningitis, endocarditis, or sepsis. 4. Use Alternatives: For mixed infections, choose compatible antibiotic combinations like ceftriaxone with doxycycline. 5. Symptom Monitoring: Watch for treatment failure signs like persistent fever or worsening symptoms.");n("Doxycycline - ","Penicillin V -  V",e.DRUG_DRUG,i.MODERATE,"  V                  .            V   .        20-40   .","Penicillin V reduces Doxycycline absorption primarily through physical interaction in the gastrointestinal tract, forming insoluble complexes. Also, Doxycycline`s bacteriostatic nature may antagonize Penicillin V`s bactericidal action against susceptible bacteria. A 20-40% decrease in Doxycycline bioavailability occurs when taken together.","                 .     V          .           .","Reduced Doxycycline efficacy in treating infections requiring consistent drug levels like chronic acne, gonorrhea, or Chlamydia. Diminished prophylactic efficacy of Penicillin V in rheumatic fever prevention or strep throat treatment. Increased risks of bacterial resistance development due to subtherapeutic dosing of both drugs.","1.   :         V. 2.     :        . 3.   :     . 4.   :          . 5.  :          .","1. Strict Dosing Separation: Take Doxycycline at least 2 hours before Penicillin V. 2. Prioritize Key Medication: In combination therapy, identify the primary drug and administer it first. 3. Monitor Clinical Response: Frequently assess infection response. 4. Adjust Treatment Duration: May need to extend treatment duration if combination is necessary. 5. Penicillin Alternatives: Use macrolides like erythromycin as alternatives if interactions are problematic.");n("Doxycycline - ","Penicillin G -  G",e.DRUG_DRUG,i.MODERATE,"    G                    .        antagonism          G            .","Even when Penicillin G is administered by injection, it can reduce Doxycycline levels due to its biliary and intestinal excretion where it interacts with orally administered Doxycycline. Additionally, antimicrobial antagonism can occur when bacteriostatic Doxycycline is used with bactericidal Penicillin G, especially against fast-growing bacteria like Streptococci and Gonococci.","            Actinomycosis      .          .                  .","Serious therapeutic failure in life-threatening infections like disseminated gonorrhea, syphilis, or Actinomycosis where this combination is sometimes used. Reduction of Doxycycline concentrations below therapeutic levels in intracellular infections. Slowed bacterial eradication in infective endocarditis or bacterial meningitis where bactericidal action is critical.","1.     :       . 2.   :    4        G. 3.   :       . 4.    :           . 5.   :      .","1. Avoid Combination in Critical Infections: Do not use together in life-threatening infections. 2. Enhanced Timing Separation: Administer Doxycycline at least 4 hours before IV Penicillin G doses. 3. Intensive Drug Monitoring: Measure levels of both drugs in critical cases. 4. Use Bactericidal Alternatives: Replace Doxycycline with a bactericidal agent like ceftriaxone when synergistic action is needed. 5. Monitor Clinical Indicators: Closely track clinical and laboratory improvement markers.");n("Dronabinol","CNS Depressants",e.DRUG_DRUG,i.MODERATE," CNS ","Synergistic CNS depression."," ","Severe drowsiness."," ","Warn patient.");n("Dronedarone","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Dronedarone. Ketoconazole    CYP3A4    Dronedarone.","Increased Dronedarone concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Dronedarone metabolic pathway.","    QT        .","Increased risk of QT prolongation, raising the risk of arrhythmias."," .    CYP3A4 .","Contraindicated. Strong CYP3A4 inhibitors must be avoided.");n("Dronedarone","Verapamil",e.DRUG_DRUG,i.HIGH,"  .         .","Exacerbated Bradycardia. Both drugs have a heart rate lowering effect.","      .","Increased risk of severe bradycardia and cardiac arrest."," .   .","Contraindicated. Avoid the combination.");n("Dronedarone","Digoxin",e.DRUG_DRUG,i.HIGH,"  Digoxin. Dronedarone    P-glycoprotein (P-gp)    Digoxin.","Increased Digoxin concentration. Dronedarone is a P-glycoprotein (P-gp) inhibitor, a Digoxin efflux transporter.","   Digoxin (      ).","Increased risk of Digoxin toxicity (e.g., bradycardia and arrhythmias)."," .    Digoxin  50%    .","Dose adjustment. Digoxin dose must be reduced by 50% and its serum levels monitored.");n("Dronedarone","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Dronedarone. Ketoconazole    CYP3A4.","Increased Dronedarone concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    QT    (Torsade de Pointes).","Increased risk of QT prolongation and Torsade de Pointes."," .   .","Contraindicated. Avoid the combination.");n("Dronedarone","Digoxin",e.DRUG_DRUG,i.HIGH,"  Digoxin. Dronedarone   P-gp.","Increased Digoxin concentration. Dronedarone inhibits P-gp.","   Digoxin (  ).","Increased risk of Digoxin toxicity (severe bradycardia)."," .    Digoxin     Dronedarone.","Dose adjustment. Digoxin dose must be halved upon initiation of Dronedarone.");n("Duloxetine - ","Ciprofloxacin - ",e.DRUG_DRUG,i.MODERATE,"    Duloxetine   Ciprofloxacin    CYP1A2    .","Ciprofloxacin is a strong CYP1A2 inhibitor, which significantly increases Duloxetine plasma levels.","             .","Marked increase in the risk of serotonergic adverse effects such as tremor, anxiety, sweating, and BP changes.","           Duloxetine     .","Requires very close monitoring. Watch for neurological/serotonergic toxicity and reduce Duloxetine dose if needed.");n("Dupilumab (Dupixent)","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,": ** **. Dupilumab   .","Mechanism: **Immune modulation**. Dupilumab modulates immune response."," : **  ** .","Clinical Significance: **Potential reduced vaccine efficacy**.","     .   .","Vaccinate before starting therapy if possible. Avoid live vaccines.");n("Dupilumab (Dupixent)","Parasitic Infections ( )",e.DRUG_DISEASE,i.MODERATE,": ** IL-4/IL-13**.     .","Mechanism: **IL-4/IL-13 Inhibition**. May impair immune response to parasites."," : ** **   .","Clinical Significance: **Uncontrolled parasitic infection**.","     Dupilumab.","Treat parasitic infections before starting Dupilumab.");n("Durvalumab (PD-L1)","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  .            .","Increased risk of infection. Immune checkpoint inhibitors may increase the risk of infection with live vaccines.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Duvelisib (Copiktra)","CMV Prophylaxis",e.DRUG_DISEASE,i.HIGH,": **  **.    CMV .","Mechanism: **Severe immunosuppression**. Risk of latent CMV reactivation."," : **   CMV**  .","Clinical Significance: **Life-threatening CMV colitis**.","  CMV.  PCR  .   Valganciclovir    .","Monitor CMV symptoms. PCR testing when suspected. Prophylaxis with Valganciclovir in high-risk patients.");n("Echinacea","Immunosuppressants",e.DRUG_DRUG,i.MODERATE," ","Immune stimulation.","  ","Antagonistic effect."," ","Avoid combination.");n("Edoxaban","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Edoxaban. Cyclosporine   P-glycoprotein (P-gp)    Edoxaban.","Increased Edoxaban concentration. Cyclosporine inhibits P-glycoprotein (P-gp), an Edoxaban efflux transporter.","  .","Increased risk of hemorrhage."," .    Edoxaban     P-gp .","Dose adjustment. Edoxaban dose must be reduced when co-administered with strong P-gp inhibitors.");n("Edoxaban","Verapamil",e.DRUG_DRUG,i.MODERATE," P-gp","P-glycoprotein inhibition.","  ","Increased edoxaban levels.","  ","Reduce edoxaban dose.");n("Edoxaban (DOAC)","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Edoxaban. Cyclosporine   P-gp    Edoxaban.","Increased Edoxaban concentration. Cyclosporine inhibits P-gp, an Edoxaban efflux transporter.","  .","Increased risk of hemorrhage."," .    Edoxaban  ( 30  )    Cyclosporine.","Dose adjustment. The usual Edoxaban dose must be reduced (to 30 mg daily) when co-administered with Cyclosporine.");n("Efavirenz","High-Fat Meal",e.DRUG_FOOD,i.MODERATE,"   Cmax  79%  AUC  28% -     ","High-fat meal increases Cmax by 79% and AUC by 28% - increasing the risk of nervous system side effects","   -     ","Increased drug level - risk of dizziness, hallucination, and sleep disorders","         ","Preferably taken on an empty stomach before bedtime to minimize CNS side effects");n("Efavirenz","Ethinyl Estradiol",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 induction reduces estrogen levels.","   ","Contraceptive failure.","      ","Use backup method or increase estrogen dose.");n("Elacestrant","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Elacestrant. Ketoconazole     CYP3A4      Elacestrant.","Increased Elacestrant toxicity. Ketoconazole is a strong inhibitor of CYP3A4, the primary metabolic pathway for Elacestrant.","                 QT.","Acute rise in drug plasma concentration, increasing the risk of serious side effects like QT prolongation."," .        Elacestrant   (   75%).","Avoid Combination. If co-administration is necessary, Elacestrant dose must be significantly reduced (up to 75%).");n("Elagolix","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Elagolix. Cyclosporine   OATP1B1    Elagolix.","Increased Elagolix concentration. Cyclosporine inhibits OATP1B1, an Elagolix uptake transporter.","    .","Increased risk of elevated liver enzymes."," .   .","Contraindicated. Avoid the combination.");n("Elexacaftor/Tezacaftor/Ivacaftor","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  . Ketoconazole    CYP3A4     .","Increased component concentration. Ketoconazole is a strong CYP3A4 inhibitor, a metabolic pathway for all three components.","          QT.","Increased risk of side effects, especially elevated liver enzymes and QT prolongation."," .          CYP3A4 .","Dose adjustment. The combined therapy dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Elexacaftor/Tezacaftor/Ivacaftor","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Elexacaftor/Tezacaftor   P-gp    Digoxin.","Decreased Digoxin concentration. Elexacaftor/Tezacaftor are P-gp inducers, a Digoxin efflux transporter.","  Digoxin              .","Reduced Digoxin efficacy, potentially leading to failure of heart failure control or arrhythmia."," .    Digoxin      .","Level monitoring. Digoxin serum levels must be monitored and dose adjusted to ensure efficacy.");n("Elexacaftor/Tezacaftor/Ivacaftor","Phenytoin",e.DRUG_DRUG,i.HIGH,"   . Phenytoin    CYP3A4.","Decreased concentration of all components. Phenytoin is a strong CYP3A4 inducer.","    .","Reduced efficacy of cystic fibrosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Elexacaftor/Tezacaftor/Ivacaftor","Rifampin",e.DRUG_DRUG,i.HIGH,"   . Rifampin    CYP3A4.","Decreased concentration of all components. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug efficacy, leading to failure of cystic fibrosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Elexacaftor/Tezacaftor/Ivacaftor","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Ivacaftor  Elexacaftor.      CYP3A4.","Increased Ivacaftor and Elexacaftor concentration. Grapefruit juice is a CYP3A4 inhibitor.","    (   ).","Increased risk of side effects (e.g., elevated liver enzymes).","  .       .","Avoid concurrent consumption. Grapefruit juice must be avoided during therapy.");n("Elranatamab (Elrexfio)","Cytokine Release Syndrome Risk Factors",e.DRUG_DISEASE,i.HIGH,": **  **.    .","Mechanism: **Excessive immune activation**. Cytokine release syndrome risk."," : **  **      .","Clinical Significance: **Severe cytokine release syndrome** with fever and hypotension.","    .  Tocilizumab .","Close monitoring during initial doses. Tocilizumab availability for emergencies.");n("Elvitegravir/Cobicistat","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Elvitegravir  Cobicistat. Phenytoin    CYP3A4.","Decreased Elvitegravir and Cobicistat concentrations. Phenytoin is a strong inducer of CYP3A4.","     .","Reduced efficacy of viral treatment and resistance development."," .   .","Contraindicated. Avoid the combination.");n("Empagliflozin","Food",e.DRUG_FOOD,i.LOW,"  Cmax  37%  Tmax     AUC","Food decreases Cmax by 37% and delays Tmax but does not affect AUC","       ","No clinical effect on overall blood sugar-lowering efficacy","     -  ","Can be taken with or without food - preferably in the morning");n("Empagliflozin","Diuretics",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic diuretic effect.","   ","Dehydration and hypotension.","    ","Monitor volume status and BP.");n("Empagliflozin (SGLT2)","Lisinopril",e.DRUG_DRUG,i.MODERATE,"    .          SGLT2.","Increased risk of hypotension. Additive antihypertensive effect due to SGLT2-induced volume depletion.","      .","Risk of hypotension, especially orthostatic.","  .        Empagliflozin.","Blood pressure monitoring. Blood pressure must be monitored, especially upon initiation of Empagliflozin.");n("Enalapril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Enalapril","Spironolactone",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Enalapril","Eplerenone",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Enalapril","Amiloride",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Enalapril","Aspirin",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Ibuprofen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Diclofenac",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Naproxen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Ketoprofen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Indomethacin",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Celecoxib",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Enalapril","Spironolactone",e.DRUG_DRUG,i.HIGH,"  ","Synergistic potassium accumulation.","  -   ","Hyperkalemia - fatal arrhythmia.","   -    ","Close K+ monitoring - especially in renal impairment.");n("Enalapril","Naproxen",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of antihypertensive effect.","  ","Elevated blood pressure."," NSAID    ","Use lowest NSAID dose for shortest duration.");n("Enasidenib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Enasidenib. Carbamazepine    CYP3A4.","Decreased Enasidenib concentration. Carbamazepine is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Enasidenib (Idhifa)","Hormonal Contraceptives",e.DRUG_DRUG,i.MODERATE,": **  UGT**.    .","Mechanism: **UGT enzyme induction**. Decreased sex hormone concentration."," : **    **.","Clinical Significance: **Potential contraceptive failure**.","      .","Use additional non-hormonal contraception.");n("Encorafenib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Encorafenib. Ketoconazole     CYP3A4      Encorafenib.","Increased Encorafenib concentration. Ketoconazole is a strong inhibitor of CYP3A4, the primary metabolic pathway for Encorafenib.","    QT       Encorafenib.","Increased risk of QT prolongation, cardiotoxicity, and other Encorafenib side effects."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Encorafenib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Encorafenib. Phenytoin    CYP3A4    Encorafenib.","Decreased Encorafenib efficacy. Phenytoin is a strong inducer of CYP3A4, an Encorafenib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Encorafenib","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Encorafenib. Diltiazem    CYP3A4    Encorafenib.","Increased Encorafenib concentration. Diltiazem is a moderate CYP3A4 inhibitor, an Encorafenib metabolic pathway.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .    Encorafenib     CYP3A4 .","Dose adjustment. Encorafenib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Encorafenib","Binimetinib",e.DRUG_DRUG,i.HIGH,"   .          .","Increased risk of combined toxicity. They are used together but increase the risk of cardiotoxicity and hemorrhage.","          .","Increased risk of cardiomyopathy and hemorrhage, requiring strict dosing protocols."," ECG.           .","ECG monitoring. Cardiac function and bleeding must be closely monitored and approved dosing protocol adhered to.");n("Encorafenib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Encorafenib.      CYP3A4    Encorafenib.","Increased Encorafenib concentration. Grapefruit juice inhibits CYP3A4, an Encorafenib metabolic pathway.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Encorafenib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Encorafenib. Phenytoin    CYP3A4    Encorafenib.","Decreased Encorafenib efficacy. Phenytoin is a strong inducer of CYP3A4, an Encorafenib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Encorafenib","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Encorafenib    CYP3A4    Midazolam.","Decreased Midazolam concentration. Encorafenib is a strong inducer of CYP3A4, a Midazolam metabolic pathway.","  Midazolam.","Reduced efficacy of Midazolam."," .    Midazolam   .","Dose adjustment. Midazolam dose must be increased or alternatives used.");n("Encorafenib","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Encorafenib    CYP3A4.","Decreased Midazolam concentration. Encorafenib is a strong inducer of CYP3A4.","  Midazolam ().","Reduced efficacy of Midazolam (sedative)."," .     CYP3A4    .","Avoid combination. Avoid sensitive CYP3A4 substrates with narrow therapeutic window.");n("Enfortumab Vedotin","Midazolam",e.DRUG_DRUG,i.MODERATE,"  Midazolam. Enfortumab Vedotin     CYP3A4     Midazolam.","Increased Midazolam levels. Enfortumab Vedotin is a moderate inhibitor of CYP3A4, reducing Midazolam metabolism.","   Midazolam ()       .","Enhanced effect of Midazolam (sedative), potentially increasing the risk of over-sedation."," .    Midazolam       Enfortumab Vedotin.","Dose adjustment. Oral Midazolam dose should be reduced when used concomitantly with Enfortumab Vedotin.");n("Enoxaparin","Clopidogrel",e.DRUG_DRUG,i.HIGH,"   ","Synergistic bleeding effect."," ","Severe bleeding.","  -     ACS","Close monitoring - may be necessary in ACS.");n("Entacapone","Phenelzine (MAOI)",e.DRUG_DRUG,i.HIGH,"       . Entacapone  COMT     .","Increased risk of hypertension and tachycardia. Entacapone inhibits COMT, increasing catecholamine levels.","   .","Severe hypertension."," .   .","Contraindicated. Avoid the combination.");n("Entrectinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Carbamazepine    CYP3A4    Entrectinib.","Decreased Entrectinib efficacy. Carbamazepine is a strong inducer of CYP3A4, an Entrectinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Entrectinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Itraconazole    CYP3A4    Entrectinib.","Increased Entrectinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Entrectinib.","       QT    .","Increased risk of side effects, especially QT prolongation, neurotoxicity, and weight gain."," .    Entrectinib     CYP3A4 .","Dose adjustment. Entrectinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Entrectinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Rifampin    CYP3A4    Entrectinib.","Decreased Entrectinib efficacy. Rifampin is a strong inducer of CYP3A4, an Entrectinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Entrectinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Phenytoin    CYP3A4    Entrectinib.","Decreased Entrectinib efficacy. Phenytoin is a strong inducer of CYP3A4, an Entrectinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Entrectinib","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  Entrectinib. Diltiazem    CYP3A4    Entrectinib.","Increased Entrectinib concentration. Diltiazem is a moderate CYP3A4 inhibitor, an Entrectinib metabolic pathway.","       QT.","Increased risk of side effects, especially QT prolongation."," .    Entrectinib     CYP3A4 .","Dose adjustment. Entrectinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Entrectinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Voriconazole    CYP3A4    Entrectinib.","Increased Entrectinib concentration. Voriconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Entrectinib.","       QT    .","Increased risk of side effects, especially QT prolongation, neurotoxicity, and weight gain."," .    Entrectinib     CYP3A4 .","Dose adjustment. Entrectinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Entrectinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Entrectinib.       CYP3A4  .","Increased Entrectinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","       QT    .","Increased risk of side effects, especially QT prolongation, neurotoxicity, and weight gain."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Entrectinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Carbamazepine    CYP3A4    Entrectinib.","Decreased Entrectinib concentration. Carbamazepine is a strong inducer of CYP3A4, an Entrectinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Entrectinib","Ritonavir",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Ritonavir    CYP3A4.","Increased Entrectinib concentration. Ritonavir is a strong inhibitor of CYP3A4.","     .","Increased risk of neurological and cardiac side effects.","  .    CYP3A4 .","Relative contraindication. Strong CYP3A4 inhibitors must be avoided.");n("Entrectinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Carbamazepine    CYP3A4.","Decreased Entrectinib concentration. Carbamazepine is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Entrectinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Entrectinib. Ketoconazole    CYP3A4.","Increased Entrectinib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","       .","Increased risk of neurotoxicity, especially extrapyramidal symptoms."," .    Entrectinib  .","Dose adjustment. Entrectinib dose must be significantly reduced.");n("Enzalutamide","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Enzalutamide     CYP3A4    Midazolam.","Decreased Midazolam concentration. Enzalutamide is a potent CYP3A4 inducer, a Midazolam metabolic pathway.","  Midazolam ()      .","Reduced efficacy of Midazolam (sedative), potentially leading to failure of sedation."," .           CYP3A4.","Avoid Combination. Narrow therapeutic index drugs metabolized by CYP3A4 must be avoided.");n("Enzalutamide","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Omeprazole. Enzalutamide     CYP2C19    Omeprazole.","Decreased Omeprazole concentration. Enzalutamide is a potent CYP2C19 inducer, an Omeprazole metabolic pathway.","  Omeprazole        .","Reduced efficacy of Omeprazole, leading to failure of gastric acid control."," .           CYP2C19.","Avoid Combination. Narrow therapeutic index drugs metabolized by CYP2C19 must be avoided.");n("Enzalutamide","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin. Enzalutamide    CYP2C9  CYP3A4    Warfarin.","Decreased Warfarin efficacy. Enzalutamide is a potent inducer of CYP2C9 and CYP3A4, which are Warfarin metabolic pathways.","   Warfarin        .","Reduced Warfarin anticoagulant effect, increasing the risk of thrombosis and embolism."," INR.    INR    Warfarin  .","INR monitoring. INR must be regularly monitored and Warfarin dose significantly increased.");n("Enzalutamide","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Enzalutamide     CYP3A4    Simvastatin.","Decreased Simvastatin concentration. Enzalutamide is a potent CYP3A4 inducer, a Simvastatin metabolic pathway.","  Simvastatin         .","Reduced Simvastatin efficacy, increasing the risk of hypercholesterolemia and cardiovascular events."," .    Simvastatin       CYP3A4.","Dose adjustment. Simvastatin dose must be increased or a statin not metabolized by CYP3A4 must be used.");n("Enzalutamide","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Enzalutamide    CYP3A4    Midazolam.","Decreased Midazolam concentration. Enzalutamide is a strong inducer of CYP3A4, a Midazolam metabolic pathway.","  Midazolam ().","Reduced efficacy of Midazolam (sedative).","    .     CYP3A4         .","Avoid combination or dose adjustment. Avoid sensitive CYP3A4 substrates with narrow therapeutic window, or increase dose significantly.");n("Enzalutamide","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin. Enzalutamide    CYP3A4  CYP2C9.","Decreased Warfarin concentration. Enzalutamide is a strong inducer of CYP3A4 and CYP2C9.","  Warfarin     .","Reduced Warfarin efficacy, leading to risk of thrombosis."," .  INR     Warfarin.","Close monitoring. Monitor INR frequently and adjust Warfarin dose.");n("Enzalutamide","Warfarin",e.DRUG_DRUG,i.HIGH," CYP2C9","CYP2C9 induction."," INR","Decreased INR.","  ","Increase warfarin dose.");n("Enzalutamide - ","Fentanyl - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4              ","Enzalutamide is a potent inducer of hepatic and intestinal CYP3A4 enzyme, the primary metabolic pathway for Fentanyl, significantly increasing its metabolic clearance","        50-70               ","Substantial decrease in Fentanyl plasma concentration by 50-70%, leading to pain control failure, opioid withdrawal symptoms, and need for more frequent higher doses","    2-3    -     4-6  -         CYP3A4    ","Increase Fentanyl dose by 2-3 fold and divide doses - monitor pain level every 4-6 hours - switch to alternative opioids not dependent on CYP3A4 like morphine or oxycodone");n("Epcoritamab (Epkinly)","Live Vaccines",e.DRUG_VACCINE,i.HIGH,": **  **.      .","Mechanism: **B-cell depletion**. Causes severe B-cell deficiency."," : **  **    .","Clinical Significance: **Immune response failure** to vaccines and vaccine disease risk.","   .     4   .","Contraindicated for live vaccines. Vaccinate at least 4 weeks before therapy.");n("Epcoritamab (Epkinly)","Anticoagulants (Warfarin)",e.DRUG_DRUG,i.MODERATE,": **  **.     .","Mechanism: **Hepatic enzyme modulation**. May alter anticoagulant metabolism."," : **  INR**    .","Clinical Significance: **INR fluctuations** and bleeding/clotting risk."," INR       .","Monitor INR weekly during first weeks of therapy.");n("Ephedrine","Atenolol",e.DRUG_DRUG,i.HIGH,"  Ephedrine   Atenolol            Ephedrine                    .","Ephedrines effect is markedly reduced because Atenolol blocks -receptors, preventing cardiac stimulation, while the -adrenergic effect of Ephedrine remains unopposed, causing marked vasoconstriction and significant hypertension.","               .","Severe hypertension, poor therapeutic response, and increased cardiovascular risk, especially in cardiac or hypertensive patients.","          .                .","Avoid combination whenever possible due to unpredictable and potentially dangerous hemodynamic responses. If necessary in emergency settings, monitor blood pressure and heart rate continuously and adjust doses cautiously.");n("Ephedrine","Bisoprolol",e.DRUG_DRUG,i.HIGH,"       Bisoprolol   1             Ephedrine  .                    .","Ephedrines cardiac stimulatory effect is significantly blunted because Bisoprolol selectively blocks 1 receptors, preventing increases in heart rate and contractility. Unopposed -adrenergic activity results in strong vasoconstriction and severe hypertension.","                   .","Marked hypertension, potential worsening of angina or heart failure, and significant loss of Ephedrine effectiveness, especially in hypotensive states."," .     (  )            .","Avoid combination. If Ephedrine must be used in emergency situations, administer minimal doses with strict monitoring of blood pressure and heart rate.");n("Ephedrine","Carvedilol",e.DRUG_DRUG,i.HIGH,"Carvedilol   1  2      1        .   Ephedrine                           .","Carvedilol blocks 1 and 2 receptors along with partial 1 blockade, profoundly altering Ephedrines pharmacologic profile. Its -mediated effects are abolished, while  stimulation becomes unpredictable, often resulting in poor response and dangerous blood pressure fluctuations.","                 .","Sudden hypotension or hypertension, markedly reduced efficacy, and increased hemodynamic instability, particularly in cardiac patients.","       .     Carvedilol        .","Avoid combination entirely due to unpredictable and potentially dangerous hemodynamic effects. Use alternative agents when the patient is on Carvedilol.");n("Ephedrine","Metoprolol",e.DRUG_DRUG,i.HIGH,"Metoprolol   1         Ephedrine     .                          .","Metoprolol selectively blocks 1 receptors, preventing Ephedrine-induced increases in heart rate and contractility. This leaves -mediated vasoconstriction unopposed, resulting in pronounced hypertension and diminished therapeutic effect.","              .","Significant hypertension, possible myocardial ischemia, and poor response to Ephedrine even at higher doses.","  .            .","Preferably avoid combination. In emergency use, administer low doses with close blood pressure monitoring.");n("Ephedrine","Propranolol",e.DRUG_DRUG,i.HIGH,"Propranolol   1  2          .  Ephedrine                    .    2             COPD.","Propranolol non-selectively blocks 1 and 2 receptors, abolishing Ephedrines cardiac and bronchodilatory effects. Unopposed -adrenergic activation leads to severe vasoconstriction and marked hypertension. 2 blockade also increases bronchospasm risk, making the interaction particularly dangerous in asthma or COPD.","                .","Severe hypertension, bronchospasm, myocardial ischemia, and possible cardiovascular collapse in sensitive patients.","  .        Propranolol       .           .","Strictly avoid combination. If Ephedrine is absolutely required in life-threatening emergencies, use minimal doses with full cardiopulmonary support available.");n("Ephedrine","Nebivolol",e.DRUG_DRUG,i.HIGH,"Nebivolol   1         NO.     1                   .  Nebivolol   NO       .","Nebivolol highly selectively blocks 1 receptors while promoting NO-mediated vasodilation. Despite this, 1 blockade blunts Ephedrines cardiac stimulation, leaving  vasoconstriction unopposed. The NO-mediated dilation may slightly buffer the reaction but does not prevent hypertensive risk.","                  .","Mild to severe hypertension, reduced Ephedrine effectiveness, and heart rate instability due to loss of 1 stimulation.","   .            .","Avoid combination when possible. If needed, titrate Ephedrine cautiously with continuous blood pressure monitoring.");n("Ephedrine","Labetalol",e.DRUG_DRUG,i.HIGH,"Labetalol          1       .              1             .            .","Labetalol blocks  receptors and strongly inhibits 1 receptors, dramatically altering Ephedrines expected response. Cardiac stimulation is eliminated and 1-mediated vasoconstriction is partially blocked, resulting in a blunted or paradoxical hypotensive response. This is especially dangerous in emergencies where Ephedrine is intended to raise blood pressure.","                .","Very poor therapeutic effect, possible hypotension, and clinical deterioration in emergencies such as shock states.","    Labetalol    .              Vasopressin.","Completely avoid combination. Use alternative pressor agents not dependent on / receptors, such as Vasopressin.");n("Epinephrine","Atenolol",e.DRUG_DRUG,i.HIGH,"Atenolol    1           .                     .","Atenolol selectively blocks beta 1 receptors, suppressing Epinephrines cardiac stimulation. Unopposed alpha-adrenergic vasoconstriction leads to severe hypertension with reflex bradycardia or arrhythmia.","              .","Severe hypertension, bradyarrhythmia, and possible myocardial ischemia.","  .              .","Avoid combination; if unavoidable in emergencies, use minimal doses with close hemodynamic monitoring.");n("Epinephrine","Bisoprolol",e.DRUG_DRUG,i.HIGH,"Bisoprolol        1       1                .","Bisoprolol blocks beta 1-mediated cardiac actions of Epinephrine, leaving alpha 1 vasoconstriction unopposed, producing marked hypertension with inadequate compensatory tachycardia.","           .","Sudden hypertension, bradyarrhythmia, and ischemic events.","           .","Avoid coadministration; use Epinephrine cautiously in emergencies such as anaphylaxis.");n("Epinephrine","Carvedilol",e.DRUG_DRUG,i.HIGH,"Carvedilol        1      .    ( 1)  ( 2)       ( 1)           .","Carvedilol blocks beta 1/beta 2 and alpha 1 receptors, creating an unpredictable response to Epinephrine. Both cardiac and bronchodilatory effects are suppressed, while alpha 1 vasoconstriction is blunted, leading to unstable hemodynamics.","               .","Poor or unpredictable response, potential hypotension or hypertension, high risk of deterioration in anaphylaxis.","  .        Vasopressin   .","Avoid combination entirely. In critical allergies, prefer fluids and Vasopressin when possible.");n("Epinephrine","Metoprolol",e.DRUG_DRUG,i.HIGH,"Metoprolol        1                .","Metoprolol blocks beta 1 effects of Epinephrine, producing unopposed alpha vasoconstriction with severe hypertension.","             .","Risk of hypertensive crisis and acute coronary symptoms."," .          ECG.","Avoid combination; titrate carefully with ECG monitoring if required.");n("Epinephrine","Propranolol",e.DRUG_DRUG,i.HIGH,"Propranolol   1   2                             .","Propranolol non-selectively blocks beta 1/beta 2, eliminating Epinephrines cardiac and bronchodilatory effects. This leaves alpha activation fully unopposed, causing extreme vasoconstriction, hypertensive crisis, and bronchospasm.","          .","Hypertensive crisis, bronchospasm, ischemia, possible cardiac arrest.","  .    Epinephrine           .","Never combine. In anaphylaxis, titrate minimal doses with full airway and cardiac support.");n("Epinephrine","Nebivolol",e.DRUG_DRUG,i.HIGH,"Nebivolol   1                            .","Nebivolol selectively blocks beta 1 while sparing alpha activation, resulting in intense vasoconstriction and exaggerated hypertension.","       .","Sudden hypertension, rhythm instability, poor Epinephrine effectiveness.","        .","Avoid combination; in emergencies, use minimal effective doses.");n("Epinephrine","Labetalol",e.DRUG_DRUG,i.HIGH,"Labetalol   1/ 2    1      .                         .","Labetalol blocks beta 1/beta 2 and alpha 1, producing a blunted or paradoxical response to Epinephrine. Effects may be abolished or reversed, leading to hypotension or lack of therapeutic benefit.","           Epinephrine  .","Loss of effect, hypotension, clinical deterioration in shock or anaphylaxis.","  .    Vasopressin  .","Avoid entirely; prefer Vasopressin-based therapy in shock.");n("Epinephrine","Beta-Blockers",e.DRUG_DRUG,i.HIGH,"     ","Antagonistic effect on adrenergic receptors.","       ","Severe hypertension, reflex bradycardia.","     ","Use alternatives to Epinephrine or adjust doses.");n("Eplerenone","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Eplerenone. Itraconazole    CYP3A4    Eplerenone.","Increased Eplerenone concentration. Itraconazole is a strong CYP3A4 inhibitor, an Eplerenone metabolic pathway.","    .","Increased risk of hyperkalemia."," .   .","Contraindicated. Avoid the combination.");n("Epoetin Alfa","Iron Supplements",e.DRUG_DRUG,i.MODERATE,"  ","Increased iron requirement."," ","Iron deficiency.","  ","Give iron supplements.");n("Eptifibatide","Aspirin/Heparin",e.DRUG_DRUG,i.HIGH,"  .      .","Increased bleeding risk. Additive antiplatelet and anticoagulant effect.","     .","Increased risk of severe and life-threatening hemorrhage."," .       .","Close monitoring. Coagulation parameters and signs of bleeding must be monitored continuously.");n("Eptinezumab","Tramadol",e.DRUG_DRUG,i.LOW,"             .","No true interaction expected, but efficacy of migraine treatment should be monitored when combined.","       .","May result in additive effect or no effect."," .         .","Symptom monitoring. Dose adjustment is usually not required, but response should be monitored.");n("Erdafitinib (Balversa)","Phosphate-Lowering Agents",e.DRUG_DRUG,i.MODERATE,": ** **. Erdafitinib      .","Mechanism: **Hyperphosphatemia**. Erdafitinib increases serum phosphate levels."," : **  **  .","Clinical Significance: **Calcium phosphate deposits** and tissue damage.","  .     .","Monitor phosphate monthly. Use phosphate binders when needed.");n("Erdafitinib (Balversa)","OCT2 Substrates (Metformin)",e.DRUG_DRUG,i.MODERATE,": **  OCT2**.   Metformin.","Mechanism: **OCT2 transporter inhibition**. Increased Metformin concentration."," : ** **  Metformin.","Clinical Significance: **Lactic acidosis** and Metformin toxicity.","  .   Metformin   .","Monitor renal function. Reduce Metformin dose if necessary.");n("Erenumab (Aimovig)","Constipation-Causing Drugs (Opioids)",e.DRUG_DRUG,i.MODERATE,": **   **. Erenumab     .","Mechanism: **Synergistic constipation effect**. Erenumab commonly causes constipation."," : ** **   .","Clinical Significance: **Severe constipation** and potential bowel obstruction.","  .  .","Use prophylactic laxatives. Patient education.");n("Ergocalciferol","Phenytoin",e.DRUG_DRUG,i.MODERATE,"   D","Vitamin D metabolism induction.","  D","Vitamin D deficiency.","   D","Increase vitamin D dose.");n("Ergot Alkaloids","Atenolol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Bisoprolol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Carvedilol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Metoprolol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Propranolol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Nebivolol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Labetalol",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","   -      ","   -      ");n("Ergot Alkaloids","Erythromycin",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","     -     -         -           ","     -     -         -           ");n("Ergot Alkaloids","Clarithromycin",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","     -     -         -           ","     -     -         -           ");n("Ergot Alkaloids","Azithromycin",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","     -     -         -           ","     -     -         -           ");n("Ergot Alkaloids","Nitroglycerin",e.DRUG_DRUG,i.MODERATE,"    -                ","Antagonism & Hypertension. Dihydroergotamine opposes nitroglycerin's vasodilatory effect.","       ","       ","   ","   ");n("Ergot Alkaloids","Isosorbide Mononitrate",e.DRUG_DRUG,i.MODERATE,"    -                ","Antagonism & Hypertension. Dihydroergotamine opposes nitroglycerin's vasodilatory effect.","       ","       ","   ","   ");n("Ergot Alkaloids","Isosorbide Dinitrate",e.DRUG_DRUG,i.MODERATE,"    -                ","Antagonism & Hypertension. Dihydroergotamine opposes nitroglycerin's vasodilatory effect.","       ","       ","   ","   ");n("Ergot Alkaloids","NNRTIs",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","    ","    ");n("Ergot Alkaloids","Protease Inhibitors",e.DRUG_DRUG,i.HIGH,"   ","Ergot Toxicity Risk. Inhibition of ergot metabolism leads to severe vasoconstriction and ischemia (Ergotism).","  ","Vascular Toxicity. Ischemia or vasospasm.","    ","    ");n("Ergot Alkaloids -  ","Efavirenz - ",e.DRUG_DRUG,i.HIGH,"       ( CYP3A4)      (  ).","Efavirenz is a potent inducer of hepatic metabolic enzymes (especially CYP3A4) responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine).","                       .","Significant decrease in Ergot Alkaloids blood concentrations, potentially leading to reduced drug efficacy and failure to control migraines or other indications.","     (         CYP3A4).            .","This combination should be avoided (migraine treatment should ideally be switched to a non-CYP3A4 affected alternative). If co-administration is necessary, monitor Ergot Alkaloids efficacy and consider a dose increase.");n("Ergot Alkaloids -  ","delavirdine - ",e.DRUG_DRUG,i.HIGH,"       ( CYP3A4)      ( ).","Delavirdine is a potent inhibitor of hepatic metabolic enzymes (especially CYP3A4) responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine).","              (Ergotism)      (Vasospasm)       .","Significant and dangerous increase in Ergot Alkaloids blood concentrations, leading to Ergotism, which includes severe peripheral vasoconstriction (Vasospasm), ischemia, and potentially gangrene.","       (  ).              .","This drug combination is absolutely contraindicated (forbidden). In cases of extreme necessity, Ergot Alkaloids must be completely discontinued before initiating Delavirdine therapy.");n("Erlotinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Erlotinib.    (PPIs)        Erlotinib.","Decreased Erlotinib concentration. PPIs reduce gastric acidity, which is necessary for Erlotinib absorption.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .             .","Contraindicated. Avoid the combination. If an antacid must be used, immediate-release antacids are preferred.");n("Erlotinib","Food",e.DRUG_FOOD,i.HIGH,"        -     ","Food significantly and unpredictably increases bioavailability - affects first-pass metabolism.","         ","Uncontrolled increase in drug levels and risk of toxicity.","     (     )","Must be taken on an empty stomach (1 hour before or 2 hours after food).");n("Erlotinib","Proton Pump Inhibitors",e.DRUG_DRUG,i.MODERATE," pH ","Increased gastric pH.","  ","Reduced erlotinib absorption.","   2   PPI","Take erlotinib 2 hours before PPI.");n("Ertapenem","Valproic Acid",e.DRUG_DRUG,i.HIGH,"   . Ertapenem            .","Decreased Valproic Acid concentration. Ertapenem increases Valproic Acid metabolism or reduces its enterohepatic recirculation.","   .","Failure of seizure control."," .       .","Contraindicated. Avoid the combination or use a carbapenem alternative.");n("Ertugliflozin (SGLT2)","Furosemide",e.DRUG_DRUG,i.MODERATE,"   /.     .","Increased risk of volume depletion/dehydration. Both drugs cause diuresis.","      .","Risk of orthostatic hypotension and renal insufficiency."," .       .","Close monitoring. Monitor fluid status, blood pressure, and renal function.");n("Erythromycin","Ciprofloxacin",e.DRUG_DRUG,i.HIGH,"        .","Arrhythmia Risk (Torsades de Pointes). Significant risk of fatal ventricular arrhythmias.","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .    (  ).","    .    (  ).");n("Erythromycin","Levofloxacin",e.DRUG_DRUG,i.HIGH,"        .","Arrhythmia Risk (Torsades de Pointes). Significant risk of fatal ventricular arrhythmias.","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .    (  ).","    .    (  ).");n("Erythromycin","Moxifloxacin",e.DRUG_DRUG,i.HIGH,"        .","Arrhythmia Risk (Torsades de Pointes). Significant risk of fatal ventricular arrhythmias.","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .    (  ).","    .    (  ).");n("Erythromycin","Ofloxacin",e.DRUG_DRUG,i.HIGH,"        .","Arrhythmia Risk (Torsades de Pointes). Significant risk of fatal ventricular arrhythmias.","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .    (  ).","    .    (  ).");n("Erythromycin","Norfloxacin",e.DRUG_DRUG,i.HIGH,"        .","Arrhythmia Risk (Torsades de Pointes). Significant risk of fatal ventricular arrhythmias.","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .    (  ).","    .    (  ).");n("Erythromycin","Cisapride",e.DRUG_DRUG,i.HIGH,"  Cisapride. Erythromycin    CYP3A4    Cisapride.","Increased Cisapride concentration. Erythromycin is a strong CYP3A4 inhibitor, a Cisapride metabolic pathway.","    QT  Torsades de Pointes.","Increased risk of QT prolongation and Torsades de Pointes."," .   .","Contraindicated. Avoid the combination.");n("Erythromycin","Simvastatin",e.DRUG_DRUG,i.HIGH,"   CYP3A4 -   ","Potent CYP3A4 inhibition blocks statin metabolism.","  (Rhabdomyolysis) -     ","Rhabdomyolysis risk - severe muscle pain and renal failure.","  -    ( )","Avoid combination - use alternative statin (pravastatin, rosuvastatin).");n("Erythromycin - ","Bromocriptine - ",e.DRUG_DRUG,i.MODERATE,"      P450 3A4 (CYP3A4)   .      .                 .          300-400        .","Erythromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme in the liver and intestine. Bromocriptine is a primary substrate for this enzyme. The inhibition results in a significant decrease in the metabolism of Bromocriptine, increasing its bioavailability and reducing its clearance. Bromocriptine plasma levels may increase by up to 300-400%, leading to drug accumulation and increased risk of toxicity.","      .  : 1.   :           . 2.   :         . 3.  :   ( )    .                   .","The severity of Bromocriptine side effects increases significantly. Risks include: 1. Cardiovascular effects: Severe hypotension, dizziness, syncope, potentially leading to shock. 2. Neurological and psychiatric effects: Severe nausea and vomiting, headache, hallucinations, confusion, psychosis, seizures. 3. Other effects: Vasospasm (Raynaud`s phenomenon), muscle cramps, nasal congestion. These symptoms can be life-threatening, especially in the elderly or patients with impaired liver function.","1.    :        CYP3A4 (   )    . 2.    :     50-75     . 3.  :    (  )       . 4.  :              . 5.  :      CYP3A4               .","1. Avoid combination if possible: Prefer an alternative antibiotic that does not inhibit CYP3A4 (such as amoxicillin or doxycycline) for patients taking Bromocriptine. 2. If combination is necessary: Reduce the Bromocriptine dose by at least 50-75% upon initiating Erythromycin. 3. Close monitoring: Frequently monitor blood pressure (especially orthostatic), mental status, and gastrointestinal symptoms. 4. Patient education: Alert the patient to immediately report any dizziness, severe nausea, changes in thinking, or hallucinations. 5. Gradual adjustment: After discontinuing Erythromycin, CYP3A4 enzyme will take several days to regain activity, so the Bromocriptine dose should be gradually increased back to the original level under supervision.");n("Erythromycin - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.MODERATE,"      (  )        P450 3A4 (CYP3A4)    .      .                      50-100.          P-glycoprotein                .","Grapefruit juice contains furanocoumarins (such as bergamottin and dihydroxybergamottin) that irreversibly inhibit the cytochrome P450 3A4 (CYP3A4) enzyme in the wall of the small intestine. Erythromycin is a primary substrate for this enzyme. This inhibition significantly reduces the first-pass metabolism of Erythromycin in the gut, increasing its bioavailability by up to 50-100%. Additionally, grapefruit juice may inhibit the P-glycoprotein transporter, reducing the efflux of Erythromycin back into the intestinal lumen, further enhancing its absorption.","               : 1.  :     QT                  torsades de pointes                 QT. 2.  :             . 3.  :        . 4.  :                 .","The primary risk is an increase in Erythromycin plasma concentration beyond the safe therapeutic range, leading to: 1. Cardiac toxicity: Increased risk of QT interval prolongation on electrocardiogram, which can lead to serious ventricular arrhythmias, including torsades de pointes, especially in patients with underlying heart conditions or those taking other QT-prolonging medications. 2. Gastrointestinal toxicity: Increased frequency and severity of GI side effects such as nausea, vomiting, abdominal cramps, and diarrhea. 3. Hepatic toxicity: Increased risk of hepatotoxicity, particularly with erythromycin estolate. 4. Hearing loss: Increased risk of ototoxicity, especially in the elderly or patients with renal impairment.","1.  :                 . 2. :                     ( )      24   . 3.  :         . 4. :           (ECG)       QT        . 5.  :                  (   ).","1. Complete Avoidance: Refrain from consuming grapefruit juice or fresh grapefruit during Erythromycin treatment and for several days after. 2. Education: Educate the patient about this serious interaction and alert them that the interaction can occur even with small amounts of juice (one glass) and its effect may last for more than 24 hours after consumption. 3. Safe Alternatives: Suggest alternatives to grapefruit juice such as orange or apple juice. 4. Monitoring: If interaction is suspected, perform ECG monitoring to detect any QT prolongation, monitor liver functions, and watch for gastrointestinal and auditory symptoms. 5. Drug Alternatives: For patients accustomed to consuming grapefruit juice, consider using alternative antibiotics that do not interact with it (such as azithromycin or doxycycline).");n("Escitalopram","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"   ( )","Increased Cyclosporine (Enzyme Inhibition). CYP3A4 inhibition leads to toxic cyclosporine levels.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","   -     ","   -     ");n("Escitalopram","Alcohol",e.DRUG_FOOD,i.HIGH,": **  **.        Escitalopram    .","Mechanism: **Additive CNS depression**. Alcohol increases the neurological side effects of Escitalopram like drowsiness and impaired judgment.",":      .      .","Result: Increased drowsiness and impaired coordination and motor skills. Avoid due to risk of cognitive impairment.",":     .","Management: Advise avoidance of alcohol during treatment.");n("Escitalopram","Caffeine",e.DRUG_FOOD,i.MODERATE,":   .   Escitalopram     .","Mechanism: Additive stimulant effect. Escitalopram does not significantly affect Caffeine metabolism.",":      .","Result: May increase nervousness, anxiety, and insomnia.",":      .","Management: Monitor symptoms and limit Caffeine intake.");n("Escitalopram","Grapefruit Juice",e.DRUG_FOOD,i.LOW,":  CYP3A4. Escitalopram   CYP2C19  CYP3A4       .","Mechanism: CYP3A4 inhibition. Escitalopram is metabolized by CYP2C19 and CYP3A4, but the interaction with grapefruit juice is of low significance.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Escitalopram","Green Tea",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with brain metabolism.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Milk",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","High-fat meals",e.DRUG_FOOD,i.LOW,":          Escitalopram.","Mechanism: Food does not significantly affect Escitalopram bioavailability.",":     .","Result: No expected clinical effect.",":       .","Management: The medication can be taken with or without food.");n("Escitalopram","High-fiber foods",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Vitamin C",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Vitamin D",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Vitamin E",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with brain metabolism.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Vitamin K",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Vitamin B12",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Folic Acid",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with brain metabolism.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Iron",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Calcium",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Magnesium",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Zinc",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Potassium",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram","Antacids",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Escitalopram - ","Cyproheptadine - ",e.DRUG_DRUG,i.MODERATE,"       (5-HT2)         ","Cyproheptadine is a potent competitive serotonin receptor (5-HT2) antagonist, directly counteracting Escitalopram mechanism of action and impairing its therapeutic efficacy","               ","Significant reduction in Escitalopram therapeutic efficacy, deterioration in treatment response, and potential relapse of depressive or anxiety symptoms","    -              -     ","Avoid combination if possible - in necessary cases, closely monitor therapeutic response and increase Escitalopram dose if needed - consider non-serotonergic alternatives");n("Esketamine (Spravato)","Alprazolam (Benzodiazepine)",e.DRUG_DRUG,i.MODERATE,"    .       .","Increased sedation and dissociation. Additive CNS depressant effects.","     .","Breathing difficulty and increased accident risk."," .       .","Close monitoring. Monitor the patient closely during and after administration.");n("Eslicarbazepine Acetate","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Eslicarbazepine   CYP.","Decreased oral contraceptive concentration. Eslicarbazepine is an inducer of CYP enzymes.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .          .","Relative contraindication. An additional non-hormonal or alternative contraceptive method must be used.");n("Esomeprazole","Methotrexate",e.DRUG_DRUG,i.HIGH,"   ","Reduced renal methotrexate excretion."," ","Methotrexate toxicity.","    ","Avoid with high-dose methotrexate.");n("Esomeprazole - ","High-Fat Meals -   ",e.DRUG_FOOD,i.MODERATE,"              ( 1   3-4 ).              .                     .       40-45%.","High-fat meals cause cholecystokinin release, leading to significant slowing of gastric emptying (from 1 hour to 3-4 hours). Esomeprazole, as a proton pump inhibitor, is coated with an acid-resistant enteric coating that protects it from degradation in the stomach. Prolonged stay in the stomach exposes the enteric coating to erosion by the acidic environment, allowing drug degradation before absorption in the small intestine. This reduces bioavailability by 40-45%.","       : 1.    . 2.         (pH <4  ). 3.         (  ). 4.        . 5.        .","Decreased plasma drug levels, leading to: 1. Reduced proton pump inhibition. 2. Inadequate gastric pH elevation (pH <4 for shorter periods). 3. Failure to control GERD symptoms (heartburn, regurgitation). 4. Slower healing of peptic ulcers or erosive esophagitis. 5. Need for longer treatment periods or higher doses.","1.  :       30-60         . 2.   :           . 3.   :                 . 4. :         . 5. :           H2        .","1. Optimal timing: Take esomeprazole on an empty stomach 30-60 minutes before breakfast to ensure fastest gastric passage. 2. Avoid high-fat meals: Avoid fatty meals at least 2 hours before taking the medication. 3. Missed dose instructions: If the morning dose is missed, do not take it with a fatty lunch; wait until the evening and take it before a light snack. 4. Monitoring: Monitor patient response to symptoms and adjust dose if necessary. 5. Alternatives: In cases of adherence difficulty, consider using H2 receptor antagonists with meals, although they are less effective.");n("Estazolam","Clarithromycin (or other strong CYP3A4 Inhibitors)",e.DRUG_DRUG,i.HIGH,"   (CYP3A4).       .","Potent Metabolic Inhibition (CYP3A4). These drugs strongly inhibit the enzyme metabolizing Estazolam.","                    .","Significant increase in Estazolam plasma concentration, leading to severe drowsiness, over-sedation, impaired motor function, and increased risk of respiratory depression.","   .          ( 50%)            (CNS).","Generally Avoid. If co-administration is necessary, reduce the Estazolam dose significantly (usually by 50%) and closely monitor for signs of CNS depression.");n("Estazolam","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"     .","Additive Central Nervous System (CNS) Depressant Effects.","          (  ).","Increased risk of severe drowsiness, dizziness, impaired concentration, respiratory depression, and coma (especially with Opioids).","   .               .","Alcohol must be completely avoided. With other depressants, use the lowest effective doses and monitor for over-sedation and breathing difficulties.");n("Estazolam","Rifampin (or other strong CYP3A4 Inducers)",e.DRUG_DRUG,i.MODERATE,"   (CYP3A4).      .","Potent Metabolic Induction (CYP3A4). These drugs increase the metabolism and breakdown of Estazolam.","             (Treatment Failure).","Decreased Estazolam plasma levels, resulting in reduced drug efficacy and a return of insomnia (Treatment Failure).","                CYP3A4 Inducers.","Estazolam dose increase or switching to an alternative hypnotic agent not affected by CYP3A4 inducers may be necessary.");n("Estradiol","Rifampin",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 induction.","  ","Hormonal therapy failure.","  ","Increase estradiol dose.");n("Estrogens","Phenobarbital",e.DRUG_DRUG,i.MODERATE,"   (      )","Reduced Estrogen Levels. Enzyme induction risks contraceptive failure.","   ","   ","       -      ","       -      ");n("Estrogens","Pentobarbital",e.DRUG_DRUG,i.MODERATE,"   (      )","Reduced Estrogen Levels. Enzyme induction risks contraceptive failure.","   ","   ","       -      ","       -      ");n("Estrogens","Secobarbital",e.DRUG_DRUG,i.MODERATE,"   (      )","Reduced Estrogen Levels. Enzyme induction risks contraceptive failure.","   ","   ","       -      ","       -      ");n("Estrogens - ","Hydrocortisone - ",e.DRUG_DRUG,i.MODERATE,"          :     -  (CBG)           .      P450 ( CYP3A4)            .          .","Estrogens increase hydrocortisone plasma concentrations through two main mechanisms: first, by increasing corticosteroid-binding globulin (CBG) production in the liver, which reduces the free biologically active fraction of hydrocortisone. Second, by inhibiting cytochrome P450 enzymes (especially CYP3A4) responsible for hydrocortisone metabolism, prolonging its half-life and reducing its clearance. This interaction is more pronounced with oral estrogens compared to transdermal patches.","        :                      .            .","Increased risk of glucocorticoid side effects, including: hyperglycemia, hypertension, fluid retention and weight gain, osteoporosis, easy bruising, impaired wound healing, increased susceptibility to infections, and mood changes. Signs of Cushing`s syndrome may appear with chronic use, even at usual hydrocortisone doses.","1.  :     25-50    . 2.  :           . 3.  :          Bffel  . 4.    :        . 5.   :             .","1. Dose Adjustment: Reduce hydrocortisone dose by 25-50% when initiating estrogen therapy. 2. Regular Monitoring: Monitor blood glucose levels, blood pressure, weight, and signs of fluid retention. 3. Clinical Monitoring: Watch for signs of hypercortisolism such as moon face, buffalo hump, and striae. 4. Prefer Non-Oral Estrogen: Consider using transdermal estrogen to reduce interaction. 5. Post-Discontinuation Monitoring: When discontinuing estrogen, may need to gradually increase hydrocortisone dose to avoid adrenal insufficiency.");n("Estrogens - ","Hydantoins - ",e.DRUG_DRUG,i.MODERATE,"  ( )     P450  ( CYP3A4 CYP2C9)              50.            (SHBG)         .            .","Hydantoins (such as phenytoin) act as potent inducers of hepatic cytochrome P450 enzymes (especially CYP3A4 and CYP2C9), increasing estrogen metabolism and reducing plasma concentrations by up to 50%. Additionally, hydantoins increase sex hormone-binding globulin (SHBG) concentration, further reducing the free active fraction of estrogen. In turn, estrogens may increase hydantoin concentrations by inhibiting their metabolism.","1.   :            . 2.   :         . 3.  :             .","1. Estrogen therapy failure: Withdrawal bleeding, hot flashes, menopausal symptoms in women on hormone replacement therapy. 2. Contraceptive failure: Increased risk of unintended pregnancy with oral contraceptives. 3. Hydantoin toxicity: Increased risk of toxicity symptoms such as nystagmus, ataxia, dysarthria, confusion, due to increased hydantoin concentrations.","1.    :    (  )   . 2.   :     50-100    . 3.  :         . 4.  :       . 5.  :             .","1. Alternative Contraception: Use barrier methods (condoms, diaphragm) or copper IUD. 2. Estrogen Dose Adjustment: Increase estrogen dose to 50-100 mcg of ethinyl estradiol. 3. Drug Monitoring: Measure hydantoin plasma levels and adjust dose as needed. 4. Clinical Monitoring: Monitor for hydantoin toxicity symptoms and estrogen therapy efficacy. 5. Hydantoin Alternatives: Consider using non-enzyme inducing anticonvulsants like levetiracetam or valproic acid.");n("Estrogens - ","Methylprednisolone -  ",e.DRUG_DRUG,i.MODERATE,"          CYP3A4             .                       .","Estrogens increase methylprednisolone concentration by inhibiting CYP3A4 enzyme responsible for its metabolism, reducing first-pass metabolism and increasing bioavailability. Estrogens also increase corticosteroid-binding globulin concentration, although this effect is less significant with methylprednisolone compared to hydrocortisone due to its lower protein binding.","        :              ( )      .         .","Marked increase in glucocorticoid effects, including: severe immunosuppression, hyperglycemia, steroid myopathy, sleep disturbances, mood changes (irritability, depression), dyspepsia, and increased risk of opportunistic infections. These effects may occur even at usual methylprednisolone doses.","1.  :      30-50    . 2.  :           . 3.  :           . 4.    :     D     . 5.  :        .","1. Dose Reduction: Reduce methylprednisolone dose by 30-50% when initiating estrogen therapy. 2. Intensive Monitoring: Monitor blood glucose levels, signs of infection, muscle function, and psychological status. 3. Dosing Timing: Administer methylprednisolone in the early morning to minimize adrenal suppression effects. 4. Osteoporosis Prevention: Prescribe calcium and vitamin D supplements for patients on long-term therapy. 5. Regular Review: Periodically assess the need for continued methylprednisolone treatment.");n("Estrogens - ","Prednisolone - ",e.DRUG_DRUG,i.MODERATE,"        CYP3A4          30-50.       (   )   ()       .         .","Estrogens inhibit prednisolone metabolism by inhibiting CYP3A4 enzyme, increasing its plasma concentration by up to 30-50%. Estrogens also increase the conversion of prednisone (inactive) to prednisolone (active) in the liver, enhancing both therapeutic and toxic effects. This interaction is more pronounced with high-dose estrogen therapy.","     :                   .          --.","Increased risk of prednisolone side effects, particularly: hypertension, edema, weight gain, dyslipidemia, elevated liver enzymes, pancreatitis, avascular necrosis, and optic neuropathy. Also increases risk of drug-induced Cushing`s syndrome and hypothalamic-pituitary-adrenal axis suppression.","1.  :   /  25-40    . 2.  :             . 3.  :        . 4.  :         . 5.  :            .","1. Dose Adjustment: Reduce prednisolone/prednisone dose by 25-40% when initiating estrogen therapy. 2. Comprehensive Monitoring: Monitor blood pressure, weight, lipid profile, liver functions, and glucose levels weekly initially. 3. Bone Assessment: Perform bone density scanning for patients on long-term therapy. 4. Protective Measures: Prescribe proton pump inhibitors for gastric protection from ulcerogenic effects. 5. Tapering Plan: Establish a gradual dose reduction plan when discontinuing treatment to avoid acute adrenal insufficiency.");n("Estrogens - ","Rifampin - ",e.DRUG_DRUG,i.MODERATE,"       P450 ( CYP3A4)    P-glycoprotein.                  60-70.               .","Rifampin is a potent and broad inducer of cytochrome P450 enzymes (especially CYP3A4) and drug transporters like P-glycoprotein. It significantly increases the metabolism of both oral and transdermal estrogens, reducing plasma concentrations by up to 60-70%. Rifampin also induces glucuronidation in the liver, increasing estrogen excretion in bile and feces.","     :           .   :        6        .               .","Complete failure of estrogen therapy: Severe withdrawal bleeding, hot flashes, vaginal dryness, and other menopausal symptoms. Contraceptive failure: Increased failure rate of oral contraceptives to 6% or more, with elevated risk of unintended pregnancy. This may occur even with high-dose estrogen or non-oral estrogen preparations.","1.    :      (     )      4-8   . 2.   :         (   ). 3.  :        . 4.  :        100        . 5.  :         (  ).","1. Additional Contraception: Use two different contraceptive methods (e.g., condoms with spermicide) throughout Rifampin treatment and for 4-8 weeks after discontinuation. 2. Alternative Hormone Therapy: Consider non-hormonal therapy for menopausal symptoms (e.g., antidepressants, gabapentin). 3. Cycle Monitoring: Carefully track withdrawal bleeding as an indicator of dose adequacy. 4. Higher Doses: May need to increase estrogen dose to 100 mcg of ethinyl estradiol, but with limited efficacy. 5. Rifampin Alternatives: Use alternative antibiotics for tuberculosis treatment if possible (e.g., isoniazid, ethambutol).");n("Etanercept","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Etanercept   (TNF receptor).","Increased risk of infection. Etanercept is an immunosuppressant (TNF receptor).","     .","Risk of developing infection from live vaccines."," .      .","Contraindicated. Live vaccines must be avoided during treatment.");n("Ethacrynic Acid","Warfarin",e.DRUG_DRUG,i.MODERATE,"   ","Warfarin displacement from protein."," INR","Increased INR."," INR","Monitor INR.");n("Ethambutol","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,"  Ethambutol.   Ethambutol   .","Decreased Ethambutol absorption. Aluminum chelates Ethambutol in the gastrointestinal tract.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   Ethambutol  4           .","Dose separation. Ethambutol must be taken at least 4 hours before aluminum-containing antacids.");n("Ethanol","Verapamil",e.DRUG_DRUG,i.MODERATE,"    ","    ","   ","Increased CNS Depression. Drowsiness and ataxia.","   ","   ");n("Ethanol -  ()","Acetaminophen -  ()",e.DRUG_DRUG,i.HIGH,"     CYP2E1  .              (NAPQI).           .","Chronic ethanol use induces the hepatic enzyme CYP2E1. This enzyme is responsible for converting a small portion of Acetaminophen into a toxic metabolite (NAPQI). Alcohol also depletes glutathione stores, which detoxify this metabolite.","      (Hepatotoxicity)                  .","Increased risk of acute and severe liver toxicity (Hepatotoxicity), which may lead to liver failure and death, especially with high doses of Acetaminophen in chronic alcohol users.","            .              .","Avoid high doses of Acetaminophen in patients with chronic ethanol consumption. The maximum recommended daily dose should not be exceeded, and concurrent alcohol intake should be avoided.");n("Ethanol -  ()","Phenobarbital - ",e.DRUG_DRUG,i.HIGH,"  (Additive/Synergistic)          (Depressants)     GABA.","Additive/Synergistic effect on the Central Nervous System (CNS) due to both agents acting as depressants that potentiate GABA activity.","     (   )        . (   )","Increased acute CNS Depression (drowsiness, ataxia, impaired consciousness), potentially leading to coma and fatal respiratory compromise. (Increased CNS Depression. Drowsiness and ataxia.)","     .","Avoid this combination whenever possible.");n("Ethanol -  ()","Pentobarbital - ",e.DRUG_DRUG,i.HIGH,"  (Additive/Synergistic)          (Depressants)     GABA.","Additive/Synergistic effect on the CNS due to both agents acting as depressants that potentiate GABA activity.","     (   )        . (   )","Increased acute CNS Depression (drowsiness, ataxia, impaired consciousness), potentially leading to coma and fatal respiratory compromise. (Increased CNS Depression. Drowsiness and ataxia.)","     .","Avoid this combination whenever possible.");n("Ethanol -  ()","Secobarbital - ",e.DRUG_DRUG,i.HIGH,"  (Additive/Synergistic)          (Depressants)     GABA.","Additive/Synergistic effect on the CNS due to both agents acting as depressants that potentiate GABA activity.","     (   )        . (   )","Increased acute CNS Depression (drowsiness, ataxia, impaired consciousness), potentially leading to coma and fatal respiratory compromise. (Increased CNS Depression. Drowsiness and ataxia.)","     .","Avoid this combination whenever possible.");n("Ethanol -  ()","Diazepam - ",e.DRUG_DRUG,i.HIGH,"               GABA.","Potent synergistic effect on CNS inhibition; Ethanol increases the depressant effect of Diazepam via GABA potentiation.","                . (   )","Increased acute CNS Depression leading to severe dizziness, ataxia, respiratory difficulty, or coma. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Lorazepam - ",e.DRUG_DRUG,i.HIGH,"               GABA.","Potent synergistic effect on CNS inhibition; Ethanol increases the depressant effect of Lorazepam via GABA potentiation.","                . (   )","Increased acute CNS Depression leading to severe dizziness, ataxia, respiratory difficulty, or coma. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Alprazolam - ",e.DRUG_DRUG,i.HIGH,"               GABA.","Potent synergistic effect on CNS inhibition; Ethanol increases the depressant effect of Alprazolam via GABA potentiation.","                . (   )","Increased acute CNS Depression leading to severe dizziness, ataxia, respiratory difficulty, or coma. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Clonazepam - ",e.DRUG_DRUG,i.HIGH,"               GABA.","Potent synergistic effect on CNS inhibition; Ethanol increases the depressant effect of Clonazepam via GABA potentiation.","                . (   )","Increased acute CNS Depression leading to severe dizziness, ataxia, respiratory difficulty, or coma. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Chloral Hydrate -  ",e.DRUG_DRUG,i.HIGH,'               .     "  ".','Synergistic effect on CNS depression, and Ethanol may increase Chloral Hydrate blood concentration. This interaction is sometimes known as the "Mickey Finn" effect.',"            . (   )","Increased acute CNS Depression, leading to severe sedation and cardiovascular effects. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Glutethimide - ",e.DRUG_DRUG,i.HIGH,"      .","Additive/Synergistic effect on CNS depression.","         .","Increased acute CNS Depression, raising the risk of overdose. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Meprobamate - ",e.DRUG_DRUG,i.HIGH,"      .","Additive/Synergistic effect on CNS depression.","             . (   )","Increased acute CNS Depression, raising the risk of overdose and respiratory depression. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Phenothiazine - ",e.DRUG_DRUG,i.HIGH,"              .","Additive/Synergistic effect on CNS depression, and Phenothiazines may increase blood Ethanol concentration.","               . (   )","Increased motor CNS depression, leading to severe sedation, hypotension, and impaired coordination. (Increased CNS Depression. Drowsiness and ataxia.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Phenytoin - ",e.DRUG_DRUG,i.MODERATE,"       (CYP2C9/CYP2C19)         .","Chronic ethanol use induces hepatic metabolic enzymes (CYP2C9/CYP2C19) responsible for Phenytoin breakdown, increasing its clearance.","         . (    - )","Decreased Phenytoin blood levels, increasing the risk of seizures. (Change in Phenytoin efficacy - decrease)","     .          .","Monitor Phenytoin concentrations closely. Increase the Phenytoin dose if necessary, especially in chronic alcohol abusers.");n("Ethanol -  ()","Disulfiram - ",e.DRUG_DRUG,i.HIGH,"     (Aldehyde Dehydrogenase)     (   )   .","Disulfiram inhibits Aldehyde Dehydrogenase, the enzyme responsible for breaking down Acetaldehyde (the primary metabolite of ethanol), leading to its accumulation.","              .     .","Severe disulfiram reaction characterized by flushing, nausea, vomiting, sweating, bronchospasm, tachycardia, and hypotension. Can potentially be fatal.","      .     .","Strictly avoid alcohol intake during Disulfiram therapy. Avoid this combination whenever possible.");n("Ethanol -  ()","Metronidazole - ",e.DRUG_DRUG,i.HIGH,"     (Aldehyde Dehydrogenase)        .","Metronidazole inhibits Aldehyde Dehydrogenase, leading to the accumulation of toxic Acetaldehyde after ethanol consumption.","         (    ). (  )","Disulfiram-like reactions (flushing, nausea, vomiting, tachycardia). (Disulfiram-like Reaction)","        3     .     .","Avoid alcohol intake completely during Metronidazole therapy and for at least 3 days after discontinuation. Avoid this combination whenever possible.");n("Ethanol -  ()","Furazolidone - ",e.DRUG_DRUG,i.HIGH,"            .","Furazolidone inhibits Aldehyde Dehydrogenase, leading to the accumulation of toxic Acetaldehyde after ethanol consumption.","         (    ). (  )","Disulfiram-like reactions (flushing, nausea, vomiting, tachycardia). (Disulfiram-like Reaction)","        4     .     .","Avoid alcohol intake completely during Furazolidone therapy and for at least 4 days after discontinuation. Avoid this combination whenever possible.");n("Ethanol -  ()","Chlorpropamide - ",e.DRUG_DRUG,i.HIGH," (  )            .","Chlorpropamide (a sulfonylurea) inhibits Aldehyde Dehydrogenase, leading to the accumulation of toxic Acetaldehyde after ethanol consumption.","    (    ). (  )","Disulfiram-like reactions (flushing, nausea, sweating, tachycardia). (Disulfiram-like Reaction)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Cephalexin - ",e.DRUG_DRUG,i.MODERATE,"           (    ).","Some cephalosporin antibiotics may cause a disulfiram-like reaction (mechanism is uncertain for Cephalexin).","         (  ). (  )","Disulfiram-like Reaction (flushing, nausea, vomiting). (Disulfiram-like Reaction. Accumulation of acetaldehyde causes flushing, nausea, and vomiting.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Ceftriaxone - ",e.DRUG_DRUG,i.MODERATE,"           (    ).","Some cephalosporin antibiotics may cause a disulfiram-like reaction (mechanism is uncertain for Ceftriaxone).","         (  ). (  )","Disulfiram-like Reaction (flushing, nausea, vomiting). (Disulfiram-like Reaction. Accumulation of acetaldehyde causes flushing, nausea, and vomiting.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Cefuroxime - ",e.DRUG_DRUG,i.MODERATE,"           (    ).","Some cephalosporin antibiotics may cause a disulfiram-like reaction (mechanism is uncertain for Cefuroxime).","         (  ). (  )","Disulfiram-like Reaction (flushing, nausea, vomiting). (Disulfiram-like Reaction. Accumulation of acetaldehyde causes flushing, nausea, and vomiting.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Cefixime - ",e.DRUG_DRUG,i.MODERATE,"           (    ).","Some cephalosporin antibiotics may cause a disulfiram-like reaction (mechanism is uncertain for Cefixime).","         (  ). (  )","Disulfiram-like Reaction (flushing, nausea, vomiting). (Disulfiram-like Reaction. Accumulation of acetaldehyde causes flushing, nausea, and vomiting.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Cefotaxime - ",e.DRUG_DRUG,i.MODERATE,"           (    ).","Some cephalosporin antibiotics may cause a disulfiram-like reaction (mechanism is uncertain for Cefotaxime).","         (  ). (  )","Disulfiram-like Reaction (flushing, nausea, vomiting). (Disulfiram-like Reaction. Accumulation of acetaldehyde causes flushing, nausea, and vomiting.)","    .","Avoid this combination whenever possible.");n("Ethanol -  ()","Insulin - ",e.DRUG_DRUG,i.MODERATE,"     (Gluconeogenesis)             .","Ethanol inhibits hepatic gluconeogenesis, especially in a fasting state, potentiating the blood sugar-lowering effect of Insulin.","      (Hypoglycemia)           . (    )","Increased risk of acute hypoglycemia, especially with excessive alcohol consumption or in a fasting state. (Increased risk of hypoglycemia)","      .          .      .","Monitor blood sugar levels closely. Excessive alcohol consumption, especially on an empty stomach, is not recommended. Insulin dose adjustment may be necessary.");n("Ethanol -  ()","Sulfonylurea -  ",e.DRUG_DRUG,i.HIGH,"        (   )    ( )     .","Ethanol increases the hypoglycemic effect of sulfonylureas (via inhibited gluconeogenesis), and some sulfonylureas (e.g., chlorpropamide) also cause a disulfiram-like reaction.","      /          (      ).","Acute hypoglycemia may occur and/or disulfiram-like reactions (Hypoglycemia and Disulfiram-like reactions).","    .","Avoid this combination whenever possible.");n("Ethinyl Estradiol","St. John's Wort",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 induction.","  ","Contraceptive failure.","  ","Use backup method.");n("Ethinylestradiol/Desogestrel","Ampicillin",e.DRUG_DRUG,i.LOW,"   .","Interruption of Enterohepatic Recirculation. Reduced drug reabsorption.","   .","   .",".",".");n("Ethinylestradiol/Desogestrel","Amoxicillin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Desogestrel","Ciprofloxacin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Desogestrel","Doxycycline",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Desogestrel","Azithromycin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Desogestrel","Rifampicin",e.DRUG_DRUG,i.HIGH,"     ","Hormone Metabolism Induction. Accelerated breakdown of hormonal contraceptives.","  ","  ","    ","    ");n("Ethinylestradiol/Desogestrel","Rifampicin",e.DRUG_DRUG,i.HIGH,"            .","Contraceptive Failure Risk. Accelerated metabolism of OCPs.","        .","        .","     ( )     .","     ( )     .");n("Ethinylestradiol/Desogestrel -  /","Carbamazepine - ",e.DRUG_DRUG,i.HIGH,"       P450  ( CYP3A4)    P-glycoprotein UGT (UDP-glucuronosyltransferase).        :   ()  ().                      50-70.         (SHBG)          .","Carbamazepine acts as a potent and broad inducer of hepatic cytochrome P450 enzymes (especially CYP3A4) and drug transporters like P-glycoprotein and UGT (UDP-glucuronosyltransferase). It significantly induces the metabolism of both components of oral contraceptives: Ethinylestradiol (estrogen) and Desogestrel (progestin). It increases estrogen metabolism via oxidation and hydroxylation, and progestin metabolism via glucuronide conjugation, reducing their plasma concentrations by up to 50-70%. Carbamazepine also induces the synthesis of sex hormone-binding globulin (SHBG), further reducing the biologically active free fraction of hormones.","1.   :        (     6-8   0.3   ). 2.  :      . 3.   :        . 4.  :                      .","1. Contraceptive failure: Significantly increased risk of unintended pregnancy (failure rate may reach 6-8% compared to 0.3% under normal conditions). 2. Breakthrough bleeding: Irregular bleeding between menstrual periods. 3. Hormone deficiency symptoms: Headache, mood swings, hot flashes, and decreased libido. 4. Reciprocal interaction: Oral contraceptives may increase carbamazepine concentrations in some cases, increasing the risk of toxicity symptoms such as dizziness, ataxia, nystagmus, and nausea.","1.    :    (  )              4-8   . 2.    :               . 3.    :        (50   )         . 4.  :               . 5.  :               .","1. Additional Contraception: Use a barrier method (condoms, diaphragm) or spermicide in addition to oral contraceptives throughout Carbamazepine treatment and for 4-8 weeks after its discontinuation. 2. Alternative Contraception: Consider non-hormonal methods like copper IUD which are unaffected by hepatic enzyme inducers. 3. Higher Hormone Doses: Use high-dose oral contraceptives (50 mcg ethinyl estradiol) under medical supervision, acknowledging that efficacy remains limited. 4. Periodic Monitoring: Regularly monitor carbamazepine plasma levels, as oral contraceptives may increase its concentration. 5. Carbamazepine Alternatives: Discuss with physician the possibility of using non-enzyme inducing anticonvulsants like levetiracetam, gabapentin, or topiramate.");n("Ethinylestradiol/Drospirenone","Ampicillin",e.DRUG_DRUG,i.LOW,"   .","Interruption of Enterohepatic Recirculation. Reduced drug reabsorption.","   .","   .",".",".");n("Ethinylestradiol/Drospirenone","Amoxicillin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Drospirenone","Ciprofloxacin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Drospirenone","Doxycycline",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Drospirenone","Azithromycin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Drospirenone","Rifampicin",e.DRUG_DRUG,i.HIGH,"     ","Hormone Metabolism Induction. Accelerated breakdown of hormonal contraceptives.","  ","  ","    ","    ");n("Ethinylestradiol/Drospirenone","Rifampicin",e.DRUG_DRUG,i.HIGH,"            .","Contraceptive Failure Risk. Accelerated metabolism of OCPs.","        .","        .","     ( )     .","     ( )     .");n("Ethinylestradiol/Drospirenone -  /","Carbamazepine - ",e.DRUG_DRUG,i.HIGH,"       P450  ( CYP3A4)         .                        50-70.       P-glycoprotein    (UGT)      .            (SHBG)         .","Carbamazepine acts as a potent and broad inducer of hepatic cytochrome P450 enzymes (especially CYP3A4), the primary metabolic pathway for both Ethinylestradiol and Drospirenone. It significantly increases the metabolism of Ethinylestradiol via hydroxylation and oxidation, and Drospirenone metabolism via oxidation, reducing their plasma concentrations by 50-70%. Carbamazepine also induces drug transporters like P-glycoprotein and glucuronidation processes (UGT), accelerating the excretion of hormone metabolites. Additionally, Carbamazepine increases the synthesis of sex hormone-binding globulin (SHBG), reducing the biologically active free fraction of hormones.","1.   :        (     7-9). 2.  :      . 3.   :               . 4.   :                . 5.  :                .","1. Contraceptive failure: Significantly increased risk of unintended pregnancy (failure rate may reach 7-9%). 2. Breakthrough bleeding: Irregular bleeding between menstrual cycles. 3. Loss of other benefits: Reduced effectiveness of Drospirenone in treating acne, premenstrual syndrome, and premenstrual dysphoric disorder. 4. Electrolyte imbalance: With decreased Drospirenone levels, its anti-aldosterone effect may diminish, potentially affecting potassium and sodium balance. 5. Reciprocal interaction: Oral contraceptives may increase carbamazepine concentrations in some cases, increasing toxicity risk.","1.     :    ( )              4-8   . 2.    :            . 3.     :      / (30-50 )    . 4.   :            . 5.  :            . 6.  :          .","1. Mandatory additional contraception: Use a barrier method (condoms) or spermicide in addition to oral contraceptives throughout Carbamazepine treatment and for 4-8 weeks after its discontinuation. 2. Alternative contraception: Copper IUD is the optimal choice as it is unaffected by hepatic enzyme inducers. 3. Do not rely on high doses: Even high-dose Ethinylestradiol/Drospirenone (30-50 mcg) does not guarantee sufficient efficacy. 4. Electrolyte monitoring: Monitor serum potassium levels, especially in patients at risk of hyperkalemia. 5. Carbamazepine alternatives: Discuss using non-enzyme inducing anticonvulsants like levetiracetam, lamotrigine, or pregabalin. 6. Periodic monitoring: Regularly monitor carbamazepine plasma levels and adjust dose as needed.");n("Ethinylestradiol/Levonorgestrel","Ampicillin",e.DRUG_DRUG,i.LOW,"   .","Interruption of Enterohepatic Recirculation. Reduced drug reabsorption.","   .","   .",".",".");n("Ethinylestradiol/Levonorgestrel","Amoxicillin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Levonorgestrel","Ciprofloxacin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Levonorgestrel","Doxycycline",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Levonorgestrel","Azithromycin",e.DRUG_DRUG,i.LOW,"          (Enterohepatic circulation).","Disruption of Enterohepatic Circulation. Antibiotics reduce gut flora required for estrogen hydrolysis and reabsorption.","      .","Potential Contraceptive Failure. Risk of pregnancy.","         .","         .");n("Ethinylestradiol/Levonorgestrel","Rifampicin",e.DRUG_DRUG,i.HIGH,"     ","Hormone Metabolism Induction. Accelerated breakdown of hormonal contraceptives.","  ","  ","    ","    ");n("Ethinylestradiol/Levonorgestrel","Rifampicin",e.DRUG_DRUG,i.HIGH,"            .","Contraceptive Failure Risk. Accelerated metabolism of OCPs.","        .","        .","     ( )     .","     ( )     .");n("Ethinylestradiol/Levonorgestrel -  /","Carbamazepine - ",e.DRUG_DRUG,i.HIGH,"       P450  ( CYP3A4)          .                       40-60.       P-glycoprotein    (UGT)      .            (SHBG)              .","Carbamazepine acts as a potent and broad inducer of hepatic cytochrome P450 enzymes (especially CYP3A4), which represent the primary metabolic pathway for both Ethinylestradiol and Levonorgestrel. It significantly increases the metabolism of Ethinylestradiol via hydroxylation, and Levonorgestrel via oxidation and reduction, reducing their plasma concentrations by 40-60%. Carbamazepine also induces drug transporters like P-glycoprotein and glucuronidation processes (UGT), accelerating the excretion of hormone metabolites. Additionally, Carbamazepine increases the synthesis of sex hormone-binding globulin (SHBG), which binds strongly to Levonorgestrel, significantly reducing its biologically active free fraction.","1.   :        (     6-8    ). 2.  :            . 3.   :         . 4.  :                 (  ). 5.     :         .","1. Contraceptive failure: Significantly increased risk of unintended pregnancy (failure rate may reach 6-8% with potent enzyme inducers). 2. Breakthrough bleeding: Irregular bleeding between menstrual cycles due to inadequate endometrial support. 3. Hormone deficiency symptoms: Headache, mood swings, hot flashes, and decreased breast volume. 4. Reciprocal interaction: Oral contraceptives may increase carbamazepine concentrations in some cases, increasing toxicity risk (dizziness, ataxia, nystagmus). 5. Seizure control failure: Hormonal fluctuations during the cycle may affect seizure threshold.","1.     :    ( )           4     . 2.    :      ()            . 3.     :        (50   )    . 4.  :         . 5.  :            . 6.  :          .","1. Mandatory additional contraception: Use a barrier method (condoms) in addition to oral contraceptives throughout Carbamazepine treatment and for at least 4 weeks after its discontinuation. 2. Alternative contraception: Copper IUD or hormonal IUD (Mirena) are better options as their local effect is unaffected by systemic enzyme inducers. 3. Do not rely on high doses: Even high-dose oral contraceptives (50 mcg ethinyl estradiol) do not provide adequate protection. 4. Seizure monitoring: Increased vigilance for possible changes in seizure pattern due to hormonal fluctuations. 5. Carbamazepine alternatives: Discuss using non-enzyme inducing anticonvulsants like levetiracetam, lamotrigine, or zonisamide. 6. Periodic monitoring: Regularly monitor carbamazepine plasma levels and adjust dose as needed.");n("Etoposide","Warfarin",e.DRUG_DRUG,i.MODERATE," INR","Increased INR."," ","Bleeding risk."," INR","Monitor INR.");n("Etoricoxib ()","Warfarin - ",e.DRUG_DRUG,i.HIGH,"     (NSAID)          .     ( )            .","Etoricoxib, as a NSAID, inhibits platelet function and can cause gastrointestinal mucosal irritation. When combined with Warfarin (an anticoagulant), it significantly increases the risk of bleeding without enhancing the antithrombotic effect.","                .      .","Increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, bruising, and bleeding from other sites. Bleeding can be life-threatening.","    .            (INR)  .           .","Avoid concomitant use if possible. If combination is necessary, monitor closely for signs of bleeding and check prothrombin time (INR) frequently. Use the lowest effective dose of Etoricoxib for the shortest possible duration.");n("Etoricoxib ()","ACE Inhibitors -     ( )",e.DRUG_DRUG,i.MODERATE,"        .          (ACEIs)           .","Etoricoxib has an anti-diuretic effect and promotes sodium retention. This counteracts the blood pressure-lowering effect of ACE Inhibitors and can impair kidney function, primarily by reducing renal prostaglandin synthesis.","    (     )   ()                 .","Reduced efficacy of antihypertensive therapy (poor blood pressure control), fluid retention (edema), and increased risk of acute renal impairment, especially in the elderly, dehydrated, or those with pre-existing kidney disease.","     (  )      .        .          .","Monitor blood pressure and renal function (serum creatinine, potassium) at the start of therapy and after dose changes. Adjustment of the antihypertensive dose may be required. Avoid use in patients with severe renal impairment.");n("Etoricoxib ()","Lithium - ",e.DRUG_DRUG,i.MODERATE,"             .                .","Etoricoxib reduces the renal clearance of Lithium, leading to decreased excretion and accumulation in the body. The exact mechanism is related to the inhibition of renal prostaglandins, which play a role in regulating renal blood flow and electrolyte excretion.","               .   :          .","Increased serum Lithium levels, which can lead to toxicity even if the Lithium dose remains unchanged. Symptoms of toxicity include: tremor, lethargy, speech disturbances, seizures, and cardiac arrhythmias.","   .              ( 3-5    )     .      .","Avoid concomitant use if possible. If combination is unavoidable, monitor serum Lithium levels closely (within 3-5 days of starting Etoricoxib) and adjust the Lithium dose as needed. Educate the patient and family about symptoms of Lithium toxicity.");n("Etrasimod","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Etrasimod. Carbamazepine    CYP3A4    Etrasimod.","Decreased Etrasimod concentration. Carbamazepine is a strong inducer of CYP3A4, an Etrasimod metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Everolimus","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Everolimus. Phenytoin    CYP3A4    Everolimus.","Decreased Everolimus concentration. Phenytoin is a strong inducer of CYP3A4, an Everolimus metabolic pathway.","              .","Reduced drug plasma concentration, leading to failure of immunosuppression or cancer treatment.","    .   CYP3A4     Everolimus  .","Avoid combination or dose adjustment. Avoid strong CYP3A4 inducers or increase Everolimus dose and monitor levels.");n("Everolimus (mTOR)","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Everolimus.      CYP3A4.","Increased Everolimus concentration. Grapefruit juice is a CYP3A4 inhibitor.","   /.","Increased risk of renal/hematological toxicity."," .         CYP3A4 ( ).","Contraindicated. Avoid grapefruit juice and other CYP3A4 inhibiting fruits (e.g., pomegranate).");n("Evinacumab","Simvastatin",e.DRUG_DRUG,i.MODERATE,"  Simvastatin. Evinacumab       CYP3A4.","Decreased Simvastatin concentration. Evinacumab may increase the expression of some CYP3A4 enzymes.","  Simvastatin   .","Reduced efficacy of Simvastatin in lowering cholesterol."," .       .","Level monitoring. Lipid levels must be monitored and statin dose adjusted.");n("Exemestane","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"  Exemestane. Carbamazepine    CYP3A4    Exemestane.","Decreased Exemestane concentration. Carbamazepine is a strong inducer of CYP3A4, an Exemestane metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure.","   .    CYP3A4 .","Avoid combination or monitoring. Strong CYP3A4 inducers must be avoided.");n("Exemestane","CYP3A4 Inducers",e.DRUG_DRUG,i.MODERATE,"  ","Exemestane metabolism induction.","  ","Reduced exemestane efficacy.","    ","Dose increase may be necessary.");n("Exenatide","Oral Medications",e.DRUG_DRUG,i.MODERATE,"  ","Delayed gastric emptying.","   ","Reduced oral drug absorption.","      ","Take oral meds 1 hour before exenatide.");n("Fam-trastuzumab deruxtecan","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"    (deruxtecan). Carbamazepine    CYP3A4.","Decreased concentration of active metabolite (deruxtecan). Carbamazepine is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Famotidine","Glipizide",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric Emptying. Faster absorption onset."," "," ","  ","  ");n("Famotidine","Dasatinib",e.DRUG_DRUG,i.MODERATE," pH ","Increased gastric pH.","  ","Reduced dasatinib absorption.","     ","Take dasatinib 2 hours before famotidine.");n("Febuxostat","Azathioprine/Mercaptopurine",e.DRUG_DRUG,i.HIGH,"  Azathioprine/Mercaptopurine. Febuxostat   Xanthine oxidase.","Increased Azathioprine/Mercaptopurine concentration. Febuxostat inhibits Xanthine oxidase enzyme.","     .","Increased risk of severe myelosuppression."," .   .","Contraindicated. Avoid the combination.");n("Febuxostat","Azathioprine",e.DRUG_DRUG,i.HIGH," XO","Xanthine oxidase inhibition."," ","Azathioprine toxicity."," ","Contraindicated.");n("Fedratinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Fedratinib. Itraconazole    CYP3A4    Fedratinib.","Increased Fedratinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Fedratinib metabolic pathway.","         (CNS)  .","Increased risk of side effects, especially Central Nervous System (CNS) toxicity and hepatotoxicity."," .    Fedratinib     CYP3A4 .","Dose adjustment. Fedratinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Fedratinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Fedratinib.       CYP3A4  .","Increased Fedratinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      .","Increased risk of side effects, especially hepatotoxicity."," .  .","Contraindicated. Avoid consumption.");n("Fedratinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Fedratinib. Rifampin    CYP3A4.","Decreased Fedratinib concentration. Rifampin is a strong inducer of CYP3A4.","      .","Reduced drug efficacy and failure of myelofibrosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Fedratinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Fedratinib. Itraconazole    CYP3A4.","Increased Fedratinib concentration. Itraconazole is a strong inhibitor of CYP3A4.","     (Wernicke's encephalopathy)  .","Increased risk of Wernicke's encephalopathy and hematological toxicity."," .    Fedratinib  .","Dose adjustment. Fedratinib dose must be significantly reduced.");n("Felodipine",Tt,e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4)**.    .","Mechanism: **Hepatic enzyme induction (CYP3A4)**. Barbiturates accelerate the metabolism of Felodipine."," : **   **        .","Clinical Significance: **Decreased felodipine levels and effects**, leading to loss of blood pressure control.","         .","Increase felodipine dose if necessary to maintain therapeutic efficacy.");n("Felodipine","Carbamazepine",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.     .","Mechanism: **CYP3A4 Enzyme induction**. Carbamazepine induces hepatic metabolism of Felodipine."," : **  **     .","Clinical Significance: **Decreased felodipine effects** and failure to lower blood pressure.","     .","Increase dose to maintain Felodipine efficacy.");n("Felodipine","Erythromycin",e.DRUG_DRUG,i.MODERATE,": ** CYP3A4**.       .","Mechanism: **CYP3A4 inhibition**. Erythromycin inhibits the enzyme responsible for Felodipine breakdown."," : **   **         .","Clinical Significance: **Increased felodipine levels and effects**, increasing the risk of hypotension and peripheral edema.","      .","Decrease dose and adjust based on blood pressure response.");n("Felodipine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4 **.      CYP3A4         .","Mechanism: **Intestinal CYP3A4 inhibition**. Grapefruit juice inhibits CYP3A4 enzyme in the intestinal wall, increasing the bioavailability of Felodipine."," : **    **               .","Clinical Significance: **Significantly increased felodipine levels**, increasing the risk of dose-dependent side effects like flushing and hypotension.","  .           .","Avoid combination strictly. Grapefruit juice or fruit should be avoided during therapy.");n("Felodipine",er,e.DRUG_DRUG,i.MODERATE,": **  (CYP3A4)**.  ( )     .","Mechanism: **Enzyme induction (CYP3A4)**. Hydantoins (e.g., Phenytoin) are strong hepatic enzyme inducers."," : **  **      .","Clinical Significance: **Decreased felodipine effects** and failure to control blood pressure.","    .","Increase dose to maintain efficacy.");n("Felodipine","Itraconazole",e.DRUG_DRUG,i.MODERATE,": ** CYP3A4**.        .","Mechanism: **CYP3A4 inhibition**. Itraconazole is a potent inhibitor of the enzyme responsible for Felodipine metabolism."," : **   **         .","Clinical Significance: **Increased felodipine levels and effects**, increasing the risk of severe hypotension and edema.","     .   .","Decrease dose when starting Itraconazole therapy. Monitor blood pressure.");n("Felodipine","Phenobarbital",e.DRUG_DRUG,i.MODERATE,"   (   )","Reduced Felodipine Efficacy. Enhanced metabolism lowers plasma levels.","        .","        .","    .      .","    .      .");n("Felodipine","Pentobarbital",e.DRUG_DRUG,i.MODERATE,"   (   )","Reduced Felodipine Efficacy. Enhanced metabolism lowers plasma levels.","        .","        .","    .      .","    .      .");n("Felodipine","Secobarbital",e.DRUG_DRUG,i.MODERATE,"   (   )","Reduced Felodipine Efficacy. Enhanced metabolism lowers plasma levels.","        .","        .","    .      .","    .      .");n("Felodipine","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"   (   )","Reduced Felodipine Efficacy. Enhanced metabolism lowers plasma levels.","        .","        .","    .      .","    .      .");n("Felodipine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Felodipine.       CYP3A4  .","Increased Felodipine concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","        .","Increased risk of hypotension, edema, and reflex tachycardia."," .  .","Contraindicated. Avoid consumption.");n("Felodipine","Amobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Aprobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Butabarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Butalbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Meghobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Pentobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Phenobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Primidone",e.DRUG_DRUG,i.MODERATE,"imidone    CYP3A4    ","imidone    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Secobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Ethotoin",e.DRUG_DRUG,i.MODERATE,"       ","       ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Fosphenytoin",e.DRUG_DRUG,i.MODERATE,"       ","       ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Mephenytoin",e.DRUG_DRUG,i.MODERATE,"       ","       ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine","Phenytoin",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled Hypertension. Reduced felodipine effect.","    -      ","    -      ");n("Felodipine - ","Erythromycin - ",e.DRUG_DRUG,i.MODERATE,"       P450 3A4 (CYP3A4)   .                 CYP3A4.                   250-350 (  2.5  3.5    ).     2-3                  .","Erythromycin is a potent and moderate inhibitor of cytochrome P450 3A4 (CYP3A4) in the liver and intestine. Felodipine is one of the most sensitive substrates for this enzyme, as its metabolism depends almost entirely on CYP3A4. The inhibition leads to a significant reduction in the first-pass metabolism of Felodipine, increasing its bioavailability by up to 250-350% (a 2.5 to 3.5-fold increase in systemic exposure). This effect begins within 2-3 days of starting Erythromycin therapy and may persist for several days after its discontinuation due to Erythromycin`s long half-life and cumulative effect.","         .   : 1.                (   ). 2.     . 3.          ( )   ( ). 4.                  .","Significant increase in the hypotensive and vasodilatory effects of Felodipine. This leads to: 1. Acute hypotension with symptoms such as severe dizziness, lightheadedness, syncope, especially upon standing (orthostatic hypotension). 2. Reflex tachycardia as a compensatory response. 3. Increased frequency and severity of Felodipine side effects like headache, flushing, peripheral edema (ankle swelling). 4. In elderly patients or those with impaired liver function, these effects may be more pronounced and dangerous.","1.    :                  . 2.    :     50-70   (:  10   5   )    . 3.  :    ( )         . 4.  :       CYP3A4     . 5.   :         3-5    . 6.  :            .","1. Avoid combination if possible: It is preferable not to combine the two drugs, especially in elderly patients or those with unstable blood pressure. 2. If combination is necessary: Reduce the Felodipine dose by at least 50-70% (e.g., from 10 mg to 5 mg or less) when starting Erythromycin therapy. 3. Intensive monitoring: Monitor blood pressure (standing and sitting) and heart rate daily during the combination period. 4. Erythromycin alternatives: Use other antibiotics that do not inhibit CYP3A4 such as amoxicillin, doxycycline, or azithromycin. 5. Adjustment upon discontinuation: When discontinuing Erythromycin, gradually increase the Felodipine dose over 3-5 days to the previous level. 6. Patient education: Alert the patient to immediately report any dizziness, fainting, or heart palpitations.");n("Felodipine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.HIGH,"      (  )      CYP3A4    .                              200-400.    4         24      .      (200 )     .","Grapefruit juice contains furanocoumarins (such as bergamottin and dihydroxybergamottin) that irreversibly inhibit CYP3A4 in the wall of the small intestine. Felodipine is one of the drugs most affected by this interaction, as inhibition of the intestinal enzyme significantly reduces the first-pass metabolism of Felodipine, increasing its bioavailability by up to 200-400%. The effect begins within 4 hours of juice consumption and may persist for more than 24 hours due to the irreversible nature of the inhibition. Even a small amount of juice (200 ml) can cause a significant interaction.","        .   : 1.               . 2.              . 3.           . 4.                           .","Significant and dangerous increase in the hypotensive effects of Felodipine. This leads to: 1. Acute and severe hypotension with threatening symptoms such as severe dizziness, syncope, and poor concentration. 2. Reflex bradycardia or cardiac arrhythmias may occur. 3. Marked increase in side effects such as severe headache, flushing, and peripheral edema. 4. In extreme cases, it may lead to ischemia of vital organs such as the heart or brain, especially in elderly patients or those with underlying cardiovascular diseases.","1.  :                   . 2.  :                      . 3.  :              4-6   24-48 . 4.  :        . 5.  :       consider             . 6.  :             .","1. Complete avoidance: Total abstinence from grapefruit juice, fresh grapefruit, or any products containing them during Felodipine therapy. 2. Comprehensive education: Educate the patient and family about the seriousness of this interaction and alert them that it can occur even with small amounts and may persist for several days. 3. Emergency monitoring: If exposure to grapefruit is suspected, monitor blood pressure and heart rate every 4-6 hours for 24-48 hours. 4. Safe alternatives: Suggest alternative juices such as orange or apple juice. 5. Drug switching: For patients who regularly consume grapefruit, consider switching to calcium channel blockers that are not affected by this interaction to the same degree, such as amlodipine. 6. Label reading: Alert the patient to read the ingredients of all food products and supplements to avoid hidden grapefruit.");n("Felodipine - ","Itraconazole - ",e.DRUG_DRUG,i.MODERATE,"       P450 3A4 (CYP3A4)     .                 CYP3A4.                       600-800 (  6-8    ).          .","Itraconazole is a potent and established inhibitor of cytochrome P450 3A4 (CYP3A4) in both the intestine and liver. Felodipine is an especially sensitive substrate for this enzyme, as its metabolism depends almost entirely on CYP3A4. The inhibition leads to a significant reduction in the first-pass metabolism of Felodipine in the intestinal wall and liver, increasing its bioavailability by up to 600-800% (a 6-8 fold increase in systemic exposure). Itraconazole also markedly prolongs the biological half-life of Felodipine.","         .   : 1.              . 2.     . 3.          ( )   ( ) . 4.             ( )  .","Significant increase in the hypotensive and vasodilatory effects of Felodipine. This leads to: 1. Acute hypotension with symptoms such as severe dizziness, lightheadedness, syncope, and poor concentration. 2. Reflex tachycardia as a compensatory response. 3. Increased frequency and severity of Felodipine side effects like headache, flushing, peripheral edema (ankle swelling), and dizziness. 4. In severe cases, ischemia of vital organs such as the heart (angina) or brain may occur.","1.    :                . 2.    :     75-90   (:  10   2.5 )    . 3.  :             . 4.  :                  . 5.  :        CYP3A4      . 6.  :           CYP3A4      . 7.  :            .","1. Avoid combination if possible: It is preferable not to combine the two drugs, especially at the start of therapy or when using high doses of Felodipine. 2. If combination is necessary: Reduce the Felodipine dose by at least 75-90% (e.g., from 10 mg to 2.5 mg) when starting Itraconazole therapy. 3. Intensive monitoring: Monitor blood pressure and heart rate daily, especially during the first week of combination. 4. Dosing timing: Consider separating the administration times by several hours, noting that this does not completely prevent the interaction. 5. Itraconazole alternatives: Use other antifungals with less CYP3A4 inhibition such as low-dose fluconazole, or terbinafine. 6. Felodipine alternatives: Use calcium channel blockers that do not rely entirely on CYP3A4, such as amlodipine, also with close monitoring. 7. Patient education: Alert the patient to immediately report any dizziness, fainting, or leg swelling.");n("Fenfluramine","Fluoxetine",e.DRUG_DRUG,i.HIGH,"   .     .","Increased risk of Serotonin Syndrome. Both increase serotonin activity.","       .","Agitation, hyperreflexia, fever, and tachycardia."," .    .","Contraindicated. Avoid the combination.");n("Fenfluramine","Fluoxetine",e.DRUG_DRUG,i.HIGH,"  Fenfluramine  . Fluoxetine   CYP2D6.","Increased Fenfluramine and metabolite concentration. Fluoxetine inhibits CYP2D6.","         (PAH).","Increased risk of valvular heart disease and Pulmonary Hypertension (PAH)."," .    Fenfluramine.","Dose adjustment. Fenfluramine dose must be reduced.");n("Fentanyl - ","Ethanol -  ()",e.DRUG_FOOD,i.CONTRAINDICATED,"                   GABA","Dangerous synergistic CNS depression where ethanol amplifies fentanyl effects on opioid and GABA receptors","            ","Acute life-threatening respiratory depression, severe hypotension, coma, respiratory arrest, and death","       -        24     -    ","Complete avoidance of alcohol during fentanyl therapy - continuous monitoring of respiratory function and vital signs for 24 hours after last dose - have naloxone and resuscitation equipment available");n("Fentanyl - ","Ritonavir - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     CYP3A4                  ","Ritonavir is a potent and comprehensive inhibitor of hepatic and intestinal CYP3A4 enzyme, the primary and nearly exclusive metabolic pathway for Fentanyl, significantly reducing its clearance and prolonging its half-life","      3-5                 ","3-5 fold increase in Fentanyl plasma concentration, acute life-threatening respiratory depression, coma, respiratory arrest, and death especially with repeated doses or drug accumulation","   -    -            -    :     75-90%      24-72 ","Absolute contraindication - avoid combination entirely - use alternative opioids like morphine or hydromorphone with close monitoring - if combination unavoidable: reduce Fentanyl dose by 75-90% with continuous respiratory monitoring for 24-72 hours");n("Fentanyl - ","Brain Tumor -  ",e.DRUG_DISEASE,i.HIGH,"       (ICP)                (hypercapnia)   ","Fentanyl may increase intracranial pressure (ICP) due to its respiratory depressant effect leading to hypercapnia and cerebral vasodilation","           ","Increased intracranial pressure, neurological deterioration, decreased level of consciousness, cerebral edema","         -     :        -   ","Use safer analgesic alternatives like low-dose morphine - if Fentanyl is necessary: continuous monitoring of ICP and neurological function - avoid high doses");n("Fentanyl - ","Intracranial Tumor -   ",e.DRUG_DISEASE,i.HIGH,"                ","Intracranial tumors may compromise the blood-brain barrier and increase CNS sensitivity to Fentanyl depressant effects","          ","Excessive CNS depression, cognitive function impairment, exacerbation of neurological symptoms","      -       -     ","Initiate therapy with very low and gradual doses - closely monitor neurological and cognitive function - individualize dose based on response");n("Fentanyl - ","Increased ICP -    ",e.DRUG_DISEASE,i.CONTRAINDICATED,"                 ICP   ","Fentanyl may cause acute increase in intracranial pressure in patients with baseline elevated ICP or cerebral edema","            ","Acute life-threatening increase in intracranial pressure, brain herniation, respiratory arrest, death","          -           (    )","Contraindicated in cases of untreated increased ICP - use alternative analgesics like paracetamol or NSAIDs (if not contraindicated)");n("Fentanyl - ","Brain Metastases -  ",e.DRUG_DISEASE,i.HIGH,"              ","Brain metastases increase blood-brain barrier fragility and alter CNS drug kinetics","         ","Unpredictable drug effects, sudden respiratory depression, exacerbation of neurological symptoms","     -     50-75% -      ","Intensive monitoring in care unit - initiate with 50-75% reduced doses - slow dose titration based on tolerance");n("Fentanyl - ","Post-Neurosurgery -    ",e.DRUG_DISEASE,i.MODERATE,"            ","Post-neurosurgery patients are more sensitive to Fentanyl effects on intracranial pressure","           ","ICP fluctuations, delayed awakening from anesthesia, respiratory complications","    -        -        ICP","Use low and intermittent doses - continuous ICP and neurological monitoring - immediate discontinuation if any signs of increased ICP appear");n("Fentanyl - ","Constipation - ",e.DRUG_DISEASE,i.HIGH,"    enteric              ","Fentanyl inhibits mu-opioid receptors in the enteric nervous system, reducing gastrointestinal motility and secretions, and increasing water absorption","          ","Severe chronic constipation, fecal impaction, pseudo-obstruction, abdominal pain, and nausea"," :    ( )   (   )   -     -    ","Prevention is essential: routinely prescribe stimulant laxatives (senna, bisacodyl) and osmotic laxatives (lactulose, polyethylene glycol) - increase fluid and fiber intake - monitor bowel movements daily");n("Fentanyl - ","Chronic Constipation -  ",e.DRUG_DISEASE,i.CONTRAINDICATED,"           ","Exacerbation of pre-existing chronic constipation due to strong inhibitory effect of Fentanyl on intestinal motility","         ","Refractory constipation, acute fecal impaction, risk of bowel obstruction, and fecal toxicity","          -         ( ) -   :       ","Avoid Fentanyl in patients with severe chronic constipation - use non-opioid analgesics or mixed opioid agonists (like tapentadol) - if necessary: initiate intensive prophylactic laxative therapy before Fentanyl");n("Fentanyl - ","Opioid-Induced Constipation -    ",e.DRUG_DISEASE,i.HIGH,"          ","Fentanyl exacerbates pre-existing or previous opioid-induced constipation","           ( )","Worsening of current constipation, resistance to conventional laxatives, need for peripheral opioid antagonists (like naloxegol)","     (  ) -    -    ","Treatment with peripheral opioid antagonists (methylnaltrexone, naloxegol) - adjust laxative regimen - monitor treatment response weekly");n("Fentanyl - ","Bowel Obstruction History -   ",e.DRUG_DISEASE,i.CONTRAINDICATED,"            ","Fentanyl may cause pseudo-obstruction or contribute to recurrence of true bowel obstruction","        ","Pseudo-obstruction, severe abdominal pain, distension, nausea, and vomiting","         -    -   :      ","Contraindicated in patients with history of bowel obstruction - use alternative analgesics - if necessary: continuous monitoring of GI symptoms and radiographic imaging");n("Fentanyl - ","Elderly with Constipation -   ",e.DRUG_DISEASE,i.HIGH,"             ","Elderly are more susceptible to Fentanyl constipating effects due to age-related decreased gastrointestinal motility","        ","Severe constipation, dehydration, delirium, and falls due to straining during defecation","        -     -     ","Initiate prophylactic laxative therapy with first Fentanyl dose - use lowest effective dose - monitor fluid balance and mental status");n("Fentanyl - ","Urinary Retention -  ",e.DRUG_DISEASE,i.MODERATE,"                      ","Fentanyl increases sympathetic and decreases parasympathetic bladder activity, impairing detrusor contraction and increasing urethral sphincter resistance","            ","Acute urinary retention, bladder distension, suprapubic pain, and increased UTI risk","       -        -       ","Monitor urine output especially with initial doses - assess bladder function in at-risk patients - use temporary catheterization if needed");n("Fentanyl - ","Seizures -  ",e.DRUG_DISEASE,i.MODERATE,"                     ","Fentanyl may lower seizure threshold via opioid receptor effects in CNS, especially with high doses or rapid injection","              ","Generalized or focal seizures, epileptiform EEG activity, especially in predisposed patients","     -     -      ","Caution in epileptic patients - avoid high and rapid doses - neurological monitoring in at-risk patients");n("Fentanyl - ","Renal Dysfunction -   ",e.DRUG_DISEASE,i.MODERATE,"        ()        ","Fentanyl is primarily hepatically metabolized, but its metabolite (norfentanyl) may accumulate in renal failure causing toxic effects","             ","Prolonged respiratory depression, excessive drowsiness, nausea, vomiting due to metabolite accumulation in severe renal impairment","      (CrCl <30 /) -    -       ","Dose adjustment in severe renal impairment (CrCl <30 mL/min) - extended respiratory monitoring - avoid chronic use in advanced kidney disease");n("Fentanyl - ","Pancreatitis -  ",e.DRUG_DISEASE,i.MODERATE,"                ","Fentanyl may cause spasm of sphincter of Oddi, increasing pancreatic duct pressure and exacerbating acute pancreatitis","          ","Worsening pancreatic pain, elevated pancreatic enzymes, prolonged acute pancreatitis duration","       -      -     ","Avoid Fentanyl in active acute pancreatitis - use alternatives like hydromorphone - close monitoring of pain and pancreatic function");n("Fentanyl - ","Liver Disease -  ",e.DRUG_DISEASE,i.HIGH,"     CYP3A4          ","Fentanyl undergoes hepatic metabolism via CYP3A4 and may accumulate in advanced liver disease with reduced metabolic clearance","            ","Severe prolonged respiratory depression, hepatic encephalopathy, coma in advanced cirrhosis patients","   50-75%       -       -     ","Reduce dose by 50-75% in moderate to severe liver disease - avoid use in acute liver failure - continuous monitoring of respiratory and neurological function");n("Ferrous Gluconate","Tetracycline",e.DRUG_DRUG,i.MODERATE,"    ","Non-absorbable Complex Formation. Chemical binding in the gut lumen prevents drug absorption.","   ","Mutual Malabsorption. Therapeutic failure.","     ","     ");n("Ferrous Gluconate","Doxycycline",e.DRUG_DRUG,i.MODERATE,"    ","Non-absorbable Complex Formation. Chemical binding in the gut lumen prevents drug absorption.","   ","Mutual Malabsorption. Therapeutic failure.","     ","     ");n("Ferrous Gluconate","Minocycline",e.DRUG_DRUG,i.MODERATE,"    ","Non-absorbable Complex Formation. Chemical binding in the gut lumen prevents drug absorption.","   ","Mutual Malabsorption. Therapeutic failure.","     ","     ");n("Ferrous Gluconate","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Gluconate","Levofloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Gluconate","Moxifloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Gluconate","Ofloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Gluconate","Norfloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Sulfate","Tetracycline",e.DRUG_DRUG,i.MODERATE,"    ","Non-absorbable Complex Formation. Chemical binding in the gut lumen prevents drug absorption.","   ","Mutual Malabsorption. Therapeutic failure.","     ","     ");n("Ferrous Sulfate","Doxycycline",e.DRUG_DRUG,i.MODERATE,"    ","Non-absorbable Complex Formation. Chemical binding in the gut lumen prevents drug absorption.","   ","Mutual Malabsorption. Therapeutic failure.","     ","     ");n("Ferrous Sulfate","Minocycline",e.DRUG_DRUG,i.MODERATE,"    ","Non-absorbable Complex Formation. Chemical binding in the gut lumen prevents drug absorption.","   ","Mutual Malabsorption. Therapeutic failure.","     ","     ");n("Ferrous Sulfate","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Sulfate","Levofloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Sulfate","Moxifloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Sulfate","Ofloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Ferrous Sulfate","Norfloxacin",e.DRUG_DRUG,i.MODERATE," ","Complexation. Formation of non-absorbable complexes in the gastrointestinal tract.","   ","Reduced Antibiotic Absorption. Treatment failure.","     ","     ");n("Fexofenadine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": **  OATP  (Intestinal OATP Transporter Inhibition)**.       ( naringin  bergamottin)      (OATP1A2)            .          ****    .","Mechanism: **Intestinal OATP transporter inhibition**. Grapefruit juice contains compounds (e.g., naringin and bergamottin) that inhibit organic anion transporting polypeptide (OATP1A2) transporters in intestinal wall, which are responsible for transporting fexofenadine from intestine into blood. Unlike most grapefruit interactions, this one **decreases** absorption rather than increasing it."," : **     ** ( 40-70%)    **    **        (Urticaria).        -          .","Clinical Significance: **Significant decrease in fexofenadine bioavailability** (by 40-70%), leading to **failure to control allergy symptoms** such as sneezing, runny nose, itchy eyes, and urticaria. Effect depends on amount and timing of juice consumption - strongest when juice is taken with or shortly before medication.","    ( ) ****   .         **  **    .        ()   .      .   (2-4 ) ** **  .","Avoid grapefruit juice (and the fruit itself) **completely** during fexofenadine treatment. If patient wants to drink citrus juice, **orange juice is safe** and does not cause this interaction. Apple juice may also cause similar (weaker) interaction so preferably avoid it. Take fexofenadine with plain water only. Time separation (2-4 hours) is **NOT sufficient** to avoid interaction.");n("Fezolinetant","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Fezolinetant. Itraconazole    CYP3A4    Fezolinetant.","Increased Fezolinetant concentration. Itraconazole is a strong CYP3A4 inhibitor, a Fezolinetant metabolic pathway.","       .","Increased risk of side effects, especially elevated liver enzymes."," .   .","Contraindicated. Avoid the combination.");n("Fezolinetant - ","Fluvoxamine - ",e.DRUG_DRUG,i.HIGH,"    CYP1A2               ","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme, which is the primary and sole metabolic pathway for Fezolinetant, leading to a significant increase in its concentration","      (     ALT)      ","Markedly increased risk of hepatotoxicity (sharp elevation in ALT liver enzymes), severe hot flashes, nausea, and abdominal pain","   -    -              ","Absolutely contraindicated - avoid combination entirely - use alternatives for hot flashes such as estrogens or gabapentin if Fluvoxamine is necessary");n("Fiber Supplements","Levothyroxine",e.DRUG_DRUG,i.MODERATE," ","Reduced absorption."," ","Hypothyroidism.","  4 ","Separate by 4 hours.");n("Fidaxomicin","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Fidaxomicin  . Cyclosporine   P-gp    Fidaxomicin.","Increased plasma concentration of Fidaxomicin. Cyclosporine inhibits P-gp, a Fidaxomicin efflux transporter.","       ().","May increase the risk of systemic side effects (theoretically).",".               .","Monitoring. Routine dose adjustment is not required, but the patient must be monitored for increased side effects.");n("Filgotinib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Filgotinib. Cyclosporine     P-glycoprotein (P-gp)    Filgotinib.","Increased Filgotinib concentration. Cyclosporine is a strong inhibitor of P-glycoprotein (P-gp), an efflux transporter for Filgotinib.","      Filgotinib     .","Increased risk of Filgotinib-related side effects, such as infections or anemia."," .    P-gp .       Filgotinib.","Dose adjustment. Strong P-gp inhibitors should be avoided. If necessary, Filgotinib dose must be reduced.");n("Filgotinib","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  Filgotinib. Fluconazole    CYP3A4    Filgotinib.","Increased Filgotinib concentration. Fluconazole is a moderate CYP3A4 inhibitor, a Filgotinib metabolic pathway.","        .","Increased risk of side effects, such as infections or anemia."," .    Filgotinib     CYP3A4 .","Dose adjustment. Filgotinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Filgotinib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Filgotinib. Cyclosporine   P-gp    Filgotinib.","Increased Filgotinib concentration. Cyclosporine inhibits P-gp, a Filgotinib efflux transporter.","        .","Increased risk of side effects, such as infections or anemia.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Filgotinib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Filgotinib. Cyclosporine   P-gp    Filgotinib.","Increased Filgotinib concentration. Cyclosporine inhibits P-gp, a Filgotinib efflux transporter.","       .","Increased risk of side effects, especially infection and hematological toxicity."," .         .","Close monitoring. Close monitoring for side effects and dose adjustment if necessary.");n("Finerenone","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Finerenone. Itraconazole     CYP3A4      Finerenone.","Increased Finerenone concentration. Itraconazole is a strong CYP3A4 inhibitor, the primary metabolic pathway for Finerenone.","     (Hyperkalemia)    .","Increased risk of severe Hyperkalemia and hypotension."," .    CYP3A4   Finerenone.","Contraindicated. Strong CYP3A4 inhibitors must be avoided with Finerenone.");n("Finerenone","Verapamil",e.DRUG_DRUG,i.HIGH,"  Finerenone. Verapamil     CYP3A4      Finerenone.","Increased Finerenone concentration. Verapamil is a moderate inhibitor of CYP3A4, the primary metabolic pathway for Finerenone.","     (Hyperkalemia)    Finerenone.","Increased risk of Hyperkalemia due to elevated Finerenone levels."," .    CYP3A4   .        .","Potassium monitoring. Moderate or strong CYP3A4 inhibitors should be avoided. If co-administration is necessary, close potassium monitoring is required.");n("Finerenone","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Finerenone. Phenytoin    CYP3A4    Finerenone.","Decreased Finerenone efficacy. Phenytoin is a strong inducer of CYP3A4, a Finerenone metabolic pathway.","           .","Reduced drug concentration, leading to failure of hyperkalemia control."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Finerenone","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Finerenone. Itraconazole    CYP3A4    Finerenone.","Increased Finerenone concentration. Itraconazole is a strong CYP3A4 inhibitor, a Finerenone metabolic pathway.","     (Hyperkalemia).","Increased risk of Hyperkalemia."," .    CYP3A4 .","Contraindicated. Strong CYP3A4 inhibitors must be avoided.");n("Finerenone","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Finerenone. Efavirenz    CYP3A4    Finerenone.","Decreased Finerenone efficacy. Efavirenz is a moderate inducer of CYP3A4, a Finerenone metabolic pathway.","           .","Reduced drug concentration, leading to failure of hyperkalemia control."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Finerenone","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Finerenone.       CYP3A4  .","Increased Finerenone concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","     (Hyperkalemia) .","Increased risk of Hyperkalemia and toxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Finerenone","Ibuprofen",e.DRUG_DRUG,i.HIGH,"     (Hyperkalemia).     .","Increased risk of Hyperkalemia. Additive effect on potassium levels.","     .","Increased risk of dangerous cardiac arrhythmias."," .        .","Close monitoring. Potassium levels and renal function must be monitored frequently.");n("Finerenone (Kerendia)","Itraconazole",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.   Finerenone  4 .","Mechanism: **Potent CYP3A4 Inhibition**. Finerenone concentration increases 4-fold."," : **  **  .","Clinical Significance: **Life-threatening hyperkalemia**.","  .   .","Absolute contraindication. Avoid combination.");n("Finerenone (Kerendia)","Spironolactone",e.DRUG_DRUG,i.HIGH,": **    **.","Mechanism: **Synergistic potassium-sparing effect**."," : **  ** .","Clinical Significance: **Severe hyperkalemia**."," .        .","Avoid combination. Monitor potassium frequently if combination necessary.");n("Finerenone (Kerendia)","ACE Inhibitors (Enalapril)",e.DRUG_DRUG,i.MODERATE,": **    **.","Mechanism: **Synergistic potassium-sparing effect**."," : **   **.","Clinical Significance: **Hyperkalemia risk**.","   (  ).","Monitor potassium regularly (weekly initially).");n("Finerenone (Kerendia)","Chronic Kidney Disease Stage 4 (   4)",e.DRUG_DISEASE,i.HIGH,": **  **.","Mechanism: **Reduced renal excretion**."," : ** **   .","Clinical Significance: **Drug accumulation** and hyperkalemia.","  CKD Stage 4-5.    CKD Stage 3.","Avoid in CKD Stage 4-5. Close monitoring in CKD Stage 3.");n("Finerenone (MRA)","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Finerenone. Itraconazole    CYP3A4.","Increased Finerenone concentration. Itraconazole is a strong inhibitor of CYP3A4.","     (Hyperkalemia)  .","Increased risk of hyperkalemia and renal insufficiency."," .   .","Contraindicated. Avoid the combination.");n("Finerenone (MRA)","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Finerenone. Phenytoin    CYP3A4.","Decreased Finerenone concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug efficacy, leading to failure of kidney disease treatment."," .   .","Contraindicated. Avoid the combination.");n("Fingolimod","Metoprolol",e.DRUG_DRUG,i.HIGH,"  .       .","Exacerbated Bradycardia. Both drugs decrease heart rate.","     (Severe Bradycardia)     Fingolimod.","Increased risk of severe Bradycardia, particularly upon initiation of Fingolimod therapy."," .      .       ECG  6 .","Contraindicated. Heart rate-lowering drugs should be avoided. If necessary, continuous ECG monitoring for 6 hours.");n("Fingolimod","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Fingolimod   (Sphingosine 1-phosphate receptor modulator).","Increased risk of infection. Fingolimod is an immunosuppressant (Sphingosine 1-phosphate receptor modulator).","     .","Risk of developing infection from live vaccines."," .        Fingolimod.","Contraindicated. Live vaccines must be avoided during Fingolimod treatment.");n("Fingolimod (S1P modulator)","Amiodarone",e.DRUG_DRUG,i.HIGH,"   .       /   QT.","Increased risk of bradycardia. Additive effect on heart rate and/or QT prolongation.","   .","Severe and dangerous bradycardia."," .   .","Contraindicated. Avoid the combination.");n("Flecainide","Ritonavir",e.DRUG_DRUG,i.HIGH,": **  (CYP2D6)**.    CYP2D6    .","Mechanism: **Metabolism inhibition (CYP2D6)**. Ritonavir inhibits the CYP2D6 enzyme responsible for Flecainide metabolism."," : **  **       (  ).","Clinical Significance: **Increased Flecainide levels**, increasing the risk of serious cardiotoxicity (ventricular arrhythmias)."," .         .","Avoid combination. If necessary, reduce Flecainide dose and monitor closely.");n("Flecainide","Propranolol",e.DRUG_DRUG,i.MODERATE,"  ","Flecainide metabolism inhibition.","  ","Increased flecainide levels."," ECG","Monitor ECG.");n("Fluconazole","Diazepam",e.DRUG_DRUG,i.HIGH,"  ","Increased Benzodiazepine Levels. Reduced metabolic clearance leads to prolonged sedation and respiratory depression risk.","     .","Severe CNS Depression. Coma and respiratory failure.","   /. (  ).","   /. (  ).");n("Fluconazole","Lorazepam",e.DRUG_DRUG,i.HIGH,"  ","Increased Benzodiazepine Levels. Reduced metabolic clearance leads to prolonged sedation and respiratory depression risk.","     .","Severe CNS Depression. Coma and respiratory failure.","   /. (  ).","   /. (  ).");n("Fluconazole","Alprazolam",e.DRUG_DRUG,i.HIGH,"  ","Increased Benzodiazepine Levels. Reduced metabolic clearance leads to prolonged sedation and respiratory depression risk.","     .","Severe CNS Depression. Coma and respiratory failure.","   /. (  ).","   /. (  ).");n("Fluconazole","Clonazepam",e.DRUG_DRUG,i.HIGH,"  ","Increased Benzodiazepine Levels. Reduced metabolic clearance leads to prolonged sedation and respiratory depression risk.","     .","Severe CNS Depression. Coma and respiratory failure.","   /. (  ).","   /. (  ).");n("Fluconazole","Buspirone () ",e.DRUG_DRUG,i.HIGH,"  ","Increased Buspirone Levels. Reduced clearance enhances effects.","     .","Severe CNS Depression. Coma and respiratory failure.","   /. (  ).","   /. (  ).");n("Fluconazole","Ciclosporin () -   ",e.DRUG_DRUG,i.HIGH,"  ","Increased Cyclosporine Levels. Risk of nephrotoxicity.","      .","      .","    . (  ).","    . (  ).");n("Fluconazole","Dexamethasone () -  ",e.DRUG_DRUG,i.MODERATE,"   (/  )","Altered Corticosteroid Levels. Azoles may inhibit or induce metabolism depending on the specific agent.","      .","      ."," . (  )."," . (  ).");n("Fluconazole","Grapefruit Juice ( )",e.DRUG_FOOD,i.MODERATE,"      ","Reduced Azole Absorption. pH-dependent absorption is impaired.","   .","   .","  .","  .");n("Fluconazole","Warfarin",e.DRUG_DRUG,i.HIGH," CYP2C9 -   ","CYP2C9 inhibition reduces warfarin metabolism."," INR  ","Increased INR and bleeding risk."," INR  2-3  -     25-50%","Monitor INR every 2-3 days - reduce warfarin dose by 25-50%.");n("Fluconazole - ","Atorvastatin - ",e.DRUG_DRUG,i.HIGH,"       P450 3A4 (CYP3A4)     .                 300-400 (     3-4 ).       P-glycoprotein OATP1B1               .","Fluconazole is a potent and moderate inhibitor of cytochrome P450 3A4 (CYP3A4), the primary metabolic pathway for Atorvastatin. Fluconazole significantly reduces Atorvastatin metabolism, increasing its plasma concentration by up to 300-400% (3-4 fold increase in systemic exposure). Fluconazole also inhibits drug transporters like P-glycoprotein and OATP1B1, reducing Atorvastatin excretion and increasing its absorption, contributing to further elevation in its levels.","1.   ():                . 2.  :           (CK). 3.  :      (ALT, AST)  . 4.   :             .","1. Rhabdomyolysis: Significantly increased risk of serious muscle breakdown that can lead to acute renal failure and death. 2. Myopathy: Muscle pain, muscle weakness, and fatigue with elevated creatine kinase (CK) levels. 3. Hepatotoxicity: Increased risk of elevated liver enzymes (ALT, AST) and hepatitis. 4. Other systemic effects: Increased risk of other Atorvastatin side effects such as sleep disturbances, headache, and gastrointestinal disorders.","1.    :            . 2.   :        2-3    . 3.    :     75-80 (:  40   10 )    . 4.  :     (CK)     2-3 . 5.  :               . 6.  :        CYP3A4        . 7.  :      CYP3A4        .","1. Avoid combination if possible: Do not use both drugs together unless benefits clearly outweigh risks. 2. Temporary Atorvastatin discontinuation: Stop Atorvastatin during Fluconazole treatment and for 2-3 days after completion. 3. If combination is necessary: Reduce Atorvastatin dose by 75-80% (e.g., from 40 mg to 10 mg) with daily symptom monitoring. 4. Intensive monitoring: Check creatine kinase (CK), creatinine, and liver enzyme levels every 2-3 days. 5. Patient education: Alert patient to immediately report any muscle pain, weakness, dark urine, or unusual fatigue. 6. Fluconazole alternatives: Use other antifungals with less CYP3A4 inhibition such as low-dose voriconazole or cautious itraconazole use. 7. Atorvastatin alternatives: Use statins not dependent on CYP3A4 like rosuvastatin or pravastatin at low doses with monitoring.");n("Fludrocortisone","High-Sodium Foods",e.DRUG_FOOD,i.MODERATE,"      -     ","Fludrocortisone retains sodium via mineralocorticoid receptors - high salt intake increases fluid retention.","   ","Edema and hypertension.","   -    -  ","Monitor salt intake - weigh daily - monitor blood pressure.");n("Fluorouracil (topical)","Leucovorin",e.DRUG_DRUG,i.MODERATE," ","Increased toxicity.","  ","Severe skin irritation."," ","Avoid combination.");n("Fluoxetine","Metoprolol",e.DRUG_DRUG,i.MODERATE,"  Metoprolol. Fluoxetine    CYP2D6.","Increased Metoprolol concentration. Fluoxetine is a strong inhibitor of CYP2D6.","      .","Increased risk of bradycardia and hypotension."," .         Metoprolol   .","Close monitoring. Monitor heart rate and blood pressure and reduce Metoprolol dose if necessary.");n("Fluoxetine","Alcohol",e.DRUG_FOOD,i.LOW,":   .        Fluoxetine    .","Mechanism: Additive CNS depression. Alcohol increases the neurological side effects of Fluoxetine like drowsiness and impaired judgment.",":      .","Result: Increased drowsiness and impaired coordination and motor skills.",":            .","Management: Advise avoidance of alcohol during treatment, but actual drug concentration interaction is low.");n("Fluoxetine","Caffeine",e.DRUG_FOOD,i.HIGH,": **  ** (CYP2D6). Fluoxetine  CYP2D6         .","Mechanism: **Metabolic Enzyme Inhibition** (CYP2D6). Fluoxetine inhibits CYP2D6, a minor metabolism pathway for Caffeine, raising Caffeine levels.",": **     **     .","Result: **Significant increase in Caffeine side effects** like anxiety, nervousness, insomnia, and palpitations.",":         .","Management: Caffeine intake must be significantly limited and symptoms monitored.");n("Fluoxetine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,":  CYP3A4. Fluoxetine    CYP3A4        .","Mechanism: CYP3A4 inhibition. Fluoxetine is partially metabolized by CYP3A4, and grapefruit juice may slightly increase its concentration.",":     Fluoxetine       .","Result: Slight increase in Fluoxetine and its active metabolite concentration, potentially increasing side effects.",":       .","Management: Avoid consuming large amounts of grapefruit juice.");n("Fluoxetine","Green Tea",e.DRUG_FOOD,i.LOW,":         .","Mechanism: Additive stimulant effect due to Caffeine content in Green Tea.",":          .","Result: Slight increase in nervousness and insomnia, especially in stimulant-sensitive patients.",":       .","Management: Monitor symptoms and limit Green Tea intake.");n("Fluoxetine","Milk",e.DRUG_FOOD,i.HIGH,":    .            .","Mechanism: No known interaction. Interaction is hypothetical, potentially due to milk's effect on digestive enzymes or absorption.",":             .","Result: No expected clinical effect, but monitor drug efficacy if changes are noted.",":  .","Management: Routine monitoring.");n("Fluoxetine","High-fat meals",e.DRUG_FOOD,i.MODERATE,":          Fluoxetine.    .","Mechanism: Food does not significantly affect Fluoxetine bioavailability. It may slightly delay absorption.",":            .","Result: Slight delay in reaching peak concentration with no effect on overall efficacy.",":       .","Management: The medication can be taken with or without food.");n("Fluoxetine","High-fiber foods",e.DRUG_FOOD,i.LOW,":         .","Mechanism: High-concentration fibers may delay the rate of drug absorption.",":      .     .","Result: Slight delay in reaching peak concentration. No clinically significant effect.",":    .","Management: No routine adjustment required.");n("Fluoxetine","Vitamin C",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with neurotransmitter metabolism.",":             .","Result: No expected clinical effect, but monitor serotonin symptoms if changes are noted.",":  .","Management: Routine monitoring.");n("Fluoxetine","Vitamin D",e.DRUG_FOOD,i.MODERATE,":      .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Vitamin E",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Vitamin K",e.DRUG_FOOD,i.HIGH,":    .           .","Mechanism: No known interaction. Interaction is hypothetical, but caution if the patient is taking blood thinners.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Vitamin B12",e.DRUG_FOOD,i.MODERATE,":      .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Folic Acid",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Iron",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Calcium",e.DRUG_FOOD,i.MODERATE,":    .        .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with absorption.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Magnesium",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Zinc",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Potassium",e.DRUG_FOOD,i.MODERATE,":      .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,":            Fluoxetine   .","Mechanism: Sodium Bicarbonate may temporarily alter gastric pH, but Fluoxetine absorption is not pH-sensitive.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Fluoxetine","Antacids",e.DRUG_FOOD,i.HIGH,":    .        .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with absorption.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Fluoxetine - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE,"      though mechanisms not fully understood","Fluoxetine may alter Digoxin pharmacokinetics through mechanisms not fully understood","           ","Altered Digoxin blood levels affecting both efficacy and safety","         ","Monitor Digoxin levels regularly and adjust dose as needed");n("Fluoxetine - ","Cyclosporine - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4     ","Fluoxetine inhibits hepatic CYP3A4 enzymes responsible for Cyclosporine metabolism","       ","Increased Cyclosporine concentration and elevated risk of renal and hepatic toxicity","      -     ","Monitor Cyclosporine levels and renal/hepatic function - reduce Cyclosporine dose if necessary");n("Fluoxetine - ","Cyproheptadine - ",e.DRUG_DRUG,i.MODERATE,"          ","Cyproheptadine is a serotonin receptor antagonist reducing Fluoxetine therapeutic efficacy","        ","Reduced therapeutic efficacy of Fluoxetine in treating depression and other disorders","    -        ","Avoid combination if possible - closely monitor therapeutic response when combination is necessary");n("Fluoxetine - ","Tobacco Smoking - ",e.DRUG_FOOD,i.MODERATE,"       CYP1A2    ","Aromatic hydrocarbons in smoke induce CYP1A2 enzyme responsible for Fluoxetine metabolism","          ","Decreased Fluoxetine blood levels potentially reducing its therapeutic efficacy","   -     ","Monitor therapeutic response - may require Fluoxetine dose increase in smokers");n("Fluoxetine - ","MAO Inhibitors -  MAO",e.DRUG_DRUG,i.CONTRAINDICATED,"           ","Synergistic increase in serotonergic activity leading to life-threatening serotonin syndrome risk","           ","Acute serotonin syndrome with hyperthermia, tremor, muscle rigidity, and mental status changes","   -   5        MAO","Absolute contraindication - 5-week washout after Fluoxetine before starting MAO inhibitors");n("Fluoxetine - ","Other SSRIs -    ",e.DRUG_DRUG,i.HIGH,"         ","Synergistic serotonergic activity and mutual inhibition of hepatic metabolism","     ","High risk of serotonin syndrome and serotonergic toxicity","      -      ","Avoid combining SSRIs - use alternatives from different drug classes");n("Fluoxetine - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       ","Cimetidine inhibits hepatic enzymes responsible for Fluoxetine metabolism","        ","Increased Fluoxetine blood levels and elevated risk of adverse effects","    -      ","Monitor for adverse effects - use alternatives like famotidine or ranitidine");n("Fluoxetine - ","Rifampin - ",e.DRUG_DRUG,i.MODERATE,"       ","Rifampin induces hepatic enzymes responsible for Fluoxetine metabolism","          ","Decreased Fluoxetine blood levels potentially reducing its therapeutic efficacy","   -   ","Monitor therapeutic response - may require Fluoxetine dose increase");n("Fluoxetine - ","Clonidine - ",e.DRUG_DRUG,i.MODERATE,"        ","Fluoxetine may reduce the antihypertensive efficacy of Clonidine","      ","Hypertension and poor blood pressure control","    -      ","Monitor blood pressure regularly - adjust Clonidine dose or use alternatives");n("Fluoxetine - ","Carbamazepine - ",e.DRUG_DRUG,i.HIGH,"   -      ","Mutual metabolic inhibition - Fluoxetine inhibits Carbamazepine metabolism and vice versa","      ","Increased levels of both drugs and elevated toxicity risk","      ","Monitor levels of both drugs and clinical signs of toxicity");n("Fluoxetine - ","Phenytoin - ",e.DRUG_DRUG,i.HIGH,"       ","Fluoxetine inhibits Phenytoin metabolism increasing its levels","   (   )","Increased Phenytoin toxicity (ataxia, nystagmus, confusion)","     -    ","Monitor Phenytoin levels and toxicity symptoms - adjust dose as needed");n("Fluoxetine - ","Decongestants -  ",e.DRUG_DRUG,i.MODERATE,"      ","Fluoxetine potentiates sympathomimetic effects of decongestants","         ","Increased risk of hypertension, tachycardia, and cardiovascular effects","       -   ","Avoid combination or use non-pharmacological alternatives - monitor vital signs");n("Fluoxetine - ","Tramadol - ",e.DRUG_DRUG,i.HIGH,"      ","Synergistic serotonergic activity and inhibition of Tramadol metabolism","    ","Increased risk of serotonin syndrome and seizures","        ","Avoid combination or use alternative analgesics with close monitoring");n("Fluoxetine - ","Thioridazine - ",e.DRUG_DRUG,i.HIGH,"  (CYP2D6).     CYP2D6   .","Metabolic Inhibition (CYP2D6). Fluoxetine is a potent inhibitor of the CYP2D6 enzyme that metabolizes Thioridazine.","               QT     ( Torsades de Pointes).","Substantial increase in Thioridazine plasma concentration, significantly raising the risk of QT interval prolongation and life-threatening cardiac arrhythmias (e.g., Torsades de Pointes).","      ( ).        QT     CYP2D6.","Co-administration is strictly contraindicated. An alternative non-QT-prolonging or non-CYP2D6 metabolized drug must be used.");n("Flurazepam","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"     .","Additive Central Nervous System (CNS) Depressant Effects.","           .","Increased risk of severe drowsiness, dizziness, impaired concentration, respiratory depression, and increased risk of falls.","   .               .","Alcohol must be completely avoided. With other depressants, use the lowest effective doses and monitor for over-sedation and breathing difficulties.");n("Flurazepam","Cimetidine (or other CYP Inhibitors)",e.DRUG_DRUG,i.MODERATE,"   ( CYP).       .","Enzymatic Metabolic Inhibition (especially CYP). These drugs slow down the breakdown of Flurazepams active metabolites.","               (Daytime Sleepiness).","Accumulation of active metabolites, leading to prolonged and increased hypnotic effect and next-day residual sleepiness.","     .       .","Monitor the patient for excessive drowsiness. A reduction in the Flurazepam dose may be necessary.");n("Flurazepam","Rifampin (or other strong CYP Inducers)",e.DRUG_DRUG,i.MODERATE,"    (CYP).       .","Potent Enzymatic Metabolic Induction (CYP). These drugs increase the metabolism of active metabolites.","            (Insomnia Recurrence).","Decreased levels of active metabolites, resulting in reduced drug efficacy and a return of insomnia (Treatment Failure).","     .            .","Monitor the patient for insomnia recurrence. A Flurazepam dose increase or switching to an alternative drug may be needed.");n("Flurazepam","Diltiazem",e.DRUG_DRUG,i.MODERATE,"     ( CYP3A4 ).      .","Inhibition of Flurazepam metabolism by Diltiazem (moderate CYP3A4 inhibitor). Diltiazem prolongs the half-life of active metabolites.","               (Daytime Sleepiness)     (CNS).","Increased concentration of Flurazepam active metabolites, leading to an increased risk of excessive next-day drowsiness and CNS depression.","         .          .","Closely monitor the patient for drowsiness, dizziness, and impaired concentration. A reduction in the Flurazepam dose may be necessary to avoid over-sedation.");n("Flurazepam","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"   (CYP3A4).        .","Inhibition of Enzymatic Metabolism (CYP3A4). Grapefruit reduces the breakdown of Flurazepams active metabolites.","                 (Daytime Sleepiness)     (CNS).","Increased concentration of Flurazepam active metabolites, leading to prolonged and increased hypnotic effect and next-day residual sleepiness and CNS depression.","       .          .","Advise the patient to avoid consuming grapefruit and its juice during treatment. If consumed, the patient should be monitored for excessive drowsiness.");n("Fluticasone","Ritonavir",e.DRUG_DRUG,i.HIGH,": **     CYP3A4**.       CYP3A4              .","Mechanism: **Severe and prolonged CYP3A4 enzyme inhibition**. Ritonavir is one of the most potent known CYP3A4 inhibitors, completely preventing fluticasone breakdown and leading to very high systemic corticosteroid accumulation."," : **     ** (   350 )   **   (Iatrogenic Cushing Syndrome)**            .   **    - (HPA Axis Suppression)**          .","Clinical Significance: **Massive increase in systemic fluticasone exposure** (up to 350-fold), causing **iatrogenic Cushing syndrome** with symptoms like weight gain, moon face, acne, and hypertension. Also causes **severe hypothalamic-pituitary-adrenal (HPA) axis suppression**, potentially leading to acute adrenal insufficiency upon abrupt discontinuation.","  ** **    .     **   CYP3A4**  ** (Beclomethasone)**  ** (Ciclesonide)**.            .        .","Avoid combination **absolutely**, especially for long-term use. Use alternative inhaled corticosteroid **not metabolized by CYP3A4** such as **beclomethasone** or **ciclesonide**. If combination has occurred, monitor for Cushing syndrome signs and check morning cortisol levels. Gradual fluticasone withdrawal if used long-term.");n("Fluticasone/Vilanterol","Beta-Blockers",e.DRUG_DRUG,i.MODERATE,"    (    )","Antagonistic bronchial effect (beta-blockade vs beta-stimulation)."," ","Asthma exacerbation.","    ","Avoid non-selective beta-blockers.");n("Fluvoxamine - ","Methadone - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4 CYP1A2             ","Fluvoxamine is a potent inhibitor of hepatic CYP3A4 and CYP1A2 enzymes responsible for Methadone metabolism, reducing its clearance and increasing its half-life","    30-40%           ","30-40% increase in Methadone concentration leading to serious respiratory depression, confusion, coma, and serotonin syndrome","    25-50%          -    ","Reduce Methadone dose by 25-50% with continuous respiratory monitoring and plasma Methadone levels - watch for opioid toxicity signs");n("Fluvoxamine - ","Tacrine - ",e.DRUG_DRUG,i.HIGH,"    CYP1A2             5-8 ","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme responsible for Tacrine primary metabolism, increasing drug exposure by 5-8 fold","      (  )    ","Increased Tacrine toxicity particularly hepatotoxicity (elevated liver enzymes), nausea, vomiting, and muscle cramps","   -       -         10-20%     ","Avoid combination entirely - use alternatives like donepezil or rivastigmine - if combination necessary, reduce Tacrine dose to 10-20% with weekly liver enzyme monitoring");n("Fluvoxamine - ","Thioridazine - ",e.DRUG_DRUG,i.HIGH,"     CYP1A2 CYP2D6          3-5 ","Fluvoxamine is a potent dual inhibitor of hepatic CYP1A2 and CYP2D6 enzymes essential for Thioridazine metabolism, increasing its concentration by 3-5 fold","   QT (>500  )              ","Significant QT interval prolongation (>500 ms), high risk of fatal Torsades de Pointes arrhythmia, hypotension, and neurotoxicity","   (   ) -        CYP1A2/CYP2D6     ","Combination absolutely contraindicated - use alternative antipsychotics not dependent on CYP1A2/CYP2D6 like quetiapine with cardiac monitoring");n("Fluvoxamine - ","Theophylline - ",e.DRUG_DRUG,i.HIGH,"    CYP1A2               ","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme responsible for Theophylline primary metabolism, reducing its clearance and significantly prolonging its half-life","    300-500             ","300-500% increase in Theophylline concentration leading to high risk of seizures, cardiac arrhythmias, nausea, vomiting, and death","    50-75    -       2-3     -     ","Reduce Theophylline dose by 50-75% when starting Fluvoxamine - monitor Theophylline blood levels every 2-3 days after initiation and adjust - monitor for neuro/cardiac toxicity signs");n("Folic Acid","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  ","Increased phenytoin metabolism."," ","Breakthrough seizures.","  ","Monitor phenytoin levels.");n("Fondaparinux","Antiplatelet Agents",e.DRUG_DRUG,i.HIGH,"   ","Additive bleeding effect."," ","Dangerous bleeding.","  ","Use with extreme caution.");n("Formoterol","Diuretics",e.DRUG_DRUG,i.MODERATE,": **     (Synergistic Hypokalemia)**.  ( -2)           (   )      .","Mechanism: **Synergistic potassium-lowering effect**. Formoterol (beta-2 agonist) causes intracellular potassium shift from extracellular to intracellular compartment, while diuretics (especially loop and thiazide) increase renal potassium excretion."," : **    (Hypokalemia)**     (K+ < 3.0 mEq/L)       **   ** (Cardiac Arrhythmias)         QT.","Clinical Significance: **Hypokalemia** that may be severe (K+ < 3.0 mEq/L), significantly increasing the risk of **serious cardiac arrhythmias** including ventricular tachycardia and QT prolongation.","      ( 1-2      ). ** **   (    ).       ( )    .    (ECG)       .","Monitor serum potassium levels regularly (every 1-2 weeks when initiating therapy, then monthly). **Potassium supplementation** when needed (dietary or supplements). Consider potassium-sparing diuretics (e.g., spironolactone) in high-risk patients. Monitor ECG in patients with cardiac disease.");n("Formoterol - ","Propranolol -  (   )",e.DRUG_DRUG,i.HIGH," .    -2      .","Pharmacodynamic Antagonism. Propranolol blocks beta-2 receptors, counteracting the bronchodilator effect of Formoterol.","     ( )        .","Loss of bronchodilator efficacy and risk of causing severe, life-threatening bronchospasm.","       .           .","Absolute Contraindication in asthma/COPD patients. Cardio-selective beta-blockers must be used with extreme caution if medically necessary.");n("Formoterol - ","Imipramine -  (TCA)",e.DRUG_DRUG,i.MODERATE,"   .       (Sympathomimetic amines).","Potentiation of cardiovascular effects. Imipramine increases the activity of sympathomimetic amines.","     (Tachycardia)     (Arrhythmias)   .","Increased risk of severe tachycardia, arrhythmias, and hypertension."," .              .","Use with caution. Closely monitor heart rate and blood pressure and adjust the dosage if necessary.");n("Formoterol - ","Tranylcypromine -  (MAOI)",e.DRUG_DRUG,i.MODERATE,"   .  MAOI    .","Potentiation of cardiovascular effects. MAOIs prevent the breakdown of sympathomimetic amines.","     (Tachycardia)     (Arrhythmias)   .","Increased risk of severe tachycardia, arrhythmias, and hypertension."," .              .","Use with caution. Closely monitor heart rate and blood pressure and adjust the dosage if necessary.");n("Formoterol - ","Furosemide -  (  )",e.DRUG_DRUG,i.MODERATE,"    .      .","Additive hypokalemic effects. Both agents contribute to lowering potassium levels.","     (Hypokalemia)          .","Significantly increased risk of hypokalemia, potentially leading to serious cardiac arrhythmias.",".            .","Monitor. Closely monitor serum potassium levels at treatment initiation.");n("Formoterol - ","Prednisone -  ()",e.DRUG_DRUG,i.MODERATE,"    .       .","Exacerbated hypokalemia risk. Corticosteroids increase renal potassium loss.","       .","Increased risk of hypokalemia and cardiac arrhythmias.",".              .","Monitor. Closely monitor serum potassium levels; potassium supplementation may be required.");n("Formoterol - ","Theophylline -  ( )",e.DRUG_DRUG,i.MODERATE,"       .    .","Additive effects on cardiac stimulation and hypokalemia. Both are bronchodilator agents.","          .","Increased risk of cardiac arrhythmias and exacerbated hypokalemia risk.",".         (ECG)    .","Monitor. Closely monitor serum potassium levels and ECG upon initiating co-therapy.");n("Fosaprepitant","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Fosaprepitant   CYP3A4    Midazolam.","Increased Midazolam concentration. Fosaprepitant inhibits CYP3A4, a Midazolam metabolic pathway.","      (CNS) .","Increased risk of Central Nervous System (CNS) depression and sedation."," .    Midazolam            CYP3A4.","Dose adjustment. Oral Midazolam dose must be significantly reduced, or a non-CYP3A4 metabolized alternative used.");n("Fosaprepitant","Warfarin",e.DRUG_DRUG,i.MODERATE,"  Warfarin. Fosaprepitant ( Aprepitant)   CYP2C9    Warfarin.","Decreased Warfarin concentration. Fosaprepitant (and the metabolite Aprepitant) induce CYP2C9, a Warfarin metabolic pathway.","  Warfarin     .","Reduced Warfarin efficacy, leading to risk of thrombosis."," .   INR   ( )     Fosaprepitant.","Close monitoring. INR must be monitored intensively (for two weeks) after initiation of Fosaprepitant therapy.");n("Foscarnet ()","Ciclosporin ()",e.DRUG_DRUG,i.HIGH,"   ","   ","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .        .","    .        .");n("Fosdenopterin (Nulibry)","No significant interactions",e.DRUG_DRUG,i.LOW,": **   **.   .","Mechanism: **No known interactions**. Very rare medication."," : ****.","Clinical Significance: **Low**.","   .","No special precautions.");n("Fosinopril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Fostamatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Fostamatinib. Rifampin    CYP3A4    Fostamatinib.","Decreased Fostamatinib concentration. Rifampin is a strong inducer of CYP3A4, a Fostamatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Fostamatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Fostamatinib. Ketoconazole    CYP3A4    Fostamatinib.","Increased Fostamatinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Fostamatinib metabolic pathway.","       .","Increased risk of diarrhea, hypertension, and hepatotoxicity."," .    Fostamatinib     CYP3A4 .","Dose adjustment. Fostamatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Fostemsavir (Rukobia)","Strong CYP3A4 Inducers (Phenytoin)",e.DRUG_DRUG,i.HIGH,": **  CYP3A4**.   Fostemsavir  .","Mechanism: **CYP3A4 induction**. Fostemsavir concentration significantly decreases."," : **      **.","Clinical Significance: **Reduced HIV treatment efficacy**."," .      .","Avoid combination. Use alternatives that do not induce hepatic enzymes.");n("Fremanezumab","Sumatriptan",e.DRUG_DRUG,i.LOW,"     (     ).","No true interaction expected (biologics are not affected by hepatic metabolism).","       .","Potential additive effect in migraine control."," .         .","Symptom monitoring. Dose adjustment is usually not required, but response should be monitored.");n("Fremanezumab (Ajovy)","Pregnancy ()",e.DRUG_DISEASE,i.MODERATE,": **  **.     .","Mechanism: **Limited safety data**. Unknown fetal effects."," : **   **.","Clinical Significance: **Potential fetal risks**.","        .","Avoid in pregnancy unless benefit outweighs risk.");n("Fulvestrant","Itraconazole",e.DRUG_DRUG,i.LOW,"     .   Fulvestrant        CYP.","No clinically significant interaction expected. Fulvestrant is mainly metabolized via non-CYP dependent pathways.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Furosemide","Gentamicin",e.DRUG_DRUG,i.HIGH,"   .    .","Increased risk of ototoxicity. Additive ototoxic effect.","    .","Increased risk of permanent hearing loss.","    .         .","Avoid combination or close monitoring. Avoid combination or closely monitor auditory function.");n("Furosemide","Cholestyramine",e.DRUG_DRUG,i.MODERATE,"    ","Reduced gastrointestinal absorption of furosemide","  ","Reduced furosemide efficacy","      ","Administer cholestyramine at least 2 hours after furosemide");n("Furosemide","Colestipol",e.DRUG_DRUG,i.MODERATE,"    ","Reduced gastrointestinal absorption of furosemide","  ","Reduced furosemide efficacy","      ","Administer colestipol at least 2 hours after furosemide");n("Furosemide","Gentamicin",e.DRUG_DRUG,i.HIGH,"  ","Synergistic ototoxicity.","  ","Permanent hearing loss.","  -   ","Avoid - or monitor hearing.");n("Furosemide","Alcohol",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Caffeine",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Green Tea",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Milk",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","High-fat meals",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","High-fiber foods",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Vitamin C",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Vitamin D",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Vitamin E",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Vitamin K",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Vitamin B12",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Folic Acid",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Iron",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Calcium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Magnesium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Zinc",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Potassium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Furosemide","Antacids",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Futibatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Futibatinib. Phenytoin     CYP3A4      Futibatinib.","Decreased Futibatinib efficacy. Phenytoin is a strong inducer of CYP3A4, the primary metabolic pathway for Futibatinib.","            .","Severe decrease in plasma drug concentration, leading to cancer treatment failure."," .   Phenytoin      CYP3A4.","Avoid Combination. Phenytoin must be replaced with an anticonvulsant that does not induce CYP3A4.");n("Futibatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Futibatinib. Phenytoin    CYP3A4.","Decreased Futibatinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Futibatinib (Lytgobi)","Nail Toxicity Risk",e.DRUG_DISEASE,i.MODERATE,": ** FGFR**.    .","Mechanism: **FGFR inhibition**. Causes nail changes."," : **  **  .","Clinical Significance: **Paronychia** and nail detachment.","  .  .  .","Prophylactic nail care. Avoid trauma. Use moisturizers.");n("G6PD Deficiency ( )","Sulfa Drugs / Aspirin / Fava Beans -   /  / ",e.DRUG_DISEASE,i.HIGH,"    G6PD           .       (  )  (  )   (  )       (ROS)  .                      .          .","Patients with G6PD deficiency have a impaired glutathione antioxidant system within red blood cells. Oxidizing agents such as sulfa drugs (e.g., sulfamethoxazole, dapsone), salicylates (high-dose aspirin), and certain foods (fava beans and some legumes) increase the production of reactive oxygen species (ROS) within the cell. This leads to hemoglobin oxidation and Heinz body formation, damage to cell membranes, and ultimately premature hemolysis of red blood cells. The severity of the reaction depends on the degree of enzyme deficiency and the patient`s genetic variant.","1.   :        (  )     . 2.   :    enough to require blood transfusion. 3.   :          . 4.   (Kernicterus):       .            .","1. Acute Hemolysis: Sudden onset of weakness, pallor, jaundice, dark urine (due to bilirubin and hemoglobin), and abdominal or back pain. 2. Hemolytic Anemia: Can be severe enough to require blood transfusion. 3. Acute Kidney Injury: In severe cases due to obstruction of renal tubules by hemoglobin breakdown products. 4. Kernicterus: In infants with severe jaundice resulting from hemolysis. Symptom severity depends on the amount of drug/food ingested and the degree of enzyme deficiency.","1.  :      (       )    . 2.   :         G6PD     . 3.   :           . 4.   :                 . 5.   :                 .","1. Strict Avoidance: Avoid all known oxidizing drugs (sulfa drugs, nitrofurantoin, some antimalarials, high-dose aspirin) and avoid consumption of fava beans and their products. 2. Safe Drug List: Consult updated lists of safe and contraindicated drugs for G6PD deficiency before prescribing any new medication. 3. Patient and Family Education: Educate the patient and family about the condition and provide them with a list of medications and foods to avoid. 4. Monitoring if Necessary: If an oxidizing drug must be used, hospitalize the patient for close monitoring of hemoglobin, bilirubin, and haptoglobin. 5. Prompt Management of Hemolysis: If hemolysis occurs, immediately discontinue the causative drug, support the patient with IV fluids, and transfuse blood if necessary.");n("Galantamine","Ketoconazole/Paroxetine",e.DRUG_DRUG,i.MODERATE,"  Galantamine.  CYP3A4/2D6    Galantamine.","Increased Galantamine concentration. CYP3A4/2D6 inhibitors reduce Galantamine metabolism.","     (  ).","Increased risk of cholinergic side effects (e.g., nausea and vomiting)."," .        .","Close monitoring. Monitor side effects and reduce dose if necessary.");n("Galcanezumab","Venlafaxine",e.DRUG_DRUG,i.LOW,"     (     ).","No true interaction expected (biologics are not affected by hepatic metabolism).","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Ganciclovir","Mycophenolate Mofetil",e.DRUG_DRUG,i.HIGH,"    .     .","Increased risk of myelosuppression. Additive hematological toxic effect.","      .","Increased risk of severe neutropenia and anemia.","  .          .","Relative contraindication. The combination must be avoided or blood counts monitored intensively.");n("Ganciclovir - ","Zidovudine - ",e.DRUG_DRUG,i.HIGH,"         .              .               lasting  .                 .          .","Both drugs cause bone marrow suppression as a major side effect. Ganciclovir inhibits myeloid cell division, while Zidovudine causes direct mitochondrial toxicity in bone marrow cells. When combined, they exhibit synergistic myelotoxicity, leading to deeper and more prolonged bone marrow suppression. The combination significantly increases the incidence and severity of neutropenia and anemia compared to either drug alone. The mechanism may also involve interference with intracellular phosphorylation processes.","1.   :         (     ). 2.   :           . 3.  :   . 4.    :       .                    .","1. Severe Neutropenia: Significantly increased risk of life-threatening opportunistic infections (e.g., sepsis, pneumonia, fungal infections). 2. Severe Anemia: May require frequent blood transfusions, with symptoms of fatigue, dyspnea, and pallor. 3. Thrombocytopenia: Increased risk of bleeding. 4. Pancytopenia: May take weeks to recover after drug discontinuation. Toxicity is more severe in patients with impaired renal function or advanced AIDS.","1.    :                 . 2.  :     (Foscarnet)   (Cidofovir)     . 3.    :     50       (CBC)     . 4.  :       (G-CSF)         . 5.    :        . 6.   :      .","1. Avoid combination if possible: This combination is relatively contraindicated, especially in patients with low baseline blood counts. 2. Use alternatives: Replace Ganciclovir with Foscarnet or Cidofovir if clinically appropriate. 3. If combination is necessary: Reduce Zidovudine dose by at least 50% and monitor complete blood count (CBC) two to three times weekly. 4. Supportive therapy: Use granulocyte colony-stimulating factor (G-CSF) for neutropenia, erythropoietin for anemia, and blood transfusion as needed. 5. Renal dose adjustment: Precisely adjust Ganciclovir dose based on glomerular filtration rate. 6. Close clinical monitoring: Watch for any signs of infection or bleeding.");n("Ganciclovir / Penciclovir -  / ","Probenecid - ",e.DRUG_DRUG,i.MODERATE,"                OAT1 OAT3.           .           (AUC)    50-100            .","Probenecid reduces the active tubular renal secretion of Ganciclovir and Penciclovir by inhibiting renal drug transporters such as OAT1 and OAT3. This leads to decreased drug clearance and increased systemic exposure. For Ganciclovir, Probenecid can increase the area under the curve (AUC) by up to 50-100%, prolonging the half-life and leading to drug accumulation, especially with multiple doses.","1.   :           (     )   (  )  . 2.   :            . 3.   :   . 4.   :          .","1. Increased Drug Toxicity: Increased frequency and severity of Ganciclovir side effects such as bone marrow suppression (neutropenia, anemia, thrombocytopenia), neurotoxicity (headache, confusion, seizures), and renal toxicity. 2. Flu-like Symptoms: Rash, fever, malaise, myalgia, which may be related to drug accumulation. 3. Gastrointestinal Disturbances: Nausea, vomiting, diarrhea. 4. Increased Renal Toxicity: Especially in patients with pre-existing renal impairment.","1.   :     (CBC)   (   )      . 2.  :           . 3.   :       . 4.  :         25-50    . 5.    :           . 6.  :            .","1. Close Neutrophil Monitoring: Monitor complete blood count (CBC) frequently (at least twice weekly) for early detection of bone marrow suppression. 2. Clinical Monitoring: Watch for symptoms of neurotoxicity and systemic toxicity such as headache, confusion, fever, and rash. 3. Renal Function Monitoring: Regularly check serum creatinine and urea levels. 4. Dose Adjustment: May require a 25-50% reduction in Ganciclovir dose when used with Probenecid. 5. Benefit-Risk Assessment: Assess the necessity of continuing the drug combination, especially if signs of toxicity appear. 6. Patient Education: Inform the patient about potential side effects and advise immediate reporting of any new symptoms.");n("Garlic Supplements","Antiplatelet Agents",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic antiplatelet effect.","  ","Increased bleeding risk.","  ","Avoid high doses.");n("Gefitinib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Gefitinib. Ketoconazole    CYP3A4    Gefitinib.","Increased Gefitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Gefitinib metabolic pathway.","     .","Increased risk of side effects, especially diarrhea.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Gefitinib","Rifampin",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 induction."," ","Treatment failure."," ","Avoid combination.");n("Gemcitabine","Radiation Therapy",e.DRUG_DRUG,i.HIGH,"   ","Synergistic tissue effect.","  ","Severe radiation toxicity.","  ","Adjust doses and timing.");n("Gemfibrozil","Statins (HMG-CoA Reductase Inhibitors)",e.DRUG_DRUG,i.HIGH,"  ","Inhibition of statin metabolism","    (Rhabdomyolysis)","Increased risk of rhabdomyolysis","   ","Refer to Lipid-lowering agents");n("Gemfibrozil - ","Atorvastatin - ",e.DRUG_DRUG,i.HIGH,"   OATP1B1          ","Gemfibrozil inhibits OATP1B1 transporter and reduces hepatic metabolism of Atorvastatin, increasing systemic exposure","         (CK)    ","Increased risk of myopathy and rhabdomyolysis, elevated muscle enzymes (CK), myalgia, weakness, and tenderness","    -   :    20    -     CK","Avoid combination if possible - if necessary: do not exceed 20 mg of Atorvastatin - monitor muscle symptoms and CK enzymes");n("Gemfibrozil - ","Simvastatin - ",e.DRUG_DRUG,i.HIGH,"          CYP3A4   OATP","Gemfibrozil increases Simvastatin concentration by inhibiting its metabolism via CYP3A4 and OATP transporters","           ","Significant increase in rhabdomyolysis risk, acute renal failure, and severe muscular toxicity","   -   -      ","Relative contraindication - avoid combination - use safer alternatives like fenofibrate");n("Gemfibrozil - ","Lovastatin - ",e.DRUG_DRUG,i.HIGH,"     CYP3A4  OATP1B1","Dual inhibition of Lovastatin metabolism via CYP3A4 and OATP1B1 transporters","         ","High risk of life-threatening muscular toxicity, rhabdomyolysis, and renal failure","   -    -      ","Avoid combination entirely - use fenofibrate as alternative - monitor muscles and kidneys if combination unavoidable");n("Gemfibrozil - ","Pravastatin - ",e.DRUG_DRUG,i.MODERATE,"         OATP1B1","Gemfibrozil increases Pravastatin concentration by inhibiting OATP1B1 transporter","          CK","Moderate increase in myopathy risk, myalgia, and elevated CK enzymes","   40    -    -   12 ","Do not exceed 40 mg of Pravastatin - monitor muscle symptoms - separate doses by 12 hours");n("Gemfibrozil - ","Rosuvastatin - ",e.DRUG_DRUG,i.MODERATE,"  OATP1B1    ","OATP1B1 transporter inhibition increases Rosuvastatin exposure","         ","Increased risk of muscular toxicity, especially with high Rosuvastatin doses","    10   -  CK  -   ","Restrict Rosuvastatin dose to 10 mg daily - monitor CK and muscles - avoid high doses");n("Gemfibrozil - ","Fluvastatin - ",e.DRUG_DRUG,i.MODERATE,"         ","Limited effect on Fluvastatin metabolism with moderate muscular toxicity risk","         CK","Mild to moderate increase in muscle pain and CK elevation risk","  40    -   ","Do not exceed 40 mg of Fluvastatin - routine clinical monitoring");n("Gemfibrozil - ","Pitavastatin - ",e.DRUG_DRUG,i.MODERATE,"       OATP1B1","Moderate effect on Pitavastatin concentration via OATP1B1 inhibition","     ","Moderate increase in muscular toxicity risk","    2   -  ","Restrict Pitavastatin dose to 2 mg daily - muscle monitoring");n("Gentamicin","Vancomycin",e.DRUG_DRUG,i.HIGH,"  .","Nephrotoxicity & Ototoxicity. Synergistic damage to kidney and inner ear.","  .","  ."," ."," .");n("Gentamicin","Cephalexin",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Gentamicin","Ceftriaxone",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Gentamicin","Cefuroxime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Gentamicin","Cefixime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Gentamicin","Cefotaxime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Gentamicin","Furosemide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Gentamicin","Torsemide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Gentamicin","Bumetanide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Gentamicin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Gentamicin","Furosemide",e.DRUG_DRUG,i.HIGH,"   ","Synergistic ototoxicity and nephrotoxicity.","    ","Permanent hearing loss and renal failure.","    -    ","Monitor hearing and renal function - avoid if possible.");n("Gilteritinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Gilteritinib. Rifampin    CYP3A4.","Decreased Gilteritinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Ginger","Anticoagulants",e.DRUG_DRUG,i.MODERATE,"  ","Anticoagulant effect.","  ","Increased bleeding risk."," ","Use cautiously.");n("Gingko Biloba","Aspirin / Warfarin",e.DRUG_FOOD,i.MODERATE,"  .","  .",".","Hemorrhage. Bleeding.",".",".");n("Ginseng","Warfarin",e.DRUG_DRUG,i.MODERATE," INR","Decreased INR.","  ","Reduced warfarin efficacy."," ","Avoid combination.");n("Givosiran","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  Phenytoin. Givosiran   CYP3A4    Phenytoin.","Decreased Phenytoin concentration. Givosiran inhibits CYP3A4, a Phenytoin metabolic pathway.","  Phenytoin        .","Reduced Phenytoin concentration, potentially leading to loss of seizure control."," .    Phenytoin     .","Level monitoring. Phenytoin levels must be monitored and dose adjusted if necessary.");n("Givosiran (siRNA)","Theophylline",e.DRUG_DRUG,i.MODERATE,"  Theophylline. Givosiran     CYP1A2   .","Increased Theophylline concentration. Givosiran indirectly increases the concentration of CYP1A2 substrates.","   Theophylline (    ).","Increased risk of Theophylline toxicity (seizures, arrhythmia)."," .   Theophylline  .","Dose adjustment. Monitor Theophylline levels and adjust the dose.");n("Glasdegib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Glasdegib. Ketoconazole    CYP3A4.","Increased Glasdegib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    QT.","Increased risk of QT prolongation.","  .    CYP3A4 .","Relative contraindication. Strong CYP3A4 inhibitors must be avoided.");n("Glasdegib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Glasdegib. Phenytoin    CYP3A4.","Decreased Glasdegib concentration. Phenytoin is a strong inducer of CYP3A4.","     .","Reduced drug efficacy and failure of cancer treatment."," .   .","Contraindicated. Avoid the combination.");n("Glasdegib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Glasdegib. Itraconazole    CYP3A4.","Increased Glasdegib concentration. Itraconazole is a strong inhibitor of CYP3A4.","    QTc.","Increased risk of QTc prolongation."," .    Glasdegib  .","Dose adjustment. Glasdegib dose must be significantly reduced.");n("Glecaprevir/Pibrentasvir","Rifampin",e.DRUG_DRUG,i.HIGH,"  Glecaprevir/Pibrentasvir. Rifampin    CYP3A4  P-gp/OATP1B1.","Decreased Glecaprevir/Pibrentasvir concentrations. Rifampin is a strong inducer of CYP3A4 and P-gp/OATP1B1.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Glecaprevir/Pibrentasvir","Food",e.DRUG_FOOD,i.MODERATE,"   Glecaprevir (83-153%)  Pibrentasvir (40-51%)","Food increases Glecaprevir absorption (83-153%) and Pibrentasvir absorption (40-51%)","     ","Increased drug levels to ensure therapeutic efficacy","     ","Must be taken with food to ensure therapeutic efficacy");ef.forEach(h=>{n(h,"Salicylates / Sulfonamides",e.DRUG_DRUG,i.HIGH,'     (Protein Displacement).                  " "   (Active Free Drug)  .','Protein Displacement. Both Salicylates and Sulfonamides compete with Sulfonylureas for binding sites on plasma albumin. This significantly increases the concentration of the "Active Free Drug" fraction in the blood.',"    (Severe Hypoglycemia)       .","Severe and prolonged hypoglycemia, due to the sudden spike in active drug concentration.","      (   )        .         .","Monitor blood glucose intensively (multiple times daily) upon initiation or dose change. Proactive reduction of the Sulfonylurea dose may be required.")});ef.forEach(h=>{$o.forEach(P=>{n(h,$o,e.DRUG_DRUG,i.MODERATE,"    (Masking of Symptoms).          (   )    .","Masking of Hypoglycemia Symptoms. Beta-blockers block the compensatory adrenergic response, preventing the appearance of crucial warning signs (e.g., tremors, palpitations, anxiety), thus delaying the recognition of hypoglycemia.","   (Unaware Hypoglycemia).           (   ).","Masked Hypoglycemia (Unaware Hypoglycemia). Increased risk of severe hypoglycemia presenting only with neuroglycopenic symptoms (e.g., confusion or loss of consciousness).","             (    )   .","Caution the patient to monitor home glucose levels frequently and rely on neuroglycopenic symptoms (e.g., intense hunger, fatigue, confusion) to detect an episode.")})});n("Glimepiride","Fluconazole",e.DRUG_DRUG,i.HIGH,"   (CYP2C9)","Inhibition of glimepiride metabolism (CYP2C9)","      (  )","Increased glimepiride hypoglycemic effect (hypoglycemia risk)","    -     ","Monitor blood glucose levels - reduce glimepiride dose if necessary");n("Glimepiride - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glimepiride","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glimepiride dose if necessary");n("Glimepiride - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Glimepiride","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glimepiride dose if necessary");n("Glimepiride - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glimepiride","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glimepiride dose if necessary");n("Glimepiride - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glimepiride","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Glimepiride dose if necessary - Use alternative NSAID");n("Glimepiride - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Glimepiride","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glimepiride dose if necessary");n("Glimepiride - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glimepiride","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glimepiride dose if necessary");n("Glimepiride - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"    ","Increased concentrations of Glimepiride","    ","Increased risk of hypoglycemia","     -       -      ( )","Monitor blood glucose concentration - Decrease Glimepiride dose if necessary - Use noninteracting sulfonylurea (eg, glyburide)");n("Glimepiride - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Glimepiride","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glimepiride dose if necessary");n("Glimepiride (Amaryl)","Aspirin (Acetylsalicylic Acid)",e.DRUG_DRUG,i.HIGH," ( )                     .","Aspirin (Acetylsalicylic Acid), particularly at high doses, potentiates the hypoglycemic effect of Glimepiride by displacing it from plasma protein binding sites and potentially impairing renal function.","    (Hypoglycemia)     .","Severe hypoglycemia. The enhanced effect can lead to dangerously low blood glucose levels requiring immediate medical intervention.","     .            .","Adjust Glimepiride dose significantly (typically reduction) and intensify blood glucose monitoring when initiating or stopping high-dose Aspirin therapy.");n("Glipizide","Clarithromycin",e.DRUG_DRUG,i.HIGH,"   ","Sulfonylurea metabolism inhibition.","  ","Dangerous hypoglycemia.","  ","Close glucose monitoring.");n("Glipizide","Alcohol",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Caffeine",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Green Tea",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Milk",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","High-fat meals",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","High-fiber foods",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Vitamin C",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Vitamin D",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Vitamin E",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Vitamin K",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Vitamin B12",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Folic Acid",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Iron",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Calcium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Magnesium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Zinc",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Potassium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide","Antacids",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Glipizide - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glipizide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glipizide dose if necessary");n("Glipizide - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Glipizide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glipizide dose if necessary");n("Glipizide - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glipizide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glipizide dose if necessary");n("Glipizide - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glipizide","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Glipizide dose if necessary - Use alternative NSAID");n("Glipizide - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Glipizide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glipizide dose if necessary");n("Glipizide - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glipizide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glipizide dose if necessary");n("Glipizide - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"    ","Increased concentrations of Glipizide","    ","Increased risk of hypoglycemia","     -       -      ( )","Monitor blood glucose concentration - Decrease Glipizide dose if necessary - Use noninteracting sulfonylurea (eg, glyburide)");n("Glipizide - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Glipizide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glipizide dose if necessary");n("Glofitamab (Columvi)","Immunosuppressants (Cyclosporine)",e.DRUG_DRUG,i.HIGH,": **  **.    .","Mechanism: **Excessive immunosuppression**. Severe opportunistic infection risk."," : **  **  .","Clinical Significance: **Life-threatening fungal and viral infections**."," .         .","Avoid combination. Use minimal immunosuppressant doses if necessary.");n("Glucagon","Beta-Blockers",e.DRUG_DRUG,i.MODERATE,"    ","Antagonistic effect on Glucagon.","      ","Reduced Glucagon efficacy in treating hypoglycemia.","        ","Monitor blood glucose closely, higher doses may be needed.");n("Glucosamine","Warfarin",e.DRUG_DRUG,i.MODERATE," INR","Increased INR."," ","Bleeding risk."," INR","Monitor INR.");n("Glyburide","Fluconazole",e.DRUG_DRUG,i.HIGH," CYP2C9 -    ","CYP2C9 inhibition increases sulfonylurea levels.","   ","Severe hypoglycemia.","   4-6  -   ","Monitor glucose every 4-6h - reduce glyburide dose.");n("Glyburide - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glyburide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glyburide dose if necessary");n("Glyburide - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Glyburide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glyburide dose if necessary");n("Glyburide - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glyburide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glyburide dose if necessary");n("Glyburide - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glyburide","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Glyburide dose if necessary - Use alternative NSAID");n("Glyburide - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Glyburide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glyburide dose if necessary");n("Glyburide - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Glyburide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Glyburide dose if necessary");n("Glyburide - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Glyburide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Glyburide dose if necessary");n("Golimumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Golimumab   (TNF inhibitor).","Increased risk of infection. Golimumab is an immunosuppressant (TNF inhibitor).","     .","Risk of developing infection from live vaccines."," .      .","Contraindicated. Live vaccines must be avoided during treatment.");n("Goserelin","QT-prolonging Drugs",e.DRUG_DRUG,i.MODERATE," QT","QT prolongation.","  ","Cardiac arrhythmia."," ECG","Monitor ECG.");n("Granisetron","SSRIs",e.DRUG_DRUG,i.MODERATE,"    (Serotonin Syndrome).","Increased risk of Serotonin Syndrome.","       .","Agitation, hyperreflexia, fever, and tachycardia."," .            .","Symptom monitoring. Serotonin syndrome symptoms must be monitored, especially upon initiation or dose increase.");n("Granisetron","Apomorphine",e.DRUG_DRUG,i.HIGH,"   ","Severe hypotension."," ","Loss of consciousness."," ","Contraindicated.");n("Green Tea Extract","Warfarin",e.DRUG_DRUG,i.MODERATE,"  K","Vitamin K content."," INR","Decreased INR.","  ","Avoid large amounts.");n("Griseofulvin","Alcohol",e.DRUG_FOOD,i.MODERATE,"  .   Griseofulvin   .","Disulfiram-like reaction. Griseofulvin may inhibit aldehyde dehydrogenase.","   .","Flushing, palpitations, nausea, vomiting."," .      .","Avoid Alcohol. Alcohol must be avoided during treatment.");n("Guar Gum","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric pH/Hydration. Altered gastric environment affects drug dissolution.","   ","   ","  ","  ");n("Guar Gum","Levofloxacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric pH/Hydration. Altered gastric environment affects drug dissolution.","   ","   ","  ","  ");n("Guar Gum","Moxifloxacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric pH/Hydration. Altered gastric environment affects drug dissolution.","   ","   ","  ","  ");n("Guar Gum","Ofloxacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric pH/Hydration. Altered gastric environment affects drug dissolution.","   ","   ","  ","  ");n("Guar Gum","Norfloxacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric pH/Hydration. Altered gastric environment affects drug dissolution.","   ","   ","  ","  ");n("Guselkumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Guselkumab    (IL-23 inhibitor).","Increased risk of viral infection. Guselkumab is an immunosuppressant (IL-23 inhibitor).","      (    ).","Risk of developing infection from live vaccines (same mechanism as other biological drugs)."," .       Guselkumab.","Contraindicated. Live vaccines must be avoided during Guselkumab treatment.");n("Guselkumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Guselkumab   IL-23.","Reduced vaccine response/Increased infection risk. Guselkumab is an IL-23 inhibitor.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Guselkumab (IL-23 Inhibitor)","Live Vaccines",e.DRUG_DRUG,i.HIGH,"  . Guselkumab         .","Increased risk of infection. Guselkumab is an immunosuppressant that reduces the immune response to live vaccines.","     .","Increased risk of developing the disease from the vaccine."," .        Guselkumab.","Contraindicated. Avoid live vaccines during Guselkumab therapy.");n("Halazepam","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"     .","Additive Central Nervous System (CNS) Depressant Effects.","              .","Substantially increased risk of severe drowsiness, dizziness, motor incoordination, respiratory depression, and increased risk of falls.","   .    ( )              .","Alcohol must be completely avoided. With other depressants (especially Opioids), use the lowest possible effective doses and closely monitor for over-sedation and breathing difficulties.");n("Halazepam","Omeprazole (or other strong CYP2C19/3A4 Inhibitors)",e.DRUG_DRUG,i.MODERATE," .     CYP3A4 / CYP2C19      ().","Metabolic Inhibition. These drugs inhibit CYP3A4 and/or CYP2C19 enzymes responsible for metabolizing the active metabolite (Nordiazepam).","    ()            .","Increased concentration of the active metabolite (Nordiazepam), leading to increased and prolonged hypnotic effect and excessive next-day drowsiness.","       .       .","Monitor the patient for excessive drowsiness and impaired consciousness. A reduction in the Halazepam dose may be necessary.");n("Halazepam","Rifampin (or other strong CYP3A4/2C19 Inducers)",e.DRUG_DRUG,i.MODERATE,"   .        ().","Potent Enzymatic Metabolic Induction. These drugs increase the metabolism of the active metabolite (Nordiazepam).","              .","Decreased levels of the active metabolite, resulting in reduced drug efficacy and a return of anxiety or seizure symptoms.","     .            .","Monitor the patient for symptom recurrence. A Halazepam dose increase or switching to an alternative drug may be needed.");n("Haloperidol","Atropine",e.DRUG_DRUG,i.MODERATE,"  .   ( )           .","Reduced Haloperidol Concentration. Anticholinergics (e.g., Atropine) may reduce Haloperidol absorption by slowing GI motility.","     .         (Dyskenisia).","Reduced Haloperidol Efficacy and Increased Psychotic Symptoms. Risk of psychotic relapse or dyskinesia.","    -      .  .","Discontinue Anticholinergics - Increase Haloperidol Dose as Needed. Monitoring is necessary.");n("Haloperidol","Hyoscine (Scopolamine)",e.DRUG_DRUG,i.MODERATE,"  .   ( )           .","Reduced Haloperidol Concentration. Anticholinergics (e.g., Hyoscine) may reduce Haloperidol absorption by slowing GI motility.","     .         (Dyskenisia).","Reduced Haloperidol Efficacy and Increased Psychotic Symptoms. Risk of psychotic relapse or dyskinesia.","    -      .  .","Discontinue Anticholinergics - Increase Haloperidol Dose as Needed. Monitoring is necessary.");n("Haloperidol","Benztropine",e.DRUG_DRUG,i.MODERATE,"  .   ( )           .","Reduced Haloperidol Concentration. Anticholinergics (e.g., Benztropine) may reduce Haloperidol absorption by slowing GI motility.","     .         (Dyskenisia).","Reduced Haloperidol Efficacy and Increased Psychotic Symptoms. Risk of psychotic relapse or dyskinesia.","    -      .  .","Discontinue Anticholinergics - Increase Haloperidol Dose as Needed. Monitoring is necessary.");n("Haloperidol","Fluconazole",e.DRUG_DRUG,i.HIGH,"  .    CYP2D6  CYP3A4    .","Increased Haloperidol Levels. Fluconazole inhibits CYP2D6 and CYP3A4 enzymes responsible for Haloperidol metabolism.","  .       (EPS)   QT ( ).","Increased Haloperidol Toxicity. Increased risk of Extrapyramidal Symptoms (EPS) and QT prolongation (cardiac risks).","        /   .      50%.","Adjust Haloperidol Dose as directed, upon starting/stopping Azole antifungals. Haloperidol dose reduction by 50% is advised.");n("Haloperidol","Itraconazole",e.DRUG_DRUG,i.HIGH,"  .    CYP3A4    .","Increased Haloperidol Levels. Itraconazole inhibits the CYP3A4 enzyme responsible for Haloperidol metabolism.","  .       (EPS)   QT ( ).","Increased Haloperidol Toxicity. Increased risk of Extrapyramidal Symptoms (EPS) and QT prolongation (cardiac risks).","        /   .     .","Adjust Haloperidol Dose as directed, upon starting/stopping Azole antifungals. Haloperidol dose reduction and monitoring are advised.");n("Haloperidol","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  .    CYP3A4    .","Increased Haloperidol Levels. Ketoconazole inhibits the CYP3A4 enzyme responsible for Haloperidol metabolism.","  .       (EPS)   QT ( ).","Increased Haloperidol Toxicity. Increased risk of Extrapyramidal Symptoms (EPS) and QT prolongation (cardiac risks).","        /   .     .","Adjust Haloperidol Dose as directed, upon starting/stopping Azole antifungals. Haloperidol dose reduction and monitoring are advised.");n("Haloperidol","Voriconazole",e.DRUG_DRUG,i.HIGH,"  .    CYP3A4  CYP2C19    .","Increased Haloperidol Levels. Voriconazole inhibits CYP3A4 and CYP2C19 enzymes responsible for Haloperidol metabolism.","  .       (EPS)   QT ( ).","Increased Haloperidol Toxicity. Increased risk of Extrapyramidal Symptoms (EPS) and QT prolongation (cardiac risks).","        /   .     .","Adjust Haloperidol Dose as directed, upon starting/stopping Azole antifungals. Haloperidol dose reduction and monitoring are advised.");n("Haloperidol","Carbamazepine - ",e.DRUG_DRUG,i.MODERATE,"   -   .    CYP3A4     . Haloperidol    .","Decreased Haloperidol Levels - Increased Carbamazepine Efficacy. Carbamazepine is a CYP3A4 inducer, increasing Haloperidol metabolism. Haloperidol may inhibit Carbamazepine metabolism.","      (  ).","Reduced Haloperidol Efficacy and Increased Carbamazepine Toxicity (e.g., dizziness, ataxia).","       .     .","Adjust the dose of one or both as directed. Clinical monitoring and drug levels are essential.");n("Haloperidol","Lithium - ",e.DRUG_DRUG,i.HIGH,"      (Neurotoxicity).            .","Mood changes, Encephalopathy, Hyperthermia (Neurotoxicity). The mechanism is unclear, potentially due to an idiosyncratic toxic reaction.","   .            (NMS).","Increased Neurotoxicity and Encephalopathy. Risk of delirium syndrome, permanent encephalopathy, and Neuroleptic Malignant Syndrome (NMS).","     -           .","Avoid this Combination if possible - Otherwise, discontinue one or both drugs immediately upon signs of neurotoxicity.");n("Heparin","Nitroglycerin",e.DRUG_DRUG,i.MODERATE,"  ","Reduced heparin efficacy."," aPTT","Decreased aPTT.","     ","Heparin dose increase may be necessary.");n("HMG-CoA Reductase Inhibitors -  HMG-CoA ","Colestipol - ",e.DRUG_DRUG,i.MODERATE,"   HMG-CoA  ()               ","Colestipol binds to HMG-CoA reductase inhibitors (statins) in the intestine and reduces their absorption, but this interaction can be used beneficially to enhance cholesterol lowering","               ","Mild decrease in statin blood levels, but overall effect on cholesterol lowering is synergistic and positive","       (    ) -     ","Take statins at different time than Colestipol (preferably evening for statins and morning for Colestipol) - monitor cholesterol levels and liver enzymes");n("Hydralazine","Metoprolol",e.DRUG_DRUG,i.MODERATE,"    .    .","Increased hypotensive effect. Additive hypotensive effect.","    (Hypotension).","Severe hypotension.","  .             .","Blood pressure monitoring. They are often combined to treat hypertension, but pressure must be carefully monitored.");n("Hydralazine - ","Diazoxide - ",e.DRUG_DRUG,i.HIGH,"  (Pharmacodynamic Synergy).         (Potent Arteriolar Vasodilators).              .","Pharmacodynamic Synergy. Both agents are potent, direct arteriolar vasodilators. The combination results in a massive additive effect on relaxing smooth muscles in the arterial walls.","                  (Dangerous Hypotension)           .","Severe vasodilation, leading to a critical and life-threatening drop in diastolic and mean arterial pressure (Dangerous Hypotension), potentially causing organ hypoperfusion, renal failure, or stroke."," .              .           (Vasopressors).","Avoid combination. This interaction is an absolute contraindication outside intensive care and continuous BP monitoring. Urgent interventions using vasopressors may be needed.");n("Hydralazine - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"  (Pharmacodynamic Synergy).     .   MAO            .        .","Pharmacodynamic Synergy. Hydralazine acts as a direct vasodilator. MAO Inhibitors possess an intrinsic hypotensive effect due to their impact on central and peripheral adrenergic tone. This combination results in exacerbated blood pressure lowering.","      (Symptomatic Hypotension)      (Dizziness)  (Syncope)     (Orthostatic Hypotension).","Severe, symptomatic hypotension, increasing the risk of dizziness, syncope, and falls, particularly orthostatic hypotension.","        .                .","Regularly monitor blood pressure upon initiation and adjust the dosage. It is advised to start with very low doses of both agents and titrate cautiously to minimize the risk of acute hypotension.");n("Hydrochlorothiazide","Lithium",e.DRUG_DRUG,i.HIGH,"  .          .","Increased Lithium concentration. Thiazide diuretics reduce renal clearance of Lithium.","    (  ).","Increased risk of Lithium toxicity (tremor, nausea, confusion).","  .           .","Dose adjustment and monitoring. Lithium dose must be reduced and drug levels closely monitored.");n("Hydrochlorothiazide","Lithium",e.DRUG_DRUG,i.HIGH,"     ","Sodium depletion increases lithium reabsorption."," ","Lithium toxicity.","   ","Monitor lithium levels weekly.");n("Hydrochlorothiazide","Alcohol",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Caffeine",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Green Tea",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Milk",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","High-fat meals",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","High-fiber foods",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Vitamin C",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Vitamin D",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Vitamin E",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Vitamin K",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Vitamin B12",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Folic Acid",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Iron",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Calcium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Magnesium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Zinc",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Potassium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrochlorothiazide","Antacids",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Hydrocortisone","Diabetes",e.DRUG_DISEASE,i.MODERATE,"    .           .","Insulin Resistance and Increased Gluconeogenesis. Cortisone stimulates liver glucose production and reduces peripheral insulin sensitivity.","    (Hyperglycemia).       .","Hyperglycemia. Loss of blood sugar control in diabetic patients.",".               ( ).","Monitor. Closely monitor blood sugar levels, and antidiabetic medication doses (especially insulin) may need adjustment.");n("Hydrocortisone","Diabetes / Hypertension",e.DRUG_DISEASE,i.MODERATE,"     ( ). Hydrocortisone      (Mineralocorticoid Activity).","Hyperglycemia & Fluid Retention. Corticosteroids induce gluconeogenesis and exhibit mineralocorticoid activity.","    .     .","Loss of Blood Sugar and Blood Pressure Control. Worsening of diabetes and hypertension.","              .","Closely monitor blood sugar and blood pressure, and doses of antidiabetic and antihypertensive medications may need frequent adjustment during treatment.");n("Hydrocortisone","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  Hydrocortisone. Phenytoin    CYP3A4.","Decreased Hydrocortisone concentration. Phenytoin is a strong inducer of CYP3A4.","           .","Reduced corticosteroid efficacy, leading to disease exacerbation or adrenal insufficiency."," .       Hydrocortisone.","Dose increase. Hydrocortisone dose may need to be increased.");n("Hydrocortisone","Cholestyramine (Colestipol)",e.DRUG_DRUG,i.MODERATE," ","Reduced absorption","  ","Reduced hydrocortisone efficacy","     -   ","Separate drugs by several hours - use appropriate alternative");n("Hydrocortisone","Rifampin",e.DRUG_DRUG,i.HIGH,"   CYP3A4","Potent CYP3A4 induction.","  ","Corticosteroid treatment failure.","   2-3 ","Increase hydrocortisone dose 2-3 fold.");n("Hydrogen Iodide","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Hydroquinone","Peroxide Products",e.DRUG_DRUG,i.MODERATE," ","Skin staining."," ","Dark pigmentation."," ","Avoid combination.");n("Hydroxychloroquine","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Hydroxychloroquine  P-gp    Digoxin.","Increased Digoxin concentration. Hydroxychloroquine inhibits P-gp, a Digoxin efflux transporter.","   Digoxin.","Increased risk of Digoxin toxicity."," .    Digoxin    .","Close monitoring. Digoxin blood levels must be monitored and dose adjusted.");n("Hydroxychloroquine","Digoxin",e.DRUG_DRUG,i.MODERATE,"  ","Increased digoxin levels."," ","Digoxin toxicity.","  ","Monitor digoxin levels.");n("Hydroxychloroquine","Methotrexate",e.DRUG_DRUG,i.MODERATE,"  ","Increased methotrexate toxicity.","  ","Bone marrow suppression.","  ","Monitor CBC.");n("Hydroxyurea","Antiretrovirals",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic bone marrow suppression."," ","Cytopenia.","  ","Monitor CBC.");n("Hydroxyzine","Azithromycin",e.DRUG_DRUG,i.HIGH,": **     QT (Synergistic QT Prolongation)**.        (IKr channels)       (Ventricular Repolarization)   QT   .         .","Mechanism: **Synergistic QT interval prolongation**. Both drugs block cardiac potassium channels (IKr channels), prolonging ventricular repolarization phase and increasing QT interval on ECG. Synergistic effect is much stronger than either drug alone."," :      **     Torsades de Pointes** (    )      **    **.     :  QT   /       .    FDA   (Black Box Warning)  .","Clinical Significance: Very high risk of **fatal ventricular arrhythmia called Torsades de Pointes** (polymorphic ventricular tachycardia), which may rapidly progress to **ventricular fibrillation and sudden cardiac death**. Risk is highest in patients with: congenital QT prolongation, hypokalemia/hypomagnesemia, bradycardia, cardiac disease, or elderly. Hydroxyzine has FDA Black Box Warning for this risk.","  ** **      .         **  **   QT  ****  ****.         ****  ****    QT.    (ECG)       .       QTc  500  .","Avoid combination **absolutely**, especially in patients with risk factors. If antibiotic is needed, **choose safe alternative** that does not prolong QT such as **amoxicillin** or **doxycycline**. If antihistamine is needed, use **loratadine** or **cetirizine** which do not prolong QT. Monitor ECG and correct electrolytes if combination has already occurred. Stop both drugs immediately if QTc exceeds 500 milliseconds.");n("Hyoscine","Metoclopramide",e.DRUG_DRUG,i.MODERATE,"     . Hyoscine     Metoclopramide    .","Antagonism of Intestinal Motility Effect. Hyoscine (anticholinergic) reduces motility, and Metoclopramide (dopamine agonist) increases motility.","  .        .","Cancellation of Both Drug Effects. Loss of therapeutic effects of both on gastrointestinal motility.","  .            .","Avoid Concurrent Use. Only one drug should be used for treatment, or they should be separated by an adequate time interval.");n("Hyoscine (Scopolamine)","Disopyramide, Estramustine, Cefpodoxime",e.DRUG_DRUG,i.MODERATE,"    (Anticholinergic effects). Hyoscine          .","Inhibition of Gastrointestinal Motility (Anticholinergic effects). Hyoscine slows GI motility, altering the absorption rate of other drugs.","   .       (   )        .","Altered Bioavailability. Absorption rate of some drugs (like certain antibiotics) may increase or decrease unpredictably.","  .            .","Monitor Drug Efficacy. Monitor the clinical response to co-administered drugs, especially those with a narrow therapeutic window.");n("Hyoscine (Scopolamine)","Lidocaine",e.DRUG_DRUG,i.MODERATE,"  . Hyoscine               Lidocaine.","Delayed Gastric Emptying. Hyoscine reduces stomach motility and delays emptying, slowing the absorption of oral drugs like Lidocaine.","   .     Lidocaine       .","Altered Lidocaine Efficacy. Onset of Lidocaine effect may be delayed, or its peak levels may change unexpectedly.","  .                 Lidocaine .","Monitor Patient Response. Closely monitor the patient for any signs of inadequate effect or increased side effects following oral Lidocaine administration.");n("Hyoscine (Scopolamine)","Lidocaine",e.DRUG_DRUG,i.MODERATE,"  . Hyoscine               Lidocaine.","Delayed Gastric Emptying. Hyoscine reduces stomach motility and delays emptying, slowing the absorption of oral drugs like Lidocaine.","   .     Lidocaine       .","Altered Lidocaine Efficacy. Onset of Lidocaine effect may be delayed, or its peak levels may change unexpectedly.","  .                 Lidocaine .","Monitor Patient Response. Closely monitor the patient for any signs of inadequate effect or increased side effects following oral Lidocaine administration.");n("Ibalizumab (Trogarzo)","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,": ** **.       .","Mechanism: **Immune modulation**. May affect immune response to live vaccines."," : **    **.","Clinical Significance: **Potential reduced vaccine efficacy**.","    .     .","Preferably vaccinate before starting therapy. Avoid live vaccines during treatment.");n("Ibandronate","Calcium Supplements",e.DRUG_DRUG,i.MODERATE,"     ","Reduced absorption due to physicochemical interaction.","  ronate","Reduced Ibandronate efficacy."," 60   ","Separate by at least 60 minutes.");n("Ibandronate","Iron Supplements",e.DRUG_DRUG,i.MODERATE," ","Reduced absorption.","  ","Reduced ibandronate efficacy.","  ","Separate by 1 hour.");n("Ibrutinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Ibrutinib. Voriconazole    CYP3A4    Ibrutinib.","Increased Ibrutinib concentration. Voriconazole is a strong CYP3A4 inhibitor, an Ibrutinib metabolic pathway.","     .","Increased risk of hemorrhage and myelosuppression."," .    Ibrutinib     CYP3A4 .","Dose adjustment. Ibrutinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ibuprofen","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Ibuprofen","Heart Failure ( )",e.DRUG_DISEASE,i.MODERATE," . Ibuprofen (NSAID)   COX           .","Fluid Retention. Ibuprofen (an NSAID) inhibits renal COX enzyme, leading to sodium and water retention and reduced diuretic effectiveness.","  .    (Volume Overload)          (  ).","Worsening Failure. Increases the volume overload burden on the heart, leading to exacerbation of heart failure symptoms (edema, dyspnea).",".   Ibuprofen       .           .","Avoid. Preferably avoid Ibuprofen in moderate to severe heart failure. If necessary, monitor weight, edema, and blood pressure closely.");n("Ibuprofen","Peptic Ulcer ( )",e.DRUG_DISEASE,i.HIGH,"     .","Prostaglandin Inhibition. COX inhibition depletes cytoprotective gastric prostaglandins, increasing ulcer risk.","      .","GI Bleeding & Perforation. Severe gastric injury.","         (PPIs) .","         (PPIs) .");n("Ibuprofen (NSAID)","Lithium",e.DRUG_DRUG,i.HIGH,"  . Ibuprofen     .","Increased Lithium concentration. Ibuprofen reduces renal clearance of Lithium.","    (  ).","Increased risk of Lithium toxicity (tremor, nausea, confusion)."," .       .    ( Paracetamol).","Avoid Combination. Avoid NSAIDs with Lithium. Use alternative analgesics (e.g., Paracetamol).");n("Idelalisib (Zydelig)","Strong CYP3A4 Substrates (Midazolam)",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.      CYP3A4.","Mechanism: **Potent CYP3A4 inhibition**. Increased concentration of CYP3A4-metabolized drugs."," : ** **  .","Clinical Significance: **Excessive sedation** and respiratory depression."," .       CYP3A4.","Avoid combination. Use alternative benzodiazepine not dependent on CYP3A4.");n("Idelalisib (Zydelig)","Pneumocystis Prophylaxis",e.DRUG_DISEASE,i.HIGH,": **  **.    .","Mechanism: **Severe immunosuppression**. High opportunistic infection risk."," : **   **  .","Clinical Significance: **Life-threatening Pneumocystis jirovecii pneumonia**.","   Trimethoprim/Sulfamethoxazole   .","Mandatory prophylaxis with Trimethoprim/Sulfamethoxazole throughout therapy.");n("Ifosfamide","Aprepitant",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased ifosfamide toxicity.","  ","Monitor neurotoxicity.");n("Imatinib","Food",e.DRUG_FOOD,i.MODERATE,"         ","Food reduces gastric irritation without significantly affecting bioavailability","   (  )","Better gastrointestinal tolerability (reduced nausea and vomiting)","     ","Must be taken with a meal and a full glass of water");n("Imatinib","Simvastatin",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition."," ","Rhabdomyolysis.","   ()","Use alternative statin (pravastatin).");n("Imipenem","Valproic Acid",e.DRUG_DRUG,i.HIGH,"   -    ","Unknown mechanism - reduces valproic acid levels.","  ","Breakthrough seizures.","  -    ()","Avoid - use alternative carbapenem (meropenem).");n("Imipenem/Cilastatin","Ciclosporin ()",e.DRUG_DRUG,i.MODERATE,"    (Additive Nephrotoxicity).   Imipenem/Cilastatin  Ciclosporin              .","Additive Nephrotoxic Effects. Both Imipenem/Cilastatin and Ciclosporin have inherent nephrotoxic properties, and concurrent use may increase the risk of kidney damage.","    ( ).         .","Increased Risk of Nephrotoxicity (Renal Failure). The combination may accelerate or worsen kidney damage.","  .         (BUN)   .      Ciclosporin     .","Monitor Renal Function. Closely monitor creatinine, BUN, and potassium levels. Cyclosporine dose adjustment or an alternative antibiotic may be required.");n("Imiquimod","Immunosuppressants",e.DRUG_DRUG,i.MODERATE,"   ","Antagonistic immune effect.","  ","Reduced imiquimod efficacy."," ","Avoid combination.");n("Imlygic (Live Virus Therapy)","Cyclosporine (Immunosuppressant)",e.DRUG_DRUG,i.HIGH,"  Imlygic   . Imlygic       .","Decreased Imlygic efficacy and increased risk of infection. Imlygic is a live modified virus requiring an immune response.","      .","Failure of immunotherapy and increased risk of viral dissemination."," .     .","Contraindicated. Systemic immunosuppressants must be avoided.");n("Inactivated Vaccines (Flu/Hep B)","Rituximab",e.DRUG_DRUG,i.MODERATE,"          .","Rituximab significantly reduces the population of antibody-producing B-cells.","      .","Reduced vaccine immunogenicity and inadequate protection.","    .          .","Preferably vaccinate before starting therapy. Booster doses may be required later after B-cell recovery.");n("Inactivated Vaccines (General)","Tofacitinib (JAK Inhibitor)",e.DRUG_DRUG,i.MODERATE,"   JAK-STAT       .","Tofacitinib inhibits the JAK-STAT pathway essential for immune cell activation and antibody production.","      .","Reduced vaccine immunogenicity and inadequate protection.","    .       .","Preferably vaccinate before starting therapy. No absolute contraindication for inactivated vaccines.");n("Inclisiran","Atorvastatin",e.DRUG_DRUG,i.LOW,"     (Inclisiran    CYP).","No true interaction expected (Inclisiran is not metabolized by CYP).","   .      .","No known effect. They are used safely together for cholesterol treatment.","    .   .","No special action required. They are used safely together.");n("Inclisiran (siRNA)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"     . Inclisiran       .","No clinically significant interaction expected. Inclisiran is cleared by ribonuclease enzymatic degradation.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Indapamide","Digoxin",e.DRUG_DRUG,i.MODERATE," ","Hypokalemia.","  ","Increased digoxin toxicity.","  ","Monitor potassium and digoxin.");n("Indinavir","Diazepam",e.DRUG_DRUG,i.HIGH,"  .      CYP3A4.","Increased Benzodiazepine Levels. Indinavir inhibits Benzodiazepine metabolism via CYP3A4.","    .     .","Increased CNS Depression. Risk of profound sedation and respiratory depression.","    .       CYP3A4 ( /).","Avoid this Combination if possible. Alternatives not metabolized by CYP3A4 (e.g., Lorazepam/Oxazepam) should be used.");n("Indinavir","Lorazepam",e.DRUG_DRUG,i.HIGH,"  .      CYP3A4.","Increased Benzodiazepine Levels. Indinavir inhibits Benzodiazepine metabolism via CYP3A4.","    .     .","Increased CNS Depression. Risk of profound sedation and respiratory depression.","    .       CYP3A4 ( /).","Avoid this Combination if possible. Alternatives not metabolized by CYP3A4 (e.g., Lorazepam/Oxazepam) should be used.");n("Indinavir","Alprazolam",e.DRUG_DRUG,i.HIGH,"  .      CYP3A4.","Increased Benzodiazepine Levels. Indinavir inhibits Benzodiazepine metabolism via CYP3A4.","    .     .","Increased CNS Depression. Risk of profound sedation and respiratory depression.","    .       CYP3A4 ( /).","Avoid this Combination if possible. Alternatives not metabolized by CYP3A4 (e.g., Lorazepam/Oxazepam) should be used.");n("Indinavir","Clonazepam",e.DRUG_DRUG,i.HIGH,"  .      CYP3A4.","Increased Benzodiazepine Levels. Indinavir inhibits Benzodiazepine metabolism via CYP3A4.","    .     .","Increased CNS Depression. Risk of profound sedation and respiratory depression.","    .       CYP3A4 ( /).","Avoid this Combination if possible. Alternatives not metabolized by CYP3A4 (e.g., Lorazepam/Oxazepam) should be used.");n("Indinavir","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  .      CYP3A4.","Increased Indinavir Levels. Fluconazole inhibits Indinavir metabolism via CYP3A4.","    (  ).","Increased Risk of Indinavir Toxicity (e.g., Nephrotoxicity).","     ( 25%).   .","Reduce Indinavir dose as necessary (by 25%). Monitor renal function.");n("Indinavir","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  .      CYP3A4.","Increased Indinavir Levels. Itraconazole inhibits Indinavir metabolism via CYP3A4.","    (  ).","Increased Risk of Indinavir Toxicity (e.g., Nephrotoxicity).","     ( 25%).   .","Reduce Indinavir dose as necessary (by 25%). Monitor renal function.");n("Indinavir","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  .      CYP3A4.","Increased Indinavir Levels. Ketoconazole inhibits Indinavir metabolism via CYP3A4.","    (  ).","Increased Risk of Indinavir Toxicity (e.g., Nephrotoxicity).","     ( 25%).   .","Reduce Indinavir dose as necessary (by 25%). Monitor renal function.");n("Indinavir","Voriconazole",e.DRUG_DRUG,i.MODERATE,"  .      CYP3A4.","Increased Indinavir Levels. Voriconazole inhibits Indinavir metabolism via CYP3A4.","    (  ).","Increased Risk of Indinavir Toxicity (e.g., Nephrotoxicity).","     ( 25%).   .","Reduce Indinavir dose as necessary (by 25%). Monitor renal function.");n("Imipramine","Clonidine",e.DRUG_DRUG,i.MODERATE,"   .  (TCA)    ( -2 )       .","Antagonism of Antihypertensive Effect. Imipramine (TCA) counteracts the effect of Clonidine (a central alpha-2 agonist) by blocking its neuronal uptake.","   (Hypertensive Crisis).     .","Hypertension. Loss of blood pressure control.",".        (TCAs)  .","Avoid. Tricyclic Antidepressants (TCAs) should be avoided with Clonidine.");n("Indinavir - ","Ergot Alkaloids -  ",e.DRUG_DRUG,i.HIGH,"       CYP3A4        ( ).","Indinavir is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which is primarily responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine).","             (Ergotism)     (Vasospasm)      .","Dangerous increase in Ergot Alkaloids blood concentrations, leading to acute Ergotism, which includes vasoconstriction (Vasospasm) and ischemia that may threaten limb viability.","     ().     .","This drug combination is absolutely contraindicated (forbidden). This co-administration must be avoided entirely.");n("Indomethacin","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Indomethacin","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,"     . Indomethacin (NSAID)  COX-1  COX-2.","Prostaglandin Inhibition. COX inhibition depletes cytoprotective gastric prostaglandins, increasing ulcer risk.","      .","GI Bleeding & Perforation. Severe gastric injury.","         (PPIs) .","Avoid and use Paracetamol, or use with Prophylactic Proton Pump Inhibitors (PPIs) with caution.");n("Indomethacin","Heart Failure",e.DRUG_DISEASE,i.MODERATE," . Indomethacin         .","Fluid Retention. Indomethacin causes sodium and water retention by inhibiting renal prostaglandins.","  .     .","Worsening Heart Failure. Increased edema and cardiac stress.",".          .","Avoid. Closely monitor weight, edema, and renal function if use is necessary.");n("Infigratinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Infigratinib. Rifampin    CYP3A4.","Decreased Infigratinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Infigratinib (Truseltiq)","Strong CYP3A4 Inhibitors (Voriconazole)",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   Infigratinib  .","Mechanism: **Potent CYP3A4 inhibition**. Significantly increased Infigratinib concentration."," : **  **  .","Clinical Significance: **Severe ocular toxicity** and retinal damage."," .    .","Avoid combination. Use alternative antifungal.");n("Infliximab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Infliximab   (TNF inhibitor).","Increased risk of infection. Infliximab is an immunosuppressant (TNF inhibitor).","     .","Risk of developing infection from live vaccines."," .      .","Contraindicated. Live vaccines must be avoided during treatment.");n("Infliximab","Live vaccines",e.DRUG_DRUG,i.HIGH,"        ","Immunosuppression increases risk of infection from live vaccines.","    ","Serious infection from live vaccines.","    ","Avoid live vaccines during treatment.");n("Infliximab","Live Vaccines",e.DRUG_DRUG,i.HIGH," ","Immunosuppression.","    ","Risk of infection from live vaccine.","  ","Avoid live vaccines.");n("Influenza Vaccine (LAIV, Live)","Oseltamivir",e.DRUG_DRUG,i.HIGH,"              .","Oseltamivir is an antiviral that inhibits the replication of the influenza virus, including the live attenuated vaccine strain.","        .","Severe reduction in vaccine efficacy and inadequate protection."," .    48     .","Contraindicated. Must postpone vaccination 48 hours after stopping the antiviral.");n("Influenza Vaccine (LAIV, Live)","Aspirin / Salicylates (in Children/Adolescents)",e.DRUG_DRUG,i.HIGH,"    .         .","Interaction does not concern vaccine efficacy. The risk is Reye's Syndrome if vaccine viral infection occurs.","   (Reye's Syndrome)         .","Risk of Reye's Syndrome, a rare, life-threatening condition affecting the liver and brain.","  .     4   . (   IIV).","Absolute contraindication. Must avoid aspirin for 4 weeks after vaccination. (Use inactivated vaccine IIV).");n("Insulin","Beta Blockers (Non-selective)",e.DRUG_DRUG,i.HIGH,"     (   )","Masking of hypoglycemia symptoms (e.g., tachycardia, tremors)","        (  )","Hypoglycemia signs and symptoms may be masked (silent hypoglycemia)","     (    ) -           ","Use cardioselective beta-blockers (e.g., bisoprolol, metoprolol, atenolol) if possible. Monitor blood glucose closely as tachycardia and tremors may be masked.");n("Insulin","Ethanol",e.DRUG_DRUG,i.MODERATE,"    ","Inhibition of hepatic gluconeogenesis","     ","Increased insulin hypoglycemic effect","     ","Consume alcohol in moderation with meals");n("Insulin","MAO Inhibitors (Isocarboxazid, Phenelzine, Tranylcypromine)",e.DRUG_DRUG,i.HIGH,"  ","Stimulation of insulin secretion","     ","Increased insulin hypoglycemic effect","    -     ","Monitor blood glucose levels - reduce insulin dose if necessary");n("Insulin","Salicylates (Aspirin, Magnesium Salicylate, Sodium Salicylate)",e.DRUG_DRUG,i.MODERATE,"  ","Increased insulin sensitivity","     ","Increased insulin hypoglycemic effect","    -     ","Monitor blood glucose levels - reduce insulin dose if necessary");n("Insulin","Alcohol",e.DRUG_FOOD,i.HIGH," ()       : (1)        (gluconeogenesis)          NADH/NAD+          (2)     (3)       .            :                .","Alcohol (ethanol) has dual dangerous effect on glucose metabolism: (1) directly inhibits hepatic gluconeogenesis by blocking key enzymes and increasing NADH/NAD+ ratio, preventing liver from producing and releasing glucose into blood, (2) depletes hepatic glycogen stores, (3) may impair awareness of early hypoglycemia symptoms. When alcohol taken with insulin or other diabetes medications, dangerous synergy occurs: insulin lowers glucose while alcohol prevents liver from compensating for this decrease, leading to severe and prolonged hypoglycemia.","        (  )     (6-12   ).  :                          .                          .","Dangerous, life-threatening hypoglycemia may persist for prolonged periods (6-12+ hours). Symptoms include: severe sweating, tremor, palpitations, intense hunger, confusion, mental disorientation, inability to concentrate, seizures, loss of consciousness, and in very severe cases coma or death. Risk is greatest when drinking on empty stomach or without adequate carbohydrates, and in type 1 diabetics or those using high insulin doses.","       .        : (1)       -          (2)    : 2   : 1    (3)          (4)      (5)          (6)     ( )  (7)      .              .","Complete alcohol avoidance is preferred for insulin-treated diabetics. If patient chooses to drink despite warnings: (1) never drink on empty stomach - must eat meal with complex carbohydrates and protein first, (2) maximum limit for men: 2 standard drinks, women: 1 standard drink daily, (3) check blood glucose before, during, after drinking and before bed, (4) eat bedtime snack, (5) inform companions about diabetes and emergency procedures, (6) always carry fast-acting sugar source (juice, candy), (7) avoid exercise after drinking. Complete avoidance in recurrent hypoglycemia or hypoglycemia unawareness.");n("Insulin","Beta-blockers",e.DRUG_DRUG,i.MODERATE,"    (   )","Masking hypoglycemia symptoms (tremor, sweating, tachycardia).","   -   ","Silent hypoglycemia - patient danger.","  -     ( )","Patient education - rely on other symptoms (hunger, fatigue).");n("Insulin","Alcohol",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Caffeine",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Green Tea",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Milk",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","High-fat meals",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","High-fiber foods",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Vitamin C",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Vitamin D",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Vitamin E",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Vitamin K",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Vitamin B12",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Folic Acid",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Iron",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Calcium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Magnesium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Zinc",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Potassium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin","Antacids",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Insulin Glargine","Beta-Blockers",e.DRUG_DRUG,i.MODERATE,"    (  )","Masking symptoms of hypoglycemia (e.g., tremors, palpitations).","   ","Masking hypoglycemia symptoms.","   ","Monitor blood glucose regularly.");n("Interferon beta-1a","Myelosuppressive drugs",e.DRUG_DRUG,i.MODERATE,"    ","Additive myelosuppressive effect.","    ","Increased risk of pancytopenia.","    ","Monitor complete blood count regularly.");n("Iodide","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Iodinated Glycerol","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Iodine","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Ipilimumab","Prednisone",e.DRUG_DRUG,i.HIGH,"  Ipilimumab.        .","Decreased efficacy of Ipilimumab. Corticosteroids are immunosuppressive and antagonize the inhibitor mechanism.","    (  ).","Reduced efficacy of immunotherapy (anti-cancer treatment)."," .       .","Contraindicated. Systemic corticosteroids must be avoided before treatment.");n("Ipilimumab (CTLA-4)","High-dose Corticosteroids",e.DRUG_DRUG,i.MODERATE,"  Ipilimumab.          CTLA-4.","Decreased Ipilimumab efficacy. High-dose corticosteroids may inhibit the immune activation enhanced by the CTLA-4 inhibitor.","   .","Failure of the anti-tumor immune response."," .       (  irAEs).","Avoid combination. Avoid high-dose systemic corticosteroids (except for management of irAEs).");n("Ipratropium","Anticholinergics",e.DRUG_DRUG,i.MODERATE,": **    (Additive Anticholinergic Effect)**.             (       )     .","Mechanism: **Additive anticholinergic effect**. Ipratropium is an inhaled anticholinergic, and when combined with other anticholinergic medications (e.g., oxybutynin, tolterodine, or tricyclic antidepressants), systemic anticholinergic effects accumulate."," : **       **   :         (     )     (   )      .","Clinical Significance: **Significantly increased systemic anticholinergic adverse effects** including: severe dry mouth, blurred vision, urinary retention (especially in men with prostate enlargement), severe constipation, mental confusion (especially in elderly), and increased intraocular pressure in glaucoma patients.","    **   65 ** (  Beers Criteria).                    .        .","Avoid concurrent use in **elderly patients over 65 years** (per Beers Criteria). If combination is necessary, use lowest possible doses of both drugs, closely monitor anticholinergic symptoms, and educate patient about side effects. Consider alternatives without anticholinergic properties.");n("Irinotecan","St. John's Wort",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 induction.","  ","Chemotherapy failure."," ","Avoid completely.");n("Iron","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE," .         ( ).","Reduced Absorption. Aluminum ions may bind to Iron in the GI tract (complex formation).","  .    .","Failure to Treat Anemia. Ineffective Iron supplementation.",".      .","Separate by at least two hours.");n("Iron","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE," .         ( ).","Reduced Absorption. Magnesium ions may bind to Iron in the GI tract (complex formation).","  .    .","Failure to Treat Anemia. Ineffective Iron supplementation.",".      .","Separate by at least two hours.");n("Iron","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE," .        ( ).","Reduced Absorption. Calcium ions bind to Iron in the GI tract (complex formation).","  .    .","Failure to Treat Anemia. Ineffective Iron supplementation.",".      .","Separate by at least two hours.");n("Iron","Vitamin E",e.DRUG_DRUG,i.MODERATE,"  E.     E   .","Vitamin E Destruction. Iron catalyzes the oxidation of Vitamin E in the GI tract.","   E.    E.","Decreased Vitamin E Efficacy. Risk of Vitamin E deficiency.","  .       .","Separate Doses. Preferably separate doses by at least two hours.");n("Iron","Levothyroxine",e.DRUG_DRUG,i.MODERATE," ","Complex formation."," ","Hypothyroidism.","  4 ","Separate by 4 hours.");n("Iron Polysaccharide","Tetracycline",e.DRUG_DRUG,i.MODERATE,"    .      .","Non-absorbable Complex Formation. Iron ions bind to Tetracycline in the intestine.","   .      .","Mutual Malabsorption. Failure in infection treatment and Iron deficiency.","     .           .","Separate Doses by at Least Two Hours. Tetracycline should be given two hours before or four hours after Iron.");n("Iron Polysaccharide","Doxycycline",e.DRUG_DRUG,i.MODERATE,"    .      .","Non-absorbable Complex Formation. Iron ions bind to Doxycycline in the intestine.","   .      .","Mutual Malabsorption. Failure in infection treatment and Iron deficiency.","     .           .","Separate Doses by at Least Two Hours. Doxycycline should be given two hours before or four hours after Iron.");n("Iron Polysaccharide","Minocycline",e.DRUG_DRUG,i.MODERATE,"    .      .","Non-absorbable Complex Formation. Iron ions bind to Minocycline in the intestine.","   .      .","Mutual Malabsorption. Failure in infection treatment and Iron deficiency.","     .           .","Separate Doses by at Least Two Hours. Minocycline should be given two hours before or four hours after Iron.");n("Iron Supplements","Tea / Coffee",e.DRUG_FOOD,i.MODERATE,"  (Tannins)       .","Tannins in Tea and Coffee bind to Iron and prevent its absorption.","      .","Lack of Benefit from Iron Dose and Persistence of Anemia.","        .","Avoid drinking tea and coffee for two hours after taking Iron.");n("Iron Supplements","Tea/Coffee",e.DRUG_FOOD,i.HIGH,"        (tannins)             (Fe2+  Fe3+)   (chelates)      .  : (1)            (2)   -        (3)          60-90%.            .    ( )     .","Tea and coffee contain polyphenols, especially tannins and chlorogenic acid, which have very high capacity to bind iron ions (Fe2+ and Fe3+) forming insoluble, non-absorbable chelate complexes in intestines. Inhibition mechanism: (1) tannins chemically bind iron in gastric and intestinal lumen before absorption, (2) formation of large iron-tannin complexes that intestinal cells cannot absorb, (3) reduction of available free absorbable iron by up to 60-90%. Black tea has stronger effect than green tea, coffee has moderate effect. Even small amounts (one cup) can significantly impact.","        (   60-90%)   : (1)            (2)    :                             (3)    :           (     )    .              .","Severe, significant reduction in iron supplement absorption (may decrease 60-90%), leading to: (1) iron deficiency anemia treatment failure or very slow therapeutic response, (2) persistent iron deficiency symptoms: severe fatigue and persistent exhaustion, skin and mucous membrane pallor, shortness of breath with minimal exertion, palpitations and tachycardia, recurrent headaches, dizziness, cold extremities, hair loss, nail weakness and cracking, glossitis, (3) in severe chronic cases: immune system weakness, growth delay in children, pregnancy problems (preterm birth and low birth weight risk), impaired cognitive performance and concentration. This interaction is critically important especially for pregnant women, children, and patients with severe anemia.","      : (1)                 -           (2)     :        (   )      (   ) (3)                  C -  C      (  3-4 )     Fe3+    Fe2+   (4)        +   C (100-200 ) (5)  :         () (6)                 ( )      (7)      /         .    :      -    .","Strict rules to ensure effective iron absorption: (1) don't drink tea or coffee at least two hours before iron intake, nor two hours after - this duration necessary to ensure complete iron absorption before tannins entry, (2) optimal time for iron supplements: morning on empty stomach one hour before breakfast (if well tolerated), or evening two hours before bed (sufficient time after dinner), (3) take iron with full glass of orange juice, grapefruit juice, or any vitamin C-rich juice - vitamin C greatly enhances iron absorption (increases 3-4 fold) by converting ferric Fe3+ to more absorbable ferrous Fe2+ form, (4) can also take iron with plain water + vitamin C tablet (100-200mg), (5) also avoid: green tea, dark herbal teas, dark soft drinks (cola), (6) if experiencing gastric irritation from iron on empty stomach, can take with light snack (crackers, banana) but not with dairy, (7) if tea/coffee drinking essential, make it weak concentration and space from iron maximally. For patients with treatment failure: review iron and beverage timing - may be the cause.");n("Iron Supplements","Dairy Products",e.DRUG_FOOD,i.MODERATE,"  (   )                    .  : (1)       (transporters)       DMT1 (Divalent Metal Transporter 1) (2)                     (3)   300-600  (  )       30-50%.    :       .","Dairy products (milk, cheese, buttermilk, yogurt) contain high calcium levels, a mineral that directly competes with iron for same absorption sites and pathways in intestinal cells. Interference mechanism: (1) calcium and iron use same absorption transporters in small intestine mucosa, especially DMT1 (Divalent Metal Transporter 1), (2) with high calcium amounts present, calcium occupies most binding sites on these transporters, reducing iron binding and absorption opportunity, (3) calcium at 300-600mg concentration (one cup milk) can reduce iron absorption 30-50%. Effect is dose-dependent: more calcium means less iron absorption.","           : (1)           (2)        () (3)      :      .     :                     .","Moderate but clinically significant reduction in iron absorption, leading to: (1) reduced iron deficiency anemia treatment efficacy and prolonged required treatment duration, (2) slow improvement in hemoglobin levels and iron stores (ferritin), (3) persistent iron deficiency symptoms for longer period: fatigue, general weakness, pallor, shortness of breath. This effect is important especially in: growing children and adolescents, pregnant and lactating women, women of childbearing age with heavy menstrual periods, post-surgery or bleeding patients, athletes.","     : (1)           - :        7     9    (2)    :                 (3)      :         (:      ) (4)    :   (   )    (5)   :             -   (6) :        (prenatal)              .","Practical recommendations for separating iron and calcium: (1) space iron supplements and dairy products by at least two hours - for example: if drinking milk at 7 AM breakfast, take iron at 9 AM or later, (2) don't take iron with: milk, cheese, buttermilk, yogurt, ice cream, or any food with large dairy amounts, (3) if also taking calcium supplements: take calcium at completely different time from iron (e.g., iron morning and calcium evening, or vice versa), (4) foods allowed with iron: fruits, vegetables (not large spinach amounts), bread, plain crackers, (5) special advice for children: don't give child iron supplements with milk bottle or immediately after nursing - wait two hours, (6) for pregnant women: if taking prenatal supplement containing both iron and calcium, ask physician about better alternative or dose splitting.");n("Iron Supplements / Thyroid Hormone (Levothyroxine)","Hot Beverages ( )",e.DRUG_FOOD,i.MODERATE,"          ( ).","Heat may damage the active ingredient and cause destruction of the chemical structure of drugs (especially Levothyroxine).","  .     .","Decreased Drug Efficacy. Severe reduction in bioavailability.","   /        .","Take medications with cool/lukewarm water and avoid very hot beverages with or immediately after them.");n(tn,"Chloramphenicol",e.DRUG_DRUG,i.MODERATE,":       (Erythropoiesis)    .","Mechanism: Chloramphenicol directly inhibits the process of red blood cell formation (Erythropoiesis) in the bone marrow."," :      (Serum Iron)         .","Clinical Significance: Increased serum iron concentrations and delayed or failed clinical response to iron therapy for anemia.","     .        (Reticulocyte count).","Use alternative antibiotic if possible. Otherwise, monitor iron stores and the reticulocyte count for bone marrow response.");n(tn,"Levodopa",e.DRUG_DRUG,i.MODERATE,":    (Chelation)    ($Fe^{2+}$$)    .","Mechanism: Chelation complex formation between iron ions ($Fe^{2+}$$) and Levodopa in the gastrointestinal tract."," :               .","Clinical Significance: Significantly decreased GI absorption of levodopa leading to reduced therapeutic efficacy and potential worsening of Parkinson's symptoms.","      ( 2-3   ).","Separate administration times as much as possible (preferably at least 2-3 hours).");n(tn,"Levothyroxine",e.DRUG_DRUG,i.MODERATE,":     (Chelation/Binding)        .","Mechanism: Gastrointestinal chelation/binding between iron ions and the Levothyroxine hormone, preventing absorption."," :             (Hypothyroidism) .","Clinical Significance: Reduced Levothyroxine absorption and blood levels, potentially causing clinical hypothyroidism.","       4 .        .","Separate doses by at least 4 hours. Levothyroxine is preferably taken on an empty stomach in the morning.");n(tn,"Mycophenolate mofetil",e.DRUG_DRUG,i.MODERATE,":            .","Mechanism: Chelate complex formation in the stomach between iron ions and Mycophenolate, preventing absorption."," :               (Transplant Rejection).","Clinical Significance: Decreased GI absorption of mycophenolate and reduced serum levels, potentially leading to transplant rejection.","      .       .","Separate administration times by at least 2 hours. Monitor mycophenolate blood levels if necessary.");n(tn,"Penicillamine",e.DRUG_DRUG,i.MODERATE,":        (    ).","Mechanism: Chelate complex formation between iron ions and Penicillamine (which is itself a chelating agent)."," :                .","Clinical Significance: Significantly decreased GI absorption of penicillamine, reducing its efficacy in treating inflammatory diseases or Wilson's disease.","           .","Administer penicillamine on an empty stomach. Separate administration times from iron by at least 2 hours.");n(tn,St,e.DRUG_DRUG,i.HIGH,":               .","Mechanism: Formation of strong, non-absorbable chelate complexes between iron ions and Tetracycline, reducing the solubility of both."," :            .      .","Clinical Significance: Reduced absorption of both drugs, leading to treatment failure for both anemia and bacterial infection. This is a classic chelation example.","    3-4 .      3 .","Separate doses by 3-4 hours. Tetracycline first, followed by iron 3 hours later.");n(tn,xt,e.DRUG_DRUG,i.HIGH,":             ().","Mechanism: Formation of strong, non-absorbable chelate complexes between iron ions and the quinolone antibiotic."," :   (  90%)              .","Clinical Significance: Severe reduction (over 90%) in antibiotic absorption and efficacy, leading to treatment failure and potential bacterial resistance.","           2-4  (   ).","Strictly avoid combination, or separate doses by at least 2-4 hours (depending on the specific quinolone).");n(tn,Pc,e.DRUG_DRUG,i.MODERATE,":     (  pH)           .","Mechanism: Alteration of gastric pH (raising pH) and formation of insoluble iron complexes in the alkaline medium, reducing absorption."," :             .","Clinical Significance: Critically decreased GI absorption of iron, leading to failure of iron therapy for anemia.","     .      / .","Separate administration times by at least 2 hours. Take iron first, before antacids/phosphate binders.");n("Isatuximab","Corticosteroids (High Dose)",e.DRUG_DRUG,i.HIGH,"     .    .","Exacerbated immunosuppression and increased infection risk. Both weaken the immune response.","     .","Increased risk of opportunistic infections and acute neutropenia.",".             .","Caution. High doses of systemic corticosteroids should be avoided except for managing infusion-related adverse reactions.");n("Isatuximab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Isatuximab      (CD38)   .","Increased risk of viral infection. Isatuximab is a monoclonal antibody (CD38) and causes immunosuppression.","     .","Risk of developing infection from live vaccines."," .       Isatuximab.","Contraindicated. Live vaccines must be avoided during Isatuximab treatment.");n("Isatuximab","Dexamethasone",e.DRUG_DRUG,i.MODERATE,"    .       (CD38 MAb  Dexamethasone/Lenalidomide).","Increased risk of myelosuppression. Additive toxicity interaction between combination therapies (CD38 MAb with Dexamethasone/Lenalidomide).","    .","Increased risk of neutropenia and infection."," .           .","Dose adjustment. Blood counts must be monitored and doses of concomitant drugs adjusted according to the treatment protocol.");n("Isatuximab (CD38)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"     . Isatuximab     .","No clinically significant interaction expected. Isatuximab is a monoclonal antibody.","   .   .","No known effect. They are used safely together.","    .","No special action required.");n("Isatuximab (CD38)","Digoxin",e.DRUG_DRUG,i.LOW,"     .    .","No clinically significant interaction expected. Monoclonal antibody.","   .","No known effect.","    .","No special action required.");n("Isavuconazole","Rifampin",e.DRUG_DRUG,i.HIGH,"  Isavuconazole. Rifampin    CYP3A4    Isavuconazole.","Decreased Isavuconazole concentration. Rifampin is a strong inducer of CYP3A4, an Isavuconazole metabolic pathway.","           .","Reduced drug plasma concentration, leading to failure of fungal infection treatment."," .   .","Contraindicated. Avoid the combination.");n("Isavuconazole","Rifampin",e.DRUG_DRUG,i.HIGH,"  Isavuconazole. Rifampin    CYP3A4.","Decreased Isavuconazole concentration. Rifampin is a strong inducer of CYP3A4.","        .","Reduced antifungal efficacy, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Isavuconazonium Sulfate","Rifampin",e.DRUG_DRUG,i.HIGH,"  Isavuconazole. Rifampin    CYP3A4/2C8.","Decreased Isavuconazole concentration. Rifampin is a strong inducer of CYP3A4/2C8.","        .","Reduced antifungal efficacy, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Isocarboxazid - ","SSRIs -    ",e.DRUG_DRUG,i.CONTRAINDICATED,"         ","Synergistic increase in serotonergic activity leading to serotonin syndrome risk","  (       )","Serotonin syndrome (fever, tremor, muscle rigidity, mental status changes)","   -   5    SSRIs   ","Absolute contraindication - 5-week washout after SSRIs before starting Isocarboxazid");n("Isocarboxazid - ","Sympathomimetics -  ",e.DRUG_DRUG,i.CONTRAINDICATED,"        ","Inhibition of catecholamine metabolism leading to dangerous hypertension","       ","Hypertensive crisis, cerebral hemorrhage, severe headache","        ","Avoid all sympathomimetics including cold and cough medications");n("Isocarboxazid - ","Tyramine-rich foods -   ",e.DRUG_FOOD,i.HIGH,"      ","Inhibition of tyramine metabolism leading to catecholamine release","      ","Hypertensive crisis, palpitations, nausea, vomiting","      ","Avoid aged cheeses, processed meats, fermented beverages");n("Isocarboxazid - ","Tricyclic Antidepressants -    ",e.DRUG_DRUG,i.HIGH,"     ","Synergistic increase in serotonin and norepinephrine activity","       ","Serotonin syndrome, hypertension, hyperthermia","  -   2-3   TCAs","Avoid combination - 2-3 week washout after TCAs");n("Isocarboxazid - ","Meperidine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"   :           ","Severe and fatal serotonergic interaction: Isocarboxazid inhibits serotonin metabolism while Meperidine increases its release and inhibits reuptake","       (>41)           ","Fulminant serotonin syndrome with hyperthermia (>41C), muscle rigidity, tremor, confusion, hypotension, respiratory depression, coma, and death","   -   -   14         -      ","Absolute contraindication - complete avoidance - 14-day washout after Isocarboxazid before using any opioids - use safe opioid alternatives like morphine");n("Isocarboxazid - ","Decongestants -  ",e.DRUG_DRUG,i.HIGH,"      ","Inhibition of metabolism of pseudoephedrine-containing decongestants","       ","Hypertensive crisis, stroke, heart attack","    -    ","Avoid all decongestants - use non-pharmacological alternatives");n("Isocarboxazid - ","CNS Stimulants -    ",e.DRUG_DRUG,i.HIGH,"     ","Synergistic increase in excitatory neurotransmitters","     ","Agitation, delirium, seizures, hypertensive crisis","       ","Avoid stimulants including caffeine-containing medications");n("Isocarboxazid (MAOI)","Tyramine-Rich Foods (Aged Wine, Beer)",e.DRUG_FOOD,i.HIGH,"     .  MAOI   .","Increased risk of Hypertensive Crisis. MAOIs prevent Tyramine metabolism.","    (  ).","Severe hypertension (potentially fatal)."," .         .","Contraindicated. The patient must adhere to a Low-Tyramine Diet.");n("Isoniazid","Tyramine-containing foods",e.DRUG_FOOD,i.MODERATE,"  . Isoniazid      (MAO)  .","Increased Tyramine concentration. Isoniazid is a weak inhibitor of Monoamine Oxidase (MAO) enzyme.","      (Hypertensive crisis).","Increased risk of hypertensive crisis.","   .       .","Avoid Tyramine-rich foods. Avoid aged cheese, cured meats, and fermented beverages.");n("Isoniazid","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Phenytoin. Isoniazid   CYP2C9/2C19    Phenytoin.","Increased Phenytoin concentration. Isoniazid inhibits CYP2C9/2C19, Phenytoin metabolic pathways.","   Phenytoin (  ).","Increased risk of Phenytoin toxicity (ataxia, nystagmus, nausea)."," .    Phenytoin    .","Dose monitoring. Phenytoin blood levels must be monitored and dose adjusted.");n("Isoproterenol","Atenolol",e.DRUG_DRUG,i.HIGH,"   . Atenolol       Isoproterenol ( ).","Complete Antagonism. Atenolol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isoproterenol","Bisoprolol",e.DRUG_DRUG,i.HIGH,"   . Bisoprolol       Isoproterenol ( ).","Complete Antagonism. Bisoprolol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isoproterenol","Carvedilol",e.DRUG_DRUG,i.HIGH,"   . Carvedilol       Isoproterenol ( ).","Complete Antagonism. Carvedilol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isoproterenol","Metoprolol",e.DRUG_DRUG,i.HIGH,"   . Metoprolol       Isoproterenol ( ).","Complete Antagonism. Metoprolol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isoproterenol","Propranolol",e.DRUG_DRUG,i.HIGH,"   . Propranolol       Isoproterenol ( ).","Complete Antagonism. Propranolol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isoproterenol","Nebivolol",e.DRUG_DRUG,i.HIGH,"   . Nebivolol       Isoproterenol ( ).","Complete Antagonism. Nebivolol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isoproterenol","Labetalol",e.DRUG_DRUG,i.HIGH,"   . Labetalol       Isoproterenol ( ).","Complete Antagonism. Labetalol blocks Beta-receptors, negating the effect of Isoproterenol (a Beta-agonist).","   .   Isoproterenol     .","Cancellation of Isoproterenol Therapeutic Effect. Loss of Isoproterenol efficacy as a cardiac stimulant or bronchodilator.","  .         Isoproterenol.","Avoid Combination. Contraindicated in critical situations requiring Isoproterenol effect.");n("Isosorbide Dinitrate","Tadalafil",e.DRUG_DRUG,i.HIGH,"  ","Dangerous vasodilation.","  ","Acute hypotension.","  -  48 ","Contraindicated - separate by 48 hours.");n("Isotretinoin","Tetracyclines",e.DRUG_DRUG,i.HIGH,"   ","Increased intracranial pressure.","     ","Severe headache and papilledema."," ","Contraindicated.");n("Isotretinoin","Vitamin A",e.DRUG_DRUG,i.HIGH,"  A ","Synergistic vitamin A toxicity.","   ","Headache, vomiting, skin peeling.","   A","Avoid vitamin A supplements.");n("Isotretinoin (Roaccutane)","Pregnancy ()",e.DRUG_DISEASE,i.CONTRAINDICATED,"   (Teratogenic). Isotretinoin    A ()     .","Severe Teratogenic Effect. Isotretinoin is a Vitamin A derivative (Retinoid) with a potent and well-documented teratogenic effect.","   .             .","Severe Congenital Malformations. Includes craniofacial, cardiac, and central nervous system anomalies, such as hydrocephalus and ear deformities.","  .   .       ( IPLEDGE)           .","Contraindicated in Pregnancy. Absolute contraindication. A strict risk management program (e.g., IPLEDGE) requiring two effective forms of contraception must be adhered to before, during, and one month after therapy.");n("Itraconazole","Diazepam",e.DRUG_DRUG,i.HIGH,"  . Itraconazole     CYP3A4    .","Increased Diazepam Levels. Itraconazole is a potent inhibitor of the CYP3A4 enzyme responsible for Diazepam metabolism.","     .          .","Severe CNS Depression and Toxicity. Risk of excessive sedation, confusion, and life-threatening respiratory depression.","   / (  ).         (   50%)  .","Monitor CNS/Sedation Status (Dose Adjustment Required). Avoid combination or significantly reduce Diazepam dose (up to 50%) and monitor closely.");n("Itraconazole","Lorazepam",e.DRUG_DRUG,i.MODERATE,"     . Lorazepam        (Glucuronidation)    CYP3A4.","No Significant Concentration Increase. Lorazepam is primarily metabolized by glucuronidation, not CYP3A4.","       .","Minor Synergistic CNS Depression may occur.","   /.  Lorazepam/Oxazepam   CYP3A4.","Monitor CNS/Sedation Status. Lorazepam/Oxazepam are preferred over CYP3A4 substrates.");n("Itraconazole","Alprazolam",e.DRUG_DRUG,i.HIGH,"  . Itraconazole     CYP3A4    .","Increased Alprazolam Levels. Itraconazole is a potent inhibitor of the CYP3A4 enzyme responsible for Alprazolam metabolism.","     .      .","Severe CNS Depression and Toxicity. Risk of excessive sedation, confusion, and respiratory depression.","   / (  ).      Alprazolam    .","Monitor CNS/Sedation Status (Dose Adjustment Required). Avoid combination or significantly reduce Alprazolam dose and monitor closely.");n("Itraconazole","Clonazepam",e.DRUG_DRUG,i.HIGH,"  . Itraconazole  CYP3A4     .","Increased Clonazepam Levels. Itraconazole inhibits CYP3A4, the major metabolic pathway for Clonazepam.","     .     (Ataxia)  .","Severe CNS Depression and Toxicity. Risk of excessive sedation, ataxia, and respiratory depression.","   / (  ).    Clonazepam    .","Monitor CNS/Sedation Status (Dose Adjustment Required). Clonazepam dose must be reduced, and monitor closely for adverse effects.");n("Itraconazole","Buspirone",e.DRUG_DRUG,i.HIGH,"  . Itraconazole  CYP3A4     .","Increased Buspirone Levels. Itraconazole inhibits CYP3A4, the major metabolic pathway for Buspirone.","     .      .","Severe CNS Depression and Toxicity. Risk of excessive sedation, dizziness, and incoordination.","   / (  ).    Buspirone    2.5      .","Monitor CNS/Sedation Status (Dose Adjustment Required). Buspirone dose should be reduced to less than 2.5 mg BID or avoid combination.");n("Itraconazole","Cola/Acidic Beverages",e.DRUG_FOOD,i.MODERATE," ( )        (pH )        .     (pH  2.5)                   .              .","Itraconazole (especially capsules) is a weak base requiring acidic environment (low pH) for proper dissolution in gastric fluid. Acidic beverages like cola (pH ~2.5), citrus juices, and carbonated drinks create ideal acidic gastric environment significantly improving drug solubility and absorption. This effect is crucial for capsules, while oral solution doesn't need this as it's pre-dissolved.","      30-50%               .              .","Notable increase in itraconazole absorption by 30-50% when capsules taken with acidic beverages, improving blood levels and antifungal therapeutic efficacy. This is particularly important in systemic or severe fungal infections where adequate therapeutic levels are crucial."," :          (   )   .            pH .  :     (  )          .   (SUBA-itraconazole):    pH.","Itraconazole capsules: Must be taken with full meal and acidic beverage (cola, orange juice, lemon) for optimal absorption. Avoid with proton pump inhibitors or antacids that raise gastric pH. Oral solution: Preferred on empty stomach (one hour before food), held in mouth seconds before swallowing for enhanced local absorption. Modern tablets (SUBA-itraconazole): Less pH-dependent.");n("Itraconazole","Digoxin",e.DRUG_DRUG,i.HIGH," P-glycoprotein","P-gp inhibition increases digoxin levels.","  -   ","Digoxin toxicity - nausea, arrhythmias.","   -    50%","Monitor digoxin levels - reduce dose by 50%.");n("Ivabradine (HCN Channel)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Ivabradine. Ketoconazole    CYP3A4.","Increased Ivabradine concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    .","Increased risk of severe bradycardia."," .   .","Contraindicated. Avoid the combination.");n("Ivacaftor","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Ivacaftor. Ketoconazole    CYP3A4    Ivacaftor.","Increased Ivacaftor concentration. Ketoconazole is a strong CYP3A4 inhibitor, an Ivacaftor metabolic pathway.","      .","Increased risk of side effects, especially hepatotoxicity."," .    Ivacaftor   (    ).","Dose adjustment. Ivacaftor dose must be significantly reduced (to once weekly).");n("Ivacaftor","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ivacaftor  . Rifampin    CYP3A4.","Significant decrease in Ivacaftor concentration. Rifampin is a strong inducer of CYP3A4.","      .","Reduced drug efficacy and failure of cystic fibrosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Ivacaftor","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Ivacaftor. Itraconazole    CYP3A4.","Increased Ivacaftor concentration. Itraconazole is a strong inhibitor of CYP3A4.","    (   ).","Increased risk of side effects (e.g., elevated liver enzymes)."," .    Ivacaftor   (      ).","Dose adjustment. Ivacaftor dose must be significantly reduced (to every other day or every third day dosing).");n("Ivacaftor (CFTR Potentiator)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Ivacaftor. Ketoconazole    CYP3A4.","Increased Ivacaftor concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    (   ).","Increased risk of side effects (e.g., elevated liver enzymes)."," .    Ivacaftor   (     ).","Dose adjustment. Ivacaftor dose must be significantly reduced (to once weekly maintenance dose).");n("Ivermectin","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Ivermectin. Itraconazole    CYP3A4.","Increased Ivermectin concentration. Itraconazole is a strong inhibitor of CYP3A4.","    ( ).","Increased risk of neurotoxicity (dizziness, ataxia)."," .    .","Close monitoring. Monitor for signs of neurotoxicity.");n("Ivermectin","Rifampin",e.DRUG_DRUG,i.MODERATE,"  Ivermectin. Rifampin    CYP3A4.","Decreased Ivermectin concentration. Rifampin is a strong inducer of CYP3A4.","  .","Reduced drug efficacy."," .   .","Close monitoring. Monitor clinical response.");n("Ivosidenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ivosidenib. Rifampin    CYP3A4    Ivosidenib.","Decreased Ivosidenib efficacy. Rifampin is a strong inducer of CYP3A4, an Ivosidenib metabolic pathway.","           .","Reduced drug plasma concentration, leading to leukemia treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ivosidenib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Ivosidenib. Voriconazole    CYP3A4    Ivosidenib.","Increased Ivosidenib concentration. Voriconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Ivosidenib.","    QT   (Differentiation Syndrome).","Increased risk of QT prolongation and Differentiation Syndrome."," .    Ivosidenib     CYP3A4 .","Dose adjustment. Ivosidenib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ivosidenib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Ivosidenib. Phenytoin    CYP3A4    Ivosidenib.","Decreased Ivosidenib efficacy. Phenytoin is a strong inducer of CYP3A4, an Ivosidenib metabolic pathway.","           .","Reduced drug plasma concentration, leading to leukemia treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ivosidenib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Ivosidenib. Clarithromycin    CYP3A4    Ivosidenib.","Increased Ivosidenib concentration. Clarithromycin is a strong CYP3A4 inhibitor, a metabolic pathway for Ivosidenib.","    QT  .","Increased risk of QT prolongation and Differentiation Syndrome."," .    Ivosidenib     CYP3A4 .","Dose adjustment. Ivosidenib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ivosidenib","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  Ivosidenib. Diltiazem    CYP3A4    Ivosidenib.","Increased Ivosidenib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a metabolic pathway for Ivosidenib.","    QT  .","Increased risk of QT prolongation and Differentiation Syndrome."," .    Ivosidenib     CYP3A4 .","Dose adjustment. Ivosidenib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Ivosidenib","Pioglitazone",e.DRUG_DRUG,i.MODERATE,"  Pioglitazone. Ivosidenib   CYP2C8    Pioglitazone.","Increased Pioglitazone concentration. Ivosidenib inhibits CYP2C8, a Pioglitazone metabolic pathway.","     Pioglitazone     .","Increased risk of Pioglitazone side effects, especially fluid retention and heart failure.","  .           Pioglitazone.","Side effect monitoring. Patient must be monitored for increased side effects and Pioglitazone dose adjusted.");n("Ivosidenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ivosidenib. Rifampin    CYP3A4.","Decreased Ivosidenib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Ivosidenib (Tibsovo)","Sensitive CYP3A4 Substrates (Simvastatin)",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.      CYP3A4.","Mechanism: **CYP3A4 inhibition**. Increased concentration of CYP3A4-metabolized drugs."," : **   **   .","Clinical Significance: **Increased rhabdomyolysis risk** with statins.","  Simvastatin       CYP3A4  Pravastatin.","Reduce Simvastatin dose or use non-CYP3A4 statin such as Pravastatin.");n("Ixekizumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Ixekizumab   IL-17A.","Reduced vaccine response/Increased infection risk. Ixekizumab is an IL-17A inhibitor.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Ixekizumab (IL-17A Inhibitor)","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  . Ixekizumab  .","Increased risk of infection. Ixekizumab is an immunosuppressant.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Kava","Hepatotoxic Drugs",e.DRUG_DRUG,i.HIGH,"  ","Synergistic hepatotoxicity."," ","Liver failure."," ","Avoid combination.");n("Ketoconazole","Diazepam",e.DRUG_DRUG,i.HIGH,"  . Ketoconazole     CYP3A4    .","Increased Diazepam Levels. Ketoconazole is a potent inhibitor of the CYP3A4 enzyme responsible for Diazepam metabolism.","     .              .","Severe CNS Depression and Toxicity. Risk of excessive sedation, confusion, and respiratory depression potentially leading to coma or respiratory failure.","   / (  ).          (   50%)  .","Monitor CNS/Sedation Status (Dose Adjustment Required). Avoid combination or significantly reduce Diazepam dose (up to 50%) and monitor closely.");n("Ketoconazole","Lorazepam",e.DRUG_DRUG,i.MODERATE,"     . Lorazepam        (Glucuronidation)    CYP3A4.","No Significant Concentration Increase. Lorazepam is primarily metabolized by glucuronidation, not CYP3A4.","       .","Minor Synergistic CNS Depression may occur.","   /. (     ).  Lorazepam/Oxazepam   CYP3A4.","Monitor CNS/Sedation Status. (Dose adjustment rarely necessary). Lorazepam/Oxazepam are preferred over CYP3A4 substrates.");n("Ketoconazole","Alprazolam",e.DRUG_DRUG,i.HIGH,"  . Ketoconazole     CYP3A4    .","Increased Alprazolam Levels. Ketoconazole is a potent inhibitor of the CYP3A4 enzyme responsible for Alprazolam metabolism.","     .      .","Severe CNS Depression and Toxicity. Risk of excessive sedation, confusion, and respiratory depression.","   / (  ).       Alprazolam    .","Monitor CNS/Sedation Status (Dose Adjustment Required). Avoid combination or significantly reduce Alprazolam dose and monitor closely.");n("Ketoconazole","Clonazepam",e.DRUG_DRUG,i.HIGH,"  . Ketoconazole  CYP3A4     .","Increased Clonazepam Levels. Ketoconazole inhibits CYP3A4, the major metabolic pathway for Clonazepam.","     .     (Ataxia)  .","Severe CNS Depression and Toxicity. Risk of excessive sedation, ataxia, and respiratory depression.","   / (  ).    Clonazepam    .","Monitor CNS/Sedation Status (Dose Adjustment Required). Clonazepam dose must be reduced, and monitor closely for adverse effects.");n("Ketoconazole","Buspirone",e.DRUG_DRUG,i.HIGH,"  . Ketoconazole  CYP3A4     .","Increased Buspirone Levels. Ketoconazole inhibits CYP3A4, the major metabolic pathway for Buspirone.","     .      .","Severe CNS Depression and Toxicity. Risk of excessive sedation, dizziness, and incoordination.","   / (  ).    Buspirone    2.5      .","Monitor CNS/Sedation Status (Dose Adjustment Required). Buspirone dose should be reduced to less than 2.5 mg BID or avoid combination.");n("Ketoprofen","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,"     . Ketoprofen (NSAID)   COX-1  COX-2               .","Direct Mucosal Irritation and Protection Reduction. Ketoprofen (NSAID) inhibits COX-1 and COX-2 enzymes, reducing protective gastric/intestinal prostaglandins, in addition to direct chemical irritation.","   (Hemorrhage).       (Peptic Ulcer)       .","Gastrointestinal Hemorrhage. Significant increase in the risk of peptic ulcer, bleeding, or life-threatening perforation.",".           .            (PPI)  .","Avoid. Contraindicated in active ulcers or recent GI bleeding history. If use is unavoidable, administer with a prophylactic proton pump inhibitor (PPI).");n("Ketoprofen","Heart Failure ( )",e.DRUG_DISEASE,i.MODERATE," . Ketoprofen (NSAID)   COX           .","Fluid Retention. Ketoprofen (an NSAID) inhibits renal COX enzyme, leading to sodium and water retention and reduced diuretic effectiveness.","  .     (Volume Overload)          (  ).","Worsening Failure. Increases the volume overload burden on the heart, leading to exacerbation of heart failure symptoms (edema, dyspnea).",".   Ketoprofen       .           .","Avoid. Preferably avoid Ketoprofen in moderate to severe heart failure. If necessary, monitor weight, edema, and blood pressure closely.");n("Ketoprofen","Peptic Ulcer ( )",e.DRUG_DISEASE,i.HIGH,"     .","Prostaglandin Inhibition. COX inhibition depletes cytoprotective gastric prostaglandins, increasing ulcer risk.","      .","GI Bleeding & Perforation. Severe gastric injury.","         (PPIs) .","         (PPIs) .");n("Ketorolac","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Ketorolac (eye drops)","Aspirin",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic bleeding effect.","  ","Intraocular bleeding."," ","Use cautiously.");n("Khat ()","Ampicillin",e.DRUG_FOOD,i.MODERATE,"   .                  ()       .","Gastrointestinal Malabsorption. Reports suggest that Khat consumption may significantly reduce the absorption of penicillin-class antibiotics (Ampicillin), possibly due to the astringent effects of compounds in Khat."," .     Ampicillin            .","Treatment Failure. Reduced serum Ampicillin concentrations may lead to ineffective antibiotic treatment and failure to eradicate the infection."," .       Ampicillin             .","Separate Administration. Separate Khat consumption and Ampicillin administration by at least two to three hours to minimize the interference with absorption.");n("Labetalol",Kh,e.DRUG_DRUG,i.HIGH,": **      **.              .","Mechanism: **Synergistic hypotensive and myocardial depressant effect**. Labetalol is an alpha/beta blocker, enhancing the vasodilatory and cardiac depressant effects of inhalation anesthetics."," : **   (Excessive Hypotension)**           .","Clinical Significance: Excessive hypotension and bradycardia, potentially placing the patient at risk of intraoperative ischemia.","      .        (      3%).","Monitor BP continuously. Caution with potent anesthetics like halothane (concentration should be kept < 3%).");n("Labetalol","Verapamil (IV)",e.DRUG_DRUG,i.HIGH," .","Cardiac Depression. Negative inotropic and chronotropic effects."," .","Cardiac Arrest. Asystole or fatal arrhythmia.",".",".");n("Labetalol","Diabetes",e.DRUG_DISEASE,i.HIGH,"   ","Masking Hypoglycemia. Adrenergic warning signs of hypoglycemia are blunted.","      ","      ","     ","     ");n("Labetalol","Diabetes ()",e.DRUG_DISEASE,i.MODERATE,"    (  ).","Masking Hypoglycemia Symptoms. Tremors and palpitations associated with hypoglycemia are blocked.","      (Hypoglycemia Unawareness)    .","      (Hypoglycemia Unawareness)    .","          .","          .");n("Labetalol","Asthma ()",e.DRUG_DISEASE,i.HIGH,"  -2     .","Beta-2 Blockade. Non-selective beta-blockade causes bronchoconstriction in susceptible patients.","    .","    .","    .    ( Bisoprolol)  .","    .    ( Bisoprolol)  .");n("Labetalol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP/Glucuronidation).        .","Enzymatic Metabolic Induction (CYP/Glucuronidation). Barbiturates induce hepatic enzymes responsible for Labetalol metabolism.","           (    /).","Decreased Labetalol plasma concentration, leading to reduced drug efficacy (less beta/alpha-blockade).","     .          .","Monitor blood pressure and heart rate. Increase the Labetalol dose if necessary to restore the desired therapeutic efficacy.");n("Labetalol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Labetalol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"                 .      .     ( )      .","Hydralazine reduces the hepatic clearance of Labetalol by decreasing liver blood flow, increasing its bioavailability. Labetalol also affects Hydralazine metabolism. This results in a mutual (bidirectional) increase in the plasma concentrations of both drugs.","           (Hypotension)   (Bradycardia)         .","Increased concentrations of both drugs lead to a risk of severe hypotension and bradycardia (from Labetalol), in addition to exacerbating Hydralazine side effects.","       .                .","Closely monitor blood pressure and heart rate. The starting dose of one or both drugs should be reduced upon co-administration to avoid severe hypotension.");n("Labetalol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Labetalol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic Hypotension. Combined effects lead to significant blood pressure drop.","     ","     ","     ","     ");n("Labetalol ()","Halothane",e.DRUG_DRUG,i.HIGH,"     (Additive Hypotensive Effect)","Additive Hypotensive Effect. Combined mechanisms of action lead to excessive blood pressure reduction.","     .","     .","  .     .      0.3%.","  .     .      0.3%.");n("Labetalol ()","Isoflurane",e.DRUG_DRUG,i.HIGH,"     (Additive Hypotensive Effect)","Additive Hypotensive Effect. Combined mechanisms of action lead to excessive blood pressure reduction.","     .","     .","  .     .      0.3%.","  .     .      0.3%.");n("Labetalol ()","Sevoflurane",e.DRUG_DRUG,i.HIGH,"     (Additive Hypotensive Effect)","Additive Hypotensive Effect. Combined mechanisms of action lead to excessive blood pressure reduction.","     .","     .","  .     .      0.3%.","  .     .      0.3%.");n("Lacosamide","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"  Lacosamide. Carbamazepine     CYP3A4     Lacosamide   .","Decreased Lacosamide concentration. Carbamazepine is a strong CYP3A4 inducer and may indirectly increase Lacosamide metabolism.","   Lacosamide           .","Decrease in Lacosamide levels, potentially leading to increased seizure frequency or loss of control."," .        Lacosamide  .","Level monitoring. Clinical response must be monitored and Lacosamide serum levels checked.");n("Lacosamide","Rifampin",e.DRUG_DRUG,i.MODERATE,"  Lacosamide. Rifampin   CYP3A4    Lacosamide.","Decreased Lacosamide concentration. Rifampin is a CYP3A4 inducer, a Lacosamide metabolic pathway.","   .","Reduced efficacy of seizure treatment."," .          .","Efficacy monitoring. Seizure control must be monitored and dose adjusted if necessary.");n("Lacosamide","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  Lacosamide. Fluconazole   CYP2C9    Lacosamide.","Increased Lacosamide concentration. Fluconazole inhibits CYP2C9, a Lacosamide metabolic pathway.","       .","Increased risk of side effects, especially dizziness and gait disturbances.","  .        .","Side effect monitoring. Patient must be monitored and dose adjusted if necessary.");n("Lacosamide","Diltiazem (CCB, CYP2C19 Inhibitor)",e.DRUG_DRUG,i.MODERATE,"    Lacosamide. Diltiazem   CYP2C19/2C9.","Slight increase in Lacosamide concentration. Diltiazem inhibits CYP2C19/2C9.","   .","Increased risk of dizziness and syncope."," .    /  .","Close monitoring. Monitor for signs of cardiac/CNS toxicity.");n("Lactic Acid Bacteria (Probiotics)","Antibiotics",e.DRUG_DRUG,i.MODERATE,"  .       .","Decreased probiotic efficacy. Antibiotics kill the live bacteria in the probiotic.","     (Gut flora replacement failure).","Failure to restore gut flora."," .     2-4    .","Dose separation. Probiotics must be taken 2-4 hours before antibiotics.");n("Lactulose","Tetracycline",e.DRUG_DRUG,i.MODERATE," ","Binding Agent. Forms complexes with the drug.","  ","  ","     ","     ");n("Lactulose","Antibiotics",e.DRUG_DRUG,i.MODERATE,"    ","Killing of lactulose-fermenting gut bacteria.","  ","Reduced lactulose efficacy."," ","Monitor efficacy.");n("Lactulose","Neomycin",e.DRUG_DRUG,i.MODERATE,"    ","Synergistic ammonia reduction.","     ","Enhanced efficacy in hepatic encephalopathy.","  ","May be beneficial.");n("Lamotrigine","Valproic Acid",e.DRUG_DRUG,i.HIGH,"  Lamotrigine. Valproic Acid    UGT    Lamotrigine.","Increased Lamotrigine concentration. Valproic Acid is a strong inhibitor of UGT enzymes, a Lamotrigine metabolic pathway.","    /    (SJS/TEN).","Increased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)."," .    Lamotrigine      Valproic Acid.","Dose adjustment. Lamotrigine dose must be significantly reduced when co-administered with Valproic Acid.");n("Lamotrigine","Valproate",e.DRUG_DRUG,i.HIGH,"  Lamotrigine. Valproate    UGT ( ).","Increased Lamotrigine concentration. Valproate is a strong inhibitor of UGT (metabolic pathway).","    /   (SJS/TEN).","Increased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)."," .    Lamotrigine   (   )    .","Dose adjustment. Lamotrigine dose must be significantly reduced (to half or less) and a slower titration schedule followed.");n("Lamotrigine","Carbamazepine",e.DRUG_DRUG,i.MODERATE,"  Lamotrigine. Carbamazepine    UGT.","Decreased Lamotrigine concentration. Carbamazepine is a strong inducer of UGT.","      .","Reduced anticonvulsant efficacy and increased risk of seizures."," .    Lamotrigine.","Dose adjustment. Lamotrigine dose must be increased.");n("Lamotrigine","Food",e.DRUG_FOOD,i.LOW,"                   .       (Cmax)     (AUC)      (Tmax).         .","Lamotrigine is rapidly and completely absorbed from the gastrointestinal tract, and food presence does not affect any fundamental pharmacokinetic parameters. There is no change in absorption rate (Cmax), extent of absorption (AUC), or time to peak (Tmax). This property provides great flexibility in drug timing.","      .                .","No clinically significant interaction exists. Blood levels and therapeutic efficacy remain identical whether the drug is taken with food or on an empty stomach.","           .             .       ()         .","Lamotrigine can be taken with or without food according to patient comfort and personal preference. This flexibility facilitates treatment adherence and allows easy integration into the patient's daily routine. If minor gastric symptoms occur (rare), it can be taken with food without concern about efficacy impact.");n("Lansoprazole","Atazanavir",e.DRUG_DRUG,i.HIGH," pH  -   ","Increased gastric pH reduces atazanavir absorption.","  ","Antiviral treatment failure."," ","Avoid combination.");n("Lapatinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Lapatinib.       CYP3A4  .","Increased Lapatinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","     .","Increased risk of cardiotoxicity and hepatotoxicity."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Lapatinib","High-Fat Meal",e.DRUG_FOOD,i.HIGH,"   AUC  325%  Cmax  284% -    ","High-fat meal increases AUC by 325% and Cmax by 284% - massive increase in absorption.","     - ","Dangerous increase in drug levels - toxicity.","     (     )","Must be taken on an empty stomach (1 hour before or 1 hour after food).");n("Lapatinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased lapatinib toxicity.","   ","Avoid grapefruit juice.");n("Larotrectinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Larotrectinib. Ketoconazole    CYP3A4    Larotrectinib.","Increased Larotrectinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Larotrectinib metabolic pathway.","      .","Increased risk of side effects, especially neurotoxicity."," .    Larotrectinib     CYP3A4 .","Dose adjustment. Larotrectinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Larotrectinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Larotrectinib. Rifampin    CYP3A4    Larotrectinib.","Decreased Larotrectinib efficacy. Rifampin is a strong inducer of CYP3A4, a Larotrectinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Larotrectinib","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  Larotrectinib. Diltiazem    CYP3A4    Larotrectinib.","Increased Larotrectinib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a Larotrectinib metabolic pathway.","      .","Increased risk of side effects, especially neurotoxicity."," .    Larotrectinib     CYP3A4 .","Dose adjustment. Larotrectinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Larotrectinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Larotrectinib.       CYP3A4  .","Increased Larotrectinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      .","Increased risk of side effects, especially neurotoxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Larotrectinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Larotrectinib. Phenytoin    CYP3A4    Larotrectinib.","Decreased Larotrectinib concentration. Phenytoin is a strong inducer of CYP3A4, a Larotrectinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Larotrectinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Larotrectinib. Phenytoin    CYP3A4.","Decreased Larotrectinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Larotrectinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Larotrectinib. Phenytoin    CYP3A4.","Decreased Larotrectinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Lasmiditan","SSRIs",e.DRUG_DRUG,i.HIGH,"    (Serotonin Syndrome).","Increased risk of Serotonin Syndrome.","       .","Agitation, hyperreflexia, fever, and tachycardia.","    .     .","Avoid combination or close monitoring. Serotonin syndrome symptoms must be monitored.");n("Latanoprost","Bimatoprost",e.DRUG_DRUG,i.MODERATE,"  ","Antagonistic effect.","   ","Reduced IOP lowering.","  ","Use only one.");n("Lecanemab","Warfarin",e.DRUG_DRUG,i.MODERATE,"   .         .","Increased risk of Cerebral Hemorrhage. Both drugs increase bleeding risk, particularly moderate cerebral microhemorrhages.","       (ARIA)     .","Increased risk of Amyloid-Related Imaging Abnormalities (ARIA) and cerebral hemorrhage in Alzheimers patients."," .           (MRI).","Caution and Monitoring. Risks and benefits must be weighed, and close monitoring with MRI scans is required.");n("Lecanemab (Leqembi)","Antiplatelet Agents (Aspirin/Clopidogrel)",e.DRUG_DRUG,i.HIGH,": **  **.","Mechanism: **Cerebral bleeding risk**."," : **ARIA-H** ( ).","Clinical Significance: **ARIA-H** (cerebral hemorrhage)."," .  MRI.","Use cautiously. MRI monitoring.");n("Ledipasvir/Sofosbuvir","St. John's Wort",e.DRUG_DRUG,i.HIGH,"  Ledipasvir/Sofosbuvir.       P-gp.","Decreased Ledipasvir/Sofosbuvir concentration. St. John's Wort is a strong inducer of P-gp.","            C.","Reduced drug plasma concentration, leading to failure of Hepatitis C treatment."," .   .","Contraindicated. Avoid the combination.");n("Lefamulin","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Lefamulin. Itraconazole    CYP3A4.","Increased Lefamulin concentration. Itraconazole is a strong inhibitor of CYP3A4.","    QT.","Increased risk of QT prolongation."," .   .","Contraindicated. Avoid the combination.");n("Lefamulin","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Lefamulin   P-gp.","Increased Digoxin concentration. Lefamulin inhibits P-gp.","   Digoxin.","Increased risk of Digoxin toxicity."," .   Digoxin     Lefamulin.","Close monitoring. Monitor Digoxin levels upon initiation or discontinuation of Lefamulin.");n("Leflunomide","Methotrexate",e.DRUG_DRUG,i.HIGH,"     .   .","Increased risk of hepatotoxicity and hematological toxicity. Additive toxic effects.","      .","Increased risk of liver failure and bone marrow suppression."," .           .","Contraindicated. Avoid combination due to serious side effects, or use very close monitoring.");n("Leflunomide","Methotrexate",e.DRUG_DRUG,i.HIGH,"    .   .","Increased risk of hepatotoxicity and hematological toxicity. Additive toxic effects.","    .","Liver damage and myelosuppression.","  .  .            .","Relative contraindication. Avoid combination. If usage is necessary, monitor liver function and blood counts monthly.");n("Leflunomide","Warfarin",e.DRUG_DRUG,i.MODERATE," CYP2C9","CYP2C9 inhibition."," INR","Increased INR."," INR ","Close INR monitoring.");n("Leflunomide","Methotrexate",e.DRUG_DRUG,i.HIGH,"  ","Synergistic hepatotoxicity."," ","Liver failure."," ","Avoid combination.");n("Lemborexant","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lemborexant. Rifampin    CYP3A4    Lemborexant.","Decreased Lemborexant efficacy. Rifampin is a strong inducer of CYP3A4, a Lemborexant metabolic pathway.","  .","Failure of insomnia treatment."," .   .","Contraindicated. Avoid the combination.");n("Lenacapavir","Rifampin",e.DRUG_DRUG,i.HIGH,"    Lenacapavir. Rifampin    CYP3A4.","Significant decrease in Lenacapavir concentration. Rifampin is a strong inducer of CYP3A4.","    .","Failure of antiretroviral treatment."," .   .","Contraindicated. Avoid the combination.");n("Lenacapavir","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Lenacapavir. Itraconazole   CYP3A4.","Increased Lenacapavir concentration. Itraconazole inhibits CYP3A4.","    QT.","Increased risk of QT prolongation."," .     .","Close monitoring. Monitor ECG and side effects.");n("Lenacapavir (Sunlenca)","Rifampin",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.   Lenacapavir  88%.","Mechanism: **Potent CYP3A4 induction**. Lenacapavir concentration decreases by 88%."," : **     **    .","Clinical Significance: **HIV treatment failure** due to subtherapeutic concentrations.","  .  Rifabutin   .","Absolute contraindication. Use Rifabutin as alternative with dose adjustment.");n("Lenacapavir (Sunlenca)","Ketoconazole",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.   Lenacapavir  .","Mechanism: **CYP3A4 inhibition**. Lenacapavir concentration doubles."," : **   **   .","Clinical Significance: **Increased risk of adverse effects** such as nausea and headache.","   .     .","No dose adjustment needed. Monitor adverse effects closely.");n("Leniolisib","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Leniolisib. Fluconazole    CYP3A4      Leniolisib.","Increased Leniolisib concentration. Fluconazole is a strong CYP3A4 inhibitor, the primary metabolic pathway for Leniolisib.","           .","Increased risk of side effects, including serious infections related to immunosuppression."," .    Leniolisib  50%      CYP3A4 .","Dose adjustment. Leniolisib dose must be reduced by 50% when co-administered with strong CYP3A4 inhibitors.");n("Lenvatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lenvatinib. Rifampin    CYP3A4    Lenvatinib.","Decreased Lenvatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Lenvatinib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lenvatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Lenvatinib. Ketoconazole    CYP3A4    Lenvatinib.","Increased Lenvatinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Lenvatinib metabolic pathway.","      .","Increased risk of hypertension, proteinuria, and hemorrhage."," .    Lenvatinib     CYP3A4 .","Dose adjustment. Lenvatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Lenvatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lenvatinib. Rifampin    CYP3A4    Lenvatinib.","Decreased Lenvatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Lenvatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lenvatinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Lenvatinib.      CYP3A4  .","Increased Lenvatinib concentration. Grapefruit juice is an inhibitor of intestinal CYP3A4.","      .","Increased risk of hypertension and nephrotoxicity."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Lenvatinib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Lenvatinib. Itraconazole   CYP3A4.","Increased Lenvatinib concentration. Itraconazole inhibits CYP3A4.","      (Proteinuria).","Increased risk of hypertension and proteinuria."," .        .","Close monitoring. Monitor blood pressure and adjust the dose if necessary.");n("Lenvatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Lenvatinib. Phenytoin    CYP3A4.","Decreased Lenvatinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure.","  .   CYP3A4 .","Relative contraindication. Avoid strong CYP3A4 inducers.");n("Letermovir (CMV)","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Letermovir. Cyclosporine   OATP1B1/3.","Increased Letermovir concentration. Cyclosporine inhibits OATP1B1/3.","     Letermovir (   ).","Increased risk of Letermovir side effects (e.g., elevated liver enzymes)."," .    Letermovir      Cyclosporine.","Dose adjustment. Letermovir dose must be significantly reduced when co-administered with Cyclosporine.");n("Letermovir (CMV)","Dabigatran",e.DRUG_DRUG,i.MODERATE,"  Dabigatran. Letermovir   P-gp.","Increased Dabigatran concentration. Letermovir inhibits P-gp.","  .","Increased risk of bleeding."," .   .","Close monitoring. Monitor for signs of bleeding.");n("Letrozole","Ketoconazole",e.DRUG_DRUG,i.LOW,"    Letrozole. Ketoconazole   CYP3A4    Letrozole.","Slight increase in Letrozole concentration. Ketoconazole inhibits CYP3A4, a Letrozole metabolic pathway.","     .","No clinically significant effect expected.","    .   .","No special action required. They are used safely together.");n("Letrozole","Tamoxifen",e.DRUG_DRUG,i.MODERATE,"  ","Antagonistic effect."," ","Reduced efficacy.","  ","Do not use together.");n("Letrozole","Estrogens",e.DRUG_DRUG,i.HIGH," ","Pharmacological antagonism.","  ","Reduced letrozole efficacy."," ","Avoid estrogen.");n("Leuprolide","Antidiabetic Agents",e.DRUG_DRUG,i.MODERATE,"   ","Altered glucose tolerance.","    ","Hyperglycemia or hypoglycemia.","  ","Monitor blood glucose.");n("Levodopa","Vitamin B6 (Pyridoxine)",e.DRUG_DRUG,i.MODERATE,"  .   B6 ()        (Peripheral Dopa Decarboxylase)               .","Increased Peripheral Breakdown. Vitamin B6 (Pyridoxine) acts as a cofactor for peripheral Dopa Decarboxylase enzyme, increasing the conversion of Levodopa to dopamine outside the CNS before it reaches the brain.","       (Parkinson's Disease).            .","Decreased Levodopa Efficacy in Parkinson's Disease Treatment. This breakdown reduces the amount of Levodopa available to enter the brain and alleviate symptoms.","  B6  .    B6            Carbidopa      .","Avoid High-Dose B6 Supplements. Avoid B6 supplements at doses exceeding the daily requirement, or use a combination product containing Carbidopa, which effectively prevents this interaction.");n("Levodopa/Carbidopa","Iron Supplements",e.DRUG_DRUG,i.HIGH,"  Levodopa.   Levodopa   .","Decreased Levodopa absorption. Iron chelates Levodopa in the gastrointestinal tract.","  Levodopa      .","Reduced Levodopa efficacy, leading to exacerbation of Parkinsons symptoms."," .      2   .","Dose separation. The two drugs must be separated by at least 2 hours.");n("Levofloxacin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  .  (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Aspirin (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  . Ibuprofen (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Ibuprofen (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  . Diclofenac (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Diclofenac (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  . Naproxen (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Naproxen (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  . Ketoprofen (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Ketoprofen (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  . Indomethacin (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Indomethacin (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  . Celecoxib (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Celecoxib (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  . Mefenamic Acid (NSAID)     Levofloxacin   GABA  .","CNS Stimulation. Mefenamic Acid (an NSAID) may act synergistically with Levofloxacin to inhibit GABA receptors in the brain."," .         .","Seizure Risk. Lowered seizure threshold, increasing the risk of seizures.",".   .      .","Avoid. Preferably avoid the combination. Closely monitor if combination is necessary.");n("Levofloxacin","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,".       Levofloxacin   .","Chelation Complex Formation. Multivalent Aluminum ions bind to Levofloxacin in the GI tract."," .     Levofloxacin       .","Decreased Absorption. Significant reduction in Levofloxacin absorption, leading to subtherapeutic levels."," .   Levofloxacin             .","Separate by Two Hours. Levofloxacin should be given at least two hours before or six hours after the Aluminum-containing antacid.");n("Levofloxacin","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE,".       Levofloxacin   .","Chelation Complex Formation. Multivalent Magnesium ions bind to Levofloxacin in the GI tract."," .     Levofloxacin       .","Decreased Absorption. Significant reduction in Levofloxacin absorption, leading to subtherapeutic levels."," .   Levofloxacin             .","Separate by Two Hours. Levofloxacin should be given at least two hours before or six hours after the Magnesium-containing antacid.");n("Levofloxacin","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,".       Levofloxacin   .","Chelation Complex Formation. Multivalent Calcium ions bind to Levofloxacin in the GI tract."," .     Levofloxacin       .","Decreased Absorption. Significant reduction in Levofloxacin absorption, leading to subtherapeutic levels."," .   Levofloxacin        .","Separate by Two Hours. Levofloxacin should be given at least two hours before or six hours after the Calcium.");n("Levofloxacin","Antacids (Mg/Al)",e.DRUG_DRUG,i.HIGH,"  Levofloxacin.      .","Decreased Levofloxacin absorption. Formation of insoluble chelation compounds.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   Levofloxacin  2    6     .","Dose separation. Levofloxacin must be taken 2 hours before or 6 hours after antacids.");n("Levofloxacin","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE,"  ","Chelation with magnesium reduces quinolone bioavailability.","   ","Reduced antibiotic efficacy, potential treatment failure.","    ","Separate doses by at least 2 hours.");n("Levonorgestrel","Efavirenz",e.DRUG_DRUG,i.HIGH,"  ","Progestin metabolism induction.","  ","Contraceptive failure.","   ","Use non-hormonal method.");n("Levothyroxine","Estrogens",e.DRUG_DRUG,i.MODERATE,"   .        (TBG)       (T4)   .","Alteration in Binding Proteins. Estrogens increase levels of Thyroxine-Binding Globulin (TBG), reducing the concentration of bioavailable free thyroxine (T4).","  .        (Hypothyroidism)   .","Decreased Levothyroxine Efficacy. May lead to the worsening or emergence of hypothyroidism symptoms.","      12     .   Levothyroxine       T4 .","Monitor Serum Thyroxine Concentrations approximately every 12 weeks after initiating Estrogen. Adjust Levothyroxine dose as necessary to compensate for the decrease in free T4.");n("Levothyroxine","Ferrous Sulfate",e.DRUG_DRUG,i.MODERATE,"    .     Levothyroxine        .","Reduced Levothyroxine Absorption. Iron may bind to Levothyroxine in the gastrointestinal tract, reducing its bioavailability.","  .       .","Decreased Levothyroxine Efficacy. May lead to the worsening of hypothyroidism.","      4   .    (TSH).    Levothyroxine  .","Separate administration times by at least 4 hours. Monitor thyroid function (TSH). Increase Levothyroxine dose amount as necessary.");n("Levothyroxine","Ferrous Gluconate",e.DRUG_DRUG,i.MODERATE,"    .     Levothyroxine        .","Reduced Levothyroxine Absorption. Iron may bind to Levothyroxine in the gastrointestinal tract, reducing its bioavailability.","  .       .","Decreased Levothyroxine Efficacy. May lead to the worsening of hypothyroidism.","      4   .    (TSH).    Levothyroxine  .","Separate administration times by at least 4 hours. Monitor thyroid function (TSH). Increase Levothyroxine dose amount as necessary.");n("Levothyroxine","Sucralfate",e.DRUG_DRUG,i.MODERATE,"    . Sucralfate (   )   Levothyroxine     .","Reduced Levothyroxine Absorption. Sucralfate (a mucosal protective agent) binds to Levothyroxine in the GI tract and prevents its absorption.","  .       .","Decreased Levothyroxine Efficacy. May lead to the worsening of hypothyroidism.","      8 .    (TSH).    Levothyroxine  .","Separate administration times by 8 hours. Monitor thyroid function (TSH). Increase Levothyroxine dose amount as necessary.");n("Levothyroxine","Soy Products",e.DRUG_FOOD,i.MODERATE,"  ","Inhibition of hormone absorption","  ","Reduced drug efficacy","      4   ","Separate drug and soy products by at least 4 hours");n("Levothyroxine","High-Fiber Foods",e.DRUG_FOOD,i.MODERATE,"  ","Fiber-Induced Malabsorption. Dietary fiber binds drug.","  ","  ","        -      ","        -      ");n("Levothyroxine","Coffee",e.DRUG_FOOD,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","  ","  ","     -     ","     -     ");n("Levothyroxine","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,"  ","Intestinal binding.","  ","Reduced levothyroxine absorption.","   4 ","Separate doses by 4 hours.");n("Levothyroxine","Ferrous Sulfate",e.DRUG_DRUG,i.MODERATE,"  -","Iron-hormone complex formation.","    ","Uncontrolled hypothyroidism.","  4  -  TSH","Separate by 4h - monitor TSH.");n("Levothyroxine","Proton Pump Inhibitors",e.DRUG_DRUG,i.MODERATE," pH  -  ","Increased gastric pH reduces absorption."," ","Hypothyroidism.","    ","May need increased levothyroxine dose.");n("Levothyroxine","Soy Products",e.DRUG_FOOD,i.MODERATE,"  ","Reduced hormone absorption.","  ","Reduced treatment efficacy.","     -    ","Take on empty stomach - avoid soy within 1 hour.");n("Levothyroxine","Soy Isoflavones",e.DRUG_FOOD,i.MODERATE,"  ","Hormone absorption inhibition."," ","Hypothyroidism.","  4 ","Separate by 4 hours.");n("Levothyroxine","Bile Acid Sequestrants",e.DRUG_DRUG,i.MODERATE,"  ","Intestinal binding.","  ","Reduced levothyroxine absorption.","  4-5 ","Separate by 4-5 hours.");n("Levothyroxine","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Levothyroxine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.MODERATE,"             .               (    ).                   .                          .          (AUC)                (Tmax)     (Cmax).","Grapefruit juice does not directly affect levothyroxine metabolism, but it affects its absorption. The juice contains compounds like furanocoumarins and naringin that can slow down intestinal motility (gastric emptying and gastrointestinal movement). Additionally, the juice may create an acidic environment or interact with the intestinal lining, slowing the drug dissolution and absorption process. Levothyroxine is a highly sensitive drug primarily absorbed in the small intestine, and any delay in its arrival at the optimal absorption site can reduce the extent and rate of its absorption. Grapefruit juice does not significantly alter the overall bioavailability (AUC) if taken hours apart, but it notably delays the time to peak concentration (Tmax) and reduces the maximum concentration (Cmax).","               : 1.     TSH       . 2.                 . 3.                      . 4.        .","Decreased levothyroxine blood concentration, especially in the morning after intake, which may lead to: 1. Instability of TSH levels, with inability to achieve the target level. 2. Persistence of hypothyroidism symptoms such as fatigue, weight gain, dry skin, and constipation despite treatment adherence. 3. Need to increase the levothyroxine dose to achieve optimal control, exposing the patient to the risk of side effects if their habits of taking it with juice change later. 4. Difficulty in interpreting blood test results and adjusting the dose.","1.   :            4              . 2.  :       30-60      . 3.  :                   . 4. :                           TSH     . 5. :       /    . 6.  :    .                    (  ).","1. Mandatory time separation: Take levothyroxine on a completely empty stomach with water only, and wait at least 4 hours before consuming grapefruit juice or any other beverage besides water. 2. Optimal timing: It is preferable to take levothyroxine early in the morning, 30-60 minutes before breakfast and any other drinks. 3. Drug education: Explain the importance of this separation to the patient, as many patients are unaware that beverages other than water can interfere. 4. Monitoring: If juice is accidentally consumed close to the medication time, monitor for hypothyroidism symptoms and inform the doctor, who may recommend checking TSH levels earlier than scheduled. 5. Consistency: Maintain a consistent routine for taking the medication and meals/beverages to avoid fluctuations in absorption. 6. Safe alternatives: Drinking water is best. If the patient desires juice, other juices like apple or orange can be chosen while maintaining an adequate separation period (at least one hour).");n("Levothyroxine - ","High-Fiber Foods -   ",e.DRUG_FOOD,i.MODERATE,"               . (  )","Dietary soluble and insoluble fibers bind to Levothyroxine in the gastrointestinal tract, preventing its dissolution and absorption. (Fiber-Induced Malabsorption. Dietary fiber binds drug.)","           . (  )","Decreased free hormone levels in the blood, potentially requiring an increase in the replacement dose. (Reduced hormone efficacy)","          .        .      .","Take the drug on an empty stomach at least one hour before breakfast. Avoid consuming high-fiber foods immediately after the dose. Maintain consistency in daily dosing time.");n("Levothyroxine - ","Coffee - ",e.DRUG_FOOD,i.MODERATE,"  (    )              . ( )","The effect of coffee (whether caffeine or other components) in reducing Levothyroxine absorption may be due to increased gut motility or a physicochemical interaction. (Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.)","      . (  )","Decreased drug bioavailability and thus reduced efficacy. (Reduced drug efficacy)","               .","Do not take the drug with coffee. Wait at least one hour before drinking coffee to ensure optimal absorption.");n("Levothyroxine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.MODERATE,"                       (    ). ( )","Some studies suggest that grapefruit juice can affect Levothyroxine absorption in the small intestine, though the mechanism is not entirely clear (possibly interference with specific transporters). (Delayed absorption)","             . (  )","Delayed peak concentration and reduced total hormone absorption, thereby diminishing treatment efficacy. (Decreased hormone absorption)","               .","To minimize interference, avoid grapefruit juice at the same time as the medication or for several hours afterward.");n("Levothyroxine - ","Cholestyramine - ",e.DRUG_DRUG,i.HIGH," (  )           .","Cholestyramine (an anion-exchange resin) binds directly to Levothyroxine in the intestine and prevents its absorption (Chelation or Binding).","                TSH.","Significant decrease in Levothyroxine absorption and efficacy, leading to worsening hypothyroidism and elevated TSH levels.","         4  ( 4-6 )      .","Separate the doses of the two drugs by at least 4 hours (preferably 4-6 hours); Levothyroxine should be taken first on an empty stomach.");n("Levothyroxine - ","Theophylline - ",e.DRUG_DRUG,i.MODERATE,"        (  CYP)       .","Levothyroxine increases the hepatic metabolism and breakdown of Theophylline (CYP enzyme induction), which accelerates Theophylline clearance from the body.","               .","Decreased Theophylline plasma concentration, which may reduce its therapeutic efficacy in respiratory disease treatment.","     .     ( )      .","Monitor Theophylline serum levels closely and adjust the dose (usually increase) when starting or stopping Levothyroxine therapy.");n("Levothyroxine - ","Warfarin - ",e.DRUG_DRUG,i.HIGH,"          (   II VII IX X).                .","Levothyroxine enhances the catabolism (breakdown) of Vitamin K-dependent clotting factors (e.g., factors II, VII, IX, X). This increases the body's sensitivity to Warfarin.","   INR (  )    .     ( 1-4    ).","Significant increase in INR and a high risk of severe and fatal bleeding. This effect appears gradually (1-4 weeks after initiating Levothyroxine).","  INR  (  1-4       )    (  )     .","Closely monitor INR (especially 1-4 weeks after starting or changing the Levothyroxine dose) and adjust the Warfarin dose (usually a reduction) to maintain the targeted therapeutic range.");n("Levothyroxine","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Licorice","Digoxin",e.DRUG_DRUG,i.MODERATE," ","Hypokalemia.","  ","Increased digoxin toxicity.","  ","Avoid large amounts.");n("Lidocaine",xn,e.DRUG_DRUG,i.MODERATE,": **   **.            .","Mechanism: **Reduced hepatic blood flow**. Beta-blockers reduce cardiac output and hepatic blood flow, decreasing Lidocaine clearance."," : **  **   (  ).","Clinical Significance: **Increased Lidocaine levels** and toxicity risk (dizziness, seizures, numbness).","   .        .","Monitor for Lidocaine toxicity signs. Lidocaine dose reduction may be required.");n("Lidocaine","Cimetidine",e.DRUG_DRUG,i.MODERATE,": **    **.        .","Mechanism: **Enzyme inhibition and reduced blood flow**. Cimetidine inhibits hepatic enzymes and reduces hepatic blood flow."," : **      75%**      .","Clinical Significance: **Increased Lidocaine levels by up to 75%**, increasing risk of neuro- and cardiotoxicity.","       .","Reduce Lidocaine dose or switch Cimetidine to another agent.");n("Lidocaine","Cimetidine",e.DRUG_DRUG,i.MODERATE,"  .  Cimetidine   CYP  ( CYP1A2  CYP3A4)    () Lidocaine.","Increased Lidocaine Concentrations. Cimetidine acts as an inhibitor of hepatic CYP enzymes (especially CYP1A2 and CYP3A4) responsible for Lidocaine metabolism (clearance).","   .     (   )   (     ).","Increased Risk of Lidocaine Toxicity. CNS toxicity (e.g., dizziness, confusion, seizures) and cardiac effects (e.g., bradycardia or arrhythmia).","  .            H2    CYP   Ranitidine  Famotidine.","Monitor Lidocaine Concentrations. Reduce the Lidocaine dose amount when necessary, or use an alternative H2-antihistamine that does not inhibit hepatic CYP, such as Ranitidine or Famotidine.");n("Linaclotide","Omeprazole",e.DRUG_DRUG,i.LOW,"    . Linaclotide          .","No true interaction expected. Linaclotide acts locally in the GI tract and is minimally absorbed.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Linagliptin (DPP-4)","Rifampin",e.DRUG_DRUG,i.MODERATE,"  Linagliptin. Rifampin    P-gp    Linagliptin.","Decreased Linagliptin concentration. Rifampin is a strong inducer of P-gp, a Linagliptin efflux pathway.","    .","Reduced glycemic efficacy.","   .     .      .","Avoid combination or monitoring. Closely monitor blood sugar. No adjusted dose is recommended.");n("Linezolid","Fluoxetine",e.DRUG_DRUG,i.HIGH," MAO. Linezolid    - (MAO)    (Reversible Non-selective MAOI)    . Fluoxetine   .","MAO Inhibition. Linezolid is a reversible non-selective MAOI, preventing monoamine breakdown. Fluoxetine elevates serotonin levels.","  (Serotonin Syndrome).          (     ).","Serotonin Syndrome. Excessive serotonin accumulation leads to a life-threatening symptom complex (hyperthermia, rigidity, altered mental status).",".   .     (Washout Period)     .","Avoid. Absolute contraindication. A sufficient washout period must be observed when switching between the two drugs.");n("Linezolid","Sertraline",e.DRUG_DRUG,i.HIGH," MAO. Linezolid (MAOI)    Sertraline (SSRI)   .","MAO Inhibition. Linezolid (MAOI) prevents monoamine breakdown, and Sertraline (SSRI) raises serotonin levels.","  (Serotonin Syndrome).      .","Serotonin Syndrome. Very high risk of Serotonin Syndrome.",".   .     .","Avoid. Absolute contraindication. A sufficient washout period must be observed.");n("Linezolid","Paroxetine",e.DRUG_DRUG,i.HIGH," MAO. Linezolid (MAOI)    Paroxetine (SSRI)   .","MAO Inhibition. Linezolid (MAOI) prevents monoamine breakdown, and Paroxetine (SSRI) raises serotonin levels.","  (Serotonin Syndrome).      .","Serotonin Syndrome. Very high risk of Serotonin Syndrome.",".   .     .","Avoid. Absolute contraindication. A sufficient washout period must be observed.");n("Linezolid","Citalopram",e.DRUG_DRUG,i.HIGH," MAO. Linezolid (MAOI)    Citalopram (SSRI)   .","MAO Inhibition. Linezolid (MAOI) prevents monoamine breakdown, and Citalopram (SSRI) raises serotonin levels.","  (Serotonin Syndrome).      .","Serotonin Syndrome. Very high risk of Serotonin Syndrome.",".   .     .","Avoid. Absolute contraindication. A sufficient washout period must be observed.");n("Linezolid","Escitalopram",e.DRUG_DRUG,i.HIGH," MAO. Linezolid (MAOI)    Escitalopram (SSRI)   .","MAO Inhibition. Linezolid (MAOI) prevents monoamine breakdown, and Escitalopram (SSRI) raises serotonin levels.","  (Serotonin Syndrome).      .","Serotonin Syndrome. Very high risk of Serotonin Syndrome.",".   .     .","Avoid. Absolute contraindication. A sufficient washout period must be observed.");n("Linezolid","Sertraline",e.DRUG_DRUG,i.HIGH,"   . Linezolid       (MAO-I).","Increased risk of Serotonin Syndrome. Linezolid is a weak Monoamine Oxidase Inhibitor (MAO-I).","         .","Mental status changes, tachycardia, hyperthermia."," .          .","Contraindicated. The combination must be avoided or monitored very closely and intensively for symptoms.");n("Linezolid","Tyramine-Rich Foods (Aged Cheese, Salami, Soy Sauce, Pickles)",e.DRUG_FOOD,i.CONTRAINDICATED,"  ","Inhibition of tyramine breakdown","     -    ","Dangerous rise in blood pressure - may lead to hypertensive crisis"," :        ","Completely avoid: Aged cheese, salami, soy sauce, pickles, fermented foods");n("Linezolid","Sertraline",e.DRUG_DRUG,i.HIGH," MAO -  ","MAO inhibition increases serotonin.","  -    ","Serotonin syndrome - fever, tremor, muscle rigidity.","  -  SSRI  ","Avoid - stop SSRI 2 weeks before.");n("Linezolid","Tyramine-rich Foods",e.DRUG_FOOD,i.HIGH," MAO -  ","MAO inhibition causes tyramine accumulation.","   ","Hypertensive crisis.","     ","Avoid aged cheese, cured meats, wine.");n("Liothyronine","Warfarin",e.DRUG_DRUG,i.MODERATE,"   ","Increased clotting factor metabolism."," INR","Increased INR."," INR","Monitor INR.");n("Liraglutide","Food",e.DRUG_FOOD,i.LOW,"   -       ","Subcutaneous injection - no direct food interaction but delays gastric emptying","    ","Delayed absorption of other oral medications","    -         ","No timing restrictions - but monitor the absorption of other oral medications");n("Lisinopril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Lisinopril","Aspirin",e.DRUG_DRUG,i.HIGH,"  .  (NSAID)           .","Pharmacodynamic Antagonism. Aspirin (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .       .     .","Avoid Combination or Closely Monitor. Closely monitor renal function and potassium. Paracetamol (Acetaminophen) is the preferred analgesic alternative.");n("Lisinopril","Ibuprofen",e.DRUG_DRUG,i.HIGH,"  . Ibuprofen (NSAID)           .","Pharmacodynamic Antagonism. Ibuprofen (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .             ( ).","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia (Triple Whammy).","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Diclofenac",e.DRUG_DRUG,i.HIGH,"  . Diclofenac (NSAID)           .","Pharmacodynamic Antagonism. Diclofenac (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Naproxen",e.DRUG_DRUG,i.HIGH,"  . Naproxen (NSAID)           .","Pharmacodynamic Antagonism. Naproxen (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Ketoprofen",e.DRUG_DRUG,i.HIGH,"  . Ketoprofen (NSAID)           .","Pharmacodynamic Antagonism. Ketoprofen (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Indomethacin",e.DRUG_DRUG,i.HIGH,"  . Indomethacin (NSAID)           .","Pharmacodynamic Antagonism. Indomethacin (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Celecoxib",e.DRUG_DRUG,i.HIGH,"  . Celecoxib (NSAID )           .","Pharmacodynamic Antagonism. Celecoxib (a selective NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"  . Mefenamic Acid (NSAID)           .","Pharmacodynamic Antagonism. Mefenamic Acid (an NSAID) inhibits renal vasodilatory prostaglandins, reducing renal blood flow.","    .            .","Renal Failure & Hyperkalemia. Can lead to acute renal impairment and increased risk of hyperkalemia.","    .      .      .","Avoid Combination or Closely Monitor. Should be avoided in susceptible patients. Closely monitor renal function and potassium.");n("Lisinopril","Potassium Chloride",e.DRUG_DRUG,i.HIGH,"   -  ","Both elevate potassium - aldosterone inhibition.","   ","Dangerous hyperkalemia.","   -  K+ ","Avoid potassium supplements - monitor K+ weekly.");n("Lisinopril","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  ","Renal prostaglandin inhibition.","   -    ","Acute renal failure - reduced antihypertensive effect.","   ","Monitor creatinine and BP.");n("Lisinopril","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Caffeine",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Grapefruit Juice",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lisinopril","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lithium","Hydrochlorothiazide",e.DRUG_DRUG,i.HIGH,"     .                  (Proximal Tubules).","Hyponatremia-Induced Lithium Retention. Thiazides cause mild hyponatremia, leading to increased Lithium reabsorption in the proximal renal tubules."," .            .","Lithium Toxicity. Elevated risk of Lithium toxicity, including tremor, confusion, and neurological instability.","  50% /  .      30%  50%        .","Reduce Dose by 50% / Monitor Lithium. Lithium dose should be reduced by 30% to 50% upon initiating Thiazide, with frequent monitoring of Lithium and Sodium levels.");n("Lithium","Chlorothiazide",e.DRUG_DRUG,i.HIGH,"     .          .","Hyponatremia-Induced Lithium Retention. Thiazides enhance Lithium reabsorption in the renal tubules."," .    .","Lithium Toxicity. Elevated risk of Lithium toxicity.","  50% /  .        .","Reduce Dose by 50% / Monitor Lithium. Lithium dose must be reduced, with frequent monitoring of Lithium and Sodium levels.");n("Lithium","Indapamide",e.DRUG_DRUG,i.HIGH,"     . Indapamide ( )    .","Hyponatremia-Induced Lithium Retention. Indapamide (a Thiazide-like diuretic) reduces Lithium clearance."," .    .","Lithium Toxicity. Elevated risk of Lithium toxicity.","  50% /  .        .","Reduce Dose by 50% / Monitor Lithium. Lithium dose must be reduced, with frequent monitoring of Lithium and Sodium levels.");n("Lithium","Haloperidol",e.DRUG_DRUG,i.HIGH,"  .                .","Uncertain Mechanism. The combination may increase the risk of neurotoxicity, especially at high doses or in cases of dehydration.","  .          (Extrapyramidal Syndrome)    .","Increased Neurotoxicity. Can progress to encephalopathy, extrapyramidal syndrome, and altered mental status.","     /// .         .","Ensure Appropriateness of Psych/Hypnotic/Sedative/Antidepressant Drugs. Closely monitor neurological signs and lithium concentrations.");n("Lithium","Carbamazepine",e.DRUG_DRUG,i.HIGH,"   .              .","Synergistic Neurotoxicity. Both drugs interact synergistically to increase the risk of neurological side effects, even at therapeutic Lithium concentrations.","   (      ).     .","Increased Neurotoxicity (muscle weakness, coma, ataxia, hyperreflexia, tremor). Risk of severe neuroleptic encephalopathy.","   .          .","Monitor Symptoms and Signs of Toxicity. Discontinue one or both drugs as needed, and monitor Lithium concentrations.");n("Lithium","Iodides ( )",e.DRUG_DRUG,i.MODERATE,"     .             .","Combined Thyroid Inhibitory Effect. Both Lithium and Iodides inhibit thyroid function and decrease hormone release.","   .      (Hypothyroidism)       .","Thyroid Dysfunction. Increased risk of hypothyroidism, or exacerbation of pre-existing hypothyroidism.","    .      (TSH T4 ) .      .","Avoid this Combination if Possible. Monitor thyroid function (TSH, free T4) regularly. Do not administer thyroid hormone unless strictly necessary.");n("Lithium","Aspirin",e.DRUG_DRUG,i.MODERATE,"    .  (NSAID)           .","Slightly Increased Lithium Levels. Aspirin (an NSAID) may reduce renal excretion of Lithium by inhibiting renal prostaglandins.","  .             .","Lithium Toxicity. Risk of Lithium toxicity, especially at high Aspirin doses or with impaired renal function.","  .       /.              .","Monitor Lithium Concentrations. Adjust dose as directed upon initiation/discontinuation. Aspirin is considered one of the safer NSAIDs with Lithium, but monitoring is necessary.");n("Lithium","Ibuprofen",e.DRUG_DRUG,i.HIGH,"  . Ibuprofen (NSAID)                 .","Increased Lithium Levels. Ibuprofen (an NSAID) significantly reduces renal excretion of Lithium by inhibiting renal prostaglandins that regulate renal blood flow.","  .          (   ).","Lithium Toxicity. Lithium concentrations may rise dangerously, causing toxicity symptoms (e.g., tremor, ataxia, nausea)."," /  .   Ibuprofen.         10-50%   .","Avoid Combination/Monitor Lithium Concentrations. Ibuprofen should preferably be avoided. If necessary, Lithium dose must be reduced by 10-50% with frequent concentration monitoring.");n("Lithium","Diclofenac",e.DRUG_DRUG,i.HIGH,"  . Diclofenac (NSAID)       .","Increased Lithium Levels. Diclofenac (an NSAID) significantly reduces renal excretion of Lithium.","  .    .","Lithium Toxicity. High risk of Lithium toxicity."," /  .   Diclofenac.        .","Avoid Combination/Monitor Lithium Concentrations. Diclofenac should be avoided. If necessary, monitor Lithium and adjust the dose.");n("Lithium","Naproxen",e.DRUG_DRUG,i.HIGH,"  . Naproxen (NSAID)       .","Increased Lithium Levels. Naproxen (an NSAID) significantly reduces renal excretion of Lithium.","  .    .","Lithium Toxicity. High risk of Lithium toxicity."," /  .   Naproxen.        .","Avoid Combination/Monitor Lithium Concentrations. Naproxen should be avoided. If necessary, monitor Lithium and adjust the dose.");n("Lithium","Ketoprofen",e.DRUG_DRUG,i.HIGH,"  . Ketoprofen (NSAID)       .","Increased Lithium Levels. Ketoprofen (an NSAID) significantly reduces renal excretion of Lithium.","  .    .","Lithium Toxicity. High risk of Lithium toxicity."," /  .   Ketoprofen.        .","Avoid Combination/Monitor Lithium Concentrations. Ketoprofen should be avoided. If necessary, monitor Lithium and adjust the dose.");n("Lithium","Indomethacin",e.DRUG_DRUG,i.HIGH,"  . Indomethacin (NSAID)             .","Increased Lithium Levels. Indomethacin (an NSAID) significantly reduces renal excretion of Lithium and is considered one of the most potent inhibitors of Lithium clearance.","  .     .","Lithium Toxicity. Extremely high risk of Lithium toxicity."," /  .   Indomethacin  .    ( ).","Avoid Combination/Monitor Lithium Concentrations. Indomethacin must be strictly avoided. Use alternative analgesics (e.g., Acetaminophen/Paracetamol).");n("Lithium","Celecoxib",e.DRUG_DRUG,i.HIGH,"  . Celecoxib (NSAID   COX-2 )       .","Increased Lithium Levels. Celecoxib (a selective COX-2 inhibitor NSAID) significantly reduces renal excretion of Lithium.","  .    .","Lithium Toxicity. High risk of Lithium toxicity."," /  .           .","Avoid Combination/Monitor Lithium Concentrations. Lithium must be closely monitored upon initiation or discontinuation, and the dose adjusted.");n("Lithium","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"  . Mefenamic Acid (NSAID)       .","Increased Lithium Levels. Mefenamic Acid (an NSAID) significantly reduces renal excretion of Lithium.","  .    .","Lithium Toxicity. High risk of Lithium toxicity."," /  .   Mefenamic Acid.        .","Avoid Combination/Monitor Lithium Concentrations. Mefenamic Acid should be avoided. If necessary, monitor Lithium and adjust the dose.");n("Lithium","Hydrochlorothiazide",e.DRUG_DRUG,i.HIGH,"  .               .","Increased Lithium concentration. Thiazide diuretics increase renal reabsorption of sodium and water, reducing Lithium clearance.","    (  ).","Increased risk of Lithium toxicity (tremor, nausea, confusion).","  .        .","Dose adjustment and monitoring. Lithium dose must be reduced and its levels closely monitored.");n("Lithium","Fluoxetine",e.DRUG_DRUG,i.MODERATE,"   .    .","Increased risk of Serotonin Syndrome. Synergistic effects of increased serotonin.","      .","Mental status changes, hyperthermia, tremor."," .    .","Close monitoring. Monitor for symptoms of Serotonin Syndrome.");n("Lithium","High-Sodium Foods",e.DRUG_FOOD,i.MODERATE,"            .                : (1)             (2)      (3)     .  :     (      )         .","Lithium and sodium compete for same transport and reabsorption mechanisms in proximal renal tubules. When dietary sodium intake increases significantly, amount of filtered sodium in kidneys rises, leading to: (1) reduced lithium reabsorption in renal tubules as sodium occupies transport sites, (2) increased lithium urinary excretion, (3) decreased blood lithium levels. Reverse is true: with sudden sodium reduction (low-salt diet, excessive sweating, diarrhea, vomiting), lithium reabsorption increases and levels rise to toxic range.","             :      (   )        .             :                   .","Noticeable decrease in lithium therapeutic efficacy with increased sodium intake, potentially causing: return of bipolar disorder symptoms (manic or depressive episodes), mood instability, sleep disturbance, increased relapse risk. Conversely, sudden sodium reduction raises lithium to toxic levels with symptoms including: severe tremor, nausea, vomiting, diarrhea, confusion, mental disorientation, muscle weakness, seizures, and in severe cases coma or permanent kidney damage.","          ()     -  2000-3000    (5-8  ). : (1)      (         ) (2)             (3)      . :       ( 3-6     )                 (8-10  )                .","Maintaining stable, balanced daily dietary sodium intake is absolutely critical - typically 2000-3000mg sodium daily (5-8g salt). Avoid: (1) sudden dietary habit changes (starting low-sodium diet suddenly or increasing salty foods), (2) extremely salty foods like pickles, processed foods, fast food except in consistent amounts, (3) using salt substitutes without physician consultation. Must: monitor blood lithium levels regularly (every 3-6 months or as directed), immediately inform physician of vomiting, diarrhea, excessive sweating, or fever, drink adequate water (8-10 glasses daily) without excess, establish clear plan with physician for situations affecting sodium balance.");n("Lithium","Caffeine",e.DRUG_FOOD,i.MODERATE,"          : (1)      (GFR)    (2)          (3)         .              .    :     (  300-400     3-4  )   .","Caffeine acts as mild diuretic and affects kidney function through multiple pathways: (1) increases glomerular filtration rate (GFR) and renal blood flow, (2) inhibits lithium reabsorption in proximal and distal renal tubules, (3) increases urine production raising fluid output volume. These combined effects lead to increased urinary lithium excretion and decreased blood levels. Effect is dose-dependent: high caffeine amounts (>300-400mg daily, equivalent to 3-4 cups coffee) have greater impact.","          : (1)      (          ) (2)   .            .              .","Moderate decrease in blood lithium levels, more pronounced with: (1) sudden caffeine consumption changes (starting high amounts suddenly or stopping suddenly after regular use), (2) irregular consumption. May cause therapeutic efficacy fluctuations and mood instability. Sudden caffeine cessation after regular use may elevate lithium levels and increase toxicity risk.","  :          .            (:    ).   :  (80-100 /)   (40-70 /)   (25-50 /)   (30-50 /)   (80-300 /). : (1)        (2)     (3)      .        (    )    .         .","Key is consistency: maintain stable daily caffeine amount at same times. If you regularly drink coffee or tea, continue same quantity and type (e.g., two morning coffees daily). Main caffeine sources: coffee (80-100mg/cup), black tea (40-70mg/cup), green tea (25-50mg/cup), soft drinks (30-50mg/can), energy drinks (80-300mg/can). Avoid: (1) sudden starting or stopping caffeine, (2) excessive energy drinks, (3) random switching between beverage types. If reducing caffeine, do gradually (decrease one cup weekly) with lithium monitoring. Inform physician of any planned caffeine consumption changes.");n("Live Vaccines ","Azathioprine",e.DRUG_DRUG,i.HIGH,"             .","Azathioprine acts as an anti-metabolite preventing the growth of T and B cells responsible for the vaccine immune response.","      .","Immunological failure and increased risk of disseminated vaccine-strain disease.","  .    (4-12    ).","Absolute contraindication. Must postpone vaccination (4-12 weeks after stopping the drug).");n("Live Vaccines (General)","Rituximab (Anti-CD20)",e.DRUG_DRUG,i.HIGH,"  CD20          .","Rituximab targets CD20 causing B-cell depletion, impairing humoral immunity needed for vaccines.","      .","Immunological failure and increased risk of disseminated vaccine-strain disease."," .    ( 6    ).","Contraindicated. Must postpone vaccination (wait 6 months after the last dose).");n("Live Vaccines (MMR, Varicella, Yellow Fever)","Immunosuppression / HIV",e.DRUG_DISEASE,i.CONTRAINDICATED,"              (Replication).","Immunodeficiency prevents a proper immune response and increases the risk of the live vaccine strain causing active infection (Replication).","    (Disseminated Vaccine Strain Infection)    .","Disseminated live vaccine strain infection, which can be fatal.","    .    (Inactivated)  .","Contraindicated in severe immunodeficiency. Use inactivated vaccines instead.");n("Live Vaccines (MMR/Varicella)","Systemic Corticosteroids (>20 mg/day Prednisone for >14 days)",e.DRUG_DRUG,i.HIGH,"         .","Corticosteroids cause systemic immunosuppression that prevents proper replication of the live vaccine virus.","        (Vaccine-strain Disease).","Risk of immunological failure and increased risk of disseminated vaccine-strain disease.","  .        .","Absolute contraindication. Must postpone vaccination until 1 month after stopping therapy.");n("Lonafarnib","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Diltiazem     CYP3A4      Lonafarnib.","Increased Lonafarnib concentration. Diltiazem is a strong CYP3A4 inhibitor, a major metabolic pathway for Lonafarnib.","    QT      .","Increased risk of QT prolongation and gastrointestinal toxicity, especially in children."," .        Lonafarnib     (ECG).","Avoid Combination. If co-administration is necessary, Lonafarnib dose should be reduced and ECG monitoring performed.");n("Lonafarnib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Ketoconazole     CYP3A4      Lonafarnib.","Increased Lonafarnib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a major metabolic pathway for Lonafarnib.","    QT     .","Increased risk of QT prolongation, gastrointestinal toxicity, and hepatotoxicity."," .    Lonafarnib     ECG  .","Avoid Combination. Lonafarnib dose must be reduced to low levels, and ECG and liver function monitored.");n("Lonafarnib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Rifampin    CYP3A4    Lonafarnib.","Decreased Lonafarnib efficacy. Rifampin is a strong inducer of CYP3A4, a Lonafarnib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lonafarnib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Itraconazole    CYP3A4    Lonafarnib.","Increased Lonafarnib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Lonafarnib metabolic pathway.","    QT     .","Increased risk of QT prolongation, gastrointestinal toxicity, and hepatotoxicity."," .    Lonafarnib     ECG  .","Avoid Combination. Lonafarnib dose must be reduced to low levels, and ECG and liver function monitored.");n("Lonafarnib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Efavirenz    CYP3A4    Lonafarnib.","Decreased Lonafarnib efficacy. Efavirenz is a moderate inducer of CYP3A4, a Lonafarnib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Lonafarnib","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Lonafarnib    CYP3A4    Simvastatin.","Increased Simvastatin concentration. Lonafarnib is a strong CYP3A4 inhibitor, a Simvastatin metabolic pathway.","    (Rhabdomyolysis)  .","Increased risk of Rhabdomyolysis and myotoxicity."," .   .","Contraindicated. Avoid the combination.");n("Lonafarnib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Phenytoin    CYP3A4    Lonafarnib.","Decreased Lonafarnib efficacy. Phenytoin is a strong inducer of CYP3A4, a Lonafarnib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lonafarnib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Lonafarnib.       CYP3A4  .","Increased Lonafarnib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .          CYP3A4.","Contraindicated. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Lonafarnib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lonafarnib. Rifampin    CYP3A4.","Decreased Lonafarnib concentration. Rifampin is a strong inducer of CYP3A4.","  .","Reduced drug efficacy."," .   .","Contraindicated. Avoid the combination.");n("Lonafarnib (Zokinvy)","Strong CYP3A4 Inhibitors (Ketoconazole)",e.DRUG_DRUG,i.HIGH,": ** CYP3A4**.   Lonafarnib  3.5 .","Mechanism: **CYP3A4 Inhibition**. Lonafarnib concentration increases 3.5-fold."," : ** **.","Clinical Significance: **Severe toxicity**.","  Lonafarnib  50%.","Reduce Lonafarnib dose by 50%.");n("Lonapegsomatropin","Prednisone",e.DRUG_DRUG,i.MODERATE,"   .       .","Decreased growth hormone efficacy. High-dose glucocorticoids inhibit the growth-promoting effect of the hormone.","   Lonapegsomatropin        .","Reduction in Lonapegsomatropin effect, leading to failure of height gain in children."," .             .","Dose adjustment. Corticosteroid dose must be monitored, especially for adrenal insufficiency, and the lowest effective dose should be used.");n("Lonapegsomatropin","Insulin",e.DRUG_DRUG,i.HIGH,"   ( ).      .","Decreased insulin effect (Insulin Resistance). Growth hormone reduces insulin sensitivity.","     (Hyperglycemia)    (Diabetic Ketoacidosis).","Increased risk of hyperglycemia and diabetic ketoacidosis (DKA)."," .               .","Dose adjustment. Blood sugar levels must be regularly monitored, and doses of insulin or other antidiabetic drugs may need to be increased.");n("Lonapegsomatropin","Prednisone",e.DRUG_DRUG,i.MODERATE,"  Lonapegsomatropin.   .","Decreased Lonapegsomatropin effect. Glucocorticoids inhibit growth."," .","Failure of growth."," .        .","Close monitoring. Corticosteroid dose should be adjusted or avoided as much as possible.");n("Loncastuximab Tesirine (Zynlonta)","Strong CYP3A4 Inducers (Rifampin)",e.DRUG_DRUG,i.MODERATE,": **   **.    .","Mechanism: **Payload metabolism induction**. Decreased toxic payload concentration."," : **  **  .","Clinical Significance: **Reduced therapeutic efficacy** against lymphoma."," .    .","Avoid combination. Use alternative antibiotic.");n("Loop Diuretics (Furosemide, Bumetanide, Torsemide)","Thiazide Diuretics",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic diuretic effect","       ","Severe diuresis, hypovolemia, and hypotension","    -     () -     ","Monitor hydration and electrolyte status - volume depletion (dehydration) may occur - monitor signs and use electrolyte replacement");n("Loperamide","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Loperamide. Itraconazole   CYP3A4  P-gp     Loperamide.","Increased Loperamide concentration. Itraconazole inhibits CYP3A4 and P-gp, Loperamide metabolic and efflux pathways.","    QT  Torsades de Pointes (   ).","Increased risk of QT prolongation and Torsades de Pointes (especially at high doses).","  .       .","Side effect monitoring. Signs of cardiac or neurological toxicity must be monitored.");n("Loperamide","Quinidine",e.DRUG_DRUG,i.MODERATE," P-glycoprotein","P-glycoprotein inhibition.","    ","Increased loperamide brain levels.","  ","Respiratory depression risk.");n("Lopinavir/Ritonavir","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lopinavir/Ritonavir. Rifampin    CYP3A4.","Decreased Lopinavir/Ritonavir concentration. Rifampin is a strong inducer of CYP3A4.","            .","Reduced drug plasma concentration, leading to viral treatment failure and resistance development."," .   .","Contraindicated. Avoid the combination.");n("Loratadine","Ketoconazole",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4    **.      CYP3A4        (Desloratadine)        .","Mechanism: **CYP3A4 enzyme inhibition responsible for loratadine metabolism**. Ketoconazole potently inhibits CYP3A4 enzyme which converts loratadine to its active metabolite desloratadine, increasing parent loratadine plasma levels."," : **  **    300% (3 ).     **  QT   **         (Torsades de Pointes)       (       QT    ).       .","Clinical Significance: **Increased loratadine concentrations** by up to 300% (3-fold). Main concern is risk of **QT interval prolongation on ECG**, potentially leading to serious ventricular arrhythmias (Torsades de Pointes) especially in patients with risk factors (e.g., hypokalemia, use of other QT-prolonging drugs, or cardiac disease). Mild to moderate drowsiness may also occur.","   (ECG)  QT      .    ( ). ** **:  ****     CYP3A4   QT.              (     ).","Monitor ECG for QT interval, especially in patients with risk factors. Correct electrolyte abnormalities (potassium and magnesium). **Preferred alternative**: use **fexofenadine** which is not metabolized by CYP3A4 and does not prolong QT. If loratadine is necessary, consider dose reduction or use alternative antifungal (e.g., low-dose fluconazole or terbinafine).");n("Loratadine","Alcohol",e.DRUG_FOOD,i.MODERATE,": **  **.   Loratadine           .","Mechanism: **Additive CNS Depression**. Although Loratadine is less sedating, alcohol increases its tranquilizing effects.",":          .","Result: Slight increase in dizziness or drowsiness, especially in sensitive individuals.",":     .","Management: Advise moderate consumption of alcohol.");n("Loratadine","Caffeine",e.DRUG_FOOD,i.LOW,":      . Loratadine       .","Mechanism: No known major clinical interaction. Loratadine does not significantly affect Caffeine metabolism.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,": ** CYP3A4**.     CYP3A4      Loratadine.","Mechanism: **CYP3A4 Inhibition**. Grapefruit juice inhibits the CYP3A4 enzyme, a major metabolic pathway for Loratadine.",":    Loratadine   (Desloratadine)        ( ).","Result: Increased Loratadine and active metabolite (Desloratadine) concentration, potentially increasing the risk of side effects (e.g., headache).",":         .","Management: Avoid consuming large amounts of grapefruit juice during treatment.");n("Loratadine","Green Tea",e.DRUG_FOOD,i.MODERATE,":     . (         ).","Mechanism: No direct interaction is known. (May contain caffeine or organic compounds that affect absorption).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Milk",e.DRUG_FOOD,i.LOW,": ** **.  (   )      Loratadine.","Mechanism: **Increased Absorption**. Food (including milk) increases the bioavailability of Loratadine.",":     Loratadine         .","Result: Slight increase in Loratadine blood concentration, but the clinical effect is usually minimal.",":    .     .","Management: No routine adjustment required. The drug can be taken with milk.");n("Loratadine","High-fat meals",e.DRUG_FOOD,i.HIGH,": ** **.           Loratadine.","Mechanism: **Increased Absorption**. High-fat meals significantly increase the bioavailability of Loratadine.",":             .","Result: Increased drug concentration in the blood, which may increase the risk of side effects.",":          ( ).","Management: May prefer taking on an empty stomach to minimize side effects (e.g., headache).");n("Loratadine","High-fiber foods",e.DRUG_FOOD,i.MODERATE,":    .      .","Mechanism: No known interaction. Fiber may slightly delay absorption.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Vitamin C",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Vitamin D",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Vitamin E",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Vitamin K",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Vitamin B12",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Folic Acid",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Iron",e.DRUG_FOOD,i.LOW,":    .   Loratadine    .","Mechanism: No known interaction. Loratadine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Calcium",e.DRUG_FOOD,i.HIGH,":    .   Loratadine    .","Mechanism: No known interaction. Loratadine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Magnesium",e.DRUG_FOOD,i.MODERATE,":    .   Loratadine    .","Mechanism: No known interaction. Loratadine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Zinc",e.DRUG_FOOD,i.LOW,":    .   Loratadine    .","Mechanism: No known interaction. Loratadine does not chelate with metal ions.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Potassium",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Loratadine","Antacids",e.DRUG_FOOD,i.LOW,":          Loratadine            .","Mechanism: Antacids may slightly increase the rate of Loratadine absorption by increasing gastric pH, but overall bioavailability is not significantly altered.",":   .      .","Result: Minimal clinical effect. A slightly quicker onset of action may be noted.",":    .   .","Management: No routine adjustment required. Routine monitoring can be applied.");n("Loratadine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4**.     CYP3A4      Loratadine.","Mechanism: **CYP3A4 Inhibition**. Grapefruit juice inhibits the CYP3A4 enzyme, a major metabolic pathway for Loratadine.",":    Loratadine   (Desloratadine)          (    ).","Result: Increased Loratadine and its active metabolite (Desloratadine) blood concentrations, potentially increasing the risk of side effects (e.g., headache or mild drowsiness).",":         .","Management: Avoid consuming large amounts of grapefruit juice during treatment.");n("Loratadine","Alcohol",e.DRUG_FOOD,i.MODERATE,": **  **.     Loratadine                   (CNS).","Mechanism: **Additive CNS Depression**. Although Loratadine is classified as a non-sedating antihistamine, consumption with alcohol may increase CNS depressive effects.",":          .","Result: Slight increase in drowsiness or dizziness, especially in sensitive individuals.",":        .","Management: Advise avoidance or limitation of alcohol during treatment.");n("Lorazepam","Fluconazole",e.DRUG_DRUG,i.HIGH,"   - Increased Benzodiazepine concentrations","Increased Benzodiazepine Concentrations. Reduced clearance.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Lorazepam","Itraconazole",e.DRUG_DRUG,i.HIGH,"   - Increased Benzodiazepine concentrations","Increased Benzodiazepine Concentrations. Reduced clearance.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Lorazepam","Ketoconazole",e.DRUG_DRUG,i.HIGH,"   - Increased Benzodiazepine concentrations","Increased Benzodiazepine Concentrations. Reduced clearance.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Lorazepam","Voriconazole",e.DRUG_DRUG,i.HIGH,"   - Increased Benzodiazepine concentrations","Increased Benzodiazepine Concentrations. Reduced clearance.","    ","Enhanced Sedation. Excessive CNS depression.","     (       ) -     ","     (       ) -     ");n("Lorazepam","Diltiazem - ",e.DRUG_DRUG,i.MODERATE,"   -       - Increased Benzodiazepine concentrations - May cause psychomotor depression or sedation","   -       - Increased Benzodiazepine concentrations - May cause psychomotor depression or sedation","    ","Enhanced Sedation. Excessive CNS depression.","   ","   ");n("Lorazepam","Grapefruit Juice -  ",e.DRUG_FOOD,i.MODERATE,"   -      - Increased efficacy of Benzodiazepine - May cause sedation and psychomotor depression","   -      - Increased efficacy of Benzodiazepine - May cause sedation and psychomotor depression","    ","Enhanced Sedation. Excessive CNS depression.","    ","    ");n("Lorazepam","Macrolide Antibiotics -   ",e.DRUG_DRUG,i.HIGH,"   -       - Increased Benzodiazepine concentrations - May cause psychomotor depression or sedation","   -       - Increased Benzodiazepine concentrations - May cause psychomotor depression or sedation","    ","Enhanced Sedation. Excessive CNS depression.","     -   :   ","     -   :   ");n("Lorlatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Lorlatinib. Phenytoin    CYP3A4    Lorlatinib.","Decreased Lorlatinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Lorlatinib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lorlatinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Lorlatinib. Itraconazole    CYP3A4    Lorlatinib.","Increased Lorlatinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Lorlatinib metabolic pathway.","      .","Increased risk of side effects, especially neurotoxicity."," .    Lorlatinib     CYP3A4 .","Dose adjustment. Lorlatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Lorlatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lorlatinib. Rifampin    CYP3A4    Lorlatinib.","Decreased Lorlatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Lorlatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lorlatinib","High Fat Meal",e.DRUG_FOOD,i.MODERATE,"  Lorlatinib.          .","Increased Lorlatinib absorption. Taking the drug with a high-fat meal increases bioavailability.","          .","Increased drug plasma concentration, increasing the risk of side effects."," .   Lorlatinib     .","Dose consistency. Lorlatinib must be taken consistently with or without food.");n("Lorlatinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Lorlatinib. Itraconazole    CYP3A4    Lorlatinib.","Increased Lorlatinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Lorlatinib metabolic pathway.","       .","Increased risk of neurological side effects and hyperlipidemia."," .    Lorlatinib     CYP3A4 .","Dose adjustment. Lorlatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Lorlatinib (ALK/ROS1 TKI)","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Lorlatinib. Itraconazole    CYP3A4    Lorlatinib.","Increased Lorlatinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Lorlatinib metabolic pathway.","    QT   .","Increased risk of QT prolongation and myelosuppression."," .   .","Contraindicated. Avoid the combination.");n("Lorlatinib (ALK/ROS1 TKI)","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Lorlatinib. Phenytoin    CYP3A4.","Decreased Lorlatinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Losartan","Ibuprofen",e.DRUG_DRUG,i.HIGH,"         . (Triple Whammy).","Decreased hypotensive effect and increased risk of acute renal failure. (Triple Whammy).","     .","Hypertension and acute renal failure.","      (  )      .","Avoid combination in high-risk patients (elderly, dehydrated) or closely monitor renal function and blood pressure.");n("Losartan","Amiloride",e.DRUG_DRUG,i.HIGH,"  ","Dual potassium retention.","  ","Hyperkalemia.","    K+  3-5 ","Avoid or monitor K+ every 3-5 days.");n("Losartan","Alcohol",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Caffeine",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Green Tea",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Milk",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","High-fat meals",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","High-fiber foods",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Vitamin C",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Vitamin D",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Vitamin E",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Vitamin K",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Vitamin B12",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Folic Acid",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Iron",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Calcium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Magnesium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Zinc",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Potassium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Losartan","Antacids",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Lovastatin","Food",e.DRUG_FOOD,i.MODERATE,"     50% -  ","Food increases bioavailability by 50% - improved solubility.","  ","Increased drug absorption.","      (   )","Take with evening meal for maximum efficacy (inhibition of nocturnal cholesterol synthesis).");n("Lumacaftor/Ivacaftor","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Lumacaftor    CYP3A4    Midazolam.","Decreased Midazolam concentration. Lumacaftor is a potent CYP3A4 inducer, a Midazolam metabolic pathway.","  Midazolam ()      .","Reduced efficacy of Midazolam (sedative), potentially leading to failure of sedation."," .           CYP3A4.","Avoid Combination. Narrow therapeutic index drugs metabolized by CYP3A4 must be avoided.");n("Lumacaftor/Ivacaftor","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ivacaftor. Lumacaftor  Rifampin    CYP3A4       Ivacaftor.","Decreased Ivacaftor concentration. Lumacaftor and Rifampin are both strong CYP3A4 inducers, significantly reducing Ivacaftor concentration.","    .","Reduced efficacy of cystic fibrosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Lumacaftor/Ivacaftor","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"      . Lumacaftor    CYP3A4.","Significant decrease in oral contraceptive concentration. Lumacaftor is a strong inducer of CYP3A4.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .           .","Relative contraindication. Non-hormonal or reliable additional contraceptive methods must be used.");n("Lumacaftor/Ivacaftor","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Lumacaftor   P-gp.","Decreased Digoxin concentration. Lumacaftor is a P-gp inducer.","  Digoxin.","Reduced Digoxin efficacy."," .   Digoxin  .","Close monitoring. Monitor Digoxin levels and adjust the dose.");n("Lumasiran","Quinidine",e.DRUG_DRUG,i.MODERATE,"    . Quinidine   P-gp     Lumasiran.","Indirect pharmacokinetic interaction. Quinidine is a P-gp inhibitor and may affect Lumasiran excretion.","    Lumasiran       .","Slight increase in Lumasiran concentration, potentially increasing the risk of side effects.","  .          .","Side effect monitoring. No absolute contraindication, but side effects must be monitored.");n("Lumasiran","Itraconazole",e.DRUG_DRUG,i.MODERATE,"    . Itraconazole   CYP3A4     Lumasiran.","Indirect pharmacokinetic interaction. Itraconazole is a CYP3A4 inhibitor and may affect Lumasiran excretion.","    Lumasiran       .","Slight increase in Lumasiran concentration, potentially increasing the risk of side effects.","  .        .","Side effect monitoring. No absolute contraindication, but monitoring is necessary.");n("Lumateperone","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Lumateperone. Itraconazole    CYP3A4    Lumateperone.","Increased Lumateperone concentration. Itraconazole is a strong CYP3A4 inhibitor, a Lumateperone metabolic pathway.","        .","Increased risk of side effects, especially somnolence and neurological side effects."," .   .","Contraindicated. Avoid the combination.");n("Lurasidone","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Lurasidone  . Ketoconazole    CYP3A4.","Significant increase in Lurasidone concentration. Ketoconazole is a strong inhibitor of CYP3A4.","   /  .","Increased risk of cardiac/CNS toxicity."," .   .","Contraindicated. Avoid the combination.");n("Lurasidone","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Lurasidone  . Phenytoin    CYP3A4.","Significant decrease in Lurasidone concentration. Phenytoin is a strong inducer of CYP3A4.","   .","Reduced antipsychotic efficacy."," .   .","Contraindicated. Avoid the combination.");n("Lurbinectedin","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Lurbinectedin. Ketoconazole     CYP3A4      Lurbinectedin.","Increased Lurbinectedin concentration. Ketoconazole is a potent CYP3A4 inhibitor, the primary metabolic pathway for Lurbinectedin.","       .","Increased risk of severe myelosuppression and hepatotoxicity."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Lurbinectedin","Rifampin",e.DRUG_DRUG,i.HIGH,"  Lurbinectedin. Rifampin    CYP3A4    Lurbinectedin.","Decreased Lurbinectedin efficacy. Rifampin is a strong inducer of CYP3A4, a Lurbinectedin metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Lurbinectedin","Quetiapine",e.DRUG_DRUG,i.MODERATE,"  Quetiapine. Lurbinectedin   CYP3A4    Quetiapine.","Increased Quetiapine concentration. Lurbinectedin is a CYP3A4 inhibitor, a Quetiapine metabolic pathway.","      QT.","Increased risk of over-sedation and QT prolongation."," .    Quetiapine  .","Dose adjustment. Quetiapine dose must be reduced and the patient monitored.");n("Luspatercept","Iron Supplements",e.DRUG_DRUG,i.LOW,"     ( ).","No true interaction expected (biologic drug).","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Lutathera (NET Therapy)","Octreotide",e.DRUG_DRUG,i.HIGH,"   . Octreotide   Lutathera   .","Competitive uptake interference. Octreotide competes with Lutathera for somatostatin receptors.","    (Lutathera)     .","Reduced uptake of the radiopharmaceutical (Lutathera) in tumor cells and treatment failure."," .   Octreotide ( )    4 .","Special action. Long-acting Octreotide must be stopped 4 weeks prior to therapy.");n("Lutathera (NET Therapy)","Omeprazole (PPI)",e.DRUG_DRUG,i.MODERATE,"    Lutathera.     .","May decrease Lutathera uptake. Requirement for specific gastric environment.","  .","Reduced treatment efficacy."," .   PPIs  24   .","Special action. PPIs must be stopped 24 hours prior to dosing.");n(ir,"Theophylline",e.DRUG_DRUG,i.HIGH,": **  (CYP1A2)**.  (  )   .","Mechanism: **Metabolism inhibition (CYP1A2)**. Macrolides (esp. Erythromycin, Clarithromycin) inhibit Theophylline metabolism."," : **  **   (    ).","Clinical Significance: **Increased Theophylline levels** and toxicity risk (nausea, vomiting, seizures, arrhythmias).","  .    25-50%.    .","Monitor Theophylline levels. Reduce dose by 25-50%. Use Azithromycin as safe alternative.");n(ir,"Warfarin",e.DRUG_DRUG,i.HIGH,": **  (CYP3A4, CYP2C9)**.  (  )   .","Mechanism: **Metabolism inhibition (CYP3A4, CYP2C9)**. Macrolides (esp. Erythromycin, Clarithromycin) inhibit Warfarin metabolism."," : **  **  INR  .","Clinical Significance: **Increased Warfarin effect**, elevated INR, and bleeding risk."," INR .     .    .","Monitor INR closely. Warfarin dose reduction may be required. Use Azithromycin as safe alternative.");n(ir,Sc,e.DRUG_DRUG,i.HIGH,": **  (CYP3A4)**.  (  )    (  ).","Mechanism: **Metabolism inhibition (CYP3A4)**. Macrolides (esp. Clarithromycin, Erythromycin) inhibit metabolism of statins (e.g., Simvastatin, Atorvastatin)."," : **      (Rhabdomyolysis)**   .","Clinical Significance: **Increased risk of myopathy, rhabdomyolysis**, and acute renal failure.","     .    (  CYP3A4).","Temporarily hold Statin during Macrolide therapy. Or use Azithromycin (does not inhibit CYP3A4).");n("Magnesium","Bisphosphonates",e.DRUG_DRUG,i.MODERATE," ","Complex formation.","  ","Reduced bisphosphonate absorption."," ","Separate by 2 hours.");n("Magnesium Hydroxide","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","Reduced Antibiotic Efficacy. Bacterial resistance or failure.","     ","     ");n("Magnesium Hydroxide","Levofloxacin",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","Reduced Antibiotic Efficacy. Bacterial resistance or failure.","     ","     ");n("Magnesium Hydroxide","Moxifloxacin",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","Reduced Antibiotic Efficacy. Bacterial resistance or failure.","     ","     ");n("Magnesium Hydroxide","Ofloxacin",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","Reduced Antibiotic Efficacy. Bacterial resistance or failure.","     ","     ");n("Magnesium Hydroxide","Norfloxacin",e.DRUG_DRUG,i.MODERATE," ","Reduced Absorption. Physicochemical interaction or altered GI motility decreases drug bioavailability.","   ","Reduced Antibiotic Efficacy. Bacterial resistance or failure.","     ","     ");n("Magnesium Hydroxide","Lidocaine",e.DRUG_DRUG,i.MODERATE," ","Local Factors. Localized interaction.","   ","   ","  ","  ");n("Magnesium Hydroxide","Tetracycline",e.DRUG_DRUG,i.MODERATE,"","Quinolones Interaction. Class effect.","  ","  ","     ","     ");n("Magnesium Hydroxide","Bisphosphonates",e.DRUG_DRUG,i.MODERATE," ","Complex formation.","  ","Reduced bisphosphonate absorption.","  2   ","Separate by at least 2 hours.");n("MAO Inhibitors (Phenelzine, Tranylcypromine, Isocarboxazid)","Tyramine-Rich Foods (Aged Cheese, Cured Meats, Soy Sauce, Beer, Wine)",e.DRUG_FOOD,i.CONTRAINDICATED,"  -     ","Tyramine accumulation - sudden rise in blood pressure","    -    ","Serious hypertensive crisis - may lead to stroke"," :           ","Strictly prohibited: Aged cheese, smoked meats, soy sauce, fermented beans, beer, red wine");n("MAO Inhibitors ( -)","Sibutramine",e.DRUG_DRUG,i.HIGH," . Sibutramine       MAOIs     .","Monoamine Accumulation. Sibutramine is a norepinephrine, serotonin, and dopamine reuptake inhibitor, and MAOIs prevent the breakdown of these neurotransmitters.","       .            .","Increased Risk of Hypertensive Crisis and Serotonin Syndrome. The combination leads to an acute and dangerously high elevation of monoamine levels, which is life-threatening.","  (  ).      (14 )    .","Avoid Combination (Absolute Contraindication). A sufficient washout period (14 days) must be observed when switching between the two drugs.");n("MAOIs","Bupropion",e.DRUG_DRUG,i.HIGH,"   . Bupropion      MAOIs       .","Increased Norepinephrine and Dopamine Concentrations. Bupropion inhibits dopamine and norepinephrine reuptake, and MAOIs prevent their breakdown, leading to excessive accumulation.","    (Hypertensive Crisis)  .           .","Increased Risk of Hypertensive Crises and Seizures. Sharp rise in blood pressure, increased risk of seizures and Serotonin Syndrome.",'  (  ).   " "  14         .','Avoid Combination (Absolute Contraindication). A "washout period" of at least 14 days must be observed between stopping one drug and starting the other.');n("MAOIs","Carbamazepine",e.DRUG_DRUG,i.HIGH," .   MAOIs   Carbamazepine    CYP3A4        (  )    .","Multifactorial Interaction. MAOIs may increase Carbamazepine concentrations by inhibiting CYP3A4, and the combination may increase the risk of Serotonin Syndrome (indirectly) and bone marrow suppression.","  Carbamazepine  .      (Agranulocytosis)  .","Increased Carbamazepine Toxicity and Serotonin Syndrome. Risk of neurotoxicity, agranulocytosis, and Serotonin Syndrome.","  -   Carbamazepine  .    Carbamazepine        .","Avoid Combination - Monitor Carbamazepine Concentrations and Toxicity. Monitor Carbamazepine levels and blood function; dose reduction may be necessary.");n("MAOIs","Insulin/Antidiabetics (  )",e.DRUG_DRUG,i.MODERATE,"    .   MAOIs          .","Enhanced Hypoglycemic Effect. MAOIs are thought to increase insulin receptor sensitivity or reduce insulin breakdown.","     (Hypoglycemia).              MAOIs.","Increased Risk of Hypoglycemia. Dangerous reduction in blood sugar levels, especially when initiating MAOIs.","     .    /   ()     .","Monitor Blood Sugar Levels Closely. Insulin/oral antidiabetic doses must be adjusted (reduced) as necessary to prevent hypoglycemia.");n("MAOIs","Levodopa",e.DRUG_DRUG,i.HIGH,"  Levodopa. MAOIs   Levodopa (   )           .","Blockade of Levodopa Breakdown. MAOIs significantly prevent the breakdown of Levodopa (which converts to dopamine), leading to massive dopamine increase in the peripheral circulation.","     .         .","Increased Risk of Hypertensive Crisis. Can lead to severe and potentially fatal blood pressure elevation.","  (  ).   Selegiline    (  MAO-B  )  .","Avoid Combination (Absolute Contraindication), except for very low-dose Selegiline (which selectively inhibits MAO-B) in Parkinson's patients.");n("MAOIs","Meperidine",e.DRUG_DRUG,i.HIGH,"             .    Meperidine   Normeperidine.","Dangerous Interaction leading to Serotonin Syndrome, CNS Depression, or Hyperthermic Reaction. Both Meperidine and its toxic metabolite Normeperidine accumulate.","     .         .","Increased Risk of Serotonin Syndrome and Neurotoxicity. Can be fatal and includes rigidity, hyperthermia, and seizures.","   .      .     .","Absolute Contraindication for Meperidine. Exercise extreme caution with other opioids. An alternative analgesic must be used.");n("MAOIs","Fluoxetine",e.DRUG_DRUG,i.HIGH,"              ","Severe Serotonin Syndrome. Excessive serotonergic activity causes autonomic instability and neuromuscular hyperactivity.","     ","     ","  (  ) -    (14  / 5 )","  (  ) -    (14  / 5 )");n("MAOIs","Sertraline",e.DRUG_DRUG,i.HIGH,"              ","Severe Serotonin Syndrome. Excessive serotonergic activity causes autonomic instability and neuromuscular hyperactivity.","     ","     ","  (  ) -    (14  / 5 )","  (  ) -    (14  / 5 )");n("MAOIs","Paroxetine",e.DRUG_DRUG,i.HIGH,"              ","Severe Serotonin Syndrome. Excessive serotonergic activity causes autonomic instability and neuromuscular hyperactivity.","     ","     ","  (  ) -    (14  / 5 )","  (  ) -    (14  / 5 )");n("MAOIs","Citalopram",e.DRUG_DRUG,i.HIGH,"              ","Severe Serotonin Syndrome. Excessive serotonergic activity causes autonomic instability and neuromuscular hyperactivity.","     ","     ","  (  ) -    (14  / 5 )","  (  ) -    (14  / 5 )");n("MAOIs","Escitalopram",e.DRUG_DRUG,i.HIGH,"              ","Severe Serotonin Syndrome. Excessive serotonergic activity causes autonomic instability and neuromuscular hyperactivity.","     ","     ","  (  ) -    (14  / 5 )","  (  ) -    (14  / 5 )");n("MAOIs","Amitriptyline",e.DRUG_DRUG,i.HIGH,"  .    (    )  MAOIs  Amitriptyline ( )      .","Monoamine Accumulation. Inhibition of monoamine metabolism (including serotonin and norepinephrine) by MAOIs and Amitriptyline (TCA) raises their synaptic levels.","    (Hypertensive Crisis)    .  .","Increased Risk of Hypertensive Crises, Serotonin Syndrome, and Seizures. A potentially fatal interaction.",'  (  ).   " "  14         .','Avoid Combination (Absolute Contraindication). A "washout period" of at least 14 days must be observed between stopping one drug and starting the other.');n("MAOIs","Imipramine",e.DRUG_DRUG,i.HIGH,"  .    (    )  MAOIs  Imipramine ( )      .","Monoamine Accumulation. Inhibition of monoamine metabolism (including serotonin and norepinephrine) by MAOIs and Imipramine (TCA) raises their synaptic levels.","    (Hypertensive Crisis)    .  .","Increased Risk of Hypertensive Crises, Serotonin Syndrome, and Seizures. A potentially fatal interaction.",'  (  ).   " "  14         .','Avoid Combination (Absolute Contraindication). A "washout period" of at least 14 days must be observed between stopping one drug and starting the other.');n("MAOIs","Clomipramine",e.DRUG_DRUG,i.HIGH,"  . Clomipramine ( )      MAOIs  .","Monoamine Accumulation. Clomipramine (TCA) increases serotonin and norepinephrine levels, and MAOIs prevent their breakdown.","    (Hypertensive Crisis)    .  .","Increased Risk of Hypertensive Crises, Serotonin Syndrome, and Seizures. A potentially fatal interaction.",'  (  ).   " "  14         .','Avoid Combination (Absolute Contraindication). A "washout period" of at least 14 days must be observed between stopping one drug and starting the other.');n("MAOIs","Nortriptyline",e.DRUG_DRUG,i.HIGH,"  . Nortriptyline ( )     MAOIs  .","Monoamine Accumulation. Nortriptyline (TCA) increases monoamine levels, and MAOIs prevent their breakdown.","    (Hypertensive Crisis)    .  .","Increased Risk of Hypertensive Crises, Serotonin Syndrome, and Seizures. A potentially fatal interaction.",'  (  ).   " "  14         .','Avoid Combination (Absolute Contraindication). A "washout period" of at least 14 days must be observed between stopping one drug and starting the other.');n("MAOIs","Fluoxetine",e.DRUG_DRUG,i.CONTRAINDICATED," . Fluoxetine (SSRI)     MAOIs       .","Increased Serotonin. Fluoxetine (SSRI) inhibits serotonin reuptake, and MAOIs prevent its breakdown, leading to excessive serotonin accumulation.","  .                .","Fatal Serotonin Syndrome. Can lead to mental status changes, autonomic instability, and neuromuscular abnormalities.","   ( MAOIs  SSRI).       Fluoxetine    MAOIs ** **    .","Two-Week Washout Period (for MAOIs before SSRI). The washout period for Fluoxetine before starting MAOIs must be **five weeks** due to its long half-life.");n("MAOIs","Sertraline",e.DRUG_DRUG,i.CONTRAINDICATED," . Sertraline (SSRI)     MAOIs       .","Increased Serotonin. Sertraline (SSRI) inhibits serotonin reuptake, and MAOIs prevent its breakdown, leading to excessive serotonin accumulation.","  .     .","Fatal Serotonin Syndrome. Very high risk of Serotonin Syndrome.","  .            (14 ).","Two-Week Washout Period. A washout period of two weeks (14 days) must separate the discontinuation of one drug and the initiation of the other.");n("MAOIs","Paroxetine",e.DRUG_DRUG,i.CONTRAINDICATED," . Paroxetine (SSRI)     MAOIs  .","Increased Serotonin. Paroxetine (SSRI) inhibits serotonin reuptake, and MAOIs prevent its breakdown.","  .     .","Fatal Serotonin Syndrome. Very high risk of Serotonin Syndrome.","  .            (14 ).","Two-Week Washout Period. A washout period of two weeks (14 days) must separate the discontinuation of one drug and the initiation of the other.");n("MAOIs","Citalopram",e.DRUG_DRUG,i.CONTRAINDICATED," . Citalopram (SSRI)     MAOIs  .","Increased Serotonin. Citalopram (SSRI) inhibits serotonin reuptake, and MAOIs prevent its breakdown.","  .     .","Fatal Serotonin Syndrome. Very high risk of Serotonin Syndrome.","  .            (14 ).","Two-Week Washout Period. A washout period of two weeks (14 days) must separate the discontinuation of one drug and the initiation of the other.");n("MAOIs","Escitalopram",e.DRUG_DRUG,i.CONTRAINDICATED," . Escitalopram (SSRI)     MAOIs  .","Increased Serotonin. Escitalopram (SSRI) inhibits serotonin reuptake, and MAOIs prevent its breakdown.","  .     .","Fatal Serotonin Syndrome. Very high risk of Serotonin Syndrome.","  .            (14 ).","Two-Week Washout Period. A washout period of two weeks (14 days) must separate the discontinuation of one drug and the initiation of the other.");n("MAOIs","Tyramine Foods (Cheese)",e.DRUG_FOOD,i.HIGH,"  . MAOIs              .","Lack of Tyramine Breakdown. MAOIs block the enzyme responsible for metabolizing Tyramine consumed in fermented or aged foods.","    (Hypertensive Crisis).                .","Hypertensive Crisis. Tyramine accumulates and causes sudden, uncontrolled release of Norepinephrine, leading to dangerously elevated blood pressure."," .           .","Dietary Restriction. A strict, Tyramine-free diet must be followed throughout the course of therapy.");n("MAOIs","Pseudoephedrine",e.DRUG_DRUG,i.HIGH,"  (Sympathomimetic Effect). MAOIs    (   Pseudoephedrine)     .","Sympathomimetic Potentiation. MAOIs prevent the breakdown of catecholamines (including Pseudoephedrine), increasing their sympathetic effects.","  .       .","Hypertensive Crisis. Leads to severe and potentially fatal blood pressure elevation.",".   .          (Sympathomimetics).","Contraindicated. Absolutely forbidden. All decongestants containing sympathomimetics must be avoided.");n("MAOIs (e.g., Phenelzine)","Tyramine-rich foods (Aged cheese, cured meats)",e.DRUG_FOOD,i.HIGH,"     .           .","Tyramine Breakdown Blockade Leads to Norepinephrine Release. Tyramine accumulation causes the sudden release of large amounts of norepinephrine from nerve endings.","     (Hypertensive Crisis)    .       .","Acute Hypertensive Crisis (potentially causing cerebral hemorrhage). A life-threatening spike in blood pressure.","      .                  .","Strict Tyramine-Free Diet. Patient must avoid aged, fermented, and smoked foods, such as aged cheese, beer/wine, cured meats, and pickled foods.");n("Maralixibat","Cholestyramine",e.DRUG_DRUG,i.HIGH,"  Maralixibat. Cholestyramine   Maralixibat  .","Decreased Maralixibat efficacy. Cholestyramine binds to Maralixibat in the intestine."," Maralixibat     (Bile flow)     .","Maralixibat failure to improve bile flow and relieve pruritus in liver diseases."," .   Maralixibat     4   Cholestyramine.","Avoid simultaneous administration. Maralixibat should be taken at least 4 hours apart from Cholestyramine.");n("Maralixibat","Omeprazole",e.DRUG_DRUG,i.MODERATE,"  Maralixibat.         Maralixibat.","Decreased Maralixibat efficacy. Proton pump inhibitors may alter the solubility and absorption of Maralixibat.","              .","Potential decrease in drug levels, reducing its ability to improve bile flow and relieve pruritus."," .         .","Efficacy monitoring. Clinical response should preferably be monitored and bile acid levels checked.");n("Maralixibat","Cholestyramine",e.DRUG_DRUG,i.HIGH,"  Maralixibat.      Maralixibat  .","Decreased Maralixibat efficacy. Bile acid sequestrants bind to Maralixibat in the intestine.","  Maralixibat         .","Reduced Maralixibat plasma concentration, decreasing its efficacy in treating pruritus."," .     Maralixibat     4   .","Dose timing. Maralixibat and bile acid sequestrants must be separated by at least 4 hours.");n("Maraviroc","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Maraviroc. Carbamazepine    CYP3A4    Maraviroc.","Decreased Maraviroc concentration. Carbamazepine is a strong inducer of CYP3A4, a Maraviroc metabolic pathway.","            .","Reduced drug plasma concentration, leading to failure of antiretroviral therapy."," .   .","Contraindicated. Avoid the combination.");n("Margetuximab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Margetuximab      (HER2)    .","Increased risk of viral infection. Margetuximab is a monoclonal antibody (HER2) and affects cellular immunity.","     .","Risk of developing infection from live vaccines."," .       Margetuximab.","Contraindicated. Live vaccines must be avoided during Margetuximab treatment.");n("Margetuximab (Margenza)","Anthracyclines (Doxorubicin)",e.DRUG_DRUG,i.HIGH,": **  **.      .","Mechanism: **Synergistic cardiotoxicity**. Both drugs cause cardiac muscle toxicity."," : **  **   .","Clinical Significance: **Congestive heart failure** and reduced ejection fraction.","    .     .","Close cardiac function monitoring with echo. Avoid concurrent use if possible.");n("Maribavir","Valganciclovir",e.DRUG_DRUG,i.HIGH,"   Valganciclovir. Maribavir   UGT    Valganciclovir.","Decreased Valganciclovir effect. Maribavir induces UGT enzymes, accelerating Valganciclovir metabolism.","  Valganciclovir             (CMV).","Valganciclovir levels drop below the therapeutic threshold, leading to CMV infection treatment failure."," .    .      Valganciclovir.","Avoid Combination. Co-administration is not recommended. Alternative drugs to Valganciclovir should be used.");n("Mavacamten","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Diltiazem    CYP3A4   CYP2C19     Mavacamten.","Increased Mavacamten levels. Diltiazem is a moderate CYP3A4 and strong CYP2C19 inhibitor, two major Mavacamten metabolizing enzymes.","    (Heart Failure)    Mavacamten     .","Increased risk of heart failure due to over-inhibition of myocardial contractility by Mavacamten."," .     CYP3A4/CYP2C19     Mavacamten.","Contraindicated. Moderate or strong CYP3A4/CYP2C19 inhibitors should be avoided with Mavacamten.");n("Mavacamten","Rifampin",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Rifampin    CYP3A4  CYP2C19    Mavacamten.","Decreased Mavacamten efficacy. Rifampin is a strong inducer of CYP3A4 and CYP2C19, two metabolic pathways for Mavacamten.","                 .","Severe decrease in plasma drug concentration, leading to loss of control over obstructive hypertrophic cardiomyopathy."," .    CYP3A4  .","Contraindicated. Strong CYP3A4 inducers must be avoided concomitantly.");n("Mavacamten","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Fluconazole   CYP2C19  CYP3A4    Mavacamten.","Increased Mavacamten concentration. Fluconazole inhibits CYP2C19 and CYP3A4, which are Mavacamten metabolic pathways.","      .","Increased risk of cardiotoxicity and congestive heart failure."," .     CYP .","Avoid Combination. Dual CYP inhibitors must be avoided.");n("Mavacamten","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Omeprazole    CYP2C19    Mavacamten.","Increased Mavacamten concentration. Omeprazole is a strong CYP2C19 inhibitor, a Mavacamten metabolic pathway.","      .","Increased risk of cardiotoxicity and congestive heart failure."," .    CYP2C19     Mavacamten.","Dose adjustment. Strong CYP2C19 inhibitors must be avoided or Mavacamten dose reduced.");n("Mavacamten","Rifampin",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Rifampin    CYP2C19  CYP3A4    Mavacamten.","Decreased Mavacamten efficacy. Rifampin is a strong inducer of CYP2C19 and CYP3A4, which are Mavacamten metabolic pathways.","              .","Reduced drug plasma concentration, leading to loss of control over hypertrophic cardiomyopathy."," .    CYP .","Avoid Combination. Strong CYP inducers must be avoided.");n("Mavacamten","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Itraconazole   CYP2C19  CYP3A4    Mavacamten.","Increased Mavacamten concentration. Itraconazole inhibits CYP2C19 and CYP3A4, which are Mavacamten metabolic pathways.","      .","Increased risk of cardiotoxicity and congestive heart failure."," .     CYP .","Avoid Combination. Dual CYP inhibitors must be avoided.");n("Mavacamten","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Diltiazem    CYP3A4    Mavacamten.","Increased Mavacamten concentration. Diltiazem is a moderate CYP3A4 inhibitor, a Mavacamten metabolic pathway.","      .","Increased risk of cardiotoxicity and congestive heart failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inhibitors must be avoided.");n("Mavacamten","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Cyclosporine   P-glycoprotein (P-gp)    Mavacamten.","Increased Mavacamten concentration. Cyclosporine inhibits P-glycoprotein (P-gp), an Mavacamten efflux pathway.","      .","Increased risk of cardiotoxicity and congestive heart failure."," .    P-gp .","Avoid Combination. Strong P-gp inhibitors must be avoided.");n("Mavacamten","Rifampin",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Rifampin   CYP3A4  P-gp     Mavacamten.","Decreased Mavacamten efficacy. Rifampin is an inducer of CYP3A4 and P-gp, Mavacamten metabolism and efflux pathways.","              .","Reduced drug plasma concentration, leading to loss of control over hypertrophic cardiomyopathy."," .    CYP3A4  P-gp .","Avoid Combination. Strong CYP3A4 and P-gp inducers must be avoided.");n("Mavacamten (Camzyos)","Verapamil",e.DRUG_DRUG,i.CONTRAINDICATED,": **   **.       .","Mechanism: **Dual cardiac contractility inhibition**. Both drugs reduce cardiac contractility."," : **  **   .","Clinical Significance: **Acute heart failure** and potential cardiogenic shock.","  .        .","Absolute contraindication. Must avoid all non-dihydropyridine calcium channel blockers.");n("Mavacamten (Camzyos)","Diltiazem",e.DRUG_DRUG,i.CONTRAINDICATED,": **     **.    .","Mechanism: **Synergistic negative inotropic effect**. Severe heart failure risk."," : **  **   .","Clinical Significance: **Severe heart failure** potentially fatal.","  .  Diltiazem   Mavacamten.","Absolute contraindication. Discontinue Diltiazem before starting Mavacamten.");n("Mavacamten (Camzyos)","Itraconazole",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP2C19**.   Mavacamten  5 .","Mechanism: **Potent CYP2C19 inhibition**. Mavacamten concentration increases 5-fold."," : **  **     .","Clinical Significance: **Severe heart failure** due to excessive contractility inhibition.","  .      Fluconazole .","Absolute contraindication. Use alternative antifungal such as Fluconazole cautiously.");n("Mavacamten (Camzyos)","Rifampin",e.DRUG_DRUG,i.HIGH,": **   CYP2C19**.   Mavacamten  85%.","Mechanism: **Potent CYP2C19 induction**. Mavacamten concentration decreases by 85%."," : **  **      .","Clinical Significance: **Loss of therapeutic efficacy** and worsening HCM symptoms."," .    .","Avoid combination. Use alternative antibiotic.");n("Mavacamten (HCM)","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Omeprazole    CYP2C19.","Increased Mavacamten concentration. Omeprazole is a strong inhibitor of CYP2C19.","       (Systolic Dysfunction).","Increased risk of systolic dysfunction and reduced ejection fraction.","  .    CYP     Mavacamten   .","Relative contraindication. Strong CYP inhibitors must be avoided or Mavacamten dose adjusted and cardiac function monitored.");n("Mavacamten (HCM)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Mavacamten. Rifampin    CYP3A4.","Decreased Mavacamten concentration. Rifampin is a strong inducer of CYP3A4.","        .","Reduced drug efficacy and failure of hypertrophic cardiomyopathy treatment."," .   .","Contraindicated. Avoid the combination.");n("Mebendazole","Metronidazole",e.DRUG_DRUG,i.MODERATE,"  .            .","Unclear Mechanism. The combination is suspected of increasing hepatic toxicity or immunologic skin reactions.","     (Stevens-Johnson Syndrome -   ).        .","Increased Risk of Stevens-Johnson Syndrome (SJS - a severe skin rash). This adverse event is rare but potentially life-threatening.","    .    Mebendazole  Metronidazole      .","Avoid Concurrent Use for Amebiasis. Mebendazole and Metronidazole should be avoided together for this indication; alternative treatments should be sought.");n("Mebendazole (Vermox)","Albendazole (Zental)",e.DRUG_DRUG,i.HIGH,"   .        .         .","Unspecified Interaction. Both drugs are benzimidazole derivatives used for worm treatment. Unwarranted co-administration may lead to cumulative toxicity.","    .       SJS   Mebendazole      .","Increased Risk of Stevens-Johnson Syndrome. Rare cases of SJS have been reported with Mebendazole, especially at high doses or with other agents.","     .               .","Avoid Combination, Use Only One. There is no therapeutic benefit to co-administering both agents, and the combination increases the risk of side effects.");n("Mebeverine - ","Butylscopolamine / Other Antispasmodics (        )",e.DRUG_DRUG,i.MODERATE,"       .     .","Additive effects on gastrointestinal smooth muscle. Both agents work to relieve spasm.","                  .","Increased risk of antispasmodic or anticholinergic side effects such as severe constipation, dry mouth, or blurred vision.",".                    .","Monitor closely. It is generally advised not to take more than one IBS antispasmodic remedy at a time to prevent additive toxicity while symptoms relief may not increase significantly.");n("Mebeverine - ","Eluxadoline - ",e.DRUG_DRUG,i.MODERATE,"    .        .","Additive effects on intestinal motility. Both agents influence tone and movement in the GI tract.","          (  )     .","Increased risk of severe constipation or exaggerated abdominal side effects (e.g., nausea, vomiting) due to excessive slowing of motility.","  .          .","Monitor closely. This combination should be used with extreme caution due to the increased risk of constipation.");n("Medroxyprogesterone","Aminoglutethimide",e.DRUG_DRUG,i.MODERATE,"  ","Progestin metabolism induction.","   ","Reduced medroxyprogesterone efficacy."," ","Increase dose.");n("Mefenamic Acid","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,"  . Mefenamic Acid (NSAID)          .","Irritation and Prostaglandin Inhibition. Mefenamic Acid (an NSAID) causes direct mucosal injury and inhibits the synthesis of cytoprotective prostaglandins.",".        .","Hemorrhage. High risk of severe gastrointestinal bleeding and ulceration.",".          .               .","Avoid use. Contraindicated in patients with active peptic ulcer or recent GI bleeding. If use is unavoidable, use the lowest effective dose for the shortest duration with gastroprotection.");n("Mefenamic Acid","Heart Failure",e.DRUG_DISEASE,i.MODERATE," . Mefenamic Acid              .","Fluid Retention. Mefenamic Acid inhibits renal prostaglandins, which impairs renal blood flow and leads to sodium and water retention, exacerbating volume overload."," .      (CHF)     .","Worsening Failure. Exacerbation of congestive heart failure (CHF) symptoms and edema, and reduced efficacy of diuretics.",".   Mefenamic Acid    .            .","Avoid use. NSAIDs are generally discouraged in heart failure patients. If used, monitor weight, signs of fluid retention, and renal function closely.");n("Mefenamic Acid","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,"     . Mefenamic Acid   COX          .","Prostaglandin Inhibition. COX inhibition depletes cytoprotective gastric prostaglandins, increasing ulcer risk.","      .        .","GI Bleeding & Perforation. High risk of acute and serious gastrointestinal complications.","         (PPIs) .       .","Avoid and use Paracetamol (Acetaminophen), or use with Proton Pump Inhibitors (PPIs) cautiously. Must be strictly avoided in cases of active ulceration.");n("Megestrol","Warfarin",e.DRUG_DRUG,i.MODERATE,"  ","Unknown mechanism.","  INR","INR changes."," INR","Monitor INR.");n("Melatonin - ","Fluvoxamine - ",e.DRUG_DRUG,i.MODERATE,"    CYP1A2            17    ","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme responsible for Melatonin primary metabolism, increasing its concentration by 17-fold and prolonging its half-life","          ","Excessive sedative effects, daytime drowsiness, dizziness, balance disturbances, and headache","    0.5-1  (10-20%   ) -      -      ","Reduce Melatonin dose to 0.5-1 mg (10-20% of usual dose) - avoid activities requiring alertness - monitor for excessive daytime drowsiness");n("Meloxicam","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Memantine","Acetazolamide",e.DRUG_DRUG,i.MODERATE,"  Memantine.           Memantine .","Increased Memantine concentration. Carbonic anhydrase inhibitors alkalize the urine, reducing Memantine renal clearance.","   Memantine ( ).","Increased risk of Memantine toxicity (dizziness, confusion)."," .        .","Close monitoring. Monitor for signs of toxicity and reduce dose if necessary.");n("Meperidine","MAO Inhibitors ",e.DRUG_DRUG,i.HIGH,"        .  MAO     Normeperidine       .","Dangerous Interaction Causing Serotonin Syndrome and Accumulation of Toxic Metabolite Normeperidine. MAOIs prevent the breakdown of Meperidine and its metabolite Normeperidine, leading to increased serotonergic and neurotoxicity.","     .         .","Increased Risk of Serotonin Syndrome and Neurotoxicity. May lead to muscle rigidity, hyperthermia, coma, and seizures.","     (  ).    14       MAO  Meperidine.","Avoid this Combination if possible (Absolute Contraindication). At least 14 days must elapse between discontinuing MAOIs and initiating Meperidine.");n("Meperidine","Phenothiazine",e.DRUG_DRUG,i.HIGH,"            .   .","Enhanced CNS Depressant Effects, leading to profound sedation and excessive drowsiness. Additive sedative effects.","   .       .","Increased CNS Depression. Risk of respiratory depression and hypotension.","     -    .          .","Avoid this Combination if possible - Monitor the patient closely. If necessary, use very low doses of both drugs.");n("Meperidine","Ritonavir",e.DRUG_DRUG,i.HIGH," Ritonavir  CYP3A4   Meperidine      Meperidine    Normeperidine.       .","Ritonavir inhibits the CYP3A4 enzyme that metabolizes Meperidine, leading to increased Meperidine concentrations and accumulation of the toxic metabolite Normeperidine. Inhibition reduces clearance of both parent drug and metabolite.","    .   Normeperidine           Meperidine     .","Decreased Efficacy and Increased Neurotoxicity. Normeperidine accumulation increases the risk of seizures and neurotoxicity, while concentration changes in Meperidine lead to variable analgesia.","     -    .       CYP3A4     .","Avoid this Combination if possible - Use an alternative opioid analgesic. Prefer analgesics not affected by CYP3A4 or those that do not produce a toxic metabolite.");n("Meperidine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.MODERATE,"     CYP3A4      ","Grapefruit juice inhibits intestinal and hepatic CYP3A4 enzyme responsible for meperidine metabolism","        30       ","Up to 30% increase in meperidine plasma concentration, enhancing analgesic effects and respiratory depression","       ","Avoid grapefruit juice consumption during meperidine therapy");n("Meperidine - ","Tobacco Smoking - ",e.DRUG_FOOD,i.MODERATE,"        CYP2B6    ","Aromatic hydrocarbons in tobacco smoke induce CYP2B6 enzyme responsible for meperidine metabolism","      20-25      ","20-25% decrease in meperidine blood levels, potentially reducing its analgesic efficacy","     -   ","Monitor analgesic efficacy in smokers - may require meperidine dose increase");n("Meperidine - ","High-Fat Meal -   ",e.DRUG_FOOD,i.LOW,"                ","High-fat meals may slow the absorption of oral meperidine but do not affect the ultimate bioavailability","           ","Delayed onset of analgesic effect, but no change in intensity or duration of effect","              ","Meperidine can be taken with or without food, but maintain consistent dosing pattern");n("Meperidine - ","Caffeine - ",e.DRUG_FOOD,i.LOW,"            ","Caffeine may reduce some sedative effects of meperidine but without significant drug interaction","     ","Mild reduction in meperidine-associated drowsiness","        ","No need to avoid caffeine, but consume in moderation");n("Meperidine - ","St. Johns Wort -   ",e.DRUG_FOOD,i.HIGH,"     CYP3A4              ","St. Johns Wort induces CYP3A4 and increases serotonergic activity, affecting meperidine metabolism and increasing risk of serotonergic toxicity","      ","Reduced meperidine efficacy, increased risk of serotonin syndrome","       ","Avoid St. Johns Wort consumption during meperidine therapy");n("Mercaptopurine","Allopurinol",e.DRUG_DRUG,i.HIGH," XO","Xanthine oxidase inhibition.","  ","Bone marrow toxicity.","  6-MP  75%","Reduce 6-MP dose by 75%.");n("Meropenem","Valproic Acid",e.DRUG_DRUG,i.HIGH,"   . Meropenem            .","Decreased Valproic Acid concentration. Meropenem increases Valproic Acid metabolism or reduces its enterohepatic recirculation.","    (Seizure control failure).","Failure of seizure control."," .       .","Contraindicated. Avoid the combination or use a carbapenem alternative.");n("Meropenem","Probenecid",e.DRUG_DRUG,i.MODERATE,"  ","Inhibition of renal excretion.","  ","Increased meropenem levels.","     ","May be beneficial to prolong treatment duration.");n("Mesalamine","Azathioprine",e.DRUG_DRUG,i.MODERATE," TPMT -   ","TPMT inhibition increases azathioprine toxicity.","  ","Bone marrow suppression.","  ","Monitor CBC.");n("Metaproterenol - ","Food (General) -  ()",e.DRUG_FOOD,i.LOW,"     2      .                /            .           .                      .","Metaproterenol, a beta-2 adrenergic receptor agonist, is often administered via inhalation. The unpleasant taste associated with it does not arise from an interaction with food, but from the active ingredient itself and/or the propellant in the inhaler, which can deposit in the mouth and throat after inhalation. Drug particles may directly interact with bitter taste receptors on the tongue. Poor inhalation technique, leading to increased drug deposition in the mouth rather than the lungs, can exacerbate the intensity of the unpleasant taste.","            : 1.         . 2.           . 3.                      .","Bitter or unpleasant medicinal taste in the mouth after each use, leading to: 1. Aversion to using the inhaler, potentially compromising treatment adherence. 2. Particular concern among children and adolescents, making asthma management more difficult. 3. Excessive mouth rinsing immediately after use, which may reduce drug efficacy if washed away from throat tissues where it can be partially absorbed.","1.   :         -            10   . 2.    (Spacer):          (pMDIs)        . 3.  :             5-10          . 4.  :           (  )       . 5. :                  .","1. Correct inhalation technique: Ensure the patient uses the device correctly - take a slow, deep breath while pressing the inhaler, and hold breath for 10 seconds if possible. 2. Use of a spacer: Using a spacer with pressurized metered-dose inhalers (pMDIs) is highly recommended to significantly reduce drug deposition in the mouth and throat. 3. Mouth rinsing: Rinse the mouth with water only or a mild mouthwash after inhalation, but wait at least 5-10 minutes after the dose to allow for some potential systemic absorption. 4. Taste masking: Drinking a sip of a sweet or acidic beverage (e.g., orange juice) after rinsing can help mask any residual taste. 5. Alternatives: If the problem persists, discuss with the doctor the possibility of switching to another inhaled medication that may have a more acceptable taste.");n("Metaraminol","Atenolol",e.DRUG_DRUG,i.HIGH,"   . Atenolol ( )   2     Metaraminol     ( )  .","Vascular Antagonism (Unopposed Alpha-Stimulation). Atenolol (a beta-blocker) prevents beta2-mediated vasodilation, leaving Metaraminol's alpha-mediated vasoconstrictive effect unopposed.","      .       (Hypertensive Crisis)    .","Uncontrolled Hypertension. Results in a severe and sudden, potentially life-threatening hypertensive crisis.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metaraminol","Bisoprolol",e.DRUG_DRUG,i.HIGH,"   . Bisoprolol ( )   2     Metaraminol     .","Vascular Antagonism (Unopposed Alpha-Stimulation). Bisoprolol (a beta-blocker) prevents beta2-mediated vasodilation, leaving Metaraminol's alpha-mediated vasoconstrictive effect unopposed.","      .       (Hypertensive Crisis)    .","Uncontrolled Hypertension. Results in a severe and sudden, potentially life-threatening hypertensive crisis.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metaraminol","Carvedilol",e.DRUG_DRUG,i.HIGH,"    (  1   Carvedilol). Carvedilol        Metaraminol ( / )     .","Vascular Antagonism (Despite Carvedilol's Alpha-Blocking Properties). Carvedilol has alpha-blocking effects, but combining it with Metaraminol (an alpha agonist/pressor) still poses a significant risk.","      .      .","Uncontrolled Hypertension. Risk of severe hypertensive episode.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metaraminol","Metoprolol",e.DRUG_DRUG,i.HIGH,"   . Metoprolol ( )   2     Metaraminol     .","Vascular Antagonism (Unopposed Alpha-Stimulation). Metoprolol (a beta-blocker) prevents beta2-mediated vasodilation, leaving Metaraminol's alpha-mediated vasoconstrictive effect unopposed.","      .       (Hypertensive Crisis)    .","Uncontrolled Hypertension. Results in a severe and sudden, potentially life-threatening hypertensive crisis.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metaraminol","Propranolol",e.DRUG_DRUG,i.HIGH,"   . Propranolol (   )   2      Metaraminol     .","Vascular Antagonism (Unopposed Alpha-Stimulation). Propranolol (a non-selective beta-blocker) strongly prevents beta2-mediated vasodilation, leaving Metaraminol's alpha-mediated vasoconstrictive effect unopposed.","      .       (Hypertensive Crisis)    .","Uncontrolled Hypertension. Results in a severe and sudden, potentially life-threatening hypertensive crisis.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metaraminol","Nebivolol",e.DRUG_DRUG,i.HIGH,"   . Nebivolol ( )   2     Metaraminol     .","Vascular Antagonism (Unopposed Alpha-Stimulation). Nebivolol (a beta-blocker) prevents beta2-mediated vasodilation, leaving Metaraminol's alpha-mediated vasoconstrictive effect unopposed.","      .          .","Uncontrolled Hypertension. Results in a severe and sudden, potentially life-threatening hypertensive crisis.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metaraminol","Labetalol",e.DRUG_DRUG,i.HIGH,"    (     Labetalol). Labetalol           Metaraminol         .","Vascular Antagonism (Despite Labetalol's Alpha-Blocking Properties). Labetalol is an alpha and beta-blocker, but combining it with an alpha agonist like Metaraminol still poses a risk due to complex vascular interaction mechanisms.","      .      .","Uncontrolled Hypertension. Risk of severe hypertensive episode.","  .          .","Avoid Concurrent Use. This combination is contraindicated due to the severe risk of hypertension.");n("Metformin","Renal Failure",e.DRUG_DISEASE,i.CONTRAINDICATED," .   Metformin      .           .","Drug Accumulation. Metformin is almost entirely cleared by the kidneys. Renal failure leads to high, accumulating levels of the drug in the body.","   (Lactic Acidosis).  Metformin        .","Risk of Lactic Acidosis. Metformin accumulation drastically and fatally increases the risk of Lactic Acidosis.",".          (eGFR)   30 mL/min/1.73m.","Contraindicated. Absolutely contraindicated if the estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73m.");n("Metformin","Contrast Dye ()",e.DRUG_DRUG,i.HIGH,"  .    (Contrast Dye)          (CIN)     Metformin.","Acute Renal Failure. Iodinated contrast dye injection can lead to contrast-induced nephropathy (CIN), which reduces Metformin clearance.","  (Lactic Acidosis).   Metformin            .","Lactic Acidosis. Metformin accumulation due to renal failure drastically increases the risk of life-threatening Lactic Acidosis.","  48 .   Metformin              48          .","Discontinue 48 Hours Before. Metformin must be stopped before or at the time of the procedure using contrast, and only resumed 48 hours later after confirming normal renal function.");n("Metformin","Renal Failure / Heart Failure",e.DRUG_DISEASE,i.CONTRAINDICATED,"   .      Metformin.            .","Drug Accumulation and Hypoxia. Impaired renal excretion prevents Metformin clearance. Heart failure increases tissue hypoxia, which enhances lactate production.","   (Lactic Acidosis) .  Metformin                   .","Risk of Fatal Lactic Acidosis. Metformin accumulation under these conditions dramatically increases the risk of Lactic Acidosis, a life-threatening medical emergency with high mortality."," .         (eGFR < 30 mL/min/1.73m)        (  ).","Contraindicated. Absolutely contraindicated if renal function is severely impaired (eGFR < 30 mL/min/1.73m) or in cases of unstable heart failure (e.g., cardiogenic shock).");n("Metformin","Cimetidine",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of renal metformin excretion","   (  )","Increased metformin concentrations (lactic acidosis risk)","    -     ","Monitor blood glucose levels - reduce metformin dose if necessary");n("Metformin","Iodine Contrast Media",e.DRUG_DRUG,i.HIGH,"     ","Risk of acute renal failure and metformin accumulation","     (Lactic Acidosis)","Increased risk of metabolic acidosis (Lactic Acidosis)","  .    48       .","Avoid this combination. Stop metformin 48 hours before and after using injectable iodine contrast agents.");n("Metformin","Alcohol",e.DRUG_FOOD,i.HIGH,"       ( )  .            . : (1)         (2)                (3)        .    -         -       (lactic acidosis)     .","Metformin and alcohol both affect body lactate (lactic acid) metabolism. Metformin reduces hepatic lactate clearance and slightly increases intestinal production. Alcohol: (1) increases lactate production in muscles and other tissues, (2) inhibits hepatic gluconeogenesis, shifting glucose metabolism toward anaerobic lactate-producing pathway, (3) impairs liver ability to convert lactate to glucose. When combined - especially with excessive drinking, fasting, or dehydration - dangerous blood lactate accumulation occurs (lactic acidosis), a life-threatening emergency.","           (   5 mmol/L)   pH .  :               (    )           .     :         (  30-50%).    :                  .","Lactic acidosis is extremely serious condition characterized by lactic acid accumulation in blood (level >5 mmol/L) with decreased blood pH. Symptoms include: severe nausea and vomiting, acute abdominal pain, extreme general weakness and unbearable fatigue, hyperventilation (rapid deep breathing to compensate acidosis), hypothermia, hypotension, tachycardia, confusion and mental disorientation. Without urgent treatment, progresses to: cardiac arrhythmias, multi-organ failure, coma, and death (mortality rate 30-50%). Risk is much higher in: patients with kidney or liver impairment, elderly, fasting individuals, dehydrated patients, or those taking high metformin doses.","       .         : (1)   :           (2)       -     (3)         /   (4)           (eGFR < 60)        .    (  ): /              .   .","Strong recommendation to completely avoid alcohol during metformin therapy. If patient chooses small amount despite risks: (1) absolute maximum: one standard drink for women, two for men daily, not every day, (2) never drink on empty stomach - eat full meal first, (3) completely avoid alcohol when fasting, ill, dehydrated, or before/after intense exercise, (4) total abstinence for patients with any degree kidney impairment (eGFR <60), liver disease, heart failure, or lactic acidosis history. Emergency warning signs (go to ER immediately): persistent nausea/vomiting, sudden severe weakness, unusual muscle pain, breathing difficulty, severe dizziness, cold extremities. Patient education essential.");n("Metformin","Iodinated Contrast",e.DRUG_DRUG,i.HIGH,"        ","Risk of lactic acidosis if acute renal failure occurs.","  -   ","Lactic acidosis - potentially fatal.","  48     -    ","Stop metformin 48h before and after contrast - verify renal function.");n("Metformin","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Caffeine",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Grapefruit Juice",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metformin","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Methadone","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Methadone. Phenytoin    CYP3A4.","Decreased Methadone concentration. Phenytoin is a strong inducer of CYP3A4.","   /    .","Risk of withdrawal symptoms and/or relapse to drug use."," .      Methadone.","Close monitoring. Close and intensive monitoring and adjustment of Methadone dose.");n("Methadone","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Methadone. Clarithromycin    CYP3A4.","Increased Methadone concentration. Clarithromycin is a strong inhibitor of CYP3A4.","       QT.","Increased risk of respiratory depression and QT prolongation."," .       .","Close monitoring. Close and intensive monitoring for signs of respiratory and cardiac toxicity.");n("Methadone - ","Phenobarbital - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4 CYP2B6         ","Phenobarbital induces hepatic CYP3A4 and CYP2B6 enzymes responsible for Methadone metabolism, increasing its clearance","      30-50     (    )","30-50% decrease in Methadone plasma levels, emergence of opioid withdrawal symptoms (anxiety, insomnia, nausea, myalgia)","    25-50 -    -      ","Increase Methadone dose by 25-50% - monitor withdrawal symptoms - readjust dose after barbiturate discontinuation");n("Methadone - ","Pentobarbital - ",e.DRUG_DRUG,i.MODERATE,"      ","Pentobarbital induces shared metabolic enzymes with Methadone","       ","Reduced Methadone efficacy, withdrawal symptoms, increased relapse risk","     -     ","Adjust Methadone dose as needed - monitor vital signs and withdrawal symptoms");n("Methadone - ","Secobarbital - ",e.DRUG_DRUG,i.MODERATE,"        ","Secobarbital increases Methadone metabolism via hepatic enzyme induction","       ","Reduced Methadone efficacy, need for higher doses, withdrawal symptoms","   -    ","Monitor patient response - gradually increase Methadone dose");n("Methadone - ","Fluvoxamine - ",e.DRUG_DRUG,i.HIGH,"    CYP2D6 CYP1A2 CYP3A4     ","Fluvoxamine is a potent inhibitor of hepatic CYP2D6, CYP1A2, and CYP3A4 enzymes responsible for Methadone metabolism","    40-60     QT  Torsades de Pointes","40-60% increase in Methadone concentration, respiratory depression, QT prolongation, Torsades de Pointes risk","    30-50 -    -   ","Reduce Methadone dose by 30-50% - ECG monitoring - respiratory function monitoring");n("Methadone - ","Hydantoins - ",e.DRUG_DRUG,i.MODERATE," ( )   CYP3A4 ","Hydantoins (e.g., Phenytoin) induce hepatic CYP3A4 enzymes","        ","Decreased Methadone levels, withdrawal symptoms, loss of addiction control","   -    -     ","Increase Methadone dose - close clinical monitoring - measure Methadone levels if possible");n("Methadone - ","Protease Inhibitors -  ",e.DRUG_DRUG,i.MODERATE,"         -     ","Some protease inhibitors induce while others inhibit metabolic enzymes - effect depends on specific drug","      -     ","Unpredictable changes in Methadone levels - either toxicity or withdrawal symptoms","   -     -     ","Close response monitoring - dose adjustment as needed - collaborate with infectious disease specialist");n("Methadone - ","Rifampin - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4     ","Rifampin is a potent inducer of primary CYP3A4 enzyme responsible for Methadone metabolism","     ( 70)      ","Sharp decrease in Methadone levels (up to 70%), severe withdrawal symptoms, addiction relapse risk","    2-3  -   -    ","Increase Methadone dose by 2-3 fold - divide doses - intensive withdrawal symptom monitoring");n("Methadone - ","Quetiapine - ",e.DRUG_DRUG,i.HIGH,"    QT          (hERG)        ","Both drugs prolong QT interval by inhibiting cardiac potassium channels (hERG), with synergistic effect increasing arrhythmia risk","  QT (>500  )      Torsades de Pointes    ","QT prolongation (>500 ms), increased risk of fatal Torsades de Pointes arrhythmia, dizziness, syncope, cardiac arrest","      -       -     -      ","Avoid combination in at-risk patients - monitor ECG before and after initiation - correct electrolyte imbalances - avoid high doses of both medications");n("Methadone - ","Promethazine - ",e.DRUG_DRUG,i.HIGH,"    QT          (hERG)        .           ","Both drugs prolong QT interval by inhibiting cardiac potassium channels (hERG), with synergistic effect increasing arrhythmia risk. Additionally, promethazine enhances the CNS depressant effect of methadone","  QT (>500  )      Torsades de Pointes      ","QT prolongation (>500 ms), increased risk of fatal Torsades de Pointes arrhythmia, severe respiratory depression, excessive sedation, coma","      -       -     -    -      ","Avoid combination in at-risk patients - monitor ECG before and after initiation - correct electrolyte imbalances - monitor respiratory function - avoid high doses of both medications");n("Methadone - ","Topiramate - ",e.DRUG_DRUG,i.MODERATE,"     :              GABA    ","Synergistic CNS depressant effect: Methadone depresses CNS via opioid receptors, while Topiramate enhances GABA activity and reduces glutamate activity","                ","Respiratory depression, excessive drowsiness, dizziness, impaired cognition and motor functions, increased risk of falls and accidents especially in elderly","     -       -     -     ","Monitor vital signs and respiratory function - initiate with low doses of both drugs - avoid driving and operating machinery - adjust doses based on individual tolerance");n("Lovastatin - ","Cyclosporine - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4     OATP1B1            5-20 ","Cyclosporine potently inhibits hepatic CYP3A4 enzyme and OATP1B1 transporter, reducing Lovastatin metabolism and excretion and increasing systemic exposure by 5-20 fold","        ()          CK   ","Massive increase in risk of myopathy and rhabdomyolysis with muscle pain, weakness, tenderness, sharp elevation in CK enzymes, and acute renal failure","    -   :    20     -      -      ","Avoid combination if possible - if necessary: do not exceed 20 mg daily of Lovastatin - regular monitoring of muscle and kidney enzymes - educate patient about myopathy symptoms");n("Methimazole","Warfarin",e.DRUG_DRUG,i.MODERATE,"       K","Effect on vitamin K-dependent clotting factors."," INR","Increased INR."," INR    ","Monitor INR when changing methimazole dose.");n("Methimazole","Theophylline",e.DRUG_DRUG,i.MODERATE,"     ","Reduced theophylline clearance in hyperthyroidism.","     ","Theophylline toxicity when treating hyperthyroidism.","  ","Reduce theophylline dose.");n("Methotrexate","Aspirin",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Ibuprofen",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Diclofenac",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Naproxen",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Ketoprofen",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Indomethacin",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Celecoxib",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Mefenamic Acid",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination."," .","Methotrexate Toxicity. Bone marrow/liver/lung damage.",".",".");n("Methotrexate","Probenecid",e.DRUG_DRUG,i.HIGH," .","Reduced Excretion. Competition for renal tubular secretion or altered urinary pH decreases drug elimination.",".",".",".",".");n("Methotrexate","NSAIDs",e.DRUG_DRUG,i.HIGH,"  Methotrexate.          Methotrexate.","Increased Methotrexate concentration. NSAIDs reduce renal clearance of Methotrexate.","   Methotrexate (    ).","Increased risk of Methotrexate toxicity (myelosuppression, renal toxicity).","    .     .","Avoid combination at high doses. Close monitoring at low doses.");n("Methotrexate","Alcohol",e.DRUG_FOOD,i.CONTRAINDICATED,"  ","Hepatotoxicity. Liver damage.","  ","  ","    ","    ");n("Methotrexate","Liver Disease / Hepatic Impairment",e.DRUG_DISEASE,i.HIGH,"      -   ","Hepatotoxicity & Metabolic Impairment. Worsening liver function.","     ","Worsening hepatic failure or encephalopathy.","   Child-Pugh -   ","Adjust dose based on Child-Pugh - monitor liver function.");n("Methotrexate","Trimethoprim",e.DRUG_DRUG,i.HIGH,"   ","Dual folate inhibition.","   ","Severe bone marrow suppression."," ","Avoid combination.");n("Methotrexate","Aspirin",e.DRUG_DRUG,i.HIGH,"   +   ","Protein displacement + reduced renal excretion."," ","Methotrexate toxicity.","   ","Avoid high-dose aspirin.");n("Methotrexate","Proton Pump Inhibitors",e.DRUG_DRUG,i.MODERATE,"  ","Reduced renal excretion."," ","Methotrexate toxicity.","   MTX ","Avoid with high-dose MTX.");n("Methotrexate","Penicillins",e.DRUG_DRUG,i.HIGH,"  ","Reduced renal excretion."," ","Methotrexate toxicity.","   MTX ","Avoid with high-dose MTX.");n("Methyldopa",jh,e.DRUG_DRUG,i.HIGH,": **  (Synergistic)**    .            (alpha/beta receptors)    .","Mechanism: **Synergistic pressor effect**. Methyldopa is a prodrug for a false neurotransmitter that sensitizes adrenergic receptors (alpha/beta receptors) to direct-acting sympathomimetics."," : **    (Acute Hypertension)**  .           (  ).","Clinical Significance: **Acute Hypertension** and potential cardiac events. This interaction is particularly dangerous with direct-acting sympathomimetics (e.g., Epinephrine and Norepinephrine).","  .  **  **   ** (Phentolamine)**         .","Monitor BP closely. **Discontinue sympathomimetic** or use **Phentolamine** (an alpha-blocker) to manage acute severe hypertension resulting from sympathetic hyperactivity.");n("Methyldopa","Oral Iron",e.DRUG_DRUG,i.MODERATE,"  ","  ","    ","Reduced Antihypertensive Effect. Elevated BP.","   ","   ");n("Methyldopa","Pseudoephedrine",e.DRUG_DRUG,i.HIGH,"     ","     ","  ","Hypertension. Elevated blood pressure.","      ","      ");n("Methyldopa","Phenylephrine",e.DRUG_DRUG,i.HIGH,"     ","     ","  ","Hypertension. Elevated blood pressure.","      ","      ");n("Methyldopa","Ephedrine",e.DRUG_DRUG,i.HIGH,"     ","     ","  ","Hypertension. Elevated blood pressure.","      ","      ");n("Methyldopa","Fluoxetine",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","    ","    ");n("Methyldopa","Sertraline",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","    ","    ");n("Methyldopa","Amitriptyline",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","    ","    ");n("Methyldopa","Venlafaxine",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","    ","    ");n("Methyldopa","Dopamine",e.DRUG_DRUG,i.HIGH,"      ","Synergistic Hypertension. Additive pressor effects.","    ","    ","   .    .","   .    .");n("Methyldopa","Norepinephrine",e.DRUG_DRUG,i.HIGH,"      ","Synergistic Hypertension. Additive pressor effects.","    ","    ","   .    .","   .    .");n("Methyldopa","Phenylpropanolamine",e.DRUG_DRUG,i.HIGH,"      ","Synergistic Hypertension. Additive pressor effects.","    ","    ","   .    .","   .    .");n("Methyldopa","Dobutamine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Dopamine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Ephedrine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Epinephrine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Mephentermine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Metaraminol",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Methoxamine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Norepinephrine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Phenylephrine",e.DRUG_DRUG,i.MODERATE,"        ","Sympathetic Antagonism. Opposing actions on the sympathetic nervous system.","  ","Hypertension. Elevated blood pressure.","   -      Phentolamine   ","   -      Phentolamine   ");n("Methyldopa","Iron Supplements",e.DRUG_DRUG,i.MODERATE,"   ","Complex formation in gut.","   ","Reduced methyldopa absorption.","  ","Separate doses by 2 hours.");n("Methyldopa","Levodopa",e.DRUG_DRUG,i.MODERATE,"      ","Competition for blood-brain barrier transport.","  ","Reduced levodopa efficacy.","  ","Monitor Parkinson symptoms.");n("Methylprednisolone","Diabetes",e.DRUG_DISEASE,i.MODERATE," .","Insulin Resistance. Drug-induced impairment of insulin sensitivity."," ."," .",".",".");n("Methylprednisolone","Diabetes / Hypertension",e.DRUG_DISEASE,i.MODERATE,"     ( ).","Hyperglycemia & Fluid Retention. Corticosteroids induce gluconeogenesis and mineralocorticoid activity.","    .","    .","          .","          .");n("Methylprednisolone","Live Vaccines",e.DRUG_DRUG,i.HIGH," ","Immunosuppression.","    ","Risk of infection from live vaccine.","   -   ","Avoid live vaccines - use inactivated vaccines.");n("Metoclopramide","Levodopa",e.DRUG_DRUG,i.MODERATE,"   . Metoclopramide       (Prokinetic).","Increased Gastrointestinal Motility. Metoclopramide is a prokinetic agent.","  .         Levodopa (        ).         (Dyskinesia)   Levodopa.","Increased Absorption Rate. Accelerated gastric emptying leads to an increased rate of Levodopa absorption. May also potentially worsen Levodopa-related dyskinesia.","  Levodopa.    Levodopa          Metoclopramide.","Adjust Levodopa Dose. Levodopa dosage may need adjustment when initiating, discontinuing, or changing Metoclopramide dosage.");n("Metoclopramide","Hyoscine",e.DRUG_DRUG,i.MODERATE,"  . Metoclopramide    (Prokinetic)  Hyoscine (   )   .","Antagonistic Effect. Metoclopramide speeds up bowel motility (Prokinetic), while Hyoscine (an anticholinergic/antispasmodic) slows it down.","  .             .","Cancellation of Both Drug Effects. Co-administration results in a reduction or cancellation of the effect of each drug on GI motility.","     .      .          .","Avoid Co-administration for GI Motility Disorders. No logical reason to use them together. If necessary, consider timing separation or using an alternative agent.");n("Metoclopramide","Pramipexole",e.DRUG_DRUG,i.HIGH,"   . Metoclopramide   .","Decreased effect of Dopamine Agonists. Metoclopramide is a dopamine receptor antagonist.","   .","Worsening of Parkinsons disease symptoms."," .   .","Contraindicated. Avoid the combination.");n("Metoclopramide","Anticholinergics",e.DRUG_DRUG,i.MODERATE," ","Pharmacological antagonism.","   ","Reduced efficacy of both drugs."," ","Avoid combination.");n("Metolazone","NSAIDs",e.DRUG_DRUG,i.MODERATE,"   ","Reduced diuretic effect."," ","Fluid retention.","   ","Monitor weight and BP.");n(["Metoprolol","Propranolol"],"Hydralazine",e.DRUG_DRUG,i.MODERATE,": **   **.   ( )         / (    ).","Mechanism: **Altered hepatic blood flow**. Hydralazine (a vasodilator) reduces hepatic blood flow, decreasing the clearance of Metoprolol/Propranolol (which undergo extensive first-pass metabolism)."," : **   **   ( )         (Hypotension)   (Bradycardia).","Clinical Significance: **Increased concentrations of both drugs** (synergistic effect), raising the risk of severe hypotension and bradycardia.","     .           .","Monitor blood pressure and heart rate. Decrease dose of one or both drugs if necessary to avoid severe adverse effects.");n(["Metoprolol","Propranolol"],"Propafenone",e.DRUG_DRUG,i.MODERATE,": **   (CYP2D6)**.      CYP2D6     .","Mechanism: **Inhibition of hepatic metabolism (CYP2D6)**. Propafenone is a potent inhibitor of the CYP2D6 enzyme responsible for the metabolism of Metoprolol and Propranolol."," : **        100%**         .","Clinical Significance: **Increased beta-blocker levels and effects by up to 100%**, increasing the risk of severe bradycardia and hypotension.","  (   - Bradycardia).          .","Monitor cardiovascular status (severe bradycardia). Decrease beta-blocker dose by half when initiating combination therapy.");n("Metoprolol",Wh,e.DRUG_DRUG,i.MODERATE,": **        (Euthyroid State)**.           (Metoprolol Clearance)     .","Mechanism: **Reduced hepatic metabolism upon reaching euthyroid state**. Treating hyperthyroidism reduces Metoprolol hepatic clearance due to decreased liver blood flow."," : **   **             .","Clinical Significance: **Increased concentrations and effects of metoprolol**, increasing the risk of bradycardia and hypotension once the thyroid status improves.","   .         .","Monitor cardiovascular status. Decrease metoprolol dose as the patient becomes euthyroid.");n(["Metoprolol","Nadolol","Pindolol","Propranolol"],"Lidocaine",e.DRUG_DRUG,i.MODERATE,": **   **.                 (First-Pass Metabolism).","Mechanism: **Reduced hepatic clearance of lidocaine**. Beta-blockers decrease liver blood flow, slowing the metabolism of lidocaine which undergoes extensive first-pass metabolism."," : **    **      (CNS Toxicity)        (Seizures).","Clinical Significance: **Increased lidocaine concentrations and toxicity risk**, manifesting as CNS toxicity (dizziness, confusion, or seizures in severe cases).","     ( ).         .","Monitor lidocaine levels (if possible). Reduce lidocaine dose by approximately half during co-therapy.");n("Metoprolol","Verapamil (IV)",e.DRUG_DRUG,i.HIGH," .","Cardiac Depression. Negative inotropic and chronotropic effects."," .","Cardiac Arrest. Asystole or fatal arrhythmia.",".",".");n("Metoprolol","Diabetes",e.DRUG_DISEASE,i.HIGH,"   ","Masking Hypoglycemia. Adrenergic warning signs of hypoglycemia are blunted.","      ","      ","     ","     ");n("Metoprolol","Diabetes ()",e.DRUG_DISEASE,i.MODERATE,"    (  ).","Masking Hypoglycemia Symptoms. Tremors and palpitations associated with hypoglycemia are blocked.","      (Hypoglycemia Unawareness)    .","      (Hypoglycemia Unawareness)    .","          .","          .");n("Metoprolol","Asthma ()",e.DRUG_DISEASE,i.HIGH,"  -2     .","Beta-2 Blockade. Non-selective beta-blockade causes bronchoconstriction in susceptible patients.","    .","    .","    .    ( Bisoprolol)  .","    .    ( Bisoprolol)  .");n("Metoprolol","Asthma",e.DRUG_DISEASE,i.HIGH," .","Bronchoconstriction. Narrowing of the airways."," ."," .",".",".");n("Metoprolol","Aspirin",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Diclofenac",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Naproxen",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Indomethacin",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Celecoxib",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"     ","Antagonism of Antihypertensive Effect. One agent causes fluid retention or vasoconstriction, countering the other's blood pressure lowering effect.","    ","Reduced Antihypertensive Effect. Elevated BP.","  ","  ");n("Metoprolol","Methimazole",e.DRUG_DRUG,i.MODERATE,"  Metoprolol.  (   )    Metoprolol (  )      (CYP2D6)       .","Increased Metoprolol Concentrations. Methimazole (an antithyroid drug) reduces Metoprolol clearance by inhibiting hepatic metabolism (CYP2D6), particularly after the thyroid state normalizes.","    Metoprolol      (Bradycardia)     (Hypotension).","Increased Metoprolol Adverse Effects, such as bradycardia or hypotension.","    .    Metoprolol  .          CYP2D6 ( Nadolol  Atenolol).","Monitor Cardiovascular Status. Reduce the Metoprolol dose as needed. Alternative beta-blockers not metabolized by CYP2D6 (e.g., Nadolol, Atenolol) may be preferred.");n("Metoprolol","Propylthiouracil",e.DRUG_DRUG,i.MODERATE,"  Metoprolol.   (   )    Metoprolol      (CYP2D6)       .","Increased Metoprolol Concentrations. Propylthiouracil reduces Metoprolol clearance by inhibiting hepatic metabolism (CYP2D6), particularly after the thyroid state normalizes.","    Metoprolol         .","Increased Metoprolol Adverse Effects, such as bradycardia or hypotension.","    .    Metoprolol  .          CYP2D6 ( Nadolol  Atenolol).","Monitor Cardiovascular Status. Reduce the Metoprolol dose as needed. Alternative beta-blockers not metabolized by CYP2D6 (e.g., Nadolol, Atenolol) may be preferred.");n("Metoprolol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP).        .","Enzymatic Metabolic Induction (CYP). Barbiturates induce hepatic enzymes responsible for Metoprolol metabolism.","           (    ).","Decreased Metoprolol plasma concentration, leading to reduced drug efficacy (less beta-blockade).","     .          .","Monitor blood pressure and heart rate. Increase the Metoprolol dose if necessary to restore the desired therapeutic efficacy.");n("Metoprolol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Metoprolol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"                 .      .     ( )      .","Hydralazine reduces the hepatic clearance of Metoprolol by decreasing liver blood flow, increasing its bioavailability. Metoprolol also affects Hydralazine metabolism. This results in a mutual (bidirectional) increase in the plasma concentrations of both drugs.","           (Hypotension)   (Bradycardia)            .","Increased concentrations of both drugs lead to a risk of severe hypotension and bradycardia (from Metoprolol), in addition to exacerbating Hydralazine side effects.","       .                .","Closely monitor blood pressure and heart rate. The starting dose of one or both drugs should be reduced upon co-administration to avoid severe hypotension.");n("Metoprolol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Metoprolol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic Hypotension. Combined effects lead to significant blood pressure drop.","     ","     ","     ","     ");n("Metoprolol","Verapamil",e.DRUG_DRUG,i.HIGH,"   -    ","Dual cardiac depression - negative chronotropic and inotropic.","   -   -  ","Severe bradycardia - heart block - heart failure.","  -   ECG ","Avoid combination - or close ECG monitoring.");n("Metoprolol","Alcohol",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Caffeine",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Green Tea",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Milk",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","High-fat meals",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","High-fiber foods",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Vitamin C",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Vitamin D",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Vitamin E",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Vitamin K",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Vitamin B12",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Folic Acid",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Iron",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Calcium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Magnesium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Zinc",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Potassium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metoprolol","Antacids",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Metronidazole","Disulfiram",e.DRUG_DRUG,i.HIGH,": **   ( CNS)**.       .","Mechanism: **Unknown (CNS toxicity)**. Combination leads to neurotoxic reactions."," : **  (Acute Psychosis)**  .","Clinical Significance: **Acute psychosis** and confusion."," .         .","Avoid combination. Wait 2 weeks after stopping Disulfiram before starting Metronidazole.");n("Metronidazole","Warfarin",e.DRUG_DRUG,i.HIGH,": **  (CYP2C9)**.    .","Mechanism: **Metabolism inhibition (CYP2C9)**. Metronidazole inhibits Warfarin metabolism."," : **  **  INR  .","Clinical Significance: **Increased Warfarin effect**, elevated INR, and bleeding risk."," INR .     20-30%  .","Monitor INR closely. Reduce Warfarin dose by 20-30% upon initiation.");n("Metronidazole","Alcohol",e.DRUG_FOOD,i.HIGH,"  . Metronidazole     (Aldehyde dehydrogenase).","Disulfiram-like reaction. Metronidazole inhibits aldehyde dehydrogenase.","     .","Flushing, palpitations, nausea, vomiting, and severe headache."," .        3   .","Contraindicated. Alcohol must be avoided during treatment and for 3 days after discontinuation.");n("Metronidazole","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin  . Metronidazole  CYP2C9    Warfarin.","Increased anticoagulant effect of Warfarin. Metronidazole inhibits CYP2C9, a Warfarin metabolic pathway.","   .","Increased risk of severe hemorrhage.","  .    Warfarin  INR       Metronidazole.","Dose adjustment and monitoring. Warfarin dose must be reduced and INR monitored frequently upon initiation or discontinuation of Metronidazole.");n("Metronidazole","Ethanol (Alcohol)",e.DRUG_DRUG,i.MODERATE,"  . Metronidazole   .","Disulfiram-like reaction. Metronidazole inhibits acetaldehyde reduction.","    .","Nausea, vomiting, abdominal cramps, and flushing."," .      3  .","Avoid combination. Avoid alcohol during therapy and for 3 days after.");n("Metronidazole","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin. Metronidazole    CYP2C9    S-Warfarin (  ).","Potentiated Warfarin Effect. Metronidazole is a strong inhibitor of CYP2C9, the enzyme responsible for S-Warfarin (the most potent enantiomer) metabolism.","  .       INR     .","Severe Bleeding Risk. Leads to an acute and dangerous rise in INR and increased risk of life-threatening hemorrhage."," .        Warfarin  50%      INR.","Avoid Combination. If use is mandatory, Warfarin dose must be reduced by 50% or more, with daily INR monitoring.");n("Metronidazole","Lithium",e.DRUG_DRUG,i.MODERATE,"    Lithium.       Metronidazole     .","Reduced Renal Excretion of Lithium. The exact mechanism is unclear, but Metronidazole may decrease Lithium clearance.","    .           (     ).","Increased Lithium Concentration and Toxicity. Leads to elevated serum Lithium levels and signs of toxicity (e.g., tremor, confusion, ataxia).","    .            .","Monitor Serum Lithium Levels. Lithium levels must be monitored frequently, and its dose adjusted as needed.");n("Metronidazole","Alcohol",e.DRUG_FOOD,i.CONTRAINDICATED,"  acetaldehyde","Inhibits acetaldehyde breakdown","  -  -  - ","Severe flushing - nausea - vomiting - palpitations","   (  )    3  ","Alcohol is strictly prohibited (even small amounts) during treatment and for 3 days after");n("Metronidazole","Histamine-Rich Foods",e.DRUG_FOOD,i.MODERATE,"  ","Slowed histamine breakdown"," ","Headache and flushing","    ","Reduce intake of fermented and canned foods");n("Metronidazole","Lithium",e.DRUG_DRUG,i.HIGH,"   ","Reduced renal clearance of lithium.","  -   ","Lithium toxicity - tremor, confusion.","  ","Monitor lithium levels.");n("Metronidazole","Disulfiram",e.DRUG_DRUG,i.HIGH,"     ","Synergistic CNS effects.","   ","Acute psychosis, confusion.","  -   2 ","Avoid - separate by 2 weeks.");n("Metronidazole (Flagyl)","Alcohol (Kohol)",e.DRUG_FOOD,i.HIGH,"     (ALDH).  Metronidazole       .","Inhibition of Acetaldehyde Dehydrogenase (ALDH) Enzyme. Metronidazole interferes with alcohol metabolism, causing Acetaldehyde accumulation (Disulfiram-like reaction).","          .       .","Violent Vomiting, Facial Flushing, Tachycardia, Hypotension, Shortness of Breath. Severe and distressing Disulfiram-like reaction symptoms.","    (   )    3  .    .","Avoid ALL Alcohol-Containing Products (even alcoholic mouthwash) during therapy and for 3 days after discontinuation. The patient must be strictly warned.");n("Metronidazole (topical)","Alcohol",e.DRUG_DRUG,i.MODERATE,"  ","Potential disulfiram reaction."," ","Flushing and nausea."," ","Avoid alcohol.");n("Metronidazole ()","Phenobarbital",e.DRUG_DRUG,i.MODERATE,"   ","Metronidazole Failure. Reduced efficacy.","   .","   .","  .      .      .","  .      .      .");n("Metronidazole ()","Pentobarbital",e.DRUG_DRUG,i.MODERATE,"   ","Metronidazole Failure. Reduced efficacy.","   .","   .","  .      .      .","  .      .      .");n("Metronidazole ()","Secobarbital",e.DRUG_DRUG,i.MODERATE,"   ","Metronidazole Failure. Reduced efficacy.","   .","   .","  .      .      .","  .      .      .");n("Metronidazole ()","Disulfiram ()",e.DRUG_DRUG,i.HIGH,"      (ALDH)                 .","Both drugs inhibit aldehyde dehydrogenase (ALDH) enzyme, leading to acetaldehyde accumulation in the body, in addition to direct neurotoxic effects on the central nervous system.","              . (   -     )","Acute confusion, delirium, psychotic symptoms, consciousness disturbances, seizures, and may progress to coma. (Similar to disulfiram-alcohol reaction but with more severe central nervous system symptoms)","   .         .            .","Completely avoid this drug combination. If necessary, replace one drug with a safe alternative. If reaction occurs, discontinue both drugs immediately and provide supportive care for neurological symptoms.");n("Metyrapone - ","Cyproheptadine - ",e.DRUG_DRUG,i.MODERATE," ( )                11--.","Cyproheptadine (as a serotonin antagonist) may reduce the expected response to the Metyrapone test or therapy by counteracting the inhibition of the 11-beta-hydroxylase enzyme.","                   . (   )","Decreased diagnostic or therapeutic efficacy of Metyrapone, potentially leading to inaccurate test results or treatment failure for Cushing's syndrome. (Decreased Metyrapone therapeutic efficacy)","      7  10             .","Cyproheptadine must be discontinued for 7 to 10 days before performing the Metyrapone test or initiating Metyrapone therapy to ensure accurate results.");n("Metyrapone - ","Hydantoin (Phenytoin) -  ()",e.DRUG_DRUG,i.MODERATE," ()           ( CYP450)        .","Phenytoin (Hydantoin) is a potent inducer of hepatic enzymes (mainly CYP450) that metabolize Metyrapone, thereby increasing Metyrapone clearance rate in the body.","              (    11--  ). (   )","Decreased Metyrapone blood levels, resulting in reduced therapeutic or diagnostic efficacy (failure to adequately inhibit 11-beta-hydroxylase enzyme). (Decreased Metyrapone therapeutic efficacy)","    (  )             .","It is recommended to double the Metyrapone dose (titrate upwards) when co-administering with Phenytoin to compensate for the increased metabolism, with careful monitoring of clinical and lab results.");n("Mexiletine",er,e.DRUG_DRUG,i.MODERATE,": **   (CYP1A2)**.     .","Mechanism: **Hepatic enzyme induction (CYP1A2)**. Phenytoin and hydantoins induce Mexiletine metabolism."," : **  **      .","Clinical Significance: **Decreased Mexiletine levels** and loss of ventricular arrhythmia control.","  .       50%  .","Monitor ECG. Mexiletine dose increase by 50% or more may be required.");n("Mexiletine ()","Hydantoins () -   ",e.DRUG_DRUG,i.MODERATE," ()      ( CYP2D6 CYP1A2)             .","Phenytoin (Hydantoin) is a potent inducer of hepatic enzymes (mainly CYP2D6 and CYP1A2) that metabolize Mexiletine, thereby increasing Mexiletine clearance rate in the body.","            (      ). (   )","Decreased Mexiletine blood levels, resulting in reduced therapeutic efficacy (failure to adequately control cardiac arrhythmia). (Decreased Mexiletine therapeutic efficacy)","    (  )               .","It is recommended to increase the Mexiletine dose (titrate upwards) when co-administering with Phenytoin to compensate for the increased metabolism, with careful monitoring of ECG and Mexiletine blood levels.");n("Midazolam","Grapefruit Juice",e.DRUG_FOOD,i.HIGH," CYP3A4      50% -    ","Intestinal CYP3A4 inhibition increases bioavailability by 50% - reduced first-pass metabolism.","   ","Increased sedation and risk of over-sedation.","   ","Avoid grapefruit juice.");n("Midostaurin","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Midostaurin. Itraconazole    CYP3A4.","Increased Midostaurin concentration. Itraconazole is a strong inhibitor of CYP3A4.","    QT  .","Increased risk of QT prolongation and hematological toxicity.","  .    CYP3A4 .","Relative contraindication. Strong CYP3A4 inhibitors must be avoided.");n("Milk Thistle","CYP3A4 Substrates",e.DRUG_DRUG,i.MODERATE," CYP3A4 ","Potential CYP3A4 inhibition.","  ","Increased drug levels."," ","Use cautiously.");n("Minocycline","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Minocycline","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Minocycline","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Minocycline","Iron Supplements",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Minocycline","Dairy Products",e.DRUG_FOOD,i.MODERATE," .","Calcium Binding. Formation of insoluble complexes."," ."," ."," ."," .");n("Minocycline","Ferrous Sulfate",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      (3-4) .       .","      (3-4) .       .");n("Minocycline","Ferrous Gluconate",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      (3-4) .       .","      (3-4) .       .");n("Minocycline","Bismuth Salts ( ) -   ",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      .","      .");n("Minocycline - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE,"           .      ( Eubacterium lentum)           .             .         30-50          (AUC)        .","Minocycline alters the gut flora by killing bacteria that do not metabolize digoxin. Normally, certain gut bacteria (such as Eubacterium lentum) metabolize a significant portion of digoxin into inactive metabolites before absorption. Minocycline inhibition of these bacteria increases the absorption of unmetabolized digoxin from the intestines. This increase in absorption can reach 30-50%, enhancing digoxin bioavailability and area under the curve (AUC) without affecting its renal clearance or half-life.","        : 1.                (0.8-2.0 /). 2.    :          (     )   (xanthopsia). 3.               .","Increased digoxin plasma levels, which may lead to: 1. Increased risk of digoxin toxicity, especially if baseline levels are at the high end of the therapeutic range (0.8-2.0 ng/mL). 2. Appearance of digoxin toxicity symptoms: nausea, vomiting, anorexia, diarrhea, cardiac arrhythmias (particularly atrial arrhythmias and premature ventricular contractions), colored vision (xanthopsia). 3. In severe cases, it may lead to atrioventricular block or ventricular tachycardia.","1.  :          5-7     . 2.  :     25-35        . 3.  :     (    ). 4.   :          . 5.  :                . 6.  :           .","1. Therapeutic monitoring: Measure digoxin plasma levels before starting minocycline, and after 5-7 days of starting combination therapy. 2. Dose adjustment: Reduce the digoxin dose by 25-35% when initiating minocycline, especially in at-risk patients. 3. Clinical monitoring: Monitor for signs of digoxin toxicity (especially nausea and cardiac arrhythmias). 4. ECG monitoring: Perform regular electrocardiograms to detect any rhythm disturbances. 5. Minocycline alternatives: If possible, use other antibiotics that do not affect intestinal digoxin metabolism, such as penicillins or cephalosporins. 6. Drug education: Alert the patient to digoxin toxicity symptoms and instruct immediate reporting if they occur.");n("Minoxidil (topical)","Corticosteroids (topical)",e.DRUG_DRUG,i.MODERATE,"  ","Increased systemic absorption.","  ","Systemic side effects."," ","Use cautiously.");n("Mipomersen","NSAIDs (e.g., Ibuprofen)",e.DRUG_DRUG,i.MODERATE,"   .     .","Increased risk of renal toxicity. Additive nephrotoxic effects."," .","Kidney damage."," .      .","Close monitoring. Monitor renal function upon initiation of therapy.");n("Mirdametinib","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Mirdametinib. Fluconazole     CYP2C9  CYP3A4     Mirdametinib.","Increased Mirdametinib levels. Fluconazole is a strong inhibitor of both CYP2C9 and CYP3A4, involved in Mirdametinib metabolism.","             .","Increased risk of drug toxicity, including severe rash and elevated liver function tests (LFTs)."," .  .        .","Avoid Combination. Alternatives are preferred. If necessary, dose adjustment and intensive monitoring are required.");n("Mirikizumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Mirikizumab    (Monoclonal Antibody)  .","Increased risk of viral infection. Mirikizumab is an immunosuppressive monoclonal antibody.","      ( MMR    ).","Risk of developing infection from live vaccines (e.g., MMR or live influenza vaccine)."," .        Mirikizumab  3    .","Contraindicated. Live vaccines must be avoided during Mirikizumab treatment and for 3 months after the last dose.");n("Mirtazapine","Phenelzine (MAOI)",e.DRUG_DRUG,i.HIGH,"   .    .","Increased risk of Serotonin Syndrome. Synergistic effects of increased serotonin.","      .","Mental status changes, hyperthermia, tremor."," .   .     (Washout period)  .","Contraindicated. Avoid the combination. A washout period must be present between the two drugs.");n("Mirvetuximab Soravtansine (Elahere)","Folic Acid Supplements",e.DRUG_DRUG,i.MODERATE,": **    **.      .","Mechanism: **Folate receptor competition**. Supplements may reduce drug efficacy."," : **      **.","Clinical Significance: **Potential reduced ovarian cancer treatment efficacy**.","     .   .","Avoid high-dose folic acid supplements. Physiologic doses acceptable.");n("MMR Vaccine (Live)","Intravenous Immunoglobulin (IVIG)",e.DRUG_VACCINE,i.HIGH,"                 .","IVIG contains ready-made antibodies that can neutralize the vaccine virus before it can induce an immune response.","       .","Immunological failure to generate the necessary protective antibodies."," .    **11 **   IVIG .","Special action. Postpone vaccination until **11 months** after high-dose IVIG.");n("Mobocertinib","Posaconazole",e.DRUG_DRUG,i.HIGH,"  Mobocertinib. Posaconazole    CYP3A4      Mobocertinib.","Increased Mobocertinib concentration. Posaconazole is a strong CYP3A4 inhibitor, the primary metabolic pathway for Mobocertinib.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .    CYP3A4 .","Contraindicated. Strong CYP3A4 inhibitors must be avoided.");n("Mobocertinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Mobocertinib. Rifampin    CYP3A4    Mobocertinib.","Decreased Mobocertinib efficacy. Rifampin is a strong inducer of CYP3A4, a Mobocertinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Mobocertinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Mobocertinib. Itraconazole    CYP3A4    Mobocertinib.","Increased Mobocertinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Mobocertinib metabolic pathway.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .    Mobocertinib     CYP3A4 .","Dose adjustment. Mobocertinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Mobocertinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Mobocertinib.       CYP3A4  .","Increased Mobocertinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Mobocertinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Mobocertinib. Rifampin    CYP3A4.","Decreased Mobocertinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Mobocertinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Mobocertinib. Voriconazole    CYP3A4.","Increased Mobocertinib concentration. Voriconazole is a strong inhibitor of CYP3A4.","    QT .","Increased risk of QT prolongation and diarrhea."," .    Mobocertinib  .","Dose adjustment. Mobocertinib dose must be significantly reduced.");n("Modafinil","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Modafinil   CYP3A4.","Decreased oral contraceptive concentration. Modafinil induces CYP3A4 enzymes.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .          .","Relative contraindication. An additional non-hormonal or alternative contraceptive method must be used.");n("Moexipril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Molnupiravir","Warfarin",e.DRUG_DRUG,i.MODERATE,": **   **.    .","Mechanism: **Potential metabolic interference**. Mechanism not fully elucidated."," : **  INR**    .","Clinical Significance: **INR fluctuations** and bleeding/clotting risk."," INR      Molnupiravir.","Monitor INR frequently during and after Molnupiravir therapy.");n("Molnupiravir","Pregnancy ()",e.DRUG_DISEASE,i.CONTRAINDICATED,": **  **. Molnupiravir    .","Mechanism: **Potential fetal toxicity**. Molnupiravir may cause genetic mutations."," : ** ** .","Clinical Significance: **Potential birth defects**.","   .       .","Contraindicated in pregnancy. Use effective contraception during and after treatment.");n("Momelotinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Momelotinib. Carbamazepine    CYP3A4    Momelotinib.","Decreased Momelotinib concentration. Carbamazepine is a strong inducer of CYP3A4, a Momelotinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Momelotinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Momelotinib.       CYP3A4  .","Increased Momelotinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      .","Increased risk of side effects, especially hemorrhage and infection."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Montelukast","Phenobarbital",e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4  CYP2C9)**.                 .","Mechanism: **Hepatic enzyme induction (CYP3A4 and CYP2C9)**. Phenobarbital is a potent inducer of hepatic enzymes, significantly accelerating montelukast metabolism and reducing its blood levels."," : **  **   (   40%)    **    **          ( )   .","Clinical Significance: **Decreased montelukast blood levels** (by up to 40%), leading to **loss of asthma symptom control**, increased exacerbation frequency, increased need for rescue bronchodilator use (e.g., albuterol), and worsening nocturnal symptoms.","     (  ACT - Asthma Control Test). **     **        (    ).           (   ).    (PEF and FEV1) .","Monitor asthma control closely (using ACT - Asthma Control Test). **Montelukast dose may need to be increased** or additional asthma controller therapy added (e.g., increased inhaled corticosteroid dose). Consider alternative anticonvulsant that does not strongly induce enzymes (e.g., levetiracetam or lamotrigine). Monitor pulmonary function (PEF and FEV1) regularly.");n("Montelukast","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Caffeine",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Grapefruit Juice",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Montelukast","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Moricizine","Cimetidine",e.DRUG_DRUG,i.MODERATE,": **  **.      .","Mechanism: **Hepatic metabolism inhibition**. Cimetidine inhibits hepatic metabolism of Moricizine."," : **  **    ( PR  QRS).","Clinical Significance: **Increased Moricizine levels** and risk of cardiotoxicity (PR and QRS prolongation).","      .   .","Reduce Moricizine dose or switch Cimetidine to Ranitidine. Monitor ECG.");n("Moricizine - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       P450   CYP2D6 CYP3A4     .               40-60     .               .     24-48       2-3    .","Cimetidine is a non-selective inhibitor of hepatic cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, responsible for the primary metabolism of moricizine. Cimetidine reduces moricizine metabolism, increasing its plasma concentration by up to 40-60%, and prolonging its biological half-life. Additionally, cimetidine reduces hepatic blood flow, further decreasing moricizine clearance. This effect begins within 24-48 hours of starting therapy and subsides within 2-3 days after discontinuing cimetidine.","              : 1.        I:   PR QRS   . 2.    :        . 3.     :   .                         .","Increased moricizine plasma levels, leading to enhancement of its therapeutic and toxic effects, including: 1. Increased Class I antiarrhythmic effects: Prolongation of PR and QRS intervals on ECG. 2. Increased risk of cardiotoxicity: Atrioventricular block, heart failure, hypotension. 3. Worsening of non-cardiac side effects: Dizziness, headache, nausea. These effects are more common and severe in elderly patients, those with impaired liver function, or those taking high doses of moricizine.","1.    :      .        . 2.   :    H2            . 3.    :     30-50    . 4.   :    (ECG)        PR QRS. 5.  :    (    )  . 6.    :         3-5    .","1. Avoid combination if possible: It is preferable not to combine moricizine and cimetidine. Seek a cimetidine alternative that does not inhibit liver enzymes. 2. Use cimetidine alternatives: Prefer other H2 receptor antagonists that do not significantly inhibit liver enzymes, such as famotidine or ranitidine. 3. If combination is necessary: Reduce the moricizine dose by 30-50% when initiating cimetidine therapy. 4. Close cardiac monitoring: Monitor ECG before and after starting cimetidine, watching for PR and QRS interval prolongation. 5. Clinical monitoring: Monitor vital signs (blood pressure, heart rate) and toxicity symptoms. 6. Adjustment upon cimetidine discontinuation: When discontinuing cimetidine, gradually increase the moricizine dose over 3-5 days to the previous level.");n("Moricizine - ","Theophylline - ",e.DRUG_DRUG,i.LOW,"         .                  .                  .                   .","There is no significant documented pharmacokinetic interaction between moricizine and theophylline. However, there may be a potential pharmacodynamic interaction due to the different effects of both drugs on the heart and central nervous system. Moricizine may cause slight tachycardia, while theophylline may cause arrhythmias at high doses. It is advisable to review the use of bronchodilators in general when prescribing antiarrhythmics, as some may interact with moricizine.","    : 1.      . 2.            . 3.           .            .","Non-specific effect that may include: 1. Minor changes in heart rate. 2. Potential increased risk of arrhythmia, especially at high doses. 3. Potential exacerbation of central nervous system side effects such as insomnia or anxiety. The risk is generally low and requires monitoring only in high-risk cases.","1.   :        . 2.  regimen :          . 3.   :       . 4.  :        . 5.  :           . 6.          .","1. Routine clinical monitoring: Regularly monitor heart rate and blood pressure. 2. Review treatment regimen: Assess the necessity of both drugs and consider alternatives if needed. 3. Avoid high doses: Use the lowest effective dose of both drugs. 4. Symptom monitoring: Watch for any new symptoms such as palpitations or dizziness. 5. Drug education: Inform the patient to report any unusual symptoms to the healthcare provider. 6. Dose adjustment is usually not required unless clinical symptoms appear.");n("Morphine - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"  ( )      P450   CYP3A4     P-glycoprotein.         ( UGT enzymes)  ( CYP3A4).                  (AUC)    40-60.         M6G (morphine-6-glucuronide).","Rifamycins (rifampin, rifabutin) act as potent and broad inducers of hepatic cytochrome P450 enzymes, especially CYP3A4, as well as drug transporters like P-glycoprotein. Morphine undergoes extensive hepatic metabolism via glucuronidation (by UGT enzymes) and oxidation (by CYP3A4). Rifamycin induction increases morphine metabolism and excretion, reducing its plasma concentration and area under the curve (AUC) by up to 40-60%. It may also reduce the efficacy of active metabolites like M6G (morphine-6-glucuronide).","         : 1.         . 2.         . 3.         . 4.                    .","Marked decrease in morphine plasma levels, leading to: 1. Reduced analgesic efficacy and failure to control pain. 2. Need for higher morphine doses to achieve required pain relief. 3. Shortened duration of analgesic effect, potentially requiring more frequent dosing. 4. In patients with acute or chronic pain, this may lead to unnecessary suffering and deterioration in quality of life.","1.   :          . 2.  :     50-100            . 3.   :             ( )   (). 4.   :         50-75   1-2   . 5.  :               . 6.   :    (    )    .","1. Close clinical monitoring: Closely monitor pain relief when starting or stopping rifamycins. 2. Dose adjustment: Increase the morphine dose by 50-100% when starting the rifamycin, being prepared for further adjustments based on pain response. 3. Use of alternative analgesics: Consider using other analgesics not affected by enzyme induction, such as fentanyl (with adjusted doses) or methadone (with caution). 4. Post-discontinuation monitoring: When discontinuing the rifamycin, gradually reduce the morphine dose by 50-75% over 1-2 weeks to avoid toxicity. 5. Drug education: Inform the patient and caregiver about the potential decrease in analgesic efficacy and instruct them to report inadequate pain control. 6. Multimodal analgesia: Use adjuvant analgesics (NSAIDs, gabapentin) to reduce reliance on opioids.");n("Mosunetuzumab","Lenalidomide",e.DRUG_DRUG,i.HIGH,"    (CRS).        .","Exacerbation of Cytokine Release Syndrome (CRS). Both agents have activating or modulating immune effects.","    CRS          .","Increased risk and severity of life-threatening CRS, especially during the dose escalation phase."," .              .","Careful management. Initiation of other immunomodulators should be delayed or used with extreme caution under intensive supervision.");n("Mosunetuzumab","Cyclosporine",e.DRUG_DRUG,i.HIGH,"   CYP450. Mosunetuzumab        CYP450 ( CYP3A4).","Altered CYP450 substrate levels. Mosunetuzumab causes cytokine release, altering CYP450 enzyme activity (especially CYP3A4).","       ( Cyclosporine)        .","Altered levels of Narrow Therapeutic Index drugs (like Cyclosporine), increasing the risk of toxicity or loss of efficacy."," .           .","Level monitoring. Levels of Narrow Therapeutic Index drugs must be closely monitored and dose adjusted.");n("Mosunetuzumab - ","Fentanyl - ",e.DRUG_DRUG,i.HIGH,"              CYP3A4     ","Mosunetuzumab causes cytokine release syndrome leading to transient inhibition followed by subsequent induction of hepatic CYP3A4 enzymes responsible for Fentanyl metabolism","       (   200%        60%  )         ","Significant and unpredictable fluctuations in Fentanyl levels (up to 200% increase during enzyme inhibition or up to 60% decrease during induction), leading to alternating between respiratory toxicity and analgesic failure","       48     -         -          ","Intensive monitoring of respiratory function and pain level for 48 hours after Mosunetuzumab dose - dynamic adjustment of Fentanyl dose based on clinical status - consider alternative opioids with wider therapeutic window");n("Mosunetuzumab (Bispecific Antibody)","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  . Mosunetuzumab       .","Increased risk of infection. Mosunetuzumab depletes B-cells and affects immune response.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Mosunetuzumab (Lunsumio)","Tumor Lysis Syndrome Risk",e.DRUG_DISEASE,i.HIGH,": **   **.    .","Mechanism: **Rapid tumor cell lysis**. Tumor lysis syndrome risk."," : **     **   .","Clinical Significance: **Hyperkalemia and hyperphosphatemia** with acute renal failure."," .  .  Allopurinol  Rasburicase.","Prophylactic hydration. Monitor electrolytes. Use Allopurinol or Rasburicase.");n("Mounjaro (Tirzepatide)","Ethanol (Alcohol)",e.DRUG_FOOD,i.MODERATE,"    .      .","Increased risk of hypoglycemia. Alcohol enhances the glucose-lowering effect.","   .","Severe hypoglycemia."," .           .","Patient education. The patient must limit alcohol intake and monitor blood sugar closely.");n("Moxifloxacin","Amiodarone",e.DRUG_DRUG,i.HIGH,"    QTc.     QTc.","Increased risk of QTc prolongation. Additive QTc prolonging effect.","       (Torsades de Pointes).","Risk of serious ventricular arrhythmia (Torsades de Pointes)."," .   .","Contraindicated. Avoid the combination.");n("Moxifloxacin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Moxifloxacin","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Moxifloxacin","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Moxifloxacin","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Moxifloxacin","Iron Supplements",e.DRUG_DRUG,i.MODERATE,"  -   ","Iron-quinolone complex formation prevents absorption.","    ","Decreased moxifloxacin plasma levels.","   4    ","Take iron 4 hours after antibiotic.");n("Mupirocin","Other topical antibiotics",e.DRUG_DRUG,i.LOW,"  ","Potential local interactions.","    ","Skin irritation, contact dermatitis.","     ","Avoid concurrent application on the same area.");n("Mycophenolate","Food",e.DRUG_FOOD,i.MODERATE,"            .   (Cmax)      40%         .     (AUC) -      -    (15% ).               .","Food affects mycophenolate absorption moderately but unevenly across pharmacokinetic parameters. Maximum concentration (Cmax) decreases significantly by up to 40%, meaning peak blood concentration is lower. However, area under curve (AUC) - representing total drug exposure - decreases less (only 15%). This difference indicates food delays and slows absorption more than reducing total absorbed amount.","                   .                     .","Moderate decrease in drug bioavailability, especially in peak concentrations that may be important in initial hours post-dose. This variability in levels may affect immunosuppressive efficacy, particularly during critical post-transplant period or during rejection episode treatment.","       (     )              .         (   )              .        .","Mycophenolate is strongly preferred on empty stomach (one hour before or two hours after food) to ensure stable and predictable blood levels, especially in transplant patients where precision is required. However, in case of gastrointestinal intolerance (nausea, diarrhea, abdominal pain), it may be taken with light food to improve adherence, ensuring consistent daily timing. Physician should be informed if administration pattern changes.");n("Mycophenolate","Antacids",e.DRUG_DRUG,i.MODERATE," ","Reduced absorption.","  ","Reduced mycophenolate efficacy.","  ","Separate doses by 2 hours.");n("Mycophenolate Mofetil","Cholestyramine",e.DRUG_DRUG,i.HIGH,"  Mycophenolate Mofetil.         Mycophenolate.","Decreased Mycophenolate Mofetil concentration. Cholestyramine reduces the enterohepatic recirculation of Mycophenolate.","          .","Reduced drug plasma concentration, leading to failure of rejection prevention.","  .       Mycophenolate .","Relative contraindication. Avoid the combination or carefully monitor Mycophenolate levels.");n("Mycophenolate Mofetil -  ","Ferrous Sulfate -  ",e.DRUG_DRUG,i.MODERATE,"             (MPA) .           (Fe)       (chelation)      .         .           50-90            MPA      (AUC).","Mycophenolate mofetil contains an ester group that is hydrolyzed in the liver to form the active mycophenolic acid (MPA). Iron salts such as ferrous sulfate contain ferrous cations (Fe) that can form non-absorbable complexes (chelation) with mycophenolate mofetil in the gastrointestinal tract. This significantly reduces drug dissolution and absorption. The bioavailability of mycophenolate mofetil can decrease by up to 50-90% when taken with iron salts, substantially reducing MPA plasma concentration and area under the curve (AUC).","      (MPA)     : 1.           . 2.        . 3.          . 4.           . 5.      MPA.","Sharp decrease in mycophenolic acid (MPA) plasma levels, leading to: 1. Reduced immunosuppressive efficacy and increased risk of graft rejection in transplant patients. 2. Increased risk of treatment failure in autoimmune diseases. 3. Need for higher mycophenolate mofetil doses to achieve therapeutic effect. 4. Increased risk of side effects if the dose is increased without proper monitoring. 5. Therapeutic instability and fluctuation in MPA levels.","1.   :          4-6     . 2.  :   MPA   (  )     . 3.  :              . 4.  :      25-50       MPA  . 5.  :                  . 6.  :          .","1. Mandatory timing separation: Take mycophenolate mofetil at least 2 hours before or 4-6 hours after taking ferrous sulfate. 2. Therapeutic monitoring: Monitor MPA plasma levels (peak and trough) before and after starting iron supplements. 3. Clinical monitoring: Monitor for signs of graft rejection in transplant patients or disease activity in autoimmune diseases. 4. Dose adjustment: Increase the mycophenolate mofetil dose by 25-50% if necessary based on MPA levels and clinical response. 5. Iron alternatives: Consider using other iron formulations such as intravenous ferric carboxymaltose for patients requiring long-term iron therapy. 6. Drug education: Educate the patient about the importance of timing separation and strict adherence to dosing instructions.");n("Mycophenolate Mofetil -  ","Ferrous Gluconate -  ",e.DRUG_DRUG,i.MODERATE,"                         (Fe)           .             .        40-80      .  MPA                 .","Although ferrous gluconate contains less elemental iron compared to ferrous sulfate, it still contains ferrous cations (Fe) capable of forming chelate complexes with mycophenolate mofetil in the gastrointestinal tract. Iron ions act as potent chelating agents, reducing the dissolution and absorption of mycophenolate mofetil. Drug bioavailability can decrease by 40-80% depending on the iron dose and timing of administration. The resulting MPA remains at risk of failing to achieve the therapeutic levels required for graft rejection prevention or control of autoimmune diseases.","       (MPA)    : 1.         . 2.           . 3.       . 4.           . 5.            .","Significant reduction in therapeutic exposure to mycophenolic acid (MPA), which may lead to: 1. Inadequate immunosuppression and increased risk of organ graft rejection. 2. Worsening of autoimmune diseases such as lupus erythematosus or lupus nephritis. 3. Reduced clinical response rate in nephrotic syndrome. 4. Need for frequent adjustments in mycophenolate mofetil dose to maintain efficacy. 5. Increased treatment costs due to the need for higher doses or more frequent monitoring.","1.   :          4-6    . 2.   MPA:   MPA           ( 1-3.5 /  ). 3.   :            . 4.  :      25-50      MPA       . 5.   :          . 6.  :         .","1. Strict timing separation: Administer mycophenolate mofetil at least 2 hours before or 4-6 hours after ferrous gluconate. 2. MPA level monitoring: Measure MPA plasma levels during combination therapy and ensure they remain within the therapeutic range (typically 1-3.5 mcg/mL for trough level). 3. Regular clinical assessment: Assess graft function or autoimmune disease activity weekly initially. 4. Dose adjustment: Increase the mycophenolate mofetil dose by 25-50% if low MPA levels or clinical signs indicate inadequate therapy. 5. Iron management alternatives: Assess the feasibility of using intravenous iron preparations to completely avoid the intestinal interaction. 6. Interaction documentation: Document the dose separation plan and patient response in the medical record.");n("Mycophenolate Mofetil -  ","Tacrolimus - ",e.DRUG_DRUG,i.MODERATE,"                (Enterohepatic Recirculation)            .","The mechanism is not entirely clear, but data suggest that Tacrolimus may alter the enterohepatic recirculation of Mycophenolate or affect its transporters, leading to increased free concentrations in the blood.","   (   - MPA)              . (  )","Increased plasma concentrations of Mycophenolate (specifically Mycophenolic Acid - MPA), which heightens the risk of its toxicity, especially bone marrow suppression and gastrointestinal effects. (Increased Mycophenolate toxicity)","     (MPA)           .         .","Monitor Mycophenolic Acid (MPA) concentrations closely, especially when starting, stopping, or changing Tacrolimus dose. Adjust the Mycophenolate dose as directed to lower the risk of toxicity.");n("Nadolol","Insulin",e.DRUG_DRUG,i.HIGH,"   ","Masking Hypoglycemia. Adrenergic warning signs of hypoglycemia are blunted.","     ","     ","   ","   ");n("Nadolol","Barbiturates",e.DRUG_DRUG,i.LOW,"    .            CYP  .","No significant metabolic interaction. Nadolol is primarily excreted renally and is not extensively metabolized by CYP enzymes.","       .           (CNS)     .","No significant clinical effect on Nadolol concentration. May have additive CNS depressant effects if Barbiturate dose is high.","     .        .","Monitor blood pressure and heart rate. Dose adjustment is not typically required due to this interaction.");n("Nadolol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Nadolol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"  (Pharmacodynamic Synergy).            (         ).              .","Pharmacodynamic Synergy. Both drugs lower blood pressure through different mechanisms (Nadolol reduces heart rate and cardiac output, Hydralazine causes vasodilation). Nadolol is renally excreted, making mutual metabolic inhibition clinically insignificant.","            (Severe Hypotension)   (Bradycardia)       .","Additive hypotensive effect, increasing the risk of severe hypotension and bradycardia (from Nadolol), especially upon initiation.","      .                .","Closely monitor blood pressure and heart rate. Start with low doses of both agents, or reduce the dose of one drug upon co-administration to avoid hypotension.");n("Nadolol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Nadolol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic Hypotension. Combined effects lead to significant blood pressure drop.","     ","     ","     ","     ");n("Nadolol ()","Lidocaine ()",e.DRUG_DRUG,i.MODERATE,"           .","Lidocaine Toxicity. Metabolic inhibition and additive cardiac depression.","              .","              .","       .         .","       .         .");n("Naltrexone/Bupropion (Contrave)","Selegiline (MAOI)",e.DRUG_DRUG,i.HIGH,"      .      .","Increased risk of hypertensive crisis and seizures. Synergistic effects on norepinephrine and dopamine.","   .","Severe hypertension."," .   .   14    MAOIs   Bupropion.","Contraindicated. Avoid the combination. Must wait 14 days after discontinuing MAOIs before starting Bupropion.");n("Nandrolone","Warfarin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Nandrolone","Heparin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Nandrolone","Enoxaparin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Nandrolone","Dabigatran",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Nandrolone","Rivaroxaban",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Nandrolone - ","Apixaban - ",e.DRUG_DRUG,i.HIGH," ( )        K (    )              .                .    Xa .               .","Nandrolone (an anabolic steroid) inhibits synthesis of vitamin K-dependent clotting factors (Factors II, VII, IX, and X) by causing cholestasis and hepatocyte damage, leading to prolonged prothrombin time. Simultaneously, it stimulates platelet production and enhances aggregation, creating a hypercoagulable state. Apixaban directly inhibits factor Xa. This dual disruption of the coagulation system creates an unstable condition with concurrent bleeding and thrombosis risks.","      (    )  (    ).              .        .","Unpredictable and concurrent risk of severe bleeding (gastrointestinal, intracranial, intramuscular) and thrombosis (deep vein thrombosis, pulmonary embolism). Rapid fluctuations between hemorrhagic and thrombotic states may occur, making clinical management difficult and hazardous. Worsening hepatotoxicity may increase apixaban concentrations.","     .     :     (AST, ALT, )   (PT) .      .           .                .","Avoid combination completely if possible. If absolutely necessary: Monitor liver functions weekly (AST, ALT, bilirubin), prothrombin time (PT), and hematocrit. Close clinical monitoring for signs of bleeding and thrombosis. Avoid use in patients with pre-existing liver disease. Consider alternative anticoagulants less dependent on hepatic metabolism such as low molecular weight heparin.");n("Nandrolone","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  ","Increased cyclosporine levels."," ","Cyclosporine toxicity.","  ","Monitor cyclosporine levels.");n("Naproxen","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Naproxen","Peptic Ulcer",e.DRUG_DISEASE,i.HIGH,".","Irritation. Direct mucosal injury or chemical irritation.",".","Hemorrhage. Bleeding.",".",".");n("Naproxen","Heart Failure",e.DRUG_DISEASE,i.MODERATE," .","Fluid Retention. Sodium and water retention exacerbates volume overload."," .","Worsening Failure. Exacerbation of condition.",".",".");n("Naproxen","Peptic Ulcer ( )",e.DRUG_DISEASE,i.HIGH,"     .","Prostaglandin Inhibition. COX inhibition depletes cytoprotective gastric prostaglandins, increasing ulcer risk.","      .","GI Bleeding & Perforation. Severe gastric injury.","         (PPIs) .","         (PPIs) .");n("Natalizumab","Azathioprine",e.DRUG_DRUG,i.HIGH,"          (PML).","Increased risk of Progressive Multifocal Leukoencephalopathy (PML).","           .","Increased immunosuppression, raising the risk of rare and severe viral infection."," .   .","Contraindicated. Avoid the combination.");n("Nebivolol","Verapamil (IV)",e.DRUG_DRUG,i.HIGH," .","Cardiac Depression. Negative inotropic and chronotropic effects."," .","Cardiac Arrest. Asystole or fatal arrhythmia.",".",".");n("Nebivolol","Diabetes",e.DRUG_DISEASE,i.HIGH,"   ","Masking Hypoglycemia. Adrenergic warning signs of hypoglycemia are blunted.","      ","      ","     ","     ");n("Nebivolol","Diabetes ()",e.DRUG_DISEASE,i.MODERATE,"    (  ).","Masking Hypoglycemia Symptoms. Tremors and palpitations associated with hypoglycemia are blocked.","      (Hypoglycemia Unawareness)    .","      (Hypoglycemia Unawareness)    .","          .","          .");n("Nebivolol","Asthma ()",e.DRUG_DISEASE,i.HIGH,"  -2     .","Beta-2 Blockade. Non-selective beta-blockade causes bronchoconstriction in susceptible patients.","    .","    .","    .    ( Bisoprolol)  .","    .    ( Bisoprolol)  .");n("Nebivolol","Asthma",e.DRUG_DISEASE,i.HIGH," .","Bronchoconstriction. Narrowing of the airways."," ."," .",".",".");n("Nebivolol","Calcium Channel Blockers",e.DRUG_DRUG,i.MODERATE,"   ","Additive cardiac effect.","   ","Bradycardia, hypotension.","   ","Monitor vital signs regularly.");n("Nefazodone - ","MAOIs -   MAO",e.DRUG_DRUG,i.CONTRAINDICATED,"           ","Massive serotonergic elevation due to combined serotonin enhancement and MAO inhibition","               ","Severe serotonin syndrome with hyperthermia, tremor, seizures, and potential fatality","        14     ","Avoid combination entirely; allow at least 14-day washout period");n("Nefazodone - ","Triazolam - ",e.DRUG_DRUG,i.CONTRAINDICATED,"   CYP3A4      ","Potent CYP3A4 inhibition causing marked elevation of Triazolam plasma levels","      ","Severe respiratory depression, extreme sedation, and loss of consciousness","        CYP3A4","Completely contraindicated  replace with benzodiazepine not metabolized by CYP3A4");n("Nefazodone - ","Cisapride - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       CYP3A4","Massive cisapride accumulation due to CYP3A4 inhibition","     QT prolongation   torsades de pointes","Severe QT prolongation leading to torsades de pointes","       ","Avoid completely due to risk of fatal arrhythmias");n("Nefazodone - ","Pimozide - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Inhibition of pimozide metabolism resulting in excessive levels","    QT    ","Dangerous arrhythmias, QT prolongation, potential sudden cardiac death","       ","Absolutely contraindicated  choose an alternative antipsychotic");n("Nefazodone - ","Carbamazepine - ",e.DRUG_DRUG,i.HIGH," :   CYP       ","Complex bidirectional interaction: carbamazepine induces CYP lowering nefazodone levels while nefazodone inhibits other metabolic pathways","         ","Loss of antidepressant effect and increased mutual hepatotoxicity","           ","Avoid if possible  or monitor liver function and drug levels closely");n("Nefazodone - ","Statins (Simvastatin, Atorvastatin, Lovastatin)",e.DRUG_DRUG,i.HIGH,"   CYP3A4      ","Strong CYP3A4 inhibition greatly increasing statin levels","  (Rhabdomyolysis)   CPK    ","Rhabdomyolysis, elevated CPK, possible acute renal failure","  Pravastatin  Rosuvastatin     CYP3A4","Use alternatives such as Pravastatin or Rosuvastatin");n("Nefazodone - ","Benzodiazepines (Alprazolam, Midazolam)",e.DRUG_DRUG,i.HIGH," CYP3A4    ","CYP3A4 inhibition causes elevated benzodiazepine levels","        ","Severe sedation, cognitive impairment, respiratory depression","      Lorazepam / Oxazepam","Reduce dose significantly or switch to Lorazepam/Oxazepam");n("Nefazodone - ","SSRIs / SNRIs",e.DRUG_DRUG,i.MODERATE,"    ","Adds synergistic serotonergic effect","      ","Risk of serotonin syndrome  sweating, tremor, seizures","       ","Close monitoring  avoid high doses");n("Nefazodone - ","Tramadol - ",e.DRUG_DRUG,i.HIGH,"  +  CYP    ","Increased serotonin plus CYP inhibition elevating tramadol levels","  +   ","Serotonin syndrome and increased seizure risk","     ","Avoid combination  use alternative analgesic");n("Nefazodone - ","Sildenafil / Tadalafil",e.DRUG_DRUG,i.MODERATE," CYP3A4    PDE-5  ","CYP3A4 inhibition markedly increases PDE-5 inhibitor levels","     ","Severe hypotension, dizziness, possible syncope","     ","Start at very low doses and monitor blood pressure");n("Nelfinavir - ","Ergot Alkaloids -  ",e.DRUG_DRUG,i.HIGH,"       CYP3A4        ( ).","Nelfinavir is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which is primarily responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine).","             (Ergotism)     (Vasospasm)      .","Dangerous increase in Ergot Alkaloids blood concentrations, leading to acute Ergotism, which includes vasoconstriction (Vasospasm) and ischemia that may threaten limb viability.","     ().     .","This drug combination is absolutely contraindicated (forbidden). This co-administration must be avoided entirely.");n("Neomycin","Vancomycin",e.DRUG_DRUG,i.HIGH,"  .","Nephrotoxicity & Ototoxicity. Synergistic damage to kidney and inner ear.","  .","  ."," ."," .");n("Neomycin","Cephalexin",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Neomycin","Ceftriaxone",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Neomycin","Cefuroxime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Neomycin","Cefixime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Neomycin","Cefotaxime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Neomycin","Furosemide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Neomycin","Torsemide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Neomycin","Bumetanide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Neomycin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neomycin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Neratinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Neratinib. Phenytoin    CYP3A4    Neratinib.","Decreased Neratinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Neratinib metabolic pathway.","          .","Severe decrease in drug concentration, leading to failure of targeted therapy."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Neratinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Neratinib. PPIs        Neratinib.","Decreased Neratinib concentration. PPIs reduce gastric acidity, which is necessary for Neratinib absorption.","            .","Severe decrease in drug plasma concentration, leading to failure of targeted therapy."," .       (PPIs)   Neratinib.","Avoid Combination. Proton pump inhibitors (PPIs) must be avoided concomitantly with Neratinib.");n("Neratinib","Famotidine",e.DRUG_DRUG,i.HIGH,"  Neratinib.  H2        Neratinib.","Decreased Neratinib concentration. H2 Blockers reduce gastric acidity, which is necessary for Neratinib absorption.","           .","Severe decrease in drug plasma concentration, leading to treatment failure."," .    H2.     3         .","Avoid Combination. H2 Blockers must be avoided. If use is essential, separate by at least 3 hours.");n("Neratinib","Aluminum Hydroxide",e.DRUG_DRUG,i.HIGH,"  Neratinib.          Neratinib.","Decreased Neratinib concentration. Antacids raise gastric pH, which is necessary for Neratinib absorption.","         .","Reduced drug plasma concentration, leading to treatment failure."," .     Neratinib    3   .","Avoid simultaneous use. Separate Neratinib and antacid administration by at least 3 hours.");n("Neratinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Neratinib. Itraconazole    CYP3A4    Neratinib.","Increased Neratinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Neratinib metabolic pathway.","     .","Increased risk of diarrhea and other side effects."," .    Neratinib     CYP3A4 .","Dose adjustment. Neratinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Neratinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Neratinib. Rifampin    CYP3A4    Neratinib.","Decreased Neratinib concentration. Rifampin is a strong inducer of CYP3A4, a Neratinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Netupitant/Palonosetron","Rifampin",e.DRUG_DRUG,i.HIGH,"  Netupitant. Rifampin    CYP3A4    Netupitant.","Decreased Netupitant efficacy. Rifampin is a strong inducer of CYP3A4, a Netupitant metabolic pathway.","                .","Reduced drug plasma concentration, leading to failure of chemotherapy-induced nausea and vomiting control."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Netupitant/Palonosetron","Rifampin",e.DRUG_DRUG,i.HIGH,"  Netupitant. Rifampin    CYP3A4    Netupitant.","Decreased Netupitant concentration. Rifampin is a strong inducer of CYP3A4, a Netupitant metabolic pathway.","           .","Reduced antiemetic efficacy, leading to failure to control nausea and vomiting."," .   .","Contraindicated. Avoid the combination.");n("Nevirapine","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Nevirapine    CYP3A4    .","Decreased oral contraceptive concentration. Nevirapine is a strong inducer of CYP3A4, a hormone metabolic pathway.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .          .","Relative contraindication. An additional non-hormonal or alternative contraceptive method must be used.");n("Nicardipine","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"  (CYP3A4).     .","Metabolic Inhibition (CYP3A4). Ciprofloxacin is a moderate CYP3A4 inhibitor.","            (Hypotension) .","Increased Nicardipine plasma concentration, leading to a higher risk of hypotension and dizziness.","       .       .","Monitor blood pressure and signs of hypotension closely. A Nicardipine dose adjustment may be necessary.");n("Nicardipine","Macrolides (e.g., Clarithromycin)",e.DRUG_DRUG,i.HIGH,"   (CYP3A4).     .","Potent Metabolic Inhibition (CYP3A4). Macrolides (like Clarithromycin) are strong inhibitors.","              (Severe Hypotension) .","Substantial increase in Nicardipine plasma levels, leading to a high risk of severe hypotension and shock.","   .      CYP3A4 ( )      .","Generally Avoid. Consider a Macrolide alternative that does not inhibit CYP3A4 (e.g., Azithromycin), or ensure intensive BP monitoring and Nicardipine dose reduction.");n("Nicardipine","Nefazodone",e.DRUG_DRUG,i.HIGH,"   (CYP3A4).      .","Potent Metabolic Inhibition (CYP3A4). Nefazodone is a strong inhibitor of Nicardipine metabolism.","                (Syncope).","Sharp increase in Nicardipine concentration, greatly increasing the risk of severe hypotension and syncope.","     .                .","Generally Avoid. If unavoidable, a significant Nicardipine dose reduction is mandatory with rigorous BP monitoring.");n("Nicardipine","Metoclopramide",e.DRUG_DRUG,i.MODERATE,"   ( CYP2D6/3A4)  .","Inhibition of Metoclopramide metabolism (via CYP2D6/3A4) by Nicardipine.","              (EPS).","Increased Metoclopramide levels, raising the risk of neurological side effects, especially Extrapyramidal Symptoms (EPS).","       .       .","Monitor the patient for signs of EPS. A reduction in the Metoclopramide dose may be necessary.");n("Nicardipine","Sulfonamides (e.g., Sulfamethoxazole/Trimethoprim)",e.DRUG_DRUG,i.MODERATE,"        ( CYP2C9/3A4).","Additive Hypotensive Effects and Potential Metabolic Effect.","            .","Enhanced blood pressure-lowering effect, increasing the risk of symptomatic hypotension.","         .","Monitor blood pressure closely, especially during the first few weeks of coadministration.");n("Nicardipine","Probucol (Prubocol)",e.DRUG_DRUG,i.LOW,"   .       QTc.      QTc.","Potential Pharmacodynamic interaction. Probucol is known to prolong the QTc interval. Nicardipine is not a known QTc prolonging agent.","       .    QTc      .","No major drug level change is expected. Monitor the QTc interval on ECG in at-risk patients.","        .         .","Clinically monitor the patient for signs of arrhythmia. Use with caution in patients with other risk factors.");n("Nicardipine - ","Tacrolimus - ",e.DRUG_DRUG,i.HIGH,"     CYP3A4.    (Substrate)   CYP3A4.","Nicardipine is a CYP3A4 inhibitor. Tacrolimus is a major substrate of CYP3A4.","               (Nephrotoxicity)   (Neurotoxicity). (  )","Dangerous increase in Tacrolimus blood concentrations, leading to heightened toxicity, particularly Nephrotoxicity and Neurotoxicity. (Increased Tacrolimus toxicity)","     (TDM).     ( 25-50%)   .","Monitor Tacrolimus concentrations closely (TDM). The Tacrolimus dose must be reduced (often 25-50%) upon initiating Nicardipine.");n("Nicardipine - ","Cyclosporine - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4.    (Substrate)   CYP3A4.","Nicardipine is a CYP3A4 inhibitor. Cyclosporine is a major substrate of CYP3A4.","               . (  )","Increased Cyclosporine blood concentrations, raising the risk of its toxicity, particularly nephrotoxicity and neurotoxicity. (Increased Cyclosporine toxicity)","     (TDM).     ( / ) .","Monitor Cyclosporine concentrations closely (TDM). Adjust the Cyclosporine dose upon starting or stopping Nicardipine.");n("Nicardipine - ","Midazolam - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4.  ()     CYP3A4.","Nicardipine is a CYP3A4 inhibitor. Midazolam (benzodiazepine) is a major substrate of CYP3A4.","          (Sedation)     .","Increased Midazolam blood concentrations, leading to enhanced sedation and CNS depressant effects.","          .      .","Closely monitor the patient for sedation and CNS effects. A dose reduction of Midazolam may be required.");n("Nicardipine - ","Quetiapine - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4.      CYP3A4.","Nicardipine is a CYP3A4 inhibitor. Quetiapine is a major substrate of CYP3A4.","     (   )              .","Increased Quetiapine blood concentrations (and decreased active metabolite concentration), which may increase the risk of side effects, such as orthostatic hypotension or sedation.","   .       .","Monitor for signs of Quetiapine toxicity. Quetiapine dose adjustment may be necessary.");n("Nicardipine - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE,"    -P (P-gp)  .    (Substrate)  P-gp.","Nicardipine is a P-glycoprotein (P-gp) inhibitor in the intestine. Digoxin is a P-gp substrate.","             . (  )","Increased Digoxin absorption into the blood, leading to heightened toxicity, especially cardiac arrhythmias. (Increased Digoxin toxicity)","    .    ( )    .","Monitor Digoxin concentrations. Adjust the Digoxin dose (usually reduction) upon starting or stopping Nicardipine.");n("Nicardipine - ","Beta-Blockers -  ",e.DRUG_DRUG,i.MODERATE,"  (Synergistic Effect)     .","Synergistic effect on cardiac contractility and vasodilation.","     (Hypotension) /   (Bradycardia)       .","Increased risk of hypotension and/or bradycardia, and potential worsening of heart failure in susceptible patients.","         .             (Negative Inotropic Effect).","Monitor blood pressure, heart rate, and cardiac function closely. Avoid simultaneous use with beta-blockers that have negative inotropic effects.");n("Nicardipine - ","Alfuzosin -  (   )",e.DRUG_DRUG,i.MODERATE,"            .","Synergistic effect in lowering blood pressure, as both are vasodilators.","     (Hypotension) .","Increased risk of hypotension and dizziness.","    .         .","Monitor blood pressure closely. Dose adjustment for one or both drugs may be necessary.");n("Nicardipine - ","Rifamycins -  ( )",e.DRUG_DRUG,i.MODERATE,"     CYP3A4      .","Rifamycins are potent inducers of the CYP3A4 enzyme, the main pathway for Nicardipine breakdown.","                   .","Sharp decrease in Nicardipine blood concentrations, leading to reduced efficacy and increased risk of hypertension or angina.","    .            .","Monitor blood pressure closely. An increase in Nicardipine dose or use of a non-interacting alternative may be required.");n("Nicardipine - ","Warfarin - ",e.DRUG_DRUG,i.MODERATE,"     ( CYP2C9/3A4).","Nicardipine may inhibit Warfarin metabolism (via CYP2C9/3A4).","            (INR).","Increased anticoagulant effect of Warfarin and increased risk of bleeding, evidenced by an elevated International Normalized Ratio (INR)."," INR            .      .","Monitor INR closely and frequently upon initiating, discontinuing, or changing the Nicardipine dose. Warfarin dose reduction may be required.");n("Nicardipine - ","Fentanyl - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4.    (Substrate)   CYP3A4.","Nicardipine is a CYP3A4 inhibitor. Fentanyl is a major substrate of CYP3A4.","               .","Dangerous increase in Fentanyl blood concentrations, increasing the risk of respiratory depression and excessive sedation.","         .      .","Monitor the patient with extreme caution for signs of respiratory depression. Proactive Fentanyl dose adjustment is warranted.");n("Nicardipine - ","Clopidogrel - ",e.DRUG_DRUG,i.MODERATE,"   CYP2C19 (    CYP2C19  CYP3A4)     (Prodrug)    CYP2C19.","Nicardipine is a CYP2C19 inhibitor (Nicardipine inhibits CYP2C19 and CYP3A4). Clopidogrel is a prodrug that requires activation via CYP2C19.","             (     ).","Decreased efficacy of Clopidogrel in inhibiting platelets, increasing the risk of thrombosis (e.g., MI or stroke).","    .            CYP2C19 ( )    .","Avoid this combination if possible. If necessary, use a Clopidogrel alternative that does not require CYP2C19 activation (e.g., Prasugrel) or a Nicardipine alternative.");n("Nicardipine - ","Rivaroxaban -  ( Apixaban)",e.DRUG_DRUG,i.MODERATE,"   CYP3A4  P-gp.      CYP3A4  P-gp.","Nicardipine is a CYP3A4 and P-gp inhibitor. Rivaroxaban is a dual substrate for both.","         .","Increased Rivaroxaban blood concentrations, raising the risk of bleeding.","      .        .","Monitor the patient closely for signs of bleeding. Rivaroxaban dose reduction may be necessary according to the treatment protocol.");n("Nicardipine - ","Carbamazepine - ",e.DRUG_DRUG,i.MODERATE,"     CYP3A4    .","Carbamazepine is a potent inducer of the CYP3A4 enzyme, which metabolizes Nicardipine.","             .","Decreased Nicardipine blood concentrations, leading to reduced efficacy and a risk of hypertension.","    .            .","Monitor blood pressure closely. An increase in Nicardipine dose or use of a non-interacting alternative may be required.");n("Nicardipine - ","Phenytoin - ",e.DRUG_DRUG,i.MODERATE,"     CYP3A4    .","Phenytoin is a potent inducer of the CYP3A4 enzyme, which metabolizes Nicardipine.","             .","Decreased Nicardipine blood concentrations, leading to reduced efficacy and a risk of hypertension.","    .            .","Monitor blood pressure closely. An increase in Nicardipine dose or use of a non-interacting alternative may be required.");n("Nicardipine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.MODERATE,"    CYP3A4      .","Grapefruit inhibits the intestinal CYP3A4 enzyme, which metabolizes Nicardipine.","              (    ).","Increased Nicardipine blood concentrations, raising the risk of vasodilator-related side effects (e.g., dizziness, headache, and hypotension).","           .","Avoid consuming grapefruit or grapefruit juice during Nicardipine therapy.");n("Nifedipine",Tt,e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4)**.    .","Mechanism: **Hepatic enzyme induction (CYP3A4)**. Barbiturates accelerate the breakdown of Nifedipine."," : **  **        .","Clinical Significance: **Decreased nifedipine effects**, leading to increased blood pressure and treatment failure.","      .","Increase dose to maintain target blood pressure.");n("Nifedipine","Cimetidine",e.DRUG_DRUG,i.MODERATE,": **  (CYP3A4)**.    CYP3A4    .","Mechanism: **Enzyme inhibition (CYP3A4)**. Cimetidine inhibits the CYP3A4 enzyme responsible for Nifedipine metabolism."," : **       80%**          .","Clinical Significance: **Increased nifedipine levels and effects by up to 80%**, increasing the risk of hypotension and reflex tachycardia.","  .         .","Monitor BP. Reduce Nifedipine dose or switch Cimetidine to Ranitidine or Famotidine.");n("Nifedipine","Rifampin",e.DRUG_DRUG,i.MODERATE,": **   (Potent CYP3A4 Induction)**.       .","Mechanism: **Potent CYP3A4 enzyme induction**. Rifampin significantly accelerates Nifedipine metabolism."," : **    **           .","Clinical Significance: **Significantly decreased nifedipine levels** and loss of therapeutic efficacy, leading to uncontrolled hypertension.","   .             .","Avoid combination if possible. May require significant Nifedipine dose increase or switching to another antihypertensive.");n("Nifedipine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Nifedipine.       CYP3A4  .","Increased Nifedipine concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","         .","Increased risk of severe hypotension, headache, and reflex tachycardia."," .  .","Contraindicated. Avoid consumption.");n("Nifedipine","Amobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Aprobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Butabarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Butalbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Meghobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Pentobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Primidone",e.DRUG_DRUG,i.MODERATE,"imidone    CYP3A4    ","imidone    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Secobarbital",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","    -      ","    -      ");n("Nifedipine","Rifampin",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","    CYP3A4    ","   -     ","Uncontrolled BP (Nifedipine). Therapeutic failure.","         ","         ");n("Nifedipine","Rifampin",e.DRUG_DRUG,i.HIGH,"   CYP3A4","Potent CYP3A4 induction.","    ","Loss of antihypertensive effect.","     ","Increase nifedipine dose or use alternative.");n("Nifedipine - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       P450   CYP3A4     .                70-80     .                  .     24-48       2-3    .","Cimetidine is a non-selective inhibitor of hepatic cytochrome P450 enzymes, particularly CYP3A4, responsible for the primary metabolism of Nifedipine. Cimetidine reduces Nifedipine metabolism, increasing its plasma concentration by up to 70-80% and prolonging its half-life. Additionally, Cimetidine reduces hepatic blood flow, further decreasing the clearance of high-extraction Nifedipine. This effect begins within 24-48 hours of starting therapy and subsides within 2-3 days after discontinuing Cimetidine.","          .                 .                  .                 .","Marked increase in the hypotensive and vasodilatory effects of Nifedipine. This may lead to acute hypotension with symptoms such as dizziness, lightheadedness, syncope, and compensatory palpitations. It may also increase the frequency and severity of Nifedipine side effects like headache, flushing, peripheral edema, and reflex tachycardia. In elderly patients or those with impaired liver function, these effects may be more pronounced.","1.   :         30-50. 2.  :              . 3.  :    H2           . 4.   :         3-5    . 5.  :          . 6.    :            .","1. Nifedipine Dose Adjustment: When initiating Cimetidine, reduce Nifedipine dose by 30-50%. 2. Close Monitoring: Monitor blood pressure and heart rate daily during the first week of combination therapy. 3. Use Alternatives: Prefer alternative H2 receptor antagonists that do not inhibit liver enzymes such as ranitidine, famotidine, or nizatidine. 4. Adjustment Upon Discontinuation: When discontinuing Cimetidine, gradually increase Nifedipine dose over 3-5 days to the previous level. 5. Patient Education: Alert the patient to report any dizziness, fainting, or severe headache. 6. Monitoring in Sensitive Groups: Increased vigilance in elderly patients and those taking extended-release Nifedipine formulations.");n("Nilotinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Nilotinib.      CYP3A4.","Increased Nilotinib concentration. Grapefruit juice is a CYP3A4 inhibitor.","    QT.","Increased risk of QT prolongation."," .     .","Contraindicated. Avoid consuming grapefruit and its juice.");n("Nilotinib","Omeprazole (PPI)",e.DRUG_DRUG,i.HIGH,"  Nilotinib. Nilotinib     .","Decreased Nilotinib concentration. Nilotinib requires an acidic environment for absorption.","     .","Reduced drug efficacy and failure of cancer treatment."," .   .","Contraindicated. Avoid the combination.");n("Nilotinib","QT-prolonging Drugs",e.DRUG_DRUG,i.HIGH," QT ","Synergistic QT prolongation.","Torsades de Pointes","Torsades de Pointes."," ","Avoid combination.");n("Nintedanib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Nintedanib. Rifampin    P-gp    Nintedanib.","Decreased Nintedanib concentration. Rifampin is a strong inducer of P-gp, a Nintedanib efflux transporter.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Nintedanib (TK Inhibitor)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Nintedanib. Rifampin    CYP3A4.","Decreased Nintedanib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug efficacy, leading to failure of pulmonary fibrosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Niraparib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Niraparib. Carbamazepine    CYP3A4    Niraparib.","Decreased Niraparib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Niraparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Niraparib","Clarithromycin",e.DRUG_DRUG,i.MODERATE,"  Niraparib. Clarithromycin    CYP3A4    Niraparib.","Increased Niraparib concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Niraparib metabolic pathway.","    (  )   .","Increased risk of hematological toxicity (myelosuppression) and other side effects."," .           .","Dose adjustment. Blood counts must be closely monitored and dose adjusted if necessary.");n("Niraparib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Niraparib. Phenytoin    CYP3A4    Niraparib.","Decreased Niraparib efficacy. Phenytoin is a strong inducer of CYP3A4, a Niraparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Niraparib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Niraparib. Rifampin    CYP3A4    Niraparib.","Decreased Niraparib efficacy. Rifampin is a strong inducer of CYP3A4, a Niraparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Niraparib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Niraparib. Itraconazole    CYP3A4    Niraparib.","Increased Niraparib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Niraparib metabolic pathway.","    (  ).","Increased risk of hematological toxicity (myelosuppression)."," .           .","Dose adjustment. Blood counts must be closely monitored and dose adjusted if necessary.");n("Niraparib","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  Niraparib. Diltiazem    CYP3A4    Niraparib.","Increased Niraparib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a Niraparib metabolic pathway.","    (  ).","Increased risk of hematological toxicity (myelosuppression)."," .           .","Dose adjustment. Blood counts must be closely monitored and dose adjusted if necessary.");n("Niraparib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Niraparib. Rifampin   P-gp    Niraparib.","Decreased Niraparib efficacy. Rifampin is a P-gp inducer, a Niraparib efflux transporter.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    P-gp .","Avoid Combination. Strong P-gp inducers must be avoided.");n("Niraparib","Itraconazole",e.DRUG_DRUG,i.LOW,"    Niraparib. Itraconazole   CYP3A4      Niraparib.","Slight increase in Niraparib concentration. Itraconazole inhibits CYP3A4, a minor metabolic pathway for Niraparib.","     .","No clinically significant effect expected.","    .   .","No special action required. They are used safely together.");n("Nirmatrelvir/Ritonavir","Simvastatin",e.DRUG_DRUG,i.HIGH,"  Simvastatin. Ritonavir (  Paxlovid)     CYP3A4    Simvastatin.","Increased Simvastatin toxicity. Ritonavir (component of Paxlovid) is a potent CYP3A4 inhibitor, responsible for Simvastatin metabolism.","     Simvastatin        (Rhabdomyolysis)  .","Dangerous rise in Simvastatin concentration, leading to increased risk of Rhabdomyolysis and kidney failure.","  ( ).  **** Simvastatin     Paxlovid  .","Avoid Combination (Contraindicated). Simvastatin must be **temporarily discontinued** during and for two days after Paxlovid therapy.");n("Nirmatrelvir/Ritonavir","Rifampin",e.DRUG_DRUG,i.HIGH,"  Nirmatrelvir. Rifampin    P-gp  CYP3A4     Paxlovid.","Decreased Nirmatrelvir efficacy. Rifampin is a strong inducer of P-gp and CYP3A4, which are Paxlovid metabolism and efflux pathways.","    Paxlovid      COVID-19   .","Severe decrease in Paxlovid concentration, leading to COVID-19 treatment failure and development of viral resistance."," .    .","Avoid Combination. Simultaneous use must be avoided.");n("Nirmatrelvir/Ritonavir","Amiodarone",e.DRUG_DRUG,i.HIGH,"  Amiodarone. Ritonavir    CYP3A4    Amiodarone.","Increased Amiodarone concentration. Ritonavir is a strong CYP3A4 inhibitor, an Amiodarone metabolic pathway.","    QT     .","Increased risk of QT prolongation and fatal arrhythmias."," .   .","Contraindicated. Avoid the combination.");n("Nirsevimab (Beyfortus)","Palivizumab (Synagis)",e.DRUG_DRUG,i.MODERATE,": **  **.     .","Mechanism: **Binding interference**. Both target the same viral protein."," : ** ** .","Clinical Significance: **Potential reduced efficacy**.","  .   .","Do not use together. Choose one only.");n("Nisoldipine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4 **.      CYP3A4      .","Mechanism: **Intestinal CYP3A4 inhibition**. Grapefruit juice inhibits intestinal CYP3A4, increasing Nisoldipine absorption."," : **    **         .","Clinical Significance: **Significantly increased nisoldipine levels**, increasing the risk of severe hypotension and edema.","          .","Avoid drinking grapefruit juice or eating the fruit while on Nisoldipine therapy.");n("Nisoldipine",er,e.DRUG_DRUG,i.MODERATE,": **  (CYP3A4)**.      .","Mechanism: **Enzyme induction (CYP3A4)**. Phenytoin and other hydantoins induce Nisoldipine metabolism."," : **  **      .","Clinical Significance: **Decreased nisoldipine effects** and failure to control blood pressure.","  .     .","Monitor BP. Nisoldipine dose increase may be required.");n("Nisoldipine - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.HIGH,"      ( )      CYP3A4         .                  400-500.       24               .","Grapefruit juice contains furanocoumarins (such as bergamottin) that irreversibly inhibit CYP3A4 in the small intestinal wall, the primary metabolic pathway for Nisoldipine. This significantly reduces the first-pass metabolism of Nisoldipine, increasing its bioavailability by up to 400-500%. This inhibition may persist for more than 24 hours after consuming a single glass of juice, leading to drug accumulation with repeated doses.","             .        .                              .","Severe and acute hypotension accompanied by symptoms such as dizziness, lightheadedness, syncope, and compensatory palpitations. Reflex bradycardia may occur. In severe cases, it can lead to hypovolemic shock, myocardial ischemia, or stroke, particularly in elderly patients and those with underlying cardiovascular diseases.","1.  :              . 2. :                     . 3.  :        . 4. :            . 5.  : Patients      consider           .","1. Complete Avoidance: Total abstinence from grapefruit juice or fresh grapefruit during Nisoldipine therapy. 2. Education: Educate the patient about the seriousness of this interaction and alert them that it can occur even with small amounts and may persist for several days. 3. Safe Alternatives: Suggest alternative juices such as orange or apple juice. 4. Monitoring: If exposure is suspected, monitor blood pressure and heart rate frequently. 5. Drug Switching: For patients who regularly consume grapefruit, consider switching to calcium channel blockers not affected by this interaction like amlodipine.");n("Nisoldipine - ","Carbamazepine - ",e.DRUG_DRUG,i.MODERATE,"      P450 ( CYP3A4)  .                80-90.        .     3-5           .","Carbamazepine is a potent and broad inducer of cytochrome P450 enzymes (especially CYP3A4) and drug transporters. It significantly increases Nisoldipine metabolism, reducing its plasma concentration by up to 80-90%. It also markedly reduces Nisoldipine`s half-life. This enzyme induction takes 3-5 days to reach peak effect and may persist for several weeks after discontinuing Carbamazepine.","                   .                    .        .","Complete therapeutic failure in blood pressure control, with blood pressure readings returning to pre-treatment levels or higher. Increased risk of cardiovascular complications such as stroke, myocardial infarction, or heart failure due to uncontrolled hypertension. Withdrawal symptoms like headache, palpitations, and anxiety may appear.","1.    :            . 2.  :     100-200       . 3.  :           . 4.  :           . 5.   :         2-3      .","1. Intensive BP Monitoring: Measure blood pressure daily, especially during the first week of combination therapy. 2. Dose Increase: Increase Nisoldipine dose by 100-200% or more, and may require divided dosing. 3. Carbamazepine Alternatives: Consider non-enzyme inducing anticonvulsants like levetiracetam or lamotrigine. 4. Nisoldipine Alternatives: Use calcium channel blockers less affected by enzyme induction like amlodipine. 5. Post-Discontinuation Monitoring: When discontinuing Carbamazepine, gradually reduce Nisoldipine dose over 2-3 weeks to avoid excessive hypotension.");n("Nisoldipine - ","Phenytoin - ",e.DRUG_DRUG,i.MODERATE,"     P450  ( CYP3A4 CYP2C9).                 (AUC)    70-80.     3-7          .","Phenytoin is a potent inducer of hepatic cytochrome P450 enzymes (especially CYP3A4 and CYP2C9). It significantly increases Nisoldipine metabolism, reducing its plasma concentration and area under the curve (AUC) by up to 70-80%. This effect begins within 3-7 days of starting therapy and persists for several weeks after discontinuing Phenytoin.","          ( )     .                      .","Loss of blood pressure control, return of hypertension symptoms (headache, dizziness), increased risk of cardiovascular events. In patients with angina pectoris, frequency of angina attacks may increase due to inadequate control of blood pressure and heart rate.","1.   :          . 2.   :    50-100   . 3.  :            . 4.  :        . 5.  :          2-4 .","1. Blood Pressure Monitoring: Measure BP twice daily during the first week of combination. 2. Increase Nisoldipine Dose: Increase dose by 50-100% and adjust based on response. 3. Therapeutic Monitoring: Monitor phenytoin plasma levels as Nisoldipine may increase its concentration. 4. Phenytoin Alternatives: Use non-enzyme inducing anticonvulsants like valproic acid. 5. Gradual Adjustment: When discontinuing Phenytoin, reduce Nisoldipine dose gradually over 2-4 weeks.");n("Nitazoxanide","Warfarin",e.DRUG_DRUG,i.MODERATE,"     Warfarin.             .","Increased anticoagulant effect of Warfarin. Not precisely known, but may be due to protein binding displacement or other effects.","  .","Increased risk of hemorrhage."," .   INR       Nitazoxanide.","Close monitoring. INR must be monitored frequently upon initiation or discontinuation of Nitazoxanide.");n("Nitroglycerin","Alteplase",e.DRUG_DRUG,i.MODERATE,": **  **.       .","Mechanism: **Inhibition of plasminogen activation**. Nitroglycerin may inhibit conversion of plasminogen to plasmin."," : **   **       .","Clinical Significance: **Decreased thrombolytic efficacy** and increased risk of treatment failure in MI.","    24-48       .","Avoid Nitroglycerin during first 24-48 hours of thrombolytic therapy if possible.");n("Nitroglycerin","Vardenafil",e.DRUG_DRUG,i.CONTRAINDICATED,"          GMP ","Synergistic vasodilation via increased cGMP levels.","     -     -  ","Severe hypotension - risk of shock and cardiovascular collapse.","    ","Avoid combination completely.");n("Nitroglycerin","Sildenafil",e.DRUG_DRUG,i.HIGH,"   ","Synergistic vasodilation.","    - ","Severe hypotension - shock.","   -  24   ","Absolute contraindication - separate by 24 hours minimum.");n("Nitroglycerin","Alcohol",e.DRUG_DRUG,i.MODERATE,"  ","Additive vasodilation."," ","Dizziness and syncope."," ","Avoid alcohol.");n("Nivolumab","Prednisone",e.DRUG_DRUG,i.HIGH,"  Nivolumab.        .","Decreased efficacy of Nivolumab. Corticosteroids are immunosuppressive and antagonize the inhibitor mechanism.","    (  ).","Reduced efficacy of immunotherapy (anti-cancer treatment)."," .       .","Contraindicated. Systemic corticosteroids must be avoided before treatment.");n("Nivolumab","Ipilimumab",e.DRUG_DRUG,i.HIGH,"  ","Synergistic immune toxicity.","   ","Colitis and hepatitis.","  -   ","Close monitoring - may be beneficial.");n("Nivolumab (Opdivo)","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,": **   **.     .","Mechanism: **Unpredictable immune activation**. May cause excessive immune response."," : **  ** .","Clinical Significance: **Potential immune-related adverse events**.","    .     .","Avoid live vaccines during therapy. Vaccinate before or after treatment.");n("Nivolumab (PD-1)","High-dose Corticosteroids",e.DRUG_DRUG,i.MODERATE,"  Nivolumab.           PD-1.","Decreased Nivolumab efficacy. High-dose corticosteroids may inhibit the T-cell response enhanced by the PD-1 inhibitor.","   .","Failure of the anti-tumor immune response."," .       (    ).","Avoid combination. Avoid high-dose systemic corticosteroids (except for management of immune-related adverse events - irAEs).");n("Nizatidine","Aspirin",e.DRUG_DRUG,i.LOW,"    ","Slight increase in aspirin absorption.","    ","Slight increase in aspirin effect.","  ","No adjustment needed.");n("Non-Selective Beta Blockers (Propranolol, Nadolol)","Asthma / Reactive Airway Disease",e.DRUG_DISEASE,i.CONTRAINDICATED,"  2           .","Blockade of bronchial 2 receptors leads to severe bronchoconstriction due to the unopposed action of constrictive mediators.","     (Status Asthmaticus)   .","Life-threatening acute asthma exacerbation (Status Asthmaticus) and severe bronchospasm."," .   1  (Cardioselective)       .","Absolute contraindication. Cardioselective 1 blockers (Metoprolol) should only be used with extreme caution if mandatory.");n("Norepinephrine","Atenolol",e.DRUG_DRUG,i.HIGH,"   ","Cardiac Antagonism. Opposing effects on cardiac function.","    ","    ","  ","  ");n("Norepinephrine","Bisoprolol",e.DRUG_DRUG,i.HIGH,"   ","Cardiac Antagonism. Opposing effects on cardiac function.","    ","    ","  ","  ");n("Norepinephrine","Carvedilol",e.DRUG_DRUG,i.HIGH,"Carvedilol    1   2    1      .     ( 1)  ( 2)        1                  .","Carvedilol blocks beta 1/beta 2 and alpha 1 receptors, creating an unpredictable response to Norepinephrine. Cardiac stimulation is suppressed, bronchodilation is ineffective, and vascular alpha 1 effects are blunted or unstable, resulting in uneven hypertension with bradycardia or arrhythmias.","               .","Unstable hypertension, bradycardia, cardiac arrhythmias, reduced therapeutic efficacy in critical conditions.","  .         Vasopressin       .","Avoid combination entirely. In emergencies, consider alternatives such as Vasopressin or fluid support with close hemodynamic monitoring.");n("Norepinephrine","Metoprolol",e.DRUG_DRUG,i.HIGH,"   ","Cardiac Antagonism. Opposing effects on cardiac function.","    ","    ","  ","  ");n("Norepinephrine","Propranolol",e.DRUG_DRUG,i.HIGH,"   ","Cardiac Antagonism. Opposing effects on cardiac function.","    ","    ","  ","  ");n("Norepinephrine","Nebivolol",e.DRUG_DRUG,i.HIGH,"   ","Cardiac Antagonism. Opposing effects on cardiac function.","    ","    ","  ","  ");n("Norepinephrine","Labetalol",e.DRUG_DRUG,i.HIGH,"   ","Cardiac Antagonism. Opposing effects on cardiac function.","    ","    ","  ","  ");n("Norethindrone","Carbamazepine",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 induction.","  ","Contraceptive failure.","  ","Use backup method.");n("Norfloxacin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Norfloxacin","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Norfloxacin","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Norfloxacin","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Norfloxacin - ","Food (General) -  ()",e.DRUG_FOOD,i.LOW,"               .                  VI       .                    .         .","Norfloxacin, as a member of the fluoroquinolone family, alters taste sensation through incompletely understood mechanisms. One theory suggests it may chelate zinc, a mineral essential for the function of carbonic anhydrase VI enzyme in saliva, an enzyme critical for proper taste. Another theory proposes the drug may directly affect taste receptor cells or sensory nerves due to its concentration in saliva. These effects are usually reversible after drug discontinuation.","      (ageusia  hypogeusia)   : 1.      . 2.  . 3.      . 4.     . 5.           .","Total or partial loss of taste sensation (ageusia or hypogeusia), leading to: 1. Significant reduction in food enjoyment. 2. Loss of appetite. 3. Unintended weight loss during therapy. 4. Patient anxiety about permanent effect. 5. Impact on treatment adherence if the taste is associated with taking the drug itself.","1. :               . 2. :                  . 3.  :                     . 4.  :      . 5.  :                     .","1. Expectations: Inform the patient that this is a rare but possible side effect of fluoroquinolones and that it is usually reversible. 2. Follow-up: If taste loss persists for more than two weeks after completing therapy, the patient should consult a doctor to rule out other causes. 3. Nutritional management: During treatment, encourage small, frequent meals with appealing aromas, as the sense of smell often compensates for taste loss. 4. Strong flavors: Use sauces, spices, and herbs to enhance flavor. 5. Treatment alternatives: For future infections requiring antibiotics, the physician may choose to avoid fluoroquinolones if these side effects are particularly bothersome.");n("Nortriptyline","Clonidine",e.DRUG_DRUG,i.MODERATE," .","Antagonism. Neutralization of effect.","  .","  .",".",".");n("NSAIDs (Ibuprofen, Naproxen, Aspirin)","Active Peptic Ulcer / History of GI Bleeding",e.DRUG_DISEASE,i.HIGH," COX-1           .","COX-1 inhibition results in decreased protective prostaglandins in the stomach, reducing mucus and increasing acid.","   (Acute GI Bleeding)  (Perforation)    .","Acute gastrointestinal bleeding, perforation, or exacerbation of an existing ulcer."," .           (PPI)   .","Absolute avoidance. If use is strictly necessary, co-administer with a PPI (Omeprazole) and monitor closely.");n("Obinutuzumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Obinutuzumab     B.","Increased risk of infection. Obinutuzumab is an immunosuppressant that depletes B-cells.","     .","Risk of developing infection from live vaccines."," .        .","Delay vaccination. Live vaccines must be delayed for a specified period around treatment.");n("Ocrelizumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  /  . Ocrelizumab   B.","Reduced vaccine response/Increased infection risk. Ocrelizumab depletes B-cells.","     .","Risk of developing infection from live vaccines."," .          .","Delay vaccination. Live and non-live vaccines must be delayed for a specified period around treatment.");n("Odefsey (HIV Combination)","Omeprazole (PPI)",e.DRUG_DRUG,i.HIGH,"  Rilpivirine.          Rilpivirine.","Decreased Rilpivirine concentration. PPIs reduce stomach acidity necessary for Rilpivirine absorption.","      .","Reduced antiretroviral efficacy and treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Odevixibat (Bylvay)","Bile Acid Sequestrants (Cholestyramine)",e.DRUG_DRUG,i.MODERATE,": **  **. Cholestyramine   Odevixibat.","Mechanism: **Intestinal binding**. Cholestyramine binds Odevixibat."," : **  Odevixibat**.","Clinical Significance: **Reduced Odevixibat efficacy**.","   4   .","Separate doses by at least 4 hours.");n("Odronextamab (Ordspono)","Hepatotoxic Drugs (Acetaminophen High-dose)",e.DRUG_DRUG,i.MODERATE,": **  **.       .","Mechanism: **Synergistic hepatotoxicity**. Both drugs may cause elevated liver enzymes."," : ** **   .","Clinical Significance: **Hepatitis** and potential liver failure.","    Acetaminophen.    .","Avoid high-dose Acetaminophen. Monitor liver enzymes weekly.");n("Ofatumumab (MS)","Prednisone",e.DRUG_DRUG,i.MODERATE,"  .    .","Increased risk of infection. Additive immunosuppressive effects.","      .","Increased risk of severe bacterial or viral infections.","    .         (  ).","Avoid concurrent use or monitoring. Avoid concurrent use with other immunosuppressants (except short courses).");n("Ofloxacin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  .","CNS Stimulation. Additive excitatory effects on the central nervous system may lower seizure threshold."," .","Seizure Risk. Lowered seizure threshold.",".",".");n("Ofloxacin","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Ofloxacin","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Ofloxacin","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Olanzapine","Smoking (Tobacco)",e.DRUG_FOOD,i.MODERATE,"  Olanzapine.   CYP1A2    Olanzapine.","Decreased Olanzapine concentration. Smoking induces CYP1A2, an Olanzapine metabolic pathway.","         .","Reduced antipsychotic efficacy, leading to exacerbation of psychotic symptoms."," .          .","Symptom monitoring. Monitor clinical response and adjust dose if the patient stops smoking.");n("Olanzapine","Tobacco Smoke",e.DRUG_DRUG,i.MODERATE,"  Olanzapine.     CYP1A2.","Decreased Olanzapine concentration. Tobacco smoking is a CYP1A2 inducer.","      .","Reduced antipsychotic efficacy and increased risk of relapse."," .    Olanzapine  .      .","Dose adjustment. Olanzapine dose must be increased in smokers. Re-evaluate dose upon smoking cessation.");n("Olanzapine/Samidorphan","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Olanzapine. Carbamazepine    CYP1A2/3A4.","Decreased Olanzapine concentration. Carbamazepine is a strong inducer of CYP1A2/3A4.","   .","Reduced antipsychotic efficacy."," .     .","Close monitoring. Monitor clinical response and adjust the dose.");n("Olaparib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Olaparib. Clarithromycin    CYP3A4      Olaparib.","Increased Olaparib concentration. Clarithromycin is a strong CYP3A4 inhibitor, the primary metabolic pathway for Olaparib.","    (  )   .","Increased risk of hematological toxicity (myelosuppression) and other side effects."," .    Olaparib     CYP3A4 .","Dose adjustment. Olaparib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Olaparib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Olaparib. Phenytoin    CYP3A4    Olaparib.","Decreased Olaparib efficacy. Phenytoin is a strong inducer of CYP3A4, an Olaparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Olaparib","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  Olaparib. Fluconazole    CYP3A4    Olaparib.","Increased Olaparib concentration. Fluconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Olaparib.","    (  ).","Increased risk of hematological toxicity (myelosuppression)."," .           .","Dose adjustment. Blood counts must be closely monitored and dose adjusted if necessary.");n("Olaparib","Ritonavir",e.DRUG_DRUG,i.HIGH,"  Olaparib. Ritonavir    CYP3A4      Olaparib.","Increased Olaparib concentration. Ritonavir is a strong CYP3A4 inhibitor, the primary metabolic pathway for Olaparib.","    (  )   .","Increased risk of hematological toxicity (myelosuppression) and other side effects."," .    Olaparib     CYP3A4 .","Dose adjustment. Olaparib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Olaparib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Olaparib. Carbamazepine    CYP3A4    Olaparib.","Decreased Olaparib efficacy. Carbamazepine is a strong inducer of CYP3A4, an Olaparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Olaparib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Olaparib. Efavirenz    CYP3A4    Olaparib.","Decreased Olaparib efficacy. Efavirenz is a moderate inducer of CYP3A4, an Olaparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Olaparib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Olaparib. Cyclosporine   P-gp    Olaparib.","Increased Olaparib concentration. Cyclosporine inhibits P-gp, an Olaparib efflux transporter.","    (  ).","Increased risk of hematological toxicity (myelosuppression).","  .         .","Side effect monitoring. Blood counts must be monitored and dose adjusted if necessary.");n("Olaparib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Olaparib. Carbamazepine    CYP3A4    Olaparib.","Decreased Olaparib concentration. Carbamazepine is a strong inducer of CYP3A4, an Olaparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Oliceridine","Phenelzine (MAOI)",e.DRUG_DRUG,i.HIGH,"   /   .  .","Increased risk of Serotonin Syndrome/CNS depression. Synergistic effects.","       .","Mental status changes, hyperthermia, respiratory depression."," .   .","Contraindicated. Avoid the combination.");n("Olmesartan","NSAIDs",e.DRUG_DRUG,i.MODERATE,"     (  )","Antagonistic effect on kidneys (dual negative effect).","      ","Reduced antihypertensive efficacy and renal failure risk.","    NSAIDs  ","Monitor blood pressure, avoid NSAIDs if possible.");n("Olorofim","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Olorofim. Phenytoin    CYP3A4    Olorofim.","Decreased Olorofim concentration. Phenytoin is a strong inducer of CYP3A4, an Olorofim metabolic pathway.","           .","Reduced drug plasma concentration, leading to failure of fungal infection treatment."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Olutasidenib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Itraconazole     CYP3A4      Olutasidenib.","Increased Olutasidenib concentration. Itraconazole is a potent CYP3A4 inhibitor, the major metabolic pathway for Olutasidenib.","       QT  .","Increased risk of side effects, especially QT prolongation and cardiac toxicity."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Olutasidenib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Phenytoin    CYP3A4    Olutasidenib.","Decreased Olutasidenib efficacy. Phenytoin is a strong inducer of CYP3A4, an Olutasidenib metabolic pathway.","           .","Reduced drug plasma concentration, leading to leukemia treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Olutasidenib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Clarithromycin    CYP3A4    Olutasidenib.","Increased Olutasidenib concentration. Clarithromycin is a strong CYP3A4 inhibitor, a metabolic pathway for Olutasidenib.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Olutasidenib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Voriconazole    CYP3A4    Olutasidenib.","Increased Olutasidenib concentration. Voriconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Olutasidenib.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Olutasidenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Rifampin    CYP3A4    Olutasidenib.","Decreased Olutasidenib efficacy. Rifampin is a strong inducer of CYP3A4, an Olutasidenib metabolic pathway.","           .","Reduced drug plasma concentration, leading to leukemia treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Olutasidenib","Erythromycin",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Erythromycin    CYP3A4    Olutasidenib.","Increased Olutasidenib concentration. Erythromycin is a moderate CYP3A4 inhibitor, a metabolic pathway for Olutasidenib.","    QT  .","Increased risk of QT prolongation and cardiotoxicity."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inhibitors must be avoided.");n("Olutasidenib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Phenytoin    CYP3A4    Olutasidenib.","Decreased Olutasidenib efficacy. Phenytoin is a strong inducer of CYP3A4, an Olutasidenib metabolic pathway.","           .","Reduced drug plasma concentration, leading to leukemia treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Olutasidenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Olutasidenib. Rifampin    CYP3A4.","Decreased Olutasidenib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Olutasidenib (Rezlidhia)","QT-Prolonging Drugs (Azithromycin)",e.DRUG_DRUG,i.HIGH,": **     QT**.     QT.","Mechanism: **Synergistic QT prolongation**. Both drugs prolong QT interval."," : **    **  Torsades de Pointes.","Clinical Significance: **Ventricular arrhythmia risk** such as Torsades de Pointes."," .    .       .","Avoid combination. Use alternative antibiotic. Monitor ECG if combination necessary.");n("Olutasidenib (Rezlidhia)","Strong CYP3A4 Inducers (Phenobarbital)",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.   Olutasidenib.","Mechanism: **CYP3A4 induction**. Olutasidenib concentration decreases."," : **      **.","Clinical Significance: **Reduced AML treatment efficacy**."," .    .","Avoid combination. Use alternative anticonvulsant.");n("Omacetaxine","Voriconazole",e.DRUG_DRUG,i.LOW,"    . Omacetaxine    (Hydrolyzed)    CYP.","No true interaction expected. Omacetaxine is primarily hydrolyzed and not metabolized via CYP.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Omaveloxolone","Omeprazole",e.DRUG_DRUG,i.MODERATE,"  Omaveloxolone. Omeprazole       Omaveloxolone.","Reduced Omaveloxolone efficacy. Omeprazole may alter the systemic absorption of Omaveloxolone.","               (Friedreichs Ataxia).","Potential decrease in drug levels, possibly leading to loss of efficacy in treating Friedreichs Ataxia."," .          .","Efficacy monitoring. No absolute contraindication, but patient response should be monitored.");n("Omaveloxolone","Famotidine",e.DRUG_DRUG,i.MODERATE,"  Omaveloxolone.      (H2 Blockers)    .","Reduced Omaveloxolone efficacy. Acid-reducing agents (H2 Blockers) may affect absorption.","              .","Potential decrease in drug levels, possibly leading to loss of efficacy in treating Friedreichs Ataxia."," .     H2     .","Efficacy monitoring. Co-administration of H2 blockers should preferably be avoided, or clinical response should be monitored.");n("Omaveloxolone - ","Gemfibrozil - ",e.DRUG_DRUG,i.HIGH,"     CYP2C8 CYP2C9           ","Gemfibrozil is a potent dual inhibitor of hepatic CYP2C8 and CYP2C9 enzymes responsible for Omaveloxolone primary metabolism, significantly reducing its clearance","      3-5      (    ALT/AST)       ","3-5 fold increase in Omaveloxolone plasma concentration, high risk of hepatotoxicity (sharp elevation in ALT/AST enzymes), edema, hypertension, and electrolyte disturbances","   -         -    :     75%    ","Avoid combination entirely - use lipid-lowering alternatives like atorvastatin or rosuvastatin - if combination unavoidable: reduce Omaveloxolone dose by 75% and monitor liver enzymes weekly");n("Omeprazole","Clopidogrel",e.DRUG_DRUG,i.HIGH," CYP2C19 -   ","CYP2C19 inhibition prevents clopidogrel activation.","    -   ","Antiplatelet failure - increased thrombosis risk.","    ","Use pantoprazole or rabeprazole instead.");n("Omeprazole","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Caffeine",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Grapefruit Juice",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Omeprazole","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("OnabotulinumtoxinA","Aminoglycosides",e.DRUG_DRUG,i.MODERATE,"   ","Potentiated neuromuscular blockade.","  ","Severe muscle weakness.","  ","Caution with combination.");n("Ondansetron","Apomorphine",e.DRUG_DRUG,i.HIGH,"       .","Increased risk of profound hypotension and loss of consciousness.","   (Circulatory collapse).","Risk of circulatory collapse."," .   .","Contraindicated. Avoid the combination.");n("Ondansetron","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  Ondansetron. Phenytoin    CYP3A4/1A2/2D6    Ondansetron.","Decreased Ondansetron concentration. Phenytoin is a strong inducer of CYP3A4/1A2/2D6, Ondansetron metabolic pathways.","  Ondansetron (    ).","Reduced efficacy of Ondansetron (failure to control nausea and vomiting)."," .       Ondansetron     .","Dose increase. Ondansetron dose may need to be increased or used more frequently.");n("Ondansetron","Tramadol",e.DRUG_DRUG,i.MODERATE,"   ","Antagonism of analgesic effect.","  ","Reduced tramadol efficacy."," ","Monitor analgesia.");n("Orlistat","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Cyclosporine. Orlistat       Cyclosporine.","Decreased Cyclosporine absorption. Orlistat reduces fat absorption necessary for Cyclosporine absorption.","       .","Reduced immunosuppressant concentration and increased risk of graft rejection."," .   Cyclosporine     Orlistat     .","Dose separation. Cyclosporine must be taken at least 2 hours before or 2 hours after Orlistat.");n("Orlistat","Levothyroxine",e.DRUG_DRUG,i.MODERATE,"  Levothyroxine. Orlistat   .","Decreased Levothyroxine absorption. Orlistat may disrupt absorption.","     .","Reduced efficacy of hypothyroidism treatment."," .      4   .","Dose separation. The two drugs must be separated by at least 4 hours.");n("Osilodrostat","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Osilodrostat. Phenytoin    CYP3A4.","Decreased Osilodrostat concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug efficacy, leading to failure of Cushing's syndrome treatment."," .   .","Contraindicated. Avoid the combination.");n("Osimertinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Osimertinib. Rifampin    CYP3A4    Osimertinib.","Decreased Osimertinib efficacy. Rifampin is a strong inducer of CYP3A4, an Osimertinib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Osimertinib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Osimertinib. Ketoconazole    CYP3A4    Osimertinib.","Increased Osimertinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, an Osimertinib metabolic pathway.","         .","Slight increase in the risk of side effects, especially diarrhea and skin reactions.","  .       .","Side effect monitoring. No contraindication, but monitoring is necessary.");n("Osimertinib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Osimertinib. Itraconazole    CYP3A4    Osimertinib.","Increased Osimertinib concentration. Itraconazole is a strong CYP3A4 inhibitor, an Osimertinib metabolic pathway.","         .","Slight increase in the risk of side effects, especially diarrhea and skin reactions.","  .       .","Side effect monitoring. No contraindication, but monitoring is necessary.");n("Osimertinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Osimertinib. Rifampin    CYP3A4    Osimertinib.","Decreased Osimertinib concentration. Rifampin is a strong inducer of CYP3A4, an Osimertinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Osimertinib (EGFR TKI)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Osimertinib. Rifampin    CYP3A4    Osimertinib.","Decreased Osimertinib concentration. Rifampin is a strong inducer of CYP3A4, an Osimertinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Oxaliplatin","QT-prolonging Drugs",e.DRUG_DRUG,i.MODERATE," QT","QT prolongation.","  ","Cardiac arrhythmia."," ECG","Monitor ECG.");n("Oxandrolone","Warfarin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Oxandrolone","Heparin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Oxandrolone","Enoxaparin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Oxandrolone","Dabigatran",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Oxandrolone","Rivaroxaban",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Oxandrolone - ","Apixaban - ",e.DRUG_DRUG,i.HIGH," ()              K (    )    .              .    Xa .            .","Oxandrolone (an anabolic steroid) causes hepatotoxicity that can reduce synthesis of vitamin K-dependent clotting factors (Factors II, VII, IX, and X), prolonging prothrombin time. Simultaneously, it increases thrombosis risk through enhanced platelet production and activation. Apixaban directly inhibits factor Xa. This dual disruption of the coagulation system creates hematologic instability.","      (   )  (    ).           .        .","Concurrent and unpredictable risk of severe bleeding (gastrointestinal, intracranial) and thrombosis (deep vein thrombosis, pulmonary embolism). Rapid fluctuations between bleeding and clotting may occur, making monitoring difficult. Worsening hepatotoxicity may increase apixaban concentrations.","   .   :       .     .       .          .","Avoid combination if possible. If necessary: Monitor liver function weekly, hematocrit, and prothrombin time. Monitor for clinical signs of bleeding and thrombosis. Avoid in patients with pre-existing liver disease. Consider alternative anticoagulants less dependent on hepatic metabolism.");n("Oxandrolone","Oral Hypoglycemics",e.DRUG_DRUG,i.MODERATE,"  ","Increased insulin sensitivity.","  ","Hypoglycemia.","   ","Reduce hypoglycemic dose.");n("Oxymetazoline","Tricyclic Antidepressants",e.DRUG_DRUG,i.MODERATE,"  ","Amplified sympathetic effect.","  ","Hypertension."," ","Use cautiously.");n("Ozanimod","Sertraline",e.DRUG_DRUG,i.MODERATE,"   . Ozanimod         MAO-B  Sertraline (SSRI)   .","Increased risk of Serotonin Syndrome. Ozanimod has metabolites with weak MAO-B inhibitory activity, and Sertraline (SSRI) increases serotonin levels.","           (   ).","Increase in serotonin levels, leading to the risk of Serotonin Syndrome (agitation, tremor, hyperthermia)."," .        SSRI.","Close monitoring. Neurological symptoms must be monitored, and the SSRI dose potentially adjusted.");n("Ozanimod","Phenelzine",e.DRUG_DRUG,i.HIGH,"     . Ozanimod     MAO-B.","Increased risk of hypertensive crisis. Ozanimod is a weak MAO-B inhibitor.","  (Norepinephrine)       .","Accumulation of Norepinephrine leading to sudden hypertension."," .   .","Contraindicated. Avoid the combination.");n("Ozanimod - ","Gemfibrozil - ",e.DRUG_DRUG,i.CONTRAINDICATED,"    CYP2C8        CC112273      ","Gemfibrozil is a potent inhibitor of hepatic CYP2C8 enzyme responsible for the metabolism of active Ozanimod metabolite CC112273, leading to its significant accumulation","      CC112273          QT      Torsades de Pointes","Substantial increase in active metabolite CC112273 concentration, high risk of severe bradycardia, heart block, dangerous QT prolongation, and risk of fatal Torsades de Pointes arrhythmia","   -    -       CYP2C8 -   :      ","Absolute contraindication - avoid combination entirely - use alternative lipid-lowering agents that do not inhibit CYP2C8 - if combination occurs: intensive cardiac monitoring and continuous ECG");n("Ozanimod (S1P modulator)","Selegiline",e.DRUG_DRUG,i.HIGH,"     .  Ozanimod       MAO-B.","Increased risk of hypertensive crisis. Ozanimod metabolites are weak, reversible MAO-B inhibitors.","   .","Severe hypertension."," .   .","Contraindicated. Avoid the combination.");n("Ozanimod (S1P)","Phenelzine (MAOI)",e.DRUG_DRUG,i.HIGH,"     . Ozanimod      MAO.","Increased risk of hypertensive crisis. Ozanimod has mild MAO inhibitory activity.","   .","Severe hypertension."," .   .","Contraindicated. Avoid the combination.");n("Ozanimod (S1P)","Gemfibrozil",e.DRUG_DRUG,i.MODERATE,"  Ozanimod. Gemfibrozil   CYP2C8.","Increased Ozanimod concentration. Gemfibrozil inhibits CYP2C8.","      .","Increased risk of bradycardia and other side effects."," .      .","Close monitoring. Monitor heart rate and side effects.");n("Ozempic (Semaglutide)","Insulin",e.DRUG_DRUG,i.HIGH,"     .     .","Increased risk of severe hypoglycemia. Additive glucose-lowering effects.","   .","Severe hypoglycemia."," .          Semaglutide.","Dose adjustment. Insulin or sulfonylurea dose must be reduced upon initiation of Semaglutide.");n("Paclitaxel","Ketoconazole",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition.","  ","Increased paclitaxel toxicity."," ","Avoid combination.");n("Pacritinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pacritinib. Rifampin    CYP3A4    Pacritinib.","Decreased Pacritinib concentration. Rifampin is a strong inducer of CYP3A4, a Pacritinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pacritinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Pacritinib.       CYP3A4  .","Increased Pacritinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      Pacritinib.","Increased risk of Pacritinib-related drug toxicity."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Palbociclib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Palbociclib. Phenytoin    CYP3A4    Palbociclib.","Decreased Palbociclib efficacy. Phenytoin is a strong inducer of CYP3A4, a Palbociclib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Palbociclib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Palbociclib. Clarithromycin    CYP3A4    Palbociclib.","Increased Palbociclib concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Palbociclib metabolic pathway.","     .","Increased risk of myelosuppression and neutropenia."," .    Palbociclib     CYP3A4 .","Dose adjustment. Palbociclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Palbociclib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Palbociclib. Itraconazole    CYP3A4    Palbociclib.","Increased Palbociclib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Palbociclib metabolic pathway.","     .","Increased risk of myelosuppression and neutropenia."," .    Palbociclib     CYP3A4 .","Dose adjustment. Palbociclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Palbociclib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Palbociclib.      CYP3A4    Palbociclib.","Increased Palbociclib concentration. Grapefruit juice inhibits CYP3A4, a Palbociclib metabolic pathway.","     .","Increased risk of myelosuppression and neutropenia."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Palbociclib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Palbociclib. Phenytoin    CYP3A4    Palbociclib.","Decreased Palbociclib concentration. Phenytoin is a strong inducer of CYP3A4, a Palbociclib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Palbociclib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Palbociclib. Itraconazole    CYP3A4.","Increased Palbociclib concentration. Itraconazole is a strong inhibitor of CYP3A4.","     .","Increased risk of myelosuppression and neutropenia.","  .    CYP3A4 .","Relative contraindication. Strong CYP3A4 inhibitors must be avoided.");n("Palonosetron","Ketoconazole",e.DRUG_DRUG,i.LOW,"    .   Palonosetron    CYP (   CYP2D6  CYP3A4).","No clinically significant interaction. Palonosetron is metabolized by multiple CYP enzymes (including CYP2D6 and CYP3A4).","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Palonosetron","Tramadol",e.DRUG_DRUG,i.MODERATE,"  ","Potential serotonin syndrome."," ","Serotonergic symptoms."," ","Monitor symptoms.");n("Pancreatin","Antacids",e.DRUG_DRUG,i.MODERATE,"   pH ","Enzyme inactivation at alkaline pH.","  ","Reduced enzyme efficacy."," ","Separate doses.");n("Pancrelipase","Acarbose",e.DRUG_DRUG,i.MODERATE,"  ","Antagonistic effect.","  ","Reduced acarbose efficacy."," ","Avoid combination.");n("Pantoprazole","Warfarin",e.DRUG_DRUG,i.MODERATE," CYP2C19 ()","CYP2C19 inhibition (minor).","   INR","Slight INR increase."," INR   ","Monitor INR when initiating.");n("Pantoprazole","Alcohol",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Caffeine",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Green Tea",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Milk",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","High-fat meals",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","High-fiber foods",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Vitamin C",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Vitamin D",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Vitamin E",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Vitamin K",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Vitamin B12",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Folic Acid",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Iron",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Calcium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Magnesium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Zinc",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Potassium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Pantoprazole","Antacids",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Paroxetine","Tamoxifen",e.DRUG_DRUG,i.HIGH,"  Tamoxifen. Paroxetine    CYP2D6      Tamoxifen    (Endoxifen).","Decreased Tamoxifen efficacy. Paroxetine is a strong inhibitor of CYP2D6, the enzyme responsible for activating Tamoxifen to the active metabolite (Endoxifen).","     .","Increased risk of breast cancer recurrence."," .   .       CYP2D6.","Contraindicated. Avoid the combination. Antidepressants that do not inhibit CYP2D6 are preferred.");n("Paroxetine","Cyclosporine - ",e.DRUG_DRUG,i.MODERATE,"   ( )","Increased Cyclosporine (Enzyme Inhibition). CYP3A4 inhibition leads to toxic cyclosporine levels.","  ","Cyclosporine Toxicity. Renal dysfunction and hypertension.","   -     ","   -     ");n("Paroxetine - ","Cyproheptadine - ",e.DRUG_DRUG,i.MODERATE,"              antagonism  ","Cyproheptadine is a serotonin receptor antagonist, which reduces the therapeutic efficacy of Paroxetine through pharmacodynamic antagonism","             ","Reduced therapeutic efficacy of Paroxetine, potential return of depressive or anxiety symptoms, and diminished antidepressant response","     -                   ","Avoid concurrent use if possible - if Cyproheptadine is necessary, closely monitor Paroxetine response and consider dose adjustment or using a non-serotonergic alternative");n("Paroxetine - ","Desipramine - ",e.DRUG_DRUG,i.HIGH,"    (TCA)   CYP2D6           ","Paroxetine inhibits the metabolism of Desipramine (TCA) via hepatic CYP2D6 enzymes, increasing Desipramine concentrations and the risk of its adverse effects","               ","Increased Desipramine toxicity including anticholinergic effects, hypotension, cardiac arrhythmias, and seizures","       -              ","Monitor plasma Desipramine concentrations and toxicity symptoms - may require significant Desipramine dose reduction or use of alternative with lower interaction potential");n("Paroxetine - ","Imipramine - ",e.DRUG_DRUG,i.HIGH,"    (TCA)   CYP2D6 CYP2C19         ","Paroxetine inhibits the metabolism of Imipramine (TCA) via hepatic CYP2D6 and CYP2C19 enzymes, increasing concentrations of both Imipramine and its active metabolite desipramine","                ","Increased Imipramine toxicity including anticholinergic effects, orthostatic hypotension, cardiac arrhythmias, and seizures","       -       50-75%       ","Monitor plasma Imipramine concentrations and toxicity symptoms - may require 50-75% Imipramine dose reduction or use of alternative with lower interaction potential");n("Parsabiv (Etelcalcetide)","Calcium-based Phosphate Binders",e.DRUG_DRUG,i.MODERATE,"    .    .","Increased risk of hypercalcemia. Additive calcium-raising effect.","   .","Severe hypercalcemia."," .        .","Close monitoring. Monitor calcium levels and adjust phosphate binder dose.");n("Patisiran","Warfarin",e.DRUG_DRUG,i.MODERATE,"   INR. Patisiran               .","Change in INR levels. Patisiran may affect serum protein levels, including Vitamin K-dependent clotting factors.","    INR       .","Increase or decrease in INR, raising the risk of bleeding or clotting."," INR.    INR     Warfarin.","INR monitoring. INR must be closely monitored and Warfarin dose adjusted.");n("Patisiran","Irinotecan",e.DRUG_DRUG,i.MODERATE,"  Irinotecan. Patisiran   UGT1A1    Irinotecan.","Increased Irinotecan concentration. Patisiran inhibits UGT1A1, an Irinotecan metabolic pathway.","    .","Increased risk of hematological toxicity and diarrhea.","  .      Irinotecan.","Side effect monitoring. Patient must be monitored and Irinotecan dose adjusted.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Simvastatin (or Lovastatin)",e.DRUG_DRUG,i.HIGH,"    . Ritonavir    CYP3A4    .","Significant increase in statin concentration. Ritonavir is a strong inhibitor of CYP3A4, the statin metabolic pathway.","   (Rhabdomyolysis)    .","Risk of severe, life-threatening Rhabdomyolysis."," .   .        Paxlovid  5  .","Contraindicated. Avoid the combination. These statins must be stopped during Paxlovid therapy and for 5 days after.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Amiodarone",e.DRUG_DRUG,i.HIGH,"  Amiodarone. Ritonavir    CYP3A4.","Increased Amiodarone concentration. Ritonavir is a strong inhibitor of CYP3A4.","    QT    (Torsade de Pointes).","Increased risk of QT prolongation and Torsade de Pointes."," .   .","Contraindicated. Avoid the combination.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Colchicine",e.DRUG_DRUG,i.HIGH,"    Colchicine. Ritonavir   CYP3A4  P-gp.","Significant increase in Colchicine concentration. Ritonavir inhibits CYP3A4 and P-gp.","     Colchicine ( ).","Increased risk of fatal Colchicine toxicity (organ failure)."," .   .","Contraindicated. Avoid the combination.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Rivaroxaban",e.DRUG_DRUG,i.HIGH,"    Rivaroxaban. Ritonavir   CYP3A4  P-gp.","Significant increase in Rivaroxaban concentration. Ritonavir inhibits CYP3A4 and P-gp.","   .","Increased risk of severe hemorrhage."," .   .","Contraindicated. Avoid the combination.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Ritonavir       .","Complex changes in hormone levels. Ritonavir can affect the metabolism of estrogen and progestin.","   (   ).","Contraceptive failure (unwanted pregnancy)."," .             7  .","Special action. A reliable non-hormonal barrier contraceptive method must be used during therapy and for 7 days after.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Phenytoin. Ritonavir    CYP2C9/19 (   CYP3A4    ).       .","Decreased Phenytoin concentration. Ritonavir is a weak inducer of CYP2C9/19 (but a CYP3A4 inhibitor, making the interaction complex). The net effect is reduced anticonvulsant levels.","   .","Failure of seizure control."," .   Phenytoin    .","Close monitoring. Monitor Phenytoin levels and adjust the dose frequently.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Tamsulosin",e.DRUG_DRUG,i.MODERATE,"  Tamsulosin. Ritonavir   CYP3A4  P-gp.","Increased Tamsulosin concentration. Ritonavir inhibits CYP3A4 and P-gp.","     .","Increased risk of orthostatic hypotension."," .    .","Close monitoring. Monitor blood pressure and dizziness.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Simvastatin",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**. Ritonavir     .","Mechanism: **Potent CYP3A4 Inhibition**. Ritonavir dramatically inhibits statin metabolism."," : **  ** (Rhabdomyolysis)     .","Clinical Significance: **Life-threatening Rhabdomyolysis** and acute renal failure risk.","  .   Simvastatin    Paxlovid (5 ).","Absolute contraindication. Must discontinue Simvastatin during Paxlovid therapy (5 days).");n("Paxlovid (Nirmatrelvir/Ritonavir)","Atorvastatin",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   Atorvastatin  5-10 .","Mechanism: **Potent CYP3A4 Inhibition**. Atorvastatin concentration increases 5-10 fold."," : **  **   .","Clinical Significance: **Rhabdomyolysis risk** and severe myalgia."," Atorvastatin     Paxlovid.        .","Temporarily discontinue Atorvastatin during Paxlovid. Or significantly reduce dose with close monitoring.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Amlodipine",e.DRUG_DRUG,i.MODERATE,": ** CYP3A4**.   Amlodipine  .","Mechanism: **CYP3A4 Inhibition**. Increased Amlodipine plasma concentration."," : **  **    .","Clinical Significance: **Severe hypotension**, dizziness, peripheral edema.","  Amlodipine  50%    Paxlovid.   .","Reduce Amlodipine dose by 50% during Paxlovid therapy. Monitor blood pressure.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Rivaroxaban",e.DRUG_DRUG,i.HIGH,": ** CYP3A4  P-glycoprotein**.     Rivaroxaban.","Mechanism: **CYP3A4 and P-gp Inhibition**. Significant increase in Rivaroxaban concentration."," : ** **   .","Clinical Significance: **Severe bleeding risk** and life-threatening hemorrhage."," .        CYP3A4 ( Apixaban  ).","Avoid combination. Use alternative anticoagulant not dependent on CYP3A4 (e.g., Apixaban with reduced dose).");n("Paxlovid (Nirmatrelvir/Ritonavir)","Midazolam (Oral)",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.   Midazolam   25 .","Mechanism: **Severe CYP3A4 Inhibition**. Midazolam concentration increases >25-fold."," : ** **    .","Clinical Significance: **Excessive sedation** and life-threatening respiratory depression.","  .  Midazolam  .","Absolute contraindication. Avoid oral Midazolam completely.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Carbamazepine",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**. Carbamazepine   Nirmatrelvir  .","Mechanism: **Potent CYP3A4 Induction**. Carbamazepine significantly reduces Nirmatrelvir concentration."," : **  COVID-19**   Paxlovid.","Clinical Significance: **COVID-19 treatment failure** and Paxlovid inefficacy.","  .   .","Absolute contraindication. Avoid combination.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Rifampin",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**. Rifampin   Nirmatrelvir   90%.","Mechanism: **Potent CYP3A4 Induction**. Rifampin reduces Nirmatrelvir concentration by >90%."," : **    COVID-19**.","Clinical Significance: **Complete COVID-19 treatment failure**.","  .   .","Absolute contraindication. Avoid combination.");n("Paxlovid (Nirmatrelvir/Ritonavir)","Tacrolimus",e.DRUG_DRUG,i.HIGH,": ** CYP3A4**.     Tacrolimus (   35 ).","Mechanism: **CYP3A4 Inhibition**. Significant Tacrolimus increase (up to 35-fold)."," : ** **  .","Clinical Significance: **Severe nephrotoxicity** and neurotoxicity.","  Tacrolimus   (80-90%).    .","Significantly reduce Tacrolimus dose (80-90%). Monitor blood levels daily.");n("Pazopanib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Pazopanib. Ketoconazole    CYP3A4    Pazopanib.","Increased Pazopanib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Pazopanib metabolic pathway.","      QT.","Increased risk of hepatotoxicity and QT prolongation."," .    Pazopanib     CYP3A4 .","Dose adjustment. Pazopanib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pazopanib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Pazopanib.      CYP3A4  .","Increased Pazopanib concentration. Grapefruit juice is an inhibitor of intestinal CYP3A4.","      QT.","Increased risk of hepatotoxicity and QT prolongation."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Pazopanib","Simvastatin",e.DRUG_DRUG,i.HIGH," OATP1B1","OATP1B1 inhibition."," ","Rhabdomyolysis."," ","Avoid combination.");n($h,["Nitroglycerin","Isosorbide Dinitrate","Isosorbide Mononitrate","Amyl Nitrite"],e.DRUG_DRUG,i.CONTRAINDICATED,": **   **.  PDE5   cGMP    cGMP     .","Mechanism: **Severe synergistic vasodilation**. PDE5 inhibitors increase cGMP levels, and nitrates increase cGMP production, causing severe vasodilation."," : **    **          .","Clinical Significance: **Severe and fatal hypotension** that may lead to MI, stroke, or death."," .   24       PDE5    (48  ).","Strictly contraindicated. Wait 24 hours after last PDE5 inhibitor dose before giving nitrates (48 hours for Tadalafil).");n("Pegcetacoplan","Warfarin",e.DRUG_DRUG,i.MODERATE,"  . Pegcetacoplan          .","Increased bleeding risk. Pegcetacoplan is an immunomodulator that indirectly increases the potential for bleeding.","            .","Increased risk of bleeding and bruising due to additive pharmacodynamic effects, particularly at the injection site."," .            .","Caution and Monitoring. No absolute contraindication, but signs of bleeding should be closely monitored.");n("Pegcetacoplan","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Pegcetacoplan   C3  (Complement C3 inhibitor).","Increased risk of infection. Pegcetacoplan is a Complement C3 inhibitor.","     .","Risk of developing infection from live vaccines."," .          Pegcetacoplan.","Delay vaccination. Patients must be vaccinated with necessary vaccines before starting Pegcetacoplan treatment.");n("Pegcetacoplan (C3 Inhibitor)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"     . Pegcetacoplan   (Peptide).","No clinically significant interaction expected. Pegcetacoplan is a peptide.","   .","No known effect.","    .","No special action required.");n("Pegvaliase","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Pegvaliase (  PKU)     .","Increased risk of infection. Pegvaliase (PKU treatment) indirectly causes immunosuppression.","     .","Risk of developing infection from live vaccines."," .        Pegvaliase.","Contraindicated. Live vaccines must be avoided during Pegvaliase treatment.");n("Pegvisomant","Insulin",e.DRUG_DRUG,i.HIGH,"  . Pegvisomant       1 (IGF-I)     .","Decreased insulin requirements. Pegvisomant lowers Insulin-like Growth Factor 1 (IGF-I) levels, which increases insulin sensitivity.","     (Hypoglycemia)      .","Increased risk of hypoglycemia in diabetic patients receiving insulin.","  .           .","Blood glucose monitoring. Blood sugar levels must be regularly monitored, and insulin doses may need to be reduced.");n("Pegvisomant","Opioids",e.DRUG_DRUG,i.MODERATE,"   Pegvisomant.            .","Increased Pegvisomant requirement. Opioids may increase growth hormone secretion, requiring an increased inhibitor dose.","    IGF-1.","Failure to control IGF-1 levels."," .   IGF-1   Pegvisomant.","Close monitoring. Monitor IGF-1 levels and adjust Pegvisomant dose.");n("Pembrolizumab","Prednisone",e.DRUG_DRUG,i.HIGH,"  Pembrolizumab.        .","Reduced Pembrolizumab efficacy. Systemic corticosteroids decrease the anti-tumor immune response.","   (Anti-tumor effect)  Pembrolizumab    .","Loss of therapeutic (anti-tumor) effect due to Pembrolizumab failing to activate immune cells."," .           .","Avoid Combination. High doses of systemic corticosteroids should be avoided except for managing severe adverse reactions.");n("Pembrolizumab","Prednisone",e.DRUG_DRUG,i.HIGH,"  Pembrolizumab.        .","Decreased efficacy of Pembrolizumab. Corticosteroids are immunosuppressive and antagonize the inhibitor mechanism.","    (  ).","Reduced efficacy of immunotherapy (anti-cancer treatment)."," .       .","Contraindicated. Systemic corticosteroids must be avoided before treatment.");n("Pembrolizumab","Immunosuppressants",e.DRUG_DRUG,i.MODERATE,"   ","Antagonistic immune effect.","   ","Reduced immunotherapy efficacy.","   ","Avoid corticosteroids unless necessary.");n("Pembrolizumab (Keytruda)","Corticosteroids (High-dose)",e.DRUG_DRUG,i.MODERATE,": ** **.       .","Mechanism: **Immunosuppression**. Corticosteroids may reduce immunotherapy efficacy."," : **   **.","Clinical Significance: **Reduced immunotherapy efficacy**.","          .","Avoid systemic corticosteroids unless needed for immune-related adverse events.");n("Pembrolizumab (Keytruda)","Autoimmune Disease (  )",e.DRUG_DISEASE,i.HIGH,": ** **. Pembrolizumab     .","Mechanism: **Immune activation**. Pembrolizumab may activate autoimmune diseases."," : **   **.","Clinical Significance: **Autoimmune disease exacerbation**.","  .   .","Use with extreme caution. Close monitoring for symptoms.");n("Pemigatinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Pemigatinib. Voriconazole    CYP3A4      Pemigatinib.","Increased Pemigatinib concentration. Voriconazole is a potent CYP3A4 inhibitor, the primary metabolic pathway for Pemigatinib.","       .","Increased risk of side effects, especially ocular toxicity and hemorrhage."," .    Pemigatinib     CYP3A4 .","Dose adjustment. Pemigatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pemigatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pemigatinib. Rifampin    CYP3A4    Pemigatinib.","Decreased Pemigatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Pemigatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pemigatinib","Posaconazole",e.DRUG_DRUG,i.HIGH,"  Pemigatinib. Posaconazole    CYP3A4    Pemigatinib.","Increased Pemigatinib concentration. Posaconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Pemigatinib.","       .","Increased risk of side effects, especially ocular toxicity and hemorrhage."," .    Pemigatinib     CYP3A4 .","Dose adjustment. Pemigatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pemigatinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Pemigatinib. Phenytoin    CYP3A4    Pemigatinib.","Decreased Pemigatinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Pemigatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pemigatinib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Pemigatinib. Efavirenz    CYP3A4    Pemigatinib.","Decreased Pemigatinib efficacy. Efavirenz is a moderate inducer of CYP3A4, a Pemigatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Pemigatinib","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Pemigatinib. Fluconazole    CYP3A4    Pemigatinib.","Increased Pemigatinib concentration. Fluconazole is a strong CYP3A4 inhibitor, a Pemigatinib metabolic pathway.","       .","Increased risk of side effects, especially ocular toxicity and hemorrhage."," .    Pemigatinib     CYP3A4 .","Dose adjustment. Pemigatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pemigatinib (Pemazyre)","Strong CYP3A4 Inducers (Carbamazepine)",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   Pemigatinib  80%.","Mechanism: **Potent CYP3A4 induction**. Pemigatinib concentration decreases by 80%."," : **    **.","Clinical Significance: **Cholangiocarcinoma treatment failure**."," .    .","Avoid combination. Use alternative anticonvulsant.");n("Pemigatinib (Pemazyre)","Hyperphosphatemia",e.DRUG_DISEASE,i.MODERATE,": ** FGF23**.      .","Mechanism: **FGF23 inhibition**. Increases renal phosphate reabsorption."," : **  **   .","Clinical Significance: **Hyperphosphatemia** and soft tissue calcification.","   .    .","Monitor phosphate every 2 weeks. Low-phosphate diet.");n("Penicillamine","Iron Supplements",e.DRUG_DRUG,i.MODERATE,"  Penicillamine.   Penicillamine   .","Decreased Penicillamine absorption. Iron chelates Penicillamine in the gastrointestinal tract.","  Penicillamine.","Reduced efficacy of Penicillamine."," .      2   .","Dose separation. The two drugs must be separated by at least 2 hours.");n("Penicillin G","Tetracycline",e.DRUG_DRUG,i.MODERATE,"  .","Reduced Penicillin Efficacy. Bacteriostatic agents may interfere with the bactericidal action of penicillins.","    .","Treatment Failure. Persistent infection.","  .","  .");n("Penicillin G","Doxycycline",e.DRUG_DRUG,i.MODERATE,"  .","Reduced Penicillin Efficacy. Bacteriostatic agents may interfere with the bactericidal action of penicillins.","    .","Treatment Failure. Persistent infection.","  .","  .");n("Penicillin G","Minocycline",e.DRUG_DRUG,i.MODERATE,"  .","Reduced Penicillin Efficacy. Bacteriostatic agents may interfere with the bactericidal action of penicillins.","    .","Treatment Failure. Persistent infection.","  .","  .");n("Penicillin G","Food ()",e.DRUG_FOOD,i.MODERATE,"     .","Reduced Penicillin Absorption. GI interaction lowers bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","       .","       .");n("Penicillin V","Tetracycline",e.DRUG_DRUG,i.MODERATE,"  .","Reduced Penicillin Efficacy. Bacteriostatic agents may interfere with the bactericidal action of penicillins.","    .","Treatment Failure. Persistent infection.","  .","  .");n("Penicillin V","Doxycycline",e.DRUG_DRUG,i.MODERATE,"  .","Reduced Penicillin Efficacy. Bacteriostatic agents may interfere with the bactericidal action of penicillins.","    .","Treatment Failure. Persistent infection.","  .","  .");n("Penicillin V","Minocycline",e.DRUG_DRUG,i.MODERATE,"  .","Reduced Penicillin Efficacy. Bacteriostatic agents may interfere with the bactericidal action of penicillins.","    .","Treatment Failure. Persistent infection.","  .","  .");n("Penicillin V","Food ()",e.DRUG_FOOD,i.MODERATE,"     .","Reduced Penicillin Absorption. GI interaction lowers bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","       .","       .");n(zc,"Methotrexate",e.DRUG_DRUG,i.HIGH,": **   **.     .","Mechanism: **Renal tubular secretion inhibition**. Penicillins inhibit renal tubular secretion of Methotrexate."," : **   ** (     ).","Clinical Significance: **Increased Methotrexate levels and toxicity** (bone marrow suppression, hepatotoxicity, nephrotoxicity).","     .        .","Avoid combination with high-dose Methotrexate. If necessary, close monitoring of levels and CBC.");n(zc,St,e.DRUG_DRUG,i.MODERATE,": **  (Antagonism)**.  ( )      ()   .","Mechanism: **Pharmacodynamic antagonism**. Penicillins (bactericidal) require actively dividing bacteria, while Tetracyclines (bacteriostatic) stop bacterial growth."," : **  **   .","Clinical Significance: **Decreased Penicillin effectiveness** in serious infections.","     (  ).","Avoid combination in serious infections (e.g., meningitis).");n("Pentobarbital","Atenolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Bisoprolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Carvedilol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Metoprolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Propranolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Nebivolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Labetalol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Pentobarbital","Prednisone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Pentobarbital","Prednisolone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Pentobarbital","Hydrocortisone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Pentobarbital","Dexamethasone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Pentobarbital","Betamethasone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Pentobarbital","Methylprednisolone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Pentobarbital","Doxycycline -  ",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","Doxycycline Failure. Enzyme induction reduces half-life.","   ","   ","    ()    ","    ()    ");n("Pentobarbital","Estrogens - ",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","Estrogen Failure. Enzyme induction reduces efficacy.","  ","  ","        ","        ");n("Pentobarbital","Ethanol - ",e.DRUG_DRUG,i.HIGH,"      ","Additive CNS Inhibition. Profound sedation.","   ","Increased CNS Depression. Drowsiness and ataxia.","  ","  ");n("Pentobarbital","Amlodipine",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Pentobarbital","Diltiazem",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Pentobarbital","Verapamil",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Pentobarbital","Nifedipine",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Pentobarbital","Griseofulvin - ",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Barbiturate Absorption. Decreased efficacy.","  ","  ","     ","     ");n("Pentobarbital","Methadone - ",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","Methadone Withdrawal. Enzyme induction lowers levels.","  ","  ","     ","     ");n("Pentobarbital","Warfarin - ",e.DRUG_DRUG,i.HIGH,"   (CYP450)    (  )","Reduced Warfarin Effect. Enzyme induction increases clotting risk.","  ","  ","    (INR) ","    (INR) ");n("Pentobarbital","Voriconazole - ",e.DRUG_DRUG,i.HIGH,"   (CYP450)   ","Barbiturate Toxicity. Metabolic inhibition.","  ","  ","     ","     ");n("Perampanel","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Perampanel. Carbamazepine    CYP3A4.","Decreased Perampanel concentration. Carbamazepine is a strong inducer of CYP3A4.","          .","Reduced anticonvulsant efficacy, leading to failure of seizure control."," .       Perampanel.","Dose increase. Perampanel dose may need to be increased.");n("Perindopril","Spironolactone",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Perindopril","Eplerenone",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Perindopril","Amiloride",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Perindopril","Aspirin",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Ibuprofen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Diclofenac",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Naproxen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Ketoprofen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Indomethacin",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Celecoxib",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Perindopril","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Pexidartinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pexidartinib. Rifampin    CYP3A4    Pexidartinib.","Decreased Pexidartinib efficacy. Rifampin is a strong inducer of CYP3A4, a Pexidartinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pexidartinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Pexidartinib. Voriconazole    CYP3A4    Pexidartinib.","Increased Pexidartinib concentration. Voriconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Pexidartinib.","      .","Increased risk of side effects, especially hepatotoxicity."," .    Pexidartinib     CYP3A4 .","Dose adjustment. Pexidartinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pexidartinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Pexidartinib. Phenytoin    CYP3A4    Pexidartinib.","Decreased Pexidartinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Pexidartinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pexidartinib","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  Pexidartinib. Fluconazole    CYP3A4    Pexidartinib.","Increased Pexidartinib concentration. Fluconazole is a strong CYP3A4 inhibitor, a Pexidartinib metabolic pathway.","      .","Increased risk of side effects, especially hepatotoxicity.","  .          .","Side effect monitoring. No contraindication, but close monitoring of liver function is necessary.");n("Pexidartinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pexidartinib. Rifampin    CYP3A4    Pexidartinib.","Decreased Pexidartinib efficacy. Rifampin is a strong inducer of CYP3A4, a Pexidartinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pexidartinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Pexidartinib. Ketoconazole    CYP3A4.","Increased Pexidartinib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","   .","Increased risk of liver toxicity."," .    Pexidartinib  .","Dose adjustment. Pexidartinib dose must be significantly reduced.");n("Phenelzine","Meperidine -  ( )",e.DRUG_DRUG,i.HIGH,"  .                 .","Additive serotonergic effects. Phenelzine prevents serotonin breakdown, and Meperidine has Serotonin Reuptake Inhibitor (SRI) activity, leading to an acute, dangerous increase in serotonin concentration.","  (Serotonin Syndrome)    (        ) .","Acute, life-threatening Serotonin Syndrome (rigidity, hyperthermia, mental status changes, autonomic instability), and coma.","  .     (Washout Period)       .","Absolute Contraindication. A washout period of at least two weeks must be observed between stopping the two drugs.");n("Phenelzine","Serotonin Reuptake Inhibitors - SSRIs/SNRIs (  )",e.DRUG_DRUG,i.HIGH,"  .      SSRIs              .","Additive serotonergic effects. Phenelzine prevents serotonin breakdown, and SSRIs block its reuptake, leading to a massive increase in synaptic serotonin concentration.","  (Serotonin Syndrome)   .","Acute, life-threatening Serotonin Syndrome.","  .     (Washout Period)        (      ).","Absolute Contraindication. A washout period of at least two weeks must be observed between stopping the two drugs (five weeks if the drug is Fluoxetine).");n("Phenelzine","Tricyclic Antidepressants - TCAs (  )",e.DRUG_DRUG,i.HIGH,"    . MAOI    TCA   .","Additive effects on Norepinephrine and Serotonin. MAOI blocks breakdown, and TCA blocks reuptake.","    (Hypertensive Crisis)  /   (Serotonin Syndrome).","Severe Hypertensive Crisis and/or Serotonin Syndrome.","  .     (Washout Period)       .","Absolute Contraindication. A washout period of at least two weeks must be observed between stopping the two drugs.");n("Phenelzine","Bupropion - ",e.DRUG_DRUG,i.HIGH,"    . MAOI      .","Additive effects on Dopamine and Norepinephrine. MAOI blocks breakdown, and Bupropion blocks reuptake.","    (Hypertensive Crisis)    (Seizures)  .","Hypertensive Crisis and significantly increased risk of Seizures.","  .     (Washout Period)       .","Absolute Contraindication. A washout period of at least two weeks must be observed between stopping the two drugs.");n("Phenelzine (MAOI)","Tyramine-Rich Foods (Aged Cheese, Cured Meats)",e.DRUG_FOOD,i.HIGH,"     .  MAOI   .","Increased risk of Hypertensive Crisis. MAOIs prevent Tyramine metabolism.","    (  ).","Severe hypertension (potentially fatal)."," .          (Low-Tyramine Diet).","Contraindicated. The patient must adhere to a Low-Tyramine Diet.");n("Phenobarbital","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Phenobarbital    CYP.","Decreased oral contraceptive concentration. Phenobarbital is a strong inducer of CYP enzymes.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .          .","Relative contraindication. An additional non-hormonal or alternative contraceptive method must be used.");const af=["Atenolol","Bisoprolol","Carvedilol","Metoprolol","Propranolol","Nebivolol","Labetalol"];af.forEach(h=>{n("Phenobarbital",h,e.DRUG_DRUG,i.MODERATE,'     (CYP450).      ()     "  "              .','Phenobarbital acts as a potent inducer of hepatic CYP450 enzymes. This induction accelerates the metabolic clearance of beta-blockers and increases their "first-pass effect", leading to significantly reduced plasma concentrations and comprised therapeutic efficacy.',"    (        )","Reduced beta-blocker efficacy (risk of hypertension or arrhythmia).","       .                     .","Closely monitor BP and heart rate. A dose increase of the beta-blocker is often required to maintain therapeutic response. Consider agents less dependent on CYP metabolism.")});Xu.forEach(h=>{n("Phenobarbital",h,e.DRUG_DRUG,i.MODERATE,"   CYP3A4     .                   .","Phenobarbital induces hepatic CYP3A4 enzymes responsible for corticosteroid metabolism. This increases clearance and shortens the half-life of the steroid, resulting in subtherapeutic serum levels.","   (        )","Reduced corticosteroid efficacy (risk of exacerbation of inflammation, asthma, or adrenal insufficiency).","      .               .","Adjust corticosteroid dose, usually by increasing it. In stress situations or severe illness, significantly higher doses may be required to prevent adrenal insufficiency.")});n("Phenobarbital","Doxycycline -  ",e.DRUG_DRUG,i.MODERATE,"              (Half-life)         .","Phenobarbital induces the hepatic metabolism of doxycycline, shortening its half-life and reducing serum concentrations to sub-therapeutic levels, potentially leading to treatment failure.","     ","Antibiotic treatment failure.","    ( 100   12 )         .","Increase doxycycline dose (e.g., to BID) or switch to an antibiotic not affected by enzyme induction.");n("Phenobarbital","Estrogens - ",e.DRUG_DRUG,i.MODERATE,"        CYP450             .","Accelerated hepatic metabolism of estrogens due to CYP450 induction reduces hormonal efficacy, posing a significant risk of contraceptive failure.","   (    )","Reduced estrogen efficacy (risk of unintended pregnancy).","         (   )      .","Recommend alternative or non-hormonal contraception (e.g., IUD, barrier methods) during therapy and for one cycle after discontinuation.");n("Phenobarbital","Ethanol - ",e.DRUG_DRUG,i.HIGH,"  (Pharmacodynamic):        (CNS Depressants).          .","Pharmacodynamic interaction: Both agents are CNS depressants. Concurrent use results in synergistic depression of the CNS and respiratory drive.","       ","Severe CNS depression, coma, or respiratory failure.","          .","Strictly avoid ethanol consumption during barbiturate therapy to prevent life-threatening toxicity.");n("Phenobarbital","Warfarin - ",e.DRUG_DRUG,i.HIGH,"   CYP2C9      . :          .","Phenobarbital induces CYP2C9, accelerating warfarin metabolism and reducing its anticoagulant effect. Note: Discontinuing phenobarbital can cause a rebound spike in warfarin levels, leading to hemorrhage.","   ( )    ","Decreased warfarin effect (clotting risk) or bleeding upon discontinuation.","       INR .        .","Increase warfarin dose based on frequent INR monitoring. Anticipate need to reduce warfarin dose if phenobarbital is discontinued.");n("Phenobarbital","Voriconazole - ",e.DRUG_DRUG,i.HIGH," :     ( )      (  ).","Complex interaction: Voriconazole inhibits phenobarbital metabolism (toxicity risk), while phenobarbital induces voriconazole metabolism (fungal treatment failure).","    ","Barbiturate toxicity and antifungal failure.","   .             .","Avoid combination if possible. If necessary, monitor serum drug levels and adjust doses with extreme caution.");const ty=["Amlodipine","Diltiazem","Verapamil","Nifedipine"];ty.forEach(h=>{n("Phenobarbital",h,e.DRUG_DRUG,i.MODERATE,"  CYP3A4                 .","Induction of CYP3A4 enzymes leads to rapid metabolism of CCBs, reducing their bioavailability and hemodynamic effects.","      ","Loss of blood pressure control or angina management.","           .","May require increasing the CCB dose or switching to a different antihypertensive class.")});n("Phenobarbital","Methadone - ",e.DRUG_DRUG,i.MODERATE,"                    .","Induced hepatic metabolism of methadone reduces plasma concentrations, potentially precipitating opioid withdrawal symptoms in dependent patients.","   (  )   ","Opioid withdrawal symptoms (anxiety, sweating, pain) and reduced analgesia.","            .","Increase methadone dose and potentially dosing frequency; monitor closely for withdrawal signs.");af.forEach(h=>{n("Phenylephrine",h,e.DRUG_DRUG,i.MODERATE,'  (Pharmacodynamic):    -1 ( )     .      ( )   "   "     .','Pharmacodynamic antagonism: Phenylephrine activates alpha-1 receptors (vasoconstriction), opposing beta-blocker effects. With non-selective beta-blockers, "unopposed alpha stimulation" may occur, causing severe hypertension and reflex bradycardia.',"           ","Reduced efficacy of both agents, or risk of severe hypertension and reflex bradycardia.","    .        .       (Cardioselective)     .","Avoid concurrent use if possible. If necessary, monitor BP closely. Cardioselective beta-blockers are preferred to minimize the risk of unopposed alpha-mediated vasoconstriction.")});n("Phenylephrine","Beta-blockers",e.DRUG_DRUG,i.MODERATE,": **     (Unopposed Alpha-Adrenergic Stimulation)**.       -1 ( ).         -2             .","Mechanism: **Unopposed alpha-adrenergic stimulation**. Phenylephrine is an alpha-1 selective sympathomimetic (vasoconstrictor). Beta-blockers prevent compensatory vasodilation via beta-2 receptors, leaving alpha-mediated vasoconstriction unopposed and significantly increased."," : **   **     (Enhanced Reflex Bradycardia).          30-50 mmHg        (< 50 /).    **   ** ( ).            .","Clinical Significance: **Severe hypertension** and enhanced reflex bradycardia. Systolic blood pressure may increase by 30-50 mmHg above normal, with very slow heart rate (< 50 bpm). Risk is highest with **non-selective beta-blockers** (e.g., propranolol). May lead to severe headache, dizziness, or rarely stroke.","   (       )      **   **.      :        **  **     -1  ( )     ** **  **  **.     :       ( ).","Avoid phenylephrine use (in eye drops, nasal sprays, or injections) in patients on beta-blockers **except when absolutely necessary**. If use is unavoidable: closely monitor BP and heart rate, use **lowest possible dose**, consider using selective beta-1 blockers (less risky), or use alternatives such as **saline solution** or **low-dose oxymetazoline**. If acute hypertension occurs: discontinue phenylephrine and treat with alpha-blockers (e.g., phentolamine).");n("Phenytoin","Cimetidine",e.DRUG_DRUG,i.HIGH,"Cimetidine is a potent inhibitor of the hepatic cytochrome P450 enzymes (specifically CYP2C9 and CYP2C19) responsible for Phenytoin metabolism.","           CYP2C9  CYP2C19.","Increased Phenytoin plasma levels, significantly raising the risk of dose-related toxicity (e.g., nystagmus, ataxia, confusion).","            (   ).","Avoid co-administration. If necessary, switch the patient to a histamine H2 blocker that has minimal CYP inhibition (like Ranitidine or Famotidine).","   .            .");n("Phenytoin","Fluconazole",e.DRUG_DRUG,i.HIGH,": **  (CYP2C9)**.    .","Mechanism: **Metabolism inhibition (CYP2C9)**. Fluconazole inhibits Phenytoin metabolism."," : **    **  .","Clinical Significance: **Significant increase in Phenytoin levels** and toxicity risk.","  .     .","Monitor Phenytoin levels. Dose reduction may be required.");n("Phenytoin","Theophylline",e.DRUG_DRUG,i.MODERATE,"Theophylline and Phenytoin mutually induce the metabolism of one another through hepatic enzyme induction (Phenytoin primarily CYP3A4/CYP2C9; Theophylline primarily CYP1A2).","      :         .","Decreased plasma levels of both drugs, potentially leading to loss of therapeutic effect and control of seizures (Phenytoin) or asthma/COPD (Theophylline).","                 .","Monitor plasma concentrations of both Theophylline and Phenytoin closely. Adjust the dose of both medications as necessary to maintain therapeutic ranges.","               .");n("Phenytoin","Cimetidine",e.DRUG_DRUG,i.MODERATE,'    (CYP2C9).    " " (Zero-order kinetics)              .',"Cimetidine inhibits CYP2C9/CYP2C19 enzymes. Since phenytoin exhibits non-linear (zero-order) pharmacokinetics, even slight metabolic inhibition causes a disproportionate spike in serum levels.","   (   )","Acute phenytoin toxicity (ataxia, nystagmus, confusion)."," .    (Famotidine)      .          .","Avoid cimetidine; switch to Famotidine (safe alternative). If concurrent use is necessary, reduce phenytoin dose and strictly monitor serum levels.");n("Phenytoin","Chloramphenicol",e.DRUG_DRUG,i.HIGH,"    CYP2C9         .","Chloramphenicol is a potent CYP2C9 inhibitor, blocking phenytoin metabolism and elevating serum concentrations to toxic ranges.","  (    )","Phenytoin toxicity (plus shared risk of bone marrow suppression).","           .","Strictly monitor phenytoin serum levels; anticipate dose reduction upon initiation.");n("Phenytoin","Isoniazid",e.DRUG_DRUG,i.HIGH,'    (    " "  - Slow Acetylators).    .','Isoniazid inhibits phenytoin metabolism (risk is higher in "slow acetylator" patients), leading to accumulation and toxicity.',"  ( )","Phenytoin toxicity (neurotoxicity).","        (  ).","Reduce phenytoin dose and monitor for signs of neurotoxicity (e.g., ataxia).");n("Phenytoin","Amiodarone",e.DRUG_DRUG,i.MODERATE,"   CYP2C9   .      ( ).","Amiodarone inhibits CYP2C9, raising phenytoin levels. Conversely, phenytoin induces amiodarone metabolism, lowering its levels (bidirectional interaction).","  +   ","Phenytoin toxicity + reduced amiodarone efficacy.","    30-50%      .","Reduce phenytoin dose by 30-50% when starting amiodarone; monitor levels of both agents.");const oy=["Ethinylestradiol/Levonorgestrel","Ethinylestradiol/Desogestrel","Ethinylestradiol/Drospirenone"];oy.forEach(h=>{n("Phenytoin",h,e.DRUG_DRUG,i.HIGH,"    CYP3A4             .","Phenytoin is a potent CYP3A4 inducer, accelerating the metabolism of contraceptive hormones significantly, leading to sub-therapeutic levels.","        ","Contraceptive failure and unintended pregnancy.","      (  )       (  ).","Use alternative non-hormonal contraception (IUD, condoms) or high-dose hormonal regimens under specialist supervision.")});Xu.forEach(h=>{n("Phenytoin",h,e.DRUG_DRUG,i.MODERATE,"  CYP3A4           50%    .","Phenytoin-mediated CYP3A4 induction reduces corticosteroid half-life by up to 50%, compromising therapeutic efficacy.","   (      )","Reduced efficacy (risk of organ rejection or asthma exacerbation).","          .","Corticosteroid dosage usually needs to be doubled to compensate for accelerated metabolism.")});n("Phenytoin","Folic Acid",e.DRUG_DRUG,i.LOW," :    .              .","Complex interaction: Phenytoin reduces folate absorption. Conversely, folic acid supplementation acts as a cofactor enhancing phenytoin metabolism, potentially lowering its levels.","   ()      ","Folate deficiency (anemia) or slight reduction in phenytoin levels.","           .","Monitor phenytoin levels when initiating folic acid; adjust dose if seizure control is compromised.");n("Phenytoin","Furosemide",e.DRUG_DRUG,i.MODERATE,"          .","Phenytoin impairs the gastrointestinal absorption of furosemide and reduces renal sensitivity to the diuretic.","    ( )","Reduced diuretic efficacy (fluid retention).","      .","Increase furosemide dose and separate administration times.");n("Phenytoin","Folic Acid-Rich Foods",e.DRUG_FOOD,i.MODERATE,"       : (1)                  (2)             CYP450          .    :     (   )    .           .","Relationship between phenytoin and folic acid is complex and bidirectional: (1) phenytoin inhibits intestinal folic acid absorption and increases its metabolism, potentially causing folate deficiency in patients, (2) folic acid in turn increases hepatic phenytoin metabolism via CYP450 enzyme induction and may enhance renal clearance, lowering blood phenytoin levels. Folate-rich foods include: dark green leafy vegetables (spinach, kale, arugula, broccoli), legumes, fortified cereals, liver. Sudden changes in these foods consumption may affect seizure control.","               : (1)        (2)         (    ).    :                         (      ).","Decreased blood phenytoin levels with significant folic acid intake increase, potentially causing: (1) loss of seizure control and increased frequency, (2) return of previously controlled seizure types (grand mal, partial seizures, absence). Risk is higher in: patients with phenytoin levels near lower therapeutic limit, or those suddenly starting folic acid supplements or radically changing diet (e.g., starting vegetarian diet rich in leafy greens)."," : (1)             -      (  )       (2)       (3)       (       )        -      (4)  :       3-6      (    10-20 mcg/mL) (5)    :      (aura)     (6)              .","Optimal strategy: (1) maintain balanced, consistent diet with moderate folate amounts - don't completely avoid leafy greens (important for health) but keep weekly amount stable, (2) avoid sudden or radical dietary changes, (3) if needing folic acid supplements (e.g., during pregnancy or treating documented folate deficiency), must discuss with neurologist first - may need phenytoin dose adjustment, (4) periodic monitoring: measure blood phenytoin levels every 3-6 months or as directed (usual therapeutic range 10-20 mcg/mL), (5) monitor for low level signs: increased seizure frequency, aura return, seizure nature changes, (6) don't start multivitamins without medical consultation as most contain folate.");n("Phenytoin","Alcohol",e.DRUG_FOOD,i.HIGH,"           : (1)   (    ):      CYP2C9  CYP2C19           (2)   (  /):          .                    .","Alcohol effect on phenytoin is paradoxical and complex, dependent on usage pattern, dose, and timing: (1) acute use (large single-occasion amounts): alcohol competes with phenytoin for hepatic CYP2C9 and CYP2C19 enzymes, temporarily inhibiting phenytoin metabolism and acutely raising levels, (2) chronic use (regular weeks/months drinking): alcohol induces same enzymes, accelerating phenytoin metabolism and lowering levels. Additionally, alcohol itself lowers brain seizure threshold increasing occurrence risk, and interacts with phenytoin adding CNS depressant effects.","     : (1)  :      (   )                 (12-48   )       (2)  :     (   )   :         (   )   (3)  :               .","Dual unpredictable risk: (1) seizure risk: either from decreased phenytoin levels (chronic drinking) or alcohol's direct brain effect lowering seizure threshold, especially during alcohol withdrawal period(12 - 48 hours after stopping) where seizure risk rises sharply, (2) toxicity risk: from elevated phenytoin levels(acute drinking) with symptoms like: severe ataxia, tremor, mental confusion, slurred speech, nystagmus(involuntary eye movement), severe dizziness, (3) additional effects: severe CNS depression, impaired motor coordination, impaired judgment and decisions, increased fall and injury risk."," :      . : (1)      (2)     (3)   .            :                          (    ).    :             (    ).     .","Absolute recommendation: completely avoid alcohol during phenytoin therapy. Reasons: (1) interaction unpredictability, (2) alcohol itself is seizure trigger, (3) dangerous interaction risk. For patients with alcohol addiction or difficulty stopping: must frankly discuss with physician for appropriate treatment plan, consider addiction treatment programs, extreme caution regarding alcohol withdrawal seizures that may be life-threatening (must stop under medical supervision). Emergency warning signs: new seizure or increased frequency, phenytoin toxicity symptoms, alcohol withdrawal seizures (severe tremor, hallucinations, profuse sweating). Careful medical follow-up absolutely essential.");n("Phenytoin - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"       : 1.   :    (   )      P450 2C9 (CYP2C9)     .          . 2.    :        ().                  .                      .","Sulfonamides interact with phenytoin through two main mechanisms: 1. Inhibition of phenytoin metabolism: Many sulfonamides (e.g., sulfamethoxazole, sulfaphenazole, sulfadiazine) are competitive inhibitors of the cytochrome P450 2C9 enzyme (CYP2C9), the primary metabolic pathway for phenytoin. This reduces phenytoin clearance and increases its biological half-life. 2. Displacement from protein binding: Both sulfonamides and phenytoin are highly bound to plasma proteins (albumin). Sulfonamides compete for the same binding sites, displacing phenytoin and increasing its free, biologically active fraction in the plasma. This combination of metabolic inhibition and protein displacement leads to a significant increase in the active free phenytoin concentration, which is responsible for both therapeutic and toxic effects.",'                       "" (10-20 /).  : 1.   :  (Nystagmus)   (Ataxia). 2.  :  (Dysarthria)  . 3.  :      ()  .                           .','Rapid increase in free active phenytoin plasma levels, leading to central nervous system phenytoin toxicity even if the total level remains within the "normal" range (10-20 mcg/mL). Symptoms include: 1. Early neurological signs: Nystagmus, dizziness, ataxia. 2. Moderate symptoms: Dysarthria, tremors, confusion. 3. Severe symptoms: Profound drowsiness, coma, seizures (paradoxical), respiratory depression. The risk is higher in patients with hypoalbuminemia, the elderly, or those with baseline phenytoin levels at the high end of the therapeutic range.',"1.   :            2-5     .    (>2 /)        . 2.   :     25-35              . 3.   :     (  )      . 4.   :         CYP2C9          /   (   ). 5.   :             . 6.   :                          .","1. Precise therapeutic monitoring: Measure both total and free phenytoin plasma levels before starting the sulfonamide, and after 2-5 days of starting combination therapy. The free phenytoin level (>2 mcg/mL) is more reliable than the total level in this scenario. 2. Proactive dose reduction: Reduce the phenytoin dose by 25-35% when initiating the sulfonamide, especially if the baseline level is high or in at-risk patients. 3. Intensive clinical monitoring: Monitor for signs of neurotoxicity (especially nystagmus and ataxia) daily during the first week of combination. 4. Use of alternative sulfonamides: If possible, use alternative antibiotics that do not potently inhibit CYP2C9 or compete strongly for protein binding, such as amoxicillin/clavulanate or quinolones (considering their other interactions). 5. Dynamic dose adjustment: Adjust the phenytoin dose based on free levels and clinical response, not just total levels. 6. Post-discontinuation monitoring: When discontinuing the sulfonamide, gradually increase the phenytoin dose back to the previous level based on monitoring, as the protein displacement effect dissipates quickly while metabolic inhibition persists for several days.");n("Phenytoin - ","Fluconazole - ",e.DRUG_DRUG,i.HIGH,"       P450 2C9 (CYP2C9)     .                   75-100 ( )       .     24-48           5-7 .   -dependent       (200 /)    .","Fluconazole is a potent and moderate inhibitor of the cytochrome P450 2C9 enzyme (CYP2C9), the primary metabolic pathway for phenytoin. This inhibition leads to a significant reduction in phenytoin metabolism, increasing its plasma concentration by up to 75-100% (doubling levels), and markedly prolonging its biological half-life. This interaction begins within 24-48 hours of starting combination therapy and peaks within 5-7 days. The interaction is dose-dependent, with higher fluconazole doses (200 mg/day) causing more severe inhibition.","           (>20 /)       : 1.   :  (Nystagmus)  (Ataxia)  (Dysarthria)   . 2.   :  . 3.   :    . 4.          .                             .","Rapid and significant increase in phenytoin plasma levels above the therapeutic range (>20 mcg/mL), leading to phenytoin toxicity which includes: 1. Central neurotoxicity: Nystagmus, ataxia, dysarthria, confusion, drowsiness, coma. 2. Gastrointestinal symptoms: Nausea, vomiting. 3. Ocular effects: Blurred vision, diplopia. 4. In severe cases, it may lead to encephalopathy and respiratory depression. Toxicity is more common and severe in the elderly, patients with impaired liver function, or those with baseline phenytoin levels at the high end of the therapeutic range.","1.   :          2-3         . 2.   :     25-50   . 3.   :     (   )    . 4.  :          CYP2C9   ()   ( ). 5.   :         . 6.  :           .","1. Mandatory therapeutic monitoring: Measure phenytoin plasma levels before starting fluconazole, after 2-3 days of starting combination therapy, then weekly during combination. 2. Proactive dose reduction: Reduce the phenytoin dose by 25-50% when initiating fluconazole. 3. Close clinical monitoring: Monitor for signs of neurotoxicity (nystagmus, ataxia, speech disturbances) daily during the first week. 4. Fluconazole alternatives: If possible, use other antifungals with less CYP2C9 inhibition, such as itraconazole (with caution) or voriconazole (with similar inhibition). 5. Dynamic dose adjustment: Adjust the phenytoin dose based on plasma levels and clinical response. 6. Drug education: Alert the patient and caregiver to phenytoin toxicity symptoms and instruct immediate reporting.");n("Phenytoin - ","Theophylline - ",e.DRUG_DRUG,i.MODERATE,"       P450   CYP1A2 CYP3A4     .                   40-60           (AUC).     3-7           2-3 .              P450.","Phenytoin acts as a potent and broad inducer of hepatic cytochrome P450 enzymes, particularly CYP1A2 and CYP3A4, responsible for the primary metabolism of theophylline. This induction leads to a significant increase in theophylline metabolism, reducing its plasma concentration by up to 40-60%, shortening its biological half-life, and lowering the area under the curve (AUC). This effect begins within 3-7 days of starting combination therapy and peaks within 2-3 weeks. The effect persists for several weeks after discontinuing phenytoin due to the time required for cytochrome P450 enzyme regeneration.","          (10-20 /)   : 1.         (    ). 2.       . 3.                      . 4.                 .","Marked decrease in theophylline plasma levels below the therapeutic range (10-20 mcg/mL), leading to: 1. Failure to control symptoms of obstructive lung diseases (asthma, COPD). 2. Increased frequency and severity of dyspnea and wheezing episodes. 3. The need for higher theophylline doses to achieve therapeutic effect, which may pose dosing challenges if phenytoin is discontinued later. 4. In patients with severe asthma, this may worsen the condition and increase the risk of respiratory complications.","1.   :          5-7        2-4   . 2.   :     50-100   .        . 3.  :       . 4.    :         50-75   2-3   . 5.  : Patients                        ()    2   (). 6.  :              .","1. Mandatory therapeutic monitoring: Measure theophylline plasma levels before starting phenytoin, after 5-7 days of starting combination therapy, then every 2-4 weeks during combination. 2. Proactive dose increase: Increase the theophylline dose by 50-100% when initiating phenytoin. More frequent divided dosing may be necessary. 3. Clinical monitoring: Regularly monitor respiratory symptoms and lung function. 4. Dose adjustment after discontinuation: When discontinuing phenytoin, gradually reduce the theophylline dose by 50-75% over 2-3 weeks to avoid toxicity. 5. Treatment alternatives: For patients requiring long-term phenytoin therapy, consider using alternative bronchodilators not affected by enzyme induction, such as long-acting anticholinergics (tiotropium) or long-acting beta-2 agonists (salmeterol). 6. Drug education: Educate the patient about the importance of adhering to the adjusted dose and reporting any changes in respiratory symptoms.");n("Phenytoin - ","Aluminum Hydroxide -  ",e.DRUG_DRUG,i.LOW,"            (Al)            chelation.        .                   .                      .","Aluminum hydroxide, as an antacid containing trivalent cations (Al), can form insoluble complexes with phenytoin in the gastrointestinal tract via chelation. This reduces the dissolution and absorption of phenytoin from the intestines. This physico-chemical interaction can occur in the stomach or intestines, particularly in a neutral to alkaline pH environment. This can lead to a decrease in the bioavailability of phenytoin, although clinical studies show variability in the extent of this effect.","          : 1.   below the therapeutic range (10-20 mcg/mL). 2.       . 3.        .                         .","Potential decrease in phenytoin plasma levels, which may lead to: 1. Concentration falling below the therapeutic range (10-20 mcg/mL). 2. Loss of seizure control or increased seizure frequency. 3. Need to adjust the phenytoin dose to maintain efficacy. The risk is greater in patients relying on precise seizure control or those with phenytoin levels at the lower end of the therapeutic range.","1.   :          2-3 .             . 2.  :               . 3.  :         . 4.   :                      . 5.  :               .","1. Timing separation of administration: Take phenytoin and aluminum hydroxide at least 2-3 hours apart. It is preferable to take phenytoin at least 1 hour before or 2 hours after the antacid. 2. Therapeutic monitoring: Monitor phenytoin plasma levels, especially when starting, stopping, or changing the antacid dose. 3. Clinical monitoring: Monitor seizure control and toxicity symptoms if the dose is adjusted. 4. Antacid alternatives: Consider using antacids containing only magnesium or only calcium, although they may also interact but to a lesser extent. 5. Drug education: Advise patients to adhere to the recommended separation intervals and avoid taking antacids at the same time as phenytoin.");n("Phenytoin - ","Magnesium Hydroxide -  ",e.DRUG_DRUG,i.LOW,"            (Mg)         .                  .                 .","Magnesium hydroxide, as an antacid containing divalent cations (Mg), can form insoluble complexes with phenytoin in the gastrointestinal tract. The interaction mechanism is similar to that of aluminum hydroxide, where magnesium cations bind to phenytoin molecules, reducing their solubility and absorption. This effect can be more pronounced with high doses of antacids or with chronic use.","          : 1.    . 2.   . 3.    .            .","Potential decrease in phenytoin plasma levels, which may lead to: 1. Subtherapeutic phenytoin concentration. 2. Risk of increased seizures. 3. Reduced anticonvulsant efficacy. The effect is cumulative if antacids are taken frequently with phenytoin.","1.  :      2-3   . 2.  :         . 3.  :      . 4.  :           . 5.   :       .","1. Timing separation: Take phenytoin and magnesium hydroxide at least 2-3 hours apart. 2. Level monitoring: Check phenytoin blood levels after starting the antacid. 3. Clinical monitoring: Watch for any changes in seizure pattern. 4. Treatment alternatives: Use antacids without magnesium if separation is difficult. 5. Avoid concurrent administration: Never take both medications at the same time.");n("Phenytoin - ","Calcium Carbonate -  ",e.DRUG_DRUG,i.LOW,"    (Ca)          .                          .                      .","Calcium carbonate, as a source of calcium (Ca) and an antacid, can bind to phenytoin and form insoluble complexes. Although calcium carbonate is generally considered less interactive than other metal-containing antacids, it can still reduce phenytoin absorption. This interaction occurs primarily in the stomach and intestines, where calcium ions compete for binding sites or create an environment that reduces phenytoin solubility.","   moderate         : 1.    . 2.       . 3.        .","Mild to moderate decrease in phenytoin plasma levels, which may lead to: 1. Reduced anticonvulsant efficacy. 2. Need for dose adjustment in some cases. 3. Risk of loss of seizure control in sensitive patients.","1.  :            . 2. :        . 3.    :      . 4.  :         . 5. :      .","1. Timing separation: Take phenytoin at least 1 hour before or 2 hours after calcium carbonate. 2. Monitoring: Monitor phenytoin levels and clinical response during coadministration. 3. Consistent scheduling: Maintain a consistent pattern of separation intervals. 4. Periodic assessment: Assess the need for dose adjustment based on phenytoin levels. 5. Education: Educate the patient about the importance of timing separation.");n("Pilocarpine (eye drops)","Anticholinergics",e.DRUG_DRUG,i.MODERATE," ","Pharmacological antagonism.","  ","Reduced pilocarpine efficacy."," ","Avoid combination.");n("Pimavanserin","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Pimavanserin. Ketoconazole    CYP3A4    Pimavanserin.","Increased Pimavanserin concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Pimavanserin metabolic pathway.","    QT.","Increased risk of QT prolongation."," .    Pimavanserin     CYP3A4 .","Dose adjustment. Pimavanserin dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pimavanserin","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Pimavanserin. Itraconazole    CYP3A4.","Increased Pimavanserin concentration. Itraconazole is a strong inhibitor of CYP3A4.","    QTc.","Increased risk of QTc prolongation."," .    Pimavanserin.","Dose adjustment. Pimavanserin dose must be reduced.");n("Pimavanserin","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pimavanserin. Rifampin    CYP3A4.","Decreased Pimavanserin concentration. Rifampin is a strong inducer of CYP3A4.","  .","Reduced drug efficacy."," .   .","Contraindicated. Avoid the combination.");n("Pimecrolimus","CYP3A4 Inhibitors",e.DRUG_DRUG,i.MODERATE,"  ","Increased systemic absorption."," ","Immunosuppression."," ","Use cautiously.");n(["Pindolol","Propranolol"],ay,e.DRUG_DRUG,i.MODERATE,": **  **.        CYP2D6         .","Mechanism: **Mutual inhibition of metabolism**. Both drug classes are substrates and inhibitors of the CYP2D6 enzyme, leading to slower clearance of both."," : **    **       (  )    ( ).","Clinical Significance: **Increased plasma levels and effects of one or both drugs**, increasing the risk of bradycardia (from BBs) and orthostatic hypotension (from Phenothiazines).","     .       .","Monitor BP and heart rate. Decrease doses if necessary to avoid adverse effects.");n("Pindolol ()","Lidocaine ()",e.DRUG_DRUG,i.MODERATE,"           .","Lidocaine Toxicity. Metabolic inhibition and additive cardiac depression.","              .","              .","       .         .","       .         .");n("Pindolol ()","Chlorpromazine",e.DRUG_DRUG,i.MODERATE,"    ","Potentiated Effect. Increased pharmacologic response.","           .","           .","       .","       .");n("Pindolol ()","Thioridazine",e.DRUG_DRUG,i.MODERATE,"   (CYP2D6).              (   ).","Partial metabolic inhibition (CYP2D6). Thioridazine may inhibit Pindolol metabolism, in addition to additive cardiovascular effects (e.g., hypotension).","                (Bradycardia).       .","May lead to increased Pindolol concentration and enhanced hypotension and bradycardia. Increased Thioridazine side effects should also be noted.","       .            .","Monitor blood pressure and heart rate closely. Reduce the dose of Pindolol or both drugs if necessary to avoid excessive hypotension.");n("Pindolol ()","Prochlorperazine",e.DRUG_DRUG,i.MODERATE,"    ","Potentiated Effect. Increased pharmacologic response.","           .","           .","       .","       .");n("Pioglitazone","Gemfibrozil",e.DRUG_DRUG,i.MODERATE," CYP2C8","CYP2C8 inhibition.","  ","Increased pioglitazone levels.","  ","Reduce pioglitazone dose.");n("Pirfenidone","Ciprofloxacin",e.DRUG_DRUG,i.HIGH,"  Pirfenidone. Ciprofloxacin    CYP1A2    Pirfenidone .","Increased Pirfenidone concentration. Ciprofloxacin is a strong inhibitor of CYP1A2, the main Pirfenidone metabolic pathway.","     .","Increased risk of nausea, vomiting, and rash."," .        .","Contraindicated. Avoid the combination or close monitoring and dose adjustment.");n("Pirfenidone - ","Fluvoxamine - ",e.DRUG_DRUG,i.HIGH,"    CYP1A2                150","Fluvoxamine is a potent inhibitor of hepatic CYP1A2 enzyme responsible for Pirfenidone primary metabolism, increasing its plasma concentration by up to 150%","                 ","Significant increase in frequency and severity of adverse effects particularly nausea, vomiting, anorexia, skin rash, photosensitivity, and hepatotoxicity","   -    -       CYP1A2          ","Absolutely contraindicated - avoid combination entirely - use alternative antidepressants that do not inhibit CYP1A2 such as sertraline or escitalopram if combination therapy is needed");n("Piroxicam","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Pirtobrutinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Rifampin     CYP3A4      Pirtobrutinib.","Decreased Pirtobrutinib efficacy. Rifampin is a strong inducer of CYP3A4, the main metabolic pathway for Pirtobrutinib.","               .","Severe decrease in plasma drug concentration, leading to loss of anti-cancer efficacy or treatment failure."," .   Rifampin        CYP3A4.","Avoid Combination. Rifampin must be replaced with an antibiotic that neither inhibits nor induces the CYP3A4 enzyme.");n("Pirtobrutinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Pirtobrutinib.       CYP3A4  .","Increased Pirtobrutinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      Pirtobrutinib.","Increased risk of Pirtobrutinib-related drug toxicity."," .          CYP3A4 (  ).","Avoid simultaneous use. Grapefruit juice and other CYP3A4-inhibiting fruits (e.g., Seville oranges) should be avoided.");n("Pirtobrutinib","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Diltiazem    CYP3A4      Pirtobrutinib.","Increased Pirtobrutinib concentration. Diltiazem is a moderate CYP3A4 inhibitor, the primary metabolic pathway for Pirtobrutinib.","      Pirtobrutinib (   ).","Increased risk of Pirtobrutinib-related drug toxicity (e.g., atrial fibrillation and infections)."," .    Pirtobrutinib     CYP3A4 .","Dose adjustment. Pirtobrutinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Pirtobrutinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Rifampin    CYP3A4    Pirtobrutinib.","Decreased Pirtobrutinib efficacy. Rifampin is a strong inducer of CYP3A4, a Pirtobrutinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pirtobrutinib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Efavirenz    CYP3A4    Pirtobrutinib.","Decreased Pirtobrutinib efficacy. Efavirenz is a moderate inducer of CYP3A4, a Pirtobrutinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Pranlukast - ","Rifampin -  (   CYP3A4  CYP2C9)",e.DRUG_DRUG,i.HIGH,"     CYP3A4  CYP2C9         .","Rifampin is a potent inducer of both CYP3A4 and CYP2C9 enzymes, significantly increasing the rate of Pranlukast metabolism and clearance.","           (Subtherapeutic Levels)        .","Severe drop in Pranlukast plasma concentration to subtherapeutic levels, leading to a loss of asthma control."," .          CYP          (     ).","Avoid Combination. An alternative antibiotic that does not heavily affect CYP enzymes should be used, or switch Pranlukast to an alternative asthma therapy (like Montelukast, which is less affected).");n("Pranlukast - ","Ketoconazole -  (   CYP3A4)",e.DRUG_DRUG,i.MODERATE,"     CYP3A4     .","Ketoconazole is a potent inhibitor of the CYP3A4 enzyme, which is the primary metabolic pathway for Pranlukast.","                   (     ).","Enzyme inhibition slows Pranlukast clearance, increasing its plasma concentration and raising the risk of dose-related side effects (e.g., headache, GI disturbances, and hepatotoxicity).",".       (LFTs).       .","Monitoring. Side effects and Liver Function Tests (LFTs) must be monitored. A reduction in the Pranlukast dose may be necessary.");n("Pranlukast - ","Fluconazole -  (   CYP2C9)",e.DRUG_DRUG,i.MODERATE,"     CYP2C9     .","Fluconazole is a potent inhibitor of the CYP2C9 enzyme, which contributes to Pranlukast metabolism.","               .","Inhibition reduces Pranlukast clearance, leading to a slight increase in concentrations and a higher likelihood of side effects.",".       (LFTs).        .","Monitoring. Side effects and Liver Function Tests (LFTs) must be monitored. No absolute contraindication, but monitoring is necessary.");n("Pirtobrutinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Itraconazole    CYP3A4    Pirtobrutinib.","Increased Pirtobrutinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Pirtobrutinib.","      Pirtobrutinib.","Increased risk of Pirtobrutinib-related drug toxicity."," .    Pirtobrutinib     CYP3A4 .","Dose adjustment. Pirtobrutinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pirtobrutinib","Erythromycin",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Erythromycin    CYP3A4    Pirtobrutinib.","Increased Pirtobrutinib concentration. Erythromycin is a moderate CYP3A4 inhibitor, a Pirtobrutinib metabolic pathway.","      Pirtobrutinib.","Increased risk of Pirtobrutinib-related drug toxicity."," .    Pirtobrutinib     CYP3A4 .","Dose adjustment. Pirtobrutinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Pirtobrutinib","Grapefruit",e.DRUG_FOOD,i.HIGH,"  Pirtobrutinib.      CYP3A4  .","Increased Pirtobrutinib concentration. Grapefruit is a strong inhibitor of intestinal CYP3A4.","      Pirtobrutinib.","Increased risk of Pirtobrutinib-related drug toxicity."," .     .","Avoid Consumption. Grapefruit and its juice must be avoided.");n("Pirtobrutinib","Diltiazem",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Diltiazem    CYP3A4    Pirtobrutinib.","Increased Pirtobrutinib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a Pirtobrutinib metabolic pathway.","      Pirtobrutinib.","Increased risk of Pirtobrutinib-related drug toxicity."," .    Pirtobrutinib     CYP3A4 .","Dose adjustment. Pirtobrutinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Pirtobrutinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Rifampin    CYP3A4    Pirtobrutinib.","Decreased Pirtobrutinib efficacy. Rifampin is a strong inducer of CYP3A4, a Pirtobrutinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Pirtobrutinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Pirtobrutinib.       CYP3A4  .","Increased Pirtobrutinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      Pirtobrutinib.","Increased risk of Pirtobrutinib-related drug toxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Pirtobrutinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Itraconazole    CYP3A4.","Increased Pirtobrutinib concentration. Itraconazole is a strong inhibitor of CYP3A4.","   .","Increased risk of side effects."," .    Pirtobrutinib  .","Dose adjustment. Pirtobrutinib dose must be significantly reduced.");n("Pirtobrutinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Pirtobrutinib. Rifampin    CYP3A4.","Decreased Pirtobrutinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Pirtobrutinib (Jaypirca)","Strong CYP3A4 Inhibitors (Clarithromycin)",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.   Pirtobrutinib.","Mechanism: **CYP3A4 inhibition**. Increased Pirtobrutinib concentration."," : ** **    .","Clinical Significance: **Increased toxicity** such as diarrhea and rash.","  Pirtobrutinib  100 mg .","Reduce Pirtobrutinib dose to 100 mg daily.");n("Plecanatide","Rifampin",e.DRUG_DRUG,i.LOW,"    . Plecanatide       CYP.","No true interaction expected. Plecanatide acts locally and is not metabolized by CYP.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Polatuzumab Vedotin","Clarithromycin",e.DRUG_DRUG,i.MODERATE,"    (MMAE). Clarithromycin   CYP3A4    MMAE.","Increased concentration of active metabolite (MMAE). Clarithromycin inhibits CYP3A4, an MMAE metabolic pathway.","      .","Increased risk of peripheral neuropathy and hematological toxicity.","   .   CYP3A4 .","Avoid combination or monitoring. Avoid strong CYP3A4 inhibitors.");n("Polatuzumab Vedotin (ADC)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"        .   (Vedotin)      CYP.","No clinically significant interaction expected with the antibody. The toxic payload (Vedotin) is minimally metabolized by CYP.","   .","No known effect.","    .","No special action required.");n("Polyethylene Glycol","Oral Medications",e.DRUG_DRUG,i.MODERATE,"  ","Increased intestinal motility.","   ","Reduced oral drug absorption.","      4 ","Take meds 1 hour before or 4 hours after.");n("Polyethylene Glycol (PEG)","Enteric Coated Drugs",e.DRUG_DRUG,i.MODERATE,"    . PEG     .","Decreased absorption of enteric coated drugs. PEG causes rapid gastrointestinal transit.","    .","Failure of therapy with the enteric coated drug."," .          PEG  .","Avoid Combination. Enteric coated drugs must be avoided concurrently with fast-acting PEG solutions.");n("Polymyxin B Sulfate -   ","Antifungals -  ",e.DRUG_DRUG,i.MODERATE,"     (chelating agent)               .        (   )     .                        .                       .","Polymyxin B acts as a chelating agent due to its polycationic nature, enabling it to bind to divalent metals such as calcium, magnesium, and zinc. Some antifungals, particularly the azole family (e.g., fluconazole, itraconazole, voriconazole), rely on an optimal intestinal environment for their absorption. The binding of Polymyxin B to metals may alter the pH and absorption environment in the gastrointestinal tract, potentially reducing the bioavailability of these antifungals. Additionally, Polymyxin B may compete with some antifungals for binding or transport sites in tissues, potentially altering their distribution.","          : 1.        . 2.          . 3.          . 4.          .                  .","Potential alteration in the efficacy of antifungal therapy, which may lead to: 1. Decreased therapeutic concentrations of antifungals in blood and tissues. 2. Failure to control fungal infections or delayed treatment response. 3. Increased risk of developing fungal drug resistance due to subtherapeutic exposure. 4. Need to adjust antifungal doses or change the treatment regimen. This risk is more significant with antifungals that have variable oral bioavailability or a narrow therapeutic window.","1.   :              2-3       . 2.  :             . 3.  :          (   )    . 4.  :                  . 5.   :              . 6.  :            .","1. Timing separation of administration: In case of oral administration of both drugs, separate them by at least 2-3 hours to minimize potential interaction in the gastrointestinal tract. 2. Clinical monitoring: Closely monitor the patient`s response to antifungal therapy, watching for signs and symptoms of fungal infection. 3. Therapeutic monitoring: If possible, monitor plasma levels of antifungals (especially for itraconazole, voriconazole, posaconazole) to ensure therapeutic levels are achieved. 4. Dose adjustment: Increasing the antifungal dose may be necessary if there is evidence of reduced absorption or inefficacy. 5. Alternative administration routes: In critical cases, consider using intravenous routes for antifungal administration to avoid intestinal interactions. 6. Interaction documentation: Document this potential interaction in the patient`s medical record and carefully monitor clinical outcomes.");n("Pomegranate Juice","CYP3A4 Substrates",e.DRUG_FOOD,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased drug levels.","  ","Avoid large amounts.");n("Ponesimod","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Ponesimod. Cyclosporine     P-gp  BCRP    Ponesimod.","Increased Ponesimod levels. Cyclosporine is a potent inhibitor of P-gp and BCRP, which are Ponesimod efflux transporters.","   Ponesimod       (Bradycardia)     .","Increased exposure to Ponesimod, raising the risk of Bradycardia and respiratory disturbances at treatment initiation."," .    Ponesimod       .","Dose adjustment. Ponesimod dose must be adjusted at treatment initiation, and heart rate monitored.");n("Ponesimod","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Ponesimod   (Sphingosine 1-phosphate receptor modulator).","Increased risk of infection. Ponesimod is an immunosuppressant (Sphingosine 1-phosphate receptor modulator).","     .","Risk of developing infection from live vaccines."," .        Ponesimod.","Contraindicated. Live vaccines must be avoided during Ponesimod treatment.");n("Ponesimod","Hormonal Contraceptives",e.DRUG_DRUG,i.LOW,"     . Ponesimod     .","No clinically significant interaction expected. Ponesimod is not a strong inducer or inhibitor.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Ponesimod - ","Fluvoxamine - ",e.DRUG_DRUG,i.MODERATE,"    CYP1A2             ","Fluvoxamine is a moderate inhibitor of hepatic CYP1A2 enzyme that contributes to Ponesimod metabolism, leading to a moderate increase in its concentration","                  ","Increased risk of bradycardia, hypotension, syncope, and cardiac arrhythmias especially during the first hours after the initial dose","         4-6     -        -      ","Monitor heart rate and blood pressure continuously for 4-6 hours after first dose - perform ECG before and after initiating combination therapy - avoid starting with full Ponesimod dose");n("Ponesimod (S1P modulator)","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Ponesimod. Carbamazepine    CYP3A4    Ponesimod.","Decreased Ponesimod concentration. Carbamazepine is a strong inducer of CYP3A4, a Ponesimod metabolic pathway.","         .","Reduced drug efficacy, leading to failure of multiple sclerosis treatment."," .   .","Contraindicated. Avoid the combination.");n("Ponesimod (S1P)","Live Vaccines",e.DRUG_DRUG,i.HIGH,"  . Ponesimod         .","Increased risk of infection. Ponesimod causes immunosuppression by reducing lymphocyte count in the blood.","     .","Increased risk of developing the disease from the vaccine."," .         4 .","Contraindicated. Avoid live vaccines during and for 4 weeks after therapy.");n("Ponesimod (S1P)","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Ponesimod. Carbamazepine    CYP3A4.","Decreased Ponesimod concentration. Carbamazepine is a strong inducer of CYP3A4.","        .","Reduced drug efficacy, leading to exacerbation of multiple sclerosis."," .   .","Contraindicated. Avoid the combination.");n("Ponesimod (S1P)","Fluconazole",e.DRUG_DRUG,i.MODERATE,"  Ponesimod. Fluconazole   CYP2C9.","Increased Ponesimod concentration. Fluconazole inhibits CYP2C9.","      .","Increased risk of bradycardia and other side effects."," .      .","Close monitoring. Monitor heart rate and side effects.");n("Posaconazole","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Posaconazole    CYP3A4    Midazolam.","Increased Midazolam concentration. Posaconazole is a strong CYP3A4 inhibitor, a Midazolam metabolic pathway.","      (CNS) .","Increased risk of Central Nervous System (CNS) depression and sedation."," .    Midazolam         CYP3A4.","Dose adjustment. Midazolam dose must be significantly reduced, or a non-CYP3A4 metabolized alternative used.");n("Posaconazole","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Cyclosporine. Posaconazole    CYP3A4    Cyclosporine.","Increased Cyclosporine concentration. Posaconazole is a strong inhibitor of CYP3A4, a Cyclosporine metabolic pathway.","   Cyclosporine ( ).","Increased risk of Cyclosporine toxicity (nephrotoxicity).","  .    Cyclosporine       .","Dose adjustment and monitoring. Cyclosporine dose must be reduced and drug blood levels monitored intensively.");n("Posaconazole (Suspension)","High-Fat Meal",e.DRUG_FOOD,i.HIGH,"      .    (  20  )  : (1)             (2)            (3)      .        (AUC)    400% ( 4-5 ).","Posaconazole suspension is tremendously affected by high-fat food. High-fat meal (>20g fat) leads to: (1) stimulation of bile salt secretion improving dissolution of poorly water-soluble drug, (2) prolonged intestinal drug residence allowing more absorption time, (3) enhanced lymphatic absorption of highly lipophilic drug. Result is remarkable AUC increase reaching 400% (4-5 fold).","                 .                     .","Massive, critical increase in drug bioavailability, transforming posaconazole from poorly absorbed to clinically effective drug. This increase is essential for achieving adequate therapeutic levels for preventing serious fungal infections in immunocompromised patients or treating invasive fungal infections."," :        (  20     -       )       .     2-4     .   :       . :      .","Oral suspension: Must be taken exclusively with full high-fat meal (containing 20g+ fat - such as meal with meat, oils, nuts) or high-calorie liquid nutritional supplement. Dividing daily dose into 2-4 times with meals improves absorption. Modern delayed-release tablets: Less food-dependent with more stable levels. Monitoring: Drug level measurement advisable to ensure efficacy.");n("Potassium Citrate","Lithium",e.DRUG_DRUG,i.MODERATE,"     ()             .","These agents increase the renal clearance (excretion) of Lithium, primarily through increased diuresis and modification of urinary pH.","             .","Decreased serum Lithium concentration, potentially leading to loss of therapeutic efficacy and symptom relapse.","      (TDM)  .          .","Closely monitor serum Lithium concentration (TDM) and clinical symptoms. A Lithium dose increase may be required to compensate for the reduced concentration.");n("Potassium Iodide","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Pralsetinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Pralsetinib. Ketoconazole    CYP3A4    Pralsetinib.","Increased Pralsetinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Pralsetinib metabolic pathway.","    QT   .","Increased risk of QT prolongation and hypertension."," .    Pralsetinib     CYP3A4 .","Dose adjustment. Pralsetinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Pralsetinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Pralsetinib. Phenytoin    CYP3A4.","Decreased Pralsetinib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Pramipexole","Metoclopramide",e.DRUG_DRUG,i.HIGH,"  Pramipexole. Metoclopramide       Pramipexole.","Decreased Pramipexole effect. Metoclopramide is a dopamine receptor antagonist, counteracting Pramipexoles effect.","   .","Worsening of Parkinsons disease symptoms."," .   .","Contraindicated. Avoid the combination.");n("Prasugrel","Omeprazole",e.DRUG_DRUG,i.LOW,"     Prasugrel . Omeprazole   CYP2C19    Prasugrel.","Slight reduction in exposure to active Prasugrel. Omeprazole inhibits CYP2C19, a Prasugrel activation pathway.","      (      Clopidogrel).","Slight decrease in anti-coagulation efficacy (less significant than with Clopidogrel)."," .        .","Symptom monitoring. Dose adjustment is usually not required, but caution should be exercised.");n("Prasugrel","Warfarin",e.DRUG_DRUG,i.HIGH,"   ","Additive anticoagulant effect."," ","Severe bleeding.","  -    ","Avoid - or very close monitoring.");n("Pravastatin","Gemfibrozil",e.DRUG_DRUG,i.HIGH," .","Transport Inhibition. Blockade of drug transporters (e.g., P-gp)."," .","Rhabdomyolysis. Muscle breakdown.",".",".");n("Pravastatin","Colestipol",e.DRUG_DRUG,i.MODERATE,"  ","Intestinal binding.","  ","Reduced statin absorption.","      4 ","Take statin 1 hour before or 4 hours after.");n("Prazosin",xn,e.DRUG_DRUG,i.MODERATE,": **    (Synergistic Hypotension)**.                    .","Mechanism: **Synergistic hypotensive effect**. Beta-blockers prevent the reflex tachycardia that might otherwise compensate for Prazosin-induced vasodilation, increasing the risk of hypotension."," : **      (Acute Postural Hypotension)**       (  ).","Clinical Significance: **Increased risk of acute postural hypotension**, especially with the first dose of Prazosin (First-dose phenomenon).","     .            .","Monitor BP closely upon initiation. Administer the first dose of Prazosin at bedtime and start with a low dose to avoid syncope.");n("Prazosin","Acebutolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Atenolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Betaxolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Bisoprolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Carteolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Esmolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Metoprolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Nadolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Penbutolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Pindolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Propranolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Sotalol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Timolol",e.DRUG_DRUG,i.MODERATE," ( 1)                       ","Synergistic Hypotension. Combined Alpha-1 and Beta blockade causes profound vasodilation and blunted reflex tachycardia, especially orthostatic.","      -  -  -  ","Orthostatic Hypotension. Fall risk.","      -        -     ","Monitor for symptoms of orthostatic hypotension. Rise slowly from sitting or lying position. Ensure adequate fluid intake.");n("Prazosin","Tadalafil",e.DRUG_DRUG,i.MODERATE,"  ","Additive vasodilation.","  ","Hypotension and syncope.","  -   ","Separate doses - monitor BP.");n("Prazosin - ","Pseudoephedrine - ",e.DRUG_DRUG,i.HIGH,"                 ","Pseudoephedrine stimulates alpha-adrenergic receptors causing vasoconstriction, while Prazosin blocks these receptors causing vasodilation","            ","Failure in blood pressure control, hypertension, resistance to antihypertensive therapy","   -          -       ","Avoid combination entirely - use alternative decongestants without alpha agonists - educate patient to read cold and flu medication contents");n("Prazosin - ","Phenylephrine - ",e.DRUG_DRUG,i.HIGH,"     -1      ","Phenylephrine is a potent direct alpha-1 adrenergic receptor agonist that completely counteracts Prazosin action","             ","Acute hypertension, hypertensive crisis, severe headache, risk of cerebral hemorrhage","  -    -           ","Contraindicated - avoid combination entirely - use alternatives for congestion like antihistamines or saline nasal solutions");n("Prazosin - ","Ephedrine - ",e.DRUG_DRUG,i.HIGH,"            ","Ephedrine causes indirect release of catecholamines and stimulates alpha receptors counteracting Prazosin effect","             ","Severe hypertension, tachycardia, cardiac arrhythmias, risk of cardiovascular events","   -         -      ","Avoid combination entirely - caution with herbal products containing Ephedra - monitor blood pressure if combination is unavoidable");n("Prazosin - ","Fluoxetine - ",e.DRUG_DRUG,i.MODERATE,"                   ","Fluoxetine may reduce the antihypertensive effect of Prazosin through multiple mechanisms including fluid retention and effects on vascular tone","            ","Reduced blood pressure control, hypertension, and potential worsening of heart failure symptoms","           -       -    ","Monitor blood pressure frequently especially during first weeks of combination - adjust Prazosin dose if needed - monitor for signs of fluid retention");n("Prazosin - ","Sertraline - ",e.DRUG_DRUG,i.MODERATE,"                 ","Sertraline may reduce the antihypertensive effect of Prazosin through multiple mechanisms including effects on vascular tone","            ","Reduced blood pressure control, hypertension, and potential worsening of heart failure symptoms","           -      ","Monitor blood pressure frequently especially during first weeks of combination - adjust Prazosin dose if needed");n("Prazosin - ","Amitriptyline - ",e.DRUG_DRUG,i.MODERATE,"                ","Amitriptyline may counteract the antihypertensive effect of Prazosin through anticholinergic mechanisms and effects on adrenergic receptors","          ","Reduced efficacy of Prazosin in lowering blood pressure, orthostatic hypertension","      -     ","Monitor blood pressure in different positions - adjust Prazosin dose based on response");n("Prazosin - ","Venlafaxine - ",e.DRUG_DRUG,i.MODERATE,"               ","Venlafaxine may reduce the antihypertensive effect of Prazosin through its effect on norepinephrine reuptake","           ","Poor blood pressure control, hypertension especially at high doses","    -           ","Monitor blood pressure regularly - consider antidepressant alternatives if blood pressure control is poor");n("Prazosin - ","Atenolol - ",e.DRUG_DRUG,i.MODERATE,"   ( )  ( )        ","Combination of Prazosin (vasodilator) and Atenolol (beta-blocker) leads to synergistic blood pressure lowering effect","         ","Orthostatic hypotension, dizziness, syncope, especially when initiating therapy","    -        -     ","Initiate therapy with low doses - monitor blood pressure in standing and lying positions - advise patient to change positions slowly");n("Prazosin - ","Metoprolol - ",e.DRUG_DRUG,i.MODERATE,"          ","Synergistic blood pressure lowering effect between vasodilator and beta-blocker","      ","Hypotension, bradycardia, dizziness, fatigue","   -     -     ","Monitor vital signs - adjust doses based on tolerance - avoid driving until condition stabilizes");n("Prazosin - ","Nadolol - ",e.DRUG_DRUG,i.MODERATE,"          ","Greater than expected blood pressure lowering effect due to combination of different mechanisms","      ","Severe hypotension, dizziness, impaired concentration","       -    -  ","Start therapy with low doses of both drugs - gradually increase doses - monitor symptoms");n("Prazosin - ","Carvedilol - ",e.DRUG_DRUG,i.MODERATE,"          ","Strong synergistic effect due to combination of vasodilator with beta and alpha blocker","      ","Marked orthostatic hypotension, dizziness, syncope","    -      -      ","Close blood pressure monitoring - initiate therapy with very low doses - educate patient about slow position changes");n("Prazosin - ","Bisoprolol - ",e.DRUG_DRUG,i.MODERATE,"        ","Greater than expected blood pressure lowering effect due to complementary mechanisms","       ","Hypotension, bradycardia, dizziness when standing","     -     ","Monitor blood pressure and heart rate - adjust doses based on clinical response");n("Prazosin - ","Propranolol - ",e.DRUG_DRUG,i.MODERATE,"          ","Synergistic blood pressure lowering effect with risk of orthostatic hypotension","      ","Hypotension, dizziness, fatigue, cold extremities","      -      ","Monitor blood pressure in different positions - avoid hazardous activities until blood pressure stabilizes");n("Prazosin - ","Sotalol - ",e.DRUG_DRUG,i.MODERATE,"          QT","Synergistic blood pressure lowering effect with risk of QT prolongation","      ","Hypotension, cardiac arrhythmias, dizziness","     -      ","Monitor ECG and blood pressure - caution in patients prone to arrhythmias");n("Prazosin - ","Verapamil - ",e.DRUG_DRUG,i.MODERATE,"             ","Synergistic blood pressure lowering effect due to combination of vasodilator and calcium channel blocker","      ","Orthostatic hypotension, dizziness, headache, syncope","    -      -        ","Initiate therapy with low doses - monitor blood pressure frequently - advise patient to rise slowly from sitting or lying position");n("Prednisolone","Diabetes",e.DRUG_DISEASE,i.MODERATE," .","Insulin Resistance. Drug-induced impairment of insulin sensitivity."," ."," .",".",".");n("Prednisolone","Diabetes / Hypertension",e.DRUG_DISEASE,i.MODERATE,"     ( ).","Hyperglycemia & Fluid Retention. Corticosteroids induce gluconeogenesis and mineralocorticoid activity.","    .","    .","          .","          .");n("Prednisolone","Ketoconazole",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","   ","Increased corticosteroid side effects.","  ","Reduce prednisolone dose.");n("Prednisolone (eye drops)","NSAIDs (eye drops)",e.DRUG_DRUG,i.MODERATE,"   ","Increased delayed healing risk."," ","Corneal ulcer."," ","Use cautiously.");n("Prednisone","Diabetes",e.DRUG_DISEASE,i.MODERATE," .","Insulin Resistance. Drug-induced impairment of insulin sensitivity."," ."," .",".",".");n("Prednisone","Diabetes / Hypertension",e.DRUG_DISEASE,i.MODERATE,"     ( ).","Hyperglycemia & Fluid Retention. Corticosteroids induce gluconeogenesis and mineralocorticoid activity.","    .","    .","          .","          .");n("Prednisone","NSAIDs",e.DRUG_DRUG,i.HIGH,"    ","Synergistic gastric irritation.","   ","Gastric ulcer and GI bleeding.","    -    ","Use PPI - avoid combination if possible.");n("Prednisone","Alcohol",e.DRUG_FOOD,i.LOW,": **   **.            Prednisone ().","Mechanism: **Additive GI Irritation**. Alcohol increases the risk of stomach irritation and ulcers, a common effect of Prednisone (corticosteroid).",":        .","Result: Slight increase in the risk of stomach pain and gastrointestinal bleeding.",":         .","Management: Advise limitation or avoidance of alcohol during treatment.");n("Prednisone","Caffeine",e.DRUG_FOOD,i.HIGH,":     . ( ).","Mechanism: No direct interaction is known. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4**.        Prednisone   Prednisolone .","Mechanism: **CYP3A4 Inhibition**. Grapefruit juice may inhibit the metabolism of Prednisone to its active form, Prednisolone.",":      .      .","Result: No major clinical effect expected. Theoretically, active drug concentration may increase.",":   .   .","Management: Monitor side effects. Avoid excessive consumption.");n("Prednisone","Green Tea",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Milk",e.DRUG_FOOD,i.HIGH,":    . ( ).","Mechanism: No known interaction. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","High-fat meals",e.DRUG_FOOD,i.MODERATE,": **   **.     Prednisone      .","Mechanism: **Increased Absorption & Reduced Irritation**. Food increases Prednisone absorption and reduces its gastric irritating effects.",":        .","Result: Increased drug bioavailability and reduced gastrointestinal side effects.",": **  Prednisone    **    .","Management: **Advise taking Prednisone with food or milk** to reduce stomach irritation.");n("Prednisone","High-fiber foods",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Vitamin C",e.DRUG_FOOD,i.HIGH,":     . ( ).","Mechanism: No direct interaction is known. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Vitamin D",e.DRUG_FOOD,i.MODERATE,": ** **.               Vitamin D.","Mechanism: **Resource Depletion**. Corticosteroids decrease Calcium absorption and increase bone loss, raising the need for Vitamin D.",":         .","Result: Increased risk of osteoporosis with long-term use.",": **     Vitamin D**    .","Management: **Calcium and Vitamin D supplementation is strongly recommended**, especially for long-term therapy.");n("Prednisone","Vitamin E",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Vitamin K",e.DRUG_FOOD,i.HIGH,":     . ( ).","Mechanism: No direct interaction is known. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Vitamin B12",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Folic Acid",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Iron",e.DRUG_FOOD,i.HIGH,":     . ( ).","Mechanism: No direct interaction is known. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Calcium",e.DRUG_FOOD,i.MODERATE,": ** **.         .","Mechanism: **Resource Depletion**. Corticosteroids decrease Calcium absorption and increase bone loss.",":         .","Result: Increased risk of osteoporosis with long-term use.",": **    **    .","Management: **Calcium supplementation is strongly recommended**, especially for long-term therapy.");n("Prednisone","Magnesium",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Zinc",e.DRUG_FOOD,i.HIGH,":     . ( ).","Mechanism: No direct interaction is known. (Hypothetical interaction).",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Potassium",e.DRUG_FOOD,i.MODERATE,": **   (Hypokalemia)**. Prednisone      .","Mechanism: **Hypokalemia**. Prednisone increases potassium excretion in the urine.",":                .","Result: Decreased body potassium levels, which may lead to muscle weakness or heart rhythm disturbances.",":          .","Management: Recommend consumption of potassium-rich foods or supplements during therapy.");n("Prednisone","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Prednisone","Antacids",e.DRUG_FOOD,i.HIGH,":             Prednisone  .","Mechanism: Antacids containing aluminum or magnesium may slightly impair the absorption of Prednisone.",":      . (   ).","Result: Slight decrease in drug absorption and efficacy. (Clinically unconfirmed effect).",": **   **       .","Management: **Advise separating doses** from antacids by at least two hours.");n("Prednisone","Sodium-Rich Foods (Salt)",e.DRUG_FOOD,i.HIGH,": **  **.         .","Mechanism: **Sodium and Water Retention**. Corticosteroid effects increase the body's retention of sodium and water.",":   ()    (Hypertension)    .","Result: Worsening of edema (swelling), high blood pressure (Hypertension), and increased strain on the heart.",": **      **  .","Management: **A low-sodium diet is strongly recommended** during therapy.");n("Prednisone","Licorice (Glycyrrhiza glabra)",e.DRUG_FOOD,i.HIGH,": **   **.               .","Mechanism: **Additive Mineralocorticoid Effects**. Licorice contains compounds that mimic corticosteroid effects, increasing sodium retention and potassium loss.",":        (Hypokalemia)    .","Result: Acute increase in the risk of hypokalemia, hypertension, and edema.",": ** **      .","Management: **Strict avoidance** of excessive licorice consumption during treatment.");n("Pretomanid","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Pretomanid. Phenytoin    CYP3A4    Pretomanid.","Decreased Pretomanid concentration. Phenytoin is a strong inducer of CYP3A4, a Pretomanid metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Probenecid","Aspirin (High Doses)",e.DRUG_DRUG,i.HIGH,"  Probenecid.            Probenecid.","Decreased Probenecid effect. High dose Aspirin inhibits uric acid reabsorption, interfering with Probenecid.","   (Gout treatment failure).","Failure of gout treatment."," .      Probenecid.","Avoid Combination. High-dose Aspirin must be avoided with Probenecid.");n("Probenecid","Cephalexin",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of Renal Tubular Secretion. Competition for transport proteins decreases renal elimination.","   ","   ","   ","   ");n("Probenecid","Ceftriaxone",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of Renal Tubular Secretion. Competition for transport proteins decreases renal elimination.","   ","   ","   ","   ");n("Probenecid","Cefuroxime",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of Renal Tubular Secretion. Competition for transport proteins decreases renal elimination.","   ","   ","   ","   ");n("Probenecid","Cefixime",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of Renal Tubular Secretion. Competition for transport proteins decreases renal elimination.","   ","   ","   ","   ");n("Probenecid","Cefotaxime",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of Renal Tubular Secretion. Competition for transport proteins decreases renal elimination.","   ","   ","   ","   ");n("Probenecid","Penicillins",e.DRUG_DRUG,i.MODERATE,"   ","Inhibition of penicillin renal secretion.","  ","Increased penicillin levels.","   -   ","May be beneficial - prolongs treatment duration.");n("Probiotics","Antibiotics",e.DRUG_DRUG,i.MODERATE,"  ","Killing of beneficial bacteria.","  ","Reduced probiotic efficacy."," ","Separate by 2 hours.");n("Probucol","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  ","Unspecified effect","    ","Potential effect on cyclosporine levels","  ","Refer to Immunosuppressants");n("Procainamide","Amiodarone",e.DRUG_DRUG,i.HIGH,": **  **.        NAPA.","Mechanism: **Reduced renal excretion**. Amiodarone decreases renal clearance of Procainamide and its active metabolite NAPA."," : **    NAPA    60%**     QT  .","Clinical Significance: **Increased Procainamide and NAPA levels by up to 60%**, increasing risk of QT prolongation and arrhythmias.","    30-50%.     ( QT).","Reduce Procainamide dose by 30-50%. Monitor levels and ECG (QT interval).");n("Procainamide","Cimetidine",e.DRUG_DRUG,i.MODERATE,": **   **.        .","Mechanism: **Inhibition of renal tubular secretion**. Cimetidine inhibits active tubular secretion of Procainamide."," : **    30-40%**  .","Clinical Significance: **Increased Procainamide levels by 30-40%** and toxicity risk.","      .  .","Reduce Procainamide dose or use Ranitidine as alternative. Monitor levels.");n("Procainamide","Trimethoprim",e.DRUG_DRUG,i.MODERATE,": **  **.      .","Mechanism: **Inhibition of tubular secretion**. Trimethoprim inhibits active renal secretion of Procainamide."," : **  **   QT.","Clinical Significance: **Increased Procainamide levels** and risk of QT prolongation.","    .    .","Monitor Procainamide levels and ECG. Dose reduction may be required.");n("Procainamide - ","Amiodarone - ",e.DRUG_DRUG,i.HIGH,"       .     P450 ( CYP2D6)       N-acetyltransferase 2 (NAT2)        N-acetylprocainamide (NAPA).        NAPA       ( OCT2).               NAPA/Procainamide       QT.","Amiodarone causes multi-pathway inhibition of procainamide metabolism and excretion. It inhibits cytochrome P450 enzymes (especially CYP2D6) responsible for procainamide metabolism, and inhibits the N-acetyltransferase 2 (NAT2) enzyme responsible for metabolizing procainamide to its active metabolite N-acetylprocainamide (NAPA). Additionally, amiodarone inhibits the renal excretion of both procainamide and NAPA by inhibiting organic cation transporters (e.g., OCT2). This leads to increased plasma levels of both compounds, with a notable increase in the NAPA/Procainamide ratio, enhancing the effect on QT interval prolongation.","     NAPA     : 1.     QT        ( torsades de pointes). 2.    :         (  ). 3.             . 4.   :    .","Significant increase in plasma levels of both procainamide and NAPA, leading to: 1. Increased risk of serious QT prolongation and ventricular arrhythmias (especially torsades de pointes). 2. Exacerbation of procainamide side effects: Hypotension, heart failure, cardiac conduction disturbances (AV block). 3. Increased risk of developing procainamide-associated lupus-like syndrome due to prolonged and high drug exposure. 4. Central neurotoxicity: Dizziness, delirium, seizures.","1.    :         . 2.   :    NAPA     ( 2-3   )     ( + NAPA)   30 /. 3.   :     50     . 4.   :       QT   . 5.  :     (    ). 6.  :              (   )       .","1. Avoid combination if possible: This combination is high-risk and should be avoided whenever possible. 2. Mandatory therapeutic monitoring: Monitor plasma levels of procainamide and NAPA frequently (every 2-3 days initially) and maintain total levels (procainamide + NAPA) below 30 mcg/mL. 3. Proactive dose reduction: Reduce the procainamide dose by at least 50% when adding amiodarone. 4. Intensive cardiac monitoring: Perform frequent ECGs to monitor QT interval and atrioventricular conduction. 5. Symptom monitoring: Watch for signs of lupus-like syndrome (arthralgia, rash, fever). 6. Treatment alternatives: Use an alternative antiarrhythmic drug that does not interact with amiodarone, such as disopyramide (with caution regarding its interactions) or antiarrhythmics from a different class.");n("Procainamide - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       NAPA   : 1.         (OCT2). 2.          .                .      NAPA    30-50.","Cimetidine reduces the renal clearance of procainamide and its metabolite NAPA through two mechanisms: 1. Inhibition of renal tubular secretion via organic cation transporters (OCT2). 2. Reduction in glomerular filtration due to a slight decrease in renal blood flow. Cimetidine does not significantly affect procainamide metabolism, but it increases the overall exposure to both the drug and its active metabolite. Plasma levels of procainamide and NAPA can increase by 30-50%.","     NAPA      : 1.     :     . 2.       QT   . 3.         . 4.                .","Moderate increase in plasma levels of procainamide and NAPA, which may lead to: 1. Increased risk of procainamide side effects: Hypotension, dizziness, nausea. 2. Slight increase in the risk of QT prolongation and cardiac arrhythmias. 3. Increased risk of developing lupus-like syndrome with chronic use. 4. These effects are more pronounced in patients with renal impairment or the elderly.","1.   :    NAPA     3-5    . 2.  :     25-35         . 3.   :    H2             . 4.  :            . 5.  :          .","1. Therapeutic level monitoring: Monitor plasma levels of procainamide and NAPA before and 3-5 days after starting cimetidine. 2. Dose adjustment: Reduce the procainamide dose by 25-35% if necessary based on plasma levels and clinical response. 3. Use cimetidine alternatives: Prefer other H2 receptor antagonists that do not significantly inhibit renal cation secretion, such as famotidine or ranitidine. 4. Clinical monitoring: Be vigilant for signs of toxicity, especially in patients with other risk factors. 5. Regular monitoring: Continue periodic monitoring of drug levels during combination therapy.");n("Procainamide - ","Ofloxacin - ",e.DRUG_DRUG,i.MODERATE,"       NAPA        (OCT2)    .        .           QT     hERG            .      NAPA    20-40.","Ofloxacin reduces the renal clearance of procainamide and its metabolite NAPA through competitive inhibition of organic cation transporters (OCT2) in the proximal renal tubules. This reduces the active tubular secretion of both compounds. Additionally, both drugs have the potential to prolong the QT interval by inhibiting the cardiac hERG channel, leading to a synergistic effect on ventricular repolarization prolongation. Plasma levels of procainamide and NAPA can increase by 20-40%.","     NAPA         QT   : 1.     QT       ( torsades de pointes). 2.    :     . 3.              (    ).","Moderate increase in plasma levels of procainamide and NAPA, combined with a synergistic effect on QT prolongation, leading to: 1. Increased risk of significant QT prolongation and ventricular arrhythmias (especially torsades de pointes). 2. Exacerbation of procainamide side effects: Hypotension, dizziness, nausea. 3. Increased risk of cardiotoxicity, especially in patients with underlying risk factors (heart failure, electrolyte imbalances).","1.      :          QT       . 2.  :    NAPA      . 3.   :          QT. 4.  :     20-30   . 5.   :        QT         / (  ). 6.   :         .","1. Avoid combination in at-risk patients: Avoid combination in patients with baseline QT prolongation, heart failure, or electrolyte imbalances. 2. Therapeutic monitoring: Monitor plasma levels of procainamide and NAPA if combination is necessary. 3. ECG monitoring: Perform ECG before and during combination therapy to monitor QT interval. 4. Dose adjustment: Reduce the procainamide dose by 20-30% if necessary. 5. Use ofloxacin alternatives: Use alternative antibiotics that do not prolong QT or inhibit renal cation secretion, such as cephalosporins or trimethoprim/sulfamethoxazole (if appropriate). 6. Electrolyte monitoring: Maintain potassium, magnesium, and calcium levels within normal range.");n("Procainamide ()","Ciprofloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Procainamide ()","Levofloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Procainamide ()","Moxifloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Procainamide ()","Ofloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Procainamide ()","Norfloxacin",e.DRUG_DRUG,i.HIGH,"         (Torsades de Pointes).","QT Prolongation & Torsades de Pointes. Additive effect on cardiac repolarization increases risk of fatal arrhythmias.","    QT      .","Fatal Arrhythmia Risk. Torsades de Pointes.","  .    (  ).","  .    (  ).");n("Prochlorperazine","Atropine",e.DRUG_DRUG,i.MODERATE,"   -     (   )","Reduced Phenothiazine Efficacy & Anticholinergic Load. Metabolic interaction lowers efficacy while additive anticholinergic effects worsen side effects.","     ","Reduced Efficacy & Increased Toxicity. Poor therapeutic index.","      ","      ");n("Prochlorperazine","Hyoscine (Scopolamine)",e.DRUG_DRUG,i.MODERATE,"   -     (   )","Reduced Phenothiazine Efficacy & Anticholinergic Load. Metabolic interaction lowers efficacy while additive anticholinergic effects worsen side effects.","     ","Reduced Efficacy & Increased Toxicity. Poor therapeutic index.","      ","      ");n("Prochlorperazine","Benztropine",e.DRUG_DRUG,i.MODERATE,"   -     (   )","Reduced Phenothiazine Efficacy & Anticholinergic Load. Metabolic interaction lowers efficacy while additive anticholinergic effects worsen side effects.","     ","Reduced Efficacy & Increased Toxicity. Poor therapeutic index.","      ","      ");n("Prochlorperazine","Ethanol - ",e.DRUG_DRUG,i.HIGH,"     (CNS)","Additive CNS Depression. Combined sedative effects.","   ","Increased CNS Depression. Drowsiness and ataxia.","  () ","  () ");n("Prochlorperazine","Propranolol - ",e.DRUG_DRUG,i.MODERATE,"      (  ) -        ","Mutual Metabolic Inhibition. Elevated levels of both drugs increase hypotensive and bradycardic risks.","     ","     ","   (    ) -        ","   (    ) -        ");n("Prochlorperazine","Ciprofloxacin - ",e.DRUG_DRUG,i.MODERATE,"   (        )","Reduced Phenothiazine Efficacy. Potential metabolic induction.","   ","   ","   -    : (  )","   -    : (  )");n("Prochlorperazine","Levodopa",e.DRUG_DRUG,i.HIGH,"  ","Dopamine receptor blockade.","  ","Worsening Parkinson symptoms.","   ","Avoid in Parkinson patients.");n("Prochlorperazine - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"    ()   CYP2D6        QT     ","Paroxetine inhibits the metabolism of Prochlorperazine (phenothiazine) via hepatic CYP2D6 enzymes, increasing its concentration and prolonging QT interval with risk of cardiac arrhythmias","         (Torsades de pointes)      ","Increased cardiotoxicity and arrhythmias including Torsades de pointes, in addition to enhanced phenothiazine side effects","     -        ECG   -      ","Avoid this combination if possible - if concurrent use is necessary, monitor ECG and drug concentrations - adjust Prochlorperazine dose as medically directed");n("Propafenone","Quinidine",e.DRUG_DRUG,i.MODERATE,": **  (CYP2D6)**.    CYP2D6    .","Mechanism: **Metabolism inhibition (CYP2D6)**. Quinidine inhibits CYP2D6 enzyme responsible for Propafenone metabolism."," : **  **    (   ).","Clinical Significance: **Increased Propafenone levels** and risk of cardiotoxicity (bradycardia, hypotension).","    30-50%.     .","Reduce Propafenone dose by 30-50%. Monitor vital signs and ECG.");n("Propafenone - ","Quinidine - ",e.DRUG_DRUG,i.MODERATE,"      P450 2D6 (CYP2D6).             .     CYP2D6                100-200 (   )    (AUC).         .          I-C    (  )         .","Quinidine is a potent inhibitor of the cytochrome P450 2D6 enzyme (CYP2D6). Propafenone relies heavily on this enzyme for its metabolism into active and inactive metabolites. Quinidine inhibition of CYP2D6 leads to a sharp decrease in propafenone clearance, increasing its plasma concentration by up to 100-200% (doubling to tripling) and the area under the curve (AUC). It also increases the proportion of unmetabolized propafenone in the blood. Additionally, both drugs possess Class I-C antiarrhythmic properties (sodium channel blockade), leading to synergistic pharmacodynamic effects on the heart.","                : 1.   :             -arrhythmic (      ). 2.     :      . 3.   :   .                     .","Significant increase in propafenone plasma levels, leading to exacerbation of its therapeutic and toxic effects, including: 1. Cardiotoxicity: Sinus bradycardia, atrioventricular block, heart failure, hypotension, pro-arrhythmic effects (worsening or induction of arrhythmias). 2. Central nervous system effects: Dizziness, blurred vision, metallic taste, tremors. 3. Gastrointestinal effects: Nausea, vomiting, constipation. The risk is higher in patients with impaired liver function, the elderly, and those with underlying structural heart disease.","1.    :            . 2.    :     50-75      . 3.  :          3-5     . 4.   :     (ECG)    PR QRS QT    (    ). 5.  :       . 6.  :           CYP2D6        (     )  .","1. Avoid combination if possible: Combining propafenone and quinidine is not preferred due to the dual pharmacokinetic and pharmacodynamic interaction. 2. If combination is necessary: Reduce the propafenone dose by at least 50-75% when initiating quinidine therapy. 3. Therapeutic monitoring: Monitor propafenone plasma levels if possible, especially after 3-5 days of starting combination therapy. 4. Intensive cardiac monitoring: Perform regular electrocardiograms (ECG) to assess PR, QRS, and QT intervals, and monitor vital signs (heart rate, blood pressure). 5. Clinical monitoring: Be vigilant for signs of cardiac and central nervous system toxicity. 6. Treatment alternatives: Use an alternative antiarrhythmic drug not affected by CYP2D6 or one that does not interact with quinidine, such as flecainide (with caution regarding its different interaction profile) or amiodarone.");n("Propafenone - ","Ritonavir - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       P450  CYP2D6 CYP3A4 CYP1A2     .                     300-400 (  4-5 ).     P-glycoprotein     .               (booster)             .","Ritonavir is a potent and complex inhibitor of cytochrome P450 enzymes, particularly CYP2D6, CYP3A4, and CYP1A2, all of which are involved in propafenone metabolism. The multi-pathway inhibition leads to a massive decrease in propafenone clearance, increasing its plasma concentration by up to 300-400% (a 4 to 5-fold increase). Ritonavir also inhibits the P-glycoprotein transporter, increasing propafenone absorption. This interaction is particularly dangerous because ritonavir is often used at low doses as a pharmacokinetic booster in HIV treatment, and clinicians may not fully appreciate the strength of its inhibitory effect.","                 : 1.    :                   -arrhythmic  (      ). 2.     :   . 3.  . 4.   .                .","Massive increase in propafenone plasma levels, leading to a risk of life-threatening propafenone toxicity, including: 1. Severe cardiotoxicity: Profound sinus bradycardia, complete atrioventricular block, myocardial suppression and heart failure, acute hypotension, serious pro-arrhythmic effects (e.g., sustained ventricular tachycardia). 2. Acute central neurotoxicity: Seizures, coma. 3. Respiratory failure. 4. Sudden cardiac death. The risk is immediate and severe, especially with full-dose ritonavir, but also exists with low boosting doses.","1.   :     .       . 2.   :                 CYP   (    )   (    QT). 3.  :                      . 4.   :                 . 5.    :                    .","1. Absolute avoidance: Combining propafenone and ritonavir is contraindicated. This combination represents a strong contraindication. 2. Immediate propafenone alternatives: For patients taking ritonavir, choose an alternative antiarrhythmic drug not significantly affected by CYP inhibitors, such as amiodarone (considering its other potential interactions) or sotalol (with caution for QT prolongation). 3. Ritonavir alternatives: If propafenone must be used, consult an infectious disease specialist about the possibility of using an HIV treatment regimen that does not contain ritonavir. 4. Urgent drug education: Ensure all patients taking propafenone are aware of the dangerous interaction with ritonavir and other protease inhibitors. 5. Emergency monitoring: If combination occurs accidentally, hospitalize the patient for continuous cardiac monitoring in the intensive care unit and provide supportive management of toxicity.");n("Propiomazine","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"      (CNS).","Additive Central Nervous System (CNS) Depressant Effects.","            .","Substantially increased risk of severe drowsiness, dizziness, motor incoordination, and enhanced respiratory depression.","   .               .","Alcohol must be completely avoided. With other depressants, use the lowest effective doses and monitor for over-sedation and breathing difficulties.");n("Propiomazine","Atropine (or other Anticholinergic Drugs)",e.DRUG_DRUG,i.HIGH,"   .","Additive Anticholinergic Effects.","               /    .","Increased risk of severe anticholinergic side effects such as urinary retention, severe constipation, blurred vision, and central confusion/delirium, especially in the elderly.","    .           .","Avoid co-administration if possible. If necessary, closely monitor the patient for signs of anticholinergic toxicity.");n("Propiomazine","Amiodarone (or other QT Prolonging Drugs)",e.DRUG_DRUG,i.MODERATE,"    QT.      QT  .","Additive effects on the QT interval. Propiomazine can mildly prolong the QT interval.","    QT    .","Increased risk of QT interval prolongation and serious cardiac arrhythmias.","   .    QT      .","Use this combination with caution. ECG monitoring of the QT interval is advised for at-risk patients.");n("Propiomazine","Meperidine",e.DRUG_DRUG,i.HIGH,"      (CNS).         .","Additive Central Nervous System (CNS) Depressant Effects. Propiomazine potentiates Meperidines sedative and respiratory depressant effects.","                   (Hypotension).","Substantially increased risk of severe drowsiness, dizziness, motor incoordination, life-threatening respiratory depression, and hypotension.","     .                  .","Avoid co-administration if possible. If necessary, significantly reduce the dosage of both drugs, start slowly, and closely monitor the patient for respiratory depression.");n("Propoxyphene - ","Ketoconazole - ",e.DRUG_DRUG,i.HIGH,"   CYP3A4        ","Propoxyphene inhibits CYP3A4 and Ketoconazole inhibits its metabolism, leading to dual inhibition","          ","Increased Propoxyphene toxicity with risk of CNS depression and cardiotoxicity","  -       ","Avoid combination - Propoxyphene has been withdrawn from markets due to safety concerns");n("Propoxyphene - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"   CYP2D6   ","Propoxyphene inhibits CYP2D6 and Paroxetine inhibits its metabolism","        ","Increased levels of both drugs with risk of intoxication and cardiotoxicity","  -      ","Avoid combination - Propoxyphene is not currently used due to its risks");n("Propoxyphene - ","Alcohol - ",e.DRUG_FOOD,i.HIGH,"      ","Synergistic sedative effect on the central nervous system","     ","Severe respiratory depression, coma, risk of death","  -     ","Strong warning - completely avoid alcohol with Propoxyphene");n("Propoxyphene - ","Diazepam - ",e.DRUG_DRUG,i.HIGH,"      ","Synergistic sedative and CNS depressant effect","    ","Respiratory depression, coma, risk of death","  -     ","Avoid combination - use safer analgesic alternatives");n("Propoxyphene - ","Amitriptyline - ",e.DRUG_DRUG,i.HIGH,"      ","Synergistic sedative effect with risk of cardiac toxicity","  QT     ","QT prolongation, cardiac arrhythmias, respiratory depression","  -     ","Avoid combination - Propoxyphene withdrawn due to cardiotoxicity");n("Propoxyphene - ","Diphenhydramine - ",e.DRUG_DRUG,i.HIGH,"    ","Synergistic sedative and anticholinergic effect","      ","Severe CNS depression, delirium, urinary retention","  -    ","Avoid combination - risk of respiratory depression and death");n("Propoxyphene - ","Methadone - ",e.DRUG_DRUG,i.CONTRAINDICATED,"   :            (CYP3A4 CYP2D6)       ","Dangerous synergistic opioid effect: both drugs depress the CNS and compete for shared metabolic enzymes (CYP3A4, CYP2D6), leading to mutual inhibition and toxic accumulation","        QT    ( Torsades de Pointes)   ","Life-threatening profound respiratory depression, coma, QT prolongation, cardiac arrhythmias (especially Torsades de Pointes), cardiac arrest, and death","   -    - :           -     ","Absolute contraindication - avoid combination entirely - note: Propoxyphene has been withdrawn from global markets due to fatal cardiotoxicity - use safer analgesic alternatives");n("Propoxyphene - ","Carbamazepine - ",e.DRUG_DRUG,i.HIGH,"   ","Propoxyphene inhibits Carbamazepine metabolism","       ","Increased Carbamazepine toxicity with dizziness, ataxia, and hepatotoxicity","  -     ","Avoid combination - monitor Carbamazepine levels if unavoidable");n("Propoxyphene - ","Warfarin - ",e.DRUG_DRUG,i.MODERATE,"     ","Propoxyphene may potentiate Warfarin effect","    ","Increased prothrombin time and bleeding risk"," INR   -    ","Monitor INR frequently - avoid combination if possible");n("Propoxyphene - ","General Note -  ",e.DRUG_DRUG,i.CONTRAINDICATED,"          ","Propoxyphene has been withdrawn from global markets due to cardiotoxicity and death risk","  (  QT  )    ","Cardiotoxicity (QT prolongation, arrhythmias), respiratory depression, addiction, deaths","   -     ","Do not use Propoxyphene - use safer alternative analgesics");n("Propoxyphene - ","Ritonavir - ",e.DRUG_DRUG,i.CONTRAINDICATED,"    CYP3A4    CYP2D6             ","Ritonavir potently inhibits CYP3A4 and Propoxyphene inhibits CYP2D6, leading to dual metabolic pathway inhibition with massive increase in Propoxyphene concentration","    3-5         (  QT Torsades de Pointes)  ","3-5 fold increase in Propoxyphene concentration with risk of acute respiratory depression, cardiotoxicity (QT prolongation, Torsades de Pointes), coma, and death","   -    -         -          ( )","Absolute contraindication - avoid combination entirely - Propoxyphene has been withdrawn from markets due to fatal risks - use safer alternatives like tramadol or hydrocodone (with monitoring)");n("Alfentanil - ","Ethanol -  ()",e.DRUG_FOOD,i.HIGH,"              ","Synergistic CNS depressant effect where ethanol enhances the sedative and depressant effects of alfentanil","           ","Acute respiratory depression, hypotension, coma, risk of death due to respiratory failure","        -       ","Completely avoid alcohol consumption during alfentanil therapy - continuous monitoring of vital signs and respiratory function");n("Propranolol","Verapamil (IV)",e.DRUG_DRUG,i.HIGH," .","Cardiac Depression. Negative inotropic and chronotropic effects."," .","Cardiac Arrest. Asystole or fatal arrhythmia.",".",".");n("Propranolol","Diabetes",e.DRUG_DISEASE,i.HIGH,"   ","Masking Hypoglycemia. Adrenergic warning signs of hypoglycemia are blunted.","      ","      ","     ","     ");n("Propranolol","Diabetes ()",e.DRUG_DISEASE,i.MODERATE,"    (  ).","Masking Hypoglycemia Symptoms. Tremors and palpitations associated with hypoglycemia are blocked.","      (Hypoglycemia Unawareness)    .","      (Hypoglycemia Unawareness)    .","          .","          .");n("Propranolol","Asthma ()",e.DRUG_DISEASE,i.HIGH,"  -2     .","Beta-2 Blockade. Non-selective beta-blockade causes bronchoconstriction in susceptible patients.","    .","    .","    .    ( Bisoprolol)  .","    .    ( Bisoprolol)  .");n("Propranolol","Asthma",e.DRUG_DISEASE,i.HIGH," .","Bronchoconstriction. Narrowing of the airways."," ."," .",".",".");n("Propranolol","Food (High-Protein)",e.DRUG_FOOD,i.MODERATE,"         .        : (1)     (hepatic blood flow):                     (2)     (first-pass metabolism):                         (3)  :             . :      30-50%       .","Propranolol is positively affected by food presence, especially protein-rich food. Food affects propranolol through several mechanisms: (1) stimulating hepatic blood flow: food, especially protein, increases blood flow to liver and intestines, improving drug absorption from intestines and delivery to circulation, (2) reducing first-pass metabolism: despite increased hepatic flow, food presence slows drug absorption and prolongs absorption duration, relatively reducing immediate exposure to extensive hepatic metabolism, (3) improving solubility: propranolol is weak base, food increases gastric acid secretion potentially improving its dissolution. Result: 30-50% bioavailability increase when taken with food versus empty stomach.","         : (1)   :                        (  ) (2)         :     (bradycardia -   50 /)    (hypotension)                  (3)         .","Moderate increase in blood propranolol levels, leading to: (1) enhanced therapeutic effects: better hypertension control, more effective heart rate reduction, better control of anxiety, tremor, or migraine symptoms (per indication), (2) possible increased side effects if levels too high: severe bradycardia (<50 bpm), hypotension with dizziness or vertigo, severe extremity coldness, unusual fatigue and exhaustion, dyspnea especially with exertion, (3) effect fluctuations with inconsistent administration pattern.",'    : (1)      :           (: 30    ) (2)           :           (  ) (3)         :         (4)     " " " " -         (5)     (extended-release):              (6) :   (    50-55 / )          (     ) (7)   :     -       (8)      -        " " (rebound hypertension/tachycardia).',`Main recommendation is total consistency: (1) choose one pattern and adhere daily: either always with food, or always before food by same duration (e.g., 30 minutes before each meal), (2) most physicians recommend taking with food or immediately after for several reasons: improved absorption and level stability, reduced potential gastric irritation, easier remembering (linking to meal times), (3) if taking for hypertension or heart problems: timing and condition consistency crucial for maintaining good control, (4) don't randomly switch between "with food" and "without food" - this will cause blood pressure and heart rate fluctuations, (5) extended-release formulations: usually taken once daily at same time, preferably with meal for better stability, (6) monitor: pulse rate (should be above 50-55 bpm usually), blood pressure, hypoglycemia signs if diabetic (propranolol may mask hypoglycemia symptoms), (7) if missed dose: don't take double dose - take next dose at scheduled time, (8) never stop propranolol suddenly - must gradually discontinue under medical supervision to avoid "rebound syndrome" (rebound hypertension/tachycardia).`);n("Ketoconazole","Acidic Beverages (Cola, Orange Juice)",e.DRUG_FOOD,i.MODERATE," ( )     (weak base)     (pH )          .         ()         .    : (1)  pH      (pH 2-3)       (2)          (3)       .    :  (pH  2.5)   (pH 3-4)      .           (PPIs)   H2   pH      .","Ketoconazole (especially tablets) is weak base drug requiring acidic environment (low pH) in stomach for proper dissolution and absorption. In acidic medium, ketoconazole converts to its ionized (charged) form which is more soluble in aqueous gastric fluid. Acidic beverages work by: (1) lowering gastric pH to more acidic levels (pH 2-3), creating ideal environment for ketoconazole dissolution, (2) significantly increasing drug ionization and solubility in gastric fluid, (3) improving absorption rate and amount from small intestine. Effective acidic beverage examples: cola (pH ~2.5), orange juice (pH 3-4), grapefruit juice, apple juice, lemonade. This effect is crucial especially for patients taking proton pump inhibitors (PPIs) or H2 antagonists that raise gastric pH and significantly reduce ketoconazole absorption.","          30-80% (       )   : (1)        (2)             (          ) (3)      (4)       .                    .","Noticeable, clinically important increase in ketoconazole absorption by 30-80% (depending on patient's baseline gastric acidity and beverage type), leading to: (1) higher, more stable drug blood levels, (2) significant therapeutic efficacy improvement against systemic or severe local fungal infections (oral or esophageal candidiasis, resistant dermatophytes, systemic fungal infections), (3) increased treatment response and cure rate, (4) reduced treatment failure or infection recurrence probability. This is very important as ketoconazole is usually used for difficult or resistant fungal infections where achieving adequate therapeutic levels is crucial for success.","    : (1) **  (  )**:       (   )    (200-250 )    -  :   ( )      .          (2)  :   (Antacids  Gaviscon, Maalox)    (PPIs    )  H2 ( ) -   pH    .     :     2-3       (3) **   PPIs    **:      -    ( )                 pH (   ) (4) :        ( )     (5)      -      (6) :         -       (7) ****:     (    )      pH        (8) :          ()   -       .","Detailed recommendations for optimal absorption: (1) **For regular tablets (not enteric-coated)**: must take with full meal (to stimulate gastric acid secretion) and full glass (200-250ml) of acidic beverage - good choices: regular cola (not diet), natural orange juice, apple juice, lemonade. Preferably drink half glass before tablet and half after, (2) completely avoid: antacids (like Gaviscon, Maalox), proton pump inhibitors (PPIs like omeprazole, lansoprazole, esomeprazole), H2 antagonists (ranitidine, famotidine) - all raise gastric pH and destroy ketoconazole absorption. If unavoidable: take ketoconazole at least 2-3 hours before them with acidic beverage, (3) **If taking necessary PPIs that cannot be stopped**: acidic beverages become more critical - specifically use cola (most acidic), and consider with physician increasing ketoconazole dose or switching to another antifungal unaffected by pH (like fluconazole or voriconazole), (4) timing: take ketoconazole with breakfast or lunch (main meals), not just light snack, (5) don't crush or chew tablets - swallow whole with acidic beverage, (6) follow-up: if infection doesn't improve within two weeks, inform physician - poor absorption may be the cause, (7) **Note**: modern ketoconazole forms (like some special pharmaceutical formulations) may be less pH-affected, but traditional regular tablets strongly need acidity, (8) alternatives: if absorption problems exist, consider itraconazole (capsules) or posaconazole - have better absorption properties in some cases.");n("Propranolol","Barbiturates",e.DRUG_DRUG,i.MODERATE,"   (CYP).        .","Enzymatic Metabolic Induction (CYP). Barbiturates induce hepatic enzymes responsible for Propranolol metabolism.","           (    ).","Decreased Propranolol plasma concentration, leading to reduced drug efficacy (less beta-blockade).","     .         .","Monitor blood pressure and heart rate. Increase the Propranolol dose if necessary to restore therapeutic efficacy.");n("Propranolol","Cimetidine",e.DRUG_DRUG,i.MODERATE,"    CYP450","Cimetidine CYP Inhibition. Cimetidine is a broad-spectrum inhibitor of CYP450 enzymes, increasing levels of co-administered drugs.","    ","    ","    -  ","    -  ");n("Propranolol - ","Hydralazine - ",e.DRUG_DRUG,i.MODERATE,"                 .      .     ( )      .","Hydralazine reduces the hepatic clearance of Propranolol by decreasing liver blood flow, increasing its bioavailability. Propranolol also affects Hydralazine metabolism. This results in a mutual (bidirectional) increase in the plasma concentrations of both drugs.","           (Hypotension)   (Bradycardia)             (    ).","Increased concentrations of both drugs lead to a risk of severe hypotension and bradycardia (from Propranolol), in addition to exacerbating Hydralazine side effects like headache and palpitations (which Propranolol may mask).","       .                    .","Closely monitor blood pressure and heart rate. The starting dose of one or both drugs should be reduced upon co-administration, with subsequent adjustments based on the patients response and blood pressure.");n("Propranolol","Clonidine",e.DRUG_DRUG,i.HIGH,"     ","Counteractive BP Regulation. Mechanisms of action oppose each other, leading to poor BP control.","    ","Hypertensive Crisis. Severe BP elevation.","   -  ","   -  ");n("Propranolol","Prazosin",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic Hypotension. Combined effects lead to significant blood pressure drop.","     ","     ","     ","     ");n("Propranolol - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       P450   CYP1A2 CYP2D6     .                50-70     .                  .     24-48       2-3    .          .","Cimetidine is a non-selective inhibitor of hepatic cytochrome P450 enzymes, particularly CYP1A2 and CYP2D6, responsible for the primary metabolism of propranolol. Cimetidine reduces propranolol metabolism, increasing its plasma concentration by up to 50-70%, and prolonging its biological half-life. Additionally, cimetidine reduces hepatic blood flow, further decreasing the clearance of high-extraction propranolol. This effect begins within 24-48 hours of starting therapy and subsides within 2-3 days after discontinuing cimetidine. The interaction is more pronounced with high propranolol doses and chronic use.","              : 1.    :    (   <50 /)     . 2.    :     . 3.        . 4.        .                         .","Increased propranolol plasma levels, leading to enhancement of its pharmacological and toxic effects, including: 1. Increased beta-blockade: Excessive bradycardia (heart rate <50 bpm), hypotension, dizziness, syncope. 2. Worsening of propranolol side effects: Fatigue, coldness, depression, nightmares, insomnia. 3. Increased risk of heart failure in susceptible patients. 4. Exacerbation of bronchospasm in asthmatic patients. These effects are more common and severe in elderly patients, those with impaired liver function, or those taking high doses of propranolol.","1.    :      .        . 2.   :    H2            . 3.    :     30-50    . 4.  :              . 5.  :      (    ). 6.    :         3-5        .","1. Avoid combination if possible: It is preferable not to combine propranolol and cimetidine. Seek a cimetidine alternative that does not inhibit liver enzymes. 2. Use cimetidine alternatives: Prefer other H2 receptor antagonists that do not significantly inhibit liver enzymes, such as famotidine or ranitidine. 3. If combination is necessary: Reduce the propranolol dose by 30-50% when initiating cimetidine therapy. 4. Close monitoring: Regularly monitor heart rate and blood pressure, especially during the first week of combination therapy. 5. Clinical monitoring: Watch for signs of increased beta-blockade (severe fatigue, dizziness, shortness of breath). 6. Adjustment upon cimetidine discontinuation: When discontinuing cimetidine, gradually increase the propranolol dose over 3-5 days to the previous level, based on clinical response.");n("Propranolol - ","Theophylline - ",e.DRUG_DRUG,i.MODERATE,"      P450   CYP1A2     .             20-30        .           .                   .","Propranolol is a competitive inhibitor of hepatic cytochrome P450 enzymes, particularly CYP1A2, the primary metabolic pathway for theophylline. Propranolol reduces theophylline metabolism, increasing its plasma concentration by 20-30%, decreasing its clearance, and increasing its biological half-life. This effect is more pronounced with high propranolol doses and chronic therapy. Additionally, propranolol may partially block the bronchodilator effects of theophylline, potentially reducing its clinical efficacy in some patients.","        : 1.               (10-20 /). 2.    :         . 3.              30 /. 4.                       .","Increased theophylline plasma levels, which may lead to: 1. Increased risk of theophylline toxicity, especially if levels are near the upper end of the therapeutic range (10-20 mcg/mL). 2. Worsening of theophylline side effects: Nausea, vomiting, headache, tremors, palpitations, arrhythmias. 3. In severe cases, it may lead to seizures, especially when theophylline levels exceed 30 mcg/mL. 4. Theoretically, beta-blockade may reduce the bronchodilator efficacy of theophylline, although the increased levels may partially counteract this effect.","1.  :             . 2.  :         20-30    . 3.  :     (   )       . 4.   : Patients                   (  )        . 5. :            .","1. Therapeutic monitoring: Monitor theophylline plasma levels upon initiation, discontinuation, or dose change of propranolol. 2. Dose adjustment: A reduction in the theophylline dose by 20-30% may be necessary when initiating propranolol therapy. 3. Clinical monitoring: Be vigilant for signs of theophylline toxicity (especially nausea, tremors, palpitations) and assess the efficacy of respiratory symptom control. 4. Use selective alternatives: For patients with obstructive lung disease who require beta-blockade, consider using cardioselective beta-blockers (e.g., bisoprolol, metoprolol) which have less effect on theophylline metabolism. 5. Education: Inform the patient about this potential interaction and symptoms of theophylline toxicity to watch for.");n("Propranolol - ","High-Protein Meals -   ",e.DRUG_FOOD,i.MODERATE,"           30-50%      .                  .                      .             .","High-protein meals increase cardiac output and hepatic blood flow by 30-50% as part of the body`s response to protein digestion. Propranolol is a drug with high hepatic extraction, meaning its bioavailability depends heavily on hepatic blood flow. Increased blood flow reduces the first-pass extraction of the drug in the liver, increasing the amount of drug reaching the systemic circulation. Additionally, proteins increase gastric acid secretion, improving propranolol dissolution.","      50-80%   : 1.    . 2.    (  <50 /). 3.    . 4.   . 5.       .                      .","Increased propranolol plasma concentration by 50-80%, leading to: 1. Enhanced beta-blockade. 2. Excessive bradycardia (heart rate <50 bpm). 3. Orthostatic hypotension. 4. Dizziness, fatigue, and syncope. 5. Worsening of heart failure symptoms in susceptible patients. The risk is higher in elderly patients, those with impaired liver function, or those taking high doses of propranolol.","1.   :         (       ). 2. :            . 3.  :                 . 4. :                    . 5.  :            .","1. Consistent administration: Always take propranolol the same way with respect to meals (always with food or always on an empty stomach). 2. Monitoring: Regularly monitor heart rate and blood pressure, especially after high-protein meals. 3. Dose adjustment: If taken consistently with food, a lower dose may be needed to maintain the therapeutic effect. 4. Alternatives: Consider using a beta-blocker with low hepatic extraction such as atenolol or metoprolol for patients who regularly consume high-protein meals. 5. Dosing timing: Avoid taking the dose immediately before or after a high-protein meal.");n("Propranolol ()","Lidocaine ()",e.DRUG_DRUG,i.MODERATE,"           .","Lidocaine Toxicity. Metabolic inhibition and additive cardiac depression.","              .","              .","       .         .","       .         .");n("Propranolol ()","Chlorpromazine",e.DRUG_DRUG,i.MODERATE,"    ","Increased Concentrations. Metabolic interaction elevates levels.","           .","           .","        .","        .");n("Propranolol ()","Thioridazine",e.DRUG_DRUG,i.HIGH,"  (CYP2D6).   /  CYP2D6   .","Metabolic Inhibition (CYP2D6). Propranolol is a moderate/strong inhibitor of the CYP2D6 enzyme that metabolizes Thioridazine.","               QT     ( Torsades de Pointes).","Substantial increase in Thioridazine plasma concentration, significantly raising the risk of QT interval prolongation and life-threatening cardiac arrhythmias (e.g., Torsades de Pointes).","      ( ).        QT     CYP2D6.","Co-administration is strictly contraindicated. An alternative non-QT-prolonging or non-CYP2D6 metabolized drug must be used.");n("Propranolol ()","Prochlorperazine",e.DRUG_DRUG,i.MODERATE,"    ","Increased Concentrations. Metabolic interaction elevates levels.","           .","           .","        .","        .");n("Propylthiouracil","Warfarin",e.DRUG_DRUG,i.MODERATE,"      K","Reduced vitamin K-dependent clotting factors."," INR","Increased INR."," INR","Monitor INR.");n("Pseudoephedrine","MAO Inhibitors",e.DRUG_DRUG,i.HIGH,": **    (Severe Sympathetic Potentiation)**.  MAO           .  (   )              .","Mechanism: **Severe sympathetic potentiation**. MAO inhibitors prevent breakdown of norepinephrine and dopamine in nerve cells, increasing their storage. Pseudoephedrine (indirect sympathomimetic) releases massive amounts of these accumulated neurotransmitters, causing very strong and sudden sympathetic stimulation."," : **      (Severe Hypertensive Crisis)**        (>200/120 mmHg)  :             .  **  ** (Hemorrhagic Stroke) **  ** **  **  ** **.     .","Clinical Significance: **Severe and dangerous acute hypertensive crisis** with blood pressure rising to fatal levels (>200/120 mmHg), accompanied by: severe headache, nosebleed, chest pain, palpitations, profuse sweating, nausea, vomiting, and visual disturbances. Risk of **hemorrhagic stroke**, **myocardial infarction**, **intracranial hemorrhage**, or **sudden death**. Interaction is extremely dangerous and life-threatening.","  . **  14   ** ( 21 )    MAO  .  ****   (    ).     **  **  ** **.          (OTC)   .    :    ****  **** .","Absolutely contraindicated. **Separate by at least 14 days** (preferably 21 days) between stopping MAO inhibitors and starting pseudoephedrine. Avoid **all** decongestants (including phenylephrine and oxymetazoline). Use safe alternatives such as **saline nasal spray** or **antihistamines**. Educate patient to read OTC medication labels to avoid decongestants. If crisis occurs: emergency treatment with IV **phentolamine** or **nitroprusside**.");n("Psyllium","Digoxin",e.DRUG_DRUG,i.MODERATE,"  ","Reduced digoxin absorption.","  ","Reduced digoxin efficacy."," ","Separate by 2 hours.");n("Pyrantel - ","Fatty Food -  ",e.DRUG_FOOD,i.HIGH,"       .   ( )              .              .                         .             200-300.","Pyrantel is an anthelmintic drug with poor water solubility. Fatty meals (rich in fats) stimulate bile and pancreatic enzyme secretion, delay gastric emptying, and increase intestinal lymphatic blood flow. Fats act as a natural solvent, significantly increasing the dissolution and absorption of pyrantel from the intestines. This increases the systemic bioavailability of the drug, which is normally intended to be local in the gut with limited systemic absorption to effectively target intestinal parasites. Fatty meals can increase the systemic absorption of pyrantel by up to 200-300%.","        : 1.     :      . 2.    :    (). 3.              . 4.           .","Significant increase in the systemic absorption of pyrantel, leading to: 1. Increased risk of systemic side effects: Nausea, vomiting, headache, dizziness, rash. 2. Potential neurotoxic symptoms: Drowsiness, confusion, tremors (rare). 3. Reduced drug concentration in the intestines, potentially decreasing its efficacy against target parasitic worms. 4. Safety concerns in sensitive populations such as children and the elderly.","1.    :      (          )             . 2.   :       (        )       (2-3 ). 3.  :                 . 4.   :              . 5.   :               .","1. Administration on an empty stomach: Take pyrantel on an empty stomach (at least 1 hour before food or 2 hours after a meal) to ensure minimal systemic absorption and maximum local concentration in the intestines. 2. Avoid fatty meals: Specifically avoid high-fat foods (fried foods, fatty meats, full-fat dairy products, oils) for a sufficient period before and after taking the medication (2-3 hours). 3. Drug education: Explain the importance of taking the medication on an empty stomach to the patient or caregiver to achieve optimal efficacy and reduce side effects. 4. Monitor for side effects: If the medication is accidentally taken with food, monitor for any systemic symptoms. 5. Do not double the dose: Do not double the dose if taken with food; simply resume the correct schedule for the next dose.");n("Quazepam","Alcohol / Opioids / Other CNS Depressants",e.DRUG_DRUG,i.HIGH,"     .","Additive Central Nervous System (CNS) Depressant Effects.","              .","Substantially increased risk of severe drowsiness, dizziness, motor incoordination, respiratory depression, and increased risk of falls.","   .                 .","Alcohol must be completely avoided. With other depressants, use the lowest possible effective doses and closely monitor for over-sedation and breathing difficulties.");n("Quazepam","Ketoconazole (or other strong CYP3A4 Inhibitors)",e.DRUG_DRUG,i.HIGH,"   (CYP3A4).       .","Potent Metabolic Inhibition (CYP3A4). These drugs slow down the metabolism of Quazepam and its active metabolites.","                  (Residual Sedation).","Increased concentration of Quazepam and active metabolites, leading to prolonged and increased hypnotic effect and severe next-day residual sedation.","   .          ( 50%)     .","Generally Avoid. If co-administration is necessary, significantly reduce the Quazepam dose (usually 50%) and monitor the patient for over-sedation.");n("Quazepam","Rifampin (or other strong CYP3A4 Inducers)",e.DRUG_DRUG,i.MODERATE,"    (CYP3A4).        .","Potent Enzymatic Metabolic Induction (CYP3A4). These drugs increase the metabolism of Quazepam and its active metabolites.","              .","Decreased levels of Quazepam and active metabolites, resulting in reduced drug efficacy, treatment failure, and recurrence of insomnia.","     .                .","Monitor the patient for insomnia recurrence. A Quazepam dose increase or switching to an alternative hypnotic agent not affected by inducers may be needed.");n("Quazepam","Diltiazem",e.DRUG_DRUG,i.MODERATE,"   (CYP3A4).        .","Inhibition of Quazepam metabolism (CYP3A4). Diltiazem is a moderate inhibitor of the enzyme metabolizing Quazepam and its active metabolites.","              (Daytime Sleepiness)     (CNS).","Increased concentration of Quazepam and its metabolites, leading to an increased risk of excessive next-day drowsiness and CNS depression.","        .          .","Closely monitor the patient for drowsiness and incoordination. A reduction in the Quazepam dose may be necessary to avoid over-sedation.");n("Quazepam","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"   (CYP3A4)  .        .","Inhibition of intestinal Enzymatic Metabolism (CYP3A4). Grapefruit reduces the breakdown of Quazepam and its active metabolites.","                .","Increased concentration of Quazepam and active metabolites, leading to prolonged and increased hypnotic effect and next-day residual sleepiness.","       .              .","Advise the patient to avoid consuming grapefruit and its juice during treatment. If consumed, the patient should be monitored for excessive drowsiness or impaired motor performance.");n("Quetiapine","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Quetiapine. Itraconazole    CYP3A4.","Increased Quetiapine concentration. Itraconazole is a strong inhibitor of CYP3A4.","        QT.","Increased risk of somnolence, hypotension, and QT prolongation."," .    Quetiapine   ( ).","Dose adjustment. Quetiapine dose must be significantly reduced (to one-sixth).");n("Quinapril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Quinidine","Amiloride",e.DRUG_DRUG,i.MODERATE,": **    **.      .","Mechanism: **Synergistic effect on potassium channels**. Both affect cardiac potassium channels."," : **    **   QT.","Clinical Significance: **Increased risk of ventricular arrhythmias** and QT prolongation.","   .       (QT) .","Avoid combination if possible. If necessary, monitor ECG (QT) and potassium.");n("Quinidine",Tt,e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4)**.      .","Mechanism: **Hepatic enzyme induction (CYP3A4)**. Barbiturates significantly induce Quinidine metabolism."," : **      50%**     .","Clinical Significance: **Decreased Quinidine levels by up to 50%** and loss of arrhythmia control.","  .          .","Monitor ECG. Significant Quinidine dose increase or drug switch may be required.");n("Quinidine","Cimetidine",e.DRUG_DRUG,i.MODERATE,": **  (CYP3A4)**.    .","Mechanism: **Metabolism inhibition (CYP3A4)**. Cimetidine inhibits Quinidine metabolism."," : **  **   (   ).","Clinical Significance: **Increased Quinidine levels** and toxicity risk (tinnitus, dizziness, arrhythmias).","      .  .","Reduce Quinidine dose or switch Cimetidine to Ranitidine. Monitor levels.");n("Quinidine","Verapamil",e.DRUG_DRUG,i.HIGH,": **  (CYP3A4)  **.        /.","Mechanism: **Metabolism inhibition (CYP3A4) and synergistic effect**. Verapamil inhibits Quinidine metabolism, and both inhibit ion channels."," : **  **      .","Clinical Significance: **Increased Quinidine levels**, severe hypotension, and bradycardia."," .        .","Avoid combination. If necessary, reduce Quinidine dose and monitor heart.");n("Quinidine",xt,e.DRUG_DRUG,i.HIGH,": **    QT**.     QT   .","Mechanism: **Synergistic QT prolongation**. Both drugs prolong the QT interval on ECG."," : **      (Torsades de Pointes)**.","Clinical Significance: **Increased risk of life-threatening ventricular arrhythmias (Torsades de Pointes)**.","   ( ).","Strictly avoid combination (Contraindicated).");n("Quinidine","Amitriptyline ()",e.DRUG_DRUG,i.HIGH,"     .     CYP2D6 (  )     QT.","Metabolic Inhibition and Additive Cardiotoxicity. Quinidine is a potent inhibitor of CYP2D6 (which metabolizes Amitriptyline); both drugs prolong the QT interval.","         QT      (Torsades de Pointes)     (  ).","Massive increase in Amitriptyline concentration, increasing the risk of QT prolongation and life-threatening cardiac arrhythmia (Torsades de Pointes), in addition to Amitriptyline toxicity (e.g., sedation, seizures).","     (  ).           (ECG)        .","Avoid this co-administration if possible (relative contraindication). If necessary, monitor ECG and Amitriptyline plasma levels, and significantly reduce the Amitriptyline dose.");n("Quinidine - ","Amiodarone - ",e.DRUG_DRUG,i.HIGH,"                .","Amiodarone significantly increases Quinidine levels by inhibiting metabolism, raising the risk of arrhythmias.","      QT      (Torsades de Pointes).","Marked QT prolongation risk with potential for dangerous ventricular arrhythmias (e.g., Torsades).","   .   :       .","Avoid combination whenever possible. If unavoidable: close monitoring and reduce Quinidine dose.");n("Quinidine - ","Phenobarbital - ",e.DRUG_DRUG,i.MODERATE,"                    .","Phenobarbital induces hepatic enzymes, significantly lowering Quinidine levels and reducing arrhythmia control.","         .","Loss of arrhythmia control due to reduced drug levels.","            .","Monitor Quinidine levels and adjust dose when starting/stopping/modifying barbiturate therapy.");n("Quinidine - ","Pentobarbital - ",e.DRUG_DRUG,i.MODERATE,"        .","Pentobarbital strongly induces metabolism, lowering Quinidine concentration.","       .","Potential loss of arrhythmia control.","           .","Monitor Quinidine levels and adjust dose with any barbiturate dose change.");n("Quinidine - ","Secobarbital - ",e.DRUG_DRUG,i.MODERATE,"         .","Secobarbital induces metabolism, reducing Quinidine exposure.","       .","Possible loss of arrhythmia control.","        .","Monitor levels and adjust Quinidine dose appropriately.");n("Quinidine - ","Aluminum Hydroxide -  ",e.DRUG_DRUG,i.MODERATE,"           .","Aluminum hydroxide increases Quinidine absorption, raising toxicity risk.","     .","Higher risk of Quinidine toxicity.","       .","Monitor levels; adjust dose upward only if clinically required.");n("Quinidine - ","Magnesium Hydroxide -  ",e.DRUG_DRUG,i.MODERATE,"       .","Magnesium hydroxide increases Quinidine levels by altering absorption.","   .","Increased risk of Quinidine toxicity.","     .","Monitor Quinidine levels and adjust as necessary.");n("Quinidine - ","Calcium Carbonate -  ",e.DRUG_DRUG,i.MODERATE,"         .","Calcium carbonate increases Quinidine exposure, raising toxicity risk.","     .","Higher risk of Quinidine toxicity.","    .","Monitor levels and modify dose cautiously.");n("Quinidine - ","Ciprofloxacin - ",e.DRUG_DRUG,i.HIGH,"                 QT.","High risk of arrhythmias including Torsades due to additive QT prolongation.","      .","Marked risk of serious ventricular arrhythmias.","  .       .","Avoid combination. Use safer quinolone alternatives.");n("Quinidine - ","Levofloxacin - ",e.DRUG_DRUG,i.HIGH,"           QT.","Severe QT prolongation risk when combined with Quinidine.","  Torsades de Pointes.","High risk of Torsades de Pointes."," .    .","Avoid this combination. Use safer alternatives.");n("Quinidine - ","Moxifloxacin - ",e.DRUG_DRUG,i.HIGH,"  QT       .","Moxifloxacin strongly prolongs QT; combined risk becomes extreme.","   .","High risk of dangerous ventricular arrhythmias.","  .","Avoid the combination entirely.");n("Quinidine - ","Ofloxacin - ",e.DRUG_DRUG,i.HIGH,"       (QT Prolongation).","Significant additive QT prolongation.","    .","Risk of ventricular arrhythmia."," .","Avoid combination.");n("Quinidine - ","Norfloxacin - ",e.DRUG_DRUG,i.HIGH,"       QT.","Major QT prolongation risk.","   .","Potential severe arrhythmia."," .","Avoid combination.");n("Quinidine - ","Ritonavir - ",e.DRUG_DRUG,i.HIGH,"           .","Ritonavir massively increases Quinidine levels by potent metabolic inhibition.","      .","High risk of Quinidine toxicity and dangerous arrhythmias.","  .","Avoid combination completely.");n("Itraconazole - ","Quinidine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     CYP3A4        .      .","Itraconazole is a strong inhibitor of the CYP3A4 enzyme, which is the major enzyme responsible for Quinidine metabolism. Inhibition prevents Quinidine clearance from the body.","               QT            (Torsades de Pointes).","Significant increase in Quinidine plasma concentration to toxic levels, leading to excessive QT prolongation and an increased risk of severe and fatal ventricular arrhythmia (Torsades de Pointes).","  .         .            CYP3A4.","Absolute Contraindication. Co-administration must be strictly avoided due to the risk of cardiotoxicity. An alternative antifungal or antiarrhythmic not affected by CYP3A4 should be used.");n("Quinidine - ","Acetazolamide / Sod. Bicarb -  /  ",e.DRUG_DRUG,i.MODERATE,"         (  ).     (pKa ~8.5-10.0)        .          ( )                  .                      .         (AUC)   20-50.","Both acetazolamide and sodium bicarbonate alkalinize the urine (increase pH). Quinidine is a weak base (pKa ~8.5-10.0) and undergoes pH-sensitive renal tubular reabsorption. Alkaline urine increases the proportion of non-ionized (uncharged) quinidine, the form that can cross renal tubular cell membranes and is passively reabsorbed back into the bloodstream. This significantly reduces the renal excretion of quinidine, decreases its renal clearance, prolongs its half-life, and elevates its plasma levels. This can increase the area under the curve (AUC) of quinidine by 20-50%.","        : 1.              . 2.    :     ( )    (  QT    )      (   - ). 3.              .","Increased quinidine plasma levels, which may lead to: 1. Increased risk of quinidine toxicity, especially if levels are near the upper end of the therapeutic range. 2. Worsening of quinidine side effects: Gastrointestinal disturbances (nausea, diarrhea), cardiac effects (QT prolongation, arrhythmia), and central nervous system effects (dizziness, cinchonism - tinnitus). 3. In patients with impaired renal function, this interaction may be more pronounced.","1. :             . 2.  :                              . 3.  :         (ECG)         QT. 4.  :           .            . 5. :           .","1. Monitoring: Monitor quinidine plasma levels upon initiation or discontinuation of acetazolamide or sodium bicarbonate. 2. Dose adjustment: A reduction in the quinidine dose may be necessary if alkalinizing agents are started, especially if baseline quinidine levels are in the high end of the therapeutic range or if signs of toxicity appear. 3. Clinical monitoring: Be vigilant for signs of quinidine toxicity and monitor ECG more frequently for QT prolongation. 4. Alternative strategies: If possible, avoid long-term concurrent use of alkalinizing agents with quinidine. For acetazolamide, consider alternatives for lowering intraocular pressure if appropriate. 5. Education: Inform the patient about this potential interaction and symptoms of toxicity to watch for.");n("Quinidine - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       P450   CYP3A4     .                50-70     .                  .         .     24-48       2-3    .","Cimetidine is a non-selective inhibitor of hepatic cytochrome P450 enzymes, particularly CYP3A4, responsible for the primary metabolism of quinidine. Cimetidine reduces quinidine metabolism, increasing its plasma concentration by up to 50-70%, and prolonging its biological half-life. Additionally, cimetidine reduces hepatic blood flow, further decreasing the clearance of high-extraction quinidine. Cimetidine may also reduce the renal tubular secretion of quinidine. This effect begins within 24-48 hours of starting therapy and subsides within 2-3 days after discontinuing cimetidine.","        (>5-6 /)         : 1.  :   QT      ( torsades de pointes)       . 2.   :     . 3.    :           (   ).                   .","Increased quinidine plasma levels above the therapeutic range (>5-6 mcg/mL), leading to an increased risk of quinidine toxicity, which includes: 1. Cardiac toxicity: QT interval prolongation, ventricular arrhythmias (especially torsades de pointes), slowed atrioventricular conduction, hypotension. 2. Gastrointestinal toxicity: Nausea, vomiting, diarrhea, loss of appetite. 3. Central nervous system toxicity: Dizziness, headache, tinnitus, hearing loss, blurred vision, confusion, delirium (especially in the elderly). These effects are more common and severe in elderly patients and those with impaired renal or hepatic function.","1.    :      .        . 2.   :    H2            . 3.    :     30-50    . 4.   :          3-5       . 5.  :    (ECG)     QT    . 6.    :         3-5          .","1. Avoid combination if possible: It is preferable not to combine quinidine and cimetidine. Seek a cimetidine alternative that does not inhibit liver enzymes. 2. Use cimetidine alternatives: Prefer other H2 receptor antagonists that do not significantly inhibit liver enzymes, such as famotidine or ranitidine. 3. If combination is necessary: Reduce the quinidine dose by 30-50% when initiating cimetidine therapy. 4. Mandatory therapeutic monitoring: Measure quinidine plasma levels before starting cimetidine, after 3-5 days of starting combination therapy, and during therapy. 5. Clinical monitoring: Monitor ECG for QT prolongation and watch for other signs of toxicity. 6. Adjustment upon cimetidine discontinuation: When discontinuing cimetidine, gradually increase the quinidine dose over 3-5 days to the previous level, based on level monitoring and clinical response.");n("Quinidine - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"  ( )      P450   CYP3A4     .                   (AUC)    80-90.       P-glycoprotein      .     3-5           .              P450.","Rifamycins (rifampin, rifabutin) act as potent and broad inducers of hepatic cytochrome P450 enzymes, especially CYP3A4, the primary metabolic pathway for quinidine. This induction leads to a significant increase in quinidine metabolism, reducing its plasma concentration and area under the curve (AUC) by up to 80-90%. Rifamycins also induce drug transporters like P-glycoprotein, increasing intestinal efflux of quinidine. This effect begins within 3-5 days of starting rifamycin therapy and peaks within two weeks. The effect persists for several weeks after discontinuing the rifamycin due to the time required for cytochrome P450 enzyme regeneration.","          (2-5 /)   : 1.          (        ). 2.         (  ). 3.           (     ). 4.                      .","Sharp decrease in quinidine plasma levels below the therapeutic range (2-5 mcg/mL), leading to: 1. Therapeutic failure in controlling cardiac arrhythmia (atrial fibrillation, atrial flutter, ventricular tachycardia). 2. Return or worsening of arrhythmia symptoms (palpitations, dizziness, syncope). 3. Increased risk of complications associated with uncontrolled arrhythmia (heart failure, thromboembolic stroke). 4. The need for significantly higher quinidine doses to achieve control, which may pose dosing challenges if the rifamycin is discontinued later.","1.   :          5-7      . 2.   :     100-200 (   )   .        . 3.  :                 . 4.    :         50-75   2-3   . 5.  :               ()   (). 6.  : Patients                        (    ).","1. Mandatory therapeutic monitoring: Measure quinidine plasma levels before starting the rifamycin, after 5-7 days of initiation, and during combination therapy. 2. Proactive dose increase: Increase the quinidine dose by 100-200% (double or triple the dose) when starting the rifamycin. More frequent divided dosing may be necessary. 3. Clinical monitoring: Closely monitor arrhythmia through ECG and patient-reported symptoms. 4. Dose adjustment after discontinuation: When discontinuing the rifamycin, gradually reduce the quinidine dose by 50-75% over 2-3 weeks to avoid toxicity. 5. Rifamycin alternatives: If possible, use alternative antibiotics that do not induce liver enzymes, such as third-generation cephalosporins (ceftriaxone) or macrolides (azithromycin). 6. Quinidine alternatives: For patients requiring long-term rifamycin therapy, consider using an alternative antiarrhythmic drug less affected by enzyme induction, such as amiodarone (considering its different interaction profile).");n("Quinidine - ","Verapamil - ",e.DRUG_DRUG,i.HIGH,"       .          CYP3A4         50-100   .       .          (   I-A )   ( )         .          .","This interaction causes serious pharmacokinetic and pharmacodynamic effects. Pharmacokinetically, verapamil inhibits quinidine metabolism by inhibiting CYP3A4, increasing quinidine plasma concentration by 50-100% and prolonging its half-life. Verapamil also reduces the renal clearance of quinidine. Pharmacodynamically, both drugs work synergistically to inhibit sodium channels (quinidine`s Class I-A effect) and calcium channels (verapamil`s effect), leading to potent and dual inhibition of cardiac conduction and contractility. This combination severely depresses the sinoatrial and atrioventricular nodes.","          : 1.     :         torsades de pointes (   QT  ). 2.              . 3.   . 4.                    .","Significantly increased risk of acute cardiovascular toxicity, including: 1. Life-threatening arrhythmias: Severe sinus bradycardia, heart block, ventricular fibrillation, torsades de pointes (due to QT prolongation from quinidine). 2. Profound hypotension and shock due to dual inhibition of myocardial contractility and peripheral vasodilation. 3. Acute heart failure. 4. Death may occur from cardiac arrest, especially in elderly patients or those with underlying cardiac dysfunction.","1.   :                    . 2.  :                   . 3.  :        (  )         . 4.  :     50     . 5.  :      (       )   . 6.  :              ( )   (    ).","1. Absolute avoidance: This combination is relatively contraindicated and should only be used in very rare cases with intensive hospital supervision. 2. Continuous monitoring: If combination is exceptionally necessary, the patient must be admitted to the cardiac care unit for continuous ECG and blood pressure monitoring. 3. Therapeutic monitoring: Measure quinidine plasma levels frequently (at least daily) and maintain levels at the lower end of the therapeutic range. 4. Dose adjustment: Reduce the quinidine dose by at least 50% when adding verapamil. 5. Emergency preparedness: Have resuscitation equipment and emergency medications (e.g., atropine, adrenaline, temporary pacemakers) readily available. 6. Therapeutic alternatives: Use alternative antiarrhythmic drugs that do not interact severely, such as beta-blockers (with caution) or amiodarone (considering its different interaction profile).");n("Quinidine - ","Amitriptyline - ",e.DRUG_DRUG,i.HIGH,"       QT    .       hERG        (IKr)             (  QT    ).          CYP2D6           100.                       .","This interaction creates a significant risk for QT prolongation and ventricular arrhythmias. Both drugs inhibit the cardiac hERG channel responsible for the rapid delayed rectifier potassium current (IKr), leading to a synergistic and additive effect on prolonging ventricular repolarization (measured as the QT interval on ECG). Additionally, quinidine inhibits amitriptyline metabolism via CYP2D6, increasing amitriptyline plasma concentrations by up to 100%. They also have cumulative anticholinergic effects that may accelerate heart rate, potentially leading to polymorphic ventricular tachycardia.","          torsades de pointes      : 1.   QTc     (>500      ). 2.     . 3.    . 4.       (     )   . 5.      ().","Massive increase in the risk of serious ventricular arrhythmias, particularly torsades de pointes, a life-threatening condition characterized by: 1. Prolonged QTc interval on ECG (>500 ms significantly increases risk). 2. Dizziness, syncope, sudden cardiac arrest. 3. Progression to ventricular fibrillation and death. 4. Exacerbation of amitriptyline`s anticholinergic side effects (dry mouth, constipation, urinary retention, confusion) due to increased levels. 5. Increased risk of amitriptyline neurotoxicity (seizures).","1.  :      .                QT (       ). 2.    :             QT .       QTc >450     >470   . 3.  :               (  ). 4.  :        QT   ( SSRIs        )        ( mexiletine   ). 5.  :          . 6.  :         (  )     .","1. Avoid combination: Combining quinidine and amitriptyline is not recommended. This is a relative contraindication, especially in patients with other risk factors for QT prolongation (female, advanced age, heart failure, electrolyte imbalances). 2. Baseline ECG screening: Before initiating either drug, perform an ECG to measure the baseline QT interval. Avoid either drug if QTc is >450 ms for men or >470 ms for women. 3. Regular monitoring: If combination is exceptionally necessary, perform weekly ECGs and monitor electrolytes (potassium, magnesium, calcium). 4. Use alternatives: Use alternative antidepressants that do not significantly prolong QT (e.g., SSRIs like citalopram or escitalopram at moderate doses, with caution) or alternative antiarrhythmic drugs (e.g., mexiletine for ventricular arrhythmias). 5. Dose adjustment: If combined, use the lowest effective dose of both drugs. 6. Patient education: Alert the patient to symptoms of arrhythmia (dizziness, palpitations, fainting) and instruct them to seek urgent medical care.");n("Quinidine - ","Opioids - ",e.DRUG_DRUG,i.MODERATE,"      P450 2D6 (CYP2D6).             CYP2D6      (   O-desmethyltramadol  ).              .             80-90         .         (   )   .","Quinidine is a potent inhibitor of the cytochrome P450 2D6 (CYP2D6) enzyme. Many opioid analgesics, particularly codeine, tramadol, and partially oxycodone, depend on CYP2D6 for conversion to their active analgesic metabolites (morphine from codeine, O-desmethyltramadol from tramadol). Quinidine inhibits this metabolic conversion, significantly reducing the formation of these active metabolites. For codeine, quinidine can reduce morphine formation by up to 80-90%, essentially rendering the drug ineffective. For opioids that do not rely on metabolic activation (such as morphine itself, hydromorphone), the interaction is minimal.",'         " " (prodrugs)   : 1.         . 2.                      (    ). 3.                           .',"Severe reduction or loss of the analgesic effect of prodrug opioids, leading to: 1. Inadequate pain control, causing patient suffering. 2. The need for higher opioid doses in an attempt to achieve analgesia, potentially increasing the risk of side effects without additional analgesic benefit (e.g., respiratory depression, constipation, nausea). 3. In the case of tramadol, failure to form the active metabolite may result in loss of its serotonin-norepinephrine reuptake inhibitor effect, potentially reducing its efficacy for certain neuropathic pain types.",'1.    " " :       .        . 2.    :       CYP2D6               . 3.   :                 . 4.  :           . 5.  :         CYP2D6             CYP2D6       (        ).',"1. Avoid combination with prodrug opioids: Avoid using quinidine with codeine or tramadol. This combination is therapeutically irrational. 2. Use appropriate opioid alternatives: Choose opioid analgesics that do not rely on CYP2D6 for activation, such as morphine, hydromorphone, or fentanyl, if an opioid must be used for a patient taking quinidine. 3. Monitor analgesic efficacy: If combination occurs, closely monitor pain relief and be prepared to change the analgesic regimen quickly if it is ineffective. 4. Drug education: Explain this interaction to patients and healthcare providers to avoid ineffective prescriptions. 5. Quinidine alternatives: If the use of CYP2D6-dependent opioids is necessary, consider using an alternative antiarrhythmic drug that does not potently inhibit CYP2D6, such as some sodium channel blockers (e.g., flecainide, considering its different safety profile).");n("quinine - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE,"    -P (P-glycoprotein)               .","Quinine inhibits the P-glycoprotein (P-gp) transporter in the intestine and kidneys, impairing Digoxin's efflux from cells and thus increasing its absorption and decreasing its renal excretion.","           (Arrhythmia)  . (    - )","Increased Digoxin serum concentration, raising the risk of associated cardiac toxicity (Arrhythmia). (Change in Digoxin efficacy - increase)","     50%    .         (ECG)     .","Reduce the Digoxin dose by 50% when initiating Quinine therapy. Monitor Digoxin serum level and ECG to detect any signs of toxicity.");n("quinine - ","Warfarin - ",e.DRUG_DRUG,i.HIGH,"     ( CYP2C9)            .","Quinine inhibits hepatic metabolic enzymes (especially CYP2C9) responsible for Warfarin breakdown, impairing its metabolism and increasing its blood level.","   INR (  )    . (  )","Significant increase in INR (International Normalized Ratio) and high risk of severe and fatal bleeding. (Increased Warfarin efficacy)","  INR     (  )    .","Closely monitor INR and adjust Warfarin dose (usually a reduction) immediately upon initiating Quinine therapy.");n("quinine - ","Rifampin - ",e.DRUG_DRUG,i.MODERATE,"      ( CYP3A4)             .","Rifampin is a potent inducer of hepatic enzymes (especially CYP3A4) responsible for Quinine metabolism and breakdown, which significantly increases the drug's clearance rate.","                   . (    )","Significant decrease in Quinine blood concentrations, potentially leading to therapeutic failure and uncontrolled infection (e.g., malaria). (Decreased Quinine level in blood)","       -             .","Monitor Quinine concentrations regularly - increase the Quinine dose if necessary to compensate for the Rifampin-induced decrease in level.");n(xt,"Didanosine",e.DRUG_DRUG,i.MODERATE,": ** **.       .","Mechanism: **Chelation**. Didanosine contains antacids (buffers) that bind to Quinolones."," : **      90%**  .","Clinical Significance: **Decreased Quinolone absorption by up to 90%** and treatment failure.","        6 .","Take Quinolone 2 hours before Didanosine or 6 hours after.");n(xt,Pc,e.DRUG_DRUG,i.HIGH,": **    (Chelation)**.    (  )     .","Mechanism: **Chelation**. Quinolones bind to cations (calcium, magnesium, aluminum) in the stomach, forming insoluble complexes that prevent absorption."," : **     **  .","Clinical Significance: **Severely reduced antibiotic absorption** and treatment failure.","      6      .","Take Quinolone 2 hours before or 6 hours after antacids or supplements.");n("Rabeprazole","Ketoconazole",e.DRUG_DRUG,i.MODERATE," pH  -   ","Increased gastric pH reduces ketoconazole absorption.","  ","Antifungal failure.","  -     ","Separate doses - take ketoconazole with acidic beverage.");n("Raloxifene","Cholestyramine",e.DRUG_DRUG,i.MODERATE," ","Reduced absorption.","  ","Reduced raloxifene efficacy."," ","Avoid combination.");n("Raltegravir","Calcium Supplements",e.DRUG_DRUG,i.MODERATE,"  Raltegravir.    ( )     .","Decreased Raltegravir concentration. Polyvalent cations (like calcium) chelate the drug in the GI tract.","     .","Reduced efficacy of antiretroviral therapy."," .         Raltegravir .","Separate timing. Calcium supplements must be avoided 2 hours before or after Raltegravir.");n("Ramipril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Ramipril","Spironolactone",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Ramipril","Eplerenone",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Ramipril","Amiloride",e.DRUG_DRUG,i.HIGH," .","Potassium Accumulation. Additive potassium-sparing effects impair renal potassium excretion."," .","Cardiac Arrest. Asystole or fatal arrhythmia.","  .","  .");n("Ramipril","Aspirin",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Ibuprofen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Diclofenac",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Naproxen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Ketoprofen",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Indomethacin",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Celecoxib",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"  ","Pharmacodynamic Antagonism. The drugs exert opposing physiological effects, potentially nullifying therapeutic benefits.","    ","Renal Failure & Hyperkalemia. Life-threatening electrolyte imbalance.","    ","    ");n("Ramipril","Trimethoprim",e.DRUG_DRUG,i.HIGH,"  ","Both are potassium-sparing.","  ","Severe hyperkalemia.","   3-5    ","Monitor K+ 3-5 days after starting treatment.");n("Ranitidine","Glipizide, Repaglinide",e.DRUG_DRUG,i.MODERATE,"  ","Increased Gastric Emptying. Faster absorption onset."," "," ","  ","  ");n("Ranitidine","Ketoconazole",e.DRUG_DRUG,i.MODERATE," pH ","Increased gastric pH.","  ","Reduced ketoconazole absorption.","  ","Separate doses by 2 hours.");n("Ranitidine","Alcohol",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Caffeine",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Green Tea",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Milk",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","High-fat meals",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","High-fiber foods",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Vitamin C",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Vitamin D",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Vitamin E",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Vitamin K",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Vitamin B12",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Folic Acid",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Iron",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Calcium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Magnesium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Zinc",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Potassium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranitidine","Antacids",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Ranolazine","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ranolazine. Rifampin    CYP3A4.","Decreased Ranolazine concentration. Rifampin is a strong inducer of CYP3A4.","    .","Reduced anti-angina efficacy."," .   .","Contraindicated. Avoid the combination.");n("Rasagiline","SSRIs",e.DRUG_DRUG,i.HIGH,"    MAO-B","Serotonin syndrome due to MAO-B inhibition.","    ","Elevated serotonin, tremors, confusion, fever.","    14   ","Avoid combination, separate by at least 14 days.");n("Rasagiline (MAO-B)","Tyramine-rich Foods",e.DRUG_FOOD,i.MODERATE,"      (   ). Rasagiline    MAO-B      .","Increased risk of hypertensive crisis (especially at high doses). Rasagiline is a selective MAO-B inhibitor, but selectivity decreases with increased dose.","  .","Hypertension.","  .       Rasagiline    1  .","Relative contraindication. Tyramine-rich foods must be avoided at Rasagiline doses greater than 1 mg daily.");n("Regorafenib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Regorafenib. Ketoconazole    CYP3A4    Regorafenib.","Increased Regorafenib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Regorafenib metabolic pathway.","    .","Increased risk of hepatotoxicity and hemorrhage."," .    Regorafenib     CYP3A4 .","Dose adjustment. Regorafenib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Regorafenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Regorafenib  . Rifampin    CYP3A4.","Decreased concentration of Regorafenib and its active metabolites. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Relebactam/Imipenem/Cilastatin","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Relebactam  Imipenem. Probenecid    .","Increased Relebactam and Imipenem concentration. Probenecid inhibits renal tubular transport.","      ().","Increased risk of CNS toxicity (seizures).","  .   .","Relative contraindication. Avoid the combination.");n("Relugolix","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Relugolix. Cyclosporine     P-glycoprotein (P-gp)      Relugolix.","Increased Relugolix concentration. Cyclosporine is a strong inhibitor of P-glycoprotein (P-gp), the major efflux transporter for Relugolix.","       QT.","Increased risk of side effects, especially QT prolongation."," / .   Relugolix  6      P-gp.","Dose adjustment/Timing. Relugolix must be taken at least 6 hours prior to the P-gp inhibitor.");n("Relugolix","Rifampin",e.DRUG_DRUG,i.HIGH,"  Relugolix. Rifampin    CYP3A4  P-gp     Relugolix.","Decreased Relugolix efficacy. Rifampin is a strong inducer of CYP3A4 and P-gp, which are Relugolix metabolism and efflux pathways.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Relugolix","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Relugolix. Cyclosporine   P-glycoprotein (P-gp)    Relugolix.","Increased Relugolix concentration. Cyclosporine inhibits P-glycoprotein (P-gp), a Relugolix efflux transporter.","      Relugolix.","Increased risk of Relugolix-related side effects."," .    P-gp .","Avoid Combination. Strong P-gp inhibitors must be avoided.");n("Relugolix","Rifampin",e.DRUG_DRUG,i.HIGH,"  Relugolix. Rifampin   P-gp    Relugolix.","Decreased Relugolix efficacy. Rifampin is a P-gp inducer, a Relugolix efflux transporter.","          .","Reduced drug plasma concentration, leading to failure of hormonal therapy."," .    P-gp .","Avoid Combination. Strong P-gp inducers must be avoided.");n("Relugolix","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  . Relugolix         ( Relugolix/Estradiol/Norethisterone acetate)  NSAIDs       .","Increased bleeding risk. Relugolix is usually used in combinations that increase bleeding risk (e.g., Relugolix/Estradiol/Norethisterone acetate), and NSAIDs increase the risk of GI bleeding.","   .","Increased risk of bleeding and bruising.","  .   NSAIDs    .","Side effect monitoring. NSAIDs must be used cautiously and signs of bleeding monitored.");n("Relugolix","Rifampin",e.DRUG_DRUG,i.HIGH,"  Relugolix. Rifampin    P-gp    Relugolix.","Decreased Relugolix concentration. Rifampin is a strong inducer of P-gp, a Relugolix efflux transporter.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Relugolix","Rifampin",e.DRUG_DRUG,i.HIGH,"  Relugolix. Rifampin    P-gp.","Decreased Relugolix concentration. Rifampin is a strong inducer of P-gp.","  .","Reduced drug efficacy."," .   .","Contraindicated. Avoid the combination.");n("Relugolix","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Relugolix. Cyclosporine   P-gp.","Increased Relugolix concentration. Cyclosporine inhibits P-gp.","   .","Increased risk of side effects."," .    .","Close monitoring. Close monitoring and dose adjustment.");n("Relugolix - ","Gemfibrozil - ",e.DRUG_DRUG,i.MODERATE,"   OATP1B1                ","Gemfibrozil inhibits hepatic OATP1B1 transporter essential for Relugolix uptake, increasing its plasma concentration by reducing hepatic distribution and clearance","      50-80              ","50-80% increase in Relugolix plasma concentration, potentially enhancing side effects such as fatigue, hot flashes, weight gain, and elevated liver enzymes","     6      -     -     ","Take Relugolix at least 6 hours before Gemfibrozil to minimize interaction - monitor liver function regularly - assess patient tolerance to side effects");n("Remdesivir","Chloroquine/Hydroxychloroquine",e.DRUG_DRUG,i.HIGH,"  Remdesivir. Chloroquine/Hydroxychloroquine       Remdesivir.","Decreased Remdesivir efficacy. Chloroquine/Hydroxychloroquine may inhibit the intracellular metabolism of Remdesivir.","    (-19).","Failure of antiviral treatment (COVID-19)."," .   .","Contraindicated. Avoid the combination.");n("Remdesivir","Chloroquine",e.DRUG_DRUG,i.HIGH,": ** **. Chloroquine     Remdesivir  .","Mechanism: **Pharmacodynamic antagonism**. Chloroquine may reduce Remdesivir antiviral efficacy."," : **  COVID-19**.","Clinical Significance: **COVID-19 treatment failure**.","  .","Avoid combination.");n("Remdesivir","Hepatic Impairment ( )",e.DRUG_DISEASE,i.HIGH,": ** **. Remdesivir     .","Mechanism: **Hepatotoxicity**. Remdesivir may elevate liver enzymes."," : **  **.","Clinical Significance: **Worsening hepatic impairment**.","   .     .","Close monitoring of liver function. Avoid in severe hepatic impairment.");n("Remimazolam","Fentanyl (Opioid)",e.DRUG_DRUG,i.HIGH,"     .   .","Increased risk of respiratory depression and somnolence. Additive depressant effects.","   .","Life-threatening respiratory depression."," .      .","Close monitoring. Close and intensive monitoring for signs of respiratory depression.");n("Repaglinide","Cyclosporine",e.DRUG_DRUG,i.HIGH," OATP1B1  CYP3A4","OATP1B1 and CYP3A4 inhibition.","  ","Severe hypoglycemia."," ","Avoid combination.");n("Retatrutide (Triple RA)","Oral Contraceptives",e.DRUG_DRUG,i.MODERATE,"   . Retatrutide   .","Decreased oral drug absorption. Retatrutide slows gastric emptying.","    .","Reduced efficacy of oral contraceptives."," .       Tirzepatide ( ).","Special action. Similar precautions to Tirzepatide must be taken (dose separation).");n("Retatrutide (Triple RA)","Warfarin",e.DRUG_DRUG,i.MODERATE,"    INR. Retatrutide         Warfarin.","Irregular effect on INR. Retatrutide slows gastric emptying, which may affect Warfarin absorption.","    .","Increased risk of bleeding or thrombosis."," .  INR       Retatrutide.","Close monitoring. Monitor INR frequently upon initiation or discontinuation of Retatrutide.");n("Reteplase","Warfarin",e.DRUG_DRUG,i.HIGH,"   ","Additive anticoagulant effect."," ","Dangerous bleeding.","    ","Stop warfarin before thrombolysis.");n("Retifanlimab","Tofacitinib",e.DRUG_DRUG,i.HIGH,"  . Retifanlimab       Tofacitinib    .","Exacerbated Immunosuppression. Retifanlimab activates immunity, and interaction with Tofacitinib may increase the risk of infection and toxicity.","          (CRS)   (  Teclistamab).","Increased risk of serious infections, including Cytokine Release Syndrome (CRS) and opportunistic infections (same mechanism as Teclistamab).","  ( ).     Tofacitinib    Retifanlimab.","Contraindicated (usually temporary). Tofacitinib should be discontinued before initiating Retifanlimab.");n("Retifanlimab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"    (  Mirikizumab/Secukinumab).","Increased risk of viral infection (same mechanism as Mirikizumab/Secukinumab).","     .","Risk of developing infection from live vaccines."," .       .","Contraindicated. Avoid live vaccines during and after treatment period.");n("Rexulti (Brexpiprazole)","Fluoxetine (SSRI, CYP2D6 Inhibitor)",e.DRUG_DRUG,i.HIGH,"  Brexpiprazole. Fluoxetine    CYP2D6.","Increased Brexpiprazole concentration. Fluoxetine is a strong inhibitor of CYP2D6.","     (EPS)   QTc.","Increased risk of extrapyramidal symptoms (EPS) and QTc prolongation."," .    Brexpiprazole.","Dose adjustment. Brexpiprazole dose must be reduced.");n("Rexulti (Brexpiprazole)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Brexpiprazole. Rifampin    CYP3A4.","Decreased Brexpiprazole concentration. Rifampin is a strong inducer of CYP3A4.","   .","Reduced antipsychotic efficacy."," .   .","Contraindicated. Avoid the combination.");n("Rezafungin","Tolbutamide",e.DRUG_DRUG,i.MODERATE,"  Tolbutamide. Rezafungin    CYP2C9    Tolbutamide.","Increased Tolbutamide concentration. Rezafungin is an inhibitor of CYP2C9, responsible for Tolbutamide metabolism.","      (Hypoglycemia)     Tolbutamide.","Increased risk of hypoglycemia resulting from elevated Tolbutamide levels.","  .            Tolbutamide.","Blood glucose monitoring. Glucose levels must be closely monitored, and Tolbutamide dose reduction may be required.");n("Rezafungin","Amiodarone",e.DRUG_DRUG,i.MODERATE,"   QT.      QT.","Exacerbated QT prolongation. Both drugs increase the QT interval.","        ( Torsades de Pointes).","Increased risk of serious ventricular arrhythmias (such as Torsades de Pointes)."," .      (ECG)  .","Caution and Monitoring. Electrocardiogram (ECG) should be performed, and close monitoring is necessary.");n("Rezafungin","Itraconazole",e.DRUG_DRUG,i.MODERATE,"    Rezafungin. Itraconazole   CYP3A4    Rezafungin.","Slight increase in Rezafungin concentration. Itraconazole inhibits CYP3A4, a Rezafungin metabolic pathway.","    QT.","Increased risk of QT prolongation."," ECG.        ECG.","ECG monitoring. No contraindication, but ECG must be monitored.");n("Rezatika (Rimegepant)","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Rezatika. Itraconazole    CYP3A4  P-gp.","Increased Rezatika concentration. Itraconazole is a strong inhibitor of CYP3A4 and P-gp.","   .","Increased risk of side effects."," .    Rezatika       CYP3A4 .","Dose adjustment. Rezatika must not be used frequently when co-administered with strong CYP3A4 inhibitors.");n("Ribociclib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Itraconazole    CYP3A4    Ribociclib.","Increased Ribociclib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Ribociclib metabolic pathway.","    QT   .","Increased risk of QT prolongation, hepatotoxicity, and neutropenia."," .    Ribociclib     CYP3A4 .","Dose adjustment. Ribociclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ribociclib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Rifampin    CYP3A4    Ribociclib.","Decreased Ribociclib efficacy. Rifampin is a strong inducer of CYP3A4, a Ribociclib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ribociclib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Phenytoin    CYP3A4    Ribociclib.","Decreased Ribociclib efficacy. Phenytoin is a strong inducer of CYP3A4, a Ribociclib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ribociclib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Voriconazole    CYP3A4    Ribociclib.","Increased Ribociclib concentration. Voriconazole is a strong CYP3A4 inhibitor, a Ribociclib metabolic pathway.","    QT   .","Increased risk of QT prolongation, hepatotoxicity, and neutropenia."," .    Ribociclib     CYP3A4 .","Dose adjustment. Ribociclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ribociclib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Itraconazole    CYP3A4    Ribociclib.","Increased Ribociclib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Ribociclib metabolic pathway.","    QT   .","Increased risk of QT prolongation and myelosuppression."," .    Ribociclib     CYP3A4 .","Dose adjustment. Ribociclib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ribociclib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Rifampin    CYP3A4    Ribociclib.","Decreased Ribociclib concentration. Rifampin is a strong inducer of CYP3A4, a Ribociclib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Ribociclib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Ribociclib. Ketoconazole    CYP3A4.","Increased Ribociclib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    QT  .","Increased risk of QT prolongation and liver toxicity.","  .   CYP3A4 .","Relative contraindication. Strong CYP3A4 inhibitors must be avoided.");n("Rifabutin","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Rifabutin. Clarithromycin    CYP3A4    Rifabutin.","Increased Rifabutin concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Rifabutin metabolic pathway.","       (Uveitis).","Increased risk of myelosuppression and uveitis."," .    Rifabutin  .","Dose adjustment. Rifabutin dose must be significantly reduced.");n("Rifampicin","High-Fat Foods",e.DRUG_FOOD,i.MODERATE," ","Slows absorption","  ","Reduced drug absorption","     -    ","Requires empty stomach for optimal absorption - take on an empty stomach");n("Rifampicin","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Hepatotoxicity. Liver damage.","   -    ","Risk of liver damage - both affect the liver","    ","Avoid alcohol completely during treatment");n("Rifampin","Isoniazid",e.DRUG_DRUG,i.HIGH,"   .       .","Increased risk of hepatotoxicity. Additive or synergistic toxic effect on the liver.","      .","Increased risk of acute liver damage and liver failure."," .     (AST/ALT)     .","Close monitoring. Liver function (AST/ALT) must be monitored regularly, especially in the first weeks.");n("Rifampin","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Rifampin    CYP3A4    .","Decreased oral contraceptive concentration. Rifampin is a strong inducer of CYP3A4, a hormone metabolic pathway.","   (   ).","Contraceptive failure (unwanted pregnancy).","  .          .","Relative contraindication. An additional non-hormonal or alternative contraceptive method must be used.");n(Oc,"Warfarin",e.DRUG_DRUG,i.HIGH,": **  (CYP2C9, CYP3A4)**.     .","Mechanism: **Metabolism induction (CYP2C9, CYP3A4)**. Rifampicin potently induces Warfarin metabolism."," : **      80%**   .","Clinical Significance: **Decreased Warfarin effect by up to 80%** and increased thrombosis risk."," INR .      (2-3 ).    .","Monitor INR closely. Significantly increase Warfarin dose (2-3 fold). Adjust upon Rifampicin discontinuation.");n(Oc,wc,e.DRUG_DRUG,i.HIGH,": **  (CYP3A4)**.        .","Mechanism: **Metabolism induction (CYP3A4)**. Rifampicin and rifamycins significantly induce antifungal metabolism."," : **       80%**  .","Clinical Significance: **Decreased antifungal levels by up to 80%** and treatment failure.","   .         .","Avoid combination if possible. If necessary, significantly increase antifungal dose.");n("Rifapentine","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin. Rifapentine    CYP3A4  CYP2C9    Warfarin.","Decreased Warfarin concentration. Rifapentine is a strong inducer of CYP3A4 and CYP2C9, Warfarin metabolic pathways.","  Warfarin     .","Reduced Warfarin efficacy, leading to risk of thrombosis."," .   INR     Warfarin  .","Close monitoring. INR must be monitored frequently and Warfarin dose significantly adjusted.");n("Rifaximin","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Rifaximin  . Ketoconazole    CYP3A4  P-gp.","Increased plasma concentration of Rifaximin. Ketoconazole is a strong inhibitor of CYP3A4 and P-gp.","     ().","Increased risk of systemic side effects (theoretically).",".               .","Monitoring. Routine dose adjustment is not required, but the patient must be monitored for increased side effects.");n("Rifaximin","P-glycoprotein Inhibitors",e.DRUG_DRUG,i.MODERATE," P-gp","P-gp inhibition.","  ","Increased rifaximin absorption.","  ","Monitor side effects.");n("Rilpivirine","Food",e.DRUG_FOOD,i.HIGH,"  AUC  40% -     ","Food increases AUC by 40% - requires an acidic environment for optimal dissolution","       ","Significant increase in bioavailability to ensure therapeutic efficacy","   (300    )   ","Must be taken with a meal (at least 300 kcal) to ensure adequate absorption");n("Rimegepant","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Rimegepant. Itraconazole    CYP3A4    Rimegepant.","Increased Rimegepant concentration. Itraconazole is a strong CYP3A4 inhibitor, a Rimegepant metabolic pathway.","      .","Increased risk of side effects, especially nausea and vomiting."," .    CYP3A4 .","Contraindicated. Strong CYP3A4 inhibitors must be avoided.");n("Riociguat","Rifampin",e.DRUG_DRUG,i.HIGH,"  Riociguat. Rifampin    CYP3A4  P-gp.","Decreased Riociguat concentration. Rifampin is a strong inducer of CYP3A4 and P-gp.","             .","Reduced drug plasma concentration, leading to failure of pulmonary hypertension treatment."," .   .","Contraindicated. Avoid the combination.");n("Riociguat","Sildenafil/Tadalafil",e.DRUG_DRUG,i.HIGH,"     .","Increased risk of severe hypotension.","   (Circulatory collapse).","Risk of circulatory collapse."," .    (    24   ).","Contraindicated. Avoid the combination (must be separated by at least 24 hours).");n("Ripretinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Ripretinib. Itraconazole   CYP3A4  P-gp    Ripretinib.","Increased Ripretinib concentration. Itraconazole inhibits CYP3A4 and P-gp, both affecting Ripretinib.","        .","Increased risk of side effects, especially hypertension and hemorrhage."," .    Ripretinib     CYP3A4 .","Dose adjustment. Ripretinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ripretinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Ripretinib. Carbamazepine    CYP3A4    Ripretinib.","Decreased Ripretinib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Ripretinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ripretinib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Ripretinib. Voriconazole    CYP3A4    Ripretinib.","Increased Ripretinib concentration. Voriconazole is a strong CYP3A4 inhibitor, a Ripretinib metabolic pathway.","        .","Increased risk of side effects, especially hypertension and hemorrhage."," .    Ripretinib     CYP3A4 .","Dose adjustment. Ripretinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ripretinib","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  Ripretinib. Diltiazem    CYP3A4    Ripretinib.","Increased Ripretinib concentration. Diltiazem is a moderate CYP3A4 inhibitor, a Ripretinib metabolic pathway.","        .","Increased risk of side effects, especially hypertension and hemorrhage."," .        .","Dose adjustment. Patient must be monitored for increased side effects.");n("Ripretinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Ripretinib. Phenytoin    CYP3A4    Ripretinib.","Decreased Ripretinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Ripretinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Risankizumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Risankizumab     (IL-23 inhibitor)   .","Increased risk of viral infection. Risankizumab is a monoclonal antibody (IL-23 inhibitor) affecting immunity.","     .","Risk of developing infection from live vaccines."," .       Risankizumab.","Contraindicated. Live vaccines must be avoided during Risankizumab treatment.");n("Risankizumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Risankizumab   IL-23.","Reduced vaccine response/Increased infection risk. Risankizumab is an IL-23 inhibitor.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Risankizumab (IL-23 Inhibitor)","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  . Risankizumab  .","Increased risk of infection. Risankizumab is an immunosuppressant.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Risedronate","NSAIDs",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic gastric irritation."," ","Gastric ulcer.","   -  PPI","Take with food - use PPI.");n("Risperidone","Paroxetine",e.DRUG_DRUG,i.MODERATE,"  Risperidone ( ). Paroxetine  CYP2D6    Risperidone.","Increased Risperidone concentration (active component). Paroxetine inhibits CYP2D6, a Risperidone metabolic pathway.","      (EPS).","Increased risk of extrapyramidal symptoms (EPS)."," .     .","Close monitoring. Monitor for extrapyramidal symptoms.");n("Ritlecitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Ritlecitinib. Ketoconazole    CYP3A4    Ritlecitinib.","Increased Ritlecitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Ritlecitinib metabolic pathway.","       .","Increased risk of side effects, especially infection and hematological toxicity."," .    Ritlecitinib     CYP3A4 .","Dose adjustment. Ritlecitinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ritlecitinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ritlecitinib. Rifampin    CYP3A4    Ritlecitinib.","Decreased Ritlecitinib efficacy. Rifampin is a strong inducer of CYP3A4, a Ritlecitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ritonavir","Fluticasone (Inhaled)",e.DRUG_DRUG,i.HIGH,"  Fluticasone . Ritonavir    CYP3A4    Fluticasone.","Increased systemic Fluticasone concentration. Ritonavir is a strong inhibitor of CYP3A4, a Fluticasone metabolic pathway.","      .","Increased risk of Cushings syndrome and adrenal suppression."," .            CYP3A4.","Contraindicated. This combination must be avoided and an alternative corticosteroid that is not metabolized by CYP3A4 used.");n("Ritonavir","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Ritonavir    CYP3A4    Midazolam.","Increased Midazolam concentration. Ritonavir is a strong CYP3A4 inhibitor, a Midazolam metabolic pathway.","     .","Increased risk of prolonged sedation and respiratory depression."," .    ( Midazolam ).","Contraindicated. Avoid the combination (especially oral Midazolam).");n("Ritonavir","Midazolam",e.DRUG_DRUG,i.HIGH,"   CYP3A4","Severe CYP3A4 inhibition dramatically increases midazolam levels.","   ","Severe respiratory depression and coma.","  -  ","Contraindicated - avoid completely.");n("Ritonavir - ","Ergot Alkaloids -  ",e.DRUG_DRUG,i.HIGH,"       CYP3A4        ( ).","Ritonavir is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which is primarily responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine).","             (Ergotism)     (Vasospasm)      .","Dangerous increase in Ergot Alkaloids blood concentrations, leading to acute Ergotism, which includes vasoconstriction (Vasospasm) and ischemia that may threaten limb viability.","     ().     .","This drug combination is absolutely contraindicated (forbidden). This co-administration must be avoided entirely.");n("Ritonavir - ","Ethinyl Estradiol -  ",e.DRUG_DRUG,i.MODERATE,"        P450 3A4 (CYP3A4)        (UGT1A1)   CYP      .                          (AUC)    40-50.          P-glycoprotein       .            (600   daily)     (100-200  daily)   regimens  .","Ritonavir, a potent protease inhibitor and inhibitor of cytochrome P450 3A4 (CYP3A4), also paradoxically induces the glucuronosyltransferase enzyme (UGT1A1) and possibly other CYP enzymes responsible for ethinyl estradiol metabolism. This induction leads to a significant increase in the metabolism of ethinyl estradiol via glucuronidation, accelerating its excretion and reducing its plasma concentration and area under the curve (AUC) by up to 40-50%. Additionally, ritonavir may induce drug transporters like P-glycoprotein, increasing the intestinal efflux of ethinyl estradiol. This interaction is more pronounced when ritonavir is used at full therapeutic doses (600 mg twice daily) compared to the low boosting doses (100-200 mg daily) used in modern therapeutic regimens.","            : 1.       . 2.    (   )            . 3.         (    ). 4.               .             (20-30 ).","Reduced efficacy of combined oral contraceptives containing ethinyl estradiol, leading to: 1. Significantly increased risk of unintended pregnancy. 2. Frequent or persistent breakthrough bleeding (bleeding between menstrual periods), indicating inadequate hormonal support for the endometrium. 3. Return of symptoms previously controlled by the pill (e.g., acne, dysmenorrhea). 4. Failure to achieve non-contraceptive benefits if the pill is used for therapeutic purposes. The risk is higher with third-generation low-dose estrogen pills (20-30 mcg).","1.       :     (  )            4     . 2.     :                         ()   . 3.  :                           . 4.   :         (    6-8)            . 5.   :                .","1. Primary use of non-hormonal contraception: Barrier methods (condoms, diaphragm) or copper IUD are recommended as the primary contraception method during ritonavir therapy and for at least 4 weeks after its discontinuation. 2. Avoid reliance on high doses: Increasing the ethinyl estradiol dose in oral contraceptives is not recommended as it does not reliably compensate for the interaction and may increase the risk of thrombotic side effects without improving efficacy. 3. Ritonavir alternatives: Discuss with the physician the possibility of using an alternative HIV treatment regimen that does not contain ritonavir, especially for women of childbearing potential relying on oral contraceptives. 4. Education and informed consent: Educate the patient about the high risk of contraceptive failure (which may reach 6-8%) and document this conversation and obtain informed consent for the alternative contraception plan. 5. Menstrual cycle monitoring: If oral contraceptives are continued, monitor for any breakthrough bleeding as an early warning sign of contraceptive failure.");n("Ritonavir ()","Fluconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","      .","      .");n("Ritonavir ()","Itraconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","      .","      .");n("Ritonavir ()","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","      .","      .");n("Ritonavir ()","Voriconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","      .","      .");n("Ritonavir ()","Clozapine ()",e.DRUG_DRUG,i.HIGH," .     CYP (   CYP1A2  CYP3A4)    .","Metabolic Inhibition. Ritonavir is a potent inhibitor of CYP enzymes (including CYP1A2 and CYP3A4) responsible for Clozapine metabolism.","                   (Seizures)       .","Massive increase in Clozapine plasma concentration, greatly increasing the risk of Clozapine toxicity, including seizures, hypotension, severe sedation, and cardiotoxicity.","    .           (   80%)      (TDM)  .","Avoid this combination if possible. If necessary, the Clozapine dose must be drastically reduced (up to 80%) and closely monitor plasma drug levels (TDM).");n("Rituximab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Rituximab     B.","Increased risk of infection. Rituximab is an immunosuppressant that depletes B-cells.","     .","Risk of developing infection from live vaccines."," .        .","Delay vaccination. Live vaccines must be delayed for a specified period around treatment.");n("Rivaroxaban","Posaconazole",e.DRUG_DRUG,i.HIGH,"  Rivaroxaban. Posaconazole    CYP3A4  P-gp (   Rivaroxaban).","Increased Rivaroxaban concentration. Posaconazole is a strong inhibitor of CYP3A4 and P-gp (Rivaroxaban metabolism and efflux pathways).","        .","Severe increase in the risk of life-threatening hemorrhage."," .    CYP3A4/P-gp  .","Contraindicated. Strong CYP3A4/P-gp inhibitors must be avoided concomitantly.");n("Rivaroxaban","Food (High-Fat Meal)",e.DRUG_FOOD,i.MODERATE," (   )        .   (15   20 ):      (  20-30  )       : (1)               (2)           (3)      .  :       (AUC)  39%  Cmax  76%     20 .   (2.5  10 ):       .","Rivaroxaban (direct oral anticoagulant) has complex food relationship depending on dose. For high doses (15mg and 20mg): food, especially high-fat meal (>20-30g fat), significantly improves bioavailability through: (1) stimulating bile salt and digestive juice secretion that improve poorly water-soluble drug dissolution, (2) slowing gastric emptying and intestinal motility, allowing longer absorption time, (3) increasing lymphatic absorption of highly lipophilic drug. Studies showed: with fatty meal, bioavailability (AUC) increases 39% and Cmax increases 76% versus empty stomach for 20mg dose. For low doses (2.5mg, 10mg): effect less clinically significant and food not required.","           15-20    : (1)         -   :   (  )     (DVT)    (PE) (2)          (3)      ( ):            -         (4)                    .","Moderate but clinically important increase in drug absorption and plasma concentration for 15-20mg doses, leading to: (1) achieving therapeutic levels required for effective anticoagulation - very important in: atrial fibrillation (preventing stroke), deep vein thrombosis (DVT) or pulmonary embolism (PE) treatment, (2) better stability in anticoagulant effect throughout day, (3) when not taken with food (for high doses): significant bioavailability decrease means inadequate protection from thrombosis - risk of stroke, pulmonary, or venous clot, (4) conversely, correct administration with food ensures optimal efficacy without excessive bleeding risk if patient adheres to prescribed dose.","   : (1) ** 15   20 :    ** -    .     (   )       .          (      ) (2) ** 2.5   10 :     ** -        (3) :          -        7  (4)      :                     (5) **     **:        K (         ) -     K       (6) ** **:          -     (7)   :          (  )   ( )       -    (8)       :  /     -     (9)      (NSAIDs    )   -   .      (10) **     ** -     -       .","Precise dose-specific recommendations: (1) **15mg and 20mg doses: must take with food** - this is mandatory, not optional. Take with main meal (breakfast, lunch, or dinner) containing reasonable food and fat amount. Not necessarily very rich meal, but regular meal sufficient (not just piece of fruit or light crackers), (2) **2.5mg and 10mg doses: can take with or without food** - flexibility available, but pattern consistency advisable, (3) timing: take rivaroxaban at same time daily ensuring stable levels - e.g., with dinner every night at 7 PM, (4) don't take double dose if missed: take missed dose immediately if remembered same day, but if next day then skip it and take next dose at its time, (5) **Warning about foods affecting coagulation**: avoid large sudden changes in vitamin K intake (in dark green leafy vegetables like spinach, kale, broccoli) - rivaroxaban less affected by vitamin K than warfarin, but dietary stability beneficial, (6) **Completely avoid**: grapefruit juice, therapeutic garlic amounts, and St. John's wort - may interact with rivaroxaban, (7) monitor bleeding signs: persistent gum bleeding, easy large bruises, blood in urine (pink or red) or stool (black tarry), recurrent nosebleeds, excessive wound bleeding - inform physician immediately, (8) before any surgery or dental procedure: inform doctor/dentist you're taking rivaroxaban - may need temporary discontinuation, (9) avoid NSAIDs (like ibuprofen, naproxen, diclofenac) as much as possible - increase bleeding risk. Use paracetamol for pain if possible, (10) **Don't stop rivaroxaban on your own** - even if feeling better - sudden discontinuation sharply increases clot risk.");n("Rivaroxaban","Aspirin",e.DRUG_DRUG,i.HIGH,"   ","Additive anticoagulant effect."," ","Severe bleeding.","  -    ","Use cautiously - low-dose aspirin only.");n("Rivaroxaban (DOAC)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Rivaroxaban. Ketoconazole    CYP3A4  P-gp     Rivaroxaban.","Increased Rivaroxaban concentration. Ketoconazole is a strong inhibitor of CYP3A4 and P-gp, Rivaroxaban metabolic and efflux pathways.","     .","Increased risk of severe and life-threatening hemorrhage."," .   .","Contraindicated. Avoid the combination.");n("Rivastigmine","Atenolol",e.DRUG_DRUG,i.MODERATE,"   .     .","Increased risk of bradycardia. Additive cholinergic effects on the heart.","  .","Slowed heart rate (bradycardia)."," .     .","Close monitoring. Monitor heart rate and symptoms.");n("Rolapitant","Metoprolol",e.DRUG_DRUG,i.MODERATE,"  Metoprolol. Rolapitant    CYP2D6    Metoprolol.","Increased Metoprolol concentration. Rolapitant is a strong CYP2D6 inhibitor, a Metoprolol metabolic pathway.","        .","Increased risk of bradycardia, hypotension, and heart block.","  .    Metoprolol       .","Side effect monitoring. Metoprolol dose must be reduced or heart rate and blood pressure monitored.");n("Ropinirole","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"  Ropinirole. Ciprofloxacin   CYP1A2    Ropinirole.","Increased Ropinirole concentration. Ciprofloxacin is an inhibitor of CYP1A2, a Ropinirole metabolic pathway.","     (  ).","Increased risk of dopaminergic side effects (e.g., nausea, dizziness)."," .        .","Close monitoring. Monitor side effects and reduce dose if necessary.");n("Rosuvastatin","Cyclosporine",e.DRUG_DRUG,i.HIGH," OATP1B1","OATP1B1 inhibition.","    ","Significant increase in rosuvastatin levels.","   5 /","Reduce dose to 5mg/day.");n("Rotigotine","Haloperidol",e.DRUG_DRUG,i.HIGH,"  Rotigotine. Haloperidol       Rotigotine.","Decreased Rotigotine effect. Haloperidol is a dopamine receptor antagonist, counteracting Rotigotines effect.","   .","Worsening of Parkinsons disease symptoms."," .   .","Contraindicated. Avoid the combination.");n("Rufinamide","Oral Contraceptives",e.DRUG_DRUG,i.MODERATE,"  ","Induction of estrogen metabolism.","    ","Failure of hormonal contraceptives.","    ","Use additional contraceptive methods.");n("Ruxolitinib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Ruxolitinib. Carbamazepine    CYP3A4    Ruxolitinib.","Decreased Ruxolitinib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Ruxolitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ruxolitinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Ruxolitinib. Itraconazole    CYP3A4    Ruxolitinib.","Increased Ruxolitinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Ruxolitinib metabolic pathway.","    .","Increased risk of hematological toxicity and infection."," .    Ruxolitinib  50%     CYP3A4 .","Dose adjustment. Ruxolitinib dose must be reduced by 50% when co-administered with strong CYP3A4 inhibitors.");n("Ruxolitinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Ruxolitinib. Phenytoin    CYP3A4    Ruxolitinib.","Decreased Ruxolitinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Ruxolitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ruxolitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Ruxolitinib. Ketoconazole    CYP3A4    Ruxolitinib.","Increased Ruxolitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Ruxolitinib metabolic pathway.","     (      ).","Increased risk of myelosuppression (anemia, neutropenia, thrombocytopenia)."," .    Ruxolitinib     CYP3A4 .","Dose adjustment. Ruxolitinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Ruxolitinib","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"  Ruxolitinib. Ciprofloxacin   CYP3A4  CYP1A2    Ruxolitinib.","Increased Ruxolitinib concentration. Ciprofloxacin inhibits CYP3A4 and CYP1A2, Ruxolitinib metabolic pathways.","     (      ).","Increased risk of myelosuppression (anemia, neutropenia, thrombocytopenia)."," .    Ruxolitinib     CYP3A4 .","Dose adjustment. Ruxolitinib dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Ruxolitinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Ruxolitinib.      CYP3A4  .","Increased Ruxolitinib concentration. Grapefruit juice is an inhibitor of intestinal CYP3A4.","    .","Increased risk of myelosuppression."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Sacituzumab govitecan","Atazanavir",e.DRUG_DRUG,i.HIGH,"    (SN-38). Atazanavir   UGT1A1    SN-38.","Increased concentration of active metabolite (SN-38). Atazanavir inhibits UGT1A1, an SN-38 clearance pathway.","     (Febrile neutropenia)  .","Increased risk of febrile neutropenia and severe diarrhea."," .    Sacituzumab govitecan     UGT1A1.","Dose adjustment. Sacituzumab govitecan dose must be reduced when co-administered with UGT1A1 inhibitors.");n("Sacituzumab Govitecan","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"   . Sacituzumab Govitecan      CYP3A4.","Increased concentration of active metabolite. Sacituzumab Govitecan has an active metabolite metabolized by CYP3A4.","    (Neutropenia)     .","Increased risk of hematological toxicity (Neutropenia) and severe diarrhea due to elevated metabolite levels."," .          .","Dose monitoring. Patient should be closely monitored and dose adjusted if necessary.");n("Sacituzumab Govitecan (Trodelvy)","UGT1A1 Inhibitors (Atazanavir)",e.DRUG_DRUG,i.MODERATE,": **  UGT1A1**.     SN-38.","Mechanism: **UGT1A1 enzyme inhibition**. Increased active metabolite SN-38 concentration."," : ** **  .","Clinical Significance: **Severe diarrhea** and neutropenia."," .       .","Avoid combination. Use alternative HIV medication.");n("Sacituzumab Govitecan (Trodelvy)","UGT1A1*28 Polymorphism",e.DRUG_DISEASE,i.HIGH,": **   UGT1A1**.     *28/*28   .","Mechanism: **Reduced UGT1A1 enzyme activity**. Patients with *28/*28 genotype have slow metabolism."," : ** **      .","Clinical Significance: **Severe toxicity** with life-threatening diarrhea and neutropenia.","    7.5 mg/kg  .  .","Reduce initial dose to 7.5 mg/kg for homozygous patients. Close monitoring.");n("Sacubitril/Valsartan","Lisinopril",e.DRUG_DRUG,i.HIGH,"    (Angioedema). Sacubitril   Neprilysin  ACE inhibitors     .","Increased risk of angioedema. Sacubitril inhibits Neprilysin, and ACE inhibitors increase angioedema-related peptides.","     .","Life-threatening swelling of the face and throat."," .      36   .","Contraindicated. The two drugs must be separated by at least 36 hours.");n("Sacubitril/Valsartan (ARNI)","Lisinopril (ACE Inhibitor)",e.DRUG_DRUG,i.HIGH,"    (Angioedema).     .","Increased risk of angioedema. Both drugs elevate bradykinin levels.","      .","Serious, life-threatening swelling of the face and throat."," .    ACE  36    Sacubitril/Valsartan.","Contraindicated. ACE inhibitors must be discontinued 36 hours before starting Sacubitril/Valsartan.");n("Sacubitril/Valsartan (ARNI)","Ibuprofen (NSAID)",e.DRUG_DRUG,i.MODERATE,"     (AKI).      .","Increased risk of Acute Kidney Injury (AKI). Synergistic effects on renal dynamics.","  .","Acute renal failure."," .            .","Close monitoring. Monitor renal function upon initiation of co-therapy, especially in high-risk patients.");n("Sacubitril/Valsartan (Entresto)","ACE Inhibitors (Enalapril)",e.DRUG_DRUG,i.CONTRAINDICATED,": **  **.     .","Mechanism: **Angioedema risk**. Both drugs increase bradykinin."," : ** **  .","Clinical Significance: **Life-threatening angioedema**.","  .   36      ACE inhibitor.","Absolute contraindication. 36-hour washout period required when switching from ACE inhibitor.");n("Sacubitril/Valsartan (Entresto)","Aliskiren (in Diabetes)",e.DRUG_DRUG,i.CONTRAINDICATED,": **   -**.","Mechanism: **Dual RAAS inhibition**."," : **  **     .","Clinical Significance: **Severe hypotension**, hyperkalemia, and renal impairment.","    .","Contraindicated in diabetic patients.");n("Sacubitril/Valsartan (Entresto)","Potassium Supplements",e.DRUG_DRUG,i.MODERATE,": ** **.","Mechanism: **Potassium retention**."," : **  **.","Clinical Significance: **Hyperkalemia**.","         .  .","Avoid potassium supplements unless documented hypokalemia. Monitor potassium.");n("Safinamide","Duloxetine",e.DRUG_DRUG,i.HIGH,"  . Safinamide    MAO-B  Duloxetine (SNRI)    .","Risk of Serotonin Syndrome. Safinamide is an MAO-B inhibitor, and Duloxetine (SNRI) increases serotonin levels.","          (      ).","Life-threatening increase in serotonergic activity, causing Serotonin Syndrome (mental status changes, hyperreflexia, autonomic instability)."," .  .       (Washout Period)  Safinamide  .","Contraindicated. Avoid combination. A washout period must be observed between Safinamide and serotonergic drugs.");n("Safinamide","St. John's Wort",e.DRUG_DRUG,i.HIGH,"   . St. John's Wort    (Serotonergic Properties).","Increased risk of Serotonin Syndrome. St. John's Wort has serotonergic properties.","    (  Duloxetine).","Exacerbation of Serotonin Syndrome risk (same mechanism as Duloxetine)."," .        .","Contraindicated. Avoid co-administration with herbal supplements with serotonergic activity.");n("Safinamide (MAO-B)","Tramadol",e.DRUG_DRUG,i.HIGH,"   .    .","Increased risk of Serotonin Syndrome. Synergistic effects of increased serotonin.","      .","Mental status changes, hyperthermia, tremor."," .   .","Contraindicated. Avoid the combination.");n("Salbutamol - ","Non-selective Beta-Blockers ( )",e.DRUG_DRUG,i.HIGH,"  (Pharmacodynamic Antagonism).       -2       .","Pharmacodynamic Antagonism. Non-selective beta-blockers block beta-2 receptors in the airways, counteracting the bronchodilator effect of Salbutamol.","    (  )        .","Loss of bronchodilator effect and risk of causing severe, life-threatening bronchospasm.","     .          ( )      .","Absolute Contraindication in asthma patients. If required, cardio-selective beta-blockers (e.g., Atenolol) must be used with extreme caution and monitoring of respiratory function.");n("Salbutamol - ","MAOIs / TCAs (     )",e.DRUG_DRUG,i.MODERATE,"   .          (Sympathomimetic amines).","Potentiation of cardiovascular effects. These agents increase the levels or activity of sympathomimetic amines.","     (Tachycardia)     (Arrhythmias)     .","Increased risk of severe tachycardia, arrhythmias, and excessive hypertension.","  .              .","Use with extreme caution. Closely monitor heart rate and blood pressure and adjust the dosage if necessary.");n("Salbutamol - ","Other Sympathomimetics (   )",e.DRUG_DRUG,i.MODERATE," - .         .","Additive beta-adrenergic stimulation. The combination leads to excessive cardiovascular stimulation.","             .","Severe cardiovascular effects such as palpitations, arrhythmias, and hypertensive crisis.","  .            .","Avoid simultaneous use. If co-administration is necessary, it should be done under intensive cardiac monitoring.");n("Salbutamol - ","Loop or Thiazide Diuretics ( )",e.DRUG_DRUG,i.MODERATE,"    .          (  ).","Additive hypokalemic effects. Both Salbutamol and diuretics cause potassium shift into the cells (or increased excretion).","     (Hypokalemia)           (Arrhythmias).","Significantly increased risk of hypokalemia, potentially leading to serious cardiac arrhythmias.",".                  .","Monitor. Closely monitor serum potassium levels, especially at treatment initiation or in at-risk patients.");n("Salbutamol - ","Corticosteroids / Xanthine Derivatives ( )",e.DRUG_DRUG,i.MODERATE,"    .        .","Exacerbated hypokalemia risk. These agents also contribute to lowering potassium levels.","       .","Increased risk of hypokalemia and cardiac arrhythmias.",".                .","Monitor. Closely monitor serum potassium levels; potassium supplementation may be required.");n("Salbutamol (Ventolin) -  ()","Hypertension / Heart Disease -    /  ",e.DRUG_DISEASE,i.MODERATE,"       -2                   -1  .       : 1.     ( )  . 2.      -2                 . 3.      .                       .","Salbutamol primarily acts as a selective agonist for beta-2 adrenergic receptors in bronchial smooth muscles, but at higher doses or with frequent use, it can also stimulate cardiac beta-1 receptors. This leads to cardiovascular effects including: 1. Increased heart rate (tachycardia) and contractility. 2. Peripheral vasodilation via vascular beta-2 receptors, which may cause an initial drop in blood pressure followed by a reflexive increase due to sympathetic nervous system activation. 3. Increased myocardial oxygen consumption. In patients with hypertension or heart disease, these regulatory mechanisms may be compromised, making them more sensitive to these effects.","              : 1.         . 2.         (    ). 3.               . 4.        . 5.           .","Worsening of the condition in patients with underlying cardiovascular diseases, potentially leading to: 1. Acute hypertension or significant blood pressure fluctuations. 2. Severe tachycardia or arrhythmias (such as atrial fibrillation, atrial flutter). 3. Increased angina symptoms or myocardial ischemia in patients with coronary artery disease. 4. Exacerbation of heart failure due to increased cardiac workload. 5. In extreme cases, it may lead to myocardial infarction or stroke.","1.   :                        . 2.  :                 . 3.    :         . 4.    :             . 5.  :                ( )      . 6.  :             .","1. Use with extreme caution: Prescribe salbutamol cautiously to patients with uncontrolled hypertension, arrhythmias, heart failure, or active coronary artery disease. 2. Close monitoring: Monitor heart rate and blood pressure before and after inhaler use, especially when initiating therapy or increasing the dose. 3. Use the lowest effective dose: Use the minimum dose that provides respiratory symptom control. 4. Avoid overuse: Educate the patient about the risks of inhaler overuse and avoid using it more than prescribed. 5. Alternative therapies: Consider alternative bronchodilators with less cardiovascular impact, such as inhaled anticholinergics (ipratropium, tiotropium) or inhaled corticosteroids for long-term control. 6. Integrated management: Ensure optimal control of underlying cardiovascular diseases before and during salbutamol therapy.");n("Ipratropium - ","Tiotropium -  (    )",e.DRUG_DRUG,i.MODERATE,"    .        .","Synergy and Pharmacodynamic Redundancy. Both agents act as muscarinic receptor antagonists in the bronchi.","                      .","May lead to minor additive bronchodilation, but also increases the risk of systemic anticholinergic side effects without significant additional clinical benefit.","     SAMA ()  LAMA ()       (       ).","Routine co-administration of a SAMA (Ipratropium) and a LAMA (Tiotropium) should be avoided due to the lack of clear benefit versus the increased risk of systemic anticholinergic side effects.");n("Salicylates - ","Acetazolamide - ",e.DRUG_DRUG,i.MODERATE,"     ( )       (BBB).                 .                          .                       .","Acetazolamide causes blood acidification (metabolic acidosis) and increases blood-brain barrier (BBB) permeability. Unbound serum salicylate increases during acidosis, facilitating salicylate entry into the central nervous system. Once in the CNS, salicylates can cause direct stimulation of the respiratory center in the medulla oblongata, leading to hyperventilation that worsens respiratory acidosis. This creates a vicious cycle where acidosis increases CNS salicylate toxicity, and increased CNS salicylates exacerbate acidosis.","           : 1.   :     . 2.  :     . 3.   :    . 4.      . 5.      .","Increased risk and severity of central nervous system salicylate toxicity, including: 1. Early toxicity symptoms: Tinnitus, dizziness, hearing loss. 2. Severe symptoms: Confusion, drowsiness, delirium, coma, seizures. 3. Metabolic disturbances: Mixed respiratory and metabolic acidosis. 4. Cerebral edema and increased intracranial pressure. 5. Respiratory failure and death in extreme cases.","1.  :        . 2.  :    /         . 3.  :       . 4.  :              . 5.  : Patients                  . 6. :         .","1. Avoid combination: Avoid combining salicylates and acetazolamide whenever possible. 2. Monitor acidosis: Monitor the patient`s acid/base status and blood pH if combination is necessary. 3. Monitor salicylates: Closely monitor serum salicylate levels. 4. Treat acidosis: If acidosis occurs, consider administering sodium bicarbonate to correct it and reduce unbound salicylate. 5. Acetazolamide alternatives: For patients requiring intraocular pressure reduction or diuresis, consider alternatives like mannitol or thiazides. 6. Education: Alert patients to signs of salicylate toxicity and report them immediately.");n("Salmeterol","Ketoconazole",e.DRUG_DRUG,i.MODERATE,": **   CYP3A4**.       CYP3A4              .","Mechanism: **Potent CYP3A4 enzyme inhibition**. Ketoconazole is a very strong inhibitor of CYP3A4 enzyme responsible for salmeterol first-pass metabolism in the liver, leading to drug accumulation."," : **     ** (   16 )     **   **        QT    .","Clinical Significance: **Substantially increased systemic salmeterol concentrations** (up to 16-fold increase), increasing the risk of **cardiovascular adverse effects** including tachycardia, QT prolongation, and serious ventricular arrhythmias.","     .         ( )       CYP3A4  (   ).    (ECG)         .","Avoid combination strictly if possible. If ketoconazole is essential, use alternative bronchodilator (e.g., albuterol) or alternative antifungal that does not strongly inhibit CYP3A4 (e.g., low-dose fluconazole). Monitor ECG and heart rate if combination cannot be avoided.");n("Salmeterol - ","Ritonavir -  (   CYP3A4)",e.DRUG_DRUG,i.HIGH,"    CYP3A4        .","Ritonavir potently inhibits CYP3A4, leading to critically slow metabolism of Salmeterol.","              ( QT         ).","Severe and critical increase in Salmeterol plasma concentration, increasing the risk of cardiotoxicity (QT prolongation, severe tachycardia, and arrhythmias).","  .              CYP3A4.","Absolute Contraindication. This combination must be strictly avoided; use an alternative bronchodilator therapy that is not affected by CYP3A4.");n("Salmeterol - ","Propranolol -  (   )",e.DRUG_DRUG,i.HIGH," .    -2          .","Pharmacodynamic Antagonism. Propranolol blocks beta-2 receptors in the airways, completely counteracting the bronchodilator effect of Salmeterol.","    ( )        .","Loss of bronchodilator effect and risk of causing severe, life-threatening bronchospasm.","        .           .","Absolute Contraindication in asthma/COPD patients. Cardio-selective beta-blockers must be used with extreme caution if medically necessary.");n("Salmeterol - ","Imipramine -  (TCA)",e.DRUG_DRUG,i.MODERATE,"   .       (Sympathomimetic amines).","Potentiation of cardiovascular effects. Imipramine increases the activity of sympathomimetic amines.","     (Tachycardia)     (Arrhythmias)   .","Increased risk of severe tachycardia, arrhythmias, and hypertension."," .              .","Use with caution. Closely monitor heart rate and blood pressure and adjust the dosage if necessary.");n("Salmeterol - ","Tranylcypromine -  (MAOI)",e.DRUG_DRUG,i.MODERATE,"   .  MAOI    .","Potentiation of cardiovascular effects. MAOIs prevent the breakdown of sympathomimetic amines.","     (Tachycardia)     (Arrhythmias)   .","Increased risk of severe tachycardia, arrhythmias, and hypertension."," .              .","Use with caution. Closely monitor heart rate and blood pressure and adjust the dosage if necessary.");n("Salmeterol - ","Furosemide -  (  )",e.DRUG_DRUG,i.MODERATE,"    .      .","Additive hypokalemic effects. Both agents contribute to lowering potassium levels.","     (Hypokalemia)          .","Significantly increased risk of hypokalemia, potentially leading to serious cardiac arrhythmias.",".            .","Monitor. Closely monitor serum potassium levels at treatment initiation.");n("Salmeterol - ","Prednisone -  ()",e.DRUG_DRUG,i.MODERATE,"    .       .","Exacerbated hypokalemia risk. Corticosteroids increase renal potassium loss.","       .","Increased risk of hypokalemia and cardiac arrhythmias.",".              .","Monitor. Closely monitor serum potassium levels; potassium supplementation may be required.");n("Saquinavir - ","Ergot Alkaloids -  ",e.DRUG_DRUG,i.HIGH,"       CYP3A4        ( ).","Saquinavir is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which is primarily responsible for the breakdown of Ergot Alkaloids (e.g., Ergotamine).","             (Ergotism)     (Vasospasm)      .","Dangerous increase in Ergot Alkaloids blood concentrations, leading to acute Ergotism, which includes vasoconstriction (Vasospasm) and ischemia that may threaten limb viability.","     ().     .","This drug combination is absolutely contraindicated (forbidden). This co-administration must be avoided entirely.");n("Saquinavir - ","Grapefruit Juice -   ",e.DRUG_FOOD,i.HIGH,"      (  )        P450 3A4 (CYP3A4)     .          .         (   200-300)        .          P-glycoprotein     .      24       .","Grapefruit juice contains furanocoumarins (such as bergamottin and dihydroxybergamottin) that irreversibly inhibit cytochrome P450 3A4 (CYP3A4) in the small intestinal wall and liver. Saquinavir is a primary substrate for this enzyme and undergoes significant first-pass metabolism. The inhibition substantially increases saquinavir bioavailability (up to 200-300%) by reducing intestinal and hepatic metabolism. Additionally, grapefruit juice may inhibit P-glycoprotein, increasing saquinavir absorption. This inhibition persists for more than 24 hours after consuming a single glass of juice.","         : 1.     :      . 2.   :      (  )      (). 3.   QT              ( torsades de pointes). 4.   .","Significant increase in saquinavir plasma concentration, leading to: 1. Increased risk of saquinavir-associated toxicity: Nausea, vomiting, diarrhea, abdominal pain. 2. Metabolic disturbances: Elevated blood lipids (hyperlipidemia), insulin resistance, fat distribution disorders (lipodystrophy). 3. Prolongation of the QT interval on ECG, increasing the risk of ventricular arrhythmias (especially torsades de pointes). 4. Potential hepatotoxicity.","1.  :             . 2.   :                  . 3.  :                . 4.  :        . 5.  :          . 6.  : Patients                 ( )   .","1. Complete avoidance: Completely avoid consuming grapefruit juice or fresh grapefruit during saquinavir therapy. 2. Comprehensive drug education: Educate the patient and family about this serious interaction and alert them that it can occur even with small amounts. 3. Toxicity monitoring: Monitor for saquinavir-associated adverse effects, and perform regular ECGs if interaction is suspected. 4. Safe alternatives: Suggest alternative juices such as orange or apple juice. 5. Therapeutic monitoring: If interaction occurs, monitor saquinavir plasma levels if possible. 6. Drug switching: For patients who regularly consume grapefruit, consider switching to other protease inhibitors less affected by this interaction (with caution), under medical supervision.");n("Sarilumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Sarilumab   IL-6.","Reduced vaccine response/Increased infection risk. Sarilumab is an IL-6 receptor antagonist.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Sarilumab (IL-6)","Simvastatin",e.DRUG_DRUG,i.MODERATE,"  Simvastatin. Sarilumab         CYP (CYP3A4)   .","Decreased Simvastatin concentration. Sarilumab reduces inflammation, which may indirectly increase CYP enzyme activity (CYP3A4).","  Simvastatin (   ).","Reduced Simvastatin efficacy (failure to lower cholesterol)."," .          .","Cholesterol monitoring. Monitor lipid levels and adjust statin dose if necessary.");n("Satralizumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Satralizumab   IL-6.","Reduced vaccine response/Increased infection risk. Satralizumab is an anti-IL-6 receptor antagonist.","  .","Reduced vaccine efficacy."," .         .","Delay vaccination. Live and non-live vaccinations are recommended to be completed before starting treatment.");n("Saw Palmetto","Anticoagulants",e.DRUG_DRUG,i.MODERATE,"   ","Potential antiplatelet effect.","  ","Increased bleeding risk."," ","Use cautiously.");n("Saxagliptin (DPP-4)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Saxagliptin. Ketoconazole    CYP3A4    Saxagliptin.","Increased Saxagliptin concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Saxagliptin metabolic pathway.","      (  ).","Increased risk of dose-related side effects (e.g., pancreatitis)."," .    Saxagliptin   (2.5 ).","Dose adjustment. Saxagliptin dose must be reduced by half (2.5 mg).");n("Saxenda (Liraglutide)","Insulin",e.DRUG_DRUG,i.HIGH,"     .     .","Increased risk of severe hypoglycemia. Additive glucose-lowering effects.","   .","Severe hypoglycemia."," .          Liraglutide.","Dose adjustment. Insulin or sulfonylurea dose must be reduced upon initiation of Liraglutide.");n("Secobarbital","Atenolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Bisoprolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Carvedilol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Metoprolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Propranolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Nebivolol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Labetalol",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","CYP450 Induction. Hepatic enzyme induction accelerates beta-blocker metabolism, reducing its plasma concentration and efficacy.","   ","Reduced Beta-Blocker Efficacy. Loss of rate/pressure control.","    ( )","    ( )");n("Secobarbital","Prednisone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Secobarbital","Prednisolone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Secobarbital","Hydrocortisone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Secobarbital","Dexamethasone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Secobarbital","Betamethasone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Secobarbital","Methylprednisolone",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism of corticosteroids leads to subtherapeutic levels.","  ","Reduced Steroid Efficacy. Flare of underlying condition.","   ( )","   ( )");n("Secobarbital","Doxycycline -  ",e.DRUG_DRUG,i.MODERATE,"   (CYP450)    ","Doxycycline Failure. Enzyme induction reduces half-life.","   ","   ","    ()    ","    ()    ");n("Secobarbital","Estrogens - ",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","Estrogen Failure. Enzyme induction reduces efficacy.","  ","  ","        ","        ");n("Secobarbital","Ethanol - ",e.DRUG_DRUG,i.HIGH,"      ","Additive CNS Inhibition. Profound sedation.","   ","Increased CNS Depression. Drowsiness and ataxia.","  ","  ");n("Secobarbital","Amlodipine",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Secobarbital","Diltiazem",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Secobarbital","Verapamil",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Secobarbital","Nifedipine",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","CYP450 Induction. Accelerated metabolism reduces the therapeutic efficacy of the object drug.","    ","Reduced CCB Efficacy. Poor BP/Angina control.","     ( )","     ( )");n("Secobarbital","Griseofulvin - ",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Barbiturate Absorption. Decreased efficacy.","  ","  ","     ","     ");n("Secobarbital","Methadone - ",e.DRUG_DRUG,i.MODERATE,"   (CYP450)   ","Methadone Withdrawal. Enzyme induction lowers levels.","  ","  ","     ","     ");n("Secobarbital","Warfarin - ",e.DRUG_DRUG,i.HIGH,"   (CYP450)    (  )","Reduced Warfarin Effect. Enzyme induction increases clotting risk.","  ","  ","    (INR) ","    (INR) ");n("Secobarbital","Voriconazole - ",e.DRUG_DRUG,i.HIGH,"   (CYP450)   ","Barbiturate Toxicity. Metabolic inhibition.","  ","  ","     ","     ");n("Secukinumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Secukinumab    (IL-17A inhibitor).","Increased risk of viral infection. Secukinumab is an immunosuppressive agent (IL-17A inhibitor).","      (  Mirikizumab).","Risk of developing infection from live vaccines (same mechanism as Mirikizumab)."," .        Secukinumab.","Contraindicated. Live vaccines must be avoided during Secukinumab treatment.");n("Secukinumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Secukinumab   IL-17A.","Reduced vaccine response/Increased infection risk. Secukinumab is an IL-17A inhibitor.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Selegiline - ","SSRIs -   ",e.DRUG_DRUG,i.CONTRAINDICATED,"           ","Synergistic increase in serotonergic activity leading to life-threatening serotonin syndrome risk","  (          )","Serotonin syndrome (fever, tremor, muscle rigidity, mental status changes, autonomic instability)","   -   5    SSRIs   ","Absolute contraindication - 5-week washout after SSRIs before starting Selegiline");n("Selegiline - ","SNRIs -    ",e.DRUG_DRUG,i.CONTRAINDICATED,"     ","Dangerous synergy in serotonin and norepinephrine activity","      ","Acute serotonin syndrome, hypertensive crisis","   -    ","Avoid combination entirely - appropriate washout period required");n("Selegiline - ","Tricyclic Antidepressants -    ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Synergy in increasing monoamine neurotransmitters","        ","Hypertensive crisis, serotonin syndrome, hyperthermia","  -   2-3 ","Contraindicated - 2-3 week washout period");n("Selegiline - ","Tyramine-rich Foods -   ",e.DRUG_FOOD,i.MODERATE,"       (   )","Inhibition of tyramine metabolism leading to catecholamine release (only at high doses)","       ","Hypertensive crisis, headache, palpitations, nausea, vomiting","   (10 /):     -   :       ","At low doses (10 mg/day): no dietary restrictions needed - At high doses: avoid aged cheeses, processed meats, fermented beverages");n("Selegiline - ","Dextromethorphan - ",e.DRUG_DRUG,i.HIGH,"   ","Synergistic serotonergic activity","   ","Serotonin syndrome, agitation, confusion","  -    ","Avoid combination - use alternative cough suppressants");n("Selegiline - ","Meperidine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"    ","Serotonergic interaction that can be fatal","      ","Hypotension, coma, respiratory arrest, death","  -    ","Strictly prohibited - use alternative opioids");n("Selegiline - ","Levodopa - ",e.DRUG_DRUG,i.MODERATE,"       ","Synergy in increasing central nervous system dopamine","    (   )","Increased dopamine side effects (nausea, vomiting, hallucinations, confusion)","    10-30%   ","Reduce Levodopa dose by 10-30% when adding Selegiline");n("Selegiline - ","QT-prolonging Drugs -    QT",e.DRUG_DRUG,i.MODERATE,"     QT   ","Additive effect on QT interval prolongation on ECG","      including Torsades de Pointes","Increased risk of ventricular arrhythmias including Torsades de Pointes","    -        QT","Monitor ECG regularly - avoid combination with other QT-prolonging drugs");n("Selegiline - ","CYP2B6/CYP3A4 Inhibitors -  ",e.DRUG_DRUG,i.MODERATE,"       ","Inhibition of Selegiline metabolism increases its blood levels","       ","Increased Selegiline side effects, risk of tyramine interactions","    -      ","Monitor for side effects - adjust Selegiline dose if necessary");n("Selegiline - ","Sympathomimetics -  ",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic adrenergic effects","         ","Hypertensive crisis, tachycardia, cardiac arrhythmias","       ","Avoid decongestants containing pseudoephedrine or phenylephrine");n("Selegiline - ","Other MAOIs -  MAO ",e.DRUG_DRUG,i.CONTRAINDICATED,"   MAO    ","Dual MAO inhibition increases interaction risks","      ","Severe hypertensive crisis, serotonin syndrome","   -      MAO ","Absolute contraindication - do not combine with any other MAOIs");n("Selexipag - ","Gemfibrozil - ",e.DRUG_DRUG,i.HIGH,"    CYP2C8         ACT-333679          ","Gemfibrozil is a potent inhibitor of hepatic CYP2C8 enzyme responsible for Selexipag metabolism to its active metabolite ACT-333679, significantly increasing active metabolite plasma concentration","    ACT-333679  3-4                 ","3-4 fold increase in active metabolite ACT-333679 concentration, significantly increased risk of adverse effects especially severe diarrhea, nausea, vomiting, headache, jaw pain, and myalgia","    -   :     50-75% -        -       ","Avoid combination if possible - if necessary: reduce Selexipag dose by 50-75% - initiate with very low dose and titrate very slowly - monitor for gastrointestinal and neurological adverse effects");n("Selinexor","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Selinexor. Voriconazole    CYP3A4      Selinexor.","Increased Selinexor concentration. Voriconazole is a strong CYP3A4 inhibitor, the primary metabolic pathway for Selinexor.","      Selinexor     .","Increased risk of severe Selinexor side effects, such as hematological and gastrointestinal toxicity."," .    Selinexor     CYP3A4 .","Dose adjustment. Selinexor dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Selinexor","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Selinexor. Phenytoin    CYP3A4    Selinexor.","Decreased Selinexor efficacy. Phenytoin is a strong inducer of CYP3A4, a Selinexor metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Selinexor - ","Fentanyl - ",e.DRUG_DRUG,i.MODERATE,"   CYP3A4              ","Selinexor induces hepatic CYP3A4 enzyme responsible for Fentanyl primary metabolism, increasing its clearance and reducing bioavailability","      30-50           ","30-50% decrease in Fentanyl plasma concentration, leading to inadequate pain control and shortened analgesic duration","    25-50   -      -          CYP3A4  ","Increase Fentanyl dose by 25-50% based on response - monitor pain level frequently - consider alternative opioids not dependent on CYP3A4 like morphine");n("Selinexor (XPO1)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Selinexor. Rifampin    CYP3A4    Selinexor.","Decreased Selinexor concentration. Rifampin is a strong inducer of CYP3A4, a Selinexor metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Selpercatinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Omeprazole        Selpercatinib.","Reduced Selpercatinib efficacy. Omeprazole decreases gastric acidity, which is necessary for Selpercatinib absorption.","          .","Decreased drug plasma concentration, leading to cancer treatment failure."," .      (PPIs)    Selpercatinib.","Avoid Combination. PPIs should be avoided during Selpercatinib treatment.");n("Selpercatinib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Selpercatinib. Cyclosporine    P-gp    Selpercatinib.","Increased Selpercatinib concentration. Cyclosporine is a P-gp inhibitor, responsible for Selpercatinib efflux.","     Selpercatinib (    ).","Increased risk of Selpercatinib side effects (such as elevated LFTs and hemorrhage)."," .            .","Dose monitoring. Drug levels or side effects should be monitored, and dose adjusted if necessary.");n("Selpercatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Rifampin    CYP3A4    Selpercatinib.","Decreased Selpercatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Selpercatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Selpercatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Ketoconazole    CYP3A4    Selpercatinib.","Increased Selpercatinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Selpercatinib metabolic pathway.","    QT  .","Increased risk of QT prolongation and hepatotoxicity."," .    Selpercatinib     CYP3A4 .","Dose adjustment. Selpercatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Selpercatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Rifampin    CYP3A4    Selpercatinib.","Decreased Selpercatinib concentration. Rifampin is a strong inducer of CYP3A4, a Selpercatinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Selpercatinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. PPIs       Selpercatinib.","Decreased Selpercatinib absorption. PPIs reduce gastric acidity, which is essential for Selpercatinib absorption.","   .","Reduced anticancer efficacy."," .  PPIs.    H2 ( )    ( ).","Contraindicated. Avoid PPIs. H2 blockers (at a suitable time) or antacids (separated by 2 hours) must be used.");n("Selpercatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Rifampin    CYP3A4.","Decreased Selpercatinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Selpercatinib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Selpercatinib. Itraconazole    CYP3A4.","Increased Selpercatinib concentration. Itraconazole is a strong inhibitor of CYP3A4.","    QT  .","Increased risk of QT prolongation and liver toxicity."," .    Selpercatinib.","Dose adjustment. Selpercatinib dose must be reduced.");n("Selpercatinib","Omeprazole (PPI)",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Selpercatinib     .","Decreased Selpercatinib concentration. Selpercatinib requires an acidic environment for absorption.","     .","Reduced drug efficacy and failure of cancer treatment."," .   .","Contraindicated. Avoid the combination.");n("Selpercatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Selpercatinib. Rifampin    CYP3A4.","Decreased Selpercatinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Selumetinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Selumetinib. Itraconazole     CYP3A4      Selumetinib.","Increased Selumetinib concentration. Itraconazole is a potent inhibitor of CYP3A4, the primary metabolic pathway for Selumetinib.","     Selumetinib      .","Increased risk of Selumetinib side effects, such as cardiomyopathy and ocular toxicity."," .    Selumetinib      CYP3A4 .","Dose adjustment. Selumetinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Selumetinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Selumetinib. Rifampin    CYP3A4    Selumetinib.","Decreased Selumetinib efficacy. Rifampin is a strong inducer of CYP3A4, a Selumetinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Selumetinib","Erythromycin",e.DRUG_DRUG,i.MODERATE,"  Selumetinib. Erythromycin    CYP3A4    Selumetinib.","Increased Selumetinib concentration. Erythromycin is a moderate CYP3A4 inhibitor, a Selumetinib metabolic pathway.","         .","Increased risk of side effects, such as cardiomyopathy and ocular toxicity."," .        .","Dose adjustment. Patient must be monitored for increased side effects.");n("Selumetinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Selumetinib.      CYP3A4    Selumetinib.","Increased Selumetinib concentration. Grapefruit juice inhibits CYP3A4, a Selumetinib metabolic pathway.","         .","Increased risk of side effects, such as cardiomyopathy and ocular toxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Selumetinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Selumetinib. Itraconazole    CYP3A4    Selumetinib.","Increased Selumetinib concentration. Itraconazole is a strong CYP3A4 inhibitor, a Selumetinib metabolic pathway.","        .","Increased risk of side effects, especially hepatotoxicity and cardiotoxicity."," .    Selumetinib     CYP3A4 .","Dose adjustment. Selumetinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Semaglutide","Levothyroxine",e.DRUG_DRUG,i.MODERATE,"  Levothyroxine. Semaglutide             .","Decreased Levothyroxine absorption. Semaglutide delays gastric emptying, reducing the absorption of oral drugs requiring precise timing.","     .","Reduced efficacy of hypothyroidism treatment.","  .   Levothyroxine  Semaglutide   (  )   TSH.","Timing adjustment and monitoring. Levothyroxine should be taken sufficiently before Semaglutide (at least one hour) and TSH levels monitored.");n("Semaglutide (GLP-1 RA)","Levothyroxine",e.DRUG_DRUG,i.MODERATE,"  Levothyroxine. Semaglutide         .","Decreased Levothyroxine absorption. Semaglutide delays gastric emptying, reducing absorption time.","  Levothyroxine      .","Reduced Levothyroxine efficacy, leading to hypothyroidism.","  .   TSH  Levothyroxine   Levothyroxine  Semaglutide  .","Thyroid monitoring. Monitor TSH and Levothyroxine levels, or take Levothyroxine well before Semaglutide.");n("Semaglutide (Oral)","Levothyroxine",e.DRUG_DRUG,i.MODERATE,"  Levothyroxine. Semaglutide   .","Decreased Levothyroxine absorption. Semaglutide slows gastric emptying.","     .","Reduced efficacy of hypothyroidism treatment.","  .   Levothyroxine  Semaglutide  30   TSH.","Dose adjustment and monitoring. Levothyroxine must be taken 30 minutes before Semaglutide, and TSH monitored.");n("Semaglutide (Oral)","Warfarin",e.DRUG_DRUG,i.MODERATE,"    INR. Semaglutide         Warfarin.","Increase or decrease in INR. Semaglutide slows gastric emptying, which may affect Warfarin absorption.","    .","Increased risk of bleeding or thrombosis."," .  INR       Semaglutide.","Close monitoring. Monitor INR frequently upon initiation or discontinuation of Semaglutide.");n("Semaglutide (Ozempic/Wegovy)","Insulin",e.DRUG_DRUG,i.MODERATE,": **    **.    .","Mechanism: **Synergistic glucose-lowering effect**. Both agents lower glucose."," : **   ** .","Clinical Significance: **Severe hypoglycemia risk**.","    20-50%   Semaglutide.    .","Reduce insulin dose by 20-50% when starting Semaglutide. Monitor glucose frequently.");n("Semaglutide (Ozempic/Wegovy)","Sulfonylureas (Glimepiride)",e.DRUG_DRUG,i.MODERATE,": **    **.","Mechanism: **Synergistic glucose-lowering effect**."," : **   **.","Clinical Significance: **Hypoglycemia risk**.","  Sulfonylurea   Semaglutide.  .","Reduce Sulfonylurea dose when starting Semaglutide. Monitor glucose.");n("Semaglutide (Ozempic/Wegovy)","Oral Contraceptives (  )",e.DRUG_DRUG,i.MODERATE,": **  **. Semaglutide    .","Mechanism: **Delayed gastric emptying**. Semaglutide slows oral drug absorption."," : **   ** .","Clinical Significance: **Potential reduced contraceptive efficacy**.","     ( )     .","Use additional contraception (e.g., condoms) during first weeks of therapy.");n("Semaglutide (Ozempic/Wegovy)","Levothyroxine",e.DRUG_DRUG,i.MODERATE,": **  **.     Levothyroxine.","Mechanism: **Delayed gastric emptying**. May affect Levothyroxine absorption."," : **     **.","Clinical Significance: **Thyroid hormone level fluctuations**."," TSH  4-6    Semaglutide.   Levothyroxine  .","Monitor TSH 4-6 weeks after starting Semaglutide. Adjust Levothyroxine dose as needed.");n("Semaglutide (Ozempic/Wegovy)","Pancreatitis History (  )",e.DRUG_DISEASE,i.HIGH,": **  **. GLP-1 agonists      .","Mechanism: **Pancreatitis risk**. GLP-1 agonists may increase pancreatitis risk."," : **  ** .","Clinical Significance: **Potential acute pancreatitis**.","      .     .","Avoid in patients with pancreatitis history. Educate patient on pancreatitis symptoms.");n("Senna","Digoxin",e.DRUG_DRUG,i.MODERATE," ","Hypokalemia.","  ","Increased digoxin toxicity."," ","Monitor potassium.");n("Senna","Warfarin",e.DRUG_DRUG,i.MODERATE," -    K","Diarrhea reduces vitamin K absorption."," INR","Increased INR."," INR","Monitor INR.");n("Serotonin - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.HIGH,"    (     )","    (     )","   ","Serotonin Syndrome Risk. Potentially fatal.","    ","    ");n("Serotonin - ","Pseudoephedrine",e.DRUG_DRUG,i.HIGH,"   ","Serotonin Syndrome Risk. Potentially fatal.","   ","Serotonin Syndrome Risk. Potentially fatal.","     -      -         ","     -      -         ");n("Serotonin - ","Phenylephrine",e.DRUG_DRUG,i.HIGH,"   ","Serotonin Syndrome Risk. Potentially fatal.","   ","Serotonin Syndrome Risk. Potentially fatal.","     -      -         ","     -      -         ");n("Serotonin - ","Ephedrine",e.DRUG_DRUG,i.HIGH,"   ","Serotonin Syndrome Risk. Potentially fatal.","   ","Serotonin Syndrome Risk. Potentially fatal.","     -      -         ","     -      -         ");n("Sertraline","Phenytoin",e.DRUG_DRUG,i.MODERATE,"            .","Sertraline may inhibit the hepatic metabolism of Phenytoin, increasing its serum levels.","         (    ).","Increased Phenytoin serum concentration and elevated risk of toxicity symptoms (ataxia, dizziness, nystagmus, confusion).","                .","Monitor Phenytoin levels closely, watch for toxicity symptoms, adjust Phenytoin dose if necessary.");n("Sertraline","MAO Inhibitors -    ",e.DRUG_DRUG,i.HIGH,"     .        MAO  .         .","Pharmacodynamic synergy: Sertraline blocks serotonin reuptake, while MAO inhibitors prevent its breakdown. This combination causes excessive, life-threatening serotonin accumulation.","   (      )     .","Severe Serotonin Syndrome (hyperthermia, muscle rigidity, mental status change) and neurotoxicity, potentially leading to death.","  .     MAO  14       ( 14 ).","Combination is contraindicated. A minimum 14-day washout period is required when switching between Sertraline and MAO inhibitors.");n("Sertraline","Citalopram/Escitalopram",e.DRUG_DRUG,i.HIGH,"  (Additive Serotonergic Effect)       (SSRI)      .      QT.","Additive serotonergic effect between two SSRIs, significantly increasing the risk of Serotonin Syndrome. There is also an increased risk of QT interval prolongation.","      (Arrhythmias).","Increased risk of Serotonin Syndrome and cardiotoxicity (Arrhythmias).","  .          .","Avoid co-administration. If used, employ lowest doses and monitor for neurological and cardiac toxicity signs.");n("Sertraline","Valproic Acid -  ",e.DRUG_DRUG,i.MODERATE,"              (SSRI)     .","Valproic acid has additive serotonergic activity, contributing to serotonin accumulation when combined with an SSRI (Sertraline), increasing the risk of neurotoxicity.","          .","Increased risk of Serotonin Syndrome and neurological side effects like tremors or confusion.","     .        .","Monitor closely for signs of Serotonin Syndrome. Reduce the dose of either agent if toxicity symptoms appear.");n("Sertraline","Cyclosporine - ",e.DRUG_DRUG,i.MODERATE,"    CYP3A4.        (    )       .","Sertraline is a weak inhibitor of CYP3A4. Inhibition of this enzyme reduces cyclosporine metabolism (a narrow therapeutic index drug), increasing its concentrations and toxicity risk.","   (     ).","Increased cyclosporine toxicity (particularly nephrotoxicity and hypertension).","         .       .","Monitor cyclosporine trough concentrations frequently when starting Sertraline. Cyclosporine dose reduction is usually necessary.");n("Sertraline","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"     (CYP450).                .","Cimetidine is a broad-spectrum CYP450 inhibitor. This inhibition slows Sertraline metabolism, increasing its plasma levels and the probability of dose-related side effects.","    (  ).","Increased Sertraline side effects (nausea, insomnia, anxiety).","   H2  ( )    .          .","Use an alternative H2 blocker (e.g., Famotidine). If Cimetidine is continued, monitor symptoms and consider reducing the Sertraline dose.");n("Sertraline","Rifampin - ",e.DRUG_DRUG,i.MODERATE,"    CYP450.        .","Rifampin is a potent CYP450 inducer. This induction rapidly increases Sertraline metabolism.","            .","Reduced Sertraline plasma levels, leading to decreased therapeutic efficacy and risk of depression relapse.","  .            .","Monitor clinical response. Significant increase in Sertraline dosage may be necessary during co-administration.");n("Sertraline","Smoking (Tobacco) ()",e.DRUG_FOOD,i.MODERATE,"         CYP1A2.          (             ).","Polycyclic aromatic hydrocarbons in tobacco smoke induce the CYP1A2 enzyme. This increases the metabolic rate of certain drugs (Sertraline is mainly metabolized by 2C19 and 2D6, but the effect is still present).","               .","Slight reduction in Sertraline plasma levels, potentially compromising therapeutic effect in heavy smokers.","  .                 .","Monitor clinical efficacy. A dose adjustment may be necessary in heavy smokers, and dose reduction may be needed if the patient quits smoking.");n("Sertraline","Digoxin",e.DRUG_DRUG,i.MODERATE,"       (Adsorption)            (P-glycoprotein).","Sertraline may physically bind to Digoxin in the GI tract (adsorption) reducing its bioavailability, or it may interfere with P-glycoprotein transport mechanisms.","             .","Reduced Digoxin levels, leading to loss of control over heart failure or arrhythmias.","            .","Monitor Digoxin serum levels frequently when starting or stopping Sertraline.");n("Sertraline","Clonidine - ",e.DRUG_DRUG,i.MODERATE,"                     (CNS).","Sertraline reduces the antihypertensive effect of Clonidine through incompletely understood mechanisms, possibly CNS antagonism or physiological opposition.","           .","Reduced Clonidine efficacy and loss of hypertension control.","   .           .","Monitor blood pressure closely. May require increasing the Clonidine dose or switching the antidepressant.");qh.forEach(h=>{n("Sertraline",h,e.DRUG_DRUG,i.MODERATE,"     (   ).                 (Sympathomimetics).","Sertraline inhibits serotonin (and weakly norepinephrine) reuptake. This increases synaptic norepinephrine, synergizing with the direct vasoconstrictive effects of sympathomimetic agents.","     (Hypertension)    (Arrhythmia)  .","Increased risk of hypertension, cardiac arrhythmias, and tachycardia.","          .            .","Avoid OTC medications containing these agents. Monitor BP and heart rate closely; adjust the dose of the pressor agent as needed.")});n("Sertraline","Alcohol",e.DRUG_FOOD,i.MODERATE,": **  **.        Sertraline    .","Mechanism: **Additive CNS depression**. Alcohol increases the neurological side effects of Sertraline like drowsiness and impaired judgment.",":      .","Result: Increased drowsiness and impaired coordination and motor skills.",":     .","Management: Advise avoidance of alcohol during treatment.");n("Sertraline","Caffeine",e.DRUG_FOOD,i.LOW,":   .   Sertraline     .","Mechanism: Additive stimulant effect. Sertraline does not significantly affect Caffeine metabolism.",":          .","Result: No major clinical effect, may increase mild nervousness.",":    .","Management: No routine adjustment required.");n("Sertraline","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,": ** CYP3A4**.    CYP3A4      Sertraline   .","Mechanism: **CYP3A4 Inhibition**. Grapefruit juice inhibits CYP3A4, an important metabolism pathway for Sertraline, increasing its concentration.",": **  Sertraline  **       (  ).","Result: **Increased Sertraline blood concentration**, increasing the risk of side effects (e.g., serotonin symptoms).",":         .","Management: Avoid consuming large amounts of grapefruit juice during treatment.");n("Sertraline","Green Tea",e.DRUG_FOOD,i.MODERATE,":         .","Mechanism: Additive stimulant effect due to Caffeine content in Green Tea.",":          .","Result: Slight increase in nervousness and insomnia, especially in stimulant-sensitive patients.",":       .","Management: Monitor symptoms and limit Green Tea intake.");n("Sertraline","Milk",e.DRUG_FOOD,i.LOW,":    .  Sertraline      .","Mechanism: No known interaction. Sertraline absorption is not significantly affected by dairy products.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Sertraline","High-fat meals",e.DRUG_FOOD,i.HIGH,": **   **.         Sertraline  .","Mechanism: **Increased Absorption and Bioavailability**. Food, especially high-fat meals, significantly increases Sertraline absorption.",": **  Sertraline   (25%  40%)**      .","Result: **Increased Sertraline blood concentration**, increasing the risk of side effects.",":   Sertraline **   **  **  **   .","Management: Advise taking Sertraline **consistently with food** or **consistently without food** to ensure consistent levels.");n("Sertraline","High-fiber foods",e.DRUG_FOOD,i.MODERATE,":            .","Mechanism: High-concentration fibers may delay the rate of drug absorption through physical interference.",":            .","Result: Slight delay in reaching peak concentration, with no major effect on overall efficacy.",":    .","Management: No routine adjustment required.");n("Sertraline","Vitamin C",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Vitamin D",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with brain metabolism.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Vitamin E",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Vitamin K",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Vitamin B12",e.DRUG_FOOD,i.HIGH,":    .         .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with brain metabolism.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Folic Acid",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No known interaction. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Iron",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Calcium",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with intestinal absorption process.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Magnesium",e.DRUG_FOOD,i.MODERATE,":    .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Zinc",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Potassium",e.DRUG_FOOD,i.HIGH,":    .          .","Mechanism: No known interaction. Interaction is hypothetical and may be due to interference with neuronal function.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","Sodium Bicarbonate",e.DRUG_FOOD,i.MODERATE,":         .","Mechanism: Sodium Bicarbonate may temporarily alter gastric pH.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Sertraline","Antacids",e.DRUG_FOOD,i.LOW,":    .   .","Mechanism: No known interaction. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Sertraline","L-Tryptophan/5-HTP",e.DRUG_FOOD,i.HIGH,": **  **. L-Tryptophan  5-HTP             Sertraline.","Mechanism: **Additive Serotonergic Effect**. L-Tryptophan and 5-HTP are serotonin precursors, increasing the available serotonin levels when combined with Sertraline.",": **     ** (Serotonin Syndrome)        .","Result: **High and increased risk of Serotonin Syndrome** characterized by tremor, hyperthermia, and severe anxiety.",": / .        Sertraline.","Management: Contraindicated/Strictly Avoid. These supplements must not be used concurrently with Sertraline.");n("Sertraline","St. John's Wort",e.DRUG_FOOD,i.HIGH,": **  **.           (SSRI)       .","Mechanism: **Additive Serotonergic Effect**. St. John's Wort has SSRI-like properties, increasing serotonergic activity in the brain.",": **    **.        CYP450.","Result: **High risk of Serotonin Syndrome**. It may also cause metabolic interactions via CYP450 enzymes.",": / .         Sertraline.","Management: Contraindicated/Strictly Avoid. This herbal supplement must not be used concurrently with Sertraline.");n("Sertraline - ","Cyproheptadine - ",e.DRUG_DRUG,i.MODERATE,"      (5-HT2)           ","Cyproheptadine is a competitive serotonin receptor (5-HT2) antagonist, reducing the therapeutic efficacy of Sertraline through pharmacodynamic antagonism","             ","Reduced therapeutic efficacy of Sertraline, potential return of depressive or anxiety symptoms, and diminished antidepressant response","     -                   ","Avoid concurrent use if possible - if Cyproheptadine is necessary, closely monitor Sertraline response and consider dose adjustment or using a non-serotonergic alternative");n("Sertraline - ","Fluoxetine - ",e.DRUG_DRUG,i.HIGH,"                   ","Combining SSRIs results in excessive synergistic serotonergic activity, with mutual inhibition of drug metabolism via hepatic enzymes","           ","High risk of severe serotonin syndrome, agitation, tremor, muscle rigidity, and hyperthermia","        -          ","Avoid combining SSRIs entirely - choose an alternative from a different drug class if combination therapy is necessary");n("Sertraline - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"                ","Combining SSRIs results in excessive synergistic serotonergic activity, with mutual inhibition of drug metabolism","       ","High risk of severe serotonin syndrome and serotonergic toxicity","        -          ","Avoid combining SSRIs entirely - choose an alternative from a different drug class if combination therapy is necessary");n("Setmelanotide","Midazolam",e.DRUG_DRUG,i.LOW,"    .   ()    CYP.","No true interaction expected. Biologic drugs (peptides) are not metabolized by CYP.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Setmelanotide (Imcivree)","Skin Darkening Medications",e.DRUG_DRUG,i.LOW,": **   **. Setmelanotide   .","Mechanism: **Synergistic pigmentation effect**. Setmelanotide causes hyperpigmentation."," : ** ** .","Clinical Significance: **Severe hyperpigmentation**."," .  .","Patient education. Monitor pigmentation.");n("Seville Orange","Felodipine",e.DRUG_FOOD,i.MODERATE," CYP3A4","CYP3A4 inhibition.","   ","Increased hypotensive effect.","  ","Avoid Seville orange.");n("Sibutramine","Dextromethorphan",e.DRUG_DRUG,i.HIGH,"           .      (Synergism)   .","Both Sibutramine and Dextromethorphan increase Serotonin levels in the Central Nervous System. This interaction leads to a synergistic effect in serotonergic activity.","    (Serotonin Syndrome)               .","Increased risk of potentially fatal Serotonin Syndrome, characterized by severe CNS irritation, mood changes, neurocognitive impairment, and tremor.","      .             .","Avoid this combination whenever possible. Treatment must be immediately discontinued and replaced upon suspicion or occurrence of Serotonin Syndrome.");n("Sibutramine - ","Ergot Alkaloids -  ",e.DRUG_DRUG,i.HIGH,"  (Ergot Alkaloids)          .      (Synergism)   .","Ergot Alkaloids and Sibutramine both increase Serotonin levels in the Central Nervous System, leading to a synergistic effect in serotonergic activity.","    (Serotonin Syndrome)              (Clonus)   . (   )","Increased risk of potentially fatal Serotonin Syndrome. Symptoms include severe CNS agitation, mood changes, myoclonus (clonus), confusion, and tremor. (Serotonin Syndrome Risk. Potentially fatal.)","      .             .","Avoid this combination whenever possible. Treatment must be immediately discontinued and replaced upon suspicion or occurrence of Serotonin Syndrome.");n("Sibutramine - ","Lithium - ",e.DRUG_DRUG,i.HIGH,"         (Serotonergic Activity)    .                  .","Both Sibutramine and Lithium contribute to increased Serotonergic Activity in the Central Nervous System. Sibutramine acts as a serotonin reuptake inhibitor, while Lithium potentiates serotonin effects, resulting in synergistic neurochemical activity.","    (Serotonin Syndrome)              (Clonus)   . (   .   .)","Increased risk of potentially fatal Serotonin Syndrome. Symptoms include severe CNS agitation, mood changes, myoclonus (clonus), confusion, and tremor. (Serotonin Syndrome Risk. Potentially fatal.)","        .             .","Avoid this drug combination whenever possible due to its high risk. Both drugs must be discontinued immediately, and supportive care must be provided upon suspicion or occurrence of Serotonin Syndrome.");n("Sibutramine - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.HIGH,"    (         )","Serotonin Syndrome Risk. Symptoms include agitation, clonus, hyperthermia, and tremor.","   ","Serotonin Syndrome Risk. Potentially fatal.","     -      ","     -      ");n("Sibutramine - ","Meperidine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"   :              ","Dangerous synergistic serotonergic effect: Sibutramine inhibits serotonin, norepinephrine, and dopamine reuptake, while Meperidine increases serotonin release and inhibits its reuptake","     :      (>41)          ","Severe serotonin syndrome with symptoms including: agitation, myoclonus, hyperthermia (>41C), tremor, muscle rigidity, hyperreflexia, confusion, autonomic instability, and coma","   -    - :               -          ","Absolute contraindication - avoid combination entirely - note: Sibutramine has been withdrawn from markets in many countries due to cardiovascular risks - use safe analgesic alternatives like paracetamol or non-serotonergic opioids");n("Meperidine - ","Alcohol - ",e.DRUG_FOOD,i.HIGH,"     :      ","Synergistic CNS depressant effect: alcohol enhances the sedative and depressant effects of meperidine","           ","Acute respiratory depression, hypotension, coma, risk of death due to respiratory failure","       ","Completely avoid alcohol consumption during meperidine therapy");n("Sibutramine - ","Selective 5HT-1 Receptor Antagonists -     5HT-1 ()",e.DRUG_DRUG,i.HIGH,"  (  )  (   5HT-1)               .","Both Sibutramine (a serotonin reuptake inhibitor) and Triptans (5HT-1 receptor agonists) contribute to cumulative serotonergic activity in the CNS, leading to a potentiated effect.","                (Myoclonus)     .","Increased risk of fatal Serotonin Syndrome. Symptoms include CNS irritability, myoclonus, altered consciousness, and severe tremor.","      .              .","Avoid this combination if possible. Otherwise, monitor closely and obtain medical treatment (discontinue drugs) immediately if Serotonin Syndrome develops.");n("Sibutramine - ","Serotonin Reuptake Inhibitors -    (SSRIs/SNRIs)",e.DRUG_DRUG,i.HIGH,"      (  )     (   )            .","Both Sibutramine and Serotonin Reuptake Inhibitors (e.g., fluoxetine, sertraline) use the same mechanism (blocking serotonin reuptake), leading to a massive, excessive increase in synaptic serotonin concentration.","                 .","Critical and potentially fatal increase in the risk of Serotonin Syndrome, with symptoms including confusion, hyperthermia, and severe shivering/tremor.","         .          .","Avoid combining two drugs with the same serotonin-increasing mechanism. Monitor closely and discontinue drugs immediately at any sign of Serotonin Syndrome.");n("Sibutramine - ","Tryptophan - ",e.DRUG_DRUG,i.HIGH,"     .    (    )             .","Tryptophan is the metabolic precursor for serotonin synthesis. Combined with Sibutramine (which prevents its reuptake), the available production of serotonin is drastically increased in the CNS, compounding the serotonergic activity.","           (Serotonin Syndrome)     .","Excessive serotonin concentration and a significantly high risk of Serotonin Syndrome, with severe neurological and muscular symptoms.","       .           .","Strictly avoid taking Tryptophan supplements concurrently with Sibutramine. Obtain urgent medical assistance if Serotonin Syndrome symptoms appear.");n("Sildenafil (Viagra)","Nitroglycerin",e.DRUG_DRUG,i.CONTRAINDICATED,"  .","Severe Vasodilation. Risk of shock.","  .","  ."," ."," .");n("Sildenafil (Viagra)","Isosorbide Mononitrate",e.DRUG_DRUG,i.CONTRAINDICATED,"  .","Severe Vasodilation. Risk of shock.","  .","  ."," ."," .");n("Sildenafil (Viagra)","Isosorbide Dinitrate",e.DRUG_DRUG,i.CONTRAINDICATED,"  .","Severe Vasodilation. Risk of shock.","  .","  ."," ."," .");n("Simethicone","Levothyroxine",e.DRUG_DRUG,i.LOW,"   ","Slight absorption reduction.","  ","Minor clinical effect.","   ","Separate doses if possible.");n("Simvastatin","Alcohol",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Caffeine",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Green Tea",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Milk",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","High-fat meals",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","High-fiber foods",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Vitamin C",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Vitamin D",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Vitamin E",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Vitamin K",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Vitamin B12",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Folic Acid",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Iron",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Calcium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Magnesium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Zinc",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Potassium",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Simvastatin","Antacids",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Siponimod","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Siponimod. Ketoconazole    CYP3A4    Siponimod.","Increased Siponimod concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Siponimod metabolic pathway.","      QT.","Increased risk of bradycardia and QT prolongation.","    .   CYP3A4     Siponimod.","Avoid combination or dose adjustment. Avoid strong CYP3A4 inhibitors or reduce Siponimod dose.");n("Siponimod (S1P modulator)","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Siponimod. Fluconazole    CYP2C9  CYP3A4.","Increased Siponimod concentration. Fluconazole is a strong inhibitor of CYP2C9 and CYP3A4.","          .","Increased risk of side effects, especially bradycardia and changes in liver function.","  .        CYP2C9     .","Relative contraindication. Avoid combination in patients with slow CYP2C9 metabolism genes or dose adjustment.");n("Siponimod (S1P)","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Siponimod. Fluconazole    CYP3A4/2C9.","Increased Siponimod concentration. Fluconazole is a strong inhibitor of CYP3A4/2C9.","      .","Increased risk of bradycardia and other side effects."," .   .","Contraindicated. Avoid the combination.");n("Siponimod (S1P)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Siponimod. Rifampin    CYP3A4.","Decreased Siponimod concentration. Rifampin is a strong inducer of CYP3A4.","        .","Reduced drug efficacy, leading to exacerbation of multiple sclerosis."," .   .","Contraindicated. Avoid the combination.");n("Sipuleucel-T","Corticosteroids",e.DRUG_DRUG,i.HIGH,"  Sipuleucel-T.        .","Decreased efficacy of Sipuleucel-T. Corticosteroids are immunosuppressive and antagonize the vaccine mechanism.","   .","Reduced efficacy of immunotherapy."," .       .","Contraindicated. Corticosteroids must be avoided before and during treatment.");n("Sirolimus","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Sirolimus.       CYP3A4    P-gp.","Increased Sirolimus concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4 and P-gp transporters.","     .","Increased risk of nephrotoxicity and hematological toxicity."," .          CYP3A4.","Contraindicated. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Sirolimus","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"         : (1)      CYP3A4        (2)   P-glycoprotein       .                350%          3-4    .","Grapefruit juice has a dual and extremely potent effect on sirolimus: (1) irreversibly inhibits CYP3A4 enzyme responsible for drug metabolism in intestines and liver, (2) inhibits P-glycoprotein, a transporter that pumps drug out of intestinal cells. This dual inhibition leads to massive, dramatic increase in sirolimus bioavailability reaching 350% or more, meaning drug levels may triple or quadruple expected levels.","              :     (    )               .       .","Extremely dangerous, life-threatening elevation in sirolimus blood levels, causing severe toxicity including: severe bone marrow suppression (leukopenia and thrombocytopenia), acute hyperlipidemia, kidney damage, painful oral ulcers, severe gastrointestinal disturbances, and increased infection risk. May require hospitalization and emergency treatment.","          (  )   .          (pomelo)   (Seville oranges).        .             .","Grapefruit juice and the fruit itself (fresh or frozen) are absolutely and strictly prohibited during sirolimus therapy. Similar-effect fruits like pomelo and Seville oranges should also be avoided. Patient must carefully read mixed juice ingredients. Patient and family education about this interaction's severity is essential, with warning labels on medication packaging.");n("Sirolimus","Ketoconazole",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition."," ","Sirolimus toxicity.","    ","Significantly reduce sirolimus dose.");n("Sirolimus - ","Cyclosporine - ",e.DRUG_DRUG,i.MODERATE,"     CYP3A4  -P (P-glycoprotein)           .","Cyclosporine inhibits both the CYP3A4 enzyme and P-glycoprotein, which are responsible for Sirolimus metabolism and efflux, thus reducing Sirolimus clearance.","                    . (  )","Increased Sirolimus blood concentrations, raising the risk of its toxicity, including myelosuppression, hyperlipidemia, and renal function deterioration. (Increased Sirolimus toxicity)","   4                 .    .","Administer Sirolimus at least 4 hours AFTER Cyclosporine administration to avoid changes in Sirolimus concentrations resulting from interaction in absorption and metabolism. Sirolimus levels must be monitored.");n("Sirolimus - ","Fluconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4      .","Fluconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which is primarily responsible for the breakdown of Sirolimus.","                  . (  )","Significant and dangerous increase in Sirolimus blood concentrations, leading to heightened toxicity related to immunosuppression, cytopenias, and pneumonitis. (Increased Sirolimus toxicity)","      .    ( )       .","Monitor Sirolimus concentrations and signs/symptoms of toxicity. Adjust the Sirolimus dose (usually reduction) as directed upon starting or stopping Azole antifungals.");n("Sirolimus - ","Itraconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4          .","Itraconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Sirolimus breakdown and dangerously increases its blood levels.","                  . (  )","Significant and dangerous increase in Sirolimus blood concentrations, leading to heightened toxicity related to immunosuppression, cytopenias, and pneumonitis. (Increased Sirolimus toxicity)","      .    ( )       .","Monitor Sirolimus concentrations and signs/symptoms of toxicity. Adjust the Sirolimus dose (usually reduction) as directed upon starting or stopping Azole antifungals.");n("Sirolimus - ","Ketoconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4          .","Ketoconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Sirolimus breakdown and dangerously increases its blood levels.","                  . (  )","Significant and dangerous increase in Sirolimus blood concentrations, leading to heightened toxicity related to immunosuppression, cytopenias, and pneumonitis. (Increased Sirolimus toxicity)","      .    ( )       .","Monitor Sirolimus concentrations and signs/symptoms of toxicity. Adjust the Sirolimus dose (usually reduction) as directed upon starting or stopping Azole antifungals.");n("Sirolimus - ","Voriconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4          .","Voriconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Sirolimus breakdown and dangerously increases its blood levels.","                  . (  )","Significant and dangerous increase in Sirolimus blood concentrations, leading to heightened toxicity related to immunosuppression, cytopenias, and pneumonitis. (Increased Sirolimus toxicity)","      .    ( )       .","Monitor Sirolimus concentrations and signs/symptoms of toxicity. Adjust the Sirolimus dose (usually reduction) as directed upon starting or stopping Azole antifungals.");n("Sirolimus - ","Diltiazem - ",e.DRUG_DRUG,i.MODERATE,"       CYP3A4        .","Diltiazem is a moderate inhibitor of the hepatic metabolic enzyme CYP3A4, leading to reduced clearance of Sirolimus from the body.","               . (  )","Increased Sirolimus blood concentrations, raising the risk of its toxicity, particularly myelosuppression and hyperlipidemia. (Increased Sirolimus toxicity)","     .                .","Monitor Sirolimus concentrations and signs/symptoms of toxicity. Adjust the Sirolimus dose upon starting or stopping Diltiazem to ensure the level remains within the safe therapeutic range.");n("Sirolimus (mTOR)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Sirolimus. Rifampin    CYP3A4.","Decreased Sirolimus concentration. Rifampin is a strong inducer of CYP3A4.","        .","Reduced immunosuppressant efficacy, leading to transplant rejection."," .   .","Contraindicated. Avoid the combination.");n("Sitagliptin","Digoxin",e.DRUG_DRUG,i.MODERATE," P-glycoprotein","P-glycoprotein inhibition.","    ","Slight increase in digoxin levels.","   ","Monitor when initiating.");n("Sitagliptin (DPP-4)","Digoxin",e.DRUG_DRUG,i.MODERATE,"    Digoxin. Sitagliptin    P-gp    Digoxin.","Slight increase in Digoxin concentration. Sitagliptin is a weak inhibitor of P-gp, a Digoxin efflux transporter.","   Digoxin ().","Increased risk of Digoxin toxicity (minor).",".    Digoxin       Sitagliptin.","Monitoring. Digoxin levels must be closely monitored upon initiation or discontinuation of Sitagliptin.");n("Skyrizi (Risankizumab)","Other Biologics (e.g., Etanercept)",e.DRUG_DRUG,i.MODERATE,"  .    .","Increased risk of infection. Additive immunosuppressive effects.","     .","Increased risk of opportunistic and serious infections.","  .        .","Relative contraindication. Combination with other immunosuppressive biologics is not recommended.");n("Sodium Acetate","Lithium",e.DRUG_DRUG,i.MODERATE,"     ()             .","These agents increase the renal clearance (excretion) of Lithium, primarily through increased diuresis and modification of urinary pH.","             .","Decreased serum Lithium concentration, potentially leading to loss of therapeutic efficacy and symptom relapse.","      (TDM)  .          .","Closely monitor serum Lithium concentration (TDM) and clinical symptoms. A Lithium dose increase may be required to compensate for the reduced concentration.");n("Sodium Bicarbonate","Lithium",e.DRUG_DRUG,i.MODERATE,"     ()             .","These agents increase the renal clearance (excretion) of Lithium, primarily through increased diuresis and modification of urinary pH.","             .","Decreased serum Lithium concentration, potentially leading to loss of therapeutic efficacy and symptom relapse.","      (TDM)  .          .","Closely monitor serum Lithium concentration (TDM) and clinical symptoms. A Lithium dose increase may be required to compensate for the reduced concentration.");n("Sodium Bicarbonate","Aspirin",e.DRUG_DRUG,i.MODERATE,"  -   ","Urine alkalinization increases salicylate excretion.","  ","Reduced aspirin efficacy."," ","Avoid combination.");n("Sodium Bicarbonate -  ","Amphetamine - ",e.DRUG_DRUG,i.MODERATE,"    (pKa ~9.9)        .             ( )              .         (   50-70)     .               .","Amphetamine acts as a weak base (pKa ~9.9) and undergoes renal tubular reabsorption that is pH-sensitive. Alkalinizing the urine using sodium bicarbonate increases the proportion of non-ionized (uncharged) amphetamine, the form that readily crosses cell membranes and is passively reabsorbed in the renal tubules. This significantly reduces the renal clearance of amphetamine (by up to 50-70%) and increases its biological half-life. The reverse mechanism is utilized in overdose treatment, where urine acidification enhances amphetamine excretion.","        (AUC)   : 1.      . 2.     :         . 3.    :     . 4.        (     )           .","Increased amphetamine plasma levels and area under the curve (AUC), leading to: 1. Amplification and prolongation of amphetamine`s pharmacological and toxic effects. 2. Increased risk of cardiovascular toxicity: Hypertension, tachycardia, arrhythmias. 3. Enhanced central nervous system effects: Insomnia, anxiety, agitation, psychosis, seizures. 4. In patients taking amphetamine therapeutically (e.g., for ADHD), this may result in a functional overdose even with the usual dose.","1.    :                  . 2.  :               . 3.  :    (      )  . 4.  :           . 5.   : Patients                 . 6. :           (    )   .","1. Avoid unnecessary combination: Avoid using sodium bicarbonate in patients taking amphetamine, unless there is a clear clinical benefit outweighing the risks. 2. Therapeutic monitoring: Monitor plasma amphetamine levels if possible, especially when initiating or adjusting the sodium bicarbonate dose. 3. Clinical monitoring: Closely monitor for signs of toxicity (blood pressure, heart rate, mental status). 4. Dose adjustment: A reduction in the amphetamine dose may be necessary if the combination is unavoidable. 5. Sodium bicarbonate alternatives: For patients requiring alkalinization, consider other agents like acetazolamide, noting it may also interact. 6. Education: Alert patients to avoid self-administered alkaline antacids and carbonated beverages (which often contain bicarbonate) during amphetamine therapy.");n("Sodium Bicarbonate -  ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,' ( )    (pKa ~3.0)         .            ()   .               (" ").            .          .','Salicylates (e.g., aspirin) are weak acids (pKa ~3.0) and are excreted in urine via glomerular filtration and tubular secretion. Alkalinizing the urine using sodium bicarbonate increases the proportion of anionic (charged) salicylate in the renal tubules. This charged form cannot be easily reabsorbed across cell membranes due to its polarity ("ion trapping"). Consequently, the renal excretion of salicylates is significantly increased, and their plasma levels decrease. This mechanism is used therapeutically in salicylate poisoning to enhance elimination.',"       : 1.         (             ). 2.         . 3.                .","Decreased plasma salicylate levels, leading to: 1. Reduced therapeutic efficacy when salicylates are used for therapeutic purposes (e.g., low-dose aspirin for cardiovascular prevention, or high-dose as an anti-inflammatory). 2. Failure to achieve the desired anti-inflammatory or analgesic effect. 3. In salicylate poisoning, this effect is desired, but in a therapeutic context, it is an adverse interaction.","1.     :            . 2.  :             (4-6 )     . 3.  :    (     )    . 4.   :                     . 5.  :                    (    )     (    )    .","1. Avoid combination in chronic therapy: Avoid the regular concurrent use of sodium bicarbonate and salicylates when salicylates are used for therapeutic purposes. 2. Timing separation: If both agents must be used, separate their administration as much as possible (4-6 hours) to minimize the effect on salicylate excretion. 3. Clinical monitoring: Monitor the efficacy of salicylates (e.g., pain or inflammation control) if bicarbonate is used. 4. In poisoning: The combination is used intentionally under medical supervision in a hospital setting to treat salicylate poisoning, with close monitoring of plasma salicylate levels and urine pH. 5. Bicarbonate alternatives: For patients requiring an antacid or alkalinization, consider agents that do not significantly affect urine pH (e.g., aluminum hydroxide, at low doses) or urine acidifying agents (e.g., high-dose vitamin C) if clinically appropriate.");n("Sodium Citrate","Lithium",e.DRUG_DRUG,i.MODERATE,"     ()             .","These agents increase the renal clearance (excretion) of Lithium, primarily through increased diuresis and modification of urinary pH.","             .","Decreased serum Lithium concentration, potentially leading to loss of therapeutic efficacy and symptom relapse.","      (TDM)  .          .","Closely monitor serum Lithium concentration (TDM) and clinical symptoms. A Lithium dose increase may be required to compensate for the reduced concentration.");n("Sodium Fluoride","Calcium Supplements",e.DRUG_DRUG,i.MODERATE," ","Complex formation.","  ","Reduced fluoride absorption.","  ","Separate doses by 2 hours.");n("Sodium Fluoride","Aluminum Antacids",e.DRUG_DRUG,i.MODERATE,"  -","Aluminum-fluoride complex formation.","  ","Reduced fluoride absorption."," ","Avoid combination.");n("Sodium Iodide","Lithium",e.DRUG_DRUG,i.MODERATE,"        .","Lithium and iodide salts increase the risk of hypothyroidism.","     .","Increased risk of hypothyroidism.","   .         .","Avoid combination if possible. Otherwise, administer thyroid hormone if necessary.");n("Sodium Lactate","Lithium",e.DRUG_DRUG,i.MODERATE,"     ()             .","These agents increase the renal clearance (excretion) of Lithium, primarily through increased diuresis and modification of urinary pH.","             .","Decreased serum Lithium concentration, potentially leading to loss of therapeutic efficacy and symptom relapse.","      (TDM)  .          .","Closely monitor serum Lithium concentration (TDM) and clinical symptoms. A Lithium dose increase may be required to compensate for the reduced concentration.");n("Sofosbuvir","Amiodarone",e.DRUG_DRUG,i.HIGH,"     .         P-gp.","Risk of severe bradycardia and cardiac arrest. Mechanism not precisely known, possibly P-gp related.","  .","Cardiac arrest and death."," .          48 .","Contraindicated. Avoid the combination or monitor ECG for 48 hours.");n("Sofosbuvir/Velpatasvir","Food",e.DRUG_FOOD,i.LOW,"     -   ","Minor effect on pharmacokinetics - stable bioavailability","      ","No clinically significant effect on treatment efficacy","    ","Can be taken with or without food");n("Sofosbuvir/Velpatasvir/Voxilaprevir","Rifampin",e.DRUG_DRUG,i.HIGH,"   . Rifampin    P-gp  CYP3A4.","Decreased concentration of all components. Rifampin is a strong inducer of P-gp and CYP3A4.","            C.","Reduced drug plasma concentration, leading to failure of Hepatitis C treatment."," .   .","Contraindicated. Avoid the combination.");n("Somatropin","Glucocorticoids",e.DRUG_DRUG,i.MODERATE," ","Growth inhibition.","   ","Reduced growth hormone efficacy.","    ","Use lowest corticosteroid dose possible.");n("Somatropin","Insulin",e.DRUG_DRUG,i.MODERATE," ","Insulin resistance.","  ","Hyperglycemia.","     ","Insulin dose increase may be necessary.");n("Sonidegib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Sonidegib. Phenytoin    CYP3A4.","Decreased Sonidegib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Sonidegib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Sonidegib. Rifampin    CYP3A4.","Decreased Sonidegib concentration. Rifampin is a strong inducer of CYP3A4.","       .","Reduced drug efficacy and failure of basal cell carcinoma treatment."," .   .","Contraindicated. Avoid the combination.");n("Sorafenib","Warfarin",e.DRUG_DRUG,i.MODERATE,"  ","Increased bleeding risk.","","Bleeding."," INR","Monitor INR.");n("Sotagliflozin","Rifampin",e.DRUG_DRUG,i.HIGH,"  Sotagliflozin. Rifampin    CYP3A4.","Decreased Sotagliflozin concentration. Rifampin is a strong inducer of CYP3A4.","    .","Reduced glycemic efficacy."," .   .","Contraindicated. Avoid the combination.");n("Sotalol",["Gatifloxacin","Moxifloxacin","Sparfloxacin"],e.DRUG_DRUG,i.HIGH,": **     QT**.          (IKr)      QT   .","Mechanism: **Synergistic QT interval prolongation**. Both Sotalol and these quinolones block cardiac potassium channels (IKr), leading to QT interval prolongation on ECG."," : **         (Torsades de pointes)**      .","Clinical Significance: **Increased risk of life-threatening ventricular arrhythmias (Torsades de pointes)**, which may progress to ventricular fibrillation.","  .        QT.    (ECG)  .","Avoid combination. Use alternative antibiotics that do not prolong the QT interval. Monitor ECG if necessary.");n("Sotalol","Furosemide",e.DRUG_DRUG,i.HIGH,"  QT","QT Prolongation. Arrhythmia risk.","    ","    ","  ","  ");n("Sotalol","Hydrochlorothiazide",e.DRUG_DRUG,i.HIGH,"  QT","QT Prolongation. Arrhythmia risk.","    ","    ","  ","  ");n("Sotalol","Spironolactone",e.DRUG_DRUG,i.HIGH,"  QT","QT Prolongation. Arrhythmia risk.","    ","    ","  ","  ");n("Sotalol","Gatifloxacin",e.DRUG_DRUG,i.HIGH,"    QT            ","Additive QT Prolongation. Concurrent use significantly increases the risk of Torsades de Pointes.","         torsades de pointes (      )","         torsades de pointes (      )","    -        ","    -        ");n("Sotalol","Oxifloxacin",e.DRUG_DRUG,i.HIGH,"    QT            ","Additive QT Prolongation. Concurrent use significantly increases the risk of Torsades de Pointes.","         torsades de pointes (      )","         torsades de pointes (      )","    -        ","    -        ");n("Sotalol","Sparfloxacin",e.DRUG_DRUG,i.HIGH,"    QT            ","Additive QT Prolongation. Concurrent use significantly increases the risk of Torsades de Pointes.","         torsades de pointes (      )","         torsades de pointes (      )","    -        ","    -        ");n("Sotalol","Azithromycin",e.DRUG_DRUG,i.HIGH," QT ","Synergistic QT prolongation.","Torsades de Pointes","Torsades de Pointes."," ECG -   QT ","Monitor ECG - avoid in long QT.");n("Sotorasib","Clarithromycin",e.DRUG_DRUG,i.MODERATE,"  Sotorasib. Clarithromycin    CYP3A4      Sotorasib.","Increased Sotorasib concentration. Clarithromycin is a strong CYP3A4 inhibitor, the primary metabolic pathway for Sotorasib.","        .","Increased risk of side effects, especially hepatotoxicity and cardiac risks."," .    CYP3A4      .","Dose monitoring. Strong CYP3A4 inhibitors should be avoided, and if necessary, close monitoring is required.");n("Sotorasib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Sotorasib. Carbamazepine    CYP3A4    Sotorasib.","Decreased Sotorasib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Sotorasib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Sotorasib","Sirolimus",e.DRUG_DRUG,i.HIGH,"  Sirolimus. Sotorasib   CYP3A4    Sirolimus.","Decreased Sirolimus concentration. Sotorasib is a CYP3A4 inducer, a Sirolimus metabolic pathway.","  Sirolimus        .","Reduced Sirolimus concentration, leading to failure of immunosuppression and organ rejection."," .           CYP3A4.   Sirolimus     .","Avoid Combination. Narrow therapeutic index drugs metabolized by CYP3A4 must be avoided. Monitor Sirolimus levels and adjust dose if necessary.");n("Sotorasib","Famotidine",e.DRUG_DRUG,i.HIGH,"  Sotorasib.          Sotorasib.","Decreased Sotorasib concentration. Acid-reducing agents reduce gastric acidity, which is necessary for Sotorasib absorption.","           .","Severe decrease in drug plasma concentration, leading to treatment failure."," .    H2 ( Famotidine)  10    Sotorasib.","Avoid Combination. H2 blockers (like Famotidine) must be avoided within 10 hours of Sotorasib administration.");n("Sotorasib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"    Sotorasib. Itraconazole   CYP3A4    Sotorasib.","Slight increase in Sotorasib concentration. Itraconazole inhibits CYP3A4, a Sotorasib metabolic pathway.","        .","Slight increase in the risk of side effects, especially hepatotoxicity.","  .          .","Side effect monitoring. Dose adjustment is usually not required, but monitoring is necessary.");n("Sotorasib","Omeprazole (PPI)",e.DRUG_DRUG,i.HIGH,"  Sotorasib. Sotorasib     .","Decreased Sotorasib concentration. Sotorasib requires an acidic environment for absorption.","     .","Reduced drug efficacy and failure of cancer treatment."," .   .         Sotorasib.","Contraindicated. Avoid the combination. Avoid strong acid reducers before Sotorasib therapy.");n("Sotorasib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Sotorasib. Ketoconazole    CYP3A4.","Increased Sotorasib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","      .","Increased risk of side effects, especially liver toxicity."," .   .","Close monitoring. Monitor liver function.");n("Sotorasib (Lumakras)","Strong CYP3A4 Inducers (Rifampin)",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   Sotorasib  51%.","Mechanism: **Potent CYP3A4 induction**. Sotorasib concentration decreases by 51%."," : **    **.","Clinical Significance: **Reduced lung cancer treatment efficacy**."," .    .","Avoid combination. Use alternative antibiotic.");n("Sotorasib (Lumakras)","P-glycoprotein Substrates (Digoxin)",e.DRUG_DRUG,i.MODERATE,": **  P-glycoprotein**.   Digoxin.","Mechanism: **P-glycoprotein transporter inhibition**. Increased Digoxin concentration."," : ** **.","Clinical Significance: **Digoxin toxicity**.","  .    30-50%.","Monitor digoxin levels. Reduce dose by 30-50%.");n("Sotorasib (Lumakras)","Hepatotoxic Drugs",e.DRUG_DRUG,i.MODERATE,": **  **. Sotorasib     .","Mechanism: **Synergistic hepatotoxicity**. Sotorasib may cause elevated liver enzymes."," : ** **.","Clinical Significance: **Hepatitis**.","        .","Monitor liver enzymes every 2 weeks during first 3 months.");n("Sparsentan","Rifampin",e.DRUG_DRUG,i.HIGH,"    Sparsentan. Rifampin     CYP3A4    Sparsentan.","Severe decrease in Sparsentan concentration. Rifampin is a strong inducer of CYP3A4, which metabolizes Sparsentan.","          .","Reduced drug efficacy in protecting the kidneys and reducing proteinuria."," .     CYP3A4    Sparsentan.","Avoid Combination. Strong CYP3A4 inducers should be avoided concomitantly with Sparsentan.");n("Sparsentan","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Sparsentan. Cyclosporine   OATP1B3  BCRP    Sparsentan.","Increased Sparsentan concentration. Cyclosporine is an inhibitor of OATP1B3 and BCRP, two Sparsentan efflux transporters.","             .","Significant increase in drug concentration, raising the risk of hepatotoxicity and hypertension."," .     OATP1B3  BCRP .","Avoid Combination. Strong OATP1B3 and BCRP inhibitors must be avoided.");n("Sparsentan","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Sparsentan. Ketoconazole    CYP3A4    Sparsentan.","Increased Sparsentan concentration. Ketoconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Sparsentan.","      .","Increased risk of hepatotoxicity and hypertension."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Sparsentan","Rifampin",e.DRUG_DRUG,i.HIGH,"  Sparsentan. Rifampin    CYP3A4    Sparsentan.","Decreased Sparsentan efficacy. Rifampin is a strong inducer of CYP3A4, a Sparsentan metabolic pathway.","          .","Reduced drug plasma concentration, leading to failure of renal treatment."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Sparsentan","Erythromycin",e.DRUG_DRUG,i.HIGH,"  Sparsentan. Erythromycin    CYP3A4    Sparsentan.","Increased Sparsentan concentration. Erythromycin is a moderate CYP3A4 inhibitor, a Sparsentan metabolic pathway.","      .","Increased risk of hepatotoxicity and hypertension."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inhibitors must be avoided.");n("Sparsentan","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Sparsentan. Itraconazole    CYP3A4    Sparsentan.","Increased Sparsentan concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Sparsentan.","      .","Increased risk of hepatotoxicity and hypertension."," .     CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Spesolimab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Spesolimab      (IL-36 receptor antagonist)   .","Increased risk of viral infection. Spesolimab is a monoclonal antibody (IL-36 receptor antagonist) affecting immunity.","     .","Risk of developing infection from live vaccines."," .       Spesolimab.","Contraindicated. Live vaccines must be avoided during Spesolimab treatment.");n("Spesolimab","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  .              Spesolimab.","Unexpected interaction. No direct pharmacokinetic interaction, but caution due to the immunomodulatory nature of Spesolimab.","      .","Increased risk of infection or exacerbation of dermatological conditions.","  .       .","Side effect monitoring. No contraindication, but monitoring is necessary.");n("Spironolactone","Lisinopril",e.DRUG_DRUG,i.HIGH,"    .     .","Increased risk of hyperkalemia. Both increase potassium levels.","       .","Risk of life-threatening arrhythmia."," .        .","Close monitoring. Potassium levels and renal function must be monitored frequently.");n("Spironolactone","Eplerenone",e.DRUG_DRUG,i.HIGH,"    ","Additive potassium-sparing effect.","  ","Dangerous hyperkalemia."," ","Avoid combination.");n("Spironolactone - ","Potassium Supplements -  ",e.DRUG_DRUG,i.HIGH,"               - (Na-K exchange).        .     (      )                    .                .                .","Spironolactone is a competitive antagonist of aldosterone receptors in the distal renal tubules, effectively inhibiting sodium-potassium exchange (Na-K exchange). This reduces potassium excretion and leads to its retention. When potassium supplements (such as potassium chloride, citrate, or bicarbonate) are added, whether oral or intravenous, a potassium load is introduced into a system already compromised in potassium elimination. This leads to rapid and dangerous accumulation of potassium in the blood, as intake exceeds the kidney`s excretory capacity. The risk is higher in patients with impaired renal function, diabetes, or the elderly.","     (    > 6.0 /)   : 1.     :        . 2.      (ECG):  T     QRS   PR  . 3.       . 4.          7.0 /.","Acute and severe hyperkalemia (blood potassium levels > 6.0 mmol/L), leading to: 1. Serious cardiac arrhythmias: Bradycardia, heart blocks, ventricular fibrillation. 2. Electrocardiogram (ECG) changes: Tall, peaked T-waves, widened QRS complex, prolonged PR interval, sine waves. 3. Muscle weakness, flaccid paralysis, and respiratory difficulty. 4. Cardiac arrest and sudden death, especially when potassium levels exceed 7.0 mmol/L.","1.  :                       . 2.  :       ( 3-7     )      . 3.  :                . 4.   :       (   ). 5. :              ( )           .","1. Complete prohibition: Do not use potassium supplements with Spironolactone except in very rare cases of documented, refractory hypokalemia, and under strict hospital supervision. 2. Frequent monitoring: Regularly monitor serum potassium levels (every 3-7 days initially, then monthly) in all patients taking Spironolactone. 3. Drug education: Warn patients against taking over-the-counter potassium supplements or salt substitutes containing potassium. 4. Dietary modification: Advise patients to avoid high-potassium foods (bananas, oranges, potatoes, tomatoes). 5. Alternatives: If diuresis is needed, consider using potassium-wasting diuretics (like thiazides) instead of Spironolactone if the patient has hypokalemia.");n("Spironolactone - ","Trimethoprim - ",e.DRUG_DRUG,i.HIGH,"           (ENaC)           .                 .                .                         (ACEI)     (ARB)   .","Trimethoprim causes hyperkalemia by inhibiting epithelial sodium channels (ENaC) in the renal collecting tubules, impairing sodium-dependent potassium secretion. Spironolactone inhibits aldosterone receptors in roughly the same anatomical location, compounding the impairment of potassium secretion. This dual and synergistic inhibition of potassium secretory mechanisms leads to a sharp decrease in renal potassium clearance. The interaction is faster and more severe in patients with diabetic nephropathy, renal failure, the elderly, or those concurrently taking ACE inhibitors or angiotensin receptor blockers.","    (  > 5.5 /)       3-7    .  : 1.      (   ). 2.     (ECG):  T    QRS. 3.   . 4.           .         (      )   .","Acute hyperkalemia (potassium levels > 5.5 mmol/L) that can develop within 3-7 days of starting the combination. Risks include: 1. Life-threatening cardiac arrhythmias (bradycardia, ventricular fibrillation). 2. ECG changes: Peaked T-waves, widened QRS complex. 3. Muscle weakness and paralysis. 4. Increased mortality, especially in hospitalized or elderly patients. The risk is higher with high-dose trimethoprim (as in Pneumocystis jirovecii pneumonia treatment) and longer treatment duration.","1.  :      .           (  )     . 2.    :              . 3.  :          3     . 4.   :         > 5.5 /    . 5. :          (  ). 6.  :                 .","1. Avoid combination: Avoid combining Spironolactone and Trimethoprim. Seek alternative antibiotics that do not cause hyperkalemia (e.g., azithromycin, doxycycline) if the patient is taking Spironolactone. 2. If combination is necessary: Temporarily discontinue Spironolactone during Trimethoprim therapy, if the underlying medical condition allows. 3. Intensive monitoring: Monitor serum potassium levels before starting therapy, after 3 days, and then weekly during combination. 4. ECG monitoring: Perform an ECG if potassium levels are > 5.5 mmol/L or if symptoms appear. 5. Education: Alert the patient to report any symptoms of hyperkalemia (weakness, palpitations, dizziness). 6. Immediate treatment: If hyperkalemia occurs, treat with potassium-binding resins, glucose and insulin, or dialysis in severe cases.");n("Spironolactone (Aldactone)","Captopril",e.DRUG_DRUG,i.HIGH,"     .","Additive Hyperkalemia. Concurrent use of potassium-elevating agents.","     (Hyperkalemia)    .","     (Hyperkalemia)    .","      .","      .");n("Spironolactone (Aldactone)","Enalapril",e.DRUG_DRUG,i.HIGH,"     .","Additive Hyperkalemia. Concurrent use of potassium-elevating agents.","     (Hyperkalemia)    .","     (Hyperkalemia)    .","      .","      .");n("Spironolactone (Aldactone)","Lisinopril",e.DRUG_DRUG,i.HIGH,"     .","Additive Hyperkalemia. Concurrent use of potassium-elevating agents.","     (Hyperkalemia)    .","     (Hyperkalemia)    .","      .","      .");n("Spironolactone (Aldactone)","Ramipril",e.DRUG_DRUG,i.HIGH,"     .","Additive Hyperkalemia. Concurrent use of potassium-elevating agents.","     (Hyperkalemia)    .","     (Hyperkalemia)    .","      .","      .");n("Spironolactone (Aldactone)","Perindopril",e.DRUG_DRUG,i.HIGH,"     .","Additive Hyperkalemia. Concurrent use of potassium-elevating agents.","     (Hyperkalemia)    .","     (Hyperkalemia)    .","      .","      .");n("St. Johns Wort -   ","Sertraline - ",e.DRUG_DRUG,i.HIGH,"       (SSRI)          (SRI)        .                       .             ( CYP2B6 CYP2C9 CYP3A4)          .                  .","Sertraline acts as a potent selective serotonin reuptake inhibitor (SSRI), while St. John`s Wort acts as a weak serotonin reuptake inhibitor (SRI) in addition to its effects on other neurotransmitter systems. Their combination leads to synergistic and dual inhibition of serotonin reuptake in central synapses, causing a significant and acute increase in extracellular serotonin levels. Furthermore, St. John`s Wort may temporarily inhibit Sertraline`s metabolic enzymes (e.g., CYP2B6, CYP2C9, CYP3A4), increasing Sertraline plasma concentration and enhancing the serotonergic effect. This dual pharmacodynamic and pharmacokinetic interaction creates a dangerous state of serotonin hyperactivation in the central nervous system.","         : 1.   :      . 2.    :           (>41)   . 3.   :           .                 .","Rapid development of life-threatening serotonin syndrome, with severe symptoms including: 1. Neurological and psychiatric symptoms: Severe agitation, hallucinations, delirium, confusion, coma. 2. Autonomic nervous system symptoms: Tachycardia, hypertension, mydriasis, high fever (>41C), nausea, vomiting, diarrhea. 3. Neuromuscular symptoms: Severe muscle rigidity, tremors, generalized myoclonus, hyperreflexia, opsithotonos. The condition can progress to rhabdomyolysis, acute renal failure, toxic epidermal necrolysis, and cardiac arrest.","1.   :             . 2.   :                      . 3.   :    3                 . 4.  :         .                    . 5.   :               .","1. Complete and absolute prohibition: The combination of St. John`s Wort and Sertraline is strictly forbidden under any circumstances. 2. Mandatory medication review: Screening for the use of all herbal supplements, especially St. John`s Wort, must be conducted for all patients before prescribing Sertraline or any SSRIs. 3. Safe washout period: A minimum of 3 weeks must elapse after discontinuing St. John`s Wort before initiating Sertraline, due to the long half-life of its active components. 4. Emergency management: If interaction is suspected, seek emergency medical care immediately. Hospital treatment requires discontinuation of all serotonergic drugs, organ system support, and symptom control with serotonin antagonists like cyproheptadine. 5. Expanded drug education: Educate patients and caregivers about early signs of serotonin syndrome and document this warning in the medical record.");n("St. Johns Wort -   ","Citalopram - ",e.DRUG_DRUG,i.HIGH,"       (SRI)          (SSRI).             .             .             ( CYP2C19 CYP3A4)        .               .","St. John`s Wort acts as a weak serotonin reuptake inhibitor (SRI), while Citalopram is a potent selective serotonin reuptake inhibitor (SSRI). Their combination leads to dual and synergistic inhibition of serotonin reuptake in central synapses. This significantly increases extracellular serotonin concentration in the central nervous system. Additionally, St. John`s Wort may inhibit some of Citalopram`s metabolic enzymes (e.g., CYP2C19, CYP3A4), increasing Citalopram concentration, thereby enhancing the effect. The degree of this pharmacodynamic and pharmacokinetic interaction is unpredictable due to variability in herbal preparations.","        : 1.    :    . 2.     :          . 3.   :       .                .","Development of serotonin syndrome, a life-threatening condition characterized by: 1. Mental status changes: Agitation, hallucinations, delirium, coma. 2. Autonomic nervous system dysfunction: Tachycardia, hypertension, mydriasis, diarrhea, fever. 3. Neuromuscular symptoms: Tremor, muscle rigidity, myoclonus, hyperreflexia. The condition can rapidly progress to multi-organ failure and death if not recognized and treated.","1.  :              . 2.  :                       . 3.  :         . 4.  :                         . 5.  :             .","1. Complete prohibition: Do not use St. John`s Wort with Citalopram or any other serotonergic drug. 2. Medication review: Actively inquire about the use of herbal supplements, including St. John`s Wort, from all patients starting or taking SSRIs. 3. Gastric lavage: If the combination occurred recently, gastric lavage may be necessary. 4. Supportive care: If syndrome develops, hospital treatment requires discontinuation of all serotonergic drugs, organ support, and use of serotonin antagonists like cyproheptadine in severe cases. 5. Washout period: Wait at least two weeks after discontinuing St. John`s Wort before starting Citalopram.");n("St. Johns Wort -   ","Escitalopram - ",e.DRUG_DRUG,i.HIGH,"          .         : 1.   :    . 2.   :     ( CYP2C19 CYP3A4).              .          .","Escitalopram is the active stereoisomer of Citalopram and a more potent selective serotonin reuptake inhibitor. St. John`s Wort interacts with Escitalopram via the same dual mechanism: 1. Pharmacodynamic effect: Synergistic inhibition of serotonin reuptake. 2. Pharmacokinetic effect: Potential inhibition of Escitalopram metabolism (via CYP2C19 and CYP3A4). This leads to a significant and non-linear increase in serotonin activity in the central nervous system. The risk is greater with Escitalopram due to its higher serotonergic selectivity and potency.","     .                   .   :   38.5             .              .","High risk of developing severe serotonin syndrome. Symptoms are similar to those described with Citalopram but may appear faster and be more severe due to Escitalopram`s higher potency. Critical signs include: fever above 38.5C, severe muscle rigidity, generalized myoclonus, and instability in blood pressure and heart rate. Death can occur from autonomic nervous system collapse, acidosis, or rhabdomyolysis.","1.   :          . 2.  :                 . 3.  :          . 4.  :          . 5.   :   3                 .","1. Complete and absolute prohibition: Combining St. John`s Wort and Escitalopram is forbidden under any circumstances. 2. Strict education: Inform patients taking Escitalopram to avoid all St. John`s Wort products, including teas, capsules, and extracts. 3. Emergency monitoring: If an interaction is suspected, seek emergency medical care immediately. 4. Hospital management: Treatment of serotonin syndrome requires intensive care, cooling, benzodiazepines for seizures, and cyproheptadine. 5. Longer safety period: Wait at least 3 weeks after discontinuing St. John`s Wort before starting Escitalopram due to the long half-life of its active components.");n("St. Johns Wort -   ","Digoxin / Theophylline / Warfarin -  /  / ",e.DRUG_DRUG,i.HIGH,"      (hypericin)  (hyperforin)        P450 ( CYP3A4      )  P-glycoprotein (    ).    : 1.    ( CYP1A2 CYP3A4). 2.    ( P-gp   ). 3.    ( CYP2C9 CYP3A4).         (AUC)    25-70.","St. John`s Wort contains hypericin and hyperforin, which are potent and broad inducers of cytochrome P450 enzymes (especially CYP3A4, responsible for metabolizing Theophylline and partially Digoxin) and the P-glycoprotein transporter (responsible for the excretion of Digoxin and Warfarin). This induction leads to: 1. Increased metabolism of Theophylline (via CYP1A2 and CYP3A4). 2. Increased excretion of Digoxin (via P-gp in the intestine and kidneys). 3. Increased metabolism of Warfarin (via CYP2C9 and CYP3A4). This reduces the bioavailability and area under the curve (AUC) of these drugs by 25-70%.","      : 1. :         . 2. :       . 3. :  INR        .    3-7        .","Serious therapeutic failure in critical chronic conditions: 1. For Digoxin: Return of heart failure or arrhythmia symptoms. 2. For Theophylline: Worsening of asthma or COPD. 3. For Warfarin: Decreased INR and increased risk of thrombosis, stroke, or pulmonary embolism. The effect begins within 3-7 days of starting the herb and persists for weeks after discontinuation.","1.  :          . 2.  :            ( )  INR ()    . 3.  :                 . 4.   :           2-4   . 5.  :                 .","1. Complete prohibition: Do not use St. John`s Wort with Digoxin, Theophylline, or Warfarin. 2. Therapeutic monitoring: For patients starting the herb while taking these drugs, monitor drug levels (Digoxin, Theophylline) or INR (for Warfarin) weekly during the first month. 3. Dose adjustment: When starting the herb, significant dose increases of these drugs may be needed, but avoiding the combination is preferred. 4. Post-discontinuation monitoring: When discontinuing the herb, gradually reduce the doses of these drugs over 2-4 weeks to avoid toxicity. 5. Mandatory education: Warn all patients taking these narrow therapeutic index drugs about the risks of using St. John`s Wort.");n("St. Johns Wort -   ","Fluoxetine - ",e.DRUG_DRUG,i.HIGH,"                        ","St. Johns Wort increases serotonergic activity through multiple mechanisms, and combination with Fluoxetine leads to a synergistic effect that significantly increases the risk of serotonin syndrome","  (          )","Serotonin syndrome (hyperthermia, diaphoresis, muscle rigidity, tremor, mental confusion, and autonomic instability)","    -             ","Avoid combination entirely - discontinue St. Johns Wort at least two weeks before starting Fluoxetine");n("St. Johns Wort -   ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"                  ","St. Johns Wort increases serotonergic activity, and combination with Paroxetine leads to a synergistic effect that increases the risk of serotonin syndrome","  (          )","Serotonin syndrome (hyperthermia, diaphoresis, muscle rigidity, tremor, mental confusion, and autonomic instability)","    -         ","Avoid combination entirely - discontinue St. Johns Wort sufficiently before starting Paroxetine");n("Statins","Liver Disease / Hepatic Impairment",e.DRUG_DISEASE,i.HIGH,"      -   ","Hepatotoxicity & Metabolic Impairment. Worsening liver function.","     ","Worsening hepatic failure or encephalopathy.","   Child-Pugh -   ","Adjust dose based on Child-Pugh - monitor liver function.");n("Stiripentol","Clobazam",e.DRUG_DRUG,i.HIGH,"  Clobazam   (N-desmethylclobazam). Stiripentol   CYP2C19.","Increased concentration of Clobazam and its active metabolite (N-desmethylclobazam). Stiripentol inhibits CYP2C19.","     .","Increased risk of sedation and neurological side effects."," .    Clobazam     .","Dose adjustment. Clobazam dose must be reduced and drug levels monitored.");n("Strontium Ranelate","Tetracyclines",e.DRUG_DRUG,i.MODERATE," ","Complex formation.","   ","Reduced absorption of both drugs."," ","Separate by 2 hours.");n("Strontium Ranelate","Quinolones",e.DRUG_DRUG,i.MODERATE," ","Complex formation.","  ","Reduced quinolone absorption."," ","Separate by 2 hours.");n("Succinylcholine","Gentamicin",e.DRUG_DRUG,i.MODERATE,"  .","Neuromuscular Blockade. Potentiation of muscle relaxation."," ."," ."," ."," .");n("Succinylcholine","Amikacin",e.DRUG_DRUG,i.MODERATE,"  .","Neuromuscular Blockade. Potentiation of muscle relaxation."," ."," ."," ."," .");n("Succinylcholine","Tobramycin",e.DRUG_DRUG,i.MODERATE,"  .","Neuromuscular Blockade. Potentiation of muscle relaxation."," ."," ."," ."," .");n("Succinylcholine","Neomycin",e.DRUG_DRUG,i.MODERATE,"  .","Neuromuscular Blockade. Potentiation of muscle relaxation."," ."," ."," ."," .");n("Sufentanil SL","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Sufentanil. Ketoconazole    CYP3A4    Sufentanil.","Increased Sufentanil concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Sufentanil metabolic pathway.","      .","Increased risk of severe respiratory depression and death."," .   .","Contraindicated. Avoid the combination.");n("Sulfamethoxazole","Phenytoin",e.DRUG_DRUG,i.MODERATE,"    +  ","Phenytoin displacement from protein + metabolic inhibition.","  -  ","Phenytoin toxicity - ataxia, nystagmus.","  ","Monitor phenytoin levels.");n("Sulfamethoxazole/Trimethoprim","Warfarin",e.DRUG_DRUG,i.HIGH,"  Warfarin  .  CYP2C9    Warfarin.","Increased anticoagulant effect of Warfarin. Inhibition of CYP2C9, a Warfarin metabolic pathway.","   .","Increased risk of severe hemorrhage.","  .    Warfarin  INR  .","Dose adjustment and monitoring. Warfarin dose must be reduced and INR monitored frequently.");n("Sulfamethoxazole/Trimethoprim","Methotrexate",e.DRUG_DRUG,i.HIGH,"  Methotrexate.        ( ).","Increased Methotrexate concentration. Displacement from protein binding and decreased renal clearance (additive toxicity).","    (  ).","Increased risk of hematological toxicity (myelosuppression)."," .         .","Contraindicated. Avoid the combination or closely monitor blood counts.");n("Sulfamethoxazole/Trimethoprim","Warfarin",e.DRUG_DRUG,i.HIGH,"       K","Inhibition of Warfarin metabolism and Vitamin K-producing flora.","     ","Significantly increased Warfarin effect, bleeding."," INR     ","Monitor INR frequently, reduce Warfarin dose.");n("Sulfapyrazone","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE," ","Binding Agent. Forms complexes with the drug.","  ","  ","     ","     ");n("Sulfasalazine","Warfarin",e.DRUG_DRUG,i.MODERATE,"  Warfarin  . Sulfasalazine   CYP2C9    Warfarin.","Increased anticoagulant effect of Warfarin. Sulfasalazine is a CYP2C9 inhibitor, a Warfarin metabolic pathway.","  .","Increased risk of hemorrhage."," .   INR     Warfarin.","Close monitoring. INR must be monitored frequently and Warfarin dose adjusted.");n("Sulfasalazine","Digoxin",e.DRUG_DRUG,i.MODERATE," ","Unknown. Mechanism not established.","   ","   ","    ","    ");n("Sulfasalazine","Methotrexate",e.DRUG_DRUG,i.MODERATE,"    ","Mutual inhibition of renal tubular secretion.","    ","Increased levels and toxicity of both drugs.","     ","Monitor liver/kidney function, blood counts.");n("Sulfasalazine","Digoxin",e.DRUG_DRUG,i.MODERATE,"  ","Reduced digoxin absorption.","  ","Reduced digoxin efficacy.","  ","Monitor digoxin levels.");n("Sulfasalazine","Folic Acid",e.DRUG_DRUG,i.MODERATE,"   ","Folate absorption inhibition.","  ","Folate deficiency.","   ","Give folic acid supplements.");n("Sulindac","Lithium",e.DRUG_DRUG,i.MODERATE,"                 .","NSAIDs decrease the renal clearance of Lithium, leading to increased serum levels.","       .","Increased serum Lithium concentration and elevated risk of toxicity.","            .     .","Monitor Lithium levels closely, adjust Lithium dose if necessary. Avoid concurrent use if possible.");n("Sunitinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Sunitinib. Rifampin    CYP3A4    Sunitinib.","Decreased Sunitinib efficacy. Rifampin is a strong inducer of CYP3A4, a Sunitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Sunitinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Sunitinib.      CYP3A4  .","Increased Sunitinib concentration. Grapefruit juice is an inhibitor of intestinal CYP3A4.","      .","Increased risk of side effects, especially cardiotoxicity."," .     .","Avoid Consumption. Grapefruit juice must be avoided.");n("Sunitinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Sunitinib.      CYP3A4.","Increased Sunitinib concentration. Grapefruit juice is a CYP3A4 inhibitor.","    (     ).","Increased risk of side effects (e.g., hypertension and hematological toxicity)."," .     .","Contraindicated. Avoid consuming grapefruit and its juice.");n("Sunitinib","Food",e.DRUG_FOOD,i.LOW,"     ","No significant effect on pharmacokinetics.","    ","No clinical interaction.","     ","Can be taken with or without food.");n("Sunitinib","Ketoconazole",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased sunitinib toxicity.","  ","Reduce sunitinib dose.");n("Sutimlimab (C1s Inhibitor)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"     . Sutimlimab     .","No clinically significant interaction expected. Sutimlimab is a monoclonal antibody.","   .","No known effect.","    .","No special action required.");n("Suvorexant","CNS Depressants",e.DRUG_DRUG,i.HIGH,"      ","Additive CNS Depression. Synergistic sedation.","   ","Respiratory depression, severe somnolence.","     ","Avoid alcohol, reduce other sedative doses.");n("Suzetrigine","Probenecid",e.DRUG_DRUG,i.MODERATE,"    Suzetrigine. Probenecid     (Renal Tubular Secretion)      Suzetrigine.","Reduced renal clearance of Suzetrigine. Probenecid inhibits renal tubular secretion, a key elimination pathway for Suzetrigine.","                   .","Slight to moderate increase in blood drug concentration, potentially increasing the risk of CNS-related side effects."," .              .","Monitor and follow up. Patient should be closely monitored for any neurological side effects, and dose adjusted if necessary.");n("Tacrolimus","Food (High-Fat)",e.DRUG_FOOD,i.HIGH,"          : (1)              (2)        (3)       .        (Cmax  27%)    (AUC  35%)          .","High-fat food leads to several negative effects on tacrolimus absorption: (1) significantly delays gastric emptying, prolonging drug exposure to acidic environment, (2) reduces drug solubility in intestinal fluid, (3) may increase intestinal first-pass metabolism. The result is sharp decrease in maximum concentration (Cmax by 27%) and area under curve (AUC by 35%), meaning substantially less drug reaches bloodstream.","                  .             (   )          .","Dangerous decrease in tacrolimus blood levels may result in subtherapeutic levels inadequate for preventing transplant rejection. This significantly increases risk of acute or chronic graft rejection (kidney, liver, heart, etc.), potentially threatening transplant success and requiring urgent therapeutic interventions.","      :           .         (          )       .          .","Tacrolimus must be taken on a completely empty stomach: at least one hour before or two hours after meals. It is critically important to maintain the same timing and conditions daily (e.g., always in morning before breakfast and evening two hours before dinner) to ensure stable and predictable blood levels. Regular therapeutic drug monitoring and dose adjustment as needed are essential.");n("Tacrolimus","Grapefruit Juice",e.DRUG_FOOD,i.HIGH," CYP3A4","CYP3A4 inhibition."," ","Tacrolimus toxicity.","   ","Avoid grapefruit juice.");n("Tacrolimus ","Nifedipine - ",e.DRUG_DRUG,i.MODERATE,"       CYP3A4          .","Nifedipine is a moderate inhibitor of the hepatic metabolic enzyme CYP3A4, leading to a slight to moderate decrease in Tacrolimus clearance.","           (  ). (  )","Increased Tacrolimus blood concentrations, raising the risk of Tacrolimus toxicity (nephrotoxicity and neurotoxicity). (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","     .      .","Monitor Tacrolimus concentrations and signs/symptoms of toxicity. Reduce the Tacrolimus dose if necessary.");n("Tacrolimus - ","Fluconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4 (    ).       .","Fluconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4 (the main pathway for Tacrolimus breakdown). This inhibition prevents Tacrolimus clearance from the body.","                (Nephrotoxicity)    (Neurotoxicity). (  )","Significant and dangerous increase in Tacrolimus blood concentrations, leading to heightened toxicity, particularly Nephrotoxicity and Neurotoxicity. (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","       .       ( 50-75%)        .","Monitor Tacrolimus concentrations closely. The Tacrolimus dose must be significantly reduced (often 50-75%) when starting Azole antifungals, and adjusted upon discontinuation.");n("Tacrolimus - ","Itraconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4          .","Itraconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Tacrolimus breakdown and dangerously increases its blood levels.","                  . (  )","Significant and dangerous increase in Tacrolimus blood concentrations, leading to heightened toxicity, particularly Nephrotoxicity and Neurotoxicity. (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","       .            .","Monitor Tacrolimus concentrations closely. The Tacrolimus dose must be significantly reduced when starting Itraconazole, and adjusted upon discontinuation.");n("Tacrolimus - ","Ketoconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4          .","Ketoconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Tacrolimus breakdown and dangerously increases its blood levels.","                  . (  )","Significant and dangerous increase in Tacrolimus blood concentrations, leading to heightened toxicity, particularly Nephrotoxicity and Neurotoxicity. (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","       .            .","Monitor Tacrolimus concentrations closely. The Tacrolimus dose must be significantly reduced when starting Ketoconazole, and adjusted upon discontinuation.");n("Tacrolimus - ","Voriconazole - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4          .","Voriconazole is a strong inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Tacrolimus breakdown and dangerously increases its blood levels.","                  . (  )","Significant and dangerous increase in Tacrolimus blood concentrations, leading to heightened toxicity, particularly Nephrotoxicity and Neurotoxicity. (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","       .            .","Monitor Tacrolimus concentrations closely. The Tacrolimus dose must be significantly reduced when starting Voriconazole, and adjusted upon discontinuation.");n("Tacrolimus - ","Caspofungin - ",e.DRUG_DRUG,i.MODERATE,"       (         ).","Caspofungin increases the clearance of Tacrolimus from the body (the exact mechanism is unclear, possibly via non-enzymatic pathways).","              . (  )","Decreased Tacrolimus blood concentrations, increasing the risk of organ rejection due to reduced Tacrolimus efficacy. (Decreased Tacrolimus efficacy)","   .          .","Monitor Tacrolimus concentrations closely. It is recommended to increase the Tacrolimus dose when starting Caspofungin, and adjust it upon discontinuation.");n("Tacrolimus - ","Erythromycin - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4    .","Erythromycin is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Tacrolimus breakdown.","           (  ). (  )","Increased Tacrolimus blood concentrations, raising the risk of Tacrolimus toxicity (nephrotoxicity and neurotoxicity). (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","     .    ( )  ( / )   .         CYP3A4.","Monitor Tacrolimus concentrations and signs/symptoms of toxicity. Adjust the Tacrolimus dose (usually reduction) upon starting or stopping the antibiotic. Use an alternative non-CYP3A4-interacting antibiotic if possible.");n("Tacrolimus - ","Clarithromycin - ",e.DRUG_DRUG,i.HIGH,"       CYP3A4    .","Clarithromycin is a potent inhibitor of the hepatic metabolic enzyme CYP3A4, which prevents Tacrolimus breakdown.","           (  ). (  )","Increased Tacrolimus blood concentrations, raising the risk of Tacrolimus toxicity (nephrotoxicity and neurotoxicity). (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","     .    ( )  ( / )   .         CYP3A4.","Monitor Tacrolimus concentrations and signs/symptoms of toxicity. Adjust the Tacrolimus dose (usually reduction) upon starting or stopping the antibiotic. Use an alternative non-CYP3A4-interacting antibiotic if possible.");n("Tacrolimus - ","Azithromycin - ",e.DRUG_DRUG,i.HIGH,"        CYP3A4           .","Although Azithromycin is considered a weaker inhibitor of CYP3A4 compared to Erythromycin and Clarithromycin, it may still cause an increase in Tacrolimus levels.","           (  ). (  )","Increased Tacrolimus blood concentrations, raising the risk of Tacrolimus toxicity (nephrotoxicity and neurotoxicity). (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","     .     ( / )   .         CYP3A4.","Monitor Tacrolimus concentrations and signs/symptoms of toxicity. Adjust the Tacrolimus dose upon starting or stopping the antibiotic. Use an alternative non-CYP3A4-interacting antibiotic if possible.");n("Tacrolimus - ","Rifamycins -  ( )",e.DRUG_DRUG,i.MODERATE," ( )       CYP3A4       .","Rifamycins (e.g., Rifampin) are potent inducers of the hepatic metabolic enzyme CYP3A4, which drastically accelerates Tacrolimus breakdown.","             . (  )","Sharp decrease in Tacrolimus blood concentrations, greatly increasing the risk of organ rejection. (Decreased Tacrolimus efficacy)","      .    (   3-5 )  ( / )  .","Monitor Tacrolimus concentrations and signs/symptoms of rejection. Adjust the Tacrolimus dose (often a 3-5 fold increase) upon starting or stopping Rifamycin therapy.");n("Tacrolimus - ","Diltiazem - ",e.DRUG_DRUG,i.HIGH,"         CYP3A4     .","Diltiazem is a moderate to strong inhibitor of the hepatic metabolic enzyme CYP3A4, which reduces Tacrolimus clearance.","           (  ). (  )","Increased Tacrolimus blood concentrations, raising the risk of Tacrolimus toxicity (nephrotoxicity and neurotoxicity). (Tacrolimus Toxicity. Nephro/Neurotoxicity.)","     .     (  25-50%)   .","Monitor Tacrolimus concentrations and signs/symptoms of toxicity. Reduce the Tacrolimus dose (often 25-50% reduction) if necessary upon starting Diltiazem.");n("Tacrolimus - ","Hydantoins -  ( )",e.DRUG_DRUG,i.MODERATE," ( )       CYP3A4     .       .","Hydantoins (e.g., Phenytoin) are potent inducers of the hepatic metabolic enzyme CYP3A4, accelerating Tacrolimus breakdown. Tacrolimus may also affect Phenytoin levels.","   (  )    (  ). (     )","Decreased Tacrolimus efficacy (due to lowered levels), and increased Phenytoin toxicity (due to elevated levels). (Decreased Tacrolimus efficacy and increased Phenytoin toxicity)","    .         (      ).","Monitor Tacrolimus and Phenytoin concentrations regularly. Adjust the dose of one or both drugs as directed (usually increase Tacrolimus dose and decrease Phenytoin dose).");n("Tacrolimus - ","Mycophenolate Mofetil -  ",e.DRUG_DRUG,i.MODERATE,"   .         (MPA)   .         .","The interaction is complex and multi-mechanistic. Tacrolimus reduces the enterohepatic recirculation of Mycophenolic Acid (MPA), lowering its levels. Mycophenolate does not significantly affect Tacrolimus concentrations.","    (  MPA      Tacrolimus). (   )","Change in drug efficacy (decreased MPA levels and potentially a slight increase in Tacrolimus level). (Change in drug efficacy)","                 .","Monitor the patient for signs of drug interaction, monitor both Mycophenolic Acid and Tacrolimus concentrations, and adjust the dose to ensure optimal immunosuppression while avoiding toxicity.");n("Tacrolimus (topical)","UV Light",e.DRUG_DRUG,i.MODERATE,"   ","Increased skin cancer risk."," ","Skin malignancies.","  ","Avoid sun exposure.");n("Tafamidis","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tafamidis. Rifampin     P-glycoprotein (P-gp)      Tafamidis.","Decreased Tafamidis efficacy. Rifampin is a potent inducer of P-glycoprotein (P-gp), a key efflux pathway for Tafamidis.","             (Transthyretin)  .","Reduced drug plasma levels, leading to loss of transthyretin stabilization effect and treatment failure."," .   Rifampin      P-gp.","Avoid Combination. Rifampin must be replaced with an antibiotic that does not induce P-gp.");n("Tafamidis - ","Gemfibrozil - ",e.DRUG_DRUG,i.MODERATE,"   UGT1A9 UGT1A8                ","Gemfibrozil inhibits hepatic UGT1A9 and UGT1A8 enzymes responsible for Tafamidis metabolism via glucuronidation, reducing its clearance and prolonging its half-life","      40-60             ","40-60% increase in Tafamidis plasma concentration, potentially increasing incidence of gastrointestinal side effects such as diarrhea, abdominal pain, and nausea","     -        25-30 -     ","Monitor for gastrointestinal side effects - if necessary, reduce Tafamidis dose by 25-30% - continue regular clinical monitoring");n("Talazoparib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Talazoparib. Itraconazole    CYP3A4    Talazoparib.","Increased Talazoparib concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Talazoparib.","       .","Increased risk of severe hematological toxicity, especially anemia."," .    Talazoparib     CYP3A4 .","Dose adjustment. Talazoparib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Talazoparib","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Talazoparib. Carbamazepine    CYP3A4    Talazoparib.","Decreased Talazoparib efficacy. Carbamazepine is a strong inducer of CYP3A4, a Talazoparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Talazoparib","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Talazoparib. Clarithromycin    CYP3A4    Talazoparib.","Increased Talazoparib concentration. Clarithromycin is a strong CYP3A4 inhibitor, a metabolic pathway for Talazoparib.","       .","Increased risk of severe hematological toxicity, especially anemia."," .    Talazoparib     CYP3A4 .","Dose adjustment. Talazoparib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Talazoparib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Talazoparib. Rifampin    CYP3A4    Talazoparib.","Decreased Talazoparib efficacy. Rifampin is a strong inducer of CYP3A4, a Talazoparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Talazoparib","Voriconazole",e.DRUG_DRUG,i.HIGH,"  Talazoparib. Voriconazole    CYP3A4    Talazoparib.","Increased Talazoparib concentration. Voriconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Talazoparib.","       .","Increased risk of severe hematological toxicity, especially anemia."," .    Talazoparib     CYP3A4 .","Dose adjustment. Talazoparib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Talazoparib","Efavirenz",e.DRUG_DRUG,i.HIGH,"  Talazoparib. Efavirenz    CYP3A4    Talazoparib.","Decreased Talazoparib efficacy. Efavirenz is a moderate inducer of CYP3A4, a Talazoparib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4   .","Avoid Combination. Moderate or strong CYP3A4 inducers must be avoided.");n("Talazoparib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Talazoparib. Cyclosporine   P-gp    Talazoparib.","Increased Talazoparib concentration. Cyclosporine inhibits P-gp, a Talazoparib efflux transporter.","       .","Increased risk of severe hematological toxicity, especially anemia."," .         .","Dose adjustment. Blood counts must be monitored and dose adjusted if necessary.");n("Talazoparib","Cyclosporine",e.DRUG_DRUG,i.MODERATE,"  Talazoparib. Cyclosporine   P-gp    Talazoparib.","Increased Talazoparib concentration. Cyclosporine inhibits P-gp, a Talazoparib efflux transporter.","     (   ).","Increased risk of myelosuppression (neutropenia, anemia)."," .    Talazoparib     P-gp .","Dose adjustment. Talazoparib dose must be reduced when co-administered with strong P-gp inhibitors.");n("Talquetamab (Talvey)","Immunosuppressants (Tacrolimus)",e.DRUG_DRUG,i.HIGH,": **  **.     .","Mechanism: **Excessive immunosuppression**. Synergistic immune suppression effect."," : **  **  .","Clinical Significance: **Severe life-threatening opportunistic infections**.","   .   .","Avoid combination if possible. Close monitoring for infections.");n("Tamoxifen","Warfarin",e.DRUG_DRUG,i.HIGH,"  ","Increased warfarin effect."," INR  ","Increased INR and bleeding risk."," INR ","Close INR monitoring.");n("Tamoxifen","Paroxetine",e.DRUG_DRUG,i.HIGH," CYP2D6 -     ","CYP2D6 inhibition prevents tamoxifen activation.","  ","Hormonal therapy failure."," SSRI  ()","Use alternative SSRI (venlafaxine).");n("Tamoxifen - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"    CYP2D6               ","Paroxetine is a potent inhibitor of hepatic CYP2D6 enzyme essential for converting Tamoxifen to its active metabolite Endoxifen, significantly reducing therapeutic efficacy","       60-75          ","Reduction in active Endoxifen concentration by up to 60-75%, increasing risk of breast cancer recurrence and hormonal treatment failure","   -       CYP2D6      ","Avoid combination entirely - choose antidepressant alternatives that do not inhibit CYP2D6 such as sertraline, escitalopram, venlafaxine, or mirtazapine");n("Tamsulosin","Ketoconazole",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased tamsulosin levels.","    ","Avoid or reduce dose.");n("Tapentadol","Venlafaxine (SNRI)",e.DRUG_DRUG,i.HIGH,"   .    .","Increased risk of Serotonin Syndrome. Synergistic effects of increased serotonin.","      .","Mental status changes, hyperthermia, tremor."," .   .","Contraindicated. Avoid the combination.");n("Tazarotene","Photosensitizing Agents",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic photosensitivity.","  ","Severe sunburn.","  ","Use sunscreen.");n("Tazemetostat","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Tazemetostat. Carbamazepine    CYP3A4      Tazemetostat.","Decreased Tazemetostat efficacy. Carbamazepine is a strong inducer of CYP3A4, the primary metabolic pathway for Tazemetostat.","            .","Severe decrease in drug plasma concentration, leading to cancer treatment failure."," .   Carbamazepine     CYP3A4.","Avoid Combination. Carbamazepine must be replaced with an anticonvulsant that does not induce CYP3A4.");n("Tebentafusp","Corticosteroids (High Dose)",e.DRUG_DRUG,i.HIGH,"  Tebentafusp.       (T-cells)    Tebentafusp.","Reduced Tebentafusp efficacy. Corticosteroids decrease T-cell activity, on which Tebentafusp relies.","    (Anti-tumor effect)  Tebentafusp    .","Risk of losing the anti-tumor effect due to Tebentafusp failing to activate immune cells."," .          .","Avoid Combination. Systemic corticosteroids should be avoided except when absolutely necessary to manage adverse reactions.");n("Tebentafusp (gp100-targeting)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"     . Tebentafusp    (Fusion Protein).","No clinically significant interaction expected. Tebentafusp is a fusion protein.","   .   .","No known effect. They are used safely together.","    .","No special action required.");n("Tebipenem Pivoxil","Probenecid",e.DRUG_DRUG,i.MODERATE,"  Tebipenem. Probenecid    .","Increased Tebipenem concentration. Probenecid inhibits renal tubular transport.","       .","Increased antibiotic efficacy, but increased risk of toxicity."," .       Tebipenem.","Close monitoring. Tebipenem dose may need to be reduced.");n("Tecartus (CAR T-cell)","High-dose Corticosteroids",e.DRUG_DRUG,i.HIGH,"  Tecartus.     (T-cells).","Decreased Tecartus efficacy. Corticosteroids kill T-cells.","  .","Failure of immunotherapy."," .      (   CRS  ICANS).","Avoid combination. High-dose corticosteroids must be avoided (except for treating Cytokine Release Syndrome - CRS or ICANS).");n("Teclistamab","Tofacitinib",e.DRUG_DRUG,i.HIGH,"  . Teclistamab          Tofacitinib .","Exacerbated Immunosuppression. Teclistamab increases inflammatory cytokines, which may transiently increase Tofacitinib levels.","          (CRS)  .","Increased risk of serious infections, including Cytokine Release Syndrome (CRS) and opportunistic infections.","  ( ).     Tofacitinib    Teclistamab  .","Contraindicated (usually temporary). Tofacitinib should be discontinued before initiating Teclistamab, and neutrophil counts monitored.");n("Teclistamab (Bispecific Antibody)","Live Vaccines",e.DRUG_DRUG,i.MODERATE,"  . Teclistamab    .","Increased risk of infection. Teclistamab affects immune cells.","     .","Increased risk of developing the disease from the vaccine.","  .    .","Relative contraindication. Avoid live vaccines.");n("Teclistamab (Tecvayli)","Live Vaccines",e.DRUG_VACCINE,i.HIGH,": **  **.     .","Mechanism: **Severe immunosuppression**. Causes T-cell and B-cell depletion."," : ** **    .","Clinical Significance: **Immunological failure** and disseminated vaccine disease risk.","   .      .","Contraindicated for live vaccines. Vaccinate at least 1 month before therapy.");n("Teclistamab (Tecvayli)","CYP450 Substrates (Warfarin)",e.DRUG_DRUG,i.MODERATE,": **   **.    .","Mechanism: **Cytochrome enzyme activity modulation**. May alter drug metabolism."," : **  INR**    .","Clinical Significance: **INR fluctuations** and bleeding/clotting risk."," INR  .   Warfarin  .","Monitor INR frequently. Adjust Warfarin dose as needed.");n("Tecovirimat","Midazolam",e.DRUG_DRUG,i.MODERATE,"  Midazolam. Tecovirimat     CYP3A4    Midazolam.","Decreased Midazolam concentration. Tecovirimat is a moderate inducer of CYP3A4, responsible for Midazolam metabolism.","  Midazolam ()          .","Reduced efficacy of Midazolam (sedative), potentially leading to failure of sedation or seizure control."," .      Midazolam       CYP3A4.","Dose monitoring. Consider increasing Midazolam dose or using an alternative not metabolized by CYP3A4.");n("Telaprevir - ","Ethinyl Estradiol -  ",e.DRUG_DRUG,i.MODERATE,"                 .        P450  CYP3A4      P-glycoprotein (P-gp).       .       ()            (AUC)    30-40.            12        .","Telaprevir, a protease inhibitor for hepatitis C treatment, significantly reduces the plasma concentration of ethinyl estradiol. The primary mechanism is potent induction of cytochrome P450 enzymes, especially CYP3A4, as well as induction of drug transporters like P-glycoprotein (P-gp). Ethinyl estradiol is a substrate for these enzymes and transporters. This induction increases the metabolism (breakdown) and excretion of ethinyl estradiol, reducing its bioavailability and area under the curve (AUC) by up to 30-40%. This interaction is clinically significant as telaprevir is typically used for 12 weeks, a period sufficient for unintended pregnancy to occur.","            : 1.     . 2.    (   )        . 3.               (      ).                (20 ).","Reduced efficacy of combined oral contraceptives containing ethinyl estradiol, leading to: 1. Increased risk of unintended pregnancy. 2. Occurrence of breakthrough bleeding (bleeding between menstrual periods) as a sign of inadequate hormonal support for the endometrium. 3. Return of pre-treatment symptoms if the pill is used for therapeutic purposes (e.g., acne, polycystic ovary syndrome). The risk is higher in patients taking low-dose estrogen pills (20 mcg).","1.      :     (  )             . 2.    :             . 3.     :                    . 4.  :                    . 5. :              .","1. Use of non-hormonal contraception: Barrier methods (condoms, diaphragm) or copper IUD are recommended throughout telaprevir treatment and for at least two weeks after its discontinuation. 2. Additional contraception: If oral contraceptives are continued, an additional barrier method should be used as a precaution. 3. Avoid reliance on high doses: Increasing the ethinyl estradiol dose is not recommended as it does not reliably compensate for the interaction and may increase the risk of thrombotic side effects. 4. Telaprevir alternatives: Discuss with the physician the possibility of using an alternative hepatitis C treatment regimen that does not include telaprevir, especially for women of childbearing potential. 5. Education: Educate the patient about the high risk of contraceptive failure and document this conversation in the medical record.");n("Telaprevir - ","Rifamycins - ",e.DRUG_DRUG,i.HIGH,"  ( )      P450 ( CYP3A4)   ( P-glycoprotein).      .                   (AUC)     90   70 .                  .          .","Rifamycins (rifampin, rifabutin) act as potent and broad inducers of cytochrome P450 enzymes (especially CYP3A4) and drug transporters (like P-glycoprotein). Telaprevir is a primary substrate for these systems. The induction leads to a significant increase in the metabolism and excretion of telaprevir, reducing its plasma concentration and area under the curve (AUC) by a massive 90% for rifampin and 70% for rifabutin. This drastically lowers telaprevir levels far below the therapeutic range necessary for hepatitis C virus suppression. The interaction is rapid, beginning within a few days of starting the rifamycin.","           : 1.      (SVR). 2.       . 3.              . 4.    . 5.        .","Complete therapeutic failure in hepatitis C treatment, leading to: 1. Failure to achieve sustained virological response (SVR). 2. Persistence of high viral load and progression of liver damage. 3. Increased risk of the virus developing resistance to telaprevir and other therapies, limiting future treatment options. 4. Waste of treatment and its high costs. 5. Continued risk of viral transmission to others if the infection persists.","1.   :       .               . 2.  :               ()   (). 3.      :     50 (  300   150  )         (2250   )    . 4.  :           4-6        . 5.  :          . 6.   :         (    )    .","1. Absolute avoidance of combination: The combination of telaprevir and rifampin is absolutely contraindicated. Combination with rifabutin is also contraindicated, but if unavoidable, strict measures apply. 2. Rifamycin alternatives: For bacterial infections, use alternative antibiotics that do not induce enzymes, such as third-generation cephalosporins (ceftriaxone) or macrolides (azithromycin). 3. If combination with rifabutin is necessary: Reduce the rifabutin dose by 50% (e.g., from 300 mg to 150 mg daily) and increase the telaprevir dose to the maximum allowed (2250 mg twice daily), with close virological monitoring. 4. Intensive monitoring: Perform hepatitis C viral load tests weekly during the first 4-6 weeks of combination therapy for early detection of failure. 5. Dosing timing: No useful time separation can avoid this potent systemic interaction. 6. Monitoring for adverse effects: Increasing the telaprevir dose raises the risk of its side effects (rash, pruritus, anemia), requiring close monitoring.");n("Telaprevir ()","Fluconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","     .","     .");n("Telaprevir ()","Itraconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","     .","     .");n("Telaprevir ()","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","     .","     .");n("Telaprevir ()","Voriconazole",e.DRUG_DRUG,i.MODERATE,"   ","Increased Protease Inhibitor Levels. CYP450 inhibition reduces clearance.","   .","   .","     .","     .");n("Tenapanor","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Tenapanor    P-gp    Digoxin.","Increased Digoxin concentration. Tenapanor is a weak P-gp inhibitor, a Digoxin efflux transporter.","   Digoxin (    ).","Increased risk of Digoxin toxicity (such as arrhythmia)."," .    Digoxin       Tenapanor.","Level monitoring. Digoxin serum levels must be monitored upon initiation or discontinuation of Tenapanor.");n("Tenecteplase","Heparin",e.DRUG_DRUG,i.HIGH,"   ","Synergistic bleeding effect."," ","Severe bleeding."," ","Close monitoring.");n("Tenofovir Alafenamide (TAF)","Rifampin",e.DRUG_DRUG,i.HIGH,"  TAF. Rifampin    P-gp.","Decreased TAF concentration. Rifampin is a strong inducer of P-gp.","  TAF      .","Reduced TAF efficacy, leading to viral treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Tenofovir Alafenamide (TAF)","Oxcarbazepine",e.DRUG_DRUG,i.HIGH,"  TAF. Oxcarbazepine   P-gp.","Decreased TAF concentration. Oxcarbazepine is a P-gp inducer.","     .","Reduced antiviral efficacy and treatment failure.","  .   .","Relative contraindication. Avoid the combination.");n("Teplizumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Teplizumab   (CD3-directed antibody).","Increased risk of infection. Teplizumab is an immunosuppressant (CD3-directed antibody).","     .","Risk of developing infection from live vaccines."," .            Teplizumab.","Contraindicated. Live vaccines must be avoided before, during, or after Teplizumab treatment.");n("Tepotinib","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Tepotinib. Omeprazole (  )        Tepotinib.","Reduced Tepotinib efficacy. Omeprazole (PPI) decreases gastric acidity, which is essential for Tepotinib absorption.","           ( ).","Decreased drug plasma concentration, leading to failure of cancer treatment (lung cancer)."," .       (PPIs).     (Antacids)  .","Avoid Combination. PPIs should be avoided. Antacids can be used with spaced administration.");n("Tepotinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tepotinib. Rifampin    CYP3A4    Tepotinib.","Decreased Tepotinib concentration. Rifampin is a strong inducer of CYP3A4, a Tepotinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Tepotinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tepotinib. Rifampin    CYP3A4.","Decreased Tepotinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Tepotinib","Itraconazole",e.DRUG_DRUG,i.MODERATE,"  Tepotinib. Itraconazole    CYP3A4.","Increased Tepotinib concentration. Itraconazole is a strong inhibitor of CYP3A4.","      .","Increased risk of side effects, especially peripheral edema."," .    Tepotinib.","Dose adjustment. Tepotinib dose must be reduced.");n("Terfenadine / Astemizole","Erythromycin",e.DRUG_DRUG,i.CONTRAINDICATED," QT.","QT Prolongation. Delayed cardiac repolarization."," ."," .",".",".");n("Terfenadine / Astemizole","Clarithromycin",e.DRUG_DRUG,i.CONTRAINDICATED," QT.","QT Prolongation. Delayed cardiac repolarization."," ."," .",".",".");n("Terfenadine / Astemizole","Azithromycin",e.DRUG_DRUG,i.CONTRAINDICATED," QT.","QT Prolongation. Delayed cardiac repolarization."," ."," .",".",".");n("Teriflunomide","Warfarin",e.DRUG_DRUG,i.MODERATE,"        CYP2C9","Teriflunomide may reduce Warfarin levels via CYP2C9 induction.","    ","Decreased anticoagulant effect of Warfarin."," INR    ","Monitor INR frequently and adjust dose.");n("Teriparatide","Digoxin",e.DRUG_DRUG,i.MODERATE,"  ","Hypercalcemia.","  ","Increased digoxin toxicity.","  ","Monitor calcium and digoxin.");n("Testosterone","Warfarin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Testosterone","Heparin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Testosterone","Enoxaparin",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Testosterone","Dabigatran",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Testosterone","Rivaroxaban",e.DRUG_DRUG,i.HIGH," ","Drug Interaction. A generic pharmacological interaction altering pharmacokinetics or pharmacodynamics.","  ","Bleeding Risk. Hemorrhage.","  ","  ");n("Testosterone - ","Apixaban - ",e.DRUG_DRUG,i.HIGH,"         (     )            .      Xa.                 .","Testosterone increases red blood cell production and clotting factors (particularly II, VII, IX, and X) by stimulating renal erythropoietin synthesis, creating a prothrombotic state. Conversely, apixaban inhibits factor Xa. This imbalance between increased clotting factors and inhibition of one factor creates an unstable state with concurrent bleeding and thrombosis risks.","            .            .             .","Increased bleeding risk due to interference in coagulation pathways, with potential for spontaneous hemorrhage. Simultaneously, increased thrombosis risk due to polycythemia and blood hyperviscosity. Hemorrhagic and thrombotic events may occur in the same patient, making clinical management complex.","      50.     .           .              .","Monitor hematocrit weekly and maintain below 50%. Monitor for clinical signs of bleeding and thrombosis. Avoid combination in patients with risk factors for either condition. If combination is necessary, consider alternative anticoagulants with wider therapeutic windows.");n("Testosterone","Warfarin",e.DRUG_DRUG,i.MODERATE,"  ","Increased warfarin sensitivity."," INR","Increased INR."," INR","Monitor INR.");n("Tetracycline","Iron Supplements",e.DRUG_DRUG,i.HIGH,"  Tetracycline.      .","Decreased Tetracycline absorption. Iron chelates Tetracycline in the gastrointestinal tract.","         .","Reduced drug plasma concentration, leading to treatment failure."," .      2-3   .","Dose separation. The two drugs must be separated by at least 2-3 hours.");n("Tetracycline","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Tetracycline","Magnesium Hydroxide",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Tetracycline","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE," (Chelation).","Chelation. Divalent/trivalent cations bind to the drug, preventing systemic absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Tetracycline","Iron Supplements",e.DRUG_DRUG,i.MODERATE,".","Chelation Complex Formation. Formation of insoluble complexes in the GI tract prevents absorption."," .","Decreased Absorption. Subtherapeutic drug levels."," ."," .");n("Tetracycline","Dairy Products",e.DRUG_FOOD,i.MODERATE," .","Calcium Binding. Formation of insoluble complexes."," ."," ."," ."," .");n("Tetracycline","Ferrous Sulfate",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      (3-4) .       .","      (3-4) .       .");n("Tetracycline","Ferrous Gluconate",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      (3-4) .       .","      (3-4) .       .");n("Tetracycline","Bismuth Salts ( ) -   ",e.DRUG_DRUG,i.MODERATE,"    ","Reduced Tetracycline Absorption. Binding with cations or altered pH impairs tetracycline bioavailability.","   .","Antibiotic Failure. Suboptimal killing.","      .","      .");n("Tetracycline","Bismuth Subsalicylate",e.DRUG_DRUG,i.MODERATE,"  -","Bismuth-tetracycline complex formation.","   ","Reduced antibiotic efficacy.","   2-3 ","Separate doses by 2-3 hours.");n("Tetracycline / Doxycycline -  / ","Dairy Products (Milk/Yogurt/Cheese) -   (//)",e.DRUG_FOOD,i.MODERATE,"            (Ca)    (Mg)  (Al)   .                      (Chelation).                        .        50-90      .              .","Dairy products contain high levels of divalent cations, especially calcium (Ca), but also magnesium (Mg) and aluminum (Al) if fortified. These cations form insoluble, non-absorbable complexes with tetracycline or doxycycline molecules in the stomach and intestines via chelation. The metal ions bind to specific hydroxyl and ketone sites on the antibiotic molecule, altering its shape and making it too large and insoluble to pass through the intestinal membrane. This can reduce absorption by 50-90%, depending on the amount of dairy consumed. The effect is more pronounced with tetracycline than doxycycline, but remains clinically significant for both.","         : 1.        (      ). 2.               (MIC)  . 3.           . 4.     .","Sharp decrease in the antibiotic`s bioavailability, leading to: 1. Therapeutic failure in the targeted bacterial infections (e.g., acne, Lyme disease, Chlamydia, Rickettsia). 2. Decrease in serum and tissue antibiotic concentrations below the minimum inhibitory concentration (MIC) for the target bacteria. 3. Increased risk of antibiotic resistance development due to subtherapeutic bacterial exposure. 4. Persistence or worsening of infection symptoms.","1.   :           4-6          . 2.  :           (240 )         . 3.   :         (     )     ///. 4.   :                      . 5.  :                           .","1. Mandatory time separation: Take tetracycline or doxycycline at least 2 hours before or 4-6 hours after consuming any dairy products or calcium-fortified foods. 2. Optimal timing: Take the medication on an empty stomach with a full glass of water (240 ml) to enhance absorption, at least 1 hour before a meal. 3. Comprehensive drug education: Provide the patient with a clear list including all dairy products (milk, cheese, yogurt, ice cream, custard) and supplements containing calcium/magnesium/iron/zinc. 4. Do not double the dose: If the medication is accidentally taken with dairy, do not double the next dose; simply resume the regular schedule with proper separation. 5. Drug alternatives: In cases where adherence to separation is difficult, consider using antibiotics that do not interact with calcium, such as some macrolides or fluoroquinolones, if appropriate for the infection.");n(St,tn,e.DRUG_DRUG,i.HIGH,": **  **.         .","Mechanism: **Bidirectional chelation**. Iron binds to Tetracycline in the intestines, preventing absorption of both."," : **   **     .","Clinical Significance: **Decreased absorption of both drugs**, leading to infection treatment failure and anemia.","   3   .    .","Separate doses by at least 3 hours. Also avoid dairy products.");n(St,Pc,e.DRUG_DRUG,i.HIGH,": **   **.    (  )  .","Mechanism: **Formation of insoluble chelates**. Tetracyclines bind to cations (calcium, magnesium, aluminum) in the stomach."," : **      90%**  .","Clinical Significance: **Decreased Tetracycline absorption by up to 90%** and treatment failure.","      6    .","Take Tetracycline 2 hours before or 6 hours after antacids.");n("Tezacaftor/Ivacaftor","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Ivacaftor  Tezacaftor. Itraconazole    CYP3A4.","Increased concentration of Ivacaftor and Tezacaftor. Itraconazole is a strong CYP3A4 inhibitor.","      .","Increased risk of hepatotoxicity and other side effects."," .    Ivacaftor  .","Dose adjustment. Ivacaftor dose must be significantly reduced.");n("Tezepelumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Tezepelumab         .","Increased risk of viral infection. Tezepelumab is a monoclonal antibody that may alter the immune response.","      (    ).","Risk of developing infection from live vaccines (same mechanism as other immunosuppressants)."," .       Tezepelumab.","Contraindicated. Live vaccines must be avoided during Tezepelumab treatment.");n("Theophylline","Erythromycin / Clarithromycin",e.DRUG_DRUG,i.MODERATE," CYP3A4.","CYP3A4 Inhibition. Blockade of the major metabolic enzyme.","  25%.","  25%."," ."," .");n("Theophylline","Cimetidine",e.DRUG_DRUG,i.MODERATE," .","Metabolic Inhibition. Competitive or non-competitive inhibition of metabolic enzymes (e.g., CYP450)."," ."," ."," ."," .");n("Theophylline","Propranolol (Non-selective BB)",e.DRUG_DRUG,i.HIGH,"  +  .","  +  ."," ."," ."," .","Avoid Combination. Contraindicated due to high risk.");n("Theophylline","Phenytoin / Carbamazepine",e.DRUG_DRUG,i.MODERATE," .","Metabolic Induction. Induction of hepatic enzymes accelerates drug clearance.","  .","  ."," ."," .");n("Theophylline","Rifampin",e.DRUG_DRUG,i.MODERATE," .","Metabolic Induction. Induction of hepatic enzymes accelerates drug clearance."," ."," ."," ."," .");n("Theophylline","Isoproterenol",e.DRUG_DRUG,i.MODERATE,"   ","Increased blood theophylline levels","   ","Increased theophylline side effects","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Cimetidine",e.DRUG_DRUG,i.HIGH,"   ","Cimetidine slows theophylline metabolism","     ( )","Significant increase in theophylline levels (toxicity risk)","   20-40%    -    ","Reduce theophylline dose by 20-40% when starting cimetidine - use ranitidine as a safe alternative");n("Theophylline","Oral Contraceptives",e.DRUG_DRUG,i.MODERATE,"    ","Contraceptives slow theophylline metabolism","   ","Increased blood theophylline levels","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Disulfiram",e.DRUG_DRUG,i.MODERATE,"   ","Disulfiram slows theophylline metabolism","   ","Increased blood theophylline levels","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Disopyramide",e.DRUG_DRUG,i.MODERATE,"  ","Increased theophylline levels","   ","Increased theophylline side effects","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Food",e.DRUG_FOOD,i.LOW,"     ","Food effect varies by drug formulation","     ","Absorption of some theophylline forms may be affected","          ","Follow doctor and pharmacist instructions regarding taking with or without food");n("Theophylline","Mexiletine",e.DRUG_DRUG,i.MODERATE,"   ","Mexiletine slows theophylline metabolism","   ","Increased blood theophylline levels","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Thiabendazole",e.DRUG_DRUG,i.MODERATE,"   ","Thiabendazole slows theophylline metabolism","   ","Increased blood theophylline levels","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Ticlopidine",e.DRUG_DRUG,i.MODERATE,"   ","Ticlopidine slows theophylline metabolism","   ","Increased blood theophylline levels","   -    ","Monitor theophylline levels - reduce dose if needed");n("Theophylline","Zileuton",e.DRUG_DRUG,i.HIGH,"     ","Zileuton significantly slows theophylline metabolism","    ","Significant increase in theophylline levels","    50%    -  ","Reduce theophylline dose by 50% when starting zileuton - monitor levels");n("Theophylline","Ciprofloxacin",e.DRUG_DRUG,i.HIGH,"   CYP1A2","Potent CYP1A2 inhibition.","  -     ","Theophylline toxicity - nausea, vomiting, seizures, arrhythmias.","   50% -  ","Reduce theophylline dose 50% - monitor levels.");n("Theophylline","Smoking",e.DRUG_DRUG,i.MODERATE," CYP1A2  ","CYP1A2 induction by hydrocarbons.","  ","Decreased theophylline levels.","    -   ","Increase dose in smokers - monitor upon quitting.");n("Theophylline","Phenytoin",e.DRUG_DRUG,i.MODERATE,": **   (CYP1A2  CYP3A4)**.                  .","Mechanism: **Hepatic enzyme induction (CYP1A2 and CYP3A4)**. Phenytoin is a potent inducer of liver enzymes responsible for theophylline metabolism, significantly accelerating its breakdown and elimination."," : **    **   (   40-60%)              (COPD)     .","Clinical Significance: **Significant decrease in serum theophylline levels** (by up to 40-60%), leading to loss of asthma or COPD symptom control and increased risk of acute respiratory exacerbations.","          .    **    50-100%**     (10-20 mcg/mL).          3-5   .","Monitor serum theophylline levels regularly when starting or stopping phenytoin. **Theophylline dose may need to be increased by 50-100%** to maintain therapeutic levels (10-20 mcg/mL). Clinical symptom monitoring and drug level testing 3-5 days after adjustment is recommended.");n("Theophylline - ","Ciprofloxacin / Enoxacin -  / ",e.DRUG_DRUG,i.HIGH,"          P450 1A2 (CYP1A2)       .          30-50  20-30 .          (AUC)       .     24-48           2-3 .       .","Both Ciprofloxacin and Enoxacin act as potent and selective inhibitors of the cytochrome P450 1A2 (CYP1A2) enzyme, the primary pathway for theophylline metabolism and elimination. This inhibition reduces theophylline clearance by up to 30-50% for Enoxacin and 20-30% for Ciprofloxacin. This leads to a significant increase in theophylline plasma concentration (AUC), prolongs its half-life, and elevates its peak and trough levels. The interaction begins within 24-48 hours of starting the antibiotic and peaks within 2-3 days. Enoxacin has the strongest inhibitory effect among fluoroquinolones.","         (>20 /)        .  : 1.  :          (   >30 /). 2.   :         (         )   . 3.           .","Rapid and dangerous increase in theophylline levels above the therapeutic range (>20 mcg/mL), leading to life-threatening theophylline toxicity. Manifestations include: 1. Neurotoxicity: Nausea, violent vomiting, headache, insomnia, tremors, confusion, seizures (especially at levels >30 mcg/mL). 2. Cardiotoxicity: Palpitations, sinus tachycardia, arrhythmias (premature atrial contractions, atrial fibrillation, ventricular tachycardia), hypotension. 3. The interaction can rapidly progress to a medical emergency requiring hospitalization.","1.    :       .        . 2.   :          24-48      1-2    . 3.   :     30-50       . 4.   :           (   ). 5.    :       CYP1A2    ()  . 6.  :            . 7.   :                 .","1. Avoid combination if possible: The combination of theophylline and Enoxacin is relatively contraindicated. For Ciprofloxacin, it should be avoided or strict precautions taken. 2. Mandatory therapeutic monitoring: Measure theophylline plasma level before starting the fluoroquinolone and 24-48 hours after initiation, then every 1-2 days during co-administration. 3. Proactive dose reduction: Reduce the theophylline dose by 30-50% immediately upon starting Enoxacin or Ciprofloxacin. 4. Close clinical monitoring: Monitor the patient closely for any early signs of toxicity (especially nausea, tremors, palpitations). 5. Use of alternative antibiotics: Choose an alternative antibiotic that does not inhibit CYP1A2, such as ceftriaxone, azithromycin (with caution), or clindamycin. 6. Urgent education: Inform the patient and family about toxicity symptoms and instruct them to seek immediate medical attention if they occur. 7. Post-discontinuation adjustment: After stopping the fluoroquinolone, gradually restore the previous theophylline dose based on level monitoring, as inhibition persists for several days.");n("Theophylline - ","Smoking (Tobacco) -  ()",e.DRUG_FOOD,i.MODERATE,"        (PAHs)       P450 1A2 (CYP1A2)     .        50-100   .         (  8      4-5   ).       7-10             .            3   .","Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs), which are potent inducers of the hepatic enzyme cytochrome P450 1A2 (CYP1A2), the primary metabolic pathway for theophylline. Smoking increases the clearance of theophylline by 50-100% compared to non-smokers. It also significantly shortens its biological half-life (from about 8 hours in non-smokers to 4-5 hours in smokers). This enzyme induction begins after smoking 7-10 cigarettes per day and peaks after several days to weeks of regular smoking. It takes 3 months to a year for enzyme activity to return to normal after smoking cessation.","          (10-20 /)   : 1.            (   ). 2.     . 3.                          .","Marked decrease in theophylline plasma levels below the therapeutic range (10-20 mcg/mL), leading to: 1. Failure to control symptoms of chronic obstructive pulmonary disease or asthma (dyspnea, wheezing, coughing). 2. Increased frequency and severity of respiratory attacks. 3. The need for abnormally high doses of theophylline to achieve a therapeutic effect, which may pose dosing challenges if the patient quits smoking later.","1.   :        1.6-2.0  /   6    0.8-1.0  /   6-8   . 2.   :       (  )         . 3.   :           30-50         1-2       . 4. :                  . 5.  : Patients                     ()    2   ( ).","1. Higher doses for smokers: Theophylline dose for adult smokers may require 1.6-2.0 mg/kg every 6 hours, compared to 0.8-1.0 mg/kg every 6-8 hours for non-smokers. 2. Mandatory therapeutic monitoring: Regularly measure trough theophylline plasma levels to precisely adjust the dose and maintain levels within the therapeutic range. 3. Smoking cessation: When a patient quits smoking, the theophylline dose should be reduced by 30-50% almost immediately and levels monitored closely every 1-2 weeks for the first three months to avoid toxicity. 4. Education: Advise smoking patients to quit and alert them to the necessity of informing their healthcare provider of any change in smoking habits. 5. Treatment alternatives: For heavy smokers, it may be appropriate to use alternative bronchodilators not affected by smoking, such as long-acting anticholinergics (tiotropium) or long-acting beta-2 agonists (formoterol, salmeterol).");n("Theophylline - ","Ciprofloxacin - ",e.DRUG_DRUG,i.MODERATE,"      P450 1A2 (CYP1A2)     .       20-30           (AUC).           .               ( 750   ).","Ciprofloxacin is a potent inhibitor of the cytochrome P450 1A2 (CYP1A2) enzyme, the primary metabolic pathway for theophylline. Ciprofloxacin reduces the clearance of theophylline by 20-30%, increases its biological half-life, and raises the area under the curve (AUC). This inhibition occurs rapidly after starting ciprofloxacin and persists throughout the treatment duration. The degree of inhibition is dose-dependent and may be more pronounced with high doses of ciprofloxacin (e.g., 750 mg twice daily).","        (>20 /)        : 1.   :     . 2.    :        (  ). 3.    :       (   >30 /). 4.            .","Increased theophylline plasma levels above the therapeutic range (>20 mcg/mL), leading to the risk of theophylline toxicity, which includes: 1. Gastrointestinal symptoms: Nausea, vomiting, diarrhea, abdominal pain. 2. Cardiovascular symptoms: Palpitations, tachycardia, arrhythmias (especially atrial fibrillation). 3. Central nervous system symptoms: Headache, insomnia, irritability, tremors, seizures (especially at levels >30 mcg/mL). 4. Toxicity can be life-threatening if not recognized and managed promptly.","1.  :          2-3          . 2.  :     25-35   . 3.  :                . 4.   :         CYP1A2     ()   ( /). 5. :             . 6.    :            .","1. Therapeutic monitoring: Measure theophylline plasma level before starting ciprofloxacin, after 2-3 days of starting combination therapy, and during therapy if symptoms appear. 2. Dose adjustment: Reduce the theophylline dose by 25-35% when initiating ciprofloxacin. 3. Clinical monitoring: Closely watch for any signs or symptoms of toxicity, especially from the central nervous system and cardiovascular system. 4. Alternative antibiotics: If possible, choose an alternative antibiotic that does not inhibit CYP1A2, such as a third-generation cephalosporin (ceftriaxone) or a macrolide (excluding erythromycin/clarithromycin). 5. Education: Inform the patient about potential toxicity symptoms and instruct them to seek medical attention immediately if they occur. 6. Post-discontinuation adjustment: After stopping ciprofloxacin, gradually restore the previous theophylline dose based on level monitoring.");n("Thiazide Diuretics / Loop Diuretics","Gout / Hyperuricemia",e.DRUG_DISEASE,i.MODERATE,"      (Uric Acid Renal Excretion)         .","Diuretics reduce renal Uric Acid excretion and increase its reabsorption, raising blood levels.","    (Acute Gout Attack)     (Hyperuricemia).","Induction of an acute gout attack and exacerbation of hyperuricemia."," .     ( )     .","Use with caution. Prescribe prophylactic Gout treatment (e.g., Allopurinol) if diuretic use is essential.");n("Thiazides - ","Gout - ",e.DRUG_DISEASE,i.MODERATE,"           (   )    : 1.     :                .               ( URAT1 OAT4)      . 2.   :             ( OAT1/3).                .","Thiazide diuretics increase serum uric acid concentration (hyperuricemia) through two main mechanisms: 1. Reduced renal excretion of uric acid: Thiazides cause a decrease in blood volume, stimulating the reabsorption of sodium and water in the proximal renal tubules. Uric acid is also secondarily reabsorbed at this site via anion exchangers (such as URAT1 and OAT4), reducing its urinary excretion. 2. Competition for secretion: Thiazides may compete with uric acid for secretion transporters in the renal tubules (e.g., OAT1/3). This effect is dose-dependent and more pronounced during the initial days and weeks of therapy.","         : 1.                  (    ).              (Podagra). 2.       . 3.                (Tophi)    . 4.                   .","Elevated serum uric acid levels, which may lead to: 1. Triggering an acute gout attack, especially in patients with a prior history of gout or other risk factors (obesity, alcohol consumption, renal failure). The attack is characterized by severe joint pain, redness, swelling, and heat, often in the big toe (Podagra). 2. Increased frequency of gout attacks in patients with existing gout. 3. In chronic untreated cases, it may progress to chronic gouty arthritis with tophus formation and permanent joint damage. 4. Chronically elevated uric acid levels may independently contribute to increased risk of cardiovascular disease and kidney disease.","1.   :                 . 2.  :           4-8       ( 6-12 ). 3.   :    (       )         (    )     . 4.  :           . 5.   :            (   )  ( ). 6.  :                         (        )          .","1. Pre-prescription assessment: Before prescribing thiazides, inquire about a personal or family history of gout or hyperuricemia. 2. Regular monitoring: Measure serum uric acid level before initiating therapy and after 4-8 weeks of starting, then periodically (every 6-12 months). 3. Gout prophylaxis: For at-risk patients (prior gout history, high baseline uric acid), consider prophylactic medication like allopurinol (after controlling an acute attack) or starting the thiazide at a low dose. 4. Dose adjustment: Use the lowest effective dose of the thiazide to minimize the impact on uric acid. 5. Lifestyle modification: Advise the patient to increase fluid intake, limit high-purine foods (red meat, seafood) and alcohol (especially beer). 6. Therapeutic alternatives: For patients experiencing recurrent gout attacks despite prophylaxis, consider alternative diuretics that do not significantly raise uric acid, such as indapamide (although it may have a mild effect) or calcium channel blockers like amlodipine for hypertension management.");n("Thiazolidinediones (Pioglitazone, Rosiglitazone)","Heart Failure",e.DRUG_DISEASE,i.CONTRAINDICATED,"                .","Cause sodium and water retention via a renal effect, increasing plasma fluid volume and putting extra strain on the heart.","   (Heart Failure)         .","Rapid exacerbation of heart failure, leading to acute edema and potential hospitalization.","    NYHA Class III-IV.         Class I-II.","Contraindicated in NYHA Class III-IV heart failure. Use with extreme caution and monitor patient weight in Class I-II.");n("Thioguanine","Busulfan",e.DRUG_DRUG,i.HIGH,"  ","Synergistic hepatotoxicity.","   ","Hepatic veno-occlusive disease.","  ","Monitor liver function.");n("Thioridazine","Atropine",e.DRUG_DRUG,i.MODERATE,"          .","Additive Anticholinergic Effects and reduced Thioridazine absorption due to decreased gastrointestinal motility.","     (      )  .","Increased risk of peripheral anticholinergic side effects (e.g., urinary retention, severe dry mouth, constipation) and central confusion.","      .       .","Closely monitor for anticholinergic symptoms. Reduce the dose of one or both drugs if necessary.");n("Thioridazine","Hyoscine (Scopolamine)",e.DRUG_DRUG,i.MODERATE,"          .","Additive Anticholinergic Effects and reduced Thioridazine absorption due to decreased gastrointestinal motility.","     (      )  .","Increased risk of peripheral anticholinergic side effects (e.g., urinary retention, severe dry mouth, constipation) and central confusion.","      .       .","Closely monitor for anticholinergic symptoms. Reduce the dose of one or both drugs if necessary.");n("Thioridazine","Benztropine",e.DRUG_DRUG,i.MODERATE,"          .","Additive Anticholinergic Effects and reduced Thioridazine absorption due to decreased gastrointestinal motility.","     (      )  .","Increased risk of peripheral anticholinergic side effects (e.g., urinary retention, severe dry mouth, constipation) and central confusion.","      .       .","Closely monitor for anticholinergic symptoms. Reduce the dose of one or both drugs if necessary.");n("Thioridazine","Ethanol - ",e.DRUG_DRUG,i.HIGH,"     (CNS).","Additive CNS Depression. Combined sedative effects.","              .","Increased CNS Depression, severe drowsiness, motor incoordination, functional impairment, and risk of respiratory depression.","  () .","Strictly avoid Ethanol (alcohol).");n("Thioridazine","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"  (CYP2D6).     CYP2D6   .","Metabolic Inhibition (CYP2D6). Paroxetine is a potent inhibitor of the CYP2D6 enzyme that metabolizes Thioridazine.","               QT     ( ).","Substantial increase in Thioridazine plasma concentration, significantly raising the risk of QT interval prolongation and life-threatening cardiac arrhythmias (Contraindicated).","      ( ).    .","Co-administration is strictly contraindicated. An alternative drug must be used.");n("Thioridazine","Propranolol - ",e.DRUG_DRUG,i.MODERATE,"      (  ) -        ","Mutual Metabolic Inhibition. Elevated levels of both drugs increase hypotensive and bradycardic risks.","     ","     ","   (    ) -        ","   (    ) -        ");n("Thioridazine","Ciprofloxacin - ",e.DRUG_DRUG,i.HIGH,"    QT.     QT           (Torsades de Pointes).","Additive QT Prolongation effects. Both drugs independently prolong the QT interval, significantly increasing the risk of life-threatening cardiac arrhythmia (Torsades de Pointes).","    QT     ( ).","Increased risk of QT interval prolongation and life-threatening cardiac arrhythmias (Cardiotoxicity).","      ( ).        QT.","Co-administration is strictly contraindicated. An antibiotic that does not prolong the QT interval must be used.");n("Ticagrelor","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Ticagrelor. Clarithromycin    CYP3A4    Ticagrelor.","Increased Ticagrelor concentration. Clarithromycin is a strong CYP3A4 inhibitor, a metabolic pathway for Ticagrelor.","     .","Increased risk of serious bleeding and dyspnea."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Ticagrelor","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ticagrelor. Rifampin    CYP3A4    Ticagrelor.","Decreased Ticagrelor efficacy. Rifampin is a strong inducer of CYP3A4, a Ticagrelor metabolic pathway.","           ().","Reduced drug plasma concentration, increasing the risk of thrombotic events (clots)."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ticagrelor","Aspirin (High Dose)",e.DRUG_DRUG,i.HIGH,"  .     .","Increased bleeding risk. Both are potent platelet inhibitors.","   .     (  100 )    Ticagrelor.","Increased risk of serious bleeding. High doses of Aspirin (above 100 mg) also reduce Ticagrelor efficacy."," .        100  .","Dose adjustment. Aspirin maintenance dose must not exceed 100 mg daily.");n("Ticagrelor","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ticagrelor. Rifampin    CYP3A4    Ticagrelor.","Decreased Ticagrelor efficacy. Rifampin is a strong inducer of CYP3A4, a Ticagrelor metabolic pathway.","               .","Reduced drug plasma concentration, leading to failure of anti-coagulation and increased risk of cardiovascular events."," .   .","Contraindicated. Avoid the combination.");n("Ticagrelor","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Ticagrelor. Clarithromycin    CYP3A4    Ticagrelor.","Increased Ticagrelor concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Ticagrelor metabolic pathway.","    .","Increased risk of hemorrhage and dyspnea."," .   .","Contraindicated. Avoid the combination.");n("Ticagrelor","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  Ticagrelor. Phenytoin    CYP3A4    Ticagrelor.","Decreased Ticagrelor concentration. Phenytoin is a strong inducer of CYP3A4, a Ticagrelor metabolic pathway.","  Ticagrelor     .","Reduced Ticagrelor efficacy, leading to risk of thrombosis."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Ticagrelor","Aspirin (High Dose)",e.DRUG_DRUG,i.MODERATE,"         ","Additive antiplatelet effect, high aspirin doses reduce Ticagrelor efficacy.","  ","Increased bleeding risk.","     (<100 )","Adhere to recommended Aspirin dose (<100 mg).");n("Ticagrelor","Simvastatin",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased statin levels.","   40 /","Do not exceed simvastatin 40mg/day.");n("Ticlopidine","Theophylline",e.DRUG_DRUG,i.MODERATE," CYP1A2","CYP1A2 inhibition."," ","Theophylline toxicity.","  ","Monitor theophylline levels.");n("Tildrakizumab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Tildrakizumab     (IL-23 inhibitor)   .","Increased risk of viral infection. Tildrakizumab is a monoclonal antibody (IL-23 inhibitor) affecting immunity.","     .","Risk of developing infection from live vaccines."," .       Tildrakizumab.","Contraindicated. Live vaccines must be avoided during Tildrakizumab treatment.");n("Tildrakizumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Tildrakizumab   IL-23.","Reduced vaccine response/Increased infection risk. Tildrakizumab is an IL-23 inhibitor.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Timolol (eye drops)","Oral Beta-blockers",e.DRUG_DRUG,i.MODERATE,"   ","Synergistic cardiac effect.","    ","Bradycardia and hypotension.","   ","Monitor pulse and BP.");n("Tinidazole","Alcohol",e.DRUG_FOOD,i.HIGH,"  . Tinidazole     (Aldehyde dehydrogenase).","Disulfiram-like reaction. Tinidazole inhibits aldehyde dehydrogenase.","     .","Flushing, palpitations, nausea, vomiting, and severe headache."," .        3   .","Contraindicated. Alcohol must be avoided during treatment and for 3 days after discontinuation.");n("Tiotropium","Atropine",e.DRUG_DRUG,i.MODERATE,": **       (Additive Antimuscarinic Effect)**.      (M1, M2, M3)            .","Mechanism: **Additive antimuscarinic effect on muscarinic receptors**. Both drugs block muscarinic receptors (M1, M2, M3) in various body systems, leading to accumulation of systemic anticholinergic effects."," : **      **   :      (Tachycardia)         (   )  **  **    .","Clinical Significance: **Markedly increased anticholinergic adverse effects** including: severe dry mouth, tachycardia, urinary retention, constipation, blurred vision, mental confusion (especially in elderly), and risk of **anticholinergic delirium** in susceptible patients.","   .        (   )       .            .","Avoid combination generally. If atropine is required for medical emergency (e.g., severe bradycardia), closely monitor patient for anticholinergic adverse effects. Consider temporarily discontinuing tiotropium if atropine use is frequent or prolonged.");n("Tirbanibulin","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Tirbanibulin. Clarithromycin     CYP3A4      Tirbanibulin.","Increased Tirbanibulin concentration. Clarithromycin is a strong CYP3A4 inhibitor, the primary metabolic pathway for Tirbanibulin.","        .","Increased risk of severe local skin reactions at the application site."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Tirbanibulin","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tirbanibulin. Rifampin    CYP3A4    Tirbanibulin.","Decreased Tirbanibulin efficacy. Rifampin is a strong inducer of CYP3A4, a Tirbanibulin metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Tirbanibulin","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Tirbanibulin. Ketoconazole    CYP3A4    Tirbanibulin.","Increased Tirbanibulin concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Tirbanibulin metabolic pathway.","    .","Increased risk of dermatological side effects.","  .        .","Side effect monitoring. No topical contraindication, but monitoring is necessary.");n("Tirbanibulin","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"    Tirbanibulin. Ketoconazole    CYP3A4.","Increased systemic exposure to Tirbanibulin. Ketoconazole is a strong inhibitor of CYP3A4.","      .","Increased risk of cutaneous or systemic side effects."," .    CYP3A4 .","Avoid combination. Strong CYP3A4 inhibitors must be avoided.");n("Tirzepatide","Ethinyl Estradiol",e.DRUG_DRUG,i.HIGH,"    . Tirzepatide          .","Decreased efficacy of oral contraceptives. Tirzepatide delays gastric emptying, reducing the absorption of oral contraceptives.","         .","Increased risk of hormonal contraceptive failure and unintended pregnancy."," .            4     Tirzepatide.","Alternative Solution. A non-oral or additional contraceptive method must be used for 4 weeks after initiating Tirzepatide.");n("Tirzepatide","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Tirzepatide          .","Decreased efficacy of oral contraceptives. Tirzepatide delays gastric emptying, reducing the absorption of oral contraceptives.","     .","Increased risk of unintended pregnancy.","  .         (Non-oral contraceptives)  4    Tirzepatide.","Change route of administration. Switching to non-oral contraceptives is recommended for 4 weeks after starting Tirzepatide.");n("Tirzepatide","Oral Contraceptives",e.DRUG_DRUG,i.MODERATE,"   . Tirzepatide   .","Decreased oral drug absorption. Tirzepatide slows gastric emptying.","    .","Reduced efficacy of oral contraceptives."," .       Tirzepatide  1     11       .","Special action. OCs must be taken 1 hour before or 11 hours after Tirzepatide, and an additional barrier method used for one month.");n("Tirzepatide (GIP/GLP-1 RA)","Oral Contraceptives",e.DRUG_DRUG,i.HIGH,"    . Tirzepatide        .","Decreased oral contraceptive concentration. Tirzepatide delays gastric emptying, reducing hormone absorption.","   (   ).","Contraceptive failure (unwanted pregnancy)."," .           4    Tirzepatide    .","Important advice. A non-oral or additional contraceptive method must be used for 4 weeks after starting Tirzepatide and any dose increase.");n("Tirzepatide (GIP/GLP-1 RA)","Digoxin",e.DRUG_DRUG,i.MODERATE,"    Digoxin. Tirzepatide          .","Slight increase in Digoxin concentration. Tirzepatide slows gastric emptying, which may increase the absorption of some drugs.","     Digoxin.","Slightly increased risk of Digoxin toxicity."," .   Digoxin     Tirzepatide.","Close monitoring. Monitor Digoxin levels upon initiation or discontinuation of Tirzepatide.");n("Tirzepatide (Mounjaro)","Insulin",e.DRUG_DRUG,i.MODERATE,": **       **.               . Tirzepatide            .","Mechanism: **Synergistic glucose-lowering effect**. Both medications work to reduce glucose levels, significantly increasing hypoglycemia risk. Tirzepatide stimulates insulin secretion and reduces glucagon, while insulin directly lowers glucose."," : **    **            .          .","Clinical Significance: **Severe hypoglycemia risk** that may lead to loss of consciousness, seizures, or diabetic coma. Elderly patients and those with renal impairment are at higher risk.","    30-50%     Tirzepatide.      (4-6  )   .        .","Reduce insulin dose by 30-50% when starting Tirzepatide. Monitor glucose levels frequently (4-6 times daily) during first weeks. Educate patient on hypoglycemia symptoms and management.");n("Tirzepatide (Mounjaro)","Warfarin",e.DRUG_DRUG,i.MODERATE,": **    **. Tirzepatide           Warfarin   .           .","Mechanism: **Significant delayed gastric emptying**. Tirzepatide slows gastric and intestinal motility, potentially altering Warfarin absorption rate and extent. This effect may be more pronounced during initial weeks of therapy."," : **     INR** (  )        (  INR)    (  INR).      .","Clinical Significance: **Unpredictable INR fluctuations** (International Normalized Ratio), potentially increasing bleeding risk (with elevated INR) or thrombosis risk (with decreased INR). Changes may be gradual and unpredictable."," INR   (  )   4-6      Tirzepatide.   Warfarin   INR.     .","Monitor INR frequently (at least weekly) during first 4-6 weeks of starting or stopping Tirzepatide. Adjust Warfarin dose based on INR values. Educate patient on bleeding and thrombosis symptoms.");n("Tirzepatide (Mounjaro)","Thyroid C-Cell Tumors (  C )",e.DRUG_DISEASE,i.CONTRAINDICATED,": **     C   **.     ( )   GLP-1/GIP      C      .            GLP-1   C.","Mechanism: **Potential stimulation of thyroid C-cell tumor growth**. Animal studies (mice and rats) showed GLP-1/GIP agonists cause C-cell hyperplasia and tumors in dose- and duration-dependent manner. Exact mechanism unclear but believed related to GLP-1 receptor stimulation on C-cells."," : **      ** (Medullary Thyroid Carcinoma - MTC)        .       MTC        2 (MEN 2)    .","Clinical Significance: **Potential risk of Medullary Thyroid Carcinoma (MTC)**, a rare but serious thyroid cancer. Patients with family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN 2) are at significantly higher risk.","                (MTC)   MEN 2.     (Calcitonin)       .      (      ).","Absolute contraindication in patients with personal or family history of MTC or MEN 2 syndrome. Check calcitonin levels before therapy in at-risk patients. Educate patient on thyroid cancer symptoms (neck mass, dysphagia, hoarseness).");n("Tisotumab Vedotin (Tivdak)","Ocular Toxins (Hydroxychloroquine)",e.DRUG_DRUG,i.MODERATE,": **  **.      .","Mechanism: **Synergistic ocular toxicity**. Both drugs cause retinal and corneal damage."," : ** **   .","Clinical Significance: **Vision deterioration** and severe dry eye.","   .   .","Use lubricating eye drops. Regular eye examinations.");n("Tivozanib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Tivozanib. Ketoconazole    CYP3A4    Tivozanib.","Increased Tivozanib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Tivozanib metabolic pathway.","    .","Increased risk of hypertension."," .    Tivozanib     CYP3A4 .","Dose adjustment. Tivozanib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Tivozanib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tivozanib. Rifampin    CYP3A4.","Decreased Tivozanib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Tivozanib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Tivozanib. Phenytoin    CYP3A4.","Decreased Tivozanib concentration. Phenytoin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Tivozanib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Tivozanib. Ketoconazole    CYP3A4.","Increased Tivozanib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","     .","Increased risk of hypertension and bleeding."," .       .","Close monitoring. Monitor blood pressure and adjust the dose as needed.");n("Tobramycin","Vancomycin",e.DRUG_DRUG,i.HIGH,"  .","Nephrotoxicity & Ototoxicity. Synergistic damage to kidney and inner ear.","  .","  ."," ."," .");n("Tobramycin","Cephalexin",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Tobramycin","Ceftriaxone",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Tobramycin","Cefuroxime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Tobramycin","Cefixime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Tobramycin","Cefotaxime",e.DRUG_DRUG,i.MODERATE,"  ","Additive Nephrotoxicity. Concurrent use of nephrotoxic agents compromises renal function synergistically.","   .","Renal Failure Risk. Acute kidney injury.","    .","    .");n("Tobramycin","Furosemide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Tobramycin","Torsemide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Tobramycin","Bumetanide",e.DRUG_DRUG,i.HIGH,"   ","Additive Ototoxicity. Synergistic damage to cochlear or vestibular hair cells.","       .","Hearing Loss. Permanent ototoxicity.","    .   .      .","    .   .      .");n("Tobramycin","Aspirin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Ibuprofen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Diclofenac",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Naproxen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Ketoprofen",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Celecoxib",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Mefenamic Acid",e.DRUG_DRUG,i.MODERATE,"  ","Increased Aminoglycoside Concentrations. Reduced renal clearance or competitive elimination leads to accumulation.","   .","Nephrotoxicity Risk. Potential for acute kidney injury.","    .            .     .","    .            .     .");n("Tobramycin","Cisplatin",e.DRUG_DRUG,i.HIGH,"   ","Additive nephrotoxicity and ototoxicity.","   ","Severe renal and auditory damage.","  -     ","Close monitoring - adjust doses based on renal function.");n("Tocilizumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Tocilizumab   IL-6.","Reduced vaccine response/Increased infection risk. Tocilizumab is an IL-6 receptor antagonist.","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Tocilizumab (IL-6)","Warfarin",e.DRUG_DRUG,i.MODERATE,"  Warfarin. Tocilizumab         CYP (CYP2C9)   .","Decreased Warfarin concentration. Tocilizumab reduces inflammation, which may indirectly increase CYP enzyme activity (CYP2C9).","  Warfarin     .","Reduced Warfarin efficacy, leading to risk of thrombosis."," .  INR       Tocilizumab   Warfarin.","Close monitoring. Monitor INR frequently upon initiation or discontinuation of Tocilizumab and adjust Warfarin dose.");n("Tofacitinib","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"   . Tofacitinib   Janus kinase (JAK)   .","Increased risk of viral infection. Tofacitinib is a Janus kinase (JAK) inhibitor and causes immunosuppression.","     .","Risk of developing infection from live vaccines."," .       Tofacitinib.","Contraindicated. Live vaccines must be avoided during Tofacitinib treatment.");n("Tofacitinib","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  . Tofacitinib   (JAK inhibitor).","Increased risk of infection. Tofacitinib is an immunosuppressant (JAK inhibitor).","     .","Risk of developing infection from live vaccines."," .        Tofacitinib.","Contraindicated. Live vaccines must be avoided during Tofacitinib treatment.");n("Tofacitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Tofacitinib. Ketoconazole    CYP3A4    Tofacitinib.","Increased Tofacitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Tofacitinib metabolic pathway.","     .","Increased risk of infection and myelosuppression."," .    Tofacitinib     CYP3A4 .","Dose adjustment. Tofacitinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Tofacitinib (JAK Inhibitor)","Fluconazole",e.DRUG_DRUG,i.HIGH,"  Tofacitinib. Fluconazole    CYP3A4  CYP2C19    Tofacitinib.","Increased Tofacitinib concentration. Fluconazole is a strong inhibitor of CYP3A4 and CYP2C19, Tofacitinib metabolic pathways.","    .","Increased risk of immunosuppression and infection."," .    Tofacitinib ( ).","Dose adjustment. Tofacitinib dose must be reduced (by half).");n("Tofacitinib (JAK Inhibitor)","Live Vaccines",e.DRUG_DRUG,i.HIGH,"  . Tofacitinib    .","Increased risk of infection. Tofacitinib is an effective immunosuppressant.","     .","Increased risk of developing the disease from the vaccine."," .        Tofacitinib.","Contraindicated. Avoid live vaccines during Tofacitinib therapy.");n("Tofacitinib (JAK)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Tofacitinib. Ketoconazole    CYP3A4.","Increased Tofacitinib concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    .","Increased risk of infection and hematological toxicity."," .    Tofacitinib ( ).","Dose adjustment. Tofacitinib dose must be reduced (by half).");n("Tofacitinib (Xeljanz)","Live Vaccines (MMR/Varicella)",e.DRUG_VACCINE,i.HIGH,": **      JAK**. Tofacitinib   JAK1  JAK3       .                         .","Mechanism: **Severe immunosuppression via JAK enzyme inhibition**. Tofacitinib inhibits JAK1 and JAK3 pathways, essential for cytokine signaling critical to immune response. This impairs immune system ability to recognize and appropriately respond to live viruses in vaccines, potentially allowing uncontrolled vaccine virus replication."," : **      **     **  ** (Disseminated Vaccine Disease)                .         .","Clinical Significance: **Failure to develop protective immunity from vaccine** with significant risk of **Disseminated Vaccine Disease**, a serious potentially fatal condition where live vaccine virus spreads throughout body. Examples include disseminated vaccine measles or severe varicella.","    (MMR     BCG)    3   .        Tofacitinib  4   .     (  )     .","Avoid all live vaccines (MMR, varicella, yellow fever, BCG) during therapy and until 3 months after discontinuation. Preferably complete all live vaccines at least 4 weeks before starting Tofacitinib. Inactivated vaccines (influenza, pneumococcal) can be used but response may be reduced.");n("Tofacitinib (Xeljanz)","Fluconazole",e.DRUG_DRUG,i.MODERATE,": **     CYP3A4  CYP2C19**. Fluconazole      Tofacitinib            1.5-2 .     Fluconazole (  200 mg/day   ).","Mechanism: **Moderate to potent CYP3A4 and CYP2C19 inhibition**. Fluconazole inhibits enzymes responsible for Tofacitinib hepatic metabolism, leading to 1.5-2 fold increase in drug concentration. Effect is dose-dependent (higher doses 200 mg/day cause greater inhibition)."," : **    ** (      )    .            .         .","Clinical Significance: **Increased risk of serious opportunistic infections** (such as tuberculosis, fungal infections, disseminated herpes zoster) due to excessive immunosuppression. Also increased adverse effects including elevated liver enzymes, anemia, and hypercholesterolemia. Elderly patients and those with renal impairment at higher risk.","  Tofacitinib  50%   Fluconazole  200 mg .     (   ).       .        .","Reduce Tofacitinib dose by 50% when using Fluconazole.");n("Tofacitinib (Xeljanz)","Rifampin",e.DRUG_DRUG,i.MODERATE,": ** CYP3A4**.   Tofacitinib  84%.","Mechanism: **CYP3A4 Induction**. Tofacitinib concentration decreases by 84%."," : **   **.","Clinical Significance: **Rheumatoid arthritis treatment failure**."," .    .","Avoid combination. Use alternative antibiotic.");n("Tofacitinib (Xeljanz)","Methotrexate",e.DRUG_DRUG,i.MODERATE,": **   **.","Mechanism: **Synergistic immunosuppressive effect**."," : **  ** .","Clinical Significance: **Increased opportunistic infection risk**.","  .  CBC .","Close monitoring for infections. Regular CBC monitoring.");n("Tofacitinib (Xeljanz)","Tuberculosis ( )",e.DRUG_DISEASE,i.HIGH,": ** **.    .","Mechanism: **Immunosuppression**. Risk of latent TB reactivation."," : ** **  .","Clinical Significance: **Life-threatening active tuberculosis**.","    .       Tofacitinib.","Screen for TB before starting therapy. Treat latent TB before starting Tofacitinib.");n("Tofersen","Amikacin",e.DRUG_DRUG,i.MODERATE,"   . Tofersen      (Neurologic Toxicity).","Increased risk of Neurotoxicity. Tofersen can cause neurologic toxicity.","     (   )     .","Exacerbation of potential neurologic toxicity symptoms (e.g., chemical meningitis) with other neurotoxic drugs."," .            .","Caution and Monitoring. Patient must be closely monitored for any signs of neurotoxicity or meningitis.");n("Tofersen","Epidural Anesthesia",e.DRUG_DRUG,i.MODERATE,"     .       .","Increased risk of neurological complications upon administration. Both are administered in the spinal cord area.","       (Lumbar Puncture)      .","Increased likelihood of complications with Lumbar Puncture such as headache or chemical meningitis.",".            .","Caution. No absolute contraindication, but caution and ensuring safe administration are required.");n("Tolazamide - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolazamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Tolazamide dose if necessary");n("Tolazamide - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Tolazamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Tolazamide dose if necessary");n("Tolazamide - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolazamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Tolazamide dose if necessary");n("Tolazamide - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolazamide","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Tolazamide dose if necessary - Use alternative NSAID");n("Tolazamide - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Tolazamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Tolazamide dose if necessary");n("Tolazamide - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolazamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Tolazamide dose if necessary");n("Tolazamide - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"    ","Increased concentrations of Tolazamide","    ","Increased risk of hypoglycemia","     -       -      ( )","Monitor blood glucose concentration - Decrease Tolazamide dose if necessary - Use noninteracting sulfonylurea (eg, glyburide)");n("Tolazamide - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Tolazamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Tolazamide dose if necessary");n("Tolbutamide","Dicumarol",e.DRUG_DRUG,i.HIGH,"  ","Tolbutamide Potentiation. Hypoglycemia risk.","      (  )","Increased tolbutamide hypoglycemic effect (hypoglycemia risk)","    -      .","Monitor blood glucose levels - reduce tolbutamide dose if necessary.");n("Tolbutamide","Fluconazole",e.DRUG_DRUG,i.HIGH,"  ","Tolbutamide Potentiation. Hypoglycemia risk.","      (  )","Increased tolbutamide hypoglycemic effect (hypoglycemia risk)","    -      ","Monitor blood glucose levels - reduce tolbutamide dose if necessary");n("Tolbutamide","Sulfinpyrazone",e.DRUG_DRUG,i.HIGH,"  ","Tolbutamide Potentiation. Hypoglycemia risk.","      (  )","Increased tolbutamide hypoglycemic effect (hypoglycemia risk)","    -      ","Monitor blood glucose levels - reduce tolbutamide dose if necessary");n("Tolbutamide - ","Chloramphenicol - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolbutamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Tolbutamide dose if necessary");n("Tolbutamide - ","Diazoxide - ",e.DRUG_DRUG,i.MODERATE,"     ","Decreased hypoglycemic effects of Tolbutamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Tolbutamide dose if necessary");n("Tolbutamide - ","MAO Inhibitors -    ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolbutamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Tolbutamide dose if necessary");n("Tolbutamide - ","Phenylbutazones -  ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolbutamide","    ","Increased risk of hypoglycemia","     -       -      ","Monitor blood glucose concentration - Decrease Tolbutamide dose if necessary - Use alternative NSAID");n("Tolbutamide - ","Rifamycins - ",e.DRUG_DRUG,i.MODERATE,"    ","Decreased concentrations of Tolbutamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Tolbutamide dose if necessary");n("Tolbutamide - ","Salicylates - ",e.DRUG_DRUG,i.MODERATE,"     ","Increased hypoglycemic effects of Tolbutamide","    ","Increased risk of hypoglycemia","     -      ","Monitor blood glucose concentration - Decrease Tolbutamide dose if necessary");n("Tolbutamide - ","Sulfonamides - ",e.DRUG_DRUG,i.MODERATE,"    ","Increased concentrations of Tolbutamide","    ","Increased risk of hypoglycemia","     -       -      ( )","Monitor blood glucose concentration - Decrease Tolbutamide dose if necessary - Use noninteracting sulfonylurea (eg, glyburide)");n("Tolbutamide - ","Thiazide Diuretics -   ",e.DRUG_DRUG,i.MODERATE,"      -      ","Increased concentrations of fasting blood glucose - Decreased hypoglycemic effects of Tolbutamide","    ","Increased risk of hyperglycemia","     -      ","Monitor blood glucose concentration - Increase Tolbutamide dose if necessary");n("Topiramate","Valproic Acid",e.DRUG_DRUG,i.MODERATE,"     (Hyperammonemia).        .","Increased risk of Hyperammonemia. Mechanism not fully clear, but may be synergistic.","    ( ).","Increased risk of encephalopathy (confusion, coma)."," .       .","Close monitoring. Ammonia levels and signs of encephalopathy must be monitored.");n("Topotecan","P-glycoprotein Inhibitors",e.DRUG_DRUG,i.MODERATE," P-gp","P-glycoprotein inhibition.","  ","Increased topotecan toxicity.","  ","Monitor CBC.");n("Toremifene","Rifampin",e.DRUG_DRUG,i.HIGH,"  Toremifene. Rifampin    CYP3A4    Toremifene.","Decreased Toremifene concentration. Rifampin is a strong inducer of CYP3A4, a Toremifene metabolic pathway.","              QT.","Reduced drug plasma concentration, leading to treatment failure, and increased risk of QT prolongation."," .   .","Contraindicated. Avoid the combination.");n("Toremifene","CYP3A4 Inhibitors",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","  ","Increased toremifene levels.","  QT","Monitor QT prolongation.");n("Torsemide","Lithium",e.DRUG_DRUG,i.HIGH,"     ","Sodium depletion increases lithium reabsorption."," ","Lithium toxicity.","   ","Monitor lithium levels weekly.");n("Tramadol","Venlafaxine",e.DRUG_DRUG,i.HIGH,"    .       .","Increased risk of Serotonin Syndrome and seizures. Synergistic effects of increased serotonin and reduced seizure threshold.","       .","Mental status changes, hyperthermia, tremor, seizures."," .   .","Contraindicated. Avoid the combination.");n("Trametinib","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Trametinib. Ketoconazole   CYP3A4    Trametinib.","Increased Trametinib concentration. Ketoconazole is a CYP3A4 inhibitor, a Trametinib metabolic pathway.","       .","Increased risk of side effects, especially skin reactions and diarrhea.","  .        .","Side effect monitoring. Patient must be monitored for increased side effects.");n("Trametinib","Phenytoin",e.DRUG_DRUG,i.MODERATE,"  Trametinib. Phenytoin   CYP3A4    Trametinib.","Decreased Trametinib efficacy. Phenytoin is a CYP3A4 inducer, a Trametinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    .","Efficacy monitoring. Clinical response must be monitored.");n("Trametinib","Rifampin",e.DRUG_DRUG,i.MODERATE,"  Trametinib. Rifampin    CYP3A4    Trametinib.","Decreased Trametinib concentration. Rifampin is a strong inducer of CYP3A4, a Trametinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .        .","Efficacy monitoring. Clinical response must be monitored and drug levels checked.");n("Trametinib","Ketoconazole",e.DRUG_DRUG,i.LOW,"    . Trametinib     CYP3A4.","No clinically significant interaction. Trametinib has minimal metabolism via CYP3A4.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Trametinib (Mekinist)","Left Ventricular Dysfunction",e.DRUG_DISEASE,i.HIGH,": ** **. Trametinib     .","Mechanism: **Cardiotoxicity**. Trametinib may cause reduced ejection fraction."," : ** **.","Clinical Significance: **Heart failure**.","    .    2-3 .","Assess cardiac function before therapy. Regular echo every 2-3 months.");n("Trametinib (Mekinist)","Ocular Disorders",e.DRUG_DISEASE,i.MODERATE,": ** **. Trametinib    .","Mechanism: **Ocular toxicity**. Trametinib may cause retinal detachment."," : ** **  .","Clinical Significance: **Visual disturbances** and retinal detachment.","       .","Eye examination before therapy and when visual symptoms appear.");n("Trandolapril","Lithium",e.DRUG_DRUG,i.MODERATE,"              .","ACE inhibitors may increase serum Lithium levels and increase the risk of toxicity.","           .","Increased serum Lithium concentration potentially leading to symptoms of Lithium toxicity.","            .","Monitor Lithium levels closely, adjust Lithium dose if necessary.");n("Tranexamic Acid","Hormonal Contraceptives",e.DRUG_DRUG,i.MODERATE,"  ","Increased thrombosis risk."," ","Venous thrombosis."," ","Use cautiously.");n("Tranylcypromine - ","Meperidine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"            ","Dangerous serotonin synergy leading to fatal serotonergic interaction specifically with Meperidine","           ","Acute fatal serotonin syndrome with hypotension, coma, respiratory arrest, and death","   -   -      ","Absolute contraindication - complete avoidance - 2-week washout period before and after therapy");n("Tranylcypromine - ","Tramadol - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       ","Dual serotonergic effect with risk of serotonin syndrome and seizures","        ","Life-threatening serotonin syndrome, epileptic seizures, and autonomic instability","   -   14    ","Absolute contraindication - 14-day washout before starting Tranylcypromine");n("Tranylcypromine - ","Dextromethorphan - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       NMDA ","Synergy in serotonin reuptake inhibition with NMDA antagonist activity","      ","Severe serotonin syndrome, hallucinations, confusion, and hyperreflexia","   -       ","Absolute contraindication - avoid all cough medications containing Dextromethorphan");n("Tranylcypromine - ","Fluoxetine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"        ","Dual inhibition of serotonin metabolism with long Fluoxetine half-life","       ","Highest risk of fatal serotonin syndrome due to Fluoxetine accumulation","   -   5    (   )","Absolute contraindication - 5-week washout after Fluoxetine (due to long half-life)");n("Tranylcypromine - ","Sertraline - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Synergistic serotonergic effect with mutual metabolic inhibition","      ","Serotonin syndrome with severe neurological and psychiatric symptoms","   -   14   ","Absolute contraindication - 14-day washout after Sertraline");n("Tranylcypromine - ","Paroxetine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       ","Dual serotonin inhibition with additional anticholinergic effect","     ","Serotonin syndrome with anticholinergic complications","   -   14   ","Absolute contraindication - 14-day washout after Paroxetine");n("Tranylcypromine - ","Citalopram - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       QT","Synergistic serotonergic effect with QT prolongation risk","     ","Serotonin syndrome and ventricular cardiac arrhythmias","   -   14   ","Absolute contraindication - 14-day washout after Citalopram");n("Tranylcypromine - ","Escitalopram - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     ","Synergistic serotonergic effect with high selectivity","    ","Rapid onset and severe serotonin syndrome","   -   14   ","Absolute contraindication - 14-day washout after Escitalopram");n("Tranylcypromine - ","Fluvoxamine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Dual serotonin inhibition with hepatic enzyme inhibition","     ","Serotonin syndrome with increased drug toxicity","   -   14   ","Absolute contraindication - 14-day washout after Fluvoxamine");n("Tranylcypromine - ","Vilazodone - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       ","Dual serotonergic effect with serotonin receptor partial activity","     ","Serotonin syndrome with psychomotor symptoms","   -   14   ","Absolute contraindication - 14-day washout after Vilazodone");n("Tranylcypromine - ","Vortioxetine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Complex serotonergic effect with multiple receptor modulation","     ","Serotonin syndrome with cognitive and motor symptoms","   -   14   ","Absolute contraindication - 14-day washout after Vortioxetine");n("Tranylcypromine - ","Venlafaxine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"    ","Dual effect on serotonin and norepinephrine","      ","Serotonin syndrome with hypertensive crisis","   -   14   ","Absolute contraindication - 14-day washout after Venlafaxine");n("Tranylcypromine - ","Duloxetine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"    ","Synergistic effect on serotonin and norepinephrine","     ","Serotonin syndrome with cardiovascular complications","   -   14   ","Absolute contraindication - 14-day washout after Duloxetine");n("Tranylcypromine - ","Desvenlafaxine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"   ","Intense serotonergic and noradrenergic effect","      ","Serotonin syndrome with severe autonomic instability","   -   14   ","Absolute contraindication - 14-day washout after Desvenlafaxine");n("Tranylcypromine - ","Milnacipran - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     ","Balanced dual effect on serotonin and norepinephrine","    ","Serotonin syndrome with noradrenergic symptoms","   -   14   ","Absolute contraindication - 14-day washout after Milnacipran");n("Tranylcypromine - ","Amitriptyline - ",e.DRUG_DRUG,i.CONTRAINDICATED,"        ","Dual effect on serotonin and norepinephrine with anticholinergic effect","         ","Hypertensive crisis and serotonin syndrome with anticholinergic complications","   -   14   ","Absolute contraindication - 14-day washout after Amitriptyline");n("Tranylcypromine - ","Imipramine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"   ","Intense noradrenergic and serotonergic effect","        ","Acute hypertensive crisis with risk of cerebral hemorrhage","   -   14   ","Absolute contraindication - 14-day washout after Imipramine");n("Tranylcypromine - ","Nortriptyline - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     ","Prominent noradrenergic effect with serotonergic component","         ","Hypertensive crisis with tachycardia and arrhythmias","   -   14   ","Absolute contraindication - 14-day washout after Nortriptyline");n("Tranylcypromine - ","Desipramine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"       ","Strong noradrenergic effect with hypertension risk","       ","Severe hypertensive crisis with cardiac complications","   -   14   ","Absolute contraindication - 14-day washout after Desipramine");n("Tranylcypromine - ","Clomipramine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Strong serotonergic effect with serotonin syndrome risk","      ","Severe serotonin syndrome with psychomotor symptoms","   -   14   ","Absolute contraindication - 14-day washout after Clomipramine");n("Tranylcypromine - ","Doxepin - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     ","Serotonergic and noradrenergic effect with sedative component","     ","Serotonin syndrome with central nervous system depression","   -   14   ","Absolute contraindication - 14-day washout after Doxepin");n("Tranylcypromine - ","Bupropion - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Dual dopaminergic and noradrenergic effect with seizure risk","         ","Severe hypertensive crisis with increased risk of epileptic seizures","   -   14   ","Absolute contraindication - 14-day washout after Bupropion");n("Tranylcypromine - ","Pseudoephedrine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"     ","Potentiation of sympathetic effect with catecholamine release","         ","Life-threatening hypertensive crisis with stroke risk","   -       ","Absolute contraindication - avoid all decongestants containing Pseudoephedrine");n("Tranylcypromine - ","Ephedrine - ",e.DRUG_DRUG,i.CONTRAINDICATED,"      ","Dual sympathetic effect with direct catecholamine release","         ","Acute hypertensive crisis with cardiac arrhythmias","   -      ","Absolute contraindication - avoid all preparations containing Ephedrine");n("Tranylcypromine - ","Phenylephrine - ",e.DRUG_DRUG,i.CONTRAINDICATED," -  ","Dual direct alpha-adrenergic effect","        ","Severe hypertensive crisis with acute vasoconstriction","   -      ","Absolute contraindication - avoid all preparations containing Phenylephrine");n("Tranylcypromine - ","Tyramine-Rich Foods -   ",e.DRUG_FOOD,i.CONTRAINDICATED," MAO-A          ","MAO-A inhibition prevents tyramine metabolism leading to uncontrolled catecholamine release","           ","Fatal hypertensive crisis with severe headache, cerebral hemorrhage, and cardiac failure","      -           -   14    ","Strict tyramine-free diet - avoid aged cheeses, processed meats, smoked fish, fermented beverages, and legumes - continue diet for 14 days after discontinuation");n("Tranylcypromine (MAOI)","Tyramine-rich Foods",e.DRUG_FOOD,i.HIGH,"     .  MAO         .","Increased risk of hypertensive crisis. MAOIs prevent the breakdown of dietary tyramine, leading to norepinephrine release.","     .","Severe hypertension and severe headache."," .      (       ).","Contraindicated. Tyramine-rich foods (aged cheese, cured meats, unpasteurized beer, pickles) must be avoided.");n("Trastuzumab Deruxtecan","Doxorubicin",e.DRUG_DRUG,i.HIGH,"   . Trastuzumab Deruxtecan      .","Increased risk of Cardiotoxicity. Trastuzumab Deruxtecan itself carries a risk of cardiotoxicity.","     (Cardiomyopathy)   .","Increased risk of cardiomyopathy and congestive heart failure."," .     (LVEF)    .","Caution and Monitoring. Cardiac function (LVEF) must be regularly monitored before and during treatment.");n("Trastuzumab Deruxtecan","Doxorubicin",e.DRUG_DRUG,i.HIGH,"    .","Increased risk of additive cardiotoxicity.","       .","Increased risk of cardiomyopathy and congestive heart failure.","  .     (LVEF)    .","Cardiac function monitoring. Cardiac function (LVEF) must be regularly monitored before and during treatment.");n("Trastuzumab Deruxtecan (ADC)","Strong CYP Inhibitors/Inducers",e.DRUG_DRUG,i.LOW,"        .   (Deruxtecan)      CYP.","No clinically significant interaction expected with the antibody. The toxic payload (Deruxtecan) is minimally metabolized by CYP.","   .","No known effect.","    .","No special action required.");n("Trastuzumab Deruxtecan (Enhertu)","Strong CYP3A4 Inhibitors (Itraconazole)",e.DRUG_DRUG,i.MODERATE,": **   **.     .","Mechanism: **Payload metabolism inhibition**. Increased toxic payload concentration."," : ** **    .","Clinical Significance: **Increased toxicity** especially interstitial lung disease."," .    .","Use cautiously. Close monitoring for respiratory symptoms.");n("Trastuzumab Deruxtecan (Enhertu)","Pulmonary Toxins (Bleomycin)",e.DRUG_DRUG,i.HIGH,": **  **.      .","Mechanism: **Synergistic pulmonary toxicity**. Both drugs cause interstitial lung disease."," : **   **  .","Clinical Significance: **Severe life-threatening interstitial lung disease**."," .    .","Avoid combination. Close monitoring for respiratory symptoms.");n("Trazodone","Ritonavir",e.DRUG_DRUG,i.HIGH,"  Trazodone. Ritonavir    CYP3A4.","Increased Trazodone concentration. Ritonavir is a strong inhibitor of CYP3A4.","        QT.","Increased risk of somnolence, hypotension, and QT prolongation."," .    Trazodone  .","Dose adjustment. Trazodone dose must be significantly reduced.");n("Trazodone",["Alcohol","BENZODIAZEPINES","Opioids"],e.DRUG_DRUG,i.HIGH,": **    **.         .","Mechanism: **Synergistic CNS Depression**. Trazodone causes sedation, which is potentiated by other CNS depressants."," : **  (Excessive Sedation)**      .","Clinical Significance: **Excessive sedation**, dizziness, fall risk, and potential respiratory depression.","      .       .","Avoid combination or use lowest effective doses. Warn patient against driving or operating machinery.");n("Trazodone",["Ketoconazole","Ritonavir","Indinavir","Clarithromycin"],e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.     .","Mechanism: **CYP3A4 Inhibition**. These drugs inhibit the metabolism of Trazodone."," : **  **          .","Clinical Significance: **Increased Trazodone levels**, increasing risk of side effects like nausea, hypotension, and syncope.","     .","Reduce Trazodone dose during concurrent use.");n("Trazodone","Carbamazepine",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.    .","Mechanism: **CYP3A4 Induction**. Carbamazepine accelerates Trazodone metabolism."," : **    **        .","Clinical Significance: **Significantly reduced Trazodone levels**, decreasing its antidepressant or hypnotic efficacy.","  .     .","Monitor clinical response. Trazodone dose increase may be required.");n("Trazodone","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4 **.    .","Mechanism: **Intestinal CYP3A4 Inhibition**. Increases Trazodone absorption."," : **    **.","Clinical Significance: **Increased risk of sedation and hypotension**.","      .","Avoid grapefruit juice during therapy.");n("Treprostinil - ","Gemfibrozil - ",e.DRUG_DRUG,i.HIGH,"    CYP2C8               ","Gemfibrozil is a potent inhibitor of hepatic CYP2C8 enzyme responsible for Treprostinil primary metabolism, reducing its clearance and significantly increasing systemic exposure","      2-4              ","2-4 fold increase in Treprostinil plasma concentration, elevated risk of severe hypotension, headache, nausea, diarrhea, rash, and jaw pain","    50-75%    -      -        -     ","Reduce Treprostinil dose by 50-75% when initiating Gemfibrozil - monitor blood pressure frequently - slow titration of Treprostinil dose based on tolerance - monitor for vascular side effects");n("Tretinoin","Benzoyl Peroxide",e.DRUG_DRUG,i.MODERATE," ","Tretinoin inactivation."," ","Reduced efficacy.","   ","Apply at different times.");n("Triamterene","Indomethacin",e.DRUG_DRUG,i.HIGH,"  ","Reduced renal function.","  ","Acute renal failure."," ","Avoid combination.");n("Triazolam","Grapefruit Juice",e.DRUG_FOOD,i.HIGH," CYP3A4 -     25%","CYP3A4 inhibition - increases drug level by 25%.","    ","Excessive drowsiness and morning hangover effect.","   ","Avoid grapefruit juice.");n("Tricyclic Antidepressants (Amitriptyline, Imipramine)","Recent Myocardial Infarction / Arrhythmias",e.DRUG_DISEASE,i.HIGH,"             QTc   .","Anticholinergic effects and cardiac sodium channel blockade, leading to QTc prolongation and conduction abnormalities.","    (Ventricular Arrhythmias)    .","Serious ventricular arrhythmias or sudden cardiac death.","       .      (SSRIs)  .","Avoid in the immediate weeks following myocardial infarction. Use SSRIs as a safer alternative.");n("Trifluridine/Tipiracil","Posaconazole",e.DRUG_DRUG,i.MODERATE,"  . Posaconazole    CYP3A4       .","Increased metabolite concentration. Posaconazole is a strong CYP3A4 inhibitor, increasing systemic exposure to drug metabolites.","    (Neutropenia) .","Increased risk of hematological toxicity (Neutropenia) and diarrhea."," .      (CBC)  .","Dose monitoring. Complete blood count (CBC) must be closely monitored.");n("Trikafta (Elexacaftor/Tezacaftor/Ivacaftor)","Rifampin",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.     Trikafta.","Mechanism: **Potent CYP3A4 Induction**. Significant Trikafta concentration decrease."," : **   **.","Clinical Significance: **Cystic fibrosis treatment failure**.","  .","Absolute contraindication.");n("Trikafta (Elexacaftor/Tezacaftor/Ivacaftor)","Itraconazole",e.DRUG_DRUG,i.MODERATE,": ** CYP3A4**.   Ivacaftor  4.5 .","Mechanism: **CYP3A4 Inhibition**. Ivacaftor concentration increases 4.5-fold."," : **  **.","Clinical Significance: **Increased adverse effects**.","  Trikafta (  ).","Reduce Trikafta dose (morning dose only).");n("Trikafta (Elexacaftor/Tezacaftor/Ivacaftor)","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,": ** CYP3A4**.","Mechanism: **CYP3A4 Inhibition**."," : **  **.","Clinical Significance: **Increased drug concentration**.","   .","Avoid grapefruit juice.");n("Trilaciclib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Trilaciclib. Rifampin     CYP3A4    Trilaciclib.","Decreased Trilaciclib efficacy. Rifampin is a strong inducer of CYP3A4, which metabolizes Trilaciclib.","                .","Reduced drug plasma concentration, decreasing its ability to protect bone marrow from chemotherapy toxicity."," .     CYP3A4    Trilaciclib.","Avoid Combination. Strong CYP3A4 inducers should be avoided concomitantly with Trilaciclib.");n("Trimethoprim-Sulfamethoxazole","Spironolactone",e.DRUG_DRUG,i.HIGH,"  ","Both drugs cause potassium retention.","   -    ","Hyperkalemia - life-threatening arrhythmias.","  -     ","Monitor potassium - avoid in renal impairment.");n("Trofinetide","Ethinyl Estradiol",e.DRUG_DRUG,i.HIGH,"    . Trofinetide     CYP3A4.","Decreased efficacy of oral contraceptives. Trofinetide is a moderate CYP3A4 inducer.","             .","Increased metabolism of oral contraceptives, leading to reduced levels and contraceptive failure."," .              .","Alternative Solution. A non-hormonal or a higher dose hormonal contraceptive method must be used.");n("Trofinetide","Carbamazepine",e.DRUG_DRUG,i.HIGH,"  Trofinetide. Carbamazepine    CYP3A4    Trofinetide.","Decreased Trofinetide efficacy. Carbamazepine is a strong inducer of CYP3A4, which metabolizes Trofinetide.","            .","Reduced drug plasma concentration, decreasing its efficacy in treating Rett syndrome."," .     CYP3A4  .","Avoid Combination. Strong CYP3A4 inducers should be avoided concomitantly.");n("Tromethamine","Lithium",e.DRUG_DRUG,i.MODERATE,"     ()             .","These agents increase the renal clearance (excretion) of Lithium, primarily through increased diuresis and modification of urinary pH.","             .","Decreased serum Lithium concentration, potentially leading to loss of therapeutic efficacy and symptom relapse.","      (TDM)  .          .","Closely monitor serum Lithium concentration (TDM) and clinical symptoms. A Lithium dose increase may be required to compensate for the reduced concentration.");n("Tucatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tucatinib. Rifampin    CYP3A4    Tucatinib.","Decreased Tucatinib efficacy. Rifampin is a strong inducer of CYP3A4, a Tucatinib metabolic pathway.","          .","Reduced drug plasma concentration, leading to cancer treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Tucatinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Tucatinib. Ketoconazole    CYP3A4    Tucatinib.","Increased Tucatinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Tucatinib metabolic pathway.","     .","Increased risk of severe diarrhea and hepatotoxicity."," .    Tucatinib     CYP3A4 .","Dose adjustment. Tucatinib dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Tucatinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Tucatinib.       CYP3A4  .","Increased Tucatinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","     .","Increased risk of severe diarrhea and hepatotoxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Tucatinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Tucatinib. Rifampin    CYP3A4.","Decreased Tucatinib concentration. Rifampin is a strong inducer of CYP3A4.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Tucatinib","Midazolam",e.DRUG_DRUG,i.HIGH,"  Midazolam. Tucatinib    CYP3A4.","Increased Midazolam concentration. Tucatinib is a strong inhibitor of CYP3A4.","      .","Increased risk of CNS and respiratory depression."," .     CYP3A4      .","Dose adjustment. Sensitive CYP3A4 substrates must be avoided or their doses significantly adjusted.");n("Tucatinib","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Tucatinib   P-gp.","Increased Digoxin concentration. Tucatinib inhibits P-gp.","   Digoxin.","Increased risk of Digoxin toxicity."," .    Digoxin  .","Dose adjustment. Digoxin dose must be reduced and its levels monitored.");n("Tucatinib (Tukysa)","CYP2C8 Substrates (Repaglinide)",e.DRUG_DRUG,i.HIGH,": **   CYP2C8**.   Repaglinide  6 .","Mechanism: **Potent CYP2C8 inhibition**. Repaglinide concentration increases 6-fold."," : **   **  .","Clinical Significance: **Severe life-threatening hypoglycemia**."," .      Metformin.","Avoid combination. Use alternative diabetes medication such as Metformin.");n("Tucatinib (Tukysa)","P-glycoprotein Substrates (Digoxin)",e.DRUG_DRUG,i.MODERATE,": **  P-glycoprotein**.   Digoxin.","Mechanism: **P-glycoprotein transporter inhibition**. Increased Digoxin concentration."," : ** **    .","Clinical Significance: **Digoxin toxicity** with cardiac arrhythmias.","  .   Digoxin  50%.","Monitor digoxin levels. Reduce Digoxin dose by 50%.");n("Typhoid Vaccine (Oral, Live)","Ciprofloxacin",e.DRUG_DRUG,i.HIGH,"     (Salmonella typhi)   .","Ciprofloxacin kills the live attenuated vaccine bacteria (Salmonella typhi) in the gastrointestinal tract.","       .","Complete failure of vaccine efficacy and no resulting protection."," .     3     .","Contraindicated. Must postpone vaccination until 3 days after stopping the antibiotic.");n("Typhoid Vaccine (Oral, Live)","Trimethoprim / Sulfamethoxazole",e.DRUG_DRUG,i.HIGH,"    DNA       .","This anti-DNA combination kills the live attenuated vaccine bacteria in the gastrointestinal tract.","       .","Complete failure of vaccine efficacy and no resulting protection."," .     3     .","Contraindicated. Must postpone vaccination until 3 days after stopping the antibiotic.");n("Ublituximab","Live Vaccines",e.DRUG_VACCINE,i.HIGH,"  /  . Ublituximab   B.","Reduced vaccine response/Increased infection risk. Ublituximab depletes B-cells.","     .","Risk of developing infection from live vaccines."," .          .","Delay vaccination. Live and non-live vaccines must be delayed for a specified period around treatment.");n("Ubrogepant","Rifampin",e.DRUG_DRUG,i.HIGH,"  Ubrogepant. Rifampin    CYP3A4    Ubrogepant.","Decreased Ubrogepant efficacy. Rifampin is a strong inducer of CYP3A4, an Ubrogepant metabolic pathway.","    .","Failure of acute migraine attack treatment."," .    CYP3A4 .","Contraindicated. Strong CYP3A4 inducers must be avoided.");n("Umbralisib (Ukoniq)","CYP3A4 Substrates (Statins)",e.DRUG_DRUG,i.MODERATE,": **  CYP3A4**.   .","Mechanism: **CYP3A4 inhibition**. Increased statin concentration."," : ** **   .","Clinical Significance: **Myalgia** and rhabdomyolysis risk.","         CYP3A4  Pravastatin.","Reduce statin dose or use non-CYP3A4 statin such as Pravastatin.");n("Upadacitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Upadacitinib. Ketoconazole     CYP3A4      Upadacitinib.","Increased Upadacitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, which is the primary metabolic pathway for Upadacitinib.","             .","Elevated drug plasma concentration, increasing the risk of serious infections related to immunosuppression."," .  **  Upadacitinib  50%**        CYP3A4.","Dose adjustment. Upadacitinib dose must be **reduced by 50%** when co-administered with a strong CYP3A4 inhibitor.");n("Upadacitinib","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,"  Upadacitinib.      CYP3A4       Upadacitinib.","Increased Upadacitinib levels. Grapefruit juice inhibits intestinal CYP3A4, reducing Upadacitinib metabolism.","      .","Increased risk of immunosuppression-related side effects."," .          CYP3A4.","Avoid simultaneous use. Grapefruit juice and other CYP3A4-inhibiting fruits should be avoided.");n("Upadacitinib","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Upadacitinib. Ketoconazole    CYP3A4    Upadacitinib.","Increased Upadacitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Upadacitinib.","       .","Increased risk of immunosuppression, infection, and other side effects."," .    Upadacitinib       CYP3A4 .","Dose adjustment. Upadacitinib dose must be halved when co-administered with strong CYP3A4 inhibitors.");n("Upadacitinib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Upadacitinib. Rifampin    CYP3A4    Upadacitinib.","Decreased Upadacitinib efficacy. Rifampin is a strong inducer of CYP3A4, an Upadacitinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Upadacitinib","Zoster Vaccine Live",e.DRUG_VACCINE,i.HIGH,"  . Upadacitinib   (JAK inhibitor).","Increased risk of infection. Upadacitinib is an immunosuppressant (JAK inhibitor).","     .","Risk of developing infection from live vaccines."," .        Upadacitinib.","Contraindicated. Live vaccines must be avoided during Upadacitinib treatment.");n("Upadacitinib","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Upadacitinib.       CYP3A4  .","Increased Upadacitinib concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","       .","Increased risk of side effects, especially infection and hematological toxicity."," .          CYP3A4.","Avoid Consumption. Grapefruit juice and other CYP3A4 inhibiting fruits must be avoided.");n("Upadacitinib","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Upadacitinib. Itraconazole    CYP3A4    Upadacitinib.","Increased Upadacitinib concentration. Itraconazole is a strong CYP3A4 inhibitor, an Upadacitinib metabolic pathway.","       .","Increased risk of side effects, especially infection and hematological toxicity."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inhibitors must be avoided.");n("Upadacitinib - ","Fentanyl - ",e.DRUG_DRUG,i.MODERATE,"      CYP3A4            ","Upadacitinib competes with Fentanyl for hepatic CYP3A4 enzyme, potentially reducing Fentanyl metabolism and increasing its plasma concentration","                   ","Moderate increase in Fentanyl concentration may lead to enhanced analgesic effects and respiratory depression, especially with high doses or chronic use","        -         -      ","Monitor vital signs and respiratory function when initiating combination - adjust Fentanyl dose if signs of respiratory depression appear - avoid high doses of both medications");n("Upadacitinib (JAK Inhibitor)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Upadacitinib. Ketoconazole    CYP3A4    Upadacitinib .","Increased Upadacitinib concentration. Ketoconazole is a strong CYP3A4 inhibitor, the main Upadacitinib metabolic pathway.","     .","Increased risk of infection and myelosuppression."," .    Upadacitinib (   ).","Dose adjustment. Upadacitinib dose must be reduced (by half or less).");n("Upadacitinib (JAK)","Rifampin",e.DRUG_DRUG,i.HIGH,"  Upadacitinib. Rifampin    CYP3A4.","Decreased Upadacitinib concentration. Rifampin is a strong inducer of CYP3A4.","  .","Reduced drug efficacy."," .   .","Contraindicated. Avoid the combination.");n("Upadacitinib (JAK)","Clarithromycin",e.DRUG_DRUG,i.MODERATE,"  Upadacitinib. Clarithromycin    CYP3A4.","Increased Upadacitinib concentration. Clarithromycin is a strong inhibitor of CYP3A4.","    .","Increased risk of infection and hematological toxicity."," .    Upadacitinib.","Dose adjustment. Upadacitinib dose must be reduced.");n("Upadacitinib (JAK)","Diltiazem (CCB, CYP3A4 Inhibitor)",e.DRUG_DRUG,i.MODERATE,"  Upadacitinib. Diltiazem   CYP3A4.","Increased Upadacitinib concentration. Diltiazem inhibits CYP3A4.","    .","Increased risk of infection and hematological toxicity."," .    Upadacitinib.","Dose adjustment. Upadacitinib dose must be reduced.");n("Ursodeoxycholic Acid","Aluminum Hydroxide",e.DRUG_DRUG,i.MODERATE,"   Ursodeoxycholic.    Ursodeoxycholic.","Decreased Ursodeoxycholic Acid efficacy. Aluminum binds to Ursodeoxycholic Acid.","         .","Reduced drug plasma concentration, leading to treatment failure."," .             Ursodeoxycholic.","Dose separation. Antacids must be taken at least two hours before or after Ursodeoxycholic Acid.");n("Ursodeoxycholic Acid","Aluminum Antacids",e.DRUG_DRUG,i.MODERATE,"  ","Intestinal binding.","   ","Reduced ursodeoxycholic acid absorption.","  ","Separate doses by 2 hours.");n("Ustekinumab","Live Vaccines",e.DRUG_VACCINE,i.MODERATE,"  /  . Ustekinumab   (IL-12/23 inhibitor).","Reduced vaccine response/Increased infection risk. Ustekinumab is an immunosuppressant (IL-12/23 inhibitor).","  .","Reduced vaccine efficacy."," .      .","Delay vaccination. Vaccinations are recommended before starting treatment.");n("Valerian","CNS Depressants",e.DRUG_DRUG,i.MODERATE," CNS ","Synergistic CNS depression."," ","Severe drowsiness."," ","Avoid combination.");n("Valproic Acid","Food",e.DRUG_FOOD,i.LOW,"                     .                    .          (AUC   )        .","Taking valproic acid with food slows gastric emptying rate, delaying drug delivery to the small intestine where primary absorption occurs. However, food provides a protective layer on the gastric mucosa and dilutes direct drug concentration on the stomach wall. The absorption delay does not affect total absorbed amount (AUC remains unchanged), only the rate of reaching peak concentration.","                :       .              .","Significant improvement in gastrointestinal tolerability, with substantial reduction in side effects such as nausea, vomiting, heartburn, and upper abdominal pain. This enhances medication adherence, especially in patients requiring high doses.","                        .       (enteric-coated)     .          .","It is strongly recommended to take valproic acid with or immediately after meals to reduce gastric irritation, especially for patients with sensitive stomachs or history of peptic ulcers. For enteric-coated formulations, food effect is minimal. Doses should be taken with regular meals to maintain a consistent pattern.");n("Valproic Acid","Liver Disease / Hepatic Impairment",e.DRUG_DISEASE,i.HIGH,"      -   ","Hepatotoxicity & Metabolic Impairment. Worsening liver function.","     ","Worsening hepatic failure or encephalopathy.","   Child-Pugh -   ","Adjust dose based on Child-Pugh - monitor liver function.");n("Valsartan - ","Potassium Supplements / Spironolactone (    )",e.DRUG_DRUG,i.HIGH,"    .             .","Additive hyperkalemic effects. Valsartan reduces potassium excretion via aldosterone inhibition, and the other drug adds extra potassium.","      (Severe Hyperkalemia)         .","Increased risk of severe, life-threatening hyperkalemia, potentially leading to fatal cardiac arrhythmias.","  .              .","Avoid the combination. If use is essential, serum potassium levels must be monitored very closely and frequently.");n("Valsartan - ","NSAIDs ( ) / COX-2 Inhibitors",e.DRUG_DRUG,i.HIGH,"    (Triple Whammy).      (GFR)          GFR    .",'Dual inhibition of renal function ("Triple Whammy"). Valsartan reduces GFR via efferent arteriole dilation, while NSAIDs reduce GFR by constricting the afferent arteriole.',"      (Acute Kidney Injury)            ()      .","Increased risk of acute kidney injury (AKI) or acute renal failure, especially in the elderly, volume-depleted, or those with pre-existing renal impairment.","       .        (  BUN)  .","Avoid the combination, especially in at-risk patients. If essential, frequently monitor renal function (Creatinine and BUN).");n("Valsartan - ","ACE Inhibitors ( ) / Aliskiren",e.DRUG_DRUG,i.HIGH,"   -- (RAAS Blockade).          .","Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS). Provides little added benefit but significantly increases side effects.","             .","Seriously increased risk of severe hypotension, hyperkalemia, and worsening renal function.","  .      RAAS       .","Absolute Contraindication. Dual RAAS blockade must be avoided, especially in patients with diabetes or renal impairment.");n("Valsartan","Lithium",e.DRUG_DRUG,i.HIGH,"  .    II       .","Increased Lithium concentration. Angiotensin II receptor blockers reduce renal clearance of Lithium.","   .","Increased risk of Lithium toxicity.","  .           .","Dose adjustment and monitoring. Lithium dose must be reduced and drug levels closely monitored.");n("Valsartan","Eplerenone",e.DRUG_DRUG,i.HIGH,"    ","Synergistic potassium retention.","  ","Dangerous hyperkalemia.","  -    ","Close monitoring - especially in diabetics.");n("Vancomycin","Furosemide",e.DRUG_DRUG,i.MODERATE,"     .   .","Increased risk of ototoxicity and nephrotoxicity. Additive toxic effects.","  .","Auditory and renal damage."," .     .","Close monitoring. Carefully monitor renal function and hearing.");n("Vancomycin","Piperacillin-Tazobactam",e.DRUG_DRUG,i.MODERATE,"  ","Synergistic nephrotoxicity.","  ","Acute kidney injury.","  ","Monitor creatinine daily.");n("Vancomycin","Indomethacin",e.DRUG_DRUG,i.MODERATE,"  ","Reduced renal clearance.","  ","Increased vancomycin levels.","  ","Monitor vancomycin trough levels.");n("Varenicline (Champix) / Bupropion","Major Depression / Suicide Risk",e.DRUG_DISEASE,i.HIGH,"            .","Neuropsychiatric effects leading to a potential increase in suicidal ideation and acute mood changes.","        .","Worsening depression, emergence of suicidal ideation, and abnormal behavioral changes.","      .       .","Monitor closely for mood changes and suicidal behavior. Discontinue medication immediately if symptoms appear.");n("Varicella Vaccine (Live)","Methotrexate",e.DRUG_DRUG,i.HIGH,"           .","Methotrexate inhibits T- and B-cell function, preventing the generation of an adequate immune response.","       .","Risk of immunological failure and increased risk of disseminated vaccine-strain disease."," .     4      .","Contraindicated. Must postpone vaccination for at least 4 weeks after stopping Methotrexate.");n("Varicella Vaccine (Live)","Varicella Zoster Immune Globulin (VZIG)",e.DRUG_VACCINE,i.HIGH,"             VZV.","VZIG contains a very high concentration of pre-formed VZV antibodies.","    (   ).","Immediate neutralization of the vaccine virus (immunological failure of protection)."," .    **5 **  VZIG.","Special action. Postpone vaccination until **5 months** after VZIG.");n("Varicella/Zoster Vaccines (Live)","Acyclovir / Valacyclovir",e.DRUG_DRUG,i.HIGH,"     (DNA Polymerase)       .","Acyclovir inhibits viral DNA polymerase, halting the replication of the live vaccine virus.","        .","Severe reduction in vaccine efficacy and inadequate protection."," .     24    14   .","Special action. Must stop antiviral 24 hours before and 14 days after vaccination.");n("Vedolizumab - ","TNF inhibitors (e.g., Infliximab, Adalimumab) -     (  )",e.DRUG_DRUG,i.HIGH,"   (  47 )     ( TNF-)                .         .","Combining vedolizumab (selective 47 integrin antagonist) with TNF inhibitors (anti-TNF- agents) results in dual immunomodulation via different pathways, increasing risk of serious infections and adverse effects. Insufficient data available on safety and efficacy of this combination.","       (   )        .        .","Significant increase in risk of serious opportunistic infections (TB, fungal, viral infections), reactivation of latent infections, and possibly increased lymphoma risk. No proven additional therapeutic benefit from combination.","       .             ( 8-12 ).      .","Avoid combining vedolizumab with TNF inhibitors. If switching from one to another is necessary, allow appropriate washout period (typically 8-12 weeks). Close monitoring for infections before, during and after switching.");n("Vedolizumab - ","Live Vaccines -   ",e.DRUG_DISEASE,i.HIGH,"             .                .","Vedolizumab suppresses immune system by inhibiting lymphocyte migration to gut and inflamed tissues. Administering live attenuated vaccines during therapy may lead to vaccine-associated infections due to inadequate immune response.","             .          .","Serious infections from live attenuated vaccines such as measles, mumps, rubella, varicella, and oral typhoid. Inadequate immune response to vaccine, failure to develop protective immunity.","      .          ( 4 ).          .","Avoid live attenuated vaccines during vedolizumab therapy. Administer recommended vaccines sufficiently before starting therapy (typically 4 weeks). If vaccines are necessary, use inactivated versions instead of live ones.");n("Vedolizumab - ","Natalizumab - ",e.DRUG_DRUG,i.HIGH,"    4   .   47 ( )    4   ( ).        .","Both drugs target 4 integrin but with different specificities. Vedolizumab targets 47 (gut-selective) while natalizumab targets 4 more broadly (includes brain). Combination may lead to comprehensive and dangerous immune suppression.","         multifocal leukoencephalopathy (PML).      .       .","Massive increase in risk of opportunistic infections, especially progressive multifocal leukoencephalopathy (PML). Bone marrow suppression, and severe immunotoxicity. No known therapeutic benefit from combination.","      .           3-6   .  PML    .","Absolute contraindication for combining vedolizumab and natalizumab. Washout period between discontinuing one and starting the other should be at least 3-6 months. PML screening before initiating either drug.");n("Vedolizumab - ","Ustekinumab - ",e.DRUG_DRUG,i.MODERATE,"   ( )  ( IL-12/IL-23)    .            .","Combining vedolizumab (anti-integrin) with ustekinumab (anti-IL-12/IL-23) inhibits two different immune pathways. Limited data available on safety of this combination, but may increase infection risk.","      .          .      .","Potential increase in bacterial and fungal infection risk. Lack of data on combined efficacy or long-term risks. Possible unexpected synergistic reaction.","            .    .       .","Avoid combination except in clinical trials or under specialist supervision with close monitoring. Thorough risk-benefit assessment. Close infection monitoring if forced combination.");n("Vedolizumab - ","Tofacitinib - ",e.DRUG_DRUG,i.HIGH,"   ( )  (  JAK)        .          .","Combining vedolizumab (immune modulator) with tofacitinib (JAK inhibitor) results in profound immune suppression via multiple mechanisms. This significantly increases risk of infections and other adverse effects.","          .      .      .","Significant increase in risk of serious infections, herpes zoster, tuberculosis, and opportunistic infections. Increased risk of venous thrombosis and pulmonary embolism. Lack of data on combined efficacy.","    .        .     .        .","Avoid combining vedolizumab with tofacitinib. If switching is necessary, allow appropriate washout period. Close monitoring for infections and thrombosis signs. Vaccinate against herpes zoster before initiation if possible.");n("Vedolizumab - ","Azathioprine - ",e.DRUG_DRUG,i.MODERATE,"    ( )     .           .","Combining vedolizumab with azathioprine (purine inhibitor) may enhance immune suppression. Some studies suggest increased efficacy but with elevated infection risks.","        (CMV).          .     .","Moderate increase in infection risk, especially viral infections (CMV). Potential increased treatment efficacy but with elevated side effects. Higher risk of bone marrow suppression.","      .      .    .      .","Can combine cautiously in treatment-resistant cases. Regular monitoring of blood count and liver function. Periodic viral infection screening. Use lowest effective azathioprine dose.");n("Vedolizumab - ","Methotrexate - ",e.DRUG_DRUG,i.MODERATE,"    (  )           .      .","Combining vedolizumab with methotrexate (antifolate) may improve efficacy in some cases but enhances immune suppression. Limited data available on specific drug interactions.","        .       .     .","Increased infection risk, potential hepatotoxicity, and bone marrow suppression. May improve treatment response in inflammatory bowel disease. Lack of long-term data.","       .       .     3-6 .","Combination possible under specialist supervision with close monitoring. Follow-up of liver function, blood count, and infection signs. Assess treatment response after 3-6 months.");n("Vedolizumab - ","Corticosteroids (e.g., Prednisone) -  ( )",e.DRUG_DRUG,i.MODERATE,"         .              .","Combining vedolizumab with corticosteroids is commonly used during treatment induction. Corticosteroids cause nonspecific immune suppression which may increase infection risk when combined.","          .    .         .","Increased infection risk, especially with high doses or prolonged steroid use. Steroid-related metabolic disorders. Steroids are typically tapered after achieving response.","      .     2-3    .     .","Use corticosteroids at lowest dose for shortest duration possible. Gradual steroid taper after 2-3 months of vedolizumab initiation. Monitor for infections and steroid side effects.");n("Velpatasvir/Sofosbuvir","Omeprazole",e.DRUG_DRUG,i.HIGH,"  Velpatasvir.    (PPIs)        Velpatasvir.","Decreased Velpatasvir concentration. PPIs reduce gastric acidity, which is necessary for Velpatasvir absorption.","         .","Reduced drug plasma concentration, leading to treatment failure.","   .   PPIs        (  ).","Avoid combination or modification. PPIs must be strictly avoided or taken at a suitable time and low dose (not always effective).");n("Vemurafenib","Rifampin",e.DRUG_DRUG,i.HIGH,"  Vemurafenib. Rifampin    CYP3A4    Vemurafenib.","Decreased Vemurafenib concentration. Rifampin is a strong inducer of CYP3A4, a Vemurafenib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .   .","Contraindicated. Avoid the combination.");n("Venetoclax (BCL-2)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Venetoclax. Ketoconazole    CYP3A4    Venetoclax.","Increased Venetoclax concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Venetoclax metabolic pathway.","     (Tumor Lysis Syndrome - TLS).","Increased risk of Tumor Lysis Syndrome (TLS)."," .     .    Venetoclax    TLS  .","Contraindicated. Avoid combination during the titration phase. Venetoclax dose must be significantly reduced and TLS monitored intensively.");n("Venetoclax (Venclexta)","Strong CYP3A4 Inhibitors (Ketoconazole)",e.DRUG_DRUG,i.CONTRAINDICATED,": **   CYP3A4**.   Venetoclax  5-7 .","Mechanism: **Potent CYP3A4 inhibition**. Venetoclax concentration increases 5-7 fold."," : **  **     .","Clinical Significance: **Life-threatening tumor lysis syndrome** and severe neutropenia.","    .    75%   .","Contraindicated during ramp-up. Reduce dose by 75% during maintenance.");n("Venetoclax (Venclexta)","P-glycoprotein Inhibitors (Cyclosporine)",e.DRUG_DRUG,i.HIGH,": **  P-glycoprotein**.   Venetoclax  .","Mechanism: **P-glycoprotein transporter inhibition**. Significantly increased Venetoclax concentration."," : **  **   .","Clinical Significance: **Tumor lysis syndrome** and severe hematologic toxicity."," .    .","Avoid combination. Use alternative immunosuppressant.");n("Venetoclax (Venclexta)","High Tumor Burden",e.DRUG_DISEASE,i.HIGH,": **   **.     .","Mechanism: **Rapid tumor cell lysis**. High tumor lysis syndrome risk."," : **   **     .","Clinical Significance: **Life-threatening hyperkalemia and hyperphosphatemia** with acute renal failure."," . Allopurinol .    6-8 .   .","Intensive hydration. Prophylactic Allopurinol. Monitor electrolytes every 6-8 hours. Slow dose ramp-up.");n("Venlafaxine","Alcohol",e.DRUG_FOOD,i.LOW,":       .        .","Mechanism: Additive sedative and CNS depressant effect. May increase the risk of drowsiness and impaired motor skills.",":        .","Result: Increased sedation and impaired coordination, and potentially increased hepatotoxicity.",":    .         .","Management: Avoid alcohol during therapy. No major interference with the drug's bioavailability.");n("Venlafaxine","Caffeine",e.DRUG_FOOD,i.HIGH,":   .   Venlafaxine (   )     .","Mechanism: Additive stimulant effect. Both Venlafaxine (especially at high doses) and Caffeine are CNS stimulants.",":         .","Result: Significantly increased Anxiety, Palpitations, Hypertension, and Insomnia.",":            .","Management: Caffeine intake must be significantly limited, and blood pressure and anxiety symptoms should be monitored.");n("Venlafaxine","Grapefruit Juice",e.DRUG_FOOD,i.MODERATE,":  CYP3A4.      Venlafaxine (  )    .","Mechanism: CYP3A4 inhibition. Affects a portion of Venlafaxine metabolism (not the major pathway), leading to a moderate clinical effect.",":        Venlafaxine.      O-desmethylvenlafaxine  .","Result: May lead to a slight increase in Venlafaxine concentration. Does not significantly affect the active metabolite O-desmethylvenlafaxine.",":           .","Management: Avoid consuming very large amounts of grapefruit juice and monitor for side effects.");n("Venlafaxine","Green Tea",e.DRUG_FOOD,i.LOW,":         .","Mechanism: Additive stimulant effect due to Caffeine content in Green Tea.",":          .","Result: Slight increase in nervousness and insomnia, especially in stimulant-sensitive patients.",":       .","Management: Monitor symptoms and limit Green Tea intake.");n("Venlafaxine","Milk",e.DRUG_FOOD,i.HIGH,":              . (   ).","Mechanism: Hypothetically, milk may affect drug absorption by interfering with the extended-release formulation. (Clinically unproven interaction).",":         .      .","Result: May lead to unexpected changes in concentration and effect. Decreased or increased bioavailability.",":   Venlafaxine XL       .       .","Management: Venlafaxine XL is advised to be taken with food to mitigate GI side effects. Avoid excessive use of milk with the dose.");n("Venlafaxine","High-fat meals",e.DRUG_FOOD,i.MODERATE,":         (AUC)    (ER/XL).","Mechanism: High-fat meal increases the absorption and drug exposure (AUC) of extended-release (ER/XL) formulations.",":        20-40%     .","Result: Increased drug bioavailability by up to 20-40%, which may increase side effects.",":   Venlafaxine ER/XL          .","Management: Venlafaxine ER/XL is advised to be taken consistently with food to minimize fluctuation and maintain regular absorption.");n("Venlafaxine","High-fiber foods",e.DRUG_FOOD,i.LOW,":              .","Mechanism: High-concentration fibers may delay the rate of drug absorption by slowing GI motility.",":            .","Result: Slight delay in reaching peak concentration, with no major effect on overall efficacy.",":    .       .","Management: No routine adjustment required. Take the medication with sufficient water.");n("Venlafaxine","Vitamin C",e.DRUG_FOOD,i.HIGH,":      ( C)         (   ).","Mechanism: Hypothetically, Ascorbic Acid (Vitamin C) may alter urine pH, affecting drug excretion (Clinically unproven interaction).",":           Venlafaxine        C.","Result: May lead to unexpected increase or decrease in Venlafaxine concentrations, especially with high doses of Vitamin C.",":          C.     .","Management: Close monitoring if high doses of Vitamin C are administered. Separate doses if possible.");n("Venlafaxine","Vitamin D",e.DRUG_FOOD,i.MODERATE,":      .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":          Venlafaxine.","Result: No expected clinical effect on Venlafaxine efficacy or toxicity.",":  .    .","Management: Routine monitoring. No need for dose adjustments.");n("Venlafaxine","Vitamin E",e.DRUG_FOOD,i.LOW,":      .   .","Mechanism: No direct metabolic interaction is known. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Venlafaxine","Vitamin K",e.DRUG_FOOD,i.HIGH,":      Venlafaxine  K. (   ).","Mechanism: No known interaction between Venlafaxine and Vitamin K. (Clinically unproven interaction).",":     .        .","Result: No expected clinical effect. Caution advised if the patient is also taking Warfarin.",":  .    .","Management: Routine monitoring. No need for dose adjustments.");n("Venlafaxine","Vitamin B12",e.DRUG_FOOD,i.MODERATE,":      .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Venlafaxine","Folic Acid",e.DRUG_FOOD,i.LOW,":      .   .","Mechanism: No direct metabolic interaction is known. The interaction is very low.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Venlafaxine","Iron",e.DRUG_FOOD,i.HIGH,":          ( )    . (   ).","Mechanism: Hypothetically, Iron ions may bind to the drug in the GI tract (chelation), hindering drug absorption. (Clinically unproven interaction).",":       Venlafaxine.","Result: May lead to reduced Venlafaxine absorption.",":           .","Management: Separate doses by at least two hours if co-administration is necessary.");n("Venlafaxine","Calcium",e.DRUG_FOOD,i.MODERATE,":         . (   ).","Mechanism: Hypothetically, Calcium ions may bind to the drug in the GI tract. (Clinically unproven interaction).",":        Venlafaxine.","Result: May lead to a slight reduction in Venlafaxine absorption.",":           .","Management: Separate doses by at least two hours if co-administration is necessary.");n("Venlafaxine","Magnesium",e.DRUG_FOOD,i.LOW,":         . (   ).","Mechanism: Hypothetically, Magnesium ions may bind to the drug in the GI tract. (Clinically unproven interaction).",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Venlafaxine","Zinc",e.DRUG_FOOD,i.HIGH,":         . (   ).","Mechanism: Hypothetically, Zinc ions may bind to the drug in the GI tract. (Clinically unproven interaction).",":       Venlafaxine.","Result: May lead to reduced Venlafaxine absorption.",":           .","Management: Separate doses by at least two hours if co-administration is necessary.");n("Venlafaxine","Potassium",e.DRUG_FOOD,i.MODERATE,":      .     .","Mechanism: No direct metabolic interaction is known. The interaction is considered non-clinical.",":     .","Result: No expected clinical effect.",":  .","Management: Routine monitoring.");n("Venlafaxine","Sodium Bicarbonate",e.DRUG_FOOD,i.LOW,":         .  Venlafaxine    .","Mechanism: Sodium Bicarbonate may temporarily alter gastric pH. Venlafaxine absorption is not pH-sensitive.",":     .","Result: No expected clinical effect.",":    .","Management: No routine adjustment required.");n("Venlafaxine","Antacids",e.DRUG_FOOD,i.HIGH,":         . (   ).","Mechanism: Antacids may temporarily alter absorption. (Clinically unproven interaction).",":      .","Result: May lead to reduced absorption.",":       .","Management: Separate doses by at least two hours.");n("Venlafaxine - ","Digoxin - ",e.DRUG_DRUG,i.MODERATE,"                  ","Venlafaxine may alter Digoxin pharmacokinetics through multiple unspecified mechanisms, potentially affecting its absorption or distribution","                ","Altered Digoxin blood levels potentially leading to either toxicity or subtherapeutic efficacy","         -      -    ","Monitor Digoxin levels before and after starting Venlafaxine - adjust Digoxin dose as needed - monitor for Digoxin toxicity symptoms");n("Venlafaxine - ","Tobacco Smoking - ",e.DRUG_DRUG,i.MODERATE,"          CYP2D6     ","Polycyclic aromatic hydrocarbons in tobacco smoke induce hepatic CYP2D6 enzyme responsible for Venlafaxine metabolism","      20-30%         ","20-30% decrease in Venlafaxine blood levels, reducing its therapeutic efficacy and increasing relapse risk","       -     25-50% -        ","Closely monitor therapeutic response in smokers - may require 25-50% Venlafaxine dose increase - educate patient about smoking impact on drug efficacy");n("Venlafaxine - ","MAO Inhibitors -  MAO",e.DRUG_DRUG,i.CONTRAINDICATED,"               ","Dangerous synergy in central nervous system serotonergic activity due to prevention of serotonin metabolism through multiple mechanisms","                ","Life-threatening serotonin syndrome with symptoms including hyperthermia, muscle rigidity, myoclonus, mental confusion, and autonomic instability","   -   14       MAO    -   7        MAO","Absolute contraindication - minimum 14-day washout after MAO inhibitors before starting Venlafaxine - 7-day washout after Venlafaxine before starting MAO inhibitors");n("Venlafaxine - ","Fluoxetine - ",e.DRUG_DRUG,i.HIGH,"      CYP2D6         O-desmethylvenlafaxine    ","Fluoxetine inhibits the metabolism of Venlafaxine via hepatic CYP2D6 enzyme, increasing concentrations of both Venlafaxine and its active metabolite O-desmethylvenlafaxine, with synergistic serotonergic activity","               ","Increased risk of severe serotonin syndrome, hypertension, tachycardia, and other dose-related adverse effects","   -          -         50%        ","Avoid combination - use alternatives from different drug classes if needed - if combination is necessary, reduce Venlafaxine dose by at least 50% and monitor for serotonin symptoms and blood pressure");n("Venlafaxine - ","Sertraline - ",e.DRUG_DRUG,i.HIGH,"                ","Combining SNRIs with SSRIs results in excessive synergistic serotonergic activity","           ","High risk of severe serotonin syndrome, agitation, tremor, hyperthermia, and muscle rigidity","    -          ","Avoid combination entirely - use alternatives from different drug classes if combination therapy is necessary");n("Venlafaxine - ","Paroxetine - ",e.DRUG_DRUG,i.HIGH,"   CYP2D6        ","Paroxetine inhibits CYP2D6 enzyme responsible for Venlafaxine metabolism, with synergistic serotonergic effect","      50%     ","Up to 50% increase in Venlafaxine concentration and elevated risk of serotonin syndrome and toxicity","  -        25-50%    ","Avoid combination - if necessary, reduce Venlafaxine dose by 25-50% and monitor for serotonin symptoms");n("Venlafaxine - ","Citalopram - ",e.DRUG_DRUG,i.HIGH,"       ","Synergistic serotonergic activity with risk of serotonin syndrome","        ","Increased risk of serotonergic symptoms such as agitation, sweating, tremor, and diarrhea","   -         ","Avoid combination - close monitoring of vital signs and neurological symptoms when combination is unavoidable");n("Venlafaxine - ","Escitalopram - ",e.DRUG_DRUG,i.HIGH,"      ","Synergistic serotonergic effect with risk of serotonin syndrome","       ","High risk of serotonergic toxicity especially at high doses","  -         ","Avoid combination - use only one antidepressant from serotonergic drug classes");n("Venlafaxine - ","Cimetidine - ",e.DRUG_DRUG,i.MODERATE,"       ","Cimetidine inhibits hepatic enzymes responsible for Venlafaxine metabolism","    25-30%    ","25-30% increase in Venlafaxine concentration and elevated risk of adverse effects","    -      ","Monitor for adverse effects - use alternatives like famotidine or ranitidine");n("Venlafaxine - ","Rifampin - ",e.DRUG_DRUG,i.MODERATE,"       ","Rifampin induces hepatic enzymes responsible for Venlafaxine metabolism","      30-40%      ","30-40% decrease in Venlafaxine blood levels potentially reducing its therapeutic efficacy","   -     25-50%","Monitor therapeutic response - may require 25-50% Venlafaxine dose increase");n("Venlafaxine - ","Clonidine - ",e.DRUG_DRUG,i.MODERATE,"            ","Venlafaxine reduces the antihypertensive efficacy of Clonidine through its effect on norepinephrine","            ","Hypertension, poor blood pressure control, especially at high Venlafaxine doses","    -        ","Monitor blood pressure regularly - adjust Clonidine dose or use antidepressant alternatives");n("Venlafaxine - ","Valproic Acid -  ",e.DRUG_DRUG,i.MODERATE,"           ","Drug interaction that may increase levels of both medications with additional serotonergic effect","      ","Increased risk of adverse effects from both Venlafaxine and Valproic Acid","      -    ","Monitor drug levels and clinical signs of toxicity - adjust doses as needed");n("Venlafaxine - ","Pseudoephedrine - ",e.DRUG_DRUG,i.MODERATE,"           ","Venlafaxine potentiates sympathomimetic effects of Pseudoephedrine through norepinephrine reuptake inhibition","        ","Increased risk of hypertension, tachycardia, palpitations, and anxiety","       -     ","Avoid combination or use non-pharmacological alternatives - monitor blood pressure and heart rate");n("Venlafaxine - ","Phenylephrine - ",e.DRUG_DRUG,i.MODERATE,"        ","Synergistic sympathomimetic effects increase pressor response","        ","Hypertension, headache, palpitations, and cardiac arrhythmias","   -    -       ","Caution with combination - monitor vital signs - use lowest effective dose of decongestant");n("Venlafaxine - ","Ephedrine - ",e.DRUG_DRUG,i.MODERATE,"          ","Synergistic effect on sympathetic nervous system increases cardiovascular effects","          ","High risk of cardiovascular events, acute hypertension, and tachycardia","    -  intensiva     ","Avoid combination if possible - intensive cardiac and blood pressure monitoring if combination is necessary");n("Verapamil",xn,e.DRUG_DRUG,i.HIGH,": **   (Synergistic Cardiac Depression)**.      .","Mechanism: **Synergistic cardiac depression**. Both decrease cardiac contractility and electrical conduction."," : **       (Heart Block)  **.","Clinical Significance: **Increased risk of severe bradycardia, heart block, and hypotension**.","  .      .    .","Monitor cardiovascular status closely. Avoid combination in heart failure patients. Reduce doses if necessary.");n("Verapamil",Zh,e.DRUG_DRUG,i.MODERATE,": **  (Pharmacodynamic Antagonism)**.            .","Mechanism: **Pharmacodynamic antagonism**. Increased extracellular calcium may counteract the calcium channel blocking effect of Verapamil."," : **   **           .","Clinical Significance: **Reversal of Verapamil therapeutic effects**, potentially leading to recurrence of hypertension or arrhythmias.","  . (:        ).","Monitor clinical response. (Note: IV Calcium is used as an antidote for Calcium Channel Blocker toxicity).");n("Verapamil","Digoxin",e.DRUG_DRUG,i.MODERATE,": ** P-glycoprotein   **.    P-gp         .","Mechanism: **P-glycoprotein inhibition and reduced renal clearance**. Verapamil inhibits intestinal and renal P-gp, increasing Digoxin absorption and reducing its excretion."," : **    50-70%**     (     ).","Clinical Significance: **Increased Digoxin levels by 50-70%**, increasing the risk of toxicity (nausea, vomiting, visual disturbances, bradycardia).","    30-50%   .     .","Reduce Digoxin dose by 30-50% when starting Verapamil. Monitor Digoxin levels and ECG.");n("Verapamil",Xh,e.DRUG_DRUG,i.HIGH,"The combination results in a synergistic effect where Verapamil potentiates the neuromuscular blockade produced by Non-depolarizing Muscle Relaxants.","  ( )             .","Prolonged respiratory paralysis and muscle weakness, which can lead to life-threatening respiratory depression or failure.","           .","Closely monitor respiration and neuromuscular function, especially post-surgery. Be prepared to support ventilation and consider reducing the dose of the muscle relaxant.","                .");n("Verapamil","Rifampin",e.DRUG_DRUG,i.MODERATE,": **   (CYP3A4)**.        .","Mechanism: **Potent enzyme induction (CYP3A4)**. Rifampin significantly accelerates hepatic metabolism of Verapamil."," : **     **           .","Clinical Significance: **Significant decrease in Verapamil levels and effects**, potentially leading to worsening angina or hypertension.","  .              .","Monitor clinical response. Verapamil dose may need significant increase, or switch to an alternative agent not affected by Rifampin.");n("Verapamil","Digoxin",e.DRUG_DRUG,i.HIGH,"  Digoxin. Verapamil   P-gp    Digoxin.","Increased Digoxin concentration. Verapamil inhibits P-gp, a Digoxin efflux transporter.","   Digoxin (    ).","Increased risk of Digoxin toxicity (such as arrhythmia).","  .    Digoxin     .","Dose adjustment and monitoring. Digoxin dose must be reduced and drug levels monitored.");n("Verapamil","Calcium Chloride",e.DRUG_DRUG,i.HIGH,"     .   .","Altered Verapamil Effect. Potential toxicity.","            .","            .","    .       .","    .       .");n("Verapamil","Lovastatin",e.DRUG_DRUG,i.HIGH,"    CYP3A4    ","Verapamil inhibits hepatic CYP3A4 enzymes responsible for lovastatin metabolism.","   -   ","Increased lovastatin concentration - risk of myopathy.","      ","Avoid combination or use alternative like pravastatin.");n("Verapamil","Atorvastatin",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","Verapamil inhibits hepatic CYP3A4 enzymes responsible for atorvastatin metabolism.","    ","Moderate increase in atorvastatin concentration.","    -  CPK","Use lowest effective dose - monitor CPK.");n("Verapamil","Quinidine",e.DRUG_DRUG,i.MODERATE,"     ","Synergistic inhibition of cardiac conduction.","    -   QT","Bradycardia - QT prolongation.","   -    ","Monitor ECG - adjust doses as needed.");n("Verapamil","Rifampin",e.DRUG_DRUG,i.MODERATE,"    CYP3A4    ","Rifampin induces hepatic CYP3A4 enzymes responsible for verapamil metabolism.","   -   ","Decreased verapamil concentration - loss of therapeutic effect.","   -   ","Increase verapamil dose - monitor therapeutic response.");n("Verapamil","Lithium",e.DRUG_DRUG,i.MODERATE,"      ","Verapamil may increase lithium neurotoxicity.","    ","Increased lithium neurotoxic side effects.","    -   ","Monitor for neurotoxicity symptoms - adjust lithium dose.");n("Verapamil","Theophylline",e.DRUG_DRUG,i.MODERATE,"   ","Verapamil inhibits theophylline metabolism.","   -  ","Increased theophylline concentration - risk of toxicity.","   -     ","Monitor theophylline concentrations - reduce dose if necessary.");n("Verapamil","Calcium Acetate",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Calcium Carbonate",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Calcium Chloride",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Calcium Citrate",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Calcium Gluconate",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Calcium Lactate",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Tricalcium Phosphate",e.DRUG_DRUG,i.MODERATE,"          ","Calcium Channel Antagonism. Exogenous calcium competes for calcium channels, potentially reversing the therapeutic effect of Verapamil.","    ","Reversal of clinical and toxic effects of verapamil.","    -      ","Monitor cardiovascular status - calcium may be used to reverse verapamil toxicity.");n("Verapamil","Atracurium",e.DRUG_DRUG,i.HIGH,"           ","Potentiation of Muscle Relaxants. Verapamil prolongs neuromuscular blockade.","      -    ","Increased effect of non-depolarizing muscle relaxants - prolonged respiratory depression.","    -    -      ","Avoid combination if possible - monitor respiratory function - adjust muscle relaxant dose as needed.");n("Verapamil","Pancuronium",e.DRUG_DRUG,i.HIGH,"           ","Potentiation of Muscle Relaxants. Verapamil prolongs neuromuscular blockade.","      -    ","Increased effect of non-depolarizing muscle relaxants - prolonged respiratory depression.","    -    -      ","Avoid combination if possible - monitor respiratory function - adjust muscle relaxant dose as needed.");n("Verapamil","Vecuronium",e.DRUG_DRUG,i.HIGH,"           ","Potentiation of Muscle Relaxants. Verapamil prolongs neuromuscular blockade.","      -    ","Increased effect of non-depolarizing muscle relaxants - prolonged respiratory depression.","    -    -      ","Avoid combination if possible - monitor respiratory function - adjust muscle relaxant dose as needed.");n("Verapamil","Tubocurarine",e.DRUG_DRUG,i.HIGH,"           ","Potentiation of Muscle Relaxants. Verapamil prolongs neuromuscular blockade.","      -    ","Increased effect of non-depolarizing muscle relaxants - prolonged respiratory depression.","    -    -      ","Avoid combination if possible - monitor respiratory function - adjust muscle relaxant dose as needed.");n("Verapamil","Atorvastatin",e.DRUG_DRUG,i.MODERATE," CYP3A4","CYP3A4 inhibition.","   ","Increased myopathy risk.","   20 /","Do not exceed atorvastatin 20mg/day.");n("Verapamil ","Calcium Gluconate",e.DRUG_DRUG,i.HIGH,"     .   .","Altered Verapamil Effect. Potential toxicity.","            .","            .","    .       .","    .       .");n("Verapamil ","Calcium Carbonate",e.DRUG_DRUG,i.HIGH,"     .   .","Altered Verapamil Effect. Potential toxicity.","            .","            .","    .       .","    .       .");n("Verapamil - ","Simvastatin - ",e.DRUG_DRUG,i.HIGH,"    CYP3A4    .                   300-400.       OATP1B1         .","Verapamil is a potent inhibitor of CYP3A4, the primary metabolic pathway for Simvastatin. It reduces the metabolism of Simvastatin to its active and inactive metabolites, increasing its plasma concentration by up to 300-400%. Verapamil also inhibits drug transporters like OATP1B1, increasing Simvastatin absorption and reducing its hepatic clearance.","                   (CK)     .        (40 )               .","Significantly increased risk of myopathy, which can progress to rhabdomyolysis with sharp elevation of creatine kinase (CK), myoglobinuria, and acute renal failure. Risk is higher with high Simvastatin doses (40 mg), in elderly patients, and those with renal impairment or thyroid dysfunction.","1.  :           20 . 2.  :            CYP3A4. 3.    :    10        . 4.  :             . 5.  :         2-4 .","1. Avoid Combination: This combination is relatively contraindicated, especially with Simvastatin doses 20 mg. 2. Use Alternatives: Replace Simvastatin with pravastatin, rosuvastatin, or fluvastatin which are not CYP3A4-dependent. 3. If Combination Necessary: Do not exceed 10 mg Simvastatin dose with weekly CK monitoring. 4. Close Monitoring: Educate patient to immediately report any muscle pain, weakness, or unusual fatigue. 5. Periodic Testing: Measure CK, creatinine, and liver function tests every 2-4 weeks.");n("Vericiguat (sGC Stimulator)","Sildenafil (PDE5 Inhibitor)",e.DRUG_DRUG,i.HIGH,"    .      .","Increased risk of hypotension. Synergistic effects on blood vessel dilation.","   .","Severe hypotension."," .   .","Contraindicated. Avoid the combination.");n("Vigabatrin","Clonazepam",e.DRUG_DRUG,i.MODERATE,"     .   .","Increased risk of CNS depression. Additive depressant effects."," .","Severe somnolence."," .        .","Close monitoring. Monitor level of consciousness and reduce doses if necessary.");n("Vildagliptin (DPP-4)","Ramipril",e.DRUG_DRUG,i.MODERATE,"    (Angioedema).          /.","Increased risk of angioedema. Mechanism not fully clear, but related to effects on the kinin/bradykinin system.","    .","Swelling of the face, lips, and throat.","         .","Avoid combination in patients with a history of angioedema.");n("Viloxazine","Ciprofloxacin",e.DRUG_DRUG,i.MODERATE,"  Viloxazine. Ciprofloxacin    CYP1A2    Viloxazine.","Increased Viloxazine concentration. Ciprofloxacin is a moderate CYP1A2 inhibitor, a Viloxazine metabolic pathway.","      .","Increased risk of side effects, such as insomnia and irritability."," .         .","Dose monitoring. No contraindication, but side effects must be monitored.");n("Viloxazine","Rifampin",e.DRUG_DRUG,i.HIGH,"  Viloxazine. Rifampin    CYP2D6 (  )  CYP3A4    Viloxazine.","Decreased Viloxazine efficacy. Rifampin is a strong inducer of CYP2D6 (indirectly) and CYP3A4, which are Viloxazine metabolic pathways.","                (ADHD).","Reduced drug plasma concentration, leading to loss of ADHD control."," .    CYP .","Avoid Combination. Strong CYP inducers must be avoided.");n("Viloxazine - ","Paroxetine - ",e.DRUG_DRUG,i.MODERATE,"    CYP2D6               ","Paroxetine is a potent inhibitor of hepatic CYP2D6 enzyme, which is the primary metabolic pathway for Viloxazine, leading to increased plasma concentrations of Viloxazine","             ","Increased risk of Viloxazine adverse effects, particularly neuropsychiatric symptoms such as mania, irritability, insomnia, and anxiety","   -    50%          ","Adjust Viloxazine dose - reduce by 50% when starting Paroxetine with close monitoring of therapeutic response and adverse effects");n("Viloxazine (Qelbree)","MAO Inhibitors",e.DRUG_DRUG,i.CONTRAINDICATED,": **   **.    MAOIs.","Mechanism: **Hypertensive crisis**. Dangerous interaction with MAOIs."," : **  **  .","Clinical Significance: **Life-threatening hypertension**."," .   14  .","Contraindicated. 14-day washout period required.");n("Viloxazine (Qelbree)","CYP1A2 Inhibitors (Fluvoxamine)",e.DRUG_DRUG,i.MODERATE,": ** CYP1A2**.   Viloxazine.","Mechanism: **CYP1A2 Inhibition**. Increased Viloxazine concentration."," : **  ** ( ).","Clinical Significance: **Increased side effects** (nausea, somnolence).","  Viloxazine  50%.","Reduce Viloxazine dose by 50%.");n("Vinblastine","Erythromycin",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition.","  ","Increased vinblastine toxicity.","  ","Reduce vinblastine dose.");n("Vincristine","Itraconazole",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition.","  ","Severe neurotoxicity."," ","Avoid combination.");n("Vitamin B12 (Injection - )","Diclofenac (Injection - )",e.DRUG_DRUG,i.MODERATE," /   .  ( )       B12 ( )           (pH).","Direct Chemical/Pharmaceutical Interaction upon Mixing. Diclofenac (aqueous solution) chemically reacts with certain forms of Vitamin B12 (e.g., Cyanocobalamin), especially in the presence of metallic ions or pH changes.","  (Precipitation)  .                   .","Precipitation in the Solution. Results in the formation of an insoluble precipitate within the syringe, rendering the solution unsuitable for injection or reducing drug potency.","     ( ).                 .","Do NOT Mix in the Same Syringe. This is a non-correctable physical incompatibility. Administer each medication separately.");n("Vitamin B6","Levodopa",e.DRUG_DRUG,i.HIGH,"   ","Increased peripheral levodopa breakdown."," ","Treatment failure.","   -  ","Avoid high doses - carbidopa protects.");n("Vitamin C","Warfarin",e.DRUG_DRUG,i.MODERATE,"   INR","Variable INR effect.","  INR","INR changes."," INR","Monitor INR.");n("Vitamin E","Warfarin",e.DRUG_DRUG,i.MODERATE,"  ","Increased bleeding risk.","","Bleeding.","   (>400 )","Avoid high doses (>400 IU).");n("Vitamin K","Warfarin",e.DRUG_DRUG,i.HIGH,"  ","Antagonistic effect."," INR","Decreased INR.","    K","Consistent vitamin K intake.");n("Voclosporin","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Voclosporin. Ketoconazole    CYP3A4    Voclosporin.","Increased Voclosporin concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Voclosporin metabolic pathway.","      .","Increased risk of nephrotoxicity and hypertension."," .   .","Contraindicated. Avoid the combination.");n("Voclosporin","Grapefruit Juice",e.DRUG_FOOD,i.HIGH,"  Voclosporin.       CYP3A4  .","Increased Voclosporin concentration. Grapefruit juice is a strong inhibitor of intestinal CYP3A4.","      .","Increased risk of nephrotoxicity and hypertension."," .  .","Contraindicated. Avoid consumption.");n("Volanesorsen","Heparin",e.DRUG_DRUG,i.HIGH,"     (Thrombocytopenia).      .","Increased risk of Thrombocytopenia. Both drugs may cause this effect.","   .","Increased risk of serious hemorrhage."," .      .","Close monitoring. Platelet count must be monitored regularly.");n("Vonoprazan","Midazolam",e.DRUG_DRUG,i.MODERATE,"  Midazolam. Vonoprazan    CYP3A4    Midazolam.","Increased Midazolam levels. Vonoprazan is a moderate inhibitor of CYP3A4, responsible for Midazolam metabolism.","    (Over-sedation)     Midazolam.","Increased risk of over-sedation resulting from elevated Midazolam levels."," .        Midazolam   .","Dose adjustment. Patient must be closely monitored and Midazolam dose adjusted if necessary.");n("Vonoprazan","Midazolam",e.DRUG_DRUG,i.MODERATE,"  Midazolam. Vonoprazan    CYP3A4    Midazolam.","Increased Midazolam concentration. Vonoprazan is a moderate CYP3A4 inhibitor, a Midazolam metabolic pathway.","   .","Increased risk of over-sedation."," .        Midazolam   .","Patient monitoring. Patient must be closely monitored and Midazolam dose adjusted if necessary.");n("Vonoprazan","Digoxin",e.DRUG_DRUG,i.MODERATE,"  Digoxin. Vonoprazan     P-glycoprotein (P-gp)    Digoxin.","Increased Digoxin concentration. Vonoprazan is a moderate P-glycoprotein (P-gp) inhibitor, a Digoxin efflux transporter.","   Digoxin (      ).","Increased risk of Digoxin toxicity (e.g., bradycardia and arrhythmias)."," .    Digoxin       .","Level monitoring. Digoxin serum levels must be monitored and dose adjusted if necessary.");n("Vonoprazan","Clopidogrel",e.DRUG_DRUG,i.MODERATE,"  Clopidogrel. Vonoprazan   CYP2C19    Clopidogrel (pro-drug).","Decreased Clopidogrel efficacy. Vonoprazan inhibits CYP2C19, a Clopidogrel (pro-drug) activation pathway.","   Clopidogrel         (  ).","Reduced concentration of active Clopidogrel metabolite, increasing the risk of cardiovascular events (failure of anti-coagulation).","    .       (PPI)   CYP2C19.","Avoid combination or use an alternative. Prefer using another PPI that does not inhibit CYP2C19.");n("Vorapaxar","Strong CYP3A Inhibitors",e.DRUG_DRUG,i.HIGH," CYP3A4","CYP3A4 inhibition.","  ","Increased bleeding risk."," ","Contraindicated.");n("Vorapaxar (PAR-1)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Vorapaxar. Ketoconazole    CYP3A4    Vorapaxar.","Increased Vorapaxar concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Vorapaxar metabolic pathway.","     .","Increased risk of severe and life-threatening hemorrhage."," .   .","Contraindicated. Avoid the combination.");n("Voriconazole","Sirolimus",e.DRUG_DRUG,i.HIGH,"  Sirolimus  . Voriconazole    CYP3A4    Sirolimus.","Significantly increased Sirolimus concentration. Voriconazole is a strong CYP3A4 inhibitor, a Sirolimus metabolic pathway.","      .","Increased risk of nephrotoxicity, hematological toxicity, and death."," .   .","Contraindicated. Avoid the combination.");n("Voriconazole","Sirolimus",e.DRUG_DRUG,i.HIGH,"  Sirolimus. Voriconazole    CYP3A4    Sirolimus.","Increased Sirolimus concentration. Voriconazole is a strong inhibitor of CYP3A4, a Sirolimus metabolic pathway.","   Sirolimus  (   ).","Increased risk of severe Sirolimus toxicity (immunosuppression, hepatotoxicity)."," .   .","Contraindicated. Avoid the combination.");n("Voriconazole","Sirolimus (mTOR Inhibitor)",e.DRUG_DRUG,i.HIGH,"  Sirolimus. Voriconazole    CYP3A4.","Increased Sirolimus concentration. Voriconazole is a strong inhibitor of CYP3A4.","     Sirolimus.","Increased risk of fatal Sirolimus toxicity."," .   .","Contraindicated. Avoid the combination.");n("Voriconazole","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Voriconazole   Phenytoin. Phenytoin    CYP2C19 Voriconazole   CYP2C9/3A4.","Decreased Voriconazole concentration and increased Phenytoin concentration. Phenytoin is a strong inducer of CYP2C19, and Voriconazole inhibits CYP2C9/3A4.","      Phenytoin.","Failure of fungal infection treatment and increased Phenytoin toxicity.","  .  .            .","Relative contraindication. Avoid combination. If usage is necessary, both drug doses must be adjusted and levels monitored.");n("Voriconazole","Diazepam",e.DRUG_DRUG,i.HIGH,"  Diazepam. Voriconazole    CYP2C19  CYP3A4    Diazepam ().","Increased Diazepam Levels. Voriconazole is a potent inhibitor of CYP2C19 and CYP3A4, the enzymes responsible for Diazepam (a benzodiazepine) metabolism.","     .   Diazepam           .","Severe CNS Depression. Elevated Diazepam levels result in prolonged sedation, excessive drowsiness, and increased risk of respiratory depression and coma.","   /.    Diazepam      .      .","Monitor CNS/Sedation Status. Diazepam dose should be significantly reduced and the patient monitored closely. Using an alternative benzodiazepine may be necessary.");n("Voriconazole","Lorazepam",e.DRUG_DRUG,i.HIGH,"  Lorazepam  . Voriconazole     Lorazepam        Lorazepam        (Glucuronidation).","Increased Lorazepam Levels (Less Prominent). Voriconazole may indirectly affect Lorazepam metabolism, although Lorazepam is primarily cleared by glucuronidation.","     .    .","Severe CNS Depression. Risk of increased sedation and drowsiness.","   /.             .","Monitor CNS/Sedation Status. Monitor the patient; dose adjustment may be necessary if excessive sedation is noted.");n("Voriconazole","Alprazolam",e.DRUG_DRUG,i.HIGH,"  Alprazolam. Voriconazole    CYP3A4    Alprazolam ().","Increased Alprazolam Levels. Voriconazole is a potent inhibitor of CYP3A4, the enzyme responsible for Alprazolam (a benzodiazepine) metabolism.","     .   Alprazolam      .","Severe CNS Depression. Elevated Alprazolam levels result in prolonged sedation and excessive drowsiness.","   /.    Alprazolam      .","Monitor CNS/Sedation Status. Alprazolam dose should be significantly reduced and the patient monitored closely.");n("Voriconazole","Clonazepam",e.DRUG_DRUG,i.HIGH,"  Clonazepam. Voriconazole    CYP3A4    Clonazepam ().","Increased Clonazepam Levels. Voriconazole is a potent inhibitor of CYP3A4, the enzyme responsible for Clonazepam (a benzodiazepine) metabolism.","     .   Clonazepam      .","Severe CNS Depression. Elevated Clonazepam levels result in prolonged sedation and excessive drowsiness.","   /.    Clonazepam      .","Monitor CNS/Sedation Status. Clonazepam dose should be significantly reduced and the patient monitored closely.");n("Voriconazole","Buspirone",e.DRUG_DRUG,i.HIGH,"  Buspirone. Voriconazole    CYP3A4    Buspirone.","Increased Buspirone Levels. Voriconazole is a potent inhibitor of CYP3A4, the enzyme responsible for Buspirone metabolism.","     .   Buspirone        .","Severe CNS Depression. Elevated Buspirone levels enhance its sedative effects and increase the risk of neurological adverse effects.","   /.    Buspirone      .","Monitor CNS/Sedation Status. Buspirone dose should be significantly reduced and the patient monitored closely.");n("Voriconazole","Ciclosporin",e.DRUG_DRUG,i.HIGH,"  Ciclosporin. Voriconazole    CYP3A4     Ciclosporin.","Increased Cyclosporine Levels. Voriconazole is a potent inhibitor of CYP3A4, the major enzyme for Ciclosporin metabolism.","      .   Ciclosporin            .","Increased Risk of Nephrotoxicity and General Cyclosporine Toxicity. Elevated Ciclosporin levels drastically increase the risk of nephrotoxicity, hypertension, and neurotoxicity.","  Ciclosporin  .    Ciclosporin    ( 50%)   Voriconazole    .","Monitor Ciclosporin Concentrations and Renal Function. Ciclosporin dose must be drastically reduced (typically by 50%) upon initiating Voriconazole, and drug levels closely monitored.");n("Voriconazole","Dexamethasone",e.DRUG_DRUG,i.MODERATE,"  Dexamethasone. Voriconazole     Dexamethasone      ( Voriconazole   ).","Decreased Dexamethasone Concentration. Voriconazole may reduce Dexamethasone levels via induction of hepatic metabolizing enzymes (Voriconazole has mixed effects).","      .      Dexamethasone ( )   .","Altered Corticosteroid Efficacy or Increased Toxicity. May lead to loss of Dexamethasone efficacy (treatment failure), or potential toxicity."," .    Dexamethasone            .","Monitor Symptoms. Monitor Dexamethasone efficacy and adjust the dose based on the patients clinical response and cortisol levels if necessary.");n("Voriconazole","Grapefruit Juice ( )",e.DRUG_FOOD,i.MODERATE,"      .         CYP3A4        Voriconazole     .","Reduced Azole Absorption. While grapefruit juice may inhibit CYP3A4, it also impairs the solubility and absorption of Voriconazole, reducing its bioavailability.","   .   Voriconazole         .","Reduced Antifungal Efficacy. Decreased Voriconazole absorption can result in subtherapeutic levels and potential fungal treatment failure.","  .           Voriconazole.","Avoid this Combination. The patient should avoid consuming grapefruit juice during Voriconazole therapy.");n("Voriconazole","Phenobarbital",e.DRUG_DRUG,i.HIGH,"   Phenobarbital.  Phenobarbital    CYP450 (   CYP2C19  CYP3A4)    Voriconazole.","Metabolic Induction by Phenobarbital. Phenobarbital is a strong inducer of CYP450 enzymes (including CYP2C19 and CYP3A4) responsible for Voriconazole metabolism.","  Voriconazole     .             .","Reduced Voriconazole Levels and Fungal Treatment Failure. Severely decreased drug levels lead to loss of efficacy and risk of fungal resistance development.","    .         .","Avoid this Combination if possible. An alternative, non-enzyme-inducing anticonvulsant should be used.");n("Voriconazole","Pentobarbital",e.DRUG_DRUG,i.HIGH,"   Pentobarbital.  Pentobarbital    CYP450    Voriconazole.","Metabolic Induction by Pentobarbital. Pentobarbital is a strong inducer of CYP450 enzymes responsible for Voriconazole metabolism.","  Voriconazole     .             .","Reduced Voriconazole Levels and Fungal Treatment Failure. Severely decreased drug levels lead to loss of efficacy and risk of fungal resistance development.","    .     Pentobarbital    .","Avoid this Combination if possible. An alternative non-enzyme-inducing agent should be used.");n("Voriconazole","Secobarbital",e.DRUG_DRUG,i.HIGH,"   Secobarbital.  Secobarbital    CYP450    Voriconazole.","Metabolic Induction by Secobarbital. Secobarbital is a strong inducer of CYP450 enzymes responsible for Voriconazole metabolism.","  Voriconazole     .             .","Reduced Voriconazole Levels and Fungal Treatment Failure. Severely decreased drug levels lead to loss of efficacy and risk of fungal resistance development.","    .     Secobarbital    .","Avoid this Combination if possible. An alternative non-enzyme-inducing agent should be used.");n("Voriconazole","Carbamazepine",e.DRUG_DRUG,i.HIGH,"   Carbamazepine.  Carbamazepine    CYP450    Voriconazole.","Metabolic Induction by Carbamazepine. Carbamazepine is a potent inducer of CYP450 enzymes responsible for Voriconazole metabolism.","  Voriconazole     .          .","Reduced Voriconazole Levels and Fungal Treatment Failure. Severely decreased drug levels may lead to loss of efficacy.","    .         .","Avoid this Combination if possible. An alternative, non-enzyme-inducing anticonvulsant should be used.");n("Voriconazole","Ergot Alkaloids ( )",e.DRUG_DRUG,i.HIGH,"   . Voriconazole    CYP3A4         ( ).","Inhibition of Ergot Alkaloid Metabolism. Voriconazole is a potent CYP3A4 inhibitor, the primary enzyme responsible for the clearance of ergot alkaloids (e.g., Ergotamine).","        (Ergotism).               .","Increased Ergot Alkaloid Levels and Ergotism. Elevated levels can lead to severe peripheral and cerebral vasoconstriction, causing ischemia and gangrene.","    .       .","Avoid this Combination if possible. Co-administration is generally contraindicated due to the high risk of severe toxicity.");n("Voriconazole","Pimozide ",e.DRUG_DRUG,i.HIGH,"        ","        ","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .","    .");n("Voriconazole","Quinidine",e.DRUG_DRUG,i.HIGH,"        ","        ","    QT    .","QT Prolongation Risk. Ventricular arrhythmias.","    .","    .");n("Voriconazole","High-Fat Meal",e.DRUG_FOOD,i.MODERATE,"            (Cmax)  34%    (AUC)  24%.               pH        .            .","High-fat food negatively affects voriconazole absorption, reducing maximum concentration (Cmax) by 34% and area under curve (AUC) by 24%. Precise mechanism is not fully understood but believed related to delayed gastric emptying, gastric pH changes, or fat effect on intestinal membrane permeability. This decrease may impact therapeutic efficacy especially in severe fungal infections.","                     .                .","Moderate but clinically significant decrease in voriconazole absorption, potentially resulting in subtherapeutic blood levels in some patients. This may impair therapeutic response to serious invasive fungal infections such as aspergillosis or systemic candidiasis.","    (  )                     .        .      (TDM)          .  :   .","Oral voriconazole (tablets or suspension) should be taken at least one hour before or two hours after meals, preferably at same time daily for stable levels. If dose missed, do not double. Therapeutic drug monitoring (TDM) recommended in high-risk patients or those not responding to therapy. IV form: Not affected by food.");n("Atazanavir","Food",e.DRUG_FOOD,i.HIGH,"      70%           (  )   .","Food increases drug bioavailability by 70%, as the drug requires a high acidic environment in the stomach (available during digestion) to increase its dissolution and absorption.","              .","Significant and necessary improvement in absorption to ensure adequate therapeutic drug levels for HIV suppression.","     (   ) -       .","Must always be taken with food (light or full meal) - should never be taken on an empty stomach.");n("Voriconazole","Rifampin",e.DRUG_DRUG,i.HIGH,"   CYP450","Potent CYP450 induction accelerates voriconazole metabolism.","  ","Antifungal treatment failure.","  -    ","Avoid combination - use alternative antifungal.");n("Vortioxetine","Fluoxetine",e.DRUG_DRUG,i.HIGH,"  Vortioxetine. Fluoxetine    CYP2D6    Vortioxetine.","Increased Vortioxetine concentration. Fluoxetine is a strong inhibitor of CYP2D6, a Vortioxetine metabolic pathway.","     .","Increased risk of nausea and serotonergic side effects."," .    Vortioxetine ( ).","Dose adjustment. Vortioxetine dose must be reduced (by half).");n("Vosoritide","Amlodipine",e.DRUG_DRUG,i.MODERATE,"   . Vosoritide        .","Exacerbated hypotension. Vosoritide can cause transient decreases in blood pressure.","     (Hypotension)     .","Increased risk of hypotension and dizziness, especially with the first dose."," .             Vosoritide.","Caution and Monitoring. Blood pressure must be monitored, and temporary discontinuation of antihypertensives may be recommended before Vosoritide administration.");n("Vowst (Fecal Microbiota)","Vancomycin (Oral)",e.DRUG_DRUG,i.HIGH,"  Vowst.   (     )     Vowst.","Decreased Vowst efficacy. Antibiotics (especially those targeting enteric organisms) kill the live bacteria in Vowst.","           (C. difficile).","Failure to restore normal gut flora and increased risk of recurrent C. difficile infection."," .        24  72    Vowst.","Avoid Combination. All antibiotics must be discontinued 24 to 72 hours prior to Vowst administration.");n("Vowst (Fecal Microbiota)","Prednisone",e.DRUG_DRUG,i.MODERATE,"  Vowst.         Vowst.","Decreased Vowst efficacy. Immunosuppressants may hinder the colonization of live bacteria in Vowst.","        .","Failure to restore normal gut flora and increased risk of recurrent infection."," .         .","Efficacy monitoring. No contraindication, but clinical response must be monitored.");n("Vowst (Fecal Microbiota)","Omeprazole",e.DRUG_DRUG,i.MODERATE,"  Vowst. PPIs            .","Decreased Vowst efficacy. PPIs increase gastric pH, which may reduce the survival of live bacteria.","        .","Failure to restore normal gut flora and increased risk of recurrent infection."," .         .","Efficacy monitoring. No contraindication, but clinical response must be monitored.");n("Voxelotor","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Voxelotor. Ketoconazole    CYP3A4    Voxelotor.","Increased Voxelotor concentration. Ketoconazole is a strong CYP3A4 inhibitor, a Voxelotor metabolic pathway.","    QT.","Increased risk of QT prolongation."," .    Voxelotor     CYP3A4 .","Dose adjustment. Voxelotor dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Voxelotor","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Voxelotor. Itraconazole    CYP3A4    Voxelotor.","Increased Voxelotor concentration. Itraconazole is a strong CYP3A4 inhibitor, a Voxelotor metabolic pathway.","    QTc.","Increased risk of QTc prolongation."," .    Voxelotor ( 50%   ).","Dose adjustment. Voxelotor dose must be reduced (to 50% of the usual dose).");n("Voxelotor","Rifampin",e.DRUG_DRUG,i.HIGH,"  Voxelotor. Rifampin    CYP3A4.","Decreased Voxelotor concentration. Rifampin is a strong inducer of CYP3A4.","       .","Reduced drug efficacy and increased risk of vaso-occlusive crises."," .   .","Contraindicated. Avoid the combination.");n("Voxelotor","Ketoconazole",e.DRUG_DRUG,i.MODERATE,"  Voxelotor. Ketoconazole    CYP3A4.","Increased Voxelotor concentration. Ketoconazole is a strong inhibitor of CYP3A4.","    QTc.","Increased risk of QTc prolongation."," .    Voxelotor.","Dose adjustment. Voxelotor dose must be reduced.");n("Voxelotor (Oxbryta)","Strong CYP3A4 Inducers (Rifampin)",e.DRUG_DRUG,i.HIGH,": ** CYP3A4**.   Voxelotor  90%.","Mechanism: **CYP3A4 Induction**. Voxelotor concentration decreases by 90%."," : **    **.","Clinical Significance: **Sickle cell disease treatment failure**."," .    .","Avoid combination. Use alternative antibiotic.");n("Voxelotor (Oxbryta)","Strong CYP3A4 Inhibitors (Itraconazole)",e.DRUG_DRUG,i.MODERATE,": ** CYP3A4**.   Voxelotor  2.5 .","Mechanism: **CYP3A4 Inhibition**. Voxelotor concentration increases 2.5-fold."," : **  **.","Clinical Significance: **Increased adverse effects**.","  Voxelotor  1000 mg   .","Reduce Voxelotor dose to 1000 mg once daily.");n("Vraylar (Cariprazine)","Clarithromycin",e.DRUG_DRUG,i.HIGH,"    Cariprazine   . Clarithromycin    CYP3A4.","Significant increase in Cariprazine and active metabolite concentration. Clarithromycin is a strong inhibitor of CYP3A4.","    QTc    (EPS).","Increased risk of QTc prolongation and extrapyramidal symptoms (EPS)."," .    Cariprazine    QTc.","Dose adjustment. Cariprazine dose must be significantly reduced, and QTc monitored.");n("Vraylar (Cariprazine)","Carbamazepine",e.DRUG_DRUG,i.HIGH,"    Cariprazine  . Carbamazepine    CYP3A4.","Significant decrease in Cariprazine and active metabolite concentration. Carbamazepine is a strong inducer of CYP3A4.","   .","Reduced antipsychotic efficacy."," .   .","Contraindicated. Avoid the combination.");n("Vutrisiran","Midazolam",e.DRUG_DRUG,i.MODERATE,"  Midazolam. Vutrisiran     CYP3A4.","Decreased Midazolam concentration. Vutrisiran may cause induction of CYP3A4 enzymes.","  Midazolam          .","Reduced efficacy of Midazolam, potentially leading to failure of sedation or seizure control."," .    Midazolam ( )  .","Efficacy monitoring. Efficacy of Midazolam (or its alternatives) must be monitored and dose adjusted.");n("Vutrisiran (RNAi)","Strong CYP Inducers/Inhibitors",e.DRUG_DRUG,i.LOW,"     . Vutrisiran       .","No clinically significant interaction expected. Vutrisiran is cleared by ribonuclease enzymatic degradation.","   .   .","No known effect. They are used safely together.","    .   .","No special action required. They are used safely together.");n("Warfarin","Acetaminophen",e.DRUG_DRUG,i.MODERATE,": **    **.    (  2 /)   .","Mechanism: **Metabolism inhibition at high doses**. Acetaminophen at high doses (>2g/day) inhibits Warfarin metabolism."," : ** INR**   .","Clinical Significance: **Increased INR** with prolonged use."," INR      .","Monitor INR when using high doses for prolonged periods.");n("Warfarin","Amiodarone",e.DRUG_DRUG,i.HIGH,": **   (CYP2C9 & CYP1A2)**.      .","Mechanism: **Potent metabolism inhibition (CYP2C9 & CYP1A2)**. Amiodarone inhibits key enzymes for Warfarin metabolism."," : **   INR**          .","Clinical Significance: **Significant INR elevation** and bleeding risk; effect may persist for weeks after stopping Amiodarone.","    30-50% .  INR .","Reduce Warfarin dose by 30-50% immediately. Monitor INR regularly.");n("Warfarin",Tt,e.DRUG_DRUG,i.HIGH,": **  (CYP2C9)**.    .","Mechanism: **Metabolism induction (CYP2C9)**. Barbiturates induce Warfarin metabolism."," : **  **   .","Clinical Significance: **Decreased Warfarin effect** and increased clotting risk.","  .  INR    .","Increase Warfarin dose. Monitor INR upon initiation or discontinuation.");n("Warfarin","Carbamazepine",e.DRUG_DRUG,i.HIGH,": **  (CYP2C9, CYP3A4)**.    .","Mechanism: **Metabolism induction (CYP2C9, CYP3A4)**. Carbamazepine induces Warfarin metabolism."," : **      50%**   .","Clinical Significance: **Decreased Warfarin effect by up to 50%** and increased clotting risk.","  .  INR .","Increase Warfarin dose. Monitor INR closely.");n("Warfarin",Hc,e.DRUG_DRUG,i.HIGH,": **   K  **.       K  ( Cefotetan)   .","Mechanism: **Vitamin K production inhibition and platelet inhibition**. Some cephalosporins kill Vitamin K-producing bacteria, and some (e.g., Cefotetan) inhibit platelet function."," : **  **  .","Clinical Significance: **Increased Warfarin effect** and bleeding risk."," INR     .    .","Monitor INR regularly upon initiation or discontinuation. Dose adjustment may be required.");n("Warfarin","Cholestyramine",e.DRUG_DRUG,i.MODERATE,": **  **.     .","Mechanism: **Intestinal binding**. Cholestyramine binds to Warfarin in the intestines."," : **  **  INR.","Clinical Significance: **Decreased Warfarin absorption** and low INR.","      4-6   .","Take Warfarin 1 hour before or 4-6 hours after Cholestyramine.");n("Warfarin","Cimetidine",e.DRUG_DRUG,i.HIGH,": **  (CYP1A2, CYP3A4, CYP2C9)**.    .","Mechanism: **Metabolism inhibition (CYP1A2, CYP3A4, CYP2C9)**. Cimetidine inhibits Warfarin metabolism."," : **  **  INR  .","Clinical Significance: **Increased Warfarin levels**, elevated INR, and bleeding risk."," .      .","Avoid combination. Use Ranitidine or Famotidine as safe alternatives.");n("Warfarin",iy,e.DRUG_DRUG,i.HIGH,": **   **.       .","Mechanism: **Protein displacement and metabolism inhibition**. Fibrates displace Warfarin from protein and inhibit its metabolism."," : **  **  INR  .","Clinical Significance: **Increased Warfarin effect**, elevated INR, and bleeding risk.","    25-50%.  INR .","Reduce Warfarin dose by 25-50%. Monitor INR regularly.");n("Warfarin",Sc,e.DRUG_DRUG,i.MODERATE,": **   (CYP2C9)**.        .","Mechanism: **Metabolic competition (CYP2C9)**. Some statins compete with Warfarin for the same enzymes."," : **    **  INR.","Clinical Significance: **Mild increase in Warfarin effect** and elevated INR."," INR      .     .","Monitor INR upon starting or changing statin dose. Minor dose adjustment may be needed.");n("Warfarin",xc,e.DRUG_DRUG,i.HIGH,": **     **.             .","Mechanism: **Synergistic bleeding effect and gastric damage**. NSAIDs inhibit platelets and cause gastric irritation, while Warfarin inhibits coagulation."," : **     **     INR.","Clinical Significance: **Risk of severe and fatal gastrointestinal bleeding**, often without changing INR.","  .      COX-2     .","Strictly avoid combination. Use Paracetamol for pain, or COX-2 inhibitors with extreme caution and gastric protection.");n("Warfarin","Vitamin K",e.DRUG_FOOD,i.HIGH,"   -  K   ","Direct pharmacological antagonism - Vitamin K is the antidote to Warfarin."," INR    ","Decreased INR and loss of anticoagulant effect.","     K -  INR","Avoid vitamin K-rich supplements - Monitor INR.");n("Warfarin","Aspirin",e.DRUG_DRUG,i.HIGH,"  (Synergistic Effect).  Warfarin      K   Aspirin (  )       .    .","Synergistic Effect. Warfarin inhibits vitamin K-dependent clotting factors, while Aspirin (even at low doses) irreversibly inhibits platelet function. The combination drastically potentiates bleeding risk.","    .             .","Significantly Increased Bleeding Risk. Very high risk of life-threatening hemorrhage, particularly gastrointestinal and intracranial bleeding.","   .                      (INR)    .","Avoid Combination Generally. If co-administration is necessary for specific cardiovascular indications, it must be done with extreme caution under specialized guidance, with regular monitoring of INR and GI status.");n("Warfarin","Ibuprofen",e.DRUG_DRUG,i.HIGH,"    . Ibuprofen            .","Antiplatelet Effect & Gastric Irritation. Ibuprofen directly inhibits platelet function, and both agents cause gastric mucosal irritation. This results in a synergistic risk of bleeding.","  .               .","Severe Gastrointestinal Hemorrhage. The combination drastically increases the risk of GI bleeding, including ulceration and potentially life-threatening hemorrhage."," .    .     ( /)    Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic (e.g., Acetaminophen/Paracetamol) for patients on Warfarin.");n("Warfarin","Diclofenac",e.DRUG_DRUG,i.HIGH,"    . Diclofenac            .","Antiplatelet Effect & Gastric Irritation. Diclofenac inhibits platelet function, and both agents contribute to gastric mucosal damage.","  .         .","Severe Gastrointestinal Hemorrhage. The combination drastically increases the risk of severe GI bleeding."," .    .        Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic for patients on Warfarin.");n("Warfarin","Naproxen",e.DRUG_DRUG,i.HIGH,"    . Naproxen              .","Antiplatelet Effect & Gastric Irritation. Naproxen causes prolonged platelet inhibition, and both agents contribute to gastric mucosal damage.","  .         .","Severe Gastrointestinal Hemorrhage. The combination drastically increases the risk of severe GI bleeding."," .    .        Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic for patients on Warfarin.");n("Warfarin","Ketoprofen",e.DRUG_DRUG,i.HIGH,"    . Ketoprofen            .","Antiplatelet Effect & Gastric Irritation. Ketoprofen inhibits platelet function, and both agents contribute to gastric mucosal damage.","  .         .","Severe Gastrointestinal Hemorrhage. The combination drastically increases the risk of severe GI bleeding."," .    .        Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic for patients on Warfarin.");n("Warfarin","Indomethacin",e.DRUG_DRUG,i.HIGH,"    . Indomethacin            .","Antiplatelet Effect & Gastric Irritation. Indomethacin inhibits platelet function, and both agents contribute to gastric mucosal damage.","  .         .","Severe Gastrointestinal Hemorrhage. The combination drastically increases the risk of severe GI bleeding."," .    .        Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic for patients on Warfarin.");n("Warfarin","Celecoxib",e.DRUG_DRUG,i.HIGH,"    +  CYP2C9. Celecoxib (NSAID)         Warfarin   CYP2C9      .","Platelet Inhibition, Gastric Irritation, & CYP2C9 Inhibition. Celecoxib increases GI bleeding risk and may inhibit Warfarin metabolism via CYP2C9, potentiating its anticoagulant effect.","   .            .","Gastrointestinal and General Bleeding. High risk of bleeding, including GI hemorrhage, due to the dual mechanism of action."," .    .        Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic for patients on Warfarin.");n("Warfarin","Mefenamic Acid",e.DRUG_DRUG,i.HIGH,"    . Mefenamic Acid            .","Antiplatelet Effect & Gastric Irritation. Mefenamic Acid inhibits platelet function, and both agents contribute to gastric mucosal damage.","  .         .","Severe Gastrointestinal Hemorrhage. The combination drastically increases the risk of severe GI bleeding."," .    .        Warfarin.","Avoid Combination. This interaction is contraindicated due to high risk. Use an alternative analgesic for patients on Warfarin.");n("Warfarin","Cimetidine",e.DRUG_DRUG,i.MODERATE,"     Warfarin. Cimetidine   CYP450  CYP2C9    S-Warfarin (  ).","Inhibition of Hepatic Enzymes Metabolizing Warfarin. Cimetidine inhibits CYP450 enzymes, particularly CYP2C9, which metabolizes S-Warfarin (the more potent enantiomer)."," INR .       (INR)   .","Increased INR and Bleeding. Leads to elevated International Normalized Ratio (INR) and increased risk of hemorrhage."," Ranitidine .    Cimetidine ( Ranitidine    )    CYP2C9    INR   Warfarin.","Use Ranitidine as an Alternative. Alternatives (like Ranitidine or PPIs) that do not inhibit CYP2C9 are preferred. Otherwise, monitor INR and adjust Warfarin dose.");n("Warfarin","Amiodarone",e.DRUG_DRUG,i.HIGH,"  Warfarin (CYP2C9). Amiodarone     CYP2C9    S-Warfarin.","Inhibition of Warfarin Metabolism (CYP2C9). Amiodarone is a potent inhibitor of CYP2C9, which metabolizes S-Warfarin.","   INR.       INR       .","Dangerously Elevated INR. Leads to an acute and sustained increase in INR, significantly raising the risk of severe bleeding.","  Warfarin 30-50%.    Warfarin    30%  50%   Amiodarone    INR  .","Reduce Warfarin Dose by 30-50%. Warfarin dosage must be reduced by 30% to 50% upon initiating Amiodarone, with daily INR monitoring for several weeks.");n("Warfarin","Cotrimoxazole (Septrin)",e.DRUG_DRUG,i.HIGH,"    . Sulfamethoxazole (  Cotrimoxazole)  CYP2C9  Warfarin     .","Metabolic Inhibition & Protein Displacement. Sulfamethoxazole (part of Cotrimoxazole) inhibits CYP2C9 and displaces Warfarin from plasma protein binding sites."," INR .      Warfarin         INR  .","Elevated INR and Bleeding. Significantly increases the free, active Warfarin concentration, leading to a sharp rise in INR and hemorrhage risk.","    Warfarin.   Cotrimoxazole.        Warfarin  50%      INR.","Avoid Combination or Reduce Warfarin. Cotrimoxazole should be avoided. If mandatory, Warfarin dose must be reduced by 50% or more, with daily INR monitoring.");n("Warfarin","Erythromycin",e.DRUG_DRUG,i.HIGH,"  . Erythromycin   CYP3A4  CYP2C9     Warfarin.","Hepatic Enzyme Inhibition. Erythromycin inhibits CYP3A4 and CYP2C9, reducing Warfarin metabolism.","  Warfarin.     INR   .","Potentiated Warfarin Effect. Leads to elevated INR and increased risk of bleeding."," INR .   INR  (   )   Warfarin  .","Monitor INR Closely. INR must be monitored regularly (especially in the first week) and Warfarin dose adjusted as needed.");n("Warfarin","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  . Clarithromycin    CYP3A4  CYP2C9     Warfarin.","Hepatic Enzyme Inhibition. Clarithromycin is a potent inhibitor of CYP3A4 and CYP2C9, reducing Warfarin metabolism.","  Warfarin.      INR   .","Potentiated Warfarin Effect. Leads to a sharp rise in INR and increased risk of bleeding."," INR .   INR  (   )   Warfarin  .","Monitor INR Closely. INR must be monitored regularly (especially in the first week) and Warfarin dose adjusted as needed.");n("Warfarin","Metronidazole (Flagyl)",e.DRUG_DRUG,i.HIGH,"  . Metronidazole    CYP2C9    S-Warfarin.","Potent Metabolic Inhibition. Metronidazole is a strong inhibitor of CYP2C9, which metabolizes S-Warfarin.","   INR.         INR   .","Sharp Increase in INR. Can lead to a significant and rapid rise in INR and severe bleeding risk.","  Warfarin.    Warfarin  50%     Metronidazole    INR.","Reduce Warfarin Dose. Warfarin dosage should be reduced by 50% or more upon initiating Metronidazole, with frequent INR monitoring.");n("Warfarin","Fluconazole",e.DRUG_DRUG,i.HIGH," CYP2C9. Fluconazole     CYP2C9    S-Warfarin.","CYP2C9 Inhibition. Fluconazole is a potent inhibitor of CYP2C9, which metabolizes S-Warfarin."," .    INR  .","Potential Bleeding. Significant increase in INR and risk of hemorrhage."," INR.   INR         Warfarin  .","Monitor INR. INR must be monitored regularly, especially within the first few days, and Warfarin dose reduced as needed.");n("Warfarin","Rifampin",e.DRUG_DRUG,i.HIGH,"  . Rifampin     CYP450  CYP2C9  CYP3A4    Warfarin.","Hepatic Enzyme Induction. Rifampin is a potent inducer of CYP450 enzymes, particularly CYP2C9 and CYP3A4, which metabolize Warfarin.","  Warfarin .        Warfarin      INR    .","Warfarin Failure and Thrombosis. Leads to a rapid and severe drop in Warfarin concentration, causing reduced INR and failure of anticoagulant protection (thrombosis risk).","  Warfarin.    Warfarin   (     )   Rifampin    INR.","Increase Warfarin Dose. Warfarin dose must be significantly increased (may need to be doubled or more) upon initiating Rifampin, with daily INR monitoring.");n("Warfarin","Phenobarbital",e.DRUG_DRUG,i.HIGH,"  . Phenobarbital     CYP450    Warfarin.","Hepatic Enzyme Induction. Phenobarbital is a strong inducer of CYP450 enzymes responsible for Warfarin metabolism.","  Warfarin.     Warfarin    INR.","Decreased Warfarin Efficacy. Leads to reduced Warfarin concentration in the blood and decreased INR.","    .    Warfarin        INR.        .","Increase Dose or Avoid Combination. Warfarin dose must be significantly increased upon initiation, with close INR monitoring. Prefer alternative, non-enzyme-inducing anticonvulsants.");n("Warfarin","Pentobarbital",e.DRUG_DRUG,i.HIGH,"  . Pentobarbital     CYP450    Warfarin.","Hepatic Enzyme Induction. Pentobarbital is a strong inducer of CYP450 enzymes responsible for Warfarin metabolism.","  Warfarin.     Warfarin    INR.","Decreased Warfarin Efficacy. Leads to reduced Warfarin concentration in the blood and decreased INR.","    .    Warfarin        INR.","Increase Dose or Avoid Combination. Warfarin dose must be significantly increased upon initiation, with close INR monitoring.");n("Warfarin","Secobarbital",e.DRUG_DRUG,i.HIGH,"  . Secobarbital     CYP450    Warfarin.","Hepatic Enzyme Induction. Secobarbital is a strong inducer of CYP450 enzymes responsible for Warfarin metabolism.","  Warfarin.     Warfarin    INR.","Decreased Warfarin Efficacy. Leads to reduced Warfarin concentration in the blood and decreased INR.","    .    Warfarin        INR.","Increase Dose or Avoid Combination. Warfarin dose must be significantly increased upon initiation, with close INR monitoring.");n("Warfarin","Carbamazepine",e.DRUG_DRUG,i.HIGH," . Carbamazepine     CYP450     Warfarin.","Metabolic Induction. Carbamazepine is a potent inducer of CYP450 enzymes, accelerating Warfarin clearance."," .     Warfarin    INR     .","Decreased Efficacy. Severe reduction in Warfarin concentration and lowered INR, increasing the risk of thrombosis."," INR.    Warfarin    INR  (   )     Carbamazepine.","Monitor INR. Warfarin dose must be significantly increased, and INR monitored regularly (at least twice weekly) when initiating or discontinuing Carbamazepine.");n("Warfarin","Cholestyramine",e.DRUG_DRUG,i.MODERATE,"   . Cholestyramine         Warfarin   .","Drug Binding in the Intestines. Cholestyramine is a bile acid sequestrant resin that can bind to Warfarin in the gastrointestinal tract."," .        Warfarin      INR.","Decreased Absorption. Binding leads to reduced Warfarin bioavailability, resulting in decreased efficacy and lower INR.","  4-6 .   Warfarin   Cholestyramine          .","Separate Doses by 4-6 hours. Administer Warfarin 1 hour before or 4 to 6 hours after Cholestyramine to minimize the interaction.");n("Warfarin","Thyroid Hormones (Levothyroxine)",e.DRUG_DRUG,i.MODERATE,"   .            K ( II VII IX X).","Increased Clotting Factor Catabolism. Thyroid hormones enhance the degradation of vitamin K-dependent clotting factors (Factors II, VII, IX, X).","  Warfarin.     INR         Levothyroxine   .","Potentiated Warfarin Effect. Leads to elevated INR and increased bleeding risk, especially upon initiation or dose increase of Levothyroxine."," INR.   INR     Warfarin (    )        .","Monitor INR. INR must be monitored frequently, and Warfarin dose adjusted (dose reduction may be required) when initiating or changing the thyroid hormone dose.");n("Warfarin","Vitamin K (Spinach, Liver)",e.DRUG_FOOD,i.MODERATE,"  (Antagonism).","Pharmacological antagonism.","  .","Reduced warfarin efficacy.","   K  .","Maintain consistent Vitamin K intake in diet.");n("Warfarin","Cranberry Juice",e.DRUG_FOOD,i.MODERATE," .","Metabolic Inhibition. Competitive or non-competitive inhibition of metabolic enzymes (e.g., CYP450)."," INR."," INR."," ."," .");n("Warfarin","Ginkgo Biloba / Garlic / Ginger",e.DRUG_FOOD,i.MODERATE,"  .","Antiplatelet effect.","  .","Increased bleeding risk.","  .","Avoid herbal supplements.");n("Warfarin","Itraconazole",e.DRUG_DRUG,i.HIGH,"   (CYP)    .","Warfarin Potentiation. CYP inhibition increases bleeding risk.","       .","Increased blood warfarin concentration and bleeding risk.","   INR   .","Close INR monitoring and warfarin dose adjustment.");n("Warfarin","Ketoconazole",e.DRUG_DRUG,i.HIGH,"   (CYP)    .","Warfarin Potentiation. CYP inhibition increases bleeding risk.","       .","Increased blood warfarin concentration and bleeding risk.","   INR   .","Close INR monitoring and warfarin dose adjustment.");n("Warfarin","Voriconazole",e.DRUG_DRUG,i.HIGH,"   (CYP)    .","Warfarin Potentiation. CYP inhibition increases bleeding risk.","       .","Increased blood warfarin concentration and bleeding risk.","   INR   .","Close INR monitoring and warfarin dose adjustment.");n("Warfarin","Green Leafy Vegetables (Vitamin K)",e.DRUG_FOOD,i.MODERATE," K    ( ).","Vitamin K antagonizes warfarin action (clotting factor).","     .","Reduced warfarin efficacy and increased clotting risk.","          .","Maintain consistent daily intake of leafy vegetables; avoid sudden changes.");n("Warfarin","Vitamin K-Rich Foods (Spinach, Kale, Broccoli, Cabbage)",e.DRUG_FOOD,i.HIGH," K   ","Vitamin K antagonizes warfarin effect","   -   ","Reduced warfarin efficacy - increased clotting risk","         -      ","Do not ban vegetables but maintain consistent daily intake - do not change green vegetable quantity suddenly");n("Warfarin","Cranberry Juice",e.DRUG_FOOD,i.HIGH,"  ","Increased warfarin effect","  ","Bleeding Risk. Hemorrhage.","         -  INR","Avoid cranberry juice or drink in small consistent amounts - monitor INR");n("Warfarin","Alcohol",e.DRUG_FOOD,i.HIGH,"     ","Increased bleeding risk and effect on liver","  ","Potential serious bleeding","       -  INR","Avoid alcohol or drink in very small amounts - monitor INR");n("Warfarin","Liver Disease / Hepatic Impairment",e.DRUG_DISEASE,i.HIGH,"    +   ","Reduced synthesis of clotting factors + reduced Warfarin metabolism.","  ","Unexpected bleeding.","   Child-Pugh -   ","Adjust dose based on Child-Pugh - monitor liver function.");n("Warfarin","Garlic ()",e.DRUG_FOOD,i.MODERATE,"            .","Garlic inhibits platelet aggregation and may reduce clotting factors, enhancing Warfarin's effect.","   (Bleeding Risk)         .","Increased risk of bleeding and bruising, especially with high doses or supplements."," INR  .       .     .","Monitor INR frequently. Avoid high doses or supplements of Garlic. Stop Garlic 1 week before surgery.");n("Warfarin","Ginkgo Biloba ()",e.DRUG_FOOD,i.HIGH,"         .","Ginkgo Biloba extracts inhibit platelet aggregation and increase blood fluidity.","        (Intracranial Hemorrhage)  .","Potentially serious bleeding, including life-threatening intracranial hemorrhage.","  .  .  INR      .","Relative contraindication. Avoid combination. Monitor INR closely if use is unavoidable.");n("Warfarin","Amoxicillin-Clavulanate",e.DRUG_DRUG,i.MODERATE,"  K ","Intestinal vitamin K inhibition."," INR  ","Increased INR and bleeding risk."," INR  3-5 ","Monitor INR after 3-5 days.");n("Warfarin","Acetaminophen",e.DRUG_DRUG,i.MODERATE," CYP2C9 ( )","CYP2C9 inhibition (at high doses)."," INR","Increased INR."," INR     2 /","Monitor INR if using >2g/day.");n("Warfarin","Vitamin K (in foods)",e.DRUG_FOOD,i.MODERATE," K   ","Vitamin K antagonizes warfarin effect."," INR -   ","Decreased INR - increased clotting risk.","     -  ","Consistent intake of leafy greens - don't avoid them.");n("Warfarin","Cranberry Juice",e.DRUG_FOOD,i.MODERATE," CYP2C9 ( )","CYP2C9 inhibition (proposed mechanism)."," INR  ","Increased INR and bleeding risk.","   -  INR","Avoid large amounts - Monitor INR.");n("Warfarin","Alcohol",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Caffeine",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Grapefruit Juice",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Green Tea",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Milk",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","High-fat meals",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","High-fiber foods",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Vitamin C",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Vitamin D",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Vitamin E",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Vitamin K",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Vitamin B12",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Folic Acid",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Iron",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Calcium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Magnesium",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Zinc",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Potassium",e.DRUG_FOOD,i.LOW,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Sodium Bicarbonate",e.DRUG_FOOD,i.HIGH,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin","Antacids",e.DRUG_FOOD,i.MODERATE,"  ","Drug-food interaction affecting absorption or metabolism.","    ","Effect on absorption or efficacy."," -    ","Monitor - separate doses if needed.");n("Warfarin - ","Vitamin K-Rich Foods -    ",e.DRUG_FOOD,i.HIGH,"  K           II, VII, IX, X           .    epoxide reductase      K   .      K              .     (   )    INR       .","Vitamin K acts as an essential cofactor in the post-translational carboxylation of clotting factors II, VII, IX, and X in the liver, granting them the ability to bind calcium and platelets. Warfarin inhibits the epoxide reductase enzyme responsible for recycling vitamin K to its active form. High vitamin K intake provides an alternative cofactor, bypassing warfarin inhibition and restoring normal clotting factor synthesis. Sudden changes in intake (either increase or decrease) cause INR fluctuations as they alter the balance between the drug and its cofactor."," INR     ( 2-3         2.5-3.5  ).          : 1.   . 2.  . 3.   . 4.   . 5.     .                K.","Decreased INR below the target therapeutic range (usually 2-3 for stroke prevention in atrial fibrillation, or 2.5-3.5 for mechanical valves). This significantly increases the risk of clotting, including: 1. Deep vein thrombosis. 2. Pulmonary embolism. 3. Thrombotic stroke. 4. Myocardial infarction. 5. Mechanical valve failure due to thrombi. These events can occur within days of a sudden increase in vitamin K intake.","1.   :       K   . 2.  :       K (     )  . 3. :  INR       . 4.  :        . 5.  :       INR      . 6. :           .","1. Consistency is key: Maintain a consistent daily intake of vitamin K, not avoidance. 2. Nutritional education: Provide the patient with a list of vitamin K-rich foods (spinach, kale, broccoli, lettuce, cilantro, parsley) and their approximate content. 3. Monitoring: Check INR weekly when making any significant dietary changes. 4. Food diary: Encourage the patient to keep a food diary to track intake. 5. Dose adjustment: Adjust warfarin dose based on INR readings, not on anticipated dietary changes. 6. Communication: Emphasize the importance of informing the doctor before making major dietary changes.");n("Warfarin ()","Cefalosporin ( Ceftriaxone)",e.DRUG_DRUG,i.HIGH,"      .","Unspecified mechanism leading to increased warfarin efficacy.","     INR     .","Increased warfarin efficacy and elevated INR, increasing bleeding risk.","   (INR).","Monitor Prothrombin Time (INR).");n("Wegovy (Semaglutide)","Ethanol (Alcohol)",e.DRUG_FOOD,i.MODERATE,"    .      .","Increased risk of hypoglycemia. Alcohol enhances the glucose-lowering effect.","   .","Severe hypoglycemia."," .       .","Patient education. The patient must limit alcohol intake.");n("Yasmin","Aspirin",e.DRUG_DRUG,i.HIGH,"  ","Increased potassium levels","  ","Cardiac arrhythmias","  ","Use Paracetamol as an alternative");n("Yellow Fever Vaccine (Live)","Cyclophosphamide",e.DRUG_DRUG,i.HIGH,"          .","Cyclophosphamide is an alkylating agent causing severe depletion of T and B lymphocytes.","         .","Complete immunological failure and increased risk of life-threatening disseminated vaccine disease.","  .     3     .","Absolute contraindication. Must postpone vaccination until 3 months after stopping chemotherapy.");n("Zafirlukast - ","Fluconazole - ",e.DRUG_DRUG,i.MODERATE,"     CYP2C9           .","Fluconazole is a potent inhibitor of the CYP2C9 enzyme, which is the primary metabolic pathway responsible for the breakdown and elimination of Zafirlukast.","                        .","Enzyme inhibition slows Zafirlukast clearance, causing plasma concentrations to accumulate and increasing the patients exposure to side effects, especially hepatotoxicity, headache, and gastrointestinal disturbances."," .        (LFTs).             .","Strict monitoring. Monitor for signs of side effects and Liver Function Tests (LFTs). There is no absolute contraindication, but a reduction in the Zafirlukast dose may be necessary.");n("Zafirlukast - ","Erythromycin - ",e.DRUG_DRUG,i.MODERATE,"     CYP3A4      .","Erythromycin is a strong inhibitor of the CYP3A4 enzyme, a secondary metabolic pathway for Zafirlukast.","  (Interaction).   CYP3A4                    .","Drug exchange. CYP3A4 inhibition reduces Zafirlukast clearance from the blood, increasing its concentration and the potential for side effects, including increased strain on the liver.",".       (LFTs)     .        .","Monitoring. Side effects and Liver Function Tests (LFTs) must be monitored due to the increase in Zafirlukast concentration. No absolute contraindication, but monitoring is necessary.");n("Zafirlukast - ","Rifampin - ",e.DRUG_DRUG,i.HIGH,"       CYP2C9  CYP3A4     .","Rifampin is a potent inducer of both CYP2C9 and CYP3A4 enzymes, which are the main metabolic pathways for Zafirlukast.","                        (Subtherapeutic Levels).","Dual induction of metabolic enzymes drastically accelerates the breakdown and elimination of Zafirlukast, causing its plasma concentration to drop to subtherapeutic (ineffective) levels."," .    CYP             .      .","Avoid Combination. Strong CYP inducers like Rifampin must be avoided, as this interaction leads to a loss of asthma control. One of the two drugs must be replaced with a suitable alternative.");n("Zafirlukast","Warfarin",e.DRUG_DRUG,i.HIGH,": **  CYP2C9**.    CYP2C9    S  ( )         .","Mechanism: **CYP2C9 enzyme inhibition**. Zafirlukast inhibits CYP2C9 enzyme which metabolizes the S-enantiomer of warfarin (more potent), reducing its clearance and increasing blood levels."," : **   INR** (   35-45%   ) **   **         .     ( 3-5    )    .","Clinical Significance: **Significant INR increase** (may be 35-45% higher than usual) and **increased risk of major bleeding** including intracranial hemorrhage, gastrointestinal bleeding, and hemarthrosis. This interaction occurs rapidly (within 3-5 days of starting zafirlukast) and can be dangerous."," INR ** ** ( 2-3 )     . **      20-30%**   .     (       ).    **   **       .","Monitor INR **frequently** (every 2-3 days) when starting or stopping zafirlukast. **Proactively reduce warfarin dose by 20-30%** when adding zafirlukast. Educate patient on bleeding signs (bruising, gum bleeding, blood in stool or urine). Consider using **montelukast instead of zafirlukast** as it does not interact with warfarin as strongly.");n("Zanubrutinib","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Zanubrutinib. Phenytoin    CYP3A4    Zanubrutinib.","Decreased Zanubrutinib efficacy. Phenytoin is a strong inducer of CYP3A4, a Zanubrutinib metabolic pathway.","         .","Reduced drug plasma concentration, leading to treatment failure."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Zanubrutinib","Warfarin",e.DRUG_DRUG,i.MODERATE,"  . Zanubrutinib     (   )   CYP2C9 (   Warfarin).","Increased bleeding risk. Zanubrutinib increases bleeding risk (due to antiplatelet effect) and affects CYP2C9 (a major Warfarin metabolism component).","    .","Increased risk of bruising and severe hemorrhage."," .   INR    Warfarin.","Close monitoring. INR must be monitored regularly and Warfarin dose adjusted.");n("Zanubrutinib","High Fat Meal",e.DRUG_FOOD,i.MODERATE,"  Zanubrutinib.        .","Increased Zanubrutinib concentration. High-fat meals increase the bioavailability of the drug.","     .","Slight increase in the risk of side effects."," .   Zanubrutinib      (  )     .","Dose consistency. Zanubrutinib should be taken consistently with or without food (to maintain consistency) or follow dose instructions precisely.");n("Zanubrutinib (Brukinsa)","Strong CYP3A4 Inhibitors (Posaconazole)",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   Zanubrutinib  3-4 .","Mechanism: **Potent CYP3A4 inhibition**. Zanubrutinib concentration increases 3-4 fold."," : **  **  .","Clinical Significance: **Increased bleeding risk** and atrial fibrillation.","  Zanubrutinib  80 mg   .","Reduce Zanubrutinib dose to 80 mg once daily.");n("Zanubrutinib (Brukinsa)","Strong CYP3A4 Inducers (Rifampin)",e.DRUG_DRUG,i.HIGH,": **   CYP3A4**.   Zanubrutinib  90%.","Mechanism: **Potent CYP3A4 induction**. Zanubrutinib concentration decreases by 90%."," : **     **.","Clinical Significance: **CLL treatment failure**."," .    .","Avoid combination. Use alternative antibiotic.");n("Zanubrutinib (Brukinsa)","Anticoagulants (Warfarin)",e.DRUG_DRUG,i.HIGH,": **   **.     .","Mechanism: **Synergistic bleeding effect**. Both drugs increase bleeding risk."," : ** **   .","Clinical Significance: **Severe bleeding** especially intracranial hemorrhage."," .         .","Avoid combination. Use alternative anticoagulant with extreme caution and close monitoring.");n("Zanubrutinib (Brukinsa)","Antiplatelet Agents (Aspirin/Clopidogrel)",e.DRUG_DRUG,i.HIGH,": **    **.   .","Mechanism: **Synergistic platelet inhibition**. Severe bleeding risk."," : **  **  .","Clinical Significance: **GI bleeding** and intracranial hemorrhage.","  .      .","Use with extreme caution. Avoid high-dose antiplatelet agents.");n("Zavegepant","Clarithromycin",e.DRUG_DRUG,i.HIGH,"  Zavegepant. Clarithromycin    CYP3A4    Zavegepant.","Increased Zavegepant concentration. Clarithromycin is a strong CYP3A4 inhibitor, a Zavegepant metabolic pathway.","         ( ).","Increased risk of side effects, especially local nasal reactions (for the spray form)."," /.     CYP3A4   24   Zavegepant.","Dose adjustment/Avoidance. Strong CYP3A4 inhibitors should be avoided for 24 hours after Zavegepant.");n("Zavegepant","Phenytoin",e.DRUG_DRUG,i.HIGH,"  Zavegepant. Phenytoin    CYP3A4    Zavegepant.","Decreased Zavegepant efficacy. Phenytoin is a strong inducer of CYP3A4, a Zavegepant metabolic pathway.","            .","Reduced drug plasma concentration, leading to failure of acute migraine treatment."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Zavegepant","Itraconazole",e.DRUG_DRUG,i.HIGH,"  Zavegepant. Itraconazole    CYP3A4    Zavegepant.","Increased Zavegepant concentration. Itraconazole is a strong CYP3A4 inhibitor, a metabolic pathway for Zavegepant.","       .","Increased risk of side effects, especially injection site reactions."," .    Zavegepant     CYP3A4 .","Dose adjustment. Zavegepant dose must be reduced when co-administered with strong CYP3A4 inhibitors.");n("Zavegepant","Rifampin",e.DRUG_DRUG,i.HIGH,"  Zavegepant. Rifampin    CYP3A4    Zavegepant.","Decreased Zavegepant efficacy. Rifampin is a strong inducer of CYP3A4, a Zavegepant metabolic pathway.","           .","Reduced drug plasma concentration, leading to failure of migraine treatment."," .    CYP3A4 .","Avoid Combination. Strong CYP3A4 inducers must be avoided.");n("Zavegepant","Diltiazem",e.DRUG_DRUG,i.MODERATE,"  Zavegepant. Diltiazem    CYP3A4    Zavegepant.","Increased Zavegepant concentration. Diltiazem is a moderate CYP3A4 inhibitor, a Zavegepant metabolic pathway.","       .","Increased risk of side effects, especially injection site reactions."," .    Zavegepant     CYP3A4 .","Dose adjustment. Zavegepant dose must be reduced when co-administered with moderate CYP3A4 inhibitors.");n("Zavegepant","Cyclosporine",e.DRUG_DRUG,i.HIGH,"  Zavegepant. Cyclosporine   P-gp    Zavegepant.","Increased Zavegepant concentration. Cyclosporine inhibits P-gp, a Zavegepant efflux transporter.","       .","Increased risk of side effects, especially injection site reactions."," .    Zavegepant     P-gp .","Dose adjustment. Zavegepant dose must be reduced when co-administered with strong P-gp inhibitors.");n("Zavegepant (CGRP)","Ketoconazole",e.DRUG_DRUG,i.HIGH,"  Zavegepant. Ketoconazole    CYP3A4  P-gp.","Increased Zavegepant concentration. Ketoconazole is a strong inhibitor of CYP3A4 and P-gp.","   .","Increased risk of side effects."," .   .","Avoid combination. Avoid concurrent administration.");n("Zidovudine","Ganciclovir",e.DRUG_DRUG,i.HIGH,": **     **.        .","Mechanism: **Synergistic bone marrow toxicity**. Both suppress bone marrow and cause cytopenias."," : **      ** (Neutropenia, Anemia)  .","Clinical Significance: **Severe neutropenia and anemia**, increasing infection risk."," .         G-CSF.","Avoid combination. If necessary, close CBC monitoring and use of G-CSF.");n("Zidovudine","Ganciclovir/Valganciclovir",e.DRUG_DRUG,i.HIGH,"   .     .","Increased risk of hematological toxicity. Additive bone marrow suppressive effect.","     .","Increased risk of anemia and neutropenia.","    .      .","Avoid combination or close monitoring. Blood counts must be monitored frequently.");n("Zidovudine ()","Atovaquone ()",e.DRUG_DRUG,i.MODERATE,"    .","Increased zidovudine blood concentrations.","    .","Increased signs and symptoms of zidovudine toxicity.","        .","Monitor for toxicity signs and reduce zidovudine dose if necessary.");n("Zinc","Haloperidol",e.DRUG_DRUG,i.MODERATE,"  ","Neurotransmitter Depletion. Reduced synaptic availability of neurotransmitters.","   ","Reduced antipsychotic efficacy"," ","Avoid combination");n("Zinc","Olanzapine",e.DRUG_DRUG,i.MODERATE,"  ","Neurotransmitter Depletion. Reduced synaptic availability of neurotransmitters.","   ","Reduced antipsychotic efficacy"," ","Avoid combination");n("Zinc","Risperidone",e.DRUG_DRUG,i.MODERATE,"  ","Neurotransmitter Depletion. Reduced synaptic availability of neurotransmitters.","   ","Reduced antipsychotic efficacy"," ","Avoid combination");n("Zinc","Quetiapine",e.DRUG_DRUG,i.MODERATE,"  ","Neurotransmitter Depletion. Reduced synaptic availability of neurotransmitters.","   ","Reduced antipsychotic efficacy"," ","Avoid combination");n("Zinc","Clozapine",e.DRUG_DRUG,i.LOW,"         .     .","No established clinical interaction leads to reduced Clozapine efficacy. Zinc is essential for multiple neurological functions.","             .","No noticeable effect or no evidence of reduced Clozapine efficacy due to Zinc.","               .","The combination is usually safe, but avoid unnecessarily high doses of Zinc and monitor clinical response.");n("Zinc","Quinolones",e.DRUG_DRUG,i.MODERATE,"","Chelation.","  ","Decreased quinolone absorption.","    ","Separate doses by at least 2 hours.");n("Zoledronic Acid","Aminoglycosides",e.DRUG_DRUG,i.HIGH,"  ","Synergistic nephrotoxicity.","  ","Acute renal failure."," ","Avoid combination.");n("Zolpidem","Ritonavir",e.DRUG_DRUG,i.HIGH,"   (CYP3A4).      .","Potent Metabolic Inhibition (CYP3A4). Ritonavir is a strong inhibitor of Zolpidem metabolism.","       (   )         (Over-Sedation)         .","Sharp increase in Zolpidem concentration (potentially several-fold), leading to a substantial increase in over-sedation, severe drowsiness, impaired psychomotor performance, and risk of respiratory depression.","   .            (  50  )          .","Generally Avoid. If unavoidable, the Zolpidem dose must be significantly reduced (usually by 50% or more) and the patient closely monitored for over-sedation and impaired consciousness.");n("Zolpidem","Opioids (e.g., Morphine)",e.DRUG_DRUG,i.HIGH,"       .   .","Increased risk of respiratory and CNS depression. Additive depressant effects.","   .","Respiratory arrest, coma, and death.","  .   .             .","Relative contraindication. Avoid the combination. If necessary, monitor closely and reduce the dose.");n("Zonisamide","Acetazolamide",e.DRUG_DRUG,i.MODERATE,"     .      .","Increased risk of metabolic acidosis and kidney stones. Synergistic effects in carbonic anhydrase inhibition."," .","Blood acidosis."," .      .","Close monitoring. Monitor bicarbonate levels and ensure adequate hydration.");n("Zoster Vaccine (Zostavax, Live)","Adalimumab (TNF Inhibitor)",e.DRUG_DRUG,i.HIGH,"     (TNF)       .","Adalimumab inhibits Tumor Necrosis Factor (TNF), which is essential for cellular immune response to live viruses.","          .","Immunological failure and increased risk of disseminated Zoster from the vaccine strain."," .     (Zostavax).     (Shingrix).","Contraindicated. Avoid the live vaccine (Zostavax). Recombinant vaccine (Shingrix) is preferred.");n("Zuranolone","Rifampin",e.DRUG_DRUG,i.HIGH,"  Zuranolone. Rifampin    CYP3A4    Zuranolone.","Decreased Zuranolone efficacy. Rifampin is a strong inducer of CYP3A4, a Zuranolone metabolic pathway.","  .","Failure of depression treatment."," .   .","Contraindicated. Avoid the combination.");n("Isotretinoin"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **   (Teratogenic)**.             .","Mechanism: **Severe Teratogenicity**. Isotretinoin causes major fetal malformations affecting CNS, heart, face, and thymus."," : **   ** -     25-35%    .  :         .","Clinical Significance: **Severe and fatal birth defects** - malformation rate reaches 25-35% of exposed pregnancies. Defects include: microcephaly, congenital heart defects, cleft palate, and mental retardation.","  . **   **.             .      .  iPLEDGE    .","Absolute contraindication. **Completely prohibited during pregnancy**. Two contraceptive methods must be used one month before treatment and until one month after stopping. Negative pregnancy test mandatory before starting. iPLEDGE program mandatory in the United States.");n("Methotrexate"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **   (Antifolate) -   DNA**.           .","Mechanism: **Antifolate - inhibits DNA synthesis**. Methotrexate prevents proliferation of rapidly dividing cells, including fetal cells."," : **    ** -    :            .","Clinical Significance: **Spontaneous abortion and severe birth defects** - Methotrexate embryopathy includes: intrauterine growth retardation, craniofacial abnormalities, neural tube defects, and limb malformations.","  . **   ** (        ).    3-6    .    5      .","Absolute contraindication. **Completely prohibited during pregnancy** (except for ectopic pregnancy under medical supervision). Must be stopped 3-6 months before planning pregnancy. Folic acid 5mg daily is essential when planning pregnancy.");n("Warfarin"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.HIGH,": **      (Warfarin Embryopathy)**.   K    .","Mechanism: **Crosses placenta causing Warfarin Embryopathy**. Inhibits vitamin K essential for bone and cartilage development."," : **    6-12** :       . **  **   .   5-10%.","Clinical Significance: **Birth defects in weeks 6-12** include: nasal hypoplasia, limb shortening, mental retardation. **Fetal and placental hemorrhage** in third trimester. Malformation rate 5-10%.","      . **     (LMWH)**   .                .","Avoid in pregnancy especially first and third trimesters. **Replace with Low Molecular Weight Heparin (LMWH)** when planning pregnancy. Can be used with extreme caution in second trimester only for mechanical heart valves under specialist supervision.");n("ACE Inhibitors"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **  - **.  ACE         .","Mechanism: **Inhibition of fetal renin-angiotensin system**. ACE inhibitors reduce fetal renal blood flow causing oligohydramnios."," : **   **:              . **  **:     .","Clinical Significance: **In 2nd/3rd trimesters**: fetal renal failure, oligohydramnios, skull ossification defects, pulmonary hypoplasia, fetal death. **In 1st trimester**: increased risk of cardiac and neural defects.","     . **    **.   Methyldopa  Labetalol  Nifedipine.         .","Contraindicated in 2nd and 3rd trimesters. **Immediate discontinuation upon pregnancy detection**. Replace with Methyldopa, Labetalol, or Nifedipine. Ultrasound monitoring of amniotic fluid and fetal renal function.");n("Valproic Acid"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **    **.          .","Mechanism: **Folate inhibition and epigenetic effects**. Valproic acid causes neural tube defects and affects brain development."," : **    **.    (10-20%)          (IQ)  7-10     (  3 ).","Clinical Significance: **Most dangerous antiepileptic for fetus**. Neural tube defects (10-20%), heart defects, cleft palate, growth delay, IQ reduction by 7-10 points, autism spectrum disorder (3x increased risk).","         . **   **.   Lamotrigine  Levetiracetam  .   5      (   ).","Contraindicated in women of childbearing age except for extreme necessity. **Pregnancy prevention program mandatory**. Replace with Lamotrigine or Levetiracetam before pregnancy. Folic acid 5mg daily before and during pregnancy (does not completely prevent defects).");n("Tetracyclines"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.HIGH,": **    **.      .","Mechanism: **Calcium binding in bones and teeth**. Tetracyclines deposit in developing calcified tissues."," : **  ** (--) **   ** **   **.    (    ).      .","Clinical Significance: **Permanent tooth discoloration** (yellow-brown-gray), **enamel hypoplasia**, **long bone growth inhibition**. Maternal hepatotoxicity (especially with high IV doses). Risk highest in 2nd and 3rd trimesters.","   15  .   Penicillins Cephalosporins  Azithromycin.         ( )       .","Avoid after week 15 of pregnancy. Replace with Penicillins, Cephalosporins, or Azithromycin. If essential in first trimester for serious infection (e.g., Rickettsia), can be used short-term under medical supervision.");n("Lithium"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.HIGH,": **       **.       .","Mechanism: **Freely crosses placenta affecting fetal heart development**. Lithium interferes with fetal cell signaling pathways."," : **  (Ebstein's Anomaly)** -      ( 0.05-0.1%  0.005%  ).               .","Clinical Significance: **Ebstein's Anomaly** - tricuspid valve malformation (risk 0.05-0.1% vs 0.005% general). Fetal goiter, nephrogenic diabetes insipidus, floppy baby syndrome, neonatal arrhythmias.","     . **    **       Lamotrigine.   :       16-20     (  )     24-48 .","Avoid in first trimester if possible. **Gradual discontinuation before planned pregnancy** and replacement with atypical antipsychotics or Lamotrigine. If essential: fetal echocardiography at weeks 16-20, monthly lithium level monitoring (renal clearance changes), temporary discontinuation 24-48 hours before delivery.");n("Statins"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **  **.         .","Mechanism: **Cholesterol synthesis inhibition**. Cholesterol is essential for steroid hormone synthesis and fetal nervous system development."," : **  **       (     ).            .","Clinical Significance: **Potential birth defects** in CNS and skeletal system (limited data but theoretical risk is significant). Limb malformations, facial defects, growth retardation reported in individual cases."," . **    **.   3    .         -    .","Contraindicated. **Immediate discontinuation upon pregnancy detection**. Stop 3 months before planning pregnancy. High cholesterol is not an acute risk justifying fetal risk - can be controlled with diet.");n("Finasteride"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": ** 5-alpha reductase -      (DHT)**. DHT     .","Mechanism: **5-alpha reductase inhibition - prevents testosterone conversion to dihydrotestosterone (DHT)**. DHT is essential for male genital development."," : **     **:   (hypospadias)      . **    ** (        ).","Clinical Significance: **Male fetal genital malformations**: hypospadias, micropenis, undescended testes. **Risk even from dermal exposure** (absorption through skin from crushed tablets or semen).","        . **       **.    Finasteride:        .  6     ().","Absolute contraindication for pregnant women or those who may become pregnant. **Pregnant women must not touch crushed tablets**. Men taking Finasteride: use condoms during intercourse with pregnant partner. Stop 6 months before planning conception (precautionary).");n("Fluoroquinolones"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **    **.       .","Mechanism: **Calcium and magnesium binding in cartilage**. Fluoroquinolones cause cartilage damage in animal studies."," : **  ** (arthropathy)   .       -      .     .","Clinical Significance: **Cartilage and joint damage** (arthropathy) in young animals. Human data limited but relatively reassuring - no significant increase in malformations proven. However, preferably avoided as precaution.","   .     (Penicillins Cephalosporins Azithromycin).       (       ):        /.","Avoid except for extreme necessity. Use safer alternatives (Penicillins, Cephalosporins, Azithromycin). If essential for serious resistant infection (e.g., anthrax, complicated resistant UTI): can be used under medical supervision after benefit/risk assessment.");n("NSAIDs"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.HIGH,": ** **.          .","Mechanism: **Prostaglandin inhibition**. Prostaglandins are essential for keeping ductus arteriosus patent and fetal renal blood flow."," : **   ( 30 )**:               . **  **:    ( ). ** **:    .","Clinical Significance: **In 3rd trimester (after 30 weeks)**: premature ductus arteriosus closure, fetal pulmonary hypertension, fetal renal failure, oligohydramnios. **In 1st trimester**: increased miscarriage risk (conflicting data). **Before delivery**: delayed labor, increased bleeding.","   30   ( ).         .   : **Paracetamol**  .   NSAIDs    30:      .","Avoid after week 30 of pregnancy (contraindicated). Cautious use in 1st and 2nd trimesters for shortest possible period. Safer alternatives: **Paracetamol** for pain and fever. If NSAIDs essential before week 30: use lowest effective dose for shortest duration.");n("Paracetamol"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **         **.      .","Mechanism: **Does not significantly cross placenta or inhibit prostaglandins**. Central mechanism makes it safer."," : **    **   .      .       ADHD          .","Clinical Significance: **Safe in all pregnancy stages** at therapeutic doses. No increase in birth defects. Recent studies suggest weak association with ADHD and autism spectrum disorders with prolonged use, but data inconclusive."," . **     **.      .     (  3   ).  : 4 /  3 /.","Safe for use. **First choice for pain and fever in pregnancy**. Use lowest effective dose for shortest duration. Avoid chronic high doses (>3g daily for weeks). Maximum dose: 4g/day, preferably 3g/day.");n("Penicillins"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **   **.      .","Mechanism: **No known teratogenic effect**. Penicillins do not interfere with fetal development."," : **    **.       .      .","Clinical Significance: **Safe in all pregnancy stages**. Extensive use for decades without increased malformations. Effective and safe for common bacterial infections."," . **    **.    .    .","Safe for use. **Preferred antibiotic in pregnancy**. No dose adjustment needed. Use as clinically indicated.");n("Insulin"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **  ** (  ).    .","Mechanism: **Does not cross placenta** (large protein molecule). Human insulin and analogs are safe."," : **     **.        .   NPH Regular   .   (Lispro Aspart Detemir Glargine)  .","Clinical Significance: **Safe and essential for diabetes treatment in pregnancy**. Good glycemic control reduces maternal and fetal risks. Human NPH and Regular insulin most studied. Insulin analogs (Lispro, Aspart, Detemir, Glargine) also safe.","  . **       1 2  **.     (      ).    .","Safe and recommended. **Preferred treatment for gestational diabetes and Type 1&2 diabetes in pregnancy**. Dose may need adjustment (requirements usually increase in 2nd and 3rd trimesters). Close glucose monitoring essential.");n("Methyldopa"," / Pregnancy",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **   **.           .","Mechanism: **Safe central antihypertensive**. Methyldopa acts on CNS without fetal effects."," : **    **.         .         .","Clinical Significance: **Safe in all pregnancy stages**. First choice for chronic hypertension treatment in pregnancy. Long-term studies on children showed no adverse effects.","  . **      **. : 250-500       3 /.    .","Safe and recommended. **First choice for hypertension in pregnancy**. Dose: 250-500mg twice daily, can increase up to 3g/day. Regular BP monitoring.");n("Methotrexate","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **     **.    DNA    .","Mechanism: **Excreted in breast milk at high concentrations**. Methotrexate inhibits DNA synthesis in rapidly dividing cells."," : **     **      .    () .","Clinical Significance: **Risk of bone marrow suppression in infant**, immunosuppression, growth retardation, hepatotoxicity. Even low doses (for rheumatism) are dangerous.","  . **  **    .     :    24     .","Absolute contraindication. **Stop breastfeeding** or choose alternative medication. If single dose necessary: stop breastfeeding for 24 hours and pump and discard milk.");n("Lithium","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,": **     30-50%    **.      .","Mechanism: **Excreted in breast milk at 30-50% of maternal plasma concentration**. Infants have low renal lithium clearance."," : **   **:              .       10-50%   .","Clinical Significance: **Lithium toxicity in infant**: lethargy, poor feeding, cyanosis, ECG changes, hypothyroidism, nephrogenic diabetes insipidus. Infant lithium levels may reach 10-50% of maternal levels.","  .   : **     ** ( 4-6 )        .    .      (Quetiapine Olanzapine).","Avoid if possible. If essential: **Close monitoring of infant lithium levels** (every 4-6 weeks), monitor renal and thyroid function, watch for toxicity signs. Avoid dehydration in infant. Consider safer alternatives (Quetiapine, Olanzapine).");n("Warfarin","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **      **.     .","Mechanism: **Excreted in breast milk in very small amounts**. Warfarin is highly protein-bound."," : **  **.          .        .","Clinical Significance: **Safe in breastfeeding**. No effects on infant coagulation in studies. Milk concentration usually below detection limit."," . **   **.       ().   K    .","Safe for use. **Can be used during breastfeeding**. Monitor infant for abnormal bleeding signs (precautionary). Give vitamin K to infant at birth as usual.");n("Ibuprofen","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **      ** (<1%   ).     .","Mechanism: **Excreted in breast milk in very small amounts** (<1% of maternal dose). Short half-life reduces accumulation."," : **  **.        .          .","Clinical Significance: **Safe in breastfeeding**. No reports of adverse effects on infants. Dose received by infant much lower than therapeutic pediatric doses."," . **   NSAIDs  **.      .     .","Safe for use. **Preferred NSAID analgesic during breastfeeding**. Use lowest effective dose for shortest duration. Avoid chronic use at high doses.");n("Paracetamol","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     ** (  2%   ).   .","Mechanism: **Excreted in breast milk in small amounts** (less than 2% of maternal dose). Rapidly metabolized and excreted."," : **   **.       .       .","Clinical Significance: **Very safe in breastfeeding**. Extensive use for decades without problem reports. First choice for pain and fever in nursing mothers.","  . **     **.      .  : 500-1000   4-6    4 /.","Safe and recommended. **First choice for pain and fever during breastfeeding**. No need to time doses with feeding. Usual dose: 500-1000mg every 4-6 hours, maximum 4g/day.");n("Sertraline","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     **.          .","Mechanism: **Excreted in breast milk in small amounts**. Sertraline and its active metabolite appear at very low levels in infant plasma."," : **   **.           2%   . **   SSRIs  **.","Clinical Significance: **Relatively safe in breastfeeding**. Infant levels usually below detection limit or <2% of maternal levels. **Preferred SSRI choice for nursing mothers**."," . **SSRI   **.      (    ). : 50-200    .","Safe for use. **Preferred SSRI during breastfeeding**. Monitor infant for abnormal signs (irritability, poor feeding, excessive drowsiness). Dose: 50-200mg daily as needed.");n("Fluoxetine","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **       SSRIs **.    (4-6 )    .","Mechanism: **Excreted in breast milk in higher amounts than other SSRIs**. Long half-life (4-6 days) causes accumulation in infant."," : ** **.     5-10%   .          . **    SSRIs**.","Clinical Significance: **Use with caution**. Infant levels may reach 5-10% of maternal levels. Reports of irritability, colic, poor weight gain in some infants. **Not first-line SSRI choice**."," . ** Sertraline  Paroxetine  **.      Fluoxetine:       (  ).     .","Use with caution. **Prefer Sertraline or Paroxetine instead**. If mother is stable on Fluoxetine: can continue with close infant monitoring (weight, behavior, feeding). Avoid starting it during breastfeeding.");n("Codeine","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,': **     CYP2D6**.  " " (Ultra-rapid metabolizers)     .','Mechanism: **Variable metabolism to morphine via CYP2D6**. "Ultra-rapid metabolizer" mothers produce high morphine in milk.'," : **    **:       **  **. 1-10%     (   ).","Clinical Significance: **Risk of opioid toxicity in infant**: severe drowsiness, feeding difficulty, respiratory depression, **documented deaths**. 1-10% of population are ultra-rapid metabolizers (higher in some ethnicities).","  / . ** FDA  (Black Box Warning)**.   Ibuprofen  Paracetamol.   :      (<4 )     .","Contraindicated / Avoid. **FDA Black Box Warning**. Replace with Ibuprofen or Paracetamol. If essential: use lowest dose for shortest duration (<4 days), close infant monitoring for toxicity signs.");n("Aspirin","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **   **.          .","Mechanism: **Excreted in breast milk**. Salicylates can accumulate in infant with high repeated doses."," : **  (75-100 ) **.   ( )  :           .","Clinical Significance: **Low doses (75-100mg) are safe**. High doses (anti-inflammatory) may cause: salicylate toxicity, platelet dysfunction, theoretical Reye's syndrome risk, rash.","  . **  (75-100  )  **.   (>300 ):       .  : Ibuprofen  Paracetamol .","Low doses are safe. **Cardiac doses (75-100mg daily) safe for use**. High doses (>300mg): avoid or use with extreme caution for shortest duration. Better alternatives: Ibuprofen or Paracetamol for pain.");n("Metronidazole","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **      **.   8 .","Mechanism: **Excreted in breast milk at concentrations similar to plasma**. Half-life 8 hours."," : ** **.  :            (  ). **   **.","Clinical Significance: **Use with caution**. May cause: metallic taste in milk, feeding refusal, diarrhea, theoretical carcinogenicity concern (animal data only). **Single dose relatively safe**."," . **  (2 )**:    12-24     . **  **:            (Amoxicillin   ).","Use with caution. **For single dose (2g)**: stop breastfeeding for 12-24 hours and pump and discard milk. **For multi-dose treatment**: can continue breastfeeding with infant monitoring, or consider alternative (Amoxicillin for many infections).");n("Levothyroxine","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     **.        .","Mechanism: **Excreted in breast milk in minimal amounts**. Thyroid hormone naturally present in milk anyway."," : **   **.     .         .","Clinical Significance: **Completely safe in breastfeeding**. No effects on infant. Dose in milk much lower than infant's natural requirements."," . **     **.            .    .","Safe and essential. **Treatment must continue during breastfeeding**. Untreated maternal hypothyroidism is more dangerous for breastfeeding than the medication. No dose adjustment needed.");n("Prednisone","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     **.     .","Mechanism: **Excreted in breast milk in small amounts**. Prednisone converts to active prednisolone."," : **  -** ( 40 /).    (>20 / )        .","Clinical Significance: **Safe at low-moderate doses** (up to 40mg/day). Chronic high doses (>20mg/day for weeks) may theoretically affect infant growth and adrenal gland."," . **  40 / **.   (>40 ):  4          50%.        .","Safe for use. **Doses up to 40mg/day are safe**. For high doses (>40mg): waiting 4 hours after dose before breastfeeding reduces infant exposure by 50%. Monitor infant growth with chronic high-dose use.");n("Omeprazole","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **        **.    .","Mechanism: **Unknown if excreted in human breast milk**. Animal studies show excretion."," : **  **.      .         .","Clinical Significance: **Probably safe**. Extensive use without problem reports. Theoretical concern about effect on infant gastric acidity."," . **   **.    .   : Famotidine (H2 blocker)    .","Safe for use. **Can be used during breastfeeding**. No special precautions. Better studied alternatives: Famotidine (H2 blocker) if concerned.");n("Atorvastatin","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **    ** (   ).       .","Mechanism: **Likely excreted in breast milk** (human data unavailable). Statins inhibit cholesterol synthesis essential for infant growth."," : **        **.     .    .","Clinical Significance: **Theoretical risk to infant nervous system growth and maturation**. Cholesterol essential for brain and myelin development. No safety data available."," . **    **.      -     .   .","Contraindicated. **Stop breastfeeding or stop medication**. High cholesterol is not an emergency - treatment can be postponed until weaning. Control with diet and exercise.");n("Metformin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **      ** (  1%   ).        .","Mechanism: **Excreted in breast milk in very small amounts** (less than 1% of maternal dose). Concentration in breast milk is very low compared to plasma."," : **  **.        .          .","Clinical Significance: **Safe in breastfeeding**. No reports of adverse effects on infants. Dose received by infant is much lower than therapeutic pediatric doses."," . **     **.       .      .","Safe for use. **Can continue treatment during breastfeeding**. No need for dose adjustment or timing of breastfeeding. Maternal blood glucose monitoring is important.");n("Insulin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **       **.         .","Mechanism: **Large protein molecule that does not transfer to breast milk**. It is broken down in the infant's digestive system if ingested."," : **   **.     .       . **     1  2**.","Clinical Significance: **Completely safe in breastfeeding**. Not absorbed from infant's intestines. Does not affect infant blood glucose. **Preferred choice for gestational, type 1 and type 2 diabetes**."," . **     **.        .     .","Safe and essential. **Must continue treatment during breastfeeding**. Uncontrolled diabetes is more dangerous for breastfeeding than insulin. Adjust doses according to maternal needs.");n("Lamotrigine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **     ** (40-60%    ).     .","Mechanism: **Excreted in breast milk at high concentrations** (40-60% of maternal plasma concentration). Accumulates in infant over time."," : ** **.     30%   .       . **  **.","Clinical Significance: **Use with caution**. Infant levels may reach 30% of maternal levels. Reports of rash, drowsiness, poor feeding. **Infant monitoring is essential**.","   . **      **.        .      .","Can be used with monitoring. **Monitor infant for rash, drowsiness, weight gain**. Check drug levels in infant if symptoms appear. Lower maternal doses reduce infant exposure.");n("Carbamazepine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **     ** (15-30%    ).     .","Mechanism: **Excreted in breast milk in moderate amounts** (15-30% of maternal plasma concentration). Rapidly metabolized in infant."," : ** **.      .       . **    **.","Clinical Significance: **Relatively safe**. Most infants show no symptoms. Rare reports of drowsiness, irritability, poor feeding. **Monitor infant liver function**.","   . **   **.    .    .","Safe for use with monitoring. **Monitor infant for drowsiness and irritability**. Periodic liver function tests. Lower maternal doses preferred.");n("Valproic Acid -  ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **     ** (1-10%    ).    .","Mechanism: **Excreted in breast milk in small amounts** (1-10% of maternal plasma concentration). Highly protein-bound."," : ** **.      .     . **    **.","Clinical Significance: **Relatively safe**. No reports of serious problems. Theoretical concern about hepatotoxicity. **Monitor liver function and platelets**."," . **     **.   .   : Lamotrigine Levetiracetam.","Safe for use. **Monitor infant liver function and platelets**. Avoid high doses. Safer alternatives: Lamotrigine, Levetiracetam.");n("Levetiracetam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     ** (5-10%    ).      .","Mechanism: **Excreted in breast milk in small amounts** (5-10% of maternal plasma concentration). Rapidly excreted by infant."," : **  **.       . **       **.","Clinical Significance: **Safe in breastfeeding**. No reports of significant adverse effects. **Considered one of the safest antiepileptics during breastfeeding**.","  . **     **.     .    .","Safe and recommended. **Preferred choice for antiepileptics during breastfeeding**. No special infant monitoring needed. Continue usual dose.");n("Ciprofloxacin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **     **.        .","Mechanism: **Excreted in breast milk in small amounts**. Quinolones bind calcium and may deposit in bones and cartilage."," : ** **.       . ** : Amoxicillin Cephalexin**.","Clinical Significance: **Use with caution**. Theoretical risk to infant cartilage development. **Preferred alternatives: Amoxicillin, Cephalexin**."," . **   **.   :    .      .","Use with caution. **Prefer alternative antibiotics**. If essential: use for shortest duration possible. Monitor infant for any abnormal symptoms.");n("Azithromycin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     **.    (68 )     .","Mechanism: **Excreted in breast milk in small amounts**. Long half-life (68 hours) but concentration in milk is low."," : **  **.      . **       **.","Clinical Significance: **Safe in breastfeeding**. No reports of adverse effects. **Preferred antibiotic for many infections during breastfeeding**."," . **   **.       .   3-5  .","Safe for use. **Can be used during breastfeeding**. No need for dose adjustment or timing of breastfeeding. Treatment usually 3-5 days.");n("Hydrochlorothiazide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,": **   **.      .    .","Mechanism: **Excreted in breast milk**. May reduce milk production due to dehydration. Affects electrolyte balance."," : ** **.  :       . **    **.","Clinical Significance: **Use with caution**. May cause: reduced milk supply, electrolyte disturbances in infant. **Not first-line antihypertensive**."," . ** Labetalol  Nifedipine  **.  :     .   .","Use with caution. **Prefer Labetalol or Nifedipine as antihypertensives**. If used: monitor milk production, infant electrolytes. Adequate maternal hydration.");n("Labetalol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **      **.       1%   .","Mechanism: **Excreted in breast milk in very small amounts**. Dose received by infant is less than 1% of maternal dose."," : **  **.       . **     **.","Clinical Significance: **Safe in breastfeeding**. No reports of effects on infants. **Preferred choice for antihypertensives during breastfeeding**.","  . **    **.    .     .","Safe and recommended. **Preferred antihypertensive during breastfeeding**. No dose adjustment needed. Monitor maternal blood pressure.");n("Cetirizine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,": **     **.       .","Mechanism: **Excreted in breast milk in small amounts**. Non-sedating antihistamines are better than sedating ones."," : **  **.       . **    **.","Clinical Significance: **Safe in breastfeeding**. No reports of effects on infants. **Preferred antihistamine during breastfeeding**."," . **  **.     ( Diphenhydramine).  : 10  .","Safe for use. **Preferred antihistamine**. Avoid sedating antihistamines (e.g., Diphenhydramine). Usual dose: 10mg daily.");n("Amiodarone","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,": **     **.     (40-55 )     .","Mechanism: **Excreted in breast milk at high concentrations**. Very long half-life (40-55 days) causes severe accumulation in infant."," : **     ** (  ) ** ** ( QT) ** **.    .","Clinical Significance: **Risk of infant hypothyroidism** (high iodine content), **cardiac toxicity** (QT prolongation), **pulmonary toxicity**. Long-term accumulation is dangerous.","  . **  **.         .        .","Absolute contraindication. **Stop breastfeeding**. Due to long half-life, excretion continues for months after stopping. Cannot resume breastfeeding even after stopping medication.");n("Venlafaxine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         -    .                  .","Mechanism: **Excreted in breast milk at high concentrations** (60-80% of maternal plasma levels). Both drug and active metabolite reach infant in significant amounts that may cause withdrawal symptoms if breastfeeding is abruptly stopped.","             .           .       .","Clinical Significance: Infant may show irritability, sleep disturbances, stomach upset, or persistent crying. Rarely, hypertension may occur in infants. Safer alternatives are preferred if available.","         .       .           .","If essential, start with lowest possible dose and monitor infant closely. Avoid abrupt discontinuation of medication or breastfeeding. Consider switching to sertraline if infant shows symptoms.");n("Propylthiouracil -  ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"          .   .           .","Mechanism: **Transfers to breast milk but at low concentration** (less than 0.1% of maternal dose). Considered safer than methimazole for breastfeeding due to lower milk concentration.","                  .         .","Clinical Significance: Theoretically may affect infant thyroid function, but studies show no significant clinical problems with usual doses. Remains preferred choice for hyperthyroidism during breastfeeding.","         .         - .      .","Divide dose into 3 times daily to reduce peak levels in milk. Perform periodic thyroid function tests for infant every 2-3 months. Maximum safe dose is 300mg daily.");n("Tramadol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      -             .           .","Mechanism: **Transfers to breast milk at 2-3% of maternal dose**, but main risk lies in variable drug metabolism between individuals. Some mothers rapidly convert drug to stronger metabolite increasing risk.","         .            .     .","Clinical Significance: Infant may experience severe drowsiness, breathing difficulties, or poor feeding. Seizures reported in infants, especially from rapid metabolizer mothers. Death cases recorded but rare.","   .         (   ).     .           .","Avoid use if possible. If essential, use lowest dose for shortest duration (less than 3 days). Monitor infant closely for toxicity signs. Do not use if mother takes other medications affecting metabolism.");n("Rivaroxaban - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"   aban      -   .                .","Mechanism: **Studies show transfer to breast milk at 2-4% of maternal dose**. Concentration in breast milk is much lower than therapeutic doses for infants, but long-term data is limited.","               .          .","Clinical Significance: No adverse effects reported in limited studies, but bleeding remains theoretical concern. Must balance treatment benefits for mother versus theoretical risks to infant.","           .    .         .","Can continue breastfeeding with close monitoring for any bleeding signs in infant. Use lowest effective dose. Consider heparin as alternative if significant concern exists.");n("Sumatriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"         (  .  )       .       .","Mechanism: **Minimal transfer to breast milk** (less than 0.2% of dose) due to large molecular size and extensive first-pass metabolism. Dose reaching infant is negligible and non-significant.","   .        .           .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered preferred choice for acute migraine attacks in nursing mothers.","     .       .        .","Can take usual dose when needed. No need to time breastfeeding or pump milk. Monitor infant for reassurance though problems are unexpected.");n("Montelukast - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        (  .  ).              .","Mechanism: **Minimal transfer to breast milk** (less than 0.5% of dose). Concentration in breast milk is very low and insufficient to produce any pharmacological effect in infant.","    .        .          .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Can continue treatment without concern with routine infant monitoring.","    (  ).     .         .","Continue usual dose (10mg daily). No special precautions needed. Continuous treatment is important for asthma control and preventing acute attacks.");n("Loratadine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .                   .","Mechanism: **Transfers to breast milk in minimal amounts**. Infant exposure estimated at less than 1% of weight-adjusted maternal dose, which is a non-therapeutic amount.","        .        .       .","Clinical Significance: No reports of adverse effects on infants. Considered one of the safest antihistamines during breastfeeding. Safe for regular daily use if necessary.","  (  )  .     .          .","Usual dose (10mg daily) is completely safe. No special precautions needed. Excellent alternative to sedating antihistamines that may affect infant.");n("Amoxicillin-Clavulanate - -","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .            .","Mechanism: **Both components transfer to breast milk but at low, non-significant concentrations**. Amoxicillin reaches in small amounts, while clavulanate reaches in lesser amounts due to metabolic clearance.","   .             Effects  .       .","Clinical Significance: Safe for use during breastfeeding. May cause mild diarrhea or rash in some infants, but these effects are rare and transient. Benefits outweigh risks in bacterial infections.","     .      .           .","Use usual dose for required treatment duration. Monitor infant for diarrhea or rash. No need to stop breastfeeding unless severe symptoms appear in infant.");n("Amlodipine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"         (  .  ).           .","Mechanism: **Minimal transfer to breast milk** (less than 0.05% of dose). Concentration in milk is very low and undetectable in most assays.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of the safest antihypertensives for nursing mothers.","    (-  ).     .          .","Continue usual dose (5-10mg daily). No special precautions needed. Monitoring maternal blood pressure is more important than discontinuing medication.");n("Domperidone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .   .               .","Mechanism: **Excreted in breast milk in minimal amounts** (less than 0.01% of maternal dose). Increases prolactin hormone which stimulates milk production, sometimes used to enhance milk supply.","         .         .          .","Clinical Significance: Safe for use during breastfeeding at doses up to 30mg daily. No adverse effects reported in studies. Should be used only when benefits to mother outweigh theoretical risks.","            .     .      .","Use at dose of 10mg three times daily for maximum 4 weeks. Monitor milk production and infant weight. Taper dose gradually when target achieved.");n("Ondansetron - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"           .   .           .","Mechanism: **Transfers to breast milk in minimal amounts** (less than 0.5% of maternal dose). Concentration in milk is insufficient to produce pharmacological effects in infant.","   .        .        .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered preferred choice for nausea and vomiting in nursing mothers.","    (-   ).    .        .","Can use usual dose (4-8mg as needed). No need to time breastfeeding. Monitor infant for reassurance though problems are unexpected.");n("Fluconazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                .    ( )      .","Mechanism: **Transfers to breast milk at high concentrations** (up to 20% of maternal plasma levels) due to its chemical properties. Long half-life (30 hours) allows drug accumulation in breast milk.","  ( )  .               .      .","Clinical Significance: Single dose (150mg) is considered safe. High or repeated doses may cause infant side effects like rash, vomiting, or diarrhea. Avoid high doses for prolonged periods.","     .        .       .","Single dose for vaginal yeast infection is safe. For long-term treatment, use lowest effective dose and monitor infant. Consider topical treatments as alternative if possible.");n("Topiramate - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      -    .            .","Mechanism: **Transfers to breast milk at 20-30% of maternal plasma concentration**. May accumulate in infant over time due to slow elimination from infant's body.","           .        .    .","Clinical Significance: Infant may show drowsiness, poor feeding, or weight loss. Rarely, metabolic acidosis may occur. Close infant monitoring is essential.","             .        .   .","If mother is stable on medication, can continue with monitoring of infant weight and drowsiness signs. Check blood acidity if abnormal symptoms appear. Lower doses are preferable.");n("Alendronate - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"      (  )         .           .","Mechanism: Due to poor gastrointestinal absorption (less than 1%), the amount reaching breast milk is minimal. Even if it reaches, its absorption from infant's intestines would be very poor.","   .        .           .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Not significantly absorbed and does not reach infant bones in effective amounts.","     ( ).     (     ).      .","Continue usual weekly dose (70mg). Take medication as directed (on empty stomach with plain water only). No special precautions needed for breastfeeding.");n("Rosuvastatin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"                          .","Mechanism: Although insufficient data on transfer to breast milk, all statins are contraindicated during breastfeeding due to their effect on cholesterol synthesis essential for infant growth.","        .             .","Clinical Significance: Cholesterol is essential for nervous system development and hormone production in infants. Inhibiting cholesterol synthesis may affect normal infant growth, especially brain and nervous system.","    .          .      ( )   .","Discontinue medication or stop breastfeeding. Cholesterol treatment is not an emergency and can be postponed until weaning. Return to non-drug therapy (diet and exercise) during breastfeeding period.");n("Dextromethorphan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"      .         .        .","Mechanism: **Transfers to breast milk in minimal amounts**. Infant exposure estimated at less than 0.05% of maternal dose, which is a non-therapeutic amount.","   .        .       .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of the safest cough medications for nursing mothers.","    .          .    .","Use usual dose as needed. Avoid preparations containing alcohol or sedating antihistamines. Use for shortest duration possible.");n("Gabapentin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      -    .          .","Mechanism: **Transfers to breast milk at 5-10% of maternal plasma concentration**. Reaches infant in noticeable amounts and may accumulate with high doses.","          .       .       .","Clinical Significance: May cause mild drowsiness in infant especially during first days of treatment. No serious effects reported, but monitoring is essential. Most infants adapt to medication over time.","    .       .            .","Start with low dose and increase gradually. Monitor infant for drowsiness especially in first week. If significant drowsiness occurs, consider reducing dose or adjusting breastfeeding timing.");n("Mebeverine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        .                .","Mechanism: **Minimal transfer to breast milk**. Drug is poorly absorbed from intestines and rapidly metabolized in liver, reducing its passage to milk.","   .        .          .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered a safe option for irritable bowel syndrome symptoms in nursing mothers.","   (   ).     .         .","Use usual dose (200mg twice daily). No special precautions needed. Can continue treatment as long as symptoms warrant.");n("Famotidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .   .             .","Mechanism: **Transfers to breast milk in minimal amounts** (less than 0.2% of maternal dose). Concentration in milk is very low and insufficient to produce pharmacological effects in infant.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of the safest antacids for nursing mothers.","    (-  ).        .      .","Can use usual dose (20-40mg daily). No need for breastfeeding timing or special precautions. Both short-term and long-term use are safe.");n("Lactulose - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"            .              .","Mechanism: **Lactulose is a non-absorbable sugar**, so it does not reach breast milk in significant amounts. Even if it reaches, it is not absorbed from infant's intestines and acts only as a local osmotic laxative.","    .     systemic .            .","Clinical Significance: Completely safe for use during breastfeeding. Causes no systemic effects in infant. May transfer in minimal amounts to milk but with no effect on infant.","   (-  ).     .         .","Use usual dose (15-30ml daily). No special precautions needed. Considered first-line treatment for chronic constipation in nursing mothers.");n("Methimazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             (    )  .          .","Mechanism: **Transfers to breast milk in higher amounts than propylthiouracil**, but low doses (less than 20mg daily) are considered safe. Reaches 16% of maternal plasma concentration in milk.","            .       .","Clinical Significance: Low doses are safe, but high doses may affect infant thyroid function. Periodic monitoring of infant thyroid function is necessary.","    (-  ).    -  .   TSH  T4   - .   preferred  .","Use lowest effective dose (5-15mg daily). Divide dose into 2-3 times daily. Perform infant TSH and T4 tests every 4-6 weeks. Propylthiouracil preferred if possible.");n("Propranolol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"       (-   ).               .","Mechanism: **Transfers to breast milk in small amounts** (1-2% of maternal dose). Concentration in milk is low, but may cause some effects due to infant sensitivity to beta-blockers.","               .     mostly   .","Clinical Significance: Infant may show mild drowsiness, decreased heart rate, or low blood sugar. These effects are rare and occur mostly with high doses.","   .      .   .       .","Use lowest effective dose. Monitor infant for drowsiness and heart rate. Avoid high doses. Labetalol is a safer alternative if needed.");n("Clindamycin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"       (.-. /).           flora .","Mechanism: **Transfers to breast milk in moderate amounts** (0.5-3.5 mg/liter). May cause gastrointestinal disturbances in infant due to effect on gut flora.","       .       .    closely  .","Clinical Significance: Infant may develop diarrhea, vomiting, or rash. Rarely, may cause colitis. Close monitoring of infant for gastrointestinal symptoms is necessary.","    .     .         .","Use only when absolutely necessary. Monitor infant for diarrhea and rash. Consider safer alternative antibiotics like amoxicillin.");n("Iron Supplements -  ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"            .             .","Mechanism: **Iron transfer to breast milk is minimal** and not affected by iron supplements. Iron concentration in milk is regulated by physiological factors, not maternal iron levels.","    .       .          .","Clinical Significance: Completely safe for use during breastfeeding. Cause no adverse effects on infant. Important for compensating maternal iron deficiency without affecting infant.","      .   -    .       .","Continue supplements as per doctor's recommendation. Usual dose 60-120mg elemental iron daily. No effect on breastfeeding or infant health.");n("Amitriptyline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"       (-   ).              .","Mechanism: **Transfers to breast milk in small amounts** (2-6% of maternal dose). Its levels in infant blood are very low, but may cause some effects due to infant sensitivity.","         .         .     .","Clinical Significance: Infant may show mild drowsiness, dry mouth, or constipation. These effects are rare and usually resolve with continued breastfeeding. Monitoring during first days is important.","         .       .  preferred    .","If mother is stable on medication, can continue with monitoring. Start with low dose if initiating new. Sertraline preferred if initiating new treatment.");n("Salbutamol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"            (  .  ).          .","Mechanism: **Minimal amount reaches breast milk with inhalational use** (less than 0.07% of dose). Oral dose transfers in higher amounts but remains low.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Inhalation is preferred method to reduce systemic exposure.","     .    .           .","Use inhaler as needed without concern. No need for breastfeeding timing. Inhalation is better than tablets to reduce amount of drug reaching milk.");n("Sitagliptin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"           .             .","Mechanism: **Limited human data available**. Animal studies show minimal transfer, but insufficient studies in nursing mothers. Likely low milk transfer due to high protein binding.","       .        .         .","Clinical Significance: Due to lack of data, complete safety cannot be guaranteed. Potential benefits should balance theoretical risks. No adverse reports but caution required.","   .          .        .","Prefer to avoid if possible. If essential, use lowest dose with monitoring of infant glucose. Insulin remains safest choice for diabetic nursing mothers.");n("Dabigatran - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .        .","Mechanism: **Limited human data available**. Animal studies show low transfer, highly protein-bound reducing milk passage. Human studies show minimal infant exposure.","               .         .","Clinical Significance: No adverse effects reported in limited studies, but bleeding remains theoretical concern. Must balance maternal treatment benefits versus infant risks.","           .    .      .","Can continue breastfeeding with close monitoring for bleeding signs in infant. Use lowest effective dose. Heparin may be safer alternative.");n("Lacosamide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .         .","Mechanism: **Transfers to breast milk at moderate concentrations** (up to 50% of maternal plasma levels). Reaches infant in significant amounts and may accumulate over time.","           .           .","Clinical Significance: Infant may show drowsiness, dizziness, or balance disturbances. No serious effects reported but monitoring essential especially in first weeks.","             .        .   .","If mother is stable on medication, can continue with monitoring of infant drowsiness and weight gain. Check drug levels in infant if symptoms appear. Lower doses preferable.");n("Sildenafil - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"              .         .","Mechanism: **Minimal human data available**. Animal studies show low transfer. Drug is actually used in infants for pulmonary hypertension treatment.","                 .      .","Clinical Significance: Given its safe use in infants at calculated doses, minimal amounts transferred via milk are unlikely to cause problems. But caution warranted due to data lack.","       .    .         .","Can continue breastfeeding with general infant monitoring. Use lowest effective dose. No adverse reports but monitoring advisable.");n("Fingolimod - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"          .    (- )     .","Mechanism: **Transfers to breast milk in significant amounts** and accumulates in infant tissues. Long half-life (6-9 days) causes dangerous accumulation in infant.","              .     .","Clinical Significance: May cause severe immune suppression in infant, increased opportunistic infection risk, and effects on heart and nervous system. Risks outweigh breastfeeding benefits.","  .      .          .       .","Absolute contraindication. Stop breastfeeding or discontinue medication. Due to long half-life, excretion continues for two weeks after stopping. Cannot resume breastfeeding even after discontinuation.");n("Apremilast - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .           .","Mechanism: **Insufficient data on transfer to breast milk**. Animal studies limited and computational models suggest low to moderate transfer.","        .              .","Clinical Significance: Due to data lack, cannot recommend use during breastfeeding. Skin diseases usually non-life-threatening, so treatment can be postponed or topical alternatives used.","   .    .         .    .","Avoid use if possible. Use topical treatments as alternative. If essential, monitor infant for any unusual symptoms. Carefully assess risk-benefit ratio.");n("Allopurinol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .               .","Mechanism: **Allopurinol and active metabolite transfer to breast milk in small amounts**. Concentration in milk lower than maternal plasma but may accumulate with high doses.","         .         .      .","Clinical Significance: No adverse effects reported in limited studies. Gout is chronic condition manageable with alternatives during breastfeeding. Benefits should outweigh theoretical risks.","      .    .         .    .","Can use if benefits outweigh risks. Use lowest effective dose. Monitor infant for rash or any unusual symptoms. Colchicine alternative for acute attacks.");n("Denosumab - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"               osteoclasts         .","Mechanism: **Large antibody with limited transfer to breast milk**, but its osteoclast-inhibiting effect may affect infant bone development if it reaches.","              .       justifying .","Clinical Significance: Due to effect on bone metabolism and potential impact on infant bone growth, considered unsafe during breastfeeding. Osteoporosis not emergency condition justifying risk."," .    .     D    .     .","Contraindicated. Postpone treatment until weaning. Use calcium/vitamin D supplements and exercise during breastfeeding period. Reassess after breastfeeding completion.");n("Finasteride - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"            .      .","Mechanism: **Transfers to breast milk and may affect sexual development** of infant, especially males. Drug known for its effect on male hormones.","       .              .","Clinical Significance: May cause abnormalities in sexual development of male infant. Nursing mothers should avoid drug exposure even dermally due to skin absorption.","  .     .       .     .","Absolute contraindication. Stop breastfeeding or discontinue medication. Avoid exposure to any finasteride-containing preparations. Use alternatives for hair loss treatment.");n("Guaifenesin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        .              .","Mechanism: **Minimal transfer to breast milk**. Drug poorly absorbed and rapidly metabolized in body, reducing its passage to milk.","   .        .       .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of the safest expectorants for nursing mothers.","    .          .    .","Use usual dose as needed. Avoid combination preparations containing alcohol or antihistamines. Use for shortest duration possible.");n("Losartan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .      -        .","Mechanism: **Limited data on transfer to breast milk**. Drug may affect infant renin-angiotensin system which is active in early months.","               .         .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May cause hypotension or theoretical renal effects.","       .        .    .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function. Use lowest effective dose.");n("Duloxetine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .-   .         .","Mechanism: **Transfers to breast milk at 0.8-3% of maternal dose**. May accumulate in infant due to slow hepatic metabolism.","        .        .     .","Clinical Significance: May cause drowsiness, poor feeding, or irritability in infant. Rarely, may affect weight gain. Monitoring in first weeks is important.","            .       .   .","If mother stable on medication, can continue with monitoring of infant weight and behavior. Start with low dose if new treatment. Sertraline is better alternative.");n("Pregabalin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .       .","Mechanism: **Transfers to breast milk in high amounts** (up to 70% of maternal plasma concentration). Accumulates in infant and may cause side effects.","         .    closely      .","Clinical Significance: May cause significant drowsiness, poor feeding, or slow weight gain. Close infant monitoring essential especially in first treatment weeks.","   .     .         .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Consider safer antiepileptic alternatives like levetiracetam.");n("Doxycycline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"            .          .","Mechanism: **Transfers to breast milk in small amounts**, but binds calcium reducing absorption. However, may cause tooth discoloration with long-term use.","   (   ).          .    .","Clinical Significance: Safe for short-term use (less than 3 weeks). Long-term use may cause infant tooth discoloration and impaired bone growth. Chronic use not recommended.","   .   .         .","Use for shortest duration possible. Avoid chronic use. Alternative antibiotics like amoxicillin are safer for long-term use.");n("Sucralfate - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"                 .     .","Mechanism: **Minimal systemic absorption** from intestines, so amount in breast milk negligible and undetectable. Acts locally in stomach only.","    .     systemic .       .","Clinical Significance: Completely safe for use during breastfeeding. Causes no systemic effects in infant. Considered one of the safest ulcer medications for nursing mothers.","   (    ).     .      necessary.","Use usual dose (1gm four times daily). No special precautions needed. Can continue treatment as long as necessary.");n("Cabergoline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"               .    .","Mechanism: **Transfers to breast milk in small amounts**, but inhibits prolactin secretion which may reduce milk production. Low doses considered safe.","  (.-.   )  .      .    .","Clinical Significance: Low doses (0.25-0.5mg twice weekly) usually safe. High doses may reduce milk production. Monitoring milk supply important.","   .     .        .","Use lowest effective dose. Monitor milk production and infant weight. If notice decreased milk supply, consult doctor immediately.");n("Alprazolam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"          .       .","Mechanism: **Transfers to breast milk in significant amounts** and may accumulate in infant. Causes significant drowsiness and may affect breathing.","            .     .","Clinical Significance: May cause severe neural depression, feeding difficulties, or respiratory depression in infant. Not recommended during breastfeeding.","   .        .    .    .","Avoid use if possible. If essential, use lowest dose for shortest duration. Monitor infant for drowsiness and breathing. Sertraline better alternative for anxiety.");n("Colchicine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                 .","Mechanism: **Transfers to breast milk in small amounts**, but cytotoxic and may affect rapidly dividing infant cells.","     .             .","Clinical Significance: Low doses for short-term treatment considered safe. High doses or chronic use may cause diarrhea or hematological effects in infant.","      .   .        .","Use for shortest duration possible for acute attack treatment. Avoid chronic use. Monitor infant for diarrhea or any unusual symptoms.");n("Tamsulosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"            .     .","Mechanism: **Minimal transfer to breast milk** due to high protein binding. Concentration in milk very low.","   .        .       .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of the safest prostate medications for nursing mothers.","   (.  ).     .      .","Use usual dose (0.4mg daily). No special precautions needed. Can continue treatment as needed.");n("Rizatriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        (  .  ).     .","Mechanism: **Minimal transfer to breast milk** (less than 0.1% of dose). Considered safe for use during breastfeeding."," .        .        .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered good option for acute migraine attacks treatment.","   (   ).    .      .","Use usual dose (10mg as needed). No need for breastfeeding timing. Can use up to twice weekly.");n("Bromhexine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"         .        .","Mechanism: **Minimal transfer to breast milk** in non-significant amounts. Drug has limited absorption and rapid hepatic metabolism.","    .        .      .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe expectorant for nursing mothers.","   (-    ).     .      .","Use usual dose (8-16mg three times daily). No special precautions needed. Can use during breastfeeding without concern.");n("Fexofenadine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"         (  .  ).      .","Mechanism: **Minimal transfer to breast milk** (less than 0.5% of dose). Concentration in milk is low and non-significant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Excellent alternative to sedating antihistamines.","   (  ).    .       .","Use usual dose (180mg daily). No need for breastfeeding timing. Suitable for regular daily use if necessary.");n("Vitamin B Complex -   ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .          .","Mechanism: **B vitamins transfer naturally to breast milk** and increase with supplements. These vitamins are water-soluble and do not accumulate in body.","     .      .       .","Clinical Significance: Completely safe and actually beneficial for mother and infant. Enhance milk quality and support infant growth. No risks with normal doses.","     .   .         .","Continue supplements as recommended. High doses are safe. Especially important for vegetarian mothers or those with unbalanced nutrition.");n("Phenazopyridine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"          .         .","Mechanism: **Transfers to breast milk** and may change milk color to orange. Drug well absorbed and reaches milk in noticeable amounts.","      .          .     .","Clinical Significance: May cause orange discoloration of infant urine. No adverse effects recorded but should avoid long-term use. Given only for temporary pain relief.","    (-   ).    .        .","Use for shortest duration possible (2-3 days maximum). Do not use as permanent treatment. Inform doctor if notice any changes in infant.");n("Calcium Supplements -  ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .         .","Mechanism: **Calcium transfers naturally to breast milk** and increases with supplements. Body regulates calcium amount in milk according to infant needs.","   .         .        .","Clinical Significance: Safe and important for mother and infant. Prevent maternal osteoporosis and support infant bone growth. No risks with recommended doses.","   -   .   .      .","Continue taking 1000-1300mg calcium daily. High doses are safe. Take with vitamin D for better absorption.");n("Levothyroxine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        .          .","Mechanism: **Minimal transfer of levothyroxine to breast milk**. Thyroid hormones naturally present in breast milk anyway.","  .          .       .","Clinical Significance: Safe and essential for use. Untreated hypothyroidism more dangerous for breastfeeding than medication. Does not affect infant thyroid function.","   .      .     .","Continue usual dose. Take medication morning on empty stomach. No special infant monitoring needed.");n("Baclofen - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May accumulate in infant especially with high doses.","           .      .","Clinical Significance: May cause drowsiness, poor feeding, or decreased muscle tone in infant. Monitoring essential especially at treatment start.","   .     .   .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Avoid high doses. Report any infant symptoms to doctor.");n("Betahistine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .           .","Mechanism: **Minimal transfer of betahistine to breast milk**. Drug rapidly metabolized in body and does not reach infant in significant amounts.","   .        .       .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered good option for vertigo treatment in nursing mothers.","   (-  ).     .      .","Use usual dose (16-48mg daily). No special precautions needed. Can use as needed without concern.");n("Hydrocortisone Cream -  ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"         .       ( ).","Mechanism: **Minimal transfer to breast milk with topical use**. Systemic absorption minimal especially with creams (compared to ointments).","   .    systemic   .      .","Clinical Significance: Safe for use during breastfeeding. No systemic effects recorded in infants. Considered one of safest topical corticosteroids.","    .       .     .","Use lowest dose for shortest duration. Avoid application on nipple before breastfeeding. Wash hands thoroughly after use.");n("Hyoscine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"           anticolinergic      .","Mechanism: **Transfers to breast milk in small amounts** but may cause anticholinergic effects in infant especially with high doses.","        .        .","Clinical Significance: May cause dry mouth, constipation, or drowsiness in infant. Short-term use safe but should avoid chronic use.","   .     anticolinergic.   .     .","Use for shortest duration possible. Monitor infant for any anticholinergic symptoms. Avoid high doses. Alternatives like paracetamol better for pain.");n("Empagliflozin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .             .","Mechanism: **Insufficient data on transfer to breast milk**. Animal studies are limited, and computational models suggest potential transfer but in unknown amounts.","          .         .       .","Clinical Significance: Due to insufficient human studies, safety cannot be determined. Theoretically may affect infant fluid and electrolyte balance. Benefits must balance with uncertainty.","   .     .          .","Prefer to avoid during breastfeeding. Insulin remains the safest option. If essential, monitor infant for dehydration and any unusual symptoms.");n("Apixaban - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .          .","Mechanism: **Transfers to breast milk in small amounts** in limited studies. Concentration in milk is low but may pose theoretical bleeding risks.","            .         .","Clinical Significance: No adverse effects in small studies, but bleeding remains a concern. Risk-benefit assessment should be done case by case.","            .         .","Can consider continuing breastfeeding with close monitoring for any bleeding signs in infant. Heparin may be a safer alternative in some cases.");n("Ustekinumab - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .            .","Mechanism: **Large antibody with minimal transfer to breast milk**, but its immunosuppressive effect raises theoretical concerns about impacts on infant immunity.","        .             .","Clinical Significance: Data is limited but small studies show no adverse effects. Skin diseases are usually not life-threatening, so treatment can be postponed or alternatives used.","       .     .      .","Can continue breastfeeding with general infant monitoring. Use topical treatments as first alternative. Assess treatment need versus theoretical risks.");n("Sulfasalazine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"       .             .","Mechanism: **Sulfasalazine and its metabolites transfer to breast milk in small amounts**. May cause diarrhea or rash in some infants, but these effects are rare.","            .       .","Clinical Significance: Generally considered safe for use during breastfeeding at doses up to 3 grams daily. Most infants show no adverse effects.","         .    .        .","Can continue treatment with monitoring of infant for diarrhea and rash. Use lowest effective dose. Give folic acid to infant if concerned.");n("Ezetimibe - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .           .","Mechanism: **Insufficient data on transfer to breast milk**. Animal studies are limited, and its effect on cholesterol synthesis raises some theoretical concern.","        .        .","Clinical Significance: Due to lack of data, cannot recommend use during breastfeeding. Lipid treatment is usually not an emergency.","   .         .     .","Postpone treatment until weaning. Focus on dietary modifications and lifestyle during breastfeeding period. Reassess after breastfeeding completion.");n("Dutasteride - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"          .        .","Mechanism: **Transfers to breast milk and may affect sexual development** of infant. Long half-life causes dangerous accumulation in infant.","       .          .","Clinical Significance: May cause abnormalities in sexual development of male infant. Nursing mothers should avoid drug exposure due to confirmed risks.","  .     .       .","Absolute contraindication. Stop breastfeeding or discontinue medication. Avoid exposure to any dutasteride-containing preparations.");n("Zonisamide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .       .","Mechanism: **Transfers to breast milk in high amounts** (up to 50% of maternal plasma concentration). May accumulate in infant and cause side effects.","         .        .   .","Clinical Significance: May cause drowsiness, poor feeding, or slow weight gain. Rarely, may cause metabolic acidosis. Close monitoring essential.","   .     .        .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Check blood acidity if unusual symptoms appear. Alternative antiepileptics may be safer.");n("Bupropion - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"            .        .","Mechanism: **Transfers to breast milk in moderate amounts** (up to 6% of maternal dose). May cause irritability or seizures in susceptible infants.","              .      .","Clinical Significance: Most infants show no adverse effects, but there are reports of irritability and seizures in rare cases. Must balance treatment benefits with risks.","            .       .    .","If mother stable on medication, can continue with monitoring of infant for irritability and seizures. Start with low dose if new treatment. Sertraline is safer alternative.");n("Theophylline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"           .          .","Mechanism: **Transfers to breast milk in noticeable amounts** and may cause irritability in infant. Concentration in milk reaches 70% of maternal plasma levels.","          .        .","Clinical Significance: May cause irritability, sleep difficulties, or gastrointestinal disturbances in infant. These effects are usually mild and improve with continued breastfeeding.","   .     .          .","Use lowest effective dose. Monitor infant for irritability and sleep disturbances. Take medication right after breastfeeding to reduce peak concentration in milk.");n("Terbinafine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .    ( )   .","Mechanism: **Transfers to breast milk in small amounts**, but data limited. Long half-life (36 hours) allows potential accumulation.","            .     .","Clinical Significance: No adverse effects in limited studies, but caution needed with long-term use. Topical treatments considered safer.","  .     .        .","Avoid long-term use. Use topical treatments as first alternative. If essential, monitor infant for any hepatic symptoms.");n("Valsartan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .     -     .","Mechanism: **Limited data on transfer to breast milk**. May affect infant renin-angiotensin system in early months.","                .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first six months. May theoretically cause hypotension.","       .        .    .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function. Use lowest effective dose.");n("Glimepiride - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .         .","Mechanism: **Insufficient data on transfer to breast milk**. Sulfonylureas may cause hypoglycemia in infant.","         .        .","Clinical Significance: Due to potential infant hypoglycemia, not recommended. Insulin remains safest choice for diabetic nursing mothers."," .     .         .","Avoid use. Switch to insulin during breastfeeding. Monitor infant blood glucose if accidentally used.");n("Eletriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        (  .  ).     .","Mechanism: **Minimal transfer to breast milk** (less than 0.02% of dose). Considered safe for use during breastfeeding."," .        .        .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered good option for acute migraine attacks treatment.","   (   ).    .      .","Use usual dose (40mg as needed). No need for breastfeeding timing. Can use up to twice weekly.");n("Buspirone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .      .","Mechanism: **Transfers to breast milk in small amounts**, but data limited. May cause mild drowsiness in infant.","     .      .     .","Clinical Significance: Most infants show no adverse effects. Limited reports of mild drowsiness. Considered safer than benzodiazepines.","           .       .","If mother stable on medication, can continue with monitoring of infant for drowsiness. Start with low dose if new treatment.");n("Misoprostol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        .           .","Mechanism: **Minimal transfer to breast milk**. Drug rapidly metabolized in body and does not reach infant in significant amounts.","   .        .      .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for ulcer prevention.","   (    ).     .      .","Use usual dose (200mcg four times daily). No special precautions needed. Can continue treatment as needed.");n("Tizanidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .          .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or decreased muscle tone in infant.","           .      .","Clinical Significance: May cause drowsiness, poor feeding, or decreased muscle tone in infant. Monitoring essential especially at treatment start.","   .     .   .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Avoid high doses. Report any infant symptoms to doctor.");n("Terazosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with high doses.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause mild hypotension. Monitoring important in first weeks.","   .       .   .    .","Use lowest effective dose. Monitor infant for any weakness or lethargy signs. Avoid high doses. Tamsulosin is safer alternative.");n("Ethosuximide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .       .","Mechanism: **Transfers to breast milk in high amounts** (up to 80% of maternal plasma concentration). Accumulates in infant and may cause side effects.","         .        .","Clinical Significance: May cause drowsiness, dizziness, or blood disorders in infant. Close monitoring essential especially with long-term use.","   .       .       .","Use lowest effective dose. Monitor infant for drowsiness and perform periodic blood tests. Alternative antiepileptics may be safer.");n("Mirtazapine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or weight gain in infant.","     .        .    .","Clinical Significance: Most infants show no adverse effects. Limited reports of drowsiness and weight gain. Considered relatively safe for use.","            .       .","If mother stable on medication, can continue with monitoring of infant weight and behavior. Start with low dose if new treatment.");n("Formoterol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"           .        .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic dose transfers in higher amounts but remains low.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Inhalation is preferred method to reduce systemic exposure.","     .    .           .","Use inhaler as needed without concern. No need for breastfeeding timing. Inhalation is better than tablets to reduce amount of drug reaching milk.");n("Carvedilol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .            .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause mild drowsiness or decreased heart rate in infant.","     .          .     .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness or decreased heart rate. Monitoring important in first weeks.","   .      .        .","Use lowest effective dose. Monitor infant for drowsiness and heart rate. Labetalol is safer alternative if possible.");n("Linagliptin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .         .","Mechanism: **Insufficient data on transfer to breast milk**. Animal studies limited and computational models suggest low transfer.","        .        .","Clinical Significance: Due to lack of data, cannot recommend use during breastfeeding. Insulin remains safest choice for diabetic nursing mothers.","   .     .         .","Avoid use if possible. Switch to insulin during breastfeeding. If essential, monitor infant for any unusual symptoms.");n("Frovatriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"        (  .  ).     .","Mechanism: **Minimal transfer to breast milk** (less than 0.1% of dose). Considered safe for use during breastfeeding."," .        .        .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered good option for acute migraine attacks treatment.","   (.   ).    .      .","Use usual dose (2.5mg as needed). No need for breastfeeding timing. Can use as needed without concern.");n("Hydroxyzine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or dry mouth in infant.","        .        .","Clinical Significance: May cause drowsiness, dry mouth, or constipation in infant. Short-term use safe but should avoid chronic use.","   .   .   .      .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Sertraline better alternative for long-term treatment.");n("Ranitidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .            .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and insufficient to produce pharmacological effects in infant.","   .        .      .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux treatment.","   (   ).     .      .","Use usual dose (150mg twice daily). No special precautions needed. Can continue treatment as needed.");n("Cyclobenzaprine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or dry mouth in infant.","        .        .","Clinical Significance: May cause drowsiness, dry mouth, or constipation in infant. Short-term use safe but should avoid chronic use.","   .   .   .     .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for muscle pain.");n("Alfuzosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with high doses.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause mild hypotension. Monitoring important in first weeks.","   .       .   .    .","Use lowest effective dose. Monitor infant for any weakness or lethargy signs. Avoid high doses. Tamsulosin is safer alternative.");n("Phenobarbital - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .         .","Mechanism: **Transfers to breast milk in high amounts**. May cause drowsiness or feeding difficulties in infant.","          .        .","Clinical Significance: May cause significant drowsiness, feeding difficulties, or slow responsiveness. Close monitoring essential especially with long-term use.","   .     .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Alternative antiepileptics may be safer.");n("Trazodone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .     .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness in infant.","     .     .    .","Clinical Significance: Most infants show no adverse effects. Limited reports of drowsiness. Considered relatively safe for use.","           .       .","If mother stable on medication, can continue with monitoring of infant for drowsiness. Start with low dose if new treatment.");n("Salmeterol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"           .        .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic dose transfers in higher amounts but remains low.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Inhalation is preferred method to reduce systemic exposure.","     .    .           .","Use inhaler as needed without concern. No need for breastfeeding timing. Inhalation is better than tablets to reduce amount of drug reaching milk.");n("Telmisartan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .     -     .","Mechanism: **Insufficient data on transfer to breast milk**. May affect infant renin-angiotensin system in early months.","        .        .","Clinical Significance: Due to lack of data, cannot recommend use during breastfeeding. Should choose safer alternatives with better data.","      .       .    .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant closely. Use lowest effective dose.");n("Pioglitazone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **No data on transfer to breast milk**. Thiazolidinediones may affect lipid metabolism in infant.","          .     .","Clinical Significance: Due to no data and effect on lipid metabolism, not recommended. Insulin remains safest choice."," .     .         .","Avoid use. Switch to insulin during breastfeeding. Monitor infant blood glucose if accidentally used.");n("Almotriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .         .","Mechanism: **Minimal transfer to breast milk**. Considered safe for use during breastfeeding based on pharmacological properties."," .        .       .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for migraine attacks treatment.","   (.   ).    .    .","Use usual dose (12.5mg as needed). No need for breastfeeding timing. Can use as needed.");n("Oxazepam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .      .","Mechanism: **Transfers to breast milk in small amounts**. May cause mild drowsiness in infant.","          .      .","Clinical Significance: Considered safest benzodiazepine during breastfeeding due to short half-life. Most infants show no adverse effects.","     .   .   .     .","Use lowest possible dose for shortest duration. Monitor infant for drowsiness. Avoid regular use. Sertraline better alternative for chronic anxiety.");n("Metoclopramide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .        .","Mechanism: **Transfers to breast milk in small amounts**. Increases prolactin secretion which may stimulate milk production.","          .    .","Clinical Significance: May cause neurological side effects in infant like drowsiness or irritability. Short-term use usually safe.","    (   ).    .      .","Use for shortest duration possible (less than 12 weeks). Monitor infant for neurological effects. Domperidone better alternative for increasing milk supply.");n("Diazepam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .       .","Mechanism: **Transfers to breast milk in significant amounts**. Accumulates in infant due to long half-life.","            .   .","Clinical Significance: May cause severe neural depression, feeding difficulties, or respiratory depression in infant. Not recommended.","   .        .    .","Avoid use if possible. If essential, use lowest dose for shortest duration. Monitor infant for drowsiness and breathing.");n("Silodosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .       .","Mechanism: **Insufficient data on transfer to breast milk**. May cause hypotension in infant.","      .        .","Clinical Significance: Due to lack of data, cannot recommend use. Should choose alternatives with better safety data.","   .       .       .","Avoid use if possible. Tamsulosin safer alternative with better data. If essential, monitor infant closely.");n("Primidone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .        .","Mechanism: **Transfers to breast milk in high amounts**. Converts to phenobarbital which causes drowsiness in infant.","          .   .","Clinical Significance: May cause significant drowsiness, feeding difficulties, or slow development. Close monitoring essential.","   .     .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Alternative antiepileptics may be safer.");n("Fluvoxamine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause irritability or sleep disturbances in infant.","     .       .   .","Clinical Significance: Most infants show no adverse effects. Limited reports of irritability and sleep disturbances. Sertraline better alternative.","          .      .","If mother stable on medication, can continue with monitoring of infant. Start with sertraline if new treatment.");n("Budesonide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"           .   .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic absorption minimal.","    .        .      .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of safest inhaled corticosteroids.","     .    .       .","Use inhaler as needed without concern. No need for breastfeeding timing. Inhalation better than tablets to reduce systemic exposure.");n("Eplerenone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .        .","Mechanism: **Insufficient data on transfer to breast milk**. May affect potassium levels and hormones in infant.","              .","Clinical Significance: Due to its effect on aldosterone and potential hormonal effects, not recommended during breastfeeding without urgent need.","          .      .","Prefer thiazide diuretics or calcium channel blockers as safer alternatives. If essential, monitor infant electrolytes.");n("Repaglinide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **No data on transfer to breast milk**. Meglitinides may cause hypoglycemia in infant.","         .     .","Clinical Significance: Due to potential hypoglycemia and lack of data, not recommended. Insulin remains safest choice."," .     .        .","Avoid use. Switch to insulin during breastfeeding. Monitor infant blood glucose if used.");n("Naratriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .          .","Mechanism: **Minimal transfer to breast milk**. Considered safe based on pharmacological properties similar to other triptans."," .        .     .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for migraine.","   (.   ).    .    .","Use usual dose (2.5mg as needed). No need for breastfeeding timing. Use only when needed.");n("Clonazepam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .        .","Mechanism: **Transfers to breast milk in significant amounts**. Accumulates in infant due to very long half-life.","            .   .","Clinical Significance: May cause severe neural depression, feeding difficulties, or withdrawal syndrome upon discontinuation. Not recommended.","   .          .   .","Avoid use if possible. If essential, use lowest dose with close infant monitoring. Buspirone better alternative.");n("Lansoprazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux.","   (-  ).     .      .","Use usual dose (15-30mg daily). No special precautions needed. Can continue treatment as needed.");n("Clonidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or hypotension in infant.","     .         .  .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness or hypotension. Monitoring important.","   .     .   .   .","Use lowest effective dose. Monitor infant for drowsiness and blood pressure. Avoid high doses. Labetalol better alternative.");n("Doxazosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with initial doses.","     .       .    .","Clinical Significance: Most infants show no adverse effects. May cause mild hypotension. Initial monitoring important.","   .       .   .    .","Use lowest effective dose. Monitor infant for any dizziness or weakness signs. Avoid high doses. Tamsulosin safer alternative.");n("Vigabatrin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .         .","Mechanism: **Transfers to breast milk in high amounts**. May cause ocular and neurological effects in infant.","        .     .","Clinical Significance: May cause retinal effects and neurological disorders in infant. Not recommended during breastfeeding.","   .        .    .","Avoid use if possible. If essential, monitor infant eyes and neurological functions. Alternative antiepileptics better.");n("Nortriptyline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .    anticolinergic  .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause anticholinergic effects in infant.","     .      .    .","Clinical Significance: Most infants show no adverse effects. May cause dry mouth or constipation. Sertraline safer alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Cromoglicic Acid -  ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"           .    .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic absorption very minimal.","    .        .      .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of safest asthma medications.","     .    .    .","Use inhaler as needed without concern. No need for breastfeeding timing. Suitable for regular and preventive use.");n("Nebivolol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .          .","Mechanism: **Limited data on transfer to breast milk**. May affect infant heart rate and blood pressure.","               .     .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause bradycardia.","       .        .","Prefer labetalol or metoprolol as safer alternatives. If essential, monitor infant heart rate.");n("Canagliflozin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .  SGLT2        .","Mechanism: **Insufficient data on transfer to breast milk**. SGLT2 inhibitors may affect infant fluid and electrolyte balance.","             .","Clinical Significance: Due to its effect on glucose excretion and potential electrolyte effects, not recommended during breastfeeding."," .     .        .","Avoid use. Switch to insulin during breastfeeding. Monitor infant hydration and electrolyte levels if used.");n("Zolmitriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Considered safe based on other triptans data."," .        .      .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for acute migraine.","   (.   ).    .        .","Use usual dose (2.5mg as needed). No need for breastfeeding timing. Can repeat dose after 2 hours if necessary.");n("Chlordiazepoxide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .         .","Mechanism: **Transfers to breast milk in significant amounts**. Accumulates in infant due to long half-life and active metabolites.","          .   .","Clinical Significance: May cause severe neural depression, floppy infant syndrome, and feeding difficulties. Not recommended.","  .      .       .","Avoid use completely. Buspirone or sertraline are safer alternatives. If used, monitor infant intensively.");n("Pantoprazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .      .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for heartburn.","   (  ).     .     .","Use usual dose (40mg daily). No special precautions needed. Suitable for short and long-term use.");n("Methocarbamol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .        .","Mechanism: **Transfers to breast milk in small amounts**. May cause mild drowsiness or dizziness in infant.","     .        .   .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness especially with high doses. Short-term use safe.","   .   .   .    .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for pain.");n("Prazosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .         .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension especially with first dose.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause sudden hypotension. Monitoring after first dose important.","   .     .   .    .","Start with very low dose. Monitor infant after first dose. Avoid high doses. Tamsulosin safer alternative.");n("Felbamate - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .         .","Mechanism: **Transfers to breast milk in high amounts**. May cause hepatic and bone marrow effects in infant.","           .","Clinical Significance: Due to hepatotoxicity and potential bone marrow toxicity, not recommended during breastfeeding.","   .          .    .","Avoid use if possible. If essential, monitor infant liver function and blood counts. Alternative antiepileptics better.");n("Maprotiline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .    anticolinergic   .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause anticholinergic effects and drowsiness in infant.","     .      .    .","Clinical Significance: Most infants show no adverse effects. May cause dry mouth or constipation. Sertraline safer alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Ipratropium - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .    .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic absorption very minimal.","    .        .      .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of safest asthma medications.","     .    .    .","Use inhaler as needed without concern. No need for breastfeeding timing. Suitable for acute and chronic use.");n("Perindopril - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                -  .","Mechanism: **Transfers to breast milk in small amounts**, but ACE inhibitors may affect infant renin-angiotensin system.","               .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause hypotension.","       .         .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function.");n("Dapagliflozin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .  SGLT2       .","Mechanism: **Insufficient data on transfer to breast milk**. SGLT2 inhibitors may affect infant fluid balance.","           .","Clinical Significance: Due to its effect on glucose excretion and potential dehydration, not recommended during breastfeeding."," .     .       .","Avoid use. Switch to insulin during breastfeeding. Monitor infant hydration if accidentally used.");n("Erenumab - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"              CGRP   .","Mechanism: **Large antibody with minimal transfer to breast milk**, but its CGRP inhibition raises theoretical concerns.","  .             .","Clinical Significance: Very limited data. Migraine usually not life-threatening, so treatment can be postponed or alternatives used.","     .     .     .","Postpone treatment until weaning if possible. Use triptans as alternative for acute treatment. Assess need versus theoretical risks.");n("Lorazepam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .      .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause mild drowsiness in infant.","          .      .","Clinical Significance: Considered one of safer benzodiazepines during breastfeeding due to short half-life. Most infants show no adverse effects.","     .   .   .     .","Use lowest possible dose for shortest duration. Monitor infant for drowsiness. Avoid regular use. Sertraline better alternative for chronic anxiety.");n("Esomeprazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .      .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for GERD treatment.","   (-  ).     .     .","Use usual dose (20-40mg daily). No special precautions needed. Suitable for short and long-term use.");n("Orphenadrine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .    anticolinergic  .","Mechanism: **Transfers to breast milk in small amounts**. May cause anticholinergic effects in infant.","         .        .","Clinical Significance: May cause dry mouth, constipation, or urinary retention in infant. Short-term use safe but should avoid chronic use.","   .    anticolinergic.   .    .","Use for shortest duration possible. Monitor infant for anticholinergic effects. Avoid high doses. Paracetamol better alternative for pain.");n("Terazosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with initial doses.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause sudden hypotension. Monitoring after first dose important.","   .     .   .    .","Start with very low dose. Monitor infant after first dose. Avoid high doses. Tamsulosin safer alternative.");n("Oxcarbazepine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in moderate amounts**. May cause drowsiness or dizziness in infant.","     .        .   .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness especially at treatment start. Close monitoring advisable.","   .     .      .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Levetiracetam safer alternative if possible.");n("Desvenlafaxine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .         .","Mechanism: **Transfers to breast milk in moderate amounts**. May cause irritability or sleep disturbances in infant.","     .       .   .","Clinical Significance: Most infants show no adverse effects. Limited reports of irritability and sleep disturbances. Sertraline better alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Montelukast - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for asthma and allergies.","   (  ).     .    .","Use usual dose (10mg daily). No special precautions needed. Suitable for regular daily use.");n("Irbesartan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .     -    .","Mechanism: **Limited data on transfer to breast milk**. May affect infant renin-angiotensin system in newborns.","            .         .","Clinical Significance: No adverse effects in limited studies, but should avoid in first months. May theoretically cause hypotension or renal effects.","           .         .","Prefer labetalol or nifedipine as safer alternatives especially in first six months. If essential, monitor infant blood pressure and renal function.");n("Semaglutide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .   GLP-1       .","Mechanism: **No data on transfer to breast milk**. GLP-1 receptor agonists may affect infant appetite and digestion.","           .","Clinical Significance: Due to its GI effects and lack of data, not recommended during breastfeeding."," .     .       .","Avoid use. Switch to insulin during breastfeeding. Monitor infant feeding if accidentally used.");n("Frovatriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .          .","Mechanism: **Minimal transfer to breast milk**. Considered safe based on pharmacological properties similar to other triptans."," .        .      .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for acute migraine.","   (.   ).    .         .","Use usual dose (2.5mg as needed). No need for breastfeeding timing. Can repeat dose after 24 hours if necessary.");n("Pregabalin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .      .","Mechanism: **Transfers to breast milk in high amounts** (up to 70% of maternal plasma concentration). May cause significant drowsiness in infant.","         .         .","Clinical Significance: May cause significant drowsiness, poor feeding, or slow weight gain. Close infant monitoring essential especially in first weeks.","   .     .   .    .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Avoid high doses. Gabapentin safer alternative.");n("Rabeprazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .      .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for gastric ulcers.","   (  ).     .     .","Use usual dose (20mg daily). No special precautions needed. Suitable for short and long-term use.");n("Tizanidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .          .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or decreased muscle tone in infant.","           .      .","Clinical Significance: May cause drowsiness, poor feeding, or decreased muscle tone in infant. Monitoring essential especially at treatment start.","   .     .   .    .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Avoid high doses. Baclofen safer alternative.");n("Silodosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .       .","Mechanism: **Insufficient data on transfer to breast milk**. May cause hypotension in infant.","      .        .","Clinical Significance: Due to lack of data, cannot recommend use. Should choose alternatives with better safety data.","   .       .       .","Avoid use if possible. Tamsulosin safer alternative with better data. If essential, monitor infant closely.");n("Rufinamide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in high amounts**. May cause drowsiness or dizziness in infant.","         .        .","Clinical Significance: May cause drowsiness, dizziness, or coordination disorders in infant. Close monitoring essential especially with long-term use.","   .     .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Alternative antiepileptics may be safer.");n("Vortioxetine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause irritability or sleep disturbances in infant.","     .       .    .","Clinical Significance: Most infants show no adverse effects. Limited reports of irritability and sleep disturbances. Sertraline safer alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Formoterol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"           .    .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic absorption very minimal.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of safest bronchodilators.","     .    .    .","Use inhaler as needed without concern. No need for breastfeeding timing. Suitable for regular and preventive use.");n("Candesartan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .     -  .","Mechanism: **Limited data on transfer to breast milk**. May affect infant renin-angiotensin system.","               .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause hypotension.","       .       .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure.");n("Linagliptin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .  DPP-4       .","Mechanism: **Insufficient data on transfer to breast milk**. DPP-4 inhibitors may affect glucose metabolism in infant.","      .        .","Clinical Significance: Due to lack of data, cannot recommend use. Insulin remains safest choice for diabetic nursing mothers."," .     .        .","Avoid use. Switch to insulin during breastfeeding. Monitor infant blood glucose if used.");n("Almotriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Considered safe based on other triptans data."," .        .      .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for acute migraine.","   (.   ).    .    .","Use usual dose (12.5mg as needed). No need for breastfeeding timing. Can use as needed.");n("Buspirone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .      .","Mechanism: **Transfers to breast milk in small amounts**. May cause mild drowsiness in infant.","     .      .     .","Clinical Significance: Most infants show no adverse effects. Limited reports of mild drowsiness. Considered safer than benzodiazepines.","          .       .","If mother stable on medication, can continue with monitoring. Start with low dose if new treatment.");n("Dexlansoprazole - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .      .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for GERD treatment.","   (-  ).     .     .","Use usual dose (30-60mg daily). No special precautions needed. Suitable for short and long-term use.");n("Carisoprodol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in small amounts**. May cause drowsiness or dizziness in infant.","     .        .   .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness especially with high doses. Short-term use safe.","   .   .   .    .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for pain.");n("Tamsulosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"            .     .","Mechanism: **Minimal transfer to breast milk** due to high protein binding. Concentration in milk very low.","   .        .       .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of safest prostate medications for nursing mothers.","   (.  ).     .      .","Use usual dose (0.4mg daily). No special precautions needed. Can continue treatment as needed.");n("Lacosamide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"             .     .","Mechanism: **Transfers to breast milk at moderate concentrations** (up to 50% of maternal plasma levels). May cause side effects in infant.","           .       .","Clinical Significance: Infant may show drowsiness, dizziness, or balance disturbances. No serious effects reported but monitoring essential.","             .   .","If mother stable on medication, can continue with monitoring of infant drowsiness and weight gain. Lower doses preferable.");n("Escitalopram - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"      .    SSRIs   .","Mechanism: **Transfers to breast milk in small amounts**. Considered one of safest SSRIs during breastfeeding."," .         .     .","Clinical Significance: Safe for use. No reports of significant adverse effects on infants. Considered second choice after sertraline.","          .      .","If mother stable on medication, can continue with routine monitoring. Start with sertraline if new treatment.");n("Theophylline - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .         .","Mechanism: **Transfers to breast milk in noticeable amounts**. May cause irritability or sleep disturbances in infant.","          .       .","Clinical Significance: May cause irritability, sleep difficulties, or gastrointestinal disturbances in infant. These effects usually mild and improve over time.","   .     .         .","Use lowest effective dose. Monitor infant for irritability and sleep disturbances. Take medication right after breastfeeding to reduce peak in milk.");n("Olmesartan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .     -    .","Mechanism: **Insufficient data on transfer to breast milk**. May affect infant renin-angiotensin system in newborns.","         .         .","Clinical Significance: Due to lack of data, cannot recommend use in first months. May theoretically cause hypotension or renal effects.","           .       .","Prefer labetalol or nifedipine as safer alternatives especially in first six months. If essential, monitor infant blood pressure.");n("Glipizide - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .         .","Mechanism: **Insufficient data on transfer to breast milk**. Sulfonylureas may cause hypoglycemia in infant.","         .     .","Clinical Significance: Due to potential infant hypoglycemia, not recommended. Insulin remains safest choice."," .     .         .","Avoid use. Switch to insulin during breastfeeding. Monitor infant blood glucose if accidentally used.");n("Naratriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .       .","Mechanism: **Minimal transfer to breast milk**. Considered safe based on pharmacological properties."," .        .     .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for migraine.","   (.   ).    .    .","Use usual dose (2.5mg as needed). No need for breastfeeding timing. Use only when needed.");n("Hydroxyzine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or dry mouth in infant.","        .        .","Clinical Significance: May cause drowsiness, dry mouth, or constipation in infant. Short-term use safe but should avoid chronic use.","   .   .   .      .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Sertraline better alternative for long-term treatment.");n("Famotidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux.","   (-  ).     .      .","Use usual dose (20-40mg daily). No special precautions needed. Can continue treatment as needed.");n("Chlorzoxazone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in small amounts**. May cause drowsiness or dizziness in infant.","     .        .   .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness especially with high doses. Short-term use safe.","   .   .   .    .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for pain.");n("Alfuzosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with initial doses.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause sudden hypotension. Monitoring after first dose important.","   .     .   .    .","Start with very low dose. Monitor infant after first dose. Avoid high doses. Tamsulosin safer alternative.");n("Tiagabine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in high amounts**. May cause drowsiness or dizziness in infant.","         .        .","Clinical Significance: May cause drowsiness, dizziness, or concentration disorders in infant. Close monitoring essential especially with long-term use.","   .     .       .","Use lowest effective dose. Monitor infant for drowsiness and weight gain. Alternative antiepileptics may be safer.");n("Duloxetine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .         .","Mechanism: **Transfers to breast milk in moderate amounts**. May cause irritability or sleep disturbances in infant.","     .       .   .","Clinical Significance: Most infants show no adverse effects. Limited reports of irritability and sleep disturbances. Sertraline better alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Salmeterol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"          .    .","Mechanism: **Minimal amount reaches breast milk with inhalational use**. Systemic absorption very minimal.","    .        .       .","Clinical Significance: Completely safe for use during breastfeeding. No reports of adverse effects on infants. Considered one of safest bronchodilators.","     .    .    .","Use inhaler as needed without concern. No need for breastfeeding timing. Suitable for regular and preventive use.");n("Fosinopril - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                -  .","Mechanism: **Transfers to breast milk in small amounts**, but ACE inhibitors may affect infant renin-angiotensin system.","               .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause hypotension.","       .         .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function.");n("Miglitol - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"              .      .","Mechanism: **Minimal systemic absorption** from intestines, so amount in breast milk negligible. Acts locally in GI tract only.","   .     systemic .        .","Clinical Significance: Safe for use during breastfeeding. Causes no systemic effects in infant. May cause mild diarrhea if reaches infant.","   (-   ).     .    .","Use usual dose (25-100mg with meals). No special precautions needed. Insulin remains preferred choice.");n("Rimegepant - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .   CGRP        .","Mechanism: **Insufficient data on transfer to breast milk**. CGRP receptor antagonists may affect vascular functions in infant.","      .          .","Clinical Significance: Due to lack of data, cannot recommend use. Migraine usually not life-threatening, so alternatives can be used.","     .     .     .","Postpone treatment until weaning if possible. Use triptans as alternative for acute treatment. Assess need versus uncertainty.");n("Trifluoperazine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .          .","Mechanism: **Transfers to breast milk in significant amounts**. May cause neurological effects and movement disorders in infant.","          .     .","Clinical Significance: May cause severe drowsiness, tremor, or extrapyramidal disorders in infant. Not recommended during breastfeeding.","  .      .       .","Avoid use completely. Sertraline or buspirone are safer alternatives. If used, monitor infant intensively.");n("Nizatidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux.","   (-  ).     .      .","Use usual dose (150-300mg daily). No special precautions needed. Can continue treatment as needed.");n("Chlorphenesin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in small amounts**. May cause drowsiness or dizziness in infant.","     .        .   .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness especially with high doses. Short-term use safe.","   .   .   .    .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for pain.");n("Dutasteride - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"            .      .","Mechanism: **Transfers to breast milk and may affect sexual development** of infant, especially males. Long half-life causes dangerous accumulation.","       .       .","Clinical Significance: May cause abnormalities in sexual development of male infant. Nursing mothers should avoid drug exposure.","  .     .       .","Absolute contraindication. Stop breastfeeding or discontinue medication. Avoid exposure to any dutasteride-containing preparations.");n("Perampanel - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .         .","Mechanism: **Transfers to breast milk in high amounts**. May cause neurological and behavioral effects in infant.","         .       .","Clinical Significance: May cause drowsiness, dizziness, or behavioral changes in infant. Close monitoring essential especially at treatment start.","   .    .       .","Use lowest effective dose. Monitor infant for drowsiness and behavior. Alternative antiepileptics may be safer.");n("Reboxetine - boxetine","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE," boxetine       .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause irritability or sleep disturbances in infant.","     .       .    .","Clinical Significance: Most infants show no adverse effects. Limited reports of irritability and sleep disturbances. Sertraline safer alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Zafirlukast - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .          .","Mechanism: **Transfers to breast milk in small amounts**. May cause hepatic effects in infant with long-term use.","  .       .    .","Clinical Significance: Safe for short-term use. Long-term use may cause hepatic effects. Periodic liver monitoring advisable.","   .       .    .","Use for shortest duration possible. Monitor liver function if used long-term. Montelukast safer alternative.");n("Trandolapril - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                -  .","Mechanism: **Transfers to breast milk in small amounts**, but ACE inhibitors may affect infant renin-angiotensin system.","               .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause hypotension.","       .         .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function.");n("Acarbose - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"              .      .","Mechanism: **Minimal systemic absorption** from intestines, so amount in breast milk negligible. Acts locally in GI tract only.","   .     systemic .         .","Clinical Significance: Safe for use during breastfeeding. Causes no systemic effects in infant. May cause diarrhea or bloating if reaches infant.","   (-   ).     .    .","Use usual dose (50-100mg with meals). No special precautions needed. Insulin remains preferred choice.");n("Ubrogepant - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .   CGRP        .","Mechanism: **Insufficient data on transfer to breast milk**. CGRP receptor antagonists may affect vascular functions in infant.","      .          .","Clinical Significance: Due to lack of data, cannot recommend use. Migraine usually not life-threatening, so alternatives can be used.","     .     .     .","Postpone treatment until weaning if possible. Use triptans as alternative for acute treatment. Assess need versus uncertainty.");n("Prochlorperazine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .          .","Mechanism: **Transfers to breast milk in significant amounts**. May cause neurological effects and movement disorders in infant.","          .     .","Clinical Significance: May cause severe drowsiness, tremor, or extrapyramidal disorders in infant. Not recommended during breastfeeding.","  .      .       .","Avoid use completely. Sertraline or buspirone are safer alternatives. If used, monitor infant intensively.");n("Roxatidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux.","   (   ).     .      .","Use usual dose (75mg twice daily). No special precautions needed. Can continue treatment as needed.");n("Eperisone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .       .","Mechanism: **Transfers to breast milk in small amounts**. May cause drowsiness or dizziness in infant.","     .        .   .","Clinical Significance: Most infants show no adverse effects. May notice mild drowsiness especially with high doses. Short-term use safe.","   .   .   .    .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for pain.");n("Finasteride - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"            .","Mechanism: **Transfers to breast milk and may affect sexual development** of infant, especially males.","       .       .","Clinical Significance: May cause abnormalities in sexual development of male infant. Nursing mothers should avoid drug exposure.","  .     .       .","Absolute contraindication. Stop breastfeeding or discontinue medication. Avoid exposure to any finasteride-containing preparations.");n("Brivaracetam - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .        .","Mechanism: **Transfers to breast milk in high amounts**. May cause neurological effects in infant.","       .       .","Clinical Significance: May cause drowsiness, dizziness, or irritability in infant. Close monitoring essential especially at treatment start.","   .    .    .","Use lowest effective dose. Monitor infant for drowsiness and behavior. Levetiracetam safer alternative.");n("Amoxapine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .    anticolinergic  .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause anticholinergic effects in infant.","     .      .    .","Clinical Significance: Most infants show no adverse effects. May cause dry mouth or constipation. Sertraline safer alternative.","         .      .","If mother stable on medication, can continue with monitoring. Start with sertraline if new treatment.");n("Pranlukast - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .          .","Mechanism: **Transfers to breast milk in small amounts**. May cause hepatic effects in infant with long-term use.","  .       .    .","Clinical Significance: Safe for short-term use. Long-term use may cause hepatic effects. Periodic liver monitoring advisable.","   .       .    .","Use for shortest duration possible. Monitor liver function if used long-term. Montelukast safer alternative.");n("Moexipril - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                -  .","Mechanism: **Transfers to breast milk in small amounts**, but ACE inhibitors may affect infant renin-angiotensin system.","               .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause hypotension.","       .         .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function.");n("Troglitazone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.CONTRAINDICATED,"          .        .","Mechanism: **Transfers to breast milk and may cause severe hepatotoxicity** in infant. Withdrawn from markets in many countries.","     .      .","Clinical Significance: High risk of hepatotoxicity in infant. Absolutely not recommended during breastfeeding.","  .     .      .","Absolute contraindication. Stop breastfeeding or discontinue medication. Use safer alternatives like metformin.");n("Atogepant - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"         .   CGRP        .","Mechanism: **Insufficient data on transfer to breast milk**. CGRP receptor antagonists may affect vascular functions in infant.","      .          .","Clinical Significance: Due to lack of data, cannot recommend use. Migraine usually not life-threatening, so alternatives can be used.","     .     .     .","Postpone treatment until weaning if possible. Use triptans as alternative for acute treatment. Assess need versus uncertainty.");n("Hydroxyzine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or dry mouth in infant.","        .        .","Clinical Significance: May cause drowsiness, dry mouth, or constipation in infant. Short-term use safe but should avoid chronic use.","   .   .   .      .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Sertraline better alternative for long-term treatment.");n("Roxatidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux.","   (   ).     .      .","Use usual dose (75mg twice daily). No special precautions needed. Can continue treatment as needed.");n("Cyclobenzaprine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .        .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or dry mouth in infant.","        .        .","Clinical Significance: May cause drowsiness, dry mouth, or constipation in infant. Short-term use safe but should avoid chronic use.","   .   .   .    .","Use for shortest duration possible. Monitor infant for drowsiness. Avoid high doses. Paracetamol better alternative for pain.");n("Doxazosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with initial doses.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause sudden hypotension. Monitoring after first dose important.","   .     .   .    .","Start with very low dose. Monitor infant after first dose. Avoid high doses. Tamsulosin safer alternative.");n("Phenytoin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or vitamin effects in infant.","     .         K.   .","Clinical Significance: Most infants show no adverse effects. May cause mild drowsiness or vitamin K deficiency. Periodic monitoring advisable.","   .   .   K .    .","Use lowest effective dose. Monitor infant for drowsiness. Give vitamin K to infant. Levetiracetam safer alternative.");n("Tranylcypromine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"                .","Mechanism: **Transfers to breast milk and may cause serious neurological and cardiovascular effects** in infant.","           .     .","Clinical Significance: May cause hypertension, seizures, or sleep disorders in infant. Not recommended during breastfeeding.","  .      .       .","Avoid use completely. Sertraline or escitalopram are safer alternatives. If used, monitor infant intensively.");n("Omalizumab - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                .","Mechanism: **Large antibody with minimal transfer to breast milk**, but its immunosuppressive effect raises theoretical concerns.","        .       .","Clinical Significance: Data limited but small studies show no adverse effects. Severe asthma may justify continuing treatment.","       .      .","Can continue breastfeeding with general infant monitoring. Assess asthma severity versus theoretical risks.");n("Quinapril - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                -  .","Mechanism: **Transfers to breast milk in small amounts**, but ACE inhibitors may affect infant renin-angiotensin system.","               .      .","Clinical Significance: No adverse effects in limited studies, but caution with infants especially in first months. May theoretically cause hypotension.","       .         .","Prefer labetalol or nifedipine as safer alternatives. If essential, monitor infant blood pressure and renal function.");n("Rosiglitazone - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                .","Mechanism: **Transfers to breast milk in small amounts**, but may affect lipid metabolism and bone development in infant.","             .     .","Clinical Significance: No direct adverse effects reported, but theoretical concern about bone growth effect. Insulin remains safest choice.","  .     .      .","Avoid chronic use. Switch to insulin during breastfeeding. Monitor infant growth if used.");n("Almotriptan - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Considered safe based on other triptans data."," .        .      .","Clinical Significance: Safe for use. No reports of adverse effects on infants. Considered acceptable option for acute migraine.","   (.   ).    .    .","Use usual dose (12.5mg as needed). No need for breastfeeding timing. Can use as needed.");n("Clorazepate - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .        .","Mechanism: **Transfers to breast milk in significant amounts**. Accumulates in infant and may cause severe neural depression.","           .   .","Clinical Significance: May cause neural depression, feeding difficulties, or withdrawal syndrome. Not recommended.","  .      .       .","Avoid use completely. Buspirone or sertraline are safer alternatives. If used, monitor infant intensively.");n("Lafutidine - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.LOW,"       .        .","Mechanism: **Minimal transfer to breast milk**. Concentration in milk is low and non-significant for infant.","   .        .     .","Clinical Significance: Safe for use during breastfeeding. No reports of adverse effects on infants. Considered safe option for acid reflux.","   (  ).     .      .","Use usual dose (10mg daily). No special precautions needed. Can continue treatment as needed.");n("Meprobamate - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"      .        .","Mechanism: **Transfers to breast milk in significant amounts**. Accumulates in infant and may cause severe neural depression.","           .   .","Clinical Significance: May cause neural depression, feeding difficulties, or withdrawal syndrome. Not recommended.","  .       .       .","Avoid use completely. Paracetamol or ibuprofen are safer alternatives for pain. If used, monitor infant intensively.");n("Terazosin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"      .           .","Mechanism: **Transfers to breast milk in small amounts**. May cause hypotension in infant especially with initial doses.","     .       .     .","Clinical Significance: Most infants show no adverse effects. May cause sudden hypotension. Monitoring after first dose important.","   .     .   .    .","Start with very low dose. Monitor infant after first dose. Avoid high doses. Tamsulosin safer alternative.");n("Ethotoin - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"        .         .","Mechanism: **Transfers to breast milk in low to moderate amounts**. May cause drowsiness or vitamin effects in infant.","     .         K.   .","Clinical Significance: Most infants show no adverse effects. May cause mild drowsiness or vitamin K deficiency. Periodic monitoring advisable.","   .   .   K .    .","Use lowest effective dose. Monitor infant for drowsiness. Give vitamin K to infant. Levetiracetam safer alternative.");n("Isocarboxazid - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.HIGH,"                .","Mechanism: **Transfers to breast milk and may cause serious neurological and cardiovascular effects** in infant.","           .     .","Clinical Significance: May cause hypertension, seizures, or sleep disorders in infant. Not recommended during breastfeeding.","  .      .       .","Avoid use completely. Sertraline or escitalopram are safer alternatives. If used, monitor infant intensively.");n("Reslizumab - ","  / Breastfeeding",e.DRUG_PREGNANCY_LACTATION,i.MODERATE,"                .","Mechanism: **Large antibody with minimal transfer to breast milk**, but its immunosuppressive effect raises theoretical concerns.","        .       .","Clinical Significance: Data limited but small studies show no adverse effects. Severe asthma may justify continuing treatment.","       .      .","Can continue breastfeeding with general infant monitoring. Assess asthma severity versus theoretical risks.");const Jo=Bh(nf),ry=Fh(Jo),sy=({severity:h})=>{let P="",x="";switch(h){case i.HIGH:P="bg-red-100 text-red-800 border-red-200",x="  (High)";break;case i.MODERATE:P="bg-orange-100 text-orange-800 border-orange-200",x=" (Moderate)";break;case i.LOW:P="bg-blue-100 text-blue-800 border-blue-200",x=" (Low)";break;case i.CONTRAINDICATED:P="bg-gray-900 text-white border-gray-700",x=" (Contraindicated)";break;default:P="bg-gray-100 text-gray-800",x=" "}return m.jsx("span",{className:`px-3 py-1 rounded-full text-xs font-bold border ${P} shadow-sm`,children:x})},cy=({interaction:h,isDarkMode:P=!1})=>{const x=W=>{var O,E,L;if(!W)return{ar:"",en:""};const X=W.split("||");return{ar:((O=X[0])==null?void 0:O.trim())||W,en:((E=X[1])==null?void 0:E.trim())||((L=X[0])==null?void 0:L.trim())||W}},f=x(h.mechanism),S=x(h.effect),w=x(h.management);return m.jsxs("div",{className:`group rounded-3xl shadow-xl overflow-hidden hover:shadow-2xl transition-all duration-500 relative ${P?"bg-slate-800 border border-slate-700 shadow-slate-900/50 hover:shadow-blue-900/30":"bg-white border border-slate-100 shadow-slate-200/50 hover:shadow-blue-900/10"}`,children:[m.jsxs("div",{className:`border-b p-4 sm:p-6 flex flex-col md:flex-row justify-between items-start md:items-center gap-3 sm:gap-4 ${P?"bg-slate-700/50 border-slate-600":"bg-slate-50/80 border-slate-100"}`,children:[m.jsxs("div",{className:"flex items-center gap-3 sm:gap-4 flex-wrap",children:[m.jsxs("div",{className:"flex items-center gap-2 sm:gap-3",children:[m.jsx("div",{className:`w-10 h-10 sm:w-12 sm:h-12 rounded-xl sm:rounded-2xl shadow-sm border flex items-center justify-center text-lg sm:text-xl font-bold ${P?"bg-slate-600 border-slate-500 text-blue-400":"bg-white border-slate-100 text-blue-600"}`,children:h.drugA.charAt(0).toUpperCase()}),m.jsxs("div",{children:[m.jsx("h3",{className:`text-base sm:text-lg md:text-xl font-bold ${P?"text-white":"text-slate-800"}`,children:h.drugA}),m.jsx("span",{className:"text-xs font-medium text-slate-400",children:" "})]})]}),m.jsx("div",{className:"hidden md:flex items-center justify-center w-6 h-6 sm:w-8 sm:h-8",children:m.jsx("svg",{className:`w-4 h-4 sm:w-5 sm:h-5 ${P?"text-slate-500":"text-slate-300"}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})}),m.jsxs("div",{className:"flex items-center gap-2 sm:gap-3",children:[m.jsx("div",{className:`w-10 h-10 sm:w-12 sm:h-12 rounded-xl sm:rounded-2xl shadow-sm border flex items-center justify-center text-lg sm:text-xl font-bold ${h.type===e.DRUG_DRUG?P?"bg-slate-600 border-slate-500 text-blue-400":"bg-white border-slate-100 text-blue-600":h.type===e.DRUG_FOOD?P?"bg-emerald-900/50 border-emerald-700 text-emerald-400":"bg-emerald-50 border-emerald-100 text-emerald-600":h.type===e.DRUG_DISEASE?P?"bg-red-900/50 border-red-700 text-red-400":"bg-red-50 border-red-100 text-red-600":h.type===e.DRUG_VACCINE?P?"bg-purple-900/50 border-purple-700 text-purple-400":"bg-purple-50 border-purple-100 text-purple-600":P?"bg-orange-900/50 border-orange-700 text-orange-400":"bg-orange-50 border-slate-100 text-orange-600"}`,children:(h.drugB||h.foodOrCondition||"?").charAt(0).toUpperCase()}),m.jsxs("div",{children:[m.jsx("h3",{className:`text-base sm:text-lg md:text-xl font-bold ${P?"text-white":"text-slate-800"}`,children:h.type===e.DRUG_DRUG?h.drugB:h.foodOrCondition}),m.jsx("span",{className:"text-xs font-medium text-slate-400",children:" "})]})]})]}),m.jsxs("div",{className:"flex flex-col md:flex-row items-end md:items-center gap-3",children:[m.jsx(sy,{severity:h.severity}),m.jsx("div",{className:"flex items-center gap-2",children:m.jsx("button",{onClick:()=>{const W=` :
${h.drugA} + ${h.drugB||h.foodOrCondition}
: ${h.severity}
: ${f.ar}
: ${S.ar}
: ${w.ar}`;navigator.clipboard.writeText(W),alert("   ")},className:`p-2 rounded-xl transition-all ${P?"bg-slate-700 text-slate-300 hover:bg-slate-600 hover:text-white":"bg-slate-100 text-slate-600 hover:bg-slate-200"}`,title:" ",children:m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 5H6a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2v-1M8 5a2 2 0 002 2h2a2 2 0 002-2M8 5a2 2 0 012-2h2a2 2 0 012 2m0 0h2a2 2 0 012 2v3m2 4H10m0 0l3-3m-3 3l3 3"})})})})]})]}),m.jsx("div",{className:"p-4 sm:p-6",children:m.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4 sm:gap-6",children:[m.jsxs("div",{className:`rounded-xl sm:rounded-2xl p-4 sm:p-5 border transition-colors ${P?"bg-blue-900/20 border-blue-800/50 hover:bg-blue-900/30":"bg-blue-50/50 border-blue-100/50 hover:bg-blue-50"}`,children:[m.jsxs("div",{className:"flex items-center gap-2 sm:gap-3 mb-2 sm:mb-3",children:[m.jsx("div",{className:`w-8 h-8 sm:w-10 sm:h-10 rounded-lg sm:rounded-xl flex items-center justify-center ${P?"bg-blue-900/50 text-blue-400":"bg-blue-100 text-blue-600"}`,children:m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})})}),m.jsx("h4",{className:`text-sm sm:text-base font-bold ${P?"text-blue-300":"text-blue-900"}`,children:""})]}),m.jsx("p",{className:`text-sm sm:text-base md:text-lg leading-relaxed font-medium ${P?"text-slate-300":"text-slate-700"}`,children:f.ar}),f.en&&f.en!==f.ar&&m.jsx("p",{className:`text-xs sm:text-sm md:text-base mt-2 font-medium text-left ${P?"text-slate-400":"text-slate-500"}`,dir:"ltr",children:f.en})]}),m.jsxs("div",{className:`rounded-2xl p-5 border transition-colors ${P?"bg-purple-900/20 border-purple-800/50 hover:bg-purple-900/30":"bg-purple-50/50 border-purple-100/50 hover:bg-purple-50"}`,children:[m.jsxs("div",{className:"flex items-center gap-3 mb-3",children:[m.jsx("div",{className:`w-10 h-10 rounded-xl flex items-center justify-center ${P?"bg-purple-900/50 text-purple-400":"bg-purple-100 text-purple-600"}`,children:m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 10V3L4 14h7v7l9-11h-7z"})})}),m.jsx("h4",{className:`font-bold ${P?"text-purple-300":"text-purple-900"}`,children:""})]}),m.jsx("p",{className:`text-lg leading-relaxed font-medium ${P?"text-slate-300":"text-slate-700"}`,children:S.ar}),S.en&&S.en!==S.ar&&m.jsx("p",{className:`text-base mt-2 font-medium text-left ${P?"text-slate-400":"text-slate-500"}`,dir:"ltr",children:S.en})]}),m.jsxs("div",{className:`rounded-2xl p-5 border transition-colors ${P?"bg-emerald-900/20 border-emerald-800/50 hover:bg-emerald-900/30":"bg-emerald-50/50 border-emerald-100/50 hover:bg-emerald-50"}`,children:[m.jsxs("div",{className:"flex items-center gap-3 mb-3",children:[m.jsx("div",{className:`w-10 h-10 rounded-xl flex items-center justify-center ${P?"bg-emerald-900/50 text-emerald-400":"bg-emerald-100 text-emerald-600"}`,children:m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"})})}),m.jsx("h4",{className:`font-bold ${P?"text-emerald-300":"text-emerald-900"}`,children:""})]}),m.jsx("p",{className:`text-lg leading-relaxed font-medium ${P?"text-slate-300":"text-slate-700"}`,children:w.ar}),w.en&&w.en!==w.ar&&m.jsx("p",{className:`text-base mt-2 font-medium text-left ${P?"text-slate-400":"text-slate-500"}`,dir:"ltr",children:w.en})]})]})})]})},ly=({isDarkMode:h})=>m.jsx("div",{className:"max-w-7xl mx-auto px-4 mt-16 mb-8",children:m.jsx("div",{className:`rounded-3xl border overflow-hidden ${h?"bg-slate-800/50 border-slate-700":"bg-amber-50 border-amber-100"}`,children:m.jsxs("div",{className:"p-6 flex flex-col md:flex-row gap-6 items-start",children:[m.jsx("div",{className:`p-3 rounded-full flex-shrink-0 ${h?"bg-red-900/30 text-red-400":"bg-amber-100 text-amber-600"}`,children:m.jsx("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"})})}),m.jsxs("div",{className:"flex-1",children:[m.jsx("h3",{className:`text-lg font-bold mb-2 ${h?"text-white":"text-slate-900"}`,children:"   "}),m.jsxs("div",{className:`prose max-w-none text-sm ${h?"text-slate-300":"text-slate-600"}`,children:[m.jsxs("p",{className:"mb-2",children:["   ",m.jsx("strong",{children:"   "}),".              ."]}),m.jsx("p",{className:"opacity-75",children:"         .              ."})]})]})]})})}),dy=({isOpen:h,onClose:P,onPrint:x,isDarkMode:f})=>{const[S,w]=re.useState(""),[W,X]=re.useState("");return h?m.jsx("div",{className:"fixed inset-0 z-[100] flex items-center justify-center p-4 bg-black/50 backdrop-blur-sm animate-in fade-in",children:m.jsxs("div",{className:`w-full max-w-md rounded-2xl shadow-2xl p-6 transform transition-all scale-100 ${f?"bg-slate-800 text-white":"bg-white text-slate-800"}`,children:[m.jsxs("div",{className:"flex items-center justify-between mb-6",children:[m.jsx("h3",{className:"text-xl font-bold",children:"  "}),m.jsx("button",{onClick:P,className:"text-slate-400 hover:text-red-500 transition-colors",children:m.jsx("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]}),m.jsxs("div",{className:"space-y-4",children:[m.jsxs("div",{children:[m.jsx("label",{className:`block text-sm font-semibold mb-2 ${f?"text-slate-300":"text-slate-700"}`,children:"  ()"}),m.jsx("input",{type:"text",value:S,onChange:O=>w(O.target.value),placeholder:":  ",className:`w-full px-4 py-2 rounded-xl border outline-none focus:ring-2 focus:ring-blue-500 transition-all ${f?"bg-slate-700 border-slate-600 text-white placeholder-slate-400":"bg-slate-50 border-slate-200 text-slate-800 placeholder-slate-400"}`})]}),m.jsxs("div",{children:[m.jsx("label",{className:`block text-sm font-semibold mb-2 ${f?"text-slate-300":"text-slate-700"}`,children:"  /  ()"}),m.jsx("input",{type:"text",value:W,onChange:O=>X(O.target.value),placeholder:": .  ",className:`w-full px-4 py-2 rounded-xl border outline-none focus:ring-2 focus:ring-blue-500 transition-all ${f?"bg-slate-700 border-slate-600 text-white placeholder-slate-400":"bg-slate-50 border-slate-200 text-slate-800 placeholder-slate-400"}`})]})]}),m.jsxs("div",{className:"flex gap-3 mt-8",children:[m.jsxs("button",{onClick:()=>x(S,W),className:"flex-1 bg-blue-600 hover:bg-blue-700 text-white font-bold py-3 px-4 rounded-xl transition-all flex items-center justify-center gap-2",children:[m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M17 17h2a2 2 0 002-2v-4a2 2 0 00-2-2H5a2 2 0 00-2 2v4a2 2 0 002 2h2m2 4h6a2 2 0 002-2v-4a2 2 0 00-2-2H9a2 2 0 00-2 2v4a2 2 0 002 2zm8-12V5a2 2 0 00-2-2H9a2 2 0 00-2 2v4h10z"})})," "]}),m.jsx("button",{onClick:P,className:`flex-1 font-bold py-3 px-4 rounded-xl transition-all ${f?"bg-slate-700 hover:bg-slate-600 text-slate-300":"bg-slate-100 hover:bg-slate-200 text-slate-600"}`,children:""})]})]})}):null},my=({isDarkMode:h=!1})=>{const P=[{number:1,title:"  ",description:"    (  )     ( )",icon:m.jsx("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2"})}),color:"blue"},{number:2,title:"  ",description:"        -    ",icon:m.jsx("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})}),color:"indigo"},{number:3,title:" ",description:"         ",icon:m.jsx("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})}),color:"purple"},{number:4,title:" ",description:"     (- - )   ",icon:m.jsx("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 4a1 1 0 011-1h16a1 1 0 011 1v2.586a1 1 0 01-.293.707l-6.414 6.414a1 1 0 00-.293.707V17l-4 4v-6.586a1 1 0 00-.293-.707L3.293 7.293A1 1 0 013 6.586V4z"})}),color:"green"},{number:5,title:"  ",description:"         ",icon:m.jsx("svg",{className:"w-8 h-8",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M17 17h2a2 2 0 002-2v-4a2 2 0 00-2-2H5a2 2 0 00-2 2v4a2 2 0 002 2h2m2 4h6a2 2 0 002-2v-4a2 2 0 00-2-2H9a2 2 0 00-2 2v4a2 2 0 002 2zm8-12V5a2 2 0 00-2-2H9a2 2 0 00-2 2v4h10z"})}),color:"orange"}],x=(f,S=!1)=>({blue:{bg:h?"bg-blue-900/30":"bg-blue-50",border:h?"border-blue-700":"border-blue-200",text:h?"text-blue-400":"text-blue-600",gradient:"from-blue-500 to-blue-600"},indigo:{bg:h?"bg-indigo-900/30":"bg-indigo-50",border:h?"border-indigo-700":"border-indigo-200",text:h?"text-indigo-400":"text-indigo-600",gradient:"from-indigo-500 to-indigo-600"},purple:{bg:h?"bg-purple-900/30":"bg-purple-50",border:h?"border-purple-700":"border-purple-200",text:h?"text-purple-400":"text-purple-600",gradient:"from-purple-500 to-purple-600"},green:{bg:h?"bg-green-900/30":"bg-green-50",border:h?"border-green-700":"border-green-200",text:h?"text-green-400":"text-green-600",gradient:"from-green-500 to-green-600"},orange:{bg:h?"bg-orange-900/30":"bg-orange-50",border:h?"border-orange-700":"border-orange-200",text:h?"text-orange-400":"text-orange-600",gradient:"from-orange-500 to-orange-600"}})[f];return m.jsx("div",{className:`py-12 sm:py-16 md:py-20 ${h?"bg-slate-900":"bg-slate-50"}`,children:m.jsxs("div",{className:"max-w-7xl mx-auto px-3 sm:px-4",children:[m.jsxs("div",{className:"text-center mb-10 sm:mb-12 md:mb-16",children:[m.jsx("div",{className:"inline-flex items-center justify-center w-16 h-16 sm:w-20 sm:h-20 rounded-2xl bg-gradient-to-br from-blue-500 to-indigo-600 mb-4 sm:mb-6",children:m.jsx("svg",{className:"w-8 h-8 sm:w-10 sm:h-10 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})}),m.jsx("h2",{className:`text-3xl sm:text-4xl md:text-5xl font-extrabold mb-3 sm:mb-4 ${h?"text-white":"text-slate-900"}`,children:"  "}),m.jsx("p",{className:`text-base sm:text-lg md:text-xl max-w-3xl mx-auto ${h?"text-slate-400":"text-slate-600"}`,children:"        "})]}),m.jsx("div",{className:"space-y-6 sm:space-y-8",children:P.map((f,S)=>{const w=x(f.color);return m.jsx("div",{className:`group relative rounded-xl sm:rounded-2xl border-2 p-4 sm:p-6 md:p-8 transition-all duration-300 hover:shadow-xl ${w.bg} ${w.border} ${h?"hover:bg-opacity-50":"hover:bg-opacity-70"}`,children:m.jsxs("div",{className:"flex flex-col sm:flex-row items-start gap-4 sm:gap-6",children:[m.jsx("div",{className:`flex-shrink-0 w-12 h-12 sm:w-16 sm:h-16 rounded-xl sm:rounded-2xl bg-gradient-to-br ${w.gradient} flex items-center justify-center shadow-lg`,children:m.jsx("span",{className:"text-white text-xl sm:text-2xl md:text-3xl font-bold",children:f.number})}),m.jsxs("div",{className:"flex-1",children:[m.jsxs("div",{className:"flex items-center gap-3 mb-2 sm:mb-3",children:[m.jsx("div",{className:w.text,children:f.icon}),m.jsx("h3",{className:`text-xl sm:text-2xl md:text-3xl font-bold ${h?"text-white":"text-slate-900"}`,children:f.title})]}),m.jsx("p",{className:`text-sm sm:text-base md:text-lg leading-relaxed ${h?"text-slate-300":"text-slate-700"}`,children:f.description})]}),S<P.length-1&&m.jsx("div",{className:`hidden lg:block absolute left-10 top-full w-0.5 h-8 bg-gradient-to-b ${w.gradient} opacity-30`})]})},f.number)})}),m.jsxs("div",{className:`mt-10 sm:mt-12 md:mt-16 text-center p-6 sm:p-8 rounded-xl sm:rounded-2xl border-2 ${h?"bg-gradient-to-br from-blue-900/20 to-indigo-900/20 border-blue-800":"bg-gradient-to-br from-blue-50 to-indigo-50 border-blue-200"}`,children:[m.jsx("div",{className:"inline-flex items-center justify-center w-12 h-12 sm:w-14 sm:h-14 rounded-full bg-gradient-to-br from-green-500 to-emerald-600 mb-4",children:m.jsx("svg",{className:"w-6 h-6 sm:w-7 sm:h-7 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})})}),m.jsx("h3",{className:`text-xl sm:text-2xl md:text-3xl font-bold mb-2 sm:mb-3 ${h?"text-white":"text-slate-900"}`,children:" "}),m.jsx("p",{className:`text-sm sm:text-base md:text-lg mb-4 sm:mb-6 ${h?"text-slate-300":"text-slate-700"}`,children:"       "}),m.jsxs("button",{onClick:()=>window.scrollTo({top:0,behavior:"smooth"}),className:"inline-flex items-center gap-2 px-6 sm:px-8 py-3 sm:py-4 bg-gradient-to-r from-blue-600 to-indigo-700 text-white font-bold text-sm sm:text-base rounded-xl sm:rounded-2xl shadow-lg hover:shadow-xl transform hover:-translate-y-1 transition-all duration-300",children:[m.jsx("svg",{className:"w-5 h-5 sm:w-6 sm:h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 10l7-7m0 0l7 7m-7-7v18"})}),"  "]})]})]})})},uy=({isDarkMode:h=!1})=>{const[P,x]=re.useState(!1),f=()=>{window.pageYOffset>300?x(!0):x(!1)},S=()=>{window.scrollTo({top:0,behavior:"smooth"})};return re.useEffect(()=>(window.addEventListener("scroll",f),()=>{window.removeEventListener("scroll",f)}),[]),m.jsx("div",{className:"fixed bottom-8 left-8 z-50",children:P&&m.jsx("button",{onClick:S,className:`p-3 rounded-full shadow-lg transition-all duration-300 transform hover:scale-110 focus:outline-none ${h?"bg-blue-600 hover:bg-blue-500 text-white shadow-blue-900/50":"bg-blue-600 hover:bg-blue-700 text-white shadow-blue-200"}`,"aria-label":"Scroll to top",children:m.jsx("svg",{className:"w-6 h-6",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",xmlns:"http://www.w3.org/2000/svg",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 10l7-7m0 0l7 7m-7-7v18"})})})})},tf=document.createElement("style");tf.textContent=`
  @import url('https://fonts.googleapis.com/css2?family=Cairo:wght@300;400;500;600;700;800&display=swap');
`;document.head.appendChild(tf);function fy(h,P){re.useEffect(()=>{const x=f=>{!h.current||h.current.contains(f.target)||P(f)};return document.addEventListener("mousedown",x),()=>{document.removeEventListener("mousedown",x)}},[h,P])}function Ic(h,P){const[x,f]=re.useState(h);return re.useEffect(()=>{const S=setTimeout(()=>{f(h)},P);return()=>{clearTimeout(S)}},[h,P]),x}const Ec=({label:h,placeholder:P,value:x,onChange:f,onSelect:S,suggestions:w,icon:W,isDarkMode:X=!1,autoFocus:O=!1})=>{const[E,L]=re.useState(-1),[_,K]=re.useState(!1),Ae=re.useRef(null),z=re.useRef(null);re.useEffect(()=>{O&&z.current&&z.current.focus()},[O]),fy(Ae,()=>{K(!1)}),re.useEffect(()=>{L(-1)},[w]),re.useEffect(()=>{x.length>=2?K(!0):K(!1)},[x]);const Ie=(Q,se)=>se?Q.split(new RegExp(`(${se})`,"gi")).map((de,F)=>de.toLowerCase()===se.toLowerCase()?m.jsx("span",{className:"bg-green-600 font-semibold",children:de},F):de):Q,ke=Q=>{S(Q),K(!1)},Pe=Q=>{if(!_||w.length===0){Q.key==="ArrowDown"&&x.length>=2&&K(!0);return}Q.key==="ArrowDown"?(Q.preventDefault(),L(se=>se<w.length-1?se+1:0)):Q.key==="ArrowUp"?(Q.preventDefault(),L(se=>se>0?se-1:w.length-1)):Q.key==="Enter"&&E>=0?(Q.preventDefault(),ke(w[E].name)):Q.key==="Escape"&&K(!1)},qe=_&&x.length>=2;return m.jsxs("div",{className:"mb-6 relative",ref:Ae,style:{zIndex:_?100:10},children:[m.jsx("label",{className:`block text-sm font-semibold mb-2 ${X?"text-slate-300":"text-slate-700"}`,children:h}),m.jsxs("div",{className:"relative",children:[W,m.jsx("input",{ref:z,type:"text",className:`w-full px-12 py-3 border-2 rounded-xl focus:ring-2 focus:ring-blue-500 outline-none transition-all text-lg ${X?"bg-slate-700 border-slate-600 text-white placeholder-slate-400 focus:border-blue-400":"bg-white border-slate-300 text-slate-800 placeholder-slate-400 focus:border-blue-500"}`,placeholder:P,value:x,onChange:Q=>f(Q.target.value),onKeyDown:Pe,onFocus:()=>{x.length>=2&&K(!0)}}),x&&m.jsx("button",{onClick:()=>{f(""),K(!1)},className:"absolute left-4 top-1/2 -translate-y-1/2 text-slate-400 hover:text-red-500 hover:bg-red-50 p-1 rounded-full transition-all",children:m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]}),qe&&m.jsxs("div",{className:`absolute top-full left-0 right-0 mt-2 border-2 rounded-xl shadow-2xl max-h-48 sm:max-h-80 overflow-y-auto ${X?"bg-slate-800 border-slate-600":"bg-white border-blue-200"}`,style:{zIndex:1e3},children:[m.jsxs("div",{className:`sticky top-0 px-4 py-2 border-b flex justify-between items-center text-xs z-[101] ${X?"bg-slate-700 border-slate-600":"bg-gradient-to-r from-blue-50 to-indigo-50 border-blue-100"}`,children:[m.jsx("span",{className:`font-semibold ${X?"text-blue-400":"text-blue-700"}`,children:w.length>0?`${w.length} `:"  "}),m.jsx("span",{className:X?"text-slate-400":"text-slate-500",children:"  "})]}),w.length>0?w.map((Q,se)=>m.jsxs("div",{className:`px-4 py-3 cursor-pointer transition-all flex items-center gap-3 ${se===E?X?"bg-slate-700 border-r-4 border-blue-400":"bg-blue-50 border-r-4 border-blue-500":X?"hover:bg-slate-700":"hover:bg-slate-50"}`,onClick:()=>ke(Q.name),onMouseEnter:()=>L(se),children:[m.jsx("div",{className:"w-10 h-10 rounded-full bg-gradient-to-br from-blue-500 to-indigo-600 flex items-center justify-center text-white font-bold text-sm flex-shrink-0",children:Q.name.charAt(0).toUpperCase()}),m.jsx("span",{className:`font-medium text-base ${X?"text-white":"text-slate-800"}`,children:Ie(Q.name,x)})]},Q.id)):m.jsx("div",{className:`px-4 py-8 text-center ${X?"text-slate-400":"text-slate-500"}`,children:"     ."})]})]})};function py(){const[h,P]=re.useState("PAIR"),[x,f]=re.useState(""),[S,w]=re.useState(""),[W,X]=re.useState(""),[O,E]=re.useState([]),[L,_]=re.useState("ALL"),[K,Ae]=re.useState("ALL"),[z,Ie]=re.useState(()=>{const g=localStorage.getItem("darkMode");return g?JSON.parse(g):!0}),[ke,Pe]=re.useState(()=>{const g=localStorage.getItem("searchHistory");return g?JSON.parse(g):[]}),[qe,Q]=re.useState(!1),[se,ti]=re.useState({patientName:"",doctorName:""}),de=Ic(x,300),F=Ic(S,300),Ve=Ic(W,300),bi=()=>{Ie(g=>{const U=!g;return localStorage.setItem("darkMode",JSON.stringify(U)),U})},ki=re.useCallback((g,U)=>{!g||!U||Pe(T=>{if(T.length>0&&(T[0].t1===g&&T[0].t2===U||T[0].t1===U&&T[0].t2===g))return T;const J=[{t1:g,t2:U,date:Date.now()},...T.filter(he=>!(he.t1===g&&he.t2===U||he.t1===U&&he.t2===g))].slice(0,5);return localStorage.setItem("searchHistory",JSON.stringify(J)),J})},[]),gi=()=>{Pe([]),localStorage.removeItem("searchHistory")},Qe=()=>{Q(!0)},_i=(g,U)=>{ti({patientName:g,doctorName:U}),Q(!1),setTimeout(()=>{window.print()},100)},Pi=g=>{g&&!O.includes(g)&&(E(U=>[...U,g]),X(""))},oi=g=>{E(U=>U.filter(T=>T!==g))},C=re.useCallback(g=>{if(!g||g.trim().length<2)return[];const U=g.toLowerCase().trim(),T=[],B=[],q=[];let J=0;const he=15;for(const le of ry){if(J>=he)break;const Ze=le.name.toLowerCase();Ze===U?(T.push(le),J++):Ze.startsWith(U)?(B.push(le),J++):Ze.includes(U)&&(q.push(le),J++)}return[...T,...B,...q].slice(0,he)},[]),H=re.useMemo(()=>C(x),[x,C]),V=re.useMemo(()=>C(S),[S,C]),pe=re.useMemo(()=>C(W),[W,C]),ce=re.useMemo(()=>{let g=[];if(h==="PAIR"){if(!de&&!F)return[];if(de.length<2&&F.length<2)return[];const U=de.trim().toLowerCase(),T=F.trim().toLowerCase();g=Jo.filter(B=>{const q=B.drugA.toLowerCase(),J=(B.drugB||"").toLowerCase(),he=(B.foodOrCondition||"").toLowerCase(),le=[q,J,he].filter(Boolean);if(U&&!T)return le.some(ri=>ri.includes(U));if(!U&&T)return le.some(ri=>ri.includes(T));const Ze=le.some(ri=>ri.includes(U)),on=le.some(ri=>ri.includes(T));return Ze&&on})}else{if(O.length<2)return[];for(let U=0;U<O.length;U++)for(let T=U+1;T<O.length;T++){const B=O[U].toLowerCase(),q=O[T].toLowerCase(),J=Jo.filter(he=>{const le=he.drugA.toLowerCase(),Ze=(he.drugB||he.foodOrCondition||"").toLowerCase(),on=le.includes(B)&&Ze.includes(q),ri=le.includes(q)&&Ze.includes(B);return on||ri});g.push(...J)}g=Array.from(new Set(g.map(U=>U.id))).map(U=>g.find(T=>T.id===U))}return L!=="ALL"&&(g=g.filter(U=>U.type===L)),K!=="ALL"&&(g=g.filter(U=>U.severity===K)),g},[h,de,F,O,L,K]);re.useEffect(()=>{h==="PAIR"&&de&&F&&ce.length>0&&de.length>=3&&F.length>=3&&ki(de,F)},[h,de,F,ce.length,ki]),re.useEffect(()=>{const g=new URLSearchParams(window.location.search),U=g.get("drug1"),T=g.get("drug2");U&&f(U),T&&w(T)},[]),re.useEffect(()=>{if(h==="PAIR"){const g=new URLSearchParams;de&&g.set("drug1",de),F&&g.set("drug2",F);const U=`${window.location.pathname}${g.toString()?"?"+g.toString():""}`;window.history.replaceState({},"",U)}},[h,de,F]);const y=h==="PAIR"&&(x!==de||S!==F)||h==="PRESCRIPTION"&&W!==Ve;return m.jsxs("div",{className:`min-h-screen flex flex-col font-['Cairo',sans-serif] transition-colors duration-300 ${z?"bg-gradient-to-br from-slate-900 via-slate-800 to-slate-900":"bg-gradient-to-br from-slate-50 via-blue-50 to-indigo-50"}`,children:[m.jsx("header",{className:`shadow-sm border-b sticky top-0 z-30 transition-colors duration-300 ${z?"bg-slate-800 border-slate-700":"bg-white border-slate-200"}`,children:m.jsxs("div",{className:"max-w-7xl mx-auto px-3 sm:px-4 py-3 sm:py-4 flex items-center justify-between",children:[m.jsxs("div",{className:"flex items-center gap-2 sm:gap-3",children:[m.jsx("div",{className:"w-8 h-8 sm:w-10 sm:h-10 bg-gradient-to-br from-blue-600 to-indigo-700 rounded-lg flex items-center justify-center",children:m.jsx("span",{className:"text-white font-bold text-base sm:text-xl",children:"Rx"})}),m.jsxs("div",{children:[m.jsx("h1",{className:`text-base sm:text-xl font-bold ${z?"text-white":"text-slate-800"}`,children:"PharmaCheck Pro"}),m.jsx("p",{className:`text-xs hidden sm:block ${z?"text-slate-400":"text-slate-500"}`,children:"Medical Interaction Checker"})]})]}),m.jsxs("div",{className:"flex items-center gap-2 sm:gap-3",children:[m.jsxs("div",{className:`flex items-center gap-1 sm:gap-2 px-2 sm:px-4 py-1.5 sm:py-2 rounded-full ${z?"bg-slate-700":"bg-blue-50"}`,children:[m.jsx("svg",{className:`w-4 h-4 sm:w-5 sm:h-5 ${z?"text-blue-400":"text-blue-600"}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"})}),m.jsxs("span",{className:`text-xs sm:text-sm font-semibold ${z?"text-blue-400":"text-blue-700"}`,children:[Jo.length.toLocaleString(),m.jsx("span",{className:"hidden sm:inline",children:" "})]})]}),m.jsx("button",{onClick:bi,className:`p-1.5 sm:p-2 rounded-full transition-all ${z?"bg-slate-700 text-yellow-400 hover:bg-slate-600":"bg-slate-100 text-slate-600 hover:bg-slate-200"}`,title:z?" ":" ",children:z?m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 3v1m0 16v1m9-9h-1M4 12H3m15.364 6.364l-.707-.707M6.343 6.343l-.707-.707m12.728 0l-.707.707M6.343 17.657l-.707.707M16 12a4 4 0 11-8 0 4 4 0 018 0z"})}):m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M20.354 15.354A9 9 0 018.646 3.646 9.003 9.003 0 0012 21a9.003 9.003 0 008.354-5.646z"})})})]})]})}),m.jsxs("div",{className:"flex-grow",children:[m.jsxs("div",{className:`relative text-white overflow-hidden transition-colors duration-300 ${z?"bg-gradient-to-br from-slate-800 via-slate-900 to-black":"bg-gradient-to-br from-cyan-500 via-blue-600 to-indigo-600"}`,children:[m.jsxs("div",{className:"absolute inset-0 overflow-hidden opacity-20 pointer-events-none",children:[m.jsx("div",{className:`absolute top-10 right-5 sm:right-10 w-48 h-48 sm:w-72 sm:h-72 rounded-full blur-3xl ${z?"bg-blue-500":"bg-white"}`}),m.jsx("div",{className:`absolute bottom-10 left-5 sm:left-10 w-64 h-64 sm:w-96 sm:h-96 rounded-full blur-3xl ${z?"bg-indigo-500":"bg-purple-300"}`}),m.jsx("div",{className:`absolute top-1/2 left-1/2 -translate-x-1/2 -translate-y-1/2 w-40 h-40 sm:w-64 sm:h-64 rounded-full blur-3xl ${z?"bg-purple-500":"bg-blue-300"}`})]}),m.jsx("div",{className:"relative max-w-7xl mx-auto px-3 sm:px-4 pt-8 sm:pt-12 md:pt-16 pb-12 sm:pb-16 md:pb-24 text-center",children:m.jsxs("div",{className:"mb-4 sm:mb-6",children:[m.jsx("h2",{className:"text-2xl sm:text-3xl md:text-5xl lg:text-6xl font-extrabold mb-3 sm:mb-4 drop-shadow-lg leading-tight",children:"    "}),m.jsx("p",{className:`text-sm sm:text-base md:text-xl lg:text-2xl max-w-3xl mx-auto leading-relaxed ${z?"text-slate-300":"text-blue-100"}`,children:"               ."})]})}),m.jsxs("div",{className:`relative rounded-xl sm:rounded-2xl shadow-2xl p-4 sm:p-6 md:p-8 max-w-5xl mx-3 sm:mx-auto border transition-colors duration-300 -mt-8 sm:-mt-12 md:-mt-16 ${z?"bg-slate-800 border-slate-700":"bg-white border-slate-100"}`,style:{zIndex:50},children:[m.jsx("div",{className:"flex justify-center mb-4 sm:mb-6 md:mb-8",children:m.jsxs("div",{className:`p-1 rounded-xl flex flex-col sm:flex-row gap-1 w-full sm:w-auto ${z?"bg-slate-700":"bg-slate-100"}`,children:[m.jsxs("button",{onClick:()=>P("PAIR"),className:`px-3 sm:px-4 md:px-6 py-2 rounded-lg font-bold text-xs sm:text-sm transition-all flex items-center justify-center gap-2 ${h==="PAIR"?"bg-white text-blue-600 shadow-md":z?"text-slate-400 hover:text-white hover:bg-slate-600":"text-slate-500 hover:text-slate-800 hover:bg-slate-200"}`,children:[m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 7h12m0 0l-4-4m4 4l-4 4m0 6H4m0 0l4 4m-4-4l4-4"})}),m.jsx("span",{className:"truncate",children:"  (  )"})]}),m.jsxs("button",{onClick:()=>P("PRESCRIPTION"),className:`px-3 sm:px-4 md:px-6 py-2 rounded-lg font-bold text-xs sm:text-sm transition-all flex items-center justify-center gap-2 ${h==="PRESCRIPTION"?"bg-white text-blue-600 shadow-md":z?"text-slate-400 hover:text-white hover:bg-slate-600":"text-slate-500 hover:text-slate-800 hover:bg-slate-200"}`,children:[m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2"})}),m.jsx("span",{className:"truncate",children:"   ( )"})]})]})}),h==="PAIR"?m.jsxs("div",{className:"grid md:grid-cols-2 gap-6 relative",style:{minHeight:"300px"},children:[m.jsx("div",{style:{zIndex:30},children:m.jsx(Ec,{label:"   ",placeholder:"  ...",value:x,onChange:f,onSelect:f,suggestions:H,isDarkMode:z,icon:m.jsx("svg",{className:"absolute right-4 top-1/2 -translate-y-1/2 w-6 h-6 text-blue-500",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})})})}),m.jsx("div",{className:"absolute top-1/2 left-1/2 -translate-x-1/2 -translate-y-1/2 z-10 hidden md:block",children:m.jsx("div",{className:"w-12 h-12 bg-gradient-to-br from-blue-500 to-indigo-600 rounded-full flex items-center justify-center shadow-lg",children:m.jsx("svg",{className:"w-6 h-6 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 7h12m0 0l-4-4m4 4l-4 4m0 6H4m0 0l4 4m-4-4l4-4"})})})}),m.jsx("div",{style:{zIndex:20},children:m.jsx(Ec,{label:"   ",placeholder:"   ...",value:S,onChange:w,onSelect:w,suggestions:V,isDarkMode:z,icon:m.jsx("svg",{className:"absolute right-4 top-1/2 -translate-y-1/2 w-6 h-6 text-indigo-500",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})})})})]}):m.jsxs("div",{className:"flex flex-col gap-6",style:{minHeight:"300px"},children:[m.jsx(Ec,{label:"   (  )",placeholder:"     Enter ...",value:W,onChange:X,onSelect:Pi,suggestions:pe,isDarkMode:z,autoFocus:!0,icon:m.jsx("svg",{className:"absolute right-4 top-1/2 -translate-y-1/2 w-6 h-6 text-purple-500",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 6v6m0 0v6m0-6h6m-6 0H6"})})}),m.jsxs("div",{className:`p-4 rounded-xl border min-h-[100px] flex flex-wrap gap-2 content-start ${z?"bg-slate-700/50 border-slate-600":"bg-slate-50 border-slate-200"}`,children:[O.length===0&&m.jsx("div",{className:`w-full text-center py-4 ${z?"text-slate-500":"text-slate-400"}`,children:"     .      ."}),O.map((g,U)=>m.jsxs("div",{className:`flex items-center gap-2 px-3 py-2 rounded-lg shadow-sm animate-fadeIn ${z?"bg-slate-600 text-white":"bg-white text-slate-800"}`,children:[m.jsx("span",{className:"font-semibold",children:g}),m.jsx("button",{onClick:()=>oi(g),className:"text-red-400 hover:text-red-500 p-1 rounded-full hover:bg-red-50/10 transition-colors",children:m.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]},U))]})]}),h==="PAIR"&&ke.length>0&&m.jsxs("div",{className:"mt-6 pt-4 border-t border-dashed border-slate-200",children:[m.jsxs("div",{className:"flex items-center justify-between mb-3",children:[m.jsx("span",{className:`text-xs font-bold uppercase tracking-wider ${z?"text-slate-400":"text-slate-500"}`,children:"  "}),m.jsx("button",{onClick:gi,className:"text-xs text-red-500 hover:text-red-600 hover:underline",children:" "})]}),m.jsx("div",{className:"flex flex-wrap gap-2",children:ke.map((g,U)=>m.jsxs("button",{onClick:()=>{f(g.t1),w(g.t2)},className:`flex items-center gap-2 px-3 py-1.5 rounded-lg text-sm transition-all ${z?"bg-slate-700 text-slate-300 hover:bg-slate-600 hover:text-white":"bg-slate-100 text-slate-600 hover:bg-slate-200 hover:text-slate-800"}`,children:[m.jsx("svg",{className:"w-3 h-3 opacity-50",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 8v4l3 3m6-3a9 9 0 11-18 0 9 9 0 0118 0z"})}),m.jsxs("span",{children:[g.t1," + ",g.t2]})]},U))})]}),(h==="PAIR"&&x&&S||h==="PRESCRIPTION"&&O.length>=2)&&m.jsx("div",{className:"mt-6 p-4 bg-blue-50 border border-blue-200 rounded-lg flex items-center gap-3",children:y?m.jsxs(m.Fragment,{children:[m.jsx("div",{className:"w-5 h-5 border-2 border-blue-500 border-t-transparent rounded-full animate-spin"}),m.jsx("span",{className:"text-blue-700 font-medium",children:" ..."})]}):m.jsxs(m.Fragment,{children:[m.jsx("svg",{className:"w-5 h-5 text-green-500",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})}),m.jsx("span",{className:"text-slate-700",children:h==="PAIR"?m.jsxs(m.Fragment,{children:["   : ",m.jsx("span",{className:"font-bold text-blue-600",children:de}),"  ",m.jsx("span",{className:"font-bold text-indigo-600",children:F})]}):m.jsxs(m.Fragment,{children:["   ",m.jsx("span",{className:"font-bold text-purple-600",children:O.length}),"   "]})})]})})]})]}),m.jsxs("div",{className:"max-w-7xl mx-auto px-3 sm:px-4 py-6 sm:py-8 md:py-12",children:[m.jsxs("div",{className:"flex flex-col sm:flex-row items-start sm:items-center justify-between gap-3 sm:gap-0 mb-4 sm:mb-6",children:[m.jsxs("h3",{className:`text-xl sm:text-2xl md:text-3xl font-bold flex items-center gap-2 sm:gap-3 ${z?"text-white":"text-slate-800"}`,children:[m.jsx("div",{className:"w-8 h-8 sm:w-10 sm:h-10 bg-gradient-to-br from-blue-500 to-indigo-600 rounded-lg flex items-center justify-center",children:m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-6 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2"})})}),m.jsx("span",{className:"hidden sm:inline",children:""})]}),ce.length>0&&m.jsxs("div",{className:"flex flex-wrap items-center gap-2 sm:gap-3",children:[m.jsxs("button",{onClick:()=>{navigator.clipboard.writeText(window.location.href),alert("   !   .")},className:`flex items-center gap-2 px-3 sm:px-4 py-2 rounded-xl font-bold transition-all text-xs sm:text-sm ${z?"bg-slate-700 text-slate-300 hover:bg-slate-600 hover:text-white":"bg-white border text-slate-600 hover:bg-slate-50"}`,children:[m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8.684 13.342C8.886 12.938 9 12.482 9 12c0-.482-.114-.938-.316-1.342m0 2.684a3 3 0 110-2.684m0 2.684l6.632 3.316m-6.632-6l6.632-3.316m0 0a3 3 0 105.367-2.684 3 3 0 00-5.367 2.684zm0 9.316a3 3 0 105.368 2.684 3 3 0 00-5.368-2.684z"})}),m.jsx("span",{className:"hidden md:inline",children:" "})]}),m.jsxs("button",{onClick:Qe,className:`flex items-center gap-2 px-3 sm:px-4 py-2 rounded-xl font-bold transition-all text-xs sm:text-sm ${z?"bg-slate-700 text-slate-300 hover:bg-slate-600 hover:text-white":"bg-white border text-slate-600 hover:bg-slate-50"}`,children:[m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M17 17h2a2 2 0 002-2v-4a2 2 0 00-2-2H5a2 2 0 00-2 2v4a2 2 0 002 2h2m2 4h6a2 2 0 002-2v-4a2 2 0 00-2-2H9a2 2 0 00-2 2v4a2 2 0 002 2zm8-12V5a2 2 0 00-2-2H9a2 2 0 00-2 2v4h10z"})}),m.jsx("span",{className:"hidden md:inline",children:" "})]}),m.jsxs("span",{className:`px-3 sm:px-4 py-2 rounded-full font-semibold text-xs sm:text-sm ${z?"bg-blue-900 text-blue-300":"bg-blue-100 text-blue-700"}`,children:[m.jsx("span",{className:"hidden sm:inline",children:"   "}),ce.length,m.jsx("span",{className:"hidden sm:inline",children:" "})]})]})]}),m.jsxs("div",{className:"print-header hidden mb-8 border-b-2 border-black pb-6",children:[m.jsxs("div",{className:"flex justify-between items-start",children:[m.jsxs("div",{children:[m.jsx("h1",{className:"text-4xl font-bold mb-2",children:"PharmaCheck Pro"}),m.jsx("p",{className:"text-gray-600 text-lg",children:"Medical Interaction Report"})]}),m.jsxs("div",{className:"text-left",children:[m.jsxs("div",{className:"text-sm text-gray-500 mb-1",children:["Date: ",new Date().toLocaleDateString("en-GB")]}),m.jsxs("div",{className:"text-sm text-gray-500",children:["Time: ",new Date().toLocaleTimeString("en-GB")]})]})]}),(se.patientName||se.doctorName)&&m.jsxs("div",{className:"mt-6 grid grid-cols-2 gap-8 bg-gray-50 p-4 rounded-lg border border-gray-200",children:[se.patientName&&m.jsxs("div",{children:[m.jsx("span",{className:"block text-xs text-gray-500 uppercase tracking-wider font-bold",children:"Patient Name"}),m.jsx("span",{className:"text-xl font-bold text-gray-900",children:se.patientName})]}),se.doctorName&&m.jsxs("div",{children:[m.jsx("span",{className:"block text-xs text-gray-500 uppercase tracking-wider font-bold",children:"Doctor / Pharmacist"}),m.jsx("span",{className:"text-xl font-bold text-gray-900",children:se.doctorName})]})]})]}),(de||F||h==="PRESCRIPTION"&&O.length>=2)&&m.jsxs("div",{className:"mb-4 sm:mb-6 flex flex-col gap-3 sm:gap-4",children:[m.jsxs("div",{className:`rounded-xl shadow-md p-2 flex gap-2 overflow-x-auto transition-colors duration-300 scrollbar-thin ${z?"bg-slate-800":"bg-white"}`,children:[m.jsxs("button",{onClick:()=>_("ALL"),className:`px-3 sm:px-4 py-2 rounded-lg font-semibold text-xs sm:text-sm transition-all whitespace-nowrap flex items-center gap-2 ${L==="ALL"?"bg-gradient-to-r from-blue-500 to-indigo-600 text-white shadow-lg":z?"text-slate-300 hover:bg-slate-700":"text-slate-600 hover:bg-slate-100"}`,children:[m.jsx("svg",{className:"w-4 h-4 sm:w-5 sm:h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 6h16M4 10h16M4 14h16M4 18h16"})}),""]}),m.jsxs("button",{onClick:()=>_(e.DRUG_DRUG),className:`px-4 py-2 rounded-lg font-semibold text-sm transition-all whitespace-nowrap flex items-center gap-2 ${L===e.DRUG_DRUG?"bg-gradient-to-r from-blue-500 to-indigo-600 text-white shadow-lg":z?"text-slate-300 hover:bg-slate-700":"text-slate-600 hover:bg-slate-100"}`,children:[m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"})})," - "]}),m.jsxs("button",{onClick:()=>_(e.DRUG_FOOD),className:`px-4 py-2 rounded-lg font-semibold text-sm transition-all whitespace-nowrap flex items-center gap-2 ${L===e.DRUG_FOOD?"bg-gradient-to-r from-green-500 to-emerald-600 text-white shadow-lg":z?"text-slate-300 hover:bg-slate-700":"text-slate-600 hover:bg-slate-100"}`,children:[m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 3h2l.4 2M7 13h10l4-8H5.4M7 13L5.4 5M7 13l-2.293 2.293c-.63.63-.184 1.707.707 1.707H17m0 0a2 2 0 100 4 2 2 0 000-4zm-8 2a2 2 0 11-4 0 2 2 0 014 0z"})})," - "]}),m.jsxs("button",{onClick:()=>_(e.DRUG_DISEASE),className:`px-4 py-2 rounded-lg font-semibold text-sm transition-all whitespace-nowrap flex items-center gap-2 ${L===e.DRUG_DISEASE?"bg-gradient-to-r from-red-500 to-rose-600 text-white shadow-lg":z?"text-slate-300 hover:bg-slate-700":"text-slate-600 hover:bg-slate-100"}`,children:[m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 8v4m0 4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})," - "]}),m.jsxs("button",{onClick:()=>_(e.DRUG_VACCINE),className:`px-4 py-2 rounded-lg font-semibold text-sm transition-all whitespace-nowrap flex items-center gap-2 ${L===e.DRUG_VACCINE?"bg-gradient-to-r from-purple-500 to-violet-600 text-white shadow-lg":z?"text-slate-300 hover:bg-slate-700":"text-slate-600 hover:bg-slate-100"}`,children:[m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4.5 10.5L12 3m0 0l1.5 1.5L6 12m6-9l1.5 1.5M13.5 4.5L21 12m0 0l-1.5 1.5L12 6m9 6l-1.5 1.5M16.5 10.5L9 18m-4.5-4.5l-3 3 3 3 3-3-3-3z"})})," - "]}),m.jsxs("button",{onClick:()=>_(e.DRUG_PREGNANCY_LACTATION),className:`px-4 py-2 rounded-lg font-semibold text-sm transition-all whitespace-nowrap flex items-center gap-2 ${L===e.DRUG_PREGNANCY_LACTATION?"bg-gradient-to-r from-pink-500 to-rose-600 text-white shadow-lg":z?"text-slate-300 hover:bg-slate-700":"text-slate-600 hover:bg-slate-100"}`,children:[m.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4.318 6.318a4.5 4.5 0 000 6.364L12 20.364l7.682-7.682a4.5 4.5 0 00-6.364-6.364L12 7.636l-1.318-1.318a4.5 4.5 0 00-6.364 0z"})})," "]})]}),m.jsxs("div",{className:`rounded-xl shadow-md p-2 flex items-center gap-2 transition-colors duration-300 ${z?"bg-slate-800":"bg-white"}`,children:[m.jsx("span",{className:`text-sm font-semibold px-2 ${z?"text-slate-400":"text-slate-500"}`,children:":"}),m.jsxs("select",{value:K,onChange:g=>Ae(g.target.value),className:`rounded-lg px-3 py-2 text-sm font-semibold outline-none border transition-all ${z?"bg-slate-700 border-slate-600 text-white focus:border-blue-500":"bg-slate-50 border-slate-200 text-slate-700 focus:border-blue-500"}`,children:[m.jsx("option",{value:"ALL",children:" "}),m.jsx("option",{value:i.CONTRAINDICATED,children:"  (Contraindicated)"}),m.jsx("option",{value:i.HIGH,children:"  (High)"}),m.jsx("option",{value:i.MODERATE,children:"  (Moderate)"}),m.jsx("option",{value:i.LOW,children:"  (Low)"}),m.jsx("option",{value:i.UNKNOWN,children:"   (Unknown)"})]})]})]}),ce.length===0?m.jsxs("div",{className:`rounded-2xl shadow-lg p-12 text-center border transition-colors duration-300 ${z?"bg-slate-800 border-slate-700":"bg-white border-slate-100"}`,children:[m.jsx("div",{className:`w-24 h-24 rounded-full flex items-center justify-center mx-auto mb-6 ${z?"bg-slate-700":"bg-gradient-to-br from-slate-100 to-slate-200"}`,children:m.jsx("svg",{className:`w-12 h-12 ${z?"text-slate-500":"text-slate-400"}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:m.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9.172 16.172a4 4 0 015.656 0M9 10h.01M15 10h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})}),m.jsx("h4",{className:`text-2xl font-bold mb-2 ${z?"text-white":"text-slate-700"}`,children:"  "}),m.jsx("p",{className:`max-w-md mx-auto ${z?"text-slate-400":"text-slate-500"}`,children:h==="PAIR"?!x&&!S?"        ":"           .":O.length<2?"     .":"       ."})]}):m.jsx("div",{className:"space-y-4",children:ce.slice(0,50).map(g=>m.jsx(cy,{interaction:g,isDarkMode:z},g.id))})]})]}),m.jsx(my,{isDarkMode:z}),m.jsx("footer",{className:`py-6 border-t mt-auto transition-colors duration-300 ${z?"bg-slate-800 border-slate-700 text-slate-400":"bg-white border-slate-200 text-slate-600"}`,children:m.jsxs("div",{className:"max-w-7xl mx-auto px-4 text-center",children:[m.jsxs("p",{className:"mb-2 font-semibold",children:["PharmaCheck Pro  ",new Date().getFullYear()]}),m.jsx("p",{className:"text-xs opacity-75",children:":          ."})]})}),m.jsx(dy,{isOpen:qe,onClose:()=>Q(!1),onPrint:_i,isDarkMode:z}),m.jsx(ly,{isDarkMode:z}),m.jsx(uy,{isDarkMode:z})]})}const of=document.getElementById("root");if(!of)throw new Error("Could not find root element to mount to");const hy=Yh.createRoot(of);hy.render(m.jsx(Oh.StrictMode,{children:m.jsx(py,{})}));
